0000875320-22-000007.txt : 20220209 0000875320-22-000007.hdr.sgml : 20220209 20220209163744 ACCESSION NUMBER: 0000875320-22-000007 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 135 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220209 DATE AS OF CHANGE: 20220209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 22607767 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 10-K 1 vrtx-20211231.htm 10-K vrtx-20211231
VERTEX PHARMACEUTICALS INC / MA00008753202021FYfalsehttp://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Memberhttp://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationP1Mhttp://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent33.333.333.333.333.333.300008753202021-01-012021-12-3100008753202021-06-30iso4217:USD00008753202022-01-31xbrli:shares0000875320us-gaap:ProductMember2021-01-012021-12-310000875320us-gaap:ProductMember2020-01-012020-12-310000875320us-gaap:ProductMember2019-01-012019-12-310000875320vrtx:CollaborativeandRoyaltyMember2021-01-012021-12-310000875320vrtx:CollaborativeandRoyaltyMember2020-01-012020-12-310000875320vrtx:CollaborativeandRoyaltyMember2019-01-012019-12-3100008753202020-01-012020-12-3100008753202019-01-012019-12-31iso4217:USDxbrli:shares00008753202021-12-3100008753202020-12-310000875320us-gaap:CommonStockMember2018-12-310000875320us-gaap:AdditionalPaidInCapitalMember2018-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310000875320us-gaap:RetainedEarningsMember2018-12-3100008753202018-12-3100008753202018-01-012018-12-310000875320srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2018-12-310000875320srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310000875320us-gaap:RetainedEarningsMember2019-01-012019-12-310000875320us-gaap:CommonStockMember2019-01-012019-12-310000875320us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310000875320us-gaap:CommonStockMember2019-12-310000875320us-gaap:AdditionalPaidInCapitalMember2019-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000875320us-gaap:RetainedEarningsMember2019-12-3100008753202019-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310000875320us-gaap:RetainedEarningsMember2020-01-012020-12-310000875320us-gaap:CommonStockMember2020-01-012020-12-310000875320us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310000875320us-gaap:CommonStockMember2020-12-310000875320us-gaap:AdditionalPaidInCapitalMember2020-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000875320us-gaap:RetainedEarningsMember2020-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310000875320us-gaap:RetainedEarningsMember2021-01-012021-12-310000875320us-gaap:CommonStockMember2021-01-012021-12-310000875320us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310000875320us-gaap:CommonStockMember2021-12-310000875320us-gaap:AdditionalPaidInCapitalMember2021-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000875320us-gaap:RetainedEarningsMember2021-12-31vrtx:segment0000875320vrtx:ORKAMBIMember2019-10-012019-12-31xbrli:pure0000875320us-gaap:BuildingAndBuildingImprovementsMembersrt:MinimumMember2021-01-012021-12-310000875320us-gaap:BuildingAndBuildingImprovementsMembersrt:MaximumMember2021-01-012021-12-310000875320us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2021-01-012021-12-310000875320us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2021-01-012021-12-310000875320us-gaap:TechnologyEquipmentMembersrt:MinimumMember2021-01-012021-12-310000875320us-gaap:TechnologyEquipmentMembersrt:MaximumMember2021-01-012021-12-310000875320us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2021-01-012021-12-310000875320srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccountingStandardsUpdate201602Member2019-01-010000875320vrtx:CRISPRTherapeuticsAGMember2019-01-012019-12-31vrtx:target0000875320vrtx:CRSIPRARJDCAMember2021-04-012021-06-300000875320vrtx:CRSIPRARJDCAMember2021-07-010000875320vrtx:CRSIPRARJDCAMembervrtx:CRISPRMember2021-07-010000875320us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembervrtx:CRISPRTherapeuticsAGMember2021-01-012021-12-310000875320us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembervrtx:CRISPRTherapeuticsAGMember2020-01-012020-12-310000875320us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembervrtx:CRISPRTherapeuticsAGMember2019-01-012019-12-310000875320us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembervrtx:CRISPRTherapeuticsAGMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310000875320us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembervrtx:CRISPRTherapeuticsAGMemberus-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310000875320us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembervrtx:CRISPRTherapeuticsAGMemberus-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-12-310000875320vrtx:CRISPRDMDDM1Member2019-01-012019-12-310000875320vrtx:CRISPRDMDDM1Member2021-01-012021-12-310000875320vrtx:CRISPRDMDDM1Member2020-01-012020-12-310000875320vrtx:KymeraTherapeuticsMember2019-01-012019-12-310000875320vrtx:KymeraTherapeuticsMember2020-01-012020-12-310000875320vrtx:ModernaAgreementMember2020-01-012020-12-310000875320vrtx:ApolLo1BioLLCMember2021-01-012021-12-310000875320vrtx:MammothBiosciencesIncMember2021-01-012021-12-310000875320vrtx:ArborBiotechnologiesIncMember2021-01-012021-12-310000875320vrtx:SkyhawkTherapeuticsIncMember2020-01-012020-12-310000875320vrtx:MolecularTemplatesIncMember2019-01-012019-12-310000875320vrtx:MerckKGaAMember2017-01-012017-01-31vrtx:oncology_research_and_development_programvrtx:clinical-stage_programvrtx:pre-clinical_program0000875320us-gaap:EmployeeStockOptionMember2021-01-012021-12-310000875320us-gaap:EmployeeStockOptionMember2020-01-012020-12-310000875320us-gaap:EmployeeStockOptionMember2019-01-012019-12-310000875320us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310000875320us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310000875320us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-12-310000875320us-gaap:EmployeeStockOptionMember2021-01-012021-12-310000875320us-gaap:EmployeeStockOptionMember2020-01-012020-12-310000875320us-gaap:EmployeeStockOptionMember2019-01-012019-12-310000875320us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310000875320us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310000875320us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Member2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Member2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Member2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel3Member2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Member2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMember2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMember2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310000875320us-gaap:FairValueInputsLevel3Member2021-12-310000875320us-gaap:FairValueInputsLevel3Membersrt:MinimumMemberus-gaap:MeasurementInputDiscountRateMember2021-12-310000875320us-gaap:FairValueInputsLevel3Membersrt:MaximumMemberus-gaap:MeasurementInputDiscountRateMember2021-12-310000875320vrtx:CashAndMoneyMarketFundsMemberus-gaap:CashAndCashEquivalentsMember2021-12-310000875320vrtx:CashAndMoneyMarketFundsMemberus-gaap:CashAndCashEquivalentsMember2020-12-310000875320vrtx:MarketableSecuritiesMemberus-gaap:USTreasurySecuritiesMember2021-12-310000875320vrtx:MarketableSecuritiesMemberus-gaap:USTreasurySecuritiesMember2020-12-310000875320vrtx:MarketableSecuritiesMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2021-12-310000875320vrtx:MarketableSecuritiesMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2020-12-310000875320vrtx:MarketableSecuritiesMemberus-gaap:CorporateDebtSecuritiesMember2021-12-310000875320vrtx:MarketableSecuritiesMemberus-gaap:CorporateDebtSecuritiesMember2020-12-310000875320vrtx:MarketableSecuritiesMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2021-12-310000875320vrtx:MarketableSecuritiesMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2020-12-310000875320vrtx:MarketableSecuritiesMember2021-12-310000875320vrtx:MarketableSecuritiesMember2020-12-310000875320us-gaap:CashAndCashEquivalentsMember2021-12-310000875320us-gaap:CashAndCashEquivalentsMember2020-12-310000875320vrtx:PubliclyTradedCompaniesSaleMember2020-01-012020-12-310000875320vrtx:PubliclyTradedCompaniesSaleMember2019-01-012019-12-310000875320vrtx:PubliclyTradedCompaniesSaleMember2020-12-310000875320vrtx:PubliclyTradedCompaniesSaleMember2019-12-310000875320vrtx:PubliclyTradedCompaniesSaleMember2021-01-012021-12-310000875320us-gaap:OtherAssetsMember2021-12-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2018-12-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-12-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2018-12-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2019-01-012019-12-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-01-012019-12-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-01-012019-12-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-12-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-12-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-12-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-12-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-12-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-12-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-12-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-12-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMembersrt:MinimumMember2021-01-012021-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMembersrt:MaximumMember2021-01-012021-12-310000875320us-gaap:CashFlowHedgingMembercurrency:EURus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2021-12-310000875320us-gaap:CashFlowHedgingMembercurrency:EURus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2020-12-310000875320currency:GBPus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2021-12-310000875320currency:GBPus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2020-12-310000875320currency:AUDus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2021-12-310000875320currency:AUDus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2020-12-310000875320currency:CADus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2021-12-310000875320currency:CADus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2020-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:CHFus-gaap:ForeignExchangeForwardMember2021-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:CHFus-gaap:ForeignExchangeForwardMember2020-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2021-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2020-12-310000875320us-gaap:NondesignatedMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMember2021-12-310000875320us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ProductMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310000875320us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ProductMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310000875320us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ProductMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310000875320us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310000875320us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310000875320us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2021-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeForwardMember2021-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherAssetsMemberus-gaap:ForeignExchangeForwardMember2021-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2021-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2020-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeForwardMember2020-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherAssetsMemberus-gaap:ForeignExchangeForwardMember2020-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2020-12-310000875320us-gaap:BuildingMember2021-12-310000875320us-gaap:BuildingMember2020-12-310000875320us-gaap:FurnitureAndFixturesMember2021-12-310000875320us-gaap:FurnitureAndFixturesMember2020-12-310000875320us-gaap:LeaseholdImprovementsMember2021-12-310000875320us-gaap:LeaseholdImprovementsMember2020-12-310000875320us-gaap:ComputerSoftwareIntangibleAssetMember2021-12-310000875320us-gaap:ComputerSoftwareIntangibleAssetMember2020-12-310000875320us-gaap:LandMember2021-12-310000875320us-gaap:LandMember2020-12-310000875320vrtx:SemmaTherapeuticsInc.Member2019-12-310000875320vrtx:ExonicsTherapeuticsMember2019-12-310000875320us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2021-12-310000875320us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2020-12-310000875320us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2019-12-310000875320us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2018-12-310000875320us-gaap:OtherAssetsMember2020-12-310000875320us-gaap:OtherAssetsMember2019-12-310000875320us-gaap:OtherAssetsMember2018-12-310000875320vrtx:FanPierLeasesMember2011-01-012011-12-31vrtx:lease0000875320vrtx:FanPierLeasesMember2011-12-31utr:sqftvrtx:building0000875320vrtx:SanDiegoLeaseMember2015-12-310000875320vrtx:SanDiegoLeaseMember2015-01-012015-12-31vrtx:term0000875320vrtx:InnovationSquareLeaseMember2019-12-310000875320vrtx:InnovationSquareLeaseMember2019-01-012019-12-31vrtx:renewal_optionvrtx:vote0000875320vrtx:ShareRepurchaseProgram2018Member2018-12-310000875320vrtx:ShareRepurchaseProgram2018Member2019-01-012019-12-310000875320vrtx:ShareRepurchaseProgram2019Member2019-07-310000875320vrtx:ShareRepurchaseProgram2019Member2020-01-012020-12-310000875320vrtx:ShareRepurchaseProgram2019Member2019-01-012019-12-310000875320vrtx:ShareRepurchaseProgram2020Member2020-11-300000875320vrtx:ShareRepurchaseProgram2020Member2021-01-012021-12-310000875320vrtx:ShareRepurchaseProgram2020Member2020-01-012020-12-310000875320vrtx:ShareRepurchaseProgram2021Member2021-06-300000875320vrtx:ShareRepurchaseProgram2021Member2021-01-012021-12-310000875320vrtx:ShareRepurchaseProgram2021Member2021-12-310000875320vrtx:StockandOptionPlan2013Member2021-12-310000875320vrtx:StockAndOptionPlan2006Member2021-12-310000875320vrtx:StockandOptionPlan2013Member2019-01-012019-12-310000875320srt:MaximumMember2021-01-012021-12-310000875320srt:WeightedAverageMember2021-12-310000875320vrtx:ExercisePriceRangeFromDollars3628ToDollars10000Member2021-01-012021-12-310000875320vrtx:ExercisePriceRangeFromDollars3628ToDollars10000Member2021-12-310000875320vrtx:ExercisePriceRangeFromDollars10001ToDollars15000Member2021-01-012021-12-310000875320vrtx:ExercisePriceRangeFromDollars10001ToDollars15000Member2021-12-310000875320vrtx:ExercisePriceRangeFromDollars15001ToDollars20000Member2021-01-012021-12-310000875320vrtx:ExercisePriceRangeFromDollars15001ToDollars20000Member2021-12-310000875320vrtx:ExercisePriceRangeFromDollars20001ToDollars28627Member2021-01-012021-12-310000875320vrtx:ExercisePriceRangeFromDollars20001ToDollars28627Member2021-12-310000875320us-gaap:RestrictedStockUnitsRSUMember2020-12-310000875320us-gaap:RestrictedStockUnitsRSUMember2021-12-310000875320us-gaap:RestrictedStockMember2020-01-012020-12-310000875320us-gaap:RestrictedStockMember2019-01-012019-12-310000875320us-gaap:RestrictedStockMember2021-01-012021-12-310000875320us-gaap:PerformanceSharesMember2021-01-012021-12-310000875320us-gaap:PerformanceSharesMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2021-01-012021-12-310000875320us-gaap:PerformanceSharesMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2021-01-012021-12-310000875320us-gaap:PerformanceSharesMember2020-12-310000875320us-gaap:PerformanceSharesMember2021-12-310000875320us-gaap:PerformanceSharesMember2020-01-012020-12-310000875320us-gaap:PerformanceSharesMember2019-01-012019-12-310000875320vrtx:EmployeeStockPurchasePlanMember2021-01-012021-12-31vrtx:period0000875320vrtx:EmployeeStockPurchasePlanMember2021-12-310000875320vrtx:FinancialPerformanceSharesMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2021-01-012021-12-310000875320vrtx:FinancialPerformanceSharesMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2021-01-012021-12-310000875320vrtx:FinancialPerformanceSharesMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2021-01-012021-12-310000875320us-gaap:CostOfSalesMember2021-01-012021-12-310000875320us-gaap:CostOfSalesMember2020-01-012020-12-310000875320us-gaap:CostOfSalesMember2019-01-012019-12-310000875320us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310000875320us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310000875320us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-12-310000875320us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-310000875320us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-310000875320us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-12-310000875320vrtx:EmployeeStockPurchasePlanMember2021-01-012021-12-310000875320vrtx:EmployeeStockPurchasePlanMember2020-01-012020-12-310000875320vrtx:EmployeeStockPurchasePlanMember2019-01-012019-12-310000875320us-gaap:RestrictedStockMember2021-12-310000875320us-gaap:EmployeeStockOptionMember2021-12-310000875320vrtx:EmployeeStockPurchasePlanMember2021-12-310000875320us-gaap:StockOptionMember2021-01-012021-12-310000875320vrtx:FinancialPerformanceSharesMember2021-01-012021-12-31vrtx:installment0000875320vrtx:NonFinancialPerformanceSharesMember2021-01-012021-12-310000875320us-gaap:EmployeeStockMember2021-01-012021-12-310000875320us-gaap:EmployeeStockMember2020-01-012020-12-310000875320us-gaap:EmployeeStockMember2019-01-012019-12-310000875320us-gaap:ForeignCountryMember2021-01-012021-12-310000875320us-gaap:DomesticCountryMember2021-12-310000875320us-gaap:StateAndLocalJurisdictionMember2021-12-310000875320us-gaap:ForeignCountryMember2021-12-310000875320vrtx:DeferredTaxAssetsMember2021-12-310000875320us-gaap:AccountsPayableAndAccruedLiabilitiesMember2021-12-31vrtx:credit_agreement0000875320us-gaap:RevolvingCreditFacilityMember2019-09-300000875320us-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMembersrt:MinimumMember2019-09-012019-09-300000875320us-gaap:RevolvingCreditFacilityMembersrt:MaximumMemberus-gaap:BaseRateMember2019-09-012019-09-300000875320us-gaap:EurodollarMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2019-09-012019-09-300000875320us-gaap:EurodollarMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2019-09-012019-09-300000875320us-gaap:LetterOfCreditMember2019-09-300000875320us-gaap:RevolvingCreditFacilityMember2020-09-300000875320us-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMembersrt:MinimumMember2020-09-012020-09-300000875320us-gaap:RevolvingCreditFacilityMembersrt:MaximumMemberus-gaap:BaseRateMember2020-09-012020-09-300000875320us-gaap:EurodollarMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2020-09-012020-09-300000875320us-gaap:EurodollarMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2020-09-012020-09-300000875320us-gaap:RevolvingCreditFacilityMember2020-09-012020-09-300000875320vrtx:TRIKAFTAKAFTRIOMember2021-01-012021-12-310000875320vrtx:TRIKAFTAKAFTRIOMember2020-01-012020-12-310000875320vrtx:TRIKAFTAKAFTRIOMember2019-01-012019-12-310000875320vrtx:SYMDEKOSYMKEVIMember2021-01-012021-12-310000875320vrtx:SYMDEKOSYMKEVIMember2020-01-012020-12-310000875320vrtx:SYMDEKOSYMKEVIMember2019-01-012019-12-310000875320vrtx:ORKAMBIMember2021-01-012021-12-310000875320vrtx:ORKAMBIMember2020-01-012020-12-310000875320vrtx:ORKAMBIMember2019-01-012019-12-310000875320vrtx:KalydecoMember2021-01-012021-12-310000875320vrtx:KalydecoMember2020-01-012020-12-310000875320vrtx:KalydecoMember2019-01-012019-12-310000875320country:USus-gaap:ProductMember2021-01-012021-12-310000875320country:USus-gaap:ProductMember2020-01-012020-12-310000875320country:USus-gaap:ProductMember2019-01-012019-12-310000875320us-gaap:ProductMembersrt:EuropeMember2021-01-012021-12-310000875320us-gaap:ProductMembersrt:EuropeMember2020-01-012020-12-310000875320us-gaap:ProductMembersrt:EuropeMember2019-01-012019-12-310000875320vrtx:OtherCountriesOutsideoftheUnitedStatesandEuropeMemberus-gaap:ProductMember2021-01-012021-12-310000875320vrtx:OtherCountriesOutsideoftheUnitedStatesandEuropeMemberus-gaap:ProductMember2020-01-012020-12-310000875320vrtx:OtherCountriesOutsideoftheUnitedStatesandEuropeMemberus-gaap:ProductMember2019-01-012019-12-310000875320vrtx:OutsidetheUnitedStatesMemberus-gaap:ProductMember2021-01-012021-12-310000875320vrtx:OutsidetheUnitedStatesMemberus-gaap:ProductMember2020-01-012020-12-310000875320vrtx:OutsidetheUnitedStatesMemberus-gaap:ProductMember2019-01-012019-12-310000875320vrtx:McKessonCorporationMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2021-01-012021-12-310000875320vrtx:McKessonCorporationMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2020-01-012020-12-310000875320vrtx:McKessonCorporationMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2019-01-012019-12-310000875320vrtx:McKessonCorporationMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2021-01-012021-12-310000875320vrtx:McKessonCorporationMemberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2020-01-012020-12-310000875320vrtx:AccredoCurascriptMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2021-01-012021-12-310000875320vrtx:AccredoCurascriptMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2020-01-012020-12-310000875320vrtx:AccredoCurascriptMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2019-01-012019-12-310000875320us-gaap:AccountsReceivableMembervrtx:AccredoCurascriptMemberus-gaap:CreditConcentrationRiskMember2021-01-012021-12-310000875320us-gaap:AccountsReceivableMembervrtx:AccredoCurascriptMemberus-gaap:CreditConcentrationRiskMember2020-01-012020-12-310000875320vrtx:WalgreenCo.Memberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2021-01-012021-12-310000875320vrtx:WalgreenCo.Memberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2020-01-012020-12-310000875320vrtx:WalgreenCo.Memberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2019-01-012019-12-310000875320vrtx:WalgreenCo.Memberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2021-01-012021-12-310000875320vrtx:WalgreenCo.Memberus-gaap:AccountsReceivableMemberus-gaap:CreditConcentrationRiskMember2020-01-012020-12-310000875320vrtx:LloydsPharmacyMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2021-01-012021-12-310000875320vrtx:LloydsPharmacyMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2020-01-012020-12-310000875320vrtx:LloydsPharmacyMemberus-gaap:SalesRevenueNetMemberus-gaap:ProductConcentrationRiskMember2019-01-012019-12-310000875320us-gaap:AccountsReceivableMembervrtx:LloydsPharmacyMemberus-gaap:CreditConcentrationRiskMember2021-01-012021-12-310000875320us-gaap:AccountsReceivableMembervrtx:LloydsPharmacyMemberus-gaap:CreditConcentrationRiskMember2020-01-012020-12-310000875320country:US2021-12-310000875320country:US2020-12-310000875320country:GB2021-12-310000875320country:GB2020-12-310000875320vrtx:OtherCountriesOutsideoftheUnitedStatesandtheUnitedKingdomMember2021-12-310000875320vrtx:OtherCountriesOutsideoftheUnitedStatesandtheUnitedKingdomMember2020-12-310000875320vrtx:OutsidetheUnitedStatesMember2021-12-310000875320vrtx:OutsidetheUnitedStatesMember2020-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
☒    ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Fiscal Year Ended December 31, 2021
or
☐    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM   TO    
Commission file number 000-19319
Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)
Massachusetts
(State or other jurisdiction of incorporation or organization)
50 Northern Avenue, Boston, Massachusetts
(Address of principal executive offices)

04-3039129
(I.R.S. Employer Identification No.)
02210
(Zip Code)
Registrant’s telephone number, including area code (617) 341-6100
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of Each ClassTrading SymbolName of Each Exchange on Which Registered
Common Stock, $0.01 Par Value Per ShareVRTXThe Nasdaq Global Select Market
Securities registered pursuant to Section 12(g) of the Exchange Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes ☒ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.  Yes ☐ No ☒
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one):
Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.   ☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  ☐ No ☒
The aggregate market value of the registrant’s common stock held by non-affiliates of the registrant based on the closing price on June 30, 2021 (the last business day of the registrant’s most recently completed second fiscal quarter of 2021) was $51.6 billion.
As of January 31, 2022, the registrant had 254,576,691 shares of common stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the definitive proxy statement for the 2022 Annual Meeting of Shareholders, which we expect to hold on May 18, 2022, are incorporated by reference into Part III of this Annual Report on Form 10-K.


VERTEX PHARMACEUTICALS INCORPORATED
ANNUAL REPORT ON FORM 10-K
TABLE OF CONTENTS
“Vertex,” “we,” “us” and “our” as used in this Annual Report on Form 10-K refer to Vertex Pharmaceuticals Incorporated, a Massachusetts corporation, and its subsidiaries.
“VERTEX®,” “KALYDECO®,” “ORKAMBI®,” “SYMDEKO®,” “SYMKEVI®” and “TRIKAFTA®” are registered trademarks of Vertex. The trademark for “KAFTRIO” is pending in the United States and registered in the European Union. Other brands, names and trademarks contained in this Annual Report on Form 10-K are the property of their respective owners.
We use the brand name for our products when we refer to the product that has been approved and with respect to the indications on the approved label. Otherwise, including in discussions of our cystic fibrosis development programs, we refer to our compounds by their scientific (or generic) name or VX developmental designation.
This Annual Report on Form 10-K contains forward-looking statements. Words such as “anticipates,” “may,” “forecasts,” “expects,” “intends,” “plans,” “potentially,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Please refer to “Special Note Regarding Forward-Looking Statements” set forth in Part I, Item 1A, for a discussion of our forward-looking statements and the related risks and uncertainties of such statements.


PART I

ITEM 1.BUSINESS
OVERVIEW
We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases with a focus on specialty markets. We have multiple approved medicines that treat the underlying cause of cystic fibrosis, or CF, a life-threatening genetic disease, and we have several ongoing clinical and research programs to advance and extend treatment of CF. Beyond CF, we have a pipeline of investigational therapies in other serious diseases where we are leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies.
Marketed Products
Our goal in CF is to develop treatment regimens that will provide benefits to all people with CF and will enhance the benefits currently provided to people taking our medicines. Our marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Collectively, our four medicines are being used to treat the majority of the approximately 83,000 people with CF in North America, Europe and Australia.
We are focused on increasing the number of people with CF eligible and able to receive our medicines through label expansions, approval of new medicines, and expanded reimbursement. We are evaluating our current medicines in additional patient populations, including younger children, with the goal of having small molecule treatments for approximately 90% of people with CF.
Research and Development
Our strategy is to discover and develop innovative medicines by combining transformative advances in the understanding of human disease biology and in the science of therapeutics. This research and early development strategy includes advancing multiple compounds from each program into early clinical trials and evaluating the resulting patient data to inform the discovery and development of additional compounds, with the goal of bringing first-in-class and best-in-class therapies to patients. Our strategy and approach are intended to increase the likelihood of successfully bringing transformative medicines to patients, and to provide durable clinical and commercial success. We are advancing programs across multiple disease areas and modalities, including:
•Cystic Fibrosis. We are evaluating in Phase 3 clinical trials a new, once-daily investigational triple combination of VX-121/tezacaftor/VX-561 (deutivacaftor). We also are researching genetic therapies and gene-editing approaches to treat the remaining approximately 10% of people with CF who are not expected to benefit from our small molecule medicines.
•Sickle Cell Disease and Beta Thalassemia. We are evaluating in Phase 3 clinical trials CTX001, an investigational CRISPR/Cas9-based gene-editing therapy for severe sickle cell disease, or SCD, and transfusion-dependent beta thalassemia, or TDT, with CRISPR Therapeutics AG, or CRISPR. Enrollment is complete, and we anticipate regulatory submissions for CTX001 in late 2022.
•APOL1-Mediated Kidney Disease. Based on positive Phase 2 data for VX-147, our small molecule for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, we expect to advance VX-147 into pivotal development in a broader population of people with APOL1-mediated kidney disease, or AMKD, in the first quarter of 2022.
•Type 1 Diabetes. We are evaluating VX-880, a stem-cell derived islet cell therapy involving the transplantation of islet cells, for the potential treatment of type 1 diabetes, or T1D, in a Phase 1/2 clinical trial, and recently announced positive Day 150 data for the first T1D patient in this clinical trial. We will continue to dose patients in 2022. We also are pursuing additional programs in T1D, in which the implanted islet cells are encapsulated in an immunoprotective device or modified to produce hypoimmune cells.

1

•Pain. We are evaluating VX-548, a NaV 1.8 inhibitor, for the non-opioid treatment of acute pain in two Phase 2 clinical trials. We expect to have data from these clinical trials in the first quarter of 2022.
•Alpha-1 Antitrypsin, or AAT, Deficiency. We obtained proof-of-mechanism for VX-864 in a Phase 2 study of protein folding correction of the Z-AAT protein. We plan to advance into the clinic one or more novel small molecule correctors intended to address the lung and liver manifestations of AAT deficiency, or AATD, in 2022.
•Duchenne muscular dystrophy, or DMD, and myotonic dystrophy type 1, or DM1. We are focused on advancing gene-editing therapies aimed at treating the underlying cause of DMD and DM1. We are also exploring potential small molecule approaches to address the underlying causal biology for both DMD and DM1.
•In addition to the clinical stage programs listed above, we have a number of early-stage research programs aimed at other targets that represent the causal human biology of serious diseases.
We plan to continue investing in our research and development programs and fostering scientific innovation by identifying additional product candidates through our internal research efforts and investing in business development transactions to access emerging technologies, products and product candidates.

CYSTIC FIBROSIS
Background
CF is a life-shortening genetic disease caused by a defective or missing cystic fibrosis transmembrane conductance regulator, or CFTR, protein resulting from mutations in the CFTR gene. To develop CF, children must inherit two defective CFTR genes, which are referred to as alleles; one allele is inherited from each parent. The vast majority of patients with CF carry at least one F508del mutation. The F508del mutation results in a defect in the CFTR protein in which the CFTR protein does not reach the surface of the cells in sufficient quantities and does not adequately transport chloride ions.
The absence of working CFTR proteins results in poor flow of salt and water into and out of cells in a number of organs, including the lungs. As a result, thick, sticky mucus builds up and blocks the passages in many organs, leading to a variety of symptoms. In particular, mucus builds up and clogs the airways in the lungs, causing chronic lung infections and progressive lung damage. CFTR potentiators such as ivacaftor and VX-561 increase the probability that the CFTR protein channels open on the cell surface, increasing the flow of salt and water into and out of the cell. CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface.

2

Our Medicines
Our medicines are collectively being used by the majority of people with CF in North America, Europe and Australia. Our approved medicines, including information regarding the indication and age groups for which the medicine is approved, are set forth in the table below.
ProductScientific Name
Region/Initial Approval (1)
IndicationEligible Age Group
vrtx-20211231_g1.jpg
elexacaftor/tezacaftor/ivacaftor and ivacaftorU.S.
(2019)		People with CF with (i) at least one F508del mutation, or (ii) another mutation that is responsive to elexacaftor/tezacaftor/ivacaftor and ivacaftor6 years of age and older
vrtx-20211231_g2.jpg
elexacaftor/tezacaftor/ivacaftor and ivacaftorE.U.
(2020)		People with CF with at least one F508del mutation6 years of age and older
vrtx-20211231_g3.jpg
tezacaftor/ivacaftor and ivacaftorU.S.
(2018)		People with CF (i) homozygous for the F508del mutation or (ii) with at least one mutation that is responsive to tezacaftor/ivacaftor6 years of age and older
vrtx-20211231_g4.jpg
tezacaftor/ivacaftor E.U.
(2018)		People with CF (i) homozygous for the F508del mutation or (ii) with one copy of the F508del mutation and one copy of certain mutations that result in residual CFTR activity6 years of age and older
vrtx-20211231_g5.jpg
lumacaftor/ivacaftorU.S.
(2015)		People with CF homozygous for the F508del mutation2 years of age and older
lumacaftor/ivacaftorE.U.
(2015)		People with CF homozygous for the F508del mutation2 years of age and older
vrtx-20211231_g6.jpg
ivacaftorU.S.
(2012)		People with CF with a mutation that is responsive to ivacaftor4 months of age and older
ivacaftorE.U.
(2012)		People with CF with R117H mutation or one of certain gating mutations4 months of age and older
(1) At the end of the Brexit transition period on January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or MHRA, in Great Britain approved licenses for supply of each product in England, Scotland and Wales. The existing European Medicines Agency, or EMA, licenses continue to authorize supply in Northern Ireland.
In addition to the European Union, or the E.U. and the United States, or the U.S., we market our products in additional countries, including the United Kingdom, or the U.K., Australia, Switzerland, Israel, and Canada. We continuously seek to increase the number of patients eligible and able to receive our current medicines through label expansions, approval of new medicines and expanded reimbursement. Since the beginning of 2021, events that have resulted from our efforts include:
•The U.S. Food and Drug Administration, or the FDA, approved the use of TRIKAFTA for children with CF 6 through 11 years of age who have at least one F508del mutation or at least one other mutation that is responsive to TRIKAFTA.
•Health Canada granted marketing authorization for TRIKAFTA for people with CF 12 years of age and older who have at least one F508del mutation. Our application for approval of TRIKAFTA for children 6 through 11 years of age has been accepted for priority review by Health Canada.

3

•In January 2022, the European Commission and the MHRA granted marketing authorization for KAFTRIO for the treatment of children with CF 6 through 11 years of age who have at least one F508del mutation in the CFTR gene.
•TRIKAFTA/KAFTRIO is now approved and reimbursed or accessible in more than 20 countries outside the U.S.

RESEARCH AND DEVELOPMENT PROGRAMS
We invest in research and development to discover and develop transformative medicines for people with serious diseases, with a focus on specialty markets. Our research strategy is to combine transformative advances in the understanding of human disease biology and the science of therapeutics to discover and develop new medicines. Our approach to drug discovery has been validated through our success in moving novel small molecule product candidates into clinical trials and obtaining marketing approvals for TRIKAFTA/KAFTRIO, KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI for the treatment of CF and INCIVEK (telaprevir) for the treatment of hepatitis C infection. In addition, we have achieved clinical proof-of-concept for gene-editing of BCL11A for the treatment of beta thalassemia and SCD, for APOL1 inhibition to decrease proteinuria in patients with APOL1-mediated kidney disease, and for NaV1.8 inhibition in the treatment of three different pain models.
We continue to research and develop small molecule product candidates for the treatment of serious diseases, including CF, APOL1-mediated kidney disease, pain, AATD, DMD and DM1. Our research and development approach includes advancing multiple candidates into clinical trials, pursuing multiple modalities and evaluating clinical and non-clinical data to inform drug discovery and development, with the goal of bringing best-in-class therapies to patients.
Over the last several years, we have expanded our capabilities to include additional innovative therapeutic modalities with a focus on cell and genetic therapies, which have the potential to treat, and in some cases, cure diseases by addressing the underlying cause of the disease. We have increased our internal investment in cell and genetic therapies, including establishment of a new research and development site in Boston, Massachusetts focused primarily on cell and genetic therapies. In addition, we have made several significant investments in external innovation, including:
•our collaborations with CRISPR to access and develop therapeutics based on the CRISPR gene-editing technology, including an agreement under which we now lead the worldwide development, manufacturing and commercialization of CTX001;
•our establishment of cell therapy programs for T1D through our acquisition of Semma;
•our establishment of genetic therapy programs for DMD and DM1, through our acquisition of Exonics; and
•our collaboration with Moderna, Inc., or Moderna, for the discovery and development of lipid nanoparticles and mRNAs that can deliver gene-editing therapies.
The experience we gained developing medicines for CF and our analysis of research and development programs conducted by other companies in our industry have shaped a disciplined strategy that guides our investments in research and development and external innovation that focuses on:
•    transformative treatments for life-threatening diseases with a high unmet medical need;
•    targets validated as playing a causal role in the human biology of a disease;
•innovative therapeutic approaches to addressing those targets;
•biological assays and clinical biomarkers designed to predict clinical responses; and
•    efficient clinical and regulatory paths to bring new medicines to patients.
To augment our internal programs, we plan to continue acquiring businesses and technologies and collaborating with biopharmaceutical and technology companies, leading academic research institutions, government laboratories, foundations and other organizations to advance research in our areas of therapeutic interest, as well as to access technologies needed to execute on our strategy. We have established such relationships with organizations around the world and intend to extend and leverage that experience to further our research efforts to discover transformational medicines for serious diseases. We will

4

continue to identify and evaluate potential acquisitions and collaborations that may be similar to or different from the transactions that we have engaged in previously.
The following chart represents our pipeline programs by disease area, stage of development, and modality, for programs that have lead assets in the clinic.
vrtx-20211231_g7.gif
CF Pipeline
We have initiated Phase 3 clinical trials evaluating a once-daily investigational triple combination of VX-121/tezacaftor/VX-561 (deutivacaftor). Clinical and preclinical data indicate that this triple combination has the potential to provide enhanced benefit beyond TRIKAFTA/KAFTRIO for people with CF who have the F508del mutation on at least one allele. Our Phase 3 program consists of two 52-week clinical trials, which will evaluate the safety and efficacy of the new combination relative to TRIKAFTA in a total of 950 people with CF. Both clinical trials will measure the regulatory-enabling endpoint of absolute change in ppFEV1, a measure of lung function, that will be analyzed for non-inferiority to TRIKAFTA. The clinical trials also are designed to assess the absolute change from baseline in ppFEV1 and sweat chloride for superiority to TRIKAFTA. We continue to identify and develop additional CFTR modulators with the goal of achieving carrier levels of CFTR activity for approximately 90% of people with CF who respond to CFTR modulators.
We continue to research genetic therapies, such as messenger ribonucleic acid, or mRNA, and gene-editing approaches, to treat the remaining approximately 10% of people with CF who do not make CFTR protein and, as a result, are not expected to benefit from our small molecule medicines. In collaboration with Moderna, we are developing CF mRNA therapeutics designed to treat the underlying cause of CF for these people by enabling cells in the lungs to produce functional CFTR protein. We are conducting enabling studies and expect to submit an Investigational New Drug Application, or IND, for this program in 2022.
Sickle Cell Disease and Beta Thalassemia
SCD and beta thalassemia are hemoglobinopathies, a group of inherited blood disorders that result from gene mutations that alter hemoglobin, a protein in red blood cells that delivers oxygen throughout the body.
SCD is caused by the change of a single amino acid in the hemoglobin gene that causes red cells to change shape in settings of low oxygen. These sickled cells block blood flow and can lead to severe pain, organ damage, and shortened life span. Treatment is typically focused on relieving pain and minimizing organ damage, requiring medication and, for some patients, monthly blood transfusions and frequent hospital visits. We believe there are approximately 25,000 patients with severe SCD in the U.S. and Europe.

5

Beta thalassemia is caused by loss-of-function mutations in hemoglobin that lead to severe anemia in patients, which causes fatigue and shortness of breath. In infants, beta thalassemia causes failure to thrive, jaundice, and feeding problems. Complications of beta thalassemia can lead to an enlarged spleen, liver and/or heart, misshapen bones and delayed puberty. Treatment for beta thalassemia varies depending on the disease severity for each patient. Patients with TDT, the most severe form of the disease, require regular blood transfusions, as frequently as every two to four weeks. Repeated blood transfusions eventually cause an unhealthy buildup of iron in the patient, leading to organ damage. We believe that there are approximately 7,000 patients with TDT in the U.S. and Europe.
We are developing CTX001, an investigational CRISPR/Cas9-based gene-editing therapy, for the treatment severe SCD and TDT, with our collaborator, CRISPR. Our therapeutic approach involves isolating hematopoietic stem and progenitor cells, or HSPCs, which give rise to red blood cells, from a patient, treating those cells ex vivo with CRISPR/Cas9 in order to modify the erythroid-specific enhancer in the BCL11A gene, and reintroducing the edited cells back into the patient. This approach has the potential to increase levels of fetal hemoglobin in erythrocytes and reduce or eliminate symptoms associated with disease.
We are investigating CTX001 in two Phase 3 open-label clinical trials designed to assess the safety and efficacy of a single dose of CTX001 in patients ages 12 to 35 with severe SCD (the CLIMB SCD-121 clinical trial) and TDT (the CLIMB THAL-111 clinical trial), respectively. Patients enrolled in the clinical trials first undergo a treatment that mobilizes a population of HSPCs from the bone marrow into the bloodstream. Blood cells are collected from the patient’s bloodstream and transferred to a manufacturing facility where the HSPCs are purified and CRISPR/Cas9 gene-editing is performed. Following manufacturing, the edited cells, now called CTX001, are transferred back to the clinical site. Patients are preconditioned with a treatment that ablates their bone marrow prior to infusion of CTX001.
Data presented to date support the profile of CTX001 as a potential one-time functional cure for people with severe SCD and TDT. CTX001 safety data to date is generally consistent with an autologous stem cell transplant and myeloablative conditioning. Enrollment is complete in the ongoing clinical trials evaluating CTX001 in severe SCD and TDT. We anticipate regulatory submissions of CTX001 in late 2022.
APOL1-Mediated Kidney Disease
Inherited mutations in the APOL1 gene play a causal role in the biology of severe proteinuric kidney diseases referred to as AMKD. Patients with AMKD inherit two mutations in the APOL1 gene resulting in significant proteinuria, and are characterized by a high risk of progression to end stage renal disease. Among patients with AMKD are those with the histological finding of FSGS and co-morbidities such as hypertension. In AMKD, the kidney’s filtering units known as the glomerulus, and specifically the cells known as podocytes, are damaged, leading to leakage of protein into the urine, deterioration in kidney function, scarring, and, ultimately, permanent kidney damage. We are evaluating multiple novel small molecules that inhibit the function of APOL1 protein with the potential to treat APOL1-mediated kidney disease, including APOL1-mediated FSGS.
In December 2021, we announced that patients with APOL1-mediated FSGS treated with VX-147 on top of standard of care achieved a statistically significant, substantial, and clinically meaningful reduction of proteinuria in a Phase 2 proof-of-concept clinical trial. VX-147 was well tolerated by patients. We anticipate completing our end of Phase 2 meetings with regulators and advancing VX-147 into pivotal development in people with APOL1-mediated kidney disease, including APOL1-mediated FSGS, in the first quarter of 2022.
Type 1 Diabetes
T1D is a chronic, metabolic disorder caused by an absence of insulin secretion by the beta cells in the pancreas. In patients with T1D, the insulin-producing islet cells of the pancreas are destroyed by the person’s own immune system, resulting in a complete lack of insulin. While insulin therapy allows patients to live for decades with the disease, challenges of insulin therapy include inadequate control of blood sugar (both hyper- and hypo-glycemia), a substantial burden of care on patients and families, and long-term vascular complications.
We are developing autologous, fully differentiated stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D, with the goal of delivering a functional cure. We are pursuing three programs for the transplant of functional islets into patients: transplantation of islet cells alone, using immunosuppression to protect the implanted cells, implantation of the islet cells inside a novel immunoprotective device, and

6

development of hypoimmune cells to optimize how we protect the implanted islet cells from the immune system.
VX-880, our first program, is a stem cell-derived, allogeneic, fully differentiated, insulin-secreting islet cell replacement therapy, using standard immunosuppression to protect the implanted cells. Our Phase 1/2 clinical trial evaluating VX-880 as a potential treatment for T1D is ongoing at multiple clinical sites in the U.S. and a Clinical Trial Application has been approved in Canada. In January 2022, we announced positive Day 150 data for the first T1D patient in the Phase 1/2 clinical trial of VX-880, including restoration of islet cell function and rapid improvements in multiple measures. In this first patient, the safety of VX-880 was generally consistent with the immunosuppressive regimen used in this study. We will continue to dose patients in 2022.
In our second program, the stem cell-derived, fully differentiated, insulin-secreting islet cells are encapsulated and implanted in an immunoprotective device. In our third program, research in earlier stages is directed toward developing hypoimmune cells to further optimize how we protect the implanted islet cells from the immune system. We are conducting IND-enabling studies for the cells and device program, and we expect to submit an IND for this program in 2022.
Pain
Pain can be debilitating and develop from a variety of pathophysiological and psychological conditions. Patients with pain can suffer from acute pain (for example, following surgery or an injury), neuropathic pain (when there is damage to a nerve), and musculoskeletal pain. Current treatments may not work well and can cause significant side effects and the risk of addiction. In addition, there is the practice of over- and mis-utilization, as well as underutilization of current pain medicines.
The selective sodium channels NaV1.8 and NaV1.7 play unique roles in the pathophysiology of pain. We have discovered multiple inhibitors of NaV1.8 as potential treatments for pain and have obtained pharmacological validation of the potential of NaV1.8 inhibition with one of our first generation NaV1.8 inhibitors in three clinical pain models: acute pain, neuropathic pain, and musculoskeletal pain. VX-548 is a next generation NaV1.8 inhibitor. We are conducting two Phase 2 dose ranging acute pain clinical trials; one following bunionectomy surgery and the other following abdominoplasty surgery. We expect to have data from both clinical trials in the first quarter of 2022.
Alpha-1 Antitrypsin Deficiency
AATD is a severe disease of the liver and lung, caused by inherited mutations in the SERPINA1 gene that encodes the AAT protein. People who inherit two mutant SERPINA1 alleles (one from each parent) develop AATD. Most people who develop AATD have two copies of a single mutation known as the Z allele. The Z-AAT mutation results in a protein folding defect in the AAT protein leading the misfolded AAT protein to accumulate in the liver (where it is produced at high levels), which can cause liver damage. As a result, the protein fails to reach other organs in adequate quantity and function, particularly the lungs, where the AAT protein’s normal role is to protect the lungs from the digestive effects of certain proteases. The unchecked activity of these proteases can cause auto-digestion of lung tissue and may lead to emphysema or chronic pulmonary obstructive disease, and lung infections over time. Currently, there is no cure or treatment that targets the underlying cause of the disease in both the liver and the lung. Available treatments are aimed at transiently increasing levels of AAT in the blood but have no effect in the liver. Patients living with AATD typically experience recurring hospital visits and a shortened life expectancy.
We seek to develop medicines that treat the underlying cause of AATD throughout the body. We have discovered multiple small molecule correctors that restore folding of the mutant AAT protein, leading to increased production of functional AAT protein. The restoration of AAT protein folding in the liver and of systemic AAT function has the potential to benefit both the liver and lung diseases caused by AATD. In June 2021, we announced that we had achieved our primary endpoint and established proof of mechanism in a Phase 2 clinical trial evaluating our Z-AAT corrector, VX-864, for the treatment of people with AATD who have two copies of the Z mutation. However, because the magnitude of treatment effect was unlikely to translate into substantial clinical benefit, we decided not to advance VX-864 into late-stage development. We continue to discover and develop additional molecules with increased potential to correct AATD, and we plan to advance one or more novel small molecule Z-AAT correctors into the clinic in 2022.
Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1
DMD and DM1 are inherited diseases that result in the weakening and breakdown of skeletal muscles over time. In 2019, we acquired Exonics and expanded our collaboration with CRISPR establishing preclinical programs to develop gene-editing therapies for DMD and DM1. We are focused on advancing gene-editing therapies aimed at treating the underlying cause of

7

DMD by restoring expression of near-full length dystrophin protein, and in DM1, by addressing the repeat expansion that causes the disease. Our collaboration with Affinia Therapeutics, Inc., or Affinia, enables access to a novel library of AAV capsids to support our ongoing research and development efforts in genetic therapies, including DMD and DM1. We also are exploring potential small molecule approaches for DMD and DM1.

COMMERCIALIZATION OF OUR MEDICINES
Commercial Organization
Our commercial organization focuses on supporting the appropriate use of TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO in the markets where these products have been approved. Our sales and marketing organizations are responsible for promoting products to health care providers, ensuring our products are distributed effectively, and obtaining reimbursement for our products from third-party payors, including governmental organizations in the U.S. and ex-U.S. markets. In the U.S., we sell our products primarily to a limited number of specialty pharmacy and specialty distributors. In international markets, we sell our products primarily to specialty distributors and retail chains, as well as hospitals and clinics, many of which are government-owned or supported.
Our U.S. field-based CF commercial team is comprised of a small number of individuals to support commercialization of our medicines for CF. We focus our CF marketing efforts in the U.S. on a relatively small number of physicians and health care professionals who write most of the prescriptions for CF medicines. Many of these physicians and health care professionals are located at a limited number of accredited centers in the U.S. focused on the treatment of CF. In international markets, we have small sales forces that support KALYDECO, ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA/KAFTRIO in jurisdictions where these products are approved.
We market our products through personal interactions with physicians and allied health care professionals. In parallel, our government affairs and public policy group advocates for policies that promote life sciences innovation and increase awareness of the diseases on which we are focusing with state and federal legislatures, government agencies, public health officials and other policymakers. We also have established programs in the U.S. that provide our products to qualified uninsured or underinsured patients at no charge or at a reduced charge, based on specific eligibility criteria.
We continue to expand our commercial organization to prepare for launch readiness for future products from our pipeline programs and are focused on launch preparation activities for our CTX001 program, including building our teams focused on patient support, market access, and healthcare provider education, as well as those engaged in the coordination of treatment centers involved in the administration of CTX001.
Reimbursement
Sales of our products depend, to a large degree, on the extent to which our products will be reimbursed by third-party payors, such as government health programs, commercial insurance, and managed health care organizations. Increasingly, these third-party payors are becoming stricter in the ways they evaluate and reimburse medical products and services. Additionally, the containment of health care costs has become a priority of federal and state governments, and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could limit our revenues. Decisions by third-party payors to not cover a product could reduce physician usage of the product.
Our CF medicines are broadly reimbursed by third-party payors in the U.S., including the federal government. We participate in the Medicaid Drug Rebate program, Medicare, and other governmental pricing programs. Medicaid is a joint federal and state program that is administered by the states for low-income and disabled beneficiaries. Under the Medicaid Drug Rebate program, we are required to pay a rebate to each state Medicaid program for our covered outpatient drugs that are dispensed to Medicaid beneficiaries as a condition of having federal funds being made available to the states for our drugs. Medicaid rebates are based on pricing data reported by us on a monthly and quarterly basis to the Centers for Medicare & Medicaid Services, or CMS, the federal agency that administers the Medicaid and Medicare programs.
Any company that participates in the Medicaid Drug Rebate program also must participate in the 340B drug pricing program, or the 340B program, and the Federal Supply Schedule, or FSS, pricing program. The 340B program, which is

8

administered by the Health Resources and Services Administration, requires participating companies to agree to charge statutorily defined covered entities no more than the 340B “ceiling price” for our covered outpatient drugs. The 340B ceiling price is calculated using a statutory formula, which is based on pricing data calculated under the Medicaid Drug Rebate program. The FSS pricing program, which is administered by the Department of Veterans Affairs, or VA, also requires participating companies to extend discounted prices to the VA, Department of Defense, Coast Guard, and Public Health Service. Similar to the 340B program, FSS prices are calculated utilizing pricing data reported by us to the VA on a quarterly and annual basis.
The Medicare Part D program provides a voluntary prescription drug benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities, which provide coverage of outpatient prescription drugs such as our CF medicines. Unlike Medicare Part A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, including CF, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutics committee. U.S. government payment for some of the costs of prescription drugs may increase demand for products for which we receive marketing approval. However, any negotiated prices for our products covered by a Part D prescription drug plan likely will be lower than the prices we might otherwise obtain.
Private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. As a result, any reduction in payment that results from Part D reimbursement may result in a similar reduction in payments from non-governmental payors for our products. Additionally, private payors, including health maintenance organizations and pharmacy benefit managers in the U.S., are adopting more aggressive utilization management techniques and are increasingly requiring significant discounts and rebates from manufacturers as a condition to including products on formulary with favorable coverage and copayment/coinsurance. As a consequence, these payors may not cover or adequately reimburse for use of our products or may do so at levels that disadvantage them relative to competitive products.
The U.S. government has shown significant interest in implementing cost-containment programs for medicines and has enacted reforms at the state and federal level designed to, among other things, modify prescription drug reimbursement amounts and methodologies, and otherwise control health care costs. For example, the American Recovery and Reinvestment Act of 2009 provided funding for the federal government to compare the effectiveness of different treatments for the same illness. A plan for the research was to be developed by the Department of Health and Human Services, or HHS, the Agency for Healthcare Research and Quality and the National Institutes of Health, or NIH, and periodic reports on the status of the research and related expenditures were to be made to the U.S. Congress. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payors, it is not clear what effect, if any, the research will have on the sales of our products. In the future, it is possible that comparative effectiveness research demonstrating benefits of a competitor’s product could adversely affect the sales of our products. If third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis.
The Patient Protection and Affordable Care Act, or ACA, was enacted in March 2010 and was designed to expand coverage for the uninsured while at the same time containing overall health care costs. With regard to pharmaceutical products, among other things, the ACA was designed to expand and increase industry rebates for drugs covered under Medicaid programs, impose an annual fee on branded pharmaceutical manufacturers, subject biological products to potential competition by lower-cost biosimilars, and make changes to the coverage requirements under the Medicare Part D program. We anticipate that the U.S. government will continue to engage in activities seeking to address drug pricing and reimbursement.
In Europe and other foreign jurisdictions, the success of our products depends largely on obtaining and maintaining government reimbursement, because patients are unable to access prescription pharmaceutical products that are not reimbursed by their governments. In some countries, such as Germany, commercial sales of a new product may begin while pricing and reimbursement terms are under discussion. In other countries, a company must complete reimbursement negotiations prior to the commencement of commercial supply of the pharmaceutical product. The requirements governing drug pricing vary widely country-by-country and region-by-region. For example, the member states of the E.U. can restrict the range of drugs for which their national health insurance systems provide reimbursement and can control the prices of

9

prescription drugs. In addition, many ex-U.S. government payers require companies to provide health economic assessments of products, which are evaluated by government agencies set up for this purpose. A member state may approve a specific price for the drug or it may instead adopt a system of direct or indirect controls on the total amount of money that a company may receive for supply of a drug. Countries also may consider increasing mandatory discounts over time in an attempt to manage increased demands on healthcare budgets. Reimbursement discussions in foreign countries often result in a reimbursement price that is lower than the net price that companies can obtain for the product in the U.S. In addition, reimbursement discussions may take a significant period of time resulting in commercialization delays. Reimbursement for our products cannot be assured because a country or region may only provide for reimbursement on terms that we do not deem adequate.
We have obtained broad reimbursement for our CF medicines in ex-U.S. markets. TRIKAFTA/KAFTRIO is reimbursed or accessible in more than 20 countries outside the U.S. We expect to continue to focus significant resources to obtain expanded reimbursement for our CF medicines and pipeline therapies in ex-U.S. markets.

STRATEGIC TRANSACTIONS AND COLLABORATIONS
As part of our business strategy, we seek to license or acquire products, product candidates, businesses and other technologies that are aligned with our corporate and research and development strategies and complement and advance our ongoing research and development efforts. In addition, we establish business relationships with collaborators to support our research activities and to lead or support development and/or commercialization of certain product candidates. We expect to continue to identify and evaluate potential acquisitions, licenses and collaborations that may be similar or different from the transactions that we have engaged in previously.
Strategic Transactions
Semma Therapeutics
In 2019, we acquired Semma, a privately-held company focused on the use of stem cell-derived human islets as a potentially curative treatment for T1D, for approximately $950.0 million in cash. Our acquisition of Semma advanced our cell therapy capabilities and supports the development of transformative therapies for T1D. We are leveraging this platform to develop cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D, with the goal of delivering a potential functional cure.
Exonics Therapeutics
In 2019, we acquired Exonics, a privately held company focused on creating transformative gene-editing therapies to repair mutations that cause DMD and other severe neuromuscular diseases, including DM1. Our acquisition of Exonics enhanced our gene-editing capabilities and supports the potential development of novel therapies for DMD and DM1. In connection with the acquisition, we acquired all of the outstanding equity of Exonics for an upfront payment of approximately $245.0 million plus customary working capital adjustments in cash, and certain potential future payments based primarily upon the successful achievement of specified development and regulatory milestones for the DMD and DM1 programs.
Collaboration and Licensing Arrangements
Joint Development and Commercialization Agreement with CRISPR
In December 2017, we entered into a joint development and commercialization agreement, or Original JDCA, with CRISPR pursuant to which we are co-developing and preparing to co-commercialize CTX001 for TDT and SCD. We entered into the Original JDCA following our exercise of an option to co-develop and co-commercialize the hemoglobinopathies program that was contained in the collaboration agreement that we entered into with CRISPR in 2015.
In April 2021, we and CRISPR amended and restated the Original JDCA, or the A&R JDCA. Pursuant to the A&R JDCA, the parties agreed to, among other things, (a) adjust the governance structure for the collaboration and adjust the responsibilities of each party thereunder; (b) adjust the allocation of net profits and net losses between the parties; and (c) exclusively license (subject to CRISPR’s reserved rights to conduct certain activities) certain intellectual property rights to us relating to the products that may be researched, developed, manufactured and commercialized under such agreement.

10

Pursuant to the A&R JDCA, we lead global development, manufacturing and commercialization of CTX001, with support from CRISPR. Subject to the terms and conditions of the A&R JDCA, we have the right to conduct all research, development, manufacturing and commercialization activities relating to the product candidates and products under the A&R JDCA (including CTX001) throughout the world, subject to CRISPR’s reserved right to conduct certain activities.
In connection with the A&R JDCA, we made a $900.0 million upfront payment to CRISPR in the second quarter of 2021. CRISPR has the potential to receive an additional one-time $200.0 million milestone payment upon receipt of the first marketing approval of CTX001 from the FDA or the European Commission.
We and CRISPR shared equally all expenses incurred under the Original JDCA. On July 1, 2021, with respect to CTX001, the net profits and net losses incurred pursuant to the A&R JDCA began to be allocated 60% to us and 40% to CRISPR, while all other product candidates and products continued to have net profits and net losses shared equally between the parties.
Either party may terminate the A&R JDCA upon the other party’s material breach, subject to specified notice and cure provisions, or, in our case, in the event that CRISPR becomes subject to specified bankruptcy, winding up, or similar circumstances. Either party may terminate the A&R JDCA in the event the other party commences or participates in any action or proceeding challenging the validity or enforceability of any patent that is licensed to such challenging party pursuant to the A&R JDCA. We also have the right to terminate the A&R JDCA for convenience at any time after giving prior written notice. If circumstances arise pursuant to which a party would have the right to terminate the A&R JDCA on account of an uncured material breach, such party may elect to keep the A&R JDCA in effect and cause such breaching party to be treated as if it had exercised its opt-out rights with respect to the products associated with such uncured material breach and the royalties payable to the breaching party would be reduced by a specified percentage.
Either party may opt out of the development of a product candidate under the A&R JDCA after predetermined points in the development of the product candidate, on a candidate-by-candidate basis. In the event of such opt-out, the party opting-out will no longer share in the net profits and net losses associated with such product candidate and, instead, the opting out party will be entitled to high single to mid-teen percentage royalties on the net sales of such product, if commercialized.
In-License Agreements
We have entered into various agreements pursuant to which we have obtained access to technologies from third parties and are conducting research and development activities with collaborators. Pursuant to these arrangements, we have obtained development and commercialization rights to resulting product candidates. Depending on the terms of the arrangements, we may be responsible for the costs of research activities, required to make upfront payments and/or milestone payments upon the achievement of certain research, development, and commercial objectives, and/or pay royalties on future sales, if any, of commercial products resulting from the collaboration. Our current in-license agreements include:
•Affinia Therapeutics, Inc. In 2020, we entered into a collaboration with Affinia to gain access to a novel library of AAV capsids to support our ongoing research and development efforts in genetic therapies, including DMD, DM1, and CF.
•Arbor Biotechnologies, Inc. In 2018, we entered into a collaboration with Arbor Biotechnologies, or Arbor, pursuant to which we are focusing on the discovery of novel proteins, including DNA endonucleases, to advance the development of new gene-editing therapies. In 2021, we entered into a new collaboration with Arbor to enhance efforts in developing ex vivo engineered cell therapies for multiple serious diseases using Arbor’s proprietary CRISPR gene-editing technology.
•CRISPR Therapeutics AG. As described above, in 2015, we entered into a collaboration with CRISPR for the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR/Cas9 gene-editing technology. We are developing CTX001 for the treatment of SCD and beta thalassemia. In addition, we have exercised options to exclusively license treatments for specific targets, including CF, that were subject to the research program. In 2019, we obtained exclusive worldwide rights to CRISPR’s intellectual property for DMD and DM1 gene-editing products through a new agreement with CRISPR.

11

•Kymera Therapeutics, Inc. In 2019, we entered into a collaboration with Kymera Therapeutics for the research and development of small molecule protein degraders. Under the collaboration, Kymera Therapeutics conducts research activities in multiple targets, and upon designation of a clinical development candidate for a target, we have the option to exclusively license molecules against the target.
•Mammoth Biosciences, Inc. In 2021, we entered into a collaboration with Mammoth Biosciences, or Mammoth, to develop in vivo gene-editing therapies for two diseases using Mammoth’s next-generation CRISPR systems.
•Moderna, Inc. In 2016, we entered into a collaboration with Moderna, pursuant to which we are seeking to identify and develop mRNA therapeutics for the treatment of CF. In 2020, we entered into a new collaboration with Moderna aimed at the discovery and development of lipid nanoparticles and mRNAs that can deliver gene-editing therapies to lung cells for the treatment of CF.
•Obsidian Therapeutics, Inc. In 2021, we entered into a collaboration with Obsidian Therapeutics, or Obsidian, aimed at the discovery of novel therapies that regulate gene-editing for the treatment of serious diseases. This collaboration enables us to leverage Obsidian’s cytoDRiVE® platform technology to discover gene-editing medicines whose therapeutic activity can be precisely controlled using small molecules.
•Skyhawk Therapeutics, Inc. In 2020, we entered into a collaboration with Skyhawk Therapeutics for the discovery and development of novel small molecules that modulate RNA splicing for the treatment of serious diseases.
•Other Arrangements. In 2019, we entered into a collaboration with Ribometrix, Inc. In 2018, we entered into agreements with Genomics plc, Merck KGaA, Darmstadt, Germany, and X-Chem, Inc. in order to support our research and development efforts.
Out-license Agreements
We have entered into various agreements pursuant to which we have out-licensed rights to certain product candidates to third-party collaborators. Pursuant to these out-license arrangements, our collaborators are responsible for all costs related to the continued development of such product candidates and obtain development and commercialization rights to these product candidates. Depending on the terms of the arrangements, our collaborators may be required to make upfront payments, milestone payments upon the achievement of certain research and development objectives and/or pay royalties on future sales, if any, of commercial products licensed under the agreement. Our current out-license agreements include a Strategic Collaboration and License Agreement with Merck KGaA, Darmstadt, Germany, that we entered into in 2017, pursuant to which we granted an exclusive worldwide license to research, develop and commercialize four oncology research and development programs.
Cystic Fibrosis Foundation Therapeutics Incorporated
In 2004, we entered into a collaboration agreement with the Cystic Fibrosis Foundation, or CFF, as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc., to support research and development activities. Pursuant to the collaboration agreement, as amended, we have agreed to pay tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor) and royalties ranging from low-single digits to mid-single digits on potential net sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor. For combination products, such as ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA/KAFTRIO (elexacaftor, tezacaftor, and ivacaftor), sales are allocated equally to each of the active pharmaceutical ingredients in the combination product.

INTELLECTUAL PROPERTY
Patents and other proprietary rights such as trademarks, trade secrets, and copyrights are critical to our business. We actively seek protection for our products and proprietary information by means of U.S. and foreign patents, trademarks, and copyrights, as appropriate. In addition, we rely upon trade secret protection and contractual arrangements to protect certain of our proprietary information and products.
Patents provide a period of exclusivity that can make it more difficult for competitors to market and use our technology.

12

We own and control patents and pending patent applications that relate to compounds, formulations, treatment of diseases, synthetic routes, intermediates, and other inventions.
To protect our intellectual property, we typically apply for patents several years before a product receives marketing approval. Under current law, a patent expires 20 years from its first effective filing date. Since the drug development process may last for many years, there may be a period of time in which we have an issued patent but not marketing approval to sell the drug. To compensate for patent term lost while a product is in clinical trials and undergoing review for marketing approval, we may be able to apply for patent term extensions or supplementary protection certificates in some countries. In addition to patent protection, we have regulatory exclusivity from U.S. and European regulatory agencies for the active pharmaceutical agents and, where applicable, their approved orphan indications for a certain time period. Regulatory exclusivity runs concurrently with patent exclusivity and provides complementary protection.
We own or hold exclusive and non-exclusive licenses to several hundred patents in the U.S. Upon approval of a New Drug Application, or NDA, or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant’s product or a method of using the product. Each of the patents listed by the NDA sponsor is published in the FDA’s Orange Book. We have ten issued U.S. patents listed in the Orange Book that cover the active pharmaceutical ingredients in KALYDECO, its marketed formulations, and/or its approved indication. We have 20 issued U.S. patents listed in the Orange Book that cover the active pharmaceutical ingredients in ORKAMBI, its marketed formulations, and/or its approved indication. We have 21 issued U.S. patents listed in the Orange Book that cover the active pharmaceutical ingredients in SYMDEKO, its marketed formulation, and/or its approved indication. We have 22 issued U.S. patents listed in the Orange Book that cover the active pharmaceutical ingredients in TRIKAFTA, its marketed formulation, and/or its approved indication.
The table below sets forth the year of projected expiration for the basic product patents covering each of our approved products. For products that are combinations of two or more active ingredients, the table lists the projected expiration of the latest expiring patent covering any of the active pharmaceutical ingredients (lumacaftor for ORKAMBI, tezacaftor for SYMDEKO/SYMKEVI and elexacaftor for TRIKAFTA/KAFTRIO). Patent term extensions, supplementary protection certificates, and pediatric exclusivity periods are not reflected in the expiration dates listed in the table below and may extend protection. In some instances, we also own later-expiring patents and applications relating to solid forms, formulations, methods of manufacture, or the use of these drugs in the treatment of particular diseases or conditions. In some cases, however, such patents may not protect our drug from generic competition after the expiration of the basic patent.
ProductProjected Expiration
of U.S. Patent		Projected Expiration
of European Patent
KALYDECO
2027
  2025 1
ORKAMBI
2030
  2026 2
SYMDEKO/SYMKEVI
2027
  2028 3
TRIKAFTA/KAFTRIO
2037
2037
1 Certain European countries have granted supplementary protection certificates for KALYDECO, which expire in 2027.
2 Certain European countries have granted supplementary protection certificates for ORKAMBI, which expire in 2030.
3 Certain European countries have granted supplementary protection certificates for SYMKEVI, which expire in 2033.
In addition to protecting our marketed products, we actively monitor and file patent applications in the U.S. and in foreign countries on inventions relating to our pipeline. For example, we also own and/or control U.S. and foreign patents and/or patent applications relating to the following:
•CTX001 and other potential gene-editing approaches for treating hemoglobinopathies.
•VX-147 and other compounds being studied for the potential treatment of APOL1-mediated kidney disease.
•VX-121, VX-561, and other CF potentiators and correctors and many other related compounds, and the use of those compounds to treat CF.
•VX-548 and other compounds being studied for the potential treatment of pain.
•VX-880 and other cell-based approaches for treating T1D.

13

•Other pre-clinical and clinical candidates and the use of such candidates to treat specified diseases.
•The manufacture, pharmaceutical compositions, related solid forms, formulations, dosing regimens, and methods of use of many of the above compounds.
We and CRISPR intend to rely upon a combination of rights, including patent rights, trade secret protection, and regulatory exclusivities to protect CTX001. CRISPR has licensed certain rights to a worldwide patent portfolio that covers various aspects of the CRISPR/Cas9 editing platform technology including, for example, compositions of matter and methods of use, including their use in targeting or cutting DNA, from Dr. Emmanuelle Charpentier. In addition to Dr. Charpentier, this patent portfolio has named inventors who assigned their rights to the Regents of the University of California or the University of Vienna, to whom we refer, together with Dr. Charpentier, as the CVC Group. CRISPR has non-exclusive or co-exclusive rights to the patent rights that protect the core CRISPR/Cas9 gene-editing technology. For example, certain third parties, including competitors, have reported obtaining a license to rights in this patent portfolio in certain fields. In addition, patents and patent applications in this patent portfolio are the subject of proceedings in the U.S., Europe, and other jurisdictions, including proceedings in the U.S. Patent and Trademark Office, or USPTO, between the CVC Group and (separately) the Broad Institute, Sigma-Aldrich, Co. LLC, or Sigma-Aldrich, and ToolGen, Inc., or ToolGen. To date, both the CVC Group and the Broad Institute have obtained granted patents that purport to cover aspects of CRISPR/Cas9 editing platform technology. The patents and patent applications within the patent portfolios of the CVC Group, the Broad Institute, Sigma-Aldrich and/or ToolGen are, or may in the future be, involved in proceedings similar to interferences or priority disputes in Europe or other foreign jurisdictions. In addition to the patent portfolio licensed from Dr. Charpentier, we own patent applications relating to the composition, manufacture, and use of CTX001.
From time to time, we enter into exclusive and non-exclusive license agreements for proprietary third-party technology used in connection with our research activities. These license agreements typically provide for the payment by us of a license fee but may also include terms providing for milestone payments or royalties for the development and/or commercialization of our drug products arising from the related research.
We cannot be certain that issued patents we own or license will be enforceable or provide adequate protection or that pending patent applications will result in issued patents. The existence of patents does not guarantee our right to practice the patented technology or commercialize the patented product. Litigation, interferences, oppositions, inter partes reviews, administrative challenges or other similar types of proceedings may be necessary in some instances to determine the validity and scope of certain patents, regulatory exclusivities or other proprietary rights, and in other instances to determine the validity, scope or non-infringement of intellectual property rights that may be claimed by third parties to be pertinent to the manufacture, use or sale of our products.

MANUFACTURING
As we market and sell our approved products and advance our product candidates through clinical development toward commercialization, we continue to build and maintain our supply chain and quality assurance resources. We rely on internal capabilities and a global network of third parties to manufacture and distribute our product candidates for clinical trials, as well as our products for commercial sale and post-approval clinical trials. In addition to establishing supply chains for each new approved product, we must adapt our supply chain for existing products to include additional formulations that are often required in order to treat younger patients or to increase scale of production for existing products. We are focused on ensuring the stability of the supply chains for our current products, including TRIKAFTA/KAFTRIO, and for our pipeline programs. In addition, we are focused on identifying and ensuring efficient manufacturing and delivery processes for the cell and genetic therapies we are developing.
We have established our own manufacturing capabilities in Boston, which we use for clinical trial and commercial supplies, including our commercial supply of TRIKAFTA/KAFTRIO, and are evaluating additional manufacturing capacity for our current and future products. We expect that we will continue to rely on third parties to meet our commercial supply needs, including for TRIKAFTA/KAFTRIO, and a significant portion of our clinical supply needs for the foreseeable future. 
Our supply chain for sourcing raw materials and manufacturing our products, including obtaining all necessary supplies, is a multi-step global endeavor. In general, these raw materials and other necessary supplies are available from multiple sources. Third-party contract manufacturers, including some in China, perform different parts of our manufacturing process. Contract manufacturers may supply us with raw materials, convert these raw materials into drug substance and/or

14

convert the drug substance or product into final dosage form. In addition, third parties assist us with packaging, warehousing, and global distribution of our products.
Establishing and managing this global supply chain for each of our products and product candidates requires a significant financial commitment and the creation and maintenance of numerous third-party contractual relationships. In order to manufacture our commercial products, we utilize both continuous manufacturing technology as well as batch manufacturing processes. While continuous process manufacturing has been used in many industries, we believe that we are the first company to obtain FDA approval for a fully-continuous drug product manufacturing process. We have a limited number of critical steps in our manufacturing process that are single sourced, including for recently launched products. To ensure the stability of our supply chains, we continue to develop alternatives for our manufacturing processes.
We have developed systems and processes to track, monitor, and oversee our and our third-party manufacturers’ activities, including a quality assurance program intended to ensure that our third-party manufacturers comply with current Good Manufacturing Practices, or cGMP. We devote substantial time, money and effort in the areas of production, quality control, and quality assurance to maintain cGMP compliance. We regularly evaluate the performance of our third-party manufacturers with the objective of confirming their continuing capabilities to meet our needs efficiently and economically. Manufacturing facilities, both foreign and domestic, are subject to inspections by or under the authority of the FDA and other U.S. and foreign government authorities. Although we actively engage with regulatory authorities, the timing of inspections and regulatory approvals for each of these facilities may be delayed for a number of reasons, including the COVID-19 pandemic.
The manufacturing processes for cell and genetic therapies are more complex than those required for small molecule drugs and require different systems, equipment, facilities, and expertise. Additionally, we are unable to utilize a single process for all of our cell and genetic therapies; they must be customized for each program and therapy. We are investing and plan to continue to invest significant resources in expanding and strengthening our manufacturing supplies, infrastructure and capabilities, independently and through third-party networks, in an effort to develop and commercialize our cell and genetic therapies. We are focused on identifying, evaluating and securing relationships with various third parties globally that will enable us to expand and strengthen such capabilities to support our current and future cell and genetic therapy programs, including CTX001.
We rely on third-party manufacturers to produce or process cell culture reagents, gene-editing components, such as Cas9 protein and guide RNA molecules, and to generate gene-edited cells to supply CTX001 for clinical trials. If approved, we expect to continue to rely on third-party manufacturers for commercial supply of CTX001. The manufacturing process for CTX001 involves a number of steps prior to the final infusion of drug product into patients. Following mobilization and collection of blood cells from the patient at the clinical site, cells are transferred to a manufacturing site where HSPCs are purified and CRISPR/Cas9 gene-editing is performed. The edited cellular product, called CTX001, is frozen and transported back to the clinical site where it is stored prior to infusion into the patient. Each step must be completed successfully, and in a timely manner, requiring coordination between us, clinical sites, third-party manufacturers and shipping vendors. To increase production to commercial levels, we are making significant investments to coordinate manufacturing and logistics activities at a larger scale across multiple facilities to serve the geographies in which we plan to seek approval for CTX001. In addition to clinical data establishing the safety and efficacy of CTX001, approval of CTX001 will require regulatory approval of the processes and facilities used to manufacture CTX001.

COMPETITION
The pharmaceutical industry is characterized by extensive research efforts, rapid technological progress, and intense competition. There are many public and private companies, including pharmaceutical companies and biotechnology companies, engaged in developing products for the indications our drugs are approved to treat and the therapeutic areas we are targeting with our research and development activities. Potential competitors also include academic institutions, government agencies, other public and private research organizations and charitable venture philanthropy organizations that conduct research, seek patent protection and/or establish collaborative arrangements for research, development, manufacturing and commercialization. Mergers and acquisitions in the pharmaceutical, biotechnology and gene therapy industries may result in a larger concentration of resources among a smaller number of our competitors. Some of our competitors may have substantially greater financial, technical, marketing and human resources than we do.
We believe that competition in our industry is based on, among other factors, innovative research, the effective and rapid

15

development of product candidates, the ability to market and obtain reimbursement for products and the ability to establish effective patent protection. We face competition based on the safety and efficacy of our product and product candidates, the timing and scope of regulatory approvals, the availability and cost of supply, marketing and sales capabilities, reimbursement coverage, price, patent protection and other factors. Our competitors may develop or commercialize more effective, safer or more affordable products than we are able to develop or commercialize or obtain more effective patent protection. As a result, our competitors may commercialize products more rapidly or effectively than we do, which would adversely affect our competitive position, the likelihood that our product candidates, if approved, would achieve and maintain market acceptance and our ability to generate meaningful revenues from our products. Future competitive products may render our products, or future products, obsolete or noncompetitive. Another key element of remaining competitive in our industry is recruiting and retaining leading scientific, technical and management personnel to conduct our research activities and advance our development programs, including with the commercial expertise to effectively market our products.
Cystic Fibrosis
A number of companies are seeking to identify and develop product candidates for the treatment of CF, including CFTR modulators and other therapies intended to address the underlying causes of CF.
AbbVie, Inc., or AbbVie, has indicated that it plans to develop a triple combination CFTR modulator therapy comprised of a potentiator and correctors. AbbVie has been conducting a dose-ranging study of a potentiator and corrector and a separate proof of concept study for a combination of their potentiator and correctors, and is expected to announce data in 2022. Proteostasis Therapeutics, Inc. was developing potential CFTR modulator therapies prior to its acquisition by Yumanity Therapeutics, Inc., or Yumanity. Following the merger, Yumanity out-licensed the CF program.
Other therapeutic approaches include addressing CF utilizing nucleic acid therapies and read-through agents, which are compounds that allow expression of a full-length protein. Nucleic acid therapies are under development by companies such as Arcturus Therapeutics Holdings, Inc., ReCode Therapeutics, Inc., Krystal Biotech, Inc., Spirovant Sciences, Inc. and 4D Molecular Therapeutics, Inc. Eloxx Pharmaceuticals, Inc. is evaluating a read-through therapy for nonsense CFTR mutations in two Phase 2 clinical trials and is planning additional trials to evaluate this therapy in combination with CFTR modulators.
Our success in rapidly developing and commercializing our products may increase the resources that our competitors allocate to the development of these potential treatments for CF. In addition, clinical trials conducted by our competitors could take place simultaneously with our own trials, and may slow down our pace of development if we are unable to recruit sufficient clinical trial subjects. If one or more competing therapies are successfully developed as a treatment for people with CF, our revenues from our current products and/or additional CF products, if then approved, could face significant competitive pressure.
Pipeline
In recent years, we have committed significant research resources to, and made significant investments in, our pipeline of potential new therapies for SCD, TDT, AMKD, T1D, pain, AATD, muscular dystrophies, and other diseases.
Sickle Cell and Beta Thalassemia
There are multiple approved treatments for SCD and beta thalassemia, including products from Novartis International AG, or Novartis, Global Blood Therapeutics, Inc. and Bristol Myers Squibb together with Acceleron Pharma, Inc., recently acquired by Merck & Co. In addition, Bluebird Bio, Inc., or Bluebird, has a gene therapy, Zynteglo (betibeglogene autotemcel) that has a conditional marketing authorization from the EMA for the treatment of certain beta thalassemia genotypes and is under FDA review in the U.S. Bluebird has indicated it anticipates withdrawing marketing authorizations for Zynteglo from both the E.U. and U.K. by early 2022. Bluebird is also developing a gene therapy program for SCD.  In addition, various companies and private academic/medical institutes are developing gene therapy or gene-editing candidates for the treatment of SCD or beta thalassemia utilizing CRISPR technology, lenti-viral vectors, zinc finger nuclease technology, or base editing.
Additional Programs
Certain of our other product candidates face competition from many pharmaceutical and biotechnology companies. For example, we are aware of other pharmaceutical and biotechnology companies actively engaged in the research and development of products for T1D, including insulin injections, pumps, and hybrid closed loop systems. People living with

16

T1D have had access to insulin as a treatment option for a century, providing for a very well entrenched standard of care. Several other companies are investing in additional approaches as a potential treatment for T1D including dual-hormonal closed loop systems, cell and gene therapies, and immunotherapies.
In acute pain, the market is dominated by conventional analgesics (e.g., opioids, non-steroidal anti-inflammatory drugs, acetaminophen and local anesthetics), low-cost generics, and reformulations aiming to provide safer, more tolerable and/or more convenient therapies. However, several companies are pursuing clinical development on novel mechanisms of action for pain indications, including some that are in early stages, targeting the sodium channels in the NaV family.
Many other pharmaceutical and biotechnology companies are investing resources for the discovery and development of small molecules and cell and gene therapies to treat the same disease areas for which we are developing therapies in our pipeline. If any of these competitors develop or successfully commercialize products involving therapies competitive with our pipeline therapies, the potential return on our investment in those pipeline therapies could be impacted.

GOVERNMENT REGULATION
Our operations and activities are subject to extensive regulation by numerous government authorities in the U.S., the E.U. and other countries. In the U.S., the E.U. and other countries, our products are subject to rigorous regulations governing their testing, manufacture, labeling, storage, record keeping, approval, and advertising and promotion. As a result of these regulations, product development and product approval processes are very expensive and time consuming. The regulatory requirements applicable to drug and biologic development, approval, and marketing are subject to change. In addition, regulations and administrative guidance often are revised or reinterpreted by the agencies in ways that may significantly affect our business and our products. It is impossible to predict whether legislative changes will be enacted, or FDA or comparable ex-U.S. regulations, guidance or interpretations will change.
United States Government Regulation
New Drug Application and Biologics License Application Approval Processes
The process required by the FDA before a drug or biologic may be marketed in the U.S. generally involves the following:
•    completion of preclinical laboratory tests, animal studies and formulation studies conducted according to Good Laboratory Practices, or GLP, and other applicable regulations;
•    submission to the FDA of an IND, which must become effective before clinical trials in the U.S. may begin;
•    performance of adequate and well-controlled clinical trials according to Good Clinical Practices, or GCP, and other clinical trial-related regulations to establish the safety and efficacy of the proposed drug for its intended use;
•    submission to the FDA of an NDA or a Biologics License Application, or BLA;
•    satisfactory completion of a pre-approval FDA inspection of the manufacturing facility or facilities at which the product will be produced to assess compliance with cGMP; and
•    FDA review and approval of the NDA or BLA.
Once a drug or biologic is identified for development, it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal pharmacology and toxicology studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND, which seeks FDA approval to test the drug or biologic in humans. Preclinical or nonclinical testing typically continues even after the IND is submitted.
If the FDA accepts the IND, the drug or biologic can then be studied in human clinical trials to determine if the product candidate is safe and effective. Clinical trials involve three separate phases that often overlap, can take many years and are expensive. These three phases, which are subject to considerable regulation, are as follows:

17

•    Phase 1. The drug or biologic initially is introduced into a limited number of healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution and elimination. In the case of some drugs or biologics for severe or life-threatening diseases, such as cancer, especially when the drug or biologic may be inherently too toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.
•    Phase 2. Clinical trials are next initiated in a limited patient population with the specified disease or condition the drug or biologic is intended to treat in order to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the drug or biologic candidate for the disease or condition it is intended to treat and to determine dosage tolerance and optimal dosage.
•    Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk-benefit ratio of the drug or biologic and provide an adequate basis for regulatory approval and product labeling.
It is possible that Phase 1, Phase 2 and Phase 3 testing may not be completed successfully within any specified period, if at all. The FDA or the sponsor may, at any time during the initial 30-day IND review period or while clinical trials are ongoing under the IND, impose a partial or complete clinical hold or suspend a clinical trial at any time for a variety of reasons, including a finding that the healthy volunteers or patients are being exposed to an unacceptable health risk. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently in other situations, and the occurrence of serious adverse events must also be reported. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health for public dissemination on the www.clinicaltrials.gov website.
Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and are commonly intended to generate additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA or BLA.
The results of drug or biologic development, preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug or biologic, proposed labeling and other relevant information are submitted to the FDA as part of an NDA or BLA requesting approval to market the drug or biologic. The FDA reviews each NDA or BLA submitted to ensure that it is sufficiently complete for substantive review before it accepts it for filing. It may request additional information rather than accept an NDA or BLA for filing.
Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA reviews an NDA or BLA to determine, among other things, whether a drug or biologic is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the drug or biologic’s identity, strength, quality and purity. The FDA may refer the NDA or BLA to an advisory committee for review and recommendation as to whether the NDA or BLA should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving an NDA or BLA, the FDA will inspect the facility or facilities where the drug or biologic is manufactured and tested. Additionally, before approving an NDA or BLA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.
The FDA may require, as a condition of approval, restricted distribution and use, enhanced labeling, special packaging or labeling, expedited reporting of certain adverse events, pre-approval of promotional materials, restrictions on direct-to-consumer advertising or commitments to conduct additional research post-approval. The FDA will issue a complete response letter if the agency decides not to approve the NDA or BLA in its present form.
Expedited Review and Approval
The FDA has developed a number of distinct approaches to make new drugs or biologics available as rapidly as possible in cases where there is no available treatment or there are advantages over existing treatments.
The FDA may grant “accelerated approval” to products that have been studied for their safety and effectiveness in treating serious illnesses and that provide meaningful therapeutic benefit to patients over existing treatments. For accelerated approval, the product must have an effect on a surrogate endpoint or an intermediate clinical endpoint that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on irreversible morbidity and mortality. When

18

approval is based on surrogate endpoints or clinical endpoints other than survival or morbidity, the sponsor will be required to conduct additional post-approval clinical studies to verify and describe the clinical benefit. These studies are known as “confirmatory trials.” Approval of a drug may be withdrawn, or the labeled indication of the drug changed if these trials fail to verify clinical benefit or do not demonstrate sufficient clinical benefit to justify the risks associated with the drug or biologic.
The FDA may grant “fast track” status to products that treat serious diseases or conditions and demonstrate the potential to address an unmet medical need. Fast track is a process designed to facilitate the development and expedite the review of such products by providing, among other things, more frequent meetings with the FDA to discuss the product’s development plan and rolling review, which allows submission of individually completed sections of an NDA or BLA for FDA review before the entire submission is completed. Fast track status does not ensure that a product will be developed more quickly or receive FDA approval.
“Breakthrough Therapy” designation is a process designed to expedite the development and review of drugs or biologics that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over available therapy on one or more clinically significant endpoints. Breakthrough Therapy designation provides all of the benefits of fast track designation in addition to robust FDA-sponsor interaction and communication to help to identify the most efficient and expeditious path for clinical development while minimizing the number of patients placed in ineffective control regimens.
“Regenerative Medicine Advanced Therapy,” or RMAT, designation is a process created by the 21st Century Cures Act in December 2016. A product is eligible for RMAT designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious disease or condition, and if preliminary clinical evidence indicates that the product has the potential to address unmet medical needs for such disease or condition. The benefits of RMAT designation include the benefits available to breakthrough therapies, including potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints.
The FDA may grant “priority review” status to a product that, if approved, would provide significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions. Priority review is intended to reduce the time it takes for the FDA to review an NDA or BLA, with the goal to take action on the application within six months from when the application is filed, compared to ten months for a standard review.
Manufacturing Quality Control
Among the conditions for NDA or BLA approval is the requirement that the prospective manufacturer’s quality control and manufacturing procedures continually conform with cGMP. Manufacturers must devote substantial time, money and effort in the areas of production, quality control, and quality assurance to maintain cGMP compliance. Material changes in manufacturing equipment, location, or process, may result in additional regulatory review and approval. The FDA, and other regulatory agencies, conduct periodic visits to inspect equipment, facilities, and processes following the initial approval of a product. If a manufacturing facility is not in substantial compliance with the applicable regulations and requirements imposed when the product was approved, regulatory or judicial enforcement action may be initiated, which may include a warning letter, suspension of manufacturing, product seizure, or an injunction against shipment of products from the facility and/or recall of products previously shipped. We rely, and expect to continue to rely, on third parties for the production of our products. Future FDA, state, and foreign inspections may identify compliance issues at the facilities of our contract manufacturers that may disrupt manufacture or distribution of our products or require substantial resources to correct.
Post-approval Requirements
Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product may result in restrictions on the product or complete withdrawal of the product from the market. In addition, under the FDCA the sponsor of an approved drug in the U.S. may not promote that drug for unapproved, or off-label, uses, although a physician may prescribe a drug for an off-label use in accordance with the practice of medicine. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Further, after approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further FDA review and approval. In addition, the FDA may require testing, including Phase 4 trials, and surveillance programs to monitor the effect of approved products that have been commercialized, and the FDA has the

19

power to prevent or limit further marketing of a product based on the results of these post-marketing programs.
Products we manufacture or distribute pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things:
•    record-keeping requirements;
•    reporting of adverse experiences with the product;
•    providing the FDA with updated safety and efficacy information;
•    drug sampling and distribution requirements;
•    notifying the FDA and gaining its approval of specified manufacturing or labeling changes;
•    complying with certain electronic records and signature requirements; and
•    complying with FDA promotion and advertising requirements.
Failure to comply with the applicable U.S. requirements at any time during the drug or biologic development process, approval process or after approval, may subject us or our collaborators to administrative or judicial sanctions, any of which could have a material adverse effect on us. These sanctions could include:
•    restrictions on marketing or manufacturing of the product;
•    safety alerts, Dear Healthcare Provider letters, press releases, or other communications containing warnings or other safety information about the product;
•    refusal to approve or delay in review of pending applications;
•    withdrawal of an approval or the implementation of limitations on a previously approved indication for use;
•    imposition of a clinical hold, a risk mitigation and evaluation strategy, or REMS, or other safety-related limitations;
•    warning letters or “untitled letters”;
•    product seizures, recalls, or detentions, or refusal to permit the import or export of products;
•    total or partial suspension of production or distribution;
•    consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; or
•    injunctions, fines, disgorgement, refusals of government contracts, or civil or criminal penalties.
United States Patent Term Restoration and Regulatory Exclusivity
Upon approval, products may be entitled to certain kinds of exclusivity under applicable intellectual property and regulatory regimes. The Drug Price Competition and Patent Term Restoration Act of 1984 (commonly known as the Hatch-Waxman Act) permits a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. The length of the patent extension is roughly based on 50 percent of the period of time from the filing of an IND for a compound to the submission of the NDA for such compound, plus 100 percent of the time period from NDA submission to regulatory approval. The extension, however, cannot exceed five years and the patent term remaining after regulatory approval cannot exceed 14 years.
If the FDA approves a drug product that contains a new chemical entity not previously approved, the product is typically entitled to five years of non-patent regulatory exclusivity. Other products may be entitled to three years of exclusivity if approval was based on the FDA’s reliance on new clinical studies essential to approval submitted by the NDA applicant.
Biologics are also entitled to exclusivity under the Biologics Price Competition and Innovation Act, or the BPCIA, which was passed as Title VII to the ACA. The law provides a pathway for approval of products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, a reference biological product is

20

granted 12 years of data exclusivity, the period of time during which an innovator’s clinical data cannot be used by other companies, from the time of first licensure of the product, and an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed “interchangeable” by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. Biologics are also eligible for orphan drug exclusivity, as discussed below. The law also includes an extensive process for the innovator biologic and biosimilar manufacturer to litigate patent infringement, validity, and enforceability prior to the approval of the biosimilar. There have been ongoing federal legislative and administrative efforts as well as judicial challenges seeking to repeal, modify or invalidate some or all of the provisions of the ACA. While none of those efforts have focused on changes to the provisions of the ACA related to the biosimilar regulatory framework, if the ACA is repealed, substantially modified, or invalidated, it is unclear what, if any, impact such action would have on biosimilar regulation.
If the NDA or BLA applicant studies the product for use by children, the FDA may grant pediatric exclusivity, which extends by 180 days each existing exclusivity (patent and regulatory) related to the product.
Orphan Drug Designation and Exclusivity
Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs or biologics intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 people in the U.S.
If a drug or biologic that has orphan drug designation subsequently receives the first FDA approval for that drug or biologic for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years following marketing approval, except in certain very limited circumstances, such as if the later product is shown to be clinically superior to the orphan product. Orphan drug exclusivity, however, also could block the approval of our drugs or biologics for seven years if a competitor first obtains approval of the same product as defined by the FDA or if our drug or biologic is determined to be contained within the competitor’s product for the same indication or disease. KALYDECO, ORKAMBI, SYMDEKO, and TRIKAFTA have been granted orphan drug exclusivity by the FDA.
Foreign Regulation
We conduct clinical trials and market our products in numerous jurisdictions outside the U.S. Most of these jurisdictions have clinical trial, product approval and post-approval regulatory processes that are similar in principle to those in the U.S. Thus, whether or not we obtain FDA approval for a product candidate, we must obtain approval by the comparable regulatory authorities of foreign countries or economic areas, such as the E.U., before we can commence clinical trials or market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.
Under the E.U. regulatory system, a company may submit marketing authorization applications either under a centralized or decentralized procedure. The centralized procedure, which is compulsory for orphan medicines, medicines produced by biotechnology, and those medicines intended to treat AIDS, cancer, neurodegenerative disorders, or diabetes, and optional for those medicines that are highly innovative, provides for the grant of a single marketing authorization that is valid for all E.U. member states. In addition to the centralized procedure, the E.U. also has a nationalized procedure, which requires a separate application to and approval determination by each country; a decentralized procedure, whereby applicants submit identical applications to several countries and receive simultaneous approval; and a mutual recognition procedure, where applicants submit an application to one country for review and other countries may accept or reject the initial decision.
Other Regulations
Pharmaceutical companies are also subject to various laws pertaining to healthcare “fraud and abuse,” including the federal Anti-Kickback Statute, or AKS, the False Claims Act, or FCA, and other state and federal laws and regulations. In the U.S., the Anti-Kickback Statute generally makes it illegal to knowingly and willfully solicit, offer, receive or pay any remuneration in return for or to induce the referral of business, including the purchase or prescription of a particular drug that is reimbursed by a state or federal health care program. The FCA prohibits knowingly and willingly presenting, or causing to

21

be presented for payment to third-party payors (including Medicare and Medicaid), any claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed or claims for medically unnecessary items or services. Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including fines and civil monetary penalties, as well as by the possibility of exclusion from federal healthcare programs (including Medicare and Medicaid). Liability under the FCA may also arise when a violation of certain laws or regulations related to the underlying products (e.g., violations regarding improper promotional activity, manufacturing regulations, or unlawful payments) contributes to the submission of a false claim. If we were subject to allegations concerning, or convicted of violating, these laws, our business could be harmed.
Laws and regulations also have been enacted by the federal government and various states to regulate the sales and marketing practices of pharmaceutical manufacturers. The laws and regulations generally limit financial interactions between manufacturers and health care providers, require manufacturers to adopt certain compliance standards or require disclosure to the government and public of such interactions. The laws include U.S. federal and state “sunshine” provisions. The federal sunshine provisions apply to pharmaceutical manufacturers with products reimbursed under certain government programs and require those manufacturers to disclose annually to the federal government (for re-disclosure to the public) certain payments and other transfers of value made to physicians and teaching hospitals and, beginning with disclosures in 2022, to certain non-physician practitioners. State laws may also require disclosure of pharmaceutical pricing information and marketing expenditures. Many of these laws and regulations contain requirements that are subject to interpretation. Outside the U.S., other countries have implemented requirements for disclosure of financial interactions with healthcare providers and additional countries may consider or implement such laws.
We are subject to various federal and foreign laws that govern our international business practices with respect to payments to government officials. Those laws include the U.S. Foreign Corrupt Practices Act, or FCPA, which prohibits U.S. companies and their representatives from paying, offering to pay, promising, or authorizing the payment of anything of value to any foreign government official, government staff member, political party, or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA’s definition of a foreign government official. We are also subject to U.K. Bribery Act 2010, or the Bribery Act, which proscribes giving and receiving bribes in the public and private sectors, bribing a foreign public official, and failing to have adequate procedures to prevent employees and other agents from giving bribes. U.S. companies that conduct business in the U.K. generally will be subject to the Bribery Act.
We are subject to federal laws, including the Medicaid Drug Rebate Program, the 340 program, and the FSS pricing program, that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs.
Our collection and use of personal data as part of our business activities is subject to various privacy and data security laws and regulations, including oversight by various regulatory or other governmental bodies, in the U.S., E.U., U.K., Canada, Australia, Brazil and other jurisdictions. Such laws and regulations have the potential to affect our business materially, continue to evolve and increasingly are being enforced.
Our present and future business has been and will continue to be subject to various other laws and regulations. Various laws, regulations, and recommendations relating to safe working conditions, laboratory practices, the experimental use of animals, and the purchase, storage, movement, import, export and use and disposal of hazardous or potentially hazardous substances are or may be applicable to our activities. In addition, as we expand our pipeline and contemplate different approaches that may incorporate the use of medical devices, such approaches may necessitate compliance with regulatory laws applicable to medical devices, including those governing the testing, manufacture, approval, distribution, and marketing of medical devices. Furthermore, the extent of government regulation, which might result from future legislation or administrative action, cannot accurately be predicted.
We have a global corporate compliance program designed to actively identify, prevent, and mitigate healthcare fraud and abuse risk through, among other things, the implementation of compliance policies and systems and through the promotion of a culture of compliance. We will continue to devote substantial resources to enhance and expand our corporate compliance program as necessary to help us manage and mitigate our evolving compliance risk environment as our business grows and expands globally. Even with these measures, however, we cannot guarantee compliance with the various complex laws and regulations to which we are subject now or in the future.

22


EMPLOYEES AND HUMAN CAPITAL MANAGEMENT
As of December 31, 2021, we had approximately 3,900 employees. Of these employees, approximately 3,100 were based in the U.S. and approximately 800 were based outside the U.S. None of our U.S. employees are covered by a collective bargaining agreement. A small number of employees outside the U.S. are covered by such agreements due to local law or industry requirements. We consider our relations with our employees to be good. We face intense competition for our personnel from our competitors and other companies throughout our industry and from universities and research institutions. Over the last several years, the challenges in recruiting and retaining employees across the biotechnology industry have increased substantially due to current industry job market dynamics.
We rely on skilled, experienced, and innovative employees to conduct the operations of our company. The biotechnology industry is very competitive, and recruiting and retaining such employees is important to the continued success of our business. We are committed to building an outstanding, committed, and passionate team at Vertex, and we focus on a culture that values inclusion, diversity, and equity. We believe that each employee brings unique perspectives and strengths, and by embracing these strengths, we can do our best work for patients. We focus on recruiting, retaining, and developing employees from a diverse range of backgrounds to conduct our research, development, commercial, and other business activities.
Our commitment to inclusion, diversity, and equity begins with our executive management team: five of the ten members are women and/or from diverse ethnic and racial minorities. On our Board of Directors, four of our ten members (40%) are women and four members (40%) are ethnic and racial minorities. As of December 31, 2021, women represented 54% of our global workforce and 41% of our leadership (VP and above). As of December 31, 2021, 36% of our U.S. workforce, and 19% of our U.S. leadership (VP and above), were ethnic and racial minorities.
Our inclusion, diversity, and equity strategy and efforts are led by a Vice President in Human Resources. Our initiatives include learning, resources, and forums that activate inclusion, diversity, and equity in our workplaces; efforts to develop a diverse pipeline of talent from early career through leadership; four global employee resource networks that promote connectivity and collaboration across levels and functions, and engage colleagues in personal and professional development opportunities, including mentoring, community outreach, and cultural awareness activities; and investments to fight racism and social injustice.
To promote our employees’ continued well-being and development, we offer a variety of inclusive benefits and opportunities. We offer comprehensive work-life benefits, including health, dental, and income protection, such as life insurance and retirement savings programs. In 2021, we continued to enhance and expand our employee benefits in response to the COVID-19 pandemic. For example, we increased company-wide personal time off, provided resources to enable employees to work from home, continued to promote and expand mental wellness tools, and enhanced child/elder care benefits for all employees. We continually review and augment our programs to include benefits such as expanded parental bonding and increased support for family planning. We have also expanded our gender affirming benefits. Our management has continued to assess and respond to the evolving needs of our workforce throughout the pandemic.
In addition, we provide our employees with career development and advancement opportunities, including job rotations, mentoring, and managerial training. We also are committed to identifying and developing our next generation leaders and have developed programs focused on talent and succession for critical roles in our organization.

OTHER MATTERS
Financial Information and Significant Customers
We operate in one segment, pharmaceuticals. Financial information about our revenue by product and significant customers is set forth in Note Q, “Segment Information,” to our consolidated financial statements included in this Annual Report on Form 10-K.

23

Information Available on the Internet
Our internet address is www.vrtx.com. Our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, and all amendments to those reports, are available to you free of charge through the “Investors-SEC Filings” section of our website as soon as reasonably practicable after those materials have been electronically filed with, or furnished to, the Securities and Exchange Commission.
Corporate Information
Vertex was incorporated in Massachusetts in 1989, and our principal executive offices are located at 50 Northern Avenue Boston, Massachusetts 02210.

INFORMATION ABOUT OUR EXECUTIVE OFFICERS
The names, ages and positions held by our executive officers are as follows:
Name
Age
Position
Reshma Kewalramani, M.D.49Chief Executive Officer and President
Jeffrey M. Leiden, M.D., Ph.D.66Executive Chairman
David Altshuler, M.D., Ph.D. 57Executive Vice President, Global Research and Chief Scientific Officer
Stuart A. Arbuckle56Executive Vice President and Chief Operating Officer
Carmen Bozic, M.D.59Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer
Joy Liu, J.D.44Senior Vice President, General Counsel
Amit K. Sachdev, J.D.54Executive Vice President, Chief Patient Officer
Bastiano Sanna, Ph.D.47Executive Vice President, Chief of Cell and Genetic Therapies
Ourania “Nia” Tatsis, Ph.D.52Executive Vice President and Chief Regulatory and Quality Officer
Charles F. Wagner, Jr.53Executive Vice President and Chief Financial Officer
Kristen C. Ambrose45Senior Vice President and Chief Accounting Officer
Dr. Kewalramani has been our Chief Executive Officer and President since April 2020 and a member of our Board of Directors since February 2020. Dr. Kewalramani was our Executive Vice President and Chief Medical Officer from April 2018 through April 2020. She was our Senior Vice President, Late Development from February 2017 until April 2018. From August 2004 to January 2017, she served in roles of increasing responsibility at Amgen Inc., most recently as Vice President, Global Clinical Development, Nephrology & Metabolic Therapeutic Area and as Vice President, U.S. Medical Organization. From 2014 through 2019, Dr. Kewalramani was the industry representative to the FDA’s Endocrine and Metabolic Drug Advisory Committee. Dr. Kewalramani also has served on the board of Ginkgo Bioworks since September 2021. She completed her internship and residency in Internal Medicine at the Massachusetts General Hospital and her fellowship in Nephrology at the Massachusetts General Hospital and Brigham and Women’s Hospital combined program. Dr. Kewalramani holds a B.A. from Boston University and an M.D. from Boston University School of Medicine. Dr. Kewalramani also completed the General Management Program at Harvard Business School and is an alumnus of the school.
Dr. Leiden is our Executive Chairman, a position he has held since in April 2020. He was our Chief Executive Officer and President from 2012 through March 2020. He has been a member of our Board of Directors since July 2009, the Chairman of our Board of Directors since May 2012, and served as our lead independent director from October 2010 through December 2011. Dr. Leiden was a Managing Director at Clarus Ventures, a life sciences venture capital firm, from 2006 through January 2012. Dr. Leiden was President and Chief Operating Officer of Abbott Laboratories, Pharmaceuticals Products Group, and a member of the Board of Directors of Abbott Laboratories from 2001 to 2006. From 1987 to 2000, Dr. Leiden held several academic appointments, including the Rawson Professor of Medicine and Pathology and Chief of Cardiology and Director of the Cardiovascular Research Institute at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health, and Professor of Medicine at Harvard Medical School. He is an elected member of both the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences. Dr. Leiden is the Chairman of Revolution Healthcare Acquisition Corp., a special purpose acquisition corporation, and a director of the Massachusetts Mutual Life Insurance Company, an insurance company. Dr. Leiden was a

24

director and the non-executive Vice Chairman of the board of Shire plc, a specialty biopharmaceutical company, from 2006 to January 2012 and a director of Quest Diagnostics, a medical diagnostics company, from December 2014 to May 2019. Dr. Leiden received his M.D., Ph.D. and B.A. degrees from the University of Chicago.
Dr. Altshuler has been our Executive Vice President, Global Research and Chief Scientific Officer since January 2015 and was a member of our Board of Directors from May 2012 through December 2014. Dr. Altshuler was one of four founding members of the Broad Institute, a research collaboration of Harvard University and the Massachusetts Institute of Technology, The Whitehead Institute and the Harvard Hospitals. He served as the Director of the Institute’s Program in Medical and Population Genetics from 2003 through December 2014 and as the Institute’s Deputy Director and Chief Academic Officer from 2009 through December 2014. Dr. Altshuler joined the faculty at Harvard Medical School and the Massachusetts General Hospital in 2000 and held the academic rank of Professor of Genetics and Medicine from 2008 through December 2014. He served as Adjunct Professor of Biology at MIT from 2012 through December 2014. Dr. Altshuler earned a B.S. from MIT, a Ph.D. from Harvard University and an M.D. from Harvard Medical School. Dr. Altshuler completed his clinical training in Internal Medicine, and in Endocrinology, Diabetes and Metabolism, at the Massachusetts General Hospital.
Mr. Arbuckle is our Executive Vice President, Chief Operating Officer, a position he has held since July 2021. Previously, Mr. Arbuckle served as Executive Vice President, Chief Commercial and Operations Officer from March 2021 to July 2021, and as our Executive Vice President, Chief Commercial Officer from September 2012 to February 2021. Prior to joining us, Mr. Arbuckle held multiple commercial leadership roles at Amgen, Inc. from July 2004 through August 2012. Mr. Arbuckle has worked in the biopharmaceuticals industry since 1986, including more than 15 years at GlaxoSmithKline plc, where he held sales and marketing roles of increasing responsibility for medicines aimed at treating respiratory, metabolic, musculoskeletal, cardiovascular and other diseases. He served as a member of the Board of Directors of Cerulean Pharma, Inc. from June 2015 through July 2017 and has served as a member of the Board of Directors of ImmunoGen, Inc. since January 2018 and of Rhythm Pharmaceuticals Inc. since July 2019. Mr. Arbuckle holds a BSc in Pharmacology and Physiology from the University of Leeds.
Dr. Bozic is our Executive Vice President, Global Medicines Development and Medical Affairs, a position she has held since October 2019, and she has been our Chief Medical Officer since April 2020. She was our Senior Vice President and Head of Global Clinical Development from May 2019 to October 2019. Prior to joining Vertex, Dr. Bozic spent more than 20 years at Biogen Inc., a biotechnology company focused on neurological diseases, most recently as Senior Vice President of Global Development and Portfolio Transformation from 2015 to May 2019 and as Senior Vice President of Clinical and Safety Sciences from 2013 to 2015. Dr. Bozic has served as the industry representative to the FDA’s Risk Communication Advisory Committee, and was a member of PhRMA’s Clinical and Preclinical Development Committee and the Board of Managers at BioMotiv. She is a member of the Clinical Advisory Board at Akili Interactive. She received her M.D., C.M., completed her residency, and was Chief Resident in Internal Medicine at McGill University. She completed her fellowship in Pulmonary and Critical Care Medicine at Brigham and Women’s Hospital, and was an Associate Physician at Beth Israel Deaconess Medical Center and Harvard Medical School before joining the biopharmaceutical industry.
Ms. Liu is our Senior Vice President, General Counsel, a position she has held since March 2021. Previously, Ms. Liu was our Senior Vice President and Deputy General Counsel from February 2020 to February 2021, and our Vice President and Deputy General Counsel from October 2019 to February 2020. Ms. Liu first joined Vertex as our Vice President, Commercial and Regulatory Legal in August 2016. Prior to Vertex, Ms. Liu was an attorney at Ropes & Gray LLP, for 14 years, the last five as a partner. Ms. Liu received her bachelor’s degree from Harvard University and her J.D. from Columbia Law School.
Mr. Sachdev is our Executive Vice President, Chief Patient Officer, a role he has held since October 2019. In addition, Mr. Sachdev has served in the role of Chief of Staff to the CEO since April 2020. He served as our Executive Vice President and Chief Regulatory Officer from January 2017 until September 2019, and as our Executive Vice President, Policy, Access and Value from October 2014 through December 2016. In 2010, he established our first international commercial operations in Canada. In 2007, he joined us as a Senior Vice President, and has led our government affairs and public policy activities, as well as our patient advocacy programs. Prior to joining us, Mr. Sachdev served as Executive Vice President, Health, of the Biotechnology Industry Organization (BIO) and was the Deputy Commissioner for Policy at the FDA, where he also served in several other senior positions. Prior to the FDA, Mr. Sachdev served as Majority Counsel to the Committee on Energy and Commerce in the U.S. House of Representatives and practiced law at the American Chemistry Council, and subsequently at the law firm of Ropes & Gray LLP. He has served as a member of the Board of Directors of Eiger BioPharmaceuticals since

25

April 2019. Mr. Sachdev holds a B.S from Carnegie Mellon University and a J.D. from Emory University School of Law.
Dr. Sanna is our Executive Vice President, Chief of Cell and Genetic Therapies, a position he has held since February 2020. From October 2019 to February 2020, he was President of Semma Therapeutics, Inc., a private biotechnology company that Vertex acquired in October 2019. Prior to the acquisition, Dr. Sanna was the Chief Executive Officer and President of Semma from May 2018 until October 2019. Dr. Sanna was Chief Operating Officer at Magenta Therapeutics from May 2016 through April 2018. He served on the leadership team of the Novartis Cell and Gene Therapy Unit as the Global Program Head of Stem Cell Transplant and early programs from 2014 through 2016. Dr. Sanna served as Global Head of Strategic Planning and Portfolio Management at the Novartis Institutes for BioMedical Research from 2010 through 2014. Dr. Sanna has served as a member of the Board of Directors of Adicet Bio, Inc., a biotechnology company since December 2020. Dr. Sanna received a Ph.D. in Biotechnology from the University of Sassari.
Dr. Tatsis is our Executive Vice President, Chief Regulatory and Quality Officer, a position she has held since August 2020. Previously, she was our Senior Vice President and Chief Regulatory Officer from October 2019 to August 2020, and our Senior Vice President, Global Regulatory Affairs from September 2017 to October 2019. Prior to joining Vertex, Dr. Tatsis held positions of increasing responsibility at several pharmaceutical companies, including Sanofi, Stemnion, Pfizer, and Wyeth. Most recently, from 2014 to 2017, she was Vice President, Head of Global Regulatory Affairs, at the Sanofi Genzyme Business Unit focused on Inflammation/Immunology, Rare Disease, Multiple Sclerosis, Ophthalmology, Neurology, and Oncology/Immuno-Oncology. Dr. Tatsis also worked as an associate staff scientist and research fellow in Immunology and Vaccine Development at the Wistar Institute and completed a post-doctoral research fellowship in Immunology at Thomas Jefferson University. She received her Ph.D. in Cell and Molecular Biology from the University of Vermont and holds a B.S. in Biology from Temple University.
Mr. Wagner is our Executive Vice President and Chief Financial Officer, a position he has held since April 2019. Prior to joining Vertex, Mr. Wagner was Chief Financial Officer and Executive Vice President, Finance, of Ortho Clinical Diagnostics, a Carlyle Group portfolio company, from June 2015 to March 2019. In that role, he led the finance, accounting, tax, treasury, global financial systems, lender relations, and acquisitions and divestiture groups, and also had shared leadership for several enterprise-wide projects. From July 2012 to June 2015, Mr. Wagner served as Executive Vice President, Chief Financial Officer of Bruker Corporation, a scientific instruments manufacturer. Prior to that, Mr. Wagner served as Chief Financial Officer for Progress Software Corporation, a provider of enterprise software, and Millipore Corporation, a global provider of products and services in the life science tools market. Mr. Wagner served as a director and chairman of the Audit Committee of Good Start Genetics, Inc., a molecular diagnostics company, from April 2014 to August 2017 and served as a director and member of the Audit Committee of Bruker Corporation from August 2010 to June 2012. Mr. Wagner holds a B.S. in Accounting from Boston College and a M.B.A from Harvard Business School.
Ms. Ambrose is our Senior Vice President, Chief Accounting Officer, a position she has held since May 2021. Ms. Ambrose previously served as our Senior Vice President, Accounting, Tax, Treasury, Strategic Sourcing and Corporate Services since March 2021. From February 2003 until she joined Vertex, Ms. Ambrose held roles of increasing responsibility at Boston Scientific Corporation, a medical device company, most recently as Vice President of Finance and Controller of the Global Endoscopy Division from July 2019 to March 2021 and as Vice President of Global Internal Audit from February 2017 to June 2019. Prior to Boston Scientific Corporation, Ms. Ambrose served as an accountant at Ernst & Young LLP. She received her B.S. in Commerce from the University of Virginia and is a Certified Public Accountant.

26

ITEM 1A. RISK FACTORS
Investing in our common stock involves a high degree of risk, and you should carefully consider the risks and uncertainties described below in addition to the other information included or incorporated by reference in this Annual Report on Form 10-K. If any of the following risks or uncertainties actually occurs, our business, financial condition or results of operations would likely suffer, possibly materially. In that case, the trading price of our common stock could decline.
SUMMARY OF RISK FACTORS
Our business is subject to numerous risks and uncertainties, discussed in more detail in the following section. These risks include, among others, the following key risks:
Risks Related to Our Business
•We invest significant resources in the research and development of therapies for serious diseases other than CF, and if we are unable to successfully commercialize one or more of these therapies, our business could be materially harmed.
•All of our product revenues and the vast majority of our total revenues are derived from sales of medicines for the treatment of CF. If we are unable to continue to increase revenues from sales of our CF medicines, our business would be materially harmed and the market price of our common stock would likely decline.
•If our competitors bring products with superior product profiles to market, our products may not be competitive and our revenues could decline.
•If we discover safety issues with any of our products or if we fail to comply with continuing U.S. and applicable foreign regulations, commercialization efforts for the product could be negatively affected, the approved product could lose its approval or sales could be suspended, and our business could be materially harmed.
•If physicians and patients do not accept our products, or if patients do not remain on treatment or comply with their prescribed dosing regimen, our product revenues would be materially harmed in future periods.
•Government and other third-party payors seek to contain costs of health care through legislative and other means. If they fail to provide coverage and adequate reimbursement rates for our products, our revenues will be harmed.
•We may experience incremental pricing pressure on our products, which could reduce our revenues and future profitability.
•Current health care laws and regulations in the U.S. and future legislative or regulatory reforms to the U.S. health care system may affect our ability to commercialize our marketed products profitably.
•We have experienced challenges commercializing products outside of the U.S., and our future revenues will be dependent on our ability to obtain adequate reimbursement for our products.
•We have limited experience developing and commercializing cell and genetic therapies and could experience challenges with these programs, which could result in delays or prevent the development, manufacturing and commercialization of our cell and genetic therapies.
Risks Related to Development and Clinical Testing of Our Products and Product Candidates
•Our product candidates remain subject to clinical testing and regulatory approval, and our future success is dependent on our ability to successfully develop additional product candidates for both CF and non-CF indications.
•If we are unable to obtain or are delayed in obtaining regulatory approval, we may incur additional costs, experience delays in commercialization, or be unable to commercialize our product candidates.
•If clinical trials are prolonged or delayed, our development timelines for the affected development program could be extended, our costs to develop the product candidate could increase and the competitive position of the product candidate could be adversely affected.
•Difficulty in enrolling patients could delay or prevent clinical trials of our product candidates, and ultimately delay or prevent regulatory approval.

27

Risks Related to Government Regulation
•If regulatory authorities interpret any of our conduct, including our marketing practices, as being in violation of applicable health care laws, including fraud and abuse laws, laws prohibiting off-label promotion, disclosure laws or other similar laws, we may be subject to civil or criminal penalties.
•If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the U.S., we could be subject to additional reimbursement requirements, penalties, sanctions and fines that could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
•If our processes and systems are not compliant with regulatory requirements, we could be subject to restrictions on marketing our products or could be delayed in submitting regulatory filings seeking approvals for our product candidates.
•We are subject to various and evolving laws and regulations governing the privacy and security of personal data, and our failure to comply could adversely affect our business, result in fines and/or criminal penalties, and damage our reputation.
Risks Related to Business Development Activities
•Our ability to execute on our long-term strategy depends in part on our ability to engage in transactions and collaborations with other entities that add to our pipeline or provide us with new commercial opportunities.
•We may not realize the anticipated benefits of acquisitions of businesses or technologies, and the integration following any such acquisition may disrupt our business and management.
•We face risks in connection with existing and future collaborations with respect to the development, manufacture and commercialization of our products and product candidates.
•We may not be able to attract collaborators or external funding for the development and commercialization of certain of our product candidates.
Risks Related to Supply, Manufacturing and Reliance on Third Parties
•We depend on third-party manufacturers and our internal capabilities to manufacture our products and the materials we require for our clinical trials. We may not be able to maintain our third-party relationships and could experience supply disruptions outside of our control.
•We rely on third parties to conduct pre-clinical work, clinical trials and other activities, and those third parties may not perform satisfactorily, including failing to meet established deadlines for the completion of such studies and/or trials or failing to satisfy regulatory requirements.
Risks Related to Intellectual Property
•If our patents do not protect our products or our products infringe third-party patents, we could be subject to litigation which could result in injunctions preventing us from selling our products or substantial liabilities.
•Uncertainty over intellectual property in the pharmaceutical and biotechnology industry has been the source of litigation and other disputes, that are inherently costly and unpredictable.
•We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.
Risks Related to Our Operations
•Risks associated with operating in foreign countries could materially adversely affect our business.
•If we fail to attract and retain skilled employees, our business could be materially harmed.
•We are subject to risks associated with the COVID-19 pandemic.
Risks Related to Financial Results and Holding Our Common Stock
•Our stock price may fluctuate.
•Our effective tax rate fluctuates, and changes in tax laws, regulations and treaties, unfavorable resolution of tax contingencies or exposure to additional income tax liabilities could have a material impact on our future taxable income.

28

Risks Related to Our Business
We invest significant resources in the research and development of therapies for serious diseases other than CF, and if we are unable to successfully commercialize one or more of these therapies, our business could be materially harmed.
We invest significant resources in the research and development of medicines for serious diseases including SCD, beta thalassemia, APOL1-mediated kidney disease, T1D, pain, AATD, DMD and DM1. Some of these programs have progressed into clinical trials, while others are still in pre-clinical development. Product development is highly uncertain and expensive, and product candidates that may appear promising in the early phases of research and development may fail to reach commercial success for many reasons, including the failure to demonstrate acceptable clinical trial results or obtain marketing approval, the inability to manufacture or commercialize the product candidate on economically feasible terms, or the appearance of safety issues. For example, in June 2021, we decided not to progress VX-864, a drug candidate for the treatment of AATD, into late-stage development based on data obtained from a Phase 2 clinical trial.
Even if we gain marketing approval for one or more pipeline products, we cannot be sure that we will obtain market acceptance or adequate reimbursement levels from third-party payors or foreign governments for such products. Additionally, many of the therapies that we are developing in our pipeline target rare diseases that affect a limited number of patients. There can be no guarantee that we will effectively identify patients that are eligible for enrollment in our clinical trials or treatment with our product candidates. Even if we do successfully identify eligible patients, the number of patients that our product candidates are able to treat may turn out to be lower than we expect or new patients may become increasingly difficult to identify, each of which may adversely affect our revenues and materially harm our business. For these and other reasons, we may never be successful in expanding our pipeline and future revenue may continue to depend on sales of our CF medicines.
All of our product revenues and the vast majority of our total revenues are derived from sales of medicines for the treatment of CF. If we are unable to continue to increase revenues from sales of our CF medicines, our business would be materially harmed and the market price of our common stock would likely decline.
Our net product revenues and the vast majority of our total revenues are derived from the sale of our CF medicines. As a result, our future success is largely dependent upon our ability to increase revenues from sales of our CF medicines. This will require us to continue to gain approval and reimbursement for our triple combination therapy in ex-U.S. markets and successfully develop and commercialize our triple combination therapy for younger children with CF.
Our concentrated source of revenues presents a number of risks to our business, including:
•that one or more competing therapies may be developed successfully as a treatment for people with CF;
•that reimbursement policies of payors and other third parties may make it difficult to obtain reimbursement or reduce the net price we receive for our products;
•that we may experience manufacturing or supply disruptions for our CF medicines; and
•that we may experience adverse developments with respect to development or commercialization of our CF medicines and/or CF product candidates.
If any of the above risks were to materialize, if we are otherwise unable to increase revenues from sales of our CF medicines, or if we do not meet the expectations of investors or public equity market analysts, our business would be materially harmed and our ability to fund our operations could be adversely affected. For example, if we are unable to increase revenues from sales of our CF medicines, our ability to fund our research and development programs for the discovery and development or acquisition of new products would be harmed, which would limit our ability to diversify our revenue base and our stock price would likely be adversely affected.
If our competitors bring products with superior product profiles to market, our products may not be competitive and our revenues could decline.
A number of companies are seeking to identify and develop product candidates for the treatment of CF and other therapeutic areas we are targeting with our research and development activities. Our success in rapidly developing and commercializing our CF medicines may increase the resources that our competitors allocate to the development of potential

29

competitive treatments. If one or more competing therapies are successfully developed as a treatment for people with CF or any of the other diseases we are currently targeting in our pipeline, our products and our net product revenues could face competitive pressures. If one or more competing therapies prove to be superior to our then existing products and/or product candidates, our business could be materially adversely affected.
In addition, our business faces competition from major pharmaceutical companies possessing substantially greater financial resources than we possess. We also face competition from numerous smaller public and private companies, academic institutions, government agencies, public and private research organizations, and charitable venture philanthropy organizations that conduct research, seek patent protection, and/or establish collaborative arrangements for research, development, manufacturing, and commercialization.
Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies also may prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.
Our products and any products that we develop in the future may not be able to compete effectively with marketed drugs or new drugs that may be developed by competitors. The risk of competition is particularly important to our company because substantially all of our revenues are related to the treatment of people with CF. There are many other companies developing products for the same patient populations that we are pursuing. In order to compete successfully in these areas, we must demonstrate improved safety, efficacy and/or tolerability, ease of manufacturing, and gain and maintain market acceptance over competing products.
If we discover safety issues with any of our products or if we fail to comply with continuing U.S. and applicable foreign regulations, commercialization efforts for the product could be negatively affected, the approved product could lose its approval or sales could be suspended, and our business could be materially harmed.
Our products are subject to continuing regulatory oversight, including the review of additional safety information. Products are more widely used by patients once approval has been obtained and therefore side effects and other problems may be observed after approval that were not seen or anticipated, or were not as prevalent or severe, during pre-approval clinical trials or nonclinical studies. The subsequent discovery of previously unknown or underestimated problems with a product could negatively affect commercial sales of the product, result in restrictions on the product or lead to the withdrawal of the product from the market. Each of our CF products shares at least one active pharmaceutical ingredient with another of our products. As a result, if any of our CF products were to experience safety issues, our other CF products may be adversely affected. The reporting of adverse safety events involving our products or public speculation about such events could cause our stock price to decline or experience periods of volatility. Our business also may be materially harmed by impaired sales of our products, denial or withdrawal of regulatory approvals, required label changes or additional clinical trials, reputational harm, or government investigations or lawsuits brought against us.
In addition, our products are subject to ongoing regulatory requirements governing the testing, manufacturing, labeling, packaging, storage, advertising, promotion, sale, distribution, import, export, recordkeeping, and submission of safety and other post-market information. We and our third-party manufacturers must comply with cGMP and other applicable regulations governing the manufacturing and distribution of our products. Regulatory authorities periodically inspect our drug manufacturing facilities, and those of our third-party manufacturers, to evaluate compliance with cGMP and other regulatory requirements.
If we or our collaborators, or third-parties acting on our behalf, fail to comply with applicable continuing regulatory requirements, we or our collaborators may be subject to fines, suspension or withdrawal of regulatory approvals for specific products, product recalls and seizures, operating restrictions and/or criminal prosecutions, any of which could have a material adverse effect on our business, reputation, financial condition, and results of operations.
If physicians and patients do not accept our products, or if patients do not remain on treatment or comply with their prescribed dosing regimen, our product revenues would be materially harmed in future periods.
Our medicines may not gain or maintain market acceptance among physicians and patients or other members of the

30

medical community. Effectively marketing our products and any of our product candidates or investigational therapies, if approved, requires substantial efforts, both prior to launch and after approval. Physicians may elect not to prescribe our products or recommend our cell or genetic therapies, and patients may elect not to take them or receive them or they may discontinue use of our products after initiation of treatment, for a variety of reasons including:
•prevalence and severity of adverse side effects;
•lack of reimbursement availability from third-party payors, including governmental entities;
•lower demonstrated efficacy, safety and/or tolerability compared to alternative treatment methods;
•lack of cost-effectiveness;
•a decision to wait for the approval of other therapies in development that have significant perceived advantages over our product;
•convenience and ease of administration;
•limitations or warnings contained in the labeling;
•the timing of market introduction of our product as well as competitive products;
•other potential advantages of alternative treatment methods; and
•inadequate sales, marketing and/or distribution support, including as a result of limitations or restrictions resulting from COVID-19.
If our medicines fail to achieve or maintain market acceptance, we may not be able to generate significant revenues in future periods.
Government and other third-party payors seek to contain costs of health care through legislative and other means. If they fail to provide coverage and adequate reimbursement rates for our products, our revenues will be harmed.
Sales of our products depend in part upon the availability of reimbursement from third-party payors. Third-party payors include government health programs such as Medicare and Medicaid in the U.S. and the national health care systems in ex-U.S. markets, managed care providers, private health insurers and other organizations. The trend in the health care industry is cost containment, and efforts of third-party payors to contain or reduce health care costs may adversely affect our ability to establish or maintain appropriate prices for our products or any drugs that we may develop and commercialize.
In most ex-U.S. markets, the pricing and reimbursement of therapeutic and other pharmaceutical products is subject to governmental control, and government authorities are making greater efforts to limit or regulate the price of drug products. In the U.S., there have been, and we expect that there will continue to be, a number of federal and state proposals to implement governmental controls that are similar to those that currently exist in Europe. For example, the ACA required manufacturers of Medicare Part D brand name drugs to provide discounts on those drugs to Medicare Part D beneficiaries during the coverage gap; increased the rebates paid by pharmaceutical companies to state Medicaid programs on drugs covered by Medicaid; and imposed an annual fee, which increases annually, on sales by branded pharmaceutical manufacturers.
Third-party payors throughout the world also have been attempting to control drug spending in light of the global economic pressures, including due to the global COVID-19 pandemic. In reimbursement negotiations, many payors are requesting price discounts and caps on total expenditures and limiting both the types and variety of drugs that they will cover if they are not able to secure them. As part of these negotiations, many ex-U.S. government payers also are requiring companies to establish product cost-effectiveness as a condition of reimbursement. These cost-effectiveness reviews may not account for many of the benefits provided by innovative medicines, and for the most part, have not taken into account the specific circumstances of products that treat rare diseases. This has led to conclusions that certain medicines, including our products in certain jurisdictions, are not cost-effective. As a result, certain countries have declined to reimburse, or delayed their reimbursement of, some of our products. Although not mandated in the U.S., various organizations have started advocating for cost-effectiveness analyses in the U.S. as well as value-based contracting in which the amount of reimbursement for a product is based on patient outcomes and other clinical or economic metrics related to the performance of such product. If U.S. payors were to adopt such assessments and make negative coverage determinations or utilize value-

31

based contracts that result in penalties to, or lower rates of, reimbursement, it could adversely affect our product revenues. Our business would be materially adversely affected if we are not able to obtain or maintain coverage and reimbursement of our products from third-party payors on a broad, timely, or satisfactory basis, or if such coverage is subject to overly broad or restrictive utilization management controls.
The increasing availability and use of innovative specialty pharmaceuticals for rare diseases, combined with their relative higher cost as compared to other types of pharmaceutical products, is generating significant third-party payor interest in developing cost-containment strategies targeted to this sector. Government regulations in both U.S. and ex-U.S. markets could further limit the prices that can be charged for our products and may limit our commercial opportunity. The increasing use of cost-effectiveness assessments in markets around the world and the financial challenges faced by many governments may lead to significant adverse effects on our business.
We may experience incremental pricing pressure on our products, which could reduce our revenues and future profitability.
There also has been an increase in state legislation and regulations related to drug pricing and drug pricing transparency. In the U.S., various states, including Nevada, Maryland, Louisiana, New York, California, Washington, Massachusetts, Connecticut, Vermont, New Hampshire, Utah, Minnesota, Oregon, Colorado, New Mexico, Virginia, Maine, Texas, North Dakota, and West Virginia, have passed legislation requiring companies to disclose extensive information relating to drug prices, drug price increases, and spending on research, development, and marketing, among other things. Although it is not always clear what states will do with the collected information, some laws were designed to obtain additional product discounts. We may continue to see more state action requiring additional disclosures or other actions. In addition, we could see increased federal activity related to drug pricing and transparency requiring disclosures or other actions instead of, or in addition to, state requirements. Similar initiatives also are occurring in, or being considered by, some of our ex-U.S. markets, including Italy and Brazil.
Complying with these laws can be expensive and requires significant personnel and operational resources. Additionally, any additional required discounts would adversely affect the pricing of, and revenues from, our products. Finally, while we seek to comply with all statutory and regulatory requirements, we face increased enforcement activity by the U.S. federal government, state governments, and private payors against pharmaceutical and biotechnology companies for pricing and reimbursement-related issues as well as inquiries from the U.S. Congress.
Other federal activities seeking to specifically address drug pricing and reimbursement include:
•rulemaking related to importation of prescription drugs from Canada, as well as guidance related to importation of prescription drugs from other foreign countries;
•attempts to establish reference pricing for certain physician-administered drugs;
•executive orders relating to drug pricing that are intended to broadly impact the pharmaceutical industry;
•changes to the federal anti-kickback statute safe harbors that eliminate anti-kickback statute discount safe harbor protection for certain manufacturer rebate arrangements;
•support for legislation allowing direct negotiation in Medicare Part D; and
•legislation relating to drug pricing, including bills that would impose rebate obligations for Medicare (and potentially other utilization) for price increases greater than the rate of inflation, require drug pricing negotiations in Medicare, redesign the Part D benefit to lower patient costs and overall spending, and introduce enhanced transparency measures into drug pricing.
We expect government scrutiny over drug pricing, reimbursement, and distribution to continue. Potential future government regulation of drug prices or reimbursement creates uncertainties about our portfolio and could have a material adverse effect on our operations.
Current health care laws and regulations in the U.S. and future legislative or regulatory reforms to the U.S. health care system may affect our ability to commercialize our marketed products profitably.
The U.S. government, individual states and some foreign jurisdictions also have been aggressively pursuing legislative

32

and regulatory reforms that could affect our ability to sell products. For example, in the U.S., there have been federal legislative and administrative efforts to repeal, substantially modify, or invalidate some or all of the provisions of the ACA, which could affect coverage and payment for medicines. The federal government additionally has proposed and enacted legislation leading to aggregate reductions of Medicare payments to providers, which ultimately could affect utilization of medicines.
Other reforms include the Bipartisan Budget Act of 2018, which contained various provisions that affect coverage and reimbursement of drugs, including an increase in the discount that manufacturers of Medicare Part D brand name drugs must provide to Medicare Part D beneficiaries during the coverage gap from 50% to 70%. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other health care funding, which could negatively affect our customers and accordingly, our financial operations. Moreover, payment methodologies may be subject to changes in health care legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models.
There also are a number of ongoing activities, including the Build Back Better Act, that could affect drug pricing in the Medicare and Medicaid programs. Those activities seek to reduce or limit the prices of drugs, make them more affordable for patients, reform Medicare Part D pharmaceutical benefits, bring more transparency to drug prices, require data collection and reporting of information such as rebates, fees, and other remuneration provided by drug manufacturers, and enable the government to negotiate prices.
Adoption of new health care reform legislation at the federal or state level could affect demand for, or pricing of, our products or product candidates if approved for sale. We cannot, however, predict the ultimate content, timing, or effect of any health care reform legislation or action, or its impact on us, including increased compliance requirements and costs, all of which may adversely affect our future business, operations, and financial results.
We have experienced challenges commercializing products outside of the U.S., and our future revenues will be dependent on our ability to obtain adequate reimbursement for our products.
In most ex-U.S. markets, the pricing and reimbursement of therapeutic and other pharmaceutical products is subject to governmental control. Given recent global economic pressures, including due to the COVID-19 pandemic, and geopolitical uncertainty, government authorities throughout the world are increasingly attempting to limit or regulate the price of drug products. The reimbursement process in ex-U.S. markets can take a significant time to conclude and reimbursement decisions are made on a country-by-country or region-by-region basis.
Our medicines treat life-threatening conditions and address relatively small patient populations, and our research and development programs are primarily focused on developing medicines to treat similar diseases. Particular attention is being paid by payors, including government and private payors, to these types of high-cost medicines, and countries are increasingly refusing to reimburse costly medicines. We have experienced challenges in obtaining timely reimbursement for our products in various countries outside the U.S. For example, we obtained reimbursement for ORKAMBI and SYMKEVI in England in the fourth quarter of 2019, four years after ORKAMBI’s initial approval in 2015. Our future product revenues, including from TRIKAFTA/KAFTRIO, depend on, among other things, our ability to complete reimbursement discussions in ex-U.S. markets for our products. There is no assurance that coverage and reimbursement will be available outside of the U.S. for our four approved medicines or any future medicine, and, even if it is available, whether the timing or the level of reimbursement will be sufficient to allow us to market our medicines. Adverse pricing limitations or a delay in obtaining coverage and reimbursement would decrease our future net product revenues and harm our business.
We have limited experience developing and commercializing cell and genetic therapies and could experience challenges with these programs, which could result in delays or prevent the development, manufacturing and commercialization of our cell and genetic therapies.
We are investing significant resources in the research, development, manufacturing, and commercialization of cell and genetic therapies. While we have previously successfully developed, manufactured, and commercialized several small molecule drugs, we have limited experience with the development, manufacture, and commercialization of cell and genetic therapies. Development, manufacturing, and commercialization of cell and genetic therapies are subject to the same risks and uncertainties as small molecules. In addition:

33

•the manufacturing processes for cell and genetic therapies are different and more complex than the manufacturing processes required for small molecule drugs and require different systems, equipment, facilities, and expertise to develop and maintain;
•we may encounter difficulties in the production of our cell and genetic therapies and ensuring that the product meets required specifications;
•there have been a limited number of regulatory approvals for genetic therapies to date, the regulatory requirements governing genetic therapies continue to evolve, and regulatory positions and interpretations can change or lead to delays or significant unexpected costs with respect to our genetic therapy programs;
•the commercial success of cell or genetic therapies, including CTX001 and VX-880, if approved, will depend in part on the medical community, patients, governments, and third-party or governmental payers accepting cell or genetic therapy products in general, and the applicable medicine as medically useful, cost-effective, ethical, and safe; and
•market acceptance will be dependent in part on the prevalence and severity of side effects associated with the procedure by which the cell or genetic therapy is administered, including, with respect to CTX001 and VX-880, if approved, the prevalence and severity of any side effects resulting from the myeloablative preconditioning regime or immunosuppression, respectively.
For programs addressing rare genetic diseases with small patient populations, we may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics, to complete our clinical studies in an adequate and timely manner. Additionally, patients may be unwilling to participate in our clinical trials because of concerns that cell and genetic therapies are unsafe or unethical, negative publicity from adverse events in the biotechnology or gene therapy industries, or for other reasons, including competitive clinical studies for similar patient populations. Moreover, adverse developments in clinical trials conducted by others of cell and genetic therapy products or products created using similar technology, or adverse public perception of the field of cell and genetic therapies, may cause the FDA and other regulatory bodies to revise the requirements for approval of any cell or genetic therapy product candidates we may develop or limit the use of products utilizing technologies such as ours, either of which could materially harm our business.
As we advance our cell and genetic therapy product candidates, we will be required to consult with various regulatory authorities, and we must comply with applicable laws, rules, and regulations, which may change from time to time, including during the course of development of our cell and genetic therapy product candidates. If we fail to do so, we may be required to delay or discontinue the clinical development of certain of our cell and genetic therapy product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Even if we comply with applicable laws, rules, and regulations, and even if we maintain close coordination with the applicable regulatory authorities with oversight over our cell and genetic therapy product candidates, our development programs may fail to succeed. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential cell or genetic therapy product to market would materially adversely affect our business, financial condition, results of operations and prospects.
The regulatory approval process and clinical trial requirements for cell and genetic therapies can be more expensive and take longer than for other, better known or more extensively studied product candidates, and regulatory requirements governing cell and genetic therapy products have changed frequently and may continue to change in the future. For example, the FDA established the Office of Tissues and Advanced Therapies within its Center for Biologics Evaluation and Research, or CBER, to consolidate the review of cell therapies and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. These and other regulatory review agencies, committees and advisory groups and the requirements and guidelines they promulgate, may lengthen the regulatory review process, require us to perform additional preclinical studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these treatment candidates or lead to significant post-approval limitations or restrictions.
In order to develop and commercialize any future cell or genetic therapies, we will need to incur substantial expenditures to develop, contract for, or otherwise arrange for the necessary manufacturing capabilities. Additionally, the manufacture of cell and genetic therapies requires significant expertise. Even with the relevant experience and expertise, manufacturers of cell and genetic therapy products often encounter difficulties in production, including difficulties with production costs and yields, quality control, and compliance with federal, state and foreign regulations. We cannot make any assurances that these

34

problems will not occur, or that we will be able to resolve or address problems that occur in a timely manner, or at all.
To the extent we develop capabilities internally, there are many risks that could result in delays and additional costs, including the need to hire and train qualified employees and obtain access to necessary equipment and third-party technology. To the extent we partner with third parties to manufacture our cell or genetic therapies, the complexity in the manufacture of our products and product candidates may require lengthy technology transfers. In addition, the third parties on which we rely to manufacture our cell or genetic therapies may experience their own compliance challenges or delays.
We also face uncertainty as to whether cell and gene therapy treatments will gain the acceptance of the public or the medical community. If we obtain regulatory approval, the commercial success of cell and gene therapy treatments will depend, in part, on the acceptance of physicians, patients, and third-party payers of gene therapy products in general, and our product candidates in particular, as medically necessary, cost-effective, and safe. In particular, our success will depend upon physicians prescribing our product candidates in lieu of existing treatments they are already familiar with and for which greater clinical data may be available. Moreover, physicians and patients may delay acceptance of cell and gene therapy product candidates until the product candidates have been on the market for a certain amount of time. In addition, medical centers that administer procedures accompanying treatment could experience capacity constraints, and these centers are subject to competing priorities that could delay patient access to procedures associated with cell and gene therapy products. Negative public opinion or more restrictive government regulations may delay or impair the successful commercialization of, and demand for, cell and gene therapies.
There also is significant uncertainty related to the insurance coverage and reimbursement of cell or genetic therapy products, including gene therapies that are potential one-time treatments. It is difficult to predict what third party payors, including U.S. or ex-U.S. governments or private insurance companies, will decide with respect to reimbursement for novel cell and genetic therapies like the ones in our pipeline. Additionally, reimbursement rates for cell and genetic therapies approved before ours could create an adverse environment for reimbursement of any therapies we ultimately commercialize. The administration of our products may require procedures for the collection of cells from patients, followed by other procedures either before or after delivery of the cell or genetic therapy. The manner and level at which reimbursement is provided for these services also is important. An inadequate reimbursement for such services may adversely affect physician decision to recommend any product for which we obtain approval in the future and our ability to market or sell them.
Given there are only a few approved cell and genetic therapy products, it also is difficult to determine how long it will take or reasonably estimate the costs to develop, manufacture, and commercialize cell or genetic therapies. In addition, our cell-based therapies include approaches involving devices, which are subject to additional regulatory requirements. If we are unable to successfully develop, manufacture, or commercialize such therapies on a timely or profitable basis, or at all, we may not realize benefits or generate cash flows based on our investments in these programs and our business, financial condition, results of operations and our stock price would likely be adversely affected.
We are dependent upon a small number of customers for a significant portion of our revenue, and the loss of, or significant reduction in sales to, these customers would adversely affect our results of operations.
In the U.S., we sell our CF products principally to a limited number of specialty pharmacy and specialty distributors, which subsequently resell our products to patients and health care providers. Internationally, we sell our products primarily to a limited number of specialty distributors and retail chains, as well as hospitals and clinics. We expect this significant customer concentration in CF to continue for the foreseeable future. Our ability to generate and grow sales of our CF medicines will depend significantly on the extent to which these specialty distributors and specialty pharmacies are able to provide adequate distribution of our products to patients and healthcare providers. The loss of any large customer, a significant reduction in sales we make to them, any cancellation of orders they have made with us, or any failure to pay for the products we have shipped to them could adversely affect our business, financial condition, and results of operations.
Risks Related to Development and Clinical Testing of Our Products and Product Candidates
Our product candidates remain subject to clinical testing and regulatory approval, and our future success is dependent on our ability to successfully develop additional product candidates for both CF and non-CF indications.
Our business depends upon the successful development and commercialization of product candidates. These product candidates are in various stages of development and must satisfy rigorous standards of safety and efficacy before they can be approved for sale by the FDA or comparable foreign regulatory authorities. To satisfy these standards, we must allocate

35

resources among our various development programs and must engage in expensive and lengthy testing of our product candidates. Discovery and development efforts for new pharmaceutical and biological products, including new combination therapies, are resource-intensive and may take 10 to 15 years or longer for each product candidate. It is impossible to predict when or if any of our product candidates will prove effective and safe in humans or will receive regulatory approval. Despite our efforts, our product candidates may not:
•offer therapeutic or other improvement over existing competitive therapies;
•show the level of safety and efficacy, including the level of statistical significance, required by the FDA or other regulatory authorities for approval of a drug or biologic;
•meet applicable regulatory standards;
•be capable of being produced in commercial quantities at acceptable costs; or
•if approved for commercial sale, be successfully marketed as pharmaceutical or biological products.
We have recently completed and/or have ongoing or planned clinical trials for several of our product candidates. The strength of our product portfolio and pipeline will depend in large part upon the outcomes of these clinical trials, including clinical trials evaluating our triple combination therapy in younger children with CF, our next generation CF medicines, our Phase 3 clinical trials of CTX001, and our clinical trials of potential medicines to treat other diseases. Failure to advance product candidates through clinical development could impair our ability to ultimately commercialize products, which could materially harm our business and long-term prospects.
Results of our clinical trials and findings from our nonclinical studies, including toxicology findings in nonclinical studies conducted concurrently with clinical trials, could lead to abrupt changes in our development activities, including the possible cessation of development activities associated with a particular product candidate or program. For example, in June 2021, we announced that we had achieved our primary endpoint and established proof of mechanism in a Phase 2 clinical trial evaluating our Z-AAT corrector, VX-864. However, because the magnitude of treatment effect was unlikely to translate into substantial clinical benefit, we decided not to advance VX-864 into late-stage development.
Moreover, clinical data are often susceptible to varying interpretations, and many companies that have believed their product candidates performed satisfactorily in clinical trials have nonetheless failed to obtain marketing approval of their product candidate. Furthermore, results from our clinical trials may not meet the level of statistical significance or otherwise provide the level of evidence or safety and efficacy required by the FDA or other regulatory authorities for approval of a product candidate. Finally, clinical trials are expensive and require significant operational resources to implement and maintain.
Many companies in the pharmaceutical and biotechnology industries, including our company, have suffered significant setbacks in later-stage clinical trials even after achieving promising results in earlier-stage clinical trials. For example, the results from completed preclinical studies and clinical trials may not be replicated in later clinical trials, and ongoing clinical trials for our product candidates may not be predictive of the results we may obtain in later-stage clinical trials or of the likelihood of approval of a product candidate for commercial sale.
In addition, from time to time, we report interim, topline, and preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change. Interim or preliminary data from a clinical trial may not be predictive of final results from the clinical trial and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment and treatment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.
The ability of third parties to review and/or analyze data from our clinical trials, including as a result of government disclosure, also may increase the risk of commercial confidentiality breaches and result in enhanced scrutiny of our clinical trial results. For example, Clinical Trial Regulation (EU) No. 536/2014, or the Clinical Trial Regulation, and the EMA policy

36

on publication of clinical data for medicinal products for human use both permit the EMA to publish clinical information submitted in MAAs. Third party review and scrutiny could result in public misconceptions regarding our drugs and product candidates. These publications could also result in the disclosure of information to our competitors that we might otherwise deem confidential, which could harm our business.
If we are unable to obtain or are delayed in obtaining regulatory approval, we may incur additional costs, experience delays in commercialization, or be unable to commercialize our product candidates.
The time required to complete clinical trials and to satisfy the FDA and other countries’ regulatory review processes is uncertain and typically takes many years. Our analysis of data obtained from nonclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We also may encounter unanticipated delays or increased costs due to government regulation from future legislation or administrative action or changes in governmental policy during the period of drug development, clinical trials and governmental regulatory review.
We may seek a Fast Track, Priority Review, Breakthrough Therapy, and/or RMAT designation for some of our product candidates. Product candidates that receive one or more of these designations may be eligible for, among other things, a priority regulatory review. Each of these designations is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for Fast Track, Priority Review, Breakthrough Therapy and/or RMAT designation, the FDA may disagree and instead determine not to make such designation. The receipt of one or more of these designations for a product candidate does not guarantee a faster development process, review or approval compared to products developed or considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our products or product candidates qualifies for Fast Track, Priority Review, Breakthrough Therapy and/or RMAT designation, the FDA may later decide to withdraw such designation if it determines that the product or product candidate no longer meets the conditions for qualification.
Any failure to obtain regulatory approvals for a product candidate would prevent us from commercializing that product candidate. Any delay in obtaining required regulatory approvals could materially adversely affect our ability to successfully commercialize a product candidate. Furthermore, any regulatory approval to market a product may be subject to limitations that we do not expect on the indicated uses for which we may market the product. Any such limitations could reduce the size or demand of the market for the drug.
We also are subject to numerous foreign regulatory requirements governing the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. Non-U.S. jurisdictions have different approval procedures than those required by the FDA, and these jurisdictions may impose additional testing requirements for our product candidates. The foreign regulatory approval process includes all of the risks associated with the FDA approval process described above, as well as risks attributable to the satisfaction of foreign requirements. Approval by the FDA does not ensure approval by regulatory authorities outside the U.S. and approval by a foreign regulatory authority does not ensure approval by the FDA. In addition, although the FDA may accept data from clinical trials conducted outside the U.S., acceptance of this data is subject to conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population also must adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to applicable local laws, FDA acceptance of the data will depend on its determination that the trials also complied with all applicable U.S. laws and regulations. If the FDA does not accept the data from any trial that we conduct outside the U.S., it would likely result in the need for additional trials, which would be costly and time-consuming and delay or permanently halt our development of the applicable product candidate.
If clinical trials are prolonged or delayed, our development timelines for the affected development program could be extended, our costs to develop the product candidate could increase and the competitive position of the product candidate could be adversely affected.
We cannot predict whether or not we will encounter problems with any of our completed, ongoing or planned clinical trials that will cause us or regulatory authorities to delay or suspend clinical trials, or delay the analysis of data from our completed or ongoing clinical trials. Among the factors that could delay our development programs are:

37

•ongoing discussions with the FDA or comparable foreign authorities regarding the scope or design of our clinical trials and the number of clinical trials we must conduct;
•failure or delay in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites;
•failure to add or delay in adding a sufficient number of clinical trial sites and obtaining IRB or independent ethics committee approval at each clinical trial site;
•suspension or termination of clinical trials of product candidates for various reasons, including non-compliance with regulatory requirements;
•clinical trial sites deviating from clinical trial protocol or dropping out of a clinical trial;
•delays in enrolling volunteers or patients into clinical trials, including as a result of low numbers of patients that meet the eligibility criteria for the trial;
•a lower than anticipated retention rate of volunteers or patients in clinical trials;
•the need to repeat clinical trials as a result of unfavorable or inconclusive results, unforeseen complications in testing or clinical investigator error;
•inadequate supply or deficient quality of product candidate materials or other materials necessary for the conduct of our clinical trials;
•unfavorable FDA or foreign regulatory authority inspection and review of a manufacturing facility that supplied clinical trial materials or its relevant manufacturing records or a clinical trial site or records of any clinical or preclinical investigation;
•unfavorable or inconclusive scientific results from clinical trials;
•serious and unexpected drug-related side-effects experienced by participants in our clinical trials or by participants in clinical trials being conducted by our competitors to evaluate product candidates with similar mechanisms of action or structures to therapies that we are developing;
•favorable results in testing of our competitors’ product candidates, or FDA or foreign regulatory authority approval of our competitors’ product candidates; or
•action by the FDA or a foreign regulatory authority to place a clinical hold or partial clinical hold on a trial or compound or deeming the clinical trial conduct as problematic.
For planning purposes, we estimate the timing of the accomplishment of various scientific, clinical, regulatory, and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials and the submission of regulatory filings. From time to time, we publicly announce the expected timing of some of these milestones. All of these milestones are based on a variety of assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in many cases for reasons beyond our control. If we do not meet these milestones as publicly announced, the commercialization of our products may be delayed and the credibility of our estimates may be adversely affected and, as a result, our stock price may decline.
Difficulty in enrolling patients could delay or prevent clinical trials of our product candidates, and ultimately delay or prevent regulatory approval.
Our ability to enroll patients in our clinical trials in sufficient numbers and on a timely basis is subject to a number of factors. Clinical trials are expensive and require significant operational resources. Delays in patient enrollment or unforeseen drop-out rates may result in increased costs and longer development times. The enrollment of patients further depends on many factors, including:
•the proximity of patients to clinical trial sites;
•the size of the patient population, the nature of the protocol, and the design of the clinical trial;

38

•our ability to recruit clinical trial investigators with the appropriate competencies and experience;
•the number of other clinical trials ongoing and competing for patients in the same indication;
•our ability to obtain and maintain patient consents;
•reporting of the preliminary results of any of our clinical trials;
•the availability of effective treatments for the relevant disease and eligibility criteria for the clinical trial;
•the risk that patients enrolled in clinical trials will drop out of the clinical trials before clinical trial completion; and
•factors we may not be able to control, such as current or potential pandemics that may limit patients, principal investigators or staff or clinical site availability (e.g., the COVID-19 pandemic).
We, our collaborators, the FDA, or other applicable regulatory authorities may suspend clinical trials of a product candidate at any time if we or they believe the healthy volunteers or patients participating in such clinical trials are being exposed to unacceptable health risks or for other reasons. Any such suspension could materially adversely affect the development of a particular product candidate and our business.
Risks Related to Government Regulation
If regulatory authorities interpret any of our conduct, including our marketing practices, as being in violation of applicable health care laws, including fraud and abuse laws, laws prohibiting off-label promotion, disclosure laws or other similar laws, we may be subject to civil or criminal penalties.
We are subject to health care fraud and abuse laws, such as the FCA and the AKS, and other similar laws and regulations both in the U.S. and in non-U.S. markets.
In the U.S., the Federal Anti-Kickback Statute prohibits knowingly and willfully offering, paying, soliciting, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the ordering, furnishing, arranging for or recommending of an item or service that is reimbursable, in whole or in part, by a federal health care program, such as Medicare or Medicaid. Because of the broad scope of the prohibition, most financial interactions between pharmaceutical manufacturers and prescribers, purchasers, third party payors and patients would be subject to the statute. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are narrow. Financial interactions must therefore be structured carefully to qualify for protection or otherwise withstand scrutiny.
Federal false claims laws, including the FCA, prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to get a false claim paid. Pharmaceutical companies have been prosecuted under these laws for a variety of alleged promotional and marketing activities, such as providing free product to customers with the expectation that the customers would bill federal programs for the product; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in promotion for uses that the FDA has not approved, known as “off-label” uses, that caused claims to be submitted to Medicaid for those off-label uses; submitting inflated “best price” information to the Medicaid Rebate Program; and certain manufacturing-related violations. The scope of this and other laws may expand in ways that make compliance more difficult and expensive.
The FDA and other regulatory agencies closely regulate the post-approval marketing and promotion of products to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. Although physicians are permitted, based on their medical judgment, to prescribe products for indications other than those approved by the FDA, manufacturers are prohibited from promoting their products for such off-label uses. We market our products to eligible people with CF for whom the applicable product has been approved and provide promotional materials and training programs to physicians regarding the use of each product in these patient populations. These eligible people do not represent all people with CF. If the FDA determines that our promotional materials, training, or other activities constitute off-label promotion, it could request that we modify our training or promotional materials or other activities, conduct corrective advertising, or subject us to regulatory enforcement actions, including the issuance of a warning or untitled letter, injunction, seizure, civil fines and criminal penalties. It also is possible that other federal, state, or foreign

39

enforcement authorities might take action if they believe that the alleged improper promotion led to the submission and payment of claims for an off-label use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. Even if it is later determined we were not in violation of these laws, we may be faced with negative publicity, incur significant expenses defending our actions, and have to divert significant management resources from other matters.
In the U.S., federal and state laws regulate financial interactions between pharmaceutical manufacturers and healthcare providers, require disclosure to government authorities and the public of such interactions, and mandate the adoption of compliance standards or programs. For example, the so-called federal “sunshine law” requires pharmaceutical manufacturers to report annually to CMS payments or other transfers of value made by that entity to physicians and teaching hospitals (and additional categories of health care practitioners beginning with reports submitted on or after January 1, 2022). We also have similar reporting obligations with respect to financial interactions throughout the E.U. We expended significant efforts to establish, and are continuing to devote significant resources to maintain and enhance, systems and processes in order to comply with these regulations. Requirements to track and disclose financial interactions with health care providers and organizations increase government and public scrutiny of these financial interactions. Failure to comply with the reporting requirements could result in significant civil monetary penalties.
The sales and marketing practices of our industry have been the subject of increased scrutiny from government authorities in the U.S. and other countries in which we market our products, and we believe that this trend will continue. Many of these laws have not been fully interpreted by the government authorities or the courts, and their provisions are subject to a variety of interpretations. While we have a corporate compliance program which, together with our policies and procedures, is designed to actively identify, prevent and mitigate risk through the implementation of compliance policies and systems and the promotion of a culture of compliance, if we are found not to be in full compliance with these laws and regulations, our business could be materially harmed. We may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from federal health care programs and/or the curtailment or restructuring of our operations. Even if we successfully defend against government challenge, responding to the challenge may cause us to incur significant legal expenses and divert our management’s attention from the operation of our business.
If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the U.S., we could be subject to additional reimbursement requirements, penalties, sanctions and fines that could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
We participate in the Medicaid Drug Rebate Program, the 340B Drug Pricing Program, and a number of other federal and state government pricing programs in the U.S. in order to obtain coverage for our products by certain government health care programs. These programs require us to pay rebates or provide discounts to certain government payers or private purchasers in connection with our products when dispensed to beneficiaries of these programs. In some cases, such as with the Medicaid Drug Rebate Program, the rebates are based on pricing and rebate calculations that we report on a monthly and quarterly basis to the government agencies that administer the programs. The terms, scope and complexity of these government pricing programs change frequently. For example, regulations finalized in December 2020 created an alternative Medicaid rebate formula for “line extensions” of oral solid dosage forms and revised regulations regarding manufacturer-sponsored patient benefit programs in the context of payor “accumulator” programs. Additionally, the expansion of the 340B Drug Discount Program through the ACA has increased the number of purchasers who are eligible for significant discounts on branded drugs. These and future changes to government pricing programs, laws, and regulations may have a material adverse impact on our revenue and operations.
We also may have reimbursement obligations or be subject to penalties if we fail to provide timely and accurate information to the government, pay the correct rebates, or offer the correct discounted pricing. Changes to the price reporting or rebate requirements of these programs would affect our obligations to pay rebates or offer discounts. For example, the removal of the current statutory 100% of Average Manufacturer Price per-unit cap on Medicaid rebate liability for single source and innovator multiple source drugs, effective as of January 1, 2024, under the American Rescue Plan Act of 2021 may affect the amount of rebates paid on prescription drugs under Medicaid and the prices that are required to be charged to covered entities under the 340B Drug Discount Program. Responding to current and future changes to these and other Medicaid Drug Rebate Program requirements may increase our costs and the complexity of compliance, will be time-consuming, and could have a material adverse effect on our results of operations.

40

If our processes and systems are not compliant with regulatory requirements, we could be subject to restrictions on marketing our products or could be delayed in submitting regulatory filings seeking approvals for our product candidates.
We have a number of regulated processes and systems that are required both prior to and following approval of our drugs and product candidates. These processes and systems are subject to continual review and periodic inspection by the FDA and other regulatory bodies. In addition, the clinical research organizations and other third parties that we work with in our non-clinical studies and clinical trials and our oversight of such parties are subject to similar reviews and periodic inspection by the FDA and other regulatory bodies. If compliance issues are identified at any point in the development and approval process, we may experience delays in filing for regulatory approval for our product candidates, or delays in obtaining regulatory approval after filing, if at all. Any later discovery of previously unknown problems or safety issues with approved drugs or manufacturing processes, or failure to comply with regulatory requirements, may result in restrictions on such drugs or manufacturing processes, withdrawal of drugs from the market, the imposition of civil or criminal penalties or a refusal by the FDA and/or other regulatory bodies to approve pending applications for marketing approval of new drugs or supplements to approved applications, any of which could have a material adverse effect on our business. In addition, we are party to agreements that transfer responsibility for complying with specified regulatory requirements, such as filing and maintenance of marketing authorizations and safety reporting or compliance with manufacturing requirements, to our collaborators and third-party manufacturers. If our collaborators or third-party manufacturers do not fulfill these regulatory obligations, any drugs for which we or they obtain approval may be subject to later restrictions on manufacturing or sale, which could have a material adverse effect on our business.
We are subject to various and evolving laws and regulations governing the privacy and security of personal data, and our failure to comply could adversely affect our business, result in fines and/or criminal penalties, and damage our reputation.
We are subject to data privacy and security laws and regulations in various jurisdictions that apply to the collection, storage, use, sharing, and security of personal data, including health information, and impose significant compliance obligations. In addition, numerous other federal and state laws, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use, disclosure and security of personal information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business.
For example, the E.U. General Data Protection Regulation, or GDPR, went into effect in 2018 and has imposed new obligations on us with respect to our processing of personal data and the cross-border transfer of such data, including higher standards of obtaining consent, more robust transparency requirements, data breach notification requirements, requirements for contractual language with our data processors, and stronger individual data rights. Different E.U. member states have interpreted the GDPR differently and many have imposed additional requirements, which add to the complexity of processing personal data in the E.U. The GDPR also imposes strict rules on the transfer of personal data to countries outside the E.U., including the U.S. and the U.K., and permits data protection authorities to impose large penalties for violations of the GDPR. The GDPR rules related to cross border data transfers continue to evolve based on E.U. court decisions and regulator guidance, which presents certain practical challenges to compliance. Compliance with the GDPR is a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with any activities falling within the scope of the GDPR.
In the U.S., California has passed the California Consumer Privacy Act (the “CCPA”), which went into effect on January 1, 2020. In November 2020, California also passed the California Privacy Rights Act (the “CPRA”), which expands and builds upon the consumer privacy rights of the CCPA. Certain other states have also enacted legislation governing the protection of personal data and several other states and the federal government are actively considering similar proposed legislation. Additionally, Brazil passed the General Data Protection Law, which went into effect in August 2020. While we continue to address the implications of the new data privacy regulations, data privacy remains an evolving landscape at both the domestic and international level, with new regulations coming into effect and continued legal challenges. Each law is also subject to various interpretations by courts and regulatory agencies, creating even more uncertainty. While we have a global privacy program that addresses such laws and regulations, our efforts to comply with the evolving data protection rules may be unsuccessful.
We must devote significant resources to understanding and complying with the changing landscape in this area. Failure to comply with data protection laws may expose us to risk of enforcement actions taken by data protection authorities, private

41

rights of action in some jurisdictions, and potential significant penalties if we are found to be non-compliant. Failure to comply with the GDPR and applicable national data protection laws of European Economic Area member states could lead to fines of up to €20,000,000 or up to 4% of the total worldwide annual revenue of the preceding financial year, whichever is higher. Some of these laws and regulations also carry the possibility of criminal sanctions. For example, while we are not directly subject to the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, or HIPAA, we could be subject to penalties, including criminal penalties if we knowingly obtain or disclose individually identifiable health information from a HIPAA-covered health care provider or research institution that has not complied with HIPAA’s requirements for disclosing such information. In addition, the commercialization of cell and gene therapies requires the collection and processing of a greater amount of personal data than traditional therapies, potentially increasing risk. Furthermore, the number of government investigations related to data security incidents and privacy violations continue to increase and government investigations typically require significant resources and generate negative publicity, which could harm our business and our reputation.
The COVID-19 pandemic has added further complexity to the processing of personal data. For example, safety measures and government health regulations intended to protect our employees, contractors, and other visitors to our sites may require the collection of certain personal data. Although we are focused on ensuring that personal data is properly protected, our efforts may be unsuccessful and we could unintentionally be subject to unauthorized access or disclosure of such personal data.
If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.
Our research and development efforts involve the regulated use of hazardous materials, chemicals, and various controlled and radioactive compounds. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards prescribed by state, federal and foreign regulations, the risk of loss of, or accidental contamination or injury from, these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We also are subject to numerous environmental, health, and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens, and the handling of biohazardous materials. Although we maintain workers’ compensation insurance to cover us for costs we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We maintain insurance to cover pollution conditions or other extraordinary or unanticipated events relating to our use and disposal of hazardous materials that we believe is appropriate based on the small amount of hazardous materials we generate. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations.
Risks Related to Business Development Activities
Our ability to execute on our long-term strategy depends in part on our ability to engage in transactions and collaborations with other entities that add to our pipeline or provide us with new commercial opportunities.
In order to achieve our long-term business objectives, we seek to license or acquire products, product candidates and other technologies that have the potential to complement our ongoing research and development efforts, access emerging technologies and license or acquire pipeline assets. These transactions may be similar to prior transactions, may be structured differently than prior transactions, or may involve larger transactions or later-stage assets. We have faced and will continue to face significant competition for the acquisition of rights to these types of products, product candidates and other technologies from a variety of other companies, many of which have significantly more financial resources and experience in business development activities than we have. In addition, non-profit organizations may be willing to provide capital to the companies that control additional products, product candidates or technologies, which may provide incentives for companies to advance these products, product candidates or technologies independently. Also, the cost of acquiring, in-licensing or otherwise obtaining rights to such products, product candidates or other technologies has grown dramatically in recent years and may be at levels that we cannot afford or that we believe are not justified by market potential. As a result, we may not be able to acquire, in-license or otherwise obtain rights to additional products, product candidates or other technologies on acceptable terms or at all.

42

We may not realize the anticipated benefits of acquisitions of businesses or technologies, and the integration following any such acquisition may disrupt our business and management.
It is challenging to effectively integrate businesses and technologies that we acquire, including the acquisitions of Semma and Exonics and the exclusive licenses that we have acquired from CRISPR and Moderna, and we may not realize the benefits anticipated from such transactions. Achieving the anticipated benefits of any transaction and successfully integrating acquired businesses or technologies involves a number of risks, including:
•failure to successfully develop and commercialize the acquired products, product candidates or technologies or to achieve other strategic objectives;
•delays or inability to progress preclinical programs into clinical development or unfavorable data from clinical trials evaluating the acquired or licensed product or product candidates;
•difficulty in integrating the products, product candidates, technologies, business operations and personnel of an acquired asset or company;
•disruption of our ongoing business and distraction of our management and employees from daily operations or other opportunities and challenges;
•the potential loss of key employees of an acquired company;
•entry into markets in which we have no or limited direct prior experience or where competitors in such markets have stronger market positions;
•potential failure of the due diligence processes to identify significant problems, liabilities or challenges of an acquired company, or acquired or licensed products, product candidate or technology, including but not limited to, problems, liabilities or challenges with respect to intellectual property, clinical or non-clinical data, safety, accounting practices, employee, or third-party relations and other known and unknown liabilities;
•liability for activities of the acquired company or licensor before the acquisition or license, including intellectual property infringement claims, violations of laws, commercial disputes, tax liabilities, and other known and unknown liabilities;
•exposure to litigation or other claims in connection with, or inheritance of claims or litigation risk as a result of an acquisition or license, including but not limited to, claims from terminated employees, customers, former equity holders or other third parties; and
•difficulties in the integration of the acquired company’s departments, systems, including accounting, human resource and other administrative systems, technologies, books and records, and procedures, as well as in maintaining uniform standards, controls, including internal control over financial reporting required by the Sarbanes-Oxley Act of 2002 and related procedures and policies.
Acquisitions, licensing arrangements and other strategic transactions are inherently risky, and ultimately, if we do not complete an announced acquisition, collaboration or strategic transaction or integrate an acquired or licensed asset, business or technology successfully and in a timely manner, we may not realize the anticipated benefits of the strategic transaction.
We may later incur impairment charges related to assets acquired in any such transaction. Even if we achieve the long-term benefits associated with our strategic transactions, our expenses and short-term costs may increase materially and adversely affect our liquidity and short-term net income. Future strategic transactions could result in potentially dilutive issuances of equity securities, the incurrence of debt, the creation of contingent liabilities, impairment expenses related to goodwill, or impairment or amortization expenses related to other intangible assets, all of which could harm our financial condition.

43

We face risks in connection with existing and future collaborations with respect to the development, manufacture and commercialization of our products and product candidates.
The risks that we face in connection with our current collaborations, including CRISPR, and any future collaborations, include the following:
•Our collaborators may change the focus of their development and commercialization efforts or may have insufficient resources or expertise to effectively develop, manufacture or commercialize our product candidates.
•The ability of some of our therapies to reach their potential could be limited if collaborators are unable to effectively develop, manufacture or commercialize these therapies or product candidates or decrease or fail to increase development or commercialization efforts related to those therapies or product candidates. Our collaboration agreements allocate development, manufacturing and commercialization responsibilities between us and our collaborators and provide our collaborators with a level of discretion in determining the amount and timing of efforts and resources that they will apply to these collaborations.
•Our collaborators may have limited experience in developing, manufacturing and commercializing therapies, either generally, or in the specific therapeutic area.
•Collaboration agreements may have the effect of limiting the areas of research and development that we may pursue, either alone or in collaboration with third parties.
•Collaborators may develop and commercialize, either alone or with others, drugs that are similar to or competitive with the products or product candidates that are the subject of their collaborations with us.
•Disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities or costs for us with respect to product candidates, or might result in litigation or arbitration. Any such disagreements would divert management attention and resources and would be time-consuming and expensive.
•Collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation.
•Collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability.
•Investigations and/or compliance or enforcement actions against a collaborator, which may expose us to indirect liability as a result of our partnership with such collaborator.
•Our collaboration agreements are subject to termination under various circumstances.
•We may be unable to control the resources our collaborators devote to our programs, products or product candidates, and the priorities and strategic objectives of our collaborators may not align precisely with ours.
Additionally, if a collaborator were to be involved in a business combination with a third party, it might de-emphasize or terminate the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities could be harmed.
We may not be able to attract collaborators or external funding for the development and commercialization of certain of our product candidates.
As part of our ongoing strategy, we may seek additional collaborative arrangements or external funding for certain of our development programs and/or seek to expand existing collaborations to cover additional commercialization and/or development activities. We have a number of research programs and clinical development programs, some of which are being developed in collaboration with a third party. At any time, we may determine that in order to continue development of a product candidate or program or successfully commercialize a drug we need to identify a collaborator or amend or expand an

44

existing collaboration. For example, in April 2021, we amended and restated the original JDCA, positioning us to lead global development, manufacturing and commercialization of CTX001, with support from CRISPR.
Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, EMA or other regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of the applicable intellectual property, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. Potentially, and depending on the circumstances, we may desire that a collaborator either agree to fund portions of a drug development program led by us, or agree to provide all of the funding and directly lead the development and commercialization of a program. No assurance can be given that any efforts we make to seek additional collaborative arrangements will be successfully completed on a timely basis or at all. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we are unable to enter into acceptable collaborative relationships, one or more of our development programs could be delayed or terminated and the possibility of our receiving a return on our investment in the program could be impaired.
Risks Related to Supply, Manufacturing and Reliance on Third Parties
We depend on third-party manufacturers and our internal capabilities to manufacture our products and the materials we require for our clinical trials. We may not be able to maintain our third-party relationships and could experience supply disruptions outside of our control.
We rely on a worldwide network of third-party manufacturers and our internal capabilities, including our own manufacturing facility in Boston, to manufacture product candidates for clinical trials as well as our medicines for commercial use. We could be subject to significant supply interruptions as a result of disruptions to third party or our internal manufacturing capabilities. Our supply chain for sourcing raw materials and manufacturing drug product ready for distribution, including obtaining necessary supplies, is a multi-step international endeavor. Third-party contract manufacturers, including some in China, perform different parts of our manufacturing process. Contract manufacturers may supply us with raw materials, convert these raw materials into drug substance and/or convert the drug substance into final dosage form. Third parties are used for packaging, warehousing and distribution of products. In cell and genetic therapies, third parties also will be used to both manufacture and deliver our therapies, which requires significant expertise and capacity to meet our requirements. This capacity may be limited by the number of other clinical trials and commercial manufacturing ongoing for other companies seeking similar support.
If third parties are unwilling or unable to meet our requirements, including as a result of the COVID-19 pandemic or because of their own supply or capacity issues, we could experience supply disruptions outside of our control. Additionally, manufacturing facilities, both foreign and domestic, are subject to inspections by the FDA and other U.S. and foreign government authorities. Although we actively engage with regulatory authorities, the timing of regulatory approvals for each of these facilities may be delayed for a variety of reasons, including as a result of the COVID-19 pandemic. In addition, we and the third parties with whom we engage are required to maintain compliance with quality regulations globally. An inability to maintain compliance with such regulations, including cGMP requirements, could cause significant disruptions to our business and operations.
Additionally, establishing, managing and expanding our global supply chain requires a significant financial commitment and the creation and maintenance of our numerous third-party contractual relationships. Although we attempt to manage the business relationships with companies in our supply chain, we could be subject to supply disruptions outside of our control.
Supply disruptions may result from a number of factors, including shortages in product raw materials, labor or technical difficulties, regulatory inspections or restrictions, shipping or customs delays, general global supply chain disruptions, or any other performance failure by us or any third-party manufacturer on which we rely. We may also experience supply disruptions if regulatory agencies are unable to inspect the manufacturing facilities on which we rely. Any such disruptions could disrupt sales of our products and/or the timing or advancement of our clinical trials.
While we have developed internal capabilities to supply product candidates for use in our clinical trials as well as our

45

medicines for commercial sale, a majority of the manufacturing steps needed to produce our medicines, product candidates, and drug products are performed through a third-party manufacturing network. We expect that we will continue to rely on third parties to meet our commercial supply needs and a significant portion of our clinical supply needs for the foreseeable future.
If we or our third-party manufacturers become unable or unwilling to continue manufacturing product and we are not able to promptly identify another manufacturer, we could experience a disruption in the commercial supply of our then-marketed medicines, which would have a significant effect on patients, our business, and our product revenues. Similarly, a disruption in the clinical supply of product candidates could delay the completion of clinical trials and affect timelines for regulatory filings. We have a limited number of critical steps in our manufacturing process that are single sourced, including for recently launched products. To ensure the stability of our supply chains, we continue to develop alternatives for our manufacturing processes. However, there can be no assurance that we will be able to establish and maintain additional manufacturers or capacity for all of our product candidates and products on a timely basis or at all.
In the course of providing its services, a contract manufacturer may develop process technology related to the manufacture of our products or product candidates that the manufacturer owns, either independently or jointly with us. This would increase our reliance on that manufacturer or require us to obtain a license from that manufacturer in order to have our products or product candidates manufactured by other suppliers utilizing the same process.
We rely on third parties to conduct pre-clinical work, clinical trials and other activities, and those third parties may not perform satisfactorily, including failing to meet established deadlines for the completion of such studies and/or trials or failing to satisfy regulatory requirements.
We rely on third parties such as CROs to help manage certain pre-clinical work and our clinical trials and on medical institutions, clinical investigators, and clinical research organizations such as the Therapeutic Development Network, which is primarily funded by the CFF, to assist in the design and review of, and to conduct our clinical trials, including enrolling qualified patients. In addition, we engage third party contractors to support numerous other research, commercial and administrative activities. Our reliance on these third parties for clinical development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the clinical trial. Moreover, the FDA requires us to comply with standards, commonly referred to as good laboratory practices and good clinical practices, for conducting, recording and reporting the results of pre-clinical and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Such standards, particularly with respect to newer cell and genetic therapies, will continue to evolve and subject us and third parties to new or changing requirements.
If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be required to replace them. Although we believe that there are a number of other third-party contractors we could engage to continue the activities, it may result in a delay of the affected clinical trial, drug development program or applicable activity. If clinical trials are not conducted in accordance with our contractual expectations or regulatory requirements, action by regulatory authorities might significantly and adversely affect the conduct or progress of these clinical trials or in specific circumstances might result in a requirement that a clinical trial be redone. Accordingly, our efforts to obtain regulatory approvals for and commercialize our product candidates could be delayed. In addition, failure of any third-party contractor to conduct activities in accordance with our expectations, including as a result of the COVID-19 pandemic, could adversely affect the relevant research, development, commercial or administrative activity.
Risks Related to Intellectual Property
If our patents do not protect our products or our products infringe third-party patents, we could be subject to litigation which could result in injunctions preventing us from selling our products or substantial liabilities.
We own and/or control numerous issued patents and pending patent applications in the U.S., as well as counterparts in other countries. Our success will depend, in significant part, on our ability to obtain and defend U.S. and foreign patents covering our products, their uses and our processes, to preserve our trade secrets and to operate without infringing the proprietary rights of third parties. We cannot be certain that any patents will issue from our pending patent applications or, even if patents issue or have issued, that the issued claims will provide us with adequate protection against competitive products or otherwise be commercially valuable.

46

Due to evolving legal standards relating to the patentability, validity, and enforceability of patents covering pharmaceutical and biotechnological inventions and the scope of claims made under these patents, our ability to obtain, maintain and enforce patents is uncertain and involves complex legal and factual questions. Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents in the U.S. The Leahy-Smith America Invents Act, or the Leahy-Smith Act, made a number of significant changes to U.S. patent law in 2011. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. For example, the first to file provisions limit the rights of an inventor who is the first to invent an invention but is not the first to file an application claiming that invention. U.S. and foreign patent applications typically are maintained in confidence for a period of time after they initially are filed with the applicable patent office. Consequently, we cannot be certain that we were the first to invent, or the first to file patent applications on, our products or product candidates or their use. If a third party also has filed a U.S. patent application relating to our products or product candidates, their uses, or a similar invention, we may have to participate in legal or administrative proceedings to determine priority of invention. For applications governed by the Leahy-Smith Act, if a third-party has an earlier filed U.S. patent application relating to our products or product candidates, their uses, or a similar invention, we may be unable to obtain an issued patent from our application.
The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability. Our patents may be challenged by third parties and certain of our patents have been challenged. This could result in the patent being deemed invalid, unenforceable or narrowed in scope, or the third party may circumvent any such issued patents. Also, our pending patent applications may not issue, and we may not receive any additional patents.
Our patents or patents we license might not contain claims that are sufficiently broad to prevent others from developing competing products. For instance, issued patents, or patents that may issue in the future, (i) relating to our small molecules may be limited to a particular molecule or molecules and may not cover similar molecules that have similar clinical properties, and (ii) relating to cell or genetic therapies may not cover similar technologies that would allow competitors to achieve similar results. Consequently, our competitors may independently develop competing products that do not infringe our patents or other intellectual property. In addition, CRISPR only has co-exclusive rights to the patent rights that protect the core CRISPR/Cas9 gene-editing technology.
The laws of many foreign jurisdictions do not protect intellectual property rights to the same extent as in the U.S. and many companies in our segment of the pharmaceutical industry have encountered significant difficulties in protecting and defending such rights in foreign jurisdictions. If we encounter such difficulties in protecting or are otherwise precluded from effectively protecting our intellectual property rights in foreign jurisdictions, our business could be substantially harmed.
Because of the extensive time required for the discovery, development, testing and regulatory review of product candidates, it is possible that a patent may expire before a product candidate can be commercialized, or a patent may expire or remain in effect for only a short period following commercialization of such product candidate. This would result in a minimal or non-existent period of patent exclusivity. If our product candidates are not commercialized significantly ahead of the expiration date of any applicable patent, or if we have no patent protection on such product candidates, then, to the extent available we would rely on other forms of exclusivity, such as regulatory exclusivity provided by the FDCA and its counterpart agencies in various jurisdictions, and/or orphan drug exclusivity.
Uncertainty over intellectual property in the pharmaceutical and biotechnology industry has been the source of litigation and other disputes that are inherently costly and unpredictable.
There is considerable uncertainty within our industry about the validity, scope, and enforceability of many issued patents in the U.S. and elsewhere in the world, and, to date, the law and practice remains in substantial flux both in the agencies that grant patents and in the courts. We cannot currently determine the ultimate scope and validity of patents which may be granted to third parties in the future or which patents might be asserted as being infringed by the manufacture, use and sale of our products.
There has been, and we expect that there may continue to be, significant litigation in the pharmaceutical industry regarding patents and other intellectual property rights. Litigation, arbitrations, administrative proceedings, and other legal actions with private parties and governmental authorities concerning patents and other intellectual property rights may be protracted, expensive, and distracting to management. Competitors may sue us as a way of delaying the introduction of our products or to remove our products from the market. Any litigation, including litigation related to Abbreviated New Drug Applications, or ANDA, litigation related to 505(b)(2) applications, interference proceedings to determine priority of

47

inventions, derivations proceedings, inter partes review, oppositions to patents in foreign countries, litigation against our collaborators or similar actions, may be costly and time consuming and could harm our business. We expect that litigation may be necessary in some instances to determine the validity and scope of certain of our proprietary rights. Litigation may be necessary in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products. Ultimately, the outcome of such litigation could adversely affect the validity and scope of our patent or other proprietary rights, hinder our ability to manufacture and market our products, or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our consolidated financial statements.
On July 24, 2020, we filed a lawsuit against Sun Pharmaceutical Industries Limited, or Sun, in the U.S. District Court for the District of Delaware, or the District Court, alleging infringement of U.S. Patent No. 10,646,481, or the ’481 patent. The lawsuit follows Vertex’s receipt of a Notice Letter on June 11, 2020, advising that Sun had submitted an ANDA to the FDA seeking approval to manufacture and market a generic version of the 150 mg tablet of KALYDECO in the U.S. The Notice Letter indicated that Sun submitted a “Paragraph IV” certification to the FDA in which Sun asserted that the ’481 patent is invalid or would not be infringed by Sun’s generic product. The ’481 patent, which expires in 2029, was issued on May 12, 2020, and listed in the Orange Book with respect to KALYDECO 150 mg tablets on June 1, 2020. Sun does not appear to challenge our other U.S. patents covering KALYDECO.
On July 13, 2021, we filed a lawsuit against Lupin Limited and Lupin Pharmaceuticals, Inc., or, collectively, Lupin, in the District Court alleging infringement of the ’481 patent. The lawsuit follows our receipt of a Notice Letter on June 2, 2021 advising that Lupin had submitted an ANDA to the FDA seeking approval to manufacture and market a generic version of the 150 mg tablet of KALYDECO in the U.S. The Notice Letter indicated that Lupin submitted a “Paragraph IV” certification to the FDA in which Lupin asserts that the ’481 patent is invalid or would not be infringed by Lupin’s generic product. Lupin does not appear to challenge our other U.S. patents covering KALYDECO.
On September 24, 2021, the District Court consolidated the cases against Sun and Lupin described above and scheduled trial for the consolidated cases beginning on October 23, 2023. We intend to vigorously enforce its intellectual property rights relating to KALYDECO, including the ’481 patent.
CRISPR has licensed certain rights to a worldwide patent portfolio that covers various aspects of the CRISPR/Cas9 editing platform technology including, for example, compositions of matter and methods of use, including their use in targeting or cutting DNA from Dr. Charpentier, one of the named inventors of this patent portfolio. The patent portfolio also has named inventors who assigned their rights to the CVC Group. For example, in connection with their collaboration, Novartis and Intellia Therapeutics, Inc. have reportedly obtained a license to this patent portfolio in certain fields. Patents and patent applications in this patent portfolio have been the subject of numerous contentious proceedings in the U.S., Europe, and other jurisdictions, including interference proceedings in the USPTO between the CVC Group and (separately) the Broad Institute, Sigma-Aldrich and ToolGen. Decisions rendered to date in these proceedings may be subject to appeal. To date, both the CVC Group and the Broad Institute have obtained granted patents that purport to cover aspects of CRISPR/Cas9 editing platform technology. The patents and patent applications within the patent portfolios of the CVC Group, the Broad Institute, Sigma-Aldrich, and/or ToolGen are, or may in the future be, involved in proceedings similar to interferences or priority disputes in Europe or other foreign jurisdictions. We can give no assurances to the ultimate outcome of these proceedings or the disputes between the CVC Group and the Broad Institute, Sigma-Aldrich and ToolGen.
In addition to the Broad Institute, other third parties have filed patent applications claiming CRISPR/Cas9-related inventions and may allege that they invented one or more of the inventions claimed by the CVC Group. Thus, the USPTO may, in the future, declare an interference between certain CVC Group patent applications and one or more patent applications. The Broad Institute, as well as other third parties, could seek to assert its issued patents against us based on our CRISPR/Cas9-based activities, including commercialization. Defense of these claims, regardless of their merit, could involve substantial litigation expense and could result in a substantial diversion of management and other employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. In that event, we could be unable to further develop and commercialize CTX001 or other products that we may develop using the CRISPR/Cas9 technology we license from CRISPR.
To the extent that valid present or future third-party patents or other intellectual property rights cover our products, product candidates or technologies, we or our strategic collaborators may seek licenses or other agreements from the holders of such rights in order to avoid or settle legal claims. Such licenses may not be available on acceptable terms, which may

48

hinder our ability to, or prevent us from being able to, manufacture and market our products. Payments under any licenses that we are able to obtain would reduce our profits derived from the covered products.
We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.
Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee’s former employer. Litigation may be necessary to defend against these claims.
In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.
If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management.
Risks Related To Our Operations
Risks associated with operating in foreign countries could materially adversely affect our business.
We have expanded our international operations over the past several years in order to market our CF medicines and expand our research and development capabilities. New laws and industry codes in the E.U. and elsewhere have expanded transparency requirements regarding payments and transfers of value to healthcare professionals, requirements surrounding patient-level clinical trial data, the protection of personal data and increased sanctions for violations. Collectively, our expansion and these new requirements are adding to our compliance costs and potentially exposes us to sanctions in the event of an infringement or failure to report in these jurisdictions. In addition, a significant portion of our commercial supply chain, including sourcing of raw materials and manufacturing, is located in China and the E.U. Consequently, we are, and will continue to be, subject to risks related to operating in foreign countries, including risks relating to intellectual property protections and business interruptions, including as a result of the COVID-19 pandemic. These risks are increased with respect to countries such as China that have substantially different local laws and business practices and weaker protections for intellectual property. Risks associated with operating a global biotechnology company include:
•differing regulatory requirements for drug approvals and regulation of approved drugs in foreign countries;
•varying reimbursement regimes and difficulties or the inability to obtain reimbursement for our products in foreign countries in a timely manner;
•differing patient treatment infrastructures, particularly since our business is focused on the treatment of serious diseases that affect relatively smaller numbers of patients and are typically prescribed by specialist physicians;
•collectability of accounts receivable;
•changes in tariffs, trade barriers, and regulatory requirements, the risks of which appear to have increased in the current political environment;
•economic weakness, including recession and inflation, or political instability in particular foreign economies and markets;
•differing levels of enforcement and/or recognition of contractual and intellectual property rights;
•complying with local laws and regulations, which can change significantly over time;

49

•foreign taxes, including withholding of payroll taxes;
•foreign currency fluctuations, which could result in reduced revenues or increased operating expenses, and other obligations incident to doing business or operating in another country;
•workforce uncertainty in countries where labor unrest is more common than in the U.S.;
•reliance on third-party vendors and suppliers;
•import and export licensing requirements, tariffs, and other trade and travel restrictions;
•global or regional public health emergencies that could affect our operations or business;
•production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and
•business interruptions resulting from geo-political actions, including war and terrorism.
Our revenues are subject to foreign exchange rate fluctuations due to the global nature of our operations. Although we have foreign currency forward contracts to hedge forecasted product revenues denominated in foreign currencies, our efforts to reduce currency exchange losses may not be successful. As a result, currency fluctuations among our reporting currency, the U.S. dollar, and the currencies in which we do business will affect our operating results, often in unpredictable ways.
In addition, our international operations are subject to regulation under U.S. law. For example, the FCPA prohibits U.S. companies and their representatives from offering, promising, authorizing or making payments to foreign officials for the purpose of obtaining or retaining business abroad. In many countries, the health care professionals we regularly interact with may meet the definition of a foreign government official for purposes of the FCPA. We also are subject to import/export control laws. Failure to comply with domestic or foreign laws could result in various adverse consequences, including the possible delay in approval or refusal to approve a product, recalls, seizures, withdrawal of an approved product from the market, the imposition of civil or criminal sanctions, the prosecution of executives overseeing our international operations and corresponding bad publicity and negative perception of our company in foreign countries.
If we fail to attract and retain skilled employees, our business could be materially harmed.
Due to the highly technical nature of our drug discovery and development activities, we require the services of highly qualified and trained scientists who have the skills necessary to conduct these activities. In addition, we need to attract and retain employees with experience in marketing and commercialization of medicines. We have entered into employment agreements with some executives and provide stock-related compensation benefits to all of our key employees that vest over time and therefore induce them to remain with us. However, the employment agreements can be terminated by the executive on relatively short notice. The value to employees of stock-related benefits that vest over time can be significantly affected by movements in our stock price and business performance, and may, at any point in time, be insufficient to counteract more lucrative offers from other companies. We face intense competition for our personnel from our competitors and other companies throughout our industry, especially with respect to employees with expertise in cell or genetic therapies. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Moreover, the growth of local biotechnology companies and the expansion of major pharmaceutical companies into the Boston area has increased competition for the available pool of skilled employees, especially in technical fields. The high cost of living can make it difficult to attract employees from other parts of the country to our Massachusetts headquarters. Current job market dynamics, caused in part by the effects of COVID-19 and other macro-level events, with many employers unable to fill existing openings at all levels of their organizations, could result in significant increases to our costs to recruit and retain employees. Challenges could adversely affect our operations and financial results if we do not have sufficient staff to perform necessary functions. In addition, the available pool of skilled employees would be further reduced if immigration laws change in a manner that increases restrictions on immigration. Our ability to continue to commercialize our products and achieve our research and development objectives depends on our ability to respond effectively to these demands. If we are unable to hire and retain qualified personnel, there could be a material adverse effect on our business.
We are subject to risks associated with the COVID-19 pandemic.
The COVID-19 pandemic has broadly affected the global economy, resulted in significant travel and work restrictions in

50

many regions and has put a significant strain on healthcare resources. COVID-19 has had, and we expect it will continue to have, an impact on our operations, an impact on the operations of our collaborators, third-party contractors and other entities, including governments, governmental agencies, and payors, with which we interact, and an impact on the people with CF who take our medicines. In addition, we have seen some delays in enrollment in certain clinical trials, supply chain delays, and regulatory delays due to the COVID-19 pandemic. To date, the most significant effect on our business operations has been the requirement that a majority of our employees work remotely. 
We continue to monitor local COVID-19 trends and government guidance for each of our site locations and are utilizing a site-specific approach to assess and permit employee access to our sites. Currently, our sites are open where appropriate and permitted by local laws and guidelines. There can be no assurance that our sites will remain open, when additional employees will gain access to our sites, or whether we will be required to pause or delay enrollment and dosing at clinical trial sites. Any site closure, pause, or delay of a clinical trial could harm our operations and delay the development of our product candidates. In addition, even if sites or clinical trials are open for enrollment, COVID-19 may nevertheless impact clinical trial enrollment or participation, for example due to suspension of in-person procedures required for enrollment, government shut-down orders, or decreased patient willingness to participate compared to pre-COVID-19 pandemic levels. COVID-19 may also impact uptake of our medicines generally and patient retention in clinical trials, potentially resulting in higher drop-out rates or missed visits, which may negatively affect the strength of our clinical trial data.
Health regulatory agencies globally may experience disruptions in their operations as a result of the COVID-19 pandemic. The FDA and comparable foreign regulatory agencies may have slower response times or lack resources to continue to monitor our clinical trials or to engage in other activities related to review of regulatory submissions in drug development. In response to the COVID-19 pandemic and the public health emergency declaration in the U.S., on March 10, 2020, the FDA announced its intention to temporarily postpone most inspections of foreign manufacturing facilities and products, and it subsequently postponed routine surveillance inspections of domestic manufacturing facilities and provided guidance regarding the conduct of clinical trials. In July 2021, the FDA stated that it had begun transitioning back to standard operations for domestic inspections, while continuing to prioritize mission-critical work for foreign inspections. The FDA may not be able to maintain this pace and further delays or setbacks are possible in the future. As a result, review, inspection, and other timelines for our product candidates may be materially delayed for an unknown period of time.
In the future, the economic impacts of the COVID-19 pandemic could affect our business directly or indirectly, including potentially affecting the net prices for our products through changes in our payor mix as a result of increased unemployment in the U.S. or increased pressure on healthcare costs in the U.S. and around the world. The effects on our research, development, manufacturing, and commercialization activities, including the continued launch and uptake of our products, will be dependent on, among other things, the severity and duration of the COVID-19 pandemic and any worsening of the global economic environment as a result thereof, as well as the impact of the pandemic on our third-party manufacturers, suppliers, distributors, subcontractors and customers. While the ultimate impact of COVID-19 on our business is highly uncertain, any negative impacts that materialize could materially adversely affect our operations, financial performance and stock price. Any negative impacts of COVID-19, alone or in combination with others, could exacerbate other risk factors discussed herein. The full extent to which the COVID-19 pandemic will negatively affect our operations, financial performance, and stock price will depend on future developments that are highly uncertain and cannot be predicted, including the scope and duration of the pandemic and actions taken by governmental authorities and other third parties in response to the pandemic.
If we fail to manage our operations effectively, our business may suffer.
We have expanded and are continuing to expand our global operations and capabilities, which has placed, and will continue to place, significant demands on our management and our operational, research and development and financial infrastructure. To effectively manage our business, we need to:
•implement and clearly communicate our corporate-wide strategies;
•enhance our operational and financial infrastructure, including our controls over records and information;
•enhance our operational, financial and management processes, including our cross-functional decision-making processes and our budget prioritization systems;
•train and manage our global employee base; and

51

•enhance our compliance and legal resources.
Our business faces potential risks relating to the U.K.’s withdrawal from the E.U.
Our European headquarters and European research facility are located in the U.K. On January 31, 2020, the U.K. formally withdrew from the E.U., also known as Brexit. The U.K. and the E.U. negotiated a detailed post-Brexit Trade and Cooperating Agreement which went into effect on January 1, 2021. As of January 1, 2021, E.U. Treaties, E.U. free movement rights and the general principals of E.U. law no longer apply in relation to the U.K. By virtue of the E.U. (Withdrawal) Act 2018, E.U. relations will continue to apply in U.K. domestic law to the extent that they are not modified or revoked by regulations under that Act. Brexit could lead to legal uncertainty and potentially divergent national laws and regulations as the U.K. determines which E.U. laws to replace or replicate. Given the lack of comparable precedent, it is unclear what financial, trade, regulatory and legal implications the withdrawal of the U.K. from the E.U. would have and how such withdrawal would affect us. Any of these effects of Brexit, among others, could adversely affect our business, financial condition and operating results.
Our business has a substantial risk of product liability claims and other litigation liability.
We are or may be involved in various legal proceedings, including securities/shareholder matters and claims related to product liability, intellectual property, employment law, and breach of contract. Such proceedings may involve claims for, or the possibility of, damages or fines and penalties involving substantial amounts of money or other relief, including but not limited to civil or criminal fines and penalties. If any of these legal proceedings were to result in an adverse outcome, it could have a material adverse effect on our business.
With respect to product liability and clinical trial risks, in the ordinary course of business we are subject to liability claims and lawsuits, including potential class actions, alleging that our products or product candidates have caused, or could cause, serious adverse events or other injury. We have product liability insurance and clinical trial insurance in amounts that we believe are adequate to cover this risk. However, our insurance may not provide adequate coverage against all potential liabilities. If a claim is brought against us, we might be required to pay legal and other expenses to defend the claim, as well as pay uncovered damage awards resulting from a claim brought successfully against us and these damages could be significant and have a material adverse effect on our financial condition. Furthermore, whether or not we are ultimately successful in defending any such claims, we might be required to direct significant financial and managerial resources to such defense and adverse publicity is likely to result.
A breakdown or breach of our information technology systems could subject us to liability or interrupt the operation of our business.
We maintain and rely extensively on information technology systems and network infrastructures for the effective operation of our business. In the course of our business, we collect, store, and transmit confidential information (including personal information and intellectual property), and it is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. A disruption, infiltration, or failure of our information technology systems or any of our data centers as a result of software or hardware malfunctions, computer viruses, cyber-attacks, employee theft or misuse, power disruptions, natural disasters, floods or accidents could cause breaches of data security and loss of critical data, which in turn could materially adversely affect our business and subject us to both private and governmental causes of action. While we have implemented security measures to minimize these risks to our data and information technology systems and have adopted a business continuity plan to deal with a disruption to our information technology systems, there can be no assurance that our efforts to protect our data and information systems will prevent breakdowns or breaches in our systems that could adversely affect our business. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks or other related liabilities.
Cyber-attacks are increasing in their frequency, sophistication, and intensity, and are becoming increasingly difficult to detect. They are often carried out by well-resourced and skilled and parties, including nation states, organized crime groups, “hacktivists” and employees or contractors acting carelessly or with malicious intent. Cyber-attacks include deployment of harmful malware and key loggers, ransomware, denial-of-service attacks, malicious websites, the use of social engineering, and other means to affect the confidentiality, integrity and availability of our technology systems and data. Cyber-attacks also include manufacturing, hardware or software supply chain attacks, which could cause a delay in the manufacturing of products or products produced for contract manufacturing or lead to a data privacy or security breach. Our key business

52

partners face similar risks, and any security breach of their systems could adversely affect our security posture. In addition, our increased use of cloud technologies heightens these third party and other operational risks, and any failure by cloud or other technology service providers to adequately safeguard their systems and prevent cyber-attacks could disrupt our operations and result in misappropriation, corruption, or loss of confidential or propriety information. Risk of cyber-attack is increased with employees working remotely, including as a result of the ongoing COVID-19 pandemic. During this time, there is an increased risk that we may be vulnerable to cybersecurity-related events such as phishing attacks and other security threats as a result of our employees, third party vendors and collaborators working remotely from non-corporate managed networks.
If our facilities were to experience a catastrophic loss, our operations would be seriously harmed.
Most of our operations, including our research and development activities, are conducted in a limited number of facilities. If any of our major facilities were to experience a catastrophic loss, due to an earthquake, severe storms, fire or similar event, our operations could be seriously harmed. For example, our corporate headquarters, as well as additional leased space that we use for certain logistical and laboratory operations and manufacturing, are located in a flood zone along the Massachusetts coast. We have adopted a business continuity plan to address most crises. However, if we are unable to fully implement our business continuity plans, we may experience delays in recovery of data and/or an inability to perform vital corporate functions, which could result in a significant disruption in our research, development, manufacturing and/or commercial activities, large expenses to repair or replace the facility and/or the loss of critical data, which could have a material adverse effect on our business.
The use of social media platforms presents risks and challenges.
Social media is being used by third parties to communicate about our products and product candidates and the diseases our therapies are designed to treat. We believe that members of the CF community may be more active on social media as compared to other patient populations due to the demographics of this patient population. Social media practices in the pharmaceutical and biotechnology industries are evolving, which creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media platforms to comment on the effectiveness of, or adverse experiences with, a product or a product candidate, which could result in reporting obligations. In addition, our employees may engage on social media in ways that may not comply with legal or regulatory requirements, which may give rise to liability, lead to the loss of trade secrets and other intellectual property, or result in public disclosure of protected personal information. There is a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. Certain data protection regulations, such as the GDPR, apply to personal data contained on social media. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur harm to our business, including damage to our reputation.
Risks Related to Financial Results and Holding Our Common Stock
Our stock price may fluctuate.
Market prices for securities of companies such as ours are highly volatile. From January 1, 2021 to December 31, 2021, our common stock traded between $176.36 and $242.99 per share. The market for our stock, like that of other companies in the biotechnology industry, has experienced significant price and volume fluctuations. The future market price of our securities could be significantly and adversely affected by factors such as:
•the information contained in our quarterly earnings releases, including updates regarding our commercialized products or our product candidates, our net product revenues and operating expenses for completed periods and guidance regarding future periods;
•announcements of FDA actions with respect to our therapies or those of our competitors, or regulatory filings for our therapies or those of our competitors, or announcements of interim or final results of clinical trials or nonclinical studies relating to our therapies or those of our competitors;
•developments in domestic and international governmental policy or regulation, for example, relating to drug pricing;
•technological innovations or the introduction of new drugs by our competitors;

53

•government regulatory action;
•public concern as to the safety of drugs developed by us or our competitors;
•developments in patent or other intellectual property rights or announcements relating to these matters;
•information disclosed by third parties regarding our business or products;
•developments relating specifically to other companies and market conditions for pharmaceutical and biotechnology stocks or stocks in general;
•business development, capital structuring or financing activities; and
•general worldwide or national economic, political and capital market conditions, including as a result of the ongoing COVID-19 pandemic.
Following periods of volatility in the market price of a company’s securities, stockholder derivative lawsuits and securities class action litigation are common. Such litigation, if instituted against us or our officers and directors, could result in substantial costs and a diversion of management’s attention and resources.
Our effective tax rate fluctuates, and changes in tax laws, regulations and treaties, unfavorable resolution of tax contingencies or exposure to additional income tax liabilities could have a material impact on our future taxable income.
Our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate globally. Our effective tax rate may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability from country to country, the results of tax authority examinations/audits of our tax filings, adjustments to the value of our uncertain tax positions, changes in accounting for income taxes, and changes in tax laws or modifications of treaties in various jurisdictions. For example, changes to the U.S. tax code are anticipated under the current administration. Any of these factors could cause us to experience an effective tax rate that is significantly different from previous periods or our current expectations.
We assess the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where we have operations to determine the potential effect on our business and any assumptions we have made about our future taxable income. We cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on our business if they were to be enacted. Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the currently available option to deduct research and development expenditures and requires taxpayers to amortize them over five years. The U.S. Congress is considering legislation that would defer the amortization requirement to future periods, however, we have no assurance that the provision will be repealed or otherwise modified. If the requirement is not repealed or modified, it will have a material impact on our cash flows beginning in 2022.
Recommendations from the Organization for Economic Co-operation and Development that are part of the base erosion and profit shifting framework could result in changes in tax laws in jurisdictions in which we do business and adversely affect our provision for income taxes and our current rate. If these recommendations, or other changes in law, were adopted by the jurisdictions in which we do business, it could adversely affect our provision for income tax and our current rate.
We are subject to ongoing tax audits in various jurisdictions, and local tax authorities may disagree with certain positions we have taken and assess additional taxes. We regularly assess the probable outcomes of these audits to determine the appropriateness of our tax provision, and we have established contingency reserves for material tax exposures. However, the calculation of our tax exposures involves the application of complex tax laws and regulations in many jurisdictions, as well as interpretations as to the legality under E.U. state aid rules of tax advantages granted in certain jurisdictions. Therefore, there can be no assurance that we will accurately predict the outcomes of these disputes or other tax audits or that issues raised by tax authorities will be resolved at a financial cost that does not exceed our related reserves and the actual outcomes of these disputes and other tax audits could have a material impact on our results of operations or financial condition.
Our quarterly operating results are subject to significant fluctuation.
Our operating results have fluctuated from quarter to quarter in the past, and we expect that they will continue to do so in the future. Our revenues are primarily dependent on the amount of net product revenues from sales of our CF medicines. Our total net product revenues could vary on a quarterly basis based on, among other factors, the timing of orders from our

54

significant customers. Additional factors that have caused quarterly fluctuations to our operating results in recent years include variable amounts of revenues, expenses related to business development activities, changes in the fair value of our strategic investments, impairment charges, charges for excess and obsolete inventories, changes in the fair value of derivative instruments and the consolidation or deconsolidation of variable interest entities. Our revenues also are subject to foreign exchange rate fluctuations due to the global nature of our operations. Although we have foreign currency forward contracts to hedge forecasted product revenues denominated in foreign currencies, our efforts to reduce currency exchange losses may not be successful. As a result, currency fluctuations among our reporting currency, the U.S. dollar, and the currencies in which we do business may affect our operating results, often in unpredictable ways. Our quarterly results also could be materially affected by significant charges, which may or may not be similar to charges we have experienced in the past. Most of our operating expenses relate to our research and development activities, do not vary directly with the amount of revenues and are difficult to adjust in the short term. As a result, if revenues in a particular quarter are below expectations, we are unlikely to reduce operating expenses proportionately for that quarter. These examples are only illustrative and other risks, including those discussed in these “Risk Factors,” could also cause fluctuations in our reported financial results. Our operating results during any one period do not necessarily suggest the results of future periods.
We expect that results from our clinical development activities and the clinical development activities of our competitors will continue to be released periodically, and may result in significant volatility in the price of our common stock.
Any new information regarding our products and product candidates or competitive products or potentially competitive product candidates can substantially affect investors’ perceptions regarding our future prospects. We, our collaborators, and our competitors periodically provide updates regarding drug development programs, typically through press releases, conference calls and presentations at medical conferences. These periodic updates often include interim or final results from clinical trials conducted by us or our competitors and/or information about our or our competitors’ expectations regarding regulatory filings and submissions as well as future clinical development of our products or product candidates, competitive products or potentially competitive product candidates. The timing of the release of information by us regarding our drug development programs is often beyond our control and is influenced by the timing of receipt of data from our clinical trials and by the general preference among pharmaceutical companies to disclose clinical data during medical conferences. In addition, the information disclosed about our clinical trials, or our competitors’ clinical trials, may be based on interim rather than final data that may involve interpretation difficulties and may in any event not accurately predict final results. The release of such information may result in volatility in the price of our common stock.
General Risk Factors
We may need to raise additional capital that may not be available.
We may need to raise additional capital in the future. Any potential public offering, private placement or debt financing may or may not be similar to the transactions that we entered into in the past. Any debt financing may be on terms that, among other things, include conversion features that could result in dilution to our then-existing security holders and restrict our ability to pay interest and dividends—although we do not intend to pay dividends for the foreseeable future. Any equity financings would result in dilution to our then-existing security holders. If adequate funds are not available on acceptable terms, or at all, we may be required to curtail significantly or discontinue one or more of our research, drug discovery or development programs, including clinical trials, incur significant cash exit costs, or attempt to obtain funds through arrangements with collaborators or others that may require us to relinquish rights to certain of our technologies, products or product candidates. Based on many factors, including general economic conditions, additional financing may not be available on acceptable terms, if at all.
Future indebtedness could materially and adversely affect our financial condition, and the terms of our credit agreements impose restrictions on our business, reducing our operational flexibility and creating default risks.
In 2019, we entered into a credit agreement providing for a $500.0 million revolving facility. In September 2020, we entered into a second credit agreement providing for a $2.0 billion revolving facility. Each of the credit agreements provides that, subject to the satisfaction of certain conditions, we may request the borrowing capacity be increased by an additional $500.0 million. If we borrow under our current credit agreements or any future credit agreement, such indebtedness could have important consequences to our business, including increasing our vulnerability to general adverse financial, business, economic and industry conditions, as well as other factors that are beyond our control. The credit agreements require that we comply with certain financial covenants, including (i) a consolidated leverage ratio covenant and (ii) a consolidated interest coverage ratio covenant, in each case to be measured on a quarterly basis. Further, the credit agreements include negative

55

covenants, subject to exceptions, restricting or limiting our ability and the ability of our subsidiaries to, among other things, incur additional indebtedness, grant liens, engage in certain investment, acquisition and disposition transactions, pay dividends, repurchase capital stock and enter into transactions with affiliates. As a result, we may be restricted from engaging in business activities that may otherwise improve our business. Failure to comply with the covenants could result in an event of default that could trigger acceleration of our indebtedness, which would require us to repay all amounts owing under the credit agreements and/or our finance leases and could have a material adverse effect on our business. Additionally, our obligations under the credit agreements are unconditionally guaranteed by certain of our domestic subsidiaries.
Issuances of additional shares of our common stock could cause the price of our common stock to decline.
As of December 31, 2021, we had 254.5 million shares of common stock issued and outstanding. As of December 31, 2021, we also had outstanding options to purchase 3.6 million shares of common stock with a weighted-average exercise price of $141.76 per share. Outstanding vested options are likely to be exercised if the market price of our common stock exceeds the applicable exercise price, and, in the future, we expect to issue additional equity awards to directors and employees. In addition, we may issue additional common stock or restricted securities in the future as part of financing activities or business development activities and any such issuances may have a dilutive effect on our then-existing shareholders. Sales of substantial amounts of our common stock in the open market, or the availability of such shares for sale, could adversely affect the price of our common stock. The issuance of restricted common stock or common stock upon exercise of any outstanding options would be dilutive, and may cause the market price for a share of our common stock to decline.
There can be no assurance that we will repurchase shares of common stock or that we will repurchase shares at favorable prices.
In June 2021, our Board of Directors authorized a share repurchase program pursuant to which we are authorized to repurchase up to $1.5 billion of our common stock by December 31, 2022. As of December 31, 2021, we had repurchased $1.0 billion of common stock and had $0.5 billion of remaining authorization for additional share repurchases pursuant to this program.
Our stock repurchases will depend upon, among other factors, our cash balances and potential future capital requirements, results of operations, financial condition, and other factors that we may deem relevant. We can provide no assurance that we will repurchase stock at favorable prices, if at all.
We have adopted anti-takeover provisions and are subject to Massachusetts corporate laws that may frustrate any attempt to remove or replace our current management or effectuate a business combination involving Vertex.
Our corporate charter and by-law provisions and Massachusetts state laws may discourage certain types of transactions involving an actual or potential change of control of Vertex that might be beneficial to us or our security holders. Our by-laws grant the directors a right to adjourn annual meetings of shareholders, and certain provisions of our by-laws may be amended only with an 80% shareholder vote. We may issue shares of any class or series of preferred stock in the future without shareholder approval and upon such terms as our Board of Directors may determine. The rights of the holders of common stock will be subject to, and may be adversely affected by, the rights of the holders of any class or series of preferred stock that may be issued in the future. Massachusetts state law prohibits us from engaging in specified business combinations, unless the combination is approved or consummated in a prescribed manner, and prohibits voting by any shareholder who acquires 20% or more of our voting stock without shareholder approval. As a result, shareholders or other parties may find it more difficult to remove or replace our current management.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K, including the descriptions of our Business set forth in Part I, Item 1, our Risk Factors set forth in Part I, Item 1A, and our Management’s Discussion and Analysis of Financial Condition and Results of Operations set forth in Part II, Item 7, contains forward-looking statements. Forward-looking statements are not purely historical and may be accompanied by words such as “anticipates,” “may,” “forecasts,” “expects,” “intends,” “plans,” “potentially,” “believes,” “seeks,” “estimates,” and other words and terms of similar meaning. Such statements may relate to:
•our expectations regarding the amount of, timing of, and trends with respect to our financial performance, including revenues, costs and expenses, and other gains and losses;

56

•our expectations regarding clinical trials, including expectations for patient enrollment, development timelines, the expected timing of data from our ongoing and planned clinical trials, and regulatory authority filings and other submissions for our therapies;
•our ability to maintain and obtain adequate reimbursement for our products, our ability to launch, commercialize and market our products or any of our other therapies for which we obtain regulatory approval and our ability to obtain label expansions for existing therapies;
•our expectations regarding our ability to continue to grow our CF business by increasing the number of people with CF eligible and able to receive our medicines and providing improved treatment options for people who are already eligible for one of our medicines;
•the data that will be generated by ongoing and planned clinical trials and the ability to use that data to advance compounds, continue development or support regulatory filings;
•our beliefs regarding the support provided by clinical trials and preclinical and nonclinical studies of our therapies for further investigation, clinical trials or potential use as a treatment;
•our plans to continue investing in our research and development programs, including anticipated timelines for our programs, and our strategy to develop our pipeline programs, alone or with third party-collaborators;
•our beliefs regarding the approximate patient populations for the disease areas on which we focus;
•the potential benefits and therapeutic scope of our acquisitions and collaborations;
•the establishment, development and maintenance of collaborative relationships, including potential milestone payments or other obligations;
•potential business development activities, including the identification of potential collaborative partners or acquisition targets;
•our ability to expand and protect our intellectual property portfolio and otherwise maintain exclusive rights to products;
•potential fluctuations in foreign currency exchange rates and the effectiveness of our foreign currency management program;
•our expectations regarding our provision for or benefit from income taxes and the utilization of our deferred tax assets;
•our ability to use our research programs to identify and develop new product candidates to address serious diseases and significant unmet medical needs;
•our plans to expand, strengthen, and invest in our global supply chains and manufacturing infrastructure and capabilities, including for cell and gene therapies;
•our ability to attract and retain skilled personnel;
•our expectations involving governmental cost containment and other regulatory efforts;
•our expectations surrounding the competitive landscape facing our products and product candidates;
•our expectations regarding the effect of the COVID-19 pandemic on, among other things, our financial performance, liquidity, business and operations, including manufacturing, supply chain, research and development activities and pipeline programs; and
•our liquidity and our expectations regarding the possibility of raising additional capital.
Forward-looking statements are subject to certain risks, uncertainties, or other factors that are difficult to predict and could cause actual events or results to differ materially from those indicated in any such statements. These risks, uncertainties, and other factors include, but are not limited to, those described in our Risk Factors, set forth in Part I, Item 1A, and elsewhere in this report and those described from time to time in our future reports filed with the Securities and Exchange Commission.
Any such forward-looking statements are made on the basis of our views and assumptions as of the date of the filing and are not estimates of future performance. Except as required by law, we undertake no obligation to publicly update any forward-looking statements. The reader is cautioned not to place undue reliance on any such statements.


57

ITEM 1B.UNRESOLVED STAFF COMMENTS
We did not receive any written comments from the Securities and Exchange Commission prior to the date 180 days before the end of the fiscal year ended December 31, 2021 regarding our filings under the Securities Exchange Act of 1934, as amended, that have not been resolved.

ITEM 2.PROPERTIES
Corporate Headquarters
We lease approximately 1.1 million square feet of office and laboratory space at our corporate headquarters in Boston, Massachusetts in two buildings pursuant to two leases that we entered into in May 2011. These leases commenced in December 2013 and extend until December 2028. We have an option to extend the term of the leases for an additional ten years.
Additional United States and Worldwide Locations
In addition to our corporate headquarters, we lease an aggregate of approximately 728,000 square feet of space globally. This space includes logistical, laboratory, commercial and manufacturing operations, as well as laboratory and office space to support our research and development organizations. We also own approximately 213,000 square feet at our continuous manufacturing facility in Massachusetts.

ITEM 3.LEGAL PROCEEDINGS
We are not currently subject to any material legal proceedings.

ITEM 4.MINE SAFETY DISCLOSURES
Not applicable.

58

PART II

ITEM 5.MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Market Information
Our common stock is traded on The Nasdaq Global Select Market under the symbol “VRTX.”
Shareholders
As of January 31, 2022, there were 107 holders of record of our common stock.
Performance Graph
vrtx-20211231_g8.gif
Dividends
We currently expect that any future earnings will be retained for use in our business. Any future determination to declare cash dividends will be subject to the discretion of our board of directors and applicable law and will depend on various factors, including our results of operations, financial condition, prospects and any other factors deemed relevant by our board of directors. In addition, our credit agreement limits our ability to pay cash dividends on our common stock.

59

Issuer Repurchases of Equity Securities
In June 2021, our board of directors approved a share repurchase program (the “2021 Share Repurchase Program”), pursuant to which we were authorized to repurchase up to $1.5 billion of our common stock by December 31, 2022.
The table set forth below shows repurchases of securities by us during the three months ended December 31, 2021 under our 2021 Share Repurchase Program.
Period
Total Number
of Shares Purchased
Average Price
Paid per Share
Total Number of Shares Purchased as Part of
Publicly Announced Plans or Programs (1)
Approximate dollar value of Shares that May Yet be
Purchased Under the Plans or Programs (1)
Oct. 1, 2021 to Oct. 31, 2021
1,984,142 $180.33 1,984,142 $500,000,086 
Nov. 1, 2021 to Nov. 30, 2021
1,900 $180.00 1,900 $499,658,094 
Dec. 1, 2021 to Dec. 31, 2021
— $— — $499,658,094 
Total1,986,042 $180.33 1,986,042 $499,658,094 
(1)Under our 2021 Share Repurchase Program, we are authorized to purchase shares from time to time through open market or privately negotiated transactions. Such purchases may be made pursuant to Rule 10b5-1 plans or other means as determined by our management and in accordance with the requirements of the Securities and Exchange Commission. The approximate dollar value of shares that may yet be repurchased is based solely on shares that may be repurchased under the share repurchase program and excludes any shares that may be repurchased under our employee equity programs.

ITEM 6.[RESERVED]

60

ITEM 7.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Our discussion and analysis of our financial condition and results of operations for 2021 as compared to 2020 are discussed below. For a discussion of our financial condition and results of operations for 2020 as compared to 2019, please refer to Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2020 Annual Report on Form 10-K, except as set forth below.
OVERVIEW
We invest in scientific innovation to create transformative medicines for people with serious diseases with a focus on specialty markets. We have four approved medicines to treat cystic fibrosis, or CF, a life-threatening genetic disease, and are focused on increasing the number of people with CF eligible and able to receive our medicines through label expansions, approval of new medicines and expanded reimbursement. We are broadening our pipeline into additional disease areas through internal research efforts and accessing external innovation through business development transactions.
Our triple combination regimen, TRIKAFTA/KAFTRIO was approved in 2019 in the United States, or U.S., and in 2020 in the European Union, or E.U. Collectively, our four medicines are being used by the majority of the approximately 83,000 people with CF in North America, Europe and Australia. We are evaluating our medicines in additional patient populations, including younger children, with the goal of having small molecule treatments for approximately 90% of people with CF.
We continue to research and develop product candidates for the treatment of serious diseases, including genetic therapies to address the remaining approximately 10% of people with CF, sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and myotonic dystrophy type 1.
Financial Highlights
Revenues
In 2021, our net product revenues continued to increase due to the uptake of KAFTRIO in Europe and continued strong performance of TRIKAFTA in the U.S., including the expanded indication of TRIKAFTA for children with CF 6 through 11 years of age.
Expenses
Our total R&D and SG&A expenses increased to $3.9 billion as compared to $2.6 billion in 2020 primarily due to a $900.0 million upfront payment we made to CRISPR in connection with an amendment to our CTX001 collaboration. In 2021, cost of sales was 12% of our net product revenues.
Cash
Our cash, cash equivalents and marketable securities increased to $7.5 billion as of December 31, 2021 as compared to $6.7 billion as of December 31, 2020 primarily due to our net product revenues and profitability, offset by repurchases of our common stock and the $900.0 million payment to CRISPR.
vrtx-20211231_g9.jpg

vrtx-20211231_g10.jpg

61

Business Updates
Marketed Products
We expect to continue to grow our CF business by increasing the number of people with CF eligible and able to receive our medicines and providing improved treatment options for people who are already eligible for one of our medicines. Since the beginning of 2021, we have made significant progress in activities supporting these efforts.
•The U.S. Food and Drug Administration, or the FDA, approved the use of TRIKAFTA for children with CF 6 through 11 years of age who have at least one F508del mutation or at least one mutation that is responsive to TRIKAFTA.
•In January 2022, the European Commission and the U.K.’s Medicines and Healthcare products Regulatory Agency granted marketing authorization for KAFTRIO in the treatment of children with CF 6 through 11 years of age who have at least one F508del mutation in the CFTR gene.
•TRIKAFTA/KAFTRIO is now approved and reimbursed or accessible in more than 20 countries outside the U.S.
•Our Phase 3 clinical trial evaluating ORKAMBI for the treatment of children with CF 12 through 24 months of age met its primary endpoint. Based on these data, we plan to submit regulatory filings in the U.S. and Europe in the first and second quarters of 2022, respectively.
Pipeline
We continue to advance a pipeline of potentially transformative small molecule, and cell and genetic therapies aimed at treating serious diseases. Since the beginning of 2021, we have made important progress in activities supporting these programs.
Cystic Fibrosis
•In the third quarter of 2021, we announced the initiation of Phase 3 clinical trials evaluating a once-daily investigational triple combination of VX-121/tezacaftor/VX-561 (deutivacaftor). Enrollment is underway in these two Phase 3 clinical trials, and we expect to complete enrollment in both trials by late 2022 or early 2023.
•We are conducting enabling studies for CF messenger ribonucleic acid, or mRNA, therapeutics designed to treat the underlying cause of CF by enabling cells in the lungs to produce functional CFTR protein for the treatment of the approximately 10% of people with CF who do not produce any CFTR protein. We expect to submit an Investigational New Drug Application, or IND, for this program in 2022.
Sickle Cell Disease and Beta Thalassemia
•We are evaluating the use of a non-viral ex vivo CRISPR gene-editing therapy, CTX001, for the treatment of severe sickle cell disease, or SCD, and transfusion-dependent beta thalassemia, or TDT. Enrollment is complete in the ongoing clinical trials evaluating CTX001 in severe SCD and TDT.
•Data presented to date support the profile of CTX001 as a potential one-time functional cure for people with severe SCD and TDT. CTX001 safety data to date is generally consistent with an autologous stem cell transplant and myeloablative conditioning. We anticipate regulatory submissions of CTX001 in late 2022.
APOL1-Mediated Kidney Disease
•In December 2021, we announced that patients with APOL1-mediated focal segmental glomerulosclerosis, or FSGS, treated with VX-147, a small molecule inhibitor of APOL1 function, on top of standard of care achieved a statistically significant, substantial and clinically meaningful reduction of proteinuria in a Phase 2 proof-of-concept clinical trial. We anticipate completing our end of Phase 2 meetings with regulators and advancing VX-147 into pivotal development in people with APOL1-mediated kidney disease, or AMKD, including APOL1-mediated FSGS, in the first quarter of 2022.

62

Type 1 Diabetes
•VX-880 is a stem cell-derived, allogeneic, fully differentiated, insulin-secreting islet cell replacement therapy, using standard immunosuppression to protect the implanted cells. Our Phase 1/2 clinical trial evaluating VX-880 as a potential treatment for type 1 diabetes, or T1D, is ongoing at multiple clinical sites in the U.S. In January 2022, we announced positive Day 150 data for the first T1D patient in this clinical trial, including restoration of islet cell function and rapid improvements in multiple measures. In this first patient, the safety of VX-880 was generally consistent with the immunosuppressive regimen used in this study. We will continue to dose patients in 2022.
•We also are pursuing additional programs in T1D, in which these stem cell-derived, fully differentiated, insulin-secreting islet cells are encapsulated and implanted in an immunoprotective device or modified to produce hypoimmune cells. We are conducting IND-enabling studies for the cells and device program, and we expect to submit an Investigational New Drug Application, or IND, for this program in 2022.
Pain
•Two Phase 2 dose ranging acute pain clinical trials evaluating VX-548, a selective small molecule inhibitor of NaV1.8, are underway; one following bunionectomy surgery and the other following abdominoplasty surgery. We expect to obtain data from the clinical trials evaluating VX-548 in the first quarter of 2022.
Alpha-1 Antitrypsin, or AAT, Deficiency
•We plan to advance one or more novel small molecule Z-AAT correctors into the clinic in 2022.
Investments in External Innovation
•Pursuant to a collaboration with CRISPR that we amended in 2021, we now lead global development, manufacturing and commercialization of CTX001, with support from CRISPR.
•We entered into research collaborations with Obsidian Therapeutics, Inc., Arbor Biotechnologies, Inc., and Mammoth Biosciences, Inc.
Our Business Environment
Our net product revenues come from the sale of our medicines for the treatment of CF. Our CF strategy involves continuing to develop and obtain approval and reimbursement for treatment regimens that will provide benefits to all people with CF and increasing the number of people with CF eligible and able to receive our medicines, including through label expansions, expanded reimbursement, and the development of new medicines. We are actively pursuing a pipeline of product candidates for the treatment of serious diseases outside of CF. Our strategy is to combine transformative advances in the understanding of human disease biology and the science of therapeutics in order to discover and develop new medicines. This approach includes advancing multiple compounds from each program, spanning multiple modalities, into early clinical trials and evaluating patient data to inform discovery and development of additional compounds, with the goal of bringing first-in-class and best-in-class therapies to patients, and to provide durable clinical and commercial success.
In pursuit of new product candidates and therapies in specialty markets, we invest in research and development. We believe that pursuing research in diverse areas allows us to balance the risks inherent in product development and may provide product candidates that will form our pipeline in future years. To supplement our internal research programs, we acquire technologies and programs and collaborate with biopharmaceutical and technology companies, leading academic research institutions, government laboratories, foundations and other organizations, as needed, to advance research in our areas of therapeutic interest and to access technologies needed to execute on our strategy.
Discovery and development of a new pharmaceutical or biological product is a difficult and lengthy process that requires significant financial resources along with extensive technical and regulatory expertise. Most chemical compounds that are investigated as potential drug or biological product candidates never progress into development, and most product candidates that do advance into development never receive marketing approval. Our investments in product candidates are subject to considerable risks. We closely monitor the results of our discovery, research, clinical trials and nonclinical studies and frequently evaluate our product development programs in light of new data and scientific, business and commercial insights, with the objective of balancing risk and potential. This process can result in rapid changes in focus and priorities as new

63

information becomes available and as we gain additional understanding of our ongoing programs and potential new programs, as well as those of our competitors.
Our business also requires ensuring appropriate manufacturing and reimbursement of our products. As we advance our product candidates through clinical development toward commercialization and market and sell our approved products, we build and maintain our supply chain and quality assurance resources. We rely on a global network of third parties and our internal capabilities to manufacture and distribute our products for commercial sale and post-approval clinical trials and to manufacture and distribute our product candidates for clinical trials. In addition to establishing supply chains for each new approved product, we adapt our supply chain for existing products to include additional formulations or to increase scale of production for existing products as needed. The processes for cell and genetic therapies can be more complex than those required for small molecule drugs and require different systems, equipment, facilities and expertise. We are focused on ensuring the stability of the supply chains for our current products, as well as for our pipeline programs.
Sales of our products depend, to a large degree, on the extent to which our products are reimbursed by third-party payors, such as government health programs, commercial insurance and managed health care organizations. Reimbursement for our products, including our potential pipeline therapies, cannot be assured and may take significant periods of time to obtain. We dedicate substantial management and other resources in order to obtain and maintain appropriate levels of reimbursement for our products from third-party payors, including governmental organizations, in the U.S. and ex-U.S. markets.
In the U.S., we have worked successfully with third-party payors in order to promptly obtain appropriate levels of reimbursement for our CF medicines. We plan to continue to engage in discussions with numerous commercial insurers and managed health care organizations, along with government health programs that are typically managed by authorities in the individual states, to ensure that payors recognize the significant benefits that our medicines provide and provide patients with appropriate levels of access to our medicines now and in the future. In Europe and other ex-U.S. markets, we seek government reimbursement for our medicines on a country-by-country or region-by-region basis, as required. This is necessary for each new medicine, as well as for label expansions for our current medicines. We expect to continue to focus significant resources to obtain expanded reimbursement for our CF medicines and, ultimately, pipeline therapies in U.S. and ex-U.S. markets.
COVID-19
We continue to monitor the impacts of the COVID-19 global pandemic on our business, including in our clinical trials, manufacturing facilities and capabilities, and ability to access necessary resources. COVID-19 has not materially affected our supply chain or the demand for our medicines, and we believe that we will be able to continue to supply all of our approved medicines to patients globally. We adjusted our business operations in response to COVID-19 and have continued to monitor local COVID-19 trends and government guidance for each of our site locations. We are utilizing a site-specific approach to assess and permit employee access to our sites. Currently, our sites are open to certain employees where appropriate and permitted by local laws and guidelines.
Strategic Transactions
Acquisitions
As part of our business strategy, we seek to acquire products, product candidates and other technologies and businesses that are aligned with our corporate and research and development strategies and complement and advance our ongoing research and development efforts. In 2019, we invested significantly in business development transactions designed to augment our pipeline, including the acquisition of Semma Therapeutics, Inc., or Semma, a privately-held company focused on the use of stem cell-derived human islets as a treatment for T1D, and Exonics Therapeutics, Inc., or Exonics, a privately-held company focused on creating transformative gene-editing therapies to repair mutations that cause Duchenne muscular dystrophy, or DMD, and other severe neuromuscular diseases, including myotonic dystrophy type 1, or DM1. In the Semma acquisition, we paid approximately $950.0 million in cash to Semma equity holders. In the Exonics acquisition, we paid approximately $245.0 million upfront to Exonics equity holders and agreed to additional payments based upon successful achievement of specified development and regulatory milestones. We expect to continue to identify and evaluate potential acquisitions and may include larger transactions or later-stage assets.
Both of our 2019 acquisitions were accounted for as business combinations. As of the acquisition date for each transaction, the cash payments, as well as the fair value of contingent consideration for Exonics, were allocated primarily to

64

goodwill and the fair value of several in-process research and development assets that we acquired. The fair value of contingent consideration related to Exonics was recorded as a liability and continues to be adjusted on a quarterly basis. As a result, these acquisitions are primarily reflected in additional assets and liabilities on our consolidated balance sheet. Operating expenses incurred by Exonics and Semma after the acquisition dates and specific expenses associated with the acquisitions are reflected in our consolidated statement of operations.
Please refer to our critical accounting policies, “Acquisitions,” for further information regarding the significant judgments and estimates related to our acquisitions.
Collaboration and Licensing Arrangements
We enter into arrangements with third parties, including collaboration and licensing arrangements, for the development, manufacture and commercialization of products, product candidates, and other technologies that have the potential to complement our ongoing research and development efforts. We expect to continue to identify and evaluate collaboration and licensing opportunities that may be similar to or different from the collaborations and licenses that we have engaged in previously.
In-License Agreements
We have entered into collaborations with biotechnology and pharmaceutical companies in order to acquire rights or to license product candidates or technologies that enhance our pipeline and/or our research capabilities. Over the last several years, we entered into collaboration agreements with a number of companies, including Arbor Biotechnologies, Inc., CRISPR, Kymera Therapeutics, Inc., Mammoth Biosciences, Inc., Moderna, Inc., and Obsidian Therapeutics, Inc. Generally, when we in-license a technology or product candidate, we make upfront payments to the collaborator, assume the costs of the program, and/or agree to make contingent payments, which could consist of milestone, royalty, and option payments. Most of these collaboration payments are expensed as research and development expenses; however, depending on many factors, including the structure of the collaboration, the significance of the in-licensed product candidate to the collaborator’s operations and the other activities in which our collaborators are engaged, the accounting for these transactions can vary significantly. Our research and development expenses included $1.1 billion in 2021, $184.6 million in 2020 and $318.3 million in 2019 related to upfront, milestone and other payments pursuant to our collaboration agreements and other business development agreements. The increase in these payments in 2021 was primarily related to the $900.0 million upfront payment we made to CRISPR that is described below.
Joint Development and Commercialization Agreement with CRISPR
In 2017, we entered into a joint development and commercialization agreement, or the Original JDCA, with CRISPR pursuant to which we are developing and preparing to commercialize CTX001 for TDT and SCD. The Original JDCA was entered into following our exercise of an option to co-develop and co-commercialize the hemoglobinopathies program that was contained in a collaboration agreement that we entered into with CRISPR in 2015.
In April 2021, we and CRISPR entered into an amendment and restatement of the Original JDCA, or the A&R JDCA. In June 2021, we made a $900.0 million upfront payment to CRISPR in connection with the closing of the transactions contemplated by the A&R JDCA. We concluded that we did not have any alternative future use for the acquired in-process research and development and recorded this upfront payment to “Research and development expenses.” Under the terms of the A&R JDCA, we are leading worldwide development, manufacturing, and commercialization of CTX001. As of July 1, 2021, 60% of the net profits and net losses for CTX001 are allocated to us and 40% of the net profits and net losses for CTX001 are allocated to CRISPR. CRISPR may earn an additional one-time $200.0 million milestone payment upon regulatory approval of CTX001. We concluded that the Original JDCA and the A&R JDCA are cost-sharing arrangements, which result in the net impact of the arrangements being recorded in “Research and development expenses” in our consolidated statements of operations.
Out-License Agreements
We also have out-licensed internally-developed programs to collaborators who are leading the development of these programs. These out-license arrangements include our agreement with Merck KGaA, Darmstadt, Germany, which licensed oncology research and development programs from us in early 2017. Pursuant to these out-licensing arrangements, our collaborators are responsible for the research, development, and commercialization costs associated with these programs, and we are entitled to receive contingent milestone and/or royalty payments. As a result, we do not expect to incur significant

65

expenses in connection with these programs and have the potential for future collaborative and royalty revenues resulting from these programs.
Please refer to Note B, “Collaborative and Other Arrangements,” for further information regarding our in-license agreements and out-license agreements.
Strategic Investments
In connection with our business development activities, we have periodically made equity investments in our collaborators. As of December 31, 2021, we held strategic equity investments in certain public and private companies, and we expect to make additional strategic equity investments in the future. While we invest the majority of our cash, cash equivalents, and marketable securities in instruments that meet specific credit quality standards and limit our exposure to any one issue or type of instrument, our strategic investments are maintained and managed separately from our other cash, cash equivalents, and marketable securities. As discussed below in “Other Income (Expense), Net” in our Results of Operations, any changes in the fair value of equity investments with readily determinable fair values (including publicly traded securities) are recorded to other income (expense), net in our consolidated statement of operations.


66

RESULTS OF OPERATIONS
2021% Change2020% Change2019
(in millions, except percentages and per share amounts)
Revenues$7,574.4 22%$6,205.7 49%$4,162.8 
Operating costs and expenses4,792.3 43%3,349.4 13%2,965.3 
Income from operations2,782.1 (3)%2,856.3 139%1,197.5 
Other non-operating (expense) income, net(51.7)**260.6 32%197.4 
Provision for income taxes388.3 (4)%405.2 86%218.1 
Net income
$2,342.1 (14)%$2,711.7 130%$1,176.8 
Net income per diluted common share$9.01 $10.29 $4.51 
Diluted shares used in per share calculations259.9 263.4 260.7 
** Not meaningful
Revenues
2021
% Change
2020
% Change
2019
(in millions, except percentages)
TRIKAFTA/KAFTRIO$5,697.2 47%$3,863.8 820%$420.1 
SYMDEKO/SYMKEVI420.4 (33)%628.6 (56)%1,417.7 
ORKAMBI771.6 (15)%907.5 (32)%1,331.9 
KALYDECO684.2 (15)%802.9 (19)%991.0 
Product revenues, net7,573.4 22%6,202.8 49%4,160.7 
Other revenues
1.0 **2.9 **2.1 
Total revenues$7,574.4 22%$6,205.7 49%$4,162.8 
** Not meaningful
Product Revenues, Net
In 2021, our net product revenues increased by $1.4 billion, or 22%, as compared to 2020 primarily due to the launch of KAFTRIO in multiple countries internationally, which was approved in the E.U. in the third quarter of 2020, and the performance of TRIKAFTA in the U.S., including the launch of TRIKAFTA in June 2021 for children with CF 6 through 11 years of age. Decreases in revenues for our products other than TRIKAFTA/KAFTRIO were primarily the result of patients switching from these medicines to TRIKAFTA/KAFTRIO.
Our net product revenues from the U.S. and from ex-U.S. markets were as follows:
2021
% Change
2020
% Change
2019
(in millions, except percentages)
United States$5,287.3 10%$4,826.4 58%$3,060.3 
ex-U.S.2,286.1 66%1,376.4 25%1,100.4 
Product revenues, net$7,573.4 22%$6,202.8 49%$4,160.7 
We expect that our net product revenues will increase in 2022 due to increasing numbers of people being treated with our medicines. The increase is expected to result from continued performance of KAFTRIO outside the U.S. and TRIKAFTA in the U.S., label expansions for our previously approved products, and expanded access to our medicines.

67

Other Revenues
Our other revenues were $1.0 million and $2.9 million in 2021 and 2020, respectively, related to collaborative milestones that we earned. Our other revenues have historically fluctuated significantly from one period to another based on our collaborative out-license activities, and may continue to fluctuate in the future.
Operating Costs and Expenses
2021
% Change
2020
% Change
2019
(in millions, except percentages)
Cost of sales$904.2 23%$736.3 34%$547.8 
Research and development expenses3,051.1 67%1,829.5 4%1,754.5 
Selling, general and administrative expenses840.1 9%770.5 17%658.5 
Change in fair value of contingent consideration(3.1)**13.1 **4.5 
Total costs and expenses$4,792.3 43%$3,349.4 13%$2,965.3 
** Not meaningful
Cost of Sales
Our cost of sales primarily consists of third-party royalties payable on net sales of our products as well as the cost of producing inventories. Pursuant to our agreement with the Cystic Fibrosis Foundation, our tiered third-party royalties on sales of TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, KALYDECO, and ORKAMBI, calculated as a percentage of net sales, range from the single digits to the sub-teens, with royalties on sales of TRIKAFTA/KAFTRIO slightly lower than for our other products. Over the last several years, our cost of sales has been increasing due to increased net product revenues. Our cost of sales as a percentage of our net product revenues was 12% in each of 2021 and 2020. In 2022, we expect our total cost of sales will increase due to expected increases in our net product revenues and our cost of sales as a percentage of our net product revenues will be similar to our cost of sales as a percentage of net product revenues in 2021 and 2020.
Research and Development Expenses
2021
% Change
2020
% Change
2019
(in millions, except percentages)
Research expenses$617.7 (3)%$636.7 (13)%$732.7 
Development expenses
2,433.4 104%1,192.8 17%1,021.8 
Total research and development expenses
$3,051.1 67%$1,829.5 4%$1,754.5 
Our research and development expenses include internal and external costs incurred for research and development of our products and product candidates and expenses related to certain technologies that we acquire or license through business development transactions. We do not assign our internal costs, such as salary and benefits, stock-based compensation expense, laboratory supplies and other direct expenses and infrastructure costs, to individual products or product candidates, because the employees within our research and development groups typically are deployed across multiple research and development programs. We assign external costs of services provided to us by clinical research organizations and other outsourced research by individual program. Apart from upfront, milestone, and other payments related to our business development activities, our internal costs are significantly greater than our external costs. All research and development costs for our products and product candidates are expensed as incurred.
Over the past three years, we have incurred $6.6 billion in research and development expenses associated with product discovery and development. The successful development of our product candidates is highly uncertain and subject to a number of risks. In addition, the duration of clinical trials may vary substantially according to the type, complexity and novelty of the product candidate and the disease indication being targeted. The FDA and comparable agencies in foreign countries impose substantial requirements on the introduction of therapeutic pharmaceutical products, typically requiring lengthy and detailed laboratory and clinical testing procedures, sampling activities and other costly and time-consuming procedures. Data obtained from nonclinical and clinical activities at any step in the testing process may be adverse and lead to discontinuation or redirection of development activities. Data obtained from these activities also are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The duration and cost of discovery, nonclinical

68

studies and clinical trials may vary significantly over the life of a project and are difficult to predict. Therefore, accurate and meaningful estimates of the ultimate costs to bring our product candidates to market are not available. Any estimates regarding development and regulatory timelines for our product candidates are highly subjective and subject to change. Until we have data from Phase 3 clinical trials, we cannot make a meaningful estimate regarding when, or if, a clinical development program will generate revenues and cash flows.
Research Expenses
2021Change %2020Change %2019
(in millions, except percentages)
Research Expenses:
Salary and benefits$136.7 5%$129.8 (4)%$134.6 
Stock-based compensation expense77.3 (10)%85.6 23%69.4 
Outsourced services and other direct expenses160.0 38%116.2 —%116.6 
Collaborative payments
105.4 (43)%184.6 (40)%307.8 
Infrastructure costs
138.3 15%120.5 16%104.3 
Total research expenses
$617.7 (3)%$636.7 (13)%$732.7 
We expect to continue to invest in our research programs with a focus on creating transformative medicines for serious diseases. Our research expenses have historically fluctuated, and are expected to continue to fluctuate, from one period to another due to upfront, milestone and certain other payments related to our business development activities that are reflected in the preceding table as collaborative payments. Our research expenses, apart from these collaborative payments, have been increasing over the last several years as we have invested in our pipeline and expanded our cell and genetic therapy capabilities.
Development Expenses
2021Change %2020Change %2019
(in millions, except percentages)
Development Expenses:
Salary and benefits$347.6 18%$295.7 18%$249.9 
Stock-based compensation expense191.0 8%177.1 14%155.2 
Outsourced services and other direct expenses629.4 23%512.2 21%425.0 
Collaborative payments
1,007.9 **— **10.5 
Infrastructure costs
257.5 24%207.8 15%181.2 
Total development expenses
$2,433.4 104%$1,192.8 17%$1,021.8 
** Not meaningful
In 2021 and 2020, costs related to our CF programs represented the largest portion of our development costs, apart from the $900.0 million upfront payment to CRISPR in 2021, which is included in the preceding table under collaborative payments. Our development expenses increased by $1.2 billion, or 104%, in 2021 as compared to 2020, primarily due to the payment to CRISPR and increased expenses related to our diversifying pipeline, including clinical trials, headcount, and infrastructure costs. We expect our development expenses, apart from payments related to our business development activities, to continue to increase in 2022 as a result of our diversifying pipeline.

69

Selling, General and Administrative Expenses
2021
% Change
2020
% Change
2019
(in millions, except percentages)
Selling, general and administrative expenses$840.1 9%$770.5 17%$658.5 
Selling, general and administrative expenses increased by 9% in 2021 as compared to 2020, primarily due to the continued investment to support the commercialization of our medicines and increased support for our pipeline products. We expect our selling, general and administrative expenses to continue to increase in 2022.
Contingent Consideration
The change in the fair value of our contingent consideration potentially payable to Exonics’ former equity holders was a $3.1 million decrease in 2021 and a $13.1 million increase in 2020. In future periods, we expect the fair value of contingent consideration to increase or decrease based on, among other things, our estimates of the probability of achieving and the timing of these contingent development and regulatory milestone payments, as well as the time value of money and changes in market interest rates.
Other Non-Operating Income (Expense), Net
Interest Income
Interest income was $4.9 million in 2021, which was lower than our interest income of $22.2 million in 2020, due to a decrease in prevailing market interest rates, despite an increase in our cash equivalents and available-for-sale debt securities. Our future interest income will be dependent on the amount of, and prevailing market interest rates on, our outstanding cash equivalents and available-for-sale debt securities.
Interest Expense
Interest expense was $61.5 million in 2021 as compared to $58.2 million in 2020. The majority of our interest expense in these periods was related to imputed interest expense associated with our leased corporate headquarters in Boston.
Other Income (Expense), Net
In 2021 and 2020, we recorded net other income of $4.9 million and $296.6 million, respectively, primarily related to net gains of $17.1 million and $311.9 million in 2021 and 2020, respectively, resulting from changes in the fair value and sales of certain of our strategic investments. As of December 31, 2021, the fair value of our investments in publicly traded companies was $230.9 million. To the extent that we continue to hold strategic investments, particularly strategic investments in publicly traded companies, we will record other income (expense) related to these strategic investments on a quarterly basis. We expect that due to the volatility of the stock price of biotechnology companies, our other income (expense), net will fluctuate in future periods based on increases or decreases in the fair value of our strategic investments.
Income Taxes
Our provision for income taxes was $388.3 million for 2021 and $405.2 million for 2020. Our effective tax rate of 14% for 2021 was lower than the U.S. statutory rate primarily due to discrete tax benefits of (i) $94.8 million associated with an increase in the U.K.’s corporate tax rate from 19% to 25%, which was enacted in June 2021 and will become effective in April 2023, and (ii) $44.1 million resulting from an R&D tax credit study that we completed in 2021.
Our effective tax rate of 13% for 2020 was lower than the U.S. statutory rate primarily due to (i) a discrete tax benefit of $209.0 million associated with the transfer of intellectual property rights to the U.K., (ii) a discrete tax benefit associated with the write-off of a long-term intercompany receivable, (iii) a discrete tax benefit associated with an increase in the U.K.’s corporate tax rate from 17% to 19%, which was enacted and became effective in July 2020, and (iv) excess tax benefits related to stock-based compensation. The impact of these items was partially offset by U.S. income tax on foreign earnings.

70

Net Income
In summary, our net income decreased to $2.3 billion in 2021 as compared to $2.7 billion in 2020 primarily due to (i) our $900.0 million upfront payment to CRISPR in 2021 and (ii) less other income derived from changes in the fair value of our strategic investments in 2021 as compared to 2020, (iii) partially offset by increased operating income in 2021, apart from the payment to CRISPR, resulting from our product revenues.

LIQUIDITY AND CAPITAL RESOURCES
The following table summarizes the components of our financial condition as of December 31, 2021 and 2020:
20212020
% Change
(in millions)
Cash, cash equivalents and marketable securities$7,524.9 $6,658.9 13%
Working Capital:
Total current assets$9,560.6 $8,133.4 18%
Total current liabilities(2,142.0)(1,877.5)14%
Total working capital$7,418.6 $6,255.9 19%
Working Capital
As of December 31, 2021, total working capital was $7.4 billion, which represented an increase of $1.2 billion from $6.3 billion as of December 31, 2020. The increase in total working capital in 2021 was primarily related to $2.6 billion of cash provided by operations, which was net of our $900.0 million payment to CRISPR, partially offset by $1.4 billion of cash used to repurchase our common stock pursuant to our share repurchase programs and purchases of property and equipment of $235.0 million.
Sources and Uses of Liquidity
As of December 31, 2021, we had cash, cash equivalents, and marketable securities of $7.5 billion, which represented an increase of $866.0 million from $6.7 billion as of December 31, 2020. We intend to rely on our existing cash, cash equivalents and marketable securities together with cash flows from product sales as our primary source of liquidity.
We expect that cash flows from our products together with our current cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next twelve months. The adequacy of our available funds to meet our future operating and capital requirements will depend on many factors, including the amounts of future revenues generated by our products, and the potential introduction of one or more of our other product candidates to the market, the level of our business development activities and the number, breadth, cost and prospects of our research and development programs.
Credit Facilities & Financing Strategy
We may borrow up to a total of $2.5 billion pursuant to two revolving credit facilities. We may repay and reborrow amounts under these revolving credit agreements without penalty. Subject to certain conditions, we may request that the borrowing capacity for each of the credit agreements be increased by an additional $500.0 million, for a total of $3.5 billion collectively. Negative covenants in our credit agreement may prohibit or limit our ability to access these sources of liquidity. As of December 31, 2021, we were in compliance with these covenants.
We may also raise additional capital by borrowing under credit agreements, through public offerings or private placements of our securities or securing new collaborative agreements or other methods of financing. We will continue to manage our capital structure and will consider all financing opportunities, whenever they may occur, that could strengthen our long-term liquidity profile. There can be no assurance that any such financing opportunities will be available on acceptable terms, if at all.

71

Cash Flows
202120202019
(in millions)
Net cash provided by (used in):
Operating activities$2,643.5 $3,253.5 $1,569.3 
Investing activities
$(340.9)$99.4 $(1,235.3)
Financing activities$(1,478.0)$(505.3)$126.8 
Operating Activities
Cash provided by operating activities was $2.6 billion in 2021 as compared to $3.3 billion in 2020 primarily due to a $369.6 million decrease in our net income resulting from the $900.0 million upfront payment we made to CRISPR in 2021. Cash provided by operating activities was $3.3 billion in 2020 as compared to $1.6 billion in 2019 primarily due to a $1.5 billion increase in our net income resulting from increased net product revenues.
Investing Activities
Cash used in investing activities was $340.9 million in 2021, primarily related to purchases of property and equipment, and, to a lesser extent, purchases of notes receivable and strategic investments. In 2020, our investing activities primarily related to $437.6 million of proceeds from sales of our strategic investments, partially offset by purchases of property and equipment. In 2019, we spent $1.2 billion to acquire Semma and Exonics.
Financing Activities
Cash used in financing activities was $1.5 billion in 2021 and $505.3 million in 2020 as compared to cash provided by financing activities of $126.8 million in 2019. In 2021 and 2020, aggregate share repurchases pursuant to our share repurchase programs were $1.4 billion and $539.1 million, respectively, which represented the largest portion of our financing activities. In 2019, our financing activities provided $126.8 million of cash related to the issuance of common stock pursuant to our employee benefit plans, partially offset by repurchases of our common stock pursuant to our share repurchase programs.
Future Capital Requirements
We have significant future capital requirements including:
•significant expected operating expenses to conduct research and development activities and to operate our organization;
•substantial facility and finance lease obligations as described below;
•royalties we pay to the Cystic Fibrosis Foundation on sales of our CF products; and
•cash paid for income taxes.
In addition, we have significant potential future capital requirements including:
•We have entered into certain collaboration agreements with third parties that include the funding of certain research, development, and commercialization efforts. Certain of our business development transactions, including collaborations and acquisitions, include the potential for future milestone and royalty payments by us upon the achievement of pre-established developmental and regulatory targets and/or commercial targets. Our obligation to fund these research and development and commercialization efforts and to pay these potential milestone and royalties is contingent upon continued involvement in the programs and/or the lack of any adverse events that could cause the discontinuance of the programs associated with our collaborations and acquisitions. We may enter into additional business development transactions, including acquisitions, collaborations, and equity investments, that require additional capital.

72

•To the extent we borrow amounts under our existing credit agreements, we would be required to repay any outstanding principal amounts in 2022 or 2024.
•As of December 31, 2021, we had $0.5 billion available under our 2021 Share Repurchase Program.
Additional information on several of our future capital requirements is provided below.
Research and Development Costs
At any point in time, we have several ongoing clinical trials at various stages of clinical development. Our clinical trial costs are dependent on, among other things, our research activities advancing to later-stage clinical development as well as the size, number, and length of our clinical trials.
Leases
Finance Leases
Our corporate headquarters is in two buildings that we lease at Fan Pier in Boston, Massachusetts. We commenced lease payments on these buildings in 2013 and the initial lease periods end in December 2028. We also lease office and laboratory space in San Diego, California. We commenced lease payments for this building in 2019 pursuant to an initial 16 year lease term. We account for each of these buildings as finance leases.
Operating Leases
The remainder of our real estate leases are accounted for as operating leases, including office and laboratory space at our Innovation Square facility near our corporate headquarters. Base rent payments commenced in 2021 pursuant to an initial 15 year lease term for this building.
Our total future minimum lease payments for our finance and operating leases for each of the next five years and in total are included in Note L, “Leases.” The total future undiscounted minimum lease payments were $796.2 million and $482.2 million related to our finance and operating leases, respectively, as of December 31, 2021.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES
Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements prepared in accordance with generally accepted accounting principles in the U.S. The preparation of these financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported periods. These items are monitored and analyzed by management for changes in facts and circumstances, and material changes in these estimates could occur in the future. Changes in estimates are reflected in reported results for the period in which the change occurs. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from our estimates if past experience or other assumptions do not turn out to be substantially accurate.
We believe that our application of the following accounting policies, each of which requires significant judgments and estimates on the part of management, are the most critical to aid in fully understanding and evaluating our reported financial results:
•revenue recognition;
•acquisitions, including intangible assets, goodwill and contingent consideration; and
•income taxes.
Our accounting policies, including the ones discussed below, are more fully described in the Notes to our consolidated financial statements, including Note A, “Nature of Business and Accounting Policies,” included in this Annual Report on Form 10-K.

73

Revenue Recognition
Product Revenues, Net
We generate product revenues from sales in the U.S. and in international markets. We sell our products principally to a limited number of specialty pharmacy and specialty distributors in the U.S., which account for the largest portion of our total revenues. We make international sales primarily to specialty distributors and retail chains, as well as hospitals and clinics, many of which are government-owned or supported customers. Our customers in the U.S. subsequently resell our products to patients and health care providers. We contract with government agencies so that our products will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. We recognize net product revenues from sales of our products when our customers obtain control of our products, which typically occurs upon delivery to our customers. Revenues from our product sales are recorded at the net sales price, or “transaction price,” which requires us to make several significant estimates regarding the net sales price.
The most significant estimate we are required to make is related to government and private payor rebates, chargebacks, discounts and fees, collectively rebates. The value of the rebates provided to third-party payors per course of treatment vary significantly and are based on government-mandated discounts and our arrangements with other third-party payors. In order to estimate our total rebates, we estimate the percentage of prescriptions that will be covered by each third-party payor, which is referred to as the payor mix. We track available information regarding changes, if any, to the payor mix for our products, to our contractual terms with third-party payors and to applicable governmental programs and regulations and levels of our products in the distribution channel. We adjust our estimated rebates based on new information, including information regarding actual rebates for our products, as it becomes available. Claims by third-party payors for rebates are submitted to us significantly after the related sales, potentially resulting in adjustments in the period in which the new information becomes known. Our credits to revenue related to prior period sales, apart from an adjustment to the transaction price for ORKAMBI distributed through early access programs in France in 2019, have not been significant (typically less than 1% of gross product revenues) and primarily related to U.S. rebates.
The following table summarizes activity related to our accruals for rebates (including a refund liability to the French government related to ORKAMBI distributed through early access programs in France, which was paid in 2020) for 2021, 2020 and 2019:
(in millions)
Balance as of December 31, 2018
$545.1 
Provision related to 2019 sales
656.0 
Adjustments related to prior year(s) sales(95.5)
Credits/payments made(469.9)
Balance as of December 31, 2019
$635.7 
Provision related to 2020 sales
1,284.1 
Adjustments related to prior year(s) sales0.6 
Credits/payments made(1,144.8)
Balance as of December 31, 2020
$775.6 
Provision related to 2021 sales
2,126.1 
Adjustments related to prior year(s) sales(27.6)
Credits/payments made(2,035.5)
Balance as of December 31, 2021
$838.6 
We have also entered into annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive. Upon exceeding the annual reimbursement amount, products are provided free of charge, which is a material right. We defer a portion of the consideration received, which includes upfront payments and fees, for shipments made up to the annual reimbursement limit as “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. In order to estimate the portion of the consideration received to recognize as revenue and the portion of the amount to defer, we rely on our forecast of the number of units we will distribute during the applicable annual period in each international market in which our contracts with

74

government-owned and supported customers limit the amount of annual reimbursement we can receive. Our forecasts are based on, among other things, our historical experience.
The preceding estimates and judgments materially affect our recognition of net product revenues. Changes in our estimates of net product revenues could have a material effect on net product revenues recorded in the period in which we determine that change occurs.
French Early Access Programs
In 2015, we began distributing ORKAMBI through early access programs in France and remained engaged in reimbursement discussions with the French government for ORKAMBI, including ORKAMBI distributed through early access programs, until November 2019, when we reached an agreement with the French government. From the time we began distributing ORKAMBI through early access programs in France, we expected that the difference between the amounts collected based on the invoiced amount and the final amount for ORKAMBI distributed through these programs would be returned to the French government. Our refund liability related to the early access programs in France was classified in “Accrued expenses” on our consolidated balance sheets.
From the first quarter of 2018 through the third quarter of 2019, we recognized net product revenues for ORKAMBI sales in France under the early access programs based on a transaction price that reflected our estimate of consideration we expected to retain that would not be subject to a significant reversal in amounts recognized, which resulted in revenue representing a portion of the invoiced amount.
Upon reaching an agreement with the French government for ORKAMBI, including the final amount for ORKAMBI distributed through early access programs in France in the fourth quarter of 2019, we updated the transaction price related to ORKAMBI distributed through early access programs and recognized net product revenues of $155.8 million related to these shipments, which occurred from 2015 through the date of our agreement with the French government, because the final amount for these shipments exceeded our previous estimate.
Acquisitions
We are required to make several significant judgments and estimates in order to calculate the purchase price for our business combinations and then allocate it to the assets that we have acquired and the liabilities that we have assumed on our consolidated balance sheet. The most significant judgments and estimates relate to the fair value of the in-process research and development assets and contingent consideration liabilities related to these business combinations. Based on these judgments and estimates, the fair value of the goodwill that we record as a result of these business combinations may be material. Once recorded, these assets are subject to quarterly impairment analysis and our contingent consideration liability is adjusted quarterly, which requires similar judgments and estimates.
Intangible Assets
In 2019, we recorded in-process research and development assets related to our acquisitions of Exonics and Semma totaling $400.0 million on our consolidated balance sheet, which remained on our consolidated balance sheet as of December 31, 2021. Each of these assets is accounted for as an indefinite-lived intangible asset and is maintained on our consolidated balance sheet until either the project underlying it is completed or the asset becomes impaired. When we determine that an asset has become impaired or we abandon a project, we write down the carrying value of the related intangible asset to its fair value and record an impairment charge in the period in which the impairment occurs.
To determine the fair value of our in-process research and development assets, we utilize the multi-period excess earnings method of the income approach, which requires us to make estimates of the probability of technical and regulatory success, development cost assumptions, revenue projections and growth rates, commercial cost estimates and appropriate discount rates. These assumptions require significant management judgment and reasonable changes in the assumptions can cause material changes to the fair value of the intangible assets. Due to the early stage of Exonics and Semma’s programs, these significant assumptions could be affected by future economic and market conditions.
Contingent Consideration
As of December 31, 2021 and 2020, we had $186.5 million and $189.6 million, respectively, of liabilities on our consolidated balance sheet attributable to the fair value of the contingent development and regulatory payments that we may

75

owe to Exonics’ former equity holders upon the achievement of certain events.
We record an increase or a decrease in the fair value of the contingent consideration liability on our consolidated balance sheet and in our consolidated statement of operations on a quarterly basis. We determine the fair value of our contingent consideration liability using a probability weighted discounted cash flow method of the income approach, which requires us to make estimates of the timing of regulatory and commercial milestone achievement and the corresponding estimated probability of technical and regulatory success rates. Significant judgment is used in determining the appropriateness of these assumptions during each reporting period. Reasonable changes in these assumptions can cause material changes to the fair value of our contingent consideration liability. Due to the early stage of Exonics’ DMD and DM1 programs, these significant assumptions could be affected by future economic and market conditions.
Goodwill
In 2021 and 2020, we did not have any business combinations; therefore, we did not record any additional goodwill on our consolidated balance sheet. In 2019, we recorded goodwill of $554.6 million and $397.1 million related to our acquisitions of Semma and Exonics, respectively. Goodwill reflects the difference between the fair value of the consideration transferred and the fair value of the net assets acquired. Thus, the goodwill that we record is dependent on the significant judgments and estimates inherent in the fair value of our in-process research and development assets and contingent consideration liabilities. We have one reporting unit for goodwill reporting purposes. We have not identified any goodwill impairment to date.
Income Taxes
We utilize the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities using enacted tax rates in effect for years in which the temporary differences are expected to reverse. If our estimate of the tax effect of reversing temporary differences is (i) not reflective of actual outcomes, (ii) modified to reflect new developments or interpretations of the tax law, or (iii) revised to incorporate new accounting principles, or changes in the expected timing or manner of the reversal, our results of operations could be materially impacted.
We provide a valuation allowance when it is more likely than not that deferred tax assets will not be realized. On a periodic basis, we reassess our valuation allowances on our deferred tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. Significant judgment is required in making these assessments to maintain or reverse our valuation allowances and, to the extent our future expectations change we would have to assess the recoverability of these deferred tax assets at that time. As of December 31, 2021, we maintained a valuation allowance of $220.4 million related primarily to U.S. state and foreign tax attributes.
We record liabilities related to uncertain tax positions by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. We adjust our liability to reflect any subsequent changes in the relevant facts and circumstances surrounding the uncertain positions. Significant judgment is required in making this assessment, and, therefore, we re-evaluate uncertain tax positions and consider various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, and changes in facts or circumstances related to a tax position.

RECENT ACCOUNTING PRONOUNCEMENTS
Refer to Note A, “Nature of Business and Accounting Policies,” in the accompanying notes to the consolidated financial statements for a discussion of recent accounting pronouncements and new accounting pronouncements adopted during 2021.


76

ITEM 7A.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
As part of our investment portfolio, we own financial instruments that are sensitive to market risks. The investment portfolio is used to preserve our capital. None of these market risk-sensitive instruments are held for trading purposes. We do not have derivative financial instruments in our investment portfolio.
Interest Rate Risk
We invest our cash in a variety of financial instruments, principally securities issued by the U.S. government and its agencies, investment-grade corporate bonds and commercial paper, and money market funds. These investments are denominated in U.S. Dollars. All of our interest-bearing securities are subject to interest rate risk and could decline in value if interest rates fluctuate, including potential fluctuations as a result of COVID-19. Substantially all of our investment portfolio consists of marketable securities with active secondary or resale markets to help ensure portfolio liquidity, and we have implemented guidelines limiting the term-to-maturity of our investment instruments. Due to the conservative nature of these instruments, we do not believe that we have material exposure to interest rate risk. If interest rates were to increase or decrease by 1%, the fair value of our investment portfolio would increase or decrease by an immaterial amount.
We entered into a credit agreement in each of 2020 and 2019. Loans under these credit agreements bear interest, at our option, at either a base rate or a Eurocurrency rate, in each case plus an applicable margin based on our consolidated leverage ratio (the ratio of our total consolidated funded indebtedness to our consolidated EBITDA for the most recently completed four fiscal quarter period). Pursuant to the credit agreement that we entered into in 2019, the applicable margin on base rate loans ranges from 0.125% to 0.500% and the applicable margin on Eurocurrency loans ranges from 1.125% to 1.500%. Pursuant to the credit agreement that we entered into in 2020, the applicable margin on base rate loans ranges from 0.500% to 0.875% and the applicable margin on Eurocurrency loans ranges from 1.500% to 1.875%. We do not believe that changes in interest rates related to either credit agreement would have a material effect on our consolidated financial statements. As of December 31, 2021, we had no principal or interest outstanding under either of our existing credit facilities. A portion of our “Interest expense” in 2022 will be dependent on whether, and to what extent, we borrow amounts under these existing facilities.
Foreign Exchange Market Risk
As a result of our foreign operations, we face exposure to movements in foreign currency exchange rates, primarily the Euro and British Pound against the U.S. Dollar. Fluctuations in the global markets, including as a result of COVID-19, may have a positive or negative effect on our foreign exchange rate exposure. The current exposures arise primarily from cash, accounts receivable, intercompany receivables and payables, payables and accruals and inventories. Both positive and negative effects to our net revenues from international product sales from movements in exchange rates are partially mitigated by the natural, opposite effect that exchange rates have on our international operating costs and expenses.
We have a foreign currency management program with the objective of reducing the effect of exchange rate fluctuations on our operating results and forecasted revenues and expenses denominated in foreign currencies. We currently have cash flow hedges for the Euro, British Pound, Canadian Dollar, Swiss Franc and Australian Dollar related to a portion of our forecasted product revenues that qualify for hedge accounting treatment under U.S. GAAP. We do not seek hedge accounting treatment for our foreign currency forward contracts related to monetary assets and liabilities that impact our operating results. As of December 31, 2021, we held foreign exchange forward contracts that were designated as cash flow hedges with notional amounts totaling $1.9 billion representing a net fair value of $38.2 million recorded on our consolidated balance sheet.
Although not predictive in nature, we believe a hypothetical 10% threshold reflects a reasonably possible near-term change in exchange rates. If the December 31, 2021 exchange rates were to change by a hypothetical 10%, the fair value recorded on our consolidated balance sheet related to our foreign exchange forward contracts that were designated as cash flow hedges as of December 31, 2021 would change by approximately $189.3 million. However, since these contracts hedge a specific portion of our forecasted product revenues denominated in certain foreign currencies, any change in the fair value of these contracts is recorded in “Accumulated other comprehensive income (loss)” on our consolidated balance sheet and is reclassified to earnings in the same periods during which the underlying product revenues affect earnings. Therefore, any change in the fair value of these contracts that would result from a hypothetical 10% change in exchange rates would be entirely offset by the change in value associated with the underlying hedged product revenues resulting in no impact on our future anticipated earnings and cash flows with respect to the hedged portion of our forecasted product revenues.

77

Equity Price Risk
Information required by this section is incorporated by reference from the discussion in the “Strategic Investments” section of this Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

ITEM 8.FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The information required by this Item 8 is contained on pages F-1 through F-45 of this Annual Report on Form 10-K.

ITEM 9.CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
Not applicable.

ITEM 9A.CONTROLS AND PROCEDURES
(1) Evaluation of Disclosure Controls and Procedures. Our chief executive officer and chief financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Annual Report on Form 10-K, have concluded that, based on such evaluation, our disclosure controls and procedures were effective. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply our judgment in evaluating the cost-benefit relationship of possible controls and procedures.
(2) Management’s Annual Report on Internal Control Over Financial Reporting. Management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) and Rule 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting include those policies and procedures that:
•    pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;
•    provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of management and our directors; and
•    provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2021. In making this assessment, we used the criteria set forth in the Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on our assessment, management has concluded that, as of December 31, 2021, our internal control over financial reporting is effective based on those criteria.
Our independent registered public accounting firm, Ernst & Young LLP, issued an attestation report on our internal control over financial reporting. See Section 4 below.

78

(3) Changes in Internal Controls. During the quarter ended December 31, 2021, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
(4) Report of Independent Registered Public Accounting Firm
To the Shareholders and the Board of Directors of Vertex Pharmaceuticals Incorporated
Opinion on Internal Control over Financial Reporting
We have audited Vertex Pharmaceuticals Incorporated’s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Vertex Pharmaceuticals Incorporated (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2021 consolidated financial statements of the Company and our report dated February 9, 2022, expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ Ernst & Young LLP
Boston, Massachusetts
February 9, 2022

79

ITEM 9B. OTHER INFORMATION
On February 7, 2022, the Company entered into an amendment to Dr. Jeffrey Leiden’s employment agreement, which was scheduled to expire on March 31, 2023. Among other things, the amendment extends the term for one year through March 31, 2024 and provides that Dr. Leiden’s equity compensation during the final year of the amended employment agreement will be equivalent to his equity compensation in the preceding year. The foregoing description of the amendment to Dr. Leiden’s employment agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement, which is filed as Exhibit 10.24 to this Annual Report on Form 10-K and incorporated by reference herein.


80

PART III
Portions of our definitive Proxy Statement for the 2022 Annual Meeting of Shareholders, or 2022 Proxy Statement, are incorporated by reference into this Part III of our Annual Report on Form 10-K.

ITEM 10.DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
The information regarding directors required by this Item 10 will be included in our 2022 Proxy Statement and is incorporated herein by reference. We expect this information to be provided under “Election of Directors,” “Corporate Governance and Risk Management,” “Shareholder Proposals for the 2022 Annual Meeting and Nominations for Director,” “Delinquent Section 16(a) Reports” and “Code of Conduct.” The information regarding executive officers required by this Item 10 is included in Part I of this Annual Report on Form 10-K.

ITEM 11.EXECUTIVE COMPENSATION
The information required by this Item 11 will be included in the 2022 Proxy Statement and is incorporated herein by reference. We expect this information to be provided under “Compensation Committee Interlocks and Insider Participation,” “Compensation Discussion and Analysis,” “Compensation and Equity Tables,” “Director Compensation,” “Management Development and Compensation Committee Report” and/or “Corporate Governance and Risk Management.”

ITEM 12.SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
The information required by this Item 12 will be included in the 2022 Proxy Statement and is incorporated herein by reference. We expect this information to be provided under “Security Ownership of Certain Beneficial Owners and Management” and “Equity Compensation Plan Information.”

ITEM 13.CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
The information required by this Item 13 will be included in the 2022 Proxy Statement and is incorporated herein by reference. We expect this information to be provided under “Election of Directors,” “Corporate Governance and Risk Management,” and “Audit and Finance Committee.”

ITEM 14.PRINCIPAL ACCOUNTANT FEES AND SERVICES
The information required by this Item 14 will be included in the 2022 Proxy Statement and is incorporated herein by reference. We expect this information to be provided under “Ratification of the Appointment of Independent Registered Public Accounting Firm.”


81

PART IV

ITEM 15.EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
(a)(1) The Financial Statements required to be filed by Items 8 and 15(c) of Form 10-K, and filed herewith, are as follows:
Page Number in this Form 10-K
Report of Independent Registered Public Accounting Firm (PCAOB ID: 42)
F-1
Consolidated Statements of Operations for the years ended December 31, 2021, 2020 and 2019
F-3
Consolidated Statements of Comprehensive Income for the years ended December 31, 2021, 2020 and 2019
F-4
Consolidated Balance Sheets as of December 31, 2021 and 2020
F-5
Consolidated Statements of Shareholders’ Equity for the years ended December 31, 2021, 2020 and 2019
F-6
Consolidated Statements of Cash Flows for the years ended December 31, 2021, 2020 and 2019
F-7
Notes to Consolidated Financial Statements
F-8
(a)(2) Financial Statement Schedules have been omitted because they are either not applicable or the required information is included in the consolidated financial statements or notes thereto listed in (a)(1) above.
(a)(3) Exhibits.
The following is a list of exhibits filed as part of this Annual Report on Form 10-K.
Exhibit Number
Exhibit Description
Filed with this report
Incorporated by
Reference herein from—Form or Schedule
Filing Date/
Period Covered
SEC File/Reg. Number
Plan of Acquisition
2.110-Q
 (Exhibit 10.1)		August 1, 2019000-19319
Governance Documents
3.110-Q
(Exhibit 3.1)		July 26, 2018000-19319
3.210-Q
(Exhibit 3.2)		May 1, 2020000-19319
Stock Certificate
4.110-K
(Exhibit 4.1)		February 15, 2018000-19319
4.210-K
(Exhibit 4.2)		February 13, 2020000-19319
Collaboration Agreement
10.110-Q
(Exhibit 10.1)		November 3, 2021000-19319
10.210-Q
(Exhibit 10.2)		November 3, 2021000-19319
10.310-Q/A
(Exhibit 10.6)		August 19, 2011000-19319
10.410-Q
(Exhibit 10.3)		November 3, 2021000-19319

82

Exhibit Number
Exhibit Description
Filed with this report
Incorporated by
Reference herein from—Form or Schedule
Filing Date/
Period Covered
SEC File/Reg. Number
10.510-Q
(Exhibit 10.4)		November 3, 2021000-19319
10.610-Q
(Exhibit 10.1)		July 30, 2021000-19319
Leases
10.710-Q
(Exhibit 10.2)		July 30, 2021000-19319
10.810-Q
(Exhibit 10.3)		July 30, 2021000-19319
Financing Agreements
10.910-Q
(Exhibit 10.1)		October 31, 2019000-19319
10.1010-K
(Exhibit 10.10)		February 11, 2021000-19319
10.1110-Q
(Exhibit 10.1)		October 30, 2020000-19319
Equity Plans
10.1210-Q
(Exhibit 10.1)		October 25, 2018000-19319
10.138-K
(Exhibit 10.2)		May 15, 2006000-19319
10.1410-K
(Exhibit 10.20)		February 13, 2015000-19319
10.15DEF 14A
(Appendix A)		April 26, 2019000-19319
10.1610-K
(Exhibit 10.17)		February 13, 2015000-19319
10.1710-K
(Exhibit 10.18)		February 13, 2015000-19319
10.1810-K
(Exhibit 10.25)		February 16, 2016000-19319
10.1910-K
(Exhibit 10.19)		February 13, 2015000-19319
10.2010-K
(Exhibit 10.17)		February 13, 2020000-19319
10.2110-K
(Exhibit 10.27)		February 16, 2016000-19319
10.22DEF 14A
(Appendix B)		April 26, 2019000-19319
Agreements with Executive Officers and Directors
10.238-K
(Exhibit 10.1)		April 1, 2020000-19319
10.24X
10.2510-K
(Exhibit 10.35)		February 22, 2012000-19319
10.268-K
(Exhibit 10.1)		July 25, 2019000-19319
10.278-K
(Exhibit 10.2)		July 25, 2019000-19319
10.2810-Q
(Exhibit 10.1)		November 6, 2012000-19319

83

Exhibit Number
Exhibit Description
Filed with this report
Incorporated by
Reference herein from—Form or Schedule
Filing Date/
Period Covered
SEC File/Reg. Number
10.2910-Q
(Exhibit 10.2)		November 6, 2012000-19319
10.3010-K
(Exhibit 10.34)		February 16, 2016000-19319
10.3110-K
(Exhibit 10.35)		February 16, 2016000-19319
10.3210-K
 (Exhibit 10.42)		February 23, 2017000-19319
10.3310-K
 (Exhibit 10.43)		February 23, 2017000-19319
10.3410-Q
(Exhibit 10.1)		May 1, 2019000-19319
10.3510-Q
(Exhibit 10.2)		May 1, 2019000-19319
10.36X
10.37X
10.3810-K
(Exhibit 10.46)		February 15, 2018000-19319
10.39X
Subsidiaries
21.1X
Consent
23.1X
Certifications
31.1X
31.2X
32.1X
101.INSXBRL InstanceX
101.SCHXBRL Taxonomy Extension SchemaX
101.CALXBRL Taxonomy Extension CalculationX
101.LABXBRL Taxonomy Extension LabelsX
101.PREXBRL Taxonomy Extension PresentationX
101.DEFXBRL Taxonomy Extension DefinitionX
104Cover Page Interactive Data File––the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.X
*    Management contract, compensatory plan or agreement.
†    Confidential portions of this document have been redacted according to the applicable rules.

ITEM 16.FORM 10-K SUMMARY
Not applicable.


84

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Vertex Pharmaceuticals Incorporated
February 9, 2022
By:
/s/ Reshma Kewalramani
Reshma Kewalramani
Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
Name
Title
Date
/s/ Reshma Kewalramani
Reshma Kewalramani
President, Chief Executive Officer and Director (Principal Executive Officer)February 9, 2022
/s/ Charles F. Wagner, Jr.
Charles F. Wagner, Jr.Executive Vice President and Chief Financial Officer (Principal Financial Officer)February 9, 2022
/s/ Kristen C. Ambrose
Kristen C. AmbroseSenior Vice President and Chief Accounting Officer (Principal Accounting Officer)February 9, 2022
/s/Jeffrey M. Leiden
Jeffrey M. LeidenExecutive ChairmanFebruary 9, 2022
/s/ Sangeeta N. Bhatia
Sangeeta N. Bhatia
DirectorFebruary 9, 2022
/s/ Lloyd Carney
Lloyd Carney
Director
February 9, 2022
/s/ Alan Garber
Alan Garber
DirectorFebruary 9, 2022
/s/ Terrence C. Kearney
Terrence C. Kearney
DirectorFebruary 9, 2022
/s/ Yuchun Lee
Yuchun Lee
DirectorFebruary 9, 2022
/s/ Margaret G. McGlynn
Margaret G. McGlynn
DirectorFebruary 9, 2022
/s/ Diana McKenzie
Diana McKenzie
DirectorFebruary 9, 2022
/s/ Bruce I. Sachs
Bruce I. Sachs
DirectorFebruary 9, 2022

85


Report of Independent Registered Public Accounting Firm
To the Shareholders and the Board of Directors of Vertex Pharmaceuticals Incorporated
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Vertex Pharmaceuticals Incorporated (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive income, shareholders’ equity, and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 9, 2022, expressed an unqualified opinion thereon.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
F-1


Revenue recognition - Payor Mix Impact on Measuring Variable Consideration
Description of the Matter
As discussed in Note A to the Company’s consolidated financial statements, the Company records product sales at the net sales price, or “transaction price,” which requires the Company to make several significant estimates regarding the net sales price. The most significant estimates relate to government rebates, chargebacks, discounts and fees, collectively rebates. Due to the delay in receipt of claims by third-party payors, the Company estimates the percentage of prescriptions that will be covered by each third-party payor, which is referred to as the payor mix. Rebate accruals inclusive of estimated amounts due for claims not yet received or processed are recorded within accrued expenses on the Company’s consolidated balance sheet.
Auditing the measurement of the Company’s net product revenues was complex and judgmental due to the significant estimation required in determining the amount of consideration that will be collected net of estimates for payor rebates. In particular, the net sales price is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with ultimate collection from third-party payors.
How We Addressed the Matter in Our Audit
We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company’s revenue recognition process, including controls over the underlying assumptions and inputs used by management to estimate amounts due to third-party payors and the completeness and accuracy of the data used in the estimates. We also tested the Company’s controls to assess the completeness and accuracy of the current and historical data that supports the estimate.
Our audit procedures to test the Company’s recognition of net product revenues included, among others, assessing the methodology used to determine the estimate and testing the significant assumptions and the underlying data used by the Company in its analysis, which included historical claims data. To assess the payor mix assumptions we tested contracted rates, historical claims and payment data and related trends, and other relevant factors. We also assessed the historical accuracy of the Company’s estimates of third-party payor rebates.
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2005.
Boston, Massachusetts
February 9, 2022

F-2


VERTEX PHARMACEUTICALS INCORPORATED
Consolidated Statements of Operations
(in millions, except per share amounts)
Year Ended December 31,
202120202019
Revenues:
Product revenues, net$7,573.4 $6,202.8 $4,160.7 
Other revenues
1.0 2.9 2.1 
Total revenues7,574.4 6,205.7 4,162.8 
Costs and expenses:
Cost of sales904.2 736.3 547.8 
Research and development expenses3,051.1 1,829.5 1,754.5 
Selling, general and administrative expenses840.1 770.5 658.5 
Change in fair value of contingent consideration(3.1)13.1 4.5 
Total costs and expenses
4,792.3 3,349.4 2,965.3 
Income from operations2,782.1 2,856.3 1,197.5 
Interest income4.9 22.2 63.7 
Interest expense(61.5)(58.2)(58.5)
Other income, net4.9 296.6 192.2 
Income before provision for income taxes2,730.4 3,116.9 1,394.9 
Provision for income taxes388.3 405.2 218.1 
Net income
$2,342.1 $2,711.7 $1,176.8 
Net income per common share:
Basic
$9.09 $10.44 $4.58 
Diluted
$9.01 $10.29 $4.51 
Shares used in per share calculations:
Basic
257.7 259.8 256.7 
Diluted
259.9 263.4 260.7 
The accompanying notes are an integral part of the consolidated financial statements.
F-3


VERTEX PHARMACEUTICALS INCORPORATED
Consolidated Statements of Comprehensive Income
(in millions)
Year ended December 31,
202120202019
Net income
$2,342.1 $2,711.7 $1,176.8 
Other comprehensive income:
Unrealized holding (losses) gains on marketable securities, net(0.8)(0.2)1.0 
Unrealized gains (losses) on foreign currency forward contracts, net of tax of $(21.8), $14.3 and $7.0, respectively
83.2 (51.6)(14.0)
Foreign currency translation adjustment2.0 (14.7)10.3 
Total other comprehensive income (loss)84.4 (66.5)(2.7)
Comprehensive income$2,426.5 $2,645.2 $1,174.1 
The accompanying notes are an integral part of the consolidated financial statements.
F-4


VERTEX PHARMACEUTICALS INCORPORATED
Consolidated Balance Sheets
(in millions, except share data)
December 31,
20212020
Assets
Current assets:
Cash and cash equivalents$6,795.0 $5,988.2 
Marketable securities729.9 670.7 
Accounts receivable, net1,136.8 885.4 
Inventories353.1 280.8 
Prepaid expenses and other current assets
545.8 308.3 
Total current assets
9,560.6 8,133.4 
Property and equipment, net1,094.1 958.5 
Goodwill1,002.2 1,002.2 
Intangible assets
400.0 400.0 
Deferred tax assets
934.5 882.8 
Operating lease assets330.3 325.6 
Other assets
110.8 49.3 
Total assets
$13,432.5 $11,751.8 
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable$195.0 $155.1 
Accrued expenses1,678.6 1,405.0 
Other current liabilities
268.4 317.4 
Total current liabilities
2,142.0 1,877.5 
Long-term finance lease liabilities509.8 539.0 
Long-term operating lease liabilities377.4 350.5 
Long-term contingent consideration186.5 189.6 
Other long-term liabilities
116.8 108.4 
Total liabilities
3,332.5 3,065.0 
Commitments and contingencies— — 
Shareholders’ equity:
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding
— — 
Common stock, $0.01 par value; 500,000,000 shares authorized, 254,479,046 and 259,889,549 shares issued and outstanding, respectively
2.5 2.6 
Additional paid-in capital6,880.8 7,894.0 
Accumulated other comprehensive income (loss)15.9 (68.5)
Retained earnings3,200.8 858.7 
Total shareholders’ equity
10,100.0 8,686.8 
Total liabilities and shareholders’ equity
$13,432.5 $11,751.8 
The accompanying notes are an integral part of the consolidated financial statements.
F-5


VERTEX PHARMACEUTICALS INCORPORATED
Consolidated Statements of Shareholders’ Equity
(in millions)

Common Stock
Additional
Paid-in Capital
Accumulated
Other
Comprehensive Income (Loss)
Retained Earnings (Accumulated Deficit)
Total
Shareholders’ Equity
Shares
Amount
Balance, December 31, 2018255.2 $2.5 $7,421.5 $0.7 $(2,989.5)$4,435.2 
Cumulative effect adjustment for adoption of new accounting guidance
— — — — (40.3)(40.3)
Other comprehensive loss, net of tax
— — — (2.7)— (2.7)
Net income
— — — — 1,176.8 1,176.8 
Repurchases of common stock(1.0)0.0 (186.0)— — (186.0)
Common stock withheld for employee tax obligations
— — (6.0)— — (6.0)
Issuance of common stock under benefit plans
4.8 0.1 345.9 — — 346.0 
Stock-based compensation expense
— — 362.2 — — 362.2 
Balance, December 31, 2019259.0 $2.6 $7,937.6 $(2.0)$(1,853.0)$6,085.2 
Other comprehensive loss, net of tax
— — — (66.5)— (66.5)
Net income
— — — — 2,711.7 2,711.7 
Repurchases of common stock(2.4)0.0 (539.1)— — (539.1)
Common stock withheld for employee tax obligations
(0.8)0.0 (200.3)— — (200.3)
Issuance of common stock under benefit plans4.1 0.0 262.7 — — 262.7 
Stock-based compensation expense
— — 433.1 — — 433.1 
Balance, December 31, 2020259.9 $2.6 $7,894.0 $(68.5)$858.7 $8,686.8 
Other comprehensive income, net of tax
— — — 84.4 — 84.4 
Net income
— — — — 2,342.1 2,342.1 
Repurchases of common stock(7.3)(0.1)(1,425.3)— — (1,425.4)
Common stock withheld for employee tax obligations
(0.6)0.0 (135.9)— — (135.9)
Issuance of common stock under benefit plans2.5 0.0 102.5 — — 102.5 
Stock-based compensation expense— — 445.5 — — 445.5 
Balance, December 31, 2021254.5 $2.5 $6,880.8 $15.9 $3,200.8 $10,100.0 
The accompanying notes are an integral part of the consolidated financial statements.
F-6


VERTEX PHARMACEUTICALS INCORPORATED
Consolidated Statements of Cash Flows
(in millions)
Year Ended December 31,
202120202019
Cash flows from operating activities:
Net income
$2,342.1 $2,711.7 $1,176.8 
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation expense441.4 429.5 360.5 
Depreciation expense125.6 109.5 106.9 
Deferred income taxes(154.6)277.3 167.4 
Gains on equity securities(17.1)(311.9)(197.6)
(Decrease) increase in fair value of contingent consideration(3.1)13.1 4.5 
Other non-cash items, net14.4 78.7 16.9 
Changes in operating assets and liabilities:
Accounts receivable, net(274.7)(223.4)(225.6)
Inventories(92.8)(132.0)(64.0)
Prepaid expenses and other assets(91.8)(297.6)35.4 
Accounts payable31.9 51.3 (22.8)
Accrued expenses305.4 122.2 172.9 
Other liabilities16.8 425.1 38.0 
Net cash provided by operating activities
2,643.5 3,253.5 1,569.3 
Cash flows from investing activities:
Payments to acquire businesses, net of cash acquired— — (1,154.2)
Purchases of available-for-sale debt securities(528.2)(431.4)(537.2)
Maturities of available-for-sale debt securities499.3 372.3 475.9 
Sale of equity securities— 437.6 94.9 
Purchases of property and equipment(235.0)(259.8)(75.4)
Investment in equity securities and notes receivable(77.0)(19.3)(39.3)
Net cash (used in) provided by investing activities
(340.9)99.4 (1,235.3)
Cash flows from financing activities:
Issuances of common stock under benefit plans102.0 264.9 343.2 
Repurchases of common stock(1,425.4)(539.1)(186.0)
Payments in connection with common stock withheld for employee tax obligations(135.9)(200.3)(6.0)
Payments on finance leases(47.0)(42.3)(39.2)
Proceeds from finance leases22.6 13.3 10.0 
Other financing activities5.7 (1.8)4.8 
Net cash (used in) provided by financing activities
(1,478.0)(505.3)126.8 
Effect of changes in exchange rates on cash
(13.4)20.6 1.6 
Net increase in cash, cash equivalents and restricted cash811.2 2,868.2 462.4 
Cash, cash equivalents and restricted cash—beginning of period
5,988.9 3,120.7 2,658.3 
Cash, cash equivalents and restricted cash—end of period
$6,800.1 $5,988.9 $3,120.7 
Supplemental disclosure of cash flow information:
Cash paid for interest$56.3 $54.5 $55.6 
Cash paid for income taxes$476.3 $191.8 $24.7 
The accompanying notes are an integral part of the consolidated financial statements.
F-7

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements

A.Nature of Business and Accounting Policies
Business
Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) is global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases with a focus on specialty markets. We have multiple approved medicines that treat the underlying cause of cystic fibrosis (“CF”), a life-threatening genetic disease, and we have several ongoing clinical and research programs to advance and extend treatment of CF. Beyond CF, we have a pipeline of investigational therapies in other serious diseases where we are leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies.
Our marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
Basis of Presentation
The accompanying consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals. Please refer to Note Q, “Segment Information,” for enterprise-wide disclosures regarding our revenues, major customers and long-lived assets by geographic area.
Use of Estimates
The preparation of consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Revenue Recognition
We recognize revenue when a customer obtains control of promised goods or services. We record the amount of revenue that reflects the consideration that we expect to receive in exchange for those goods or services. We apply the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) we satisfy each performance obligation. 
We only apply the five-step model to contracts when it is probable that we will collect the consideration to which we are entitled in exchange for the goods or services that we transfer to the customer. Once a contract is determined to be within the scope of Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”) at contract inception, we review the contract to determine which performance obligations we must deliver and which of these performance obligations are distinct. We recognize as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. Generally, our performance obligations are transferred to customers at a point in time, typically upon delivery.
Product Revenues, Net
We sell our products principally to a limited number of specialty pharmacy and specialty distributors in the United States (“U.S.”), which account for the largest portion of our total revenues. We make international sales primarily to specialty
F-8

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

distributors and retail chains, as well as hospitals and clinics, many of which are government-owned or supported. Our customers in the U.S. subsequently resell the products to patients and health care providers. We recognize net product revenues from sales when our customers obtain control of our products, which typically occurs upon delivery to our customers. Our payment terms are approximately 30 days in the U.S. and consistent with prevailing practice in international markets.
Revenues from product sales are recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from (a) invoice discounts for prompt payment and distribution fees, (b) government and private payor rebates, chargebacks, discounts and fees and (c) costs of co-pay assistance programs for patients, as well as other incentives for certain indirect customers. Reserves are established for the estimates of variable consideration based on the amounts earned or to be claimed on the related sales. The reserves are classified as reductions to “Accounts receivable, net” if payable to a customer or “Accrued expenses” if payable to a third-party. Where appropriate, we utilize the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in net product revenues only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary from our estimates, we adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.
Invoice Discounts and Distribution Fees: We generally provide invoice discounts on product sales to our customers for prompt payment and pays fees for distribution services, such as fees for certain data that customers provide to us. We estimate that, based on our experience, our customers will earn these discounts and fees, and deduct the full amount of these discounts and fees from our gross product revenues and accounts receivable at the time such revenues are recognized.
Rebates, Chargebacks, Discounts and Fees: We contract with government agencies (our “Third-party Payors”) so that products will be eligible for purchase by, or partial or full reimbursement from, such Third-party Payors. We estimate the rebates, chargebacks, discounts and fees we will provide to Third-party Payors and deduct these estimated amounts from our gross product revenues at the time the revenues are recognized. For each product, we estimate the aggregate rebates, chargebacks and discounts that we will provide to Third-party Payors based upon (i) our contracts with these Third-party Payors, (ii) the government-mandated discounts and fees applicable to government-funded programs, (iii) information obtained from our customers and other third-party data regarding the payor mix for such product and (iv) historical experience.
Other Incentives: Other incentives that we offer include co-pay mitigation rebates that we provide to commercially insured patients who have coverage and who reside in states that permit co-pay mitigation programs. Based upon the terms of our co-pay mitigation programs, we estimate average co-pay mitigation amounts for each of our products in order to establish appropriate accruals.
We make significant estimates and judgments that materially affect our recognition of net product revenues. We adjust our estimated rebates, chargebacks and discounts based on new information, including information regarding actual rebates, chargebacks and discounts for our products, as it becomes available. Claims by third-party payors for rebates, chargebacks and discounts frequently are submitted to us significantly after the related sales, potentially resulting in adjustments in the period in which the new information becomes known. Our credits to product revenue related to prior period sales have not been significant and primarily related to rebates and discounts.
We exclude taxes collected from customers relating to product sales and remitted to governmental authorities from revenues.
Contract Liabilities
We recorded contract liabilities of $171.7 million and $191.5 million as of December 31, 2021 and 2020, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive. Upon exceeding the annual reimbursement amount, products are provided free of
F-9

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

charge, which is a material right. These contracts include upfront payments and fees. We defer a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. Our product revenue contracts include performance obligations that are one year or less.
Our contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as our fiscal year. In these markets we recognize revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year. During the years ended December 31, 2021, 2020 and 2019, we recorded $191.5 million, $62.3 million and $24.9 million, respectively, of revenues that were recorded as contract liabilities at the beginning of the year.
French Early Access Programs
In 2015, we began distributing ORKAMBI through early access programs in France and remained engaged in reimbursement discussions with the French government until November 2019, when we reached an agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs. From the time we began distributing ORKAMBI through early access programs in France, we expected the difference between the amounts collected based on the invoiced amount and the final amount for ORKAMBI distributed through early access programs would be returned to the French government.
Through the third quarter of 2019, we recognized net product revenues for ORKAMBI sales in France under the early access programs based on a transaction price that reflected our estimate of consideration we expected to retain that would not be subject to a significant reversal in amounts recognized. When determining if variable consideration should be constrained, we consider whether there are factors outside our control that could result in a significant reversal of revenue. In making these assessments, we consider the likelihood and magnitude of a potential reversal of revenue.
Upon reaching an agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs in November 2019, we updated the transaction price to reflect the final amount for ORKAMBI distributed through early access programs. As a result, we recognized net product revenues of $155.8 million related to prior period ORKAMBI early access program sales in the fourth quarter of 2019 because the updated transaction price for ORKAMBI distributed through these programs exceeded our previous estimate of the consideration we expected to retain that would not be subject to a significant reversal in amounts recognized. We paid the final amount due to the French government in 2020.
Other Revenues
We have not recorded significant revenues other than our product revenues during the three years ended December 31, 2021; however, in future periods, we may recognize collaborative revenues generated through collaborative research, development and/or commercialization agreements related to one or more of the following: nonrefundable, upfront license fees; development and commercial milestones; funding of research and/or development activities; and royalties on net sales of licensed products. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to our collaborator.
For each collaborative research, development, and/or commercialization agreement that results in revenue, we identify all material performance obligations and determine the transaction price by estimating the amount of variable consideration at the outset of the contract. We constrain (reduce) the estimate of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract.
Once the estimated transaction price is established, amounts are allocated to each separate performance obligation that has been identified on a relative standalone selling price basis.
Upfront License Fees: If we determine that a license to our intellectual property is distinct from the other performance obligations identified in an arrangement, we recognize revenue from the related nonrefundable, upfront license fees based on the relative standalone selling price prescribed to the license compared to the total selling price of
F-10

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

the arrangement. We recognize revenue when the license is transferred to our collaborator and our collaborator is able to use and benefit from the license. For licenses that are not distinct from other obligations identified in the arrangement, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, we apply an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.
Development and Regulatory Milestone Payments: Depending on facts and circumstances, we may include certain milestones in the estimated transaction price or fully constrain the milestones. We include a milestone payment in the transaction price in the reporting period that it is probable that recording revenue in the period will not result in a significant reversal in amounts recognized in future periods. This may result in us recognizing revenues from certain milestones and a corresponding contract asset in a reporting period before the milestone is achieved. We fully constrain milestone payments that have not been included in the transaction price to date until we conclude that their achievement is probable and that recognition of the related revenue will not result in a significant reversal in amounts recognized in future periods. We re-evaluate the probability of achievement of such development milestones and any related constraint each reporting period and adjust our estimate of the overall transaction price, including the amount of collaborative revenue that we have recorded, if necessary.
Research and Development Activities/Transition Services: If we are entitled to reimbursement from our collaborators for specified research and development expenses, we account for the related services as separate performance obligations if these services represent a material right. We also determine whether to account for the reimbursement of research and development expenses as collaborative revenues or an offset to research and development expenses in accordance with the provisions of gross or net revenue presentation. We recognize the corresponding revenues or record the corresponding offset to research and development expenses as we satisfy the related performance obligations.
Concentration of Credit Risk
Financial instruments that potentially subject us to concentration of credit risk consist principally of money market funds and marketable securities. We place these investments with highly rated financial institutions, and, by policy, limit the amount of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. We also maintain a foreign currency hedging program that includes foreign currency forward contracts with several counterparties. We have not experienced any credit losses related to these financial instruments and do not believe we are exposed to any significant credit risk related to these instruments.
We are also subject to credit risk from our accounts receivable related to our product sales and collaborators. We evaluate the creditworthiness of each of our customers and have determined that all our material customers are creditworthy. To date, we have not experienced significant losses with respect to the collection of our accounts receivable. We believe that our allowances, which are not significant to our consolidated financial statements, are adequate at December 31, 2021. Please refer to Note Q, “Segment Information,” for further information.
Cash and Cash Equivalents
We consider all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.
Marketable Securities
As of December 31, 2021, our marketable securities consisted of investments in available-for-sale debt securities and corporate equity securities with readily determinable fair values. We classify marketable securities available to fund current operations as current assets on our consolidated balance sheets. Marketable securities are classified as long-term assets on our consolidated balance sheets if (i) they have been in an unrealized loss position for longer than one year and (ii) we have the ability and intent to hold them (a) until the carrying value is recovered and (b) such holding period may be longer than one year. Our marketable securities are stated at fair value. The fair value of these securities is based on quoted prices for
F-11

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

identical or similar assets.
We record unrealized gains (losses) on available-for-sale debt securities as a component of “Accumulated other comprehensive income (loss),” which is a separate component of shareholders’ equity on our consolidated balance sheet, until such gains and losses are realized. Realized gains and losses, if any, are determined using the specific identification method.
We record changes in the fair value of our investments in corporate equity securities to “Other income, net” in our consolidated statements of operations. Realized gains and losses, which are also included in “Other income, net,” are determined on an original weighted-average cost basis.
We adopted Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”) as of January 1, 2020, which did not have a significant impact on our consolidated financial statements. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires us to record an allowance for credit losses using an expected loss model, which replaces the incurred loss model required under the previous guidance. A credit loss is limited to the amount by which the amortized cost of an investment exceeds its fair value. A previously recognized credit loss may be decreased in subsequent periods if our estimate of fair value for the investment increases. To determine whether to record a credit loss, we consider issuer specific credit ratings and historical losses as well as current economic conditions and our expectations for future economic conditions.
Accounts Receivable
We deduct invoice discounts for prompt payment and fees for distribution services from our accounts receivable based on our experience that our customers will earn these discounts and fees. Our estimates for our allowance for credit losses, which has not been significant to date, is determined based on existing contractual payment terms, historical payment patterns, current economic conditions and our expectation for future economic conditions.
Stock-based Compensation Expense
We expense the fair value of employee restricted stock units and other forms of stock-based employee compensation over the associated employee service period on a straight-line basis. Stock-based compensation expense is determined based on the fair value of the award at the grant date and is adjusted each period to reflect actual forfeitures and the outcomes of certain performance conditions.
For awards with performance conditions in which the award does not vest unless the performance condition is met, we recognize expense if, and to the extent that, we estimate that achievement of the performance condition is probable. If we conclude that vesting is probable, we recognize expense from the date we reach this conclusion through the estimated vesting date.
We provide to employees who have rendered a certain number of years of service to Vertex and meet certain age requirements, partial or full acceleration of vesting of these equity awards, subject to certain conditions including a notification period, upon a termination of employment other than for cause. Approximately 5% of our employees were eligible for partial or full acceleration of any of their equity awards as of December 31, 2021. We recognize stock-based compensation expense related to these awards over a service period reflecting qualified employees’ eligibility for partial or full acceleration of vesting.
Please refer to Note N, “Stock-based Compensation Expense,” for tables displaying our stock-based compensation expense by type of award and by line item within our consolidated statements of operations.
Research and Development Expenses
Research and development expenses are comprised of costs we incur in performing research and development activities, including salary and benefits; stock-based compensation expense; outsourced services and other direct expenses, including clinical trial and pharmaceutical development costs; collaborative payments; and infrastructure costs, including facilities costs and depreciation expense. We recognize research and development expenses as incurred. We capitalize nonrefundable advance payments we make for research and development activities and expense the payments as the related goods are
F-12

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

delivered or the related services are performed.
Inventories
We value our inventories at the lower-of-cost or net realizable value. We determine the cost of our inventories, which include amounts related to materials and manufacturing overhead, on a first-in, first-out basis. We perform an assessment of the recoverability of our capitalized inventory during each reporting period and write down any excess and obsolete inventories to their net realizable value in the period in which the impairment is first identified. Shipping and handling costs incurred for inventory purchases are capitalized and recorded upon sale in “Cost of sales” in our consolidated statements of operations. Shipping and handling costs incurred for product shipments are recorded as incurred in “Cost of sales” in our consolidated statements of operations.
We capitalize inventories produced in preparation for initiating sales of a product candidate when the related product candidate is considered to have a high likelihood of regulatory approval and the related costs are expected to be recoverable through sales of the inventories. In determining whether to capitalize such inventories, we evaluate, among other factors, information regarding the product candidate’s safety and efficacy, the status of regulatory submissions and communications with regulatory authorities and the outlook for commercial sales, including the existence of current or anticipated competitive drugs and the availability of reimbursement. In addition, we evaluate risks associated with manufacturing the product candidate and the remaining shelf-life of the inventories.
Property and Equipment
Property and equipment are recorded at cost, net of accumulated depreciation. Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset generally as follows:
DescriptionEstimated Useful Life
Buildings and improvements
15 to 40 years
Furniture and equipment
7 to 10 years
Leasehold improvements; assets under finance leasesThe shorter of the useful life of the assets or the estimated remaining term of the associated lease
Computers and software
3 to 5 years
Maintenance and repairs to an asset that do not improve or extend its life are charged to operations. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in our consolidated statements of operations. We perform an assessment of the fair value of the assets if indicators of impairment are identified during a reporting period and record the assets at the lower of the net book value or the fair value of the assets.
We capitalize internal costs incurred to develop software for internal use during the application development stage. Amortization of capitalized internally developed software costs is recorded in depreciation expense over the useful life of the related asset.
Leases
We determine whether an arrangement contains a lease at inception. If a lease is identified in an arrangement, we recognize a right-of-use asset and liability on our consolidated balance sheet and determine whether the lease should be classified as a finance or operating lease. We do not recognize assets or liabilities for leases with lease terms of less than 12 months.
A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to Vertex by the end of the lease term, (ii) we hold an option to purchase the leased asset that we are reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no
F-13

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

alternative use at the end of the lease term. All other leases are recorded as operating leases.
Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate implicit is not readily determinable, we utilize our incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease.
We do not separate lease and non-lease components when determining which lease payments to include in the calculation of our lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, we reflect the option in the lease term if it is reasonably certain we will exercise the option.
Finance leases are recorded in “Property and equipment, net,” “Other current liabilities” and “Long-term finance lease liabilities,” and operating leases are recorded in “Operating lease assets,” “Other current liabilities” and “Long-term operating lease liabilities” on our consolidated balance sheet.
Income Taxes
Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the income tax bases of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. On a periodic basis, we reassess the valuation allowance on our deferred income tax assets weighing positive and negative evidence to assess the recoverability of our deferred tax assets. We include, among other things, our recent financial performance and our future projections in this periodic assessment.
We record liabilities related to uncertain tax positions by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. We evaluate our uncertain tax positions on a quarterly basis and consider various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in our tax returns, and changes in facts or circumstances related to a tax position. We adjust our liabilities to reflect any subsequent changes in the relevant facts and circumstances surrounding the uncertain positions. We accrue interest and penalties related to unrecognized tax benefits as a component of our “Provision for income taxes.”
As part of the U.S. Tax Cut and Jobs Act of 2017, we are subject to a territorial tax system, under which we must establish an accounting policy to provide for tax on Global Intangible Low Taxed Income (“GILTI”) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a current tax expense in our “Provision for income taxes.”
Variable Interest Entities
We review each collaboration agreement pursuant to which we license assets owned by a collaborator in order to determine whether or not we have a variable interest via the license agreement with our collaborator and if the variable interest is a variable interest in our collaborator as a whole and whether or not we are the primary beneficiary of that variable interest entity (“VIE”). If we determine we are the primary beneficiary of a VIE at the onset of our collaboration agreement, the collaboration is treated as a business combination and we consolidate the financial statements of the VIE into our consolidated financial statements until we are no longer the primary beneficiary of the consolidated VIE, or no longer have a variable interest in the VIE. As of December 31, 2021 and 2020, we did not have any consolidated VIEs.
Fair Value of In-process Research and Development Assets and Contingent Payments
The present-value models we use to estimate the fair values of in-process research and development assets and contingent payments pursuant to collaborations and acquisitions incorporate significant assumptions.
F-14

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

Our discounted cash flow models pertaining to in-process research and development assets include: (i) assumptions regarding the probability of obtaining marketing approval for a product candidate; (ii) the timing of and the expected costs to develop and commercialize a product candidate; (iii) estimates of future cash flows from potential product sales with respect to a product candidate; and (iv) appropriate discount and tax rates.
We base our estimates of the probability of achieving the milestones relevant to the fair value of contingent payments, which could include milestone, royalty and option payments, on industry data. Estimates included in the discounted cash flow models pertaining to contingent payments also include: (i) estimate regarding the timing of the relevant development and commercial milestones and royalties, (ii) and appropriate discount rates. We record any increases or decreases in the fair value of our contingent payments as charges or credits to “Change in fair value of contingent consideration” in our consolidated statement of operations. Please refer to Note D, “Fair Value Measurements,” for further information.
In-process Research and Development Assets
We record the fair value of in-process research and development assets as of the transaction date of a business combination. Each of these assets is accounted for as an indefinite-lived intangible asset and is maintained on our consolidated balance sheet until either the underlying project is completed or the asset becomes impaired. If the asset becomes impaired or is abandoned, the carrying value of the related intangible asset is written down to its fair value, and an impairment charge is recorded in the period in which the impairment occurs. If a project is completed, the carrying value of the related intangible asset is amortized as a part of “Cost of sales” over the remaining estimated life of the asset beginning in the period in which the project is completed. In-process research and development assets are tested for impairment on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstances suggest that impairment may exist.
In-process research and development that is acquired in a transaction that does not qualify as a business combination under U.S. GAAP and that does not have an alternative future use is recorded to “Research and development expenses” in the period in which it is acquired.
Goodwill
The difference between the purchase price and the fair value of assets acquired and liabilities assumed in a business combination is allocated to goodwill. Goodwill is evaluated for impairment on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstances suggest that impairment may exist. As noted in Basis of Presentation above, we have one operating segment, pharmaceuticals, which is our only reporting unit.
Hedging Activities
We recognize the fair value of hedging instruments that are designated and qualify as hedging instruments pursuant to U.S. GAAP, foreign currency forward contracts, as either assets or liabilities on our consolidated balance sheets. Changes in the fair value of these instruments are recorded each period in “Accumulated other comprehensive income (loss)” as unrealized gains and losses until the forecasted underlying transaction occurs. Unrealized gains and losses on these foreign currency forward contracts are included in “Prepaid expenses and other current assets” or “Other assets,” and “Other current liabilities” or “Other long-term liabilities,” respectively, on our consolidated balance sheets depending on the remaining period until their contractual maturity. Realized gains and losses for the effective portion of such contracts are recognized in “Product revenues, net” in our consolidated statement of operations in the same period that we recognize the product revenues that were impacted by the hedged foreign exchange rate changes. We classify the cash flows from hedging instruments in the same category as the cash flows from the hedged items.
Certain of our hedging instruments are subject to master netting arrangements to reduce the risk arising from such transactions with our counterparties. We present unrealized gains and losses on our foreign currency forward contracts on a gross basis within our consolidated balance sheets.
We also enter into foreign currency forward contracts with contractual maturities of less than one month designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities including intercompany balances. These contracts are not designated as hedging instruments pursuant to U.S. GAAP. Realized gains and losses for such
F-15

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

contracts are recognized in “Other income, net” in our consolidated statement of operations each period.
Comprehensive Income
Comprehensive income consists of net income and other comprehensive income (loss), which includes foreign currency translation adjustments and unrealized gains and losses on foreign currency forward contracts and certain marketable securities. For purposes of comprehensive income disclosures, we record provisions for or benefits from income taxes related to the unrealized gains and losses on foreign currency forward contracts and certain marketable securities. We do not record provisions for or benefits from income taxes related to our cumulative translation adjustment, as we intend to permanently reinvest undistributed earnings in our foreign subsidiaries.
Foreign Currency Translation and Transactions
The majority of our operations occur in entities that have the U.S. dollar denominated as their functional currency. The assets and liabilities of our entities with functional currencies other than the U.S. dollar are translated into U.S. dollars at exchange rates in effect at the end of the year. Revenue and expense amounts for these entities are translated using the average exchange rates for the period. Net unrealized gains and losses resulting from foreign currency translation are included in “Accumulated other comprehensive income (loss).” Net foreign currency exchange transaction losses, which are included in “Other income, net” on our consolidated statement of operations, were $13.9 million, $16.1 million and $5.2 million for 2021, 2020 and 2019, respectively. These net foreign currency exchange losses are presented net of the impact of the foreign currency forward contracts designed to mitigate their effect on our consolidated statement of operations.
Share Repurchase Programs
Repurchases of our common stock are recorded as reductions to “Common Stock” and “Additional paid-in capital” pursuant to our established accounting policy. Repurchases in excess of the par value will be recorded as reductions to “Retained earnings” in the event that “Additional paid-in capital” is reduced to zero.
Net Income Per Common Share
Basic net income per common share is based upon the weighted-average number of common shares outstanding during the period. Diluted net income per common share utilizing the treasury-stock method is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive. Potentially dilutive shares result from the assumed exercise of outstanding stock options and assumed vesting of restricted stock units (including performance-based restricted stock units) (the proceeds of which are then assumed to have been used to repurchase outstanding stock using the treasury-stock method).
Recently Adopted Accounting Standards
Income Taxes
In 2019, the Financial Accounting Standards Board (“FASB”) issued ASU 2019-12, Income Taxes (Topic 740) (“ASU 2019-12”), which simplifies the accounting for income taxes. ASU 2019-12 became effective on January 1, 2021. The adoption of ASU 2019-12 did not have a significant impact on our consolidated financial statements.
Internal-Use Software
In 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU 2018-15”), which clarifies the accounting for implementation costs in cloud computing arrangements. ASU 2018-15 became effective on January 1, 2020. The adoption of ASU 2018-15 resulted in an insignificant amount of additional assets recorded on our consolidated balance sheet.
Fair Value Measurement
In 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which modifies the disclosure requirements for fair
F-16

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

value measurements. ASU 2018-13 became effective on January 1, 2020. The adoption of ASU 2018-13 resulted in additional disclosures related to our Level 3 inputs. Please refer to Note D, “Fair Value Measurements,” for further information.
Credit Losses
In 2016, the FASB issued ASU 2016-13, which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 became effective on January 1, 2020. The adoption of ASU 2016-13 did not have a significant impact on our consolidated financial statements.
Leases
On January 1, 2019, we adopted ASC 842 using the modified-retrospective method. Until December 31, 2018, we applied build-to-suit accounting and were the deemed owner of our leased corporate headquarters in Boston and research site in San Diego. Under the amended guidance that became effective January 1, 2019, we account for these buildings as finance leases. As of January 1, 2019, we recorded a cumulative effect adjustment to increase our “Accumulated deficit” by $40.3 million to reflect our build-to-suit leases as finance leases pursuant to ASC 842.
Recently Issued Accounting Standards
We do not expect any recently issued accounting standards to have a significant impact on our consolidated financial statements.

B.Collaborative and Other Arrangements
We have entered into numerous agreements pursuant to which we collaborate with third parties on research, development and commercialization programs, including in-license and out-license agreements or acquire assets. Our “Research and development expenses” included $1.1 billion, $184.6 million and $318.3 million related to upfront and milestone payments pursuant to our in-license agreements and asset acquisitions in 2021, 2020 and 2019, respectively.
In-license Agreements
We have entered into a number of in-license agreements in order to advance and obtain access to technologies and services related to our research and early-development activities. We are generally required to make an upfront payment upon execution of our license agreements; development, regulatory and commercialization milestones payments upon the achievement of certain product research, development and commercialization objectives; and royalty payments on future sales, if any, of commercial products resulting from our collaborations.
Pursuant to the terms of our in-license agreements, our collaborators typically lead the discovery efforts and we lead all preclinical, development and commercialization activities associated with the advancement of any product candidates and fund all expenses.
We typically can terminate our in-license agreements by providing advance notice to our collaborators; the required length of notice is dependent on whether any product developed under the license agreement has received marketing approval. Our license agreements may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, these license agreements generally remain in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired.
CRISPR Therapeutics AG
CRISPR-Cas9 Gene-editing Therapies
In 2015, we entered into a strategic collaboration, option and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new
F-17

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. We had the exclusive right to license certain targets. In 2019, we paid an aggregate of $30.0 million to exclusively license three targets, including CF, pursuant to the CRISPR Agreement. We recorded the $30.0 million total option payment to “Research and development expenses.” For each of the three targets that we elected to license, CRISPR has the potential to receive up to an additional $410.0 million in development, regulatory and commercial milestones as well as royalties on net product sales.
In 2017, we entered into a joint development and commercialization agreement with CRISPR pursuant to the terms of the CRISPR Agreement (the “Original CTX001 JDCA”), under which we and CRISPR were co-developing and preparing to co-commercialize CTX001 for the treatment of hemoglobinopathies, including treatments for sickle cell disease and transfusion-dependent beta thalassemia.
In the second quarter of 2021, we and CRISPR amended and restated the Original CTX001 JDCA (the “A&R JDCA”), pursuant to which the parties agreed to, among other things, (a) adjust the governance structure for the collaboration and adjust the responsibilities of each party thereunder; (b) adjust the allocation of net profits and net losses between the parties; and (c) exclusively license (subject to CRISPR’s reserved rights to conduct certain activities) certain intellectual property rights to us relating to the products that may be researched, developed, manufactured and commercialized under such agreement.
Pursuant to the A&R JDCA, we are now leading global development, manufacturing and commercialization of CTX001, with support from CRISPR. Subject to the terms and conditions of the A&R JDCA, we also have the right to conduct all research, development, manufacturing and commercialization activities relating to the product candidates and products under the A&R JDCA (including CTX001) throughout the world subject to CRISPR’s reserved right to conduct certain activities.
In connection with the A&R JDCA, we made a $900.0 million upfront payment to CRISPR in the second quarter of 2021. We concluded that we did not have any alternative future use for the acquired in-process research and development and recorded this upfront payment to “Research and development expenses.” CRISPR has the potential to receive an additional one-time $200.0 million milestone payment upon receipt of the first marketing approval of CTX001 from the U.S. Food and Drug Administration or the European Commission.
We and CRISPR shared equally all expenses incurred under the Original CTX001 JDCA. On July 1, 2021, with respect to CTX001, the net profits and net losses incurred pursuant to the A&R JDCA began to be allocated 60% to us and 40% to CRISPR, while all other product candidates and products continue to have net profits and net losses shared equally between the parties. We concluded that the Original CTX001 JDCA and the A&R JDCA are cost-sharing arrangements, which result in the net impact of the arrangements being recorded in “Research and development expenses” in our consolidated statements of operations. During the three years ended December 31, 2021, we recognized the following amounts in total related to these agreements:
202120202019
(in millions)
Total research and development expenses incurred under the Original CTX001 JDCA and A&R JDCA$230.4 $101.2 $60.3 
Vertex’s share recognized in “Research and development expenses” in consolidated statements of operations
129.0 50.6 30.1 
Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1
In 2019, we entered into a separate strategic collaboration and license agreement (the “CRISPR DMD/DM1 Agreement”) with CRISPR. Pursuant to this agreement, we received an exclusive worldwide license to CRISPR’s existing and future intellectual property for Duchenne muscular dystrophy (“DMD”) and myotonic dystrophy type 1 (“DM1”) and we made an upfront payment of $175.0 million to CRISPR. We concluded that we did not have any alternative future use for the acquired in-process research and development and recorded the upfront payment to “Research and development expenses.” We recorded $12.5 million and $25.0 million to “Research and development expenses” in 2021 and 2020, respectively, related to pre-clinical milestones earned by CRISPR under the CRISPR DMD/DM1 Agreement. CRISPR has the potential to receive up to an additional $787.5 million in research, development, regulatory and commercial milestones for the DMD and
F-18

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

DM1 programs as well as royalties on net product sales. CRISPR has the option to co-develop and co-commercialize all DM1 products globally and forego the milestones and royalties associated with the DM1 program. We fund all expenses associated with the collaboration.
Kymera Therapeutics Inc.
In 2019, we entered into a strategic research and development collaboration agreement with Kymera Therapeutics Inc. (“Kymera”) to advance small molecule protein degraders against multiple targets. Kymera’s proprietary platform technology is being applied in the collaboration activities in exchange for an upfront payment of $50.0 million. We have the exclusive right to license up to six protein targets, for each of which Kymera may receive up to $170.0 million in payments, including development, regulatory and commercial milestones as well as royalties on net product sales. We determined that substantially all of the fair value of the Kymera collaboration agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. We concluded that we did not have any alternative future use for the acquired in-process research and development and recorded the $50.0 million upfront payment to “Research and development expenses.”
In addition to the upfront payment, we purchased $20.0 million of Kymera’s preferred stock that converted to common stock when Kymera became a publicly traded company in 2020.
Moderna, Inc.
In 2016, we entered into a strategic collaboration and licensing agreement with Moderna, Inc. (“Moderna”), pursuant to which the parties are seeking to identify and develop messenger ribonucleic acid (“mRNA”) therapeutics for the treatment of CF.
In 2020, we entered into a new strategic collaboration and licensing agreement with Moderna (the “2020 Moderna Agreement”) aimed at the discovery and development of lipid nanoparticles and mRNAs that can deliver gene-editing therapies to lung cells for the treatment of CF. Pursuant to the 2020 Moderna Agreement, we paid Moderna an upfront payment of $75.0 million and Moderna is eligible to receive up to $380.0 million in development, regulatory and commercial milestones as well as royalties on net product sales. We determined that substantially all the fair value of the 2020 Moderna Agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. We concluded that we did not have any alternative future use for the acquired in-process research and development and recorded the upfront payment to “Research and development expenses.”
Additional In-License Agreements and Other Arrangements
In 2016, we entered into a strategic collaboration and license agreement with ApoLo1 Bio, LLC (“ApoLo1”) related to our drug discovery efforts in APOL1-mediated kidney disease. In 2021, based on positive results from a Phase 2 proof-of-concept study of VX-147 in patients with APOL1-mediated focal segmental glomerulosclerosis, we paid ApoLo1 a $15.0 million milestone and exercised our $60.0 million option to buy-out all future development milestones, regulatory milestones and future royalties on net product sales. We recorded these payments to “Research and development expenses” because we concluded that we did not have any alternative future use for the acquired in-process research and development.
In addition to the collaborative arrangements described above, we recorded upfront, option and milestone payments totaling $125.8 million in 2021, $84.6 million in 2020 and $63.3 million in 2019 to “Research and development expenses” related to additional in-license agreements and other business development transactions that we do not consider to be individually significant to our consolidated financial statements. These payments included upfront payments of $31.0 million to Mammoth Biosciences, Inc. (“Mammoth”) and $25.0 million to Arbor Biotechnologies, Inc. (“Arbor”) in 2021, $40.0 million to Skyhawk Therapeutics, Inc. (“Skyhawk”) in 2020, and $25.9 million to Molecular Templates, Inc. (“Molecular”) in 2019.
For Mammoth, Arbor, Skyhawk, Molecular and several other in-license agreements that are not individually significant to our consolidated financial statements, we determined that substantially all the fair value of each individual agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. We concluded that we did not have any alternative future use for the acquired in-process research and development
F-19

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

associated with the agreements and recorded the upfront payments for these agreements to “Research and development expenses.” Please refer to Note D, “Fair Value Measurements,” and Note E, “Marketable Securities and Equity Investments,” for further information regarding our investments in our collaborators.
Out-license Agreements
We have entered into licensing agreements pursuant to which we have out-licensed rights to certain product candidates to third-party collaborators. Pursuant to these out-license agreements, our collaborators become responsible for all costs related to the continued development of such product candidates and obtain development and commercialization rights to these product candidates. Depending on the terms of the agreements, our collaborators may be required to make upfront payments, milestone payments upon the achievement of certain product research and development objectives and may also be required to pay royalties on future sales, if any, of commercial products resulting from the collaboration. The termination provisions associated with these collaborations are generally the same as those described above related to our in-license agreements.
Merck KGaA, Darmstadt, Germany
In 2017, we entered into a strategic collaboration and license agreement (the “Oncology Agreement”) with Merck KGaA, Darmstadt, Germany (the “Licensee”). Pursuant to the Oncology Agreement, we granted the Licensee an exclusive worldwide license to research, develop and commercialize four oncology research and development programs including two clinical-stage programs targeting DNA damage repair: our ataxia telangiectasia and Rad3-related protein kinase inhibitor program, or ATR program, including VX-970 and VX-803, and our DNA-dependent protein kinase inhibitor program, or DNA-PK program, including VX-984. In addition, we granted the Licensee exclusive, worldwide rights to two pre-clinical programs.
In 2018, we entered into an agreement with Merck KGaA, Darmstadt, Germany (the “DNA-PK Agreement”) whereby we licensed the two lead Vertex DNA-PK compounds from our DNA-PK program for use in the field of gene integration for six specific indications. Merck KGaA, Darmstadt, Germany has the potential to receive additional milestones, primarily related to approval and reimbursement in various markets, as well as royalties on net product sales.
Cystic Fibrosis Foundation
We have a research, development and commercialization agreement that was originally entered into in 2004 with the Cystic Fibrosis Foundation, as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc. This agreement was most recently amended in 2016. Pursuant to the agreement, as amended, we agreed to pay royalties ranging from low-single digits to mid-single digits on potential sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor, and tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor). For combination products, such as ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), sales are allocated equally to each of the active pharmaceutical ingredients in the combination product. We record our royalties payable to the Cystic Fibrosis Foundation to “Cost of sales.”

F-20

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

C.Earnings Per Share
The following table sets forth the computation of basic and diluted net income per common share for the periods ended:
202120202019
(in millions, except per share amounts)
Net income $2,342.1 $2,711.7 $1,176.8 
Basic weighted-average common shares outstanding257.7 259.8 256.7 
Effect of potentially dilutive securities:
Stock options1.1 1.8 2.2 
Restricted stock units (including PSUs)
1.1 1.7 1.7 
Employee stock purchase program
0.0 0.1 0.1 
Diluted weighted-average common shares outstanding259.9 263.4 260.7 
Basic net income per common share$9.09 $10.44 $4.58 
Diluted net income per common share$9.01 $10.29 $4.51 
We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:
202120202019
(in millions)
Stock options0.7 0.3 2.8 
Unvested restricted stock units (including PSUs)0.4 0.3 — 

D.Fair Value Measurements
The following fair value hierarchy is used to classify assets and liabilities based on observable inputs and unobservable inputs used in order to determine the fair value of our financial assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.
Our investment strategy is focused on capital preservation. We invest in instruments that meet the credit quality standards outlined in our investment policy, which also limits the amount of credit exposure to any one issue or type of instrument. We maintain strategic investments separately from the investment policy that governs our other cash, cash equivalents and marketable securities as described in Note E, “Marketable Securities and Equity Investments.” Additionally, we utilize foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on our consolidated statement of operations.
During the three years ended December 31, 2021, we did not record any other-than-temporary impairment charges related to our financial assets.
F-21

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $3.3 billion and $2.8 billion of cash as of December 31, 2021 and 2020, respectively):
As of December 31, 2021As of December 31, 2020
Fair Value Hierarchy
Fair Value Hierarchy
Total
Level 1
Level 2
Level 3
Total
Level 1
Level 2
Level 3
(in millions)
Financial instruments carried at fair value (asset position):
Cash equivalents:
Money market funds$3,478.1 $3,478.1 $— $— $3,141.1 $3,141.1 $— $— 
Marketable securities:
Corporate equity securities230.9 230.9 — — 195.8 15.7 180.1 — 
U.S. Treasury securities86.4 86.4 — — — — — — 
Government-sponsored enterprise securities69.0 69.0 — — 80.0 80.0 — — 
Corporate debt securities90.9 — 90.9 — 231.6 — 231.6 — 
Commercial paper252.7 — 252.7 — 163.3 — 163.3 — 
Prepaid expenses and other current assets:
Foreign currency forward contracts44.5 — 44.5 — — — — — 
Other assets:
Foreign currency forward contracts2.0 — 2.0 — — — — — 
Total financial assets
$4,254.5 $3,864.4 $390.1 $— $3,811.8 $3,236.8 $575.0 $— 
Financial instruments carried at fair value (liability position):
Other current liabilities:
Foreign currency forward contracts$(5.6)$— $(5.6)$— $(59.2)$— $(59.2)$— 
Long-term contingent consideration(186.5)— — (186.5)(189.6)— — (189.6)
Other long-term liabilities:
Foreign currency forward contracts(2.7)— (2.7)— (4.3)— (4.3)— 
Total financial liabilities$(194.8)$— $(8.3)$(186.5)$(253.1)$— $(63.5)$(189.6)
Please refer to Note E, “Marketable Securities and Equity Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.
Fair Value of Corporate Equity Securities
We classify our investments in publicly traded corporate equity securities as “Marketable securities” on our consolidated balance sheets. Generally, our investments in the common stock of publicly traded companies are valued based on Level 1 inputs because they have readily determinable fair values. However, certain of our investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments. Please refer to Note E, “Marketable Securities and Equity Investments,” for further information on these investments.
Fair Value of Contingent Consideration
In 2019, we acquired Exonics Therapeutics, Inc. (“Exonics”), a privately-held company focused on creating transformative gene-editing therapies to repair mutations that cause DMD and other severe neuromuscular diseases, including DM1. Our Level 3 contingent consideration liabilities are related to $678.3 million of development and regulatory milestones potentially payable to Exonics’ former equity holders. We base our estimates of the probability of achieving the milestones relevant to the fair value of contingent payments on industry data attributable to rare diseases. The discount rates used in the valuation model for contingent payments, which were between 0.9% and 2.3% as of December 31, 2021, represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Due to the uncertainties associated with development and commercialization of product candidates in the pharmaceutical industry and the effects of changes in other assumptions
F-22

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

including discount rates, we expect our estimates regarding the fair value of contingent consideration to change in the future, resulting in adjustments to the fair value of our contingent consideration liabilities, and the effect of any such adjustments could be material.
The following table represents a rollforward of the fair value of our contingent consideration liabilities:
Year Ended December 31, 2021
(in millions)
Balance at December 31, 2020
$189.6 
Decrease in fair value of contingent payments
(3.1)
Balance at December 31, 2021
$186.5 

E.Marketable Securities and Equity Investments
A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $3.3 billion and $2.8 billion of cash as of December 31, 2021 and 2020, respectively), is shown below:
As of December 31, 2021As of December 31, 2020
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair Value
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair Value
(in millions)
Cash equivalents:
Money market funds
$3,478.1 $— $— $3,478.1 $3,141.1 $— $— $3,141.1 
Marketable securities:
U.S. Treasury securities$86.6 $— $(0.2)$86.4 $— $— $— $— 
Government-sponsored enterprise securities
69.0 — — 69.0 80.0 — — 80.0 
Corporate debt securities
91.1 — (0.2)90.9 231.3 0.4 (0.1)231.6 
Commercial paper
252.8 — (0.1)252.7 163.3 — — 163.3 
Total marketable debt securities499.5 — (0.5)499.0 474.6 0.4 (0.1)474.9 
Corporate equity securities
69.4 167.1 (5.6)230.9 51.4 144.4 — 195.8 
Total marketable securities$568.9 $167.1 $(6.1)$729.9 $526.0 $144.8 $(0.1)$670.7 
Available-for-sale debt securities were classified on our consolidated balance sheets at fair value as follows:
December 31,
20212020
(in millions)
Cash and cash equivalents$3,478.1 $3,141.1 
Marketable securities
499.0 474.9 
Total
$3,977.1 $3,616.0 
F-23

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

Available-for-sale debt securities by contractual maturity were as follows:
December 31,
20212020
(in millions)
Matures within one year$3,912.3 $3,526.2 
Matures after one year through five years
64.8 89.8 
Total
$3,977.1 $3,616.0 
We have a limited number of available-for-sale debt securities in insignificant loss positions as of December 31, 2021, which we do not intend to sell and have concluded we will not be required to sell before recovery of the amortized costs for the investments at maturity. We did not record any charges for other-than-temporary declines in the fair value of available-for-sale debt securities or gross realized gains or losses in 2021, 2020 or 2019.
We record changes in the fair value of our investments in corporate equity securities to “Other income, net” in our consolidated statements of operations. During the three years ended December 31, 2021, our net unrealized gains on corporate equity securities held at the conclusion of each period were as follows:
202120202019
(in millions)
Net unrealized gains$17.1 $136.2 $143.2 
During the years ended December 31, 2020 and 2019, we sold the common stock of publicly traded companies, which were primarily sales of our investment in CRISPR, resulting in the following:
20202019
(in millions)
Proceeds received$437.6 $94.9 
Weighted-average cost basis$103.3 $29.8 
During the year ended December 31, 2021, we did not sell any common stock of publicly traded companies.
As of December 31, 2021, the carrying value of our equity investments without readily determinable fair values, which are recorded in “Other assets” on our consolidated balance sheets, was $85.8 million.

F-24

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

F.Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
Unrealized Holding Gains (Losses), Net of Tax
Foreign Currency Translation AdjustmentOn Available-For-Sale Debt SecuritiesOn Foreign Currency Forward ContractsTotal
(in millions)
Balance as of December 31, 2018
$(11.2)$(0.5)$12.4 $0.7 
Other comprehensive income before reclassifications10.3 1.0 11.5 22.8 
Amounts reclassified from accumulated other comprehensive income (loss)— — (25.5)(25.5)
Net current period other comprehensive income (loss)10.3 1.0 (14.0)(2.7)
Balance as of December 31, 2019
$(0.9)$0.5 $(1.6)$(2.0)
Other comprehensive loss before reclassifications(14.7)(0.2)(54.5)(69.4)
Amounts reclassified from accumulated other comprehensive income (loss)— — 2.9 2.9 
Net current period other comprehensive loss(14.7)(0.2)(51.6)(66.5)
Balance as of December 31, 2020
$(15.6)$0.3 $(53.2)$(68.5)
Other comprehensive income (loss) before reclassifications2.0 (0.8)59.7 60.9 
Amounts reclassified from accumulated other comprehensive income (loss)— — 23.5 23.5 
Net current period other comprehensive income (loss)2.0 (0.8)83.2 84.4 
Balance as of December 31, 2021
$(13.6)$(0.5)$30.0 $15.9 

G.Hedging
Foreign currency forward contracts - Designated as hedging instruments
We maintain a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of our forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under U.S. GAAP having contractual durations from one to eighteen months. We recognize realized gains and losses for the effective portion of such contracts in “Product revenues, net” in our consolidated statements of operations in the same period that we recognize the product revenues that were impacted by the hedged foreign exchange rate changes.
We formally document the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as our risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. We also formally assess, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of December 31, 2021, all hedges were determined to be highly effective.
F-25

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

We consider the impact of our counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of December 31, 2021 and December 31, 2020, credit risk did not change the fair value of our foreign currency forward contracts.
The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:
As of December 31,
20212020
Foreign Currency(in millions)
Euro$1,364.5 $745.1 
British pound sterling
287.7 160.4 
Australian dollar
96.3 99.9 
Canadian dollar
89.9 86.5 
Swiss Franc54.1 — 
Total foreign currency forward contracts
$1,892.5 $1,091.9 
Foreign currency forward contracts - Not designated as hedging instruments
We also enter into foreign currency forward contracts with contractual maturities of less than one month, which are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under U.S. GAAP. We recognize realized gains and losses for such contracts in “Other income, net” in our consolidated statements of operations each period. As of December 31, 2021, the notional amount of our outstanding foreign currency forward contracts where hedge accounting under U.S. GAAP is not applied was $580.7 million.
During the three years ended December 31, 2021, we recognized the following related to foreign currency forward contracts in our consolidated statements of operations:
December 31,
202120202019
(in millions)
Designated as hedging instruments - Reclassified from AOCI
Product revenues, net$(30.0)$(3.7)$32.5 
Not designated as hedging instruments
Other income, net$(18.6)$22.1 $(4.8)
Total reported in the Consolidated Statement of Operations
Product revenues, net$7,573.4 $6,202.8 $4,160.7 
Other income, net$4.9 $296.6 $192.2 
F-26

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our consolidated balance sheets:
As of December 31, 2021
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets
$44.5 
Other current liabilities
$(5.6)
Other assets
2.0 
Other long-term liabilities
(2.7)
Total assets
$46.5 
Total liabilities
$(8.3)
As of December 31, 2020
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets
$— 
Other current liabilities
$(59.2)
Other assets
— 
Other long-term liabilities
(4.3)
Total assets
$— 
Total liabilities
$(63.5)
As of December 31, 2021, we expect the amounts that are related to foreign exchange forward contracts designated as cash flow hedges under U.S. GAAP recorded in “Prepaid expenses and other current assets” and “Other current liabilities” to be reclassified to earnings within twelve months.
As discussed in Note A, “Note A, “Nature of Business and Accounting Policies,” we present the fair value of our foreign currency forward contracts on a gross basis within our consolidated balance sheets. The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our consolidated balance sheets:
As of December 31, 2021
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$46.5 $— $46.5 $(8.3)$38.2 
Total liabilities(8.3)— (8.3)8.3 — 
As of December 31, 2020
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$— $— $— $— $— 
Total liabilities(63.5)— (63.5)— (63.5)

F-27

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

H.Inventories
Inventories consisted of the following:
As of December 31,
20212020
(in millions)
Raw materials$42.4 $46.2 
Work-in-process224.0 161.3 
Finished goods
86.7 73.3 
Total
$353.1 $280.8 

I.Property and Equipment
Property and equipment, net consisted of the following:
As of December 31,
20212020
(in millions)
Buildings and improvements$892.5 $876.1 
Furniture and equipment407.3 346.7 
Leasehold improvements363.5 234.6 
Computers and software293.7 258.6 
Land33.1 33.1 
Total property and equipment, gross1,990.1 1,749.1 
Less: accumulated depreciation
(896.0)(790.6)
Total property and equipment, net
$1,094.1 $958.5 
We recorded depreciation expense of $125.6 million, $109.5 million and $106.9 million in 2021, 2020 and 2019, respectively, which includes our finance lease amortization.

J.Intangible Assets and Goodwill
Intangible Assets
As of December 31, 2021 and 2020, we had $400.0 million of in-process research and development intangible assets classified as “Intangible assets” on our consolidated balance sheets. In 2019, we recorded $387.0 million and $13.0 million of in-process research and development intangible assets related to our acquisitions of Semma Therapeutics, Inc. (“Semma”) and Exonics, respectively.
Goodwill
As of December 31, 2021 and 2020, goodwill of $1.0 billion was recorded on our consolidated balance sheets. During 2019, we recorded goodwill of $554.6 million and $397.1 million related to our acquisitions of Semma and Exonics, respectively.

F-28

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

K.Additional Balance Sheet Detail
Prepaid expenses and other current assets consisted of the following:
As of December 31,
20212020
(in millions)
Tax related prepaid and receivables$358.6 $228.6 
Other187.2 79.7 
Total
$545.8 $308.3 
Accrued expenses consisted of the following:
As of December 31,
20212020
(in millions)
Product revenue accruals$847.4 $781.9 
Payroll and benefits191.3 169.4 
Research, development and commercial contract costs171.6 136.7 
Royalty payable200.4 165.4 
Tax related accruals
211.3 104.2 
Other
56.6 47.4 
Total
$1,678.6 $1,405.0 
Other current liabilities consisted of the following:
As of December 31,
20212020
(in millions)
Contract liabilities$171.7 $191.5 
Finance lease liabilities46.9 42.4 
Fair value of cash flow hedges5.6 59.2 
Other44.2 24.3 
Total$268.4 $317.4 
F-29

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

The cash, cash equivalents and restricted cash balances at the beginning and ending of each period presented in our consolidated statements of cash flows consisted of the following:
As of December 31,
2021202020192018
(in millions)
Cash and cash equivalents$6,795.0 $5,988.2 $3,109.3 $2,650.1 
Prepaid expenses and other current assets
5.1 0.7 8.0 4.9 
Other assets
— — 3.4 3.3 
Cash, cash equivalents and restricted cash per consolidated statement of cash flows$6,800.1 $5,988.9 $3,120.7 $2,658.3 
Our restricted cash, if any, is included in “Prepaid expenses and other current assets” and “Other assets” on our consolidated balance sheets.

L.Leases
Finance Leases
Our finance lease assets and liabilities primarily relate to our corporate headquarters in Boston and research site in San Diego (the “Buildings”). These Buildings are classified as finance leases because the present value of the sum of the lease payments associated with the Buildings exceeds substantially all of the fair value of the Buildings. We also have outstanding finance leases for equipment and land.
Corporate Headquarters
In 2011, we entered into two lease agreements, pursuant to which we lease approximately 1.1 million square feet of office and laboratory space in two buildings in Boston, Massachusetts for a term of 15 years. Base rent payments commenced in December 2013 and will continue through December 2028. We utilize this initial period as our lease term. We have an option to extend the lease term for an additional ten years.
San Diego Lease
In 2015, we entered into a lease agreement pursuant to which we lease approximately 170,000 square feet of office and laboratory space in San Diego, California for a term of 16 years. Base rent payments commenced in the second quarter of 2019 and will continue through May 2034. We utilize this initial period as our lease term. We have an option to extend the lease term for up to two additional five-year terms.
Operating Leases
Our operating leases relate to our real estate leases that are not classified as finance leases.
Innovation Square Lease
In 2019, we entered into an agreement to lease approximately 269,000 square feet of office and laboratory space near our corporate headquarters in Boston, Massachusetts. The lease agreement includes an initial term of 15 years plus a period to install leasehold improvements, with an option to extend the lease term for up to two additional ten-year periods. Base rent payments commenced in 2021. We have utilized the initial period, which commenced in the third quarter of 2020 upon occupation of the building, as our lease term.
Please refer to our accounting policy, Leases, in Note A, “Nature of Business and Accounting Policies,” for further information on the accounting treatment for our finance and operating leases.
F-30

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

Aggregate Lease Information
The components of lease cost recorded in our consolidated statement of operations were as follows:
202120202019
(in millions)
Operating lease cost$33.9 $23.1 $12.0 
Finance lease cost
Amortization of leased assets51.9 51.2 49.8 
Interest on lease liabilities47.4 50.2 52.8 
Variable lease cost33.6 30.8 28.0 
Sublease income(0.4)(4.0)(6.4)
Net lease cost$166.4 $151.3 $136.2 
Our variable lease cost during 2021, 2020 and 2019 primarily related to operating expenses, taxes and insurance associated with our finance leases.
Our leases are included on our consolidated balance sheets as follows:
As of December 31,
20212020
(in millions)
Finance leases
Property and equipment, net$400.1 $431.2 
Total finance lease assets
$400.1 $431.2 
Other current liabilities$46.9 $42.5 
Long-term finance lease liabilities509.8 539.0 
Total finance lease liabilities
$556.7 $581.5 
Operating leases
Operating lease assets$330.3 $325.6 
Total operating lease assets
$330.3 $325.6 
Other current liabilities$33.3 $10.5 
Long-term operating lease liabilities377.4 350.5 
Total operating lease liabilities
$410.7 $361.0 
F-31

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

Maturities of our finance and operating lease liabilities as of December 31, 2021 were as follows:
Year
Finance Leases
Operating Leases
Total
(in millions)
2022$87.9 $41.9 $129.8 
202393.2 42.0 135.2 
202497.6 38.6 136.2 
202595.9 35.7 131.6 
202694.2 33.7 127.9 
Thereafter
327.4 290.3 617.7 
Total lease payments
796.2 482.2 1,278.4 
Less: tenant allowance— (6.5)(6.5)
Less: amount representing interest
(239.5)(65.0)(304.5)
Present value of lease liabilities
$556.7 $410.7 $967.4 
The weighted-average remaining lease terms and discount rates related to our leases were as follows:
As of December 31,
20212020
Weighted-average remaining lease term (in years)
Finance leases10.7311.58
Operating leases12.8114.10
Weighted-average discount rate
Finance leases
8.11 %8.36 %
Operating leases
2.19 %2.28 %
Supplemental cash flow information related to our leases was as follows:
202120202019
(in millions)
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases$21.5 $16.3 $10.7 
Operating cash flows from finance leases$46.2 $48.9 $50.5 
Financing cash flows from finance leases$47.0 $42.3 $39.2 
Right-of-use assets obtained in exchange for lease obligations
Operating leases
$36.3 $293.6 $34.6 
Finance leases
$— $33.1 $— 

F-32

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

M.Common Stock, Preferred Stock and Equity Plans
Common Stock and Preferred Stock
We are authorized to issue 500.0 million shares of common stock. Holders of common stock are entitled to one vote per share. Holders of common stock are entitled to receive dividends, if and when declared by our Board of Directors, and to share ratably in our assets legally available for distribution to our shareholders in the event of liquidation. Holders of common stock have no preemptive, subscription, redemption or conversion rights. The holders of common stock do not have cumulative voting rights.
We are authorized to issue 1.0 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our shareholders. As of December 31, 2021 and 2020, we had no shares of preferred stock issued or outstanding.
Share Repurchase Programs
In 2018, our Board of Directors approved a share repurchase program (the “2018 Share Repurchase Program”), pursuant to which we repurchased $500.0 million of our common stock in 2018 and 2019. During the year ended December 31, 2019, we repurchased 0.8 million shares of our common stock under the 2018 Share Repurchase Program for an aggregate of $150.0 million.
In July 2019, our Board of Directors approved a second share repurchase program (the “2019 Share Repurchase Program”), pursuant to which we repurchased $500.0 million of our common stock in 2019 and 2020. During the years ended December 31, 2020 and 2019, we repurchased 2.1 million and 0.2 million shares, respectively, of our common stock under the 2019 Share Repurchase Program for an aggregate of $464.0 million and $36.0 million, respectively.
In November 2020, our Board of Directors approved a third share repurchase program (the “2020 Share Repurchase Program”), pursuant to which we repurchased $500.0 million of our common stock in 2020 and 2021. During the years ended December 31, 2021 and 2020, we repurchased 2.0 million and 0.3 million shares, respectively, of our common stock under the 2020 Share Repurchase Program for an aggregate of $424.9 million and $75.1 million, respectively.
In June 2021, our Board of Directors approved a fourth share repurchase program (the “2021 Share Repurchase Program”), pursuant to which we are authorized to repurchase up to $1.5 billion of our common stock by December 31, 2022. During the year ended December 31, 2021, we repurchased 5.3 million shares of our common stock under the 2021 Share Repurchase Program for an aggregate of $1.0 billion. We expect to fund further repurchases of our common stock through a combination of cash on hand and cash generated by operations. As of December 31, 2021, $499.7 million remained authorized for repurchases of common stock under the 2021 Share Repurchase Program.
Repurchases of our common stock are recorded as reductions to “Common stock” and “Additional paid-in capital.”
Stock and Option Plans
The purpose of each of our stock and option plans is to attract, retain and motivate our employees, consultants and directors. Awards granted under these plans can be nonstatutory stock options (“NSOs”), incentive stock options (“ISOs”), restricted stock units (“RSUs”) including performance-based RSUs (“PSUs”), restricted stock (“RSs”), or other equity-based awards, as specified in the individual plans.
F-33

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

Shares issued under all of our plans are funded through the issuance of new shares. The following table contains information about our equity plans:
As of December 31, 2021
Title of Plan
Group Eligible
Type of Award
Granted
Awards
Outstanding
Additional Awards
Authorized for Grant
(in thousands)
2013 Stock and Option PlanEmployees, Non-employee Directors and ConsultantsNSO, RS, RSU and PSU7,306 9,558 
2006 Stock and Option PlanEmployees, Non-employee Directors and ConsultantsNSO, RS and RSU292 — 
Total
7,598 9,558 
All options granted under our 2013 Stock and Option Plan (“2013 Plan”) and 2006 Stock and Option Plan (“2006 Plan”) were granted with an exercise price equal to the fair value of the underlying common stock on the date of grant. As of December 31, 2021, we are only authorized to make new equity awards under our 2013 Plan. Under the 2013 Plan, no stock options can be awarded with an exercise price less than the fair market value on the date of grant. In 2019, our shareholders approved an increase in the number of shares authorized for issuance pursuant to the 2013 Stock and Option Plan of 5.0 million shares.
During the three years ended December 31, 2021, grants to current employees and directors primarily had a grant date that was the same as the date the award was approved by our Board of Directors. During the three years ended December 31, 2021, for grants to new employees and directors, the date of grant for awards was the employee’s first day of employment or the date the director was elected to our Board of Directors. All options awarded under our stock and option plans expire not more than 10 years from the grant date.
Stock Options
The following table summarizes information related to the outstanding and exercisable options during the year ended December 31, 2021:
Stock Options
Weighted-average
Exercise Price
Weighted-average Remaining Contractual Life
Aggregate Intrinsic
Value
(in thousands)(per share)(in years)(in millions)
Outstanding at December 31, 20204,238 $140.47 
Granted27 $217.20 
Exercised(518)$125.78 
Forfeited(136)$177.28 
Expired
— $— 
Outstanding at December 31, 20213,611 $141.76 5.42$288.6 
Exercisable at December 31, 20213,149 $136.13 5.19$269.6 
The aggregate intrinsic value in the table above represents the total pre-tax amount, net of exercise price, that would have been received by option holders if all option holders had exercised all options with an exercise price lower than the market price on the last business day of 2021, which was $221.27 based on the average of the high and low price of our common stock on that date.
F-34

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

The total intrinsic value (the amount by which the fair market value exceeded the exercise price) of stock options exercised during 2021, 2020 and 2019 was $43.0 million, $255.0 million and $325.9 million, respectively. The total cash we received as a result of employee stock option exercises during 2021, 2020 and 2019 was $64.2 million, $228.2 million and $317.8 million, respectively.
The following table summarizes information about stock options outstanding and exercisable at December 31, 2021:
Options Outstanding
Options Exercisable
Range of Exercise Prices
Number
Outstanding
Weighted-average
Remaining Contractual Life
Weighted-average
Exercise Price
Number
Exercisable
Weighted-average
Exercise Price
(in thousands)(in years)(per share)(in thousands)(per share)
$36.28–$100.00
1,085 3.70$82.14 1,085 $82.14 
$100.01–$150.00
362 3.56$123.15 362 $123.15 
$150.01–$200.00
2,114 6.53$173.03 1,652$171.04 
$200.01–$286.27
50 8.92$248.51 50 $248.51 
Total
3,611 5.42$141.76 3,149 $136.13 
Restricted Stock Units (excluding PSUs) and Restricted Stock
The following table summarizes our restricted stock unit activity during the year ended December 31, 2021:
Restricted Stock Units (excluding PSUs)
Number of Shares
Weighted-average
Grant-date
Fair Value
(in thousands)(per share)
Unvested at December 31, 20202,722 $206.99 
Granted1,927 $208.48 
Vested(1,331)$193.29 
Cancelled
(409)$214.68 
Unvested at December 31, 20212,909 $213.17 
The total fair value of restricted stock units that vested during 2021, 2020 and 2019 (measured on the date of vesting) was $281.1 million, $370.3 million and $178.2 million, respectively. The total fair value of restricted stock that vested during 2020 and 2019 (measured on the date of vesting) was $21.4 million and $70.7 million, respectively. We have not granted any restricted stock since 2016, therefore, we did not have any restricted stock vest in 2021.
Performance-based RSUs (PSUs)
The potential range of shares issuable pursuant to our PSU awards range from 0% to 200% of the target shares based on financial and non-financial measures. Fifty percent of PSUs that could be earned have a one-year performance period with the amount actually earned dependent upon our financial performance and with vesting of the earned shares in three equal installments over a three-year period. The remaining 50% of PSUs that could be earned have a three-year performance period with the amount actually earned dependent upon the achievement of multiple clinical development milestones and with the earned shares cliff vesting at the end of the three-year performance period.
F-35

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

The following table summarizes our PSU activity during the year ended December 31, 2021:
Performance-Based RSU
Number of Units
Weighted-average
Grant-date
Fair Value
(in thousands)(per share)
Unvested at December 31, 2020 (1)656 $202.06 
Granted (2)954 $212.44 
Vested(431)$183.94 
Cancelled
(101)$214.72 
Unvested at December 31, 20211,078 $215.85 
(1) “Unvested” represents our PSUs at target to the extent performance has not been certified plus the actual number of shares that continue to be subject to service conditions for which the performance has been achieved and certified.
(2) “Granted” represents (i) the target number of shares issuable for grants during 2021 and (ii) any change in the number of shares issuable pursuant to outstanding PSUs based on performance certification during 2021.
The total fair value of PSUs that vested during 2021, 2020 and 2019 (measured on the date of vesting) was $92.2 million, $138.5 million and $73.3 million, respectively.
Employee Stock Purchase Plan
We have an employee stock purchase plan (the “ESPP”). The ESPP permits eligible employees to enroll in a twelve-month offering period comprising two six-month purchase periods. Participants may purchase shares of our common stock, through payroll deductions, at a price equal to 85% of the fair market value of the common stock on the first day of the applicable twelve-month offering period, or the last day of the applicable six-month purchase period, whichever is lower. Purchase dates under the ESPP occur on or about May 14 and November 14 of each year. As of December 31, 2021, there were 1.8 million shares of common stock authorized for issuance pursuant to the ESPP.
In 2021, the following shares were issued to employees under the ESPP:
Year Ended December 31, 2021
Number of shares (in thousands)219 
Average price paid per share$171.57 
Employee Benefits
We have a 401(k) retirement plan (the “Vertex 401(k) Plan”) in which substantially all of our permanent U.S. employees are eligible to participate. Participants may contribute up to 60% of their annual compensation to the Vertex 401(k) Plan, subject to statutory limitations. We may declare discretionary matching contributions to the Vertex 401(k) Plan. We pay matching contributions in the form of cash. For the years ended December 31, 2021, 2020 and 2019, we contributed approximately $21.8 million, $19.2 million and $15.8 million to the plan, respectively.

N.Stock-based Compensation Expense
We recognize share-based payments to employees as compensation expense using the fair value method. The fair value of stock options and shares purchased pursuant to the ESPP is calculated using the Black-Scholes option pricing model. The fair value of restricted stock units, including PSUs, is based on the intrinsic value on the date of grant. Stock-based compensation, measured at the grant date based on the fair value of the award, is typically recognized as expense ratably over the requisite service period.
F-36

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

The effect of stock-based compensation expense during the three years ended December 31, 2021 was as follows:
202120202019
(in millions)
Stock-based compensation expense by line item:
Cost of sales$6.3 $5.6 $5.6 
Research and development expenses268.3 262.7 224.6 
Selling, general and administrative expenses
166.8 161.2 130.3 
Total stock-based compensation expense included in costs and expenses
441.4 429.5 360.5 
Income tax effect(82.9)(147.0)(124.2)
Total stock-based compensation included in costs and expenses, net of tax$358.5 $282.5 $236.3 
The stock-based compensation expense by type of award during the three years ended December 31, 2021 was as follows:
202120202019
(in millions)
Stock-based compensation expense by type of award:
Restricted stock units (including PSUs)$384.3 $360.4 $254.3 
Stock options36.8 59.7 96.7 
ESPP share issuances24.4 13.0 11.2 
Stock-based compensation expense related to inventories(4.1)(3.6)(1.7)
Total stock-based compensation expense included in costs and expenses
$441.4 $429.5 $360.5 
We capitalize a portion of our stock-based compensation expense to inventories, all of which is attributable to employees who support the manufacturing of our products.
The following table sets forth our unrecognized stock-based compensation expense as of December 31, 2021, by type of award and the weighted-average period over which that expense is expected to be recognized:
As of December 31, 2021
Unrecognized Expense
Weighted-average Recognition Period
(in millions)(in years)
Type of award:
Restricted stock units (including PSUs)$423.3 1.91
Stock options19.1 1.09
ESPP share issuances12.6 0.54
Total unrecognized stock-based compensation expense$455.0 
Stock Options
In each of the three years ended December 31, 2021, we issued stock options to our non-employee directors. In 2019, we issued stock options with service conditions, which were generally the vesting periods of the awards, to our employees. We use the Black-Scholes option pricing model to estimate the fair value of stock options at the grant date. The Black-Scholes option pricing model uses the option exercise price as well as estimates and assumptions related to the expected price volatility of our stock, the rate of return on risk-free investments, the expected period during which the options will be outstanding, and the expected dividend yield for our stock to estimate the fair value of a stock option on the grant date. The
F-37

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

options granted during 2021, 2020 and 2019 had a weighted-average grant-date fair value per share of $65.94, $88.37 and $61.32, respectively.
The fair value of each option granted during 2021, 2020 and 2019 was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:
202120202019
Stock options granted27,30222,6361,520,743
Expected stock price volatility35.03%35.87%36.99%
Risk-free interest rate0.86%0.43%2.32%
Expected term of options (in years)4.504.674.27
Expected annual dividends———
The weighted-average valuation assumptions were determined as follows:
•Expected stock price volatility: Expected stock price volatility is calculated using the trailing one-month average of daily implied volatilities prior to the grant date. Implied volatility is based on options to purchase our stock with remaining terms of greater than one year that are regularly traded in the market.
•Risk-free interest rate: We base the risk-free interest rate on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected option term.
•Expected term of options: The expected term of options represents the period of time options are expected to be outstanding. We use historical data to estimate employee exercise and post-vest termination behavior. We believe that all groups of employees exhibit similar exercise and post-vest termination behavior and therefore do not stratify employees into multiple groups in determining the expected term of options.
•Expected annual dividends: The estimate for annual dividends is $0.00 because we have not historically paid, and do not intend for the foreseeable future to pay, a dividend.
Restricted Stock Units and Performance-based Restricted Stock Units
We award restricted stock units with service conditions, which are generally the vesting periods of the awards.
We grant PSUs to certain members of senior management. Half of the PSUs contain financial goals as the performance metric and the other half contain non-financial goals. A target number of shares is established for each award; however, the actual number of shares that are issued when an award vests may range from zero to 200% of the target amount depending upon the level of achievement of the applicable performance metric. The financial-based PSUs vest in three equal installments over a three-year period and are expensed ratably over that same period based upon an assessment of the likely level of achievement. The non-financial based PSUs cliff vest at the end of the three-year performance period and are expensed on a straight-line basis over that same period based upon an assessment of the likely level of achievement.
F-38

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

Employee Stock Purchase Plan
The weighted-average fair value of each purchase right granted during 2021, 2020 and 2019 was $51.71, $65.88 and $47.79, respectively. The following table reflects the weighted-average assumptions used in the Black-Scholes option pricing model for 2021, 2020 and 2019:
202120202019
Expected stock price volatility34.06%37.70%33.43%
Risk-free interest rate0.05%0.11%2.08%
Expected term (in years)0.690.710.74
Expected annual dividends———
The weighted-average assumptions used in our Black-Scholes option pricing model were determined utilizing calculations similar to those described under Stock Options above.

O.Income Taxes
We are subject to U.S. federal, state, and foreign income taxes. The components of income before provision for income taxes during the three years ended December 31, 2021, consisted of the following:
202120202019
(in millions)
United States$2,030.7 $2,885.4 $1,263.4 
Foreign
699.7 231.5 131.5 
Income before provision for income taxes$2,730.4 $3,116.9 $1,394.9 
The components of the provision for income taxes during the three years ended December 31, 2021, consisted of the following:
202120202019
(in millions)
Current taxes:
Federal$374.9 $71.4 $— 
Foreign141.5 37.6 37.2 
State
26.5 18.9 13.5 
Total current taxes
542.9 127.9 50.7 
Deferred taxes:
Federal(36.9)510.2 184.3 
Foreign(98.4)(239.6)(24.8)
State
(19.3)6.7 7.9 
Total deferred taxes(154.6)277.3 167.4 
Provision for income taxes$388.3 $405.2 $218.1 
F-39

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

A reconciliation between the U.S. federal statutory rate of 21% and our effective tax rate is as follows:
202120202019
Federal statutory tax rate21.0 %21.0 %21.0 %
State taxes, net of federal benefit0.8 %0.6 %0.6 %
Foreign income tax rate differential(0.3)%0.2 %0.4 %
Tax credits(6.4)%(1.8)%(4.3)%
Tax rate change
(3.5)%(1.2)%— %
Stock compensation (benefit), shortfalls and cancellations
0.0 %(2.3)%(4.0)%
Long-term intercompany receivable write-off— %(1.7)%— %
Uncertain tax positions
2.0 %1.3 %1.0 %
Inter-entity transfer of intellectual property rights
— %(6.7)%— %
U.S. tax on foreign earnings, net of credits0.7 %2.7 %— %
Other
(0.1)%0.9 %0.9 %
Effective tax rate14.2 %13.0 %15.6 %
Our 14% effective tax rate for 2021 was lower than the U.S. statutory rate primarily due to discrete tax benefits of (i) $94.8 million associated with an increase in the United Kingdom’s (“U.K.”) corporate tax rate from 19% to 25%, which was enacted in June 2021 and will become effective in April 2023, and (ii) $44.1 million resulting from an R&D tax credit study that we completed in 2021.
Our 13% effective tax rate for 2020 was lower than the U.S. statutory rate primarily due to (i) a discrete tax benefit of $209.0 million associated with an intra-entity transfer of intellectual property rights to our U.K. entity, (ii) a discrete tax benefit associated with the write-off of a long-term intercompany receivable, (iii) a discrete tax benefit associated with an increase in the U.K.’s corporate tax rate from 17% to 19%, which was enacted and became effective in July 2020, and (iv) excess tax benefits related to stock-based compensation. The impact of these items was partially offset by U.S. income tax on foreign earnings.
Our 16% effective tax rate for 2019 was lower than the U.S. statutory rate primarily due to excess tax benefits related to stock-based compensation and research and development tax credits.
F-40

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

Deferred tax assets and liabilities are determined based on the difference between financial statement and tax bases using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred taxes were as follows:
As of December 31,
20212020
(in millions)
Deferred tax assets:
Net operating loss$106.6 $140.6 
Tax credit carryforwards202.4 406.1 
Intangible assets802.8 507.5 
Stock-based compensation94.6 89.2 
Accrued expenses48.6 47.3 
Finance lease liabilities103.4 118.7 
Operating lease assets81.1 65.0 
Other41.7 22.1 
Gross deferred tax assets1,481.2 1,396.5 
Valuation allowance(220.4)(213.8)
Total deferred tax assets1,260.8 1,182.7 
Deferred tax liabilities:
Property and equipment(118.2)(117.0)
Acquired intangibles(87.0)(87.0)
Operating lease liabilities(64.8)(63.3)
Other(56.3)(32.6)
Total deferred tax liabilities(326.3)(299.9)
Net deferred tax assets$934.5 $882.8 
On a periodic basis, we reassess the valuation allowance on our deferred income tax assets, weighing positive and negative evidence to assess the recoverability of our deferred tax assets. As of December 31, 2021, we maintained a valuation allowance of $220.4 million related primarily to U.S. state tax attributes.
As of December 31, 2021, we had net operating loss (“NOL”) carryforwards of $29.8 million and tax credit carryforwards of $4.1 million, which are subject to annual utilization limitations for U.S. federal income tax purposes. As of December 31, 2021, we had NOL carryforwards of $616.3 million and tax credit carryforwards of $237.2 million for U.S. state income tax purposes. In 2030, $26.0 million of our U.S. federal NOLs will begin to expire, while the remaining portion may be carried forward indefinitely. The state NOL and tax credit carryforwards expire at various dates through 2041 and may be used to offset future state income tax liabilities. As of December 31, 2021, we had foreign NOL carryforwards of $292.5 million and foreign tax credit carryforwards of $22.2 million. The foreign NOL carryforwards may be carried forward indefinitely, with the exception of $44.3 million that will expire at various dates through 2040. The foreign tax credit carryforwards will begin to expire in 2024.
F-41

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

Unrecognized tax benefits during the three years ended December 31, 2021 were as follows:
202120202019
(in millions)
Balance at beginning of the period$86.6 $33.9 $19.5 
Increases related to current period tax positions42.0 26.7 14.5 
Increases related to prior period tax positions19.9 26.7 0.6 
Decreases related to prior period tax positions— — (0.2)
Settlement with tax authorities— — (0.5)
Statute of limitations expiration
(1.3)(0.7)— 
Balance at end of period
$147.2 $86.6 $33.9 
As of December 31, 2021, we have classified $14.4 million and $132.8 million of our unrecognized tax benefits as credits to “Deferred tax assets” and “Accrued expenses,” respectively, on our consolidated balance sheet.
We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. Unrecognized tax benefits represent the aggregate tax effect of differences between tax return positions and the benefits recognized in our consolidated financial statements. As of December 31, 2021, 2020 and 2019, we had $129.5 million, $75.8 million and $33.9 million, respectively, of net unrecognized tax benefits, which would affect our tax rate if recognized. We do not expect that our unrecognized tax benefits will materially change within the next twelve months. We did not recognize any material interest or penalties related to uncertain tax positions during the three years ended December 31, 2021.
As of December 31, 2021, foreign earnings have been retained by our foreign subsidiaries for indefinite reinvestment. Upon repatriation of those earnings, in the form of dividends or otherwise, we could be subject to U.S. federal withholding taxes payable to various foreign countries and income taxes in certain states. We are permanently reinvested for book/tax basis differences. These permanently reinvested basis differences could reverse if we sell our foreign subsidiaries or various other events, none of which were considered probable as of December 31, 2021. The tax liabilities described above would not be material to our consolidated financial statements.
We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We have various income tax audits ongoing at any time throughout the world. Except for jurisdictions where we have NOLs or tax credit carryforwards, we are no longer subject to any tax assessment from tax authorities for years prior to 2018.

P.Commitments and Contingencies
Revolving Credit Facilities
Vertex and certain of its subsidiaries have entered into two credit agreements (the “Credit Agreements”) with Bank of America, N.A., as administrative agent and the lenders referred to therein (the “Lenders”). The Credit Agreements were not drawn upon at closing and we have not drawn upon them to date. Amounts drawn pursuant to the Credit Agreements, if any, will be used for general corporate purposes. Any amounts borrowed under the Credit Agreements will bear interest, at our option, at either a base rate or a Eurocurrency rate, in each case plus an applicable margin based on our consolidated leverage ratio (the ratio of our total consolidated funded indebtedness to our consolidated EBITDA for the most recently completed four fiscal quarter period).
In September 2019, Vertex and certain of its subsidiaries entered into a $500.0 million unsecured revolving facility (the “2019 Credit Agreement”) with the Lenders, which matures on September 17, 2024. Under the 2019 Credit Agreement, the applicable margins on base rate loans range from 0.125% to 0.500% and the applicable margins on Eurocurrency loans range from 1.125% to 1.500%. The 2019 Credit Agreement provides a sublimit of $50.0 million for letters of credit.
In September 2020, Vertex and certain of its subsidiaries entered into a $2.0 billion unsecured revolving facility (the
F-42

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

“2020 Credit Agreement”) with the Lenders, which matures on September 18, 2022. Under the 2020 Credit Agreement, the applicable margins on base rate loans range from 0.500% to 0.875% and the applicable margins on Eurocurrency loans range from 1.500% to 1.875%. The 2020 Credit Agreement does not support letters of credit.
Subject to satisfaction of certain conditions, we may request that the borrowing capacity for each of the Credit Agreements be increased by an additional $500.0 million. Any amounts borrowed pursuant to the Credit Agreements are guaranteed by certain of our existing and future domestic subsidiaries, subject to certain exceptions.
The Credit Agreements contain customary representations and warranties and affirmative and negative covenants, including financial covenants to maintain (x) subject to certain limited exceptions, a consolidated leverage ratio of 3.50 to 1.00, subject to an increase to 4.00 to 1.00 following a material acquisition and (y) a consolidated interest coverage ratio of 2.50 to 1.00, in each case measured on a quarterly basis. As of December 31, 2021, we were in compliance with the covenants described above. The Credit Agreements also contain customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans.
Direct costs related to the Credit Agreements are recorded over the term of the Credit Agreements and were not material to our financial statements.
Guaranties and Indemnifications
As permitted under Massachusetts law, our Articles of Organization and By-laws provide that we will indemnify certain of our officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that we could be required to make under these indemnification provisions is unlimited. However, we have purchased directors’ and officers’ liability insurance policies that could reduce our monetary exposure and enable us to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and we believe the estimated fair value of these indemnification arrangements is minimal.
We customarily agree in the ordinary course of our business to indemnification provisions in agreements with clinical trial investigators and sites in our drug development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for us, and our real estate leases. We also customarily agree to certain indemnification provisions in our drug discovery, development and commercialization collaboration agreements. With respect to our clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of our contractual obligations arising out of the research or clinical testing of our compounds or product candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by us, to violations of law by us or to certain breaches of our contractual obligations. The indemnification provisions appearing in our collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for our collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although we believe the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that we could be required to make under these provisions is generally unlimited. We have purchased insurance policies covering personal injury, property damage and general liability that reduce our exposure for indemnification and would enable us in many cases to recover all or a portion of any future amounts paid. We have never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, we believe the estimated fair value of these indemnification arrangements is minimal.
Other Contingencies
We have certain contingent liabilities that arise in the ordinary course of our business activities. We accrue a reserve for contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. Other than our contingent consideration liabilities discussed in Note D, “Fair Value Measurements,” there were no material contingent liabilities accrued as of December 31, 2021 or 2020.
F-43

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)


Q.Segment Information
Segment reporting is prepared on the same basis that our chief executive officer, who is our chief operating decision maker, manages the business, makes operating decisions and assesses performance. We operate in one segment, pharmaceuticals. Enterprise-wide disclosures about revenues, significant customers, and property and equipment, net by location are presented below.
Revenues by Product
Product revenues, net consisted of the following:
202120202019
(in millions)
TRIKAFTA/KAFTRIO$5,697.2 $3,863.8 $420.1 
SYMDEKO/SYMKEVI420.4 628.6 1,417.7 
ORKAMBI771.6 907.5 1,331.9 
KALYDECO684.2 802.9 991.0 
Total product revenues, net$7,573.4 $6,202.8 $4,160.7 
Product Revenues by Geographic Location
Net product revenues are attributed to countries based on the location of the customer and consisted of the following:
202120202019
(in millions)
United States$5,287.3 $4,826.4 $3,060.3 
Outside of the United States
Europe1,972.9 1,126.5 885.9 
Other
313.2 249.9 214.5 
Total product revenues outside of the United States
2,286.1 1,376.4 1,100.4 
Total product revenues, net
$7,573.4 $6,202.8 $4,160.7 
Significant Customers
Gross product revenues and accounts receivable from each of our customers who individually accounted for 10% or more of total gross product revenues and/or 10% or more of total accounts receivable consisted of the following:
Percent of
Total Gross Product Revenues
Percent of
Accounts Receivable
Year Ended December 31,
As of December 31,
20212020201920212020
McKesson Corporation22 %20 %17 %21 %14 %
Accredo/Curascript12 %15 %14 %10 %10 %
Walgreen Co.10 %14 %15 %<10 %10 %
Lloyds Pharmacy*<10%<10%<10%15 %19 %
*A wholly-owned subsidiary of McKesson Corporation in the U.K.
F-44

VERTEX PHARMACEUTICALS INCORPORATED
Notes to Consolidated Financial Statements (Continued)

Long-lived Assets by Location
Long-lived assets by location consisted of the following:
As of December 31,
20212020
(in millions)
United States$1,348.1 $1,207.7 
Outside of the United States
United Kingdom60.9 61.5 
Other15.4 14.9 
Total long-lived assets outside of the United States76.3 76.4 
Total long-lived assets$1,424.4 $1,284.1 

F-45
 EX-10.24 2 a10k_2021-exhibit1024.htm EX-10.24 Document
EXHIBIT 10.24
AMENDMENT NO. 1 TO
EMPLOYMENT AGREEMENT

This AMENDMENT NO. 1 is made and entered into effective as of February 7, 2022 (the “Effective Date”) to the employment agreement dated as of April 1, 2020 (the “Employment Agreement”), between Vertex Pharmaceuticals Incorporated (the “Company”) and Jeffrey M. Leiden, MD., Ph.D. (the “Executive”).
    NOW, THEREFORE, in consideration of the mutual covenants set forth herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Executive agree as follows:

1.That Section 2 of the Employment Agreement is hereby amended by deleting “March 31, 2023” and replacing it with “March 31, 2024”.

2.That Section 3(d) of the Employment Agreement is hereby amended by deleting “2023” and replacing it with “2024”.

3.That Section 4(c) of the Employment Agreement is hereby amended in its entirety by replacing it with the following:

“(c) Equity Awards. During the Term of this Agreement, and provided that the Executive has remained in continuous service with the Company through the applicable grant date, subject to the approval of the Board or the Compensation Committee thereof, the Executive will receive the following annual grants of equity awards (the “Annual Stock Awards”). Each Annual Stock Award will be made during the applicable time period set forth below. Fifty percent (50%) of each Annual Stock Award will be in the form of fully vested shares of Company common stock and fifty percent (50%) will be in the form of performance stock units and the Annual Stock Award will have an aggregate grant date value (with performance stock units valued based on target, and the number of shares or units granted, as applicable, determined by dividing such values by the fair market value of the Company’s common stock) as follows:
(i)$9,000,000 for fiscal year 2020 (to be granted in the first calendar quarter of 2021) (“Year 1”);
(ii)$8,500,000 for fiscal year 2021 (to be granted in the first calendar quarter of 2022) (“Year 2”);
(iii)$6,500,000 for fiscal year 2022 (to be granted in the first calendar quarter of 2023) (“Year 3”); and
(iv)$6,500,000 for fiscal year 2023 (to be granted in the first calendar quarter of 2024) (“Year 4”).
Both one-year and three-year performance criteria will apply to the performance stock units granted in Year 1, and one-year performance criteria will apply to the performance stock units granted in Year 2, Year 3 and Year 4. The terms and conditions applicable to each Annual Stock Award shall otherwise be as prescribed by the Compensation Committee, with each Annual Stock Award evidenced by an award agreement that is substantially similar to the form of award agreement used for such type of award for Company executives generally, except for such changes as are necessary or desirable to reflect the terms of the Executive’s employment hereunder.”
1052971v1

4.That Section 4(d) of the Employment Agreement is hereby amended adding a final sentence to such Section as follows:
“In order to facilitate the Executive’s receipt of benefits under the Employee Benefit Plans in 2022, 2023 and 2024, the Company will make a cash payment to executive of $65,000 in each of February 2022, February 2023 and February 2024.”
5.Except as amended hereby and expressly provided herein, the Employment Agreement shall remain in full force and effect.
    IN WITNESS WHEREOF, this Amendment No. 1 has been executed as a sealed instrument by the Company, by its duly authorized representative, and by the Executive, as of the date first above written.







THE COMPANY:    
THE EXECUTIVE:
VERTEX PHARMACEUTICALS
INCORPORATED
By:
 /s/ Bruce I. Sachs
 /s/ Jeffrey M. Leiden
Bruce I. Sachs
Lead Independent Director and Chairman of MDCC
Jeffrey M. Leiden, M.D., Ph.D




1052971v1
 EX-10.36 3 a10k_2021-exhibit1036.htm EX-10.36 Document
Exhibit 10.36
EMPLOYMENT AGREEMENT
This Employment Agreement (this “Agreement”) is made and entered into as of this 1st day of August, 2020, by and between Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (together with its successors and assigns, the “Company”), and Nia Tatsis (the “Executive”).
W IT N E S S E T H
WHEREAS, the Company and the Executive desire that the Executive be appointed and serve as an Executive Vice President of the Company as of the Effective Date; and
WHEREAS, the Company and the Executive desire to enter into this Agreement to set forth the terms of the Executive’s continued employment with the Company;
NOW, THEREFORE, in consideration of the promises and mutual covenants contained herein and for other good and valuable consideration, the receipt of which mutually is acknowledged, the Company and the Executive (each individually a “Party”, and together the “Parties”) agree as follows:
1. DEFINITIONS.
“Accrued Benefits” shall mean (i) any Base Salary earned by the Executive but not then paid and (ii) any accrued and vested but then unpaid benefits under the Benefit Plans, in each case, through the date of termination of the Executive’s employment.
“Base Salary” shall mean the Executive’s base salary in accordance with Section 4 below.
“Benefit Plans” shall mean all employee welfare and pension benefit plans, programs and/or arrangements offered by the Company to its senior executives.
“Board” shall mean the Board of Directors of the Company.
“Cause” shall mean:
(i)the Executive is convicted of a crime involving moral turpitude;
(ii)the Executive’s willful refusal or failure to follow a lawful directive or instruction of the Company’s Board of Directors or the individual(s) to whom the Executive reports, provided that the Executive receives prior written notice of the directive(s) or instruction(s) that the Executive failed to follow, and provided further that the Company, in good faith, gives the Executive 30 days to correct such failure and further provided that if the Executive corrects the failure(s), any termination of the Executive’s employment on account of such failure shall not be treated for purposes of this Agreement as a termination of employment for “Cause”;
(iii)the Executive commits a material breach of the Company’s insider trading policy or of any provision of this Agreement or the agreement between the Company and the Executive entitled “Employee Non-Disclosure, Non-Competition and Inventions Agreement” dated as of July 23, 2017 (the “Inventions Agreement”); or
(iv)the Executive commits a breach of the code of conduct or any other material policy of the Company or any of its affiliates that is damaging to the financial condition or reputation of the Company or any of its affiliates.



“Change of Control” shall have the meaning set forth in the Change of Control Agreement.

    “Change of Control Agreement” shall mean the Change of Control letter agreement between the Company and the Executive of even date herewith.
    “Code” shall mean the Internal Revenue Code of 1986, as amended.
“Common Stock” shall mean the common stock of the Company.
“Compensation Committee” shall mean the Management Development and Compensation Committee of the Board.
“Disability” or “Disabled” shall mean a disability as determined under the Company’s long-term disability plan or program in effect at the time the disability first occurs, or if no such plan or program exists at the time of disability, then a “disability” as defined under Section 22(e)(3) of the Code.
“Effective Date” shall mean August 1, 2020.
“Good Reason” shall mean that, without the Executive’s consent, one or more of the following events occurs:
(i)the Executive’s duties are materially diminished to an extent that results in the Executive no longer being an “officer,” as such term is defined in Rule 16a-1(f) promulgated under the Securities Exchange Act of 1934;
(ii)the Executive’s Base Salary is decreased unless such reduction is part of an across-the-board proportionate reduction in the base salaries of the Company’s senior management team; or
(iii)    the office to which the Executive is assigned is relocated to a place 35 or more miles away and such relocation is not (A) at the Executive’s request or (B) in connection with a change in location of the Company’s principal executive offices;
provided that Good Reason shall not exist unless and until within 30 days after the event giving rise to Good Reason under either (i) or (ii) above has occurred, the Executive delivers a written termination notice to the Company stating that an event giving rise to Good Reason has occurred and identifying with reasonable detail the event that the Executive asserts constitutes Good Reason under either (i) or (ii) above and the Company fails or refuses to cure or eliminate the event giving rise to Good Reason on or within 30 days after receiving such notice and, with respect to the event giving rise to Good Reason under (iii) above, the Executive delivers a written termination notice to the Company within 30 days after the event giving rise to Good Reason occurs. To avoid doubt, the termination of the Executive’s employment will become effective at the close of business on the thirtieth day after the Company receives the Executive’s termination notice, unless, in the case of an event giving rise to Good Reason under either (i) or (ii) above, the Company cures or eliminates the event giving rise to Good Reason prior to such time.
“Severance Payment” shall mean an amount equal to (x) 100% of the sum of (A) the Base Salary in effect on the date of termination of the Executive’s employment, plus (B) the full amount of the Target Bonus for the Executive for the year in which the Executive’s employment is terminated, plus (y) any annual bonus earned by the Executive in respect of the year prior to the year in which the termination of the Executive’s employment occurs, if not yet paid; provided, however, that if the Executive terminates the Executive’s employment for Good Reason based on a reduction in Base Salary, then the Base Salary to be used in calculating the Severance Payment shall be the Base Salary in effect immediately prior to such reduction in Base Salary.
        2



“Target Bonus” shall mean the target cash bonus for which the Executive is eligible on an annual basis, at a level consistent with the Executive’s title and responsibilities, under the Company’s bonus program then in effect and applicable to the Company’s senior executives generally.
2. TERM OF EMPLOYMENT.
The Company hereby continues to employ the Executive, and the Executive hereby accepts such employment as of the Effective Date, continuing until termination in accordance with the terms of this Agreement. The period during which the Executive is employed hereunder is referred to in this Agreement as the “term of employment.”
3. POSITION.
On the Effective Date, the Executive will be employed as one of the Company’s Executive Vice Presidents.
4. BASE SALARY.
The Executive’s annualized Base Salary as of the Effective Date will be $550,000, payable in accordance with the regular payroll practices of the Company. The Base Salary shall be reviewed no less frequently than annually, and any increases thereto (which shall thereafter be deemed the Executive’s Base Salary) shall be solely within the discretion of the Board or the Compensation Committee.
5. ANNUAL BONUS.
During the term of employment, the Executive shall be eligible to participate in the Company’s annual cash incentive compensation program applicable to the Company’s senior executives generally, as any such programs are established and modified from time to time by the Board or the Compensation Committee in its sole discretion, and in accordance with the terms of such program, with a Target Bonus as determined by the Board or the Compensation Committee. The Target Bonus for fiscal year 2020 is 70% of Base Salary.
6. EQUITY COMPENSATION PROGRAMS.
During the term of employment, the Executive shall be eligible to participate in the Company’s equity incentive compensation programs applicable to the Company’s senior executives, as such programs may be established and modified from time to time by the Board or the Compensation Committee in its sole discretion. Nothing in this Agreement shall preclude the Company from amending or terminating any of its equity incentive compensation plans, programs or arrangements.
7. EMPLOYEE BENEFIT PROGRAMS.
During the term of employment, the Executive shall be entitled to participate in the Benefit Plans, as such Benefit Plans may be amended from time to time, to the same extent and on the same terms applicable to other senior executives. Nothing in this Agreement shall preclude the Company from amending or terminating any of the Benefit Plans.
8. VACATION.
During the term of employment, the Executive shall be entitled to at least 20 paid vacation days each calendar year in accordance with the Company’s vacation policy then in effect.
        3



9. TERMINATION OF EMPLOYMENT.
(a) Termination in Connection with a Change of Control. To the extent the Executive is entitled, in connection with the Executive’s termination of employment, to severance or other benefits under the Change of Control Agreement, the Executive shall not be entitled to any benefits under this Section 9.
(b) Termination by the Company for Cause; or Termination by the Executive without Good Reason. If the Company terminates the Executive’s employment for Cause, or if the Executive terminates the Executive’s employment, other than for Good Reason, death or Disability, the term of employment shall end as of the date specified below, and the Executive shall be entitled to the Accrued Benefits. Any equity awards held by the Executive on the date of termination shall be governed by the applicable equity plan, any applicable grant agreements and any applicable Company securities trading policies. Termination by the Company for Cause shall be effective as of the date specified in the notice of termination provided by the Company to the Executive. Termination by the Executive other than for Good Reason, death or Disability shall be effective upon 60 days’ prior written notice to the Company. Other than as set forth expressly in this Section 9(b), the Company shall have no obligation or liability to the Executive.
(c) Termination by the Company Without Cause; or Termination by the Executive for Good Reason. If the Executive's employment is terminated by the Company without Cause (other than due to death or Disability), or is terminated by the Executive for Good Reason (in accordance with the notice and cure provisions set forth in the definition of “Good Reason” above), the Executive shall be entitled to the Accrued Benefits. In addition, the Executive shall be entitled to the following:
(i)    a lump sum cash payment to the Executive in an amount equal to the Severance Payment, payable within ten days after execution of the Release (defined below) and expiration, without revocation, of any applicable revocation periods under the Release, provided that if the 60-day period during which the Release is required to become effective and irrevocable begins in one calendar year and ends in another calendar year, the Severance Payment shall not be made before the first day of the second calendar year;
(ii)    if COBRA coverage is elected by the Executive, the Company shall pay the cost of insurance continuation premiums on the Executive’s behalf (whether or not covered by COBRA) to continue standard medical, dental and life insurance coverage for the Executive and the Executive’s eligible dependents (or the cash equivalent of same in the event the Executive or the Executive’s eligible dependents are ineligible for continued coverage), on a monthly basis, until the earlier of:
(A)    the date 12 months after the date the Executive’s employment is terminated; or
(B)    the date, or dates, on which the Executive receives equivalent coverage and benefits under the plans, programs and/or arrangements of a subsequent employer (such coverage and benefits to be determined on a coverage-by-coverage or benefit-by-benefit basis).
    Other than as set forth expressly in this Section 9(c), the Company shall have no obligation or liability to the Executive.
    (d) Conditions to Severance. Any payments and benefits provided under this Section 9, other than the Accrued Benefits, shall be subject to and in exchange for a general release of all claims against the Company, its subsidiaries, and their officers, directors, agents and representatives (the “Release”), which is executed by the Executive (or the Executive’s estate, as
        4



applicable) and becomes enforceable and non-revocable within 60 days of the date of the Executive’s termination of employment. Moreover, notwithstanding anything to the contrary in this Agreement, if at the time of the Executive’s termination of employment, the Executive is a “specified employee” (as defined below), any payment of “nonqualified deferred compensation” (as defined under Section 409A of the Code, as amended, including the regulations thereunder (“Section 409A”)) that is payable on a “separation from service” (as defined below) shall not commence until the first full business day that is six months and one day after the applicable separation from service (or, if earlier, the Executive’s death) (the “Deferred Payment Date”); except (A) to the extent of amounts that do not constitute a deferral of compensation within the meaning of Treasury regulation Section 1.409A-1(b) (including without limitation by reason of the safe harbor set forth in Section 1.409A-1(b)(9)(iii), as determined by the Company in its reasonable discretion); (B) benefits that qualify as excepted welfare benefits pursuant to Treasury regulation Section 1.409A-1(a)(5); or (C) other amounts or benefits that are not subject to the requirements of Section 409A. Any payments that would otherwise have been made between the separation from service and the Deferred Payment Date, but for this paragraph, shall be made in a lump sum on the Deferred Payment Date. For purposes of this Agreement, to the extent required to ensure compliance with Section 409A of the Code, all references to “termination of employment” and correlative phrases shall be construed to require a “separation from service” (as defined in Section 1.409A-1(h) of the Treasury regulations, after giving effect to the presumptions contained therein), and the term “specified employee” means an individual determined by the Company to be a specified employee under Treasury regulation Section 1.409A-1(i).
10. ASSIGNABILITY; BINDING NATURE.
This Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors, heirs (in the case of the Executive) and assigns. No rights or obligations of the Company under this Agreement may be assigned or transferred by the Company except that such rights or obligations may be assigned or transferred pursuant to a merger or consolidation in which the Company is not the continuing entity, or the sale or liquidation of all or substantially all of the assets of the Company; provided, however, that the assignee or transferee is the successor to all or substantially all of the assets of the Company and such assignee or transferee assumes the liabilities, obligations and duties of the Company, as contained in this Agreement, either contractually or as a matter of law.
11. REPRESENTATIONS.
The Company represents and warrants that it is fully authorized and empowered to enter into this Agreement, and that the performance of its obligations under this Agreement will not violate any agreement between it and any other person, firm or organization. The Executive represents and warrants that no agreement exists between the Executive and any other person, firm or organization that would be violated by the performance of the Executive’s obligations under this Agreement.
12. INDEMNIFICATION; INSURANCE.
    The Executive shall at all times be indemnified and eligible for advancement of expenses on the same basis as is provided for the Company’s other executive officers and in accordance with the provisions of the Company’s charter and by-laws then in effect. The Executive shall also be covered under all of the Company’s policies of liability insurance maintained for the benefit of its directors and officers on the same basis as is provided for its other executive officers.
13. ENTIRE AGREEMENT; TERMINATION.
This Agreement, the agreements referenced herein and the Inventions Agreement previously entered into between the Executive and the Company contain the entire understanding
        5



and agreement between the Parties concerning the subject matter hereof and supersedes as of the Effective Date all prior agreements, understandings, discussions, negotiations and undertakings, whether written or oral, between the Parties with respect thereto and supersedes and terminates as of the Effective Date the offer letter dated July 21, 2017. Subject to the terms of this Agreement, the Company shall be entitled to terminate the Executive’s employment at any time, and the Executive may terminate the Executive’s employment by the Company, at any time subject to the provisions of Section 9(b) of this Agreement, in each case by written notice provided in accordance with Section 20 of this Agreement.
14. AMENDMENT OR WAIVER.
No provision in this Agreement may be amended unless such amendment is agreed to in writing and signed by the Executive and an authorized officer of the Company provided that the Company may, without the Executive’s consent, unilaterally adopt amendments that may be required so that this Agreement continues to comply with applicable law or regulations, including without limitation Section 409A. No waiver by either Party of any breach by the other Party of any condition or provision contained in this Agreement to be performed by such other Party shall be deemed a waiver of a similar or dissimilar condition or provision at the same or any prior or subsequent time. Any waiver must be in writing and signed by the Executive or an authorized officer of the Company, as the case may be.
15. SEVERABILITY.
If any provision or portion of this Agreement shall be determined to be invalid or unenforceable for any reason, in whole or in part, the remaining provisions of this Agreement shall be unaffected thereby and shall remain in full force and effect to the fullest extent permitted by law.
16. SURVIVORSHIP.
The respective rights and obligations of the Parties hereunder shall survive any termination of the Executive’s employment to the extent necessary to the intended preservation of such rights and obligations.
17. BENEFICIARIES/REFERENCES.
The Executive shall be entitled, to the extent permitted under any applicable law, to select and change a beneficiary or beneficiaries to receive any compensation or benefit payable hereunder following the Executive’s death by giving the Company written notice thereof. In the event of the Executive’s death or a judicial determination of the Executive’s incompetence, reference in this Agreement to the Executive shall be deemed, where appropriate, to refer to the Executive’s beneficiary, estate or other legal representative.
18. GOVERNING LAW/JURISDICTION.
This Agreement shall be governed by and construed and interpreted in accordance with the laws of The Commonwealth of Massachusetts without reference to principles of conflict of laws.
19. RESOLUTION OF DISPUTES.
Any disputes arising under or in connection with this Agreement will, at the election of the Executive or the Company, be resolved by binding arbitration, to be held in Massachusetts in accordance with the Rules and Procedures of the American Arbitration Association. If arbitration is elected, the Executive and the Company shall mutually select the arbitrator. If the Executive and the Company cannot agree on the selection of an arbitrator, each Party shall select an arbitrator and the two arbitrators shall select a third arbitrator, and the three arbitrators shall form an arbitration panel that shall resolve the dispute by majority vote. Judgment upon the award
        6



rendered by the arbitrator or arbitrators may be entered in any court having jurisdiction thereof. Costs of the arbitrator or arbitrators and other similar costs in connection with an arbitration shall be shared equally by the Parties; all other costs, such as attorneys’ fees incurred by each Party, shall be borne by the Party incurring such costs.
20. NOTICES.
    All notices that are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, addressed as follows:

If to the Company:    Vertex Pharmaceuticals Incorporated
    50 Northern Avenue
    Boston, MA 02210
    Attn: Corporate Secretary
        
If to the Executive:    at the Executive’s home address listed in the Company records.

    Any such notice shall be deemed to have been given: (a) when delivered if personally delivered or sent by facsimile on a business day; (b) on the business day after dispatch if sent by nationally-recognized overnight courier; and/or (c) on the fifth business day following the date of mailing if sent by mail.
21. HEADINGS.
The headings of the sections contained in this Agreement are for convenience only and shall not be deemed to control or affect the meaning or construction of any provision of this Agreement.
22. COUNTERPARTS.
This Agreement may be executed in two or more counterparts.
23. SECTION 409A OF THE CODE.
    It is the intention of the Company and the Executive that this Agreement and the payments provided for herein are either exempt from or meet the requirements of Section 409A. The Company and the Executive agree to cooperate in good faith in preparing and executing such amendments to this Agreement, if any, as the Company or the Executive may reasonably request solely for the purpose of assuring that this Agreement and the payments provided hereunder remain exempt from or meet the requirements of Section 409A, as applicable. Nothing in this Agreement shall require the Company to increase the Executive’s compensation or make the Executive whole for any such changes. In no event, however, shall the Company have any liability relating to the failure or alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Section 409A.
Each payment made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments. The Executive’s right to payment or reimbursement for any expenses hereunder shall be subject to the following additional rules: (i) the amount of expenses eligible for payment or reimbursement during any calendar year shall not affect the expenses eligible for payment or reimbursement in any other calendar year, (ii) payment or reimbursement shall be made not later than December 31 of the calendar year following the calendar year in which the expense or payment was incurred, and (iii) the right to payment or reimbursement shall not be subject to liquidation or exchange for any other benefit.
        7



24.CLAWBACK.
    The payment of all amounts and the equity granted to the Executive by the Company pursuant to this Agreement or otherwise shall be subject to and shall be deemed amended hereby to incorporate any policy applicable to the executives of the Company adopted by the Company requiring the repayment of compensation paid or provided to the Executive.
25.     TAX WITHHOLDING; NO GUARANTEE OF ANY TAX CONSEQUENCES.
    All payments hereunder shall be subject to all applicable withholding for any federal, state or local income taxes including any excise taxes under the Code. Notwithstanding any other provision of this Agreement to the contrary or other representation, the Company does not in any way guarantee the tax consequences of any payment or compensation under this Agreement including, without limitation, under Section 409A.
IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first written above.
    Vertex Pharmaceuticals Incorporated

    /s/ Reshma Kewalramani
    _______________________________________
    Name: Reshma Kewalramani
    Title: CEO and President


    Executive

    /s/ Nia Tatsis
    _______________________________________
    Name: Nia Tatsis
        8


 EX-10.37 4 a10k_2021-exhibit1037.htm EX-10.37 Document
Exhibit 10.37
image_0a.jpg                VERTEX PHARMACEUTICALS INCORPORATED
                            50 NORTHERN AVENUE BOSTON, MA 02210
    TEL. 617.341.6100




August 1, 2020

Nia Tatsis
[Address]

RE:    Change of Control Agreement

Dear Nia:

You are a key member of the senior management team of Vertex Pharmaceuticals Incorporated (the “Company”). As a result, the Company would like to provide you with the following “change of control” benefits to help ensure that if the Company becomes involved in a “change of control” transaction, there will be no distraction from your attention to the needs of the Company.

I.    Definitions. For the purposes of this Change of Control Agreement (this “Agreement”), capitalized terms used herein shall have the following meanings:

1.“Cause” shall mean:

(a)your conviction of a crime involving moral turpitude;

(b)your willful refusal or failure to follow a lawful directive or instruction of the Company’s Board of Directors or the individual(s) to whom you report, provided that you receive prior written notice of the directive(s) or instruction(s) that you failed to follow, and provided further that the Company, in good faith, gives you 30 days to correct such failure and further provided that if you correct the failure(s), any termination of your employment on account of such failure shall not be treated for purposes of this Agreement as a termination of employment for “Cause”;

(c)your material breach of the Company’s insider trading policy or of any provision of the Employment Agreement entered into between you and the Company on the date hereof (the “Employment Agreement”) or the agreement between you and the Company entitled “Employee Non-Disclosure, Non-Competition and Inventions Agreement” dated as of July 23, 2017 (the “Inventions Agreement”); or

(d)your breach of the code of conduct or any other material policy of the Company or any of its affiliates that is damaging to the financial condition or reputation of the Company or any of its affiliates.
2.“Change of Control” shall mean that:

(a)any “person” or “group” as such terms are used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Act”), becomes a beneficial owner, as such term is used in Rule 13d-3 promulgated under the Act, of securities of the Company representing more than 50% of the combined voting power of the outstanding securities of the Company having the right to vote in the election of directors; or

(b)    all or substantially all the business or assets of the Company are sold or disposed of, or the Company or a subsidiary of the Company combines with another company


Page 2
pursuant to a merger, consolidation, or other similar transaction, other than (i) a transaction solely for the purpose of reincorporating the Company or one of its subsidiaries in a different jurisdiction or recapitalizing or reclassifying the Company’s stock; or (ii) a merger or consolidation in which the shareholders of the Company immediately prior to such merger or consolidation continue to own at least a majority of the outstanding voting securities of the Company or the surviving entity immediately after such merger or consolidation.

3.“Code” shall mean the Internal Revenue Code of 1986, as amended.
4.“Disability” shall mean a disability as determined under the Company's long-term disability plan or program in effect at the time the disability first occurs, or if no such plan or program exists at the time of disability, then a “disability” as defined under Section 22(e)(3) of the Code.
5.“Good Reason” shall mean one of the following events has occurred without your consent:

(a)you suffer a material reduction in the authorities, duties or job title and responsibilities associated with your position as an Executive Vice President of the Company;

(b)your annual base salary is decreased;

(c)the office to which you are assigned is relocated to a place 35 or more miles away; or

(d)following a Change of Control, the Company’s successor fails to assume the Company’s rights and obligations under this Agreement;

provided that Good Reason shall not exist unless and until within 30 days after the event giving rise to Good Reason under (a), (b), (c) or (d) above has occurred, you deliver a written termination notice to the Company stating that an event giving rise to Good Reason has occurred and identifying with reasonable detail the event that you assert constitutes Good Reason under (a), (b), (c) or (d) above and the Company fails or refuses to cure or eliminate the event giving rise to Good Reason on or within 30 days after receiving your notice. To avoid doubt, the termination of your employment will become effective at the close of business on the thirtieth day after the Company receives your termination notice, unless the Company cures or eliminates the event giving rise to Good Reason prior to such time.

6.“Termination Date” shall mean the last day of your employment with the Company.
II.Severance Benefits upon Change of Control. If:
(A)your employment is terminated by the Company (except for termination for Cause or due to a Disability or death) and the Termination Date is within 90 days prior to a Change of Control or within 12 months after a Change of Control; or
(B)you (i) terminate your employment for Good Reason (in accordance with the notice and cure provisions set forth in Section I.5 above) and (ii) the


Page 3
event giving rise to Good Reason occurs within 90 days prior to a Change of Control or within 12 months after a Change of Control;
then, you shall receive the following benefits:

1.Severance Payment. In exchange for your execution of a general release, in a form satisfactory to the Company, of all claims against the Company, its subsidiaries, and its and their officers, directors and representatives, that becomes enforceable and irrevocable within the 60-day period following the Termination Date, the Company shall make a cash payment (the “Severance Payment”) to you in an amount equal to the sum of:

(a)(i) your annual base salary (provided, however, that if you terminate your employment for Good Reason based on a reduction in your annual base salary, then the annual base salary to be used in calculating the Severance Payment shall be your annual base salary in effect immediately prior to such reduction in annual base salary) plus (ii) your target bonus under any bonus program applicable to you for the year in which the Termination Date occurs; plus
    
(b)a pro rata portion of your target bonus for the portion of the year in which the Termination Date occurs under any bonus program applicable to you, calculated based on the number of days you were employed during such year; plus

(c)all other cash incentive compensation awards earned by you but not paid prior to the Termination Date; provided that, if a fiscal year has been completed and the incentive award for such fiscal year has not been determined, the incentive compensation for such completed fiscal year shall equal the target bonus for such fiscal year.

Except with respect to any portion of the Severance Payment that is delayed as set forth in this paragraph, the Severance Payment shall be made in cash within ten days after the execution by you of the general release referred to above and expiration without revocation of any applicable revocation periods under such general release (or, if the Change of Control resulting in your becoming entitled to such benefits occurs after such execution and expiration, within ten days after the Change of Control), provided that, if the 60-day period during which the general release is required to become effective and irrevocable begins in one calendar year and ends in another calendar year, the Severance Payment shall not be made before the first day of the second calendar year.

If you are a “specified employee” (as defined below) on the Termination Date, the commencement of the delivery of any such payments that constitute nonqualified deferred compensation payable upon a “separation from service” (as defined below) will be delayed until the first business day that is more than six months after your Termination Date. The determination of whether, and the extent to which, any of the payments to be made to you hereunder are nonqualified deferred compensation shall be made after the application of all applicable exclusions, including those set forth under Treasury Reg. § 1.409A-1(b)(9) and Treasury Reg. § 1.409A-1(a)(5). For purposes of this Agreement, to the extent required to ensure compliance with Section 409A of the Code, all references to “termination of employment” and correlative phrases shall be construed to require a “separation from service” (as defined in Treasury Reg. §1.409A-1(h) after giving effect to the presumptions contained therein), and the term “specified employee” means an individual determined by the Company to be a specified employee under Treasury Reg.


Page 4
§1.409A-1(i). Each payment made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments. Your right to payment or reimbursement for any expenses hereunder that would constitute nonqualified deferred compensation subject to Section 409A of the Code will be subject to the following additional rules: (i) the amount of expenses eligible for payment or reimbursement during any calendar year shall not affect the expenses eligible for payment or reimbursement in any other calendar year, (ii) payment or reimbursement shall be made not later than December 31 of the calendar year following the calendar year in which the expense or payment was incurred, and (iii) the right to payment or reimbursement shall not be subject to liquidation or exchange for any other benefit.

2.Accelerated Vesting.

(a)On the Termination Date, stock options for the purchase of the Company’s securities held by you as of the Termination Date and not then vested and exercisable shall immediately become vested and exercisable in full. The options to which this accelerated vesting applies shall remain exercisable until the earlier of (a) the end of the 90-day period immediately following the later of (i) the Termination Date or (ii) the date of the Change of Control and (b) the date the stock option(s) would otherwise expire; and

(b)On the Termination Date, each outstanding restricted stock unit grant shall be accelerated and the Shares shall be delivered to you within two business days (subject to (i) your making satisfactory arrangements with the Company providing for the payment to the Company of all required withholding taxes and (ii) with the number of shares subject to the restricted stock unit grants that contain performance criteria vesting at target or, if the applicable performance criteria have already been certified, based on earned shares or units as set forth in the applicable restricted stock unit grant agreement).

If your employment terminates during the 90-day period prior to a Change of Control, the accelerated vesting and settlement, if applicable, set forth above shall become effective immediately prior to such Change of Control. Notwithstanding anything to the contrary in this Agreement, the terms of any option agreement or restricted stock unit agreement shall govern the acceleration, if any, of vesting and period of exercisability of such awards, as applicable, except to the extent that the terms of this Agreement are more favorable to you.

3.Continued Insurance Coverage. If COBRA coverage is elected by you, the Company shall pay the cost of insurance continuation premiums on your behalf (whether or not covered by COBRA) to continue standard medical, dental and life insurance coverage for you (or the cash equivalent of same if you are ineligible for continued coverage), on a monthly basis, until the earlier of (i) the date 12 months after the Termination Date or (ii) the date you begin receiving substantially equivalent coverage and benefits through a subsequent employer.

4.    No Mitigation. You shall not be required to mitigate the amount of the Severance Payment or any other benefit provided under this Agreement by seeking other employment or otherwise, nor shall the amount of any payment or benefit provided for in this Agreement be reduced (except as provided in Article II Section 3(ii)) by any compensation earned by you as the result of other employment, by retirement benefits, or


Page 5
be offset against any amount claimed to be owed by you to the Company or otherwise (except for any required withholding taxes); provided, that if the Company makes any other severance payments to you under any other program or agreement, including the Employment Agreement, such amounts shall be offset against the payments the Company is obligated to make pursuant to this Agreement.

III.Miscellaneous.

1.Employee’s Obligations. Upon termination of employment, you shall promptly deliver to the Company all property of the Company and all material documents, statistics, account records, programs and other similar tangible items which may by in your possession or under your control and which relate to the business or affairs of the Company or its subsidiaries, and no copies of any such documents or any part thereof shall be retained by you.

2.Entire Agreement. This Agreement, the Employment Agreement and the Inventions Agreement executed by you covers the entire understanding of the parties as to the subject matter hereof, superseding all prior understandings and agreements related hereto. No modification or amendment of the terms and conditions of this Agreement shall be effective unless in writing and signed by the parties or their respective duly authorized agents, provided, however, that the Company may, without your consent, unilaterally adopt amendments that may be required so that this Agreement continues to comply with applicable law or regulation, including without limitation Section 409A of the Code, provided such amendments do not adversely affect the benefits to be provided to you under Section II of this Agreement. In no event shall the Company have any liability relating to the failure or alleged failure of any payment or benefit under this Agreement to comply with or be exempt from, the requirements of Section 409A of the Code.

3.Governing Law. This Agreement shall be governed by the laws of The Commonwealth of Massachusetts, as applied to contracts entered into and performed entirely in Massachusetts by Massachusetts residents.

4.Successors and Assigns. This Agreement may be assigned by the Company upon a sale, transfer or reorganization of the Company. Upon a Change of Control, the Company shall require the successor to assume the Company’s rights and obligations under this Agreement. The Company’s failure to do so shall constitute Good Reason and a material breach of this Agreement. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their successors, permitted assigns, legal representatives and heirs.




Page 6
Kindly indicate your acceptance of the foregoing by signing and dating this Agreement as noted below, and returning one fully executed original to my attention.

Very truly yours,

Vertex Pharmaceuticals Incorporated


By:        /s/ Reshma Kewalramani    
Name: Reshma Kewalramani
Title: CEO and President

ACCEPTED AND AGREED:

/s/ Nia Tatsis
    

Nia Tatsis


 EX-10.39 5 a10k_2021-exhibit1039.htm EX-10.39 Document
Exhibit 10.39


Vertex Pharmaceuticals Incorporated Annual Non-Employee Board Compensation
Annual Retainer
$100,000
Committee Chair Compensation
Audit & Finance Committee Chair
$30,000 annual retainer
Management Development & Compensation Committee Chair
$25,000 annual retainer
Corporate Governance & Nominating Committee Chair
$25,000 annual retainer
Science & Technology Committee Chair
$25,000 annual retainer
Committee Membership Fee (Non-Chairs)
Audit & Finance Committee Member
$15,000 annual retainer
Management Development & Compensation Committee Member
$12,500 annual retainer
Corporate Governance & Nominating Committee Member
$10,000 annual retainer
Science & Technology Committee Member
$10,000 annual retainer
Lead Independent Director Compensation
$40,000 annual retainer
Annual Equity Grants
Annually on May 1, $400,000 in value-based awards, comprised at the director's election of restricted stock units and/or options
•Options are fully vested upon grant
•Restricted stock units cliff vest on the 1 year anniversary of the grant date
Initial Equity Grants
On date director joins the board of directors, a $400,000 restricted stock unit award that vests on the first anniversary of the grant date.
Each of our non-employee directors is eligible to defer the cash and restricted stock portion of his/her compensation set forth above and elect to receive deferred stock units that convert to common stock in specified circumstances.



 EX-21.1 6 a10k_2021-exhibit211.htm EX-21.1 Document

Exhibit 21.1

Subsidiaries of Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (San Diego) LLC, a Delaware limited liability company
 
Vertex Securities Corporation, a Massachusetts corporation

Vertex Pharmaceuticals (Distribution) Incorporated, a Delaware corporation
 
Vertex Pharmaceuticals (Cayman) Limited, a Cayman Islands company (3)

Vertex Pharmaceuticals (Cayman III) Limited, a Cayman Islands company (5)

Vertex Pharmaceuticals (Cayman 509) Limited, a Cayman Islands company

Vertex Pharmaceuticals (Cayman 765) Limited, a Cayman Islands company

Vertex Pharmaceuticals (Cayman 787) Limited, a Cayman Islands company
 
Vertex Pharmaceuticals (Delaware) LLC, a Delaware limited liability company

Vertex Pharmaceuticals (Puerto Rico) LLC, a Delaware limited liability company
Vertex Pharmaceuticals (Canada) Incorporated, a Canadian company (1)

Vertex Pharmaceuticals (Singapore) Pte. Ltd., a Singapore company

Vertex Holdings, Inc., a Delaware corporation
 
Vertex Pharmaceuticals (Europe) Limited, a United Kingdom company (5)

Vertex Pharmaceuticals (Ireland) Limited, an Irish company (6)
 
Vertex Pharmaceuticals (U.K.) Limited, a United Kingdom company (6)
 
Vertex Pharmaceuticals (France) SAS, a French company
 
Vertex Pharmaceuticals (Germany) GmbH, a German company

Vertex Pharmaceuticals (Australia) Pty. Ltd., an Australian company

Vertex Pharmaceuticals (Spain), S.L., a Spanish company
 
Vertex Pharmaceuticals (Netherlands) B.V., a Dutch company

Vertex Pharmaceuticals (Italy) S.r.L., an Italian company

Vertex Farmaceutica do Brasil LTDA, a Brazilian company (4)
Vertex Pharmaceuticals GmbH, an Austrian company (6)
Vertex Pharmaceuticals (Portugal), Unipessoal Lda., a Portuguese company (6)
Vertex Pharmaceuticals (CH) GmbH, a Swiss company (6)
Vertex Pharmaceuticals (Sweden) AB, a Sweden company (6)
Vertex Pharmaceuticals Single Member Societe Anonyme, a Greek company (6)


Vertex Pharmaceuticals (Poland) sp. z.o.o (5) (6)
The Vertex Foundation, Inc., a Delaware corporation
Torreyana Insurance Company, Inc., a Vermont corporation
Vertex Pharmaceuticals (Czech Republic) s.r.o (6)
Vertex Pharmaceuticals (Belgium) BV (6)



------------------------------
(1) a subsidiary of Vertex Pharmaceuticals (Delaware) LLC
(2) a subsidiary of Vertex Pharmaceuticals (Singapore) Pte. Ltd.
(3) a subsidiary of Vertex Holdings, Inc.
(4) a subsidiary of Vertex Pharmaceuticals (UK) Limited
(5) a subsidiary of Vertex Pharmaceuticals (Cayman) Limited
(6) a subsidiary of Vertex Pharmaceuticals (Europe) Limited




 EX-23.1 7 a10k_2021-exhibit231.htm EX-23.1 Document

Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1)Registration Statement (Form S-3 No. 333-229656) of Vertex Pharmaceuticals Incorporated,
(2)Registration Statements (Form S-8 Nos. 333-134482, 333-150946, 333-160442, 333-166803 and 333-184787) pertaining to the Vertex Pharmaceuticals Incorporated Amended and Restated 2006 Stock and Option Plan (formerly known as the Vertex Pharmaceuticals Incorporated 2006 Stock and Option Plan),
(3)Registration Statements (Form S-8 Nos. 333-184784 and 333-232945) pertaining to the Vertex Pharmaceuticals Incorporated Employee Stock Purchase Plan, and
(4)Registration Statements (Form S-8 Nos. 333-226363, 333-219559, 333-188737, 333-197466, 333-206075 and 333-232948) pertaining to the Amended and Restated Vertex Pharmaceuticals Incorporated 2013 Stock and Option Plan (formerly known as the Vertex Pharmaceuticals Incorporated 2013 Stock and Option Plan);
of our reports dated February 9, 2022, with respect to the consolidated financial statements of Vertex Pharmaceuticals Incorporated and the effectiveness of internal control over financial reporting of Vertex Pharmaceuticals Incorporated, included in this Annual Report (Form 10-K) of Vertex Pharmaceuticals Incorporated for the year ended December 31, 2021.
        /s/ Ernst & Young LLP
Boston, Massachusetts
February 9, 2022

EX-31.1 8 a10k_2021-exhibit311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION
I, Reshma Kewalramani, certify that:
1.I have reviewed this Annual Report on Form 10-K of Vertex Pharmaceuticals Incorporated;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:
February 9, 2022
/s/ Reshma Kewalramani
Reshma Kewalramani
Chief Executive Officer and President

 EX-31.2 9 a10k_2021-exhibit312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION
I, Charles F. Wagner, Jr., certify that:
1.I have reviewed this Annual Report on Form 10-K of Vertex Pharmaceuticals Incorporated;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 9, 2022/s/ Charles F. Wagner, Jr.
Charles F. Wagner, Jr.
Executive Vice President and Chief Financial Officer

 EX-32.1 10 a10k_2021-exhibit321.htm EX-32.1 Document

Exhibit 32.1
SECTION 906 CEO/CFO CERTIFICATION
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) each of the undersigned officers of Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:
The Annual Report on Form 10-K for the year ended December 31, 2021 (the “Form 10-K”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: February 9, 2022
/s/ Reshma Kewalramani
Reshma Kewalramani
Chief Executive Officer and President
Date: February 9, 2022
/s/ Charles F. Wagner, Jr.
Charles F. Wagner, Jr.
Executive Vice President and Chief Financial Officer



 EX-101.SCH 11 vrtx-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0002002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 1001003 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1002004 - Statement - Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1003005 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004006 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1005007 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006008 - Statement - Consolidated Statements of Shareholders’ Equity link:presentationLink link:calculationLink link:definitionLink 1007009 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Nature of Business and Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Nature of Business and Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Nature of Business and Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Nature of Business and Accounting Policies - Business Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Nature of Business and Accounting Policies - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Nature of Business and Accounting Policies - Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Nature of Business and Accounting Policies - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2408405 - Disclosure - Nature of Business and Accounting Policies - Goodwill Hedging Activities Foreign Currency Gain (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 2409406 - Disclosure - Nature of Business and Accounting Policies - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2110102 - Disclosure - Collaborative and Other Arrangements link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - Collaborative and Other Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 2412407 - Disclosure - Collaborative and Other Arrangements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2413408 - Disclosure - Collaborative and Other Arrangements - CRISPR Therapeutics AG (Details) link:presentationLink link:calculationLink link:definitionLink 2414409 - Disclosure - Collaborative and Other Arrangements - Kymera, Moderna and Other In-License Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 2415410 - Disclosure - Collaborative and Other Arrangements - Merck KGaA (Details) link:presentationLink link:calculationLink link:definitionLink 2116103 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2317303 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2418411 - Disclosure - Earnings Per Share - Schedule of Computation (Details) link:presentationLink link:calculationLink link:definitionLink 2419412 - Disclosure - Earnings Per Share - Anti-dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2120104 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2321304 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2422413 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2423414 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2424415 - Disclosure - Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2125105 - Disclosure - Marketable Securities and Equity Investments link:presentationLink link:calculationLink link:definitionLink 2326305 - Disclosure - Marketable Securities and Equity Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2427416 - Disclosure - Marketable Securities and Equity Investments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2428417 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2428417 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2429418 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2430419 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 2131106 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 2332306 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 2433420 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 2134107 - Disclosure - Hedging link:presentationLink link:calculationLink link:definitionLink 2335307 - Disclosure - Hedging (Tables) link:presentationLink link:calculationLink link:definitionLink 2436421 - Disclosure - Hedging - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2437422 - Disclosure - Hedging - Notional Amount (Details) link:presentationLink link:calculationLink link:definitionLink 2438423 - Disclosure - Hedging - Cash Flow Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2439424 - Disclosure - Hedging - Derivative Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2440425 - Disclosure - Hedging - Offsetting Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 2141108 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2342308 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2443426 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2144109 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2345309 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2446427 - Disclosure - Property and Equipment - Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2447428 - Disclosure - Property and Equipment - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2148110 - Disclosure - Intangible Assets and Goodwill link:presentationLink link:calculationLink link:definitionLink 2449429 - Disclosure - Intangible Assets and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2150111 - Disclosure - Additional Balance Sheet Detail link:presentationLink link:calculationLink link:definitionLink 2351310 - Disclosure - Additional Balance Sheet Detail (Tables) link:presentationLink link:calculationLink link:definitionLink 2452430 - Disclosure - Additional Balance Sheet Detail - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2453431 - Disclosure - Additional Balance Sheet Detail - Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2454432 - Disclosure - Additional Balance Sheet Detail - Additional Cash Flow (Details) link:presentationLink link:calculationLink link:definitionLink 2155112 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2356311 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2457433 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2458434 - Disclosure - Leases - Components of Lease Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2459435 - Disclosure - Leases - Balance Sheet Classification of Lease Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2460436 - Disclosure - Leases - Maturities of Operating and Financing Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2460436 - Disclosure - Leases - Maturities of Operating and Financing Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2460436 - Disclosure - Leases - Maturities of Operating and Financing Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2461437 - Disclosure - Leases - Weighted-Average Remaining Lease Terms and Discount Rates (Details) link:presentationLink link:calculationLink link:definitionLink 2462438 - Disclosure - Leases - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 2163113 - Disclosure - Common Stock, Preferred Stock and Equity Plans link:presentationLink link:calculationLink link:definitionLink 2364312 - Disclosure - Common Stock, Preferred Stock and Equity Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 2465439 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Common Stock and Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2466440 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Share Repurchase Program (Details) link:presentationLink link:calculationLink link:definitionLink 2467441 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Stock and Option Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2468442 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Outstanding and Vested Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 2469443 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Stock Options Outstanding and Exercisable (Details) link:presentationLink link:calculationLink link:definitionLink 2470444 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Restricted Stock and Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 2471445 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Performance-based RSUs (PSUs) (Details) link:presentationLink link:calculationLink link:definitionLink 2472446 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Employee Stock Purchase Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2473447 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Employee Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 2174114 - Disclosure - Stock-based Compensation Expense link:presentationLink link:calculationLink link:definitionLink 2375313 - Disclosure - Stock-based Compensation Expense (Tables) link:presentationLink link:calculationLink link:definitionLink 2476448 - Disclosure - Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2177115 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2378314 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2479449 - Disclosure - Income Taxes - Components of Income and Provision for (Benefit from) Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2480450 - Disclosure - Income Taxes - Effective Income Tax Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2481451 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2482452 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2483453 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 2184116 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2485454 - Disclosure - Commitments and Contingencies - Revolving Credit Facility (Details) link:presentationLink link:calculationLink link:definitionLink 2486455 - Disclosure - Commitments and Contingencies - Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2187117 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 2388315 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2489456 - Disclosure - Segment Information - Revenues by Product (Details) link:presentationLink link:calculationLink link:definitionLink 2490457 - Disclosure - Segment Information - Revenue by Geographic Location (Details) link:presentationLink link:calculationLink link:definitionLink 2491458 - Disclosure - Segment Information - Significant Customers (Details) link:presentationLink link:calculationLink link:definitionLink 2492459 - Disclosure - Segment Information - Property and Equipment, Net by Location (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 vrtx-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 13 vrtx-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 14 vrtx-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Customer [Domain] Customer [Domain] Accrued expenses Deferred Tax Assets, Accrued Expenses and Other The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from currently nondeductible expenses in accrued and other expenses, which can only be deducted for tax purposes when such items are actually incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken. On Available-For-Sale Debt Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Letter of Credit Letter of Credit [Member] State Current State and Local Tax Expense (Benefit) Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Leasehold improvements Leasehold Improvements [Member] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Property and equipment, net Finance Lease, Right-Of-Use Asset, Gross Finance Lease, Right-Of-Use Asset, Gross Gross Amounts Presented Derivative Liability Security Exchange Name Security Exchange Name Fair Value Equity Securities, FV-NI, Current Cancelled ( in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Operating leases Operating Lease, Weighted Average Remaining Lease Term Foreign Currency Translation and Transactions Foreign Currency Transactions and Translations Policy [Policy Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Hedging Activities Derivatives, Policy [Policy Text Block] Accredo/Curascript Accredo/Curascript [Member] Accredo/Curascript [Member] Additional awards authorized for grant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Expected stock price volatility (percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Acquired intangibles Deferred Tax Liabilities, Intangible Assets Total intrinsic value of stock options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Schedule of Foreign Exchange Contracts, Condensed Consolidated Statements of Operations Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Exercise price, low end of range ( in usd per share) Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Number of shares remaining for repurchases Stock Repurchase Program, Remaining Authorized Repurchase Amount Increases related to prior period tax positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Net deferred tax assets Deferred Tax Assets, Net Operating leases Operating Lease, Weighted Average Discount Rate, Percent Schedule of Inventories by Type Schedule of Inventory, Current [Table Text Block] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Revenues related to performance obligations Contract with Customer, Liability, Revenue Recognized Research and development expenses Research and Development Expense [Member] Total deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Potential awards, percent of target shares, maximum Share-Based Compensation By Share-Based Payment Award, Award Percentage Of Target, Maximum Share-Based Compensation By Share-Based Payment Award, Award Percentage Of Target, Maximum Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Cash Flow Hedging Cash Flow Hedging [Member] Award Type [Domain] Award Type [Domain] Local Phone Number Local Phone Number Weighted-average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Money market funds Cash and Money Market Funds [Member] Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time. Stock options exercisable at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding Preferred Stock, Value, Issued Currency [Axis] Currency [Axis] Retained Earnings (Accumulated Deficit) Retained Earnings [Member] Area of real estate property (in square feet) Area of Real Estate Property Operating lease liabilities Deferred Tax Liabilities, Leasing Arrangements 2025 Finance Lease And Operating Lease, Liability, Payments, Due Year Four Finance Lease And Operating Lease, Liability, Payments, Due Year Four Collaborative arrangement research and development expenses Collaborative Arrangement, Research and Development Expenses Collaborative Arrangement, Research and Development Expenses Components of income (loss) before provision for (benefit from) income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Operating leases Leases, Operating [Abstract] Accounts receivable, net Increase (Decrease) in Accounts Receivable Collaborative arrangement, option payment Collaborative Arrangement, Option Payment Collaborative Arrangement, Option Payment Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Common stock withheld for employee tax obligations (in shares) Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Payments on finance leases Financing cash flows from finance leases Finance Lease, Principal Payments Stock-based Compensation Expense Compensation Related Costs, Policy [Policy Text Block] Basic ( in usd per share) Basic net income per common share (in dollars per share) Earnings Per Share, Basic Operating loss carryforwards, subject to expiration Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Sublease income Sublease Income Beginning of the period (in shares) End of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number ApolLo1 Bio, LLC ApolLo1 Bio, LLC [Member] ApolLo1 Bio, LLC Unrecognized Tax Benefits [Line Items] Unrecognized Tax Benefits [Line Items] Unrecognized Tax Benefits Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] ESPP share issuances Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Commercial paper Commercial Paper [Member] Other non-cash items, net Other Noncash Income (Expense) Number of credit agreements Number Of Credit Agreements Number Of Credit Agreements Gross Amounts Recognized Derivative Asset, Fair Value, Gross Asset Number of pre-clinical stage programs Collaborative Arrangement, Right to License, Number Of Pre-Clinical Stage Programs Collaborative Arrangement, Right to License, Number Of Pre-Clinical Stage Programs Walgreen Co. Walgreen Co. [Member] Walgreen Co. [Member] Restricted cash and cash equivalents Restricted Cash and Cash Equivalents Property and equipment Deferred Tax Liabilities, Property, Plant and Equipment Non-financial performance shares Non-Financial Performance Shares [Member] Non-Financial Performance Shares Revenues and Property and Equipment by Location Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] SYMDEKO/SYMKEVI SYMDEKO/SYMKEVI [Member] SYMDEKO/SYMKEVI [Member] Entity Voluntary Filers Entity Voluntary Filers CRISPR DMD/DM1 CRISPR DMD/DM1 [Member] CRISPR Therapeutics DMD/DM1 [Member] Issuance of common stock under benefit plans Stock Issued During Period, Value, Employee Benefit Plan Plan Name [Axis] Plan Name [Axis] Financial instruments carried at fair value (asset position): Assets, Fair Value Disclosure [Abstract] Level 1 Fair Value, Inputs, Level 1 [Member] Other-than-temporary declines in fair value of available-for-sale debt securities Other than Temporary Impairment Losses, Investments Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entity Small Business Entity Small Business Operating Leases Lessee, Operating Lease, Liability, Payment, Due [Abstract] Cash equivalents: Cash and cash equivalents Cash and Cash Equivalents [Member] Base Rate Base Rate [Member] Increases related to current period tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Commitments and Contingencies Commitments Disclosure [Text Block] Stock-based compensation expense: Share-based Compensation Allocation [Abstract] -- None. No documentation exists for this element. -- Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] Net unrecognized tax benefits which would affect the tax rate if recognized Unrecognized Tax Benefits that Would Impact Effective Tax Rate Accounts payable Increase (Decrease) in Accounts Payable Hedging Relationship [Domain] Hedging Relationship [Domain] Expected annual dividends Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments Derivative liability current, foreign currency forward contracts Derivative Liability, Current Entity Interactive Data Current Entity Interactive Data Current Additional Balance Sheet Detail Additional Financial Information Disclosure [Text Block] Settlement with tax authorities Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Marketable securities Marketable Securities, Current Change in fair value of contingent consideration (Decrease) increase in fair value of contingent consideration Decrease in fair value of contingent payments Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Balance Sheet Location [Domain] Balance Sheet Location [Domain] Balance at beginning of the period Balance at end of period Unrecognized tax benefits Unrecognized Tax Benefits Gross deferred tax assets Deferred Tax Assets, Gross Income Tax Authority [Domain] Income Tax Authority [Domain] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Derivative asset current, foreign currency forward contracts Derivative Asset, Current Entity Address, State or Province Entity Address, State or Province Leases Lessee, Finance Leases [Text Block] Amounts reclassified from accumulated other comprehensive income (loss) Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Collaborative arrangement development and regulatory potential milestone payments maximum Collaborative Arrangement Development And Regulatory Potential Milestone Payments Maximum Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are approved and commercialized. Deferred tax assets Deferred Income Tax Assets, Net United Kingdom UNITED KINGDOM Current liabilities: Liabilities, Current [Abstract] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Weighted average exercise price exercisable at the end of the period ( in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Inventories Inventory Disclosure [Text Block] Corporate equity securities Equity Securities [Member] Percentage of employees eligible for acceleration of equity awards (less than) (percent) Percentage of employees eligible for acceleration of equity awards Percentage of employees eligible for acceleration of equity awards Accounting Policies [Abstract] Accounting Policies [Abstract] Number of optional renewal terms Lessee, Operating Lease, Number Of Renewal Options Lessee, Operating Lease, Number Of Renewal Options Outstanding (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Derivative Instrument [Axis] Derivative Instrument [Axis] Marketable Securities and Equity Investments Cash, Cash Equivalents, and Marketable Securities [Text Block] Federal Current Federal Tax Expense (Benefit) Present value of lease liabilities Operating Lease, Liability Schedule of PSU Activity Share-based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block] Document Transition Report Document Transition Report Financial performance shares Financial Performance Shares [Member] Financial Performance Shares Common stock, $0.01 par value; 500,000,000 shares authorized, 254,479,046 and 259,889,549 shares issued and outstanding, respectively Common Stock, Value, Issued Finance leases Finance Lease, Weighted Average Discount Rate, Percent Weighted-average Recognition Period Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Beginning of the period ( in usd per share) End of the period ( in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Right to license, number of development programs Collaborative Arrangement, Right To License, Number Of Development Programs Collaborative Arrangement, Right To License, Number Of Development Programs Investment in equity securities and notes receivable Payment to Acquire Preferred Stock and Notes Receivable Payment to Acquire Preferred Stock and Notes Receivable Leases Lessee, Operating Leases [Text Block] Amortization of leased assets Finance Lease, Right-of-Use Asset, Amortization Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Schedule of Assumptions Used to Estimate the Grant Date Fair Value of Options Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Product Concentration Risk Product Concentration Risk [Member] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Foreign Deferred Foreign Income Tax Expense (Benefit) Legal Entity [Axis] Legal Entity [Axis] Share-based payment arrangements (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Marketable Securities Marketable Securities, Policy [Policy Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Interest expense Interest Income (Expense), Net British pound sterling United Kingdom, Pounds Summary of Unrecognized Tax Benefits Summary of Income Tax Contingencies [Table Text Block] Income Tax Authority [Axis] Income Tax Authority [Axis] Work-in-process Inventory, Work in Process, Net of Reserves Fair value of cash flow hedges Cash Flow Hedge Derivative Instrument Liabilities at Fair Value Computers and software Technology Equipment [Member] Thereafter Finance Lease, Liability, to be Paid, after Year Five Prepaid expenses and other current assets Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Stock options outstanding and exercisable Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] Selling, general and administrative expenses Selling, General and Administrative Expenses [Member] Entity [Domain] Entity [Domain] Accrued expenses Total Accrued Liabilities, Current Revenue Product revenues, net Total product revenues, net Revenue from Contract with Customer, Excluding Assessed Tax Stock-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Finished goods Inventory, Finished Goods, Net of Reserves Long-term intercompany receivable write-off Effective Income Tax Rate Reconciliation, Intercompany Receivable Write-Off, Percent Effective Income Tax Rate Reconciliation, Intercompany Receivable Write-Off, Percent Stock options Stock options Share-based Payment Arrangement, Option [Member] Equity [Abstract] Equity [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Comprehensive Income Comprehensive Income, Policy [Policy Text Block] Tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Percent Less: tenant allowance Finance Lease and Operating Lease, Liability, Tenant Allowance Finance Lease and Operating Lease, Liability, Tenant Allowance Operating lease assets Deferred Tax Assets, Operating Lease Assets Deferred Tax Assets, Operating Lease Assets Measurement Input Type [Domain] Measurement Input Type [Domain] Variable Rate [Axis] Variable Rate [Axis] Segment Information Segment Reporting Disclosure [Text Block] Uncertain tax positions Effective Income Tax Rate Reconciliation, Uncertian Tax Positions, Percent Effective Income Tax Rate Reconciliation, Uncertian Tax Positions, Percent Finance leases Finance Lease, Weighted Average Remaining Lease Term Other comprehensive income (loss) before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent Canadian dollar Canada, Dollars Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Weighted-average discount rate Weighted Average Discount Rate [Abstract] Weighted Average Discount Rate [Abstract] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Matures after one year through five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Variable Rate [Domain] Variable Rate [Domain] Additional Paid-in Capital Additional Paid-in Capital [Member] Intangible assets Deferred Tax Assets Intangibles The component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets related to intangible assets. $200.01–$286.27 Exercise Price Range From Dollars 200.01 to Dollars $286.27 [Member] Exercise Price Range From Dollars 200.01 to Dollars $286.27 Other assets Other Assets [Member] Other income, net Other Nonoperating Income (Expense) Other liabilities Increase (Decrease) in Other Operating Liabilities Remaining milestone payment Business Combination, Remaining Milestone Payment Business Combination, Remaining Milestone Payment Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Gross Unrealized Losses Equity Securities, FV-NI, Unrealized Loss Schedule of Collaborative Arrangement on Research and Development Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Raw materials Inventory, Raw Materials, Net of Reserves Summary of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Award Type [Axis] Award Type [Axis] Schedule of Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Skyhawk Therapeutics Inc Skyhawk Therapeutics Inc [Member] Skyhawk Therapeutics Inc Beginning balance Ending balance Stockholders' Equity Attributable to Parent Fair Value of In-process Research and Development Assets and Contingent Payments In-process Research and Development Assets and Contingent Payments [Policy Text Block] Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets and contingent payments of an acquired entity to be used in the research and development activities of the combined enterprise. Common stock, number of votes per share Common Stock, Votes Per Each Share Common Stock, Votes Per Each Share City Area Code City Area Code Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Designated as hedging instruments Designated as Hedging Instrument [Member] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Repurchases of common stock Payments for Repurchase of Common Stock Number of leases Lease Agreement, Number of Leases Represents the number of leases entered by the reporting entity. Property and equipment useful life Property, Plant and Equipment, Useful Life AOCI, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type [Axis] Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type [Axis] This element represents the grouping of share-based compensation award types. Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Long-term operating lease liabilities Operating Lease, Liability, Noncurrent Total lease payments Finance Lease, Liability, Payment, Due Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Total current taxes Current Income Tax Expense (Benefit) Income tax effect Share-based Payment Arrangement, Expense, Tax Benefit Market share price ( in usd per share) Share Price Research and Development Expenses Research, Development, and Computer Software, Policy [Policy Text Block] Lease agreement initial term Lessee, Operating Lease, Term of Contract Restricted stock units (including PSUs) Restricted Stock Units (excluding PSUs) Restricted Stock Units (RSUs) [Member] Present value of lease liabilities Finance Lease, Liability Number of purchase periods Share-based Compensation Arrangement by Share-based Payment Award, Number of Purchase Periods Share-based Compensation Arrangement by Share-based Payment Award, Number of Purchase Periods Total deferred tax liabilities Deferred Tax Liabilities, Gross Operating Loss and Tax Credit, Carryforwards [Table] Operating Loss and Tax Credit, Carryforwards [Table] Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization and tax credit carryforwards. Tranche two Share-based Payment Arrangement, Tranche Two [Member] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Contingent liabilities Contingent Liabilities Amount of material contingent liabilities outstanding Income Statement [Abstract] Income Statement [Abstract] Entity Registrant Name Entity Registrant Name 2024 Finance Lease, Liability, to be Paid, Year Three 2025 Finance Lease, Liability, to be Paid, Year Four Options outstanding, weighted-average exercise price ( in usd per share) Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price Collaborative Arrangement Agreement [Domain] Collaborative Arrangement Agreement [Domain] Listing of significant collaboration agreements. Forfeited ( in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Provision for income taxes Provision for income taxes Income Tax Expense (Benefit) Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Summary of Cash, Cash Equivalents and Marketable Securities Cash, Cash Equivalents and Investments [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Schedule of Stock Options Outstanding and Exercisable Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Percent of Accounts Receivable Accounts Receivable [Member] Total lease payments Lessee, Operating Lease, Liability, to be Paid Cancelled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period In-process Research and Development Assets Goodwill and Intangible Assets Indefinite-Lived Assets [Policy Text Block] Describes an entity's accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets. Repurchases of common stock Repurchases of common stock Stock Repurchased During Period, Value Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Indemnification claims Indemnification Claims Amount of indemnification claims currently outstanding Length of lease Lessee Leasing Arrangements, Capital Leases, Term of Contract Lessee Leasing Arrangements, Capital Leases, Term of Contract Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Stock compensation (benefit), shortfalls and cancellations Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent Debt covenant, increase in consolidated leverage ratio Debt Covenant, Increase In Consolidated Leverage Ratio Debt Covenant, Increase In Consolidated Leverage Ratio Other indefinite-lived intangible assets Other Indefinite-lived Intangible Assets Schedule of Cash Equivalents and Available-for-sale Securities [Table] Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of the cash and cash equivalents and available-for-sale investments held by the entity. Percent of Total Gross Product Revenues Revenue Benchmark [Member] Weighted-average grant-date fair value, granted ( in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Component [Domain] Equity Component [Domain] 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Less: amount representing interest Finance Lease And Operating Lease, Liability, Undiscounted Excess Amount Finance Lease And Operating Lease, Liability, Undiscounted Excess Amount Deferred tax assets: Components of Deferred Tax Assets [Abstract] Property and equipment, net Total property and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Share Repurchase Programs Stockholders' Equity, Policy [Policy Text Block] Employee stock purchase program (in shares) Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements Counterparty Name [Domain] Counterparty Name [Domain] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Weighted Average Weighted Average [Member] Finance lease liabilities Finance Lease, Liability, Current Issuance of common stock under benefit plans (in shares) Stock Issued During Period, Shares, Employee Benefit Plan Income before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Level 2 Fair Value, Inputs, Level 2 [Member] Type of Adoption [Domain] Accounting Standards Update [Domain] Deferred tax benefit Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Auditor Location Auditor Location Segment Reporting [Abstract] Segment Reporting [Abstract] Option to extend lease term Lessee, Finance Lease, Term of Contract Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Interest on lease liabilities Finance Lease, Interest Expense Use of Estimates Use of Estimates, Policy [Policy Text Block] Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Financial instruments carried at fair value (liability position): Financial Liabilities Fair Value Disclosure [Abstract] Total other comprehensive income (loss) Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Finance Leases Finance Lease, Liability, Payment, Due [Abstract] Title of 12(b) Security Title of 12(b) Security Moderna Agreement Moderna Agreement [Member] Moderna Agreement [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Average price paid per share ( in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased Document Type Document Type Product and Service [Domain] Product and Service [Domain] Product revenue accruals Product Sales Accrued Liabilities Total of product sales allowances and reserves that reflect a liability established to represent expected future costs. Legal Offset Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Optional term of lease agreement (in years) Lessee, Operating Lease, Renewal Term Balance at December 31, 2020 Balance at December 31, 2021 Business Combination, Contingent Consideration, Liability Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Weighted-average cost basis Amortized Cost Equity Securities, FV-NI, Cost Revolving Credit Facility Revolving Credit Facility [Member] Fair Value by Measurement Frequency [Axis] Measurement Frequency [Axis] Summary of cash, cash equivalents and marketable securities Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Line Items] -- None. No documentation exists for this element. -- Share-based Payment Arrangement, Option, Exercise Price Range [Table] Share-based Payment Arrangement, Option, Exercise Price Range [Table] Schedule of Lease Cost Lease, Cost [Table Text Block] Geographical [Axis] Geographical [Axis] Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] State and Local Jurisdiction State and Local Jurisdiction [Member] Corporate Headquarters Fan Pier Leases [Member] Represents the fan pier leases. Vesting [Domain] Vesting [Domain] Product revenues, net Product revenues, net Product [Member] Total financial liabilities Financial Liabilities Fair Value Disclosure Hedging Relationship [Axis] Hedging Relationship [Axis] Share Repurchase Program 2020 Share Repurchase Program 2020 [Member] Share Repurchase Program 2020 [Member] Net unrealized gains Unrealized Gain (Loss) on Investments Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Shares used in per share calculations: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Schedule of Restricted Stock and Restricted Stock Units Activity Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Schedule of Finance Lease, Liability, Maturity Finance Lease, Liability, Fiscal Year Maturity [Table Text Block] Fair Value Measurements Fair Value Disclosures [Text Block] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Other current liabilities Finance Leases, Other Current Liabilities Finance Leases, Other Current Liabilities Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Share Repurchase Program 2021 Share Repurchase Program 2021 [Member] Share Repurchase Program 2021 Optional renewal term length Lessee Leasing Arrangements, Capital Leases, Renewal Term Lessee Leasing Arrangements, Capital Leases, Renewal Term Foreign Tax Authority Foreign Tax Authority [Member] Royalty payable Accrued Royalties, Current Gross Unrealized Gains Debt and Equity Securities, Unrealized Gain Debt and Equity Securities, Unrealized Gain Derivative [Table] Derivative [Table] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] 2024 Finance Lease And Operating Lease, Liability, Payment, Due Year Three Finance Lease And Operating Lease, Liability, Payment, Due Year Three Computers and software Computer Software, Intangible Asset [Member] Document Period End Date Document Period End Date Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Marketable securities: Marketable securities Marketable Securities [Member] Marketable Securities [Member] Stock Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Exonics Therapeutics Exonics Therapeutics [Member] Exonics Therapeutics [Member] Arbor Biotechnologies, Inc Arbor Biotechnologies, Inc [Member] Arbor Biotechnologies, Inc Sale of equity securities Proceeds from Sale of Debt and Equity Securities, FV-NI, Held-for-investment State taxes, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent State Deferred State and Local Income Tax Expense (Benefit) Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Finance lease liabilities Deferred Tax Assets, Lease Obligation Deferred Tax Assets, Lease Obligation Income Statement Location [Domain] Income Statement Location [Domain] Less: tenant allowance Lessee, Operating Lease, Liability, Tenant Allowance Lessee, Operating Lease, Liability, Tenant Allowance Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Additional shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Semma Therapeutics, Inc. Semma Therapeutics, Inc. [Member] Semma Therapeutics, Inc. [Member] Marketable securities: Marketable Securities Net income per common share: Earnings Per Share [Abstract] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Gains on equity securities Equity Securities, FV-NI, Unrealized Gain (Loss) Contract liabilities Other Contract Liabilities Current Other Contract liabilities, Current Outstanding at beginning of period ( in usd per share) Outstanding at end of period ( in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Costs and expenses: Costs and Expenses [Abstract] Percent of awards in tranche Share-Based Compensation By Share-Based Payment Award, Percent of Awards in Tranche Share-Based Compensation By Share-Based Payment Award, Percent of Awards in Tranche Europe Europe [Member] Entity Current Reporting Status Entity Current Reporting Status Effective tax rate Effective tax rate Effective Income Tax Rate Reconciliation, Percent Proceeds received Proceeds from Sale and Maturity of Marketable Securities Counterparty Name [Axis] Counterparty Name [Axis] United States UNITED STATES Discount Rate Measurement Input, Discount Rate [Member] Significant Customers Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Tax related accruals Taxes Payable, Current Leases [Abstract] Leases [Abstract] Income Taxes Income Tax, Policy [Policy Text Block] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Diluted (in shares) Diluted weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted United States Income (Loss) from Continuing Operations before Income Taxes, Domestic Income Taxes Income Tax Disclosure [Text Block] Schedule of Outstanding and Vested Options Share-based Payment Arrangement, Option, Activity [Table Text Block] Basis spread on variable rate (percent) Debt Instrument, Basis Spread on Variable Rate Fair Value Debt and Equity Securities, Fair Value Debt and Equity Securities, Fair Value Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Name of Property [Axis] Name of Property [Axis] Credit Facility [Axis] Credit Facility [Axis] Indefinite-Lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Not designated as hedging instrument Not Designated as Hedging Instrument [Member] Entity Address, Address Line One Entity Address, Address Line One Total lease payments Finance Lease And Operating Lease, Liability, Payments, Due Finance Lease And Operating Lease, Liability, Payments, Due Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Unrealized holding (losses) gains on marketable securities, net Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Schedule of Prepaid, and Other Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Entity Shell Company Entity Shell Company Total Finance Leas and Operating Lease, Liabilities, Payments, Due [Abstract] Finance Leas and Operating Lease, Liabilities, Payments, Due [Abstract] Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Expected term of options (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Total current liabilities Liabilities, Current Employee stock purchase plan Employee Stock [Member] Payments in connection with common stock withheld for employee tax obligations Payment, Tax Withholding, Share-based Payment Arrangement Foreign currency forward contracts Foreign Exchange Forward [Member] Money market funds Money Market Funds [Member] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Current Fiscal Year End Date Current Fiscal Year End Date Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Statement [Table] Statement [Table] Line of credit facility, additional borrowing capacity Line Of Credit Facility Additional Borrowing Capacity Amount of increased borrowing capacity available in the future. Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Recently Adopted Accounting Standards and Recently Issued Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Other Deferred Tax Assets, Other Weighted-average assumptions for options and ESPP subscriptions granted Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Unrecognized Expense Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Statistical Measurement [Axis] Statistical Measurement [Axis] Accounts Receivable Accounts Receivable [Policy Text Block] Long-term finance lease liabilities Finance Lease, Liability, Noncurrent Goodwill Goodwill Total assets Offsetting Derivative Assets [Abstract] Foreign income tax rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Schedule of Unrecognized Stock-Based Compensation Expense Schedule of Unrecognized Share-based Compensation Expense [Table Text Block] Disclosure as of the latest balance-sheet date presented of the total compensation cost related to outstanding, nonvested share-based compensation awards not yet recognized, net of estimated forfeitures, and the weighted average period over which those unrecognized costs are expected to be reported. 2006 Stock and Option Plan Stock and Option Plan 2006 [Member] The element describes the details pertaining to the 2006 Stock and Option Plan. Operating lease cost Operating Lease, Cost Maximum percentage of annual compensation contributed by the participant (percent) Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Total deferred taxes Deferred Income Tax Expense (Benefit) Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Number of shares authorized to be repurchased Stock Repurchase Program, Authorized Amount Hedging Designation [Domain] Hedging Designation [Domain] Federal statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Net Income Per Common Share Earnings Per Share, Policy [Policy Text Block] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Net income Net income Net income Net Income (Loss) Attributable to Parent Operating lease assets Total operating lease assets Operating Lease, Right-of-Use Asset Schedule of Cash Flow Hedging Instruments Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Net operating loss Deferred Tax Assets, Operating Loss Carryforwards Debt covenant, consolidated leverage ratio Debt Covenant, Consolidated Leverage Ratio Consolidated leverage ratio that must be maintained in order to be in compliance with debt covenants. Payroll and benefits Employee-related Liabilities, Current Income Statement Location [Axis] Income Statement Location [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Schedule of Offsetting Assets Offsetting Assets [Table Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Revenues: Revenue from Contract with Customer [Abstract] Additional paid-in capital Additional Paid in Capital, Common Stock Other assets Other Assets, Noncurrent Entity File Number Entity File Number Stock-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Deferred Tax Assets Deferred Tax Assets [Member] Deferred Tax Assets [Member] Credit Concentration Risk Credit Concentration Risk [Member] Less: tenant allowance Finance Lease, Liability ,Tenant Allowance Finance Lease, Liability ,Tenant Allowance Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Variable lease cost Variable Lease, Cost Buildings and improvements Building [Member] Restricted stock vested in period, total fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Granted ( in usd per share) Granted (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Total property and equipment, gross Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Maturities of available-for-sale debt securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale Restricted Cash and Cash Equivalents Items [Line Items] Restricted Cash and Cash Equivalents Items [Line Items] Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Axis] Exercise Price Range [Axis] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Stock Options Equity Option [Member] Credit Facility [Domain] Credit Facility [Domain] Schedule of Fair Value of Our Contingent Consideration Liabilities Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Assets Assets [Abstract] Land Land [Member] Finance leases Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Schedule of Components of Lease in Balance Sheets Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Other revenues Collaborative and Royalty [Member] Collaborative and Royalty [Member] Hedging Derivative Instruments and Hedging Activities Disclosure [Text Block] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Restrictions on Cash and Cash Equivalents [Table] Restrictions on Cash and Cash Equivalents [Table] Concentration risk percentage Concentration Risk, Percentage Intangible Assets and Goodwill Goodwill and Intangible Assets Disclosure [Text Block] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Issuances of common stock under benefit plans Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Total marketable debt securities Debt Securities, Available-for-sale [Abstract] Share Repurchase Program 2018 Share Repurchase Program 2018 [Member] Share Repurchase Program 2018 [Member] Other Other Sundry Liabilities, Current Gross Amounts Not Offset Derivative Liability, Not Offset, Policy Election Deduction Contingent consideration, measurement input (percent) Business Combination, Contingent Consideration, Liability, Measurement Input Operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Vesting percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Stock-based compensation expense related to inventories Share-based Payment Arrangement, Amount Capitalized CRSIPR A&R JDCA CRSIPR A&R JDCA [Member] CRISPR Amended and restated the Original CTX001 JDCA Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Other Other Countries Outside of the United States and the United Kingdom [Member] Other Countries Outside of the United States and the United Kingdom [Member] Amount of optional renewal terms Amount of Optional Renewal Terms Amount of Optional Renewal Terms Number of operating segments Number of Operating Segments McKesson Corporation McKesson Corporation [Member] McKesson Corporation [Member] 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three Defined contribution plan, cost Defined Contribution Plan, Cost Number of Shares Number of Units Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Tax credit carryforwards Deferred Tax Assets, Tax Credit Carryforwards Interest income Investment Income, Interest and Dividend Common stock withheld for employee tax obligations Share-based Payment Arrangement, Decrease for Tax Withholding Obligation Number of shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Operating cash flows from operating leases Operating Lease, Payments Australian dollar Australia, Dollars Common Stock, Preferred Stock and Equity Plans Common Stock, Preferred Stock and Equity Plans Disclosure [Text Block] Disclosures related to shares available for future issuance, descriptions of the stock and option plans, and the rights associated with each share. Right-of-use assets obtained in exchange for lease obligations Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract] Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract] Total finance lease assets Finance Lease, Right-of-Use Asset, after Accumulated Amortization Total financial assets Assets, Fair Value Disclosure Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Investment in collaborative partner, pursuant to convertible loan agreement Collaborative Arrangement, Investment in Collaborative Partner, Amount Collaborative Arrangement, Investment in Collaborative Partner, Amount Total liabilities and shareholders’ equity Liabilities and Equity Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Other Other Accrued Liabilities, Current Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Deferred tax benefit Effective Income Tax Rate Reconciliation, Inter-Entity Transfer Of Intellectual Property Rights, Amount Effective Income Tax Rate Reconciliation, Inter-Entity Transfer Of Intellectual Property Rights, Amount Tranche one Share-based Payment Arrangement, Tranche One [Member] Publicly Traded Companies Sale Publicly Traded Companies Sale [Member] Publicly Traded Companies Sale [Member] Lloyds Pharmacy Lloyds Pharmacy [Member] Lloyds Pharmacy 2026 Lessee, Operating Lease, Liability, to be Paid, Year Five Exercised ( in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted-average 
Grant-date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Legal Offset Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Audit Information [Abstract] Audit Information [Abstract] Concentration Risk [Line Items] Concentration Risk [Line Items] Derivative [Line Items] Derivative [Line Items] Options exercisable, weighted-average exercise price ( in usd per share) Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Research, development and commercial contract costs Accrued Research Development and Commercial Contract Costs This element represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for R&D and commercial of the entity. It is used to reflect the current portion of liabilities (due within one year or within the normal operating cycle, if longer). Earnings Per Share Earnings Per Share [Text Block] KALYDECO KALYDECO [Member] KALYDECO inventories, net Molecular Templates, Inc Molecular Templates, Inc [Member] Molecular Templates, Inc Minimum Minimum [Member] Potential awards, percent of target shares, minimum Share-Based Compensation By Share-Based Payment Award, Award Percentage Of Target, Minimum Share-Based Compensation By Share-Based Payment Award, Award Percentage Of Target, Minimum Inter-entity transfer of intellectual property rights Effective Income Tax Rate Reconciliation, Inter-Entity Transfer Of Intellectual Property Rights, Percent Effective Income Tax Rate Reconciliation, Inter-Entity Transfer Of Intellectual Property Rights, Percent Duration of purchase period Share-based Compensation Arrangement by Share-based Payment Award, Duration of Purchase Period Share-based Compensation Arrangement by Share-based Payment Award, Duration of Purchase Period 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two Effect of changes in exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] ORKAMBI ORKAMBI [Member] ORKAMBI [Member] Selling, general and administrative expenses Selling, General and Administrative Expense Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Finance leases Finance Lease, Right-of-Use Asset, after Accumulated Amortization [Abstract] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Payments to acquire businesses, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Tax related prepaid and receivables Tax Related Prepaid and Receivables Tax Related Prepaid and Receivables Foreign Currency Translation Adjustment Foreign Currency Forward Contract Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Schedule of Components of Provision for (Benefit From) Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Options exercisable (in shares) Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Stock-based Compensation Expense Share-based Payment Arrangement [Text Block] Cash paid for amounts included in the measurement of lease liabilities Cash Flow, Lessee [Abstract] Cash Flow, Lessee [Abstract] Level 3 Fair Value, Inputs, Level 3 [Member] Leases Lessee, Leases [Policy Text Block] Less: accumulated depreciation Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization Up-front payment Collaborative Arrangement Up-front License Fee The amount of the up-front license fee paid by the entity pursuant to a collaborative arrangement. 2023 Finance Lease And Operating Lease, Liability, Payment, Due Year Two Finance Lease And Operating Lease, Liability, Payment, Due Year Two Revenues by Product Revenue from External Customers by Products and Services [Table Text Block] Net foreign currency transaction loss Foreign Currency Transaction Gain (Loss), before Tax Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Performance-based RSUs Performance Shares [Member] Commitments and contingencies Commitments and Contingencies 2013 Stock and Option Plan Stock and Option Plan 2013 [Member] Stock and Option Plan 2013 [Member] Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Emerging Growth Company Entity Emerging Growth Company Class of Treasury Stock [Table] Class of Treasury Stock [Table] Restricted Stock Restricted stock units (including PSUs) Restricted Stock [Member] Auditor Name Auditor Name Cover [Abstract] Cover [Abstract] Gross Unrealized Gains Equity Securities, FV-NI, Unrealized Gain Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Total costs and expenses Costs and Expenses Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Amortized Cost Debt and Equity Securities, Cost Debt and Equity Securities, Cost Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Summary of Other Current Liabilities Other Current Liabilities [Table Text Block] Collaborative Arrangements by Agreement [Axis] Collaborative Arrangements by Agreement [Axis] Significant terms of collaboration arrangements, by individual agreement. Less: amount representing interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Share Repurchase Program 2019 Share Repurchase Program 2019 [Member] Share Repurchase Program [Member] Cash Cash Schedule of Additional Cash Flow Information Condensed Cash Flow Statement [Table Text Block] Financial Instrument [Axis] Financial Instrument [Axis] Unrecognized Tax Benefits [Table] Unrecognized Tax Benefits [Table] Unrecognized Tax Benefits Options outstanding, weighted-average remaining contractual life Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term Less: amount representing interest Finance Lease, Liability, Undiscounted Excess Amount Current taxes: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] San Diego Lease San Diego Lease [Member] San Diego Lease [Member] 2026 Finance Lease, Liability, to be Paid, Year Five Common Stock Common Stock [Member] Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Income from operations Operating Income (Loss) Total liabilities Offsetting Derivative Liabilities [Abstract] Other current liabilities Operating Lease, Liability, Current Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Nature of Business and Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Collaborative and Other Arrangements Collaborative Arrangement Disclosure [Text Block] Hedging Designation [Axis] Hedging Designation [Axis] Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Depreciation expense Depreciation Purchases of available-for-sale debt securities Payments to Acquire Debt Securities, Available-for-sale Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Notional amount of foreign currency forward contract Derivative, Notional Amount Deferred tax benefit Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Schedule of Stock and Stock Equity Plans Schedule of Stock and Stock Option, Equity Plans [Table Text Block] This schedule discloses the information pertaining to stock and stock option plans relating to the entity's equity. Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Other current liabilities Total Other Liabilities, Current 2022 Finance Lease And Operating Lease, Liability, Payment, Due Next Twelve Months Finance Lease And Operating Lease, Liability, Payment, Due Next Twelve Months Total liabilities Liabilities Collaborative arrangement, milestone payment Collaborative Arrangement, Milestone Payment Collaborative Arrangement, Milestone Payment Merck KGaA Merck KGaA [Member] Merck KGaA Granted ( in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Stock-based compensation expense Share-based Payment Arrangement, Expensed and Capitalized, Amount Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Corporate equity securities Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract] Measurement Input Type [Axis] Measurement Input Type [Axis] Mammoth Biosciences, Inc Mammoth Biosciences, Inc [Member] Mammoth Biosciences, Inc Operating loss carryforwards Operating Loss Carryforwards Common stock, shares issued (in shares) Common Stock, Shares, Issued Schedule of Sale of Equity Investments Debt Securities, Trading, and Equity Securities, FV-NI [Table Text Block] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Entity Address, City or Town Entity Address, City or Town Variable Interest Entities Consolidation, Variable Interest Entity, Policy [Policy Text Block] Eurodollar Eurodollar [Member] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Indefinite-Lived Intangible Assets by Major Class [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Unrealized gains (losses) on foreign currency forward contracts, net of tax of $(21.8), $14.3 and $7.0, respectively Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Balance Sheet Location [Axis] Balance Sheet Location [Axis] Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Derivative asset noncurrent, foreign currency forward contracts Derivative Asset, Noncurrent Deferred income taxes Increase (Decrease) in Other Deferred Liability Awards outstanding (in shares) Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Outstanding, Number Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Outstanding, Number Measurement Frequency [Domain] Measurement Frequency [Domain] Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] 2022 Finance Lease, Liability, to be Paid, Year One Deferred taxes: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] 2026 Finance Lease And Operating Lease, Liability, Payments, Due Year Five Finance Lease And Operating Lease, Liability, Payments, Due Year Five Retained earnings Accumulated deficit Retained Earnings (Accumulated Deficit) Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Number of shares (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Entity Filer Category Entity Filer Category Schedule of Weighted-Average Remaining Lease Terms and Discount Rates Schedule of Weighted-Average Remaining Lease Terms and Discount Rates Related to Leases [Table Text Block] Schedule of Weighted-Average Remaining Lease Terms and Discount Rates Related to Leases [Table Text Block] Unrealized (losses) gains on foreign currency forward contracts, tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent Risk-free interest rate (percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate U.S. Treasury securities US Treasury Securities [Member] Concentration Risk [Table] Concentration Risk [Table] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Schedule of Foreign Exchange Contracts Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block] Weighted-average Remaining Contractual Life Weighted Average, Remaining Contractual Life [Abstract] -- None. No documentation exists for this element. -- Schedule of Shares Issued Under Employee Stock Purchase Plan Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block] Total cash received from employees as a result of employee stock option exercises Proceeds from Stock Options Exercised 2023 Finance Lease, Liability, to be Paid, Year Two Schedule of Supplemental Cash Flow Information Lease, Supplemental Cash Flow Information [Table Text Block] Lease, Supplemental Cash Flow Information [Table Text Block] Derivative term Derivative, Term of Contract Total shareholders’ equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Amendment Flag Amendment Flag Proceeds from finance leases Proceeds From Finance Leases Proceeds From Finance Leases Equity Components [Axis] Equity Components [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Inventories Total Inventory, Net Granted (in shares) Stock options granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Federal Deferred Federal Income Tax Expense (Benefit) Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Expired ( in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Long-term contingent consideration Long-term contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Product and Service [Axis] Product and Service [Axis] Share-based Payment Arrangement, Additional Disclosure [Abstract] Share-based Payment Arrangement, Additional Disclosure [Abstract] Equity securities without readily determinable fair value, amount Equity Securities without Readily Determinable Fair Value, Amount Preferred stock, par value ( in usd per share) Preferred Stock, Par or Stated Value Per Share Entity Public Float Entity Public Float Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type [Domain] Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type [Domain] This element represents an individual share-based compensation award type. Repurchases of common stock (in shares) Repurchases of common stock (in shares) Stock Repurchased During Period, Shares Accrued expenses Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Statement [Line Items] Statement [Line Items] Statement [Line Items] $150.01–$200.00 Exercise Price Range from Dollars 150.01 to Dollars 200.00 [Member] Represents the range of exercise prices from $150.01 to $200.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. Weighted-average remaining lease term (in years) Weighted-Average Remaining Lease [Abstract] Weighted-Average Remaining Lease [Abstract] Domestic Tax Authority Domestic Tax Authority [Member] $100.01–$150.00 Exercise Price Range from Dollars 100.01 to Dollars 150.00 [Member] Represents the range of exercise prices from $100.01 to $150.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. Fair Value Debt Securities Total Debt Securities, Available-for-sale Accrued expenses Accrued Liabilities, Current [Abstract] Schedule of Stock-Based Compensation Expense by Type of Award Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Valuation allowance Valuation allowance Deferred Tax Assets, Valuation Allowance Customer [Axis] Customer [Axis] Document Annual Report Document Annual Report Schedule of Stock-Based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Vesting [Axis] Vesting [Axis] Total assets Assets Deferred tax liabilities: Components of Deferred Tax Liabilities [Abstract] Plan Name [Domain] Plan Name [Domain] Kymera Therapeutics Kymera Therapeutics [Member] Kymera Therapeutics [Member] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Geographical [Domain] Geographical [Domain] CRISPR CRISPR [Member] CRISPR Research and development expenses Research and Development Expense Derivative Contract [Domain] Derivative Contract [Domain] $36.28–$100.00 Exercise Price Range from Dollars 36.28 to Dollars 100.00 [Member] Represents the range of exercise prices from $36.28 to $100.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities [Member] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Present value of lease liabilities Finance Lease And Operating Lease, Liability Finance Lease And Operating Lease, Liability All Currencies [Domain] All Currencies [Domain] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Tax credit carryforwards Tax Credit Carryforward, Amount Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Furniture and equipment Furniture and equipment Furniture and Fixtures [Member] Basic (in shares) Basic weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in usd per share) Diluted net income per common share (in dollars per share) Earnings Per Share, Diluted U.S. tax on foreign earnings, net of credits Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent Effect of potentially dilutive securities: Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract] Innovation Square Lease Innovation Square Lease [Member] Innovation Square Lease Cash paid for income taxes Income Taxes Paid, Net Swiss Franc Switzerland, Francs Accounting Standards Update [Extensible List] Accounting Standards Update [Extensible Enumeration] Finance lease cost Lease, Cost [Abstract] Intangible assets Intangible Assets, Net (Excluding Goodwill) Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Contract liabilities Contract with Customer, Liability Other comprehensive income: Other Comprehensive Income (Loss), Net of Tax [Abstract] Other long-term liabilities Other Noncurrent Liabilities [Member] Derivative liability noncurrent, foreign currency forward contracts Derivative Liability, Noncurrent Right to license, number of clinical stage programs Collaborative Arrangement, Right to License, Number Of Clinical Stage Programs Collaborative Arrangement, Right To License, Number Of Clinical Stage Programs Corporate debt securities Corporate Debt Securities [Member] Accounts payable Accounts Payable, Current Gross Amounts Not Offset Derivative Asset, Not Offset, Policy Election Deduction Depreciation expense Depreciation, Depletion and Amortization Tax rate change Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Schedule of Financial Assets Subject to Fair Value Measurements (Excluding Vie Cash and Cash Equivalents, Which are Recorded as Restricted Cash and Cash Equivalents (Vie)) Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Total stock-based compensation included in costs and expenses, net of tax Share-based Payment Arrangement, Expense, after Tax Tax Carryforwards [Line Items] Tax Carryforwards [Line Items] -- None. No documentation exists for this element. -- CRISPR Therapeutics CRISPR Therapeutics AG [Member] CRISPR Therapeutics AG Accumulated Other Comprehensive Income (Loss) Total AOCI Attributable to Parent [Member] Inventories Increase (Decrease) in Inventories Allocation of net profits and net losses, percent Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Schedule of Company’s Net Unrealized Gains on Corporate Equity Securities Unrealized Gain (Loss) on Investments [Table Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Cost of sales Cost of Goods and Services Sold Entity Central Index Key Entity Central Index Key Eligible employee purchase price percentage of fair value Share-based Compensation Arrangement by Share-based Payment Award, Eligible Employee Purchase Price Percentage of Fair Value This element represents the percentage of the fair market value of the entity's common stock on the first day of the applicable offering period or last day of the applicable purchase period that eligible employees may purchase shares of the entity's common stock under the employee stock purchase plan. Antidilutive Securities Excluded from Computation of Earnings Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Net lease cost Lease, Cost Exercise price, high end of range ( in usd per share) Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Shareholders’ equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Decreases related to prior period tax positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions TRIKAFTA/KAFTRIO TRIKAFTA/KAFTRIO [Member] TRIKAFTA/KAFTRIO Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Other Other Countries Outside of the United States and Europe [Member] Other Countries Outside of the United States and Europe [Member] Other long-term liabilities Other Liabilities, Noncurrent Gross Amounts Offset Derivative Asset, Fair Value, Gross Liability Trading Symbol Trading Symbol Number of installments Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments Gross Amounts Presented Derivative Asset Other Deferred Tax Liabilities, Other Gross Amounts Offset Derivative Liability, Fair Value, Gross Asset Other current liabilities Other Current Liabilities [Member] Line of Credit Facility [Table] Line of Credit Facility [Table] Tranche three Share-based Payment Arrangement, Tranche Three [Member] Lease agreements number of buildings Lease Agreements Number of Buildings Represents number of buildings under lease agreements. Thereafter Finance Lease And Operating Lease, Liability, Payments, Due After Year Five Finance Lease And Operating Lease, Liability, Payments, Due After Year Five Stock-based compensation expense related to inventories Share-based Payment Arrangement, Expense Exercisable (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Other current liabilities Other Liabilities, Current [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Government-sponsored enterprise securities US Government-sponsored Enterprises Debt Securities [Member] Schedule of Components of Income Before Provision for (Benefit From) Income Taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Cash, cash equivalents and restricted cash—beginning of period Cash, cash equivalents and restricted cash—end of period Cash, cash equivalents and restricted cash per consolidated statement of cash flows Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Common stock, par value ( in usd per share) Common Stock, Par or Stated Value Per Share Current assets: Assets, Current [Abstract] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Other financing activities Proceeds from (Payments for) Other Financing Activities Cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercise Price Range [Domain] Exercise Price Range [Domain] Recurring basis Fair Value, Recurring [Member] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Statute of limitations expiration Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations On Foreign Currency Forward Contracts Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Schedule of Potential Gross Common Equivalent Shares Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Auditor Firm ID Auditor Firm ID Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Buildings and improvements Building and Building Improvements [Member] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Performance period Share-Based Compensation by Share-Based Payment Award, Performance Period Share-Based Compensation by Share-Based Payment Award, Performance Period Vested ( in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Gross Unrealized Losses Debt and Equity Securities, Unrealized Loss Debt and Equity Securities, Unrealized Loss Euro Euro Member Countries, Euro Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Operating cash flows from finance leases Finance Lease, Interest Payment on Liability Total product revenues outside of the United States Total long-lived assets outside of the United States Outside the United States [Member] Outside the United States [Member] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Total long-lived assets Long-Lived Assets Other Other Assets, Current Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Schedule of Offsetting Liabilities Offsetting Liabilities [Table Text Block] Gross Amounts Recognized Derivative Liability, Fair Value, Gross Liability Right to license, number of targets (up to) Collaborative Arrangement, Right To License, Number Of Targets Collaborative Arrangement, Right To License, Number Of Targets Schedule of Reconciliation of the Provision for (Benefit From) Income Taxes Income Tax Expense (Benefit) Continuing Operations, Income Tax Reconciliation [Table Text Block] This block of text may be used to disclose all or parts of the required information for reconciliation of income tax provisions. Options outstanding (in shares) Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding Cost of sales Cost of Sales [Member] Name of Property [Domain] Name of Property [Domain] Inventories Inventory, Policy [Policy Text Block] Debt covenant, minimum consolidated EBITDA Debt Covenant, interest Coverage Ratio Minimum consolidated EBITDA that must be maintained in order to be in compliance with debt covenants. Foreign Current Foreign Tax Expense (Benefit) Matures within one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Schedule of Assumptions Used to Estimate the Grant Date Fair Value Employee Stock Purchase Plan Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Offering period (in months) Share-based Compensation Arrangement by Share-based Payment Award, Offering Period Share-based Compensation Arrangement by Share-based Payment Award, Offering Period Aggregate Intrinsic Value Aggregate intrinsic value [Abstract] -- None. No documentation exists for this element. -- EX-101.PRE 15 vrtx-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 16 image_0a.jpg GRAPHIC begin 644 image_0a.jpg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end GRAPHIC 17 vrtx-20211231_g1.jpg GRAPHIC begin 644 vrtx-20211231_g1.jpg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end GRAPHIC 18 vrtx-20211231_g10.jpg GRAPHIC begin 644 vrtx-20211231_g10.jpg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end GRAPHIC 19 vrtx-20211231_g2.jpg GRAPHIC begin 644 vrtx-20211231_g2.jpg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end GRAPHIC 20 vrtx-20211231_g3.jpg GRAPHIC begin 644 vrtx-20211231_g3.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X0 Z17AI9@ 34T *@ @ U$0 $ M ! 0 %$1 0 ! 7$5$2 0 ! 7$0 #_VP!# (! 0(! M 0(" @(" @(" P4# P,# P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L, M# P,!PD.#PT,#@L,# S_VP!# 0(" @,# P8# P8," <(# P,# P,# P,# P, M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P 1" %4 M W\# 2( A$! Q$!_\0 'P 04! 0$! 0$ $" P0%!@<("0H+ M_\0 M1 @$# P($ P4%! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$( M(T*QP152T? D,V)R@@D*%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W M^/GZ_\0 'P$ P$! 0$! 0$! 0 $" P0%!@<("0H+_\0 M1$ @$" M! 0#! <%! 0 0)W $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 5 M8G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F M9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:W MN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! M (1 Q$ /P#]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH :1GF@+AJ.B ]#\*>$_#<6C7][,F>#-(7"9(YPB#&<9;K7V1_P2-_X+F+^V]X M[7X=_$#1]-\.^/+B%Y]+N=.9UL-9$:EI(EC=F:*94#/C7UH0]I):'Z/49S0>E<'\??C?IWP ^'UQKFH1R M7#*X@M;9#M:ZF;)5 >PP"2>NL_ M\%&OB1J&LM<6]QI.GV^[*VL=FKH!Z%GRQ]SD?A7TQ^R'^US#^T78W6GZA:PZ M?XBTU!+-%"3Y-S%D#S(P22,,0"I)QE>3GCNQ&5UZ,/:2M;RZ%RHRBKL] ^.? MQ4M_@M\*]8\231^=_9\0\J(G'G2LP2-?H689(Z#)[5^;?Q"^._BSXGZ[)J&K M:YJ$CNY>.&*9HX+?G($: X4#\_4D\U^A'[7?PVOOBM^S]KVCZ:K2:@4CN+>( M=9FBD5]@]V"D#W(K\RYH7M9FCD5HY(V*LK##*1U!'K7L\/TZ3C*3^*_X&^'2 MM?J?2?[$?[6^O:)\1]/\+^(-2NM6T;6I5M(&N9#++9SM@1[6.3L9L*5)P-P( MQ@@_=H&3FOS/_8Z^%VH?$WX]>'_LL,C6>BWD6I7TX!V0QQ.' )[%V4*!UYST M!(_3(# KSLZITX5_WI6;XG\.:?XR\/7VDZI9V^H:;J5N]K=VMQ&)(KB)U*NCJ>"K*2"#U! MKIP.)]AB(5K7Y6G;T9I1J>SFI]G<_D'KZ)_X),>&=:\5?\%'_@];Z$MQ]LMO M$EO>SF($E;6$F6YSCHIA20'V/?I7Z8_'?_@UV\!^.?'EQJ'@7XB:QX'TFZF, MITJZTL:M'; G)2&0S1.%';>7([DU]1_\$[?^"27PW_X)U07>H:"U]XB\9:I# M]FO/$&I!1,(20QA@C7Y88RRJ2/F9B!N8@*%_3\TXRP-7!2A2O*7?@#PS?Q+(UC9W\L5QMSM5I$& MPD?\ 89/+/VJ9YV(HRI3<)=!U%% M%=&%HNM6C37VFD:7A[Q]IGBCY;6Y4R8R8G^ M5Q^!Z_49%;BMYAKYG61E(:/*LIR".U=5X9^,&K: RQS2?;X5_AE/S#Z-U_/- M?B'#?CI0J2]CFT.1_P T;M?-/5?*Y]1C>%*D?>P\K^3W^_;\CVXG%&=8',:?ML%5C->3O;U6 MZ9\M7P]6C+DJQ:?F24445[!@&<5SOQ&^(NC_ N\+W&L:Y>QV-C; !I'R2S' MHJJ.68]@.:Z%AFOC/_@JAK]Y_:_A/3=TBZ?Y<]UM&=LDN57)[$JO3TWGUKHP M6']O75-[,NG'FE8ZN7_@J)X3&K^6OA_7WL]^//'E"0CU";OTW5[Y\,/BAHOQ M>\*V^M:#>+>64V5)^Z\3CJCKU5AZ'L01D$&ORAKZB_X)<:_>0?$WQ%I:^8VG MW&F"ZD&?E66.5%3CU*R/^5>YF63T:5!U*>C7XF]2BE&Z/N!NE-DD6->,_^ M$?U3XO>#8=461HI$BN_M$<#K]Y9)8PT:$=,,P.>.M>X>#O'.C_$3PQ9ZUH.J M:?K6CZA'YMM?6%REQ;W*=-R2(2K#@\@]J_D-K]+/^#:K]J_Q%X'_ &K+KX53 M7=Q=>$_&=A<7D5FSDQV5_!'YGGH"<+OB21' 'S$1DGY!7V^<<$K"X1XBC-MQ M5VG;5+>UMCUL5E*ITG-/5'OO_!RU^Q!XF^*>A>%OB]X9T^[UB'PG92Z7K]M; M1-++:VF\S1W05_=[YS7'D?&,L#AEAIPYE'9IV^3,\'FS MHT^22O;8_/O_ (-K/V&/$WP;\(^*?BQXLTRZT9O&5M#IV@VMU$8[B2R5O-DN M2IY6.1_+"9P6$1;!5D)_5+;\])&NP;<4H^[7R^99A/&XF6)J*SET[);(\W$5 MY5:CJ2ZCJ**"P KC,2.@MNKCOBS\>/"/P0T!M2\5:]I^BV?.PW$HWS$H+LN#U4UZ M&#RG$XI_NH.W?9?>?'\1<>9+DD+XZLE+I%:R?R7YNR/OCQ'XITWP?H]Q?ZIJ M%GI]C:KOFGN9EBCB'JS,0 /J:\V^#/[:WP^^/GQ(U3POX5UK^U=0TJW%S)(D M3+!*N_8WEN0-^TE-?CWJOVSQ=XAU#6I%8M'#*^RW MA)X^2%<1K_P%1GOFN\_X)S_$:3X7_MC>"[II'6WU.[.E3J#@2BX4QH#])&C; MZJ*^FEPG[+"RJ5)7DDVDMM/S/Q:CX^O&YU0P>#HJ-&4U&4I/WFF[726BM?;4 M_:RBFQMNC4^HIU?$G],K74**** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH C^Z*\__:"&- L_^OC/_CK5Z$SX%<7\<]--[X.:1>MM*LGXQ4*>_*W\EJ_P1Z64R4<93;[_F>,T445_!)^O#6]OTK<\,_$+5/## M6]PS1#_EE)\R?@.WX8K%)P*;\U>EEV;8S 5%5PE24&NJ;7Y=/(YL1A:=:/+5 MBFO,]>\,?'2QU$K'J$;64O3=G=&?QZC\1^-=M9:E#J$*RPR)+&W1D8,#^-?- MC$]JNZ)XCOO#L_F65Q);MG) /RM]5Z'\:_;N&?'+&8>U'-H*J_P U^)]&IRIKS#]J#]G&S_:/\$1V,EP+/5=/;$/YJ?Z'\*] T7Q'9^(K19K.X6: M/N5/W3Z$=0?8U_0?#7'&59K:I@*JYM^5Z-?)[_(^1Q66XG"O]Y&R[[K[S\_9 M_P#@GA\3H=<^RKI>GR0;L?;%OXO)Z]<$B3W^YFOK3]D[]ERU_9P\+7"S31ZA MKFJ%6O+E%*HH7.V*//.T$DY."Q.2!@ >O!,TX'FOM\5FE>O#DG9+RZG'*K*2 MLQ":^//^"SO_ 3[U#]O_P#99CTOPVUNGC3PG>'5]&29Q&EZ?+9);4N>$\Q2 M"K' WQH"54L1]A9RM(QP?[M<^#Q53#UHUZ7Q1=T%&HZN0R^2;&XTJ99F8MM&U=OS!CT*Y#=B:_6?_@WS_P""5_C+ MX)>/+SXS?$C1;OPW=2:>]AX>TB^C\N] EQYMU+&?FA^53&B, Q$CD@ *6_6G M[,DOW@I_"G[-HKZK-.,L1C,,\.H*/-HW>]UY::7/2Q&;5*M/V=K7W'TA.*0/ MDT2RK&FYBH7WKX\\EM)78TMQ36D5!R0!ZGBOFO\ :1_X*A_#7X!7%SIL-U-X MH\06Y*/9:: Z0N.TDQ_=KSP0"S ]5KX2_:"_X*E_%#XW?:+33[[_ (0_19"= MMKI;E;AE]'N#\Q('!*; >ZU[V7\.XO%>\ERQ[O3[EN?EO%/BYD&2WINI[2HO MLQL[/LWLO,_2?]H#]MOX=_LVVTD?B'7[?^TE77 6XOG'J 1Y4>?3YR.H85\9W,\ES.\ MDS-))(Q9W8[F8GDDGN33]5]Z7GM]W^9_-7%GCEGF:7I8-^ MPIOI%^\UYO\ RL:7B_QKK'Q UV;5-K;\V-SFNT_9SE9?VAO +* MS*R^(]/*E3@@BYCY%<8HRU>O?L%> IOB-^V!X"L8XRRP:I'J$A'15MLSDG_O MV!SU) [USX^2AAYS>R3_ "/8X6P\Z^;8>E3^*4XI>MT?MO:?\>B?[HJ5_NTD M2;(U']T8H8\&OQ26K/\ 3.G&T4F.HHHJ2PHHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** $' JAK6EIK&F7%O)_J[B-HV^A&*O$\K1V^]7-B:$*U*5&HKQ MDFFNZ>C*C)Q?,CYLU73)M'U":UN%VS0N5;WQW^AZU6#[A_M5ZU\8OAY)K=O_ M &E9Q[KJ%?WJ*.95'I_M#]1] *\GK^$N.N$\1D>93HU$_9N[C+HUTU[K:Q^K M93F4,504E\75=G_DP%%%%?$GL!1110 G\'X5=T#Q'=>';];BUD:*1>H_A<>C M#N*H@[:<:ZL'CJV%JQK4).,XNZ:=FGW31C5HPJ1<)JZ9[QX$\;P^-=)\Z/Y+ MB/"S1D\JW^!['_"N@0[J^?? WBF3PGXCAN@S>2QVRK_>4]?Q'4?2O?H;A;B% M65LJP!!'H:_M3PSXT_M[+[5[>UIV4O.^SMY]3\OSS*_J=;W?AEJO+NOD9OCC MQ=9^ O"6HZUJ$ACLM+@>XF(&6VJ,X [D] .Y(K\_/BK^W5X^^(>O32:?JUQX M?TW>1;VEDPC9%SQND W,V,9.0/0"OMG]J3P;?>/_ ( ^*-)TU6EOKBS+PQJ, MM*R,LFP>[;<#W(K\OR,&OW#(*>K/JC]DS]N[Q!)X\T_P M[XPO/[6T_5IEM8+UT59K25CA-Q 9"Q );D9SG P?MSJ*_*/X*^"[[X@_%7P M_I.GK(UQ=7L7S)UA16#/)GL%4%L^U?JT@PE8>E3JKV2M=:HG$12EH1W$X M@C9V*JB#)S7Y@_\ !1;_ (*77WQ*UK4/!/@+4IK'PW:L]MJ.I6S[9-48'#)& MXY6'@C(.9.?X#A_H+_@KA^U--\&?@U#X3T>X:'6_&@DA>1#\UM:+@3-[%]P0 M>S.005%?E.C;2*^@X7R6,X_6JRO_ "K]3^5?'#Q(K8>H\ARV;B[)SDG9Z[13 MZ:;C0,FE88- ;%(3FOT _DN4G)\T@HHHH)"@'!HHSB@ -?H3_P $3_V>IH[C M7?B1J%NZQS1_V5I+L/\ 6#<&N) /3AD;!"+W//"AB/VB^&7P]TGX5>!=+\.Z':K8Z7I,"V M\$2]E'222>37QO%.:1A2^JTW[TM_)?\ !/Z0\". ZV)QRSS%1M3I MWY+_ &I;77DN_>QTU%%%?G)_9 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4&BB@"(K^5<'X]^#T7B"22\T_;;W3&QT%*/3NGW3Z,ZL+C*N'J>TI.S_/U/G/7/#UYX>N?*O+>2 MW;L2/E;Z'H?PJGCBOI"]TZ'4[=H;B&.:-ARK@,#^!KB?%'P)LK_=)I\C6DG7 M8?F0_P!1^OTK^;^)O W&8>];*9*I'^5V3^3V?X'VN!XJI3M'$KE?=:K_ ('X MGD?S4[&16QXC\ ZIX6+-=6[-$/\ EJGS)^?;\<5B_>:OQ+,,IQ>!J.CBJ<=?6Z:@NYS9*\"%W62PB2LT-:PZ4C-DF'-B.G3F49?%9/GBF[06_*:=^H M:W%;.M>B_K45N'<"W'H^=#\N2IN[$I2EEDDBLLL%Y8D8D)[X'#A:6CQE6)UQ M58%>@5[/4N[#S6=SU^62-R1:8ADX E$GXD)0Q#$%@L7,0EI=PNX*]$<'].H< MLVKGF,U=L"IX;1EQPG,"SF;BO91$,2U42B9RM;XJ^'>./2M@IX!51G/MA&7) M<) R&)$M*,U92DE;E6[/DZ0"]WH>(PA<+82E.1(=-"4 )=&@Y99$D0.XK#T4 M86OH6@*W2MI6 ;?:SO?D6X$Z=?("* !V?C**TYL2HS0$%EVDIMHJDY=D7[K M2*_&\^TZ(FSNZ@ QJ\"(2 (%>HG?\TQFXK*B3*00J*K'9!7IUT9ZM9Y7?CN/ M6GCT,8!0):@-0#@8HAA$A/GQ M:B[A%_6E6F?N@LB,L%[3:-'^%-*YE)21(CJOC9&Y7L*W@L.V/O\V9V(@?X7@ M*:#B$32:&-(1GPRRF:1!"$I!>/_DF6U77MV[/ *LR%T9"NJ@$ MR9 3*5>MI"PK"0SM19F3TC$]O)0:#QO)+0!R/2E8&5;#['@/LK. NK5@U!%( M$25OIJSDH\BX0D%):U'+IANVRMX'BUBKT)R*%IA3 %ESHSR/FMEHK*94RGK1 MWAKD?CQ#K@#/A6:10"@)8TQ@Q-&B0IN@=++4)IZ?/,,UVQ 5NA6Z=V,@5SPO M>][U97KF]7E7<*9L%I)(D Q%L13$^U('71A7DD1EFFU1FQ]@*JB'#>=EK.#[ MQG.U@F^(YY,S/#.=LC&.DQ04XADT)R8X2Y05@MIHL_:AX/GK\^MJ!K<5RBU M2DLPCX7XRVWI2W@[R^S-^4 M,U#6!O"$!IH(:".(53F0:%#R**^L2Q2Y2_(-TR)WG^J@MY;0K5?E=XSSV54Y M54$"UQIMB1(4QT(@)EE!F/;>!V\"XC48I'8-IZQ/)$S=9K*'QK4/IBD&5.,I4T54XZ4#D[[ED$EU42$>@4 MLO6NO W0G=V5VQ*66F[5A%>H.7L>BL 51(/&-*W/RNO$K;QP[= M:B'?]4G8[ Z=2Z<]4$-29K)DI%7$FR1)4-%:"8%&Y:N)7*%>X]+7%.JSZW49 M9>!@)/$I!X)FDR0N@< ?CJM,4W1L=8$C%>J/#NK5AEX=:F?W[$X#0E5DPI+4 M!'A)N.J#(-(I:CPW-MO8/DU\1:'IS;.Y7/3"_1YPMS,8NWYGWPT_IG'!PI6! MYM?P]OTQ#@F,K'@.=T:#?BYW3$3UHBC(N&@%&@902+./>F<"3C5EYRARE M]5:]'51U/'^K3B''H)@A7@(C8$4@+B)3T>@AJ. LM^S),[!V0Z[((VAA@*S# M66 %_=V OIXVW#%#S.[C)2H8KJ@Q@7-%0 A%K$6#)#)&!\!!=\<@B5H)& M/=\+8H*-A"8EP5.79@TKBPVJH*^@KS'Z;6&".?\"9<&IG"6AEA4?P!") M<4H3F12SF8'!]5QEC'XE@M83P3+F_GTS037W;\@$,_>#Z+@344GB#.K_(#0O MG@>),]RAJGNOZH$>;>.]IHT8/$\^^G_CGKCXUKN?N& IJ2X]3DE114HJQQ# M\-@@)0V*"K=P[L^M9MYG)/;+I^U>.S1D)"T;?2X,I@DD?.6# M -PS.2GIK4$YU!35O+'U4MTE6XM0[YRDF3-JC8$8N+66>6_ W2H)US,G!.:9\YP35"!22Q2)SSBE GE(JX@!E4<9C4-Z^# M45';WI.#.X9M.2BHL%T:MC-W ,= 1(UB%B'JBMT0B=%,$*EU9$Q+)Q(\>28O MN3&H@?UMQ6M+]."*RZ5Q.;O 9PJBIR")9M$0L+2XZ2A.C,1W6 *=6 GB%RM( M>%^#^%L+3T 8^DAY<%*!]V!=4DJH8+00!D7KHF=PU4Q=&41GU^TT1&YTT,2: M& FNM<-7X%#M5=:6*_?@T4R5K)JI#QBA4@//1AG'M($0(ZJXCD8MN7(Z,\L: M?9>>ZKO7A&HU4V]ZMC2[&0_%+PX9E2!X+0$A%3$B2@),>H;*+JZ013L5H,*V MPG95L)V8J36T955PGEUO<_P?%2H1"XAIB$812YTF6KN414:\0JC1]0\?T+>I M*5>$+H_0V)%XZ_'$\L1+YV_1I? ^ M6EXTH\*[(AAB--=$:12=S<&NR,6@,EIEM-8QVE*E%^Z$TJK[Q;4H M;:ZN0E'%>*2$ Z<$0%!B+7=$!AE.CQYIAY3=$;ELL? 92VALE]<;_B7 MZQ^ERF)+L]C,644+Z2D(3I@H@> MNS,>JT=F-[T$F+D[&16#B<817!E.P-E,C(V9N!QR-I$GSNG$W>G&MZ^5TBJE MM8[2ECDSNQM.JV=FU^.TF<^7]8$:G2V14AH"21GBDU-$07*.9N6,N7$QTDIF ME MI_6NV*SQFOM7XT=VFGKDRL0J]D(:%696GT:%T>_ABA=TE])XU''C3D:D=#X5 MJ'3-WG[Y\^].-[[R= -264AGZDWY/3! MDW?91L-+%S;@Y#TP&UR**]]&^7SE>]]JEHL-,'"M9K_]2*[-[716+M3L=SQ. MO^L!;K_ZZ+*2_)LYD"[;B;>+57VI#'R10MKW:3AA0,&>7I+IZ*93.:>(+<&8 M7T_1W>@."TY?.9F.^A"4P]K9NFYF5T=E!_0+/W0.^A@LWU4 M7T8_+C-=JTWT=L?ZQ21/FQOM=5"1[H3RHN1J0YT 5VAQ#_M%0WCNSE);<.B+ MFVJ7#?&>K+$%Q[:$.2:H]XKZF",XH)FYDDZ36VXL]6BDJ=47SY@/-CPXVB=Q M,";3EA^(V7;8V_X;/[__DKW[]1V::1_I]HN7Q_B\X^Z+ -T/;TZP+?GV[[?' MV\<7S+;RG0][V/Y?']_M=X^QK[3[X;\XMI>?T50[WM[9[G5W^GOO/KP4_YR< M.J"BV;:YRX/0(3I'A%.4@#1 O*:"&(5[ DR,7M(GS\13T.8A)KJJ!/5 "2J M+C=$@0:M@2EC39*9#:B)R(#MD1<,83FQTE MQFKA7$"2TKP0% /6*H):4<#ES;/]WA-6N]^,P%P^B^\ETW/?0=^K9ZU:DZS5 MQ/3'O.9T]R7)6G0_5R%;RPJL"V1GNL3=%Q5XP'4#&+\WW:+)\7"Y+O&]25D7 MQX';LO9:[SFP>H9>54[8:@K>/7V_.:=Q^> XYXP(PS1J7%D00UD@SFLOA:0V M^U!,0:M7EY2]-0Y3-SS(JKSWZ'AO52G$*N_="^_-U%8KK"DGF<0Z1@G8;(EE M,1,!//ID3&(E3X1XJM@* GGNBONE@U"L?^&F8^OC)3VGJZS.%S-RWILHLG7W%>1S;T?CJKRS@Q-06OZ]? M"!<7U.*YGWO#V87]^T3\,+F/Q&7L_T^N_]D=CY[\Z_S <=33YFUY_BU,T+/_ MYX?XT!OXC]W]U'_E#=!,_5];KW>V_NG\_I_-U]W-YUMO=EX^W_SMS\[+[>>O M7O_^ZO7FSM:+AS#,[<$8&QL/.L_G'05_Z1VX@]!S_0GYRQ?>,$\I[K5%, M:I#26."9JFQ,U"XRRQ>"POTSPP(>H?ZX41^*V#AJ,BB.RSO'$T_1ZNU9O3VK MMV?U]JS>GM7;LWI[/BYOSV[1!$K(2&^\A[,P.$B=X^2&U=?SD;A2W7>B M;^)O?S?[[-5!>HN[;"XV[^&?+@U.WG[X-W[GWR M^__9>]>E-I.D6_A6%.PWWIB.<#%U/G3O(((VV$-_(V%CV6[XXZ@C"$N(+8G& MO//ULW"O48+?G>V MU]F!M]C] <_7WM[XE38FLCE<"0QGP1R MP1'$I>?(BL!1,M:;$(F46:./OUU/IG^).2/[ID5&T]3QA 7G,X4^]@HC+ZO3Q%A4="N"L)IEY1 MBUT*R-(("*<"1D8DB0PG0;'$E%9D94TN3NFJY)"[VO MYI\2SH0&EU,*GA GD2,M'$; T;3RQ!O&=4H4Q M\E0*Q"DWR%!"$0\L!86#9YR\E/S36_--ES:UZVNL'=A_8LW6VJU.*Z?CP=)W M.8Z6:O;7:5^M(_A?'\:GE6"LC@:U=K??KUVDQ_9SYA=JG@M&U+=/ CP7?/:T!;_*GW:Q MULO"0;TX_HJ+\)3YY[X+4W>6[SLX@!?K=&$>SV/>J/J#G(C6JW[>.OHG]@?# M9$,[N$Q86ZW!B 18+?-0-"5Q@"5M 2TX]\$9+AW71FNL'-/^VP8 E<$$$Y3_ MWP?8=[X< MV:_F9/L0OO,5H.;PH%5O[O*]C8_G>_GSG<;AWONZV.UL,7A^7'^_>?KWN48I'LWHS5VHS.A]9]1S9K5D"B68"2#+F"$7B$,.FL% M3I1@L$H>/ 4&09S3W%'81&!ZJQDE%S-ZPY\J,WK?&8U8&VN91+#A2YA1:Y . M(8*U8IFD,$H*M[)VU+W! '[]@T$%^KT N\99S1_ 5AN'.-\%H <6<&"/T"!V MCKL]"_L"3&K>!JN]*V\$$ZJTL^UY<&$@';#-76C8U_8M;(+YYWGW&UYYN,ME M<,@_S["_6ILW]WDIV,%H:&%8C_9O&[2L_3NYG\*'X$MYO >Q$O@;G$T.(.S8 M__M_-*7XC^T\0?!QW^W$-[6C.*A^3O[(5[@A*-P?5P?D>Q['7L6S^JL7>_6H M]&"#B&Y*NI8S_A(DJ(X$*V-,MQ:"IX"-5C =II8L I< MN0B8>0PS,>B=Q)6U#5A 1_O5^AL<].+H5+<&O!%6QQ2.F5<0K"G8%JY;ZL_7 MYT%LA\P)\XV&_+.?=Q=8=-$":86%U^J&*94-UPO0[E7I,+6>Y)'8/:V:;L,75(#RO-.\9RPP66$GP[,8'E_'YV?@0 ML]!B"B)*-<6+JJ9H3*$SI93BE>0DWS.&.S4LY]1#;[[\<-IJ>-K[N M'-2;F[C1V3K;;GX^WZ5[W^MTIU/OP,_I9W)#=>/P.]_[6B>-\UVR]W[S1[WY MD>X>;HE&$QRA#CA%[W?/X.?G>\W/[._SKY!8"6Z=T>+RQ> .C! 6A\[$J\,#ZG" K,*KFSA!R/ M"F$FL=8"]A*=6]VRY:IO* A4$.@!CUH+ CTT C7&%"CZR/+\((XYR6=X"EGC M"4HN)(MA XE4Y6;;;*D0Z&IFQXV\$XBY8!*3;(\9XDB$FADVZ?H;P+([=)@XZ M?G;$@:LTF8QS;W)V3+_;#J,SBTZGFQ\:ED8^M3@^<>V6;Y_5!K!ZJD28#KP4 MK*MQ&DXOUHY[ )(]>)E:/O7LWSS7RX=R;W>V/GW8>5/KQ?Y)>Y ?\N) L#H% MR<97%)Z*PM/4RTXA=A?3"& :Y__D*SYF*&'T><+HR[CXBL[1RXK,?^AUX8E# MS@KRL?5/#"4L_TI\4DVPM)19ZF+DVC.3DS-2SE_4WAK#YHZ*72RE=[UN)Y;:=Q9ZP7U]6ER^M?@?EWML[W.E\ZN\TZKI^OD^WWX'V^K\.S[O[8 M:VZ>@6= ZS>\U/T?X#ET=@\;G;VO>P?U\X_G]8W/?/<N-__Z MWMC8/;\6J/<,<\5T0C$P@S@U&ED:)$HXJB"5E!2?9BY8Z>PJ2_5O^( 5EX)+L?JR*EFK/] MUNQI';,*F3QCK)[VBB\&JXD5/A-%'VW@,N7VCRD1)1G!!O":S5KINEDE,H\1 M^-T_C=9;6$X%B>="XOK5IE$T$I@:((9, Q)KCYR7 E&KA.81:V;\RAK![/[B MELLGHU00YX4BC@,W1R8E!9.8&VU<<%88F4_KA--29<29A106Q%D4XHRY'Q9* M4Y@.Y!F+B%O*D,58(Q9@+Q#:21^ 'M'E$GEZ,.[W\Q9/S_ L[_9JI=/YZ\Z% M#%$)K!UGW#CI"(["$AV5T@(S-W]-ZQV\O%+M>OUL&C<.OW^3BFN%!4:*1HNX M3"\*1UXI+K@%TT!(S5.L&M M(03/JN5U?=_].AR&G>$H;$P,PJ7NXGH'H'_PLD5N[F&S\"S?OR4))BM-0-@+ M(/M [I$)BB&NJ=61.IR,65G38LK6>W'J=AOSV7H;Y MG:H5;F,BQ!O#%8]@@EDG1"7) C;*.8[3-U+5U)8.B ]Y/(A'?8#YK4I"(Z^NY4D* M_7RQB8O&U\WL,I/=\WV27>!Z^NZU!(P/L4L?4D0[KN_4GG MI%V9[I Z7IF+VG R:O_*V>2__5P68JK*PR^?YZ&7UB=_$,-).VZGB5>MWG3* MHLMON602*(^_\NK[WQ(FFG)O$?AW"E:>,T@;I5'$G"7A@W?&/\MLY.9D>F]M ME)][TLG)PN=Y,\L.VU@=R$X81Z6_5+FI8^-HC8PC2R7]-FP;VSGN'N5W?%:9 MP\#C5O&0R\V=.BQ7!3&+%^@@JYK+A:<.XU4SH^Q'>=AE>%B]JM5L>>F+SY]> MQ$=GZN6[A+FOXTJRVG^Z[?S@M?>5VE3% V+_MS>UK-[03;6F_;'8].VI'WVM MV?'ONCWXYU'M[4FO%X_\6:W9@ZNUA_QJ/1R>#(.'CYM _X)RO+=A%"]%$F&P M43XHJ&4Q[=HX(EF:+3_0T-]8W?"#4]L+.: PR-'(68;^U5:&7&V]L@B4I*34 M<3Q 'NP%,,P9^CLYZI"N9$WZU_STO.F'E^^=3_FJ?(0PO*.),X,,9Q M"DYX)Y(1T7EA)?=5RHR>=G27U?'A;S=B+/E4]P"(8NSUA^=Y2W3^=K< RD76 MS/;&3FOO<.NTWMF"^WG^[U6?>/S>;[&WHTF$_N\\?ZO M3OUP_6SW$-[M_"/=:WYIU<_??6_ L^YUMDX;S4:K3M]UKN7I$8&M<\RA:'1" M7&N"3/ ,P50Q(6BR,F:U$S)%:N"WY4F6+O4;!6]&>",9,R0 T$1KN+'2.J&M MI\IFU:64>,&;)\";<9:>-MY@J2BB,;>R2<(":*"3BV74RC&+D2%22\BP8&3*?44N$- LJ#JWN M3>D4]+B2V61N'@H_J2:.NP4!:,01)N(YRZ7W_:M/ZM9V+D^"8TXV$Y-^V-],.BUW$F5 M?]#L?K"]>+1,=5// <$^3D: :#0Q*$I18(GGQ"\ +THMLM)IIKUQTIM#RX+#((\%NXH,(Q0CRWB<3 7%2D&/*2&O)$ :2+7BAFD9:8(@[3 MAJRS 26N&4[@FD:2O9[[]PHN=KR\=JRT]X(XJF6(/%IBB0[,.Z85Q=1I4>QX M.>UX(GK!D]=*&XN:7!@6.W; MGP@!Q%!+O6YGOO3\.P4,9@W0/FM86WC X#J:906&]:YO#?/\!A^JGK,_1[A? M*#$4Y)L%^3Y/QA04]HD1GI 0)"#NJ4)& L(!X M2 &$I0"$R; (E2KJD)!33B.>E$+&8X488P#^DL= P\H:G5+#L7QX4&1&*ID1 M9D?M!V_.OG)O]_5\0I NL:<9L'-$.(.HRYZF MRE%H&Q12#DNMJ'8ZJ>EB)W?+B2D 5@!LF5Y\KE!;KJ(WTAF3,-'LHF@F:/@#'O KERY@#BF'!F1&,J-%6B4FD5:1=)EH6$%Q5XO MBFEFJ.7,:6TI9S@:S+!2694%"RR5*"CV^"@V$>FC3#J<:$3 C 7BQ$ODM!6( MFL!C#)X'27*D[SZ1_\="L:+BR9&'TDDR M&82P@G(=G76)"2D%HY%PX:I\"(HOVB+A>8X\2D7JP^/?]\E@FK&*,NX""B&: M?/Z)D68L(..HM=P&&@RICCX7>]3Q"Z-YGF>?KP\)-%7*>BJ3QH%['TP@27-J M,OT70J:"!,N.!!.E'8*EH 1'2F:U;P %!%-)$2;2T6ATX)D)X7O)?A<@>*% M8)GQP*.E"#AQIKD6B4C-+8U@]@+3 @1+#@03@1V:3#2&.?"!4D!<<(VT]PI% MZJ0CS <<]J"2E(\$*10"@@D5IJ2Y3F/DOL&XMA7Z'2JD1,<0Z6'0DF M@B,V&DQ"5. -Y.HPJBBRC.4T*&J=A"DD4:VL23-%-7L)D:#HV!0=FP?5V;MW M5*0(6RPC)&Z>5G!8P>+ZM\1XD(%YY(+QB ,$(JN3R06T'L.\>\]<4;9X!?:^ M@-A'L?=EM??ZI;U;;:F4)J& @?YPYPPRQCGD&!91Y\PJ3(J]OP)[?[@01U' M>'P#]Y<&CEUPFB2,1#(.<=C,D=%*(<*54<[$W&,EGP#?3"T=*\&2]),'JN&S&731N9M"XR<&((FVS M=/D;I63U,:'NQV1@@A+LF07WQ$5B$$\D@H_".?+186P9(\S[!\CD*$7L+P 1 M'C"/HR#"(R/".'1!.*?$BTK7#\@/,X -,'THD4"ECC(!YUU\1DKV2F(\"(1X0'S M.@HB/#(BC.,C,BE.2'+(<)KC(](C+9-%!$L79,3&$KVR)N6"<[V6I/[E12K= M4%R4;DIQXFR@+CU.(L%U6*2<*5N56%L1N8_"61QS<>)<6%Z*$^\+SV>3,9U( M##5)6$03L8AK[9%-RB-BL++1V!2KZAQ1BJP+CKTT')LGH.VX_B3H$K$P 4*PDIP-QU'VGF&+&7,F.BT]33' MG^XMNUX0K"#8$B+87 $WHZ)-W 6.!1<.P"LFQJ6+SHE@J"U,["FP;!PZLS+2 MH!)&RC,-6&8!QKS6""8H9JD;81U@F6#W"J87'"LX]LQQ3$F2='+:<$LX]]0J M@36G 5,:HA*NX-A3X-A$P$_[Z+%("-!,(,Z80$YKH&C2R*@M5R3&E36I%]'P M:_D"?B]>\.9*K591OEFTGQE-R$<@5&O"4_(:T [ 39 0@B*"5V<@Y.(,A,S0 M"*B4M#X" )Y/AM08L]8$0I A/GVJT5? _280U/G R PJ4"O>GA8-QC,I1@ST& D0MH0 ' MAB+#N$=,*H6%D)AZG&-4^CE4N!%0Z$ (UN0-8)#1P)IT!XW=$4L$YY9[+ M0@>6U?XG4J(T>#R**^023PB0 Z8 QQ3G-'8;AL, 4%EA4%QE$1EWP"?X CD2Q!7#&!M#&Y87 B MTCL36006(*?UE%E6%"AJ-T7MYCF%0HKZQ9( (YZ,EEBK!:%*("]XSAB7'CE" M !VEH ",@; 8BOK%:[#W^P<]BKTOJ[V/PR$\86T3!2OW42/P8S5RL 81(8P0 MSDP,V!9[?P7VOH#81A'$6!H#'\<[3'+&LZB03X'"A@Y6[H)DB%LE(H9UK7(> M"V4+ZT!7K'L)K7L!,8MBW4MCW>,XAN(X2:UR)S9L$4_6(2.I19XJIH,.SF&_ M=-9=]&YFT+NY?UCB5U5X+QSR%I^[4<,DXA[<%$V! MQ0AEA7=:A2C5 R5Q_,1HGN>!S?-'@25)WBAX\,AX,!&V$%X[(A**+F'$7>3( M MRCW#8X$Q^5HEE\%D>!@J6#@B?-WB@ \,@ , YK<-CP+14.B>A=CEN2K,J/ M$>8I2YDIH0@ @)Y6GE,8P:N&@<6G;Q08>&08&,<_F,4R)AX1"_ '#Y@B&RU# MS N;>Y@QD^,?FD]I6+2,,% $;2I!&W(O09OAVTU+LRGUB0L;H.7>#N9Q$+$1 MCCAF&>&$!X%M-$()IPCG4AFEJP+&>?S"4L!X7XBG5_HO18FQ=!PQJH#I.6Z1 MHS2B2+0V@D)#@(,2Z0I Z=8A!2%HIIIEZ-BBROU+DA9 MD/*U(.4\AP[$,PXL4KND.9'$LB MB9&:Y, KY;<#9<''A>/C.&A(68PZ,8J, M41%QR1VRF#H4N4S8D)B8H& M7&^GJ4^,J8*2CXB2XYBJ%I+:H#7B"B= 2261X=(A%[WVE"8N=*@T:!?50^WI M4;**N_Z["LM?!AV'K]8XZ8 =^.&_\^IM'9U4>8Y5\/3BU3JVM]\ZNG@#&*QZY-=+PH))D 1OE',?I M&U%Z9?);MS[/:)101M+J]E>3Y"8>Z!%#P30#QOO5BY=__+M?'1:UJE@U#%>F M?@&G1U?A:@.N^@^LH7Q.U!_TX"Y'@_[Z4?A/##!I^^M@2O^T!JW8WVCU?;O; M/^G%)MS_SS:@W)/#V?X%G)W7S__;@(,-5J-PSI MUSJ&>^/=3P;O_7V ?>?+D?UJ3K8/Z^?;&YMTM[/% 8+:]?.=@\;7G8-=>-9= MND7ANKR^\5$T#G<._C[_>-8X_/P-]@A!:%3(L Q)(C'D!([(:>?!K77:$#G< M7, \8UC/-4)"&N^<(LQ(L!U&7'1&4&#E/.(8 EVI1=@DCF%B8 Z ]HV&_Z;A M3UKF-1 8SL:O[W3UR6@,)D3#<_H!E[!P@M%)F82UHG !L?)S6WXX.ZVN^'MK M +CE?[[55Y;[KMN#?QZ-LEG]6:[/.K6]4+UNWA+Z-53;B#GV4U7?VG[M8#C( MM=9XY=^$OI^#ZDT(?42*4[WWUUCKV-;1 /Y?LY>O=-SK[O=L!UYM$.$10VW0 MK77 CO?AW6N#@UB#K2[Z03[O\@?V:!^>![Z?1F,8?PQ_6.O!Q_OYQW#IX^&I M9?RPOGT2AC?\U5P.#NR@9GL1[C4YI?!$![74[IY6(P&7@@T^]FJ?5S^M MUMZOKW^H'=A_\OA<7.C$MFOAI#<4.!B6:%^919@5CUH_T$$KP$O]_IJP[KQQ M^BWZP#V.!"6 A-S(+2#-C$- BPV/"EBRH"MKW:,XLIN\S'ZV8=&H29+*"\8\ MU\P;*Z.CE!,-@!K2]/S'VS:L9NQUMM/;T4Q>*U]K62 M<.SN'P$HP=\ CL_!UO;!H/LU>Q2J7K@CD!@#2RX:F ",_HD_F#!>P();VE$<5+\C?^2/9:2![U4DN[+Q_@#^4T%U!43'\<)VX5 M#!5&G$X^_F"(-E?1:O0QP))6YQB>#^[BSJJ/5A@2IL/B!6ZNUI[EGE$92[M] M!MZ-K[:^ZH5[L3T&#.@\;^F;*6_5:OC9]O$OT;CVX(9[?_V M)N/W:6RWJSP,F/=>J_\=]K8CNU]->*WK#DM>I@\L?WCB:GI MQ<'$3ZHG7*UMI6R*E9G!\(0(7BA0A#@:T]J_6K_]^L%KK7[MJ#NX^>@P"?;Z M-+R!:\YTT8,\A='VARS)Q4RCKM^@NF(-5AI<P?O(PQVIQY"4PPJG,N6RK!R;1/JF>8[0\KJ^&HS#\S8W/'IP=YW*P M*E8QR[HZ;<$:SC,[LI7*P(9/U&L-KS+\[>CZE8F[F-]XN*Q6:^O3D[#>5#8Z MLJ]J%5TNH8MINSYIJ]<2MWX6,QG!HV0Y.M'MM_('?A^BX3_QC]-6&!QA?/7-_G^#S! MT6OEGGHIX>AOFSN-#?_KGWXS_I.??WM MYN?FUMOU_WZJ;37>;N]\V-Y9;VYNO(37;'0'P]WR[23%>P>>(WB'@!6?QF3O M7V\OHA:_/<2;3ULZ/PFR_#)HD76\MH M8QC&]&_L#L,?PSXV_??XS97'"*U0T8C1+GGSD2[B&[]XI!O1N >,TW[RL/>= MM.-V J.!=6C;(Y&Y[;1],@"OZ"B'CL?.\8?1CM1O5NG]KSED>^Z_,1,HEH(C MP1A!/.93I. <\A9KS@(EU+CK(=AG89'-RGC:0'HKUECQS?Y)!YX7+M*OEO;1 M:+W4;+5@,BFLPF$!OF9[_8OUWAVOHEF8WGQAM]_O@]DPM*,7NV!=U0&C#?#6 MY6->HL'\"R@"7+:=Z>-O\\SOHDH"'V/BIR>,;9[TNO=1H7JA"8,O,^4/''*5 M"S32]VF_NX_G7W;/OKN\/&^??SW>;'L^U/U[," M/[-Z(5CU3N+,,1AOI#%1B(1B M>^TJK7*:HL,\>C4O6Y5&.^>I$BD(2CBSV*7J/R8IEKRD\?[$J.#0'#CT<9+[ M.*LD_%^AZ$A.R=,4&6TELHQ:GHAUO!*?U&IA/<.>J:34RS91ZF*PA%BID^UI:JK!^DE,*VRVX\_!H[!XLX57(^)/DE3114688IP!!0B3I5(+_ M!66<*2SA42'H\R1+2#CD)!,/W" *Q*D60!!(1#' _-#$-<^YWT:NLB5R5DJC MC85;:*#&*$>QLD 2O'/:"AV=<$0FHF4A"8]MH6.2X"-QS#,YTHQU5B.3#$.! M$DLI&"]W&"S4+*RPN803[F][;^V1#0MA"*_"2?&<&EA]Q$L<.>;!17!2#67" M8&L2H84A/"K^[%XY0Z%,1FDL /Z4,,+R M6JA4@5F*!09BR ,5-DI@\XES0BU.(12&\-@6.F8(@1CLDR<()PH,00J&' D6 M;%4XZZBA(FJP4'G_(\[G&D5X"N/Z=-KJ]VLPTD>^].?^B39GH-9ZARWF27L3 MK"'<:/BKD]$M(+.BP,H[OU<1:2^% MTPY'G\#[$'RI#C-+?&#!9FHBIEI3Q[,,I,72 !&0GL)*\,#6%;W_[K_T3;*? MB?F>735?[(SS,&/(90%)SHQ!!FN+\N%"H%X =2/+V"A[.>(']+H$&;V\YD2? MSB?+CS/.*5LD4/S8K8&P)&HI4DL:,&93=8R MX&U&2NXEEN(GC2A*;NP3TCOP&CFX[2IBI!V0.AYM)2NL4# T8>L$CSH?/K_1 MAB[,<5R$Z3QQ2*@ 9P'.A0!G(DG*8 /34G-/E#,:4R!GT3'*<5"+Y=0%.!=$ MK'.X36@M(T#(Q-V2+Y3OQMIU]Y2$[59ZD7%@>T,!NY&*6+ME7:L]$ML;RNP- M;0R6I^]VP$+.:F[8;7&H_=J/UU3ICF8QU.OR$G.)5-ZJ15FU3LU/W>W$N^M0 M1@N7'PI0_ERSYLU4=8Z[J7&<'F1%M!LJ?;XN-V"=SBU_>&S_<\\ MC:O!MBGQS,2@N0S&>2*]A']%C[,@['3'<*OQKA"<^P%!'3>:'[]Y+Y5-)""% M&0!!2CGSGV#$#67&X,"H!I8B-)Z2_G]1U'U=LO1AE8MVHF\#1+02,)'\&-LG M@^VT[OU)YZ2=3>FVCL6O7KAH>V/KFZ9>P( +%(@#4HHE>/,$9I]Y;E4TUD>L MGZ5PT<9)KU(L.LA[3R_&VEG,8D1#L?(I6#DIXSM2J[R4/:IT&H<;V@Q8.0^: M/R_=(J-6)3%WT2T29E6KV31[YKDL@5^:NUWV%[<DZSAPM'N\*O@@NH M-G99'W!1F??OMUBPV?.=W*?=-T7>K3XC(X( MYVE=;T1D(CB1)*:&">@>8=1%-_]H:'+P] MZX=A@X\RUGC_2[>?O_Q1VY9 MVGC?:#>:[5;]\&.^ZUG]1GO2<+#7W.LT*/S_< OO'7[D>QN;O/%^"^_2SV3[ MZ]998R._X=;9-3&.0"FW)#AD'=&(2YV0BTJ@D)S"B7FOA+ZEA_/L3>Z7KWZF M(--+1286.&;,) HQ@W%V@3,!!5$!NR$'9[JX0MDFIK&4)#IZ9!IG,T@!4E1 M*HNPR.5]DN<,84>02IX$:33&$@,R33DE*,"T3,;[DH%IGN[LG,8DB6/"69Y8 MLE;KI'.36YXP5C3C$C$C7"+FU^E5!8X>'HX:8Z)D" Z>6(U#(%#U[2-5Y/(.1&SDT)@CSG'7T>5X.J M:'#$+&A'N3#.&2LMH8EJR;BD_NY!D&I1-;I'HW/\H_UA0LGFC^-XU(]E&Y]K M&[\B&D+ >X#I<<@*E84(#$4VL("(2?"%&?$)>^:S8AJ>(:Y12-!C M(-%$+,-J[@..$B4>".*6):2QE\C G]9(BI/W*VM\52\'!QHYDQ?WNNAT7@', MLCB\Y1H/$@!X3I&GH>Y%+QYW>SGRU!JVBK[2&/RR'7A.TMZ^3-*^4SCJ%SMN MN<9]5N-/%&.6.QQUO[RB,4 MNW];CN43O2N@]6)!R\4@E7 TA[!DM,Y2Z[AB.E#K"9\[A%5 ZZE!:R+H13U6 M-FJ$C5&(!^J1I2(AF$W8?S##,9B5-?D&9G:*NUE JX#6.!>%E-<> AV+"R MQM_D!FCW[E&X?.*DS\#-+5D7+^K 80[@O9.>1SGP?"08W3RM(+2"TO5OGMJ< M=2\1#CZ@K+(%'BN7*/E(& F&)^;R.<,+;-!2\.>%XH]0G"8MM24JGZ(!$S 6 M!R6HM"H!T2L)%T^-/_5+_#'*8ZF=1<'&W'^&1Z1)9$@;R63R0AK/5M:HD5.R MO0H"%01:3@0*2N) ";6 *K"E!F>X=%P#'\+*,>WG=CT+ BT8@3Y?(I#CN6;$ M2D1B8(@K89'%6J%$%&,. $E$L;)&#%VE2X1 ,PCKYG_G5=DZ.JG.L*](BUUD M:&07\KC;;^4/_%YIG+7^B2.IK]&RG_C62.\%C[]B7;_;/AG<_I49-,R612[N M':+R6L>+B3\/+K-;CNU^1*X7[7=D$SS_[[9]:L_Z*_^^^N+PUJ/+FWS_!QB@ MM?_K>G#3>\C'/?[0WU"/J8;^R^9.<_/OVH?_K._4U]]N?FYNO5W_[Z?:5N/M M]LZ'[9WUYN;&2WC-1C?KV@ZZ5U-.WK6.[)%OV?8X^:1?^]?;H>G&\-M#O/FT MI7,IU#F)&L,-Q0H6$@&//DC.K%7CQ3\L725Z\0_[_$96WUU5E)*950CG5M![C-.2Z?)YE8C[34WB M7POIF0<2$WS*H86KA]^/]_^NG6ZM_'Q M?._]7KMQ_N?WO<,ZW;O1=#$O&1^<;V:GHO&0H-D\:DF24"T=(LH9;'#5F5'-& M123*DY0*07TR /L\25"#YB;RG'\=1$)<8(ZT9!@)3PS.G=VI ()*IPC\/V8" MTA/QTQ<)@.WNT3X:Q%YG00SU%>/A/*R.DT@H]#N:'2TE,'5:\>?#"8VM ]R>DR8BETX(>^*0Q18C9C$+ MU-M$55I9XW)A =W%6YK'?7FD_:FX+W?=HR;<%VJ$ MC(%&1#P']X5(A8Q, 44NE? N.HWIRII>9?"D&N"2QEP6ZU -Q ^^V M*_)_Z_"LNTTOX-ZTT=FB]:\[W_$ XC'12'LAM?0,!QQ7UH29(E!7 M$MQ+@OMS2^B_PQ_.LH!,=D <)S91O3#R6I+?EP0<2_+[TV2/6 )4SVF&K>:&">VP(%8& MA0.W)))"^9X8&">S1X#3>6\,\A@#Y>,6@%&EB)@(VCG,% LDMV6X3_9(27XO MR>\EN_!E9Q?.L3TDDJ0,-C M-?=$.9,K#[&.CE&.@RI<>NFVC"M)\2SH:#SA M*$8*6X:)!MGH,/(V)N=HQ<9>>:Q[-YI*VK>#9W MW:8F/)MD*$R&=;!J9$0<1X$TIQ'V*NPYI=)09U?6))M2N_4"$N.O]VAY#O+Z MMTA3OZF=QBH7Q0\JB7W;@1D89+E].ZC97JQ5W61BR.TN+@3VXZAIP_T%]GO1 MY[D+M=91+7,:BO^8.3^F^CSYH_K]Z+NWGJI>?!9>PN57\J/TM^%[1=L[@B72 MKYVV!@?P)(/3V/XGUCKP5@?]U7F%_9=BJD.K[T]R]^(\LKE?26W]S<4H7?^G M'9STJH8*?Y[TX5K]X9"O>Y]70FZL\ $,RL,HOKD81E@RQ[W8SX,\O2W##*T8 M8"^P-;!WN)VS_=;EX/^BS\)J[8%;E&RG!*MK,&H />B7IB.']6]"!^PE=4@+ MELN@*$':.QA$YX5-)H#30H>[>=7K9CV[A$DJDYSV@43#HV'.&>^\M(EK3<"E MN=&DY+'F=2(WO4SN^<=O6LNDH@P(6!8%EU,D9(462$9N ^'&*^RO3RZ.TAB@ M:C$HSYVA1CE+@B/. M<58;G!U7:),NNRZUCOIPK]PZ:-Y=:(;N+K6I?=FN_'MREYC:?>F7!G'+]WXY MUJ52;UEJZIY5 6!YV.?WL&2VR_[B,.?79ZSJQF>?0='!G;OOW*=4:$&E&H_4 M$W?ZP+VO:/CZR/7; :=L_PB^'EYL7= 2C?:0EY:1?OB1_C!T6?9\H(S[C!+5<;^EMJ*'\91;IU;4T0F!5?E(;S]'/LY# M%K<\Z=L^<'W+D[[;\HEEO2@Q1[%[N$EW\P'@^[\Z<'6\U]EEV\UUL=O\\Z!^ M_O%'H[G.ZLV]SO;U \'#=@M^?@#WPKN=_"8[\*<7]8WV0?W]YGEC8Y/4-SP\ MSR[_^[P^J'\:ISIZ01V5'#&& ^*1:&1,\$@%%S7%44KK%RKF>+=SO%4E%YUMMF/U)!LQG%1_*4 T+Q"-28\6S',7 M<@:'E(@'+@&(1$(*V$YD04K#R8)$BPL$%0AZIEQG(@Z4<6A]W^8,HK[;=B(!0 %.?3MPA@%.S6[=]^$5CE!S8Z^44V)QN=!7!"G#-"5S;8P9%2*#> M*8MDX!Z "UNDP8%#FF$<%/S64;6RQO04B92G8U"/))6R!*'W:55%CU:=_XH) MTZLH8WDLP/DX&;5V)-@4.^SJ62"N)%4@KY<""N4 F@"T;QXU3S!ICY7)H M#Q53?F[[[D2A2#'1.4UT(B[J3&!$$(62D@;QI!VP>NP1TSI18Z)/,99-]IE9 MYE(8YEF)(B[:;,<[*\><).$<$B)S8Q8\\Z<*_3W2;O M[]L;X7O]Z[O#O8TLI_:9-3Y=C['YLWKSRR%\'M[KSX,&O-?>X9\']P_>;GEPKH(S4)4691T[D&)M($5F)(PI8,Y>8$)XN[B"[9.\67'JV MN/2::R@?#YG&!X$)6R^$YLACE[-R4VY)0 0 %WJ(*NE?RXUL M$^E?U$;.";A]G' @7]$09)4RR"LMM'2:)I66$=E*9>;+SV4M#<9>#.9,UA(3;>[=8*QDGK\FVO&:2S,?SX0G9&@L3& 8$<<=XEXS M9*/02$0AC1-4:J_+EOM<[7HYMMR'*]PL=C^7W4]$Z((FQ ="$19Y'R>!(Z,, M,&\I.U?F:'^=%DZ2K]#5%T=L,D_\SM5 M%FMC@G5H#%<\B<[?2X;<.>N-4^_V(7"_:[\@F>.O? M;?O4GO57_GUUN&"L1@]E\E,_P+#^8F4LY83=2("O)NS+YDYS\^_:A_^L[]37 MWVY^;FZ]7?_OI]I6X^WVSH?MG?7FYL9+>,WS=^^ZR)_"G ?P@ M;S7]VK_>=D<-C'][B#>?MG1FN/X(3%$^5Z@N=^7ZZ F']C^7C>\?_^Y7AT6M M*E8-P\,V"-\Z^@?&O-L[VVCU?;O;/^DM36?P[8W-"T;RH][9.MMKMBM&4C__ M#NS#\]VO6WSO_;M6_?RS:#1WX3K[IS<[@V^>[1[^U=[^FCN#U\_AOJ)Q?G"P M>W@ C&;KO-'\3AJ'NV(;F,??Y[OTFPJ$"\8TLGG4N-4)&2%)SOU,WD=MG;G1 M%IS[Y!16R4<1>8A)LT"$YSP)HPE6X7I;\(LQK\ZMYFZH_0/P)MM M Q&^7#QOJQ*LP5(UEG^"Y<._8>6YCI(APW',Z3 .**FV\ =P 8'&,O_LN\^BZ(QJO"BSNHCO"]2H=*I8L M5,.!LE6N%]^9FZQ2=3<9BU\^[&PZ%O>553#W+E"]=25.+>M<"H6*86"*D3?7 M^%71J;AE^&ZT/2_EY(L;V<7JI)B7N/Z>O/[Z,;1UI@=I=^QIK9,#H>!_ENKK MUY(D&Z*DQE4I#9)+(RUQ.!@O!/82,YMFU4F\]"-@&=4O5E$54-^)\!;_+-%Q M]UV]BE&8'#?.]^%SGQEX$V3[ZR[>WOA.MIN;&)Z+-CJ[I[OGNZ3Q?J_5.+L> M)O_(MC? ^VAZDJ^]=_B1PW5$'9ZSOK%+]P[_/&P ?^B*\:T,6;6D[X"/8N'GO')/ O:41LUPC:+H"OXF]8>(R\%4]0Y&Q*OFD.^ MPM9&3T?6OG9[WQ%XP,>]KH_]UY8[_Y3\)H_\UM&'X;@7E+D[RES)FE@&<@$BR5#T6'C6"\[-@]1/9X;O64:M_$$-MO]L- M_2D1Z5FA:%;'ZUE#T<*)P\7PO\^C7Z#H[E#T>9(X, [KT].(!,,,B(,/R#HE MD*%6)NZHTCSW:)*K:HG8X8LSEGP?#+%]9HQJOZA>#C[<4QEW)BW_0(KA9Z[CXRMKSKF_9 M6IKZ%D)6)7F$ IXQK+VS#VU[-%@_"IO_[Z1UG(NCEK'@Y>,%6L'O&JV] MPW>'N[1Q6']?Q_6O>]]W#W?:NTWXSL;Z^2[]?%IO;O&,/%!&X\X M3!(R,+C(Q20C5L'0B*^7O)"4O%'6)>(XM]XY!A^);O&:(QL9%C$3D/'+8YRSULFRH$D9PSZ0FT2EK1$HT@+_$9PU_W^I&P=^'RA/QO]'VXTY^ MS.WTN3_4._\SIFXOKGM_TCG)0DEA(Q[WX#85,X>OKG>Z,*SG=JFDD.[JAUU( M(6TW-^%Z'^G>UYW6;F<3US>VSN'Z[;WFP7=X.KB/A^N\:^VU;D@AB7H3GGUC MK[WW_J]6OD?]L [O\J6]_7[G,$LR-9_!2\OY'@L\UM>-) M4CY/>F":)[UX-=A4RD5NYUK82DFMH]'SX(711CMBL(J>P09,"]=ZKG!UI=S$ MV10L=A0E'SD0KIC5H0Q'T6&JL0N2!;FRQK%:J@3V4FZRZ,0B[[2Q'$N-";=< M.\T#$&Q,&3#OX' A)\_8VL?DQ :8UUQ2QFC""/BH0-JJF.OHG5.)QECE*_$% M)(D_UW*5IS#4RB0.NNV?A[5*DOLE-\&,.,&=T]YPFHS##/8LX"C.&5OB0,\8 MK:Y4M!"'.9$6(VM90L!!" (/.@!!4=%*S"4A'-!JJB;VLX\#%6N_M':3C(F$ M1+'&3V]#*YJ:'1DDN(N&! M8LNC,EAXRA0CGHK"39XK6EVI_' L! < S?A7"#CDD#$2>TQ52PD#&AE MV%)Y4B5NLF!K)T$I+Z-D27ANN-,47!!!H[%>1>Q"X2;/V-HGI+^$=-&FW"]; M1I2K3)#Q/"(9N'1*8>%$YB9"WY^;E+C)''$3H"0E2G(;-CE!J:8:%BO#7"OJ MM "OR7!@(\XK$0H3>:[8Y">92-01$YA?I&.@B"*,9+%%QA'V MGMN (_$ZKJR1-\;@1>MM++V<1H&11Q6(*##RW&!D(@F&),I@\I&E-(OV1(8L M]A%9;B,E2M'@3(81Q)VGU_P3TZOB M.#X Z'V?Y$[2!*(-YTCB+%0=E4$:<94?>T?9/*UVDXHYKG^C.I>,&-A- MG#:YJ8 %VI@,8EQ1[3%F(M'L*V/#B\1MD;@MJ/S2(YASH7(!WCF!MWX)O$9( M8Y/#"$O*$;?.HER,BRAC.'K,",%D9>3*Z[*,?^S/@GK?9EDZ>[R\ENGM?WOSDPPA0) M09$$C;B4$EDB(M+,:XVC"L$(X#]43'&I+X3:WLPUUT)QFK34EBC-?0@PO18' M):BT*A%#JKG&%W,] ]"7N9YEKAO[W[RAUL#P(V4-0"X+"ME$* PSI@DV7S1?@MH547A^\LH%N]' M$'#.N3RP5]4H; N8A.)T$=LXXJ"Y3=71>+'P]^ M;3CZ%4IW 0>ULP1K#5M ;QO[ 7W4""YT(0'AL=-D\; M'[\%P15V +%.9(D<[W.>D)"(&*N!C+,HM'V2T$V9V7O.;"+1,THD$B+I7+P; MD?6!(A%4]#0YAPW+HF=X2C+$[5P0H !0ZGC883TSP&A[0/LR&(0(1+!;A=?@ M,Y>X9X<;@F_#7UJI%0/\I/:__T=3BO_8NOZQZN?DCUJ^$Q#(W" C1V"J7"=G MVQ6;[!]$^.1J;>MHQ$-/)R(1_O@--@*B#+&(&FL1U\(BYX&Q>&&!E7,5=<@:.%I-6:IW=DJM M(BKE%$F9,9!QK9T#%U79X!EA*I39?X39)XW];[#=!.F]0U%D311L8/:CBR@% MQIDU1,E P$=E/YO\.\-2+PX3*0?="G"L_W\GK7XK7[RB/9]BIV-K39AA8+LG M@Y;OOP'<\:NU?XT0K/K "+5^&_9*^M$]JCXWZ1ZOSL[[EH:[CNG[RZ.L^Z-W MFS=(?4?>JF]S7&<#!O/J@,&?UO>_&4:P3MPAY3B&;2&7PDB2D' \,J-HCN0\ M!C7V;.THHJ67(B7ID)O;I1C!_:OMCJC<+ M1]PXZ;6.]J?PQ#L#P((XXWQ+Z/4Q@_U3X(44Z!BEWJ-HW)>6&9X5_,\(]&!@D82\XM0 -EX*0*CARG !("1CBDX+ V MP/R-FI)X=3G#,W&X6:G9PQY%C*XS8BLRUWD?=X?/^GOU&O!(HZ:*HZ29B6^- M;HO'7[$.H.]D]<2>U_8A<+]KO MR.;LGM]M^]2>]5?^?76X8*Q&#V7R4S_ L/YB92SEA$T_;?JRN=/<_+OVX3_K M._7UMYN?FUMOU__[J;;5>+N]\V%[9[VYN?$27K/1'<#% %O>3A*-8?98R[9K MGP;P@TK+NO:OMQ>G*+\]Q)M/6SK/^KSR_UN:\TJUJM@CG%>NPRTS<-OVY?K9 M.AK2 _CI$AY9-M[L?=WIU#]=9P5;N$XW?^P=_@G?_W+8R-?.V0W-?;+W]?-Y_7#KQ_;7G#RX M^^/O\X\_ZJ??1$HN27 =G$L6<2LY IC7R"1NM+,T6BVN'UD&:ZF/20K%,/BMJ?(Z?A4W8::AMQ8%MW.;/\]1- 0:F0CC\A'[Y.3 I9M MO+[RGD4(;;0&+I(YAP?ZW;P<:OX$%LW1X/)@YV&:F$\;B,?M:F[P*J/J+EW- M!5M5PBR^43A>U>1NG.F_7$9V3L>L9%,0GH @*U_\J9>>J*_EK;"]TT7_*MW>8NWGO_5WNW\^YP>V/W MO-[<:==I_M[NZ>5W+BOYUMGVQI>#[8WV8?WK7P>-PYWONYTOK=VO==XXK/^ MYS[?!7^H<;C^8[*9>:.Y^:-^_O%;8%IRXS0B+( O1&-$F@J!A/ >_- @';%0L]]\UD+]#P$])Q=A1ZIO!0>4Q0( X/TB)+X)^<6*]] ME$3&!#R5+A?TO/BV6E7XL'31>I0BB&&4]NTP-E< 92Y ^7B#RWBJ:6 L(,&, M0=P:AG1*#ND \^)88ES[E36BU2I=HEXXI?/5DFW^Q4(79Z'7MGR?8N[O;5"T M(2(N,48N:H.H]3PJRKS5*>L +E5KNN40,%XZ+< Y]?Y&@U*4I1YO@%X,HB]. M[Z_RXS:'QZ-7C\H+Q-\%XC_?(&&1L! \R\#.<^6Z),@" 4/818^%,=8JOK(F MN%C5"_+JGEX>ZI'"404["W8^H2I?PJP,50D[@021''$?+#)6.X0) MIE3XX+FC*VL,ZU7V8K#S%FF]R2R^ATVH^^0/8CAIQ^VT[GWO)(;_MJQKM5N# M5NPW\V.]WM2YC[DDC+!(4A;:-<3#HN0T(6? 9_/)$6*2)>JFM,RSR)8;3?]I,MK7AOV*AYY5Z2Q2[YB%]A$0G))NCQF0@G0U?4(U@8C#'0PC\ M^G?5;8-M9H,!VY1:3<"^AYK65==:M89G->S*7?VCW0JHKCVQOQ/IF*X]M@%7T#A;IS73%9 M%%6;[7[89/5S_QN>?+Y[!/=L>[Z34^O^^'X*SSC=/*H?[9RO_]YZ?U75#C\W MSSW<^Q%Z43_:/?SRNWY^<+![]/5@=_LO4&S6SG;H[N'F]CH?]7O;7-N+1!-J MF4'8,H=XC QI(R@2G$5'8]#"A*55S=4*GR&_D^+R5D#GV5W>"NA,%W2&%?"4 M,DDR&E%4WN44[@Q9[SPREC-MA0K6RJ55I:Z>I)U1*0!IBR-,/$8H7W.S*ZK3._8JL3EU6AZR 2ALY2PDE[23B MB6FD)8O(.P*":'DR51$?:9ZNBLR>0UQ?Y/ -]& LU8VYX5B8CX,IV7M.+R_G)3W M@SFITJ84R)H(LKZ/T@M&M6$D4A23%8@K8I#&$B.5$DY"1!J$ LA29*:B=J9D M/2FR.U5S0Y'=EY#=$;I!@_+>:P0PRX%N:(*<) I%'VG.><5L3LU*F'RZ_WTQ M0DQ *EIGMMD]JYW8L^SR4>P/SVU_N,"=:MR+)O-(:-D9.U1)3C N#"+..<1- ML$BKD/$E1D,D%=+I?.".9TJ3*5:'&:,%14*G+*'#S9\0$@6O C,(0UQ8WX^. MQ=@(:AFP@1QN3Z28*0F=C> [\GJA=B,)E:XYDHQ%WA7=9-HT <8^=C[W25D! MH,< D!^E"-(KDD(&($,%4 0MD>$D(F69UT)QJW"F"&0*!Q/%,C2"0B**AAEF";!8RXZSI^>/&->;0,S2 _&D_5, MS@?>A%(RW90]U]RB"O@\!GSV1ZD!SP4DA?*(4V_@!R@HEN<8,U!.E#?*2<:6 M5H5\^IE",1[,KIQ.-W%/D=-IR>F0),3(HM4TH"!MQ10<B7.-< /[/46(FDJ!&6X:PB<#. ME]?5S4I1\/@5+9Q5+IWS"5K#TF;%T2)XU M['">TX@=<UU#,^#]S8/ZN??\>X/>-Z'GZ!-[Y_7&U=TYJ-- MLK6=V]8\V#GZ3C:WOPBX5FS]6&?U[:_-';H.[=PYW_JP2:_DZM'!RJ P:"B. M:L1Y$,B*Y%'"1K#DLD$R]*/-9BEBI>3J*:CS[,%S!76FC#HCOG#,!Y%4RI&M M!G$!/ZRG'BEAA5?)"B-$/X6&F"'46?@XN8^-8WOL8ZT9;2?>1=>*2\VT3UX' M0_]W'OD+K#DK2/,8I!F+IB M7H4.V$:[]LLV>S&;GKWM'-12LW5:.XAA_Y&M:-\_6/WFR"A!-!$0C4?;G_G3S<'U/:!)!,;%( M)6X1]U(BBXT![40E;;V-E-JE55'R[RRR$$^+,A0A?B$A/AL78LZ=T5PI%$U4 MB#.?4P&/B&-%6,!(]"+%YN]%VKQ].5_24YPRD^P:CUSXKALOI\8.U/B>:M9?-LLL8#P\K@1SE&".N2!4 M!:.?B-%CV8H65AF97D&] MUX?*!X2UY;_S$FX<]VS5U]%(CH$8R$R$3UJ=1K[@797HL?$K#F)\!C(R@ MPWAXBW70MU[W]EL>$+PT*U%;'Q$U5P)&1GX>M([_^?7OC_=K?WVH;]?=;7S]O?5W;7O^P"-VLM[KPL&ZK]KYU7&%"E5>U M[S:1*[=\Z\('^=2C4_OC?5]T8_C7<_3\IJ73_WD%-?J[D=+$8E ,>*216Z=- M(LQ880)E(207EIXKBK;3[K[[Y@]BZ#7C5H(Q@8YT8K@X-KH3GM:_[(G MF,' 0#P2)B;$+??(.4^129K0Z(*1C-X53CLC,+Q]$"MOBN6^3T7\OU[C%U"C M+!2YT%$[=KJPPK+@5-\[V\Q.1_!EMPJH=1%DXACVU^KJ>)RWVNR@$:T_J)U MDUJA=@(/R>(1:HWC6JO7KL)R+^6Q,Y3"4<>.$KQ[\([+%3SJ8Q*E#,D6#>!06.1$%"IQJ1QACRL:E5;FLS/0RWLW1.6A!IUGJ MVRLYWQ=T>EET&BF()PGC+'HD1$B($^^1IE8A@ZEAA%CM>"XZL6RTGBDO_(). M!9WN0B<:78P8MEX7&->:N*2Y,2P:I4'S4B2C$S$%G680G>HCF8\L#]$1BSS7 M!'%&(Z 3I4A1I1T501$)Z,26"3:+6"^OH-."HI-/F&LC*16. M*Q,,EQ4ZZ8).LXA.0^YD*792.(E(,GJ0MX0GBCS5.$4OF#'9.W99"KQ"9@B= MWGJ]P,_M>&(;H19_GV0_COZ)?FLL6[;M=&+W*36&WT2,%>8X 89A@3'AA DM M'1.",*4CQXSZAQJHOEYZ4]P,: 6D)@*I+V/)(SFW*G""K,U)[4,4R&IO$74L M:!]<3%'F1 E/!J@2##F[@FI4LZ!TL E(AWBHK:8(ZK0% M=<@F&.BI(>;*X")AQ+E0R$D2D73&2L,2UE8MK>*GYW@M@CJ[@II@!TV>8&NC MX2":1@O*G3(B:LU4M \U6Q1!G;*@CA@EK" 6=#2-@H;-E&N>D#9,(Y6L%$*Y M9'E:6M5//\PI@CJ[@JJEX-FC7#G!.,BJ%MQSHX(GGGNI'ZS!%T&=MJ".U!IS M-I]N&.0ESF<;PB#-K401* \CU&JF05#Y3*45G8TZO:^GF_>+5CU9_7X3Z<^\ MY )8@M:)2^".V$5#HE+6"6X-(7AZZO>H 3$U?L> SF.[5;!I(FP:RWFLC 9L MB@;AE$ M]S$A(!4)$2:"2":YY.T2X)"FA/XY0[;#DL-PRD(,A%]:9C@)#O. MK='**&9ED+![R>BFIYH7(9Z.$ \)!M32>KD!6IBM8)K1-5?0_]KN,/[!K5I9 M\%OP]B4BH K>S@3>CEHS8[8P.XJ\%@1QD7-TDR 0P\Z%8*+!W%>1471Z M'H,%;PO>%KQ]B9BN@K>S@;&.XXI%;(PVLX219P$:!?H[3'C%LZ4'99 =K#>6=K7K]^'G%*R:[ M_OMR6%_^[>/#HE7)47VP??T=8=W&T"'IG=C)2;PY@O\4W/_P\!9@_ MK1_6#^H?ON#-'^M\Z],&_+T)T+^!L8[OV] ML[W/=P[7Y'55&ZO/ZA_4]%7G@,@"\1J)SF5&*;%($X6!-X-A( MB65_,Z]2G:_EW=,R'+7".3@J<"VY(TFG% 5)042AS;44UB\QJULGL0U@<+Q? MYK6^_64/5%M!%.A )KMV X(99%6$:68Q:(Q%\$Y=G5>,30R8C$ MHE<*&[=TRWON[^#X>R0\6S.ME$J!<^>SAT2,EC-.*:.1WU,GXOE@O7KBNT87 M>(E_2-V,/N+5+B9LLDSHL\%1TJ /S=R' 8&HB$5S6*JG=M(&+M^&!M2J2BDQ M5W+H4XOV2:N=/SB(-OQ?S[:[L9VY3>VO5J<+RV-P(A]MVQ_4.@VX$+[[!CW] MT(C[K=H?.9?\@,'\U6LT\\YU05_^M5+;/H!;:Y=?U&P[UGP3VMA(#> RMC/> M^D[-16][<$M^["#5?>U7SD=QD;>^TSNZ^+7?X1-[UD]X#T]M^4;%D4X;W8/J MDN&;XV\?8^C _:[3M;"6;1,& WY<)L2WC?;XJRYO7JG]@(%M=EJU _L+ONYU M\R.J[/Q7F@]Z5.7/<%*Y)U23 #]69GEAWTB2:LWR7DPN M]F)R[?A_H_[Q8FO^U>[^?E>AS=I^.U9>++ =N-C>2GT,&M/%H=<^Z^.GH+*! M*%RJXOC-[=WKOS($&&PM.#!L#;Z26(GIRT6[]A]KH10.+6I=+YO]2]>EX9 M@@Q<*0\_N(G$J1S@!PJ2Y19VQE#9,E@:1S@227&UV?^Y% MKKRU3"+G"> #%1P9FA3RSB:)0;&V.@ ^B*N:6BV/&=# O_+F4)GQ+EFG;QW! M+[YO!KRL;0(SQBK0. 58N=2=@%6V6[W]@]'KJ*[89:\+3/T\7U%9%AN9GUZ4 M? *6G*EZ?VO**ZJZHZ*B0*A:)Q7RP"8&*RK"*X?4N%I]U4($'A]"5?80'ON< MBW' E%;VTUDLW#M3W%J+9<4=BM. /8B0YI*3ER+L(> M 2N5" $ %(_[R^_JHIQ#K6*H-U;+8Y8[<)>NF\--0)1:M8 M!XPM(PX#GV"P8SG13\E$Q#5ZR:9++]\@8Z#U#YM[&E"14)$0(< Q.2<&&6TQ M2C[H:$C0)B?E)PHOPRJ\SAHFHY:7LK)<>V^;#9B7XX:=@%9((;&FV5R<:U^: M!,PXYY9T$1OH!'<5U1075%.,0OJ 6V8\SW(*:+[6;MOC_3[+?&]/LGWMPIK< M/FI=$H["-RX7#-L\W-\##80D)152P0'?D"0AJUU"03"II,&%=E#ZP[RL6G/X!+&7X!W]$YJ=YE:NA4O>/JJO5U!6CMJ]0"> MT]9)G_N,$)*B'-VRX&TX_F4A&%J54I*WV9I>2#3 M?!E\*@ST]K.P_3WG \XI6!$#AH^ ^UOD0@:I7,@AF*"X@PTM-7Y%E!'I&DQE M ;[J@C 7YSZ7:LILQ8K?75S0/;#=ZA#FN-6]\R!F M#I6+C>/CUJ_^F>:W/M.::R7#W*!D'(_H%_#W4[6)(#W%-F$>"&CY45EIN+:2 M*X$U,XS=XNQ=M(DG@F_V.]S8XU@$ AP0.2$"X@Y^R_[7"%BA)TD:D;1;6J72 M/%F;. ;L?M!I[Q4C9G5^>TVQ'?B]Y3/F2\;X$(5DDM5VOVEIW-)9%(_+M84W MS[_LI4"<=2ZB8"6#C5T'4#Q,!+S*-"LQHJ2XW=!9.VGV8'HO] ! FL8Q"#8H M$]5:.&@U 9". '5^79RE50?NTU$*VGW&MM=_U!7$BDDQ;+W*/BX@/P2X8R#8 M4ZD,"T;)BC2:"])X#;JNGY]<7U@7AR@#YMC7'(JR<,MJ(YOG.WM!)*YCKK4C M$LU(EI##)&N]U% 3)1!\_C1E8;K8492"VY0"^&POV,"X)QR!9F 0-\(B8S* M) $J(<%4DE29I6_6"?J@\0#C1?9:'%H4!H:(/F*,&R*6!_;3:Z:/[D&C?<7R M03'@2W:;]KYWTB># V^>BS.[Y9OL&O-'$C_WF]^.";H^(/S6^VSNR K!20L4 MH;/EVC/[,4^H=HTK6Z\Q;,MY[=1;P(#6EB_\UNJVVVM77E]_]3IP1Z?O/K30;L;-\X9B?]['4:UO.?Z>#_Z"GDF7G^E:G M9WE4X(&OR?IXW0/;B(4!JY:["V\? 6ZSJM M9J][^RVW2,580? 9D9./B.$K@SKR\Z ]+)6^'Y&#R?H)0 ?M?V>;I_:LL_3O M\8Y#KP>/-_G]SS! MP5?S/+0WZR0_[/^=7O]O[7/_UG[NKGV?OW[]L;[M;^_ MU3;J[[>^?M[ZNK:]_F$1NIG1I),A^/UHF$[?*R-O8M\NTE5U:G^\O_"B_M=S M]/RFI7.'<_F]SN)7G+Z)-$0G[(@EABLOK6\[_N/GGB4.V*RB*!H.'#<%@2P+*L? !X5=IKKX6IS./##";*L! MB@SLM\(:H#-]BNAAYH$G^ASV65'G:R&%8PGU!I0$OJ^=QG:L3,.M9DZP]VYB MFCP*6C J54CHD'948:@P.DU[THGO+G[Y,S0Z)TU[]JYQ7/6QNNG/\1>(&U(9 MYO?UOQ[LRDJM"&KRQCQ(L3AX\6#/7JGV["M1M?WOD.NAL$V_3HY":ZQE(J=YLWA:BCY MT_H_'FA^;RCY[(\/+N-SU_@0,S8^3Q4D(JZ.U(,R$LSX,/T!^^L@E*#SKTG& M:[HU>EZE",^X+:/B'4\JW+U@67 6NC;YH]24NP*@QBWV67N9^^BF02*:G_7S MG=/ZT3^-W4_UHYVC';SU88-N?=JANSDQS?D77C_:/-_9_GA0?W\U$0VT#32; MW1__^Q.N;NP>?N&;ASM\]W#WY\[V)JM_V*<[YSDQSCK^[_G&,+'MX9??>SXF MBI/G"&O!$ =E'[G +"+!@LI/%$XJ+:TR]O0\B[-7R:"@SH*B3JZ;DK34EBC- M?0@ -!8'):BT*A%#*M3!%ZCS@#2Q!76FASIK>R'$Q%+ B 5+$4^&(Z-80%0I M8YBC-&(+S)(]/9=VP9R".2]5 4!)'"BA%G"DLDX;+AW7P'NPUQ0"N8\ M!^:,5%>SQD?')0HBIY2F,B'G.J>I.D=<7X?Q%7J%QRG(Z /P?/QTGE^D=7:E]5EY?I'6)TKK MD-O#5+"$=4*<*X$X(0JV51;A1V0J)<]<2B"M].G0QT #.-*"+)!X@QN:H.TJ,H)7K MG9PA\T$Q_,TZ?2]2.C4I7=L3,+_:$8-R&EU0L5W(:>$YDE@9Z75@,8&*S?!, MF?B*C,XZ:2\R^F09'5)U%S7 )3?(2>M0+L&';' 8_C0 JM1IC,W2*M7%M>LE MQ>M;+BZ;27KCV+>.XANSM__QFCS]8N@WJI$OT#(1M/AQDJYB\$%3C[1BN32( M#L@I'!!E//I@,!"$L+2*;S"Q_ZO8ZQ9!.J?.SXMT3D-GY^P[Y?9',A9'/JO+S(YM-D=,QX&&_!R8*3KW\45'#RR3@)3%8#>>7&(\UU0#SFDE=46^1(E%1[ M3:.CN68"66$%)0M*%I2TI2 ME,@J(4%#9!PY&RUBTBE4Y4]'-0N"SE4[%H:;&>;U=KL M'$18*Z.)K^II->JY/(?HH^Y4EJ-D>6I)@:^ED%Y$?("/S#]]H-Z/(7!H.]^ KW[\./AYO8._+X.!-V?[6P?0+L_'E7/^O&U>7G/A09_^(7M0)MV MCT#'_['YNW[X%33W?QKU\_\]V/KT#WR6V[I.=C]]_UUELW@_S&8176#:""28 M!ZZOK4=&^HAT""Q)9HPGNHSVM$;;)N*9\PY90P7BW#"DN5%(8ZNXR27XUFN'4U+@4H\222R,M M<3@8+P3V$C.;S<<2)=8.=98&=X_H(=4]J)A*+"''$A"7)>4N2L2=KI9#3& #ML"FD$ M9\_M\F'*R:WV69KK(O>?B/+M[PA]#<-T)9/;K:YMCA^'7,U8W#]HFNR4[*V? MH+^I _(G4L0'9) L2#T14H_E@8I1*U#O/&+)9:1F$ADB#-(B"*H583+H*1'$ M265@/MR%"I:]'2Q[*N\L6/8,6#925<4(!1,C$7$Z9Z", 5FK%<+*RR"<\]1- MBW6^%)8-*.E%0RX6KJB0ZA6*>(QT^ 8?IUDI-?*(5B[0 5,YF)@RR/A14[EW M(7F*!3)!6\0IUL@D&$V,-<'" _H[4T9[6J,=#$"YP@XYR3'B4C%DC;-(1A)P M\OL!'GS,+6 M)A7MH>9)N5 :JX02@"8 *3/(!HR1=9YX3;1.P@);DXM8(Z@@SX(BS]1/)@KR M3 MYSD8J_A)G'?8H8FL0]T(A&SU'1F(G!5?$A7PH2E?$#"'/PGM._=TZWD?= MV#ZZ@M+VP,XO#%@_*ZTJ$#T11/\< M)5/)&IMT\H@&P@&BL_;&G$1,>\)X $ZE(T"TD"OJN8_ZYLFN5,#K#8'7LS+- M EZ3@M=(-2_/<6*@_\6!4GA>*D M,)THV*W+I"TE#G:^K;E79O*JUWB)T%GL")UI*4Z7RZCX2CZ9@ZR?5?RC4J+6 M]F0P%N9((1)33I%F,+*<4I1T3,Q;FAS/M<08?GHBR=DS1Q?<65#8D[3GB5B%-(RAP:Z+E'+N=Y4%$DI@B@3RYES*AX>J'18EQ_=N-ZZVZ: M5RSKQ3A5".+< /7Y*$$4'-AA=!J1Q'2V4G&D54K(&J,,=43XJ*=$$(N)O:#8 M[/2ZT,VY1['-$347.TY<0($YC+CU$FEO(Y(:&X65=KXJF3T-NEEL[<76/D<6 MVA*B]GB((0 MEQ"CDI92 %$2,KN38VF0,U&AZ*6P(IC@J2O#/;7AUBEXP'&! M2* 6^O;J&F+!G2?CSE!%Q-0"X&B- M")$1<6]L#D3FB+'HL,3"!,&75@DNX8"O$PYX]8RA! 2^/M\I@4:/A1XZ2GEB M%,DD:E#$"51'P27*:(-B<*#C2$,E!5V&*?7TFL>SYX11A/6%2$(1UB<(ZY G M*.U#Q-@BBG.!DG0WHVYAM+I-;&6J0T5X@SK)#622(7N/911,YU6%KEH!). M.;KPJ>(QXU:L I$%(F>'%A>(G!@BAV0X):M_\X+N''CUXO,GO?X8!6OT?U_[WZGB39WWHK\5>5D/_ MS_K7[?7_UC[_9^WKYMK[]>_;&^_7_OY6VZB_W_KZ>>OKVO;ZAT7H9KW5A8=U M6[7WHU75^S'N#= +OW7A@US7L%/[XWU?=&/XUW/T_*:ET_]Y!37ZNQ.1ANB$ M';'$<.6EM8$3&C5S0<1H[-(M]QEG@;0ZRN!*SGUPP&$QTS&[46@7_.66/,"Q M\3W862MPH@0;K7GP%+9=XISFC@)0VV#V/F0U!<-_:*BOC&^_?\=.)\9;-N%- MV^VUX=_M#*S;\-J_FBW_RYLHAGM_ M[VSO\YU#^/M\'S;H+V+W*+=C)U?/.M\\_[F'?3*6!X5 $:3]8W"'-4/$<^* M^FBLXE(M FTY@?'MMGOQV2?OQN0/9=(&DU;?WMD#VD.IDBGG$"6()[?5)NQ]!7G\O'LQR Y[82K56KWV92BO7?[W#?E:SU1T?HH]'+K9K MC"S7\OJJG<9V#A&JI5:SV3KMO*L]!5:SOVM>?T-B5-$_&)VF/>G$=Q>__!D: MG9.F/7O7.*[Z6-WTY_@+Q,EU@V9^7__K 6\PP&45R=1A8$X=O'C *E8J5G&% MS?:_RZEDJ;KU:[Q"'O4=62'X<4^]J[%$KL!641K[3(V5#WKL/5;["8WSEYK, MK1)&;I&PUT@"LA-M^V83_!TC\0#O\(4>M,$^7?M[/&_*%(=O7/^^M]S18@WO M,)U)&>!G&>#J4.Z&4;WO^/(A!;@FP(9;+R5BLG?>,$D#;?!UC+$WC_H?C>,: M/+8)RF+G7V,&N2D=&_S%0LV'KLH>H*M.$'&QV($5+Z6J99/U]FFK0,]$T+,YJJ%QI:2A7B&;A$7< MZX",I!(1*E@U2=@"]!BV0B=#GN?C/47*7DD/*=+V.&D;43^X\-$QHT#&F$1< MZ CJAZ)(!ZXFR6\< 'E\U&TO CI(X5TQ&CIO(DD.,0,$8B; M@)&5RB$GDS :&^-Q9N-,3+HGSD/ X7RP-')-Q-\/VC$6 MN)H(KKZ,,GA' A$9J8RQP"FH%DA3Q9!26"C#:2"> H-74\NT.4,FS2*RKZH, M%-%]A.B.J ,65($D<$"$@0;.53;YJ:B0I]YP(I66*:=>TT5TB^@^AYY0Y/H74SHMH4!*,(NZ515I;C!SQ>?/E3.2*DH3)IVL*Q6[_.$U!/$I3*#:. M&=04/K9Z[8)6$Z'5]U%%(3+FF8\2&6DTXMH99$D WN$,)5)Z894!14$\W?>A M)#U;?(F=1%$HDOL(R1W1$Q2/S$MI$,N%@;B@##GJ$Y+"N\@Q)TJ8G +MZ7EQ MBN0NKN1.KB<4^7V*_ YWWA04#3$*E/,!(&YQ0B98AJ),R49/@\ZE*@@CBUA\ M<3[T!%E.%&89NR;2$QJ_BE5C,K3:&0O:<($$"XH!T3J =D 8TMY$1**WA/L4 M362@)_"9,FH4B9U1B9U(3RB2.[GDCN@)1FGJN;= +$S6ZVW6\)-"3 FK,0M! MNE"5PBK\Y4[M,MUO*$%IA[%,SY M405#6*&DMCX?FR;$ W>@8,B(L'="ZF09,[FB RWE5XK<3E'#*/+[%/D=43.( M2]P'+9%5U"+. D.&IH"LL0EKI;@V MH&1,T:CRX/QL!0D?JX$4N)L([O9'E0[+N:*<6>1A3D#I< )9K3BBT1O*;&0Z MQ:559:;GJSE)PL)YL9P6(7\Q=:4(^X3"/J*AI,")HDPB&6Q"7&F'C(T**:*# M:OR. 9W'=DEA,1G>_1S+ZN2]#=I) MI&/2B.=<U"6QQ]4J^2XF"&QG9DCE)GQU^KK%_8(.MVM MM>-).W;B<55VJ)%KQ\1.=S:.6 KZ/?X8Y?MQ:'1\GN$8UG][F/&U:KX+\$T$ M?.NG?V]O7)8C)RPR+")&)C*&.#4\AY0G%%F42<@4N61+JY29)V%?<39_ T)[ MIXY1A'=JPOOE4G@]BS9; A 1"82788:,Y 'QJ*0G1'DI)= 6<4,RVB*[178G M4S>*!$]-@G!Y7!#(=6+Q?ZOAB6IQT'SW'QH.D/ MT&QO(;.BLI6]8;*]X?>H:F82S]F]*#*>:=@;!$%:.(NTR2F"C28F KL30D[- MO7=Z\O'*!NF"E 4I9Q8I;^'7!2LGQLJA)BP [@+'%N$8#>(B!>0DY8AJDI04 MUEFEU MBBE7^5Y:-7)Z@=ROCYN5">/?70LOO=32^UVK]XY ,OSUO\?^'%_ISEJ!$R78 M:,V#I\88XISFCL(0V&#V/N25CN$_-%SR(XO\FS^(H=>,K?2CDK48UJ#U=C]^ MC4>V<7RQW+=C^PAD-WP8V."^VF[L?(U-^"=T6]4EG>WN<;KVVOP_'4,]_[>V=X'B8"_S_<)O$OL'N5V[/S^ M[_F7\_J'M;UH#24V"21BCA(RH#I9J0A2FN;:3R%0"T 1 3-.8 JZ[5Z\R]!D M+C:KQG&(QP"$^C4L3W20DJ1V.E@BR/;72*U]L4@&=JAN7B8U6">U"V-MK9U7 M"EQ8+95:MU5K]=K]JSOPO':LV4XMM;(72>==;=QX=?^P].7+QWS(#N-2"=4E M!/0%&<:G:4\Z\=W%+W]"TTZ:]NQ=X[CJ9773G^,O$"?738+Y??VO_SQMA.[! M.X-7,#5Y8QH8) .7V[^YZ+,4K0M!'/?;N M5Q+ZN*?>TUBMQ8,>>X_1]]YS&G-C/4]RTR)Z)<*C;B0\:YULX?T0?3QRL5UC M9'ELMWOJL(R0]@GVO!D?L[S)/<2O_R$]?G,CAR=97]-U\WH-A>+'0[:SVA^- MX]I9M.W.M0.O209E:@ONT:?5S]+(MQ-"-- &!]1E&J%#<^$-<)?N,8F6??MI MS;UZ!QD+\(&.^'>AU\XB.:'G^>@?9]N_OBG47]_5>/^>58__,GJ1_6C';I!H*UP_1>^N;T&]^YC:!=H MWVN_=^&]5;7V;\, 86E2SBB1"(HW 0SY(R@B$:+!59>1L665K.=DEW72I\Q M6NXMB0T'\7 !4V^%Y,YQ8Z.43'JM&-.@OU=B@XO8O+K8G%V*#16).JXX8LY2 MQ"5SR 8A08J((\X91E/.JTI6A+Y3;-Y.181+:^E3-LS[">5\2?[C-\QQXW.1 M_>>5_2^C6Z9,$= XNT#8 +*O8;?4WFDD3?R6603GA05GN&EZS82C&F0F2H^X(AX9SQ6RF@'N91?Q'(Q*^ K!#]DT+];C MQ:(1E5B\(A&=R6>\/:/-V$G#K"#NU)\Q&X[/LQ1S>8M!YF:WY\6,#+_5(^*X MET\,IN(4P2=00D=/AS_'=C9R7[I'(%IVT ?LH'Z4>L9 8),$K!/8&L1Y2,AA MHE#$3,!7@G AEU;U"B&SD8+E-63@_RM9G)X9-R8AWP4W7@\WALP;\(%R"4 1 MDB(Y,-,@[21!+/!(><+)N0HWV(Q4"WU]W"@I+1YLP)N<8,UO+.RK$*P[318% M*I\,E?NC%(N80 06/!=+\X@;KI S$?!2:HZM8#@QN[1*5\B,%$Q[?:@L4?0S M2[$*(5#0(K.>"V(KY*"Z(,>#/=^?T=.] MDHEOO9.39LSILFWSO>T.^R9_F)GBPKZ]OL=D=$0$B[#*:5VX(\C) MZ)'GRB6G930BS:4+^^CDUSS,?BW!]-<:P_F_S4_==D;=U.?+2UVM<(4?Y:5N M5HS44W?\)F2%$#9U+W6\HN>GL?!*.GW__ZJQZD5VX0M]8K;_,*?3V=663NQ,'7 *@8I M83O ,7RS%X!8P,!T#V+M"(A%KUUQD;NS.,W2&?0B/>/M!"X,#;F7E!>H;+MU M5&O=XZ/YY).O^4^NL)CI$1ZE2C\\I\Q%0:I%28U -@\_'NX>?H5W;A+0E/'N MAR]TY_#@;VWOD_J/G=.=[;6S3;K!1@,UMCYLG.UY[)55.2T"RY9IB3ER#EL4 MF6)$F!2$SJF1R0VI&>>^_DI!G@5%'J$X3:"H6Z(T]R$ V%@9#5M+OFE52)76,&=@CMS M@CM!21PHH1:PA /P.,.EXQKX#U8.]M>,.\0,< =PJ.#."^'.\#S- NQ;J@(* MDAK$4RX%$8-!)@DM#%$^.M$/39TAW'F+ 7U7UV6#E'# \83U"":-($N29\'!EL@U<#QU0WG(A9=-$L?L-+.!1R75IEYNJ5]^L>9%^]Z7*JU M>7#_7:1GO&AJL-? QZ_Y=]1*J-?)Y6(ZL=NIM5S7PH650WW\[0_L\7ZL/.[[ MKO0M!VVN0OJFDJI])E/]S\/N$+<;C]<1M6PM(:ESBRNDH/0S&R3"5$; K>",-9 M#,#BIN ,6\XI"SS-JPVKP-/+PQ.HF,E)PP(G"%.6#>R@9SIC*8I8!AI8C 3[ MI55JV,J3\_P5="KH-*\FKH).+XA.0P.8-IPSJ2G"7 ;$)97($"Z0"2Y*+ CQ ME@-UXC,%3B7-^F/2K)?CA@7%XE=19$>/)$:0>*0NR[O4^!T#.H_M5D'HB1#Z MY[AZBX4&;=8GE' $!AF=0UH(B520(B3N#2%I">!8PW[\YPR=4Y1CTH);,Z?A MWH);!9\>A4_9.3=%3J+&R+H #))2CHR-'E'&D!JYOQW7LF- MXUYUL'[3)W?EPAV(YNK_N/:_5V]-H3L0*YG#$DY:G49^[KLJ*V_C5QRDM!W( MW,A=@[?@X2W6=5K-7O?V6QZ0JW=6\A9_1(Q>4;Q'?N8^56)J8R+$&\,5C]P: M:7A02;* C7*.X[1'C%FZN.O@TLGGQ.Y'Y-K1_D0V0:_?V>:I/>LL_7M\N&"L M!HTRN=7/,*SWK(R9G+!KZ2^K"?MG_>OV^G]KG_^S]G5S[?WZ]^V-]VM_?ZMM MU-]O??V\]75M>_W#(G2SWNK"P[JMVOO6<96MM$J=/8C9L)&/[U'#V_:>D\X/GC-C9])5,Y>L6AW5RYZ,S+OWU\6.0*5M4P/&-J_O>M MHZ/6\;=NR__\W(XIMMLQ5'^M'8?U_^L!5_G^>T_N'KT>;1/\V=QI44_4?K M;/?#/PU@-W!O'=K[]7!G^VMC\]/7G[L__K=9/US#]4\[9[L__FD VSBMGW_9 M,]Y*+)- 1I*$N(*!M8IYI$GRH.YJ;EWJ\\Y*YM8RQTO**X4UH3IX'C73 7L< M(J9!6JU8O)K2OS\IM6H>EFN7\]+_H&:/0ZT_-;5J;FZMX%M)X16BT)^T^QLT MW@$)+#D&KI,6FDNC7721:6>D$S@73[EG(WH^2:Z>^*[1!:3R#]C.1P>V&LZ!ZTVW%?53VAT.KU8NU4SZAS +9VI5-#:J'^\JA2- M(,JWZD5KEVT;5WN.>T&EG6SS;W][ C1!N;$([)(8Z%0IH) MC*A6/#G'G-(QQT/C&X+V+C)^U_I3F_-:^_Y2[^1Y6*G]I]4,L7WMBVKMP IN M=)O]E7/KFOD%A&.Z)Q0C2^?J3O1/9C>?8WO=^H-J#5TO#0^+Y[35#IUX?+EN M\-M;-WSKRQY7TKG@$H)="/1>#7JO<]2#1@$"39/&5*BEU=9QO+YJ\J363F*[ MOVP>ODK:T4?0"6L D( ;QZ&S7&ND"D]/#^)QGN.FS9CJSJI2+G^U;#ODAWYH MP)W=5ANNSQ?#DZH7Y_+AH/Z>98?R?/W S[P9]VT3/K6_;*-9%6[)3N:AT>FV M&ZY7+<]!K9CJ*0>#Q@_2O,=?%PG>&[!7AFKSN[V'!Q:Z<]RJG;1C/#K)"N]R MK=-S'=]NG.0[EZ'/H?H&;H%6@"" 4M^IZM9D-.ZLU+;AI0>W/#ZTX.'=_EM\ M[ZC7UZGS^&=/Y<$3RN;S],UGG,.6_>=A.+)#ZOM[C,6$#1!;(3%&G!**,I(C M&1RU"OM$!5M:)0_;?4XN>55? +)D'\7M K8&ERQ?E^;E<=$#(@D@T3RN+C"B(^4!:W>MU.%QH(8W"O#?P-[N>G]<%(U M2Q6)&0KA2NWAJL',F-JJ55?[&D]Z;7^0XX(_MUO[;7O4F3\U9^,8^!31R[U_[(G# ?/E/\9WY8[;;QJ:XA?_X+B&^OW>E9 M4&*!(I\>-/Q!YG/#1X?:_YO ]\%ZJD+P1',=N:?8L>1(\,$*;#V3-F,+T0_ ME@I2ALT>M'JH8ZU59==(4;5N09OSS?/-/>4$X4HGE!)EH&LECHR7$F'A2621 MI&C5O;8^6(-Y08X9&AK]I3K0 8A9J7WHM;/"D9??6;3M&N@]L'2N: W$+%]= M7!/R2\>%2]AISRSG%I:5D$%;$WR,@2D^L6O-E646^MWX# +<"M\&+2@K[,85 MANOG/_<@JF .I$HE02+A(C%O8SO'*]0OH-VORU9=:#1=2N MUM2=6-:OPWA4!(HM\@+ M9A"W0)"<508!0=6!:-A.%. 6$7?AUAS:.8$ _&^O>38 R@>P@ BK.#R8#)@7 M)P-:)IFL\)6;+T^@8RCG.9/<*P\36I$!@U4A \\L5-"N_3W&0>-3+"(%\X%X MS&/T&W_Y+;I"7QF2K "N ,B.HYXIR!XJ(8#E"A.(4C"1B ML@I^[O&D&-:*(T4C[.5&*N2,4X@&YB,6F$6A,T.\GB1O''3ZLYV/2#HGL!4V M?L7FV?+]K/'V3>\FUMA_U21[W(NB3J&.=RVWL_KVESWL''4PT@AS(8$Z9I6(]]9H8)6V5T^GV-3 .-/.I3-1!3ZBH5O^8]GZ%HGO0:#]8GP#F]L+Z M1 X(Q"%@#S+&A> V45#;;>2,)^=5')PN$H:+/O&L0D;S488A7F )J@2LM^Q( MF @RVA,D?11*>*?]_<;%>_2)2^6 D@?K$U<<$QZO3P3I$B."*=A0.!?*Q!2) MC%IA;+"4DV=&*$SRT0HL!28)R.XQ;/&D_N'[GE26)EAAR'JB8)L'5@D$3*)( MM$P,MF&5=-8M[MGD)UL1GA.%8[!!,<>54=E=P@@1K&*,2&Z*AOER$,0R!%DB M1?2.(^ER[D;*&;)14J2=CH:Y'$P@LFYQ/77C%>OSI&K%'7O?=-2*%P6?PB@? MCCV'@#W 0H1SL-9@(A#W3L*"RTD+?# )%+\\8[GL!+^AM.&C58P7Q9ZR(.Z" M'E[?WM\C-(+61R+R*N<^TRD??#F-&-4L*0SD"1(<6&.@S*[_W,\WZJ>3L,3LF"_<1U MII^)6;QQ;*.;A^M[S@8KJ;7(&P;+S&./C%$182N3\C08R?DMP3(#;%NI_8BU M^#O3C"H&!I;69?3'$)MN7H;=@W:KMW\ .S=\[!K]4)DJZ"R7:H5?#S*+S?]7 M'^S'XYQB=Q"0UT^WVSJ^B"#I+\P;0'*BM4J 607%$[!NSBTQ@EIGB<5)&XR# MN=EU^5XH',C3UWAD&\>P5H>[\?":8A.<8.W6/ZSM.68(-MG5.6$+:Y%D . X8E<-+J5-Z.T8+J,U@(GBDV3J+L1^OV.DUNS:G M]\G7A0NE#B#]%!2]3@VDYS@#_J7(96VN>IN'(7$YUOFXT[7='MQU-FA8OU&= MVA^#95;_MM49*G2-XYP'*,==WGSUQMC50*"Z[8;O7@8VY+UC>/'7;]\O+QX) MS(2MJ0)Q>!5R%3//%U[>]7GDKAM>,7SXR%67X:"QRI@R>*RM1FDY"V!6]!NI MT2]GEK$)EE".#^UEZ0JTD0RO)T-Y",K0;TS#= MFU;I:AHF*2*6CL+UA!,5=)(X)4&9#3C&7%-Y+K;(ODWC(M:MOT799O-BF^SO M4YDH9:4HVPD'ZDZ%SIUL5O35WGH,S>DKZRNUY\R1]LT? $MKQJUTD1FM^K?/ M4T:2I&WG)"5O.C_:]LX>=S$$(BV"\=6(LZB1X0HCSRB-SG"2#+NZKA6508$V M;:027#IGO)!,RTBB\=%A>S4_6N98J=5LMDXK&-& ?+L,WZ>([.ZG6 M7F6FFB"MQB\SOHEH;/T^K\.:&U75?MT$%<'YY)UEO'Z.*(]61U0C)K%'03UP_JF+4 M\,[Y_CD\[^R_YQO=>N.R@)PW1L9D.1)$$,2MX(MU)Z9+'/*>H(_*821S%:F&C.L+ Y M19VYGIQL[LO/%QF?HHR_+!._H9Y"D?V'R?X(":+38MY H55^M-RQ4E7L,? MNN\4T>K:YL-/D)_3M#-^LLQ $D*KE[U4[SU:OGK^]?#MZ/44HI'(:BD0%QAXL +-*,3IFJ-?&7@J"OWO M*L3EIDC;^8D"7\OA;(,(Z?%8[!R,=+OOR640;4-/%W;/M&E>.KX6,.C[+-'$*98^R2;;1KOW)"F.RJFS^I MFMX\R]%68]D,6OV0Z3 H[5.]Y-;"M,L7*L"/[,U;Q?(,XK7Z M]M4AR]U:J7T?32/?_W YU^X>CTL?Q+E7#[J]W\W8R26"[?&PX["F?L;N1?]O M[&"_(-R@%,Q8\?%A4K7C'-?>CCDKT""P_%I%X"NI,RY#&T=SIUUV\^99AX=- MMI>PI)3&PBAL-5=>.\Z#U\)9I:A3)-R3$?VFO&E/W56&;INE7O?#(BVA38?? M]ZA.(0 '13PRD?,\8V0]IR@RK#%,*$R?SZFN[BW8/8=I5D8RO74/VO&>S-/+ M?<&M8L1]K]V&Q@_3:8QGT,BX +V&%E>ELVW_SCX $YT:Z>VJBE>ZX 0U :_ M#[X=H$UUR240#$IW7T_ .):N[D&=R" Q[$B%EC=W8ODZ:/53DO51]:(+%W=7 MIC3U9Z>6&NU.[NM9E;FD^C9+:TZB,=;-BQ=53XK-6"7A@";=UM'1W? "D(?0 M?DM:E/C[!)X P-[MUXRO4/JN,&],J!,I2"P MS-V/9>Z:=IX;6UW<3ZR 2J=TZJE;>4!IG&K1NSE/1W\+[V_>5S$;/ MD[W@I>IJ!H5.[RCO?.=Q/(="E;ZHC^]9 D?J4E>8/2#4U1,N M,#X\+ _KNZ?&Y\Q+ @6&5PQ[7)C_XF0/*(U]SL:^5JJ#A0PDO&.C+C'>]X[> MC^J/&)"%;MC].(]1F.L79J+/V4Q4EL!3E\!E!M_L7EHENLSVQK\;J8SMQ '" METG%-V D&\<=4!CF4,*JA..3!S9/.SIXUER+)P[5+<,T,DPG<6"/+V-TUU*J MC"IEB.X:HH&%_/GCXF]W:7L-QX2M4>V^>[TF_*UKIH0-+C4X]C*G;?562.X< M-S9*R:37BC%MC!F407T^/XV!QO(F/<-:9)-N\,W#KP?U\Z\'NT??H7WK>&O[ MX+!^_M=/>!??.:S_W#G:/-L\N^*@ 3]:FYN?Q%;GS;9 MYJ8(BXL0R9PBX0+"2?/!%-A M:94O4S9+\8)3$:?$U,4Y!:S;2><346MR]MF9"+4* YTFH@T9*&'**NH$LBQXQ!6.R-$ 7%0* MS_.\1Q4!T8A:H=?]6><>U1;F&5,RD,X! [V0_,=QT/DUB?[QVB0T^V9L5*6C MKM?)'G5DO)R@0C0G@N4O8P9.RCR/(2#)E4-<4(%T"!)A+9PC"K[19&E5D.OF MS6O'2W-D$"B6S4(R7Y9D7H!5X9G/ FA#GDE!8Z9,6A1A6H%G"H8,U0EQS3!V MW'BB]-(JH6)%+>"1S<(\X^U8.C^VVBDVWIZM\]5YYA.-G8-YZ[5CL7@^#K>_ MCQ)1QSF/+HF<% QP._F K+08.1*"3U@#>%O ;78]-??#B>CLV06*M;,0T9U"?TS@B%L32'A+Y:/L,J&/[>&HF+:1Z=<]8ZS&,PPEH7.L7M2T'_SBB; M920I1G%$4A&/>*XW8[!3")8]8UP+03F96HK;V3-#%/MJH;4O;5^]AFMWT]I[ M,*_0W0=BWN@)O]&)@ ;/B "Z2Z4'Y=T$1",'_5U2$BA?8,Q;F&<\0[6AV;*X MWA,#19YBB'V&++:SN3?,9B+;$B#U_*#O1XEN@ADF2C-D7)"()Z>1(3*AI"TC M05OGHEA:9 YMQP M7$29_?(M>N,VS)65\;*[1>P7[,MG.2*Z= M[=@^HHN6E?2E9;X^)#8Z:N>3"P@DG"#.H@.*XQ)B6%GGG:),R9Q\F=.K*4V? MHRYD(1.+0B:FHS&)9V01EUFGJ@Q.0+5>F27:L/ Y<-9',MI.S?XS7E\E:Z$\&P (MQ,MX31 T2LG(*6 M4] W8 $: ;MB 9HFR@V9G'3!*N$\PM99T 8#1B9@AI@EU 5BO25][^05PLK1 M9K$ 3<<"=+M@WV8!(L4"]#29'[$ ,1JBT1ZHC(D2F(U3R!$1$16:1VJ8)%9G M"Q Q4[$ %3+Q1LC$;@*;(&\;+M/;=NZ] W+P40;*7V?0;E]GT^Z4_!U4[^S6& MK&O]BK5V/&G'3JP*\.6O6EW;K,%'J&M_U^P1C'9WN78\&Q4V;MM.MN5X'QJ?3N:C^-RC8>M#P!U65O__W&/U'_O_L M?6E36\FR[5]1\-Y]T1WATJEY\+E!A-M@7TX<"=L-]H$O1(U&("&N)(SAU[^L M+0DT,0N0Q.Z(Q@S:4^W,E4-EKM1>\60YMX(#C%E.F>$\@)2+$+6?#5TWC1A= MC2#E"8/T6/WHYX'Q3 IL(C*"4,25% @(S%! 4C&@<7KDKYTY@V]Z8/,("@PT3^9FZ]-VMYCX M^KZ8+08*,)BP-3".(T<-0 -?'V)=M]T\Z]U\R#U&7BP* 'U"C$\LX_[6S^I_+E?SY\JWWXN+F[L_7QP[__KFS5/VY_^[+][?_?@%T4!?>6/CWW5C>'/YWCR6:)S-?MR M%#7ZN"ZEB%@ZFK0@G*B@D\0I"_"DM&,)*O#ZB+!SY59,NB-_%)!=^!C96^A;YME#R^-OVS7T#>XI@9R>O\N1>=CEN M?);GL7=>V]DZL"%&C%T>,BXPXMPD9)RG*-+ C9$J*9?6UCF[9=[XNP?)D% < MU%]J2Y3F/@00&XN#$E1:E8@AA0SAH0Q-S]4H96C!9&CO0&I%I?0@0R!,($-! M(Z=#1,IK850R200"WJNX=6A]!J6'R%%0$@=**%S348A"$; M&>(&<@1R5U ,&ILL!PI%B$* B@^ZG3;MW EED*WDS!^UT'(\A$],(G@G!B"G$G#;*82,0"3DIZ M[12&\%OR*EU4(U@*P!,$8.^ 4AVY(09YF00@CPG($A:0H\P1$>"O"N?\B[Y% M E[?@I5"\'@A /-CL5$W-R<7R^O;%UD#D]G+$$.9Q#I* U,BE@Y)GUSC&JC-5KE0C: MG#A00*V6B1@)_;G!G_C5:'(C7_& MU\IO"NY0H7KF?,R0X>T4GBDW?F)VM.GG"__*O?[9)[JF+V*!CT" M?>[UGDMYN675AQ7):%AFLH22>+)74WZ1 MK"KQ:G,L'M/S0JC56*N8!"/<1*&E9X*99#16RD=]1\'.3DO?3M-OW3MM[F_L-^L[6Q@^[[W8^M\[^C3\5YKE^=C M]G_L7M3_GFC=:WT_KK=V2>TH[^I^@V?\*O9W_CJ$ZS5J/[[!]7[B^N?]YO[. M%BDF27X^/G M9?W'5JXA^@WG.9 F"8^Q01$3A3AG"3DJ%0I,D.B(\JDH8).S1_]H$)Q_KJ!T M[IZ>EM+YZM+I#ZR/GG%M47 ,(^XE0899@JPG!@O'@PEJ;1U LHJGZW3O'\H^ MFF>B'!VTUO#." K 0:(,7"JN-4^>81^IQXH&_30JK4N*:AP%HP'202CE&P)-$@2XU"(B0F><1*^@"Z^@X^MD =Y"7SS..9 M9QYEQ.]#!O%(I9]6]K?-1_QR,%#_>,U Y;4+23HDD@*'DGB&C+?@4$IG, U, M29O H:PJ7++1E&PT3Z:V>YSW,9O:[L5P:.R0O^+/QDD&I;\LG,Z/T-B4T<8] MT>?:":%2""Y/Z6[\^"^W]L[S5J#3R5!!"!(@)N I686L(2'/ M@L_;+1H"J##8;)DU(_/1>X$++I[E7N BB*<_B,3%1 1!!$0$<28<,IA[1 ,. MT2FJ":]%WC?J8/W&+J\\D&W84HPB+,,XXQSRQPUW#"K,5=12XD7;B^P MC*L?ILO7F3:-DZ548Q1DR!0#UB#'B-+KBRS]SL M>Y25+C?[5A $1C;[A(K6:2L13IE_ALF$#(\)"8X=" :S(8^>8%4AR^&CY?#1 M)V>['N=>E)M]*X4^URY(5)HXJS2220G$.3?($*X0]5CB(+0$R8"(@+(J>7)N M?X&]D#+P6/# 8]9N7QEX/$CK1S;TA.,:>XJ1L=PB+IU'VBF)$HW&A@A>J54K M&GB4#D[IX)3;>2L&;:/;>0%>N_<:(^*5'_!Y.IGI/56R5 4.4=4">C1E:]^+ M[N=Y'Y2GUA%I,74L,"'NW;)A\%;4?GX[K<,UZZRL\ MZU=:/X+GV_G6@NLU]W]LLMK.M\8V?)_W\^#%$_@_H BQ$.(^07B$HT7,%(,; M+2=,#C9,YKJ?M^#B6>[G+8)X^@,AN#=6>^1- EM'A$?&4(9L2@PS>51;1S5/21WCZ.'<36#.'( M'>(B1&0<:*VWSKCH3 J!@ZZ^(PM59E;V]CU^N^]11KS<[EM!&!C9[N,^N@3O M'UGF,.*6"62D$"@)6DQ]H):GM759%:SL[2N+VY^<#7N<]U%N]ZT4^HQL]P4; MN98>*4DE."$1T(=ICIPSFL= K38:XEG%JIB57LBR>2&K$)&4;7W/"P8CNX#: M4,U\$$A3SW/V@((K(@52+B1!F,0B9C!X)\7T/F#IC)3.R$HX(^76W#-G0$:V MYC#5P2O*4%0L@O>A,++6&/ ^I.0,_ \13/8^2!4O4@ZD;+5[T:TYI;SS@23# M:98):2E6X)^['[NT:_'>Y='A[NM_*,QJ\'A'/)>6#(*Z[!>U$&6<4S"2?C(3A!Q=7> MQURWYA984PR 3B3$MDC/)(!JD5"\J"?0+QU+)*5=EJ M]SJ!<*1.$\M%H,+R8+3A4B0<0:5E\(22A=N:*V/=A^GR=>++21\TQPY1;1WB M&DOD$M-(8Q)DB,1)#JZGF-XE7_J"US?9:?=M0-$( M R99161T5,A&FZQCVH(I6%O754/+3KNR$/W)V:['>1?EUMM*H<^U!R(SZCC MG!2TS1X(07F[']#'$$\8T3IB" BXKHI9\>JJ>"%EW+'@<4?9:?=DK1_MM,-2 MR<0$BCE5Q2.Q2,.;1\$91@5XHABO:-Q1^C>E?U/NYJT8LHWNYCF#(\&:(<5L M0APGBXSD$BE+'8L8I(/Q!71H7JO1;GP +1W9S"OV]QBMTJO=O(78N]MI]VQS M,9I$;ASMN/J^8HB2&I=BE!B4RTA+BLXS(;"7&!1OX7+49;'6O.!V\_+?.UM7 M<,M$U-$HCERRN=?+@R>I@D)1:^^L$!0KMK;.WDGR9+1]D-:5-9TOG]YVU@J< M*,%&:QX\-<80YS0O.@AL,&5Z^^T@Q-?K\BIKC%+4(ZOSX!8+7[21!+$8E$B, M2!THQ)I5/I_\=EG-^;:K.1_GF93Y[=6"G[TK^*%">!$)05Y%A3@#XV,UR:12 M.IB42$:@M77"257)!:KN+,.9,IPI>T]>""U^7J%%A"@&)$ B0I-$7#N,K)0& M&692Q%@2;5P.9P@W;RF<*;VFTFLJL^8KAWN;Y\5^X-_X_,#11)67 1E+$P"? MI\@YE],ZG@IJ4S0^,^XR626+U();I,W_TW"R(=J70B\HNJ&RW\D?\[9MG>9$J7_[>[?Y9@1BB,O79\63X M,^=G_&$,9Z"0:;:J7]]<<6\?3L+$;XH'^P!B\ZO1N]C)[VT'[N^O)OQI2=5V MO!Q_D^UO?&]L;^S"L76XWV]'>SO?&K7/627_U:P??0 5W+O8_Y'+\8_/ZWG# M*B9%$DXH6*L1YT$C%UU$R2;Y6B0!NI_ B>IVS>-L.SJL(]909*H1Z MYS""G]ILML^S !M>!^X23=2ONL4^E1;)<(SAT+PU69W!O [SJ.V2P2DU[VHWO MA]_\,S2ZITU[\;YQ4CQK<= _QR^0M\HF=]SR]?I__N=Y(_0.WVO 4%G8Z<%^ MW^#"_;^2:O&G"1#M_TW(*N4W_QE7R8U_N^VT1%69?MQI[[@DUG._64JJ6M%[ MG?:./=4[8V8S]=&'>K8W2B*Y01)?V/C@!QB?&7NN3UW@D8CDIBAH1B"T6JO? MC_(K[53IN\GWW]J^SY*52W_+T@_#"63[\43EOUWG'^N?.Q8.#+87[VM6%NF9 M/ME&I_+=-L_B0NKKH!7\=:+EV2OV1^,$/(SV&9PCC*#SA:OM3;)_N>:J._\Q+7+#WQOIWF\ M=U2#>PZ'^ZU="K_G^Q\G4TR?#FM'/R_V=KX?P[.1[8VOE[6-P\/M'Q#C7GXZ MJM-/+;@F_/[P^#^7M4%:O=_JBKE7CGD4DHZ()VV1Q;S+XFW#E?GS%<^?/P[G9N?/GQ?F)G+HA;>[ 1U,E8'FQ02C#A>+J#2N@EG;?B=7:W3@"5&^U0 M^F[S@[6OH[Z;U%R91!FB)DC$*=$ :R0@F9S"G&-C\D1P\L[,( TJ.P:7V'=[ M$QV#3\2[%W3BQN&N].3F#GG7GIP@BJ08-:*40+AJ(D=.\H283<$PQF4P)'MR MNLKU F'>G+)Q2^#)?2^BF3>6?/MC93VY_NLL/;GYP]KN6!;.4!DSTP,F@>9B M$X\,EP:IZ*.$GS(C9/;D&)MNUYO:&RD3<$OAQ+V)!-SR.''C2%+OS:Z.6IZ?9_:G10;8XY?Z=L] .WV1GT[:HBGB5BD3"[A=P!T M-CB+!-?8RAB-<'1MG>-IJ+N_9U>FYQ;)LRO3R[ITQK8 MRSJ[A09'/^H%:D:U3)P@[^ +Y]HC*S+?1; NY5%GAF5P?&=F^(%/ZF"?@VJ6 M2<(R2?B(AZ20T[YA%0"V0@4QY2G[E#" MJN3)]2QON=?]YK;@7B9QK:3@DI7_FA%VX7(*U3:)T7#<-' !:?-A\)!?U;.;;=RZV2].:?1Q&MM*10, MN2- <1]'2RXIBCR^^1Z086?KP JI>,(841K!6PI*(BTY1@$'DPS7'%N:Y^&1 MZO1^: 64HPG?O'N06 5B ]/<6"8I=\&Y8'4N*!$Q>.)T*,0*#\5JNC6F%*N% M%ZN]@QBPEXX1! B2$+@:#&GB.+(T&.SAU4N)U]:9PM5I,I6A6!78]A#)PAX; MK#TX-#1PFT"R(G>4.*4(5DSZ+%G$#"2+F%*REDRR:&VC=N IN"M"*:0BU8C3 M%)"CWB&/N0@FA"B(S<.J=76ZC>H:L,#6GL;,LA&;%]7*O2WR;%O\K%98$<^L M%LQY%;CQ7!- :X!.A;7U/I1PN>1"S6J7_H!IY\'U9HA@)Q$WSB+MF4(Q&L4H MPSSB;(5)=7K^^J/1,BFI*?4BS[SE,GF-B4X!)T.%DX:%$BV77+#J&U\/%&$X M,"H0#3& 8%F%K!4:6>R9-%9J"/K7UL$,3\=Y-X'ECU@YM+]BY:3=J_SL=Q.! M[%U,@V6W<>)CAD7Y+D-A)\*+BN\JYP"*C5!Y8!LU )NG2EM&/5T[V?NY(S-7[#>[B,G?;2YR\>+YJ;R$\A.J!%J."9JWS[>[=;^6,&&=%B/<[-:8_3=@_NH@&.5J%FV3'JJWNE MT>V>%21DIV<=^.ZD!PY9P9 &3UNQ6>^Z@V-2I]VZ&3U.!ILKXYD," JB9HH( M;#F$'C99ZS0G"=!# EK<'SU^=7J_;X".F_"B^ +O,E.:V)]Q.^W &XJ]6N.D MT3IK7<$ HF\.!_;X]L:' TM]2BYG'WU.1AHMD,-)@\4BAD9+C$QL;7UZ$M]_ M90E9 3FPOTLYV-[8.[ <8)"XA# '?X4'3)%3EB)AK8H@%8&Q/(@5SY($P)$< M;/6*%1U"2A\S02A2XP1 -*-.]I'A2'3]FT&\UJT^4)0" ?(4@#&6JGXB?PLG8 &/UAG)[9 G=^WH:/Q),W+5ZBON,/ MP(O0TG..''4.Q,LPE*-IL*PV*LZS)QG6UC\U4N]BVA4^[2]YEK-L??MY -\^ M:X:*BY5H.R<@:7U'I'(; >VCI.9.07$W"\K0@9CABPZG^EQ)R!L3B^-S^/G MZ\!EQ<,8J9Z< ,]G'N8:CT?-EL"I.-L@=#5%N M<)ZAXY3S3)T(O_Y?N S\V(7HN%D$)I7VK]AY/HE\?[B^@))20L:.YT M5"(F#X&8B#R&:)SE04%41H1@+M[E.3V/N7N[)LU?U,"D 4(%2ZE&@@?PG%,0 M"-Q:BZP)D3#O"<%AYA#K_WJR(7N4/)2&[+E@XM(?2).\CDDA;;!">=L6&4X] M(E(8IIB-W/B[8.*)IJSXI#]LQ%\%[&XU3".M]$V ']!6.^16;[=/B M ZU&$] ?C&OWVMA-6S@X-%UMH.2ZVN(C\/F!/7PF.2W-VPO([>:!4!!]4\V0 MCAC\6.:&BY$(IE:YT%R.Y'KRP=DH6B1/R+DJG[A)B86,*1 MKX>=:Q[@GQ&Y3K3'R":X__>V>6XONFO_&']P>.K!Z4V^_C,LT'K!6_V4&0B+ MDO/]OOEM9_,_E2__\^%;[OM M'IRLUZY\;)\4U= V9^T_785!?_?@%_T8YH^/?=6-X<$Y[\>*SM4T:F;I8#9ZY,SA:8 M'(VE#1Z!B4EY9#<'XV,PXE';1)7F6(55'3A3;*<\=+S,LDV7X4(_=KH,X<\R M78;(9Y@N0]3CSGK'=!EE[K<&Y729>\T-&-W&_6NXC;N0LRF6?ZVO9\D4(WS* M43(+-$HF_UP.9RF'LY3#65YR.$OE#W*SU*PF1^3#*@LY35X:IH5QA#/JC/(4 M,QN==)3RA1S0LA*]X6V\=[DIMC<^0>AVV-C^L06?WQ+PM\/M#?C\3H![^798 M.SJ^J$TV/D*(5]LYYK4?6WS[,QQS!.'>4?-PK[7)(=PC=0K/_7GS8GMGZWQB M!@O7@6$K3>9#BXAKI9$+WB(G1*+>ZBB%7EN70BY0UV/9VUWV=M^GM_MQ0%;V M=J\$Q(WP=BN*-7,$@0!8Q+'WR/I@$7,A.NRHL;HHHZ-5O$@H]^8FL%3^H(]S MS):7QO&!+(Y/*]9]S2DLI8/V /0:&[3"K4Y118\$TP[QB#72D<*/27C*1?(B MMZ,;,=T'5XY966('[6WP.#X-T,HQ*ZL#>",,W2DDQE.>JV(9XA8[9!TV"'.& MN0N,N:1RYR^M\D7"O'+,RDJGT!Y*N+T\KMID32)]\6&KN> M>X[*&QV38C!E7G'+75+<"&-X'I<1$E5.>1=-.29EA;%O;$R*$30DR4 ]O'&( M6R$!!2&NY08SG?NCF.-Y$#)63QXA]5#-*U-\98KO.1W!QX%@62FW$@AX[?U1 M&B717".=%$:<ND5Z]S4,HYXVW^T?ASE)%RZD5'NK.WCIF@GK5<8L/3'+7O+P+S3EQ":M;QQ?U(\\KL-SU(Y^'EA)L.3.(&5S M>CT2BPQ-%K%<\26L,,2;M75#;QU@\A )$P(NJ*TA21L>!'8V."&YC!P+B/5H M.4)DE21L8_= 6ZI)X *IP')$G]NR?1[]P#F3'FNI'8/8GNGJM&/[Z'DB,E&L M%<4\&L:UM%9)^#DF'(W'B=!RGL@J2=G1Y@&CEENF&6+!>L158@A>>T0:$\$3 M"<9&OK:NV"TCOB9GB]R?:.;Y7(CBC.\;(!,-?P^G8K-UVFQ?Q%CYNY@Y\>6L M ^Y:-U:^-.W)\@UI& YW@2O'X8/UAVF<#A_L%!ZL\D=V?09>\.;?7[X,7. _ M^RRS^3?9SVSE^941//9&=D^')RR(O^))I]W,=,5W$(TZIP165@=J"=<^N" " M-DDP+@,8RG OHE%W"X@,.$?=)(ALIQ0[5\R-)7'C&(M6[;)VX%0$U]5$Q F7 MB"?.\G0_C#1)+&@:@S!B;;UW'IN_(FK!.SV>[KV8^9O]P[H-*KH+A%(% L M3R#%R."@P',68ZF9_\L)G!LG'6*CTY*00DA$]3FFP=)2<58HH@P M0Q&WP2(M-$&9LC>*8*CP>FV]V_A] WY3==IG/P\KI_:BL$HAAK-"Q+KO2VK@_!2N;Q-)V*=>VS M7J5F+_I[GH07J:%Z^U=1E'7U2Y##:/UAP21;K7PH3.U4Y=9@$FCE/']Y6.E2 M8!/ 3IM-$D.L5F[]K/<_)GW[O?3@.*Y;/>83L3ZX8R972# M$;VL[=1RH1%$B0RZ^F/+@>GZEZFA-^< M30G_'"2K_5)*/*/Z8U1OD:RJ62+W:@01]\]GE3U"YK&,X'Y_P.QO?P MJ'8$=[BS=5EK?3NL_3U18]G:XC7ZK];VSL]SN+_+VN57N-]-4?^Q2[<_UR[J MK?IA[:AVL?]Y\_=_+K=&J\RE95@;Z9%7$FPXUP8Y:37"0JH4-00,JJBQ-,M2 M8SY7GL*EP[I!'?(@'WIJ87&OB+>?U&RX8F7T;Z*?\G$!^?S*Z(>W-5$D7R2T MAT'Z$,C#TF^SO2R(C[%F1\D5 $XRL >L#.4B-PJI$A5J$5K MDWQ\U>KB59C\%4]BFAIKL@P1[U59285C\L?QGY5.[#4Z_2FA4_4DW^&EQM_# M3V87;%A=DLM%^L7HW3.7RYM[C6(<*7P9;NSEJA-[DL^[6_V[.A(] QIV.?K'+F#CU49??V_O3>_FT?K1[H&)Q!!&,6+.1<0#L4@G;Y"( M1.ND4F RK*W+&\8E@X V.A5;+'51J#*T5,,LX[38OAOKK>C9WEFOW;FH-!LM MT/WB-54KH!E9WN#=-[.$AD;79]UHGUCX9,OV_&%.#?G1=WOS!8O3G=H;#QQT M$.1L=9%,M=W#:N738$,IY^V[$R/@^N!]G;P?JX5_5SF/(XH2\A94IPT2"2H% M2OF0VM$GZLMT[>@-"O.QW84K^O;/DS)O?XNZP'W5#J+#GG)M47 >(XYIA-!- M&)0IKR)Q/!8L,/2VQ/T#R]05ITE+;0FXDCX$>.\6!R6HM"J!ZCZX3+T4@B<* M@3^0E#"MN$,*RX0R)RVRR0FD)&7,*^=XKH @YI9>A0<7D@+>]-,Z.+UV9@(\<9PQ2.W1AH>5"9#P":+ M-$X'%(NU>SG8X\1V>N)^T&O.6+Y:UI>_^OBRZ"KM+\/S[KIN@._4;.?FO.TT MFDKXEJ>Y9_7O]KI3F83N@NRR7M0V=H>:W:Q#_+ZWL]_8;^TWX1BNOK[[VC?/U=NGH[-;J_ M\:E1O_S6K._L'X%F7]1W?A[D$=9"AH@$MBI36R;DF)$HJI $ECXQS=:N>H;# MAPR05 5CK*2 "HQSKK5AV 0M _;)!\4G=V6+G#KJ=Z".OIG*YN_\?9R*RY,,(P!FF( (T>I8-PH)2SEM@BD.T.3U4^[#I;U="#. MXUO&MCL>JL3^>E?.NL.YSR.=L*W8.VR'?@?'>(/LH$JQWSQ5V//!5M>PTBC, MK+G(U49@-OU9H7\C%_VK:4$>_O:'[68NZRC.6^24\P=:[1";L^X"+@CVV^=3 M]6\H^Q#==Q#5^.;95:/SNWS5JV;G?+5&-OLG74"+[NMJ951&1]?L M7>6JXS=WYL.!Q0']P\>N,WZW14U>3E,6-]2[.,UY*@B+KEY?R&]G^$(Z-N>I M+BKM7X,M_D[\W[-&MP'7&#;E]XNYY? M&WOG0A$QBYMOV9B5T-^49KIP/EW>(3V(%8O_6^WOH MVH/Y;SO>C_2E>XD^-VM$6J1_5R%ZK=E&[_(KW-_8/ZSM; M9'MC3^Q_WF6U'_#SC_KQ1+FEP!J+H//X':L15T(CYYE&V&DG)1>!<[&V+F?0 M:I4SL$L86DP8RE7"D;DH#4_<6JZ#(80Q993B $;IP;4])0P]#PR-3*:FE&)) M, HN*<3S; AKA44J!9^LPTS)M+8NJK*$H1*&E@6&3 R,4Z&5RN0#V!)I@Z2$ M3!I64E##T+#-5'.@@%N*HL4,0J&#RF^Q&VW''Q9%(2'^BLWV:='5,>QDC)IF8\O+R&P1L.CK:&0&LL,BIQC%& 3B7#KD@M?P?ICUEA.O#5U; MIU(_/3:;X\"8>:?:WKSF)B*#],D[Z0*7"1NAI'!&2^*32":6P;2ZI,[6$O-75S-#>#@0P_R%M3]U6NI_C?V.)$9EJ4*&O48+5W_>,3?CESW>5G_$D=FRSB!AL:#5. M&MU>IZA(G@X:^A6+#X&Q^V9HEAO&@B !XH5C]:7H<,B MP-CN:.A@0R2YM!5%93'B6CF ,450=B*CE-)3C]?6B90S.NB6/I]::NY5 E)H M$Y*RB0G-.?..4AJX]M0RX[029>BP()I['3IPIZ,A>3O6&X[ :^3("JH0LX"Z M,I/4I9@UE\SH@2XU=V4T-TC+@Q/8"Q*YY,DP1J*7SE+,0)\?/MZLU-QGT=RQ MT$$0JU)"3N>M@V02TLD$E"1+,5/P.ROS&#R\4*44+UH!>6/H0"=#A\EN#O2L M%%FW:FTQL._N+HY^7RC\M7$"'^CV^IVKV=R%D MHC1ZI$.@B$NI,H.'1EQ(PR,GF">ZMLXYJ?)EX6)]A?3H&];YN=,SE3K_/#I_ M';HH!4JOA4#.28FX"RH/DDF(,4-#PIHJKT#GJ9DQ![C4^5+GYT_%5>K\L^C\ M2- #,NL9H019 &K$BEQ$5-S5LHDZS(J]=R#C%*I7T>I1TJOB)).8(VD M\."0)$>1598B+Z,FVGEI2*8.Y:HZS;Q=:O5*:/7E= ^R^Q6PV=^6FIEB;OLYK] BVTM%G]OJ1Y[VPE,1FD4 M'F04?H[&;]PR;2(-* 9CMZYISDHT"LGI$LH M+:%T5;;L2BA]+)2.L"]8:U/P#H'URVW/22(7)$:2Z.BPTA-)'0NE(JL(2,'W$)92D)."5"HD,Q1H1HIRQW% 9]Y&5?7%[V M,6^DY&8ON=GG2*,W8[1AY8_QT89/VC=?M5S52O.4YER\ITI;1CU7,5EI\L1U MQRR1VNN'L[87X;6[)00?1.!N,@(?_7B>($!6)1/%:QM?+[<_?[VH_8!K'=5P M[<&S7W_# MN7GM\Q;=WMB[A+C]=ZWU'>[SP^4$L[OBCF.F'.+*1\0#)<@1D\M=K7$"*^&5 M6EMGFB]40W))JER"U6U@I8AG5@OFO K<>*Y)PIA)JK"VWH?PX%W&$JQ>#ZRN M=R IB]AB8Y$A%.=B#H>L]!CIY*DPSKLD>+^1Z,D-PR58E6#U4MRM2FI*O0C* M>BZ3UYCH%' R5#AI6'CP/EX)5J\&5B-[?-%;3G5B@%/>(/B6(!,E0P(S!Z;( M,5N;5V8DEE^E97;1).(I&"\ P=%US8G:R&P %L.\J$?3@]9*O>K*?=( M7*&DTT:*A!QQ'O$8&7(V640)Q=J;9WR5@9Y M2JG<*Z/<+%H7/$UW,C; MQ>=L'+1:PG?;Z5OT[9\G\'CA"SQN.V0,ZWZTIXT>+"7\]D,+WDJO!+4'@=HX MT3RA 3M%4>3$(BX3S5,W$G*1Y@8V;*F,:^N\2I[ "U5F0A=8R5^'P[%4\N=7 M\NNP1%#F'>$ZSZ\#)=>.(:L81H#F7CMB%4^9Z6?&3,Y2R5="R5^'TK%4\F=7 M\I'PA"E"'"$")G.RRW08EN9Q:>"+&W&@VS&&(4_XR+A) 727C#$*4G(2 N&0VG&- V,6C&G M,6-S5YP%[SDH(;2$T&6A@"PA]*$0.D+]J(V4RF"D<1X5'QA!SCF+#&ZU?$TR/.0:?[J]'Z__]L?QG#6C.VT>]*YRGG.+N 80,=.?KBW MS)U9O_QYD+SB,KJ$'#<6<9^_(\0@'QG&DE(=65Q:[LP^IV5!AMFGI8R]3'39 MZ1T64GHV(BEWJXSM9NF>XL]\-TW F?. 637Z]Q<#L@!)]F>LG!8I^$H;?ARH M6N_0]JXSBMWB6S\HEG"Y=&)X?^\K2T7,:7"54?487D[!JDJ8N;-'4ES5Y+%T MEK==DA#U/#?+7H3JTBPIU>6'V=HX5_;"*9K'!Y,7WAKJW*C",U?_E=9YU)I6 M!H9S]M[&8Y>M7/Y;EO_'I D9[.<6EJF_HSOC;;R^X"\@8MS,VEFNTO@J%7SA MST)L>L^Y@!)<@(4:#?@V&$W?3D=DR21:\EV-9A\P]DEP&:CSC@M'M>>4B6 9 MMH2X2 ^VYEAH76^?_ +YBZ%H%>D6Y2:3#2/U=F\O]JZ+MU8DS7EZO/]Y[S=\ M[F)[I\;W+C_ [_/W'\[KG^&>?\"9-O:;]FN7U2Z_B@E>&4HU4_ N452,(YX"0X9JC!A+\(\) MPH:4=XK80K%>S;L[[&DE7@NKW3.3B8\B!GXA3>X[[9_:G1%/'JZ>VIV6[<&] MPY)WHW\?SCK9#2NU_7[:?KTOC)-EBON$A%("<>XMREL9*'G"L:+84&3A32,BI%,L86JL!- P,]JQ5H>=ZFES2A96N6=O-SZ&0K+T M$)98V2]&6'"9Y=YA9'U(B#/AD%&2(,-5""01" ER/WD5F_EZ"$N;+2GYHQY$ M8"F9M8Q@X0+G,0HKE2>Y&,I;F80H'84EPXZQMFT=>)11*A1QGI*;6:2V?M>.C@_ %N;AYBD MH +B-H^'TR$@084@>5X-O.VU=2[$T\G^YJAA2YCDF:X->'S=_/,!1W'&]T4E MO+]'67 _V[T]D>V^9TGMZU82?&?KU.)9YD,H(9](1J6]U=" XQXK]WI5BMPJ=RH<_/QYXW>8:7;Q\<, MPJ%P0+OO!J7-Y[$3*S_C2>S89O.BN-T,EKFXHE\'W1T^15%6 \<-;NBJUZ!: M^1$K9[E; 3[T5Q/D%?WM#]M-6,[^/51.0?#R"5OM$)M%GP)< )S?_B')-CJ5 M7[9Y5A3OC-^\[7"&NL6Q@[_&W['C&W"7^6-%F?AY M;#;SO\.;Z3-#6%C#UN#J(Y1X^4Q75=_]4_QJPU\;S4;O8JR?XUWQV4Y^.OAU M)_;..B<5N(%.HWN,4A:$1F&.,@ME]]W$B?N5YZ'?I3&L/8\C[Q)NV<'/9[UN M#^X6/O7NJH[]ZBR@(6!@X;<7C=@,.="XOKL[5M^.K7^^[5G+/U'+" "3C7OC MY*PPIV,J.E +F3-GI^UN(7OOBW5M_(J#*O2!]S!RU$"C\?4AU@%BG_5N/N0> MY?6+@@Z?$%,32SCR];!S7=KX,R+7B?88V03W_]XVS^U%=^T?XP\.3STXO/)9HG/593:*>O6T0CF;;$**>XH<&%1*SFU))$E16J'T84 MM_LAYTYL]!1C+B(UBO,0M+ J>!6U(19'Y^Y0@5<"@"&<%[@:K_"^[P=DYH(" MT[-9KQQ:,$G3+4K%D2B_UE$ !_,QV */^_MX5C7V*GB)7F.[*-SF1FGB8^ MFV)F_FN2F7G@^7W.C]G=.NFGT(95]A_ZBU#\<0.6X!.LP/>\ %=!&U[2H.WQ M;8*[;'OG^, ) 9KC!;)8:L23R!OD0J,0F'?,<&U\7%N7HFJF"6O>/4IBGC@' MK)28UY,87MNH'<#KXA(+@H(/%''I<"8[4EEVX+=)<@U&.$ MYHGSI4JA>4VAV?EPX+EP4?&(+',2Y3(K9(S5B!K&D_,V$ ^65Y(JF^9Z?PI//\2DP&S>?;:;8T%$F'@4CD%]V7HNMXL.Q$/SH^H-P2P@$A M+-4<<:,TTAS>OH!]" MGW6++O?[93"*Q$UOK#]^R@\N+?WO/CM_W\Q)2-O+-['8:F]RG]O$O9 M^?W 3?8B\=.=+^GP5OW3\\9:8V50[T_.6BBT>VAP TL?9PWVX!O;G[^2[9W# MX_VCO^#8G[A&_]7<._K7,03@Y[7+#ZQ^^==1?>,GVYLDC6MM\?V-7;']^5NK M!G[Z]L;7R[W6]T:M]34?=UG;\*SVN8:W-P+XYYMC@VL,(5H1A7QT!'$F!7*2 M"40<"(05');8 NZH=PQ/QVBOW3K_9M7UB02WI;HNE[J.T.0JS"-W'+%D%>+< M&>2("BB9F"BU,5='@;K2=Y)-ERR7ZOI*ZOI$,M5279=*74XS?;N][J M0K2T$O>P$K6Q&,PI#^^5(8^I1IPJBJQ,%E&;%.68"JWDVCH353QM(?[KM9VZ M55;$)Q8ME(JX%(IX'5T%\,:I- J)E Q$5Y0AH[Q&UF*/DPHJ:ELHHIXN95$UY@Y% MG"NMP](YX-]&>@D 6*W5S0&^KRKGT0K@RQL0JP5X$HAQ2$5/$ M/>;(8>>18XIY(JP(,:RM\ZK MW(NE>FT)^C:H_SI4M>61-=&B5"394G 6S3" M(!XC0\XFCK!*V&JN/'AQ6=>D*G7MN73M45YSJ6O+H6LC_K*74<>L:QXK@KB3 M#EEI!(J42Q>8X@H7=HW>KFMO.SM]Y2W;DY,SV[SBH[F9C?CMQ.335'A/3$[/ MLXCP-J39&+S$P>>[X[6%J?$[!G09.^VRK/!!Z#-&6YPHTU'YA(BQV:L.@#Y& M4>2E)#X$9KA+:^O_[_]H2N@_YU,&7&;-[D$5_K3$=:FARZZAU[ZXMTJ0) D2 MED3PQ9U$+K&$K.=,!1JM(JK4T!?7T".1'!A(I 4K3WU- GDJDN$K'%%''$KR&_R1CA94$&&F+.P2 YA!.5)YS^3$2J!77(K\VJF\8A9>!*[;\=4BO"KRZMQ18?^^\LR/<.LJ MWG%SE4:W O#ES_KDJ=><)[V.A0_ #VTX8PLNGBXGT^^TQ?>DVA>WK6\8?P^Q$FU()?I1-;MG%2 MW"$(?;=/U1+AY'"]0YL94/O$O?FG7B53ZW7B3WBR3N;*[=C,Y=OH,[V 'AS' M7K52*LI+*LH-E7"OJR _8B&#?2+@V3."/N]6_JY4=$,7N M6>>BTHW^K--7!A"WF!(HX) W?DTQE-E^[9!(N!#:K([M%C@<<*9\D2M> MH0+Y08"OB(,'-$19$ZJE&+\*WD]L,+^N'.^,LDI/;GUWXBD(;L$AFX5I('&9 M*[R0QR&!=V?T%.T)\NHKZO##!F!R)T<>&=GM&$OU%>OY%85WIMPZ;7=[*/-H M5_K>2M^9-ERC5^DV8 $! MYQ]PD2'S=B>"TH'?U*Z<[P*QKL$7G-I3VPC]F0(#/,L>RDE_BD"?C#"C?BS< ME'36.P/@R^ZUO8"#KD3Q(5[PPLP<^0;*!:N0%;]/0+4+JM,?"O$E=HI,S8F/ M@VE9LS^\?)-*?@SF>F16UN$#]<.CL^+I[Y@>8A\V/.0AAFQQ%JCO6'_Y>[>( M)'WL]"!DK+2* 2[% X(7E-T!N);MPURU\C^VF8;/7AR9D3XBG\'0V;.#^,) MW.) >O);[\("7%0*J*^D3KLUF.+TH.IDHKV/FBDBL.522D YZS0GR1(IP03= MWR3]ZO1^WV"/;C)"Q1=0]9P+AQ>YG7:*]:R!@]8Z:ZULLO8)YDC4=O8.N-*& M6T50H&"3.)81::$,HL)0PJD0T$1DYI'Y/WC&&::2^G/93_ZLO"<')6']%LJWV6DWX1 M7DSVURMGIX/\21.0JUE,+O*'.=C+;^C*YIR>@N4O/)5I>.U/,KH"T8%9+Z"Z M"/@ 96^4Q\8)H&FSF:\U(921V/S CY[P)PG6D2&A'<" M5[WVWK\X;-KBB\$I4W)B#'%_6=W0,(DHF@-N89&<5(\80T,02!A6.!&FR, MX@.A0'G#8'*K<)@@*V;,#9)B)QER.C9[9A=]*2F\K"Z\U^''^[!4P)TM]NIB MMSN*<JJ*.8T'W?&3V/F5@68HS! M8/#R$N5*.@L.CO216*F\#NXN'OWY32S;_-^S1N\BAW6=LT*AMG-V<.?0GI2S MS![H*_TDM,G@ GD4B/B/+Q'A1U-9&U=D*HBK%ABJ4XS5.< M=CX<)+ NSAF+&/8*<<- G!26"%P5&[QPGD<(X[BJJFFVO(DQB[<&]"\P6G'H MGQ3NR= [R"M1SQ"#"BE;4HD)3;P4DV%9/3L+T0 M08!_DKSEG NOL08?)4BE*74^V,FYC#MCPP7[ P [,35!;/J[DK?-&\QU6U?% MK_<89YAW'6>X9.]O;*1]W!C#F6[^G0M3CC]%YSK?.ZI= MUH[V^#X<.S'_T&L!L9,ER+L [K,S$MSGP)!+#C,?F ,W>FV=\2J>%PMP.5#M MZ5KZQ-18J:5+H:4C@SF$H$$2AWC2/A.>:&0P*&WBR4<6@C3%/ !553,*Q4HM M?24M?6+&L=329=#2$4H%&0O\)2COCR*NO4.&>888U@*SR)S1'K24W9>!">(E(R#.ZF+!(YZ8" M86L"=R$XNI'5B4 M\P)*E[S4PGEJX;5#K@!JC=,)@4M'$8]>(1MU0$X:Y:(QCFF1M9!,%T.46OA6 M7>Y2"^>AA?516T@PN-4240H1,0>W!UD#/RIIF-/81FJ*J1UXNHRDG-IQT]2. MF29GRIT6=LR'0$\/>Y3RC2)!"W@8"EQQ0I$1GC1$NF6#D(X,4U](G9 MZE)#EUU#KWUQ$:,FGC!P#2CXXA&#&R[S/&KOK7,4FTA%J:$OKJ%/S&27&KKD M&CKBP1.=F+5>(B:#0YQ3@8S+Q'$F$<83IQR31XWJF"((6?+6]UE=5WF.P3VZ MKB8G>ISEFJC+_/?AB(;BK$/VZV+&0KN;#^GZ3L/E(V!-.L]-?/Q NH,^R\&@ MK?0U.9DKUK5_Q8<0U-Q;\FXB01GP5B1"O#%<\;.SKCZ^+*JJ6+$,S]M$NW7BVZVX8W]O-+J^V>Z> M=1:G"W9G_UR'X[^26NM?K=I4 M%^P6KK=V?]?!NH!5^=V_QY]\?^=3<^_H ]ZC<*\;NQ=[K;W+_USNX?K&UP-& MM0J)&X0-EQ!FZ=Q1'P6*FN49&+#:4D]VP2:5#$XA8LDM%S3I9)+5-+AD!!;& M3';!]I>] NL.TG-[-^K,YM*[KS=^?R)X%PVE 5/*M;!:Q40- Y.GC&-8WHM& MZ?4M56:.!MO2/7-'>1@)6(YB9$F*(;-!OX/;L;W89Q+/G.'@HX+9*E:ZEU?Z M!5O2^R_XKV)*P[6.P3]=<* _G(1/_=M;K+;S5U"XVM'F >6PP$Q;)%2*B(L M7HC*/*X$TRBE(99/*1PE7KM,?9&8XTI(E]O3!3:&*NVH9+/:SN$MG+9/^O28 M:2@8KC](X[33_M7H9OW*/>.C0C.D]BFH83-]77]'/S,7@J>R$7W!R5UA_29S M^ HWVFUTB]DV:4!?/VAW?Y&^\SM7YJ7[SK6J2JX?TWK>=EW_J)]YP,%'JCD\K0%O51?^JJMS\/ZUN]<*"(F5VJYNLMF M+U.NO(/3-G.P_N=SU"=.[;DNS/YJG@I3C(@!7WAJ3_4A3XDK]WS65\T#_]\G M/>+HHQ6,C@OU; _(<3\J>KG.<2,Q.S/P[W:W^ZG3;@T85&'=MD]CIY_!FXAN M8G<8WXPGKD_.6BBT>VAPL:OLM5S2<*>?O6[_KL%/>S^^'^T?'?_>^_$50IL] MO'?TU_'^AA>U#;BO']]:]1]?27TR>WVT>;%W"=?]46]M[WPZW-_X!N?XUJA] MAON\/#ZOM7(V?(] F(0G&I8$"TPEY9&-02&N@T5.,XY<'CN>A(G.!3 1[S## M577#Y).GJ,NPZ.0!:C//XK(2O%84O(3B-&FI+5&:^Q KRP.2E!I52*&W+&% M7H+7XH+7]>:X,<') . 5B9 7I$CG7A"W .DX6"QL2J#E]80]I?@58+7DH!7 M4!('2J@%C." 7LYPZ;@&/PPKQ[2_H[J@!*^%!:^1N@$#KY<(0U#RE" >F4#& M1HU,2$9+HQ/5>&V=O*.2+11XS:G4^'[1[HT);/(:.T:%'@_V628VRR=AG3YL M06;"\U)CV")$CX-75:+4@U!JK._.8*PI2QA19@WB1"2DC=$H@2$RW!=3M]?6 MI3%/CPYO:4EX+@?KOJ6.;UZ;%R&<*K7YD=I\'3 E:CAU4B+GC8. R5ED9?XQ M11JM-H+DP@UX>=5I?II2FU=&FQL!WIH%#>^_0Q+4 GMLUQ_,WRD>^^Z MKFA6:(X+M#*8OPCQV.;O7L?"TC=.;.=BJQ=;W7K[)-]EI]V$A_LYI%XJH"BRB9/-K+48^LYAQQS"UC7FB1Q\31=V [YI9SFI\R+GBZO83E M$I:7,K N8?E58/DZ+/=&1,]40,3G)E^" S*),@3F.C#GB'&,KJVS=X3(ZO20 MO!*62U@N87GU,B0E++\&+(_D5[@C&G/M$84@"?&@#7*>:.2QYY$R(0S+^95W MS/ 5@N5[-:&_5-/;QZL&JV$#'*A&9CC/G.ZRR_UO+]5;]Z1>NK(G;LG:S);J9LN> MN+(GKNR)*WOBRIZXUPDF/YYU.O!"^E['^WOHTHL0'Z_L.>9*<+O0N\:?^M0C M3]F:7[5$U:Q'7)E4T]PW9@?(-)"CJ7AY13)"IW"> ,=]_5UK??V]OW&,]R[K MC>V=OXYKG_]UM+_1;.P??>5POD:M,V+S8W_AT#/=W5*-;HO;Y MZ_E>JWZ\_>-?K?K&3XB]MRXFJF&59X$DZY'SF"-NI$)&28PX!)I!7Y=;6"9]#[\/B$3^4*OOLH4NILG-2V>O0Q0D: MO!,.>9$]!$,MA"Z,(X,Y\TXR+K3)R9.J+#5V=37VV7S]4F/GH[$C/KWP4<=, MGAU#'KHKN0?[:A2RCL=(0]!!^T)CZ0)I[,+PDTP,I:"OQEA2\':6?"6OX_P7 MB__A)/R[[SE5O1Z(!J:+4(9'L_F/$J:'H_[/WI4UM)%O:?T7!.W>B.\))Y[[8 M$T30!O=P;P-MC-N-OQ"Y@FPMC!9C^/7OR:H2DD#8+ ()J#O3&+1452[G.<\Y M>18K2$1"1D^QU5Z%E,N-+)6^?=0XQ)M; W1Q]0OWNP/;:OC)\,5[V ;3:4MW MS*%\TD#V4(;#->E.-8+="L$.)BT&9S-1U(!@,M>+-MXC:Q)&B3.AJ.",Y^ ) MP>F\T_F6/HFZEO6%&ANUK,])UL=6!I8X+Q-#&A.+N+4:.948HCJ"B2&)P$0! M6Z&JEO5:UA_30*EE?3ZR/EE*79/(K&0HX"@0Y_##&@9[F3#/I!3)1@]Z?7X= M;!XG"?^Q#C$6(8@;,440AW"?_*EJS#=:C#LE)-W4F?-R'_(%1<_-3LMZY@?[ MOSRN(=R' <-OES7G""RJ-:@UZ#PTZ-&D9:P#D99$BV2('/'H"=(F!I2D2_!7 MBL: 9*G"Q.1=H0@C\%292I* MPG+K+\U7V1))[@LJP7"/3)FG>WB_9%R_7(,:?>:!/E^GN#XL!K:"H:B80YP0 MCAP3 @7FM+$LZ:3=RIK1,U*(;\[UZ]";)9;>.9#]6GH?57K'K)\JZTW.G;$: M4\23B$7.&[!^"@B,N0H4YQ9>9D8:32V^ST)\Y\#X:_%]3/&=[-D589&,=2"T M(+F2S097IAT>. M>[ CG)$14^:Y<2MK5*G[!RK4TOXZ)"EJ'RV8'42JN1477[X\FJ?6ANBO:SLA+K -\#.KO5[W27Z\X@D1$PHC'()&S-/\F. \61R&!Q3&MYQ9NNO@NQG5S^1HT MEQ4TYVX"UZ Y+] <3$BRG!'GN4.@U!@"\T7(I#QH.B##'(NY9=?4 MH%F#9@V:C^9)J$%S7J Y]B!8S[A+5*(8: #0=!)9;0,2GC-OA28JYN!DHE?) MLP'-PL7PV\#"32_B L@[$-!]=_93JDTLQL+EV\TNP$^.LUT8N( ML:1% A9BYE*(Y<3/X][H>4[L442N%^U79!,\_VO;.K5G_97?I@<.HZXN;_+] M'V""UO[']>"F4X^\[%-_I:5W,?5_;^[M;_[3^.M_U_>VU]]N?MS?>KO^YX?& MUL[;W;V_=O?6]S'7AQCYK*U3_KR$&J4Z$L&[:"@-F%*NA=4J)FH885P9Q[ LU6;Q MN.NYP9T07@H;N9.2PT>X)_]0;?KU.RU8P" M].Z>Q%XQNO[%1_Y/N5;U>J2:M5R7763M71177C2G&M%HKK$D,J MWQ-BE3-Y[=MXE5S[WH\N2^@JU_1.E_WQ+8G0]<-J?J/+_N0LZQ8%P'YPNE7I MJL48B5=4=4'1LF*Y07VXYSQ^_++'3\S4^)_]H>Z[*SIOI-7N4W[NQ82A=(9M M!UI[KB>56SOO+CN0-D><8\Q<886FV>OZJ ?UA]%23GWXPMF$Z!-EMI6WJ7WP MY?CKSI?/7SY_@O_:F_AS>XL??/E*/^]__+[]!;YW?MR&S[:O>IL^-W?_>$]W MVCNMSVW@P_M[^5K-W?W/K9W]S;/M+^ML]X_/Q\"&+[> U8D3'EU"7+B(."<& MV9A_V,2=MD8:;K*S:14_@:JOBQ"@?]VIZFI=77I.B'3/8\ :D98$D<:U.2P1 ME&%I$!&YOP3#"0QV LOGB4Y84DJ$JA&I1J1E1:1[GK'5B+0L1Q!([$J$*:Y^Y=$6PM6&:EHJ@1Z<:(].S+\A?''F7\\*M&)PZRGW7D@76E M[_Z%545\5"N3W04_9Z=CQWX-G+<#SJGFPI)A[CP1R%&>P[\81UI)B83&8'-R MR;BV*VMX1IFFA?0Z7#PTUF7>ELY"K-%DL6@R-@P-PT%XPI#3@0 -XPQI+2B* MT7JN%(E8D(PF5].E:S2IT60YK+L:31:*)A-&'7:&1$H4"CX!FM#DD:6>(F<\ M5H$F*J2NT>1%'1B6]5HG\C_+&)C0!!G-30>;=>>JAS;8D)28M&E6>(ZHL MPIBK467>J#)AU!$K##?&HZBP0UQQ!32%$Q0Y9U93A;$7&57N77KGN:#*LS^+ M PEK^%X,S<&]RHL^02A\=-OM]E@(+[XMUZ9&O=NAGI\TSI+2EEEED1?!@W'F M,3(8")405!,9+>51YT+EBV]%MGC JWWB#X =B[#.:NRX!W9,=$+33KK@WN830^77?:\I_B M[71A3X4A?,RU8E6B\,.Q[<7?;3^&MQ,+_;;;']20?#M(GFXGKIC5BDB',!<, M 21K9!(S2'A" Q?8BIAR@,.],Y&?B]^M]MD_-T.RAIN'AIMQ_P9N(]%4!:2B MCHA3+9")1"""E>$ZB:1T;EU8>_AKI%G6T\$::988:<9-#T+0T5N)D0K :7BB M MG@)9*$N1"D<1Q6=HW/(#8O#VF>?2;>GUVP6P>QUVXT]YB"B;DJ/GY"WN&E9C"E8E*"_"5QN3:S5WL52?[ QJ M3]VA)J$3*AT2UPT(0LQRNNL5)3WT>\/3LPGEC M3XTQM\68L2THHP[&Y_ NF>MR8J60880@%KEEF("V(2&?-JKZM+%&ER4^;:SY MS+)BS=@:%#Q);9Q$C /"<$(Y,I1)1#2SUM.$F<7+P6>6"'26YNAQ0;/QL>/A M26VS4Y1N&;7TJT\-E]!4+)>J:7,D_E^CA:I9VMV0$T]:@AJP43A@:6#T<03, M3")+&4/,QZ28)L1XF3WV]0%A[;9?^FHM-9XL"$_&5I_3D;#H"7)69JLO>J2E M22@YP!,CM>*Y&P.9<0)8XTF-)T_5]*OQ9+YX,F'98-00^NE&(O]TW(!X"M%@CLT+8: M)[WN"3SV6:-8M/M8=B_%:;:80\#-8AWWJV7<35L3B_A7M89[Q1+67K3Y8BV9 MM 6)DESFL/TD<M-IU_^P/!N^ 1S7NW!9WQC:C MM$BWIU'&A<8XE)Q"A7B%NK44F M2HQ<)%[JH+SV18>^JU3MA;KC:O?^\AX7UIBR0$R9#!1-C,.^0-G3GUL[!.2T M\TB9%)V78!D6#=QK3*DQ9?EMP#EB2FWMS0MKQM8>]5QIQ@VPEESZG'.%C+$2 M$4\==QA3A=/%3JD!:K-)Z^#+L#]JQ4Y=JOC50 MLJD,0<&YH=BC%&U /!*'#!<1125#"M3F^C'9T".U3[[VR3\3&Z]&D/LCR-BL M2S0Q*L".$PGX%@_)(I=P +/..V6CITK*C""F=JK7,/* MR-J$@3="=YAKQ^2!C-Z%P69#M-'OMIJA?.?98^CC'.&]A5LV.T.8R=V3V"L+ MN-;(>4ODY%-G=5I%)DU$U.?4/LDU,CJIG(J#4U \4.U7U@B_?\_D.4K0DX3< M!3CD:[1:J.%8H]5\T&IL+D;!1,!2(I%S!CFW.279>\0,,5X!>QQ('H19XBT.$,<]AJ/:G;1EPP- MG_\YQK[]=\=^,L/=]A;>:7_\OO/'-OQ[\+U\QB/^>?]=Z^#+.CZ@\*P;'\] MS,]SN,#.QM>SG2\>[^QOP;.\/^0T)& ?'(B)UH@+2I"-,J)(!;,DXBA+,^J* MH/^K$:\X*')01R,O5^/4]ANM[FGL-0;'L!T'Q[%1!!WW!W8P''1[9^7G3WJP MGCW8CXTPA,MT&Z'9][TX*"]9]4'IYVCD7YJ_-O[KVBTV[(=+^RLQP"G@R8ZK MP'DT6C*19-)64JUH[WF"W;L4$DH!"=X"J^USL1/FB-^+ZV<[& MUJ'WC#E.+3)$4L293TAC:Y'@EEGE@I:!KJP9/J/W=@,0K97W@^WWNQZ6(X;& M:7-PW("=U^S ?K+]V&A6NQ"V#+S]'X"$T&T7H3#J3;_Q2_Z-XC-_UQL=UCN?#Y1O\>=F(I![EK MSRD\'>SEO&LF9 8^M@[;OY4_QUX5'_RE>E__?%^_/]W9.#KTF!'FHD5).HFX(PR!\>Z0]]P*D9O-)[FRQOF,6(.+?=V+ M_6$+%-E1N?]@6^_]MVV?O-DH-F:9J '0.@QG&6X'C=-8=)1JQ6H_YL5?;4S' M^#Q/6G%/_TA-*^Y/*[YO;VP?"J_Q2QV5=&G@E-=2Y]409^ 1K6#GH6"_9%KIDB*:( F*%G$.D&4( VYI>'"."T8XF$ODJH/N!PJ6F#LK MV#M*8B'*O4[L440.,/TKL@F>_[5MG=JS_LIOTP.'45>7-_G^#S!!:__C>G#3 M6R+J8J=>S9SZOS?W]C?_:?SUO^M[V^MO-S_N;[U=__-#8VOG[>[>7[M[Z_N; M&\]AF#O=02QH"V!WX:$O9/]=LV.!P0+!^0 ($HN(P<8O%;S'\.M#C'S6UBE_ M7D*-4HL(X:6PD3LI.5>&6S#7F7$&?J4L!%8JP.)QUS.-)B:Y:*AS"B>>.#&* M1Q>XEI)&'$B\D0@L'A$V(M#07H9G0%F@=G%0]I@&8\.!Q3%HPJUL+P(@9\H( M7P=:5N!WMU0+H0EJI!<[/@+B#TYC!$)TL=C]T6(7ERRT GRWWQCVLQ-C1/5& MZJ>?^5VIE0I-E"]_!BHAOUP2Q.D;E@\6OY]$7^F7'FB-7C^NCLA,=7@R!V_9 M-%OYX(]C&+;B;AI-'Q"6]6+RUCOAS_'4[6<^O0^W_KT%FN_%\94#O+U_=.BP MWI$H_S,.*&UWV)R'*/XTX,5<^.B,TI%*!BSG9OL( "N:W M7HC?1O0QVXT-1E[=)G+[I],R$7 M+O6\9A;/=?^9Y[C_?@&*5?DN^[\N+BU^$8$X,PCPZP?-6%OD-5Y.VLQ.KEY7 M.@W!U&AU^U8F;3X=;-HB"NV':[H_WT)VRGM[;7.P,S]=3V0O_)GZ!58:;'\%SP#%_Q MYR_OVMOM;7S0WC[?W6A].=A_U_SG?[0.Z]V5WX]W7[8V_O_YS_KX*,=T<;*\?\L 3 M]]@CF4^&>=(&::$84DHJ%I)G@:65-8+EW,),[QDN.L_X\AJ$GBD(<0 ;%S#U M5DCN'#_Y.N=#/L"[$([*@BRC0&GSN#CX? M)QE0"DI%EPQRU (#"ISF,E0:,66D,Y(HJDGAR5B]&G^_D/H/=267)T49:HF= MC\2.Z0(LBO,J@9%B0T1Q+\?[L]49 MV,Y1,Y^KE2Z]NGW!0_&$(F[Y"N2,%Z#&F=OAS,$4,Z",44$],@' ACN&D9,N MGY^;0"6VP6"_LJ:!&5Q-AWKROI%:1N?%#&H9G;N,3G !@W7 )B B&+8AF'N=!%@(V&.>O8@<:8TQ$BEQ M:1,U5(%T:W/_2HBU2^(.$KKN?6\(%"26HE%[)![9(U'-?X5,.4Z_*&%=(\ZM M$.?KE'?":^NL=B@2*G.?1(*,P08)RT441@CMP\H:UTMU9EH[)Y:,3]3B^J#B M.B8(UGN#B=+(<:L1CT8BXPU!6,$+EG&O" %Q5:M7RW'4?HJ'%[DR1S(V6D4E MA8G\N]I1\;A,X<^\ +L.9J*P2VK(N17D;)Y.EF>G 4?JC$(4H =QT!7(4C!/ MQ10,*) MQ+A25DD+@DKT_3L4U^Z#N[3G'.>R%/R@#FM8!#48!U_G12A?JV'G=K#S?:H# MIXL>)V,1SRD?7*N(G#8"V4AY@(4CAO*5-4WN'T=5NQ"65U@?AA[4PCH781US M!$X%PPE+Y'61)*$MTM8EA*-Q(44M4ZYG(<717^'[UNOS]5Y&P. M;H$;5[5Y?@#T8 RA6*CG78+]D='I?(H^:,)$(A1AHS#BQ%/DH@4BH;3@*DFJ M$] '\HIK,N\VL#UR.%8N14>81\H' M;%VR1.#"I4$EGEOIA]JE\:P$_\$H2"WX4G+5!'YB=2-NI+\TX^\';73+7I8Q?\;-HNN MA"\L\G;!;JJ)EEJCY?BK93N#]4[8'*U(K79NIW;8)-^,4GAL @$=+D'MA.21 MTT _L?,,1ZJ,U[0,_[]Z@'9S.[B.P5UBL7T OEB+[8.([9@M:JH)(8&#V%J& M>.0D1\X'9$-DBAO&99)9;-6,D-R%B.W+.=I:][##,R5LCLOLU6=;"R(-?W2[ MX;39:@'PC*L>7JZ"6&<(W 6/^"2-2))PS:5&T0B%.+<4.4\-X@36T2:K) \K M:_I^<%0??"VQ'#\LBZCE^"'E>"(;F&BCB1*(\ES3E&J@%+E4B"+.ILB"PBXM MDQR_'&_$Y3S@^]8)>1FVS<.RBYQ?").WWNL! I7-[6OTN17Z;$T5#0%8B(%0 M@@26%E@$X1<=PZ&JGR@H*\LAF%Q6HG1)T2_&QY09UW> =DF2X/HBG7 MDN2*Y39E_Z9'FC.+!!@CP2=&;9 K:T+>"UEJ?\(22^C#,H%:0N\FH6/='ZS% M1&J%/"$8<9P]?D(X9.%_0-PYMX:LK#$ZHP;P4_84+*_*GQ$_.R1.,6KCG(MS;EX3;>F&3XKG#JD;&MGZH9 R&LT;.,$OML-3=]PMM_L MOVJ">=;HING[C&^PVECOY[V!B.4-^7'UPRK((KQ1[KC! MH-=TPT'LKU[ U).1\1^)R;'-$CEH=,=Q>;DHYR___?\T3-N;G=T_B]_(FU\; MWO9Z9[ S3VTO]&\K/MXZSK4'Q2TT]XYJQ26'WU3TB3D9;BH^XZ+X\)AO)Y^H MEIK94K--ML\/#KE2VJ8(ZAE'DVO?8Z0]EC _2A*EI0RE VJ&=KX0E(S>61@\ MP%=SL!S[ 6#T;?$XDWMAO0UTX9DG^=]C0]#M_:U# GPYZ$"1UEP@H-08&1\) M"MYQ[)16D>5NBM=61*XV!8#(<=,?-VPO-OI#]R7Z0:'/.\"%6HWA )3X>:EY M6\UV0UM0OG"DWSVA4U--UE6WS9.@2KGL \6Z1C,+ER"$%6>X%B#%C0D#RV M"7054]=60QYMBPN<*9G<3)39Z@"J,/QJ(>KK!TU_+D/)AQ)=][N;WT^:O:IC M8+V-9FXCOK.Q=1B$4\X*CPSA'($D4V0P9H@Z$4C$*G";C0-Y;;N?T2ZJ3- I MA06ZI]_(J5P-%X'U9YT7\[K$0B&V8F7*9BNTM(![Q99JVS/X0H%/33 YJK5M M9!LAP2<'L76VVMB'KY8;-FNX'T);>4\P3\#$!1M^V&\$^%XVI'O=X=$Q[&Q. MBBM4-Q[VLPG=A2$EV&V--!P,>_&J=$Q$W/Q<# 2&@U'*(@J( MRYUSUA);-%2YJJ%'YF2)<]>#QPV@$B"H.3@NH#9^]_%D4*'U(K95K.28"DQS*QCC8*ORGYH)@V/0E(76OH'BQ-,[ M]%H0NOGA1,^ \KGYW,&3FEQ[S;>5TX)YO?XIO39A@#ZKUSCJ"S/.7P$X>@MB^OR'>+DTA1._#SNC9[GQ!Y% MY'K1?@65!<__VK9.[5E_Y;?I@<.HJ\N;?/\'F*"U_W$]N.DM?<2+G7HU<^K_ MWMS;W_RG\=?_KN]MK[_=_+B_]7;]SP^-K9VWNWM_[>ZM[V]N/(=A[G0+L>\V MWG8[Q2%A<1;PKMFQ'=\$HO\A<^,BQ[+QR]M2=&/X]2%&/FOKE#\OH4:I!(A) M+AKJG,*))TZ O$47N):21@P&SL4)^\ZP#5/C+SDYK!4X48*-UCQX:HPA#LB? MH\YZ&\SA1E9[&/X/C?7?M,;[,&S#:,]VTT7(:#D_1Q%F+O;WX5Z_M[K^ZXM3 M6@=X^_SC(;%&)*D]TBYWI'<6V#2S"L@2\4HRXS'W*XT(JOT$)G70&\8;@=#B M,?EC)Q_1'G7@*Z5EZF('*!D(2!CVLK&;^1CHT1@;9]'VP$B%1PY7#4BP'[,& MSM[@?/(Y46ST#D(%W)$+7#ZOYC2[[D^#H6Y2S_4&X=*5&%A/,=46+%NPI MR_,-:@7?IISO5'3/3^LZ+__\X'I^?C0_Q$S-SWT%B8C+,W6C\N!+/DV_@%E9 MV;+]7V\S7T\_*^-WVRK"ML!B+VSMPJW>3079*./7[I..^TS#B.MPX!^Y[":) M+%@OOU/S\0[=)#O[VQCN#??]NUU$SVULGG[>;WWY MO _/WKPT.ABQ#H8%QC7FKBDN3$L&J4QT8IDO"&FQIM'PYNS"[R)V!DK M!.S#A#'*D1C(2!(0/-8>+,SYC=(T::DM49K[$$"6+0Y* M4&E5 C.F$&P\$NR[NU%JP7Y@P1Y;09P0K[&,B'AG5\?-6K"74+"#DCA00BT(*P?)=F J.# DM,9@.VB?!9N82K#OX:^H!?MA M!7O"W- !3, 4).PMH1%/B:.\J"@HR[#RQHKI,79Y\7N;&"0A ;W[& MQM,MD_QDC(V_\HK5P'5/X'H_:6JX"!P3[ T4I%*(BQRQK7U 08 "(I9Y2GCA M)WF&?ME:K)?#U*C%>DYB/38TO,$X..61!HL#^(@RR&HE4'0Y9Y MSJ'&1GQX*^-%.$@>R\JX6+";X=9DYF=J?H\!G<=>M\:S6^'9QTGKPU,7%?88 MF4@96!]<(XNE0Q$+[(&T4.?*(2\49I$EY[S-QLG52B-U<]8'EJNU%^$\6:X>,EZW_"98-/I][28_7K:8G<\&P@TF#!!:5B60=(H([ MH"=2(2NQ1BP)(TP _83)W.A)[3I=7M%?K$%2B_YCB?[8,C&.,)^T0YCD2FG& M,Z0Q]D@H2YDWC(HH:M%_JJ+_="R3G\M^+>.WDO$)$X51F8A*'!&"78Z_-,B9 M1)$#LR4YR6/D(9LH5Z.TGG\/Z8DR/M7W4?[P:T(74<"(B&RX#.Q@."@ZP$P6 MI8\7U1@OU>"JG2R+LF#V8A@6#S.-97_F2DZ[:?WDI)4K<;=BM:*[Z<_Q>M: M=BM \Y?2^#G!8*50'(&T6 FD1>N$@G3,46LL]7AECXG MW[4W8BYR/V&II!!P(!8CEBS-K544;9E*7RLUFI&R_7C9EI78ED'DA^-&FB2:JIDRGG C)@ M<%%JI)TV*,E@M$G>Z"1R:N#U3;*>4K_ENB-]#8S+!(QU"+L4@KJA%Q3M@49#31S+4$98V+-2[6N%B7REQ&7)R,HW0"!^4-LLIX MQ'7,*=G9[\<]C2%$+269:ZG,1>)BX2_XK6CN,=E[:]P-YVFT6OEQZ\UOL>%; MMM]OIMP@[S9-[Q*(9<+8>VTBATWAB(UP7>:L#$)S?F^[KNYF-[.;W?G._N:A MP81S+#3R7!1=KP.R(0)+8=A'QK"E,A9%7?BUO1.+!INW6?! I>(V"4V-Y(D2 M'0+GG%'+9+0&^WK!'VS!CPZC5EA+QA!A"9"7*(4,3P1Y(UEPS.0H4%AP1E?U M]2M>-2$>7MM\R?:K]H1%-[/LPJ7XS:@K91F<7?2E+-XA;XHM5'UJW?O>$#X4 MOY_$3C_V7XT^TXO]D^AS_\'<;#,_!3R"GVR4YBK'9/\XQL&E;H=/ 6$_54#: MB]^:\31/U'&%O[[&#HR^E^?5Q='?S7(V\F=[<3#L=?I%NW';:A6OE:VO MJMJCK;-&%Z:V[ \)P^B4?=S<6V3.=]$N^E:P];#^Q_UC._C4';;"5OL$'F:SF$'8 M[/"1/1A?C6K7H!H'RGJ(@^7"<(JT4P%0C1JPN(U R0?)7,32% Y(.JL6\@C5 M7MUJ-SRPTZ7>#7?>#?Y0!R^3<[ ;>,[2THX@XYQ"CIA<739QPL&Z4.)'*NZV MI.:!C9!BV 9K^K.&/;>P/;[%QB)[?KN?D$&=HT MO2A=$6..,>K.#8/.'<'Z)9MSF?( W8'IRASUK%C4T4?[0]=OAJ;MY1G.E&W< M4AZ^T^Q\@V7(U :(V$DW7^;$#F"-1LWE@:;UX\7]"AXX*-N$MTOR]0UH2R?T M\TIVX9W>:;,?"_;CBXT)#+)?-H#/R_IQ]<-J(\40>[ )\BXZ[K9"L:#V.SS> MB3TKNIK")T=]RD?#@*MU!L48,FXVBQZ\U;?@D4:;I2!JY0ZTO:)3&BQ(R4A' M8\W$#I[5=;M??ROVNNTW^Y,DLNB#WK_VRU<^7PT4*'7L]0NI@\'W(PC.M,S904ICA;-2>]KBOFQ\[FH&4']SRH5M.Z M9JO(= !=T/>]IH/O6]>%W5("1A9.6)L+B80IOQD!?GHB!9LA-6'6IC;?> == MV#/3&^OB9=A6H\4JIN%5H]4%;5=\?+2Z7P"6^J%9QGX5VZ\0S-'W)JYJAX7- MVNT<=0L[:% XZ#9+@"M.SPZ[@Y+>^>TVVL!;&]^]_%D4.S9J;O 'LG;8^0: MV]G]L]A7^1ZE8=SPMM<[@^^=VE[H%R*99:+3A><'$.]-RF7Q#)7-W.\72YM"E^N]3!^V[;Y+K>\@7!L#$1XHWABD=NC30\ MJ"19P$8!5<;IL*BX>9--.IVFH2\]#UI@K_:_+J;U\>\^/2UFE1>S\+ =UM]V MV^UFH8OZ&\V^;W7[PUYE\]_O/OZS_D!W]Y8/^141VY"0)9:CCAU"1G8YMGF"-X+ M C]X:2B M,6PG@FZP$$F2P-+1G,+%@*U01D*KP492'*7^[!/3'R!:E.-[:^< M)$P)Y"5)+]?HY_>??EX>L-?>>X9MX PVB]-&Y4$+1\# $C_I%/]PXEE<\75S M8%M-?P-%LQ>_=5O?,JR_+1'XG?65%GYZ6O-OH%3Q>[$?1NP*.$?675-4IE ^ M1>O@PHL&"N%:D[942X?V"'A[WFSSS;+:VGDW I1OO<'WU[!?@1OMIG(IUDP^3X;,R"K@W]V+FP8_&+0YO-LYVC0T^)<4$*9(2Q #$<#%H1(C(D46HP M2*A.*VN#T^Y5*[;B'!>+VV_\DDE,Y7*OY&&\"I7+_=>RELKOMO,U[Z[U F+L MJ\;.ZOKJJTQS;6B#J=(?Y$S%;]D'G*G)R)';RF9?+]N-([=_-[^>R?K4W?\L M/S>Z9TF3KSQ22;PK[-IM#P,^R(BJH&MQUQ+8N?0KNU2;>PZ>%J M8 QG(V4=*)NM[N2ZO5XWN_.'>:"S;S.ZNNU=6-^O&I4#H'LR*#P0.=ZZ61@D M-MLYL?0C9#=_8W/8ZY;N?7]6O%R8@M&"F>+S)T]:PZP\&O8BR:%10EMQH3#S M-*653298TD:1AUHN6?EK=?PSZ Z*T4_:),/"U,_XZ.#O#M#5F;;+YN];^QOK MQ2SFR[:[_<(949ISP,9/6K$T!;.-ULQBW_B_H07(&Y49A6WR]$![J]/X -9" M:1:6YQ WQ/$I"+>WCPC@ MGS">$6!7JO-LVWYOMH?MWXL=#F+XUI[ .X.SI^*/?&P<_TH Q\$@\A1[A4AB M"G$@4T@SS1$-PE,=8I06KZP)C&?T/KOP3P\[H!R'>4_T+GA-JE9E"E[SZE[! MFVF SY^N4'CDMX2U@XMG2WABRQ)5>#)X/A4<(=G,R[\JCP0O@TUQN3%RM;H@ M2_!K]ED6]NRUN[I3L(5+&ULYX+ D**L=X8IA[;$1"B?CJ)4:-G:9-F:JM+$; M[/ - *VM#JBS81[$[]F5].&D%VW8[?P-% ,1JPS, J@!M'PY-1)A*5; Q!ZWJ//,P>V3G?/G3> M&V!\ 0'/@3V"C4?::IH-%1,2TU28HD3#G. @ZERZ+@)98X;;0'/Q*B)5P)H$ MK9BIE_JAEOKK(5/**"H5"CKD@$&5D-&PU%)(P&-O..8Y?FPV')2VW4S*D(]/ M\F$5F"F9^A:U<#(5OA75#1([*S&.V5-EN/;**J^P2BD$0VJJ^ZC;!6^?;QU* MHP3F!(.ZL"IG!@JD(Y:(. .@S(0(7F2N^R.JFZU$L <'V9D .Z+T93S!DZY+ MYA_%CV'^:4DUH2I%'BE7@3HM7+",IJB9-)&6<4H+D0GS\F2";)\?'((Z%%ZI M@!C)K:^=2%U$>S2_ MQ3>GS3 X'B7?3'RKDB\\_HIU_6YK.+C^*]=(9IDSX8M-OBRR^@YQ>FD*)WX> M]\9EY(XBNO_#8]>PR3_WL@]6_ M-_?V-_]I_/6_ZWO;ZV\W/^YOO5W_\T-C:^?M[MY?NWOK^YL;SV&8.]U!+)RC M;R<=H^\N@CH^7 1U-'YY.SJ0^_4A1CYKZ_S@_'!ISP-_*- 7WC"*Y^4-TX4W MC$Y[PV9<_E&\801[&S2FC K&<;!&*B_ +HO:"*M]JHJDF:I(6FT3S4>ALVVP MB< $%9I&BA+/Y2\, X6NA4#6.:$9%EAB>KV+Y-;F;U**N!@T]5%QK;PFS'-A MH[ &)[AEO=0/L]0[&Q\/B<1:>H<1I9F[:4.1H32AA(5T5$7'8M&=4*M9GH[' M\X89Y3,$$,+ #D[2N2"(PV (*.Z"2J'>(P^R1_CVQM$A=]$2D$H4O2.P1U0. M#XH,><.8\DXD'NVU+I+;PX'GT1GA(K/,EG@D'(V_8#,K0"%V@&SF.H3\\.>GV M!L_" ?)A'-+:!T+93]7^SF.JO!^PLT.93%"$Q+9MCN[^OV%.1B@2(HH,P9&[ MH>$K?T/A(BJB'8J8^%GQ%2[F.-^B%GT1A)^#(4)Y*R#;C^I1*0*@9KE3UB\> MJ/8RWE ,MTYW]K\>8F8]3@2TLO$>+'<&-CE.'EDA*>$L9_B0GYVH7Q.S\], MH2)L^VAH054/8KFW)EQY.8 E?F_V!Z,8I33,I@3(-\C5H.FG_'RO)H.^1Q>) M181Y$;G^]"1^=BA7%J="V(=]>%[;.QOG$MMQ,O"I[>4Y'265V)2:60**0#/X MNY.SC?,?OOLM@M%9 ME1F5EA1%MJIG?-NM=TVY:W;WMPX3VSLH4QA]4LCB-92QTP9;;)ZUF4?/DPG4YUG>7 M4@NO"ZR&#=&=H9++I,G*Z3DK M0/QTE'H*?S0'K3(R/'Z//=_LC[/R>O!XH2!%8ZU>7-+[V(J]BQ38$6,+PU@% M6'>'@_X !#!_HW"C/$'BM-'L957CN_W!5.;U]10TYW+W BH6#;]ON *L-^',"ZMNSIJV(-UW-)NE8L1'BW=V0[S7-[H9M^/T/PP?XH MZJ8TKC.RY#2$9C5+5RR9+G!PG[T0^1*AV*+=7IEW>F' MVRSW2]257OY$>T1 MO%I8[[%=0E:G$TL--X*L9J\!'_[6]$7JM.V,;I-3&T8W*<&K7<8;-$ZZ@XP= M6><6TI^?KS*L3NQ9N;]'([I(=,]^A&:5A]*V7^,X'2/GA4]OC')>^H4MTNS# M)RO#8+7QOV 5@H"-J]Z!@>B/"Z_"Q804+0M46=5J-&6CUT:YWV=P2X#_ KM/ M@!_D9+[RF4<)ZV$(;^59;W<[<5! \O>3(NNRN#" ?/8?#PN[)@O_MR(Q)#N+ M1L@(]FPU*R.0/+%-&,.#%SVZ3"\NB=W;8H_\M*4&>W%48YMO;VP>*AFHCB8B M$WD"@DH-_*8H8H1$HGET(9\Q[,Q(\[J\BRMA'!?^RHIB0CV^&J5-N=AJPK8N M5$7V2[3+;![;S*406L-8J9$9@E(8Z4>53@%1R?H>-L$35+F?X@7[:>:IRJIR M5% #-"MHQ%[.31KV2O:3)=,-^\U1CM./$*0SF7E7P)Z'^^>"H8U!57$EUZ]H M'MD"3_.B@!U1%L_(]PF]X1&(U[?8ZIZ,@B6/>K:=/48GV;XH(X'ZT0(67;E7 MSL^,[:8OW29=F+YN#\$5$A""C,W-P;!R=8RX5^:5H#>+8A;CB\%#5J%&\&:A M4D$391G.+U4(7BJ#8;_<6?G9P1YMY3U5G'$7K4#+ B %Z[PRWQ.^F!]/Z'A: MFOT"^\Y>3QR/#1XISU15X^1+Y@&?G,#/JKQ#(:DSM>;4WFA4"7.3KU6:I3^YEB5E+"AS M-Z]2O_!R-SM?AK"'!244;!M(.:Q\L]NJ?&^Y$Z4];4SH]!S?Y(]+ M)E&E\@TRY@SAFEW7RH]1>NUZS2(7,]?(J'CGQ21U)Z<17CF876ZD 4@E\FY M,JO%>U7YQEM.;TF!?C!*&!O,=7[;I8BJ(><[^P52GD D)Q-B6_%;01 GZFJ--D=IW555;G+,_'$^)2QO6CQ>6;,& M#+PB+O&A^?,T7Q[/X 1S_G2%,,]@P 64%RIF6MQ>71&V//11!O:85!=//<&= M+RCSJ+;6%'?)Y*<8WIA,PXYL%X!<;)A):IU+1MV488_&VLFV0O':=(6UT:=S M5GI,N8M6ML:&1>VA; WE]M@C 9BV_G^H758;Z]X77.4H%ZE;,+%;&B? ;H%H ME^JF/$%Z6E99'Y^4E\,93-43*P0@*^(;<]=L/'PKOEP2LZ+^,NSSK+I[WTK) MN>9FI\<1>-H@;X^+ZF?% U1"4=1P!B51!$^.ZB>T@8V65&H(^#SU$5#Z)=+8 M+/L.\.-BSZXVRE6$RU_4*A@]TJ@(6[EQIZJK7:@NF(P<<=O8>#5*C'Z7A>#O M0@BV2U=L229&]:8'504O^/'@=6$O&\P7>W7PYW@TM<%\M0H3VS[WATSAR)G5 M2#,1$:?1(^.E18ESXYF0WGG]"*WFZD6\SR)Z[;R+F" 6O$)<6(N,LP(YBCTE MD5-ISIFY>G4,S,X>&U3DT=0[- MR\ZA641Q3?74BVN^7YKBFFI5L4>HKODA'N5]NA<+Z[)SM(PE-GW%"[K\\\9[ MMOW'O]L[[6VR<[Z%#[[ Y_;A.^>;9'?_8D7?#G^"L]V M>M ^H ?G']GVE[TF/-/Q#CP?< JQT_XH#MK;^.#\W^U<]&YWPQ]B:Z+ B@= MM03('2?(Z62 ZYF !=?.,76Y9"7F*0#?MI)X5=:+<9Y%'9A3@JH@+Y?8K&:_ ML=4IR1EHXCL4UOSY7:>?TFK.-->>1NIX#-(!WTQ<824D_&7YC?3:XM7\:/)Z MH[U;FH/QQ%;!+=D([<-NKXIS7Q2V]\?-F'+@AQ\6T2'546E.NNOF:XP_DST_ MI2,VL^WLZB@\4/!1>'I@#Z73;&31OBK>[,_X5A5)6I11'A]?9 ]48?J67R@, MYVN-A7XYV@>KCCD"A%&!S-W1(*II?BH5,A\;++;H[OM#(I*)/@FP' (8@I$1 M8)3291O":IV82U2NK'4[\:K-4*WKJ\;)L87I]7%8-/3KKS8VL]X_R1X5=)J] MW.$"F@N'\G!0%)<'J=1?^R^+P_O^&S9/R?KF- MA#LKJI97?K?L32V"H?-90FQU3Y^BSVVOFI,\MK_*,YTK$/J0^M0?QS!LQ=VT MF8/,SC[!RDV@>_5T[WK=]N9W6-Z.;;T=+=?O9]7S]M<[X4-UK/FRM?#[0R=\ M2 )KY#%)B <7D=51(T6#=QH;YH2XK%6?A/:JUGI"AK- %A[%HJ%$==)S$?#[ M^C[6 XRQ: ,ZMO^+OJ/%D=A)/[X>_?(&,.:D9<]>-SO%$Q=?>C-] W%RI>UH M<;_R[5POC^5(/U?(](58YD]>^C5?)M>_]Z+*$ MKG)-[W39']^2"%T_K.8WNFS1D+;:$#,Z=E_7F/L''YW13;NREQ?3._J*75>X MB;*RN-PX^'[CGVXK/-T[&%]M'[S\\X/K^?G1_! S-3_W%20B+L_4U1;43V^: M?LEGZ&529?_7V\S7M=V[?S#^[*19J@;U^WM;_UE_M[_^6_ZYM[5[VT[EDV/% MC:NE/R.WBWPJ:>)W,V(./OV[_WG_Y.O!E_7O!^TM M^&_O^/,?6WCG?)/!];_N?H+[;!R#6;,%!LR[XYW1=_[Y][%KA]9N>Z^YO?$. MGN-=,Q\]PO,P>!88RWL!8^*[?\#HOK2:!Y\VZ3_G6X/M#_C[G_N;@^W%NB*4:BQAXHLIHX;A3E@A&G*:RRB.M0.L&_8QKT%HT:)U= M@)8G/#J6VP0%EQ"GN=&$BQ*9!.LMX3T; +38*RW9C%;(-6C5H+6"=(%%:243L(4M5_?R#0JG'I5KBT,R93DHND) "1H[GL,>," M.4\D8C3ZE-NZ."Y7UCC%JV2)4.G6QFLJ_O>DC-)]L%J_CC&7@U!MX"@[4E[+CAA ME4@2>>9H;MRJD<41H^ P&'@!N\1I"4'\OA T&P8>E!A=NN6U_L<7+\8F<.TU MQT09PT5N7 .;(*2H)/6YM^_CF#^U&-].C,<6C@G&^D P,EQAQ%,$)D$\0UZ" M]0J4D'A.5M8DU:NR%N/G*\8@KA1H(XT28\X-LX;11!AE5@1=N5X?WB"HO1CS MD_$):X%2H1,#\68F@*I6GB(C/4:$F>AEU$06':=><:)6U1))^4LX[-K=^\_Z M]N]WLQ-NZH5YTLAD;+3.DD0$,1PTDZ9$"R6HLXY@Q5EM)RP=^+R?M!.H44I: M:9!51" NA4&Y_C,*S$?!&<]YGBMK2I'[$XSE](S844GN@@=&TG+*,8GTV8^QZ6A1O82 DX!#$!:6"8:K71@7_=M8 MI)8S*ZR)W('5$#PH)^4B@!6W5?^VVE!8)O3Y.&DH*!\(L$2,-+8&<1QD3CT+ M*$7O!5@18/4!PP#.>/_PL-H3N;QB+, @M)%AYVCDB42M"*RY U'FU@E&:T-A M&<5X;"@PXU,, E;'$A!C1G*B.0BT35P"I8"_F5]9TYC>GT+48KR\8BP%DSA0 M::T+7%'JM/=2X!2J54.S^ 5YS%[(ECYNOX;:&VSO K8LA MBQVUEC.93\6I=5PQ':CUA->)1D\.;L=6,[7&>>848I9*@%L9D.;$YA(Q$FM# MN!!R94V^@I6=6Z)1#;ZT#(R;+A!9::<2F!W4HFD>76 ]PRS*QVQ@BSLL9? :S>/R)R:>"V\([\5I3" MFBS)/5FC\TE4QAM5')NLD/='S/V\3HZ;OO%G50AP,=7R1@\ULS+>>B?\V>T< M_=G\%D.6\T'_][/QD]O6>F[93%U!@'=M0@' M+PPS),!J7"X'ZZQ4U"I.E,YM(T"0X3]OK02ZC)G!3[*\WDX<7/'Q%24N[6#0 M:[IAU=C&YW8XO5R;WQ6=@:JJL1=%,4==G*J=6'5WJVOTU37ZGM[#UC7ZZAI] M=8V^ND;?RZ[1!Y.X("OZ8Z?H3UGT!NG7U?E>2,T8%Y2)-&A!=2;4+$?D!:L$ M-QP[$^KCOCDY1+JGNW^\Q[N?-L7N'W\?;W]9Q]L;6_#9S>_YOKL;[XYW]C^W MX3-BY\,EA\B7]7P_ <_&/W_:/-O>>'^Z_>6CV-[?A#&^Y]N?-LE.^P ^\Y5< MJLYGA2",$(FP4"Q';7&DBZHRTCNCP>!20>7J?!2X-ENBT.^ZT%4-6C_,5P'( MBLQC;67@+#*;L IYCQLG5!2/%$U:@]8<06M\:":X<-$PC+SA!O&();(R8:2Y MY I+;(3"V8NKJ9Q;C$(-6C5H/31HT<@SS^(.$\>Y)3IR8WED7%NC'7VDZGPU M:,T/M":.GACU!.@Q148'8%K HI&6"9A6=,XZYKWB.I<4!?Q:*J;U2$EVB[-J M=X>#W -[Y O_H9$[UUR!^AJ/'[B]N&VV.N*;/4 M*,DX!^H>?4RA=C,\+>4W50P&>QUU< $Q+@7BW MDM4HH11.!S5/+I47P:S).)K;M'IFN<;",?C5>D&=U%Z$1RH;64OY'*5\;)?GOH8: M8!QII2+BECED%M' MM52O#8W*5ZBNB/+77Q.ZB!BRTK0%@[8W'=)59ZQ?J5#G2.=M)122>OZ,4L'5E/U8Z*P26E-$1'2(.YX0MI2CP*G K2.MR;1E35&6%T_ MYCF+,4M8RV"3!7;)P9PTT9C(P*B@-!@N4UT_9AG%>,)X2"81BP6*ABK$ S-( M!^&19[",C ))U'AEC7)3UX]YSF),J A3BQ8!6LMC7,YYY61R(D"(\+7IL,2 MBO%D_1BJN'21(Q*419PSC;0V&%'&.''#V!8B#KLH?$!!:L ')PQR M6#KDB G:19R<(D5!;C6_ ,<:'YX5/GBF>4H&:$3P'!O0-EPDAJU@R5O'3!U+ M^-3P8<+(<@#Y@@6,O#0R%^D,2 OXS6D9HM/1XE"$4\"N>3KXL!S'-W2)CF]N M4NASRK;ZV535!9$>;X*>C2:IRWT^+TWBIP[/ DV42XP4<0QQCS$"H\(A;;R2 M209M<9Q;N<^Y"]F"O?8UW-9P6Y?[K.'V9W [-NRUYHIB;E'""@Q[ M:]TU0" MYF(6 7BQR(%5D51Q=VT MU^Q__?TL_WP'FZ7;>\E5.W-I?FN&H6VUSD;?CR&C?X/@?S7@GW:W5P93%*Z_HVOO_MMU7YGU5,^EWJ?! MJUS)N]3[I&H5F/=#5*7$XFZ7_4D)32+JAZT?]J$>5M[LLO,O 'F74ID_M+M^ M&$LW"[$643+RK]C+]\_H>T.\7::G+T^A2D5XN0+[3T+\;K%73+U5GOY661^1 MC[T+\C%CARQ!7=FGOU$.HNTU-H$?A\8&3';;Q5Z#D5L1/[SX;ZL.;M)=?)ZSGY4L?SA)/ I3L[]A'!>>^I)SMRT M*#[[PN[;_C^QW^]V&F^[O9-N;[J+4AUW>_UY4F>8B<'E@@)42^L9B9)I3ES0 MB?E@K%4T!8&-^TG %+WLAI[R/6>?.@_EX: ?&\9X>[.^U#]K_ M;A^'_ZS_GV9/"3Y$E+YAPRDB3$@V%( M2RU1$H[#RG%K/ ,XN'?9@$>(H%V$5/SK3M4QZ_#^.<&,HPR0Q> 4F.(I.(TE M0$K4*6KO>9 _"12J8>9A868<] /H8I-/&&!&4<2=3\@$$9#&%, G>45DAAE< MPTP-,\L',YC+D*/35(B,*R6<2DZ!VB1266/ISPHRU##SH# S&>RB"(X\&<1( M;G"K S*NV E%YQ3 MK%TB4M9&TT)A9B(W&=1 2-HB@0,838X09&UP2"A0 A28**5%@9<:9FJ863Z8 M2? PQ#I'#$_<*VESJQ69K)98:QY_5B6NAID'A9G=,9L16%N3B$;1*(6X%PGI M)"WB)MA 3 0C-P*;>0K9S8N'F6??PV7=^UX,W=_>#GNV[WO-D\&=W-?/L,+> M3!043B3,0@A848YSO8#HA4[&!B]"4+@F6XM#P:F^&20P:C1-P*XT1CQ(C;0) M\)MB0+,<+)QA@()+4MAV\4!7E^.O(H7_%R(=%6V34F2$YCW81P)NXV+2)D[I. ML\F7Q3P3M8I5^+&%]]>7H[BU7+_M*\EQ!HX=R+#NU9U[>7C((7E 2X-\8$:S6ODB/P3>P MN/4.=@>+#A;G,@LD)V.2P4#!BMK'8F/TAI$A.5*RAR&K!(NYS&U.TFO&"%') M,K-P)8@(20IC"H-&--)[ZF#Q&547OPZ3=[NEM.KB4=<_OJC41CJ9@ZXF5X>@ MM0M>>_!>@:DVT&42R!WB%@AQ)R3'%-9,!K&5"[?"8=.$3GUA4A0+Y")SM64( MB!M&'''U$-<%5A>0EC4RYRI3(0.H:X.*[$JQ# \^9 6=#ZT4+(Z#)UF+2AM8;Q%UW M;[7^,=G_]GI0D;U1RH4:E7/HE(M*VLQP8;7C!:@#%^)>9?!EQY&KXLA4A'<2!!IHDR^-%35'"HITM#,V %JY6K+.!KWWSB:37% 6 M*6)RO09UI48TE\G4( EL4");S6&^5E5$*5'48C$G:RC:U,/\SZC,]-ED>ICW MUEZ^#^RUTN%70VSZ?!( =WT:H-!""]M& ]#JK&B.$ M CUAME*PF$N8 ;GLHT0A^38(#!!%T+&*DI6U6(RN@ P6OH/%10DS>6IR[?P% M*EA)ALQ=Z?*^6F\Z-Y/)H9C^OE/X#A[$O7$>A]W#-DC[K#&C:^.=F23-J]$/ MH]-K<[&*57O=@&*\?R[3E^FVZ-VY_\,UNF?!?_J\<"_SK/CJ\;^=?P (]^F?0J1H^4M_:JCP;.E_WMC: MWOC/VLM_KV\]7W^\\6K[Z>/U9S^M/=U\_&+KY8NM]>V-)_?A,C>G^WRP_2F; M^,YLB$9HLE/?C7?"3AJ'R=I/^_R+#Z5I1'SQ^*/IEOSE(J[\K$?G+]&X>=3X MZ.6#0W#HDBXZ8LDFEF(J6FG)\*N ESS2BUONV1&O+IKW;+KS3DP8XO):4YCD M=8Z':\^FZ>1,Y_/7(09C=;"HK(OH P3'WRD$@V D>'DETUX]TLTM0_AK&29' MRW"?!-% VYL(HA&,+/G!Q:6T'#EU,[6KRY2PAE=OFWU86(H2EC^/TMWQ4?@7 M"* L2?I$?HKR 2L07CA7+NM^K>RUA!F6H'%T!U?I"XZH^+ 3=G1[7ZZBTVRE M ?:KG7'SZS.>N7>;"IS[I@%_UB7>[5S)-538 MJG'_?7K6+L)I\?;-Z4XZV-UEH_Y(GC\+979XKM\<;C[Y^=>WKS?XN.NRG>?- M]K_&;[<3G_][/L^&?OO+._GB5*8P_?_M+T_EYNNMR9OM=7K^Y$>^IJWW?/[) M)E_K\P_?CY\W5?@CH M1D.-DAU"6WV@>M@.1/<4B)*)E7''RQ(D4E8^-GD.:9WQ"J,.,R ZM4/1@6C) M0'2\OZEU@,(WJY4') 8BE45P4(0OR5@377&S&M^'6MK14*/SAP"B)=7:KM3N M7ASL[XUS^3-)@M%LF6IT1]JHAR1TGX;??\%\;K>/ MZ#\/5*2ID!45Q2X$+:%+22<+&"FV+NS:W?U20.5$*Q2B3]6"$9&C>\&Q/+O[ MG+4H52K;FG!,TSU2-+HC(W-[->HB+-,:=NMMMC4&MLR*(8-5J&K5F4!7W]W] MLBQS+H7C@I7*:Z&LS((IF!,NU>;S(R0JY#AD:@.6;D_$![3,SV$O;GNZ'R9K MDU.E.-.;Y'6ZM-F%N.0,>;*5/(-2)?"V!!.*5(8=%=G<&<-2<"G-,X8 I/@. M: '@H8V/L*UYVHK$,4CR5)S.Z<$C:T;P"8B8=;G"I=LT96TQ2E<36E1:.RC! M6U\RQ[>I6.Q<8UDV?M\/?:17?W;7-_^ 6Z-W">B]$^UE*,-&B\"2K* M[!.13$9"N$52IY<&#(7U[^;Y6R45K,Y:$)6F>I*C<-I$P>R:Z35YYW43,GB( M&@=+^@QG."M.&74([1 Z.(0B0V7,4J= !F/K3RK&@$G. CCO;Y%]ZQ Z((0> MTV4'9#-J)ZB4-C^,I/!*>WZ9C;<@HS$XJZYR>/LRSSL#H>>T+I]L5;ZP>?G* M?767-,CV)N@SFZ#I_";HK^,T'_)_[_<_3![] 5!+ P04 " "QA$E41J!# M<8\< ""5@$ $0 '9R='@M,C R,3$R,S$N>'-D[3U=<^,VDN_Y%3Q?U56V M*AJ+$N6/N4RV9-F>U8T]5LF>9/_;3X:%@#PQR8W=F^!:YTC?W(^N MN80KH-$/<]R/;^ZGLZ7GK3^>G[^^OGYX[7_ 9''>ZW;U\W\^/CSSIF=A6QLY MWU.MWV;$CMKWS]GK&7!AU'Q#O+=4<_;@@XE7M'E/UWM]/6K)\" !9N2X'G#, M'6;+(QUONX9N/@Q]?,SK=3E?O]%*4+&\'EB0S. ]>GFG \PB:^1Z\QV1U M"^? MRF([_SA QO-$;2H#MB023G5(/': V0!O:]@!=TU,&$)%W[Y0=.88-!J MC8FG.1FP.7!GO)LN\3@8^RC&OD"4#]@$'M=/UMZ-OBL#=0YMSV6_.C&.#V^N M=78NWP/?[2P 6-?H11(RZ$GXI'IO$IJJ7U]?G[\QU:,G <['$<[$GX;+U&SAP'#^@CIKD?(_6=PGEDVS/S4XZ-X/_Y M"(A)L%UB4,[7!*\A\1!TDW,;1[ D*/RAZ\)K/KA%,2E\R<7]%_^^TU@5_U^"F+Z M]K_'YUMP7O7S*0AR4(VO9] O]+V&K$]G(TP=\PE8T-ZQY]^FXWQ'BY.,&T<8 M(YQQ9W[I4K^7_E_KQ'Y\1^.0&@/]^7P?8 ^5[T+KR?F%_[VOXB%PV$0 N*<; MTG!IIN:"A0\C+@IX._0MY(VIU24KWA,9%F=@Q)RFZM!+L$C3N,7R[=.ERF'RU7Y,T?M;2^5] VRV^GY>0NA5-JMI8+'$C&[W0B2Q M$)<6(#M)PW,/&FL"3&(Y#;K=2WDYG491QK(]+RE'EMBV(''O_O"1MSW$3N9@ M$\OOHMN]DK>,2?3_]9]7/?WRO[6 S$F2\Q%PE_U>5YC1 M*%:-HVV1G+X"SR<0SV]\%SG0=8%C#4T>/$3.8D(Y9=)UNHRLY! )Y-73N[H> M+(Z1:]K8I>CHCP ODT^$6:.HM1BW%B$_22W-[,:E)R5%ML]XB!3I[!?^U::) M3XK_+V!F-RC.$)U(F/UNOW^8, ,B)U'N\3YZ^140%N'8P%OH 60W)]Q" B)Q M&UW#.$CRTMAJ$ MA+4$Y9,>%$GIV M"2W9"RWLQDE5"EVP8.]L2U^R)>6:+5Z:UA 1#;%B7!H\0EQ?,2+2O,F.^$D= MBD3U&6/K%=GV/Z"UH(^')IUP$=M9O<<$HH4S"G,P/@/D/5I5ZM(7J]&5 MP0/1]=4HZI86]DN+.Z:%/=.BKFFL;]J/K'=_.RE:D: ?(#76C:M/&JM8*:X- M'NNNKQ0!L5:*>(1M&\QPX(]3#CUY2TB&U#]W%D'X2RX85X9$&-S1NWK6ITSA MY++C6+4DVI.<8E[(1P!D40E7_[K>KR>S-J[[2SD^M"Q."]B)%)0*)O4P D+K MJC/GK9:@.UI,-9E:<[*S>1(:30Z0X_-ZD!(OQB!>@;?(NK MC@($1+4D56WX^:0 >0+ZLEU1+CUB"Q('1 W&E+3)UKW#!8%!NR:5HBI-L:(8 M!M]3JZ,H04=^TL*N)!J.G4[8'2WNSTF#\J3Y"(GY_L2=P()3Q.0D5X&1NQG7^C9Z%R$0J,X@OR$%O-9R<[_FGY-@PR%WVOJD-<"9_8HET9>F;?*T=H'2VB$:5 MAE1.QHRR9^AXR$*VSV: 9VCZA$?<#A"H&*%8HM=T42,E44:D$U'18C*M%.D] M0.178/OP$0+&-.GH4#Z@<*;J=?7L=@'#HW%$6A)3VT4@/V>)P(435T_O2XNC MC;-7+F,/C>E41RJT>CVVDI>5X2ET4R;=>^0 QT3 'KHN]-@>Q@,",V3S^>'9 MG_TO-#T/YX(>J@,-D!9K2I\NY>4U9=<=+>@/7^ E>J2%7=(\7&PS3FH5RC9Z MR!Q5OD]%G[+$9&2%Y]T2G#U8D>H0$ZN.8>B9_5F!ZL1ON,\<]4%+=2*E3&W4 ME$= OM.OIK-J[(*&&1C>=NQLH.M).V/2N,3^V4#/[L/'J).NN$EWC0/GH3KK6 MM*1_UX^O;;_K)WW[Z^G;<$,YPYK1J>"9M2A7>JP/FFL4RE8+[D0.JE67?'.MFP%28#I^B9_HGEUFVVU1 ^UJ(NM5+RA:?HKU@L8)#[DE$EAV=]2):@D40G7 MU7U=SZ8R)S"'B1/Y!59XGOI)>/L_T#!=G&=;6D "K8](H8 MQ?:Y;_0RN4T59=I"&QL>M)&15M14;",-/9N0'$*VCZWRUBT-(+9>@WXAB]MH ME\)/KW,BOPA4;&DNC%XFYRCB?Z?EY^0^QT':5G7;/$@3:+,); M2-"&6YDZ 9MR)&*A71N]3 I"++08;=LC)R%/GN9S%WI>BN,UAIH0C5!@1M?H M9;818X'%B!.R:^?P8O$:Q\-$LOI6LKG0+39T/7M,*P'=3A;+N\=9(*&+3"<5 M(;O;Z"8G/K^"[-4CL9 MOHCS->(T4GC$AF/H%".[8[AC&G/G06B!FF7PQX59I)S&8K!Q9/7E9X] MGAQC2V:P1PA/4F%4+@&B K M+#WJ1N4Q@OJ 7F"(JFQ&-T1*:#X'+)&HJMR9H\+I1V56W429CK /D>$]V=JT MY(:F27Q8)+EZQ[4:I2=6E[[1KVK+@[0'U@F1NK3]U)90AKMWT>Y64\I1B%BL M!8;1S^QL2FA!W"+>1VNCK(,"HC+""UN*_:N!GBU0$0"VCJ?R#E.JO=@UNNAG M_=>H!FS[/*#@RP\]JR:!16R"+HU^9I\^%,KIC%E&7"S+$#N0WWG%GU2_$T . MD5AH5T8_LT^_$UJ,FAVOX8];7<8_8$QRTA[9P'71' 5WUX<"R"OK4%FL!U$1 MR_S:Z&>V^G3..D"W\%7>C]";K0 M.^G"GZD+OT&T6'K0&FXHKQ9P"E< .9%X7B!9L9F<,9ME'D^!5V."J$]"K FZ MT<]L;^\T(2+:":EJ.[*A^#EAKA@1:8W3;K$N//OKM0$':7,?VU.W4\HZ]%'P6K\5^AZ8;. @>^@(;(4Q>IR M91B'^AT=+=$5_CKH3-@^[,Y)>4H&>\BGM%COWB QDR,;)DQ6IT;1@' M+D1V5B?2EWVE2O3II$O%0IW2L4>0Z<4O]YY\HSUZ!W-4C:Y0FRZ[AI'9I*RL M33'Y1)O,0]ZKDSX5RW4""0_Z.":I\_?W G]IWD-*J,DUAG=,#*;G)5U M)M&%#N^#QCJA_R^ M19F&D=DO+!=9"PU@4$#R!;S)EC&)FXN-VZ6>O:HG MK%;)P=O)XRH%8_:!Q$;JJI^=3)+\;J-!2O PF8<*&E:;5=PG6J M>(C Q3+3C4%FGVM/9FTOV9$P@\':E?XX\*Q"=:1B*;+CSR52C.CP$7O4K%-6L@$ULTZZ-0<8/R9,8GZPX 78A6DCB9,^2K)]M M/T.6O;M>(O,!FU7#*K7P"H5[W34&,C8Q%BZ3;4Q,BZB=Y,S[\HSHLHD=SG>\ MD>]Z=%5%JC@CU1"*):L;@^QV4*YD$S2T'9&30'E?"LH0S[:-#%]I[&)1LPH2 MQ+\=AP<])T_HD]@<,*2JP83Y>]!F8\% M@?RY^]5?S2!YFM_XR&99L%0+P,SE]X!^.IL#FZ53.& %PV.F0D 'V?R6T4]G M'O$IW-N,V.@C%1;"%NOXIS/+)Z%O[/J4"O)\]NLSP?[ZTUG0''EP=:9YO'GX MQ/'@ I(Q?<&PG)T7?MN7+1WVX&5)_[6&%+7I/D+6R^0W!5T+/JFX?>.?8GFD MP_YR/UJ8G666^)K1=/P\F8J_(-U&B5YCU@< ^NI9.P):7\L=#DUHO M.99D/'^HH]%J8Q M(=JPCA:RHSJB*M\>O)L%E7L^G9D\=E.))2OL4!-,MA(\R3^CUNOJUV+]+X=3 M84P\0->%D!E0:B@3>NN.P!IYP Z+U$&RPO/H%F:!':Z#[)VT/@*28$)XM(+* MB [3*>OU/<&K6S:DB=N_Z%V]X/"'WJ7_$\N])C(5E*'(B.VFUEN.J=#BRX*K M\*U<%TLJ2? @R0M\\VYL:K7$[D=%5._( B^B(L$%=M?Z+H$XOG-]A-WB42Z$ M*?\NY+!C35[&BEMP]HY&W%Q"R[?ATSR:@!*'O_9K%91+O"XZ1:0>E"R"@=O, MSMB&]8Q2M9.VX1Q^Z\-_04!>7G$A.VKCJZ\M[SOG3_R9C4Q[^T* %>2, H>J M^#.PH=CX2P"J8/SV2B:TMG9-6(!'O[[S@W,4;_93PX?VG88KBD;$?+PQQX6D5\2^.EEWU74^MA? M4>!_L+P:8+.LF@?L%B_4):$5]6.2,ZU;<(V"U#1=#*SLG!QL>;&IU UO%H?]*F!0 M-MX7&$;FLK#+>5D5#F1!/*=/6:T$%L%DY3SI%+)[\H7.6]2E$WN9!Z-5P1^M MM-!SPY7>/=6%9I:.:8RJ6N[D)^V^X 72AQYS"E_92RE^% .K^NG\_ F=): 5 M7L_%)XXHR%]L/4OA%'7'GN%JE=JDHZNF#R7; B(0%<9X=$%:P@+@'B/P*;+]X:)<#*JKECY"8W[]\!D.Q M9F>:J:#-<:26+6?9/XS_&[H:H-,)5<7A!B#>R7M,V!HAELL#5.EH"L@+D5"SB_K0I2+BR.,DP51XE3>,K-U2$H%;%4PS6V'[!^ M@_##PT@LVMRF*D@VZ0_QM=33_%MX%Q E(XCSE ,J:FT+\P:N:N8;7*DDSW2J M5K0>CJXCE,KOV@4,+*@;4>Y"_JE]>$>FKP.* M,KXG(-^IY9PEW:<2-U0 H8(>"?.#>MUN5]\E"/6N+GJ7!V0;";"IP(G(@<;S MZE?YA.$"#R=N497/VW@'BHKX?-7BT"^ +.A2NZ&H]@[;\6?D3/5XZ@?U2V9C M(8Q*XZ7Z@O-E/UFWF77L2_74W0+>6-['Y9;-"OZ,KXSKKF;Y5G5!$%DV!%L- MB:JAV.&"^LL+:K'&S-=R7&3R:;ULT[\4[-@!"[:'"RT\HD1X#4"KA\(5[]%/::T!] MU/0F- O*,'\'V%'Z.,LZ+>9&/62J#NE$2 ,4;951JYS8+"L;[8=@/+8A> ;. M+8*+P!TKF=KSFJI@ ![-+W2RPJHG 7ZEG^_(*[0U\ MI$-P*1?-JX=8U4&=OZ2?%:SC$P7Z)[SK%4,%%? >_UA.::K>Y[W#*-42_3Y+ MGD4YCEY\Q4YXLS"P$]+AXBN)@$B!_G7,19W4B0K85%4 F4SL;[0?Q$/ H6\G MV.5GM=W0!3PHQ5N,6 E'D8WO$=YPASX=+XE#<:6+T<+V1W<^==Z=^GN9?(4ON9I5=J3?"3I7 TJGY4+05?)EW M&^+<.F7NVDA\3+@&F>T;L$#L>+[;F^3=+E:FY@D=7:V"HW)X'NQ! 'L*'?@* M;+X?51SD$@(=_9LR=;+3CGGP3."K24$KFLOS-/TR?+P9E^1$I!NI, W4'EI/ M=&W!ID^9X$03^(\?I$CD"?[*:MK0GMT!<\F[+Y-:R:A9+=?1*>+1LOY1.Q(_4*&R#U)-[W[%*(C0E0"J8 &%BB9Y*+-$' MAQ7%$6!3@1._ 9NE'CHC7'*T(Z>A"OU/%"NIFS[&_\7(B L O00U@%42DFIC5B3Q2"[Z>F#P5MUH;:T2.$LB.$M[ $95F437K2:$ELML M?ZH8@>CT?A&$JF?,,RL6\:11V%P%PSOZ^78+7[WM%?DJ<=R&,"E]5,$9*,WC*X8Z]4OX" M[*U%^UAR(\M>*Q5DD@D>A0=>PE Q\P3XB7OY[?5"!(KNL*=S.>G,0B>OL3/" MCHMM9+$#NP^P>DZH!)[C9HC6WD"_]:.S7^GLE^:WZHLIJ;!IGY]G-78VT.67 MR2(GU68"B.= 4K) .12MLC4Q'\%JA;WE#<*NB2 E*#%+BT!4L)V!9W3[>'O[ M6%*G):^E"E^0,=[<=7^:V6@14I:U^AG OX"U/\S&*VO9BVS(?K'ERD8HBT!9 M@4W5G5?IN M"I/?N[*-*\C^1BCAI_F\B:-1DA242$X+"VSME=G2VD9DZ,E=P7T2P1)>SD:/H\GDR'T_^Y'944.91QD%K;%S]V8N>2( )NFMC#)W\1",Q_8& MY.41QE2$Q.?6C4W_K&X"I1OD&[Q#,4H)FDV?9 OYR4L@U%E:QR7K*YQ52@$I MNJ1F0>F(%>6Q8_\0_L&TP(?F5K)K"F+P4)O)7QJ&I8Y"XQ3ARR._ Z MY!2FXX=&HQKGR3*(W0N)THF%,"I,C^]PK6%C:\D:))5PFO+J)$8I:J%2!PHA M*NPMC^+H.6[QTD?FWKF"UJI:O;JUAOZ="@TE[7DC/*^6U5$.W=&W:0Z283)\I2A@L!5/B>>^!,$ P6&F5C+Z^I"M^PF_'" MF'*8\Q&81)^.EG#84+L>3XZIB5$RD-<\(<6#5Z&'57,+: ]:V?V?&Y]ZS-0U MH.O*&;6W#/EN\T9Z'ZP:$F6-=-U%=N1&L64VL&WQR8*&J?QYKMK/YY1IKKFD M@OWEA_\'4$L#!!0 ( +&$253T'*MJ&SH ")J @ 5 =G)T>"TR,#(Q M,3(S,5]C86PN>&ULY7UIDYLWDN;W^15>S]?--NZC8WHV9%GN<83;4DCR],XG M!HZ$Q&F*U) L2;6_?A,DJU0'JXH'0+YR1SCD*I+%]P'R ?) 9N+?_L^7#Y/O M/N%\,9Y-__(]_Q/[_CN3]_]Y?O?W_X,[OO_\^__\B__]K\ _N^/KW_] M[J=9NOB T^5WS^<8EIB_^SQ>OO_N[QD7__BNS&M?OG^_7'[\ M\P\_?/[\^4]?XGSRI]G\W0^",?G#U:>_WWS\R[W/?Y:K3W/O_0^K=Z\_NAAO M^R!]+?_A__[MUS?I/7X(,)XNEF&:Z@,6XS\O5B_^.DMAN9KS)W%]]^ GZF]P M]3&H+P$7(/F?OBSR]__^+]]]MYZ.^6R"K[%\5___^^M?;CWRTWSYY4]I]N&' M^N8/SV?3Q6PRSE6R;Y;T;Q7U8E9>?L3Y"NZ"QK#ZSN7E1_S+]XOQAX\3O'KM M_1S+7[ZOWTA8!.=BC>1?=_C6'[ZB36&2+B:KUW^EWS??7>$U!(Y?ECC-N)ZE MJR=/9NG6AR951K/YU5].0L3)ZM71Q0+>A?!Q] LME0_XZVRQ^)FX3R"6X^D% M+9VOC_T1RVR.Z\^]#5]P\>+++JE960@/$-8?[U!(-:R_GP^=Y J%]XA7%D)/MH"Y/;X;3'XV3]_1_."<]MCOO_N,=4?<;+=K9&&>[E'\]F+? M?.*'Q<6'#ZOOA#%-]-7?U[UWF-QJ7]RWK66<;NM;HL^3\:3XZ;)%]&1@$A;(/*0P2H=#*ETK0V>QR;; M?WRO\1-.+_"*#?.0EG\GG_?YQ6))3YB_^)(F%]5=?K98(/V7B1*C:((,'FG4 M1D90Z!+X'"1D2PHG&2PL\R[C/P#LD&S68[ET=]'TEEVS1?1\ME@N:"EOU,AB M9'6PB;D"0ON5U4)+.8L$.05/ADN4TO9907>1[&E[PC?%CZ.FO9GPR4J],9X0 M3.+,2G*#T(#*B1,3HP(F(Z=?)!.JCZ*^!>-XDZ2?&K4JDY0+!RV5IQ4J,L14 M LB0O79*15/,MQT9.>\N?#@?[QLMPV!!0TM[ W2S8_R(4RSCY2@&,MZRSX 5 M@F*T';F8$KAB4(:HLDE]MNL' UJUV[-I^.FOY_.+JJ0+C(<-[&7YZVR6Z[>^P?FG<<+%F]DDCQAZY8HLD&RQ582* MK*-Z+I-=*,[+J$4_NV0[IB%MG4=Q8IMUTD ,S0C_&A=(7_.^NIQD6$]F'ZL[ M>A7YX%R8)),"(0OMQXD'(,K M#?U7VI3G84+ GN4/X^EXL:RZ_M-UB"S;Y!2J#$G:RET6P'.YBE=([PTC;O<) M?NZ&;TA!T*:,Z2">9M3Y\6(QGI(+_GSV(9+E5Z=F;2V^(U+7P]UQWEB,S^;S M0*^NSG>?OZ\__C)]]F%V,:6M\H$_^74 MU[9PRWR,;5_?*S'CR:$TRM#8\AQR1UZ6&NDC_X-VMV(@>RY(UF@A>))U0/(7 M/5;+Y:*,OE?!POEB%.\.WL59B39$8^).ZR M=5!DI#FQC Q+OUJMF$/A*J@2^IU,'@Y\6$Y &\YM/7H\D6P[!3>-5IF7HB&Q MFL?GL@>GF =92"=H&92Q^M3!S7,[!7W(L)= *C,W/:%!.#..F\-AK8D'3 *;F_JYXX!W].LID\ M#XOW/T]FG_\#\SO\:QA/ZXO/RA+GKS%-PF(Q+N-UNC6Y(W5PZW$D[J,/9.:[ M3.ZN,@8A<&.@AJ #ESJ87IFCS<8ZV\;L>^UH!5*9B.9 \7%FI>D G@C.21-4YZ+TEZ<5B%T&>:0 GM# M7"/GY]9) BH_ADDMQGGS'G%Y=#G+[2]K&2QY!&:CT,B;Y2S]X_UL0L1?O/B? MB_'RDGBPSH?:*M 'SN&=*2K*G*%D64#E0#LEN16@L[2H8G3&]['2V^ _=J=^ M14-"6C%Y!><_P^0"1\R5%+058&)1Q'D>(#CF(".*;*3Q7O;Q &9)1? ;& MW=W\CA57P^R!#Q]FTQLH9*1MW*0$VM9;SN XW3%Z%RE"X^5,E@WL5 '6ET K.I_!<&R.PT M$(UQP)UPZ$QP6N<^C-L/Z)!.18= OXYB;IALM"07'?.+,)_2P!(X*H8(/_9@XY)JR2]3JG/0?#Z^6U&L?;;ER.O;(E>"T"C!*W6 MX,"3A,"B]TPF>A?[^&.W8 S)[3A RO>VS(.GN!E77\UKR>GR\M4D3&O57UW* MJYP_^OGG\;0&"W[%L,#7=49?EM\7N *]"G#>6F^TUZ?Q59SSV8>Z!?R_U:\C M[P5/@O;X%&OJET$!/@J$P+B)(C&;'.M"G?YC&Y)3TX"/ R-#,Y+79.?/X\ED M9!4IEU0D,$1ZNE((3O (F>64/)*JR'V21*\0#,EE:4"8@R:V9:N-,'TW)O-B M/10R+:]K+Z^1);(K)#()1M?TE"!I>#IZR$GD[+)TV<=.-31/HQN2"]& #LT% MTHPJ/VWB<]>E/M< 1[YP)IWSP%0-O#!6:W01@>80F1?*1]\G0O8PIB'9^0UH MT6CRV_<6V*;,1MX%[GWD9(99//$:A^AQ;/@9K%TJ8;X<2 M[430]G!\PTSR53=&.:(D]U%YX P308GD0!IM03LO4Z#-*_$^T8"M<'9A@?V& M6'#TE#>3_E6R_A@7(ZTE+T)&\(PQ4#'0IJ1E!INLB;[0N\)VD?D-$ W'<^5? MQL1T*(J!B2F#DLE!0&_ ,D7&-TL\Y3Z6T'TL0_+C#Y7\73(?.>/-F'S34;LN M0;FQO#0KSG)2M#)K6K#69XBE,"C,9S+$LLVNSX'.$\"&Y$NWXD1+670R?[;" M@#DC_>BEZGDV-;4_S&^&_@\3$Y+T0& MHU3YNQ!&1*UDGCQ*ES6P]*K$4K/DM>,C$:G:,4Q4@#! M"D_;?G"%R< Q]_%#MN,9J-%^"!^VY"X<*X"6Z3+S"\Q;1EBB+=SY!,9*E0C5T5T[,:D"(D7MF*_]^$7U4SB-*40E0'MO19 VVM3GU.81 M4 /5CNV9T4HP[7J&M4E.#$*R0KLZ9$_3H:QE]732@BRBI) M*9$^S>=Z%"$- M1A>WY]\9Q-TX6?3*EC#<*WI6@.BKQ^'(/O'"D?=NE)#)*V,Z!>6N HJ MB]JMVQ8(UD:0S)*3IUGDN5NIT(.HAJ1VVQ&CF1R:WD\TI8]^%F3AZ)%;Y@,M@\3;J(8TO%1.\D?/,\-BQ3P8QA?M?PD_74C<>AJ MA!B3,]YF D;[DK*,U3[M@HRW9 (OQ>74AP [@!O2"5$[7K26RND;GVY:]S2] M?O;KEW9K\FL_J]5_YQ\O?%S5S]SI)X5E:CC]M#AB%9IS< M>.#,U)+U("$J1>0AJX!E*1EG?0I[=L?8ML]DW>&PJCDR?6HUH3 08Y90DO92 M9(RAD[FQ=Y_)$U[JTH,MC[>=W$<,[4)*[\,NI[)!"-4+A;0 MUWNBN/+@#9D_*+E6C%F.V"E$M!7/D)R2$W&C@6 :EIE\K7RCGR>XK00N!#*7 MF=3@G"1CV1I%;I0G9UM:93PK$5F?&,\NZ(;DO)R(0,V%UO)>J'G-"?P)U_^G ML5<3ZZJ>YCI?:U0X]QA*(8.\7LP1:>0N$%B1@V:NQ. ZG0+OBG!(GM&):-5% M>,VHM0Z3?XWQ_/SIM_'O4P(Z&?\_S%=]+$=1"<>#$\!4CJ"4RQ"*%83-NA"2 M+"'V.5;;#=^>CE7W"\E.P:L.DOOF+EQ)417:CCF$&&-U*\G!7 4FL[4H633. M]#GW']"%*Z>J]CL1K8=(G;;96_74D2;R]LWN41M,F8Q3XZ0!%41-)B/J>9T9 MF:FZR-SI3NN'(.U98_B'V%/;R*>CW7<_^EZO?6<8R4Y0@9/98.IXDRIDD7+C M"9J/G2X\VP7=+B1R?S 2-9=:1SY=Q?17N5PI^6!]!):5(DM!,P@Z\'HS" ]6 M8Y:=2G4>A;4+@_P?GD&'RJDC=39A_RL_9FOX?Q2C%(P7!S';0#1GM<./DN"5 MT28Q5I+ID]MQ&-Z=0JKL#\^VYJ(]@4;5WO M#DDZ&0KGD"G XAWMP2+6 M%$%96S5CD2DX:T^UK^V'?"<2_L%.!DXJ[=Y!WZT E2>;43D%)CNR)ND7B,XQ MT#XSF87P#OO40.X!W'FRU.' MR_K&9-L;(5!1PE@+I;Q'KS;4! M/!;)7+1*\4[T?1+;GA[&68Z6FI.PK<2:,^DUKBXJ>3M[&[[\?;Q\7WL'T.@) M[@/9Y$Q()I&7VN1)U=,*"3XF \+3"\AI"9A.=]@W+@>PB@$;K@S!E+1-4T-"\2B'42MHR)+3"31)[[W**P]+?(_!*O: MR>EHZM3ZP%L*_B:V&@YDP=;+E)RK_4N2E! L.;$YW\Z>I?^Y&),AL4E9Q_6EMJL@ROJ=/!*"S%@3#!0,M#_D3(Y2E@B>>X5& MF1Q5GXXU^Z#V-91E%[/B;V&YP;-* M!KV\;NH8)I/%R_(P_!%ZFB.L63*Z]H-Q*4*4Y-HGKYBWRCE9^N1X-($_I".V M4W'SY&+OPMB*YV5Y.P^K8.4UL/_ 22XS\M?JI-7AC+*SGM6:;:4+UC,^,J$B M,2I[S35Y^2[K_@3=%>V0SK[.P,J]IT@H I4X0A!U6[) MTNK:-(]639\"ZMTQ?@M%U-WU_:+HU0'L1YE.:@)J' ML(J OTGO,5],<%9/9#Y>+#>M3Y:DY _JA;;7]Q_;%NWPP33JD/;W%9LQ/_N$ M\_ .?[OX$''^LOPTGES43FVKD]:7%\O%,DRK]B(G4A7F:-L@DTB 4EAJF"C1 M?L)JA,B5I/MD0>X)]%BM^,#C[CWGQ[ 8IY%47.0Z#2Q*FA57;WY&+<$+);@O M&%'U*5_>"^:0$@AZ\NZN?NPGR[9U,G4S#I/-N?(*W.U.[U\/_#8[]\WF$2,O M> [U2D7MI:QW%^=U6].H IF//$NG>C6-/1;[D/*63TG,$TO]M&Q=M_;Y?3I> MOMKD3#Q[-\<-;):C,"$IX!;KO7L$.Z:0 6DT.A//?"?W]6CH0XJM#(ZKS63> MS7K\.8SGJWL!_H9A<;$>T6)S1A4FZZIPFJT;-6UO+N)_8UHN9UO_] A#LQ>4 M8VW2DTQ1(_/U&M8---<@?AHOTF16<8QT,3%G3!!8;914#+F\&!-(##XFIBHO M.V:@/ GP^%Z=<_+1:B+DECO=.#I3BZO ^N)H\&361)<51!UYE%DS*WKUZ'P8 MU9",T1XLNM^8LY&$!G(GML<419"%B\&!YY53PV+CYBD++%/=O03P(9D M&)YM0SM03HTO(-LVU&R<5XJXK#R9H$H;"2Y9!,N+S*P(ZU0?VCP(J<_%9-O& M;DJV:+0 :QR).4<%(=!BCK;>=J13*+:/ ; SQ"%9 VTXM-ME9<=*J^N%92-; M*^^=J[=!JTR#YKY>J%+[^ZG($CEMUO4)*6U#,R35W8W,CL>2@Y"5'84^)ZZB%'9:8\\+VWKQ\8*66LDX$#>42U M)BHY<-I'D"X9S%&(S.TQP[C]N$$DL3<5[:V,D_93WB9)Z4E[6C7%T/&$.O@V5-CU.I#>]NX9F;#WC'=EPK7F'B6GG$:4$+,O MH$SB$$T14+!PSTBW*F:.(<'UDX9@VYY<_H?-<[OPT9W4\(KR*[C-'5JUWGJQ MK,DBBY&SVB86)9GA6"^F"0R\,;9V5G59+#Q:I0_:]S M6KBW-_0?LA5_WR%CLEDGV*]2QAK80CW$(+PY*6%K!W70JH^'0R: MP!^"*?%-\?9PX7?C[>W:NAL!0IY98$G8=3=O%;F"B%8 *O(DT )* M7;B1Y):C.,:W.29D<_ *%K1]&Y8U^%51'?.&!A4"..&KT>&T=WTNI3O.1#_/ M&6A3BNRIC8\37=?+9%=#C\Y:7R^JRK[>FLQ4 N\-JQ<&94R"*;1]&M \A&@( M9EU7PC01Q=D5YC7MRS;:Q\N:D#4/:7D1)IO*]I42K/5Q#7*-=[9 MG$N2W()@!*"H_8ZSXA#K1=CT@V/92'*"AV21MYZ)K^T7:K_"\?3E%/\+P_QK M:$_&$EB1"#9K"TK8 M7W!^,%DU8(2=[5&>;G*=Q#T,]=N;B?_])4S"=RF[]B M?E:6."?(;]_/9Q?OWO\\_K1"?R, '9.DF2L"&".=I0)'<+6MIJSWG/I48K&G M">T>/(0AV >#)&Q;X7>N6J:]#5]>54>$5LFMTK978957DTV]9;T4(J7GH&+M$!1=(!L4 M?4Y<2>GZZ/8C@1]]Z7L:KP.BKS%-PF(Q+N.TDO[UP[=.5V2&1^L2\,AJ,35M M_UXZ4@2)S'9DNOK M2AZ%G9+@-L0"I79<4F@".!4K=NM*,84+VZ?=Y]'0!]6%\)R$/2T)NFG\_\#\ M;CQ]][*4!2YKE=;7#,]CU/PN7WNL;M\;>B.%OK4,:11,U+R0V2A%[51DE(/@ MC(64>&)DPCD;^E0G;H73+N_ZVD)]6>X_Z7(42K0LI@2V9N*H;&@Q99DA&!^M M#H5KV^>8>E>$0U*PQS/GX7SLAG+J6%AY>0US=?Z]2B(?.1U\YO7.WI@]*.D) M&WT9V,)C%(C6RU,MG6WX!J7R>E*HF9!ZE7_QO84%O_+96#S>ZV+R:3<;I\L6$/E0O,"'T.2*M"Q=J<-]% M^JEP"\P*GCD:TLV]"=AS?*V+<$:6YQR23E!0%%#%.J@WZ=8[]MBJP%=UJNZ\ MBV28F_M@N/I4]@NRUJ&D.UE-T>Z _8;[8C#CDA#YJ/@A5 L>^_0 M]3GM/]T8NW3J&!7.6."V@'#2$ DS@^BJ5U^3)6-21J<^IWL[N%Y#T4F#8N]. MC3WV$FO/]?[DQD0VMXI9T-87>0+E3::A1P7)($^R%,UDGU9?!X =J)+ZQNC9 MEA/=JN5'+B5C1"P0;!:@A*8E)*P%[9@-W$0EO#F#H=X\'K5V4;U$;YSED%R] MY M#A)BX!YU3=DF''%3O=?@PNF&JA0-XLF<(:G_1=(\>K*(:7T-CUG%"47N. M:9'J^3]-0^ 2G,I:2>-84GW2=7?#-] =NRESFLFGVSE)31*<$MV.:P:QY5N. M/05Y"EBC0X^KQUR2IAU)6J]!U1YK-HE:@UNJUX? "_EG241RQ?HD*MU$<7Q+ MZF9X)';?(/*O<]KVN3G@2W)"J)]NSI9%0NAD:5S=IA1N7:&U[C: ? M88@<\)1C#95C!];(D'GPIC+Z^>8=Y:\KNU^6WQ=KXW25P'LCF_0G_#C'-%ZO MBVG>E)*%=:!:J8C6."A<>U %,T26' AG=(E>>NO[=*;K/[8&-T\>@G"=&KCC M]%L=F$&:=$[[0P;V$K:6YF4]:FXS]/)E]KC59^/5< M]Y?I8CF_^'![F3W[>M([*HH9$/."EIFM3/,"M'GA.U P$-2 M@2V9=4HY-B/=36?T.EW@:A:D2V2;90&%)?* 373@HX@0!8^":8^)]3FC?@S5 MD(Y6>M"GF42:<60URC<7TSR_W#+6H%3AFDS"+"S1-KL,028&Q5JI"@O)I4[- M AZ#-:1K9'JPI)U,VC7Q6=N(VRY*S2B%M B:D1)55KAZW3D"8P%SDLF@[E,; M]B"DHTRT5_-935&MO6H6]Y\P8DS%9!1"[3,+JA;X15$0,*G .,M!2[V3A?;X M$DMVLR23[=[!)QX]AN,QQ%<S#Q]P7B]\O7)% M:IO,Q/B3SJL.VTET@K=7I MZ]EEF-P!N^X.)5N*Q1U"L@]5YF3.C!. SU(GH%+B0#SNM<6 RN\#[GS5O [$('_4W3 MX5@)M/7+'AZC+EH';15P(ZJO& 0$3SY!XL)PDJ<1MF/3NQU-[^T$,=\T01K* MY3PG']?O786R>AUQ//B@KF<9NPVOT:%%?<:=ZR/(^%C.QXELU,WUXK=?N/') MD8XF.J\R<(\:E%<.HDD.3$(T44B&JD^3NZ-@MXB$W[]U_=GR>9C/+\?3=^MX M*2)MN?6RW)"M \5SAJ D&?VO.9M65+.R>F5SD'Z$7MWMBX_5HP? ;Z0W5\]971LB3)0FU^:BQ%H0_TCSD/MK?!U4+Y(+;R*$+FDD1E#OJ/1M :"DPJC MSTGU:51S'\N0--5A4K]G@!\WWUT.5^]F^M[,YV4Z&>TTC;"0"ZF2%."TK+V8 MI5!:,MJP^H1T=@0X)(73AB$])-.%-K],ES@G3;?9<4<&A=?T8!!*UIXHY$9& MGB*XG$+TOBC&^N0Z/0)J2"'C]O0X1@+-*/&?83ZN\::OPW-22U>/C$UM**H8 M5^"U5,#)E%(I84J=ZNKO01E2 +B-^(^;[69"?W-!&%8,K W91RA9S926]?2* M%%[L.-R,7CV_U2M_8XFO ML[7#]&:@\6BOXJBGMG$YV@V\5?+Q+9OR:V>=E W+/'#PW""9DYYX4@OJ771" M6T,4#'TB= \ :NNKW$M 8Z4DJP2#2.L)%.<:@A<""$74TM[=2%3201 D5,).JB8^E21 M/PEM2![-"?ERH&Q.X1"/ZB%Z**;>.2AK1E?-62PL$B N6""-G'6?C?014$?E M_CSRO:ON;*.DR6]0T@/+OO9]H[%[P1QP9[@*7!89PU,*>ZZ;V[]R CG4%N$9-'5K!%'AF6R8&4VT9(K$3JU2MP*IQG#%P\4A(VLQ>CK M27<@#476="$M%9P&%BUM8+(HE+M=3[_+TX;*],/$_R#'FTQV7Y[?4#6).:MR M(9M$E$RN&3)PG#!&K8/)*DD7^^_L S<"VI&EAU0Z>[E?[WB=E6O+)5QURKAK MQ;3P< ]^8AOOMLV C_1L[^TJM0)\N]WX*ERN[G;_J9:IU2)(Q1)(FVHK6>U) ME98"F6D3BP_1\MT*4/=^=#-=]?#3?I_F\2+-+J;+6NQN+#>&"Y%NF3.NET2+(CP"&8 H.@U2$".RV;B!XX M2LA<3M%"EH&FP# %KL9W&!.U>3=QWO5/^GD4XA!L@^$P:F^AG913/\\NYJ,0 M3!8R1T@FU[N\R#^*W'LH*I?HO.')]4FJW17AD+**SLZHO45V6D*-/Q'=20?+ M;,C2%:Q>@UO=;%_[,^2('"7+'OLD-.^*<$B%J>*<,J&\"WM'6QF+PS M'"(6#8IITM8NZ#HUAAN&0JH[+F&+J/;#)E1/S59/0/*T@(6 MB9J4B>Q5.-G4G!Q>F/M@0AUN9.XCRF9;^*^X6" ^'7;["A.]CS%F P5KAJX+ M"-ZE>@&99<'7*XDZ&0=[0QV":WQ&YO45[2DW^0?/@Y+,/D=22,;7*[$U\28J MKB 6R[-0.:%3#7?ZW4[R&FWW#P[:,L&PWF#!F-'U[B\.(:8"ABM!XN(H;)], MS+U@?F/;?A.*[;3W-Y'K:?;_!Z$69W+Q0H-TW*^K*GSV]=+;I"U7A-7V*N,] M .XWI@>Z4+&_G$]NDHRD-4%J)8"<6U)7.5>?1%G"*7P]FC.LT]'/K@C/LS@# MRS)I;4EM1P0ER:*,+&=P,NJ:.ZB8ZG,VV&UQGJYBO0/SVJS$?83:NRIDI+WP M7A=5RV;KE2_6@^-20N')*J4MDM]RREJ0(6SP)^50"\&T,> ?'>[=7 JA'4JO MR(>IFD3I0.JDGJJDD%@H:*/<,=UPGZ<.Z3BK*SGZRN.R^, M8X@R(#>J&5&:2^*,YR.?9R,?E,M9D>^892 ;H=C:LM224RFTU"XXSSKD_#^4 ML-0O<0NS3S8Y3BK4D>)4C(QEA@XB+R7)Q+TW)PR3'9:X-:!]]S@B'9K,M8\0 MSW,F0B"%%FQ5AJ!<33GGD8'7(D)Q+ A:,FA+GY2N/8%^8QMX6\;U%.H9-O1; MV43>2D6Z)P C'Z]:)Q*B#P&,%DHA*Z)$WGY+?SC#JV.NFV-&JIH<++!V Y7D MMX04))#CFYP5F0ESOO/N77/=AK>M'TRG@S/@]A'D67;V%VZ"O9,V_OM!"P1O9/&!O)7/ &N M'8%B%@62%8E<4UF4V[_UPOXX3ILRR(2RF;EZV5W=)# Z<%E9D-:XXNO-3_(; M21DQ3_W,0 MW&]7#;2C8G\YG[2T7#*']/@ P:G:_[Y>,5-#CQXMCZ;PHF1IN/'W:92DG#.: M^00LKAIU)P>!H:=5SUSF-E@53QB,^<8V[+THL-/&O)<\NA\G(UEB7 8/(EL$ M9>H=R%H$$JE#%[4EA[M/_&3 Q\FGHD<+F9PGGGVOC-AP9@BV >F,(?\AU12) M8B'[DEG60AKL8"$_6>G=WD:^-W*'(>K:6++$FAA&QA/I+J4@HLTZNA*C/$^- M\A!KX$]/MJ,+Y/>1[\G-Y7MHF8Y,>:-!JL1)MQ#NX&FFZ#4,WGB7.U4X'XKX M&]OO.['R)/(^9Z2\6OE2(%ID#(2HG7+)T"$MF34DC;&0092]W;]-ZUX03E;$ MBRQD%UT"'D6],DLY\+S4\[-B;3$^Q7C"WJ0'%O$.3QD<3*>#2WOW$>1Y(N45 MI34^1'+;(9=4TRO00N!104$3/,OU&N7SQDF^_1!)$]IU%>Q >XN.[@033]%= ME)YYWOZB=P=]G@ZCJ"43S)()PBI[LJ;-2Y$?R0JWR928]-W>).?N,+IS\7UQ M$65T@G;C4/=EC;0*'0.9+!H71$QV"#W8OB7%NA==]E6H>PGL]-5,5BEZ?JPW MD$4:NN$PCVK.ECUKN5 S,UUY-LEYGF\ GLN91*)$3[1U,G=]S&DCZ MZ"!I=X@@S]C A0MRWXQ"D*K0HB!O$9PK$DAKI>ABB#&:\_-M:)THA\>XO85Y MOC1*+E%Y10:1PB! \7H9%+,(PIN@:L*%L7UNC>F11GFZ^V\'QKB]17F^:*3A MRH60REJ M@J16P1;.['G:B/?)'Y2!)U9O==$H:F\L5Z\(" D,6L]+*=+H$W8D'I(#WI0I MNR4/[B.,OBOBP78Y.6J/W$; C.2*%=HKHK0.B@O.&N]%9B?DRY ;DYV/1TV$ M=\)F"YH[)'HS<$%[4CVT +PDU9,UXSP8K@._8U-V;K8PF$L8#J%&GWD?Z@'T MG8M:3W( +XAPPD:@9SG M]&#P+#M<#:?A^D[K&O@Q\NO']DLBV>?P_S6QY_/%DL^ MJOT(K&89:#]6Y/#:!-[R!"$QYF0LI/_[),&U&\,0 ATGX.O=V/Z92-#L8.D% M[6ZS2\0W./\T3KA]PFB2?L0IEO'R9YKK+5,YDHJ0)U>#WEK5O!@)40I+0^%2 M!V%R+'U2G-K@WS., G\4]IY!^MU4^R]3^A$)+"XJQMFT6B&SLGXY3/.K^>S3 M>$$/*+/Y9CQU[F_\V1'ZO]W#CS42.DU#(TOB^<5\3H"NG[9AT ;(*/'DM(X% MI&865!8!@DX<#$IABA!,R3XI1(_C.G:3W7S[ST@;29C<'W86#*,+#@K3]6HK MS!!J7U 9/#/UYK.L^N3K/0%L2#J](7/N[H(MQ=-,,5^!FLUI=J?W05F98["B MD+\N,BA/GI2G[1YLR)8'Y;/LU.#]"6!#.)$X(6=:B*ER/+T83]]M CZSZ>)').,!;Y@,+[XLYX&$,YZ&^>4O-*>+WV;T[G1) MTTV/>??+=(ES7"Q'QC%7%"T&@YRFS$H#3A=-MJMD:&TV7L0NW.LXJ#/,]T_T MPV(Y3B/KC?*,C']G5:U'*!Q\L1RT*2EIE65R;"CS>05Z2%;%4+A^=WLX%2?. MN6EL=.?(U':<12<(-I+WB+2#QDB_EB!*LD8GR?KHH\,Q#\G(^0-1^!!&-&/P M3UB0=')^2-MKGDUR@32P9*20C700O,Q@/"VDU9Q)M]RCAQ#* M(C7IHPA:(=D[,8J:U^>A>&](?5G-3)_HV3XHA^36GH)5S277V%+=LF663& 0 MP:ULG4"P7! .>"'V6\<9-SU=TUY!YX>&:ZU(4JD(PM4KU0WI"E=< =1DYCG% M?, ^?7_V";4/P3D\CBD/Q'U:2.5DEF_Q3,0@$*QWAD!%&J]Q FAU2F9)&3C3 MIYQP+\MW"%Y86ZZTE,LICEU?E()I.?[TU:5[C>15IO%DO'I$F_/579_2\"#U MH($U.C'=\FS2K-OT0[BLY;98E:>]W'1=L=X=+K* MUB?=EL;S]S7WYI?IBVE(2\R;SXP82L-7_3-L;5!H#:_Y"0:RPLA+\D[D/F?+ MAV,>DC+LQ,-[&2FG$7"[_*D=\&ZWA9$F*O)02@P0N KDI=L(,;%2KYE1]3[& MY&TZ&R4?0CTDK3L@4C81\DEI^>PJXZ%"OZ#ON[SUX9$)Y(+D74A"N\#V%2[FMH@ MP",FR)D66 H6;>GCN.Z'<\\:M[XII0.BX(&2/"G;7B[?X_Q9_N^+Q7)5RS)R MV7@,AA:"<^3%2>XA./2 Q4:CC2<73YR-VY4/_'3F/ZPQC?'83(*63HO%8)8G4':ZIFEC"!=41:Y1Y/ZY":U M0+\+5^T_'U>;"KU-0?$NL%<)+?3NQS"]I'=P_"G$"?Y]3O/^LI17]![!'PF3 M3);!@"NR]LM/#((D>B$K+*,6:,UNS5R:0=J%A>Z/P<(SRO*DV^9OLQH4OJ"/ M$>I-0'][W56M"ARA+-EQ%L'JVG#:AP31D [@WD>O0N8QGB]JN=]8=B&S_V.0 M>2"$.-T&^_LTX9P40'7O7LT6X]747:U%YSOX8%#R]Z$ZLSE_01"TOW\[#=$'FQ\M27YQ,Z&\OPN35?$:S MM[Q\7>5X/1CC0N"9=KML'X(<-J=#9^[]&_8:V\,XFH%X&D M3!N5=A9\#!F$U3+YJ!3J/F[G-C2M4G.NO_.O\]EB,8J*%EO1&I+BAJCMR<[- MQH&+&!@*,G%%GWCD=CQ#.J<^FA,/9>$<(8+FF5K76/XS3"[6,_VU8;1-VC.! MH"*C;0^EA=I8!*(VP3(MG>O4?6<'<(/JL]&?*4=*IQ]M;NS/==!<:>L##37: M:N7E8&N]38!4!&9MC+2)GX8RMX$U'W<=;+!6!E$R9%V;"[N2(/AL0>;DG%79 M*GZBP=X;X#2JUCQH MEF/LJU>WH1KVIMF!)$>+IM_&N=;]03FA,@]@;"0LE;VQ=OLUTLMJ%3#N^P3E M=C&_&HSR:VM'^O;G83Z_++-Y;5JV&'&3,2G):)&B!J5D@5"< BUM5HB9F="W M>&L'D(/>5/=GT)-[:2-Q]5LUUSD?M\$%P:U7AH-.'.L!? #:]S5DSYS03.2L M3[2,M@,<4J;C*7C40$QM8H#WD/TR78;INQH@)T404^2UZPJ+-6LHDO$<1/(0 M V;N?V:7;/01I(%K6PP(&,-EQZUVNYYHUR<.*2>P^W[68M8[ M$6+5*_UEG(S?K69JQ QI4:4+6#+%0-5L1.](RS)K9,E,C/[O]*0AY=YU M)\ QL]Q)\+>[Y:]?&V5KR#=.$HB*D6A8VP62.PO)F11B*4JHW6[+V.EQ0TII MZTZ!H^>[GW&SWHRR%MJ[@I E,O+,HH)Z]0)D\MA8E$%K?Z)CJIT5Q*DRS4[B M,^\MA--$(+/3Y+ ;!IDGLK]93??5B8QP%04Z'UQB?>,K3T<@CUH"-[[UK[-9 M_CR>3$@_?_5 [GHDFY7+$C=:<4F2*:Z>Y==6F]E!9-D;73371?9>+8=!'V(P MZFCF/;*\3B#@'EOS#=A58Y#BN'&'PV)DL&3R?S5$64][9;TG*:0(4C(?M2%/ M@Y^2?UL@#C%8=2*>'2NPSGQ:JQJFR0+%>H\SKS<$FH00G!$@'7KEDB!?M;N^ MOPMJB%&N$W%F?Z%T9LE5#MNK2;W^>YI?_,_%^&/E\BAR0\.,''S&52=H#;[P M#"DGIXR7)?KN"1V[ !UBC.I$;&HCO!V3$#>OUW_JK4+__B__'U!+ P04 M" "QA$E4;UITE+.9 #5)0< %0 '9R='@M,C R,3$R,S%?9&5F+GAM;.R] M6W<;1Y(N^KY_A8_G]40[[Y=9T[.7)-L].B-;6I(\O=^X\A(I84P"&@"4I?WK M3R1 4A1(D%5 90&D-.V128I&?1GQ569$9%S^[7]_.CO]X2/.%Y/9].\_\K^Q M'W_ :9KER?3=WW_\X^VOX'[\W__^O_[7O_T_ /_GZ>L7/_P\2^=G.%W^\&R. M88GYA[\FR_<__#/CXL\?RGQV]L,_9_,_)Q\#P+^O_J-GLP^?YY-W[Y<_"";$ MYM_._]4P58J*#M G"\IH!BYG!EQ;;DQ4+%KW_[[[5Y6U2CHQ\-)K4!D17&(% M4F$R"E92\'SUH:>3Z9__6O^(88$_T.*FB]6W?__Q_7+YX5]_^NFOO_[ZVZZ]_VGUMU>_NIC<]HOTL?RG__/; MBS?I/9X%F$P7RS!-7QY C\_+J__P.AK]T_HOZ5<7DW]=K/[[%[,4EBOUW+N$ M'[;^1OT.+G\-ZH^ "Y#\;Y\6^<=__U\__+"67)BG^>P47V/YX>++/UX_OXET M,EW^E"=G/UW\SD_A])00KSYA^?D#_OW'Q>3LPRE>_NS]',M6])=+KJ!TA?,O M]=-^VAO3>P(R3^<1@7Z*TTKP 3'>]NG[8[[Z+,A8POGI+$H>&2%:9#9BD;>Y,IBTOFE;"(*ZY<__U'UI@OOWQ*I^?5-'RR6"#]D]^&3R<^.1N,\,!]3J!X M(LA2RGK***>5TC:&0W#G-K#C\ZB)XON1:V^MW20:WY=HSV:+Y>+)-/_RZ0.= M\KBXDD.02-U$S9M0_3@MYY!1-V( B_+/V:S M7-&]P?G'2<+%F]EI/F$B,Z^E!F\]K9G82>3D#(1D)F5)*\ZWV&H#D>!V3./3 M8!B]W4*& 83>@ ZO<8'T@>\)UL^TGYW./M17X&+Q)U9%D8+3M.;(0:'CX#!Y M,(4CO01>)9<;'3)WP'HDI!A.]#=Y(?;EQ1L\I;]Z]P^T8P8#SADRI(J)4256M)1-.#?2 A\) M:8^1#C=9KX8VJ4]0L*"XY,"Q6HY6D,Q$TE"DM3Y!,.= #WX#DQM (:F#^7D-8 +W:KWW%YXIGPN60'O!0ZH(2D M;5!$#2Z'X)4RB;DV;O4V1(^ #0.(NH$M\'+Y'N>_SZ:SKW>P2_O<:<\*)_O$ M>Z-HR>5?&AUJ<:89RM'\)+_)]:&8#QZ,"J0U!2= MC8ZV0& YQ5B$-2R71EM+LT4]>#H>B\)OB0Z*3I!7-\%K55^XX@+]-CDVB-I:I,1<[N)O0SS%DQQ"8%H%L,Q42/7*V0<.QM'" MO19"-_)^O\8Q($>NE1,U/\/V$.9M&\@/Z^*0?TVGLP7FO_^XG)_CEQ_.IDO\ MM/SE=/7 O_^XP'?UBUWYL)@O3U[-9_D\+5_.+W+YGGR:D.LN0TDZTMZG,YF" MOBCPGI%0B)_9,/+J9:LOGS:AOM!.IDHY9L*(W?A#/D,;&M$NZ+TH?1U$VU#R3FT3B0O35%:D*3 M$@,5!'UE4X$BT&BG8Z*CZJ'J_JNJPH.HOH]T&UB4%\!^6YE+)XX);5%)D)$' M\99X'952,&.I&75)"D;4/AFVM ;[E.8/7 N>0=62H0&I.YXG+#&)V M&ISPC'OR+3QOD]3 MJ(25/CLHDOY01=*A2EXO,!2^,.^%%FW"J#V!'D44M0]/;KEB;Z:8!C7"-\,A M='!R)[T!$:6HUT02G*,C--%N[AW#6&*;.H@CB%,U5=YFJ&(OR3,]3JPUS$\LC)\-^LF\0EEQE/SZ;G7V@4[GZ M;Q_Q2S;)[[A\6=Z&3Z]F\Y4*ELOY))XO:Y3F[>P5T7JZ/$FUDU/$#*%:XLIP MI.TS&7#9B(C%6,=-NZS4W8$_;IZ-J=4&R?!?YS0YC#%))L"94,C/"ZMN8PJ4 MEB(K3XZ >)2)8F,29G>)-TB$7RWS-7XXGZ?WM.[\\_F M*@E"23^XS+'#7$]6.E97Z?@G*C"=G,I0JU')BZQ-%XCA(&TQ)6!$*UE#1ZH? MVD=.L-;Z:Y 4_R3_]_FZ-G'Q&D]KN.SMK"MT*5.PLG#PWI(GZ7@]IU%#]H); M*[7WC?HN[0'Z<3-P+&TVR-U?">7Y8G%^VZ'^R]F'T]EGO*PD>74:IB>(PDCN M S!#(E)!!@@V>"#7P7(KHV>N402I)]+'3;FF>FM0(+ %[\H N VN\@5C(18P M5J_Y B*$P,DU9\]JW/WB8K>]P\/BI>W$+\_;.T[QE6L/8WJLV!<]'@4Z1E M1^N=Y0J%?N09Y?OH? ]A'CJC_,82UMM1/;MFTWK0K9(L2Q":I*/ D(E?T^T3 M1$W[)HHBBR_!V]QJH[P#UI'DG/=2]S;F["WV%M6X7V.ZR-CK JI/ GIO3MP* M:]Q$] ;JVRS-'4SVHQ'#L9I&&VI1E%!D63L#GNQ8\#YEF;QC@;?QM4@ M'*!$?W\5W>@_NH]\&V0";O%Y+\!9-)SY2":4*AF4+(*L)S*FC&"&W-?@"F_3 MI^5.6(^!",/)O<$N0![/^=GYZKYB6^K0!5"OM"NA!""#B8"*REY!AK:3*F/4 M 55I1)"N$!\%69KHHT'ZX&M,%.O5@0]6U.TCA H!=-R'1!]69[DV8>5=%>U?1%] MG1<'6@<&*AH%P:?:?,YBTCD6A9W"Y)WJ'+L@>L >9Q.A#[@I=,%W69O; >'@ M)=#=L(U?#SV\3GL09@^%#%PLW1&I$HJS% 5D5M,D>$U37;61J&7"2AG:]H;K MDW!(RMQ11GT,C.FCAY&9\N62[^*4U 8%UHNOI"I6]'1*"FM(V58ZYS5CI9,] M,LPIM(%NW#K>%MKM3-,'% MQ>C&:U>_/U?C['2G<;][/G'/W.RY[/W+3'YZ]K#YK,I?9G61C52B8P$%)$G \;(7,L;%40C M&>@H&$>MBF!M\J'OA#6^"S@NPV[&'8?248,8Y)W@OG[C_R_FVBG,%%0*K"0/ M2DA:Q2&PU6;0/SN\4&TR+34:5]I^W;'D(.@E1QZEZ4('^"$YH MKUQ$-%=T$^Y)FHT'CQOP;:BW+LP80NB'(HBP#JW1$F30]>($%03#+5@N?GSBP!ALO0P;ND@-HH.Y\137:H%SIAU M&@OG4732^EN98P16 M.Z]Y([1:I<1S=#R6I+N%5N]Z^M[];U>?7"L!ZY#=JX__ M8FTS89.L7;Z]X[6[IRMD\DCRS,CP]MY6:ZB--W,_M@&Z_][^A#\66,Y/7TP* MGI#ZM"HA 1>80'E<^1FESOTA-R/F5!JUS>H ;OQ(PL!\N:5M\* *:=&?,;W' M?'Z*+\M6L&M70:$P1K $LA11B[!,#>A%\\6W&:'5%.);#WY@S311R M:.?]7MD]_?R6/F)E8693[U]EJF7;%^,YG!.1F*$P,4]?LC9IX!W '2R'JPDI MNNY6.RJG37_[+:NG#[CL"MX!8M,:HPX@#U-Q-+B"NQ)H3^TSC.EIRX06CBLC1.HB9UTFH4=,&G!TD0ZBCL#:9-FV-.\$[(C-[5\7.6FNE M@:7]Z_F,:'\=?*I?G6)3 156 X,+!F(H!3Y %&S#"8)QSS70>ST]F[SU=KO@3FI=#)K/H8B7I;G.K]# -//Q46G=2^ M31[ 5DB/CQ?#2'_@:H;7-4Z[.E"ER=86\B6S$;Z6[I!7R0J#X&DOLQI5CIT" M-ITRB*\>^R@=G=T%VT*[EU6Y'6 ,7I!R#<#X52<[JF!3B7O(;^"J@.MP.-,\ MI% @\D(;AQ49_*IB/P@9 E-8L-/,M>-0XQV5(,-JL8_8!M;>;R2IL_.S"R"1 M&>\PEIJ"0T!DJK4KT4-)/#*&C,70R73OI+^O'CUN-<;.PI\-(;D!S>L5D/#I M&A">H^5!.Y!)ASHZH!:[:D^V04HI?_0#5.'.DFL_^:[37>(_9K/\ MU^3T]#\POZL>8%I./M)3[N^(9X]9W M$%EMW BS0-N_JB.#I%(V&!>RD[$H(8T3H72\$=X5V7Y^U\\XGWQ<)49\N;I1 MLNC$Z!WR1=1^&+25>5$2&)3&2!G1V#9%)+> V3OM]V(R_4LRI,.JJ^#Z%F=Q M@CP%'VRHTU4DJ+BZJB+/II@L1+19:]>FA^Q62./[E?MJ_T8J[B#2;A!X^K+0 MMS@_>UDNL]9/1/;&"Z_!HB'#S24']:0&1^\S]UK%*-JD0FQ#]/!),(BL&X28 M-O;1M_,P71 LDNWEEOH4"_U.+5;PW FKC*L=M'U-!?,0H_(@M1>,98$BM=D" M>X!\^$QII9$&Y2/72+V*O9BBR;>3$C2650XH0DRJSHLPR*67NI3F^\:8&1\- M-XG>\CR63(XO:W@^7= #ZV>^GBS^7# DN2?CXC 6.JQ:T7GKJV^U*J=7>U6F7S2C9K-WX7JD-;HOOJ[W2S= M7_@-'-F+Z-#/N""$X:K=E.")<>XSG:"Q@$)1P!7N0$NE%-G-B*[3E4MO2MR. MYS'8&0-(NH$?^R(,1G11^(-F/#[;)HO,.'EN94M&4-> MU:E8C [$6+L.<N.:,V%3 2E=ON&NQ7.(:@M%9:,G(*VHS4.@>8$.W M-+_6B_UGXDF:+$^42%S85.NI4RTL\Q(<=Q:2%]:BIN]UFR*\^[&-OZ\-R9/[ MFI[OJ8L6Z>23:9BF]?)?3]Z]7[XL?RRP-IU:7G7\?EG6OS4)IZ]FBY4Z-B;) MQ:ARR+7_:51E/:+11V_H6\>Y%"Y:UH90@\!_7)P;7Z,-S*_;!;3V2)U27! \ MD)AK\T)X!TQ-@T:WH3I,P*BA,C>+;8;2Q%@L,8P9HQE"8L*"RJJFV.H"W.?L M?2XJA397V>.QXY[8T8')T4..;R?MKLNMD[)W5,' )0J?!*%)Q4YR@=1-L4#:*.G+" M T>TT03,W ]7RW?,,ZF&MDJ::. P ZJZ(/P^H&IGG?8?-[2+0@XSH(HK(Q-S M'H2E UCYPH%\?@59ZJA-S,&5\4;>'?. JL:,Z:.'0P^H\L4%)P,=F2@1E,-J MN=$?J'7TR619PHA'TD,84-5+N_L,J.JCFO;7:5\UDB43;#4>]GJGX&>OG[]Y M]?HM_31\P//E)"V>_&./B[6]GK?G%=MP:]VX; N,6T%F3-(^*!9*T++(X(TB M>Y4KZT_V>O*^LW&VM(!^,LV_SZ9IRU]?*UQ8? EG"I5IH:B@&$MNH*OI\86^ M2DHFSQ7+.;=QFX=<19/>XB]7+_NK\+E^THFM_WIG1_W/B.X,%(U:GW^.ZZ&-![O!/AZA[H[>S%))'M@Y*,<,%\^2^A7K5 M6-L^U%S3P(Q0Z%CP?+_Y*CM#^\[*0^AXP%C)G:OYX\.O\UEMM;QZQWY%/)&> M:/:UH!SDK1U.Y<"AH2>[<7$&X_\SK A=7*3.;+-3)?3U7](LGA9 M?L?EJ_FL3%8"K*6VN"!O+%4C %-!Y4@<.9*+IY)(X)5W(%#5 6Y,2K_GJ)=. M.+YSK+GV;A)/-2'>YOYZ(J34UFEZ.W+$:F=F\-SP6E3#)%F:4JF\%\4VG_B= M3 -JY"9M=!O+'Q=(3WE/$KMVA/_RZ4/=9!+W-, N_OYWRG53%LW"6:&&_(Q@!0O)@>NY@9&!5Q%L\Y7(_>9_M Z*'IY M0M%M.M,.OY:Q4@ /SN CH<.ATPQ7P?B:38#S#V&^_/Q[.%LWL@RB,.]4G=,2 M+2CAZ"TU9$?DE+UC/AEM>1=.=[L+N07!X;ON'H80LP$5,W1O5_QP3OMZ6.#5 MQ+Q-B!?W0EU #M_(MRN\ ]S=[ZW)V5AJ.!AG2C)%E!#)TJQ=A)(N$%C6P)VC M?Z>HG._4S> A<.6N2_O#4*6/] U:0RZ> M_%?C,]N\DM]FVF]]QLB-:MMH9#:\.,>ZUKDQ5I='P[WW#B(=D*"X=N"-I--3 M>Y6\M3;SN)<[=RSSRH_$U&BGG;$BX9L#?+M@_-:&F/?2VR[#JG<1^EB7>S>P M 2613N%=#0L^DAS<,/B]9OGKUX_>?W__?SL MR65S+NXL>J%!%.D(CN+@F$80PDBIT#N!MJ-R-S_[\2EU+^FU>6-__NWGGW_C ME[/JW=[.-/]-$K M!_]_5/T2UE^NM'S+0[]QVWY?-0R8D5"AK%%@;,\.Q=$"Z7NWH1'8L>MUC5S=381VQM M3MO+8S\C=\9JT,4@>0*%SI_,,J1BA3%,6IE%CW-V[!-V/\'>/$5WD$J#UD87 MU6K2$Z D[F:130 M9^SJ< MF%P2%PR#R$7.S/(H1)MY.D=!JWNZBQR>57W4TX!-V[;Q:TC_.5F^?U5ORM[. MMJ8TKM?B9+5*!($O&$%9[R!D9H!YRY@MY 2GN[S-X#I!?"&%O[ M>F0A0>5H@?Q?#>BR99B2"K*-X74 FMQC9AV&)7T4T( ==R;E7_8>I./3U7,S M&FYJR[ (3B0-J9A@1>;&,VS"D0[@QC>$!E3GC8;:P^IBZ/9MMV4@&EV,=\Q" MD$+1BQ$YD&.B@+X@":#D?/-&M6D^>*LDU"[+/);$Y58R$ JET]D0H2OU.$J( MV9!(HO3)^!A,.'@B[G!Y(.B$3T+6H7&,@8HL0W3T-BB6< MX8H;C+0?9-H:"OT1:>N_OW-17S1'U,THTMLA+2K0V=;C\SKNU^ZH&X[O M7&RNO;$:(]WHAE(\[=G:DDA6\\8R+YM]&?9G R[:61 ML=H:?=T[4V?43@@%,OH:4:#E1X8A'XH@BA$M5[B%JPOC'1:>5XZ1A"V/>%("TQ[*6,V MM"2'#JM?W*-=+?(R(30*%8*M&)@%Y94AVU\EB"8J8U!F6FCW]LF'V>F+&7\ZF;UX\>RR'BM:(U<9OL(3T; 8\(G69VTFRQN=X[%;1.:6 M#W]L*MU7?D/'>W\+9V>SY7O"LT@3G"9E#9 +DE^E AU%=6(J M)^_*"ZVB%]TZ0=_QD,>FWZ'D.71X]3V>GLW>3Z\AB$4$D0[Z1 MJ*8&,XF0\0(R:&L*&J%#QS?XKL<\-ET/)].AHZ)O_OS\/OSUYW6CX NP("1& M3=9D<75"G"7CP*E86_4:B=RB"*9;,/2NISPV70\FT:$;M/]&(DKGIV'^%L\^ MG(;E=0HRJ2TR6E[QP8/2B3P()B3M/TR+Q.@'K)LM?<=#'INBAY+GUC[IXR4= M_H;S].=__B,\:9E5>.,AK=,&[U[51EZ@UR:CY%*F8I0O)G@OO WT8$W'G=$B7^H;'":+ @KDZ8C1@5P6!R1LL1L33!$UV\S\>_VE*!K*1FOYK-W M\T R3,[G2'L%>%[3RVNUHF.B3MDS*F")4L460^IN@?+ KPW[D'&/M*Y]=3AJ M N%R$_TS^HQ)"J=OEN$=7N$W3#DCK ;TCHXH;>BPHE6 EXQQ.L:PI/U&[O0 M\YV%X^AQK #[[?A?S?'V)23C4TG1 5,D-958A,BC 3I&!,]W M-HZFS0$C2PVO48V0)?C,(;DZ]1')PH^"C/'"%'/,J"A,;&+R?,^UV)G11T*' MAY5K(4,6@ED%GED)*O!$@F8.+&KDZ&R)3G_/M1B %3OE6O31SJ&NTKM@_-9R M+7KI;9<[]5V$?BB"H/()L2"0EDVMLTU08V80?2BZA.BE[]A=\L'G6C3G11]9 M#\V'JQ#611C3&$N/=I;\$E% %300+=-@I/!:H[6I8XK%Q@'";]Z'.5Z>HS,Z1\\^G"_7K3%VC_SV^OP]@[Z[KV4C MWBLECTP(:YWU2N807=1*"1F(!(P;=M+K27LV8IPN)WER>E[I^0;3^9R$@HM? M/J73/_!V7Z]8O=9SV"9>F<)X#:$E^B!*V]F%1$K)-=*YJ[6WN- >SMSB^@G& M-H"'X-.F#[>[*AHT^/LGUG (YB785#5LM=O#Q?+I9AFDD&3\-BDDY, MD(H7A[3[*UHV#W0.A*C!JX2&1X$JEB:\Z07S&^55.U4VZ-QU*]B?JP@QWT#\ M)/_W^;KV\DE<+.?DJ)Y(Y55()!F#M4F]%1E"3 )*DC(KEQ1W;8)8>P+_SLWF MZFX0A:7]>KZRA\,I">ML-EUC?K)11!=/\>UL]3-ZN3!?U.E=]Y9.E$4E M4R2C5]6&Q\YIB$)(,*P4S317<;-KRG"M"O?$/CYG1Z7+S8:'8^JZ3<_,^U?P MR_^<3Y:?_R!-OMIL5;8XJ8T]DM41N!/TJKOJU;MJGIALLK1,%-;&/MP;^G>N MMM-T@XUUB\VR37PGFBD9Z7^05)W(9[(F87D#20?/"F)@/HQI@&X#^OV8'UR= M Z9S7\+=%,+:,BZ"T;:=.60O5BT\"!0W'H(L2K$D."]M4L)NA?.-,FE_U308 M.[,)ZH+7)\D[99 )D*M,V5)$[>,1P3@OG8E*"]FF>^ 60-\YL[-ZFK;+V%-* MZYM9%A%9- <JZ.-C;@6*GSC9E,7AK/9)L)(,.N8ZS4C:-@Y@$I<.B4C2L] M_!7FN/P^1KCTV%SEM+. M:FG@N'[QJNNJ28IAK8WKE\XW/>^Z@B_+F.97IV%ZK?%WES4U'2G28E6'F42R M!UDV-\1CT?1#8;'*NJB23*UYK>^XY/1Z8N2^MEB#9+!2A2#6:2\1.YE."9XB9YKK-- M;9R;;9#&=V\.K_%-5V<0=36X3WZ-B^5\DFJTIT*K4[*A-4,(NO::,Q*5B%[26]F$2W?"^LZG =6V=6]JEK5UNPT]8-K6W0\8.&^K MQVHV$K=T2B(B+\@S5SP8+Z5@F*3)CFN!]D9\Y.Y''4GF5E$A^MJ:1[$2:PLO MVLI0UV0%DZ)VPJK<:6[/@\WBJ;V 1#!SL*$'71D\&-#>K"W999QDZ"#R@D\4GP=N8 MH]]X^',?'A^0 D<3_MQOX4\_W_X!ZRF&W 1GT9$NR.93V3((U9=-BF%)-C&] M.=#D./;VNQ;U2$*SO:@Z[.X_&&4:1!MN1W9]8F4'?$V#MO^KS$+R3]3:8*[R8HZ;IO'.Q* @N,"4-MX6UF6E_&+[=%S)]J'3KH\91@ZD8 M/6+V"2R& IK0V'I"P2IN=.!9<0V=4A'%$P=5GN= Z-]1#]Z8-08R]7*NLZ1 M_C"T[N@-0@W:!6:#M%HTX<61!4:;#$)<7*Z(O$%AOQR^KH2>UZSP5=-.>:7W]8?A<5[>CGC[\+'HY'FUMF;^D/W1OPZ?F"%K)8D*$9)]/5 MN_H:JQ!IG3>FZ,6(11$T,"+0X5!8G5/++&B=2N+1<<^Z#5?J\]1OD1YM5=/ M(K\%Z[-9'>7YCL#15XL)/2>L#[.U*#]?.S.>3\G).='6D VIR5DQH=09 QF< M$!JX349S;K)1;7S# ; ECW9P<#X$/H_UCN3FY6OW3SU=?_L>$WMAY>O_Y16UE?-%^ MRG*M5""))CI@5/'@M&!@0D["HA3*MZFO[H;O4/<9!^+.-@8/I\,&1L*M[N)- MO%=MZNX'V_2*HA?B:6=ZI"(\^]1H9Z+M-(GSUV&_3$MI=\@.ZDU<@+EC8!48?$Z8[ M$89_^^\W2O90P:82]Y#?@)O^)AQ7"DNET/.=3+4#+T)4A1,P*:V61BG6*4I^ M'&K<[^1I,[.SRZ Y)Q43MH U\R 2L*!5]F!39D);2Q+L5-E M?R?]??7H\8[AO80_&T)R Q^GOX5/UX#0R1U9L0GH%"<^%JTAZ-K?.$>G5%(8 M_7"OX%>/?H JW%ER#0SGS8CO5:&H5D)FX1,0Q^IDX<" ENE >E8\K4R81KU= MMB'Z-NVG0?74H)74;;@N?(@NR)H&BK9C.TQ4:!@==B#&'@H8:8NY0!@#"ALE MO0>BOA%:"#J_' ?.7$A1BE"P33N4L:EQ3SAG;&;TD?L(C/AYLDBU9.MU6%X> MKMK1L8@J S>UXYF-!6*A S)HAU%+;V5I4S%]/[;Q8S=#:?(>@NRIAO9S*VZ/ M84VF89HFX71]/H>OSN TB+1<&@);:0C#$(*C,)CB<#A<@B7758 ML4W"][W0'GJJ4!\&WB@L&51O#:H(:CXF+;_^J[9U_AA.O[J^^ +XI!A7'6<+ M-M3["F,#A( 2 K,N:1F"$VUN>SI#/$!UP;#JO257=GC=M# [P_Q/7#4'_U)B M<:*03&QM"WB6)- KA!"0G'*?F/&6OHJIS89T&YK'1HV])=X@I_!GG!-'5X/? M5FM_1KMIS=1-R47E10""%LC4)9HZGQ0X%PO729$!W.8$WP+HL7%A"+DW"&!M MPJK38B^0B8)&&(^0.?.TVA# %YT@&:59YM$9WB8$NAW38R?%CM)OT/-\Z[I/ M>!"9UPF?VBM5AT):\+[.2*]5>*DH8UBCF7K;(#TV5@PC^P8MS:^/(6_.Q#KS.*K0YY_:"_;C9-IY&FWI>UR1U#9[527+% M(^C $BCR!\%K*\&8@,%PP94:A*1*G6V4H90%&VJ,ABR M/[GGT1_M?<\#KB?=R](_B/:/II[T\A5]/J47_GS567V52JR5E5%)B"5E(.M4 MT2N9!: MC/.HN>&-F'P[H(>?Y]>+'=LVTCVTU,"3>#L/TT7!>17+&YQ_G"1: M\LMR"]I%34Y9W/Y7%SDK7=;2-#%PR-4J\3&4B*!8LU44^V:<%]_'R]KUSUV.G:1[4M;J9G4_R\OBS]]7R:%Y=U M5BPXY[(AH3"RR"6=(9.^OH 99,>L) MYU^NUB\+4Q336B(''P*A$F0M.TOX1$T=YM8KZ]O,O+@=SS=,FP$4U&"W^>/- MV_G*GKV)#'44M-P R+DDTS4D\-71XLA#*B[R&-M<>6_'] W39R!%-0CE_O'F M'[./.)_6E;[Y,)LN9N0<_4)^Z_S#?+*HPY3B\B9F]$JH)"$D*T Q3KX[8@$; M=0C"%:U-FWX>NZ#]IFG76+D-PL3/9O,/LWE8XJW@Z#@.'GV&9#.]+2019<"N*:-R" M?VP"=>^W=S#^]%'*6+T;K_;EBU,X19TEK1:(QKJ.ET<((4C3NHY,&0#K( WT5"AENGHS%[-I< MKGPK?8P'LH^&TF&+5+%>+2Z[@/W>QWAXO>_59G87I1V\CW'2(9!;ZVJ7ME73 M4P8^1K(.>-!!1ZM]:7.-=P0,&Z:/\7@$ZZ.KD?H8\XMSG+9L(Q1AJ:$.VL Y M!Z?I6T[XF)$D(-FF6=(=H([#I!I(G1WZ&.^BBY8VU35HX@*:4%KG8#0(:6G) M-:KF;3+@HF-"R!"Y:-,YZ0Y0WQI-=M'%R%W1=5&)65,@H22W(]58K&(*C S" M&%9D-FW"V0^X*_K0--E%%UM#BX-UV;JM:4.8YG4NP_/I1UPLFTSE'.2Y>_;/ M&G[M&\VRC+-U5FPQ>/!->H_Y_!1?EMK0 M9:.I"WF73S[2$RJ\7V?S-^$ZRA=72?JTN;$B<@*6?1T=)N@5J:T+)?/:>Z[L M#4MERSS" < ,,H>3%Y8B9[1QZUK'Z1D#VM5KM@66&N.KW<_:W/V-.H?S( 2X M=?1F'X$WL*^>GWV@[;J^9R_+M7?NQ*.5M5()M(H!5*CWBUY(0.Z*99()D]O$ MQ;< ^L:H,81:6N333><83B?_%_,_2(0O9HO%R^EU>!BT=3IS2-E6,ENS;H41 MT2=6#&)T;1RW>X!]8^P94DT-+GA?S6<),2]^):G5Y9-$?@O+*H'/+\NMC;2* MC99XGB [&]>5N5$Y T5$&?R0W!^=EDNA+,U0766>TM?6)U]I%Y!!&* >5").!"02X*"T:E0AR' M49TA?^.4:Z/: 5/P]I3:^G84E=4LN PQ%@DJUIH>15LQUR;$(#6FDAN[K*-4 MY1^48J-KZEAJ[Y^&TS!-^.8]XO)%_>VJT7JQ953B*_2U[J>^,A91V>?@]L60RBF0:1Q MT$JN+FOYWLQGIV8^O6C2LCO*+CH^]F8^7!8N3"IT]M< FBH%HG22EAB]REP& M&=H4XQT_7W=LYG,T=.VCV@%INCIN7IW'TTDZ_4P+RIB?SY-E>GVJ =>(]Q+C;-F.F@_UK!KRL^; M\[.S,/\\*QM63*C72S<_8H14K!T1C92D-82\-M*WM$,FE"Y%Q*2,R2YP:[1; MD3$KY)W3MW;$=N#$+B:LPD2G,0(Y/QHK133QKA.>]<1)'9M?\15 M1V1=K$N"C/W :>T>F;I=\J"LQ!5<['P9: M@:?MV6'=G@L'X81)B6-BODT[U?VQ?V,.QLC*;F E;DT5U;777E(*2JY-UFU] M5YU0($0(.@4C4VAS#7CX'-Y#:;=K%F\?U8Q$F:\MS1/"%06C=RI@C8]Z>J=\ M- ELLE[01NR\'R\!_&MLWVFTG[H:^ -W(ZP&XHF@$]QJ'L":0 +@!,Z%.B$X M^8)1>K(>QFE.?Q/;=T+MIZZ1"E-.BG V,VVA^,A Z=IHST>B>Q!"I<*9TVU: M%]R&YCMI^JID0%-]93I6K^'JBN4+KM4!&X+E,GM59^^22:@5 V?)3PE.6]HG MO4YFP_;9/;><-!DBK92(7'(ML,N0.8^&*T-G7[0_TCER=7J>F!A-B 5!T'$'2M+YYAWY;;3I,6?)<>.;\]_ZD>/J M2=]YL:/4CZVJ,*A,V@\:=*P#UQF9E($7 0QS80D9MX%W8LRW4E6X,XW&U-2Q M5!5N2\0T(2./64'2B:PQ$B7$J!2Y< G1L6QUHZ+"QY3WWXL0'?/^^RCFV/.G MNZSE>][_3GG_O6C2,I%Z%QT?.V^C0,O3*N!1!\@CF9D^:0%&"^8=9UJ5-@'M MX^?KCGG_1T/7/JH=.N^_'C"US<_M2<[\,['//!\_U[JFS61?8.\T#MF>.HD.:(@?R8[3PMF"+1,A%AKDR76IK!M M,D ?[;#572@TL**:S.O=81ZGK-UV6(C @V:$&1&"E+S.B]62MFP3&@V!_@:' MK>Y'N\;*;7#->_?T3BX9+SQK<,Q$4%G6+MDV0 J&_L_6MJZM!F4^WF&K^U!L M.'4U&=S[U33/WV?+Y]-T>IYQ=:%Y<;1ON.^7;T$1M"$+":EX 4JE"*$VPBM> M*K)%A>&F34;[[IB_:1:.HN@&B:!;F\CX*'C@Z"%;0:8EBCK/5B)(&P/Z$)QN MU-CW477OVB?2-HAJ&IR0=[2>Z8+L>_>NWCKLWJ-I%P6,V[VK6%^4ILV5>ZU! M"6?(\R"7U3H=BO;<.-VF-\5#Z=[5B!E]Y-Z $7>>@?1XC[(8L%'4E"U91PGY M EHIP8P+C@RU-L;.49DS0VGOEJ$3@XA^P C2ZG"]K1G 96 K"&.]0!#:>E!: M.X@J)]"F>(X*K=D<]+4EJ+C]&0]>OT/*<.L;/_[DI4N+JMQ6H1>65\D38TQC MZHMEK E->\EHH^V']"5PGH5#$Y1!XU649)I:[[2-.JKN4YOZHMKO1/EBFG=) MOO#.NIRT!:-" 66C!\>M 70*B[+UW6MS-=8+YFB5H1YCT(%%*"9PVALB[0V2 M-@@9(K,I6>]SF[JIXZT,;<>GG8M$^VBIP?7.1G'T!NH+![=HFR6=5-X9"XHG M,S9VB-'$NVUU9G2"K-9$VY%R4K4,PY<$)H M"-D)%CB=Z:Y-!?NQ1*&::;YKL*F/!L:-)'1!]CW8U%N'W4,*NRA@Y&D"6D3C MR)UEJS:+@2/$J MPY$7QS! ;E8<_E&!3(V;TD?O8P2:'A<7,)'BK"9OP%EQF M"5;#B!4O*!IU#G\PP:9>VNL3;.HC^AP:& M]EG/1KC'ZR",HGT]6T?>1HD)3=92%,^8])R=]'S6G@&+;@_[XCU%Z1+Z2-PU MJE9,T3;KLF(0@XR(/'G3:/?NBW3?,^PUIM.P6$S*9/WNUGF;'3 \.Y_/:<=] MA?/)+/^.RY?E;?CTI39>.Y<]5R!BY/3F,SKN0Z#3WUJ95'0NZ#99F2U6SEZ%*IH3 M'5ARU<#T6-O:*FLA%*N IY*3=49[WR;-8#>\WZDWAJ(;)$/=*L99FMPNI]L6 M@%P7EPH'S6M3&>T2Q*(4D+0$DZ'0/VTJ6O>&_IVT(ZN_08KR77;,)>Y7M6DX MJ?4V^"$)4;LC05+$,.6L 2*FMIP4DLSM:JH89LADD25@FT/_/ENRF6.\OO@IME@NK 9M !5F )R M\VNG=%:3@"+7FZTXQG6*1[V-'=5):Z:F8[F9?;.DM=4/6M.ZKF\V767[U.L# M(7S@DEG DFNM5K3@H@[@I(\RF*23;-/=_DY8A[JC;4>&&U[:4$IIUGCW"M-% MS+D+J*:7M;?".LP][8#JN[5_Y1"R'XT83A=TI9J^LF@ZLVD+CBR3$>SHQ[6G M;S1M0I(C$N*>V]FQ^=!'Y"U&_GS9)E<%?*?KZ^C\W^?K1-*+&R7/@^.&50<.]:,Z<3TD?&H>&UTW;W MN01&N&N^PJ^GL[_^ _,[7/NW%W #!DQ"6]#6DD_I2H#@DP-O@\ 4E4BA3:^) MGD ?&9<&UTV+"6'WV_N7558A2*_(Q'>!%5 I.CJ^C0;C@Q>".RFQ33%U9XB/ MC#X#ZF-KT'6P;)5*[,GTW>]A/J<#^.,^E4W;/FK/_)-."#<238K4/*12=.%) MR8S>2D=2SZ*8R(S DVT?NF_1PGSR/M@(7)RTAUW+*9:$]5H@L=>L/ RDZ%5$;8+"-H'%;8C&WZ;&X]/-8H\!M-*D+.@2 MU^^S*OMP^N1L=CY=GG!=1"X\0%*<<&FK(.2L(">,+DIE1:.V7-L0?9MLV4,K M#>SM722RCI RY#9K0S07*.HA3<=UG?\:3!#&"R5D$4>S%X]ZQ7$,+&NIS4-? M?BSFRY/78?H.5P&XXE+.R6G@.9%=:LC5"$BV(S!6=07BLG%"!QA][BJZ*WYX7^S^6XD]5+"IQ#WD MUU"=-A5AD(X]97)U]K2$B!@(3A:&,V&S[-1*[SC4N.4N87@M]A';P-K[C21U M=GYVV<21,_;B7\&=#2&Y M1V$%)'RZ!B2[7(B1 0H&!DIF.B2D,_ M8+N,7-0FK)>UXQVP-K[2MW^% M>;XX( W/(409@#$OUX7'+AJDE==K'6^#4FW21.Y"=ZQ.,9D1!^)-V#"[[-IOL"$ER> NL2T>] M [ Q+)6;T(XG7#*T?F\_N 923CM;YA: **)S1EM()3+:M9F$R-%!EL9++H(I MMDV;E9%9LT/\Y&"DZ:.31ET2+_.J">#E2>R,TIQV6\>2 >6R A_(Q(NL=@OS MA5O>)IYR*YR#F3S[JNN6MHC[R7JKU3-X&O)7Z6,#Y"+?^GD#)23?CW6S_9V1 M/C$EB]%:H79>RQ*5*IR9X$)P)W=^\E!6YHNK9"R;ZH /;H [:T$%S^OX-P$> M12F"&5M2J_[I-\ T2PQ%*UC0/D+)68.JX^TB%QKHC6(F9Z^Y;1V_/Y[$T-UT MWSG=LX^LFWI2:PO>)T2!G(%EH8XW5(YL^62!#/L8K'-9N]8NTH%2,X?6.PSO>0X/0+4!=CW$/RP^NT<3=U%.:.&X&UP49AB01;+07'-@4#2 M(4YN.2',-ILV&]"C",&W(4T?G8P6@C>N)"Y%A"0SK9>[ J[.\A]8K.-[ MO\T0?"]U=0K!]Y'U2+;,53YOY"GF.K%9N;K::#3X6O$OK/.)I1A]H[:NQUU? MT<8NV4GJ#3(5[TSD[8+M>]7$CKKLDQ&_BR+&KIHHGC;)$B-XR22HG 4$PT5M M$,Z\",8+T::SYL.JFFC&D3[R'[MJ(LL:)F(&BJMQH\)H]ZP3X93PFN3A;+%M MN/& JB9ZZ:]/U40?X0])I ^KTUJ;B4J+D%SZXG^9%<[3@NL':B]5IGG MV*E^LU-5[O4G/V0;8B\I#I@PF"XPG#PY/;W 4S,H+WSA#I@ZV D+3'][-_OX MT^6SUEJ^_&ZEY95^[\(R?C.+W;4S:R3: 7?W.[&EHJ*4&J$(GT$E;L$;6\ S MGGW*7EO/'J2Z[VAZT5;;?23:0LN__/'Z)*>066U6&4NA72K4SLO!2,C&*,XT M)F/OZH/56ZOTS/%.XN&DOZG.OJ(;\*2]PO"/IZ].N.;HC;? E"(,UG.('NEX M-,4I,C$-+W>%_7JKCY[Y&-375W1-]M@_?CX12L<4;8"0U"IY1T*D9T-V*6F% M)/]PEZ7F(X6JD]/5[7,D/I%#BG#'"?G2LZ%)/O MVNTC@*R1E=C%0:B5@&,2B@" M9D8'\?A9$R^&F[+^$:?G6&IYKC>)B@?1/ M?AL^G2!ZH04A9KH.1";]0=#,0U&ICD-,'EF;E/T=P!Y)!^3]>'5SZ&I;I36X MYUO-(_A]-IU]P-KLOK[/=1S!+Y\^D(N+)\IQ*THB.$D44-F*VIM%0T2A54FL MQ&Z1N-Z4NAO7HV3/@*H8JUWVG=D13S^O%W U1>S%;#U@]NGG;?<>Z^AG#K)X MD<@E3K521*[,\Z* (YGJ7M?9&P?8V@==XT$;<@]+VR,EQJ%K3&H(\-5\EL_3 M\N7\#"\5=JB)C-ZN*[=MR$X_"7'<1%E M-J#"!NXW?(&G]J2X0'3IA74!-7@K\*UPQK]+V5]3-]4^D)A'XT! P8HC$\!Y MG4 Q;R&H[""$:+A7&;GJ9.\?H^[ON%@92?5]I-O WKH =ID-: 2S2!"BX)S MT/*\YP5X,M)P6CGYZTU,HJ]@C-NS>B#5S(:2:P/OZ^X!NR$6G3/+X%,A3J<< MZ10+&H3D26?#E%%MZE"/1?8- M3ILM,R^#TLX5 B0\E!'HP_.AC\@;\*#CX.WB MG&+,K5IK^GH#1Q)PTD%27O.(J1C6?/;P0QB!WD>9NXU [Z.)!@;,:TRG8;&8 ME,GZ9'UYOGQ9.HR[7;T]&$H2G@5 :>1ZKJYCFK"+7$Q-056F33G1/JB_FS]W MFC^C$:)!ARM\?@R$%'W4':#\WK/57A-]DL*B0ZH M.H)5I@+>F@)8(BTI\!A+:1<)\49 MC(2^&& ^)8?6Q!#;S-K=#_?X%NB8+!F(H#NH>.Q*YZ!,RL9RX$R3@Y>#A>!( M0-[*R(PA^UV--^KY>"J=C]H$'4RA#;JHWUG7UP7;]R+J'779IT!V%T6,740M M8LDR:P\1-2?'7RCZ2IHZRI/+Y*.4K'77J(=01-V,(WWD/W81M44GBK<>"$BH MO4,T1*\S&/K*&LE3L)T&2S_F(NI>^NM31-U'^..-GHN!6U=T[<>8&"A7KSP= M*@BA&,.TC4[>56[R^'K:'K4),X 2;U)+-^N)V@77]W:YO;37M3GJ+J(?LUVN M+-DHY *$1G+NO P0M8L@32I:ANA<;M,JZB&TRVW"B#X2/U"[W"@10]T5DY8. M%$8-P8L .O+HLD-G?:NQ"P^I76XO3>[0+K>/&AI8*K>-VV/]+THRQ;,DTY"A/[O_X!C-_/($I6(";F,AU M*;F.?8J0./+H79+ZSH8>1SKSYTIP+\N7']82O.6)\;;XI#@(4PJHXCC$1$NW MP0F5!99<6E<:;4=W)+. >G!B>P!E(!TT#?_?BO'%),3)Z63Y^<0FSD(D.\TK M5IO76PF.>0U6J(3*^YQEFZ!*5X2/GB^[Z:)I8';MZA>NBBG1@&?9T'%*KKZ7 MT8)WOMA8' %J,Q/DF&9)#:+W_O(\=)W?/2X>2RJCT@JX1%J*2+KV:D1P*+R6 M4AN6VIPPQQIWVT'#W8)C?20]9@2D"Z[OP;%>VNL:"ME%]&-20V"T/.A$M+>N M3JPWY('5K""%GDN'2H@V#3L>0G"L"2/Z2/Q P;%0C"B^!"@< ]G#.H!+2M5O M#=?2IV#5]^!8/TWN$!SKHX:QLY)2O9WD48$1'D$IEL%9:0&]+T[JS#AK/;OT M&+.2]CDH9,U)0LL\@A*:+ETK(8HP&D6H5BF30E> MZ=#F N8!I0[UTE^?U*$^PA_)YN@P ,WH$!CW#+A+!512FE [#X4%8XUA7,@V M7LQN>!^KG3*PIAK4UVT?G]8%V/?YEML MX:+ ITRGM=91"@PAE#95;(]B?F4;TO3120.R;)FI:*+T 6L57J$MUV.=J:@0 M>)(IJX@BRC9M"XY^?F4O=76;7]E#U@ULF:?A-$P3OGF/>)6QNRX(T!Y9D Q< M0 [*D7T?HLF@!>HZ#==EC4\'9$U-CNW8 M#F-S#*/##L380P$-3HH[$":IO/:B0$RE]E:)!4+0#GP4VBLCH_!M,C[&IL8] MAL78S.@C]R:=%_%#F.2+OMNU_>"Z@'DUPV*Y2EI:7%T2>+*::N=!FS2H3.=; MC&0[13KN>!')&=ZF"*\[QO&MC*$T>Z-Q8Q.UM.JI_Q4@RU-A3 6PHE8AIH+@ M.$O F3 FB*B];<.3&U >#1WV$W*#;>,Z&R\SU29X"2[2ZC(F!*,$&=B1,_#> M&' 14ZSSW%6C5GIWPGI<;!A$^ UN[BX'.Z1M^+@7,4ENP0FMJO>EP7.F@?D@ M+).!1]%VRL8V9(^+'T.I8&MH=.B*B)>ET/ZV_*H,8(!Y5'=^[#!5$=V1;]1% M^,A8D9%+QITR69H1.0G71XP?&5$2D&*2.^0,4CTD$: QUHRKI31 MR7!E1.MN"R^&JHRX373K@_1)7*SNNDY0.7H=8H1LE*JQ /!25,3L*2V7(C< M*%!V/[;CR'+OPX<;>]&P\A^_)F)=MT%FM=>QEJS:_[^]-UMN(UG2!N_G*<;F MWKMC7\QFQDRU'=,<5:E,I=-M_Q7,8Y/030+Z ;"JU$\_'@"X@029 #(2 $GK MTRP2I#)]^2+"W<,75[=CQXC&DL"Y[+B2/+!TE'J((]7.]*W5?4II=E%)TZ23 M)3DWA/YCMAPV=%V\H:0J@58).%,8*!4->6>\3L6V@L6@0^:MTT^>HN\%0ZF)7*)]-FUN]34I>.B!V$W6#O( - M>GZ;+E8"^'UZ,8[??[[(<>D%Y#JW@[X9%48XM3:!)2.1D)H3!)DR?8F)"U

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

U$XNS/1/JNHL*";KB29V*<9*C1R]M!YOZ8GGX M>P5WI(M3LSQ]&J4I-MRB[$S)-F@#LYTB7R5-:7Q2CC &;L?(*CC+-!N3+*EU M2YI/2-G7KTR.T#=2N8V^#.$0SK3WHXE99.(L)&.,_*CUCCKY978[KWUXC$EX M89@=OW(VE[:];HY1R71>WG$;%4>;OZ@G9$)C1>5(:#^DKM!7/W"L;J@OF7'$ M,^UF[X3-F^>4Z)5>@S:MYJD<#*R8(ME,S&%K#^B))<'K\>/]@?[4^QH-9>)- ML6DV'XQL#S-&OK;N\>80AI?[:V6XE,&^7@6<,8T>0]17EGP,Q_+G7;2;+-AG MZ;Y>4@]Y&)GU-A[NF*>+;]I7-%>5N.+TEOO]$9?O]8_[E?8;:W6&;LU/?.\5 MI?26U.!_B7F?-_PHIJ2'B:W35*'^?E=*#+B*($*DS33L;K7(?OCZUD32JXK^ MAG ZFVKZ(O>A6._9;,)TU=$'&5#*8UM)P@V>B>:&%7$ULXG\!D*R!KV(TD'N M8BD]ZH^=5?BW6D''MBU]V5=NF&1D( &5I##?/M&XC?J^=QFBN6SEK"QTSSC& MHA%&W($C5[3FS+Z_VZ'8#JFRZ^(HEWVU8OE1-Z*>]"J>NOKM#S1PF>W4PNO\ MH?G6!1M[S>$':JRUX",2-^(3ECX.[=WXDPQI]M/. #(>L 5L(.3.8+;\4?[3 M&I)K5D]J@^,67]^_PP^L+DIP'C MKROR'AP9G#;'N>UF3YQ@JX5K["=.Q _/1NQ(\"H<3;IL1GI9!).3XS*$?R7C M\NG,5+@=XNBZZ9.]XH-Z"=*0VAY;1TTKXFG:HID*+_N(1,LXY>^"1]F=HJ^P M==W>_*0UF\M%8UL#WW1L7H(-1NW:[+L>=@44AXX*HAZP7IYIN\].XH2^/8O;JL?R M$S_LYW"Q")1_/M/>_>KM X*&\1DJ1M5R@XRJO=[M$W_%OED=>,(W_MKI07=\8CW>E!5S]MRX!-N6K SU&])6R_'1 M_>Q%E7!)PU&>!\D%8RL9ZS6-X _]C2<2>NO6#>^]P<2>E77>BL^ZM4K*(J8# M*=*M2"NGJ9.%/!+G.T4)"_5"/5"OA(;Y#P+P>*31C$\[1:1)%#:B0P_]H^W? MXY>_S$A)'&B"$#$Z60:\?O%AI'8<$GQ2)L@S:/^YINSJ9W!0#;HD\80)?8-[ M $EQ^;$!]I/M Q&+"U1AN1 &8*$HBB[ 4O MW^NNV79T5X ?]E&E.FV.5 W-EE9M'W5NZ'[P]%S/)[O'BJ>>B-V&H[V7K1V? MFL%CE5[5E.G>U44V>[M98YWU%+?YB'S_RK' !J2>'L,\R+2T('"1.GNG\NBQ M01*-@)>V>F=R]0"F$G;$0Q ]_[S9AYKE7)29F+)] 5;#X4_81_&+]WTKHJM# M3LI\A4VLQO:2;)+;P'Z!73->"Y^;YQ7K PY8O8E/'C@&;-_N;Q$VS$N<&-OG M:CPV7)EV#WOGRZ\D6%,L/%:B_#3>SGJ-1H;GY AV>Z9NLD K6F^.8[,Z/\TL M)K/'18-@O9T>^V63*#M?:(%.U.T$4CN7R$C_E62!.VK@9UFCNXK?D0!N@!7X M03(J%N[OC!$=XZ_3>%]YF\Y<7JU;_?&C5P:)(\:G38E[H+I'#R)OMC"?^@34 MB@18U5#Z#YEA,>U#IL;(%JEXZLQPEK2,[VGQ87!J*GR( M%(YZ79CIBA6R0]T0L,EC%M"?4',(RH\"CS]](4>\K&,9+*07V]C?=@U]3206 M;?H4(*Z+H2?1H[A=PN-E*EYE9N*G_IQQHC6?LG%0W6BYAW]6XS4\=C_ODZWG[B)0@>_H*[=ON^Y1%Y)NL[$0!AZL[N5< MWJQJD!])CWX]D$"4/G[VO0.[8Y;]SK?^[:C04UG#.[9!/;0F4!-Z79V/CUZ4 MS<>/PAOIEV)JA^CTP@0>A0W6-G'8G^(9(('K7!M,IY]1:Y@,$GT,:<*E,?J: M\?!#GKH:_%O07IY3B@77A=+%S]0A(="'BZ(RS(#)A$X+ ^&/C=OQ8:J5>T>*#UIUGZ0!1)U@AJ\YCQ$I]U) M)$4G^35.K)\VRH(_07&JN[:'CUJ8"KJV]UC>=XFFF;_X,GI/UK?$X#+&#\K! MFE+B9=R)\,&.VOZ:DN9E&1>_<3-R3^Z1$NHC6O%#9 M94K^YL"G(*^:8&[)&12=&["NM3:D^#D ,\#*C,R3]4ZO^<<-D3!!B3#J^E/Z M0+5^?4)$&+HJ$R6,6\C*L<&1,^?^JANVAF.805!1OP_\)-Z]M*_L(,D!;HH3 M&V0VI!.GEX2K@?,DZ\_&P\ M_$D2]]/FG+L+A<9VPBNAPVIN+ES==2ZU?,5-_#(,+\1OM_>+QXHC]"@U3AUOGF IWWSS"E.4DWO^*9]'47A#8 M-@QRNP)&[FFD^O%#EU-:M=M3.?8OF;Y>0PV"3RIIH\CO&K2Q]H#0PPOO2U_ M*EF0[DCU[G6#.9,NGNL+L>N?DN^BXE[5_QN_9]):@S]FKZ3M^,<=K!&_#$_% M1F)[6S#S"MO7Y=R6.@[V+%'--+1@#IO)@DM1D?&58QT]FWS&'/6>K5R<0@XL M(GAF:#,JD4=90VVLO5STVOE= >-)](5!00['U)")Y""UM_D/CE4K3J-8\E)$ M7DOMLX\Z?BLB_WB0%E8-=YG)";VNN8L$BJ\NHT;5U&[OQD1G3/D%IO M@T#9P&HOJAYQ6>7>BS$G^JCB;;:XWI(GJV(F77E<]+A3ZD#'(Q8WS#=')^\ MRAM9B0R.<[.[DRQ)K5$ATLK_J4RX5@4W-(WJ96(^)7-?O,T1PD^<*KG(;#EV M_=&N]KITRCC/D[Z**,/%_C"W'+5<.RX7KM9&-'*I*_ZZZ#.Z[6(ML\5(P#IY M<&PB?+EF?1+\)!D7L93KQRXQF%G2/(B__TEDO>BSH4B]&?:P M,E'TFX47 [8;WVY$Q%"\8%R%?*,A4EZT2WJGJ1):IV"-WB>P! :)&H,/F$^=7MCD"1W MRH,1]V+UXZUK:M, _CV >! )G.*^/^+P;Q]E#Y_$#O+E\LOS?$XI,KPTREY] M!&T@;&X/*8'H4TS>C/_\A0#$\%)OS+C1!VS=OC(T%W2:N5ZV&[L;U)-]9#\6 M'V$6?U!:)K+W/D!@C"TU>$[ZQ?^S_S_J+U+$ M #S 4 =G)T>"TR,#(Q,3(S,5]G,RYJ<&?4>V=84U&7;A 4I2--:E2: M@HI(EQ(;("!$0(JT*+T("$B'1$6*2%&JU*CT&BFA2^A(EQIZ[S6AA$#:C=_, MW#L_OOL\=^;^F)F=LY+S/*?M==;:[WK??4XHXY1Y )NVAI8&@(:&!O""^@%0 M%@!WU?V<[ $ 75V ! . ^@U6<#T%#7:/Y^Z;,#Z/ZN P \[/H7_\\Z]1= MF0(\!)RAH?F[_&NC/4O[MYVCHZ,]2W^.GOZOG;_ >.'\>8;S]/0,S P,C$S4 M1G^!A969B>7O^M^3_#W\[U'4A>D\_7FF_W"C- '8S],\HX71TEP%G&&GH66G MH;0!@-2^GJ7Y1P/\:Z,Y0TMW]ARU2PR,U!V0;-3NT]*>H7;V+!W5-9I@ZG8 M'?O9BU>D[Y_CT'])?]6#\\Z[+]_/"S\H:^8R&,2(R%A[OK_ P,USB9=/5$S\ MVG4)63EY!46ENP\?J6MH/M;2-GQF9&QB^MS,QM;.WL'1R=GKC;>/KY]_0,B' MT+#PB(^1E?OV@ M#3_UOZI7^Q4O\Y08T!' M_]>7>>\\&7[V7-%X1E##!+?!/7=16B\N 8G+2V]BVO5- M\"D)OC^D$[*SN'P.U35NU@LCF6L,N*<@(3 !"F!^%1&5>1/[JRV3]@_Q^@*( MN?,Z]VQ):'2;QFXT)OB9F'(=WM>X6]=.Y T&%NC,KYB$5HO]KV(VN^872M%ZY2L M]W/I[_AH0VD/CD0.(-^!R+E6E[W(N0K*3^^0%X0VAG17[TX\'H'G7QA"GL*UR&TP9..O M'T&:PT2I16;M+>-!9('QT+G:SSTWTW?>"8TI*?/^S-%JFC[?<1[D\RX^E3A MBFGD<09R0%7]8-L_?X\%W%PV2SR<%_S/ .G7Y(%SM\^;9D?W_! M<"C,RP&E^Y(3VM*Y0&RYN#9#]:GA)M";.FGS6RUU":/SM#E#NFV=EXWBB. M684O2;%"G.[F9#1^S]TTWG/Q=?&X%"<9D:%==S>3H3SNO.K]TG06\7'K*V;H M%:>IP53]@NW5O(EI\OVM=3A>I#/,&\$%:]8DLYJOZWC@>MPOFL_V6],E(C^D MN'G%1+[4HL&IGIILQ';"\')335 E[$K']WE(1&KGN\.T@J@\[;JACA+!G^*B M5S[W<80*5B<+U\H= 8D0+HI@Y\H71L[/?OR&/(QKL"A_B7 ;8G.\_:KGX M\-*+:*BIS8W"QRVA-SEXS:,@3&2T>+2TIF@)+PM4C^@KN MZFH:CXVIE5@9-!I1[TJ68W(R%(#I(^H(FT[,]7!U3.\8?SG7HDFD"0-[Q1P= M.>B;DF]B;Z3S/T[V()%8S0B:,HLU? M!4V+=N]"M= H6+/"&^6^A[A(\WJ8M.LKV9/9E;N;RR55G4;:@Q[ERN_O2 X0 MW0EW_%@7U8HGPQ +&6J;^WI6KTN8X@BU#W)BZVW1WPS!7 ?L!8K*S97$&".Q MJMM$'@SA(=XEZY,@O7;9T/9!;59UA-@J^4"H.+A?]QH^]IO.XL,?T5Y:9+1^ MO WN-WF8 H >U!\B^A!XQ0HR@^CBP$1/JQ _'C)O:;!U?S3HI\LO.\ *'I!PEU@=R&,.:DO/44.'GT?^ I4FJDO]>H/ M6&T<%EW@JPUE+>X/JI[2J5X]TBP*[5XQ$]CW:9P!;S.JO9@9=>J&FA%[*( 0 M;]#\=RMQ4JX*S:)[&/GNZ"VY/O=F]OO^.9LFGKQNN]NV]AHQ)BJUH2V ;1VN MK[3'=V"ZC-Z(I-[RTZ\JCWX>^<8N9A9D^ER-*M!ML:2G#OK?UISZ&H[_U47M M/VIGY)56OS$V#^U.)F2QZTHG/2@B+2UF,31I;>?*UZR/9 M!/ANZXB7JZ9DE>\DP];N2E9W>?I[91.C!7@47]7;'H&AX$8N,B^X5RT:?= ' MO=(*O?NT0,HF[>$7"D#6#=VG:M*]-F+C9Y =O*V"6#XFX(BQ;N*<#E=K03F8D7,[[![==A#W&,U0FF=3'L$S:P MI>IT+,2O.LG03HN X(C)WQHU#1!J8_]\']'-=_J)?,$#,7L?J]!F9G82G3?M M]'[S/CS1+N;9LZ61XM@3D]H4VT.GI][7U]&+[@:1^G5J\VX)$R*FZ)M-G+OO M44I4[K$,G&QM P(H -L2^A:H8&/-$$)-Q/GB!,3R_A4M]0_2X:FB+[M/HK"2 M+_;3T)\[&IZ@Z%6,KU[RV5@[YOWS8W/DJ24X6\6% CAK1LH@"_D-D-E) MAHO'(2]'N34B'T7N[; W;1TG:=DP\[$/,S6MQ2!WA5BP_;%8CE;N@+&00J?3 ML=A\S=4IB*E%3ONO[C?3<5#<@P@UM)RV M] -W^/#P?'E>$2^82&0_R0PX\[I^48N]"2C-'@>]#W%/?ZW=LB!T-6K*P\1I MZEDULDKUE;%!P9 7^%G@'E$ 26#S2UO,#%UP_S3+.[Q[%!$D;GM:B=":7.<7;-1/1;NP=*4$'Z>IY5Z,?T46.$X; M-TXD4''#!?0REB.('Q,;";WA5_&D;C"MP_C/QB1SR8B&\L<;B0T3M[0SC96 M/1?2N=FYFXT?P)Y5$0^_E#97BV7'Y^EBH+$>L$)G[H#@Z,*] MU,"4I&N+0L6]]V@W7?H:F^-$GOS4KL+14-5-U"NL;X0WL[.Z]6"KY';UATRUQR;L M".)9C<#5^@&\.*C-28V'/#[+6.^Q9GQUN2B./4YH_&5 OQ M[9_E!08F<;K95<,'(.ZLI:V.M6>W_>Y*R-K)\6J#9YWJ+45_('$CI.(?:?QN MT>#\/),V^+"DY8/(:]_._ ^P\^1U!(CT+4R6$72*'Z"6GO4G>*YVHM>P[EY( MJOJ6JT07WA-%D L"1SP3-P\O>YJ'DH2)%A'9-^SNZ'<8NJ-6_?HX]2'-XENM MYE.')0-,Q >C*K>;S*=E'H%6$N!WH+35"Y'MXF?2#DQRDNW'>\^JFUPP>.I2 MZ JU5(EYI<&=X;@_&NG2>[3'%/2F;$2[,U]CS.!P)F,0WIE/U%RR1";EL'QG MZ&'Z>,-U\$L(+1[=%P5VKO_A%T-HK3A),KEH7N5Y#R09;/*=Z(+;Y<7V\(8C M!289/,B.&U*I$V3Z'IL:@W32MDHMQ*&0 I##PS7R)%QZ0;B/H6='V\LOX0;1[](]&0K6+HF'J:F6EW<63!'\RUA7\TZ!+;]H MU;&"\(@2;A?ET%2U%?",V@=O^G'T(9#9H\,H=3+W3.'J7.(ZNFMO7TV3*VGQ M->+X2_E>'6%@8(**BIE CN]HM>XZ*[@(?QFN'?6I:PM-]U&5O.JR!9Y0QED@ M2>DJ-U]7Z I]+W4.-=M?X2R\9K$3J7)0>5%/CY$C[AQ J(%#=MX?4=UNG[C5 M&N>CTU/0*5$>5\&6BC\@,RI3 '2$$9 [!3!AKRK5ZNJ6*8O)6!@]M$UI\E"KB-E\%1@XA/'*%IV MX3@ @_E1WG:7U"P#C ':]Z.Q2';IAH8,$V:30652(7#&WREG0(<][5D1>&(2 M/1U\13&;-?Y1>;%3;63H,2)6)6G(Q$;'0]>)BUZ$9M,/D4H!. 'Q$L!6R%L3 MGKNO% S]LMJXE[,FG+[=?;!4&0^<0:BP,=Y6-6Z\2/J&FB^ <:HI!/\8!C=2 M !] ZI\SJNK,$VOL#@-##B[2T^4V!98$3L!8%K%6^Q9ENX>$I+65!L/%U?MQ MLVD%.Q)2%?S*:GW;#0-#L$E:W!3>ER _I06,\"; =D0MNW(G*8!L*ZT- I)0 MNPUQ)J!;8)4*1&Y(AY#2P780XTO6T##TF.^A00Y> M*LDR#?$R6B)1SV=B5JW]13*7A[UB$] 3=D2IL.][1LW"H%T-V1_(GH4AQT#VT_*M=G0# ;*54,+)J8= )_FVY+9VG] M5HS6#9F-GK+]M@1#!M^\Z\P8QP^,LI8VI)*6OV)&^ M-YSI[BUN%![N3E2\_.GK"5?'M1X3!+39ZDS:HL+.NWG)2TLW?CI_V;S(/F@\ M)1,'VQL7.!)A.1J(C0L3\@H4H0"$QQ=>J6RMC@<\(U_7NQXP ZS"P;'K\-W( M1/*.B%:Y''#FTO?8_GMDG0A,A0988FX^$(@I?<>R>7+<-'L] MO@4J'+8NXW_#IQLU:XC&"FH._3KE#ZT)?6XNT<2F^1VQ V;"#Q,"I9"!@68^ M!@>-_;/!X)Z#7L2F]Z^Y,#/$K:UE>_Q2^QCT#"8IJ\3YXJ7MRAJA1>MSYLY1 M\RS+A[2U5U$@-0GRC)4:/ARA*P8OLO"#Z_7Q_F MYBAE3P8'"$&%KF\.%()L!Z;JVR[Z'8 Q>U%2(&0ER^.>:"UO_^O;T.E-R?W8><3[O<;+1",,.3ZO.-K#.Y"G-^.E^HL!L<"S3\W5 M1D\K0RY8U*X*)=XMFI"T=/[8IG[=4=-#\;V\CT1^B+C<20B5]'!3\2\9$J0] MAF2EPS,:I':V^A3C)F-R7A%L1R\)W-%82@Q_?X?%=@W/ ER7PDN&[^@J-,-# MGN+!FC6.WBB^"U?\V8AC8Y_>R03R3+,%RGR^KP])6)]ZC/BV$)0D$SM6)$D! M2)# *Q !E<6\#+GWRH CE00@ZR2DPV7? M4POZYV\"?-?ZKP'D3CFH50%,RLR-6;+$?\DWK^N4A4V8Z?RD $P5SM5\9M7M MX3LG.'9_'-T%*3?9+D% QV"JMWAO'O9XEF].)O5VOF1%?__R\X&4UP## MI=A)J3 (ZQMXJ-79(:+R]\F2F.3LIBK,HU\)ON+U''%:R]0%W8'5<[ID<%JB ML*<#$Z5>GOP9(_QVR]JC1Z5=8V1C+H[*NLTM_6^1MM^,Z*M#/6&V_PWFF/[? M[!Q5GEY%);Z&JN)5>2)$X@[ 4^YOINN^[#\.#HY%P<;J%U/:Q69:&@0(X:^5 M.G@7ROX8Q.IM'(.S[OZLZ:X)R!R*KR"2P.E' ZQ6?@%KW0W5<3/U%]6,3X7" M,85^BXV??PU_']F9Y(^P2947*'K;1#Y7 ^<,NE".FA&#"YMIH5^>?*8 ]$]) MDB>HCPW,'2_WS*_'%0!7?,#+.-@[7(V01(ZRYL5:B#>5YKS#9VH>&)9],1<2 MQK 4+%CW>;OUL5$ 204'XFM3V'9KTBJBK8(IC^==_OIB0?=%2SXGLJK*0$%6 M1)Z9RDAVZFXX%6G6!&G2^7"($+X]7'6(M8;KD)ET!(F>FHTQGT$,V-L*3*?H M+.A P-M8 Q1RX/3WX$C B\^PPRN0$C^%-)T+;6Q9,)\?3B0T)++LP$(WW.BV MFZ7U,(EWBTF! 8N*!/[<>ZLFX3+DG&P6W)$1_'IE+1Z<]IOP4*BX^[YEV_YC M0'R7V*^XU&DYF+-AB4'\:HC3"3!-0_>5/P70#)_H:8&=<5U5 PX3ZXM")^2F M2^UJ$OV4?84^-2D^I;DL8!(L[.]1$< T:$$!M WPJ,^#PN^NELFK9(AU!%8/ M9#OVP@[Y<@:,?>/K'>0EV0H,$I^_BG<]!<:B,/IS4:[8>%PM5GW$T[WLSPJY MHX(>;WS&Z&0C[&MW4\SMUBTKGBBFD>WF=J<(O$". M%0.K@"!?Y'=$7QJ.Z1(]!JXZL*]ZRS!U-][)/4B'+U7_=N74M]1\?R8FK+)! M>D$5W#$Y$N 6G0?9G SM/*UW4?;)-#F5>*\;[$50@S7SJ[@NX<((G3P__31U M7TDCHTKZ#D/FG/:7!@22K*6[T2PRMUM?VO09.T%AHK5'0:#FVD9OPWBIK.O^ MDX-6)1MXN,"CZ.O/C.SM%8T$M0ZY#H^WRZBC$8'=Z_S48TX!L)E/^RFW2H7Y M[RZUK[2<:EYH9:( G2SZ"\K:)/82'#42W 8!5#QYFG?MW7Y_4UL/G.A56RE M9=GZ8Y]+L:IM+^\?(FQC;K[S$_!N#[)ZV3X4][JER/\760SJ-^]N,) MBV?6']I89]+5D5VUOKP^,05_Q[ZCICZHUS0>&%M[:G(P%\,2_7,P%=5& 4CA MQ2=>)UANRJV<9E)+V:3X0ZS68[>4RK2.)=NUXU?!\+RUR#W]L6?&QDS%=\XK MT9GT):N=IP"L*XDW2[8RSWH3SH[ '>C3_-7\P$3ZZI$7Z(/05\P*)>+N8L%M M]J?P>V7-I:CY!#(X)HLZDHI#T5N#J!R_@5 UN>>;_3\WGU;!7W?R']1Q@ZR* M\-@]JV:,+070'NQ II;M=;%?I?31V@+W0^NJ&Y-GATA@D$+E3R-5WMT$!ZI6 MG!-?SO)(1/"24$>(;=;QK47.ML*35!7+DC 4*8!"+MH?P+[Z$K4)2#AK,]8>[/ QB-M/ATRGX=J+:X3GGG!*_ M,'3KV*).@?PNH?#<\\;W-=&PQ?;1U?5M&VYLI@(\9> 0B!A#V29=99OS(LZW MKB"Q=U8CA^NG3@^5,TPL*P:OS'A["-B4QQ\H_/&6Z]R"\3!6:.:UKN .;'G= MFP.@_J6Z25L&*9D.<1IN.DK3G=@29E!K6KCN:-<-=:T-05;/&*/0UE)G1 H9 MZ''J30&OLTU]7%JY892V^IE>YZW_-JK^DN =9F@JJ17R%8)Q M]R5J!^EBU=#NQ."IC7('D&^/R_>HP)/P?<3PF)+<23*;>O&K^'WB%U+]@KJV MMZ+SAX(31&T9GBJ\K91.[WG_-YBY_4^:S#U>J]O!F=PC_'#\L5:X%)'%:W>Z1HJ(04'2<2D^[+W=0M@'I55,;2?>XY.+J<)*UZ_=@&JFJWT$= M%Z#F9VY!S%1A00%H'S(X19OC-5<@ Q[M6D"7;O_H@7>H"805*6$I)4A'L*$] M;=NC[$'@]4NTF+4#KF318E?BU7K(6Q_IUB4M7I/=J3+2,Y@AQ*E)!G="YF8] MB2=D4 /N_M_33.1>'LQGX2^0VIHG'5NMA$0 MCH3[S$J6RQJH^;)_UX.@[]8W4-:722]X?8-YOF)GR) NBDWC&2 M=O\8H@>%O\J<'4>$8A]-P7RY(]C3_E1B/X,$\_81(^J*(0<7SSVH_&-Z2W_W@^]S_)9)\ZGKGZ^CHMS=R6QFLE8M$\!8"_ MUDGD7#+#*R\1$&>(()= 2Q-=(_+0J&B$GNNR-TM96Q0#-T.WSNT7%Z;>WA>N MH$D>:Q_%/4M"O;><.% Q;#=E"J'#GGQ(C1[2DJR:>U0/]RMRLV)Q:L-"8N>8 M0?/%P$L-S(O7;B%U/8&<3IM- R\#79BLU?>J'@]:F@NR/*:/R\N!Y@;1X0=R MH7^ #+(0[G6RP[A:.8FEQCVC;BSCO5\.;5;4+ M&,C'Y^"+M8;-5C*1]5%Q>FCD:)JN8 +FY,L=@G6C%_9F0NJ^J JB.7*J@[Q]V683 M=CK:A)I!/"9E#"O49<&\K4DZ%$ H].."I1I4M!4A3UZ!_<'41!HW#:R<9(UJ M:E_[@:IC[3D'FBU5QKT=1B$;S^.K1JH&/;(M-=.#I]N60"4^!GS]6%4X+CD< M\6UC[=X&_$D!<*SRNZ0N2.;3G;R=V\@KLS>A] <+KK8_$=I?H_B>OK[.:D9J M26Z)W:< >&'NLH2RN5O\A]]R1^G'/C,AW8/NX+T*B9987/Q""?=,*5+7><&U M9/BG>)'T=N&W"J'N;%S.W2]Y/$K;X1]:1MK&HAFTN@V<1)"NO[AB_\SAK]*W M;%1"PJPDL'9M=K#J/>&*:I'@]9W6BZWC#:4HT[[@T1$T$,.SP +'\"^PA"RH MRJ2Y\HU>/F (=9HKCOL);-M]'EO/]YM4"'+\)8FSP*L6^!4]B]Y5&ZB2-#>= M>I4<7WWADFI%5'P_E^G\$CUVV]O)QB,N4=4B(X[(3HY\70IY&(;W3!30T8^^ MYJ5UJ+M)\GYUF!3\UE#' Q)#EJ8*T *B,U8SPK81B7T4<+,V>/#YQ+CY5VO! M,%M->ZH:D"8GXGB('# R@XP_06<3+<2*_>#S$_]CEE:U9+1F?]@@&HJ_/FAK M$;*??KN+QB<=9Z/HQ16>M9-CGX0+R%KS"^QX$J[0"ZK(]](P\/D4IZ6%TU4H MVO#:;O+[$2G9##+[KYZB^8_:E322(:S.!;.&&_9)QE7@/_3ZPMKVU[W6!=Y! M:H9AA>['NE!^\B1PWP?$AMI6]J4 LO@:>]Y3 +.BZS"E8&'0LF$X!0!<'Y"F M4@F\\*Z4,I!7 H;;7& ZM%&)T DX.% M4,M9R7C@:FSQW1*CD'8G!+S''GDN[%$#Y+)E$ =Q6&JA#'F:LI/N. M[7 .%G_Y+?_SY6?-H8:M=LB9H+YA)R\);J5]NRY]\L:F6CC(C/QR"77.@W.S MAS_NEJ.JA53A8>-6N=K2]45'ST+3$N#!&VC>5X?E#:LL@DISFJ7VD^!5]8%2 M&@J ;P'I'GXZ%F/>/[PKC\!>W87T>9VBOP>=*8^;>M3H)!PG[Q*-NBW\(Q:+ MH&U)C^4/6W2&/<^YYIF[(X+6\;9R<&"SWGC6A'(0V1WK)^FO)SR]JP\9SUL3 MUKS^=)/6!RY.B"86OB$@!2=7)]6!,W+Z^"^)=@&>5IH'I"5=*0)/Q]WVS/;8 M;=^*ATCHYHZ/!:N;Y TWN4TX=^-9?'T;"$ATZ^YR(C/XDX-0C-P MN=D*&H%IT7*;D+.@^2\4 )?:-:NIOM+GDW@9K2\A*NCR"Z55I]GL<5X[PN(/ M=^#CW$YA6?>ULX<&O=&[TQ3 72#=FNEV=PZ3D)#G<>JOC*1?YN4ZJT%=5!+* M.H>O-D<.OZE7+B(].+W/_ O98*]E[S5HI"F"WMPC%DQI@=*G5@;"F")S8\Y.C^ MU+J IY*;=/E=;WIY9I\6F>F=)]Z76[B\^&N8?*'8B^".IRP[5*%P%^LI@#_M@>GFY.5?)LM0\\, "B N#C*?3,4+ M*F\AMI%G6:@,%'#EZ4P^ ^>;G#XNH7Z5Z29._52)IFL_HO[060_=GABOI0!\ MLFD=IBXVS0+]@ MR44@_A:$^!G& !MO@I_J>EAULE( J.$CD#(60M:R@.!-5F-[I8?^!AY! 8BW MSDN=GM3\(_(MG=K'8+P8B@AG?8O:6J4*/RU[Q(B7U+$9? 'VA4BM#?N@9@H M_1OJ2,H#UZ@E5'X\IA]*0G&#AL:WJ>&A_1=$[N/MHP8J5>;_$O%_HVU9BC_^ M7=0UO'1]QU- )30_T5MX?6$[-9SD*FPRC1V1$2%EE!RX,L%0=48.A_N+9%VV&22 MY33A&W@-[G*V%=]@E,?E>!P 3,:"/J6KQO4_2H\ MS3_)!O>GX=9A:\6PXS^(%B ;='".K<%(4HX"B%&Q]*^MIHLW22\D\4#I#?\8 MBX#8B>H.WB+8K=,1+ZWC9?,-(SA*W$R#-<$X@L-4=+XGN8*7K+2JPW2*;H)PJ("PRJW83:C0F"S)OL7F M0^:0=^J=P*@"E9CY?65T_V+YM@;O9#$?L?'@J/=3U)V@18%Q!FQRG(_+J+*L M>WQ2EN]K&)\([+I"@,FJPPX5>LZJ8P.)AF,JPO."#PGTFG]VA3I6R9S&=;]2 M6";D*VA7"G]*R!/[*JNVV;*>5$N61!5L;[P9K2Y7\FN-OBV@],&TP7MF)HNS M=&I_XKGW*Y+, 2>VQDN/7GAU$<5'9J FG74)(G"6+N^;G];&PB5Q="ZV#0+V6/$NZ9AUTL[Q=?"[N(3??V2$2X;?;-6&SE_XA" MQT$C_@6(_L4T]("GPSHGL!F(]@+(<2"&SWU[#Q-BCO4I2 K7#GGSFA99FFO- MK8B>2<_O9[D#ON>R#UG4)')Z+=&WQ7+H%BA$R3'S";:U.^0J3'Q[%WB-=C4H MH-9FSZK#Y NZ(T_QN;J3[UPY2'XIEL.SD3?!R3H^8;DTB]_R9NGNX3[(<;2U M1/&([(VA)W* R0Q:BZ!("%M)(] /MZBJM_J]$V+ MWK*8T'N\T!R%((]W;MH0)(G<(PWZWNQU=5$ER-#<'91S3="V!8Z6J3=@1Z-# MCZ:5(Q&=%6'J)-DU.;8%[2R*PXZ9I*Q<['?L*_0 IV[VR98.6Y(45,%]!AZU M3E.M+'?1B_ H"F#^._Q2D,>BEIR6BFNAT_:0>^24WDM7U_/]#SY &NC!< _5 MKM7&#BK+M:5&3]U[($;MNCL-?M'17:XC=%=V1U??VF7%RNHZ^SW+!<^F?-YG MK_;OS";)A)4I!@A-5 [-W!S$$I67C'725B5OO4\0%7>L%752^Z0QZ?[]6!%T M4]J7M2.37FX1AM3%^R0;N5*8]4>W-JKC=+PS&I?$V3UZ* M,GFGR6I0.7K7J>I4^.C&@'R+W8B0)+_^ _:9:CMJXIX(C?>U:Z"_7#G)^0B; M-SH1Q:+(#"M8S<70WC_KOMR-C$-?/Y<]OYRZY>YZH"BNABTTZ2=+XHL68X6T M(198H5_%W+\I +T1T9K?H+TR1'$+QN>J\Y%MU@JU+DBU$:643A^N7'*J>>'8 M75)7W0W/W<-H[GT9O4D]QI*'='A]PYL_-NF1>Y;)P43TKZ)2#*1S0#!(+47D M#Q&RJ'M#P_,BL\:SJ..3S_)C0FWLEER*M[0"$V\11U'&?C60[$PA0V00?U1@ M@1AY2ZJ7M$YH2?:YB))LI(4UVQ)]Y\W';U))ELOBCM1EE?5/+D$AN?>?"@=Y M-]_3\_<80ST .2 FDYM1E6MAJ,J&ZX4WYY( M>[TP4X M($I?;6N*Q9#"N\=F"#S]MH7XHH96F]#N1<1-\')2W,E->%=FROT?D?NQC<(O MVWD[ARJ"M!8#@><=T7Q)!?XN>>-F&K:9BXM&,8K/O.WM+P-4=8/4"53:T>Q8 M"6,$>^00E89-('51"7+2[&UVBLZ?^K[J&$X\;[(8WC8P15@\;C>O M'ISO+H'BG (D*8 O^!B;PYB>C?YQ%=G<^JHL_'/XGSN;QE2(N[E( 32& M/DZ^<)58>H1SR>M-+-F[[Q1TOD3JE/PRNC,+_YR$,@ (J&<$!Y+3K%/BTA M+IH5PSRON_,M3@NA-NUF>(G&A7GGGD%:\],.C$G/8U@W1#\D['QLT9;>S4XC MI&KN1D8][02ME4"=H0,0C-DO%_4D?F#$Y(V[.:4/!,%/(&)^G3Y^'\ M"HXK,;@LH*)0&%/$QT903:H4XVRTG<_0JLZ4BL&>ZG$HL4 M9^UW?LWZ06 J5B%R&A2G-80PR?PQ*SV*$,.!NRJ./'7REPA#5TEFJ7(Z;X!; M2\1+)O,40!3,$2B()VOQFV%C/R)!TM6<:08I60)K- JN^IFO 5R=59 ,E*'5 MD1I#FA7I$3P.M0DU_'BJM;"D_+2Y5K,^#KQ;01Q8?[B#4=#*^AM";>#U_9]$ M20QC*XQ-Y?Y\+5=EL)?ID*62<45#W!F4;K9)19 $%;A2B-9X2Q%IQ,=L[-DH M55?O#SSFY'*L OE1L8> H)G$87;.9BH%(#/43?Z28O<\?^GV?FY];G9RZ4=2 M%[S\9"DV-1X9Y$N0I>;ZBP8.K(9+L%2'_,Y\AO$#=OM4B (X,1:X]9/)?XO0 MQ D+0J-3W;ZSY#@(X(8U9>_DV[YY8=2\S*9)Q]ZO'M0H0PMA5M,>="*S#FY# M9SYC-9YGZ.-.O$W[O*NV1E5-IDVIO,Y(G)"+8J8 7LV=* ,C@#C!.@I@,!I2 MRP/#2@.=L(SD5C3D5+IH4U&*M&@5O@A[/'#"^8<"X"?&4H7Q MP#]4\ [B7U4P),[[G_#?Z<6Y8]%-E/#^7!::F!!'W8Z2#7ZISFFR*H[#Z&LX M(:YV9)?1"E6>FXJVNC:W![D+'9[#&*#"815!R7Q>=8/:4]U MQ&=B!3MO@>I<%O:B(!B3@4@8NVBJ*H,.*_W&=IO$Y*-;M^1/9T2*_^2)4&SX+1?\?NUIX.XWY]A)='0W*^3 M&=1;T..'VBLD"F!-.F$"?JL:KC8=0F(CQP([M2.Y7^BAG%6 ^=?G%$L?I:-_ ML3"F61V!:R%'FBLUL=FY0C)( ?ZXW>5X0O' ^F-G-I16%DB#Z^KCDC]%@9%$ M&LQN>YRQ]/9DNPNH,28;]P]DW3,LYBC;0@C:#X'=JF1LX>O=;' NT<1 MF^;Z4FT<<13_$77]K)UYR):Z5<+PD2XL9=T.]KBWJGC$H\;?T'+8H'H>Q0BO MF!"+QB,^PAQ8\3(>ZUPTY$/6 +D%30 M[7^F*A@%)6= \]11LA^D=H;*@]-B2:*I*/U>U(PS+)2LB4%0+T.MA/04 .3* M218NXZ_L'!*?!FJ;$4TI !V;GU1 8J**!P=9&KZH>%UZ7G*"/*?;QAZ$B]K7 M1ZCYW!Z,QK[[.3R+BSF"*S;I].2/+G?\EY90D*3NGX7RHNF+K^_^].,;KXO, M$/7%2\D''5_TD*>]VMS#_Q6<)&F+] R^:/DHUN*??5GAT3IV]=H-O;?:EI+'H%QMTBY-J0BZ+F-1C%I M39=\C3ZG@JG.C"\6WRRG_,5=SID\U;JL2"^>>ECQ))S]_?L"9<5?M^IDEA7% MVU40'STX6EXF?%)\]??M>;R MF$,&31$TJ8Z"R7SD :^^O%9_\4AOO)9&^5#W[Y\U Q>[]=K6WM,XT!>B-8", M!@VUU]6KE_UY.X+?=J\3@H)-AV-]=F#J]5#-H9RJR-#=I:C]+@H@V&29 FBG M / WP.U2$1=[@.$=:?,$;M#EZ@C+Z7?K0]T,9$F^5 R0FSS8",(>Q@DZ=&1> M0\4\,&T[36@TF4^KBLE[2V]V^@1TWMH>H9]/OD$T5#Q]L%SCK_ABHSNG;CW^ M\-?<[!="C;&7VPH#)D\63H\8Y(G&!OKZ\,T,"Y M/[YT;IU'R#MT930J/0AW(.O:J?X!YGB;11=I3H;KTXVG$?<4INY)/3.8?9;\-G@ MFQ@0F=$5X5@M;88_;DU*138^^+6;T,'_02A77%2 Q'O6OZ:4HWW88F1'2ARE@:'IAXK13&SZ]E MTO+,,&0B-Q7F(6G>&!8A-P5B6D>;Q7SW8LZ(C@*K''0W"T?* MT55(JP (O$;$"'43AK6'%>)U?O^$J/Y:/@-BF&CG-\_R*A4^/SJ:]A*W(N8 M]"6;]#M)[,L,FRWSFR:HFW'F5=M?#DXZV5_>F=#(,._V1-VP1HB[SM2)SDP MG&-=)!N%"C2R"P8K,_ M0W'UER1.B53[9F[2#BG(^&S8345J"<&:Q)<9[971ZO+*25CDS#-IFGNOY_U:&2%L/Q,7)&226W+C#*H?#3N336H/1>ES M.$TR@STN!'\[93DZV:+2;T5JI8V%.-:MK+4B )O,3C=K;F^9(2O(^PJ70UPY M6.M:\3-ZSXC?WO,#]:&S^*[ MCX5$5DQW!6 MDB.XRKOUNS <'@5R_G)UGP9%3A5*3L==F#M)I:OA2G(N]_X@&O1+GV_4N3:@ M4\.^WS6?>GAQ-^ZY0*B1_J;6&90>R@:!%ZD.)0NN&P>@VR3-81?Q<;87Y3YD M]0YO:S5/5&3W*IV%2PXP-MDT*'$1DLT@C4OZ5QQ'@0;KF0K(!!YQJ6O9*.ZY99A:76:B]_<9Y*^= MDO:,EN#UO*B.K2,Z6J..YT7'!^TPUC<@_HT[IEM\>FD%DUK'W^NJM+)4&[?. M2*Y!HN$8+?=0$.=\DNNMEJ46OH24E_()A"LWHYB:)F+=R^G$Q^I?-]AIZ(W^ M6%I%0K*( VG]C3'^H9=J5T:7#+NU!P:=AZ$EP"_^I5D+[AT@SB .K$! =:AW MWT/UQJCW5I-/1)J\JAXI/>I:NH[*91$&QN%X<<1.K/@.#).ZJ:NM' CC6+]5-9GP&BOPO7E_ M5;__S_SMJ4Q>_BK)?10N%2-WW(J:Y.A(O47EK]X.Q1;5O?(G$?L\T4V';^Q> M;K1@= M]>7CZKGO)/J.6CVG#(P0CTR'^$Z!E4'=:'N]92E.JWIRFWBJ DQ"40%V/A)4 M"8:_1 3)C8@IEVB-OOD,)E98<_MU#D8JTL:O*NU ,AF^ A46+).WC[#O#^;% M.Q L^#JTEWRL7WEOI'\J=[*ONR!P8BO=J&_I] M,*E83TA>24ZWBMV= 3:\S3C<7C:&?"""'9: S!.;23*BHTG?F7QO=X=+WG#[ MGAA>1@?LJ/R0B)_^L20I0^+.,N:Z7OC9%VROI<[YU/GOG(HL\PC'3P.?0C,R M@B4\V]+*HDM 'EVDI;_(( MR!RD6I&V\D'01E_]2#GK'?B/?^]]"N#%J4G3/7L.R^J=*]CW[K$P 2)XL2LE M"HLYV_(@;\;Z&?TTWT(1[@F<_BCHAI,W#GYB!QWPJO 0>5V(4O]J>GMG^ M"#?A.J( B#R,;V 5%$ H)S"QX=Z'J".0/96-*"]I3<7^.WZ(JDY#[]L'>8*33D&#Q(D6?+>?RA3KI\*=2WIWW,MU%?# M'*K4U ?CK\FAMEN_E;Y;Z'R_U3&9+IK%>M"9^\B3KO\7;PQ+F^IKK?F7J.L- M^HL9.AV3I+&28HBELUGB8:[3KIM UXW^P#B8U M D94:=K4$J]QAEH0JM=(* M+MP/0C@1V!"2KR.T M(27=;"JL.#-PMHOA/,CO/7+IQ6N_5X7AE85#P78S.$OP'WQRA$RI2A^YY%U4 M#MW<#>,NU[Y;'QM+B+'IY"VCM)MB!R;&\F/5)LIJV$BQ8)0% RD53Z6S=-MX M0XSV&(?-0J"JX=-/='.;A5*W>,.QS$NO',BUA;'.N)HW@8&.1C;5'[DT .<5 M@?>MC(6C"@J@J\RE.U.8$4(#8GWA8X$N6/#CTV3'(O+-K)/#5/GJ&L=EXX]9 MHL]-@[HUGZK+5JEM+**"&QPP%:THMC=CE6A92RG32K>?LV:=L@Z8%^I!600] M6+-0 S^6I7_I*48@O.7NV%"/:VWV<)Z[AIZ9RF&W8!8AK*H9Z\T0MU+" U0= M7/6@'UR3:3'P+M\L*W(O'TT[',TE.Q)K5!)W+($ML$^-E_' I4\@-KS-TS2= MT1L#W1O=VGE[FE33S'ZY,N$RZC%.?*+<^APW](8C[&P0 M;;Y?SLON2_6W:!&$Q\KVOQC)#'($%POHR-Q%O91LR\>-%_Z(2-H! M9\PWPIE?MR+R[P5(J7"_A%PP#\W&-B10 &%'*+*](&*_X< MBVU39@=I/%)JX,?:-QS[/Z MUMU[_H.0F@7/Y?1M141Q@?F%Y*?:QI'FMQ#$N10\-^O- ?R 3,)\AE:/B1AI M'&$99WE13:PHZ?3<=V\G7,0K=Y&W[Q]]9+SSPGOMTM(YE'LC%[D3Q QENL]' M)<*G-],_1S&&O05[0BNTZA[BD0'WATMP2UV?R"=5JZE"Y#1(5ZW,?0)?!SMF7*S-' G MTE@YRZV&Y;E64S=3ZDXSUHVO,D&BO7/ ^Y@":%+S_:@6>])X)JKL$D-D74SI M=3.(R!1XZ!BD&,O<%T"_O4)XXE>$L\)N!ZR%N?-)7WGVJ_SS;C4J2B#!FXAI M9:I5%!97<8]H4,KW UDT#'F[F$>##(97'1VJ4QBZ. J:C<]5G**'1_)TV'4[ MG!11M?"/\]BOO8A+1?IN&=KN.<.Z,&.'W>1M-$'=$5*YUU(/Y' TL+,7LARM MD+:_4@!($51%Y\Y9!QO8FT&\0WM, M$D]WW_Y#:<7W[O>1,6.J9Y0Y_IALWS#XR.&9R2IWAZZ1?%5%[M\WT#R^ MR>SFDU,:0SHW2KD51S6>I\0" !=$#KE.D 1O6+/)'M'.VW?!/4PAWFGR;KQ@ M?RVO]+35:0GJ(9_W"9G@,ZGDC,(8@:;JW".LKC;@W1>44FO:/\%F+1U%\ S&W2E6N_.@*B^RSH=>O,9P.XW])7X7IVWS[ M E[4OI3_8J'/V!CRZ5!S?AK4,E$*^X@S97#SW#R5DI^%?\1V*:H8QT0O!!NV M15>#A[V9[RV7WBR9M;K7!;RF6HN8F/L QX#W/E YTJ6R'V8L#0O7UYF7,E] MM:G7IC V)X57XH/R5%2^]";-Y8W18V%U_7>A @PGSD0[NAUM9H2">Q-I2O)4 MT=KN[ VHJ#HNTAWK"GQK-O#AR)TI%I_B%! #3[?9D1_@]AK>HUF'20P8'AQ M_KPYM6Q8[_[3MME*?^V\\(:5,A9&OD#"%"T]NBAHV&+F6K(@77YRR&.H M,8KT$37_ RI&2I(+#);2#RP);&;")^OYSLA%J%K-?"4VYM[Q$8)N*!?5D JI M_.WSK 1>T]VC""^TN/2_:'O/L":[;ETT%D2:*(ATHH"@@J#T'A7I @H"2HM* M$R)-.H1$07J)=$4@:D"D1KK2(KV+]$Z T&M"#:3M\'[?6FOOL]:/<^WKG+\I MSS/+F/>X[S'F'+-E7#+ J=R>)>].?2?JU>C>0_X^U9&V<(5PL]?8KVM6T&UJ*T3!X-VB?DZ MITC6+N_70.5;\>B;]O%SXVM/TOVSXT(EO_?\TA4).7LY1)5O6P;ZS5_2'E=K MV4<>1O0 O_HCVD;=KLX6JFLYF,N4X\8F?.9I #:$TO_+^*/131K@M6W!MA(5 M =XV,2!SD/OVPBXZ?J*KUZ?5Y[S 'Y 3$R[=&UZ6%?C%)*_@8$^VS,QL0[FR M[CFE.2U>1T0F%-M5(9^*K6QW1;8)MX[I^"9?B30I-3TS&ZK MSK;#G1*(?(^'1_QJXS1S9RYB(0VD=BW5P'3)(_C<-SY;P"DYE4L1!6LF>?RH M'V6)"PWJ2G<,?0G45CC7MW %< 1,:OSWA1JC!..YL^U'?)1R/#9D%\'H[#&Z M8NF3BG1RJQ$.F6:(5FK[FO^&<4;BT<8@G)EJMIVBU%E$5S4,[@ICI$W&9>S; MQS3 >(G,:^JJ'DP1=*K6 0]IH0'8K^S(;S$3$?*<&JXS-;?)CD4S0-GM[VI710[U@D?X(8RI3$!Z'HS/>5N2WIMF;L >EV)6$ MLT/(X2?:''>,1U[0/HM1 ;4ABD+]M$+7QJC"WJU,!V897MO'&W?@D:K[1H8 B MX52#0-6&.$G2OVK_"2%M7R>J<.CYSZXQE_,+1>X/A;XWLW_P3*:3I?:&TX=- M@MBPX/MYLX1RGW*4"+Y00T1AMK:5\#K'DMT6*5;I3!X ^=6?)@?@MS;X\9MM MS5G\M=P*BI (S;#TX;MQ?;J_5&V\VN?/WST=PK1I#@N,+0#49*?KL4=@)W-+4W5!=#7R[)^=1E41V/\>^S7^US83RCD$%V8^I>5X MQ^A+ME?1&>]/]!H0&Z, 36:CU;J#=5!>*C@P-X)-'Y3X$-M9RT@ B M9" %&K&(&/=HL]H-V5BPWA&LZ:<%1DZZ.M^ M&!V'FEF/X]WY8?OMKP M;'4N/]][F :(^*0!CU)*8DB8R8UO,TB]O3)4'R55E$!?3#KTE8VB_^*TI)L: MYTS-]TVUYS(;U376:H$JM\BQS4+<7^.-G\&EW=T7![<6JZO3(3$Q47Q/'5*Z M.B1*NF1OSR?JB6;I?:5NXQ[7IF\N.A=+28DZ.Z1:2(L6MTEVM]&_30P0^^(T M!2YT"+"19)-ZLCJ]A2&?(@+C?RX)-H\>6!94R&=?SHJ"%>W90?9P5"95O*8E M48(D+;V_4)OJ-RTZ:#_44EA0:>4_K82*55KO+F%LF&<$S(1(M-#'FZX"[=RO M(IJE(\U5'4VJ^#00*O \D92?'XT)WCUK@MAM6DM)X M;IR=D^2?T=,(P>B '+%$X>FD;*N)52!'!:\\I/7$G[3G(IJ0"ZMF"SP)% V;-T%[ MZ!(8'ZRWGH6H^>('$=*D(A5?XYM:5:%%-[IIJ)O=9G,ZWC/#*CS[\&6N^(%T M+04<3J639Y7TH@^/'PL?R0= ^YVE/V$2B&'94$Y"6N0+K-TL\**MV"FW4(.L MNZ%_%Q[O%6;"&\;;PBII !?GP-1//V=A0Z_P\SL#'D(1V_*4$T49-T!#;30 M= @RQ=%/91))'^9-O%N1\/Z\SA?&4-M7_OTY>]^*5H-SC%$VYXRG<$#%#+/Z M-6KNSBIX?J(R+DP;LF^'\R-S.LTJML8\37=GFU@.3'ZS@>G[7?;Q"0UPP4S( M"NFGC7X#A[@3Q=CC,(Y$*?DXH%\,5$+(9K/HB_!J1^#B$VW8(\KN56TFUPR+ MNC2"&#_'H-5"FM-('PW0!$SQ= _EW31DLLCE,D\?^CE57E.^MU?1MY,;KF:< M[Z]H537D';16IVA2YHJ?G-#MZ^$,+) 6(4OL@O>YZ*CRHP$7%./.3#9,GVY[ M\O&=>>#?1X)ULVH,'SQ*E->;SHXMY_)C%,PP?MJ*[,D6;G;)?UM-RX?K@(^A M(XR$1>>F#\50.4H7Z6^0_$K?(>KHHMZEERG)(47MPM'DX]H(EG2+N[=84U-& MA. @BQ]')57.?9%U0 H$IVN+)_V]H@Y;41Z7V%6^5WH2I$(NN-VU.K.F8J9! M'\G>K7/GYR:!YV=$XALPU[6VN(= ?4AA^M/LU/SR_-WW[ M-2OT]S$$^#I1W."N,EMOJ7>T(5^ MK8?*XET)'TYT7 /,C[RC#L#/RTL3KUFL*\\,XUW?52]%'V^-JBC2&$5_ ML$;]LD9,E9U_O'OES=I[]=CJZ=;DI(/'2,74Z!YDAN<[<J!A^A*Q8H8'[H2\Y)_VA!#6BCI?7U:%^?FK#&*]D/Z" M!I":UGBF9U,39\X/W;$WJ>K[27 MIN*^O!DKR\C0U[D'Z8%#(CY1F65)3Y=![&H2/C7:>+.4[O&L NY>5E.58AU& MUE.B+]EM>L243H_X\"7D*0U9>.CM@(-\?0^?T!W&*2N6"/3;[XGHZ_W>R:8+ MU163IJ[?$J%_]D':U[Y&$\N.'OQC%*O^U7.JTA'C'')(QY_IV]3G9$E") I! M./D4!/("9TG"7$A=5):\KQ68>!C0!=CDXQQT=G][F@.^^PP=LK:7Q1O]%'IS MZ1#Y6T-N,$]#LCG(*",O\'4!_.,^(_E"[JP9.@[^S6-A0$1>S.U5=PK MC/O&[!)3K? M"_LUB%0,JLJAFI=F":[3E_SE\8FI_3&[4=D9@2;5S\T_ FLTWWPI%@<5\^:O L-'%YF?+%E45 M(2F5U498_Z$HNQB7XJ'=W6)C'*(Q$X2+: P.:JS^NEDV?-/VS"O[UK843VK_ M+5;U00OK2;3 @.ZDRB/F>!F3^+5'+WZ4K_U-Y?MZ8)_NO#Y@7D)DQ-$ IU;! M;%#/_&6^0@VC')2->DZCKU3LX_=!>:UW-\_*QVOC>@-)*"J+%DD9WG@;5R<^ MI_#)M7+$FB5W-8R1Q2.&E,=/61XL#F2_'I0%XQ8H5H?L6Z/Y!-V8P;^ 9"4< MQUR\=VU-$SVF,,&:F$".(F76C#BKR&6:V?B%DD/W&+(A):%I2$ PUW0* M$6R.GB^&UENPI$\2'6;8-.?:F@VYFRQ?;]8/;PF716Y,GJ\!6-, I2A)XV=, MA3)^-XJ",70>94YDH@&8+)HI=FT'/S8K\.O@9S\Q*%^]&V(E+_5FQ>^]M X3ZE#_8\A-((&8.B@ 1+99L&;-(![+C6I%^QN M)RY_S&,OPUO>X=&46'I;L@^X#E/UQ"4;.8(FJ1,$579F 9$HE*'E[1 ]J2BY M1-!M+QW-.TJ?V99.)08R4^"#-(!ZWD#R0A?G\A917'K=@:Y,+0AWB_L+-P?WZ$HZH?U1;$@G9&_K;M\&5#G':G1TH@GB[,31Q'KA M1[!,K>_1SQX:W'=1P# M@^^]OT9+-(.,F*]]SGC(V'T<7:=AQJT7-WIX;GACT&+WIN0+>P=UGA<8NC>=^0H\BR/>)MGX MHXVKPE _!L7Y%7PCF&(OZ+_^N>RDE(%7X4 MM3$I(J-DLS3FE;3.%ERG'WW!*[6=^JQA=BFRB._BT()8HLU$'Q ";Q"%O^!W MOW@(OUAK9E\VWG#;\.2X0V=YY"@D5?#<,(,IJ+EPM%T3G'V^M>2R&3@YT%R\ M"7-ZE*R,UTCZLO+^D ^6Y"R8?6%O/.&[6<>FA[)ZKWQE*'"I"*:<;K<4TZR2 M-/%U';'K]-;?@.V]@S<^V62Q8D&JV-AO98SSN'X"TO[BBV@V )2N^!G\*/$; M9,\9O?JK+WUCA*IFB3OYDI">C0\S-8'EX"#0Y%3&QB/P1ZU#]T#J6ZCQ%RLB MLND@/7C]]J3E="/>@#.V,'+U<=[^Y03BR P-T J*Z(>*$TOFC%F[ZC _]JZO M]\T+=$:)W,"0F>ZXMV*T9P4:!K_A=^#GIA%DY")<@')923^5A==8H4F[LVBP MJ$JF#%- .>=LQ#_I+4\*(G%";=WCD67L[Z Z>;S%@8O6RF*%\>:O_>RX"M@F9!%#O([>>"J^ M/H&_! F6NP_\BZH#6>H]/%/63C0C4@O#P<+#GEY[OZ\I5)_H(L^"&=3MT M.1"I&M! ZN30S6'W<_Z*#I/?<==]O)L/+[P/_'ZC7PCC>9?'A0+BC8[G>Y?? M]1)-=-@!11#IS78*R)1D $9G5P2G;F"T?(.OT$&+SD=#/#7Q2P]*B&]Q,1?$ M(XO/&WY;V4A#:X?;4=50I9I GQ97:_"UAR^_OA%^ MOLB&\8>K$&NHS,>UOR8KB"W?;/T'?N][C!&KI_BL:I3^2@8VQNO]GC%Y&%OO\C[P5G'M.97B2_D%>N-81)*&7]1/"$/F3.[;-LV/!DY#&G$: M<<#>5W\KRM$"[7U=_%S>SRN2X\^*E%QL:A(('B=945D82*(Z^*6V6U#MOQOF MZN+-I@$JV9YB0U4U#<+6Y_J_*^.VOH@NW@5?C#V$Q\'JTG!?HK_P_5TC:GRG M Z(_)MR3]YR3J51S6X?,J^ H5/DF7C@ME/J?YR!@>E;K(')%]JH#[9' MJ(T6\",>-&<,?#(MGXP8J/^O2)U54O1A#)4YC/2X@Z1"9@QB$YLM(C^::QPV ME^;?2!R_Q9AY:Y.Y@,%$F4U8J+4^,V%?*K@40LBE,H,)#?6*L*&C'4V%#8DF M8TJ<(^.#YK8>=\UJ4[&SJU^")7!$+^DG&29+1+L""OS4=3-\<6=^M4Q@VZ-$T^7AS8P:Q92CRP^S1IM[) MO+!)6; /W<9X0([^4..Y8*LY[3PW/D'>/\AL1EO6]<\]UP[N.]P) *H>6%)$ M9%K;F,)3GGJ/^06SX\ZQS%9/WLTP_=U"-MH.3AS"K.7MN:]?(7$NTQVE15,D MM'UC2\TF[WY1_BJS;.K:?*NQL-S*A"=_I ##P3PN^G8YM/:A=A\8,2?QIT+' M'%7C='0U:9[XJHR)]=(YYEO1I08[P1-3I?K7OI:HWZ&3@E.]-,!+]S>6[!LB M^$XZYE*O5#UUW1SQ-ODNY)J-VC3@7>^$GV0R?:\+BD8*UK.XT !EV!9#NT;+ M^2#W\E^^A?GL:3X7%I630(VK=_<$0MN%,0'8MV V>M>=,$Y*9&,\QI@89N>& M&1?B2W"5SCZUF-IOT9BT5FK.L\OQ"_U]-K;_L40^)VP=PSBP!3I+J'GK[/C4 MNLQ:#1ZL95-1^[7*> ">]42)+I$29A WQKR.+JQFW>@*YUW,)\<9O,.6@L%JC4CGSH^#5JZ/J M&]F422QXJNQ"ELR)#;!7YC.[Z$9]03_; G+OHC2;4OHWG:S^9O&7>MM=9883 M8,.1+Z3\.L@<.U'*^/B8%-T_!O]S>FJ\+,/0G7_/W'JQ_BI]V<\3\"*-F'^? MK>LI%91EAG13_Q",7*RO1R?#4V OR2W_=\$M\O\> M<6 !8VA!='Z>B84[?L,LH6>4% MB+-$[3G^7OYIK:BK/(GJO#P>FRJ\NLJ/U4Z$NRD44"U6TRM::_*MP>!):UM; M6_T!0[4_]HE.=JF.=ATOCL-:*/,AJ8H>_;FCH[F@KJX.2^>EC]V)#]9?=W<' M2.J))G7(V]0['J@SP-#)"W(_Y HKDJ8.Z&IA#-@@$-#V9/-:&TD_W=3R'M-R MVBK68T6,L3N(F<)Q#+1T^[H-U$DS)APT&P!W>U.7]/O$C8E[ZN9/Z5 +O%>" MK&EP_Q161/.TY*=7$3KECN$*(,DRQ0X. MH&/">^ =+S"G44:^X3W5*KH/R2GY4/U$38X@;X,Z6XFU3^D-H>/@#U#%>I8\ M(9HL^W<3,V?QM;JG4$\@PWH2]_J>YY#=:0Y0O<>=VR---?769IE>5K4$J;* M/!=N#ANL"V==2_>V0&U_S24_\<$248I+#1\E[>;O)J:(N&N[V)X]I\.N5JAA M9.^.RX=5C/.X1*G5U>W)-0U&\J41T$M@5#HX#*KNOA^G:9+$,!%99$=_$G!6 M2R!KZ^C&2E\R(:Y6 M+RW=OA X9RF1X=C(C:N*+0V.A33Q7,*""HXOI#+_"4NH= MGH><794@8*G,3TET,Y.!^CB7UWBQA]4^%#HP>JAAX'.F('\1IRA>40';#CZ>R4[E?C[YN-1J(MA3;=_8VW%J$[D'4*KW: M/%G[->4DA90O1)?>4CY]H?WR3@*X!(0WDAYOH_*%SD!E7#@ELZ[]U1]S^;S! M)F%WX/7,XW2TC =@NACPFXN(C4T_XJ0R?2'L&[\%52A$)UG+!8*BLFV$#[VV MDZZ47:1M\ MK2F%B]>LPSIT0XP4-LWWT*E4J>-ELQOLU2;K7S:+C:IP#Z.*_E3]%BP-LL]8 M$OU@]CYNE)>YX9S,PXREU3M=PA*L0:91HQ+;9(T;18R!;G0EOV<%G%0NUGO; MO?)];B;[ZQ:W;WKP@#ED'AJ<3VV \\!$)Z0^S6TA^(I:0W\6#A_YIM^\^NO! MB8I,&W^U^5N>ZUYM==0_R#+&=W"'+08:X 71MJ&H_Y[0XJ+YCI2[-:M[ EXF M^ VSC,<9P\!;_$I?XB7T#\-<2N:3]'SUKNY4%'LNU(JG/2L(=LRPSH5XZ?V2 MJQ&;J&I/C+Y6++O"G@2?*<:<XEU_#X;DN_F%,CB=&KW. M 7Q9L/T,T(!YMW^ 7KZWW:_:Y1>O91[78'[:_GP@ 4S' OS#7J(8-0ODILE&U=UK2IU.589^CJO4'4VJQHPXZ&_D4"Z&RGWMV@> M=RO:CO!_M&]]7]U6O D]][5F(<7>..4@6.*0,.##'W=C7Z+ *JI(ZMDS0@]+ M=*F@K19_M5Y0T@>A[BLQ$Z>-'7:(! M[@V^4Z JX.N_9+>/FM<,9',_=*JYZ!H?LZZ8?E0VL[1A@R?A)B5H@+/HZ/(Z M$T>;UE&]A:G+FY;<+,+QM2EM9^J=N)+G\#1 [=!2YY'!>\7-%#0J_'[FEJ?]LM3="1P87\[#"_7:6"#-_KY(TCZ MHY%7GR/%'*[,P8FLT=EO!T^JCLRV17KS]S)!#JIM*+6I54<^S:DCMWXSYCC1B:H1S]LTP(3+D9'H;XH=\SCQ M>/%/PJ[/]%Z"VRWA<\S&,\&^-DGN.MO!0;)[V]'W@Y?YAU,QUT'U)T/[8_ON M",%)!M#G%40VO'1S_8WJ[3'O(/'$:U,_Q)/))3K(_7E[,)$+=FEUO&XD M]!.]$?RQME6D),X0YE]8K^G$&E?H>@> MS*>!^;93.S"N_R%W.0W4/RZMD$8#B (;D?NWQ*E)UA:]=+,D44#@OQ3(_W9T MY?,=L++RAW"Z_ZO'_QZ@*A,MS)GO M#GI'5$CJ,'9\_ 3^4,%1ZR>$'#$*&)FJGN0EZ J=.Y)IYL49N:C<]Q)3X@3 M961$>ZU'+J]'CK/!^L^*-6^,Z4P&]",Z&S23K,$N=(-2 567S7/HVRAVCVSC MO5#N8MR78[IWLMZ]316R9DP4N=ZV :?KG&GGV5IRM"1+'610O]"[4PHV$*_H+%WS/4>*SU2#$C'N18U!ILC>Z [1[J.'*F*;"$K/+^"-[&?/^.#)?89J4R/\"&@,$RI M6)COWP][[)QE:]SBI$;-2$2Q6DHL;A!I28;3N=16;B.:66M&.H+O4AQS?E/. M:,/+Z+J+.GR?3VT7X/@VY:[H!7_#3GI1!+8_F'67\*Q(5'OJ!2BK4UZE'V;* M7SR5+K&#(IW_SSH+*UJ,.8 ],8CO"T000.<4#.<=4Z5% M37=#/SL.K- UX-H=?0K=2$.4Z;H(:4D7749;-( FU^%USB!*1,SD=IL[3 MQJD$C >0(7C;U4W#>ZM/%Q.RTYUD=-=?_VF>3]J3)]'U$X/1"+8)6\(>FWYI MXFJ_E>7NJNBO*'X:0. F.&YL[I>_5/1C)XN:JDG,3-92OZI,\HZD H,KSR_H M1-5\F,/X$,F/=)Y\#1P*+&,,+1>+Z*R),-;;8O3T5-QR8!PYMWY"_./CH&N\@-[>U=3*7F?MNXU2O5UITW3$K6^!/R1UWN](9 B")L^>)D4;^/ M#T^T)O@@*-QF+8\]N5#,CU_,%T^4NG<(4$_8;197&!J0;?IOP MQ:3K#(JCIU%4!C#=231-4L_2 '\[ NB#^0E-5=0AJ_?.("BL:4CB]6H: .=# M (TI]1X>2/]"#L#7#MCA?QU 9";XQ]U%^#@*M&'1#<#_ MXXW>\/_6IGTC66IPU^9S*@:_13EC2@/\3CM$&OY46K-.:^V-J*0!+L$X_1%- M?D^>^&1J!,G,.SGNWN!?96H_X)H3H3(OX76HX098\L4I.*':M8W,53,3F[I> M,&>U_J--Q9"N_?CSJ+91IK^Q!*2QQ.=BQWR788GR5$U M94G&M>G3/PT0=1BM8E$-;Z K M^GDBE Y^8$7@D8&\_Y-_11XR8),:)_[S4*76?QRJ)&#_ST.5*; 9L2159]FW M8 EX@R9\YO,^J$P\8@%_$+$8OM/&C4_@8%5QCFR*RA94]'NL'HA,"R52.1DM M+IB9?"O&[OG"OSX]./]L&\I:,CKVNA44%,QA8W7C7ZIE_Q-E$,V8[RM>\YL6&RZ69[NW.D=Z6)^2FS7G)Z.G%GL<91!-RD@O[$G[ MC1XJS?B6RIR26AJ$6?M"YIQC!.*4/O%NW @J1\&>8._7U&_$1XM(W&C[]3&> MZ\X\\BXX&XPW8B>*N?@+JX/:L.<+3ZU]M,J4UL^$S_-/.:8$]?Q]IZ;3 )- MSF%FXI%EBJ%0/Z]@7)S)]H@EX5SHZRL5 [S^_7]DDJJ1M1M_&F4*RK.LH*0:G M&9OC-]<%'8&:X24)2.A%$98D@&!F*S/:^JQ5Q%Y'>[UFO.E"U*O1= MY3*+0*G]1OA3"K:8N&/W6V"/CDLD0/6/VC9L['*C6#1SEM\73W=N2?Z9JD&G MJNZ2ZS9YO^;;X>!E?D1G(C*).)!NP-BXERR8J8W:=MO:TD/-J^QB1NE$>)L< M0,DFB\Q&<7>7U==R3$LI*1!.27[.&GOLP#@4%E#I55W?1K>FZ_Y:/HAQD/70 M)[L MT=!6RF6MVK+B0&1/87S2ZLYW)3-K ,.#\! M-5OAKNN+O*Y002LW)UU3""2==OR3ZF.B([H*UY!HV$3Y=-"S68T M (^_KS$CL<:\W[$W,V?:T/'PM&#?+\V& ZYT"Y9T2JF,:5COSKWLJ^$M2GLQ M53VR!_!]5R+=I[)XS8#>D76[LWS1.1.3W1<]$GG:/H#.3(*8-[ESH,?)SUB" M]#X-L/[TJY53TA=8; M)K)ZY8]*9*(3RS1 E%SZU"9D,1%;;K;FS5K0 .]D;=]_Y+V)P]IY8#J^VZ;N9;0'NF! MJ7N%@NZ[@G ;K.41*R/'W(^.N_4O]X/('P^!7/[2[Y9W+B$=@;:C#\84F4&NB%FN:^=$#H1L_8MUDG3EX[1]ML3"\1]JS MJJ\M69%8XD0>I0]O3D.L"OQN=[&VF^A^\#!+WCZ[*[][T3/Y]@7*9'):VBH, ME.Y!=4TRJY1)7NE"E5GL!H&2-.CD"#.33P-2R[Z'% M*>4T@!.1!G V'EMJ%N([*3\H&K&A BU"3$ZV[6B_ABV+NMI1AEWVLF[K>@J[ M[LU%R^?H?\T3'*@^Y/JXL%LR:OE!996080GI* #VNFYDC/L,#A]+I^CK*^/MO^?/!YT/0.?1C;T(4Q9% M!)$T05&O7)L#@?&G;*1:&IM\?W*BR6=3TL3S_-JFT"EW9XT/(/NOSMW@R;^0 M7YE( T2 81&'='-L01* MO16\;/4LBF+3#1?-\&4(GP%5=]D6:@>@N]F)(NP;S--LQ((\,JCV$X6QY:S[ MJU!%)A\.\@P<S3%&Z42K!^\1OCLOC['(+)(+EGMF:=K*?6UN_YQE7 M8\FN KO5#:.;1V,OZU^1&RF%5'D]TCWJWWHQ@JE:HB78AJ=0D]6U G'@R>I[ M]>)MX+2C^MJ?J)4[MI!:RD<-UDG87["0FO+L-:Y8E90Y2M$@KK/*.,OQ*'*H M9-5#=62]9*'I.>D:ND&$C$LN45YTAT?G.%-O(G/ >%W,&Q">/C&.WZ%W ]C3 M\HE]K9_G$1]=?PM/P<+TWL-'[, 6;\MW\],5DMR_O-P?]DUH'<+1=?*E0 MZ/(9 %@' ,Q:>'I@RO$M:EH!9JD;6#)BUR[\M66 T5,=Z9QRX112/7IQ3T I M\+^K^(FF+?8-_\:]BB9I_U49$RLY5D1-_8O#H'N"'%\NH>N$*3:R''8TM 1(;0/2.8I[3.S>\ M1\1-R).TZ+,D@:>_6I0&*-&)WQ@&R7:4QF\)$.8[DYP0AA]W<5D2A&#C]J$E M#VC:D#VF[DAD#9:0/%_6*:^BXAS<[T?N\VKZRCG'?^GG-K5W_P.Y5Y9?89/W MCW^KRB+FLQ7#A ,[*023U7@+^^.7'%XZ0,Y*X63Z$P0E@@! M;>7/X70Q4UTCNQI)RR.1T?Z=QG[M(U^KX>DJT=>^UI^G%OSOE69%?/GAS.2G M] XEQR$K#Q!UQ<_H5O,$LI\XF^(Z>G1=GNA$LB,V43DQXZBVH[2/=?;#N6$\ M23O9#U[<4X_^W%:5JW^T>2[FJ#FG'_M)9Z>J7Z;\DN&]I*D_:WWB\!XA"+@( MCMM8[+>BFB$>IA&^P)3IBW#T./8H@WXM]*U9'8_;NZS)UO:N6T MGEC-\^%4\%__@AAD)GL[;)DV-E0E>!-]A?LMN$M,$ ?CK^K*"K)83:DB7]B:(>\3JD8K M>C^'B(9&F""B]8&3+W2R19ES@8?R_?&AXU+ M#F]KP2KA31E4=GAOUB\:(%0QFX[0RE"Z>$>JTVW\3*+%)VKE3"UU@>HT01=/ M]03Q'?HB/PF?A^D_.AZT)>E0S,Y2,7RF7Q\T^P?,"%_JM:;SY.QD&F!XDON@ M?AY(D(;JD/_2=2CR$)B8?+P?0;EK9HM\N(8DRB4BB%YI#=C#G1$0WODJ<,V- MA81]S4Y,JQ>AOH3/&),1'?H2>VBJP +>CPK=ZR7SZ>G1 .<\B*HT@$;@$I5U M/N>?QAV_).._7H)#X%'*A]46:W>/HQY0(>#V4C&0% 4BFE>]Q?_?:JF..Y=>>TE>?)E$C,SNE78<[N+$6#Q#> M.F(*S_VO_+5X5OUX197!DV$Y,[-';Q@!S,0T*LO[V_]\?8R;DQ8="_X1D3TB MYF#G2MAAZYA^E]*EXI/2'TW?V<'VG15WG!9E*B4FZ;[VTU-@Y<$;8XK:)'Q% M&8_WM,X'Q5<5Q'?G* M9.0_2E':G.L_1!$1X81!_-,<5@=P> 9.W-4FR7 ,^!V)?X@@7M-&DF3\7QNS M$V&Z[F1/./[M$8^(YP,PS,U<1 M@Y\C%2Q!_/Q!,5T3'>8\E\-8$Q^L>^3G*TOJ 4YTR"\Y/#639)"HLS^ CVBN M*>T@;I--XTNKOV5^89BHV1Q[$H]2&X#L#NSKTB="?SE0NE']GG'D<%[PG#O' MTP^QN@UIFMH-)\7F>1L 'Y4!<2B)GQBZORA?6E\K@G5A+NVQ,Z_.M/] *G0N MBXUN%8V^3V0W>G'4'G"Y1A7I%M3\!\$\ M]#CH+0W 5PY"(-G*>R^^Y+;U1>:UU4IXBDHI^4_Z^KS*$T*%W#V#.=-K*[&, M)HJG;: #2->@1E:&^@'9>-N:&]]R&&_NZVFL3FICIFU/O3UX[WW55,C]@CWV M:>Y&GC0,%+VQ-DIR9U33336,>>JF E[?$]I:K\JA ,&U% 3XH^<=?O;A[R_3 MA^HQWZRFG_:R#64.0N1D[\_B4GA.%A8J70XY*Q+"9LN> MC2].KW$$!'Z+<+^E7EIJR"L(&F,4H,RNO=V=O"I:,AQL2F%OAL)1ROA>.5CW M'/9;P<[+PYL(^8->\OD0/3H-2N)?.CO0[^5F=Z!])69,]T'%G MF"3%Y&NT+/@]-(!PQR/=ZM*HPR8+"V2;WS+DYEPWFE_US*-E]7K>WP;?)-59:C MQ(@Y!-$(=GDM?5B!!GCEPLW]4[VV@^Y+]UW:U"PV1I_\[(L%WT?L<*OFYR_* MYVLZZQL&*JS#"N -7*W8,9,=:I,?\.BT_/XE14^P-!T31=3D*6])7,M^V@IQ M>Y":KE)F5_&##1[QU9)8S@G!$O C.SN+>>7FY)(4T1I,-]W?J*FB;D"50V.K MYF-(_781=)(3D#O^7Z5\47*.;YA5^K0 VIW%]:CI6N1^'"4.RD@R7I%FCRSW M'WGX>.Q,CLMIB]3I3_9MEWW&&])&1PIE*BYW&-ONY0AHZ9N8?AN'Y*N1FR0: M<SV*P.;=8U8_E@-V2WHPB#,LF1;&78[-3)32 M7NAHO7LZA"U &OMJ9!U$YM*<;4$BX';NG(8>)17#H0LNYHFW%L5U3I10=UV% MZ9A<0!@%IO&0(7MN0MTY,4U>CXE)93L[H%#HTYEQ =4,$NM-2N;]G(M[S@H# M%ML08Y%5(%$4W0I!A(,K@N/C!V2<8;?#UJ7.(]-ZS)ROP _>FH2.FX*+,]1A M7+!.O]=/J(/ <_9QE67^GXSN!: M]!<]XX2DOZ3V]9=JN)??9QH%8>\1CJ"'&^ 8MSC^E'\+;?B]1.VK<2F8F&CR M<0#V,^P/&/\9Y Q9^R3A=2YT;F,\,^K4V<14&D W$EYS91(P(_E=8E-)Y]:" M.XM&-7H(2.?*ND87EG*,U;\(VKWL[5O'HOJI+_'P$\3>AT0OG(UX,Y]UENT7 ME$U+D!L9!WW%L^#@U[ M]_V4TMPI0QA3:"CX*PV UV(?OXJ6RX3,5G[QK#;@\#&\_H0&Z.*^;,A'DDCQ M4$'*(^[:IEURH Z'H 5Q&!2=.N-J3\SUYCDF=A: 7I<>0+,KR.9(SZ,3-44P M(WC#LWH58!2V/ ,F4/%![QM1"MO>F)%7G0;I]%K_*B]2HHT>,$: +JY3F:&7 M"8S1TKZ?@B]U6F5^JCPL9.SBT2ANOG;P'/R.*D:XN10+-?CN,K(C-S)>U)WF M9X(\=):,M9D@O##T)U]YNU1(X!A7D;:@ZE)85IB:L>9=*PL7D76/IL&SQOD9QK%=&N \5+L^XB!-TCM3[L<*7TI 1I!L@ L[>*JJ" 8C M.C6-9-TFG$.B5@CE(^.9@[ZI?31 KY[]LTA,S'F) ]/]8**A'5YV!AL!E1!1J@@Q&?^Z]]\"-QBC2&44-<%L12B=2Z*!_$IB4R["*0PR]Y:-T M550SBZ4$86F Y8<6=4V@[5L1O=L@,4(954]2IQ"^FPUE0Z81T$7PF5CDME\5 M>%^:SE"6UP(/)8@@OJ,1ZEDZ5Q /\J$!7E!ZJ?%5Z#Y9],%U>L>0;50>>MN- M0^D^$O3T^]=H,KT[VO]QN_-I]Q7P>RR>3K,.U=:V2&M#1]O8?LP5S R: M/A(!(]A]UG(:8*Q@54F3LG$$Z@&&!U^&SZ>#<> D#1OT7W?BY27RN_IK\%\Y M-(!J)_GPOWU$$A*C=PY:#TX'9=9RT&?HN#RG^W%VL@S'_A9'_(0O:[8%?@QI M*UP9N60$KQ:-2P*%KY*YZDH^/:C-&I]3")^;UHZ^_WQ'Y'H#X[(6_&Z_V![( M"$) 4IDM\$_K66##&L)/[*Y_(R8:;Q0HM)U^T-Q9CY1L-&*\8_$-LOA3]2+* MW!O\./W0#=:S&]V^8,&@*?L-$S[IL+P^L&L($W_[HY&9XD>?84.R/6+.;STI M>V7[0:F+$&?*[J(.A$9SL\E:OA?GDJ-DK+[@_] 0C$H*G.CO@(:/'.]R;J:K;R'+_Q1KQ_E-)%Y'"&0W M ?YW?C/^W^E-Z7]G-QND>X0(I/MD-;IQEN%!+;;\8.GN8>^:F"==WA;^HR(P MME"BQ0PY\F][9V?GLL>J]EF-<,R7ZXP9O,':$@0_*K,TWM(X!%@1$56(,TSW MK9#>[TEH>YSY\4,00[+^F\!K:&"H9VK&,AWJ4V/I,,;[OK.8GSU] 'S*,PTU M!$TRWE*3S)(XX-R_3?RAH0#KGF8G,"7U5% -/"#GGV3%.4/3V>)5?Y*]I917TIRB?&1M&PXF=M M76W"LY"S=C)ZSSNO+#MN=WVOZX^@";0S'3 M8<&>(I4YA726!FC6Z,>3*K6 MCQICGE6)O5JD;+A,2"(Q=:V,!A"#(V%7/#3$P\NN/U_R,[)LM!DY+"Y8#*;K M^M,9E)I/C>.9Z$8:@&O*R; V.)UM'KUCI=]&57^"G'W].BMN>YOW'C6Y=?K9 MI&HT-;#?/"RA[^-3([/_5=UW1C75=>L&44%$D0XB1*5WZ44@@B]=C$B3(A$! M:5*E$XB"%&D1$%!04'H/57I"+]*;H?Z_^V/] MV6./O??::\TYGV?-]JZ9:M1DHY- UJ9'6V0Q(AN60PS\0\FQ;^O#B$LI&B=5 MYE[SNKMW,4!TV,Z#D\=\W0KF[8-F@=FG9X O^,Y@%3Z\?5&X5'I#92[_&$PX M$ VN.3V(*82;$<[+]RU#9>*76DE7L*\E\LQU/U36)W7V_E7 _]#$0EN#PUZ MY]*$$"16!%&);S/B%7Q36[!"Q+J-N?YR$>_MVH@/=]=*17YHDS9OGC2D,Y6. MUQ@&\",RIXF%;;=B5BC+9N8!3N&89A>>!0LA3H,-K^8+; M]K3*)M>/>SB7N 9U:)]^]6ES::-[(CQ0(FKS,TWK5:S6:FBDHF*BC57S1:[W M_H8NLU8(]*:&3+Z\9[P#86"_4[S#N,=]L*U5>R0^*%84%D>D-IT17:GTX!86 MSGOQYN.;IQ=/?!%QL/D$5)4GB(UTM7WAVN,5\ /"DO?=U]9S9@9E>V^]46- M 7U[C9&1XG[?C4T:AS?(+*>I*?BLML-]QY%%NM.9O^UQ/Q[VQ05 M/WHBH3$O.&3>_<:MM".&)_Z>H3K'EP_S@/L)^NA!"$9/_.T =N H?["O390O M;B'Y9OLF5WJ=U3*"0./\Q7(#.(PR['C)K?:^0#FC!$:%V3$RE^E=?Y$/-8BW M3/9'_54R<5J+ER7(DY?K(8:[)8W#%GQ?L9D4*/6U3&C]8- MJ_I>H5LGG[DBUCDXU1%>L'GA:&.F#W=^WSGMH\S-BSO$#\J M^=EE7;EYJBW.X3D%1C&RV]Z)1-/5U?'N!3NO4ZZ]"!%)( F6JX>18SMONP!+%@7D\>);ORC2'K4+*OEJ]G<^]] M?1O HM!I1,: *)L!G L&.3X^6G_+&0+R"A^VL>'[?P\3YO B.&U;+S7>C&1 M\B)))KS%&ABC[>IQ]$931 RKQTBE3?\?GC@U9:<#_VGA]]^XS'RBZV=0C<[' MP(Y:5[B2:G@OIX5MKLYI2[>IGS3":^W-Z0T+T.W@RMT]ISWK(Q>R\/W$X><) M3QR0_!"<7N4STA.TY(G_>^[)UT ISB"O5\IR%!!7 BOYOJ\$;ES[+7TX?>?" MC-H#T)!,(I[C0L"5*Q(21R;\4RFX7N^'42WU-?N:=6C2%>*=5BYA&_9>AE"C MQZY;?5F[R[/PW1.@AB=3Z!M#Z8$;IAL_R_I6(?;"R-TC<3A!;! M;,! F"+VA*<:I)$;D2OCVTW1S?0-U/K["^^6ED(<4;=QZKW7D: MP HQ(\31,ED7^T.VP?BGN*BC$EPJ7V.Q9+LK];WU27]9J](0!6HZK,1&OY_U MGPMY^\HS3H>OPT5]'PE%D_AVB '0. +C8CK;R*+(QK.OBD']@AJL,UG'3ME3 MSGY@VGF"BP=3ZDSU/H4+OJY5 .8Z+<4 \:;TDS=$0&HY1A M\Y&HBICV++.!MAF=F4SS+%+O\%4XB@TZM*-QDUF5AN:U6M!Z87>-OM_[[F ZE([W :F#A> M\@F'FCHUHLI=$G-C_/MY"A1!"K8M7N1PY/YZ M\!"&2W'X;"&D+BS[)]QUIHOSP6:EH+)3:[@,GE/Q$];7YG>![CZH'_J*@[7U MI#>_9R9?(P#![XE.7H4/07 BFMM23H50'DSR^TIEM?L12H:,S^I](<*B!6]? M#!0TO)<_#MDG; *EC,,CE(SR?:NW0)-RU:RHB9]QXV8GQ?5=P4I;,; )BZ]T M_@,2I%TONZ1YZ^",?''9.3)=:AK<7;(40K3YI:,=14>MV7:=1)$NNZN!9.Q^ MT1='>0:X*GP47(.U7;Y?.7?Y 0_<@U#^O)>=FRO<\0I'[$,_NQK$6,.+TQYJ>]:TFX3,== M'&2=;HVLBOJ4W%)I&4%"8PK#6+1;#QRTS;*(ZS[U$R!U&Y5( <0MXO_2H^K_ M";[]NQY5S6> Z'D,'1'Z]T'T::PM:=. (+X'"O7E)VGB0*>=?EO*"W/_NCB/Z\9_\;XZ[0$UJ6"-*\R03,Y!%1TC0)3CM MV?54G9)IY,5;9X"/\':Z8VG4FA\D7>;O:YP@K 3NVQG XN#\HG7;W)YX%I73P(M4 R-$X5^N4.GN?F$0WB=@T1[()ET7U(COL_! 1>G$+=PK_I26Q3' M.O!=/QZ5)+@M)S3A2^L#1X:>;2T)T'5=W(&L0,I>N(]B#8VT7I\!J";2U^R8 MW'Y+W>FU"V[7Z!?7'"J) 68!,8_@.($V+NX1Z;EP+H7&9UY.MN;.P*^#-93Y*"F>$;'OCK&H7:T9FT>%4.08X?#'./C5EM/F[H0PB69B$1["\M$> M*1.VV3Y)>YO'AV8)KS&FR4;;=N7MUJVPM=UY"@AWFEM;-C^$IGJ&C*(N+23' M?,H;"C--Z\;_U$\[]7QZ,+FVT8+5F,3.A4"J3_]5DT^E"O=3#EL&WT3ER0:::K&IM)VUCK6+:869S#22%PQ/?6$F5T M3L&"8X=^H&$"X8N-C.1C=;7CTHPS0'$,;%ZMH7J):KL8TS/O^;2D<7%&B*-F M/U6+!Z\WI))F&/#9;O2M\KI!ZUB^F)F[\XDPG"/U1:GGC(71LP[A0@?QWL-7 M"X:D*NPN@'61&)@(3L_&K!5BVRY:;*T*4*E^.WQOI#$QW-^-2VH M 525)H&%M0W%L%52"0D_JL"9Z'QFFWN:& +Y%0[_*&9\*WHO^[/;0T%$](X+ M3UU-O$.60]:7J/IZ%COK;IZTK%/TQ'*#%"^O.4NEN2891W>17F.Y.VFN1Y=O M!>O],M,)X*G+.SD);9^NKGZJ)QVO)]UKJD*=SP".B CZ#A5#M)A:M'7,VCL(!'PO5^EARP@Z\?F)'W!@(IS&.L_V M1G^9Y4:^L+KR9(6+9?+4KE+_?V0OP_;L?J..&/\S>]F$0-]#>K0W\B^W+,>_ MLI>'2'#8>?8RW;[FV%2Y2N)>.('9]4@_88G,Z7%:TJG>J6UI='0^M.XEEAO3 M[];^4M:BX=14R@'TF(R==.5T14G;0E:?UBB9K#U3,BPEBP]'+I$;?S6B7)&] M V(BWH;P=IR%9UHZI \\6Q%:#2^Q]#4QJQ@]F,HOVCTX&5Z=]8V=N!M';6NK M\OVMTR8<)WB\10]JAC _]]UL^4D[>V,L6W).]0(VLW\MC4KK>:SJ+6[.A@MO M"3ZA _M'"#3F6=VS7S197N!%OH>K%<=D9Z2*_O\BYY#)O9R6OP&&*C+:@V$/OX^?/ M &P;Z70-FG;%]G6AOQ,*QKMXJFNK/W;RZ&UIOI2D5KJAI7 9I0JR=<6)](4> M?D/&877&*C>[FE2+QEMLJE-_KK]\8LKQ@Y?R@O8" !'17^.8K:!88]3'-6.2 MZPD#XUR7+.E8U=AH=W28K3,2)BT1F: '[/E7^CS. '1(<5^[Q8YX<<)]A(-_ M7_I#T6_#CR@.[FLW'\G?K9-0K,7WG*"[=+YFG-@4#?P149$,]17Z]"J;M>+Q M.K&ML5&02H8]15I^&O7M!6YI$18>Q.$0=FR)EF[D0O.P(USBV#N XT M/F5M<_XJCL[4N)YM*I!=[](-G1AB6:T!P=,KP63.:4=W87H3*3#*7?DS1BN, M^?: #Y_DW0^25VL)@ TM0-S>[C8O6?TE8Q A+]):%PZ+T@3&[AFYEC#/EX8V MNKGS?%9^^T13$S$ B4;=@H+Q#WR1S@'M*>T=^8%WA"+G1&37OVY%2NQEP!\H M;'AHRQQ,0&C1):.;)<^"Q)>#N#LM95>^/%>PVJL5&OM9]UMBW]GU#SP(1][! MEZ XQ!*0M<]](7430K-.WZ7>6&3\<4;K#QV7TZ_B).6C2UPAM:<5I"NMY'L9 M&HCY.[M*PHN%YN:N3.M'9P"GR,4)G8I7EY>9:53P(')YAOL&>":[_Z'BNN\N5>,$K7Z+0_,7824S%_^O90?_/J)V%MN=@C5!#O?=SP!9%2:AZ#I8 MLRP=P8[J+>S?A?:0_@^A/=R)T%$A#6.4)&R^$%8*(PCWO=IV_\42>7_SL"@\0)JFY-*:R%E'(=?+*8ATMH/0H2&MRIG%'[+3S%\2?E M:@3? VP?1W!146YP%@.UO&8L=E D$^?0ZRBN]&.W B,=,V7L:4XQ,/^3A^;$/"0.7H M;>$B4@^(I8APWEDKRQP^/3TT<%.8 M-5VL[#M/L"% @*8TI2B,GBWZD%+2_C_"73 M"GX%2);2YI9=0)&EWG%W M(&*8>UY5KG#@%^7=";F" M]<$5TG4HY#>)$JHY3#!8F$)4;)A9I'Z2?>1#[6N?!8CI:KT=3:2^34_6O'=( MXY8WB<4-E%P_ 41=H JX MA!("#]8K#;70]W13:ZS(7 )\98US+%S#8+#P0I:;:@EADSLW)EQRV,GN%+3Y M<*5!!BO%V"I#3-0=H./WTRP(7)HX-I[_+6X!MUT!JB0([# -,>6JH=) M? Y[]L>1%[Z9=FT>-J? MW:YRF'^*RQPX?JM@L-5TDX!F3UPLW5O)IW(AJNSC-<-Q2[S]#D*?A;#.Q*1M MWHVT7-M*_4J:B.G/ MF*KEN9L@9T@8[,)\*HF!CL6A;-;\#- 3TY!N7V\][J>_8Y7^%'!X^Q7R&K$( M-8^PY,%5.*M$S0L'(&CL]RX@8-SP;78T,3ZKZ/89H-RTDA7V6+_9L M4GDVBG0%HV2T:*D9-_RI<,P@99+>X2=AN[KWF XG""$P^:,78C\$SH,O;%QP M9;9XQ:EVQ*"S3FVR2K,$5UJ[96?',[^(DE"=345%U6:G&"C%<$M)2?0P>&@? M2K_-0XR4-Y0D78:+R 1"?(BOX8N/Y9>B?1B72&40K>([E\J?-TQM=*I3/N__ MV/+/ 57W^0$5I R"T9N;N$]B#YFW$,Y_4(;+;.-U]7K8RO88Y',=MIZ2D)89 MH'*%#?$--)^8C@&?O!H5(?'[#H#ME^",]HJ!O=#:^>*I_'7XR2LZA9/3US*G M?*RNKO7#2+E(J5 CHG'"D#+$9VH9IH[C7.A[= FTW=LBFR]CK[[+UCBU-0>^ MZRB0@90FQ?\=T/@T_ME[;*)5HE7P-65S::Y/-/IZINE72.-S&"UGN4Z/6=^H MA7K5'QO[4GHJ<8)3UAZ="2MQZ;QPI1<_>"A*WT#28(SGZ3[S Q]XAPC@C(V; M8MG785YNJ<:JQ&6K1*\S@(,VU6\4M Z65M5'T,+I+PQ$S7*FZF#%HG(W61AL M3DR>%+T#S)H= M+!C&\ZKNF)(2]^;:4#A>< MIJD;UA&O&"%1$&;2?'7;:BVF/&\M(D=EP/T]1ON:H;X&BRRH>?:&/CJ+WYX. M5VT:8[:2>L$E^N$RT^O G]7MQ;?$X[!7VT6KO.$J)[E+VKFYVA2MK9VQLN!Q,9D+Y/05X]:)^*%J/C%/#REWUI;.W1);S\KRR@S3** MLA$+VE;&GAQ2R;T74W?X8 IL,&I"W4F7L&^77U@'#/,2 M9YJF]IR1Q3_Y_)5Z^X7#Y[2:EN X*]&UP4X@7%M\;C=8(FLZ.OCZM:, M]*UO4A+^TJX:A]44P6AX#:Z$Q>RR(>*%Y,G$4CXE,M0,X4S608SM'=,F@\#2 M@2V.$A*:2S1V;^-^C'BSL>09(&?COFQ5,]7G%UVM$CO3[V]]_58P9QC4=P; M:' RME2SU"6W/3<@,0A7W2&K&9'CAS99WG[7>3X% $)&Z2$N.*=6;Q7ZH>*# M&;%^-+BL*EK]4F/#2_D%_2$C0P#@@'FOMIK90-^S- 5)9,W]@D\/G[VX:&O& M-DWT:'?\_FV*_&5FO"NUYLTJ="-0R@5GD,9P,7?Y2.4XP^PD->Y9W&4FNN^< M)X?%&5/)7A?W^SA93TR:?NDA7\%,]3-IGACF%ZK;QT_P#GX\K\S$UQPIH?%& M'0!-/0]*(GX#+;@']Q>BWUNC$W87[:>7M-D T_WFGX21:6B8%_''ZXBB2L$8[86UQY6C(G= M*?OH@7Q:?PEP!KC!20F[P;XD<\I*92Z1&HB*X(:DJG0"W\0#GLTJTSJJXY*$)1D_Z?A6MI;WST MEJN,U5>)=NK0I'$ZO$JB[L%0DF[ @NO"8\2+C^9P=5!S%GRWPQ6A1G_7A%X7 M1422T]1 V9Q)BP[$X4\CY,0E"+( IH4YNU\2>FKR'BA=;^IDM[$%K[H=U?7. M$$;=KD#%M"BE*H_HJ@8-YK6KFUZZ.*^ONAHRK0'UE8F6&KC[8-ZC5%5=DWX,P!M59MW5V8E<-S*6ZW.65%!M66&UG"J61WB!ZUJ1#Q!OR M>QP[!O#NOM>,?("5TUQ4#T1?\942W/%T4',,U0>^$7$ERD6G;OU?19->47/F M7?'X@E-$A:5WO:QQ V]QK(KI]%9+B@S! MN3*""GSQ^@YDS7-J"@Q$S !US 00W>#=IG]"KVM.35;/&P(9&4%-,6ND1L09 MX$#8G\@UU0==(.\M(#&&CUB,9#8M@?,V! E@EOO<<[_$CGVSH!"YA H/&KM] M,',SY*TVUT_-R# @.TTB9U(!J:!S#2E@4_,5'2[!IG3++V?8P6.$'_AF$TF.V("+$)0P(26,O/&9[N(AFH^.[P;L,K_)$8KBH'%U?Y)8C+ MMPK! A:H]&;0=4UW&&6+/ -4 2XV$=_+B$_ -4>5M!>[%N#M9ENZ M+C^[%E5SID)J.DRUC7U>9)=J<3!1_D;N*_?^T:02R,]9+HKWF3L )1*$YZ-G MH>IJ56:2[P5[4I[&.PA[CKG,Q!T>,NE#DM)G5/]Q#:D_'HF=$=X3)EV]((%_ M-6='>I>$PLL$U4NL(L7)*_PCJ*FN/F<]\$O9"M9&/QV]%S#]B_ MT4A9_171/RU!\2GN:Q[5[$*#K9**A$YAN4/A@>8R4LJ-)"ZSL*[?K/[+/3XQ M:5LXUW9LL^S$*]8#!O0G7B0_^\:4W*0*O]:O/HYK$D;U#"J_M0B2( D([Q]8 M&:@=0>_[P3,5%IXF8AX_)3?ML.OJ0MER>^FCJ2CY]6Q?M,Y,*: M",#FQ]?Z[K0]Z41G"ACD9/OP##OGQ)N8-;H$4@Q'"B#ZX-O',Q9I6I! M5L6FSM\E:5^7$Z,@V:&X Y2$-U!?&M@(VGJGA0U_7D0!41,>_K7O."[T=7"J M($!JT7?DG>0L3PO^EHVS#*;;)7VCX0OA4%R4* "2.$",BT^&DZ[ ,<=',4F; M!F%C#1*+3M'UCC?]WU;4D@0S%GC6XC70RI-(3AS9/E[\A$-@^LE[4&1;R2JG MPZ-\7(N[YNK&8'=(NHTX 7O*1_7AWN?0W9ZDY^E_CD!PW\+FKV< P=1$-L71 M4QW!:E>9NL"#LCU\R8AYVBU<]B*$JJULG>LNNK(&+6]^_^0%I;*O,=,N*U0< M*])O?^EXP_BQFB] MLH91L=2=5N>KNG=.A8*=)D@,Y!\LC[P'-:N%;Y$8ZP:WEJ'*LQ6DL#+X,9M? M$6CFH<5^FY4;MB$K ZFUV[*BL.-D$!^CF,@UI4TD(NU"=Y9.T2/II;L$QJ@V M8.7.#^>2S:&!'S@^6;JU.N=T \!>:XN=_=O2W1*5(MPZ.:PX0596]*B)7I1*DQ$;)=?8 MGE\ULWK[<(LK86X9_D>#.N8^U(^U^V<')60S-8Z5HV01(36A*>,3ZU M7O?X&W7D["SS9%G> @=02OR+ M+R[9YY?W]@XU0E>T3_C%QIL1?R_P*RB$W4W%O.TSV"HF)@O)7KQX!C": 0X\ MOC'?JD1!])7%FR(P#_";5N N M#FV _1?_Y?)VGQ20F M5\S4&Y8Y3E)>1%Q^0\AQ,;R]:?!GL61[M1K<6 )MS]J42^,UC#ZNU]3^9?N)X% M2*3*K4=#FR0NM+2L)?JWY-3.0<A*W M8L]4+M53NH+'VH2A/W7H[7"L@:6F+B+"4FR*F\6*)5OD=CPU-W7KREHNV''^ ML#@(WU87\MS1I#HE= 0S8M$[W#5G_%+/Z-?RRSIQ*@(OUJY-PV@0*H=P4JV? M>*;K1K48Z7N<(8T931S6A_ P2YC^MN)][)&O?Z#7C8I7&)88R::]-YMX"&Q& MX7@@[:X1Q_>0%4ZV\T19-?:5QD]Z[M7$SYG\JT<>WQ319 FJ !(8N1=VMY;> MN!8H-Z3Q847KA7-^Y G85EO%OHR 1FA(LNVX^/X M?A:,78240[Y)2":X**MH>[G:M6JK8> CS&H7QQM6A?Q=;I@%K<&L+'*2X#@(W .=GY)I4.*J&/0.$G:XI=D@PL6 TN&-Y M. $7*H=8I$^,#/UI#/J" KZ\&L-6K.8=_$GJ(B'G2RAZ?%VO;96Z-\RUR]6? M 7B7WX7!;I[GR<6= 7CH_I4G-VTRU;D**O8] VQ7XR4?XDV@-"C,8-+]YX_9 M6?;U:CY!/TY_O_.F^<34]./'*Q3=@+C(Z%SZF_)Y1FG=&Y[N.^>03.(?2);S MC0S)&$Q624+G;KFLUV> :JJW1@^E G,62JF>B/+QD ",!\RA2_#Q@,6YMU!U MOE2_>2#CNJ%LDA 21]+[XR835*I^_^ MSR(8.X;JPIJ1?,CU7+4GAJO9_ *5\5%Z&]LE*4!H[G^'9=< ;I!*NJ9O=$>1 M.-M\7PBD:K]8//.$!W+XLQQ>*V*'>P[F+EN^%:Q*,"/^0%[8G*NP:]?3;9D\ M"' 1?8SW:UF\WW7E/A_XZ-GU;ZJ7P+?1.QO!YAC$96(]ZB41=%2+>^V\N"?2 MH)\=EJS=Z!YJK/SRXUMP$@XPSY!U&;!$M2X?H.BK@^S/)$Y7[P6> 7H)KNV( MZU9M;.+%"W>1%7H.Q)4QD$HOP=JX)6X3X@AK9@V2WJBCZVC4;1952K#WGTF8 M*^(M+[70,%G3G_*P->?4RYQ(E8)7"?K$(]SZ' &>*$<,&^)"%R"WS0_ ]AMRB6A7I:.5!?%.-,+#?"$ M:E-,.;[]OJ*QM>>F4J_2:<4;$N\!_F*? +:$+\.4<"8MM23@!X'1&,$1?9]4 MA^R> H>?=0?/P342T294V.,C&&9@^P[F=*TU3:#,O% !Z9L%27(RU5#KX3@# M7(W&!U^YR,S#M>^RI'KB;[)RL*'S]=/WK=^]I/F.%WDO\W3I(H(_\12-F.B! MN+%11TW$MTI6>(&-9%:/9CXRSGD]M7$T]/6O*TVZ[]GW4K\/"$RPO5[1#'&O M(!:0@JLX%3DM?^D&1%C75'^AT>;(LXW3:K[(1:U,+;,'VCXOZ.N' ;4+?S@4 MIQ[@#SYTT/:.I"9L7C%'W(NGL4,P#WB76L M$D5!KHBEJIA]HQ]'A:5VX\T];Y"P:O=)@:Y3;9%+DI-?5IA]O]'2RZ+<\5BG M/Z"H=(PN(AIXE3=)'7.*2^I02J_\L^\W 3QLVTX _<4]C0[US6PZ77N'0 Z4 MV)_FP-W/ $J(8IYJ6'>3S*&G>XWC!B8EN9= >6^A84TXO^=#IKS,\O")G M\8W]>.&1G)*UGS]@$6Z-OE"+2B86."C(9&2&@5-^D2):3)-#SJ7.C>(IABU68Y4O]@17/>NO/<.Y5I7K&Q0K_X%;M21Y>/LH., M#S2!*BZG<&/Z8UB/WD@&L[M,L*YNG0[ MG84;YS[(K^19-DW+FL@OO0DK,#++0X2J[."KCB_>*RYW-J+Y_H+B\<.4"P9O MVZ&Q:P=,+S.*SH,&OO^+R0$RSX-3N06LNK(SW@I714L&_LD\ R =JP;"BER] M3WY[CS@K<"P:3QUT%2Z1*!]T'10PM,S 5C[!CIORC5A M=04@FO@$MZP5_EKW3&J"X-5("76F& MC=-1KDN.MF(+2DJ(J,<1^53[.?S[ M0=[3(P65K;CJH8+7JZEZ+@*CT551=R#)IP;5+Q-0^R4<2ZAMB@7XQ%R3G.5M MK$KVM9@B[M=:U XE6=NW'+[6 U4';>(!/,\5/;Y^NETRV[7:82VP(/ +>5?G M7F2]\P1/P\0*"&,@/OD^J!]4L;(L*WFM\$AB.O M#1\HRP(KQM>-R\S,.T#!T@\B08!+4"FR=-L0DWF&I6,>+GJ7.:UTYPN;VK>H M[E,_##K5)^$%C)3=8B;"@D@ !68L5/^S$ YN2[73N;\!T_1E;-[[M1?^^26W M8^+6V+&^>2">V/9)7QU:BR_])Z5KA*%LQ60O]U([TQ/A\V!EMO_,]R)O$&I" MS;&=(\F(3Q#Y7/&=0':IB?C"W'5<*AB7N*BG^13+6_)C(4;M*L]0IT;[ MX0Y>5K'CNVHN+"\'$PUN^ED:>.!)EAF1E\^+O_T]Z%,$OE\NTB6.$?*$$W0* M?R:]XTGZ)W4"\#VF)5+@0D/2C9[CC CR;G92(-!E_MKHRQG?@=1!WR^MMSLY MN_HK>A,=B5F_>]?RW_\ Q5XA1'K7B6:_#["J#K[7R&Q-0S4OM.Q>@)B!_$K> M]BOWT->M8.E?CJPIUEIA 1F3"@W55B_-Z;B(Z*AN(%1T#OD039]$+VJ+_ M!-%0J+)G1 (*1=_+ ?W9IC:J0@(PJ2VG,:UZ[@O$FPZIN_<$SP.X\L4;+XMIPOUXRDBI71CF>A4]<$ M3Q@[%\'#;1"3B*77,K']AIOGMY/CIOK*3_VO:-L<.?3")B*SJ>VC> MN.8THV/ZTF!,/VA#'"\$."IQ95K8)R ;!8=Z,*.F?L;":(Y@XP%'H#&0$SSRXX2?#PN2?>2;[=CNF*_6?CHO1VXJ MORIQ*.GVNY#?I%_GD4B<08/H(Y_3]NR!]P2A-JE92S7CU17%139SVC<=G*6? M%3C**DDYT!LXY@74Q&:3+/(6IOV]M[%LYALY4S&;IFL\,6,SI9+@[Y0 @!+M M?H3#4$BVZJSKSQ[2E5-$*.G&DI3((RG:X>M,=T-KTPO%!1N3AO9J"P6%&IZ&*!:GI='$$E__H'?Z9#E'B-OLIC, FW?WLL,4 M+T?UZU=%E18?MKTE56T :5'6B# 0U<[=&LQQB/1]CIK'3_],?2AA7!=>Z5Q3 M9\X19K74&4Z%R7K8L%\W?VPYG,:5DNQ%G7L\?G 0\[*EH !1^@-YR&02&Q3% M%%\._$?7_[N1=T087RM1Q+\B6P.=_U*FXM\-#OI?03Q!E1O_D>WV_S(N_UC# M7/[V7[3L_V50G$W\#U!+ P04 " "QA$E4[99L.)=" !(10 % '9R M='@M,C R,3$R,S%?9S0N:G!GK+MG7!/1V_[+W:?W9,Y MR7S.S)G/7'/.];N^5TY"GB(O I?UM'2U "HJ*N IY060EP 5S4 7)P P, !$ M 0"X"% ;7P:H*'M4_]Z,68#S__8!@(/%^,K_[%,^ ?(LFH;V BWMOWKQ$OVEBQ?I+M+2TC'2T=$S4 KM)29F1@:F?_O_+O*O M^[]>E(WA(NU%AO_7A=P&L%P$2JEBJ:D$@',L5-0L5.0N $2Y5QJJ_Q3@OPK5 M.>KS-!WL)L-H0=GGK\(NT5WEX.3BOGE+2%A$5$Y>05%)6>7^ TTM M;1U=/5,S;E _YL2-7 MSCUB@Y]-EZV:N?BQ.5%!N:,DT?NO5ODT58GV@-8<-V$9QT$&: 4)DKA^O)8+ MB2ZC W;KMUSH*Z+<'UG;IE0.[53M2US9[,H17.]XPC7^=%YC2#CI[1IZS^W9 M :%RY1<8S];\-FK/M"R=]C&1W?ANV]RO.US7?*8L/<0DNI8*.2W#8U+GG<9O M'XO4?"WWR3<=,!OWF^5C85NPLYY^SS0F^[,R4B-N%]9 MGN>L23^7&G%'DYFSEZKYSVI<_FUU:DEH[=,@7E_:W!1>>^H)W0KNWU@? M+T.L__?,E*PH8ZT7Q9>--;D^GXL6_O^E7LC69+@CS[M7>>_7'S:G9AL]W'#I MW\:W56HQ/N<394]-F!LO#;)'W1AMX$_!0,U[E0.8!V.E3VIMI@M"K"?=/=V# M(;^/OG&90QT<-F?_U!$]0CQ6HC=(H@3%4=AMJ#2&X^UQ]B,# M+- '(WZ>YW$!9E$FD3SZ(M?'Y*_3O[\BPE[->SW]SO.*#0_OL+N0<>8/(+HR MDCQ49HP@&R+X4;-(X&T6A\]=@6^^7DJ#7%K_*6[TV#K,UUHT'@O#7"W]'/2^ MV*:;N^Q'$^(/MZ;E1V9S$\,0OUV(,*QC@4?-I83T.]@C1:.V=%O%HZ@ZM(ZG M*5V2G=W>^4I8U^[UL /IS)4&9!WR?<_Z[;,_+J6CLP_J)K\4Z(V+20:UQ#\A M(E!/>>+#(6P2!-TR-__&<))_R@XR!;:?O23^FAR MH"UR9H:Z#[Y@OL]97UI-UJC. M.X"&I' "G@3VT96 7OBLFR[.&T/=91(X>Q?CU[(M7G_5Z[Y"DMS5@[GWYLL? M=+4.8AUY1.F+;1LZV0Z:/<",:MVU_.YE:.23@D;IA%-TS5)-R$7CX^O[B M!E9QT;E;%1*70]-\?<6-)ZALAV";.[UM@?[I(R@]UY8D*LWK0 O@HT\55P(( MEWD6.7I1,TSXY5O%GLNE].7/C[:XLY,*7468,HH&?UEK^TG+E:Y+B\^;%J1WVW7[P\(JJ[S;X(:YI\R#'!;,S'KIKS06RK?Y=#9TL_E:\<^TS^W3YB M;\=EK*QZ[\7KO\E75YO6&B=P%!.\CY #N/#8JEB$VM16GWZ^117LO=O)] 56 MR:[GMD7=*(VH7V]3[>>B>)%,_[6I]]DHQ/;C+O] MOZ^\_UT9@?M>V;Y,47GG&*&S<">L8K7-#X4^^BJ6S;OMR *C<\VH%:'.(.?& M)(O*#SD!BBQ%J_:XUR1X3@68!8.,\.;*AAAQ1<0D%]7[UJ_Y-^F7E[4^/(OC M^'7]7DVQF;]);0Z"#*AFNV2-URX-\;MFLSM>K3=:8SYU%!K@(JC"..5C?738 MHX))C]K6E9H9/=TCBD5];*QJR #U$?>8R$2\Q /$X=@QDI'@]FTR;2>XAMYS M@YI'EO%W@]KEZ4UFPU?J!K[\3#C[)230[ZT1]7GS[&$:]"?6_SV]CLIB"O4: M=E.LO2EDLI1 CX$B/B0C'#L]$L<#'NBN%MX#4\>WO9E!%1 D,39? VR!F*5J0.]&7IC@ M KI8Y NZ4XO,\YKOQ[Z.2@H/3_B9R1M&A50AQE%<(!MR#NPHH;?=#;Y$N%GP M]\3ZB-]XW'Y,:"QKM]_C8#G117":ZYK#=9XZR9T4SD,P3CB^;9\3U[L,RRG_ MJV)1C'3Y\#2U)/61?.=,8U,JS>4K5'-,.T\SXSI:X%A&G!N2((*[.M$J$.FF M&M-_ZGF]+@45Y,8JZ,H>A4[\.5!?M^?U2NS,-2 O;#W"TL63[0A6VO_K--1< M5<3S]_$"2V#N4,?$A>4#\VB-:/#[^,]\ T&%[V'J=@L7XA]&O)PL3+_&>/V, MN1%LO0&['EAGQ(%+=*D'5??HW6D)8R(#II-D8/SQ_7!(#S1@&6L?W6W6X6B* M]7T^8P)A*Y_ YY\]QC<71FYV((K?/1D)GMYI+I\<7(O9U=LPS_K:B+#*]RB8 MJBR9;2GVSCYVUAW>JYT=JZN.^)IJM&0\.I?=.3>YC(D3XH&DV/D)$F;=B;MS M9_!7R9([B:>"_CG5I,Q)_NN-C;/XAFO3.?Y/M3>_M@0RT'6@.<+ST)"HE7K& M5B?5-?B^]!&6C\;3!S(WS^=U_##C1D$X$K,M(CG0-+M:EGYJZ!T;)\0A6CGK MN!E!*Q MC&Q4^_;_W8^$@<\?.J*%%[R4(6Q0T1'HP]T;FMB0R(V!J#5!?%S4 MP5!+$&TWBKD3_=JZO\CN/M9F^J&Q#EMX P.A,Y,9NO(7\H#UKYTRWG:3NJM1 M(XG*W+WJ!X'(!KV& L# M%8U3;-S$Q4M"+RW"56;4)'Q '%]MC**X\T<4IE9B9:5WJ,\9P+V\)5Q&?TK+ MBQ#T,F>.U_S!HNV:^BP7^YTFU^,9RH98 E$&Z#)59$5>Q+N?O2?Y\-PXH\D" M+^[)KC]NW:QR*@[PZ8G\CX(]?S.#-W))O/'6\7=QSR2.VQ$KOQ!63-:ZG-72 MQX*'D+8CM%@&HKF\HM_G^,1X]H]&)CJJ#55GT^E7_(20>,TQFK]!+;:2= Y %3U7IVUZSZUDY:6>91=BON(T3P)M#+!U\3FXB^7\Q\3.#B@H:>WQ M"_.V$3T3W4-UA[VF%LO^^P>9G3)=R[?&K5Q"ZR!>&$TVRYGL%\::;,#_?KWP MFDM/4XZ!#%@?@F=IEW?)0!M\NJD[6VQD*=I 6[?FS\N;:^?C?D;_4HT09U)= M8?D!1X)2V! M37LYLA3_"!>@CY%Z+]FLF8=#'+_T**^X$7MQYLG;1)D2!?973!QK8@EQ;V'% M\9E.38=J515TN87FA7ZAS&F+V4IM&(TK@ MW;T0T1V$W&5Y,>#R=8X,G/? D,2I0&>7D __/FZ51<_!I-#$[B1HV8IT)<@[ MZCXIA/N47[G/.<,A,)91*MJX\=#;I>#0M?=+RG(JB)VN:EH]E#_^4",P]>+> MI%O%UC!.?TG5#U>:/Z>%DGO5])3YS&FBZ^[#NN_-?LTR MZGM#6(Z&U;NP[4M2[3DISQQ=?\/<#C7L1Z#7W;Y*_;%PG8B[71H!::,+N&L; MT&%T3G=9W4FU+T^@9_SDBO85I54JPM#:/"KL0#R'/6/]4?NST:2D^D1;FP,= MHAM7=&'DYZTA1]PI=,@.32Q]_,+_8STCKW#AU&L:.UK&NU2:(ISKJ-\/Y=FU MDETDV#M48W*#1E BOU=(5.K]D2*5$NP*>/B'1RR][7H4^&_'-X0R$ MWXW7G$#:5UO5#,OY6''QBC9Y!EP1%O0 1'ITCC12646ZED7T6H3GA7&9^"Z& M-*'>T7[O\2#7L=J4#%U%AUF]?M,C+V.=^!9V5+.LOIT+=C:"S?@.S7^JB>Q; MWH\:-<#GYQDG6J)9ZRWVA>QXS;4RU;@+I^8!H3*N-J'WZ(O&\Q"*%EPTCR_# MDD]OML3"*G5;S6_"30;8+OS(=S;C>LX6@M":W))@&TMP (F)A3*JO#8\^_P? MX8T=M7:P:'>D_8TXOYJZ4O2U)CI<_"?*])Y.%7-*2FODZW7+;_;N/!^N.]Y- MBCA#]$RT7MO4X$VW'Y//DORII29^HLNEKBK-GW?(;ASCT<=EUF5:6*Y[+G0)B&;;CFA1GIBI MW1M.B3HKYN<3!UX#6P82'2:ZMHG4I &5[WC/]_-\C2B%;]N-:FEW4FZ7KSH] MC,OS\.GVZ%5Y*%-6?J1!^7@J&6@Q)0-7",.+WFF$=]ZHXZU" M4N+0S_VI4I+AY-(",:H@KLZ^NM[92G MVD5R].EV/>!H-=9"7"-C?>I2EG:?:%8%ZCZ1F3UF"?16.O!^EWX(XVJB0)Y0 MZJ;L$/X.&=#;D8UV4^DEZ(%YG5H#V#N"#,5X&#K*.1LK78K%"OUJ=]T(@PWK M[']'?),7Q$;^@*]H<97,E(=MJ?AB3WLS/_"'REPL&[!9UHXZXD'>PMN,O%PG MK4ZZ\, >A%NG(K)J"7KH)_=E%*\GM%]H#:L#S9AZ%=4DUI0U56J_/UV006I?&3$T)16@5+._>OU/[^\AF MJF(5SWM@)+&?VMXA+/S%_%V[T[4WF2+(D9W#A %I)RL>JN2$*>XC=%"/$+V6 MF7 +*'4^JL.;.2KHEL^GD0'IWQX%JC==K.2R1MS*,_YZRNA,.KBB_G 6&O\V MA8X/*DJ&RMH].PF6H/WW%<$S3;9'M$*8I.6]*+34TF#Q,I+%-C1>?R1WX0;5 M]_SG7D4Q!,-?]]YLA3 @"%^(A>#%0A1+*]CUQ.+,H]AOD0PP>@C0\\F8LNVE MKPQD>>UT^=&9J[JK&[7 VWU(-_YHJ=$O*64E#M[7*'Z%ZKQ1,4699:WW^\E M*-T2?)&"R54G43"9P-DN?E',S0\5I;01A$]E+RO8U#2@&9]^;@:Z1W\65N9Z MY9URH756J'T)W<#Q:?G&KS/)F6GH+/@3],&R^(K&2Z-S=0 M5UME;5-Z"I)ZL7 >=@WZH)8T-DJXOL+XBJ<,/+-[5!I3D*;.='R/R7M2O426 M#%R:; LUAJ^^1-MBE$U)"85Z1O5_7D[N/[#PGGW-SF+)"4B88)@C:E!7_\JZ MG'W-<2ZRFI.<=M^[;O7\8[#,MVOQ15^\PSU&[[VZV&[-XPC2+SLYZ$5 10N1(C M5HW].D:2@OU88":8+F;L&AF@4=%(IQ@3,Q^&CL=C$?4?D>Y]TC>4W*.#.&^, M:2C!V_E@/ 3#"3 EMU4_"=L3?#E$\^[*C/Z0X(,%+^SI16/BS)$4#ZD3QON= M&"NE<>4%/J\VNVFU@4:9QN9GVO6J0+)$F+X MGQ,6^^XUP9N^C@10+]O!G+_IIV7EOXV>T_V(@U<&2N(OV1[= ;UBN('X%@+. A&%QC072>> M;5C]HNK'Z[V#FR#QA*2M1%I(R9BWDUWQ6-PMQ(@U&((3GFWC%R^.;A__@4GT M*.#P"SVUJ;;>SB,,KE-P_B,X-Y:BBVX3V1QHXGI!J)Q_73"4V5NMPJLR5^1Y M[Q1@M 1Y!^$A ZY#'(3GN/'BP+;MQO'8$=N:QE?W@P0AT[\C-7/*!.%!H[#D &Z:JRC)_/,P-H63#%GAXX=O3P-,(T4I% M? VCAG<^@(UI\ U77#^LR=(PVC5X*+-G>EZ0[\/.GKT1CB]TB'')9;ACK-?" MVLU3$S5_!$YM=AV2#HH+>;N466>$P+RJ=IM/LFAIDH YC^2@S4!Q_"HC8*>< M<&OW]8*@K_.X:GVW >B=AU>,O-D4\O/<>SB@@WJ^/^R4V(U(EZ3PYG.!U)V0 MRS^ C^):6=&2X>6!AY :=&NTI*0DX7X 8[-_9>MX0W+EXQ/_-DE#(^!*(%); MLFVXVU$!86SB7C\S0$* ;O;P&GQ:A8:(_$XNT&CQ^ M:)^>#X4*Q=Y+$#8>7=D;MJWIX-0_K[I_KDQF3FX'[+A1P)*$SMFI7(K1?R^^ MZQ?/J<_I-F#MP#3\O<<$Z#SQ#M^D\B@+ICJBMKFU\!U$/!"CZ(R5UY3VCI=O MFNAV*!F@)V[,]K9#-]3CL5&75V;*U8-,&C^<>:1F)=:GX]C1A\O(]QJLVRY% M@I]NGG5!KM2\) W07VUTKTL9;/\($4'E5K5L;K!$H]&J]15YG4QZR5 MN:O7KEX4X(ZARKD%?:JP\U3Y-'DEZ[OIJ5BNFW74FV93MR*K/N]"UT;-D2'Z MUQ;Z+GE/[[9OWF>*&FEY+,X?$)5DO(; C_Y%F@V]14I>0P\I%G*-^WF-3LP< M] F55'N,V,R3@6"P!YIZTTZ1' MB7'>B-.E?N$Y(/4NAPJD;CL R\Y+,VSD= MS*])+#B6I7='\72;%MP&B"(&@7B9A]H8U)I#3W(NL^FNYFV4Z9Y,#5.^9CZ+NTL:#[D PR@#8C SBAP21T M[YVD9?";G>>COC7I-R9\I[2F)$Z^F67?W"QY7%+%=&'M&E5CXVU>S:B>@6>5 M/ H&="B(_XT.G8[ M*L<-$9?YW[>0@1M M>/-ZY<96R_(#@/.M^,O;$QJLPQZU$GI;\S][>FXA0M[/:?,*YXG_ZGT-FS.QCAZ*_-I0A>9+;F:R3[)*,+JBI_*NG4MGJ%IQX'6VI&F* M><_X6F2"3>L"VF@4AX__]D0Z##O>LE6%$I0J#5UP:$0ET0IXF-$6<]9(N#I<%-ED3LXYU MU305"OSR*G)--5,Q_:FQPEB_N:^Z"M_L$]@+25=&@W"Z[BFDL0Q MCLT3,)KJ-.DN'U[$;/$:V_'EL-N#RD*BS7N.1!!N'V-_GY@$H]K*OI8XP1,* M[L3&L&)MK\ :7Y0=<6'6$AI4\AV^F>TNCID2:!7*[&S8#KL^)A-OO7E!R-I]0,PWE M"I&XQ>5?-W\GU6*C/_X&5[N3,AT39_POJ;B<>D@W\PS(-*'6\PK$VN7P2O%7 ME[B)NB]&FJ*%,J$.XJ';,9B #O"[4)N-1:\@'MZYYH9;'*Q^"7 03PGK9 M[,&BL24E1P 5I&2A$D1@S>A8J 9%[M1*6(^,/L%TE=QL&!,TDE&]U7O6Y-6Y M9K[JV>;?UT=-UY+=2Y/T*+94.[N45+.3YK.!JL'%=T$'OX*D2C:?%K=8-UK\ M#9%;$YK!:J]AW^.%H8:86XAZ"S S 2+?Q-A_;>2K^4?^+3U"YYQ3M;L\B)\T MV"H(D31BQX',VY*>'=:_C$?F\^R_209AT(\J2T6 DGA5'/N1I^IEH=AE:2%ZE^WCG$PG\SN!NZ#$7B"T M@(UF=EO@3=R6UN/09_@ W*0=NG[';T7"IWW2@+^8,5J?9OS[W/ =!R.5!\]^ ME]W28E!YRHM!$-J)S6![MX4I_'*9O_20_$ED;43(!X$]S=.?Q3S+'^,8$O:> M)+QN3_DF] M=?;'C>/[@=".-]YJ>Z'ZI'>7P[IIHE:DQJ:_(-PJ+"0J47G1)RHA.2GUX3YM MA257^S72Q%V9(3J=LK(RF8OJ+:7H'&PZ3L@/KP;UQ7"$[TW<0]B.AJ9J;ZLW M$="HKP]??N^]GS"#,D$MIH'YRT.: M[7QV&5*;;7'))%:ZQC]8U3^X\(SVC9KF^XX5S!/93WV'W=\U%:L-1_2(1_X' MSB/)Q@BQI:$M 870=%=""&5$/I+&9PI[XF=LK&I&Y4LWFQ67TN.R[!E8J[I& MM+NJGQER(0S:%'W--MC/=/%^!!ADNA_K@F%"\?8SEXOQB?N^B*G(9YM\EB*B]%SH^9?2)\'=><-7ZZ[2J9TM)P MK8CN\K&3L"0=D@MF^[WTE>+(I5_GW(F90G#IN!SU[[HE[YMT*WM'[KT_/H10F[9.A>GA1"GM%AJW/8RDAXV MJ<%R<-QB$NBW:R!>>]&Y,>A&DR[,0O+2Z:>KN_(/G>T=ZU3,VDI[8NBH9L2>-;ISL+@Q,!F[!FV 2*_=@S G0Q M]HSV8^OUB6-Z=0[]Q*6 ^Y[J8W_I?JPTW.FN_)T"H V@Q7F0+>O"77K%-T=( MUL#O4'/&W8'&[?)EM[Z*W!?7KQ!+W)39'K=4ODKX9.;1Z9WI$)J!J5]BC^\% M1ZI$11Y?JI"P;[F(L;6IFRY;_S"A\S46ZY!@'E4A_1MQNG>"U<'EE?9[VM\D M V]V/,J/K>2?+>/O!\I?]T*?,JM,8ZZH=G<*93[O&QR\H.$F57Z/;28%64$& MQ,!RM;^)]3$'UIVJTZ\F\+9JPY7^]N=[] M[4ZJPJ:@[4#[4OAE[TZIG?IH@EAAX$KG),*PW-FSR*7QK0%C=\T/?N6$2+IO M\J?[^(?P]JN>>6,5?I!([JSFNBII[]PM$_9 ^'2T1P!3FVX8L#8U.>/PO?5J MH%&1O9PMSW3I@MV K_.A]GL[T$:R[-!Q:>2^*$)9TR9=KMPW^V\Y]_@IZ#'T M$A$%NTH(K8^0BV>ULG(U!9BRBF_7-C' WXIEZFB7.4:UA-S3J7I55OXWFG = M5XJ7"\0O1G3%+",O;5L_],Z4_Y6ZKF\"GTZ7Y8$QN)DNDH'=#QBQ1;6/9*!# M<871;F+B,E"5#:FU=N=[*^.A.?2PB';.V_JYDF&6YE!X">)P/'2;$/<$V;MC MQ^3&V!4HHJ4?P%-X&%M^2HB?&XRYRZ5FV0&O\B1,[\N35_I__ZD\RLUTZM&V&.#>\=/H2+Q88Q&T.$XOJWEX3Z MK!5VI\]D3P:YEG>0X$ZBLWA1?F-Y?HY3=NFD\V]",<7[VDD#N^CJE2X[Z=%= M0@NHYW7?K>Z.SN#7EZB.#CG<5H\]94=:6$D7T_#WB:EDP [G5F1T,,B$S(_T MB+U=W:.!NO$:_/<+LASN 9^>!\^X87TGH6!>Z;[23M!L39K]AS3C,%/:ND5K MF1#Q2!0?C %J.-9*!77X33!VYJW?_P$8?F2^=E$ M)8%E>1OT3H-YY'A P;%A]-CM,5*B '0PHLRFDM/%TOT*7!O0$PAWWI\^[.87 M_UB8]77Z6XW6JBXEJC9%Z!S)R%!ORH18MH_FB8R;)9YDU#9CP2655BETG"+V M!3?[.+]#"A);2"N'M"2ZOZ.KKF9Q[PV_C7D2@E$AM4 M8UQ#G?!\N!GL)ICD:G=S[*I0.LG)=C?]EL>JZ)[/SE>4'X%V<1L416(8\950 M -TP&I$0J*F/A9_W_FP.^LA^PJMIK?203XU&HQ@R#,\8(]FC Z1*Q,'+$^G)Q'P=HY6WED<$IO;.E%A;P5> MXAK)MH&^.3"0%7^&VI].A@FT2)'H>_SG"1)8@W\]5"F)J2P92/R^XHFGN4L& M\@Q_X?*Z\B=RZ6)\M:4?>OOVUK"43,E"*:JD#A: K MF+$(=!8J#NR,XOYK205M^G-U3\ [*^HG]/8);<*>6+,'[ M2Z'PQSD_6IG(P(\8#@] M]B#?\?(Q_I=LS4TD3BB P!J,Q[X;=X?:+.-==J#T'LLZSU_V2M;]A&V=/+X+ MDD7;["&5'4_OF_U&RAE5$^L&MX9V'TG\XH<:@+)80Z+8QQA$KL5> -PSM()@ M5/?/U6R=(<&6"U_6T8P/I:YZOZQ4,U8=G'S+76-C7;1=I6_6>!Q*RAGV#8$P MNRC4*2B@IZ>GN[YUGA>^$2=H'&%NW/8( )@ 9!AX\7L.FV#=B!KKXI2#@&JQ MTSB2C1=>>DX)EB>CY[T5AKIS\A1Y<(S\.823J.U"XLU>)%1ZWH0JTFM)]ZSX MO.(YHH<(=1T)YRQN]W! J0S NENWX44%XP%P_QP\NC2952\!L_] MP&RF">C] FW?GY,W#!*&'6XH2=6/2L2>(;8IC%M,4LHYS=2X!E]\>'P4-''? MABO:S_Q!2J+N@M&V*0;%2+#H;PBX&4FS)&H8X&$2;9'D:=C"GO:#6'^8#+\R MO"%UDHJZ EXJAE%F]N\E##4ES1?*(W&GK<03F4"7P6B!X /4.#?J$"NT ._J M> K>I$/.H7X1KU,,*2/C4$DB4HVV6&N@;L,LWN 3]4%- *A!&F-[ VW1:@[H&-%@W7-ZZ M((JI28]561FBB-.7#(-/.T>:%4F7V#$G)':A79E&QK6.SGS<\O7G:QFNY2.. MG\%Q=K?5'=G/WF,"EE*B>I@CK"3&MF_Z/2D (7T#'68SV^O5UY248GQ'^)R?_RH7FG<@R[P:Z3UQ[J=E9 M&NNA\=$-W,VRW8_M1#JD_/,,=>$R(_K]"'#(=SSZPAK)+*6=](LBP+OP%\QO M-+@PCG7=I*EJRW0V#,-V<@IX448,N828QI5CN#N70)T??+IF,MPKA\77FM)H MUY]&&PZ3AF\ 8*6'3]C5TRGY??M)@ZG2/EYZ4M;3U/5=4,4V56/:I'P!L(* M99A'H3"-V[B6?-R%P9?3..OK =#/Z,E71:+,^(\?M8G^SVS!!!8I;##>KAP) MU1N[?BKQ9L0WM[,T4^Z ^?/4:_P/5*=F6W*5!4FH MR0Z"F4'N?@][,_4M3!+Y$ZH]1ZV^((++0AI>6 MP+9">AC0FW.\STQ*UH2DY%0:_==2XPQ\LQLY#L:)]!(^[<>#M^=!1.%HE!CX M>69_7+)H2>I;,USAK?7JV3' M?%G0R F"2C4W128JB(C$"43H6%@ '#R5F15N?W->Y]0:O2$#+A+LGFIB2&N( M3A%WB)"GY-[DC$[&.J>:QYJADJ"/[7A5LSFW:[F.AF7Y":%.0UMDI2Q>IGNL M;4F:Q>_IC/=T78U_"])C:R-WP)/OU\N*=^V13);R%,3EAR]FD $ZDIKUT,W) M*/LG"45_126Z'/08SPMU T^&/B4FM$D\"[2T0JIL. ML;8N)Y458\UOTL/JYOV_B=Z7-+RX^/$N.#<'K>WYP3JJ:W\ZUQUDEK GA [] M.[J[]LKJ0Z5F8'(2\5<5LZ8F^X$S@7UEI2(&$XZ-KAD]4GWG60X57%X=AO12?](^XJ@3M&3 M$(XYE)G\2="XKD7?DN7E%B)HB$0W1K)"KS#J2V&NM-(*):7RB10Z^SDDU9X5 MB D.U?+?GB?5GK)0J,N.F(E:TH&-!'#WY+Q\]IO@BBQJN]-1\$.I@8(-Y\2$ M"O>]5"RW!V7M:"@G\Q$SX4MY9, IRWIDY,_7R1II8FF!*$--8E>A-#-$FKX( M-.^H7KJ&@]\^JY"4A##4P#50MV!_EB7SO0D4 MQD.]R,$9M%[>TC@W)DGMRL^:-EC%L""7ZB.MQ#?KD/%&'0CL]J+(E,'VZ+(@,"E;3#S 70##P'[/<5V$!.C7,4X>&(7'! %E;= M6,L+6[7TY*/*SJD#=9-6;1I>FV#50LQ'O8"P!";<0"P=[]XIB!5]V[<:JWV. MBKC"_7FE>*@\-$4M05L^L#0D=?T4M;5QF"W6U3>YJ.,00(&,=;,C5[)%2K]5V0M0H9<'1I2@N7>RTWR%S28PQ+K(4E)]0U#V$? MX-B9=_[BU0,].TI*L:4\SVYNQT%GTYG318:\6]Z!=EZK6G[=76X%J?2&NG&( MQKBGY9(!]:$M9B8E1PC=Z-@_D8=L.#_9)UP>(NGM?X#OL-.2/L@? M^Z)6LT[!1&$"!Q<9$'H3W$L&'N8=C40+(U^#RR]4GL+I"%:4:Z2!<(/@=Z#C M8UI28B>D9N#DO]OA?1C"'0H)%H&/4KG/]BA0%Y*&@ZS';R#S PCOA.&3XV0@ M_P>1TAZF"<*U[S-26DY(*?H0 _Z40RG"%2F*.G5"_A?A:A<$*M?C=R$8\"^B M92<9.+V%!A]O@<[T>.9([+\(CA0)TEV&X&GFR,#FUXJ,[P2Q=%P_&1",[T+] M-\OZ@M^U&!^EQ^/+C="H'P3Z74CU MIDZ%0:Q .?S$*1XJ-1G"'_(=9JTD/M MGH7C#4\*A"XC?P?&$+?IM\^Z2'?1<-*#H!-B"!F8=07%6BVW4@ _S!W>KG 3 M-^#CO)+#:]5LQ_K^;2,L1W37W3%*VWOL#K/GJ0MI?_ZT"6N";HF*I8B8T;F_ M*@5E 3-^I%IW]N[F<.D!+K^?W_:8[ZE&$XE MT [-!6*D.-A5*L+M5HR;F_/R/E-WDUZ*F5:UEK)"1?#+E][$GO;%J[0'46W9 MRABAG1.,X:S%J$/C,%1[:;:*3B_"6M'$?#F!28;Y5UEAD:#E?MCQV60[&&T! MG]*%&A7:0DW066F$ASNC_BTN5^"]@?-?#9E /Y7A)]J)%=9'9:MY>2[N-SUK0=W!(&-8'[CV:@S>DB!8 MC;F:VN\>^"G:GY$/50*G8!?4H M(VD9*Y[*'V"QV^ 24 U'9PXS:0%<9?M+A>^X?%5EO&J+6^)$]7F#X:-LF>8] M[?,>CP:E$Z)+/H%W,GO8T]"S"[5'+F/1$:,:1!B6/#+L)M:A%GW23 =9 +"'Q0 RM?6^B61NO3G@<><">HX51C/ \,-$\_8Q0Z+S!M!*6[WLM MX?BWC.[>GH6!N3/B6]QR5;"S*TK.#P\%'8Z>C5[CY1=> M+FN%36XGU\8FMC3*3P[G@<\U=-(?"W4VK'^Q3LX1#;95]$\Y*PQ5K#Y6[]WY M2 :&*!2[GZ ]+4 &LKW)P() /@-/@7R^&4B6Y@R!PU>?J4YW3%;=P(L_A9?& MDT[9Q,5X&$M*C]@/G7G M\1T_?.+J.WT&WEKGO^G5[+,36<U'J0AUSO+$'Z%8]*2.V2W6 MW)]Y_BEEQJY14=CE*R.$!@K@RHM@@R#^(V96<=->[Z7=.Z$5YS(<7IS&!;Y3 MY^P9;#X2FJDE R_A\;*PD84:R#LU QZU5-D!K*WT;:W9QR0=DND/B;!5_@_7 MD0VI>MDO*OU/) 8.K>'MX$_"@6DJ4$;Q-_W$O(SI"M+ UL(&CZ\!_U\R<-Z+ MF*W=%1_/ 9-IK3^40UWH),4]AE;9Z=%]5?>_]A$OJQ4J=OR0 :2'\9SBP0:! MJIUW1K^\J+Z_YL:10 EEKM]!BC..0%7."9LX'#LDOVMK*+9/3O;PFCR[G MH 02V3-(Q_Q5*P[FX_?2FGG?WX7M^:\ M8TH))V[H?5(G-N=,VNW8B$1'F86W5%>&SDXH85I/@)(\3A7^URKG+OCH^>2H MUP8A>CL8U0=ZCQL@ S=;;?X:D0%#V1-)\+';4:&I_7\60?V@EXC/^#X::[*Q ML1EK E PGI+TM]^4:+T=F&&"@;]&?AEIOEND,ZG8Z#X-=FA.7JS.>_W0HU

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

&&-JA*A#$K0C2QVJX*?E M1FWJRP6=;YCN>J_;WSYQK.9)OZ2J>:Z*1NRVT+5P()Z!WL#E.AQ0S_2FL502 MW@2UC":1NL8(67A6AR,UDD.U%V)VGM3+6%QTH)ZY=#R_Z679]]RE5[[:,^L" MEZN_JL;>GQ;/FW7U6;523EK'G&3$F&,$1!)!5:<_ X32%.191"!#(LD+H\A? M@[&FQIE:MG_[/U$6_J=EE;Y+@)H9@XY@\LR$2LI BZG*E"M!U0LN10T2#[XS M TSG&B.LP4101(2@5@+*0L%YB$ MR*APL]VP4[-P?W\&0DD8/-='M#9'7<90FYP/^@#0]Y%A5^8]7\@6U4;N0 KN M!5F;!3EN- M(L9AGD:Y7 Q0!"#"(2AHP0#)&(QXSO,\B6;KY1K/#5:$GD)8K0];4?R]>>;- M3 9!;[!"C "H[X/5/=M=ZG"QP4FCB6H,Q:]W.'$W%19+R@A3,M("XW-J[%:0 M@9A>7$_ZWGN\U66@]GMKS=![#J%O8WOGJ1JV$GX A!EJ6($!"G^H",I-T M:GN<;75Z:1HV$\9 M+*ZE?:/\%D^@G\]^\35@SPB..K>U36W5V9"8*I'^@LO%YV55O>-22I6A,R,D MC'A&.$A@HA:'E (2RF4BIED>HBA)$,I:[XG9\F Q>@\WB&?*5S5[1),:3-O4 MX/5.A6 NY;<,_["8#3-:=XWP2+N8DP4%&EB5X,$O2O0_W01$2Z]2"QV&B]AC MYC9\Q&+\<<-)[($Y"B_I<8M^S/8.5V7U1=Q2JL[TI$U>.ZH/PR4R@1G)608@ MA@F .6& \!"" C&&((*<0*ORXV;#3LU\U5+7.=2\:K?"=MQEB+<9;;E'T3-C M;0'P%3NDG/*4X="C4I0='(?L9'EUSQ 7OM)VG]2G3B[;!LPF M492*$!1A+NFH2# H$AY)3I*6%J%9+!*K+J]GQID:]73$;#)_OG[[W=)N.@>I M&=DX ,HSNW0D;%-BW4?)7H'!;6S$F;'&C6JXK/!1/,*5K_=C@[OETU.IB\ZH M[9TJU21I1YI&):]F!-(PSJ1%@@6D (HL!23-!4@CG!"6TASF5B'T%\::&BMT M1-5',;0KK!TY7$+8C" 8]5& ?LCLCR*QIP@ ,IU1Q:;Q1Z<) \4/*,+FD MA_-9)RECY6YH,]#C,&K31+ DC"+B"*"H0$ R2 )0PBD0!64%CBG)_$&X[E>3?38\Z\:73"XPNN7]2-?J0SS%7_DBZI\X759 M*G4LSS.5'5M G A,&!AA@7!289"W+/4J\GX4V/;;@CX M4LDO3;2. BI#7-5\^T4=@EO6;+*=&3,CSB/>GLFZ"[46/=B3O2VOUQZ)-[T$ MG!Z)]P3/5QE2(QG>JAZI#4 7"I-:W<:. ADO9[4;\L,37SVH#J"KY8_UHQH- M+UYG21A#E$ &*,(80!CF $%)>BR/2)%(MN.Y41?S*^-,C=)J48-6UJ 6-FBD M->.P:]!>YBJ'@'GFI)Y8&1./(1(G"*;B],\/RY=_EW?0W/(_4'T$]4=-*-?N M/0IQ&"K8$H3IUWL>0LUQ54E&6>DR+J_:ZM(A+[.(XBQ+> X2E(22"G*YKR19 M"*2Y$VSHXU[^'1-Z:.CIZL7]*.*K[Q:KTJZ;MKXMH=..&0T%#$HI+4 M8$8P0"(6 +(0XC"D,<>Q71>&D^/8/.[C-%W8B5D_[G:\0VVBJ]7@@ZB[HP691KBM5]%=5&5/FQ?VW MWVUWD:>Q->/;P0^?9ZX]?.H\> ,O0N"484^/-"J[7E3VD%DO?]E^)W8K'W$Y M%[_)^9XQPEE4) G(4A62E- 0%*@H0,(YIE$<%WG(3'=>G?M.S;AJ1 N4;.;[ MJBY0U_=1/=7W?99CHKG5+NF$GKUW1=U[C;8+.J% =]=SZL_V+]G=4MH#VU*) M"8X1(Q$!O, 00%[(URS""0@+E"2YB-(L-DIS.;KSU%XT+9QUE">5Z+YZI[_0;]^@JG>L7[]QNEGIBK ?7WXK M?U_(WYR2$L!#8:/$S'W)JK^M? M5DNYA][)J&/=+<-=#( V,X+=PN?[/%(+&^RDO0D^_A7\]NGF$$UW%K(Y/D[- M98-A1[6=S6$X-*0MKNQ[5E$G99Y,J[I=L,_+QF34HU2[,08U(@$&K'44@X('%4@!A12A.(4T:Y2:&;,(16R^JS$"JJ34KQQOY+2-53Z T= _- <[_NO%I$/UQ#I$8I\6FW'\<<' M@XP<='Q:Q>-(XS/?ZYD6WJEKLBUC4B=MKK^M\5H7U/HBZJ^5>'Z_K$H5H:<8 M9U&59"ZOJM:S*(1)EA(((D@0@)@F (L( E9D!)(BA2B*K'H .!%K:E;57F&@ MO2) C6HWP58YY6#=JA>T^@5_[#0,E(J69I:CZ38CJ_$GT3/%.9Z_#XO-DRXC MM%RX[('@%'6W^>YN1!LW%=XIG$=9\F[OWB/%Y#TG:US7W.UNT=4R,XO3))'\ MS0&.U#D=PA00! D01* 4,H[#U,BTNS;0U$R\IGZP[@Q8V52QO03F9N'R^1Q$"+O3P2D^_W MW/CBZE'E]LG_J+N_X+G*]CNL>L$Y0R$K4I (R98PI@7 &:4@3Z*8L32$&;(R MA(U&G9J=JYNYZV0AQPXVS:QQ][Z;/03A.L1$KN-SNPHU&'G=K M;@/&T7[=ZN)^U%1GD-16X^==+TX=!;I[4?(00AHA"I(B*P#D60)0)F+ ,8GS MI$AIQJS*CAB-.C5J^K9Y>L*K5[4[:S*L:@6"S[8]3.W -V,IYY!Z9JFS$'HM MI&F%DE-R,AMY5'*R N.0G.PN=MA!I7KW>ONPXOKS[<^RFJ$DS%@88Y#I:/)$ M]07D<0JRI(AH&DB!W\HX:T:"9M.@\$FU0>X MWET3;XVK@]8J0_ =JTY"^; H14EUBQ2^>M)90ITV*:IO6$>A&X5^N6#E2\DV M>![@5CW?#53.0=FK?\K1S=Z^?$@SV#/U\G^7DU_I$GR61ICP?C_3]Z[-S>.*^?#7P55.97,J3(VO( DD/SEN>UO*GMF7#/> MG$KM'RI<;2:RY(B2=YQ/_P*\2-2- BB09MY4G3/K&9-$]]/D@T:CT8U2R),T M@$A%$238G)')6*94IG L18_^C;V$L?K0WJPO8]7(:&4:H)EZGN8,3:XUT']S MK$O?SU!V?NUPN(_;GK:KCT=;#5#I 2I%?+>N[8GC $UM725Y@W:W/<$ZW0BW M[\/ZE/XRE0>_RV?]"C_JL>Y6RX<5?8J"D-0'W' F9<:3&*8(4[V<#T-(<9) M(6E$!> MX^]I=&U9]/R8BM6ZU0'GPW(A3))BN?OQ>;[\&V,&X#K(NRM%/;M&-_MLAU?0<>A12N@Z6AKZN M?,HU^=,YG7]9%.O59AOP520E >4<:J.A41/3/. MU*AKE_&ZD],IK'X)5SLOQ -: W-/'Z!ZI@*?A6& W-[CL=X@6?>LPJ>S;\]? MWB-L8XZU\N7#PF2/WM.?[^5"JGQ=[:C.*%;:ST%)U0D<$:P@#I6 "H-XN)(4Z.%MJRF7BUHI'6KLG<988MPC2_O'%IY]RQ7,3&,JY_&ZV,[]MUH7)!LX7#]5UQ=]E_O"XEN+V M1:[H@_PNGVB^T+\V'3M,[9,-G=_+U5,TPU*%B2 93$QI+A1E <1<(!AEBH@@ MSB*<.>7Q3D2OJ4T,M?A@N=/H!OQ9*P-II0U8->J4W8%J?< \5Y8UQ29F!-M& MW=.0=D)S8JE[W3ONCKZ6/G,K<^&F;L]Q QK]00D *!'0OVV_9(WZH-8?; $ M+02 @_&)*'UF@3,U\3R>43^;D1)P0<.(4R@%X:8N M,=&,D2+(<1PAS!G'+.B1.N0DQ/^1E"$WP[B$;GSB_-9GP\=(#.J%VO!GNZ>1 M"-0+'*N3VIX3?[8;<%5&?M4&1B^PZEH?]3JKZBZX*6FX+A]0;.MWAC*AE*&S.H3A4'J5-"LORA36VHTIU36]*! M>>C]M!KANDV5B;C4>H!WM29_O0$[93O[\XXZ8&7 W;44+! M]4_LDT%)%Q]S^; L*;M.1XNCF,5<<*BH$! E.()8" IIJ%(9,H%CHNS:5YP; MPN5['*=SA182E%)6OHE+=M\)!"TB[%>B,G0081^.7EF/)W!Q272\#I^Q%\%U$*SXN)'_(>GJ<_XB9U1D2DDF M81(+;%(837'M,("!C(C(, F#,+JZ%-N)@:?F[^E7)_6PG#T%\14KV2N!>[-% M['H)F 1W-!U9A)B&*5 (QUJC3*)4DB'@2)6Y+T,,1IL8TE8!]VH(=@V>Y7+P& MDJ%7@2TT!FA7=59US[5@#T<9N1CL&26/J\&>N[#?U[SK/&S*2I]:F;V7:KF2 MVZ6<+#[KO^8/BQDBC. TX:9.((&(IQAB2B6,I$@3O=I2@50NGWU_4:;&#[58 M;M1PA27L.&0E3IJN/2GE^Z4H5N\J>)=J6!.$?PZ%)8RLQV(F\7W%O M@!TT1YS\LHOEV.,RCAL@1RSD>/N5/LC)LO(SD>$LY1S#1")342G&D-$XAC+& ML8J0YJO(Z8Q[]W!3XZ&J9"6OMZK[\U$WQHY^RM7(C>:RG&U],8#[THG*,)[, MZ2'?QJGI5/^L?]-]5S]"N7VA^=P<[M!KI!]T+DV1]5UM]5O.-T^;N4EB+-N: M[CH[&B^K6F?I%=8LEF$DF8_$3"_"67UK MXR=L'K6)-4*[4I4?Z]DQVGC&&+'71;M!PU9!J(6%A591_]M.+7#28C=-^$DK MYX\GO6+ME4[]2#8JZWH%\Y"<_3Z\IU.X>J"+_'_*0,R'Y:)8SG-1_N4]+?+B MF[JKDL&K?]H4^4(6Q4=9\%5>YOK?+H26T^2VZCFFK%YOZD1O*X7PA/$X"3&4 M>D4+$0\DQ$K_P<,DH4E*4YFZ^91#2CLUE_0K76]69;671I6R\\-. ]"HX.BC M#FIR2Q=W*H8OZ[Z MH!*/Z^F/ ?[10F&40?OFDIPN2?TQ+_A\66B2W-%/0B1A1!$H,V5F'*F@V4V! M+.:QC /*!+5J&-!C[*G-'_OE[0V!5$&.=E%OU[P4>T/8S0,#P3LPJY]M' !V M<@_$S#T \YP!8S_^R+DQSL <9\VX/Z(?H_T_*1[*:&^1/RQ*3JVJ@X5IF"%3 M RC4/C/""$%&&(.(($0CDD:*6Q4"ZAYF:CQ52PE:8O:J#78&5#LBNAZJ@3FG M!TK.Y-(-@E<>.3/4J)31K>XA.URX^HJZ-N\/3^+/2)R04*D8"J$T$:A80$(C MI)T:C!07*4N%DQ=S>IBI$4&9KUC7\> M.8&L#H;UJ.IR#*T='5P/V,!T<+'F MR5?]#90](B]@UZ]8R5EH_-<..1YJ_%(>9]4]65GC_-4^6\S>KC_0U>I54]*_ MT_E&SE2$ I9)!"G1?R"CCR!SK)GP+#K+'ONYGZ, M]-$4B>%Y-:-F*0T(2S,8):$YV(,%9$H12 ),$I8BF:G0[O#TJ<>[?!GC')QN M2]?/-=F#SXY%^D(R^$;H3BQ_9'!*6:_?_-X HW[:IU0[_()/7M/O0VT.]MTO M;[DF@Y4\W'/<[3>:W<=9QM(@"6,-]5K-80H(S 2,9Q4SR+%0"-\D8=M^R MHP0],BX&_MSOZL8RY4X-/=KG!\+D A1;)=R8P-4^=F0Q!.;C\$DCN3E87,L. M+)(M_%%/3^B\LI.K#*,26$^ #CFN[V-Z9JJUMCRT;Z37QJV&L_?ZIX+R\BA* M?=R6$:*9+J4P0#&#*%4(,HX"&.BW5H5F(RE+7=92CN-/;E5U=K^CW)9N_;W: M85H_T@78O^F/CTM3!=(QI.MJ-SMZ'- :;[;QY,\0[@EG_>#TFUKF*,.X263] M #I*%^OYF"%."VR[YGQ3VVX9=\NB[$GUZ>=:+XER3>6_Y<5Z1C$2F"(!)3'+ M0T$32!7-H)18Q"2+(A8(?^<*[ 6;&LE:)-/?M/I0:6=TURRFT1#\L=,1&"4= M^=:;T>V(^"U,.3!#>[?BI\7FJ3XHZS/!RS/R(QZ[:"5QI $*8)9$L1I&G!)$Z?DA7,#38VW M&^F: MKZDU95S8#Z.!E_-?_P)UV);9\*UW#A&Q6^3CR>.'Z:\H'W=.?WZ417/-6E6?Z:+S7+XM/"_U) ME"V#OFL2FR6I8#B)! PRPR:<"T@(BJ'*&,E$PBA.4[<8I-/XTXM ?I1*:B(1 MID8U8%5UW#Y5@VP-8$ M>N.=G'JA.4!5(%L)WJ 0D",XIVO_N#ZD3X'I;;/9,J%)+]5;353,ENSZM6RE M% $^:J M?JJ4 *46+C6:^QFGFQ)'@GQ@8NQ">]M!JX6Z2RML;X9PJ:<]N$%&*KE]_Y@7 MH&BL(ZIL=%F ]:.9G+8]WX%>(*[K7F7K)2BV)JQ^6E8'R9Y+TZWDO(I2Z O- M8TR_G_7K/Q5ERM3Z]1=?U;RO,D%WP>]^CQZQ)OA5NN^7#;_N49Y2!^Y6IF1; M-=1:RV &?C:7S%(5IEP9ET)R"5'*$XBI9)":4[Y"Q4RDI$<)!WL)>OCL8]1I MV$L=>*Z%+S])V4A^9;K >9OTS!2X#N*W2Q)HY+XIYZ;U38GRIXLH7Y\?(]K1[B>A6?K,+E7-[A\W\JMV3^__E/,7^;?E8OU8S!*9H)@( D.2 MF1/[G$%&!(T>]>Y+"HOMH8%G&.,2$>F)+V^MJ M6U,AH6/[OE;I!FBE@-$*5&J!2J\QS>00!1G37"/%0\8QFUNDPQ?,G3&/JP<9 M+_KA"X^].(BWA_9;.;0FSED6$I$($D,E)8-(<@IQ',8PC&,2!@*%9:D&>[^V M]>RIS4%7ENANHV;GR_;$8N#)XC<+ )P=UA.J>G52V\\?U3$]H=BA,WKJDAX. MZ+FJ+7_+Y[)8+Q>RYH,9HFF ,>,PT9\G1"Q1D(8I@YRFH6E.E*A$6F^PV8XZ MM>7^05&H=L6 IT9T\%S)[N#16!O!PL$< MJ!N>%L7OX-V$K=.")#H.K@#PZ! M[DA^GQ>4W=PZ5[0ZW3?KAXWGIKGJM^>..=_<@]W_)E?\O_[M5WI;G_!!F:(I M)Q3&-$DA4B*%-%4,4A$DB!']?Q98D_C!PZ?&U:5XP,CGP!F'@%D0[A4P#,RK M.P3Z].,^A,*!):^ 9"0RM'@YW*CNC,J=C'9XSWC$=4;:/7XZ=XW/4EWM0UGO M7W?7U-1W:]*^JWWZXE=]Y;KXLKB3JWPI_B[SA\>U%+A'[(#_]U,+FA;Q; MY5S.$KV*Q!QC&(6IU*M+)2'#0L$H55AQO=!,F-/YTQ%EGQJ)EI)+ =Z9/,Y- M(4R6#"B,KN=;J[VY_>W6R1.UZL!S0KOR65OOO;JV@+V"DR72C/8W=3I;<0,J M!,RK46%P QH40 T#:' )1!#UU$;U'HC%&<;1OX)5'P;U#!V9>2&%6&@6?&" MH-\VZV)-%Z)LP;A>Y8LBYU5U-1H@% 1U M#NPKZ=1FO):@GF>XWK;T-)^-8:$)S%ZVDU=+WQNPU=AW9;[!K3+NK-1;VFG- M0=>"[CSC7#W@%?,+NRP7.Y2K??F'9;$.9RRFL0JY.6"3*8B4?G_T2@K!E*LX MRF*]L(V0\X3B1;2IS2 #%&+V8T*'>61TPXPX<9PL^%P7>A9U[=;G?%UU"_-_ M5M$_OOZG #_BC<_Y7F$]2?)^1WB;58-^U_.J)LIVC3.34O(H40$45'&($ \A MS0B!C""H&NH?I-&==!Q5Q?T\\O7_'8A M_IZO'Y>;]7=)13Y__2BU@_R4+\I*HC1?E6N06U:497=FE(0H2$(!1=EE*2BS M]LH^<9G"6901$3G%E*X7:6JN_X?EZMGLZ,OZ)'#ORL8>K&4W"XQK@X%)OSY? MWZYV_/G?X=U/)1 1C"#)(@&S**5A*B+"F5.+O_-#38TL=P<\YUI4P-NR M]BUQ?@2OG3/E![2!2;-U(-;@]<$*KRNJB)^#8J"ZX$?#O5&E[W-JGZ_=??:. MGJU!EYJ&%N5^;1F-*[X4Q4:*68I"S!!6, C"&*)(",@2O?!*(F6RAT6BPMBI M&>CI<:9&$Y685<&[FWH[ ^2EJ/TW.,YA;$<7'I ;F"MJT'Y4H%5":@>A%--C M@\]N'/RV]#PSUKA-/+L5/FK;>>'R?OQPOZ(F)6<7%C*=0:LRD?6O;HM"KHM= M@4W*8QF&1$!N^OXACDT9OT# "'&J2,*IQ$[1&F<)IL8I>V51:?7?.DS[9?$B MBW69C^M&*>YFL2.;0<$>F(:.VOS5$N]*^9T,C#L4H77FK-YP>F4S=RE&Y;G> M(!TR8/\']2QPNJKKZA]/[:$,XY21"*9F>85,&Q,BM",5Q5&6)*G^4SFY3^>' MFAK;;27U[$1U@&U';7X@')C#=NCM>5/>G:G+8/BM.GI^N'&KC%Y4^ZBJZ.4[ MW,A#R'SVJ2R6?2N$?ECQ0?_X;76__',QXT@[2HDPJRP20D1X#&F09-I_BD.2 MDC2((JL.2!UC3(TN*C%!+><-,))J'(&1U8X@N@#M9@9/, U,";T0LB8$"PQ. M,$$A^2\/RY=_UG>7)/#?R/P(JQ_++[_KN:-\\A:*-=^ZS:5]HRN+8CG/11F@ M_W>ZRHVK^66A/RSM]E=#WNG?\]>9E")44G_PJ6+ZT]]VIB@10285Q$FB"4L2 M#%G $(QQ0#+$"&5VQ=#.#3 U7MK)YYC&> B<'=U< \?0#LE6M,L[Z.YI@F?T M]IOT=SC(N"E\9U0\2L@[=UW/(S/;'C"WG&^>-G-S-J2LYVWRLU?RT;1X?9%5 MES.SS730.(DA[: DBD'$LABB(!209@&!H3FA_3K_3IO]V'< VH\Y4P$4B0P:Q8%(3,HL@ M"4S(*"8!XD2RB(E^A&PS_)3Y=R<_+!4 .PU I8(Y]_8W^I]+30%S6C2="!V3 MJAWMY4J]OJTP(M-:&. 2XE=PJ@MP U&HE0AOQ)@N\)PG2*>G7-%HZPSQ?J#% MX^?Y\L__)\6#_)7F"_./MTHSS7?)S2>=JYQ7)PX7IB?O':UZ=*D$*Q4D4,7& MD\TR"JDB'$8B2@*">!:&3LD)_D6<&J_^OEC)J@X$>- Z%."=2:"4VD%:+H!: MKF3^L*B[?_%74&>E ?U2ED>"BANPD&M#":;UN/[/7]Y%X2_XKS?@+R'Z)2YW MYO^2_1+< "WS<]56>_[:H^^5W]?$CJK?UO@#T_E%!_D&&!V!41*46MX H^?V MM]0H"PZU+2VN]35M509HW36(-?QW_?(KYO@-PP:!^62OL6%&ZC/-(3H>ATF:*0)#:4Z%APQ!EG$!5:)0@O7O1&"U;WMIH*G-#;6< MH!04-)+V.J!X%EL[*O:!V,"$V@\L9QJ\A(17,CL[V*B4=$GE0V*Y>'WO5/I# MJOJZ7+=B;PAA%*3*E(R@(411FD%* @R%_B/C1/$L(8XY]9T#3HTN!@R+7L3> M=I/7'Z*#[^V>#UT:F?4">YA=7#N$?*?C=P\Z=EZ^%00G$O3M[NM'/Q_E*G^I M.JF4*_"O6INZ S B:1A$20@Y";1_DD@"]0\8*DU!F'',96K5\^3R4%.CG)VD M@!I1P6(KZHW%ZM6-A#HL8$<_?G =F'A:D)92WH"=F/YXYC(47AFF8[A1N>6R MVH>L8G%'/S[1#+4R;3$_RNJ_7Q;EG/VQSH?==LN<$458E&$%0\8CB)#BD%)" MH<1AF@9!DL;(:?5C._#TN*9.W=1&3%F75AF0$&G1H2EV 58 M[N1T/_8SN'&[&71*)AMZW[8L__J^NTSL^\XRL=O3K%N%]UM+5#I/Q/ .97HF M\@*,5.;G[5\$M[I!(UBGL^[0D../5[=H!!3WZAZ-,5Z_!<^VGF6K@-WGE?SO MC8D-?%P^T7PQPVG(0X8H%"0-(8HI@YC0%"8A3I#^]XRD3OD#%F-.;79O%UK< MB@K^J(1UW/6Q@=QNJ>,9R('GW)X8.B]J'%#QNIZQ&7?4I8P#$(>K&)=;^Q'/ M+>>FOXHI76#XS#C/OS\+NI91$*9!5)\;"2+)1)QED$5I#%$J$*0*AS!,.!)Z M+9)2@5VHQVK4J9'/3FBPE1I48@,C-PPB-P:RP]Z.@[PC.C +68 YP D?)Y2\ MLI+=R*/RDA,8A\SD=G-/IRA?F+WRWTS\9ANPJ=VRXN-&?I4_U_=_ROF+_-MR ML7XL9BI&68 IAQG)"$0*Q9"H$,& X)!IR=((6P5-^@HP-<;2[Z(C)3E#;NDA M#0CDP$15BPY*V6]VT=\;L%X")O4J-->+S_^0= 6^+3QVKNP+F5]?RE6(<1VK MGA =>5E]G]-WL[R*05?;\/?T9]W\[KU<2)6O/RP-K6XTL]:%-Y>+8MM51 D4 MQP'/8$1,;:<0$X@Q5I#%7"4107%&G$X^7R'+U,ANNT%3[GW]B^OV>7^;V.ZO MCX+TX!OP-3._OSPC[_9?#=QQ M.L#UC^RQ#=>F[]N%V)4K/L?G9K+^G+_(61+C(,()@SC "40)EA"'*H,H9E%D MSIP3GL[6RS6=6VRR]1;#B4BWP@SJ-:8.^R7]X;?8!AL%U#$]2*"U *T"YT=> M9:/+#=#:5'ZET6<4@SAL3XUBF)$VGX8UD-O&TM6X=FX;]7_Z>)M"5R.PM^5S M_=/Z.?G?I2G]*L4GNEKHX8I6_KF>)G.>KV=!J$1&0Q-%E3%$"@M(J/8H@BAF M4M)$<.;4S_'RD%-SV1N)@:Q%=G/:;3".4IF$E,,T-JT$D HA%9F$*16,!+$@ MBF5-7^7[T:'>[Y5\/_(Q"%%)ZAUSN_60W[=UX"E\^Z(VTH)W;21K@<^G%SDO M:^S1\;IZL1AVU$6*/0R':Q&'.Z_H M^G'?VNMW#=+YQPD6$9!1!%Y1\9@D0F M".II( PRB4,2.T6MO4DVM>EB)Q]X[FX"/K#%[!CN3>PP,!%ZZ.O>LN(@K=Q] M(NZ_@;L7Z<9OV^X3U)/-VKT.T)/1]3JS'.^;*@NN/R[G^N:BROW:1>###",< M($@#IB RS3XIBV*(@TQH'QZ',:5.;&TSZM28>"MTV5>F)?8_-6F8%K'>*XQ@ M2<"^H1V:7'V@ZDZ:+BCY)42KD<:^)*4?7#6!^+A9:<^VHKZJ M.<2GI^?Y\E7*\J([_5H^:LJ\T^]8,0L3)02F&*9",HCB4$"F,@'#*"49R5B8 M2*=@0T\YID9D5?*N^=[J5C&]>\3T-8PME0T.]^#DIH6K>\F 2H?:_]NU[6L4 MJ<@/-*J 4A>?C'<5F)XYL)\L([/B58 =\^1UC^O;].9S/I>K#YJC'Y:KUUF( M@U3)6,*8* J1$ Q2RD(8J32-DS!+0FJU[#[S_*DQ724B*&4$C9"N76[V$>RF M+@^X#$Q);I#T:&MS4O$K6]KL/W/D=C8G%3IN97/ZLCXG;.N2GTOU=YD_/*ZE MN'V1*_H@OTN3^][LX]S+U5-!%^)C7I19J=_UT,5W64;[ULORDL-:Y"21**,I M@C$/B5[&A0BR &.-.<8L2 *%L%5&^[!B3HU$VG5V&U5AK2O8*EMOI);JEC47 M&X5!J;'+6S )JP[ME?DP**BU-1FQE;XN!>S'M+K+^=LI6'^LT[=O M_Q8X'K\=VCC=AV\'&WW$H[=#([A_\';PT=ZRRO>N=G-"(\8HU@X%Y?H/DH20 MI%%U6"Y$FJ3JWK]+H1%1^;6&UG<(<-D*G:>EC&$G M__DJ@TH]?A[+&$8XF=\RRL#]YJ_??]RORO(BKS^D=K;+?M=U[0F9B@"E40(9 MPJ;O9J0@P1F"&>,D4 F.8NI4T% M<4:$=DLS*#'7/)$) 0DS?P0J2R*6$)8HM^X2IX:9&D?L25EY$;UZ.9X!U8XA MKH=J8';H@5*/SA!=('CN!W%RJ)&[0'2I>]S[H?/JOA7:7_0SEZM7$ZN=+TUQ MLFUV9H!9(&(E(4%I A&B&%+"))01SG""5$A"IY8/'6--C1*VHH*=K+US8;LP MMB,'3\@-S!!]0>M19_TB')Y+JY\?;^1JZA<5/RZ@?OF6:UM-?ZY"_)]^\D>S M%OK0!/9;B;35^=V^%]P.>6L#PCY2-AJ$IJN;_$7_"?:&!/)G7JP+ MDP@"UH]Y >2\Y*I? (2>$LMZHM>9+N;ZS/&2P'IJNY?:U?<9UZX=3N^JG#T] MUR:?MHU;' M=9H37;\OM!$[#W#U75?X,;3KTF)T\XVXNCBWE=Y] .\&-$J.M,3P:H*!5AE^ M9'RCA897@,^O-?P.TV_>N%LMN92B^*SA*$?\5FVG?_HI5SS7HLTDX1AACO7* M(@E,+= 4,L(X9%F,%$LER;!378>+(TZ-V^]-:5' 3;;F2G*9OVAV,&\/D+6E M"D#U__0OB\V\##XTOP!%R1;+Y]I)JQ1T#"1=MI =A7O%?6!2;F2M<*XXMQ87 M;.7U1ZW6T'@ER\NCCDI_UB <$IK]C<-TNS"%*>__7,YD1C-&>0BS( LADB2" M)(H53"D-:*RX5-RIY;'EN%.C*_VVQ7Y[6S0 V_', + -S#8.G2RTX.-ULCA M:M0&%LW8D^I;<0"(:[N*P]M[!&C+9__8/#]7 18Z;[+JORS4H41F!X56*I4*9I%PFHCKN?X4Z.GO?562Y'6<9B6+@ZAPQZF ML0C6#@OXP,16$]IEF*\[EMP#>8>X[; 6&"ET.X@EW"*X_7'L#.+V>.QX<=S^ M.N^%,9BE62Q2J#&>(2HC1FD#",MI6SS;ID MH>57K9T9>3G7#WUHCL3,LH3P2"4("IP0B!A5D&44PS#(8NVDID%,$INV/G[% MX#Q95]'?T]W++-YJMU&4 M/T^>FM>V%0X8Z>QK M*N[#U4U]5X$P,'M9ZN]40/&DKKU+)^X_;;2BB2>5:)=+/'U!CX!=>W.B'1\L M9ERE-([TVBF(9*"_0HDA(9)!D9)$?Y,R$Y'55]@]S-0^R?V=-55'ON>EK XA MG_.P6L34O( UU@ZD$1+L[1#XPBD#"1=Z@8,)A22,4\AQ MH*1F%991Y)2)T3'8U*BC54NI)6WOH\Z=.-M1B"_T!F:0_L"Y)UY8(.(WVZ)K MP'%3+"Q4/\JKL+FG'XW<+M:YR.<;$S'?563Y]--$9Z0P'H]AK4WEM7Y33=/* M.[FJDF=?3S^@G& 3C(60,8$J(]J#D8I"&F(.,\:8* LU)4XL-*"L4R.QMJ1[ ME8MZ>$%#FMB. "=BN*?ULYDR>(Z#IE7N'E'=4ZAX!^$/F'V-(7_6V]',^ M+LT9NYF*4X6C0--]H#!$"]GJ ;F#I[H^:A'M<1'@,7Y=J-]\:5N8X4OUR>Z_B6*VMT?97K M69*$ <_T.E71D&DW4>IE:Y *31F4H4C&(4=.A7+:#Y\:/32R.=?KW$,,<:P$ MU9YTJDQ?=A4QR(2(($YCJJC^'XJ02QI);\3&2@:Y BL[FNR+P,"\N!7K!FC! M!B@WUE)WF/IB9H"W*2C64NUL!;'V-2.7V*_/:/VJ+UP77^H^X3."..>8A3"D M%&G/*4XA06$&59*D7"F5Z?^,4D__I'A38]-2.M.BI7=K7,_6DR$C&"7T[=<664S-:*PTUK&;MBIS7@+'+(:Q33M:VL.(5NV?,>$3_6%2++Q(^#8Y&3[!/9O$ MX760@:)6Q07?6D]I>;4OL'6P#\IM-L6'[E8YES/!*$HSQF&280%15-9))AQF M2<33,) T4DYM>,968&I342F^B928%?6F$.!9KJJ0B>^(B>\WP5-,Y0WM.X&H M2V$;=FG!T(Z]'-:1WM9T R4:(P9B!K+CN*$:WTI,*Y@SD(F54V>#:%KS[G+W)&>8A8*"*8$D0ABF4$&8HR&(@TI5E MDCAUB@_UDF)JD]G]HUS)LMVZV]S5SP1V$]#@P X\BU3RFYF@UN!"<;VJVWU9 M8L]HXF\&N I(KS3>3Y)1N?@JL X)];J']6/%]YM"+U&*0E,XRQK9=RK&(I6QVE+]7S&7W:0WVO].7&G MC[\IT NL7J?"ZR0:=4KT M[AU.CGH6Y39+%:FY/D8L/7WU8_Y.I%KT&J8U() MC3'3$UZ8FOK^9KL8!T) $3)!$R94*JUFO7,#3&TBJV4LX^>UF$[GFLX"V4UR M/N 9F+=Z(&--1I?4[^(7?6^+6_3?#GGE[,-'H8I+JC5?_\7K^OF\VWXAU1// MQ#$>'E:EWW'J&#&/41B10,& 1=KO32F#)-%_C95@813$B"JG#A]72S0URC@9 MZMQ%AF[ K1!E)T@Z]]'>^GJ+VOE;H]IIQ+"U7Q,Y^UO>8/7J2J=%S77NFV)UY_K-2!:PJ78!H M*0.4R;AXJ3(N:*F0(SWWMJ E+8]AEX'IN#;)CV.3U&J MAY@+PFFVR3N='PM MG'YIN+[5#^S;WZ[.BJS:Z=&5=KU-6211#M$<5)^).(D$%@AJ M9Y= A*( $I81B!%.8QXP'@FGNOIVPTZ-2+=25XWK;L SK9GR^DP/2T/84:1_ M> =?6C?(_JB0U3+K]QA44M=EC[3<55:%S\YV+D!Y;F]G-?3(/>YQ>1/G[B:(6DSRK3 M+B9]_B+W3_1C74:W,,2\S -6 JS(-'?+PEH M=;8ABRB+0AY&F%J=I78:=6J?]%9PT);81^Y%&XQ=GY=N\XWYSCP+WE]J)6QQ8+?]HE79*,A9&"1(P%51 MQ$P5B##B4$9$J%A%2F&K^ED#R3O0B>!M[3Q2"X/[Q[P LFKU"%;R63^[G'3I N0+D;_D8M/T!ZLMS-MO M BWM:\3ZQ5/#@^%0[^R4,,"PX[58& ZSO=X, PYS1:? [_)9?PR/9J2/&W-Z MKSJ.4(Y?S)3D2$8XA"@-]<(D%1FD<:H@+0]<4X5"PIO+LCL%\^AG902M):TH!)W>^:NDMAS T0K=/PW-^P>=OS& MA58PG&Q*:'=GWRJG?&4.77R4U7^_+&XY7VUD^^#W[4)\6S_*U>Z8QNYW,QXH MQ%G H JEGBBRB$"L> B3-$5IQ%)!E%,UP&L%FAI]U=(#6158<2ZI>J5Y[%AL M3- 'YKA&%?"N4>:O9E>R,4.[9(9)82U5:I] V_W>9RE3/_!Z+G]ZI5 CETSU M ^%QF55/S[VRO=IOVTHW%%$6:MJ$0:+,J25M.;^L_Z;5"H*_R2+FG)2RV"(;'=^B$C+T: M-:!4H>JB7(L-*NQ-78/F7RK\P1^5,BYQ_IZ&<(CE#V^0D>+UWWNW*@3+@ M:L))LC'8L]&P[GC]EYV1ZJ]CE]$(U')5/D*OR9_U=&X>(JH# &;]4$6CP/-R MKW2XO? %J /^5\;OZ[+-&'_ZW3?"^U?^:@>T^!!N:#OTNP'-*4SMF>[ MTC"*5,05#%,40Y1&$C*, J@DQA%'F-',JC&S_9!3F^0:H2&MRX>M&K&K1O:@ MK'M@ LBO4EO',G[L8 *+ZMUG ":E.TK=[TG@<[Z39'J6[W=FS4O]2OP7KG'\PAU=6K\U2)<&$\BR! M(E0,(I5R2!%A4$BF>!KP-(N=SNZ='&5J/-T(65:1O]VL'Y>K?/WJ6);_))QV M(8NK01J8=DF!I[_"4,VJ&,\_E''6$-Y"&3X,,LU0QM9(]=?Q?RR4<:![N?I!YZWVWQ\E6^_^-D-)C )%8QB& M&$/$<0II1!*841Q2BBG*N%/Y(=N!IS;A[8H@N+G(UD"+(&0T3;7?IC)A^D,R M2/7?H<)Q%D99&B>!G"WD^@U@WF9]KH=>DVC96F4IAD(ZB@(1!1R2R)S=C0,& M,=+N'%7ZC68A2Q*4N'1('N25GF;W9&N,[=: 0R W]+)P_Q6] 5L=H)Y@8:&U M\+O!1%Y"ND!RN*9WO[SF_'B4S?:@*A&[CJB1C"149AA(S/;&B M-(&8A 12+"+!>!B)V*F>]<41IS:C7I>@>1E@2PKR"=O W',BE_(&U.(.4BS/ M&AR_Q'-QU'$9QQ:$(ZJQOK%G,'M;_L[B@-/9!BF[<_FA2&@4*0DS&2&(<,0A M9DK!-".A)!+%@EKM70XDW]3X:^_DJ5F$P_?')T^;]JSLM3I4JJ\MM7*,LWNV MM&6$_NWL-[03MZLQ:GELN+NI%OCCOHS.>"WO,+ 9_.XL>)9QW#V)80 ^VLT8 M:)B^I?>6SW*U?KW3'\;Z=B%,"<#GZB2L(:JR9GH6,X9CR6&@J=\T *;ZY6>) MJ9D3UJ%IK/EW]2K>%,L9@E<1) BB)S(BI$D) H@SA"F 8L3AWKKEJ,.37^WTH( M:".BH^MN@;-><\6A"@2D93')4 E(N)"0*T%Q*!!!,G7KE^4+Z5&[8HV"M>72 MQ^^;.GA,NBY?6Z8JE?+>@!V:MQ?1=%^3V./C=YUA,>ZX:P=[(([6 PZWNG>3 M^AO]S^7JPZ98+Y\T399N#<*$13S1_,W"%"+&]4\"*R@DE4P1&JL V_:2.G[\ MU)B[$UBL:'S[_)YJ4?(])ROJ#!U'3,$44Q2R"(60*67A$*2F,:95=[%N0&F]KDV M,H)*2%!)Z5Y^=@_$[N_6!S1#S^QNJ/0J'7M*]:NKQ.X]=/2"L*=4.E7[]>1U M/0M*;&O-V?4PFI?&T3]]4]\E7SXL\O^1HJHO]&%9K(M=L%YA1),PH3!@3*\. M$C.!FZ =&KZ9)T:";,H-;P&_IBL&D';<"QM"@'Q72&'S ?I/-OYMC,8N' MJD.P4(%@&88HS:C9M4\@4RR&$F5Q("(9I2IRF1Y:SYX:H=>B]8K[MR&S(]F> M0 Q,BY88.!/:"6V]4E#[^:.2Q@G%#C_S4Y?T3/LK SDS3GF213*$H>()1 (E MD)I("R4XS82*0H&%4X9Q^5BGSW&L_&% 2]DAQ\^7VU#E*BMO_;;_/S$RZRX5)D_BF6F'4=NG )@N4$B4BGA*8 MI;&>'@F7D$K.("9(Q6D2!5AF+M.C_=!3FSVWNP1K^A/,=_+^B]NWZX"]W?<] M#*)#AU2W0IO5Y=X&3+O2Z1!)N>YX>:44A^%'I1UW6 ZIJ<<3>N9>Z5?IJWZY MZA8?<1AR%(4,>(X-5LZ M9\42;-Z:MZ%(_XM]''?SA6:7V2QOJ.Y^"K7,ZG",&"<0BZ5IK\$!Q CKF#&%(FS M()5)ZA2 /'C^U(CO RT>P;.6K:SBD=?"NG:7V(?0SHFY IB!^:Z1#!C1S,X, MGV_*XB2M;1G07'33ZOIPR]?YB_>F#R=A\MS#87^,D5LRG%3PN,/"Z(Z04,443&@0AM4\K. MCC(U!FA+Z+B(Z4:SFP:\830P&;C!XY1S=E']JU//SH\P6@;:127;B6B7+^ZQ MTOGP_^2R?$=BSB M"[B!2:079CV.T%T&P_/9N8X!1SXT=UGUX]-R%O?X+@D>IQ'>%5]M=7+B# N% M%(4\Q)FF%$8AT50"%>81ES)3!!,_%<'/B3 UHOE+G/X2X6T]<*^MSL83 M%%(L(QA%&='S722DLFKGZ3[TU&:Z1G)0BUZN-4^4YG2N9VIK"CMG>QB !Y[M M;+$=H V/.UZ^BY[:#C]V]5-'6$Z4075]@OL6Y8?-TV9>+@\^*27YNCIT]4W= MBFK6J]>I5&(513*&D4PUBVGJ,JW)(TADJHA*DX1*Z_U*NR&GQEX[J4$E]@VH M!"]+D]:B]]C5M#3 Y2U._[ .O7_B!U&GC5 WD*[>%;4<;K0M4C?UV_NECG?V M""A\SA>F=$_5M7 AMKDNY3\TE/2U2<813&62080XAC2*]"I8"H9XS.), M6N7!= TR-6=1BPAV,CIZA9UH=O.P+XR&7JTZPF/- #;Z=Y1H:FZO'+OF;R4S ME*S0^?A1:,!&P>:[M[JV7_SKJUR;=.Z[U?(E%U*\?_V]D.++8LLJN_3D&9*2 MAEFD8!PP$_^2*:1)@&&:B4A1$L)D$7\MN6B,LM_,A MO9S2?:TM[ )@PR \,*48<,L3!G*$<"Z#&(J0:@<&8P1Q*F(8 M$QQ'":-$)E:Q+XNQIN;'F&/YO)15,]=.6$>&Z@+7CI(\038P!QFT*C%!6\ZF MKIH_OK& PRO!=(TW*J-8*'Y((3:W].,,T]FV;&Q;E6;1JZJ]P#PU'6O$M\5W MTQIQ9R,(UA$)L]PD0E$&.<0B22 /&(4L*< M6AIZDVQJ?+1K)GP#MM*7>UUM^>L"AHYY>O[,:<=I;V*DH2-J?NSC3(C>L?1* MG_ZD&Y5LO8-Z2,W^!^A)Y)O5(E_KP?0 G_.?YJNDX\NIY="E/ Q(E" HN!41< M(LB2.-6.-@JBA&0Q(58%0/QB.\I$-C"REE.0%[R&GE/VH&K$'""1Y3(:?F>% M\\.-2_,7U3[B[C9/ '$\Q?:"DX#!1@LDD"(G RHV;G<:?'EV78H%W^:+.?_VK&YVXH:]G M/Y.RKR")]!\HD"&DC&$8I%P%<:0BB9D+=P^&_1AT7B'_9ZT"I)4.@"^?GI:- M-?92CD@)?P-*,7W-UWT0LWK#.(FP:B3 M2B]P#N>9?@_I-_5\HGI.6SP4=W)5/O]C/M_HH6><\R3,*($AHQPBS/0"P/BI ML4QY%O(P2$3@-LF<&6EZTTDM6,E5FT+L#E\X4M8Y:'&4?4.W] M"\R@E"F1@9[:&7&*>GD =I23I36L"[D&^4)/$;)$MCU7E)"+^E22;]CMY@0/ M8 [,_HV$)FFTXOL;4$OIC^0OP."5SL^--2IQ7U#XD*(O7=Z3C,L4T_Q%?BF_ MCWOZ\SM=2],99,'S>5XFK7V7SW2]RNNN(9^7*SU9+!IQ9B$7"65)!D6 M'=* M,@:I7B% @>-$81ZDRLT[O5JBJ;'0[[_\^*4L:*XY1U6B EG+>E-RD_:BJJT_ MQ]V^ZXUGR5!CFF1H+FMT 94R93UTHP[8U\=$U7<:&1/5.H%/6]OI3Y%WA9+< M.= 7T'[9\FJIQN557R >,;"W!WN,V=33P)&G?BO^"A9J: M44JU%YA%$:1)C&&8J?%T95[SI;G8.CN$,=;;A=ZX^,;=;E 4Q35Z"Q4FW$(9I: M>$)X^+B$@TQO'ZEP!] J=M'CL3T.4GU9+)8O)=?_^.^-'JE,\:_WA2+.<"(8 MAXC')K]$!<8OCF&::(^9BYB)U*JKSZ6!ID:C.U%!)6MU_,3A5$\7JMUDZ!.K MP5GN)$Q]2J)TX>5P],D3;B.==W)]S=R.-EE@T7F>J>O^\0XQ66BQ=W+)YOJ^ M!?EKCUD634%Y)%.<1-K]Q#*4$$4\@0Q%"I(X#1)&<9@QZ5:3_W"(J3'C85G^ MRZ[?S3,R)7WSZEY M7'S_[)4]SR1^^'^?9UA0%?& PC"+FTYA.(QA$L82(4XSQJT6F>V'3NU#_O%G M7A3@\XHNSF]RGD>H^UOMJ_? 7Z=6>?T_8>#O6RH-C2Y_U:!WQ&J+XU<6QWZ+RE2T@9\I>6=_>C[W* M5<2'9;&+:'*"4A:S$#*L@48\B2!&@8 J%4G$J4RD3%UXZFB$J3%24YRCJA[# MEZ[-N(XAM".8JX 9F$KJHB1&ND'"M6=U]TH+QZ.,2@!GE3S\U,]?V+O#GC:F M88CJ1(E>/6Q;JOVZ7(H_\_E\EF%)4E.".I"(0OW-,TC##$,2R$030$2D<$H- ML!ET:I_^3F9 2Z&=V_!=QMEV]>\7O<'C 5O@*GG+> !XM^OX M!N:7?:3JZ..[WY9%\=>*:9;*!"-OCO::[^C*:]*/!5Q>J:9KO%$9QD+Q0V*Q MN:4OGU0M._Z>KQ\_;(JU?O)J5T&0QG&B$J1@AHCV9%!$($G,WJZ,,A2&0:R$ MU6:NU6A3=(/','5TCCLP> M%LH?\X?-3?T8Y)OI8'&"H,R4TI!45G5V+T(-:H[.D/QD.*]?CD*WCXJX:AW(!;'S.9IF#FY,Q=&G":'#I?+AZ@'NZIOUMW$6D'AO2$WRC\MY-U MX(8OMLCXI[*N0<&4D$5,LTQ 5&09)SJ M]6.8,H$)XP&=+>0#74MQWZ>OZ\EAK;X44GTI1X,/]]6TNI4V7/,*%ENI;[;' MXIJ<"5 7#]2.7N6O.Q+3)>O8\9(/L$=O![M=S=RT:&J(EK"=F S4%?;TF&_4 M&+83@/.]8;MOZW$(X8,YOX.YMK.5P+&-DJXUT?..B]>Z]6,_MU(='J#M/ MA_@89[Q3)!Y1V3MMXO.Y??=\5L]F?/E1LO6/[?G>;4%2)3%3&0Q%A"#*XAC2 M-,M@'&/%LS"@A#KN^72,-K4);RLL$%K:UN%GUXV?+H1M-WX\X3;XA-1 9@0% M.TD'" Q88>)YYZ=KQ)%W?BR4/][YL;G)2X_J#_4J4R4B%802R!&+-8$H!3%6 M(60BBW 02$$CIQ-NIX>9&G-L^R,_5V)>U6/Z@]."_7J !J:(P][1-W5O+H\+ M]&X,ANP'_>$MEN/=ZE[H\WQX];6AP#+9[>MR_4TI_*C M%)ORAUFJ6*1DED*J]!\H2T-(PRB%,- F"KP1!A0R?H!@HCVLGP M1F%%)X#.AQG='M.7^9Y7DE?%KO3/?RFW+M&+9K$78O?Z[?:WS^:Y;P.*6,<$CBT*0SAS&D,0M@ M@C'-,$5A% H7CO4JW=1HMU&N+#5Z4?_U;$ZOM]WRFZ6>+,W9>")8^\E:76 K%\38[-V1F*CGRD]OFL2 M6:I8=X8$1DM0JNEQ>V(0^+W.+7XE''6Z&03NKN:JGR^% MR2_7B^AR(OQ4K:>WAU09IUF4< 8E2A*(6!Q"@E *19003*EBB4Q<3O^Z#>\T MK8QP(/C>C &*M38#9$;V\O!,([PY.Z,G#?VOVL,T=4DJ#JE#%+OV!&OZTW$? MQ\UFEOL[@UEB:-HV\M;PW]%7,V'OY[S4HM\ JK2O87Q\CSM"O5#SNU/D)L*X M.TB]X#G:6>KWE![IGJ;+>JN_>O%;OI!?UO*IF"51@H-$")@Q&D&$>6IRS@F, M$H521&(II-5^<_D'JFS,VD:0KZKA^U5RWG):/_ B#TE)1X$:?.5,/S M=X^70'A1@[VTP,M7]\F1__[EQ]WW^T>YHL]RL\YY +XTR--BM)05M4EQSH\WA:D*4?E 9FRQ, @=M? M^]3G[P#+)0_<"VACI7>?!,]7FO9%)+JSK\_?/F)2]44=]G.E+U_>.W5Q\[29 M&\_UW,'M^E5-PB!# 4MAEF*AE]4\@XQ%! I,,R9)("*O."/G.5;4ST53=03F2T.CZ@=P.7 MO5H=7Q9?%B_Z15FN@R"2Y(QAP$: DR[ 229/2:L=% MG>-9?4/[N:L#,U!+..=>+AVXVG'/]5B-V-C/%,!^UTCZ5Q-VML&N3[>7RYCX M;OS2,>+8/6 N*W^B'8S%31[/I]YOELM55[M+VFG219U=LLL2I42 M,M6KD*N/IMO),C6_9R>UV:,Q6S7/E>#E)H[Y M^[P4_\9TMN],%?)N-9LHP&BV&#I2ON3YWZLY>?,N1N^O8Z;6P[Q]B?-W;"P.F3N^,C>- MSLN=O."=]@NK?W:,GG1";N=.^P)R\%FGQ/!'A6$EZ0UHR>JU0OE%1'R7*#\_ MX-@URB^J?J)(^>5[^C'*[POMF\_S_Y'B5YHO#%=]*]WTJJ7U8:YD'(9)I#(- M;Y(1B+@@D*@@@UDJ4ZZD"(+,B6*<1I\:Y[13)TV4A"Y>__$?QX:C!K#$QR'G ME>#<)!B5\7J! AH#QEZD#'Z M+I.+]3=E^H+MA)'%C^5]&4& D];GZO82&Y[7O MV>%&7OE>4OMXW7OQ#C>"$#*??5JL]<+K@S1UP#7S"/GSW^3KC&&E:!JF4*F0 MF-J,(:1!(F"(4IHD3 0BMG+3SHXP-3JHA 2UE* 4$V@Y[9CA/)#=A. %GH%Y MP!D9:P*XJ/V)[[Z0_)>'Y5]4JOFJ+U_8 M8R_X].F85ES^_>ONDOJDU*U) _\TS\M^HI^>GN?+5RGO].OSJ"^Z6VF.J:/U M]*%]7'$6LC1BL4B@8 I#%*<"$DX"4X)((HP4H\)^XWA$P2='/;4&0-8J@.=: M!_!LE&@VETU!9CT?*W,L^<4HXK"?.>9[8;$U/5%K#\RD[5.*;;W;FZ2 O8*3 MIQF-]C=@^ZXT ( & 5!" .[VWI7=$?:)OBL.&^43?6=&VE6_;QU^ BM3^:DH MXP[KQT-^,/]2*[2(K[MKFVW* M+DDW>HY<5;]O/H#J%[L1-6R_>,H=>(-7KC/18$QYQLM*> .4]U(8WF+\GH=) M]#<0\8#H]4*40H00HXE2''/A4H-G^V0G!AZA MO([)')F7AQI,]1PW(MW!9<>$O4 8F,I*F6[ AR[EG1GH2%&O%+)[^J@<<*34 MX4=\?$'/&HXG_<4J$^UVLWYQN]FI5+FJ'U[-K^_TV;5C*&]PKSV$+\; M__+W9[U$*G_Z+7_*U[,$IYF4"$&&27D*6$"2<@Q%P'C")>.2.G6H'U+8J7EK MCCJ6F8M$1@V4G M2WI5>IG27K75JP!8J _JA2XQAC M]IR)S'B/R[F^HZ@2:+\LZAJU=Z8&_'+1/GU^OS3]<$W#Y^5T#/HCB3*DDPI))24ZDGA90C K,D3DC 4!:D3ITD_(HWM=FF? -J[>I$ M9R!++?_%<4[Q:T7+6>3-;#/TO-%2[)_JM/(;L%4.U-H=U6785Q T&H(_&AU] MEN\=!'R_=)0:!]VA>&&:4_N=6^/)A8::B>_KSO5Q(<]ZN.6M>?)?% M9K[6XYI8A9Z.EJN[W:< \?F/%R2I(G0+GF < 91E"I((ZZ@ M8FG&E0R"++7*U#X_Q-0<[$;(?ZZE="F@>Q)"B\2DJX$9F-D.,>E3+O,T."Z5 MA:\%::R<&=L7R+%@<)?ZW<6"3]XY8J'@+LGWBP1W7MG/1[U;+;53M'XUH9'U M[4(8I_G9O 8?\X+/EZ;/Q>Z(+DECH=*009;P&"+!!&0\(A#) =1D@8AY2ZQ M")?!IT:$C>SE(8RMX&[.I!/X=D[C4) .3*&-V#>@%'P?5+"3'?PQR-GH/JAY M=?:L#S:'SUNL9/9RTNACD1B_H\ZH 12[D4NE__7V1FS85>G*3A7ZW M/FV,1/4D&ZD0LXA%,&6):4U.$:0BR2!.8\*PR9JG5L=J^HLP-6XKE7!P7OKA M;N'Y#8[FP+365$FN%0"U!DTZ;:4$J+2H.*_4HX\#V<\&#@[FX+88R0$=S"9N M#NM5<'8ZM/V>/)[#>Y7F>P[Q=4_JYS"78[::P9D(\F9ERD?/,BF22#O$>OG/ MD3E[91QE$4,AHTAF5*&0!V[%XL\/YO)AC5,=OOJNYLO% ]1SU!.8[\1V\XH[ M$+;S@?V@-LK4T)+R!NSD].?97L;"JQ_;,=RH7NMEM0]]5(L[^A'&1[G*7ZI* MC*:7Y/;8P:^K95$T [[.J$S"E,D$9G%*(4JU TI4&D.L J8D"9,TICWV>>Q& MG^A.3BDDN'TR#*\G:J6T!FY<8@F^':]XQ'(X MX>25?RR''I6+W. XY"7'N]UK3=ROJ-D>__'ZQ);S698D@4 RA3&C3/LP00"I MBC@,$HEH1'&F['8TCIX\M35N+1RHI+.O*+$/5S=Q7 7"T)L6=OH[U8TXJ6OO M>A'[3QNM3L1))=KU(4Y?,&9=B*\;LY#YIDQ-*CJ?ET6I9C11222B#"*L$HA4 M3"#1/@4D62@%SE@4)?'PE1].B3:U3[^2T2SX\Y:48QS&/VDXBSC8FYEC8!*R M*K[POK/X0FW,;PI\F8(QQZB=<*U11PJTC6_3YXH)V*/9:8T]ILCI<30^V8!XFG_!HD+=E# 13@\L\'Y\48FAHN*'W/$Y5NNG?JW MD;7]@%M)2C.!TH")#,.4QARB1(20!0F!0L9I$C I4X9=\N#LAIW:,MIG=+X3 M;E?/P1>(X_D36XE/1>@'D<^HT<$QLXSKLK5G=?D7+PH=J,;!%> MD[Z&LCCF)(,1,7&_$!%(TBS17DT2J%B04#&KN)_5:%/CH&H7O=ZHO3+EX"S" M=OSC#;>!::?.?ZHA:TDZ0/MS*TS\)R"<'7'\'(1+RI],0[AX4\]*5?E"?E,? MM.>4KS]37K)5V91HAM-81!))R)"I%8T4@5@B"F6&"..0;R@-C![] 7,O1S6)3#\ELXU_DT7,0\Q4(!%$)!,0!2J"3"0!)%D48JD2P:13 M_S"GT:=&*;6$8&U$]%'(ZASJ=J0R&)8C;@V>+#75X%R*/X#OT@NX$4I$G9-@ M C6?+H!C5\3ITD-Z)%J4109O'_2SROVA9L_H_2:?FTR.0OL_8<09CB!6)(8H M#BDD6/\4,I1& 8W2.!;6N1.71IL:897R KH5&"RV^1&LD=EA/_TBV-V\Y1W" MH1VB$KV=K&"77?)^"/0<$@Q\HCA2SL#W71.%$V]AW6E@?O#"^NHL8(M7YQ[_ MQ8>,MVUOJ\_>3KSU33UXN&JF**LA%N+;LUQ14[.C_(=M *V>[8N/&WFK- '^ MAZ2KS_F+G%'&190$"0REZ>P=91S20&'(XI#I%6Q&PS"PV8?W(,O4MNSO'^5* M4B.A ]=<:0X+'A\/Y(%9OE8$U&R_$&"K"ZBK0;=B^(U"-T"K!$J=@%$*&*W& M,Y##5#&>H4::2,8PF-OLX@?BSKGGRB'&FYG\8+$W;WEZ9,\>,//2^%*<7M)\ M^FE^E+,L5"PB',,@EAPB017$$4XA)DJ*,(TCE%DUYW,;=FKKC;)&8[VRY^V\ M4%G)VR[;ER]>M+F6*^<='4N+V,50_./\UL&36F2/_5.<(/+;'<5NZ'%[GSC! M<=39Q.WN*T*\['+*+3M,N:UJ:3=UM$VP^>\R?WC4XMZ^:-)]D-^EZ8^NN?># M*:U*^7I#Y_=R]11J J12I&D*&>84(AHC2&F (0GC. VBB,H>@>)Q=9@:F[94 M ._R!7C5,UK1IX'"R*^"0_1ZN@8>D<9[]B:M<=AV9#!(W( &"U"# ;9H@!8< MP.#A.:#^-K;T'Y8?68_Q@_MO8ZB36P1O)(J?^C!U+L>V$P!F.(DB)B")T@@B M%.O)D*4,*D13Q"(:2^Q40_'">%.;KGPF;'6@;#>[>,1NX)G@1+68)H-KB%X( MEL ,6CKF<,PWK1]S!H!+163.W=:/6KY+/J=%D:N<5ST--^MOZI;SS=.F7##7 MY;">GE?R45-E_B*_+/0"6WY<&JJ;280I"M,$4AP;YF$84H4C2".$$IE%F$5. M7[9\^?'K4ON7"^.'_GC6#NAR)<4GTU;F M>947LO@HV7K7J[9.Y$()">.4Q3#BYB B310DA"@8)XR2E).8H,B%F/L(,34Z MWFD BT8%(+YYED]X\_\48K-7)K:#89_WTNE!ZU^OJ<_-1W+8IWS MVX7XK/\]?UB4>OA!BF66Q#$,DTA!)!F#.%4A#&-"(Y8))6*G*=.X ML50_ ![%13T]MA]U?Z#%H_F_Z>/P0N>&6+[K\58YU_ZU^84>=_\?6E?.9!RB M*$81Y"+5Q!W$IK=M'$ >2IK%$=?N<#RK.O7]6-/5VHZ^KY+)A0@.)1N.$XR0 M-X#K/\L>MK6LY;>_VFI2_KYL=1O]*Y,/^:+ -V,E>_=)8[_#?6C?XV9#(,T M22F!E"("$9,2XB"4,$AC[4YQF@KD=$+?8LRIK6@KD35[:IEOP#-=@1R:TE\47#[,J4IRQ%(4,"I7HE9N2VL%/N(+, M]#;"<8RP7L +]F&J',>9=94[=J6=W=K*@PHW M)MR62(\HI>/Y]0N %U&2+0,42',>.FW+$G'.=X0/P,&YA!%DB,N3F**_U(O4 MY:/@B 5WM.^;*+=. 7#Y.NA#>J(/@:HP]ZS/"K.T6G^PZL MKF;MKB'[PHL092SV8.(G*41A@B'A'H&8"YS$7I F@=7FSGCDN3'.8X3.."U=_W8![^K=PUVHKOUM%NAY=RK;C;ZY!YT*U">\Y;;/6#H M@;1D?]Y4U5;PC]NUY,'[^O)=>;@J_G[_L''%Z'HNSX_&HMQL1'V*$P'9]B!S_)9>KS+[>9'N<[_)?A7 M54*O-_R]_#IW(MROU^2+._+*J_+ MEFW4]0U=BMN\VBQHA--$Q D,8J::Z&49I(APF,8\40%M(C"^BVBY5X5UUGW5+'BMQEUT^/BYSIC+0E)S;C7SI-E_E=0WH:D$D M^4Z)"6ILC=<02'"$LSP8LDFM#& 40D\B#-(QPY@4Q\JB5 ]IR_+F=!^Z* M+NV_#OUE3^H%=9'456ZUK91N:1$S3A\1YY'YNE]-3(D.WBGAWU^ SVJ_K@,8 ME I ZZ#39G3PNW-_R$ $W0;%6\HP;;C\,(". ND'/N;7Q2;G^7*KFH?O M2NM<_V+++1=<\;'R,&]KVKW+KLE:9?97;8)/KQ .%L3G20A9P&*(/,8@"06" M@D9^1A 7$4+#"N&X$G%N+-HOMG)?RM/11IVY=;]VT"3%[<):ZJO[P>5OG)G9 M\.+N38TW=K!%SVY]]?HER5H%ZXUT3T7UH5;)76+C1-5S7!MCI((ZSL1\HQH[ MKF%^N>R.\Y'LEA,N\L7EEN?R^_5/89EJD$ M^^U[^?,_Y&.G34(&+RK1SN&7WS!L)]=L$G7]/#GE/SQ] MK02_*6Z*GZKTUEZN"LVRQ..(PR#R$$0IBB$.B0<%YEZ,?+E+$Y%-)1WSH:TF M[P1E"3]*XI ]8DYW,Q;#3[I+L8?E,(\G$8L2A*84;UM4WD0\+#&/(P]9) 1#Q FU&NK[(.KTE[\EK MQUMFD)M1EG,@1V:K5D@-8?=+7^01W&M6(#DE*+.1)^4F*S .:, "A82U24\@C3BL0HN"B(>&S==_5!!ICJ;I.R:']=E;/14ZW5?LLQIM#"'&66- _+(O-4*#=ZU M8K]76.\:33>BCU*,PAXQIR1F,?RD3&8/RR&=#7B"':?I=M7/QY'3I]WK_6YV M]V*=E>N5BOZILX@6?A"P@&0>U!5:$8E]B'G$89*1*&!9J%*T35C.A3!SX[V> M@%9E3]J,0^:N_Y#/G_SD6Q$EPVQ2%@8 MT"1$,*'JECQ4%0(BDD$6A(22+(H(-KH?F9UF9QBS$&*/ M"8A\A"$6*8%I1+$048P$CMLTD0?#DZ_1R$:$NI_Z\3#!0EO'J^U$!4I6T_M2 M"]P-3K3N8)QF7=)]+)4+M%E==B)?' +J'$Z+\Z=S6"&1V5+J"^MI.[MJWQ6:M9^Y)"(RG MZW,ZGX@S:]]>[U3;W_2\U7-V[W&3S,KG%&CGW;-_&^8YN@]KZO#T$,Z='8BL!)CVU#H'F\& YZ!GGUY.Y43W' MY%;=-D,+3PD?Z+(PJQCQ)(.&$A(TE$/:ON0V;#SHW> M=M$%N\Z1=:Y+UE0;62J%;,M;F9G C,W< SLRCQW4:6EE[ER190$ZL<-CH"O3K2W.CH024-J!A^55$ K,5/46Q%!@*S!')OY&S&.H7@\XML3,PNOG"KN) MG'UG8&CGXS/!Y:1K[^0#IO/HF>BQY\@S^H [+X-Z[68C5M7"R\(P1!C7Z:0( M\UB2J\_EAH(*@2+!4&Q5HO'D:'-;V5XXW()O^@]:9,M2BJ?!'NXI& 3AV[@& MS-!SX@LX0F7TP_]NQ#<_[1\I;W*\/_[0P,Q8*7?3EU1O2A8D$Q&/6 @#Y!.( M4I]!&@D?9&'2]LSBPS60]1-".(<[ 9FQ,4(+<:D,O3 M@-CGG+Z@M=O,TL-!ILT??4'%HRS1E]XW;#+KL)"]9L.+ (<>B:GJ *ZV!2Q) M(/5P CD2E.' 3Z5Z-M/Y>(BY36@MH=WT?08WLPE\'AIC'YATZ-U!YV]WT_AE MW9U.Y&>&F70JOZSFX60^\F[3OY%.BC6.<_B:H&V$7$WV6[%W=7Z$F<^,B+ YBE5/E"8@IQB%.8110% M L51S%.+*';;\8WFTEO%LE^N5+1AI=I,-47+[5C)V AFU.04TZD"VUOI=A$+ M_1[;%TV5VQ'"&6S1ZR![+^KGR1(<5A$D<,>JHB/^)!)+=4208#FN(PYA1ALYK3 MPT68VPY+"PLV)5C6XEZ 0@NL;^)KD<&[[:-\AV$>[!G6.4UOTV ^,M'MR=]/ M)VW:;(&'$MRVEJC5D!M?T"@RN@4LKOM'M\1$<0 C6<0N1N L,$\&#PQ[\G11 M!6=IOA=N<-Z3!BQ!-P4K5^*!_&KQ+R61=6]56T1"W5M MJ5\_.'G&J4]$)C<* >411*&'8,I9!'&<4N0E@G!F%"D\BG1S6[CZKH%]N=L@ M,EUPM%(O9.4:O&L *K(N:HEJW16C:VL LR !5 5]26 M&U">5VQ9RF\ 62XE"8-'LE:!H?5<7HM_;O.UKI2A"_ULVFF]/IKZ>?W]V,CO MQV/+ -5OCA;JL2QU<@UW/NATR_M8>.VM_*,-XK)X5-V.YW*[^5&NE8OH:R&? M^,=&#E<7KKB7TZ6Z_B76+*_$_5KN5KZH'4R[7U'!E"HM6FM3=ZE,!>9I$#"( M T8A(GX**9,;!Y+2./,)3W!D53%V(KGGMI%HQ-(AZ(VDX%U>U,6?*B?5G]S; MWLP3.$.+CKRA>+8B4_],5XM\ 5K]@%80: TOFIY9H*?BV(661C/&!&64W,L^ M@R))HQG$K 32>,,/6\RNRFISE_U!EEU*B.?)A2=C,21^+)<=&GJ0!E1 0C-" M@@1E";5:=HY&F-L"H014&\M*B6BW'!RC9T;<9V$RN@NSAD-+-T)PRXNZ.V6T MXU$FY9X7E3QDB9??:#>?J_5F\460Y76ELG N"][K'_I1/,IC5+T3_BPM?Y?= MKU7E_;Y6, T MB%.(0J3V/22$89J1)&!IS#UF? WWZG!S(PA=!),U$E^ 55[HDEC2PI4T E>< M#:X_W#Q\O+0L,7H:=(-[,*=0CLPE&L6K#L6\+75=>\H*Z7Y%_DKZQQ3 YU3=5[&IW(M\N_%T070@O@XDF?3 M&'KW*B\D=/29?4*IH8.+'=(C>W.:I*U M&E&?CT5PZ-TR \:MK^N5,:?U?)D!<.0',_S8,"*Y_$GRI;H#EL]7OK9=V6E% M8;^33?/;_\@U(R_N"O&_@JQWG5:XQ,%#L0=C/_4A\GT"J8^8_$EUNZ.8AK&5 M2_P\<>9&0UI>4>D%5ZW(A0!/4EX[6CK30F:L-1WN4VP_^^7K.\U@5JZATFT_ MO:+131Y]+Y>:Q%3UCX*#/_+B^U)T?]9M:"Z 4AM(]=W1HAODG;+FF2)-2JIN MX#OD7$=/'7KQ*#4O-G7\^O/#D^1Z]F-%UG]>_LJK!4JS,%57$;%/)=6F M&8-I0N0_<>B)0!#!B%5Z[&L#SHU6]^0%2F#0R0N^*8DMZWR]BKCIW:4['$>_ MRAP.X8![33-<'%]SOC+HQ+>>9A <7X(:?FY@P%X32GZ7O=!S:O6X+)^$T&$8 M]_++]T.^0P5B*)ZK&U=5U795QUL<1 $'A(1)&B(8H(A"A'T?DIBG$ <1Q[$O MJ.]E5D%ZX\DZ-X+K1_CWA 9?FX#AZVJ3KU1;/!4@_&R7/-"B 30I,+#\R)?>-?JJ]X@G#7H!.X[WOS9C5#B8PCMN OA'EG3:(;WS@ MCP+W)AARH!N#_]^VVNBVB*J<'JE^Z+J8#V4;[2X^BTT= J^::#V45_(M.DV* M"_[A21'K3=%U:KADF_RGWN!?TDHNOFRS2"*.TM /(,-^!)&?()B**(-RB6.I M1R.>VC7L&5O@N2UI/7W5"M8FKPA0B$V7N%+JWW2;C,=&5=5LMNPZ:)!.S_^T M=**,_?TP=+/,R.HC+V<]52] HVQ=1OA"&;I3&$B-V\RV=TKI]^K/2F]PW_L. MO--[G[QX#W;]5';ZRR-+@X##E6TJ8[GUW8PM]+3>G8E,<.3_F6K< 6$<>NFE M)QH(TZ?=6_JK\UV6B;44I^X/O/"0S[R 1U"$0091XF-((DIAXA,O2[E'/;/N M3"Z%FMNJU4H''K5X.CMJ51:;'Z;944XM9A I\@9V&/M8='Y'^LZ*M7)O8#F+ M")4WL.!$<2P36M(N:,4QY"=#6UR--5T C&-T]L)D7#][P')Z^?W[6I?-NU%M M(W M^2_8&Q*(7WFUJ701C(TJKB&6FBM^ Q Z6A$,T3K)]*\]8SH&-]1FCYE-/_,2 MX_8-<2M_^OO?VE?D/XK.__ZW_P=02P,$% @ L81)5/\FE:!.\@ 7(T+ M !4 !VOR*G[NN@$OO2 MUM770ENUII0IF:3LNC,O-"R.$#L9I(ID**7^]>,X9.R+#LD#'H2JK;(D!H/B M\>6#P]WA__\B__]G\1\G^>O7_STXM%/#^#^?JGYTOP:T@__3%=?_KI[PE6O_^4EXNS MG_Z^6/X^_>()^??N'SU??/ZVG)Y^6O_$*>>W?[O\5TUESC)8 BX:(K6BQ*9$ M"5.&:1TD#<;^WZ?_*I.2445*G'"*R 1 ;*29Q$Q%X#1'[UCWI;/I_/=_+7\$ MOX*?D+GYJOOQ+W_ZM%Y__M>??_[CCS_^_#4L9W]>+$]_YI2*GR\^_:?MQ[_> M^?P?HOLT<\[]W/WV\J.KZ7T?Q*]E/_^?7]Y\B)_@S)/I?+7V\U@>L)K^ZZI[ M\\TB^G4G\^_2]=.#GR@_D8N/D?(689P(]N>OJ_2G?_^7GW[:B&.YF,%[R#^5 MOW][__K&([\LUU__'!=G/Y=?_OQ\@5!XYT\+J=T_77_[#'_YTVIZ]GEV^=ZG M)>2__*G\0WPD9XQO'OB_KO[QSU?/_KR$%<*EX_4-OK']CO*TW>F KVN8)]CP M=O&$V2+>^-"L2':QO/B7,Q]@UKT[23"==-]\$E;KI8_K2;0\AHBPDHD"D3X% MXIC$'P7D'"&#U?XFVX7D%=+<*6(%\<^GBR\_XQ?_7$3Q#UE>DLW+3B9W'KF1 MS7ZT7ZR]C_C920H^ @^:..-QX607B?<>B- Q"IT,#U8?3/KU)]ZD_+I>3Y;Q MI\4RP1(-R,4C_3+>T?%-\&X_\?-GO\0O(O'3=)8N_G6Q)$/H;+T80'H;U2"Y M?_H)N_B\6*XGR64*-C$2L@EH M-GDFGBM.6$A)9)V<"V$P[5]_"+:6Y-!Z@SZE,A#]I*XA)*)4GC&@3GIA]L\;C^]%S)4N\@81*HC M(^/E?#U=?WLUG<&OYV5PLT91U@O^ \H?GB_/Y>OGM^2+!A#)FI9 H MD8CNL=3(B8^X#VK<$5F"0#E7 X'C44)Z8<6VCI7A9-T$=#[ZKZ\3BF^:IYNT MUM8B!LF3@!A(9@H98097 \94Z#?)*+@PV3@Q$&@>(*$77%SK;Z1S81#.N!;K/1.ALR[8)Q&7 ;3,'H0S@G\X.!))['M\OK45;1\BA M@FT)'<_QY=OEQ\4?\XD&IJVTCEBE)9$0@7C&' %E;#:0'@_9#2< M\1Q"J"WAHMLGWR[?+1=?IO.('E9"]]I$CH0G#+LX".)\DB3:9#,X0R4=RB6Y MGX)^"&DX&SJ8>%N"R;O%:NUG_]_T<^=+<6^T\=H0IE5 L%M&@O! LDXT"EM.A^XIO9+674_;9NT^+^46*AH'EF@E&!+)<(&O1IDE!C%60 M8I)2Q\.MP>VG]E-_PSG/@\0X,@0^0#Q?(GP9#Q^GZQE,('HJ2HI6\>R)-.CX M!&\QPO:0A52&8]1T, 1N/[4?!!I.=AXDQI$A\''I2SW3AV]G83&;!*M\E)03 M1SU&RE9PX@.7A%'G<=,*EF9YL/YO/+*?\AO.;^XOP$86_\NO\9.?GT*7F!4. M:%:*$F5<*$D33H(5E$2M 8RBC,K#C[_N>W(_'#2QO:NI9I )>JX"9:'1G87HB,XR9QXP.I;I8%P\2D(_@#2? MK1Q"P$T@Y3\7LW-4P+([Y%NN)CR(Z!GS1.L2$2OT>!S#^$DY69DVBSR%EW"M#'@HF]U/0#R;-)RP'$&\3,.FLX'._AM/%\MN$$<(X( MD1PZ4I$1:STG7" 37.A 8:CRBQL/[@>*YE.4^PNS"2Q\./.SV;/SU70.J]4D M*,F"98#8]6CQ?"DS#$82P8+ Y^>(TAD("S<>W \+#60;+4]S^ M_KI<_+'^]'QQ]MG/OTT\#8PQFXF0'$5BJ"9!2$>\CEK)H#4+0]F'>PGHAXV& MTYA#"7=DC+R.>7ERGJ;XB9/U&E8;';R:^=.)Y9[;9!'IS"@B8PS$.V.(AH X M%]EE?WP\A#6EU'01?__P"<6V>GN^+M>22V)_ MDHP.'C(G2D7DQFE&G'>;$QTN4Z!J@'NPWZ>C'TZ:SW\.)NI&+A"MKJJ5(3W[ M]KY0 O,('^'K^AE^^/>)$%E8))Y !%%* B+QX#-1TN6@CZ+OD]+N3 MV'"RM([@VS!#R-;2SU[/$WS]&WR;<)<92DF0%'4I)LGH&LR:V']T-%PQG2(83:%"XV-[,W3# '' S7Q%DC,0A3B&M)8SDY,LX9S5,: MKNG%G<[PGN#;^S3LJA+U[R>Y\7RK/N>F[3VZUQT MYSL.;F#T.%4']C$JCYKC+10:'WFCEN1SXRHG5P@F=!(1]^\^O&(\=I M8C258_9F#Q0YXG*:'2D*T:,,DZ,+*&+X4SDPW?T:P\< MIW]150#L+,2G&XNW_KH>.T M+:H*@[WDV>*._GPQ7RUFTU22'MV=M"X5LLAO/\/FOOQJGSV^Q[<.T+9P-\H/ M] /.5^34^\^3DB4Z@\L'7@)*"J.M58[D:!%0H5S4\8BO[%CP1@0 RAY96-FO M0J?U[7.ZU?4SS-:KBW47?O1A!I/DO:=*>F*Z M%#S5@03G<<>SV4:G.%?I,==_?_9NTC&.2S&D[B^,R0!R'G%K62W7DW?+13J/ MZ[?+#[#\,HUP\G6ZFE#AH(2B.G#0-W(K'O,Q+G. #KF$$ M?[J-CXMARL7BS._'0^2<[H+!12W073GN,K$S/) M'+2R*D3SJ/^Q%S[NDC$.2(;1[%V8'"CF$;%RL6RVC/P"W85'2[DR( 41Z$"5 MN_",!%J.[JA4$(%&QQ^K_-]_K[E!QN@8.52MBZ%D/") .B?^^6*&;W7]F[Z MGZ?WBV]^MOZVY<0[&SV/G A0I?A4!&)I5.B09R.X=U2X?BF81Q\S3B@[/!H& M%F@#MN-RR\70 5[CR]7$@F:,A5"N/6%09@P*AF-X)FBFRB<:TZ/GG ,XJY>T MC(.; =V1@<3< %#>PQ>8G\,KE!+&CIWG_O?I^M/S\]4:O?JK5+^3VC.I$/_& M:9121BE9Y]%2&DLI")"R#GIZ$MB(A[LG#A;UE=(^UEY^C;/S4J%TLEH!_I<^ M^J\3%ZWQFCO"7(KE%@6R*(0@";*T2DIEPF-U8=5P=Q^QXV*P"FAV ^;!&MP; MI%]@&18#P?3Y8M4Y%B^_?H8Y\G$I.2^B$K'4Y=,(1)92[,"R0)Z"#JXTWG:/ M=?O:'XL/4=3(/CJ,T1M$[ U8N<+'V_S7Q2)=]TX_+&9I0GFB3@E%7->H -<" M+@5&"1?H>B2!$DJ/W;X\#$#WTS2NS1I&Y_< :0 %- "E]Z@-). 3LO$"+>]L M\;DLMZVP)D8&'KU5**/ -LW/[*:9 0-<<$[&1PM/#MD:'R%K7)M4!5##J:&) M_>T#S&;E]AG,8>EGR-1).IO.N\;A)?2]X(M)SZ)1EE!16D G[8FWPA/&K=9& M:ROH8Y?]#H@7>]$WSOEI59Q54$P#1NSB$NSSQ5F8SCL-%=\1&44YE_/*:=J> M39XLEZ6G3W=D^;QK[_-Z?G)6NI*_S0_\DS=3'Z:STA5LXKB5'!]/K'04;;O7 MQ-H2S&<=@HPT*_'8Q:+]\7HD!L<9:%,5\"U"HPD3?5O:$^#4R]+ND$'QK@U' M*?-8QD$9([6C6K#CA![C#,^I[B_N+>S]#>QB[6>#@&5;VS$_W9S$OUFL5A,? MF,TV&%1KJ;4WTI2V1AB#&\&\T)PE5>>TZ!YBQMVI!XY2#Q5V WAY/?\"JW41 MR8:'KI<-OE/.,I=RLD2EC-NPUR@N>9!$9N\=Z5C+[5U MTA\/433N9C8XD@80>P/P>;O^!,M?%_/%34M[$?U8Y6AFZ,$Y5T9'&.J(=502 MSR2-&(?G&.I8IL?I&F>47*U-;C@5- "HJYWZXMQB.C]'IJYJ8I]!7BQA\[F/ M_BNL7GY%MQ*5AD')\ELG3Y1&+"<>BRY$OUAK$V.\UPX,,UJN$D_T%W(!E>>F7P[-K-7*9E M-.>Q0[E43!.9A24N6$J$"8)Q=#^=>FS2P?Y >8BBD6;M50+-(')OP+KA%!6"<%?Z%$'DN BB)]3:!!:Z7Q\%/!TYXQZ4#Z/I[\!G=[$WD2R_ MS<:+Z>Q\#6D"Y6B,:D4BI[B\> 2LD$CRK@0V>I$;9W2L0<(&O=D_"@(VD?T M36#H[S ]_824G^"7^M/MD*FW^4[SM$NIY90S;01K MF*]S.KXKI2/-$*VTXU754P,[85_^-J9:L.Q$9H8PH3FZB=J0P%TF'FRTI7<* MJ[1#[D3FN#MG7<3L"<_=U=>RE=Q:_;N=)KU0U(A0;E587JY6.()Q;R#"VLR9 M#BK).KG:'0D==V=N :&#J'! C!ZAF4/IIKR$3S!?3;]LTW\W&3FLJ\-]7U^M MO<-W>1FHS\/E,]_FS5-.YNF>9U\BE25.O0.+?B#+1&I\Y:U%/] SK963S,1* M-82[$3IL>BSZ*$ H3[@L-RR"- 1=7DZ8M%P:295)=0*/W=-C]?V^"DAY/'>V MB_0;\/BZL[9[)%-X0<;>YH_^ZZ9/(KZ_!+^"%[#Y^ZH-'RA'K0DDJW+#1L?2 M>,OB?A G0B7I52]V@?L=R1Z$.V-W& Y DB/K.>&D7WRQ4]GY>IM7BQ7?@;; MF9Y36)VD_SK?%,-<2J1,84,PK-?+:3A?EW_UD9 RTZKT M:7MTA&B=W6(_7L;=/1I=*4>"1L.+X]5BB5'N?#.4,7[[N/3S59G5N.&V_#3; M\+Z3Y7!66I.R(3';4A5./4;"21+M0$677.*/3K8:?MU487/<8NU&E]3X@&IX MM=W0S2/LZJR$4XIA-):1W>PEL1PB45&'')(/$>H4C1Q(^+CEYHVNB!I*;Z"0 MY1Y.+[B4"\L-ZY.+8(X?-0FAD, M9.-DJ#?+ZA.LT7V;54Y7WWS6,7/7CW Y4B([2(N(*D8SX@*5PDGB+,_XAY9" M9X, KG.Y^,B)[&&"BJN(0GEG$BO'_+S7V$SN'MYZOI'!\V];-W MB]7TQC@!RZ1C42:23=9$6N>(S3J0E+7ARE,A*GG\?:@[U%*6%F?KJPOH0?#H M-$9O&,&54R/ 9,L(3U)L M"\2-QO7(.1,!G)&ZSCGK(T2->_(S/*B&DG\#4#J)L?1E6F%( +@ZD*5?87W! M"W,\&18\X8JCC&QD)#"9":X4KAQC*,)*;M(C5(V;11L>3(-IH $TE?XH<_S( MM]+) ND,&,!&8F3,Y<0DD."I(P&,+Q-'=;9UT'.=BG'/ X9'R]X2;@ =[Y;P MV4\O.G?AKMQE+V[(:!(89.^S)5:P[IA-$!]5Z126&&@O&*L4F?4@;MP&-,-C M:6A]- "QF\1K%2./21$/5!$911D.$Q4QSF1!792*N3K[U\ZPJ=9LIL*&M;>, M&S@S?+3DKY)(GYK4U9?*2=+R4 MYB;T"2)X#$] *R.E2)Q6\NZ_3UT+7O\@$!I<%0W Z\7VL9?-EBY9FR0CH@.& M.H\R$ID5VDRM2A[.>&-UBL;5 =7#-+7@] \"I8'$WL35YLN^OO=MTA/@RKN0 MRM%U*:%+3!'KD3L>)*.@60ZQ3IN_1\EJ(0P8!$C#";\!8W0MY"U] [=!#0]* MF. S 8INF[3 2DB08-2DK7")UFNS=2\ZX+1Z'1,[!PFX ,1OZ)U%+J[/F MA&9>\OR2HARX)*9,2O MQ-\_+68H]%6))-??+D6#[CV@>^9)2F7>4+GD' "Q'DWF5"464B5+TI?"9N[T MUJE!J:*H!JS0-;YNY_: @W<"Y6.UY!@.(#O.6$,D3Q8=/"YXI7Z?#],T;E5! M'0P\#+1#%-( M"X.)-_Y;^4T\B+12\%8Q8TGPB KDF5/?$ CSSFWRKI@N*]C MR>ZGIQE(':3M!\Z"#Q!]&P!:GN-3[\AHDI)563*.Y!=++M&F.Y\$L2Z#]9I& M2^M$9@^2-.[V5P]& RB@ 21U <,];'3>HC&1>)O14*NL2# N$:5]\"E$Q7.= M@[T'"!HW95T)14,(OP$,W<>!@011>Q*H+PU/328NH;)Y#CI1#S[R.BV?]D1. MM4QU)>0<*/(&XKOK9X"7HPFOY2R$8SQY,$2ETFC/,D,"LY%HY+&D,7@R=3:R M[Q#6S'96S]$>4C4-)K/O8\F 34ER210K-:71X(9MLR4R4*4RM*WH'0P<$PR8AGCS@-+QA\G-M@1?=7. MD(]C)8=12!,;\C4V)H+;R#,HHF7&=<&AW P"7J:&.0-A IH;\^F71NI57?1?VMR8V$EV2P#BYPHY4IE3CD,+^T,%7,@K9%> M5!KL_ A1XYXF'P5-0ZFD@8WNKH1>S[?U7_=V W_>P]M,YI(OQEC?NY^5IG)86>XG+TL=.2U8V"U/.(;4A-(7$C]D0P$> 0P/IT>\E2R;:XN(MU6@Z2PP904OBLW+$H(BMSUEH5Z>4XGN4 M]0*NJP7<8Z?=#U=.Z\VZ;_19';0U]R/?7*]3[%';;C]\.8,+%7-"Y!':-M[,WL%DK\[;)[;.IR$!=SU-$O\:!L!%**:]$O M$9PXGCA)D*D)PKM ZPS.[$??V,G*@5'T> IR$"4UX#S>Y&HSZO?D?/UIL9S^ M-Z1)U-'9&"RAPJ C(CB0(&))M!KN)'52H':241B'V>K4Z M1TYX#)3)9(G*Z$I(4<:*.< 5XYRDUDMO0IUSPH=I&CL#.0*T]E!&H["Z,:2< M*0I),A*%*0$,>IZ")B92YI0S@M$ZM:H]B!L[[U<9;4.KIRW$W=GY!16@ M/4@BHB]QLF(DQ$R)C(I3H5!>KDX4] A18R?>CH>P@]31(K(N-WX.7J,AIEUO M3JD$"=P[DI/(TB<6C:US3^T!@L8M'3P^HO900XMHNK[+4P8:2AM*7^8%2Q00 M<51;8GAF(3#&;*PV%_%!JL8MYSL^KO952.L3MZX/"NPXO9E//S#+^IUOKS;R M\'N<#)]M?23;'[3,BJ(94KFT6F(F$YL1EII*9DNKK)"JCS;LVTSH !E\+$=@ M$^>XIAEP69BNEUQ6Q&$L3$(PSAHF@:O*(\DZ.IK)GPZ$B[L'DWM+O8'M[I+Z MC41*< M^GX(.@<+OP$DW>+AQ>+,3^<32R4'Y@,1%O=[F:TFKNOC[6(2T5GJ69T;8/>2 MTPAR#E?W8FC9-P"@:X[>+W 68#D1P4@7DB$< JXME1BQ4@*AH%*D/#@%U3-0 M&U+&!,>[PT/HN%TT *@OE_FNV7,266SSY[@QI]*1Q]<*3Q18H5,$)0'66G$ M0V\2QSWLJP"T*KIIXE[+[;K=+1^L3+RP" 'GK"_3#Q4)/DFBP"CAE532USE! MOI^><0_WA@?4 %(?T62MENO)\\V"0/R_S!GB^ATLIXOT-I^DQ>=.+\6EI %< M#DH1I3PE,I3Z0U<:E$@#4:60)?2ZB(OI2U$B!R_Z16Q71-PZE M[7J37#(: R>)FE(O37$_9Z%TH[,"/46-*Z27,SX(F,8,Y^I@8 > [:&0QB%V MDO[K?-6UG-A:8J6!@PZ.1%EX X>6F!N-*#'"6J -;OZO\>5JDGQ2@9:S;H6QB;2I3$ZPJDQV+&44/CE6Y_[$ M75H:*=$;,*VYGYB;\,LQJEB6CH4O8//WZ_G=XX/WB]GLU6+YAU^F29#<")Z M3CM1"D)*0I#L-!KZDOSU-*-HO!=)ESOLE2:][7E;L%I@>%0X'::'9O#4IQ?" MO1=S-S?O)E$$C@%2(AY*VU_- $U^U,0FS0-D;2RKTU3@0,+']=*.B=1C:K@) MGP^9NN)P8B&$*$KHI,N]$8XA?&E43:02/$GG*/Y5!: WR!@W\WI,N.TO_2; MTPGF/7P^7\9/**GTXGQ96A-LK&[G0DR$D2K+D(GU%*4#13I".D(C#1HW 69E MG:L[WZ=MW/L41]]_A]/3[MAS&^S-X;2<9WT/X$6]%7;8#VZN,]NH]= 4&'Q=].18B>B-R.2TVW:BN[CHU+\\^SQ;? )[!'/)T_6[FYQ, K@5S MGE"-DI5>>.*-=P3#-L.,"([:BJW1=J!TW%Y21WT YKZ9K^ #++],(&[F\A[@XG7??LNWOKKS(H 11W7U8#9%8E3PQ MQE*=H_5.U>F.7INS?FO@AS@3:@HD#2R:NV=D,@H62]@J#57(0'"X+PE.("EN MLE:IU4)G0N:$IVC(=$KG@-&TZ@YG((_KC M(K":CNKN!Y7LASC_.5 1C<#I),;%>3?"ZD-9%"B4U6^?RRWUE^7B^6H:9O!F MNEI/LA4V&I>1-4>+F^()OI,(3!C91.#U.X4T,I3ZF]PW._ M^O1JMOAC=9/XP[HZ7'UIM68.#] ]? ^'RP==7M%75F:;/2,,31F1"O>TP!0E M'GB*#!"#MD[+SL>H&N#$N7SGN^7BRQ3E]^S;;^@NOIY?#DT^B>OIE\TD^&X, MWSF^M_TE:NA2-B8!>*,BP767B[?(,/XO6[UC4E)+LZ=U\NC#T-](3>*AJ+OG M0/O8RFT@%+AYC$^-,TQ'18SR@/Y'QDT"G" FF&A8#-[0.B5FNQ=15 /8&#AX MM+9B%Z4T@*AKP789ZH"B[!R0CXL2-<_C= 8WV/NXZ"GM2\GB0M;.98:AD4$O M0R9)@DR"V!R$X4 #B]4/0:?;>3HY M*^6D_[T]A&428L0-B@?E<9=",7DI+,' 4C'/14R5JI7Z4#>N96T:HH,KMP' MWDV[=<71+RZHV0X"^C8)(*G"G8E$7DH'M5/$1XP7K''.4)2F#W6BU+X4CEN^ MWC1PJRBY ?!N"2 FPB1 M%O<0%R603#4SB1LF0QU[VX^^<0OAFP9N!04?6M4T"'"?G:^F' 6IO-. MUYM(X13U4%*4*-SE%@)+C^]V^GG^J;Q\/IM+B5DN+1= B4FAM-U1&!:SKGHW2JEQD[.\3H%5?QK'O4O0-&8K*;H! MHWJ7L^TQ^ KE#M,O7=^5( (-LC2>0W>-2&4Y"5YFDC('SCR#(.HTE^Q#76M- M'X9!QG*":&K6?K^=?4.B+)2[O):@7KU42D;'B@BO"D M$I$4-/$ZQ>X"CM95 Y$ M./1B9)#H+0?JR@PC,#)&9U6=U-AW26NM/<21=^1]%-2J)[@\O\HQ%V=ZNZHN M)7KM=Q-F,L14.AX[+^/>4"V-TB/V(WB2" =1FD-X+%_X=%$ MX^+BB66BM.N&@R=B8U1$*YM*U426HU?.CNMK-E#$54F=^P-U@6NP)E!+ +C: M0;@V,26"]:71&BY/4>;UHN=#(&FFC;+:FSK>P##T-W*SY4CEWS65VX#M18_\ MXEIL_,?Y= D7)VRPZ1E81++]39J 92 A),*ECKA_E0(@D)%8QKU+Y7H1K0/< M7:ALLGB\*HH61U)I.ZU3[K!X\L5/9R6T+$UB_ RNBBM>0$"[ (+K&'$[*UZZ MS-22D .RFG6Y7IEIIG4N"^Y(:),%X*-B=T#%-I&\0N%&@+1ZA=+_Q:^WO'2) MN@WG&&@^][/9ZFU^F/6)%%FQF-'!CY83Z7U&8=-(DG!4"0]66E8'ST.0WZ2' M?%24'QT$+7@:UY@NG+S-'Y>^-#VX8ND_8);R8CGM5%$$,='>>DZM(A&8(I(Y M@Y&L366&&*>>*:]=G4SN/M2.F]QM#-=55-P"C&_O4,@T2G']K31/6N/"+=6= MGS>)URH@VKC55 @.N4[NK#^-X^9W6X!L'76.[RJ7!@$7 MW%UC;DM+URL$N?MUL8;K=1)29FLIMP6^]YIN7;J#(*_KGFPYTO\U1E:_QC7F9)8G;S?W7EHM+ MM,*/SM3)-1[&V56 +Y./5A5MII, M)5?%Z2,!W;B@:6$%;4.%5XOEU4"(LW"1("M\H2"J4-*!>EX%@+ MDA-8X< ;:GS5B.]AVII,+1\5R\.JKQVO^H*QG=OF!RNEQ 5(I.08T-*22K0J MD9"RL-X[8RK5]NQ+<9.)XS$P7%75[2![(UIX4^J=WBVG*.7/I6GS1@83$WV. MQE&4G&9E[%,DWDA.5%+*6P/ ;)W3Z$?):C()?$R,#J>T\8&X2"VOX0GN!!3S!SY\<:BAR$D0:_"$*N3ID&A+&F=D]K^-#:9L#TF6BNILX&$ M[8;USXY M"XG24$UL5$FPJ-F&E=FH2L082R=7KB@E$CC*4WI'(O4\^YBT MCW7.UWH2..ZXYFIXK*&>!ESGUW/\+EQ&90PDAL83QCW$H$MW8-!EC'0F(6I! M0$<4DF! 4ZU>7C<(&7F^3@UEW[G,OK_DFP!.Z;7WT7^%U04'WCHJF=/$"2]( M*7=##C!T="HID027S->YD7.7EI'OYQX%/@?)O\7)<[^6:T"PR!=W-?T\70W= M>[>836-)8-Y@H-_TN7Y??/ $NCWH'V@*W=W'7&),>BIY*=%/N=R0"@@O?,<3 MF;C0(8FLH=*@H =I.KC3[_+4S[=3&:ZF_N$/S_QJNGJ;WUW3WH4N7L J+J>? M+^8ZW*'M(VKBV:P4P(@LHPFYF&#MBY- 2=!9$&YBHEKFD&T=@55E:^3Y-,/@ M\TZOX&: \&3-:76S>F3S.I:9-8GI'!ANX-0;W,HIPMB7 Z/DM4_@LY-/S;G4 I.2IU D4:I 'U^OEIC3+2\O0R$9\%DK3&X MHI+(XET$S@,17CM/>:+"QBI VHW.D<=0+#:^*!=NEUR.^ YU7?)&WER4R6,#:Z8 M!M#VBU_^#NMRE_ZJ-\F&I4G@+M&8,@F6)2*]1$X$UX2BU+R)+'!5YR[CPS2- M/#.I#JX&4D$#8"I=;J[:ZM^9/K)E*K,,F4I!(E.A$X[F%Y-8=L>.4T@+GWJ!PDX-,+#&EFBZX?4G$)D-ES?,B'15[_ M@5*_S217H;00!2*TH$0J4RH!T:#[TO99F2Q8I>G*>Y';"X_NB>&QON(:0.?% M!*:[24!.0]9*D& 8KC+&/;%<4Z(55128C-K4.I6_GZ)^&5GZQ$ VB/P;P-&# MO=_N)I>CARP]\*$/9EM>'T]3Y"G\^D:WDR_0-J\>9M7&H3(Q?BC<\'*+3-) MK$4;%R6-D!!_7JA>T#R0D'Z ?"JG"T=730/;]"/L7OQJNPE$YM&/1?\C:EGF M4T<4I@B"*"YISJ4D7]4I!^E-8C\T/K6#B#H::@!Z+V Y_>)+!] [B\@)S6F* MG@116HB4;DW>*TF,3Y #'Y.B[APS3U ]=3.W,82 <-H*GDI9?P">8K9&83 M1-U?W4G+=47% %U8CL%41)EYAM*CCE/)07&;ZUS5ZTMA/Z0]M=.$*OII '>O M%DN8GLZ?G^.SY\C'TL]7**NN\=(\=3_.-GV8[F0:O0]")K3446@,Z"U'IN/1[Q6\L^>_UG;6G4LKNI'4L,J8T&P/4K_'%- M4,O%'%]&N)8,NL.?TQ 5SP2]55S=*^\'OJ1UE M5-77D[TZ^K&DV>M='-U^_7&NC=['2_U+H\DR84()15/I_\ 8(S[:3%B(+)GL M1!1U3B+K71I]L#SA6CQNHY9< ,D"W0$)UA&7DR06C$<_U"M/JS5V_@YMS5X6 MW04IO2M&]E/)D[57%[_\U2^77:;H!:S]=%;/@CWXP./8M'[\'N%JO!"4)9E) M=K9TN?$4-T,NB \QE#8*0?FG=C7^U_.S ,NW>=N;N@SW/=W,=N"X'C/7D3 . MN/-+;8@W&MW12*4%;3"JKE.J]"!)S=JT77!QQR,;1 %/UI1M;]6^A[@XG4_+ MXVK;LH>?>!QCUI/C^M;,&A&U8ZJ4\Y8I0HD3+S(EJER?L0J4K330NJ(U>SB\ M>;M\WC4T?CV__HENH,T,.J=Y$IP/P0M!C"NM-I,3I8.=)4%&2)HJZJL-^#R M[&:MXB[XVB%.'5B18]>=/%_,\*W%QJ\Y0?\&6>OX?/;MY'0)W>N3K]/5A +- MC(I N,0_)/,9G5H/A'MK3,P@8L]AWGV?./:\S*,A8%%;':UB[)*C%XLS/YU/ MN,$PJ5SP$%X!D08D\9H98IAP*5D?9! '0>S6 \=!6$4]]T'2(4(?&TAOW__M MY)=GKW^!XK-.HD'BF-'$:HEN;T0KCZ(QA%%JT+YG=N="X -PN?&U#8+B()4M M!I%?V[G^1RTR^L_P>@UGJTG6GD- %Z#$1!@G=:.R!/+/-"^GMBY5NL!W,.EC MS]L]]EXXCLX; /E]K9W>3'V8SJ;K;Y,$P .+FFA=+GQ E"24.[4J<,I R8PD MU;H7\3!93]-1VQ,B=V],#*2OUL%W,V_PWY F%K3.("4Q(J#P1$C$">L(%MX&YT/DW;>01X'J;1!O#ZG99X+[]NATF5TFC\+WWT7R>&^5(WPPD7 MU!'IR^FUY0KW)9:8RLFR5&5G]**[7PX^3R=Y=#O63VCXDF24D8GAI%)R"(*[XOLQR[KU0"*,Z.=SA MD]J;H=FP+"TA_2DJ Q!$BV^ ^IQ-NRLG&4/5&&&V'2N+G^@*%OT??IE6DX"+ MT6L'))< %0--1DJX26R63EJ&H6:4WX/D@30TFYO>!28WAY@?1Q]/]CSOHD3# M7ZO.J&T2'WOFD7KU]^6ZO@$,^&EG J+,,=SS9#!\>]RZ[20+F>%#9K M#W=!S9V*^1KJ:2"Z>9";9]\^XE=TIP-)FW*7/1+OF26RFZEN>4"(2(C4X4M: MIWB^!W$C#YZK@HJ^!8%[JJAEU!6&MN)ED!^GBY>OC[[O%Q\V:0:MF=5( ,P M,+@MI%+, 4'A DV61(U3;^65Q><<"\S39X2(T&A,P*:!$43T9%;ZICR*M4ILWV8IG%SV+4!-I N M!DSI'="]'>*G^6*V./UV*:4+5IS@*I8!>!Y*8W!<)3Y"Z9NE(C=@A7)U,L\/ MDC1N?KDVJH;1Q(BF:K5<3]Z7-'OG-@B=C"E=2),N*:-LRR6X3(EW:'6- IGZ MM>[$;[T&'?SI-FQN/';D\;\UG?C]Q=L")K909E0Q'WTF@67$L^&).%,*Q3P7 MWE.)U/5JBMX?%6-Z/ >H[+;2]Y#?R&K_93J?GIV?;0D/5#L+(9<3-21<1(E\ M!T=R9(%2H#3X7@YQ+\7?>/3(JM]'<8LAI#BV^OW7:X2S% SSRA(151FI*\IP M9T<83/U[2[&!F.7!3?#-Y9$[Y28*A3;1V:Y'OD5H M1X$.$[K/SIE2AU?G_/'[M(WK;8Z;#]Q/02U#[K<5Y//9FVD&C/R-DMEW%P7+ ML#;H*CPR<<$FPT**N=)-S1[$-9J9V1,/?>&VIW*>[*GO1=?+_X!T6A)5<3W] MTDV N]7(ZZ\84[Y9E-'U=4^$]Z7G.*?%@TBK_DFRC.C=&^=PU?M2-QX3;O8B MD1295#F8Y"LUPZMWDGS56W.SU^BL,%@1HMQ)["[W E1*I*!<,/-S(='=A-[#S7I'_>H[2."]VO4SB[4+?C"Y)L P(Y)+&XD!)T(J2 M5#JQ,N0HBSH=2Q^C:EP4':3N!Z%SH.R;PM%%'>VU_*H67'OP@7#;=KH@&0+7U1U_ M"CG:J*:L.9V(SLT0)*24W$L#6F?MY/SWCGH@,N\": _1-P"A M7Q<8R6YX@ O;F0QNYDYBT*$I&N50KFXRRTCA2P13#@CJ%('<0TQKP-E'R[E/FWDJ[9/Q%<^1:!!:(Q.@39T+VO<0,VZ^O4XX MMI^D&P#+PVWV@$7O/+IF-B6!J.]2P1A79)TX#R8I92MUI&ZSS^'!RN[=X' 7 MR3< H6LK"I9G;_-%)#'AN(8<=XH8T(Y(&RTIA]?$2N^94S($7CV+>(.B5ESD M80 TB-P;P,_#0TTN$OW/R@W",FAVXIA%WT];0FDYE3+@2 C2$:$B8C+H+*RLDT^I=ZYV;=@ZABEQ.?U9 MB(!4>O!03KR"0+@0*5&KI?9U=L='B&KVO&T7;#PR\?X@)32P59ZD_SI?K3LO M$>WR(XU0-G6H3GD3?$(CK#&T"0E*1SU)A/5@A*;*LDK#)W8A?8.4$@IZ#HSG7N1-R[>#D?!;>LUN$I&+E)_?GYV/NNBHI$&[;QTF97IA9(DH8+2(7F;>^52!T'6F(=^=3"P \#V4$CC$+MR M-K9FV67KK?!HED$ D1:*9X%_@%+!19U$]DH:Q=V^R!C%\MVB)H:\-+N MWPVN-48\ MZRXZ?YLWGYKZV;O%:KKIX;J&^:JTM'PS7:TG 5>O3X:7,]J, 5!PQ 6G\4?< M,@2WP= ZF!R$_!:CBV%@>WSMMGA#[<;4%HSBWZX_P?+Z2)]]CJZ^_Z4'GU3M M2/= !U-OEZ=^/OWOCM;GB_EJ,9NFS6*8IW?7^+B&FTLL7>N?J\"%TIG>EHY M4HE$7':XA!UX8(J:!'62H(.0?_B5] ^0'LIG;KZYO M.>_CH2G[*6B2D"TEB@I#))>>8&"LRH]@#-6"BCI]8YNPGU>](!X,EK]/EK2)3/X)]W@7Q M#W>8'AGZ34>?U^]GJ>%\LS_^#(Z8&L_*,/K&_[^_/;U(Z0'0^"H^NB M5%9$(NZ(\UH3+;2,EBET+NH4L8RZ(SPZ=O,]/AP7VRL/[]Y_Q'?]9SA?3^/JY*\U;>UCSZMO:GMSVY2EM4Y)RU(@5G=SZ2U&<&7J M!0/I5086N*]3?_N#^MZ3T(V7#9*4$M5-"C-$AW\HY:5CVF?U5%SN'\&H[X+O M^I[V3N@8NP2A%(/!$I6U_O:K/]MTN?4\4V=EZ0@72N!B!0G:XIX5D[/41:WZ M#:WN5V9P#P6MS'$9!Q&+ =4S=M]H^'R.OI%?P>5 ^=LL7;1=CSKS[ -1J5QD MBBH33S%89M;BWQBI6M>K@TN_KM)]R1JQIN5@S2]JJV%$;&T\\GM\L8LNNU)F M%@!(C"83F:@@+BM%4G9"..T2O5TH]5"@]. S1NQ)74>;B^%%.SI"'K+?S[Y= MBJY;6"QHYIRS)*!%)I(I2YP6:*Z5D]$98Q(+_?#2\XFM##D8=8>KIZ-6@7?) MT45)(D.Q"+3EP5IG[S_ M?UX\/[GHP<>L <<5X5E8)%\R8JD"PKD60H*S'$Q/8-S^[G&VK6,!XB!)C@^$ M@N<7O[QX\0N[F(^7''],R M["W)$8&08#IY Z=^]G*^GJZ_==MI5ZTKP1(=71E9%!3Q4DMBG4N:48.R>*SN M8@7QSZ>++S_C5W=Q]3]D>4DV+SN$W//05N9NC.K='JJ,D7&TH7J[EH1V#ACR M+R!%Q#_7Q(&CA&J6G/76.5&G(^"]Y/3"A_S!MX_A%-8 ZNX*S]\OK^VB MBCJJZ,&0I%P9PHI.E_6:DL!X2M2PP'F=9G [$MI$LN[%66'X\ALAD"D<9;X1#6ASE!J,L8'L4Y!\Y!< MC-Q-IR;<>MYXJ*[[!G#_&O>J,[@LG'A3_L%%.P9'RW"V%(BW!O.5H%8'A6& M:=H;GIAVM,ZEQ![$-0FQ?:!PI\? L'IIL5:NE'$[2PWQ@I?+-($1=, EP1;0Z7"BS@VORYK(C Y?)< &29&W0G;6E MBWC&5U&*Z)C$0#+5N=L^)!>]K*CY)W$:1X/'Z-GK!SA[VS4A>>>_E1\F'@7) M!>YJRE&TVMG@KI8-)UX# ),*1CYY*S+Y=O@H\U.1G\0\AY]_+AE MAVTC<3B]M8K,:TXX2OP]G)9^7XOEMW>+-;XU];-?IC-8K1=SV*['U2_^Z_3L M_&PB*=6,4T<2^-(U*63BRV0M3S5ZAI9ZQWK6F@U-VKBE!FTC^CCZ;A7MOWU^ MM5Q@/+M9SZ\ )L)199B11!N6B%2FM&./ K<8:Z,''\'UK(?J^\AQ3S+;1N=A M^FD5=2>SV3:!\C;_"NMWRT6>=@(O\Y1@]0Z6L3@Z$#-(B^)+P3HB(X_$26<) M!ZDBYU0()PZ"8C\ZQDVTMXW/"IIL%;2W]X$)%T(9JW EI@#%#T\$ TY6IGI3 M@9ZXD#(=!,_;3^P%1/W/"<2#M-,JY+[3-L,"Y2D!VGX(O.0^! DR2UQ:*KMH M618'.IP#=#JIEDMJ&XX#:NY)-CSY&R["I?]E@1B8^XL/O)YO_9C+C/4A4P0' MIZ%^8Y2#I-)4LQ1C?"P7K8F5KHP)X QCG\2(22(&GEA*H!YH."^_VND_^E#JF[ 2+O>Z3[Z*C5H%W^\Z;9-EQ M+Q+AQDGDJ51K9"CR$Y8)Y7VZ/;;@Q[]/OI.>][E/OHO0QP;2QDV[7I!P48=C M=+0Y*^(X;@A2FDAPX7&,*8-SBCJ60[__%,I% MJ7/@TGM3:*8&W06I24 ;3((.4FL0">72"QCW?_\3N%&^-RP&D.C8H#CYO)B] M6;!GT\6;-\\O;KP%HT57]\X=@AJR)BZB/(Q)V0JPEH5^_07N^?(G<*]\;S@< M*LNQL?"+/SM;K#\A_:LXA7F$U>MYW/+!+;-*&$]2!@PJI,?MMHP[9I9IQY4, MCO=+&#_RD'$.TXYD*@:2[=@8.5FBE)"+-<1/\\5L<3J]SDG(W/.H@21>7+$R M2<0'EHGPRN@,FBO?TW(\]IAQ#K6.9$,&D^_82/GP^[=/_H_?KSM-5XQX+B H M]-2S+:,Z#3I/5H:2P]8"F 'N=;_T_V-/&>?,Z3@X&4RZ8\/D%_RN>#[SRX]P M]KF,)[S&!Q7* $5Q9.<=D2IB9$>Y0#M)%8\4WZ#]8I9''C+.2="Q_--A9-O M%:!!C\Q"L$$8D.B@F](Y*%N"6ZTBD4+TF3..KMF/40[_E#I,[I,1'!T>8YO/ M_L57/B:9&(X'X;".AG#K\A4HI'=8"=;_BN*=1%K\3)/8KCMM%/ZVB M[O$2ZZPTUPQC89=UQH"XC$I)C)>+9MS;!)Y2>1 "_UE*XP='XW!Z:Q69^Y=* M!\FUQ:5)LE];I,L4JX[TAC5;!.]3P3.HR.'ZB( M?G <5]!DJZ"]4P:;'>XM"@,"V_6_B.@1N90D,GF3%\2^PC+__[:_^I&9)\9V'U*\9?IROIHJ"M06,MIU X-)21%2B'>TX MR>"DCY[JQ.JD!'_4HF#-1?8._>9HRPU3$(D$[AW)5%)+M0Q"19[ M%07OHJ-6@7?[?!"DBX#T$021+MVL(BGGA20XGU7VZ(F[GCW"#T/,#GEH=2'3ZB^?;+[=[[CX.3]XU0- ME)N__9#+=&3B4EHI&$F,E>ICFXD7,I)(O<:]ET;#Z@PE>8BB0^.KV]_[$27X M##_P^R1EYQQHCB$F]>6<5!%K-!":54 %6^5N-X2MQ.HE2>/ZB8-@XG;\,HSX MGX+UZ&*]O4X('_BFP2W)?116MR>9>Q59(HZ6M$[Q>IR+FE!N+;"4TL9PYZ?$/=WN>^>#@'8J7 M<2/9RK@>1>%/87.^$-$B7Q/ 44].WW_X!MY?VYJ;^\FF\R#]X@.G[?EK=3B M'Y):+A$J5/8:PM3@]G[H6NI2_S0 T* ],>@V$\D4+B&*P;+35$0GM*.BSJC2 M8?EHU!G8!7WUC.;.BF[ 1SCYPR]3F6+=85T3((_H[F2H' MW('-55!Z@XQ6BF:.CX?;LZ#W5DX#R+KPIR$5*<%\M=7@]8J0J\]L*XD[CJ_8 MGJ=W,S^_-@1/)I5E1G=(2E^D*1@*DBDB10+&-;71LSIFM (W(T]^WA]5,?_AMRXS32HB8#1'. M&2(5!?26RCT0+4#RX$2J%+H_2M;(-3ZM87$X%>Z-QR^P#(NAO,O#/*AK)YPB M) V9$FIP$4J3!?%EHW*)B>AC5#3629H.Q4$KM6SC^[1C0*(!X_PKK#=COLOL MH@D3.C.&[I9"HT D-V7FMA0$-Q3(7BEG4AT_]@89(SN@HR!A,91:FC"P?X=2 MJ0'I!+_4GUY6:G0"6KT]7Z_6?IY0:MVYQD1[(5FV0!R7*"CF(W$^*/3T(V@6 M.,A0)[S?BBW(TOKH4?$VE BA@R!A.IA*!6D<"Y()KFK*AB,MSN"3<0V ^G M?5SOXJA06XRJ]Z>"])?_.)^NOY68]MWY,G[RUX>234JKLFA4(,QR-"NV7 RT MQ0G322=A*,^TCD=\,.GC^BO-XWPPK3< \P?\LH?$/5%4BH#_*Z,>F.A([;WZM=UV0@U>Z/W 4NK6'.)^XK=)MD3G%[28PDQ[NF M9,@$TXYXD:6DD3.6ZUP3O9><<9M[-8'"P]74@)6\S<1V#4VBLU(#Y41T7=)S MYJ4S62#:.F%UD(J+.AU\'B!HW/Y>3>)M'U4]A;*_^X4]8-W?XP\8O/!O!WYJ M5_XI7=IU,$>H]*7+8$+DH5-'(%@+-'E)X3BKNM'*O^Q5&2^EB6*Z"^<$"8): MM. >K,@.S7>=\_]_BLJ_7=!7N?)O%T4WL$L?R/.S;_=_05=-I)GVUH ES@M& M9#*4^%)-%%$=.9I(U>V.W&T#4"]H[ZG/!O#Y<&D;! >07"0& MO"<2REA#I\?(TK0V398RN3 '_ MT"BGX,I%;AN]I\8+HW@53#5<85@55\.IHP%L#98/R=('U_%-C%=Q=FB/.RJ?7SRSCJE.]]U7O0E43AC8.49"-HY()PSQE&8B=*3HZ(04>)W3]4?)&M=P M#8:1V\9H.%4\&2.S?R.GQ[ZNCL&IV-+I44@I\#%3W%-, MS?'"X6C%HE*CZX M)( R+^O<*JMI=JYOYWFQ/#NT M*=3N#ZGC%/3GZQBN@HDB6%Y"85^F'R2FB3-H'&560?[_[+UI MVI>/LFQU.T*V')8\$_<3(FN3V$T!&I"4K?GU;Q8(K@) '. 43L']SG38LF7Q MY/)45F96+LEJ:1N-0#I)A++GK7$[WGGY_24RUL7,ZP7 M.5FNE4*PIEX)JGAP6C PF")%EU(HWZ9%:3_Z.D'E:<&S#<+C:;(G?#Z^\[[G M;_W0)HID62@&0FE)'I15@#%:4)D9B2D$H1K;UWW([ 2M(^)D&Q1'5UI/B/QY M_N7F^FHE,7GWU"\=S\E)B#YD4+($\(5"16:CU3I[XTOC!.WW1'6"MO&AL UT M1^IE0HA=+:]GO]?^T-4)Y)PS67B&HHTC82@!Z)($C@[I,M#,\KUR2O13'P&) M_NDYB)Y\MI/X>)*K]'#Y]P":-=9=*2R60G0Z67UA8B"HPFO"7I(3;)1B>Y5& M[ ^;*>W,$2I[KO0#Y#>QVG^YF%]\OOF\)CREJ%+4!KAFM4Q>./ J.; Q,:&- M93'L%7OOI?@GGYY8]8H6WOP ;.P09)01!6/%H+,I^/ F<,8I,#2 MZ"%T.TW3!D#CZ'P/(!V@@ ZA5!.[M:3M=[R^,^S:D4G.*@$WM3/>A@*AD'%& M[7+0TEM9VI0?O$Q;?] Z! 4O@.M(E70 LC&L_]N'?P\5\I;'?<[UW2"Z_7%SF MJ^O%/*\GWLU"R$41*V $N3BJ, 4A,0M:QQ)Y<-RS9Y'(EI700[YZ_EG,XZ#5 M5DT=6*\-O&VI:[H3_;?G?LU,6T/AO";GV]2-4KDD<$)HX#8:S;E)IM%KX0C$ MGW\X/8[M/#4.SJ;>[0U)8QXO\/)61?A$1>]OPK]RO+Y>;/RC8U?%C4!*F]JY ML65TB@J[S$(.+F:HO1R@G*;(+GL!V@GM%/?(&NU8/H\*.YU-2+D6*T15ZE S M"@R*0E 2C1*1>QY\M\%9[Q5V0[#7KL)NB(H[\%3NCY."X_G(!U!5QU [L,2YU?TY2K& M]WGY]2*2B-Z5#=Q=U9SAU>;?NEMU99@SS!+OAI$\H_,DSQA!*H8VUQRV;'/A MC,G%Q. > U:+3G3< ;Y_H;CUVR^X_'>^?G,S3U?KK#1GZ)Q+AH3( IUW.O3. MH@.'7&N4B3EL,Y%N,SW38FXZ?#Q_3CA>65VL8;J=2_)RZ$]3P]^@%X\TR_\]-GL=OM\6(4:C,:^$! MHB4AE0 A$H?"('-.8S:N<=I\.W'G_Y8_0F)R9!WV!,M-#*W/+L_,%94T6!VK M96=DV;$V]11)KC*WHK2>_K:=N$[RY6,!8H\6WF.TTRG@KN[/[=JVQZ"3).E MW05.@O,9$%. $I*UN83*ULD0]YRZ3B W%B3VZ1H_1C\]86YWL[V-646K.1CK MZJ)!3Y<$TJ^PD"OAR7U)KO&C_O'C-;HN-AKU!AY+DSWA,1A<5F34%8I;D(\>: MFE),@9$HC&%%)M,FTW?LD*#V'MXD$#M$+SU!;)0:?!.5%-%R*/4YLLYY!Y*I M@L(R2XQI9F/C 7__?U/CR('*R7'1P:&XY7E#$?-]#3-R::,3&7@Q9#T2D^ X M722E<"-='>^2VR1X7B2M$T_R]+!YOA)G5!UV ,K:WTGBJG^K=4E?\?+)_?; MX*P85\?,6+!8I]X9BX"8)2"S+FJ)Z$2;^8%[DSCQRJ9QH;&A#W=\/74 P-OJ MRWJS/+R=SU160FI;P+.:JI4D,\P4N?G(C+?TJQ#;&,)-U$R\P+$IK(Z6?A>5 MB#_F)9V(NJ;L5EJOR>[7ON$875!>(! SY*!8.A3.1P7.A<)U5$:X-H[C%H*F MC63:(FD,'71@CIZS07Y$7',B2C;"^ R),T_2001?=(1HE&:)!V=XFZ+6[31- M&U.<%E ':J(#3&V5TXRC2/59$K17"E1@%KPOY)36O;NQ* KMVZ1;MI(T;5%? M6T2-HX?# ;6XQLMQVS8?A4&[A&:]B5'X ";$ (H)$EKT$:0S9'\55V@:%0X, M([239/+D469+_79@#Q\L^R/^[OP%*WVV%*N D35\X9H!*G10!#,8:C.WX8UO MV>^IZJ1%LP4K__;"2;Q/'(S?RI M8H=\O-$%$D8"8%D/R]:>1H'$!L)SCN V['QV^#='\PO+^0'[]([Z]Q>7UB MD+]:+NO:H-7-_?I3_>7/\U>?ZX:#=R]=W]_XC),_)XL2H$2I/F/VX'+2X,BU MH]\3.<8V/1 G8K"3_/"9'Z;38>R(F.'4!^^1A1%!ZRPJ;W60J"# 8]()*#A/ M7K,@C&W3;M[J=FE?&GWF!^(PW1]YN_PT3VVBX4TE/3A/MU/'?IY_S5?7JZ-_ M2+"[]\\^.I8]C(N10M5'/[\.=7EU]]T'4AZ" 5F'=) K(I0DFVC$:BN&@L!T M*5(6DW6;JLC]:1RC1/19W2%];9."/I#\?Z _^N]90)\>DZQFA(,LF8J1B&5SVW&CY[.-KZ/GW*ZN(Z0.6')28*WAZ);)Y>Y^4U<;K^K=NZO4?'+D=- MKI*'5%PF_T4S8A U<,>C("$'J=J\C@PF==HX_D3H;*O 0#E! !U!Z=_TI+V]]V/78GE1X MDEE'8+DP4-&3H0^>(B['M'-1HHYM,F#?D=(?< [1\6),@7> F&W+U[23B8O, M0/JD*? Q$(@6+5V4??KL)EQ?Q\EM- M(>7T>O'Y"\[KAFPR!7=CN9/07!4.-EEB*12Z84+R]*ML8[+::O-B1F6_3_V- MMBH.@L"BF3ZF1M?AM\_;^TYPQP0K(I%/DCROS_8!0D8ZY#AA".GFB>["*?1(<=W/B5R1DO+ ;.##A=N[4]8X!&UWU^N=1=&Z+P-KON MZM?/,BMRH+XWE-H,$GX'@/F9S/3%LEX [\JC;.;,9RMK,R!H%1 4UDU27DC( MW!7+)!,FM5ERLX6@LPQ$QH'5&"KJ &DOO%'/,FKK=.) KD ].-;<#O@)V4=6 M3,[!M9FC_P)A9WESCH.\,576 0)_6RYBSNGJ#4FYBFM5!WE=)?;M7=DX$+'8 M8.E,14B.'(Y5WWY0SD 100:=,*=&DQ4&DSI-CWL7*&VKU@YP^_Q-\ M+ZZN9T(X(U.(4'WWS^C,MOB_),.;BY?^($=5L'4G2R MBJXQ)';Z6B^*HK@V.4'QN8Z]3@5<=@(8HLJZ!%9RF_5*9U+KA2H1 ZA!ASHP MC1$CR O))Z?"8F;<(G\)X?]1M5Y# #5JK=<0377@V&Y[#S.8,@])0=11@K^!#U-,!RD9]'@LB6QZS@6#K=-]L M'/BH!1@MF'><:57:N+A__U?P0;!J^0H^1,=3OU.NU\/\LICG;[;JK MBBI%.T'7#21M3"TL0 @L6^")&<&"JN^N>]W<.S_S-WK]'J3Z11,]=& Q_WC_ M8;D:Y_'(N;G;1Q@ESUEX\,EY$A#+0&+)$&HAJ,QU6V&;=Z'M-$W;X3?UG,KQ9$PT]S^L"7Y<557KG?W_$H:]:!80".FA&/.0-* MR2%SKB5=+09]FXK;0ZB=MNVO(\@V5G0'8'Z]6'Y9+/$Z;V2&2\8+KU.TF F@ MDJQK8RU"1$/_9VLA09M.U9UD33LPN1MXCJ>Z+G#X^7->5B']AE_R\M?%]<_S M>'F3*?'5AN&FT /)@FJ?=9M01 M@D^B] [@O;5#R0?!D6&(/M%*"&8>.'(QF1;Q'7:M3-!,.TOQ>&Y8/4,/4 MN)Y5MD8\0].61.#V;TR;AAD9&V/* M1N4X&0.(+/6=!28-L;MA9__[%:60QRH2738P>VX MG:7[=W9=K(O"4F3"$R?%\KH6R==RS]7,\YFS.KB"B>+F3'_A3E',SCT8[[%XHWEJU#TS ME-)I';JQD?("$$=56P?;H%_@+\:;SW6T?D[_6"ZNKIXV<_R0RV*9/^!?,YV9 MTLQ:8(X<&"7Y*M/$@ 012"!1"-8FNS<*^=-ZG=,"N(&"^S>V6YFN[4F/F$Y% M2J45:"[H F/>@8NVSN!%H7()/H33N 8'D3_M^V"GJ#YT31M%=0C!(U37/1BK'ST3 MY*58S1&L01(8)V8>;R;7F]W/&1LWR5/"ZX&%7N$^;3=_'Q MS!&P&DO*IH!/]9PI*R$D7NH,&9)>*'[+A]3WF3['.;B@MIUMQ=Y24)MAJ M+Y)+3GF06&ME,V<4\7$$'KA1TB;%8YMGQ]-M;G[VW/SL.EC7:19MD\R6C+.A M"X!'#ICI*C!"A4)QC.&IS1O!'L2=S12D(5AZGHX86TD=)&6W-L-(I9FL ;(H MB4)EYAPX(31@:>!'>@DLL M@C&L2(J+LVBTDNPL&]$&:7Y((]H0-4PZ1OBEUJEH)3,H!'!9DW6">T!6"HCL M?! BQX+A[]J*=@@ZQI1G%_.E'S(T^^1BO+,N1;+01B&Q9X,'QZV![%0NRM;& MOC95$X/(G!9QK5VF=AKKX/+;N];3YX :68!BD(/2P4&0VE%X$YB-T7K?*"@< MM22WV:78$"2'5N<.T=@1.?SK:7.MNW-,X=OKQ7P5D-_@Y=U>C,ESL.\MI&(:;2>ZV1YNMVG?*V/B]N]!1?S M=_/\_S(N'UY:I$-ALF2K?=)T]HD5Q[(!IY+DB>>(XC1M;P?C@=M7A;Y)S'[XM%SKKU%6 MKGAH4_J*[1ZOA&]*0?]92^N_Z4EW4Y]3)_RO,K.G(_S^F_ MRZN"J /IW:5HFMI?]8?.)45VL1/&UMDM'2N. N: M%04JN0*NQ 0ZQ"!29(3-< :VZ%'R;("$'\Z)]U$ZS1PX+T*=\4'G!(.&:$/Q MP3+%91N'ZDC"N[)D0["T(T7>7(%G;.B.2#P._,*I3%W+A. S?&I1;$DZ@%>% MG&_$3)>A"1!]4#%;$W5LLQ9M7%LWY(#,B&/+A16UB(R\B\(4>(UU>!&K,S@# MU\]W#XX5*0Z@LBLK-@0EWT6$K53307+B/6DDUYCZ5EZ5M<5\]0I0"X&$\,@E MLY!+JEM%@@47-(*3/DBL0I-MYD7M)&OB\7S-T/#\\AQ--1W@[!D/Z\H/ITMV MI?;.RGHJK7(06(H0'/WK.C\@F#8/-AO)F?BE>#QU;^QB/D;V'0#HT;%;+1*Y MO%5,^M?-;4YP7??C.7K.D@0G2@159UN'A(:$9;VQ227O&TVXVXN^'N[$HX"P M_6H<2RM]8>W7?/W0 OF0@:ZMMM7*K_D3W.@BF0$I.<5(UM2M1X+,O/;"*9,% M]XV>H 92VL-(FT;X&U]3?2'QCA'BL];"OKE<_/G/G#[FWU:B7[.'&7,4FH)U M:Q,H5Q#01P?>HL@Q*!&QS0";@83V,,VF$0Y'UU-?,-SF\]YM!D&47I&;ZY 5 M4#$XQAH$TCZ(VHF_, 73UG;^^K)X-T,?M0@!E5 MV\AK!4Q2# +*D#./WC3JR1A*Z<3CN4\5P#958 < _3W'2[RZNB@7M^T,;TC4 M>_#\^F99U?1;7EXLJM?RKGS OQX25=JYY,DW$2%P4%B3WX@6A+4RJN AFF9&;(XR $FN#A5>!3(<3 M(+3Q]#\2L6[4J/(=+=."<7I\?)=>/$I9!\/MRXJ5]]>XO!X%=._BQ>W\^^<2 MOKH7U_7U\B+E'M]T?]!V.VQV[O]65582+35QC%*).:X6H"*3*60-. M<#KVA@F*>:T4O$TEU)&$3YNEZ [^IX1!!SO,-OAF1JLD6:U]XJ9._A>28I/J MFQEFR$>3!1N5%Q_H2(\^(K-;;!ZIK",=Z9_FJ4WM6DU:7\P_'E*4=O='CZXV MVTC#2&5D/Y+XOA(]%2"$@IO;WM=Y6G_S5:3?NFW[N+B*EXNKF^7#3'&.Z"UG M!5+FANY2@=6/)'7'B/3O@^6-]@0<0?3Q$^(&?_JAD!,E>J,-@LZ9G \7#:"D M\^%L$1P5%N;:6*]CJ)YZXM=I\/G]D+D3Z;G'@MTUDX=W'CS] 6,9P(:= \? MS*ED?$X12-D95$H:@L@,LA51NJBY56V MW5Q?U4''1,$#@;\MKBY6B8EGI>V)2\:B9'1(O"/960>(SM5A[5)842(Y)(U[ M$XYBX'R-XQ#4;F]H.)WV.TQ$$:][M70\XSH6D04B Y/I3E#D!D/P+H 6.HMH MR"]F;1X#QJ%_ZG%6TT!^ MUW@/B'@_YFL,W+D6D? ).C(USET/I/X3732<&TRLC99V#&YF#8A.[W! M/S$..C@#[TJYRM?7)-ZW%Q@N+E?R?<:2Y4GXNG'-R!0HTC "B$D)1@F35$@! MA6@"[3V(FS:'.A5BQ]9:5T!\=46_>,Y-"28;CPJT9DA7BPW@!4_ $HJ8BW4H M&SWE[J1KVC3I]/ [6E<=)PA^Q>5R)=PC6G>W_:BQD@:[:>P@?5 *N7Y:*4AD M?$#Q8"&8:$"8.M@IHTF-5O^>5Q9U78G),K=)FP!(CG2MWE7@+!U*-"B,%XH\ MZ#8W[<$DGV^*8 @R1\B?'J#A"6_EJ^7U[/?J J\:$XN+*46G@:?HZZ";!)B9 M FX$,N^<-G&O/!;]U$>0I']Z#L TOQO\E6$<6I M]AYH"2%G)+*3,)P)F^1>@T?WA\F4#9='J.RYT@^0W\1J_^5B?O'YYO.:<,X8 MY])8(&A+4*BP#L+*4'A)6'CV(>^5^]A+\4\^/;'J#U'<8@PI3JU^_.L1X%1UML4':O?K#]U/_XT]-D:T=3_\%2["!>WW0__GYQ M]>_;Y4))H5?% ],U"9:UJ>/G$Q"PHV0L,([R9'[L'55GE]H_PI\874M=(>XN M+_N!_N2ZNS)&5I*))!5;TQEU,C:*HL"'H(+P)1K99I7<+JKZ\V /T_U64!VI MB Y ]2SC3__X)R[3VB0;GA"#1&#,R]L%0RZ83)*JC;7>HE)MWN]W4=4+J([5 M_:*1(CH U=JF_YBOB*.'E7M,2.T]9W3(% >E?(%0T())VA?+!+.\S021S?2< MW6/?"/?A")KI$E_K Z@")T=4UO$[=;>0T11",%WC42VB%3:P1C6KVRB:UEB- MH>T7 72 Z#N T*^+>5KSD.^LK+0F24$AS&I,B1*:CE@BCEPT6:8HM3!M[-,& M8GH#SB%:7HPK\@Y0L]%HWPW#^>';6FR_Y]L185>?+K[<.ILH.;D&&ORJ,R<; M#LY(8EJ;9+QQF,,):TA?I/?L:@H:!8HC:[8#_&Y@8WVPLPC.&6TAED#QD&<2 M L\.DC1>'S5?KDFWAFUVA;A6#2@ M7**X",G_"$Q9"L0+M[Q-,+F1G"[NUV-5O6&+]'%R[P \AYC_M_?3;5RP,CLM M('MR3]J\ M,^.Z4)S%$:+B-3=I%45:=!>DF(,+4EGA6UO&IQ2=WW/4V$@[0D,]EXT^X6J$ MVM&-/V^T M*7J>V@BI2%)#GC&@Q/-4VBJCD2&C(KTBD44B36BULS?A7IK;/A M8\XB2=JV3*&=>\3D$13ONQ\':Z.!:W)()QRRC MH9@*BF*UYB1'"(*,N;*26^8I$-.G>B_HJ>+S !7O]\XT1-Y=HF8=I6,1@;$Z M]L;X HKQ2-&U<1"F0=K>]YUIB.@[@-"/]R\>KZ[6/#T8 M[G6&AC%=6*28PM:970IM'8KN'4@7F53!V])HN?L>Q/4&K$-0\-U5-JY*ND#9 M0=GJ9'E.7%&PD>MKGB^2'(+$JW_ N='D%X@VBPP:ODN=(&(\_GH\@;XZ0.7V M++=%%X0I%F2Q'!37'(@9NBA,JIPDFTP;X/V]7IL&X6'OUZ8ARND 99M?/8PK MD4L1(,I$\N%UHZ\7&1*SWB,+Q?,V];!G]=HT2-5[O38-D7L'X-E9(QQX#$FE M6&>IDG2"T>!K$EA8YR.+(?A&&VB/KN(_0=5BFTOP(-EWA:,-9<'%T^DJ(8"7 M3-91 P+0<%&GKS(OT'@AVJP[.=/:_$&Z'U*;/T01'8!J9TEXDC6"9@:*JR%U M873R7(V%A-+;0.J,ZW-'Z3[(;7Y0Q0Q<=OB[7SH^.W6>>169L4E:&[K M&%/R(!TG@=2E5UZKQ%/8JT=MKZ[%QU_NI;SP\!OL*%E.B(&XIGGVZO)R37]] M*5@WKQ05I-09BO )5.06O+$%/./)Q^2U];O>F*YR_#\?%U__[]TW;C%Q]T\K M3*S0L(N&Z;J9#]?F8F31]@"/G_[X?98B)E87*892Z%Q@W62,1D(R1G&F E.*:+:>0_"93+HI3I$+ M9GC9E9T9K'KZYC2IO7:J'RK&'E3_ZH\?9T+I$(-%P*C(F4$O(1"MD%R,6F72 M'>[R*H=? G_\.$U VT[U0\78@^I?O_IQEKFO$YD5,&%6U0&<^*W5 1I3B9EA M=*/>__3-:3S!=JH?*L8N5/_/-S/#LY6Z#NG6M2%0.@7.*0/<)^>*QF+2KE!@ MN.K_^6::DN>&JA\HQ@[2"P^1T-O[PD8;B4S-B69G5X:+ S(AP&=!_@LC<<0V MZZ4W$--+5?R8F<[#)-T56)Y5K68K&&H?H-01JHH)!X%7>R<",XE.#;>M!X\< M4%=\@AS4@:K>MUIXB-P[KA9^]HKTZ/GS^,KAEW_V6%7$ [GHH*+8UK1&+@F, M\&3.N,"Z!CQ"(M^LO_P[7;/P_W\^[>+VP41/WS;]H)Q M>ULDE,6+2,%^K*=3K@* HH!G.OY>*Q)_JY*N4_'8BYUMB_WC*W=.@J&)'Q9^ M6R[23;Q^MWR?EU\OXNU(4.9\])PC^%IIK@H:"*PP<-XJ;;,FMWJ\J;F;*.@0 MH1T@93&BVOJ 73WW:P[N8CG,@A57E_)Y' M]V1,]YYQO&:_A\F18NX@B%DSJ9 2SF4@.Y#H2\20.[WD!'HTTG"0E9)L[ M^@D9DV/D6+4NQI+QP0#YFI=A,=9.K#O;>[OEN.[\6LQ7OL6JHR$4G1)+X&.A M$Q13($.+&BCPB#H9IHQJTR^TDZQ>ZJ*[O.?&5VP'ANP9#^MCZU!IYXH 9I$. MFZ%?!941I&2"6) ZFC8=DAO)F=;[&E'=B[%EWP& 'NTV_+#$^=7MX7R5_G5S M=?VH#:8XIQASJ_F OCYFD,2<=!"5USSD6 QK8^_VHV]:B(T A$5SK71QJ1ZZ M7G-U5C.6*#Q#R-+(NE23W!*FB5N1BJDU=\JT23 ?0W4O5=I=7\DG@T4'!O=0 M7M=6Q6NZL")&LBIU-HB,!;PU!7()=1_>T!OIT^!H)V _9(-T/Z3T;HH@.0+6SY)S#T*VLDCVCW6G3XG])[-DCW0WK/ABBB U!MF1,4D%M7 M=)T.%!DH5Y\+7%: 6(QAV@8GVTRW.V(*UVFG\?9W@8Z@RBX!N3ZQLB2C,A<@ M="8OU4N$H%T :6+1$H-SJ4WK_UD-^!JD[7T'? T1?0<0VF>:5) Y8SUC44L' M*@<-Z 6"#CRXY+*SOE6-[+D.^!J$@@,&? U120N*VKV!-T$1<>*O /4[/0EWM[7IVMOC=9!0-+9U0D& MY)EJA6!4S )S8DY-4*SZ=E ?B/D/]\<:J+H# /^>O^;Y37Y#6KD+J_[[XOK3 MZYNK:Q+PDH*BRYM4RWVOKC+]+WW OV8Y>Z$%@8UI8V^EB)IY*"K:Q'3TF;6I M;#^ V%YBUO$P\UVRN*T".\#H*M]-E\7B2UZ2,*NO44__3W]]R?.K/%..6U$B MD1]% 96LJ.M@*4[/0JL260G[C5D9#,?=='5<,S8.\D942\?M4P^"?(,7R__" MRYM\?-_4CA\Z5L/4OG1WT"F5/(904\#:F$Q(<9Q\OBC!.X?)J:0QG&X*X$2[ M%PI7Q91@P+-DR.\ED^QEL"0#7VPHSOO49M[YWV;WPA 4O;1[88@V.K@@MVTA MCBIEI2ZD-B]UM S_9[H5!*MYSQ_< >7>)FKO'E!PL M1QU)%M;5W4N&PN]:F*.RY])E)40;__ZL4K.#M+UO:G:(Z#N T#YY0"Q&%%\0 M"L](+J9&BKZ5JO]HN)8^HE6-;K9S3;O015")]NC<,Q5-YKLN\+1A@H":13#D6T7H!W%F5\0S2_9 RGB&*Z !4.ZM'E):A,.:!Q$.&'(, MIUF 8IDV!;W2V.8!Z4S+> ;I?D@9SQ!%= "J [>5&(W(N&? 72R@HM+$I?-0 M&!IK#.-"GG#DS#C;ADZV:&'L6W)D?76 RNU;3@K+WMKH(.5<-X85!3XFNA&T M#E)D1"QMFF?^7MN&!N%A[VU#0Y33 P#I 5T *7?EOD+7J3U4WA]P;KMV5O- M,KZNI1C75_>Y.$^W?1W]8Z,&E"^(62/_[06&B\O5(_M=(3=)(^68P2A!3F7@#+PW!ES(,=2-DZK1T*.=9$V; M/&B)I%$4T0NJ?EW,XS9^N!1262>1!M"W%?KB[OF:%;V4?%09A20!7'Z9P1=Q:=4$GDDDKK+HWMU/62T#P0 M ELA-9(^^L?8G<']-K.1,PR1;F_%B"]F)3CF-3F+*F9%)S')-MF$?2GLI7SA M)%@[3"_#\>9O\3;/'U?3!YL7KK\KA0[1]9-2\!%6?NS\L6,5K^]/>P?EZX4I M;:)1D'FJKS:./"B#"7)42;)B5-ZYUO5O4;X>%%HTG#Q1I>A\!N7(B\P&M*EO MZ]R4G$UC&9QY^?H0%+U4OCY$&UU=G,->2U'I)&P@$=774D;N 7(K()8EX2: M2=\FROR;53L,PU0Y#E-,!RC:_NK-D@T/IZ#*H=7!>9XK;%9*[RT24+ C+ MVG2#G56UPR!5[U7M,$3N'8!G2V=*P5(2<[6?5Y!<7)$0F& @F4UTJ!)WM@UZ MCNC[.EDQ_#$7WPCR[A(UZ_.D12HA^ 2)> !E103G.".V4A$I:XFFS3/A6?5] M#=+VOGU?0T3? 83VFO^$*FAN$V@7/-E2E0!1!)":.T'FU:-K%1*>:]_7(!0< M,I)K@$JZ0-F._I.B0N+<(CA>=XE+Y'7O%1U(Y1"#Q")YFY+CH_N^3E;1/G:, M=Y#LN\+1AI83$U$DJRTX#/75,P5 9AR@5CHP&3AQUQA'9]7W-4CW0_J^ABBB M U#M;COJ*$:4(I&UC,LE&FM5:>P5!*:.CX MR6ZK$.\?%;)R(L00(!FE:M6' 732U$$54ELN1&K4-?,R;;U8HP/5_[RX:EQ= M=("NO2HT5%)>ASJ4VKI:C^88\50212W9<25Y8&F22H8.*F;&1L0A!31#U-,5 MY%;DWS/VC^5J9N%=F8:2=*O3B01G"L7&*AH(@1-_S@H6@PZ9MWYOWT7?M.G. MD\%N-!6-74DS&O[H1A I%<8M,#1U3H[PX /SH*,G*0GELVF=8[BE9-J\PFDQ M-4SLAYNMQ35>MH#-KXOK6X']MKB\B-]^NLQQE>++=6D[_6)6&!T-:Q-81KZK M4CE!D"G37V+BPA7,C5;^#B1T6F?_M* ;56G=6K1'KD+E]=5'BKVOKE\O+NM: MP25>_II)"B2*]S?A7R2 #XM?\(I^X]=;/;Q:+FN 7;-!3Z4TBP&-1&= HM)U M29('C'1J2U!,"V\5+Z>]DVT79QVJEJ[CGA0)U%143,0@0R"4Y M1ECW0GD!J$24MC;>E]9#HD=H'#AIR'TT/ YM)ABBJQX=AGM.GL9XMXD%J5"I M8!VP5 >(>NG J21 FA"]9CQFW_K1;!=]_87@[6 XFIZZ,H2/Y%5'BA2F_&K% M5&U=U'6XB(F08["!Y:"$/A78B)S^0O'VV!JJA:/M68/8_/ZTO1C^!I1M5@UV:O6^MPK#"/=?%2&"^ MGN*4# 1C-%CNK;8^R6S:-\BWY;&_:/V4E_^$>!G;ZH_8$OOS_"O]B,6RWM]/ MJ-VO]?7Q'S^ZQ74K+2.ULM[]_&\;F@RU#T8'5\"7P$&M1H=PY8%I[UG2B3G6 M9N+*#J*.M9X;?O0'$N4/]-_\>\8,8\XS.F%.U+2M5A PFB:#> M1=6T4?)8^'ANE4;30X_+X!X=VE7MT;%F9/U#QC0FF^@Z@4EQ1>2L5 &.D4+, MR SY6DQ [9((+G)C0INA*0U-ROOXB7S)2[I,[S^R'LJU$O(#K'UP2'>U!$RZ M]H((!/1T1[*0O*,K4NGNP:UD8())'+8PQ5CN98J,U9:=P9G['/W^IKOL%7EZMG/?? M24O+K_EJ%HUVS!0$6_URI7V$($L&7IR6F6D>;)M)UB_3UJ^U&8*5K8[-.#KI M(.%PS]%_+Y;__GG^VW(1\]4SED02SCO&P :K=, .824G="\!!G:O&SN M0=RT^?WF.!M)*ST![DVXF;-MG?'&@C::4GH!$7LZ09\Q'I5%ADH"CTA%IW"FBLJFO'BXYM MO/+'5$R;F6\.G:%R'JVF9T3OFBSLE[R\_H;S]-/_W%Q\J?G/0_SKC3_G: _[ M9>I&\K'O/O3;)54M[5S4R^/BLA> P),EW(=*!L+6([K1BZ2RZ.BZ7O=S8T MTE:/L?^F\W]X[G''3VMBJ1IF(U_&&./>6>\*,"=)]887P.@54!@F4_$)BVCS M@C^=O7K O2F.\X(%'#HZ8$Q3+*I*K=L(KG",(H4V:9&7:>O=-@W!S=ZVZ3#- MG(M%VO3OR#<\(EMYP%>:6+ AG)W,LB$S.69#5UF)J8Z\G?2GLWC :PRW*S10&06I;@Q#7J:T[%!)[^W2'::<+R/UP0S)]&'F+!0/J2$ZNB1*4, *8$NI&:Y6WTS3MXV!K)(VDBPY0]3;C5?ZTN$P_ M?_ZR7'Q=51_?L4(&VFD2$6 HB@Z(SN R$Y"8M@KI?XFWN?)V$#7M6V!K7(VE MC0Z ]7KQ^Y$W[>M@:;.-KJ /8O<7YW=3)% 3WV0FP-I-LM G@"OU% M",FX"D;[W.96?*!AVBZ8YM;J,%EW@)*MDGE[/R%!:>396 &YU" YU.$(W$:P M26;K(IK"V@R/?9FV:7VK:=,,ARFH9\BM7,AYW36\NOU_O_CXZ?I=^>/JU@K_ MD,N"W,P8;S[?U"ZR]&,F#N+%K;KGZ=7GQ?+ZXG]7_S@+F.K>E$""J"\G-GL( M)"80TD=>E)>\T13M$S#7:6AZ(![WA?M$X#C?\[*G,!09)L/K9><%"2,'NJ^T MY!!0ZKIP2*=&OD%3MCH-NB<](PT T<^@F$-E4NB<[BF8Q%DNT200O/8,)A(1 MNJ! 1&Z24:+81LVJ[7GK-)\:[1TJGE]Q./C,..:0FS[^ MO+B\/,3,[/IQ(W26[DGK2$;E[H<3AIY_>D/SA,V11:4M>%1U0Z@L=6EM!N-2 M-,*GXD2; 3J#R#S6V.SUL4?3'3#[F)V#E$L=V%TR!%VK&[WA5FE'YZ>-U1U& MY[0&JQW.GANOAMKKL2QUA\$XJFG^Q9_:TM2U=*.&(9'9Y#/S&DSMGE ET#5J ME 0=G+$AYKH8^?PMWN.1$G0.+N87U_DMN;/???HVPRQS'0&/$;+G@H+V;, 5 MBH^\9+RV3@;+VTSB'4;G.5F\(3C;-1!D9.U-F)"LQF*VFN$6%K?!U:-!;5<_ M?'OU<9E7OUX5NC'ABL_)@(S)@](Y@5=DU660.BI&4GQ>R/6]T1OTQ5YJ3L=7 M^:*U_'L%U3U'=WL9E2S>\0+D=)!K@-(#$F? 0T)>BD_L^:R1@9AZ]L%I(-50 MS_L@Z1BA3PVD]_GS9_SP*2_Q2[ZYOHA7/\_C_[FK1\LN.NWK%)1:Y4A,0:C; MIK.7,A-_DEF^%WAV?*1#P!RESD4#V4Z-D9_^6LR)^L>'!]X0+_X=LO^*_%\O4EUA5S M=R\4,GF?'3G()E.4K&3M8M*Y;O8U7IBBK$NMAGP,I[:7NIEFKM+)5-D!7-]= MTXE[@=&9"\H5R3W%,+;6S)8,SC,#)@6,0JO@&U4P[T/=U'/:6F/D^=J@L176 M 0CO8NN9%J@*7?H@K.&@C). #@640G>D8DEA:IN>F7H8VXG!=)#@>TR;ODKI MHOYYO/P!+^NC_/M/^:Z]_9"$ZFL&(-@7D:0ED>Z16O3A),*6%V^7//MQ;9ZHCV* M\&,-TX.B;FL]+O#RYWE9+#^O%+[I_<%Q8;U XL4(DI3) 3";##I3&.-L#B6U MJ1T=3.K4.^M/A\CG5J^M5L_-/!X^AFF/G]K45#8M/0:MT M]>U3)[#*$&!"Y$ZV>42>V& >^/F'DR:C4,)9#:'41AJ.FD(U'P%M]MI$YG0(7K\O+SJASCN(5AXR$*]B7-[0]Q]6(CT;V<]23%:Y#$F$.K(_ M$5/)>$"3DBG%!(.M7U9?HG'JI;K3X;:1'CM Z$IFZR42VYGR3.58@H=DN"$7 MRBIRH4*@LT>@\@E%]FV<^KW(F[:J?$I+\@WFU^17/'J MTYO+Q9_O2:7YOM?QT9505RM)&6H_;=VSQ!RX4,CKKG5CFMLZ[F8?;-+G'^&2 M_NDY)@^C;]J.]BG >0(]GEO@M!;W3W]]J:*H]6Z/3^Y:^H?7[(WUZ:8AV,$R MZ"1.DUH[+RP'P^K4]Q#K4@ *[&/Q=7@S<^+YH^UYQVFKM]8/^-?O>=66]/"U MWW/,%U]7 ?7,&EO+'N8P0G1!:H^%:NI?0N\^'SCMD&@*=)T_= M8XJ_%V?S5DKK8S\K47+#HH-48SEE6"*W).:ZE"&E5$LZ=)NVX.]I.>_PYA", MC:27#I#U]')Y*JP[EK11/JB4@?P)!ZJ0+^QC98D\''1:9X%M#/@>Q)UW"',, M]L;67(]MK[O1<0.O0 MMYEA_B)IY^U@#D'<=T^BV\YKV.L[P4VBSEB ML:I T1)!61W!:29 "V95EDR&1F^,+Y(V;;32!F)M]#*U25K+JJZ8)"(^_9B_ MYLO%W6"8UXO/G_.RUI6\7LQ7DEO= 3.GL7 5Z!#Y4F.YE$1$@2!2B&$8(6&EC=;(JJ M9,O:/#!O(6C:AY&V!FP,'70 I0_X5[[Z#;_59.,]"]+R8@4"3Z)NT:EK4$E" M@$IFZ9ER1;7I/]E S+3#?MM"Z%C9=P"?VYAEFY1F.CB=F"T@3:+#8'2=4R0D M1)]]$D*ID-NL%=U-UUZ@,N<)JA$UT@&^MC.231 JN C6&P.JU(2D1?(64^%. M%1X=:],< \RV(*L1 S/ M7SO'M%A')J^Z?;DZ)GDUIL:FCA-O,]WKT&/#87*U,=I+!;8NAU#9(Y!5SA"S M<"))8W)Z-H)M2TCXPH>F35Z-JM%%(_%V[O+1."96Q <5>7% M0!"Y3K6UAB>6@V:-UE/MH&I:*]4"5Z/KH@-DCW*OK-WBQ_"^\O,DSS[Q'7QAPPXE-+5CML@I@,Y<H'6!C9L,E:&+$&62"Z"B H"_6GZE?=FJ2DD*RDI". M-:MRRAP"9P*8L#%%-$+Q-NW+ PD][P*?(6C[U:Z1%X=,@3:B/L,)"^CK?E=.##-;F&!M8M?]:>P/:H>@8F!*%E!"4+^158,U*VDS6O6@9K5%9MWQ\'PJE9FGA1E Z3N = M(.8E'V$U4/#M_63!)%$Q[P5IO5;_2I4@Y"3!ZR!%-%P9V^8V'$9G+_-HVWM@ M#?77 3HW\_3J^C4NE]\NYA]O$]JZ%.URX>1X% DJE-5N'PF<%:XR#TG&-L_U M>Y$W[17:$A\;WB/&558'"'Q)?C-C Z^CZB'SC'7J8 (?R?S'$JSPW!>?VCS! MOD39M#;PA+@;544=0*Z2_XR%[UA\^B\>,\MB]$9H+312,]!)Q^Z/O4[E) M>[3T_X"Y3N.R48-';H%%%93C,>K2YB ^I>-8:_0V4W23'U>^7#W,) M!%L$7>;DKP)JDR [1D;7VE)RF\>3751-ZW =@8+GMF(TT7=PJ=WR\NY+KOMB MYA^?<\.44\G8 HG^#BH1-ZZ0B?.6\\C(,;2IS/K7[RYT>Z8QJ.HGX&#,M(>2YF, %K37]U"#S3! PAE-/2J$;Q[]@W#?VT M^G#Z;&"@SF0&%[ADS!2C99NZ-PO,"G M+J:_S;V2T_RHB.C6V#UC2F74V4L!11$_2M19EV@Y."_1I.!YV',7V[Y?[.KN M. 0F[>3;@3^RL93[%[R^6=+?G['&1?&&XBXZ )(NWD2WKW,Y 7=8M!%)EM#F M#64 D=,&T",:I5:*Z0!SFYRPEU@L*J H4H).=J1?GO?/'QTW5.K[X2KQ_)VZXOHGZEOO0X-0X7C'P_N8+17BUW^6AX/C1[J9G[!GFLF3)DD?+ZO@J MGB#XNC\V2.Y"24FXL!= AW][VH$#8R&OL.7^'C]UI$S$ M_I2WR4\8)Z13IHZ'XY*P%LBD$,* 6[HOR8>SN5&!;HM,^.IG_IBOXO+BRSW6 M9ZDH9ES)P&RHDVN3 4Q1@V761N=LS+95"F8K45WE*89@8+,[=KS@)]YY\GO& MRY^NZE8,"J=?Q7CS^69U$?^8B9IXL3Z5]_R]*[\M%^2"7G];5=<6$3QW_N8KZ]KP_,PIC,DX6<':_+:PM@< HB M_46[I(.181]G:*1@\&T?71%C.^8MM#&U,[/BXM7'95[EUGZ]J:?C7;F]?VHG>/!QB9V9QM%/1J-$16*SWNS!. MA9;E"CM(F[HXH9TM&E_\3+RMG,2)XRR@S&. M*90U!"4/7 M=RPY,9=C;'//O4#8U*4%K2$VCD:FO_7NY$28Q2N?UR1H=\?>K"@6:W8V-%3(VT5Y]K MSLG,7\*Y/SZVYOIIID;ES/ $W+-0G1 -(EAF*2LYP23%QV;<&<]]O[I?6 M9.>$HY92[[<*\_7B\Y?%O-KGQ6WZ=CW%[>A"S)=^\$BUF(/H;U..B (>DS+U"\EH,#E.R!V@Y''^]/?:4O.N_'&55^VO%&XNKR_^ M=Z66F6(\K/906UM6ZZ,">.'I+'CK2BY8F-FK#O>H9M =!'9@> Z'P8Y>T+%T MTAG4?I[3S\U7UVLW8):LU:KV39NL,ME6F2 DCH"8LU$E,MEH[>X.HCHP4DT@ M=8SL.X#1?^'RHE;//%S,**7#R!E$P4@PS+@Z2-1"X>#PM^"8YX^U5O/#^![R3'B'R9-7SU*M[LZ9@;/<@E%1"F+! M8Z-IIL,LQZGZLT?QB <)M=^IC8\GJ+^^Q*NKBW)Q.T=]GJK(^5LQN.\34*'8W9"Q PYZP J*H3@KP!Z9$7,W/.>V:\A.A2G3@>$B!/'K))4ZY M;9-6>(&PKO)08_E6QRI@TL;;G0S-L @4DDY$EISL)RJ*M96T$*(KGDQHE-@F M_["1G*ZR5*.C9Y"P)[RLGLKC_CWZ7C EBF2B9Y!<4"0.NM"=T=^ZWV==5"[8]Z5V__J B]_6URMILO^5-^VKBYJK<3%U?4L M1R&E4P'H5)1:;BZ!Y)<@"*X*93!1<14]\HP72@2]"4>!5VB1GQ^)@/R2?PQ/Y)#KMMYMKO4OE M(E_59NZU:'">UMP_$],8]40'?W&D6J)Q.&Y31U2J#53>@?HV.<8]">RGXFA",!ZBK'/!(($J MSVRL]?#6@< Z2BP03RA6TR_06N6,%G9"%%82IZTIZ0F'@Q5V)DA\L[A9SHK7 M4N;L00<,]8DS0O5^0(:88G29^&NSDGY?"J>M3ND(AX/5=2XPO/B:9R6HX+-D M(*2BXU4(,@XY ^5]X%8[CO*$%5$;*)RVW*4G& Y5UQG <%5,?<^<)V-.1"C@ MNC9(UR)#+XV&Y%!%X75BH?V;SHMD3EODT D@#U?<&:!RI@/YOJE(\CD2G;(D MR/M-RH"T#$4(I4369MWB2Y1-6PW1"?8&J:>G+HA[9CYD^I?7KRXO%W_6WYPA M4:_J:A+T*9%GZP6@CIY8TRP'+[EA^BG>]NB"V/:U:>LA&F.HCP)W33W_%?'5U.\%V%C.74A1BCWL)*M<7]B@-")>-$XG5UK73V;%M9$Y; M##&E41M%<9V#<^:%-9S7)*9% 0HIE/=(;D)@2CFNDTONA""\]C63#4= M1 >;9M[N]6Z3R3I[% 4DG5-03)-HN5$@C;1<\4"'63>!X*$43_O\U@Y#>TS" M'EVA9P3;4*T=)O<,J58DA!TYN00<^3:6AMDRV5*>Q,ZK=7L#J:'J._< MT'G[\J,4DR%XD#[5(0I9@ LQ@N8L8E8YHND G],_V?6)T,$J/#.,KEZ%!$-N MHB6G/*"A8(T<*2^YA"15Q.BCSVK:*[^/Q[PN$3I8@><&T)J9ERZ88!("5N]% MF2 K7$44W****/7S+2JN1Q&Z;3/?'T"=*@"SPB@3]^/'**,=11R=H4<[:S) MBW%T%$5.0BFZ)J)N-1;T '*G?0#L#JJ'J_*,\#I3@1@0/ )SLBY>Q@".H'*2PJ1\)=S+U_.%*N%RT4A:LR+4$!#6X7)LEC=?1 MHT#-#U]OU>>C87-TM=5"/R\T.UG<^AHEBU*I*#+GK@3ZBW(09-#@B^&,_KV7 M:0+;U^=S8A^&#'MCZ&/J._?1$RG.TR#1B>"2X$5 "E*"DKF^SJ=8_S%E;5'%N-^2 MW,-IZ&KPY"$OB:?404_#O%]MX_/.>=WT$"65=1QM!*YR3?6;!*X:<>Z9C$(8 M;IX_;N]1'W8()=.\&)X4*]L*R9HKKB.#N!>S=^]07CA;K"F >K4=39(=8%F M#"8%$72.*C4!YZ3/@V>#R4/4=)907#TX(='B&$D4A=>@1*PSU)RJN]0U8QAE M$0W!.-U;X'G!<;"JS@J03QZ8D%L3&7G83-3B8H^<7&)AP4I,+&#T(;TX6N0X M$J9Y^CL/0!ZLJO,$9$W0JT2^NF6K@=QU%&XJ)-CLP98@E4F&<6T; G*RI[XS M ^1059T=()\^&UD;1,E:@T!A:FERA*!M3:R29^*^:!PD&K. WC/ MGY?(X4C)DO2\J]W=)EE IA+0\2K*>^V8W^^1[Z#/3_/:USD CU'1T4\II\3B MUL7;-0\3](]MR MATZK+8!,D!A6815HA[LI"237RN'+K,RJ MK$SF;-2!#0C*O@[X.D?G($H[*9A.DK%*U_D@W&4RP. 1O"=&=>#!>QOBG>G) M \!QI,.]SG&WDQ;ZG3Z];]_4R8/3\F/TBJ5WCMPM]B'7-_UB_VL$#8@1-"!& MUX 87@/_PMK '_.;;T3'9_K5\S"=79/P"1?GU??\M%YE/I*_/[Q=\OZO'$C^ M _')0A:\QH/DSU[1_F6IF XI51B:5,LNRNE(]9-M =E4[6-74_V M@)V[XZ*Z7] MK*6#0[*ITOH='?7;Y=>O9ZMA6>'LQ[#\\O/9_#_O9F6^.%\]_."=CRV?/] V MQS[ MLR"0X">EH]Q6)5?36H0LF/2"%Z-S.<)Z=4W/B('2$&I^=B':2^8=(.=NA/=N M1L_%Y<6:EP^SVU,U36&<85$!LX46T10X>*$CY&P9ZNB$$.U#\:(QK@[3P-YPHC ]SH?8^V1;?OH@[?']N)AH)VQJ^??-F11213)(WBK M*"P0K*SPMVH8H+6T*MC0Q-COTW'8SM@F<;ZY)\ZZ;7PV7UXN\!/)\@?Z]7]/ M=.!,"*8@'[0 XW-]A.XX.3M@C?0KQ M#%OZI?4+CN6=GN*GC8_22BO%K &MBR)01@X^, O11!YET39PT;N/^BU]P7QY MAA_*M56L_OSPM>KFH51O;0,=,XBKH$!Q8ATM_8T"!5JLO:G\&[O=Y9?]WM^5 M;]H%!O=\TQ%DWT' ?X?++R3>'RCJRV3*7W&V7&GL#L_+-^EB^JW>+KO/,0_& M6I4,X:?>JM#DA(-D$9QTC%O4M3]&$T,[G/9Q]UH&0.I(:CP%X-9/EV\N+[[, M%]/_P?P[K3"+.V)8V>X/W]_^@8LT7>UY)OQ82GS,99\);,C ?M@WL;MR7=,X!\7!OT91GPHD8](8I^FB]M(^\$GO\^F%YN< MA/"Q).L\H*=P7RG2UZH1DDR%9!21\]1FSDU+KL8=.-+.&,93?0]F\*0[^!47 MJTJB6<*U9_A/6.0/EQ?+"\I3IK//&YCWJ>2HM _[U;/X=\2H7OURD+_5,E]:Y38&?BD7J M[(&D7@=?<0L^&08Q%^%,=*SX-D-O!V9DW%DG1XQI6BKXA+?*[OP8?>/^3QY0 M SO@VX^UR;:S)-KLP/$B**?4&JS1""K4CL+*4O0LG%;>R^)-FY+X87;@KI]V M1YH/LXF)$Y$Q:P-9N,J@4K;@;-9@!'(=$KKDVI0F/4-45]MONV#@H1\<2O!C MWX&[P\<_YQ>XI#CE;4A?5CQ-7%">2^1U@[ R8A5$D@VP@L7[S(URVW4!?NXM M7>US[0.)8>7801!WWRD_@G= )H3B"0JR.A'*(H1(&-?.)$-F7^FVGJ M:KME:!#M(?9. 70G;Y[8$)2I V1'.VR=OS[_W6&G;#MRW2=AB4AHU,[5-*"'8 M1:PG'1(D$]$69H)M=)([<,)V%I;+#^73 L/RG5ELC$RMJ_Q6:(SO)Z ME(/@!:<@45G/63*>\39%JAM)ZBI9VT7_CY*U083>P5KXM!6^^6.ZG"1K+%,A M 3.UB;@T 2*2LM$[E$EF7U2CTZ^--(V+GX&4_M3N_N$:Z!9+/\UK3Q]*,D+0 M6*?0L=HX**14QZ4G0*N$]\11DFU"\^>H&A=/0VE^*T#MH8:Q=Y*>9D0P[OZ! MYQ$7==2O5$6LF*F#BDA4H>8=(G+OR>;"(TQMJOQ[X4T]XF0?AL/A(K? 2K--A^/#)5]I-LK5 1;,Y.2 M(7\;..2L BA-2:WG28,SS+*D7!)^RWKB%]XT[O[B<:&REW2[A0I?,U-D8M;7 M]DU&%_I2=TX1+21OH@I.9>.WNQKSTIO&W44\,E3VD6X'X>]5>OE4DO!^.L-W M%WB^G$030V#.@LE!DL2DA5C;5: U.@5ME7\X/6;0/8=GB1MWY6J37 VMDPY@ MMJ+^<=9P-/@NP8NT]5 8<#3(':J;SM'VSW!VB1,>I;)&1LC.)V*(+,<%64"D++U7D96' MG?V. +85:3T4#XR#M=TUTQ_4UO[ZIA_YK>.^_9EK%RY$YKHP#275^$2% %&0 M45DK//>>R]2H(]S^-/=0E'#LM7=P79[RR?/ZHSNWPHYP[+SYI4<[<]Z2[S8' MSB8:E:*MCK".33!"0F0\00HI.Q&$=KK-8C7L@?-+!?MO%HMZI7#52^^'[[<_ ML^ZOM[JF)BLKKZNCIOHUS+J4!805;[L*>LP4DIP"9;%(IB\L.A'$\CD9YZ M!X7TKX<(O/?:D8^5QE'Y_%#Y]P":ZR.RJ)AP.H-#"A*4406"+Z7.36*VR")R MV>HRV?:P&?,\\@"5/53Z'O(;6>W_"'],SR_/UX0;71L=>@V&.T)\= FB%0&R M3R8KIP-/6]V0W4KQ]UX]LNKW4=Q\""EVD"/6>/&7<'X%_\!+YK8(T%Z1!+A# M2E X4KHK?72"_IK;C("\2\7(A\VC+B ':Z4C1*V/TIC$8+-@P%1M/)UDJE:5 MZN#ZG"@93;I1"Y;[=(P;ENROSPW V$.XHQ\\/\I3!>/R^@0]+RZZF];9/SM/Y*.'O4-Z&48HSW#&B1=J!B M0/!&U;X)-A8,S*%KLP74D*D.:M)/V&@& DLO=O.HI>9C4<1'*^X?7Z>+ZP:% MTWF>*!Y,4I&#,\FMKQ%%:6FEY5F)4 LM&C7<&XJ%#HKO1[:)HP/AA&MK[D28 M]/6?N+QN-[MN2-Z^T&9;"HY5=;.71!KU?"A*&40&MF2R!$J]P2>1@=N0O18E M)]7SF(SAMQ]"2HH7ZZ"HY$%):\ 'J4&7S!,3Q1VIQ?4K*<'9!5_M2G!V46H/ MU12KHQY>LK,)/7B;%:@Z[\V'.I'!H9)::Z'#5MU*_IPE.#NI_,D2G%WDWP-H MKC?MF8F:&0XQU$N"3A;P0EBP6G-EE*>T=*O>@:=8@K.3RC:4X.PBOY'5_B^L M$QTQO_F&BW## '>:F[I_Y]%4Y',-42D."6UD,IILV5:'YEL!X$D2^BC)V4F1 M\R&EVDNZ>EB2% K*9&(!X1PE)4([B+PHT#:C2T:5*'R;2.@X9V$G4 :TSR(V M$@).&?/KM.M.6O9Q?G;V\WQ1OSDA)R(82@[6&4/)>;*TO,@Z T7$G+ (WZ@9 M;QM^3O[0;"=4#F44PT'D=1G*^LRPQ, Q90[!%G)465D(400P-F7B74:A&EU< M&9J5$S6/ ?'9SF3V ,O>UO+UZIKW15A<=&$SJ\/"Y;OKO5]NLO81#12AZW5. M[RE,S0YJ>6?$*&Q(?2XJ]_DXT2/E?JWE )CTL+#43>RK'NB/FRW&^'KA( MPO88C= "@JGC/!SQZCP7(*V6K$@TS#9L6+ 3K2=Z%-P0[&W5O3N@_16@9_@Y M7*Q_=FR_3W(N.+VXK,,!KJW:8 F)YP))6@1E#5EUA;<[PIP*&!>A=7#7BQV6#,:+*PG6V'[69F7$G M5[Q"JSD4,*_":AZG6LDZIR2I)!=1X\>0P7/#P4N4KGAEE&S37G&,]7 M:#&'@>7 O/SMK ^+60>F=;-]+02&)CO. M""6V_QUU 5N09.ZVT0)N2D.ZMA MW<3*B>;F?6ST'@:,5V(=M]6[/TV7Z6R^K$'I36E/5B()ZSTE<*:0RXJTLFK# M0/FDM=(N:NPS'GN6K1--\ONPFN$ T\-FUG +[(.2@NOMD%\7TX03IW-PF6

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�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end

U4LY2YT7"U>V3UD9]8AXK^)^N97JOK1R,[ M/7;B:\VRJ7E?R7A$GGR60/A0G?A!E8WH,'=?*B/@$4E.($+]ZIWBDHH^N;M; MPW* :EG.KK@>:ZSX5G+\X!@.2('B@%'.RD@FTZO3 XF&V%@"Y>?;NWI,^O:/ MO=Y9UCZ4O^1H).6CX(=&I"7TW'Y3'>+756I9897@H(L#HG,R @?2 \\ZE.3D MO?17;.\A7C;" 2?WHD*+O)T'S%3+YN7>N!__8CG&KD,K?W]>51,1:.W] M)*=<@?=M^8=G%YSE.E+JW)=JQ'4*V R9FS<^O:\GR^P .WXY$$J MT1HY_R6M/H7!*FF%W.8\0J:N>V<:[F7/(0*;AO)]UB3BWTH,=7]^1*=D;4\0 MF,\NJ9]J1,JTH$ON-O*ECOWZLR(',>S7:LM;F(2"ZS*10S3L6F:ZS-:?R+.4%^E5USE@R89O[%XOXEPB&S#&[RL<)*]\0-I-+ M3:2UU&D\];XQ73*J+3!A86[9.GD):W)AY(>(7S&&3[U_4EO3HH$P+H)P\#+; M1I0;TJQ!.R[KLXUD\,WEJPX//S.%1-I^O,?[82PL)D4Q."R0&D&^,OK!9*9) M9V.D>C@V>S/P\1*UO>*/B)GNJ_[9"R[MR1+=4O4V]=Y\)= M/ND5?F2OWDVMIF@7R-_J/ND4D?-%PIF5EC#+GSJ6)TY%OD8=M(^VRPF M7K-H*X@7F//3N#PR4B?QW6L1@0->L^?C@(^?_;<5<0!+7J+5G?&R^@@G/3:.XHA>'#' MY:^SQ4-/$3>(6^ :^;UF(BHH#$@IJ6OB/]=!=Y8%OVH! "P$Q "KD8J>E;:> MAI6.&\H)974%A4!9086%K: BXE9BR@=S'X?#Q_]> HE)!K/\ULFW$W+V@ENH&)B *)H !, #K@!*, ; MX "4P;CL,Z$ .Y!4'Q2!!CP MEWT6"I=?U(?:*#FBG7_FE C], \*:'0:)23(\H9\9.% MZC &GX4_\-2'>#TDPO[/",K#"#!OO]!XRR%<.,@#?KT6OT9Y^-ZWJM/[<32_ M-5"\>_^S^P.%E_UIS_CN"7^YW9P(X M>SCBC1*_B$YB@_)PMG7_A[8,0T,/5<,W@#^,#_@'*P64?EGS03;T?AGKOMHD M[HY(&-S=R/$*OKE!_I(.\7X<"!P%']+]@/K%/V23(MQ0'BY_09&@W) (Y*^> M5$4?SZ2]CP/#U-8>:)0:W!GN9HV&V^[GWL?E<(B@."#&8_ QZDX(CO\+^A-Z MN#G^'&C^*/R_8C3=$?"_8$BL'=$&UHB_X&A@<) /[HU6=[]DH'GEL%,C.T3_ MA9C<'N7F>\$1B3@L*=H#Y2\=HO&E:PNWL_;8[]7(/>%NZ+\A-SI$_Y6/?Y&B4"SATN>81_8N?NQ9R9W3%V,,;%5>IZ,ECG<;CL-72N^^Z?&86%7E?91Q M[V5L4^^WM->ET_1+EMOKK=CE;69X2YBRWSD. S M0'I:_'4WF(GTX[8JAA)H^/BO+/SK'/#^SL)?MT'6#:+5>.UGOD MZ,<'R_<9Z@]Q58"HVZTGT;R?89&+EQW[= OK_DBN/Q!&M=+W(YQT/7/FP?E2 M398O>3&>XRU/'#UOJR<7#HF/PE,3,/?>V6'L7/WJWQCG]B>["8[,K%(A3RK. M%5FKLW0M667EIW1M!7HY*;M%:C&$*&/,4/& M#7;Q&1Q@L=//U^AG&J7MV^H2M1=\W+38"\.>;[T>!HU]<.E.^?O/Z8^71GRG M%*HPEF\+BX8>QSY(KI7D"3\R0)I<4(/:T=:I"-S1G'O(*BDJQ%E[X_*'\B'_ MV&"2W426[9$I:'V_\V:!M]M6)8I]MD4W('(Y4&WON-RJ>3-5_1?M 0N7M:CQ M;>0:BW/!>E!G_B9ZMSJ@(^[50H*LN1@U3>'H2_IILSG%P0W?P5E#'&!:AD1C MB[MWDA;M2#1$6,,6RH,\91JQ9JQEPXZ(Z2X9#VDQ]-YUM_GU$H>=./Z?&E@>SK MJ*8K1N7DI\VMQ (]H5_1>NK<_2I@Y9X%*_=R(.[C7VI;WW(O[,&*ZVP1:W^? MJTOYV!BQF>KD<3&,_-QQH=R>A-["IH(,%F&SVM0LA%.-&0X@P@'7J_I7JYL% M*A=F/GVIL=1^[AGO(#!L.F0V78%EGI:V,CJ!S02_:CDFJA8_.\&3AL;1I:CJ MNOJB*8PXNWA;V-[+Y6BNL\W+J>N/O[>P*2[="'>/YZTQ:7QX=V+QXBWVO@[% M;]\%V039DUOGQ&V';R^5RB^XL[!L&(UW;T1^V%#% =K;;]/O?2SLG,&(8^S: MDN+O6)?=5!Q1Q:Q+;.YN*L+X-HN_%.UQ.N86- 4,7Y1<==SKP11]P5Y^/K90 M8_^NAKFA1O\=8L,A&?SR+)@W#:3="O[\S,?Y&HO-49&P+>],&J%$^LA%'. > M'B,IY"YM(]]QYOZ3&^;0>/+*MM[AG<^IQH.!=B^"+1P2Y\[O]8OMA'_>RZ[+ M'RK!YH[)=#QO?XQADW)-/7YL/G)^22\]4Q]> _'?D&J]]C$Z4'JQ;W1XI#HE M^?:(C/(UTA1E;\+-$R\G.F$?V!WBQI^@UJN^TT,Y' ![9T?" MR"OZ?'@-B>PJX2E\B0-Z!K&1:W&^EQORUGM%^]9<1@(_:E3X[VX$CK5.,#]5 MIZNK#!?62+CY*)U.+HA=LH(-2K];L=MY/OK]]&>/9)5^F(5^L?MSK&>P-[6D M:"2C?LYZ2K&Q"2:I)R=KZL2]FZ8<6,\EKQPS66YHV_T6&^+9''>39NA#\W2N M5U)J#)4-7K>FCYHO#2M4XX 1*M1JP^97LVF,QV#5L3$['5?1Z;X^^E,?NLU; M AWV.OU1Q5QA-R]Q&C:0CU^4?GY9Z;1H,SS#_YT&4Q3FH^U<1HDOPJBU?;9. MF:+_A6'0&)\ J6OTUZ5XZ8;$(@1B?&T/8?M=$>[TT;MR W9RN].-A)N-K3J M/^H#^?EOU??'2P44M*_$5!6X"+@0L5WH/5(ZEWJ*<)$B5666U2Q' M>M!8WU*",/LCDD:B-L"APGFP=-LRM0&T^:LS"="+B4]@YQ:)+ MK7_]!E[_E!NX8G"R>!XSD+Z^6-PK+-"835&=7RI<56R+X;CN0*AA93DZ%2@M M91/U%5LWL,7'TV$369.CT'H_F7* M^WU0D;5:+F_!PZH9 +)9M$!20,K_)V8 MA#YH?_V[_ANB8!][]_RX&%A)NUE];,XD2B)AR\ML3$\> M/N*$[]9J#6F<[BB([LSW0#_M]T]Y[Z\T+3LU.NK9V8YIDOM2%JMJF%]8?L)> M^,<%0>'^P9.-U+GMX=@45C_^=; QOGK8PF7)%>(ZZ7J+$]6CZ#BSH]R+ W#= M\P'/7]@.]\J4KE=P;D(S5OJIRQ?8I_I'=][/'!=?M^D?FT*LF6FUE$\X =/F MW:3LZUE]-C,&"?7NPUKLBVO75Q07O2.[291Y=RV%+&H'^D]+TA:@ZS-UAC:' MIT?4/*/[<#U($LM!:$!"8L8V/7GL M^[>2R:1H%GV0B^VF2>^PW,;'8 M>O43-R&PC9I=*AS0.*<9&ZFJ-B!A&&7FE#^A#GOE$M6P:IX9^5ZJX4-;9_#: MU2JAD806P\TGYI(K?K6*^$6N9-AZ\#- >_AZ3V-W2;5#I.%.&\*PI>##ZV=% MZO%2QW8B=F2BKF/ F^G139+(7:>&D1(9<42VOVW[#+KJ#76?;Y_! M^"4DAKTK=:N-&0EU]469S/F8:@4%OQ1_)BG=C0/@3GO?/O/+"=>\/=_$4%S%.4&68E_HZ1'PU(17! )GM?4>!& M7T=2+W0GCDNDN+UL2+INZ.M:7N!*8A4V=Z2P>#WDL;?G@P:[TK[U2R/$&<5[ M 5Y;[)DX@"*MA=TJ3XL5'D#]Q4%H5M%X-NYZD );_=2,VAYQ=8MZ:?8:"^5T M#V]F5;E4>X@/3N)LZF: M=881N?UQ)J,JU65O'(*[,+VC!JB2+#@ZM'/FA:-GUW@+?0UJQ=^B$P<4&:5" MWU*.'X5*9B^"026;-T*HQW0;WR.8KW%(;04^>2VOR)V-59]R8;:3U,@NT"$O MI10N_]3MX'YNHVJT7R$>>U?H/+Q/(>KAP!V-1#;V8>3)"AR06)6::Q([Z6_9 M_K9TVL+]DS94O(^&O=>K2@]E5%^4Y[EV!R,?[W_?B*K&(219T6MF' <,([>Y M%B]%%,<&WA+:[:=2X,PX;Z9SMYF$S5?;PB7MCB'B9..Z= +ZR0-V$C M09L.([R_N% NTX(#G#]TJ.V [W-K1P)[V'?RT1?OAM%J]T,P78S1+?PNG?2K M46WO$1C;E>5.K#L"ZXVQP@%5I-CA0.P%G>961#]MO@$<5F$GI&W-T\%ALH)P M-.89EI3%^*OT^#($IJ.VT]RM3%R77U17:+2^AB';2L8&)(HK_#0>]]1*;M9I M:V_[]9JTDW-RA!RQCVD:FE2U;Q9M/:/-PDM^^4A(RUG?.IGWIHKJXCA@JQ+, MX^N6E:L5J>'A\(*J=6A_B<2GR=M?3X07*2S.D>" /7,8#O@*VQ:P..&L_1$[ M!O]^DU<^%(-NF&[$]:PI%'TL]LUJ,Y_2C=5>E1:?WFBI>HI=O8H# K%^!I$J M.TVFTRDE_F?"7S]E9Q^@65?\82"WV)!LZ5_0S(B)>[(GF.A%W33H Q\LVJAJ M^##QW69 ;4]QR%];?\W!8+W^L0P\V6!T)USEZZ:39U!%#=NHW:C^H#M+Y],4 MD4L4'_O[I1XCVFP>A=WGU-NNY)&[$?AE[)')6DI(<'>>2Y:51VK'%XPE.$\9 MO!Y:+;?>O!YH-MTWXRL;H+"D[[72X*J$ _(_'PO-SVI+KF'%IF@,&Q86QJ1] M3O#C\Y JV]WTK3IF;-39'2A91W^\:*VV-K*T#_9FI,5,/S_W_5QYN=.ZX-OZ MG;GT ME&<<\*%LQTC/3#:X9N_TY,+WU(3MD!?8XK7\D0?%T_ZW!H$:Y@U]#\,18%W1 MX%U][G0KAGTF4!FVV;/CBP.4EZZ,YM>Q#O(W'VM8*T_DJ^VQ;_%X6I5RSV>R MH5AA5#AT6[MG9 $':&P:1;=[]2M$CZ2'.;Z(&X)^]LZ:B! 49/2EZ7"R@JW[ M(WS9P>9Z"6.UO=25+X<#"N/'/_<)P%$>K KOEV=;/-GT-5*60V$K@AUKGS7Y M44."<),OP3,-RH$%,[9Z45&GWZ=%"+- &?A3\^OT/&6\+LA+/K>("HFJ. KV M9$&F'.P?!NW IM+BS]Z% R1WQ+3"NQKL_+/:!'>U5"U2,LL7!L<]YT=P0*=_ MA ;7W'&-%G]QN9&YI;P!.W'OS4'O7$_?@?$>C15H0LW@SEM#/QR@MC?NH%"Z M=F[Z[3MI)W^?=@D;7R?_H(\#QF:#*NB2-OX:__6*^7E4T1I(NL/G21^M.K]D MC*5XM[+US 9V8DSDD4?LQ6_;6S:S_&^Z[L_=R>L)S*Y*25Y;2-YQ2MZM:U!- M;0>G.GGKA:4! A%V K'=[>:RI:5"59%^#M<<\E[#RPR/!R1Q]34,[EAI9'\S MQ-)9H8QG.MZ^;S].6SHFTP^O#:;5[-4>(OQDUO"I'_R3Q>6HSQ@-A>#5^U7LIC):XA'PCDJ*-YH;5'Z?+603A\TVV@8U MCWN7N3BI\I3-+1:(CR0HBS=0>>:;D6'KU169A^# M@Y>&&VY.+@Q7I=;?ZZ]F3-;<*C>.=DT-J2QK3 JKZ0FF]9.87XL247BQELNN M01S9&J"BS)DU;NBL*Y::%CWYU3BJ)%2Q$>PIIAI>[83*/O>_GH] M]\@K=H: M[),5V*9Z^ZYU5(-:,:W9F2\PN:I"MK=FK<$&!]"JSUX_,-V-. M.LG0=/>#HW =99:_QA>G3M9LEGZ M$0>0S_IZ? II$SFW.4]DI!;3R$SN$FWCZ'K91WQ)_U&":=?F^ON=A@*V9,OX M](K4[,5UR<#7 >/=)I\L7. >=OIF%6-3,)F]DRPM1N.S+.]7AG?L^N>0Y;7Y M&L4"!:D9&,1:2FI6N?Z5D+SI,Z+*+-9O7_.%+;?MOL7U3B>'/K2*#;%P+I]5 M*(9]&V+B?N H->A4]P;#Z-'0,XH#@#66XF2K/O.EO+XQN$6OO^,MZDQL2&Y[ MDDA]CY$U8M )8_1YH:5PM,RW(6^'KY3I\4*;I[VCK:D9TJ]1ICC"/[:L/3DU MW;]_?@.T6%5U;3Y/&NOI0+-< M?*XHFFUVZ[Y(?CJ[E$3%RQ/^:K#YYNS3%F8G#3>PH2,;@E&D?*+L-&G.RN4O M*Z%/"::D.[KR"ZO?S!_BSZ.D1RY@>&>(ZP?FP$:M2F.5 ]U+) M2QV'=9E0]WS$IWP8L_;0LIE%@\.N6IIQNB$V.[-L%Y5I'_"1D%+>2B>8Y+SU MNR&GX1F)I=**@5T%'&#U$2.4/9-3D8?>-!"4)!&N:O=ZSFIJ75!8/6H15Q;9 M,J@OK]VS$[C%=52_&2&:\PV=EU->^'1OXYOO)GH(>L_$HZ2VJ,P"?ESB04*O M5W>G;FR%K!"?S&Y@.@Z0GK9?O\$_5XWJMU)C&V;UM#C^\54W*XRO92:K1YFU MHM=K=E,4%OAZ8!H'2%4XS-6=:Q4?K7O68.SBT*;A"4X!81M.):.J0_-K?!C% MANTRY]H'J6I%/+&-W$,#1N=)Y.G/'/+3)FCL6FA*KP%VQ]5F3O5LQTF,]IN.[//K92*D*_'A ? MCS )H/90Z$@:L%(9+.H=,&V*+!=92J_8R!*08N(OVF;F\^/*7=MSL-",)_0C M-)]EHHY[T^H4^#3#U*%B/J 3L26KV%4G+F^6;>6.S!K;E$]KYV"-&>,QE. M[_)H0/BAUKQVP$&HW%?][+?J GEM(?;":S*UD_#OLJ=KK["8>_:%.+!;MCOF M5:=FSPS-Y0W;60WYADOX)BTSA^P-%.6$I/A::GD:;DEKY>7LF#XN3#\Q["CK M6ES,>B]&T[!JRT=\,+RN ;DVC5%<'4U_M[9N,;"C'+APWJ^\?TDSW'T^- G> MBPTJKQ_U%[/P^HB]WJ!KDBU[8C=94]"]#7#UAM5)G8IT'@FOOX.)*_[2=E2_ MW?E#.L\=OI.\F4:NT+ZZ-8Q.',5X[ M<;[".\7W4@V3B6QM/BN_6*X.9U9JCBEIL7@P*3[@3UF'TES*.Q6!06SW#>R4 MH0;K:KZ%EYP^/V+&WB?[2*#M;5:P[; #LW) ;.8;^P%$]XZB-MC2U+)U$T)" MNDL$WK9ZS=]H+Y^<>)!B?M*GM;!V!!R;A_H-AA,PM OL>=\L9K#Q:V<]GIA' M5$3%)*NR@I88D1HZ\UECSE-U9-9=Q%$J/LC6/XDF?&'4GQ$'R,9B2==""RM$ MC\6+EU_MCYZG#(L MT)[[S-&AK:+[PV(+O_-X?]^.G\6.XMJ#H ]+?;QXWLV"+GS'UB-V5OYP ;YANN%1OH\ZCL+?G:"9\TPYN\%5F MUKS[?7[ 2*I2XO*L@P6-_\DZJB1Y[>Y 615P-D1NF:U=6+[N& J.^^T^Z!XS M\Q,MCDWKP<_!H4S1").$ ^X$ONU;O:Y^=@=2N6X\F,E,=<[^SQ-3?4R)* M7U5BR:B"7;FW 34##MU],\/8H#QY#0_]GB!V;6EF1A;7)(=9A\?^1Z=$^45/ MLO?A $(M'-"WB+4;55L/G+*WV>[B?K0;X.$O6!C#%-\7I5_MGLO=VW4)-9B' M&DH1+$_MV6&+P:24FT'E4^UJ]M@O])^=T9[%T&W'?QN(-RQGH9@^%F>R\J&\ M@N]CP?S0^SHR5 MI\2B]9>N-$^SPX=5X7:=)>-EA<]*!&79'_M?]EPLKK!=;(5AZL$QML'^8A.3 M%[JP$.4I(8\J3QZ#IH1>2J?O6N=KJ3E74!X0BLB.04S+,XZ=YS6]I9E4I M"K#D*X"O#.47?$D:;0Y*P5)"&D5K!V;+)]D M+VWJ?G3S#'Q"L5LG,,V?.W.,&JIT_K"A)9#O@0$[%L M*-[<+)W5CTF.'9@.K1!I^+AC2N-YLB$18\:9IYAJ(;)MR/T(!^ &#W:J3NWO MQ5@ ^Y>H ( 6N #8 BC !H #'( .8 _":/!QWX?P!TJ._R\H\*=8E$%?!! & MH( T<+AG3W2P+TT*D!VDA?MZQ-T>C7:1$1)R=A>TQN]T"<)03D+>UBY"4$%A M(4!.T=O%&N8 1W/8P!%(9WG.I9H&3@ZDK3RGL;BFL*:+,MP>>7H)>H(,H-(025EI86$A81 M$A$1 "D$W'V L[N7/LR#H1;H[[8FUA0G!'N!/<&>T.%AI4Z) 65.\7\=^6[A^$FIK_GM3)Z1>U.UH/ M;O?OJ=WQVZ]">G!WE(<;# Z2<_UF5O%$_^\PJWB">OUB1SHZ>KBCW:S1*+>_ M%_('P5]4=+']%UD&(T!"T=^$AV?-_@7Y8?1/Z;8P&3N4FY,UJ!/2R1H!%[KN M D?@9;G(*+O!\=DP0*$<#VU,_7?N?E[_$__S^M\??/"+X"//"5)(" A+"HA( M&T"A,E!1&5%A 6$Q&6'A U)-E"W2SN<7J;2 ,%1 1-S@\.J@@+#X;U+0Z&VM MT=;_";&FILS!@09KQXLHF ?>LM0ORG-Z>"!M9:151%7$E:4O2"E+02\J0:%2 MDJ)B%Y7$I50O7E014[H@>2C@3T80(V@+\HI(PV$2PJ)V C;BPC8"8F+2< %I M::BD@+@M'&9C;2TN92-J<\BO[NR.MG;&'\"_.*24&$X7%)$ &X'LQ,0 MD[25%) 2M;,3@$N+0&UA-C!Q<5&10WX]N+,M$M^*E!VMW=WE.?=/N.'- .P] M?M>"C#[:V@WMX:+CAK)#.H(%HV3MCH1QZ*DI<7* M#(@WM8#!G<[K$ =L(D[ M(FW-'UR.="0T$BT(_P@>- 77'!$_PP>A!V1>".5<;1V1H"%(O#S. 2GPK\] M^2@G=,!Z*%CH+Y+EA/Z:L-S/VH.[(3WAMJJ@0([]]BZ#_*,^]@U!#"H&$Q:1 MA@K Q4%/6EA,1$ :*B$I8"T,%Q>1L!85D9"RYOS);/LWQB )ATN+28N*"HB" M>@B(28M("5B+B8@)6$M+VT%A,&$[&ZCD(3_J?VZ-!P+<_J4U"/U%[TM(=] J M?/ZL!'VXZS]6PGXG)F,-PPL$J]0:+"G.GTCDWY@M.'8(0Z&28L*2(L(24F F ME:%B%R6EE,0DQ255Q"5$#GF][.'.ATT>'&? IBDF P6'&O'#)G] YHZR0WM9 MN\$O(,"2^-N>15_BK[W* 1_,'K0;.#AR"ATJ_3_6Z#]KB/^@U;_JO R'_5G)S0/]?N 1_T.)_%Y *> \KQ>O(H*N'$J$W!.;J6CIZVJ?D5E?\V# MZM(5I#.*X @ .#FCW?"3=!/3JQRD'0 !0 Z0 % L(:YNVCJJQKLG]Q64>; MS^2!WPZ4L=%_+@) MA.][>N#/IA-> >$@3R3<"X1[09C;T<,)"<+XZPX,3G!K=P#8/[3,C8;#[/&_ M/X,_YNQFH*<,PG( 0$:%^ .V^0-&P[WWKZHHHUQ\]H]-6 2DM+<5R" M>SG"T6@!';!2K-UL.9113B[6SCX <*#SOCOZ3U])?Q34OXW\#QV^;@^@5=W] M.H,<:_^-^SLZU#, D%H'R^;A;YQ- @!4W , IJ'?..ZG $ +UEMYYQ_Z',/; MRQ_+04@X3!!F_T/"=B/^JY8"!WZ@>;ASN8)N MKM";@3@6YXQ^]2!W>^[O[G# M0A")]]R1^S (" 4> C$ HE *I !Y "%0 E0 =0" MC4 ST 9\!/J 86 ,^ [, 3^ #6 7 H&00J@A]!!F"#N$!\('$8%(010@*I K M$#V(*>0:! %QAGA ;D#N0$(AT9!$2!HD!U(,J8(T0EHA79!!R%?(#&0%LD- M2$!%P$# 2G":0(A BN "@0:! 8$% 8+ E<"7X"Y!!,%C@F<$^03E!(T$;01] M!&,$$QPE.$ H12A,J$VH17">T(W0@#"!\0QA$^(RPDK"9L(>PA M'".<)]PF(B&B)^(@$B"2);I$9$@$(W(E"B *(THD>DY43M1$U$/TE>@'$9:8 MFIB%F(]8AEB=V(080>Q%'$0<1YQ%7$;\EKB/^#OQ!@D)R3$27A))DDLDIB37 M2?Q(PDB228I(7I%TD4R0K).2DC*3\I'*DVJ36I.B28-($TCS21M(NTF_DVZ1 M49*QDXF0J9)=)7,FNTT61Y9+5D_6339%MDM^A)R'7(95!%4V52OJ :I5JFIJ4]3GZ>^2HVFCJ#.H7Y#_85Z MBX:>1I!&G<:6)I FB::/*!^Q M/A)P).E(U9&!(^MT]'10.FTZ)[HPNERZ5KKIHZ1'3Q]5.6I[].[1]*-OCD[0 M$])ST2O3P^COT&?0OZ7_SD#"P,N@SG"=(92A@*�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end GRAPHIC 21 vrtx-20211231_g4.jpg GRAPHIC begin 644 vrtx-20211231_g4.jpg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end GRAPHIC 22 vrtx-20211231_g5.jpg GRAPHIC begin 644 vrtx-20211231_g5.jpg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end GRAPHIC 23 vrtx-20211231_g6.jpg GRAPHIC begin 644 vrtx-20211231_g6.jpg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end GRAPHIC 24 vrtx-20211231_g7.gif GRAPHIC begin 644 vrtx-20211231_g7.gif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end GRAPHIC 25 vrtx-20211231_g8.gif GRAPHIC begin 644 vrtx-20211231_g8.gif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vrtx-20211231_g9.jpg GRAPHIC begin 644 vrtx-20211231_g9.jpg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htm IDEA: XBRL DOCUMENT v3.22.0.1
Cover Page - USD ($)
$ in Billions
 12 Months Ended
Dec. 31, 2021
Jan. 31, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2021    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 000-19319    
Entity Registrant Name VERTEX PHARMACEUTICALS INC / MA    
Entity Incorporation, State or Country Code MA    
Entity Tax Identification Number 04-3039129    
Entity Address, Address Line One 50 Northern Avenue    
Entity Address, City or Town Boston    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02210    
City Area Code 617    
Local Phone Number 341-6100    
Title of 12(b) Security Common Stock, $0.01 Par Value Per Share    
Trading Symbol VRTX    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 51.6
Entity Common Stock, Shares Outstanding   254,576,691  
Documents Incorporated by Reference Portions of the definitive proxy statement for the 2022 Annual Meeting of Shareholders, which we expect to hold on May 18, 2022, are incorporated by reference into Part III of this Annual Report on Form 10-K.    
Entity Central Index Key 0000875320    
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Amendment Flag false    

XML 28 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
Audit Information
 12 Months Ended
Dec. 31, 2021
Audit Information [Abstract]  
Auditor Firm ID 42
Auditor Name Ernst & Young LLP
Auditor Location Boston, Massachusetts
XML 29 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Revenues:      
Revenue $ 7,574.4 $ 6,205.7 $ 4,162.8
Costs and expenses:      
Cost of sales 904.2 736.3 547.8
Research and development expenses 3,051.1 1,829.5 1,754.5
Selling, general and administrative expenses 840.1 770.5 658.5
Change in fair value of contingent consideration (3.1) 13.1 4.5
Total costs and expenses 4,792.3 3,349.4 2,965.3
Income from operations 2,782.1 2,856.3 1,197.5
Interest income 4.9 22.2 63.7
Interest expense (61.5) (58.2) (58.5)
Other income, net 4.9 296.6 192.2
Income before provision for income taxes 2,730.4 3,116.9 1,394.9
Provision for income taxes 388.3 405.2 218.1
Net income $ 2,342.1 $ 2,711.7 $ 1,176.8
Net income per common share:      
Basic ( in usd per share) $ 9.09 $ 10.44 $ 4.58
Diluted (in usd per share) $ 9.01 $ 10.29 $ 4.51
Shares used in per share calculations:      
Basic (in shares) 257.7 259.8 256.7
Diluted (in shares) 259.9 263.4 260.7
Product revenues, net      
Revenues:      
Revenue $ 7,573.4 $ 6,202.8 $ 4,160.7
Other revenues      
Revenues:      
Revenue $ 1.0 $ 2.9 $ 2.1
XML 30 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Statement of Comprehensive Income [Abstract]      
Net income $ 2,342.1 $ 2,711.7 $ 1,176.8
Other comprehensive income:      
Unrealized holding (losses) gains on marketable securities, net (0.8) (0.2) 1.0
Unrealized gains (losses) on foreign currency forward contracts, net of tax of $(21.8), $14.3 and $7.0, respectively 83.2 (51.6) (14.0)
Foreign currency translation adjustment 2.0 (14.7) 10.3
Total other comprehensive income (loss) 84.4 (66.5) (2.7)
Comprehensive income $ 2,426.5 $ 2,645.2 $ 1,174.1
XML 31 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Statement of Comprehensive Income [Abstract]      
Unrealized (losses) gains on foreign currency forward contracts, tax $ (21.8) $ 14.3 $ 7.0
XML 32 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 6,795.0 $ 5,988.2
Marketable securities 729.9 670.7
Accounts receivable, net 1,136.8 885.4
Inventories 353.1 280.8
Prepaid expenses and other current assets 545.8 308.3
Total current assets 9,560.6 8,133.4
Property and equipment, net 1,094.1 958.5
Goodwill 1,002.2 1,002.2
Intangible assets 400.0 400.0
Deferred tax assets 934.5 882.8
Operating lease assets 330.3 325.6
Other assets 110.8 49.3
Total assets 13,432.5 11,751.8
Current liabilities:    
Accounts payable 195.0 155.1
Accrued expenses 1,678.6 1,405.0
Other current liabilities 268.4 317.4
Total current liabilities 2,142.0 1,877.5
Long-term finance lease liabilities 509.8 539.0
Long-term operating lease liabilities 377.4 350.5
Long-term contingent consideration 186.5 189.6
Other long-term liabilities 116.8 108.4
Total liabilities 3,332.5 3,065.0
Commitments and contingencies 0.0 0.0
Shareholders’ equity:    
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding 0.0 0.0
Common stock, $0.01 par value; 500,000,000 shares authorized, 254,479,046 and 259,889,549 shares issued and outstanding, respectively 2.5 2.6
Additional paid-in capital 6,880.8 7,894.0
Accumulated other comprehensive income (loss) 15.9 (68.5)
Retained earnings 3,200.8 858.7
Total shareholders’ equity 10,100.0 8,686.8
Total liabilities and shareholders’ equity $ 13,432.5 $ 11,751.8
XML 33 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Preferred stock, par value ( in usd per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 1,000,000 1,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value ( in usd per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 500,000,000 500,000,000
Common stock, shares issued (in shares) 254,479,046 259,889,549
Common stock, shares outstanding (in shares) 254,479,046 259,889,549
XML 34 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Shareholders’ Equity - USD ($)
shares in Millions, $ in Millions
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Retained Earnings (Accumulated Deficit)
Retained Earnings (Accumulated Deficit)
Cumulative Effect, Period of Adoption, Adjustment
Beginning balance (in shares) at Dec. 31, 2018     255.2        
Beginning balance at Dec. 31, 2018 $ 4,435.2 $ (40.3) $ 2.5 $ 7,421.5 $ 0.7 $ (2,989.5) $ (40.3)
Increase (Decrease) in Stockholders' Equity              
Other comprehensive income (loss), net of tax (2.7)       (2.7)    
Net income 1,176.8         1,176.8  
Repurchases of common stock (in shares)     (1.0)        
Repurchases of common stock (186.0)     (186.0)      
Common stock withheld for employee tax obligations (6.0)     (6.0)      
Issuance of common stock under benefit plans (in shares)     4.8        
Issuance of common stock under benefit plans 346.0   $ 0.1 345.9      
Stock-based compensation expense 362.2     362.2      
Ending balance (in shares) at Dec. 31, 2019     259.0        
Ending balance at Dec. 31, 2019 6,085.2   $ 2.6 7,937.6 (2.0) (1,853.0)  
Increase (Decrease) in Stockholders' Equity              
Other comprehensive income (loss), net of tax (66.5)       (66.5)    
Net income 2,711.7         2,711.7  
Repurchases of common stock (in shares)     (2.4)        
Repurchases of common stock (539.1)     (539.1)      
Common stock withheld for employee tax obligations (in shares)     (0.8)        
Common stock withheld for employee tax obligations (200.3)     (200.3)      
Issuance of common stock under benefit plans (in shares)     4.1        
Issuance of common stock under benefit plans 262.7     262.7      
Stock-based compensation expense 433.1     433.1      
Ending balance (in shares) at Dec. 31, 2020     259.9        
Ending balance at Dec. 31, 2020 8,686.8   $ 2.6 7,894.0 (68.5) 858.7  
Increase (Decrease) in Stockholders' Equity              
Other comprehensive income (loss), net of tax 84.4       84.4    
Net income 2,342.1         2,342.1  
Repurchases of common stock (in shares)     (7.3)        
Repurchases of common stock (1,425.4)   $ (0.1) (1,425.3)      
Common stock withheld for employee tax obligations (in shares)     (0.6)        
Common stock withheld for employee tax obligations (135.9)     (135.9)      
Issuance of common stock under benefit plans (in shares)     2.5        
Issuance of common stock under benefit plans 102.5     102.5      
Stock-based compensation expense 445.5     445.5      
Ending balance (in shares) at Dec. 31, 2021     254.5        
Ending balance at Dec. 31, 2021 $ 10,100.0   $ 2.5 $ 6,880.8 $ 15.9 $ 3,200.8  
XML 35 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities:      
Net income $ 2,342.1 $ 2,711.7 $ 1,176.8
Adjustments to reconcile net income to net cash provided by operating activities:      
Stock-based compensation expense 441.4 429.5 360.5
Depreciation expense 125.6 109.5 106.9
Deferred income taxes (154.6) 277.3 167.4
Gains on equity securities (17.1) (311.9) (197.6)
(Decrease) increase in fair value of contingent consideration (3.1) 13.1 4.5
Other non-cash items, net 14.4 78.7 16.9
Changes in operating assets and liabilities:      
Accounts receivable, net (274.7) (223.4) (225.6)
Inventories (92.8) (132.0) (64.0)
Prepaid expenses and other assets (91.8) (297.6) 35.4
Accounts payable 31.9 51.3 (22.8)
Accrued expenses 305.4 122.2 172.9
Other liabilities 16.8 425.1 38.0
Net cash provided by operating activities 2,643.5 3,253.5 1,569.3
Cash flows from investing activities:      
Payments to acquire businesses, net of cash acquired 0.0 0.0 (1,154.2)
Purchases of available-for-sale debt securities (528.2) (431.4) (537.2)
Maturities of available-for-sale debt securities 499.3 372.3 475.9
Sale of equity securities 0.0 437.6 94.9
Purchases of property and equipment (235.0) (259.8) (75.4)
Investment in equity securities and notes receivable (77.0) (19.3) (39.3)
Net cash (used in) provided by investing activities (340.9) 99.4 (1,235.3)
Cash flows from financing activities:      
Issuances of common stock under benefit plans 102.0 264.9 343.2
Repurchases of common stock (1,425.4) (539.1) (186.0)
Payments in connection with common stock withheld for employee tax obligations (135.9) (200.3) (6.0)
Payments on finance leases (47.0) (42.3) (39.2)
Proceeds from finance leases 22.6 13.3 10.0
Other financing activities 5.7 (1.8) 4.8
Net cash (used in) provided by financing activities (1,478.0) (505.3) 126.8
Effect of changes in exchange rates on cash (13.4) 20.6 1.6
Net increase in cash, cash equivalents and restricted cash 811.2 2,868.2 462.4
Cash, cash equivalents and restricted cash—beginning of period 5,988.9 3,120.7 2,658.3
Cash, cash equivalents and restricted cash—end of period 6,800.1 5,988.9 3,120.7
Supplemental disclosure of cash flow information:      
Cash paid for interest 56.3 54.5 55.6
Cash paid for income taxes $ 476.3 $ 191.8 $ 24.7
XML 36 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
Nature of Business and Accounting Policies
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Nature of Business and Accounting Policies Nature of Business and Accounting Policies
Business
Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) is global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases with a focus on specialty markets. We have multiple approved medicines that treat the underlying cause of cystic fibrosis (“CF”), a life-threatening genetic disease, and we have several ongoing clinical and research programs to advance and extend treatment of CF. Beyond CF, we have a pipeline of investigational therapies in other serious diseases where we are leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies.
Our marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
Basis of Presentation
The accompanying consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals. Please refer to Note Q, “Segment Information,” for enterprise-wide disclosures regarding our revenues, major customers and long-lived assets by geographic area.
Use of Estimates
The preparation of consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Revenue Recognition
We recognize revenue when a customer obtains control of promised goods or services. We record the amount of revenue that reflects the consideration that we expect to receive in exchange for those goods or services. We apply the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) we satisfy each performance obligation. 
We only apply the five-step model to contracts when it is probable that we will collect the consideration to which we are entitled in exchange for the goods or services that we transfer to the customer. Once a contract is determined to be within the scope of Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”) at contract inception, we review the contract to determine which performance obligations we must deliver and which of these performance obligations are distinct. We recognize as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. Generally, our performance obligations are transferred to customers at a point in time, typically upon delivery.
Product Revenues, Net
We sell our products principally to a limited number of specialty pharmacy and specialty distributors in the United States (“U.S.”), which account for the largest portion of our total revenues. We make international sales primarily to specialty
distributors and retail chains, as well as hospitals and clinics, many of which are government-owned or supported. Our customers in the U.S. subsequently resell the products to patients and health care providers. We recognize net product revenues from sales when our customers obtain control of our products, which typically occurs upon delivery to our customers. Our payment terms are approximately 30 days in the U.S. and consistent with prevailing practice in international markets.
Revenues from product sales are recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from (a) invoice discounts for prompt payment and distribution fees, (b) government and private payor rebates, chargebacks, discounts and fees and (c) costs of co-pay assistance programs for patients, as well as other incentives for certain indirect customers. Reserves are established for the estimates of variable consideration based on the amounts earned or to be claimed on the related sales. The reserves are classified as reductions to “Accounts receivable, net” if payable to a customer or “Accrued expenses” if payable to a third-party. Where appropriate, we utilize the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in net product revenues only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary from our estimates, we adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.
Invoice Discounts and Distribution Fees: We generally provide invoice discounts on product sales to our customers for prompt payment and pays fees for distribution services, such as fees for certain data that customers provide to us. We estimate that, based on our experience, our customers will earn these discounts and fees, and deduct the full amount of these discounts and fees from our gross product revenues and accounts receivable at the time such revenues are recognized.
Rebates, Chargebacks, Discounts and Fees: We contract with government agencies (our “Third-party Payors”) so that products will be eligible for purchase by, or partial or full reimbursement from, such Third-party Payors. We estimate the rebates, chargebacks, discounts and fees we will provide to Third-party Payors and deduct these estimated amounts from our gross product revenues at the time the revenues are recognized. For each product, we estimate the aggregate rebates, chargebacks and discounts that we will provide to Third-party Payors based upon (i) our contracts with these Third-party Payors, (ii) the government-mandated discounts and fees applicable to government-funded programs, (iii) information obtained from our customers and other third-party data regarding the payor mix for such product and (iv) historical experience.
Other Incentives: Other incentives that we offer include co-pay mitigation rebates that we provide to commercially insured patients who have coverage and who reside in states that permit co-pay mitigation programs. Based upon the terms of our co-pay mitigation programs, we estimate average co-pay mitigation amounts for each of our products in order to establish appropriate accruals.
We make significant estimates and judgments that materially affect our recognition of net product revenues. We adjust our estimated rebates, chargebacks and discounts based on new information, including information regarding actual rebates, chargebacks and discounts for our products, as it becomes available. Claims by third-party payors for rebates, chargebacks and discounts frequently are submitted to us significantly after the related sales, potentially resulting in adjustments in the period in which the new information becomes known. Our credits to product revenue related to prior period sales have not been significant and primarily related to rebates and discounts.
We exclude taxes collected from customers relating to product sales and remitted to governmental authorities from revenues.
Contract Liabilities
We recorded contract liabilities of $171.7 million and $191.5 million as of December 31, 2021 and 2020, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive. Upon exceeding the annual reimbursement amount, products are provided free of
charge, which is a material right. These contracts include upfront payments and fees. We defer a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. Our product revenue contracts include performance obligations that are one year or less.
Our contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as our fiscal year. In these markets we recognize revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year. During the years ended December 31, 2021, 2020 and 2019, we recorded $191.5 million, $62.3 million and $24.9 million, respectively, of revenues that were recorded as contract liabilities at the beginning of the year.
French Early Access Programs
In 2015, we began distributing ORKAMBI through early access programs in France and remained engaged in reimbursement discussions with the French government until November 2019, when we reached an agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs. From the time we began distributing ORKAMBI through early access programs in France, we expected the difference between the amounts collected based on the invoiced amount and the final amount for ORKAMBI distributed through early access programs would be returned to the French government.
Through the third quarter of 2019, we recognized net product revenues for ORKAMBI sales in France under the early access programs based on a transaction price that reflected our estimate of consideration we expected to retain that would not be subject to a significant reversal in amounts recognized. When determining if variable consideration should be constrained, we consider whether there are factors outside our control that could result in a significant reversal of revenue. In making these assessments, we consider the likelihood and magnitude of a potential reversal of revenue.
Upon reaching an agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs in November 2019, we updated the transaction price to reflect the final amount for ORKAMBI distributed through early access programs. As a result, we recognized net product revenues of $155.8 million related to prior period ORKAMBI early access program sales in the fourth quarter of 2019 because the updated transaction price for ORKAMBI distributed through these programs exceeded our previous estimate of the consideration we expected to retain that would not be subject to a significant reversal in amounts recognized. We paid the final amount due to the French government in 2020.
Other Revenues
We have not recorded significant revenues other than our product revenues during the three years ended December 31, 2021; however, in future periods, we may recognize collaborative revenues generated through collaborative research, development and/or commercialization agreements related to one or more of the following: nonrefundable, upfront license fees; development and commercial milestones; funding of research and/or development activities; and royalties on net sales of licensed products. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to our collaborator.
For each collaborative research, development, and/or commercialization agreement that results in revenue, we identify all material performance obligations and determine the transaction price by estimating the amount of variable consideration at the outset of the contract. We constrain (reduce) the estimate of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract.
Once the estimated transaction price is established, amounts are allocated to each separate performance obligation that has been identified on a relative standalone selling price basis.
Upfront License Fees: If we determine that a license to our intellectual property is distinct from the other performance obligations identified in an arrangement, we recognize revenue from the related nonrefundable, upfront license fees based on the relative standalone selling price prescribed to the license compared to the total selling price of
the arrangement. We recognize revenue when the license is transferred to our collaborator and our collaborator is able to use and benefit from the license. For licenses that are not distinct from other obligations identified in the arrangement, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, we apply an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.
Development and Regulatory Milestone Payments: Depending on facts and circumstances, we may include certain milestones in the estimated transaction price or fully constrain the milestones. We include a milestone payment in the transaction price in the reporting period that it is probable that recording revenue in the period will not result in a significant reversal in amounts recognized in future periods. This may result in us recognizing revenues from certain milestones and a corresponding contract asset in a reporting period before the milestone is achieved. We fully constrain milestone payments that have not been included in the transaction price to date until we conclude that their achievement is probable and that recognition of the related revenue will not result in a significant reversal in amounts recognized in future periods. We re-evaluate the probability of achievement of such development milestones and any related constraint each reporting period and adjust our estimate of the overall transaction price, including the amount of collaborative revenue that we have recorded, if necessary.
Research and Development Activities/Transition Services: If we are entitled to reimbursement from our collaborators for specified research and development expenses, we account for the related services as separate performance obligations if these services represent a material right. We also determine whether to account for the reimbursement of research and development expenses as collaborative revenues or an offset to research and development expenses in accordance with the provisions of gross or net revenue presentation. We recognize the corresponding revenues or record the corresponding offset to research and development expenses as we satisfy the related performance obligations.
Concentration of Credit Risk
Financial instruments that potentially subject us to concentration of credit risk consist principally of money market funds and marketable securities. We place these investments with highly rated financial institutions, and, by policy, limit the amount of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. We also maintain a foreign currency hedging program that includes foreign currency forward contracts with several counterparties. We have not experienced any credit losses related to these financial instruments and do not believe we are exposed to any significant credit risk related to these instruments.
We are also subject to credit risk from our accounts receivable related to our product sales and collaborators. We evaluate the creditworthiness of each of our customers and have determined that all our material customers are creditworthy. To date, we have not experienced significant losses with respect to the collection of our accounts receivable. We believe that our allowances, which are not significant to our consolidated financial statements, are adequate at December 31, 2021. Please refer to Note Q, “Segment Information,” for further information.
Cash and Cash Equivalents
We consider all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.
Marketable Securities
As of December 31, 2021, our marketable securities consisted of investments in available-for-sale debt securities and corporate equity securities with readily determinable fair values. We classify marketable securities available to fund current operations as current assets on our consolidated balance sheets. Marketable securities are classified as long-term assets on our consolidated balance sheets if (i) they have been in an unrealized loss position for longer than one year and (ii) we have the ability and intent to hold them (a) until the carrying value is recovered and (b) such holding period may be longer than one year. Our marketable securities are stated at fair value. The fair value of these securities is based on quoted prices for
identical or similar assets.
We record unrealized gains (losses) on available-for-sale debt securities as a component of “Accumulated other comprehensive income (loss),” which is a separate component of shareholders’ equity on our consolidated balance sheet, until such gains and losses are realized. Realized gains and losses, if any, are determined using the specific identification method.
We record changes in the fair value of our investments in corporate equity securities to “Other income, net” in our consolidated statements of operations. Realized gains and losses, which are also included in “Other income, net,” are determined on an original weighted-average cost basis.
We adopted Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”) as of January 1, 2020, which did not have a significant impact on our consolidated financial statements. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires us to record an allowance for credit losses using an expected loss model, which replaces the incurred loss model required under the previous guidance. A credit loss is limited to the amount by which the amortized cost of an investment exceeds its fair value. A previously recognized credit loss may be decreased in subsequent periods if our estimate of fair value for the investment increases. To determine whether to record a credit loss, we consider issuer specific credit ratings and historical losses as well as current economic conditions and our expectations for future economic conditions.
Accounts Receivable
We deduct invoice discounts for prompt payment and fees for distribution services from our accounts receivable based on our experience that our customers will earn these discounts and fees. Our estimates for our allowance for credit losses, which has not been significant to date, is determined based on existing contractual payment terms, historical payment patterns, current economic conditions and our expectation for future economic conditions.
Stock-based Compensation Expense
We expense the fair value of employee restricted stock units and other forms of stock-based employee compensation over the associated employee service period on a straight-line basis. Stock-based compensation expense is determined based on the fair value of the award at the grant date and is adjusted each period to reflect actual forfeitures and the outcomes of certain performance conditions.
For awards with performance conditions in which the award does not vest unless the performance condition is met, we recognize expense if, and to the extent that, we estimate that achievement of the performance condition is probable. If we conclude that vesting is probable, we recognize expense from the date we reach this conclusion through the estimated vesting date.
We provide to employees who have rendered a certain number of years of service to Vertex and meet certain age requirements, partial or full acceleration of vesting of these equity awards, subject to certain conditions including a notification period, upon a termination of employment other than for cause. Approximately 5% of our employees were eligible for partial or full acceleration of any of their equity awards as of December 31, 2021. We recognize stock-based compensation expense related to these awards over a service period reflecting qualified employees’ eligibility for partial or full acceleration of vesting.
Please refer to Note N, “Stock-based Compensation Expense,” for tables displaying our stock-based compensation expense by type of award and by line item within our consolidated statements of operations.
Research and Development Expenses
Research and development expenses are comprised of costs we incur in performing research and development activities, including salary and benefits; stock-based compensation expense; outsourced services and other direct expenses, including clinical trial and pharmaceutical development costs; collaborative payments; and infrastructure costs, including facilities costs and depreciation expense. We recognize research and development expenses as incurred. We capitalize nonrefundable advance payments we make for research and development activities and expense the payments as the related goods are
delivered or the related services are performed.
Inventories
We value our inventories at the lower-of-cost or net realizable value. We determine the cost of our inventories, which include amounts related to materials and manufacturing overhead, on a first-in, first-out basis. We perform an assessment of the recoverability of our capitalized inventory during each reporting period and write down any excess and obsolete inventories to their net realizable value in the period in which the impairment is first identified. Shipping and handling costs incurred for inventory purchases are capitalized and recorded upon sale in “Cost of sales” in our consolidated statements of operations. Shipping and handling costs incurred for product shipments are recorded as incurred in “Cost of sales” in our consolidated statements of operations.
We capitalize inventories produced in preparation for initiating sales of a product candidate when the related product candidate is considered to have a high likelihood of regulatory approval and the related costs are expected to be recoverable through sales of the inventories. In determining whether to capitalize such inventories, we evaluate, among other factors, information regarding the product candidate’s safety and efficacy, the status of regulatory submissions and communications with regulatory authorities and the outlook for commercial sales, including the existence of current or anticipated competitive drugs and the availability of reimbursement. In addition, we evaluate risks associated with manufacturing the product candidate and the remaining shelf-life of the inventories.
Property and Equipment
Property and equipment are recorded at cost, net of accumulated depreciation. Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset generally as follows:
DescriptionEstimated Useful Life
Buildings and improvements
15 to 40 years
Furniture and equipment
7 to 10 years
Leasehold improvements; assets under finance leasesThe shorter of the useful life of the assets or the estimated remaining term of the associated lease
Computers and software
3 to 5 years
Maintenance and repairs to an asset that do not improve or extend its life are charged to operations. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in our consolidated statements of operations. We perform an assessment of the fair value of the assets if indicators of impairment are identified during a reporting period and record the assets at the lower of the net book value or the fair value of the assets.
We capitalize internal costs incurred to develop software for internal use during the application development stage. Amortization of capitalized internally developed software costs is recorded in depreciation expense over the useful life of the related asset.
Leases
We determine whether an arrangement contains a lease at inception. If a lease is identified in an arrangement, we recognize a right-of-use asset and liability on our consolidated balance sheet and determine whether the lease should be classified as a finance or operating lease. We do not recognize assets or liabilities for leases with lease terms of less than 12 months.
A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to Vertex by the end of the lease term, (ii) we hold an option to purchase the leased asset that we are reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no
alternative use at the end of the lease term. All other leases are recorded as operating leases.
Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate implicit is not readily determinable, we utilize our incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease.
We do not separate lease and non-lease components when determining which lease payments to include in the calculation of our lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, we reflect the option in the lease term if it is reasonably certain we will exercise the option.
Finance leases are recorded in “Property and equipment, net,” “Other current liabilities” and “Long-term finance lease liabilities,” and operating leases are recorded in “Operating lease assets,” “Other current liabilities” and “Long-term operating lease liabilities” on our consolidated balance sheet.
Income Taxes
Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the income tax bases of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. On a periodic basis, we reassess the valuation allowance on our deferred income tax assets weighing positive and negative evidence to assess the recoverability of our deferred tax assets. We include, among other things, our recent financial performance and our future projections in this periodic assessment.
We record liabilities related to uncertain tax positions by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. We evaluate our uncertain tax positions on a quarterly basis and consider various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in our tax returns, and changes in facts or circumstances related to a tax position. We adjust our liabilities to reflect any subsequent changes in the relevant facts and circumstances surrounding the uncertain positions. We accrue interest and penalties related to unrecognized tax benefits as a component of our “Provision for income taxes.”
As part of the U.S. Tax Cut and Jobs Act of 2017, we are subject to a territorial tax system, under which we must establish an accounting policy to provide for tax on Global Intangible Low Taxed Income (“GILTI”) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a current tax expense in our “Provision for income taxes.”
Variable Interest Entities
We review each collaboration agreement pursuant to which we license assets owned by a collaborator in order to determine whether or not we have a variable interest via the license agreement with our collaborator and if the variable interest is a variable interest in our collaborator as a whole and whether or not we are the primary beneficiary of that variable interest entity (“VIE”). If we determine we are the primary beneficiary of a VIE at the onset of our collaboration agreement, the collaboration is treated as a business combination and we consolidate the financial statements of the VIE into our consolidated financial statements until we are no longer the primary beneficiary of the consolidated VIE, or no longer have a variable interest in the VIE. As of December 31, 2021 and 2020, we did not have any consolidated VIEs.
Fair Value of In-process Research and Development Assets and Contingent Payments
The present-value models we use to estimate the fair values of in-process research and development assets and contingent payments pursuant to collaborations and acquisitions incorporate significant assumptions.
Our discounted cash flow models pertaining to in-process research and development assets include: (i) assumptions regarding the probability of obtaining marketing approval for a product candidate; (ii) the timing of and the expected costs to develop and commercialize a product candidate; (iii) estimates of future cash flows from potential product sales with respect to a product candidate; and (iv) appropriate discount and tax rates.
We base our estimates of the probability of achieving the milestones relevant to the fair value of contingent payments, which could include milestone, royalty and option payments, on industry data. Estimates included in the discounted cash flow models pertaining to contingent payments also include: (i) estimate regarding the timing of the relevant development and commercial milestones and royalties, (ii) and appropriate discount rates. We record any increases or decreases in the fair value of our contingent payments as charges or credits to “Change in fair value of contingent consideration” in our consolidated statement of operations. Please refer to Note D, “Fair Value Measurements,” for further information.
In-process Research and Development Assets
We record the fair value of in-process research and development assets as of the transaction date of a business combination. Each of these assets is accounted for as an indefinite-lived intangible asset and is maintained on our consolidated balance sheet until either the underlying project is completed or the asset becomes impaired. If the asset becomes impaired or is abandoned, the carrying value of the related intangible asset is written down to its fair value, and an impairment charge is recorded in the period in which the impairment occurs. If a project is completed, the carrying value of the related intangible asset is amortized as a part of “Cost of sales” over the remaining estimated life of the asset beginning in the period in which the project is completed. In-process research and development assets are tested for impairment on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstances suggest that impairment may exist.
In-process research and development that is acquired in a transaction that does not qualify as a business combination under U.S. GAAP and that does not have an alternative future use is recorded to “Research and development expenses” in the period in which it is acquired.
Goodwill
The difference between the purchase price and the fair value of assets acquired and liabilities assumed in a business combination is allocated to goodwill. Goodwill is evaluated for impairment on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstances suggest that impairment may exist. As noted in Basis of Presentation above, we have one operating segment, pharmaceuticals, which is our only reporting unit.
Hedging Activities
We recognize the fair value of hedging instruments that are designated and qualify as hedging instruments pursuant to U.S. GAAP, foreign currency forward contracts, as either assets or liabilities on our consolidated balance sheets. Changes in the fair value of these instruments are recorded each period in “Accumulated other comprehensive income (loss)” as unrealized gains and losses until the forecasted underlying transaction occurs. Unrealized gains and losses on these foreign currency forward contracts are included in “Prepaid expenses and other current assets” or “Other assets,” and “Other current liabilities” or “Other long-term liabilities,” respectively, on our consolidated balance sheets depending on the remaining period until their contractual maturity. Realized gains and losses for the effective portion of such contracts are recognized in “Product revenues, net” in our consolidated statement of operations in the same period that we recognize the product revenues that were impacted by the hedged foreign exchange rate changes. We classify the cash flows from hedging instruments in the same category as the cash flows from the hedged items.
Certain of our hedging instruments are subject to master netting arrangements to reduce the risk arising from such transactions with our counterparties. We present unrealized gains and losses on our foreign currency forward contracts on a gross basis within our consolidated balance sheets.
We also enter into foreign currency forward contracts with contractual maturities of less than one month designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities including intercompany balances. These contracts are not designated as hedging instruments pursuant to U.S. GAAP. Realized gains and losses for such
contracts are recognized in “Other income, net” in our consolidated statement of operations each period.
Comprehensive Income
Comprehensive income consists of net income and other comprehensive income (loss), which includes foreign currency translation adjustments and unrealized gains and losses on foreign currency forward contracts and certain marketable securities. For purposes of comprehensive income disclosures, we record provisions for or benefits from income taxes related to the unrealized gains and losses on foreign currency forward contracts and certain marketable securities. We do not record provisions for or benefits from income taxes related to our cumulative translation adjustment, as we intend to permanently reinvest undistributed earnings in our foreign subsidiaries.
Foreign Currency Translation and Transactions
The majority of our operations occur in entities that have the U.S. dollar denominated as their functional currency. The assets and liabilities of our entities with functional currencies other than the U.S. dollar are translated into U.S. dollars at exchange rates in effect at the end of the year. Revenue and expense amounts for these entities are translated using the average exchange rates for the period. Net unrealized gains and losses resulting from foreign currency translation are included in “Accumulated other comprehensive income (loss).” Net foreign currency exchange transaction losses, which are included in “Other income, net” on our consolidated statement of operations, were $13.9 million, $16.1 million and $5.2 million for 2021, 2020 and 2019, respectively. These net foreign currency exchange losses are presented net of the impact of the foreign currency forward contracts designed to mitigate their effect on our consolidated statement of operations.
Share Repurchase Programs
Repurchases of our common stock are recorded as reductions to “Common Stock” and “Additional paid-in capital” pursuant to our established accounting policy. Repurchases in excess of the par value will be recorded as reductions to “Retained earnings” in the event that “Additional paid-in capital” is reduced to zero.
Net Income Per Common Share
Basic net income per common share is based upon the weighted-average number of common shares outstanding during the period. Diluted net income per common share utilizing the treasury-stock method is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive. Potentially dilutive shares result from the assumed exercise of outstanding stock options and assumed vesting of restricted stock units (including performance-based restricted stock units) (the proceeds of which are then assumed to have been used to repurchase outstanding stock using the treasury-stock method).
Recently Adopted Accounting Standards
Income Taxes
In 2019, the Financial Accounting Standards Board (“FASB”) issued ASU 2019-12, Income Taxes (Topic 740) (“ASU 2019-12”), which simplifies the accounting for income taxes. ASU 2019-12 became effective on January 1, 2021. The adoption of ASU 2019-12 did not have a significant impact on our consolidated financial statements.
Internal-Use Software
In 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU 2018-15”), which clarifies the accounting for implementation costs in cloud computing arrangements. ASU 2018-15 became effective on January 1, 2020. The adoption of ASU 2018-15 resulted in an insignificant amount of additional assets recorded on our consolidated balance sheet.
Fair Value Measurement
In 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which modifies the disclosure requirements for fair
value measurements. ASU 2018-13 became effective on January 1, 2020. The adoption of ASU 2018-13 resulted in additional disclosures related to our Level 3 inputs. Please refer to Note D, “Fair Value Measurements,” for further information.
Credit Losses
In 2016, the FASB issued ASU 2016-13, which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 became effective on January 1, 2020. The adoption of ASU 2016-13 did not have a significant impact on our consolidated financial statements.
Leases
On January 1, 2019, we adopted ASC 842 using the modified-retrospective method. Until December 31, 2018, we applied build-to-suit accounting and were the deemed owner of our leased corporate headquarters in Boston and research site in San Diego. Under the amended guidance that became effective January 1, 2019, we account for these buildings as finance leases. As of January 1, 2019, we recorded a cumulative effect adjustment to increase our “Accumulated deficit” by $40.3 million to reflect our build-to-suit leases as finance leases pursuant to ASC 842.
Recently Issued Accounting Standards
We do not expect any recently issued accounting standards to have a significant impact on our consolidated financial statements.
XML 37 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaborative and Other Arrangements
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Collaborative and Other Arrangements Collaborative and Other Arrangements
We have entered into numerous agreements pursuant to which we collaborate with third parties on research, development and commercialization programs, including in-license and out-license agreements or acquire assets. Our “Research and development expenses” included $1.1 billion, $184.6 million and $318.3 million related to upfront and milestone payments pursuant to our in-license agreements and asset acquisitions in 2021, 2020 and 2019, respectively.
In-license Agreements
We have entered into a number of in-license agreements in order to advance and obtain access to technologies and services related to our research and early-development activities. We are generally required to make an upfront payment upon execution of our license agreements; development, regulatory and commercialization milestones payments upon the achievement of certain product research, development and commercialization objectives; and royalty payments on future sales, if any, of commercial products resulting from our collaborations.
Pursuant to the terms of our in-license agreements, our collaborators typically lead the discovery efforts and we lead all preclinical, development and commercialization activities associated with the advancement of any product candidates and fund all expenses.
We typically can terminate our in-license agreements by providing advance notice to our collaborators; the required length of notice is dependent on whether any product developed under the license agreement has received marketing approval. Our license agreements may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, these license agreements generally remain in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired.
CRISPR Therapeutics AG
CRISPR-Cas9 Gene-editing Therapies
In 2015, we entered into a strategic collaboration, option and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new
treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. We had the exclusive right to license certain targets. In 2019, we paid an aggregate of $30.0 million to exclusively license three targets, including CF, pursuant to the CRISPR Agreement. We recorded the $30.0 million total option payment to “Research and development expenses.” For each of the three targets that we elected to license, CRISPR has the potential to receive up to an additional $410.0 million in development, regulatory and commercial milestones as well as royalties on net product sales.
In 2017, we entered into a joint development and commercialization agreement with CRISPR pursuant to the terms of the CRISPR Agreement (the “Original CTX001 JDCA”), under which we and CRISPR were co-developing and preparing to co-commercialize CTX001 for the treatment of hemoglobinopathies, including treatments for sickle cell disease and transfusion-dependent beta thalassemia.
In the second quarter of 2021, we and CRISPR amended and restated the Original CTX001 JDCA (the “A&R JDCA”), pursuant to which the parties agreed to, among other things, (a) adjust the governance structure for the collaboration and adjust the responsibilities of each party thereunder; (b) adjust the allocation of net profits and net losses between the parties; and (c) exclusively license (subject to CRISPR’s reserved rights to conduct certain activities) certain intellectual property rights to us relating to the products that may be researched, developed, manufactured and commercialized under such agreement.
Pursuant to the A&R JDCA, we are now leading global development, manufacturing and commercialization of CTX001, with support from CRISPR. Subject to the terms and conditions of the A&R JDCA, we also have the right to conduct all research, development, manufacturing and commercialization activities relating to the product candidates and products under the A&R JDCA (including CTX001) throughout the world subject to CRISPR’s reserved right to conduct certain activities.
In connection with the A&R JDCA, we made a $900.0 million upfront payment to CRISPR in the second quarter of 2021. We concluded that we did not have any alternative future use for the acquired in-process research and development and recorded this upfront payment to “Research and development expenses.” CRISPR has the potential to receive an additional one-time $200.0 million milestone payment upon receipt of the first marketing approval of CTX001 from the U.S. Food and Drug Administration or the European Commission.
We and CRISPR shared equally all expenses incurred under the Original CTX001 JDCA. On July 1, 2021, with respect to CTX001, the net profits and net losses incurred pursuant to the A&R JDCA began to be allocated 60% to us and 40% to CRISPR, while all other product candidates and products continue to have net profits and net losses shared equally between the parties. We concluded that the Original CTX001 JDCA and the A&R JDCA are cost-sharing arrangements, which result in the net impact of the arrangements being recorded in “Research and development expenses” in our consolidated statements of operations. During the three years ended December 31, 2021, we recognized the following amounts in total related to these agreements:
202120202019
(in millions)
Total research and development expenses incurred under the Original CTX001 JDCA and A&R JDCA$230.4 $101.2 $60.3 
Vertex’s share recognized in “Research and development expenses” in consolidated statements of operations
129.0 50.6 30.1 
Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1
In 2019, we entered into a separate strategic collaboration and license agreement (the “CRISPR DMD/DM1 Agreement”) with CRISPR. Pursuant to this agreement, we received an exclusive worldwide license to CRISPR’s existing and future intellectual property for Duchenne muscular dystrophy (“DMD”) and myotonic dystrophy type 1 (“DM1”) and we made an upfront payment of $175.0 million to CRISPR. We concluded that we did not have any alternative future use for the acquired in-process research and development and recorded the upfront payment to “Research and development expenses.” We recorded $12.5 million and $25.0 million to “Research and development expenses” in 2021 and 2020, respectively, related to pre-clinical milestones earned by CRISPR under the CRISPR DMD/DM1 Agreement. CRISPR has the potential to receive up to an additional $787.5 million in research, development, regulatory and commercial milestones for the DMD and
DM1 programs as well as royalties on net product sales. CRISPR has the option to co-develop and co-commercialize all DM1 products globally and forego the milestones and royalties associated with the DM1 program. We fund all expenses associated with the collaboration.
Kymera Therapeutics Inc.
In 2019, we entered into a strategic research and development collaboration agreement with Kymera Therapeutics Inc. (“Kymera”) to advance small molecule protein degraders against multiple targets. Kymera’s proprietary platform technology is being applied in the collaboration activities in exchange for an upfront payment of $50.0 million. We have the exclusive right to license up to six protein targets, for each of which Kymera may receive up to $170.0 million in payments, including development, regulatory and commercial milestones as well as royalties on net product sales. We determined that substantially all of the fair value of the Kymera collaboration agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. We concluded that we did not have any alternative future use for the acquired in-process research and development and recorded the $50.0 million upfront payment to “Research and development expenses.”
In addition to the upfront payment, we purchased $20.0 million of Kymera’s preferred stock that converted to common stock when Kymera became a publicly traded company in 2020.
Moderna, Inc.
In 2016, we entered into a strategic collaboration and licensing agreement with Moderna, Inc. (“Moderna”), pursuant to which the parties are seeking to identify and develop messenger ribonucleic acid (“mRNA”) therapeutics for the treatment of CF.
In 2020, we entered into a new strategic collaboration and licensing agreement with Moderna (the “2020 Moderna Agreement”) aimed at the discovery and development of lipid nanoparticles and mRNAs that can deliver gene-editing therapies to lung cells for the treatment of CF. Pursuant to the 2020 Moderna Agreement, we paid Moderna an upfront payment of $75.0 million and Moderna is eligible to receive up to $380.0 million in development, regulatory and commercial milestones as well as royalties on net product sales. We determined that substantially all the fair value of the 2020 Moderna Agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. We concluded that we did not have any alternative future use for the acquired in-process research and development and recorded the upfront payment to “Research and development expenses.”
Additional In-License Agreements and Other Arrangements
In 2016, we entered into a strategic collaboration and license agreement with ApoLo1 Bio, LLC (“ApoLo1”) related to our drug discovery efforts in APOL1-mediated kidney disease. In 2021, based on positive results from a Phase 2 proof-of-concept study of VX-147 in patients with APOL1-mediated focal segmental glomerulosclerosis, we paid ApoLo1 a $15.0 million milestone and exercised our $60.0 million option to buy-out all future development milestones, regulatory milestones and future royalties on net product sales. We recorded these payments to “Research and development expenses” because we concluded that we did not have any alternative future use for the acquired in-process research and development.
In addition to the collaborative arrangements described above, we recorded upfront, option and milestone payments totaling $125.8 million in 2021, $84.6 million in 2020 and $63.3 million in 2019 to “Research and development expenses” related to additional in-license agreements and other business development transactions that we do not consider to be individually significant to our consolidated financial statements. These payments included upfront payments of $31.0 million to Mammoth Biosciences, Inc. (“Mammoth”) and $25.0 million to Arbor Biotechnologies, Inc. (“Arbor”) in 2021, $40.0 million to Skyhawk Therapeutics, Inc. (“Skyhawk”) in 2020, and $25.9 million to Molecular Templates, Inc. (“Molecular”) in 2019.
For Mammoth, Arbor, Skyhawk, Molecular and several other in-license agreements that are not individually significant to our consolidated financial statements, we determined that substantially all the fair value of each individual agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. We concluded that we did not have any alternative future use for the acquired in-process research and development
associated with the agreements and recorded the upfront payments for these agreements to “Research and development expenses.” Please refer to Note D, “Fair Value Measurements,” and Note E, “Marketable Securities and Equity Investments,” for further information regarding our investments in our collaborators.
Out-license Agreements
We have entered into licensing agreements pursuant to which we have out-licensed rights to certain product candidates to third-party collaborators. Pursuant to these out-license agreements, our collaborators become responsible for all costs related to the continued development of such product candidates and obtain development and commercialization rights to these product candidates. Depending on the terms of the agreements, our collaborators may be required to make upfront payments, milestone payments upon the achievement of certain product research and development objectives and may also be required to pay royalties on future sales, if any, of commercial products resulting from the collaboration. The termination provisions associated with these collaborations are generally the same as those described above related to our in-license agreements.
Merck KGaA, Darmstadt, Germany
In 2017, we entered into a strategic collaboration and license agreement (the “Oncology Agreement”) with Merck KGaA, Darmstadt, Germany (the “Licensee”). Pursuant to the Oncology Agreement, we granted the Licensee an exclusive worldwide license to research, develop and commercialize four oncology research and development programs including two clinical-stage programs targeting DNA damage repair: our ataxia telangiectasia and Rad3-related protein kinase inhibitor program, or ATR program, including VX-970 and VX-803, and our DNA-dependent protein kinase inhibitor program, or DNA-PK program, including VX-984. In addition, we granted the Licensee exclusive, worldwide rights to two pre-clinical programs.
In 2018, we entered into an agreement with Merck KGaA, Darmstadt, Germany (the “DNA-PK Agreement”) whereby we licensed the two lead Vertex DNA-PK compounds from our DNA-PK program for use in the field of gene integration for six specific indications. Merck KGaA, Darmstadt, Germany has the potential to receive additional milestones, primarily related to approval and reimbursement in various markets, as well as royalties on net product sales.
Cystic Fibrosis Foundation
We have a research, development and commercialization agreement that was originally entered into in 2004 with the Cystic Fibrosis Foundation, as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc. This agreement was most recently amended in 2016. Pursuant to the agreement, as amended, we agreed to pay royalties ranging from low-single digits to mid-single digits on potential sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor, and tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor). For combination products, such as ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), sales are allocated equally to each of the active pharmaceutical ingredients in the combination product. We record our royalties payable to the Cystic Fibrosis Foundation to “Cost of sales.”
XML 38 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
Earnings Per Share
 12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
The following table sets forth the computation of basic and diluted net income per common share for the periods ended:
202120202019
(in millions, except per share amounts)
Net income $2,342.1 $2,711.7 $1,176.8 
Basic weighted-average common shares outstanding257.7 259.8 256.7 
Effect of potentially dilutive securities:
Stock options1.1 1.8 2.2 
Restricted stock units (including PSUs)
1.1 1.7 1.7 
Employee stock purchase program
0.0 0.1 0.1 
Diluted weighted-average common shares outstanding259.9 263.4 260.7 
Basic net income per common share$9.09 $10.44 $4.58 
Diluted net income per common share$9.01 $10.29 $4.51 
We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:
202120202019
(in millions)
Stock options0.7 0.3 2.8 
Unvested restricted stock units (including PSUs)0.4 0.3 — 
XML 39 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements
 12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The following fair value hierarchy is used to classify assets and liabilities based on observable inputs and unobservable inputs used in order to determine the fair value of our financial assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.
Our investment strategy is focused on capital preservation. We invest in instruments that meet the credit quality standards outlined in our investment policy, which also limits the amount of credit exposure to any one issue or type of instrument. We maintain strategic investments separately from the investment policy that governs our other cash, cash equivalents and marketable securities as described in Note E, “Marketable Securities and Equity Investments.” Additionally, we utilize foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on our consolidated statement of operations.
During the three years ended December 31, 2021, we did not record any other-than-temporary impairment charges related to our financial assets.
The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $3.3 billion and $2.8 billion of cash as of December 31, 2021 and 2020, respectively):
As of December 31, 2021As of December 31, 2020
Fair Value Hierarchy
Fair Value Hierarchy
Total
Level 1
Level 2
Level 3
Total
Level 1
Level 2
Level 3
(in millions)
Financial instruments carried at fair value (asset position):
Cash equivalents:
Money market funds$3,478.1 $3,478.1 $— $— $3,141.1 $3,141.1 $— $— 
Marketable securities:
Corporate equity securities230.9 230.9 — — 195.8 15.7 180.1 — 
U.S. Treasury securities86.4 86.4 — — — — — — 
Government-sponsored enterprise securities69.0 69.0 — — 80.0 80.0 — — 
Corporate debt securities90.9 — 90.9 — 231.6 — 231.6 — 
Commercial paper252.7 — 252.7 — 163.3 — 163.3 — 
Prepaid expenses and other current assets:
Foreign currency forward contracts44.5 — 44.5 — — — — — 
Other assets:
Foreign currency forward contracts2.0 — 2.0 — — — — — 
Total financial assets
$4,254.5 $3,864.4 $390.1 $— $3,811.8 $3,236.8 $575.0 $— 
Financial instruments carried at fair value (liability position):
Other current liabilities:
Foreign currency forward contracts$(5.6)$— $(5.6)$— $(59.2)$— $(59.2)$— 
Long-term contingent consideration(186.5)— — (186.5)(189.6)— — (189.6)
Other long-term liabilities:
Foreign currency forward contracts(2.7)— (2.7)— (4.3)— (4.3)— 
Total financial liabilities$(194.8)$— $(8.3)$(186.5)$(253.1)$— $(63.5)$(189.6)
Please refer to Note E, “Marketable Securities and Equity Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.
Fair Value of Corporate Equity Securities
We classify our investments in publicly traded corporate equity securities as “Marketable securities” on our consolidated balance sheets. Generally, our investments in the common stock of publicly traded companies are valued based on Level 1 inputs because they have readily determinable fair values. However, certain of our investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments. Please refer to Note E, “Marketable Securities and Equity Investments,” for further information on these investments.
Fair Value of Contingent Consideration
In 2019, we acquired Exonics Therapeutics, Inc. (“Exonics”), a privately-held company focused on creating transformative gene-editing therapies to repair mutations that cause DMD and other severe neuromuscular diseases, including DM1. Our Level 3 contingent consideration liabilities are related to $678.3 million of development and regulatory milestones potentially payable to Exonics’ former equity holders. We base our estimates of the probability of achieving the milestones relevant to the fair value of contingent payments on industry data attributable to rare diseases. The discount rates used in the valuation model for contingent payments, which were between 0.9% and 2.3% as of December 31, 2021, represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Due to the uncertainties associated with development and commercialization of product candidates in the pharmaceutical industry and the effects of changes in other assumptions
including discount rates, we expect our estimates regarding the fair value of contingent consideration to change in the future, resulting in adjustments to the fair value of our contingent consideration liabilities, and the effect of any such adjustments could be material.
The following table represents a rollforward of the fair value of our contingent consideration liabilities:
Year Ended December 31, 2021
(in millions)
Balance at December 31, 2020
$189.6 
Decrease in fair value of contingent payments
(3.1)
Balance at December 31, 2021
$186.5 
XML 40 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
Marketable Securities and Equity Investments
 12 Months Ended
Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities and Equity Investments Marketable Securities and Equity Investments
A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $3.3 billion and $2.8 billion of cash as of December 31, 2021 and 2020, respectively), is shown below:
As of December 31, 2021As of December 31, 2020
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair Value
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair Value
(in millions)
Cash equivalents:
Money market funds
$3,478.1 $— $— $3,478.1 $3,141.1 $— $— $3,141.1 
Marketable securities:
U.S. Treasury securities$86.6 $— $(0.2)$86.4 $— $— $— $— 
Government-sponsored enterprise securities
69.0 — — 69.0 80.0 — — 80.0 
Corporate debt securities
91.1 — (0.2)90.9 231.3 0.4 (0.1)231.6 
Commercial paper
252.8 — (0.1)252.7 163.3 — — 163.3 
Total marketable debt securities499.5 — (0.5)499.0 474.6 0.4 (0.1)474.9 
Corporate equity securities
69.4 167.1 (5.6)230.9 51.4 144.4 — 195.8 
Total marketable securities$568.9 $167.1 $(6.1)$729.9 $526.0 $144.8 $(0.1)$670.7 
Available-for-sale debt securities were classified on our consolidated balance sheets at fair value as follows:
December 31,
20212020
(in millions)
Cash and cash equivalents$3,478.1 $3,141.1 
Marketable securities
499.0 474.9 
Total
$3,977.1 $3,616.0 
Available-for-sale debt securities by contractual maturity were as follows:
December 31,
20212020
(in millions)
Matures within one year$3,912.3 $3,526.2 
Matures after one year through five years
64.8 89.8 
Total
$3,977.1 $3,616.0 
We have a limited number of available-for-sale debt securities in insignificant loss positions as of December 31, 2021, which we do not intend to sell and have concluded we will not be required to sell before recovery of the amortized costs for the investments at maturity. We did not record any charges for other-than-temporary declines in the fair value of available-for-sale debt securities or gross realized gains or losses in 2021, 2020 or 2019.
We record changes in the fair value of our investments in corporate equity securities to “Other income, net” in our consolidated statements of operations. During the three years ended December 31, 2021, our net unrealized gains on corporate equity securities held at the conclusion of each period were as follows:
202120202019
(in millions)
Net unrealized gains$17.1 $136.2 $143.2 
During the years ended December 31, 2020 and 2019, we sold the common stock of publicly traded companies, which were primarily sales of our investment in CRISPR, resulting in the following:
20202019
(in millions)
Proceeds received$437.6 $94.9 
Weighted-average cost basis$103.3 $29.8 
During the year ended December 31, 2021, we did not sell any common stock of publicly traded companies.
As of December 31, 2021, the carrying value of our equity investments without readily determinable fair values, which are recorded in “Other assets” on our consolidated balance sheets, was $85.8 million.
XML 41 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
Accumulated Other Comprehensive Income (Loss)
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
Unrealized Holding Gains (Losses), Net of Tax
Foreign Currency Translation AdjustmentOn Available-For-Sale Debt SecuritiesOn Foreign Currency Forward ContractsTotal
(in millions)
Balance as of December 31, 2018
$(11.2)$(0.5)$12.4 $0.7 
Other comprehensive income before reclassifications10.3 1.0 11.5 22.8 
Amounts reclassified from accumulated other comprehensive income (loss)— — (25.5)(25.5)
Net current period other comprehensive income (loss)10.3 1.0 (14.0)(2.7)
Balance as of December 31, 2019
$(0.9)$0.5 $(1.6)$(2.0)
Other comprehensive loss before reclassifications(14.7)(0.2)(54.5)(69.4)
Amounts reclassified from accumulated other comprehensive income (loss)— — 2.9 2.9 
Net current period other comprehensive loss(14.7)(0.2)(51.6)(66.5)
Balance as of December 31, 2020
$(15.6)$0.3 $(53.2)$(68.5)
Other comprehensive income (loss) before reclassifications2.0 (0.8)59.7 60.9 
Amounts reclassified from accumulated other comprehensive income (loss)— — 23.5 23.5 
Net current period other comprehensive income (loss)2.0 (0.8)83.2 84.4 
Balance as of December 31, 2021
$(13.6)$(0.5)$30.0 $15.9 
XML 42 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
Hedging
 12 Months Ended
Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Hedging Hedging
Foreign currency forward contracts - Designated as hedging instruments
We maintain a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of our forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under U.S. GAAP having contractual durations from one to eighteen months. We recognize realized gains and losses for the effective portion of such contracts in “Product revenues, net” in our consolidated statements of operations in the same period that we recognize the product revenues that were impacted by the hedged foreign exchange rate changes.
We formally document the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as our risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. We also formally assess, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of December 31, 2021, all hedges were determined to be highly effective.
We consider the impact of our counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of December 31, 2021 and December 31, 2020, credit risk did not change the fair value of our foreign currency forward contracts.
The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:
As of December 31,
20212020
Foreign Currency(in millions)
Euro$1,364.5 $745.1 
British pound sterling
287.7 160.4 
Australian dollar
96.3 99.9 
Canadian dollar
89.9 86.5 
Swiss Franc54.1 — 
Total foreign currency forward contracts
$1,892.5 $1,091.9 
Foreign currency forward contracts - Not designated as hedging instruments
We also enter into foreign currency forward contracts with contractual maturities of less than one month, which are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under U.S. GAAP. We recognize realized gains and losses for such contracts in “Other income, net” in our consolidated statements of operations each period. As of December 31, 2021, the notional amount of our outstanding foreign currency forward contracts where hedge accounting under U.S. GAAP is not applied was $580.7 million.
During the three years ended December 31, 2021, we recognized the following related to foreign currency forward contracts in our consolidated statements of operations:
December 31,
202120202019
(in millions)
Designated as hedging instruments - Reclassified from AOCI
Product revenues, net$(30.0)$(3.7)$32.5 
Not designated as hedging instruments
Other income, net$(18.6)$22.1 $(4.8)
Total reported in the Consolidated Statement of Operations
Product revenues, net$7,573.4 $6,202.8 $4,160.7 
Other income, net$4.9 $296.6 $192.2 
The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our consolidated balance sheets:
As of December 31, 2021
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets
$44.5 
Other current liabilities
$(5.6)
Other assets
2.0 
Other long-term liabilities
(2.7)
Total assets
$46.5 
Total liabilities
$(8.3)
As of December 31, 2020
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets
$— 
Other current liabilities
$(59.2)
Other assets
— 
Other long-term liabilities
(4.3)
Total assets
$— 
Total liabilities
$(63.5)
As of December 31, 2021, we expect the amounts that are related to foreign exchange forward contracts designated as cash flow hedges under U.S. GAAP recorded in “Prepaid expenses and other current assets” and “Other current liabilities” to be reclassified to earnings within twelve months.
As discussed in Note A, “Note A, “Nature of Business and Accounting Policies,” we present the fair value of our foreign currency forward contracts on a gross basis within our consolidated balance sheets. The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our consolidated balance sheets:
As of December 31, 2021
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$46.5 $— $46.5 $(8.3)$38.2 
Total liabilities(8.3)— (8.3)8.3 — 
As of December 31, 2020
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$— $— $— $— $— 
Total liabilities(63.5)— (63.5)— (63.5)
XML 43 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
Inventories
 12 Months Ended
Dec. 31, 2021
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories consisted of the following:
As of December 31,
20212020
(in millions)
Raw materials$42.4 $46.2 
Work-in-process224.0 161.3 
Finished goods
86.7 73.3 
Total
$353.1 $280.8 
XML 44 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property and Equipment
 12 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
Property and Equipment Property and Equipment
Property and equipment, net consisted of the following:
As of December 31,
20212020
(in millions)
Buildings and improvements$892.5 $876.1 
Furniture and equipment407.3 346.7 
Leasehold improvements363.5 234.6 
Computers and software293.7 258.6 
Land33.1 33.1 
Total property and equipment, gross1,990.1 1,749.1 
Less: accumulated depreciation
(896.0)(790.6)
Total property and equipment, net
$1,094.1 $958.5 
We recorded depreciation expense of $125.6 million, $109.5 million and $106.9 million in 2021, 2020 and 2019, respectively, which includes our finance lease amortization.
XML 45 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1
Intangible Assets and Goodwill
 12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Goodwill Intangible Assets and Goodwill
Intangible Assets
As of December 31, 2021 and 2020, we had $400.0 million of in-process research and development intangible assets classified as “Intangible assets” on our consolidated balance sheets. In 2019, we recorded $387.0 million and $13.0 million of in-process research and development intangible assets related to our acquisitions of Semma Therapeutics, Inc. (“Semma”) and Exonics, respectively.
Goodwill
As of December 31, 2021 and 2020, goodwill of $1.0 billion was recorded on our consolidated balance sheets. During 2019, we recorded goodwill of $554.6 million and $397.1 million related to our acquisitions of Semma and Exonics, respectively.
XML 46 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
Additional Balance Sheet Detail
 12 Months Ended
Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Additional Balance Sheet Detail Additional Balance Sheet Detail
Prepaid expenses and other current assets consisted of the following:
As of December 31,
20212020
(in millions)
Tax related prepaid and receivables$358.6 $228.6 
Other187.2 79.7 
Total
$545.8 $308.3 
Accrued expenses consisted of the following:
As of December 31,
20212020
(in millions)
Product revenue accruals$847.4 $781.9 
Payroll and benefits191.3 169.4 
Research, development and commercial contract costs171.6 136.7 
Royalty payable200.4 165.4 
Tax related accruals
211.3 104.2 
Other
56.6 47.4 
Total
$1,678.6 $1,405.0 
Other current liabilities consisted of the following:
As of December 31,
20212020
(in millions)
Contract liabilities$171.7 $191.5 
Finance lease liabilities46.9 42.4 
Fair value of cash flow hedges5.6 59.2 
Other44.2 24.3 
Total$268.4 $317.4 
The cash, cash equivalents and restricted cash balances at the beginning and ending of each period presented in our consolidated statements of cash flows consisted of the following:
As of December 31,
2021202020192018
(in millions)
Cash and cash equivalents$6,795.0 $5,988.2 $3,109.3 $2,650.1 
Prepaid expenses and other current assets
5.1 0.7 8.0 4.9 
Other assets
— — 3.4 3.3 
Cash, cash equivalents and restricted cash per consolidated statement of cash flows$6,800.1 $5,988.9 $3,120.7 $2,658.3 
Our restricted cash, if any, is included in “Prepaid expenses and other current assets” and “Other assets” on our consolidated balance sheets.
XML 47 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases
 12 Months Ended
Dec. 31, 2021
Leases [Abstract]  
Leases Leases
Finance Leases
Our finance lease assets and liabilities primarily relate to our corporate headquarters in Boston and research site in San Diego (the “Buildings”). These Buildings are classified as finance leases because the present value of the sum of the lease payments associated with the Buildings exceeds substantially all of the fair value of the Buildings. We also have outstanding finance leases for equipment and land.
Corporate Headquarters
In 2011, we entered into two lease agreements, pursuant to which we lease approximately 1.1 million square feet of office and laboratory space in two buildings in Boston, Massachusetts for a term of 15 years. Base rent payments commenced in December 2013 and will continue through December 2028. We utilize this initial period as our lease term. We have an option to extend the lease term for an additional ten years.
San Diego Lease
In 2015, we entered into a lease agreement pursuant to which we lease approximately 170,000 square feet of office and laboratory space in San Diego, California for a term of 16 years. Base rent payments commenced in the second quarter of 2019 and will continue through May 2034. We utilize this initial period as our lease term. We have an option to extend the lease term for up to two additional five-year terms.
Operating Leases
Our operating leases relate to our real estate leases that are not classified as finance leases.
Innovation Square Lease
In 2019, we entered into an agreement to lease approximately 269,000 square feet of office and laboratory space near our corporate headquarters in Boston, Massachusetts. The lease agreement includes an initial term of 15 years plus a period to install leasehold improvements, with an option to extend the lease term for up to two additional ten-year periods. Base rent payments commenced in 2021. We have utilized the initial period, which commenced in the third quarter of 2020 upon occupation of the building, as our lease term.
Please refer to our accounting policy, Leases, in Note A, “Nature of Business and Accounting Policies,” for further information on the accounting treatment for our finance and operating leases.
Aggregate Lease Information
The components of lease cost recorded in our consolidated statement of operations were as follows:
202120202019
(in millions)
Operating lease cost$33.9 $23.1 $12.0 
Finance lease cost
Amortization of leased assets51.9 51.2 49.8 
Interest on lease liabilities47.4 50.2 52.8 
Variable lease cost33.6 30.8 28.0 
Sublease income(0.4)(4.0)(6.4)
Net lease cost$166.4 $151.3 $136.2 
Our variable lease cost during 2021, 2020 and 2019 primarily related to operating expenses, taxes and insurance associated with our finance leases.
Our leases are included on our consolidated balance sheets as follows:
As of December 31,
20212020
(in millions)
Finance leases
Property and equipment, net$400.1 $431.2 
Total finance lease assets
$400.1 $431.2 
Other current liabilities$46.9 $42.5 
Long-term finance lease liabilities509.8 539.0 
Total finance lease liabilities
$556.7 $581.5 
Operating leases
Operating lease assets$330.3 $325.6 
Total operating lease assets
$330.3 $325.6 
Other current liabilities$33.3 $10.5 
Long-term operating lease liabilities377.4 350.5 
Total operating lease liabilities
$410.7 $361.0 
Maturities of our finance and operating lease liabilities as of December 31, 2021 were as follows:
Year
Finance Leases
Operating Leases
Total
(in millions)
2022$87.9 $41.9 $129.8 
202393.2 42.0 135.2 
202497.6 38.6 136.2 
202595.9 35.7 131.6 
202694.2 33.7 127.9 
Thereafter
327.4 290.3 617.7 
Total lease payments
796.2 482.2 1,278.4 
Less: tenant allowance— (6.5)(6.5)
Less: amount representing interest
(239.5)(65.0)(304.5)
Present value of lease liabilities
$556.7 $410.7 $967.4 
The weighted-average remaining lease terms and discount rates related to our leases were as follows:
As of December 31,
20212020
Weighted-average remaining lease term (in years)
Finance leases10.7311.58
Operating leases12.8114.10
Weighted-average discount rate
Finance leases
8.11 %8.36 %
Operating leases
2.19 %2.28 %
Supplemental cash flow information related to our leases was as follows:
202120202019
(in millions)
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases$21.5 $16.3 $10.7 
Operating cash flows from finance leases$46.2 $48.9 $50.5 
Financing cash flows from finance leases$47.0 $42.3 $39.2 
Right-of-use assets obtained in exchange for lease obligations
Operating leases
$36.3 $293.6 $34.6 
Finance leases
$— $33.1 $— 
Leases Leases
Finance Leases
Our finance lease assets and liabilities primarily relate to our corporate headquarters in Boston and research site in San Diego (the “Buildings”). These Buildings are classified as finance leases because the present value of the sum of the lease payments associated with the Buildings exceeds substantially all of the fair value of the Buildings. We also have outstanding finance leases for equipment and land.
Corporate Headquarters
In 2011, we entered into two lease agreements, pursuant to which we lease approximately 1.1 million square feet of office and laboratory space in two buildings in Boston, Massachusetts for a term of 15 years. Base rent payments commenced in December 2013 and will continue through December 2028. We utilize this initial period as our lease term. We have an option to extend the lease term for an additional ten years.
San Diego Lease
In 2015, we entered into a lease agreement pursuant to which we lease approximately 170,000 square feet of office and laboratory space in San Diego, California for a term of 16 years. Base rent payments commenced in the second quarter of 2019 and will continue through May 2034. We utilize this initial period as our lease term. We have an option to extend the lease term for up to two additional five-year terms.
Operating Leases
Our operating leases relate to our real estate leases that are not classified as finance leases.
Innovation Square Lease
In 2019, we entered into an agreement to lease approximately 269,000 square feet of office and laboratory space near our corporate headquarters in Boston, Massachusetts. The lease agreement includes an initial term of 15 years plus a period to install leasehold improvements, with an option to extend the lease term for up to two additional ten-year periods. Base rent payments commenced in 2021. We have utilized the initial period, which commenced in the third quarter of 2020 upon occupation of the building, as our lease term.
Please refer to our accounting policy, Leases, in Note A, “Nature of Business and Accounting Policies,” for further information on the accounting treatment for our finance and operating leases.
Aggregate Lease Information
The components of lease cost recorded in our consolidated statement of operations were as follows:
202120202019
(in millions)
Operating lease cost$33.9 $23.1 $12.0 
Finance lease cost
Amortization of leased assets51.9 51.2 49.8 
Interest on lease liabilities47.4 50.2 52.8 
Variable lease cost33.6 30.8 28.0 
Sublease income(0.4)(4.0)(6.4)
Net lease cost$166.4 $151.3 $136.2 
Our variable lease cost during 2021, 2020 and 2019 primarily related to operating expenses, taxes and insurance associated with our finance leases.
Our leases are included on our consolidated balance sheets as follows:
As of December 31,
20212020
(in millions)
Finance leases
Property and equipment, net$400.1 $431.2 
Total finance lease assets
$400.1 $431.2 
Other current liabilities$46.9 $42.5 
Long-term finance lease liabilities509.8 539.0 
Total finance lease liabilities
$556.7 $581.5 
Operating leases
Operating lease assets$330.3 $325.6 
Total operating lease assets
$330.3 $325.6 
Other current liabilities$33.3 $10.5 
Long-term operating lease liabilities377.4 350.5 
Total operating lease liabilities
$410.7 $361.0 
Maturities of our finance and operating lease liabilities as of December 31, 2021 were as follows:
Year
Finance Leases
Operating Leases
Total
(in millions)
2022$87.9 $41.9 $129.8 
202393.2 42.0 135.2 
202497.6 38.6 136.2 
202595.9 35.7 131.6 
202694.2 33.7 127.9 
Thereafter
327.4 290.3 617.7 
Total lease payments
796.2 482.2 1,278.4 
Less: tenant allowance— (6.5)(6.5)
Less: amount representing interest
(239.5)(65.0)(304.5)
Present value of lease liabilities
$556.7 $410.7 $967.4 
The weighted-average remaining lease terms and discount rates related to our leases were as follows:
As of December 31,
20212020
Weighted-average remaining lease term (in years)
Finance leases10.7311.58
Operating leases12.8114.10
Weighted-average discount rate
Finance leases
8.11 %8.36 %
Operating leases
2.19 %2.28 %
Supplemental cash flow information related to our leases was as follows:
202120202019
(in millions)
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases$21.5 $16.3 $10.7 
Operating cash flows from finance leases$46.2 $48.9 $50.5 
Financing cash flows from finance leases$47.0 $42.3 $39.2 
Right-of-use assets obtained in exchange for lease obligations
Operating leases
$36.3 $293.6 $34.6 
Finance leases
$— $33.1 $— 
XML 48 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
Common Stock, Preferred Stock and Equity Plans
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Common Stock, Preferred Stock and Equity Plans Common Stock, Preferred Stock and Equity Plans
Common Stock and Preferred Stock
We are authorized to issue 500.0 million shares of common stock. Holders of common stock are entitled to one vote per share. Holders of common stock are entitled to receive dividends, if and when declared by our Board of Directors, and to share ratably in our assets legally available for distribution to our shareholders in the event of liquidation. Holders of common stock have no preemptive, subscription, redemption or conversion rights. The holders of common stock do not have cumulative voting rights.
We are authorized to issue 1.0 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our shareholders. As of December 31, 2021 and 2020, we had no shares of preferred stock issued or outstanding.
Share Repurchase Programs
In 2018, our Board of Directors approved a share repurchase program (the “2018 Share Repurchase Program”), pursuant to which we repurchased $500.0 million of our common stock in 2018 and 2019. During the year ended December 31, 2019, we repurchased 0.8 million shares of our common stock under the 2018 Share Repurchase Program for an aggregate of $150.0 million.
In July 2019, our Board of Directors approved a second share repurchase program (the “2019 Share Repurchase Program”), pursuant to which we repurchased $500.0 million of our common stock in 2019 and 2020. During the years ended December 31, 2020 and 2019, we repurchased 2.1 million and 0.2 million shares, respectively, of our common stock under the 2019 Share Repurchase Program for an aggregate of $464.0 million and $36.0 million, respectively.
In November 2020, our Board of Directors approved a third share repurchase program (the “2020 Share Repurchase Program”), pursuant to which we repurchased $500.0 million of our common stock in 2020 and 2021. During the years ended December 31, 2021 and 2020, we repurchased 2.0 million and 0.3 million shares, respectively, of our common stock under the 2020 Share Repurchase Program for an aggregate of $424.9 million and $75.1 million, respectively.
In June 2021, our Board of Directors approved a fourth share repurchase program (the “2021 Share Repurchase Program”), pursuant to which we are authorized to repurchase up to $1.5 billion of our common stock by December 31, 2022. During the year ended December 31, 2021, we repurchased 5.3 million shares of our common stock under the 2021 Share Repurchase Program for an aggregate of $1.0 billion. We expect to fund further repurchases of our common stock through a combination of cash on hand and cash generated by operations. As of December 31, 2021, $499.7 million remained authorized for repurchases of common stock under the 2021 Share Repurchase Program.
Repurchases of our common stock are recorded as reductions to “Common stock” and “Additional paid-in capital.”
Stock and Option Plans
The purpose of each of our stock and option plans is to attract, retain and motivate our employees, consultants and directors. Awards granted under these plans can be nonstatutory stock options (“NSOs”), incentive stock options (“ISOs”), restricted stock units (“RSUs”) including performance-based RSUs (“PSUs”), restricted stock (“RSs”), or other equity-based awards, as specified in the individual plans.
Shares issued under all of our plans are funded through the issuance of new shares. The following table contains information about our equity plans:
As of December 31, 2021
Title of Plan
Group Eligible
Type of Award
Granted
Awards
Outstanding
Additional Awards
Authorized for Grant
(in thousands)
2013 Stock and Option PlanEmployees, Non-employee Directors and ConsultantsNSO, RS, RSU and PSU7,306 9,558 
2006 Stock and Option PlanEmployees, Non-employee Directors and ConsultantsNSO, RS and RSU292 — 
Total
7,598 9,558 
All options granted under our 2013 Stock and Option Plan (“2013 Plan”) and 2006 Stock and Option Plan (“2006 Plan”) were granted with an exercise price equal to the fair value of the underlying common stock on the date of grant. As of December 31, 2021, we are only authorized to make new equity awards under our 2013 Plan. Under the 2013 Plan, no stock options can be awarded with an exercise price less than the fair market value on the date of grant. In 2019, our shareholders approved an increase in the number of shares authorized for issuance pursuant to the 2013 Stock and Option Plan of 5.0 million shares.
During the three years ended December 31, 2021, grants to current employees and directors primarily had a grant date that was the same as the date the award was approved by our Board of Directors. During the three years ended December 31, 2021, for grants to new employees and directors, the date of grant for awards was the employee’s first day of employment or the date the director was elected to our Board of Directors. All options awarded under our stock and option plans expire not more than 10 years from the grant date.
Stock Options
The following table summarizes information related to the outstanding and exercisable options during the year ended December 31, 2021:
Stock Options
Weighted-average
Exercise Price
Weighted-average Remaining Contractual Life
Aggregate Intrinsic
Value
(in thousands)(per share)(in years)(in millions)
Outstanding at December 31, 20204,238 $140.47 
Granted27 $217.20 
Exercised(518)$125.78 
Forfeited(136)$177.28 
Expired
— $— 
Outstanding at December 31, 20213,611 $141.76 5.42$288.6 
Exercisable at December 31, 20213,149 $136.13 5.19$269.6 
The aggregate intrinsic value in the table above represents the total pre-tax amount, net of exercise price, that would have been received by option holders if all option holders had exercised all options with an exercise price lower than the market price on the last business day of 2021, which was $221.27 based on the average of the high and low price of our common stock on that date.
The total intrinsic value (the amount by which the fair market value exceeded the exercise price) of stock options exercised during 2021, 2020 and 2019 was $43.0 million, $255.0 million and $325.9 million, respectively. The total cash we received as a result of employee stock option exercises during 2021, 2020 and 2019 was $64.2 million, $228.2 million and $317.8 million, respectively.
The following table summarizes information about stock options outstanding and exercisable at December 31, 2021:
Options Outstanding
Options Exercisable
Range of Exercise Prices
Number
Outstanding
Weighted-average
Remaining Contractual Life
Weighted-average
Exercise Price
Number
Exercisable
Weighted-average
Exercise Price
(in thousands)(in years)(per share)(in thousands)(per share)
$36.28–$100.00
1,085 3.70$82.14 1,085 $82.14 
$100.01–$150.00
362 3.56$123.15 362 $123.15 
$150.01–$200.00
2,114 6.53$173.03 1,652$171.04 
$200.01–$286.27
50 8.92$248.51 50 $248.51 
Total
3,611 5.42$141.76 3,149 $136.13 
Restricted Stock Units (excluding PSUs) and Restricted Stock
The following table summarizes our restricted stock unit activity during the year ended December 31, 2021:
Restricted Stock Units (excluding PSUs)
Number of Shares
Weighted-average
Grant-date
Fair Value
(in thousands)(per share)
Unvested at December 31, 20202,722 $206.99 
Granted1,927 $208.48 
Vested(1,331)$193.29 
Cancelled
(409)$214.68 
Unvested at December 31, 20212,909 $213.17 
The total fair value of restricted stock units that vested during 2021, 2020 and 2019 (measured on the date of vesting) was $281.1 million, $370.3 million and $178.2 million, respectively. The total fair value of restricted stock that vested during 2020 and 2019 (measured on the date of vesting) was $21.4 million and $70.7 million, respectively. We have not granted any restricted stock since 2016, therefore, we did not have any restricted stock vest in 2021.
Performance-based RSUs (PSUs)
The potential range of shares issuable pursuant to our PSU awards range from 0% to 200% of the target shares based on financial and non-financial measures. Fifty percent of PSUs that could be earned have a one-year performance period with the amount actually earned dependent upon our financial performance and with vesting of the earned shares in three equal installments over a three-year period. The remaining 50% of PSUs that could be earned have a three-year performance period with the amount actually earned dependent upon the achievement of multiple clinical development milestones and with the earned shares cliff vesting at the end of the three-year performance period.
The following table summarizes our PSU activity during the year ended December 31, 2021:
Performance-Based RSU
Number of Units
Weighted-average
Grant-date
Fair Value
(in thousands)(per share)
Unvested at December 31, 2020 (1)656 $202.06 
Granted (2)954 $212.44 
Vested(431)$183.94 
Cancelled
(101)$214.72 
Unvested at December 31, 20211,078 $215.85 
(1) “Unvested” represents our PSUs at target to the extent performance has not been certified plus the actual number of shares that continue to be subject to service conditions for which the performance has been achieved and certified.
(2) “Granted” represents (i) the target number of shares issuable for grants during 2021 and (ii) any change in the number of shares issuable pursuant to outstanding PSUs based on performance certification during 2021.
The total fair value of PSUs that vested during 2021, 2020 and 2019 (measured on the date of vesting) was $92.2 million, $138.5 million and $73.3 million, respectively.
Employee Stock Purchase Plan
We have an employee stock purchase plan (the “ESPP”). The ESPP permits eligible employees to enroll in a twelve-month offering period comprising two six-month purchase periods. Participants may purchase shares of our common stock, through payroll deductions, at a price equal to 85% of the fair market value of the common stock on the first day of the applicable twelve-month offering period, or the last day of the applicable six-month purchase period, whichever is lower. Purchase dates under the ESPP occur on or about May 14 and November 14 of each year. As of December 31, 2021, there were 1.8 million shares of common stock authorized for issuance pursuant to the ESPP.
In 2021, the following shares were issued to employees under the ESPP:
Year Ended December 31, 2021
Number of shares (in thousands)219 
Average price paid per share$171.57 
Employee Benefits
We have a 401(k) retirement plan (the “Vertex 401(k) Plan”) in which substantially all of our permanent U.S. employees are eligible to participate. Participants may contribute up to 60% of their annual compensation to the Vertex 401(k) Plan, subject to statutory limitations. We may declare discretionary matching contributions to the Vertex 401(k) Plan. We pay matching contributions in the form of cash. For the years ended December 31, 2021, 2020 and 2019, we contributed approximately $21.8 million, $19.2 million and $15.8 million to the plan, respectively.
XML 49 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-based Compensation Expense
 12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Stock-based Compensation Expense Stock-based Compensation ExpenseWe recognize share-based payments to employees as compensation expense using the fair value method. The fair value of stock options and shares purchased pursuant to the ESPP is calculated using the Black-Scholes option pricing model. The fair value of restricted stock units, including PSUs, is based on the intrinsic value on the date of grant. Stock-based compensation, measured at the grant date based on the fair value of the award, is typically recognized as expense ratably over the requisite service period.
The effect of stock-based compensation expense during the three years ended December 31, 2021 was as follows:
202120202019
(in millions)
Stock-based compensation expense by line item:
Cost of sales$6.3 $5.6 $5.6 
Research and development expenses268.3 262.7 224.6 
Selling, general and administrative expenses
166.8 161.2 130.3 
Total stock-based compensation expense included in costs and expenses
441.4 429.5 360.5 
Income tax effect(82.9)(147.0)(124.2)
Total stock-based compensation included in costs and expenses, net of tax$358.5 $282.5 $236.3 
The stock-based compensation expense by type of award during the three years ended December 31, 2021 was as follows:
202120202019
(in millions)
Stock-based compensation expense by type of award:
Restricted stock units (including PSUs)$384.3 $360.4 $254.3 
Stock options36.8 59.7 96.7 
ESPP share issuances24.4 13.0 11.2 
Stock-based compensation expense related to inventories(4.1)(3.6)(1.7)
Total stock-based compensation expense included in costs and expenses
$441.4 $429.5 $360.5 
We capitalize a portion of our stock-based compensation expense to inventories, all of which is attributable to employees who support the manufacturing of our products.
The following table sets forth our unrecognized stock-based compensation expense as of December 31, 2021, by type of award and the weighted-average period over which that expense is expected to be recognized:
As of December 31, 2021
Unrecognized Expense
Weighted-average Recognition Period
(in millions)(in years)
Type of award:
Restricted stock units (including PSUs)$423.3 1.91
Stock options19.1 1.09
ESPP share issuances12.6 0.54
Total unrecognized stock-based compensation expense$455.0 
Stock Options
In each of the three years ended December 31, 2021, we issued stock options to our non-employee directors. In 2019, we issued stock options with service conditions, which were generally the vesting periods of the awards, to our employees. We use the Black-Scholes option pricing model to estimate the fair value of stock options at the grant date. The Black-Scholes option pricing model uses the option exercise price as well as estimates and assumptions related to the expected price volatility of our stock, the rate of return on risk-free investments, the expected period during which the options will be outstanding, and the expected dividend yield for our stock to estimate the fair value of a stock option on the grant date. The
options granted during 2021, 2020 and 2019 had a weighted-average grant-date fair value per share of $65.94, $88.37 and $61.32, respectively.
The fair value of each option granted during 2021, 2020 and 2019 was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:
202120202019
Stock options granted27,30222,6361,520,743
Expected stock price volatility35.03%35.87%36.99%
Risk-free interest rate0.86%0.43%2.32%
Expected term of options (in years)4.504.674.27
Expected annual dividends———
The weighted-average valuation assumptions were determined as follows:
•Expected stock price volatility: Expected stock price volatility is calculated using the trailing one-month average of daily implied volatilities prior to the grant date. Implied volatility is based on options to purchase our stock with remaining terms of greater than one year that are regularly traded in the market.
•Risk-free interest rate: We base the risk-free interest rate on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected option term.
•Expected term of options: The expected term of options represents the period of time options are expected to be outstanding. We use historical data to estimate employee exercise and post-vest termination behavior. We believe that all groups of employees exhibit similar exercise and post-vest termination behavior and therefore do not stratify employees into multiple groups in determining the expected term of options.
•Expected annual dividends: The estimate for annual dividends is $0.00 because we have not historically paid, and do not intend for the foreseeable future to pay, a dividend.
Restricted Stock Units and Performance-based Restricted Stock Units
We award restricted stock units with service conditions, which are generally the vesting periods of the awards.
We grant PSUs to certain members of senior management. Half of the PSUs contain financial goals as the performance metric and the other half contain non-financial goals. A target number of shares is established for each award; however, the actual number of shares that are issued when an award vests may range from zero to 200% of the target amount depending upon the level of achievement of the applicable performance metric. The financial-based PSUs vest in three equal installments over a three-year period and are expensed ratably over that same period based upon an assessment of the likely level of achievement. The non-financial based PSUs cliff vest at the end of the three-year performance period and are expensed on a straight-line basis over that same period based upon an assessment of the likely level of achievement.
Employee Stock Purchase Plan
The weighted-average fair value of each purchase right granted during 2021, 2020 and 2019 was $51.71, $65.88 and $47.79, respectively. The following table reflects the weighted-average assumptions used in the Black-Scholes option pricing model for 2021, 2020 and 2019:
202120202019
Expected stock price volatility34.06%37.70%33.43%
Risk-free interest rate0.05%0.11%2.08%
Expected term (in years)0.690.710.74
Expected annual dividends———
The weighted-average assumptions used in our Black-Scholes option pricing model were determined utilizing calculations similar to those described under Stock Options above.
XML 50 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
We are subject to U.S. federal, state, and foreign income taxes. The components of income before provision for income taxes during the three years ended December 31, 2021, consisted of the following:
202120202019
(in millions)
United States$2,030.7 $2,885.4 $1,263.4 
Foreign
699.7 231.5 131.5 
Income before provision for income taxes$2,730.4 $3,116.9 $1,394.9 
The components of the provision for income taxes during the three years ended December 31, 2021, consisted of the following:
202120202019
(in millions)
Current taxes:
Federal$374.9 $71.4 $— 
Foreign141.5 37.6 37.2 
State
26.5 18.9 13.5 
Total current taxes
542.9 127.9 50.7 
Deferred taxes:
Federal(36.9)510.2 184.3 
Foreign(98.4)(239.6)(24.8)
State
(19.3)6.7 7.9 
Total deferred taxes(154.6)277.3 167.4 
Provision for income taxes$388.3 $405.2 $218.1 
A reconciliation between the U.S. federal statutory rate of 21% and our effective tax rate is as follows:
202120202019
Federal statutory tax rate21.0 %21.0 %21.0 %
State taxes, net of federal benefit0.8 %0.6 %0.6 %
Foreign income tax rate differential(0.3)%0.2 %0.4 %
Tax credits(6.4)%(1.8)%(4.3)%
Tax rate change
(3.5)%(1.2)%— %
Stock compensation (benefit), shortfalls and cancellations
0.0 %(2.3)%(4.0)%
Long-term intercompany receivable write-off— %(1.7)%— %
Uncertain tax positions
2.0 %1.3 %1.0 %
Inter-entity transfer of intellectual property rights
— %(6.7)%— %
U.S. tax on foreign earnings, net of credits0.7 %2.7 %— %
Other
(0.1)%0.9 %0.9 %
Effective tax rate14.2 %13.0 %15.6 %
Our 14% effective tax rate for 2021 was lower than the U.S. statutory rate primarily due to discrete tax benefits of (i) $94.8 million associated with an increase in the United Kingdom’s (“U.K.”) corporate tax rate from 19% to 25%, which was enacted in June 2021 and will become effective in April 2023, and (ii) $44.1 million resulting from an R&D tax credit study that we completed in 2021.
Our 13% effective tax rate for 2020 was lower than the U.S. statutory rate primarily due to (i) a discrete tax benefit of $209.0 million associated with an intra-entity transfer of intellectual property rights to our U.K. entity, (ii) a discrete tax benefit associated with the write-off of a long-term intercompany receivable, (iii) a discrete tax benefit associated with an increase in the U.K.’s corporate tax rate from 17% to 19%, which was enacted and became effective in July 2020, and (iv) excess tax benefits related to stock-based compensation. The impact of these items was partially offset by U.S. income tax on foreign earnings.
Our 16% effective tax rate for 2019 was lower than the U.S. statutory rate primarily due to excess tax benefits related to stock-based compensation and research and development tax credits.
Deferred tax assets and liabilities are determined based on the difference between financial statement and tax bases using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred taxes were as follows:
As of December 31,
20212020
(in millions)
Deferred tax assets:
Net operating loss$106.6 $140.6 
Tax credit carryforwards202.4 406.1 
Intangible assets802.8 507.5 
Stock-based compensation94.6 89.2 
Accrued expenses48.6 47.3 
Finance lease liabilities103.4 118.7 
Operating lease assets81.1 65.0 
Other41.7 22.1 
Gross deferred tax assets1,481.2 1,396.5 
Valuation allowance(220.4)(213.8)
Total deferred tax assets1,260.8 1,182.7 
Deferred tax liabilities:
Property and equipment(118.2)(117.0)
Acquired intangibles(87.0)(87.0)
Operating lease liabilities(64.8)(63.3)
Other(56.3)(32.6)
Total deferred tax liabilities(326.3)(299.9)
Net deferred tax assets$934.5 $882.8 
On a periodic basis, we reassess the valuation allowance on our deferred income tax assets, weighing positive and negative evidence to assess the recoverability of our deferred tax assets. As of December 31, 2021, we maintained a valuation allowance of $220.4 million related primarily to U.S. state tax attributes.
As of December 31, 2021, we had net operating loss (“NOL”) carryforwards of $29.8 million and tax credit carryforwards of $4.1 million, which are subject to annual utilization limitations for U.S. federal income tax purposes. As of December 31, 2021, we had NOL carryforwards of $616.3 million and tax credit carryforwards of $237.2 million for U.S. state income tax purposes. In 2030, $26.0 million of our U.S. federal NOLs will begin to expire, while the remaining portion may be carried forward indefinitely. The state NOL and tax credit carryforwards expire at various dates through 2041 and may be used to offset future state income tax liabilities. As of December 31, 2021, we had foreign NOL carryforwards of $292.5 million and foreign tax credit carryforwards of $22.2 million. The foreign NOL carryforwards may be carried forward indefinitely, with the exception of $44.3 million that will expire at various dates through 2040. The foreign tax credit carryforwards will begin to expire in 2024.
Unrecognized tax benefits during the three years ended December 31, 2021 were as follows:
202120202019
(in millions)
Balance at beginning of the period$86.6 $33.9 $19.5 
Increases related to current period tax positions42.0 26.7 14.5 
Increases related to prior period tax positions19.9 26.7 0.6 
Decreases related to prior period tax positions— — (0.2)
Settlement with tax authorities— — (0.5)
Statute of limitations expiration
(1.3)(0.7)— 
Balance at end of period
$147.2 $86.6 $33.9 
As of December 31, 2021, we have classified $14.4 million and $132.8 million of our unrecognized tax benefits as credits to “Deferred tax assets” and “Accrued expenses,” respectively, on our consolidated balance sheet.
We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. Unrecognized tax benefits represent the aggregate tax effect of differences between tax return positions and the benefits recognized in our consolidated financial statements. As of December 31, 2021, 2020 and 2019, we had $129.5 million, $75.8 million and $33.9 million, respectively, of net unrecognized tax benefits, which would affect our tax rate if recognized. We do not expect that our unrecognized tax benefits will materially change within the next twelve months. We did not recognize any material interest or penalties related to uncertain tax positions during the three years ended December 31, 2021.
As of December 31, 2021, foreign earnings have been retained by our foreign subsidiaries for indefinite reinvestment. Upon repatriation of those earnings, in the form of dividends or otherwise, we could be subject to U.S. federal withholding taxes payable to various foreign countries and income taxes in certain states. We are permanently reinvested for book/tax basis differences. These permanently reinvested basis differences could reverse if we sell our foreign subsidiaries or various other events, none of which were considered probable as of December 31, 2021. The tax liabilities described above would not be material to our consolidated financial statements.
We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We have various income tax audits ongoing at any time throughout the world. Except for jurisdictions where we have NOLs or tax credit carryforwards, we are no longer subject to any tax assessment from tax authorities for years prior to 2018.
XML 51 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Revolving Credit Facilities
Vertex and certain of its subsidiaries have entered into two credit agreements (the “Credit Agreements”) with Bank of America, N.A., as administrative agent and the lenders referred to therein (the “Lenders”). The Credit Agreements were not drawn upon at closing and we have not drawn upon them to date. Amounts drawn pursuant to the Credit Agreements, if any, will be used for general corporate purposes. Any amounts borrowed under the Credit Agreements will bear interest, at our option, at either a base rate or a Eurocurrency rate, in each case plus an applicable margin based on our consolidated leverage ratio (the ratio of our total consolidated funded indebtedness to our consolidated EBITDA for the most recently completed four fiscal quarter period).
In September 2019, Vertex and certain of its subsidiaries entered into a $500.0 million unsecured revolving facility (the “2019 Credit Agreement”) with the Lenders, which matures on September 17, 2024. Under the 2019 Credit Agreement, the applicable margins on base rate loans range from 0.125% to 0.500% and the applicable margins on Eurocurrency loans range from 1.125% to 1.500%. The 2019 Credit Agreement provides a sublimit of $50.0 million for letters of credit.
In September 2020, Vertex and certain of its subsidiaries entered into a $2.0 billion unsecured revolving facility (the
“2020 Credit Agreement”) with the Lenders, which matures on September 18, 2022. Under the 2020 Credit Agreement, the applicable margins on base rate loans range from 0.500% to 0.875% and the applicable margins on Eurocurrency loans range from 1.500% to 1.875%. The 2020 Credit Agreement does not support letters of credit.
Subject to satisfaction of certain conditions, we may request that the borrowing capacity for each of the Credit Agreements be increased by an additional $500.0 million. Any amounts borrowed pursuant to the Credit Agreements are guaranteed by certain of our existing and future domestic subsidiaries, subject to certain exceptions.
The Credit Agreements contain customary representations and warranties and affirmative and negative covenants, including financial covenants to maintain (x) subject to certain limited exceptions, a consolidated leverage ratio of 3.50 to 1.00, subject to an increase to 4.00 to 1.00 following a material acquisition and (y) a consolidated interest coverage ratio of 2.50 to 1.00, in each case measured on a quarterly basis. As of December 31, 2021, we were in compliance with the covenants described above. The Credit Agreements also contain customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans.
Direct costs related to the Credit Agreements are recorded over the term of the Credit Agreements and were not material to our financial statements.
Guaranties and Indemnifications
As permitted under Massachusetts law, our Articles of Organization and By-laws provide that we will indemnify certain of our officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that we could be required to make under these indemnification provisions is unlimited. However, we have purchased directors’ and officers’ liability insurance policies that could reduce our monetary exposure and enable us to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and we believe the estimated fair value of these indemnification arrangements is minimal.
We customarily agree in the ordinary course of our business to indemnification provisions in agreements with clinical trial investigators and sites in our drug development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for us, and our real estate leases. We also customarily agree to certain indemnification provisions in our drug discovery, development and commercialization collaboration agreements. With respect to our clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of our contractual obligations arising out of the research or clinical testing of our compounds or product candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by us, to violations of law by us or to certain breaches of our contractual obligations. The indemnification provisions appearing in our collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for our collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although we believe the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that we could be required to make under these provisions is generally unlimited. We have purchased insurance policies covering personal injury, property damage and general liability that reduce our exposure for indemnification and would enable us in many cases to recover all or a portion of any future amounts paid. We have never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, we believe the estimated fair value of these indemnification arrangements is minimal.
Other Contingencies
We have certain contingent liabilities that arise in the ordinary course of our business activities. We accrue a reserve for contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. Other than our contingent consideration liabilities discussed in Note D, “Fair Value Measurements,” there were no material contingent liabilities accrued as of December 31, 2021 or 2020.
XML 52 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Information
 12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Segment Information Segment Information
Segment reporting is prepared on the same basis that our chief executive officer, who is our chief operating decision maker, manages the business, makes operating decisions and assesses performance. We operate in one segment, pharmaceuticals. Enterprise-wide disclosures about revenues, significant customers, and property and equipment, net by location are presented below.
Revenues by Product
Product revenues, net consisted of the following:
202120202019
(in millions)
TRIKAFTA/KAFTRIO$5,697.2 $3,863.8 $420.1 
SYMDEKO/SYMKEVI420.4 628.6 1,417.7 
ORKAMBI771.6 907.5 1,331.9 
KALYDECO684.2 802.9 991.0 
Total product revenues, net$7,573.4 $6,202.8 $4,160.7 
Product Revenues by Geographic Location
Net product revenues are attributed to countries based on the location of the customer and consisted of the following:
202120202019
(in millions)
United States$5,287.3 $4,826.4 $3,060.3 
Outside of the United States
Europe1,972.9 1,126.5 885.9 
Other
313.2 249.9 214.5 
Total product revenues outside of the United States
2,286.1 1,376.4 1,100.4 
Total product revenues, net
$7,573.4 $6,202.8 $4,160.7 
Significant Customers
Gross product revenues and accounts receivable from each of our customers who individually accounted for 10% or more of total gross product revenues and/or 10% or more of total accounts receivable consisted of the following:
Percent of
Total Gross Product Revenues
Percent of
Accounts Receivable
Year Ended December 31,
As of December 31,
20212020201920212020
McKesson Corporation22 %20 %17 %21 %14 %
Accredo/Curascript12 %15 %14 %10 %10 %
Walgreen Co.10 %14 %15 %<10 %10 %
Lloyds Pharmacy*<10%<10%<10%15 %19 %
*A wholly-owned subsidiary of McKesson Corporation in the U.K.
Long-lived Assets by Location
Long-lived assets by location consisted of the following:
As of December 31,
20212020
(in millions)
United States$1,348.1 $1,207.7 
Outside of the United States
United Kingdom60.9 61.5 
Other15.4 14.9 
Total long-lived assets outside of the United States76.3 76.4 
Total long-lived assets$1,424.4 $1,284.1 
XML 53 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
Nature of Business and Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals. Please refer to Note Q, “Segment Information,” for enterprise-wide disclosures regarding our revenues, major customers and long-lived assets by geographic area.
Use of Estimates
Use of Estimates
The preparation of consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Revenue Recognition
Revenue Recognition
We recognize revenue when a customer obtains control of promised goods or services. We record the amount of revenue that reflects the consideration that we expect to receive in exchange for those goods or services. We apply the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) we satisfy each performance obligation. 
We only apply the five-step model to contracts when it is probable that we will collect the consideration to which we are entitled in exchange for the goods or services that we transfer to the customer. Once a contract is determined to be within the scope of Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”) at contract inception, we review the contract to determine which performance obligations we must deliver and which of these performance obligations are distinct. We recognize as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. Generally, our performance obligations are transferred to customers at a point in time, typically upon delivery.
Product Revenues, Net
We sell our products principally to a limited number of specialty pharmacy and specialty distributors in the United States (“U.S.”), which account for the largest portion of our total revenues. We make international sales primarily to specialty
distributors and retail chains, as well as hospitals and clinics, many of which are government-owned or supported. Our customers in the U.S. subsequently resell the products to patients and health care providers. We recognize net product revenues from sales when our customers obtain control of our products, which typically occurs upon delivery to our customers. Our payment terms are approximately 30 days in the U.S. and consistent with prevailing practice in international markets.
Revenues from product sales are recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from (a) invoice discounts for prompt payment and distribution fees, (b) government and private payor rebates, chargebacks, discounts and fees and (c) costs of co-pay assistance programs for patients, as well as other incentives for certain indirect customers. Reserves are established for the estimates of variable consideration based on the amounts earned or to be claimed on the related sales. The reserves are classified as reductions to “Accounts receivable, net” if payable to a customer or “Accrued expenses” if payable to a third-party. Where appropriate, we utilize the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in net product revenues only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary from our estimates, we adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.
Invoice Discounts and Distribution Fees: We generally provide invoice discounts on product sales to our customers for prompt payment and pays fees for distribution services, such as fees for certain data that customers provide to us. We estimate that, based on our experience, our customers will earn these discounts and fees, and deduct the full amount of these discounts and fees from our gross product revenues and accounts receivable at the time such revenues are recognized.
Rebates, Chargebacks, Discounts and Fees: We contract with government agencies (our “Third-party Payors”) so that products will be eligible for purchase by, or partial or full reimbursement from, such Third-party Payors. We estimate the rebates, chargebacks, discounts and fees we will provide to Third-party Payors and deduct these estimated amounts from our gross product revenues at the time the revenues are recognized. For each product, we estimate the aggregate rebates, chargebacks and discounts that we will provide to Third-party Payors based upon (i) our contracts with these Third-party Payors, (ii) the government-mandated discounts and fees applicable to government-funded programs, (iii) information obtained from our customers and other third-party data regarding the payor mix for such product and (iv) historical experience.
Other Incentives: Other incentives that we offer include co-pay mitigation rebates that we provide to commercially insured patients who have coverage and who reside in states that permit co-pay mitigation programs. Based upon the terms of our co-pay mitigation programs, we estimate average co-pay mitigation amounts for each of our products in order to establish appropriate accruals.
We make significant estimates and judgments that materially affect our recognition of net product revenues. We adjust our estimated rebates, chargebacks and discounts based on new information, including information regarding actual rebates, chargebacks and discounts for our products, as it becomes available. Claims by third-party payors for rebates, chargebacks and discounts frequently are submitted to us significantly after the related sales, potentially resulting in adjustments in the period in which the new information becomes known. Our credits to product revenue related to prior period sales have not been significant and primarily related to rebates and discounts.
We exclude taxes collected from customers relating to product sales and remitted to governmental authorities from revenues.
Contract Liabilities
We recorded contract liabilities of $171.7 million and $191.5 million as of December 31, 2021 and 2020, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive. Upon exceeding the annual reimbursement amount, products are provided free of
charge, which is a material right. These contracts include upfront payments and fees. We defer a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. Our product revenue contracts include performance obligations that are one year or less.
Our contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as our fiscal year. In these markets we recognize revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year. During the years ended December 31, 2021, 2020 and 2019, we recorded $191.5 million, $62.3 million and $24.9 million, respectively, of revenues that were recorded as contract liabilities at the beginning of the year.
French Early Access Programs
In 2015, we began distributing ORKAMBI through early access programs in France and remained engaged in reimbursement discussions with the French government until November 2019, when we reached an agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs. From the time we began distributing ORKAMBI through early access programs in France, we expected the difference between the amounts collected based on the invoiced amount and the final amount for ORKAMBI distributed through early access programs would be returned to the French government.
Through the third quarter of 2019, we recognized net product revenues for ORKAMBI sales in France under the early access programs based on a transaction price that reflected our estimate of consideration we expected to retain that would not be subject to a significant reversal in amounts recognized. When determining if variable consideration should be constrained, we consider whether there are factors outside our control that could result in a significant reversal of revenue. In making these assessments, we consider the likelihood and magnitude of a potential reversal of revenue.
Upon reaching an agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs in November 2019, we updated the transaction price to reflect the final amount for ORKAMBI distributed through early access programs. As a result, we recognized net product revenues of $155.8 million related to prior period ORKAMBI early access program sales in the fourth quarter of 2019 because the updated transaction price for ORKAMBI distributed through these programs exceeded our previous estimate of the consideration we expected to retain that would not be subject to a significant reversal in amounts recognized. We paid the final amount due to the French government in 2020.
Other Revenues
We have not recorded significant revenues other than our product revenues during the three years ended December 31, 2021; however, in future periods, we may recognize collaborative revenues generated through collaborative research, development and/or commercialization agreements related to one or more of the following: nonrefundable, upfront license fees; development and commercial milestones; funding of research and/or development activities; and royalties on net sales of licensed products. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to our collaborator.
For each collaborative research, development, and/or commercialization agreement that results in revenue, we identify all material performance obligations and determine the transaction price by estimating the amount of variable consideration at the outset of the contract. We constrain (reduce) the estimate of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract.
Once the estimated transaction price is established, amounts are allocated to each separate performance obligation that has been identified on a relative standalone selling price basis.
Upfront License Fees: If we determine that a license to our intellectual property is distinct from the other performance obligations identified in an arrangement, we recognize revenue from the related nonrefundable, upfront license fees based on the relative standalone selling price prescribed to the license compared to the total selling price of
the arrangement. We recognize revenue when the license is transferred to our collaborator and our collaborator is able to use and benefit from the license. For licenses that are not distinct from other obligations identified in the arrangement, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, we apply an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.
Development and Regulatory Milestone Payments: Depending on facts and circumstances, we may include certain milestones in the estimated transaction price or fully constrain the milestones. We include a milestone payment in the transaction price in the reporting period that it is probable that recording revenue in the period will not result in a significant reversal in amounts recognized in future periods. This may result in us recognizing revenues from certain milestones and a corresponding contract asset in a reporting period before the milestone is achieved. We fully constrain milestone payments that have not been included in the transaction price to date until we conclude that their achievement is probable and that recognition of the related revenue will not result in a significant reversal in amounts recognized in future periods. We re-evaluate the probability of achievement of such development milestones and any related constraint each reporting period and adjust our estimate of the overall transaction price, including the amount of collaborative revenue that we have recorded, if necessary.
Research and Development Activities/Transition Services: If we are entitled to reimbursement from our collaborators for specified research and development expenses, we account for the related services as separate performance obligations if these services represent a material right. We also determine whether to account for the reimbursement of research and development expenses as collaborative revenues or an offset to research and development expenses in accordance with the provisions of gross or net revenue presentation. We recognize the corresponding revenues or record the corresponding offset to research and development expenses as we satisfy the related performance obligations.
Concentration of Credit Risk
Concentration of Credit Risk
Financial instruments that potentially subject us to concentration of credit risk consist principally of money market funds and marketable securities. We place these investments with highly rated financial institutions, and, by policy, limit the amount of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. We also maintain a foreign currency hedging program that includes foreign currency forward contracts with several counterparties. We have not experienced any credit losses related to these financial instruments and do not believe we are exposed to any significant credit risk related to these instruments.
We are also subject to credit risk from our accounts receivable related to our product sales and collaborators. We evaluate the creditworthiness of each of our customers and have determined that all our material customers are creditworthy. To date, we have not experienced significant losses with respect to the collection of our accounts receivable. We believe that our allowances, which are not significant to our consolidated financial statements, are adequate at December 31, 2021.
Cash and Cash Equivalents Cash and Cash EquivalentsWe consider all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.
Marketable Securities
Marketable Securities
As of December 31, 2021, our marketable securities consisted of investments in available-for-sale debt securities and corporate equity securities with readily determinable fair values. We classify marketable securities available to fund current operations as current assets on our consolidated balance sheets. Marketable securities are classified as long-term assets on our consolidated balance sheets if (i) they have been in an unrealized loss position for longer than one year and (ii) we have the ability and intent to hold them (a) until the carrying value is recovered and (b) such holding period may be longer than one year. Our marketable securities are stated at fair value. The fair value of these securities is based on quoted prices for
identical or similar assets.
We record unrealized gains (losses) on available-for-sale debt securities as a component of “Accumulated other comprehensive income (loss),” which is a separate component of shareholders’ equity on our consolidated balance sheet, until such gains and losses are realized. Realized gains and losses, if any, are determined using the specific identification method.
We record changes in the fair value of our investments in corporate equity securities to “Other income, net” in our consolidated statements of operations. Realized gains and losses, which are also included in “Other income, net,” are determined on an original weighted-average cost basis.
We adopted Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”) as of January 1, 2020, which did not have a significant impact on our consolidated financial statements. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires us to record an allowance for credit losses using an expected loss model, which replaces the incurred loss model required under the previous guidance. A credit loss is limited to the amount by which the amortized cost of an investment exceeds its fair value. A previously recognized credit loss may be decreased in subsequent periods if our estimate of fair value for the investment increases. To determine whether to record a credit loss, we consider issuer specific credit ratings and historical losses as well as current economic conditions and our expectations for future economic conditions.
Accounts Receivable Accounts Receivable We deduct invoice discounts for prompt payment and fees for distribution services from our accounts receivable based on our experience that our customers will earn these discounts and fees. Our estimates for our allowance for credit losses, which has not been significant to date, is determined based on existing contractual payment terms, historical payment patterns, current economic conditions and our expectation for future economic conditions.
Stock-based Compensation Expense
Stock-based Compensation Expense
We expense the fair value of employee restricted stock units and other forms of stock-based employee compensation over the associated employee service period on a straight-line basis. Stock-based compensation expense is determined based on the fair value of the award at the grant date and is adjusted each period to reflect actual forfeitures and the outcomes of certain performance conditions.
For awards with performance conditions in which the award does not vest unless the performance condition is met, we recognize expense if, and to the extent that, we estimate that achievement of the performance condition is probable. If we conclude that vesting is probable, we recognize expense from the date we reach this conclusion through the estimated vesting date.
We provide to employees who have rendered a certain number of years of service to Vertex and meet certain age requirements, partial or full acceleration of vesting of these equity awards, subject to certain conditions including a notification period, upon a termination of employment other than for cause. Approximately 5% of our employees were eligible for partial or full acceleration of any of their equity awards as of December 31, 2021. We recognize stock-based compensation expense related to these awards over a service period reflecting qualified employees’ eligibility for partial or full acceleration of vesting.
Research and Development Expenses
Research and Development Expenses
Research and development expenses are comprised of costs we incur in performing research and development activities, including salary and benefits; stock-based compensation expense; outsourced services and other direct expenses, including clinical trial and pharmaceutical development costs; collaborative payments; and infrastructure costs, including facilities costs and depreciation expense. We recognize research and development expenses as incurred. We capitalize nonrefundable advance payments we make for research and development activities and expense the payments as the related goods are
delivered or the related services are performed.
Inventories
Inventories
We value our inventories at the lower-of-cost or net realizable value. We determine the cost of our inventories, which include amounts related to materials and manufacturing overhead, on a first-in, first-out basis. We perform an assessment of the recoverability of our capitalized inventory during each reporting period and write down any excess and obsolete inventories to their net realizable value in the period in which the impairment is first identified. Shipping and handling costs incurred for inventory purchases are capitalized and recorded upon sale in “Cost of sales” in our consolidated statements of operations. Shipping and handling costs incurred for product shipments are recorded as incurred in “Cost of sales” in our consolidated statements of operations.
We capitalize inventories produced in preparation for initiating sales of a product candidate when the related product candidate is considered to have a high likelihood of regulatory approval and the related costs are expected to be recoverable through sales of the inventories. In determining whether to capitalize such inventories, we evaluate, among other factors, information regarding the product candidate’s safety and efficacy, the status of regulatory submissions and communications with regulatory authorities and the outlook for commercial sales, including the existence of current or anticipated competitive drugs and the availability of reimbursement. In addition, we evaluate risks associated with manufacturing the product candidate and the remaining shelf-life of the inventories.
Property and Equipment
Property and Equipment
Property and equipment are recorded at cost, net of accumulated depreciation. Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset generally as follows:
DescriptionEstimated Useful Life
Buildings and improvements
15 to 40 years
Furniture and equipment
7 to 10 years
Leasehold improvements; assets under finance leasesThe shorter of the useful life of the assets or the estimated remaining term of the associated lease
Computers and software
3 to 5 years
Maintenance and repairs to an asset that do not improve or extend its life are charged to operations. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in our consolidated statements of operations. We perform an assessment of the fair value of the assets if indicators of impairment are identified during a reporting period and record the assets at the lower of the net book value or the fair value of the assets.
We capitalize internal costs incurred to develop software for internal use during the application development stage. Amortization of capitalized internally developed software costs is recorded in depreciation expense over the useful life of the related asset.
Leases
Leases
We determine whether an arrangement contains a lease at inception. If a lease is identified in an arrangement, we recognize a right-of-use asset and liability on our consolidated balance sheet and determine whether the lease should be classified as a finance or operating lease. We do not recognize assets or liabilities for leases with lease terms of less than 12 months.
A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to Vertex by the end of the lease term, (ii) we hold an option to purchase the leased asset that we are reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no
alternative use at the end of the lease term. All other leases are recorded as operating leases.
Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate implicit is not readily determinable, we utilize our incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease.
We do not separate lease and non-lease components when determining which lease payments to include in the calculation of our lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, we reflect the option in the lease term if it is reasonably certain we will exercise the option.
Finance leases are recorded in “Property and equipment, net,” “Other current liabilities” and “Long-term finance lease liabilities,” and operating leases are recorded in “Operating lease assets,” “Other current liabilities” and “Long-term operating lease liabilities” on our consolidated balance sheet.
Income Taxes
Income Taxes
Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the income tax bases of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. On a periodic basis, we reassess the valuation allowance on our deferred income tax assets weighing positive and negative evidence to assess the recoverability of our deferred tax assets. We include, among other things, our recent financial performance and our future projections in this periodic assessment.
We record liabilities related to uncertain tax positions by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. We evaluate our uncertain tax positions on a quarterly basis and consider various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in our tax returns, and changes in facts or circumstances related to a tax position. We adjust our liabilities to reflect any subsequent changes in the relevant facts and circumstances surrounding the uncertain positions. We accrue interest and penalties related to unrecognized tax benefits as a component of our “Provision for income taxes.”
As part of the U.S. Tax Cut and Jobs Act of 2017, we are subject to a territorial tax system, under which we must establish an accounting policy to provide for tax on Global Intangible Low Taxed Income (“GILTI”) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a current tax expense in our “Provision for income taxes.”
Variable Interest Entities
Variable Interest Entities
We review each collaboration agreement pursuant to which we license assets owned by a collaborator in order to determine whether or not we have a variable interest via the license agreement with our collaborator and if the variable interest is a variable interest in our collaborator as a whole and whether or not we are the primary beneficiary of that variable interest entity (“VIE”). If we determine we are the primary beneficiary of a VIE at the onset of our collaboration agreement, the collaboration is treated as a business combination and we consolidate the financial statements of the VIE into our consolidated financial statements until we are no longer the primary beneficiary of the consolidated VIE, or no longer have a variable interest in the VIE. As of December 31, 2021 and 2020, we did not have any consolidated VIEs.
Fair Value of In-process Research and Development Assets and Contingent Payments
Fair Value of In-process Research and Development Assets and Contingent Payments
The present-value models we use to estimate the fair values of in-process research and development assets and contingent payments pursuant to collaborations and acquisitions incorporate significant assumptions.
Our discounted cash flow models pertaining to in-process research and development assets include: (i) assumptions regarding the probability of obtaining marketing approval for a product candidate; (ii) the timing of and the expected costs to develop and commercialize a product candidate; (iii) estimates of future cash flows from potential product sales with respect to a product candidate; and (iv) appropriate discount and tax rates. We base our estimates of the probability of achieving the milestones relevant to the fair value of contingent payments, which could include milestone, royalty and option payments, on industry data. Estimates included in the discounted cash flow models pertaining to contingent payments also include: (i) estimate regarding the timing of the relevant development and commercial milestones and royalties, (ii) and appropriate discount rates. We record any increases or decreases in the fair value of our contingent payments as charges or credits to “Change in fair value of contingent consideration” in our consolidated statement of operations.
In-process Research and Development Assets
In-process Research and Development Assets
We record the fair value of in-process research and development assets as of the transaction date of a business combination. Each of these assets is accounted for as an indefinite-lived intangible asset and is maintained on our consolidated balance sheet until either the underlying project is completed or the asset becomes impaired. If the asset becomes impaired or is abandoned, the carrying value of the related intangible asset is written down to its fair value, and an impairment charge is recorded in the period in which the impairment occurs. If a project is completed, the carrying value of the related intangible asset is amortized as a part of “Cost of sales” over the remaining estimated life of the asset beginning in the period in which the project is completed. In-process research and development assets are tested for impairment on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstances suggest that impairment may exist.
In-process research and development that is acquired in a transaction that does not qualify as a business combination under U.S. GAAP and that does not have an alternative future use is recorded to “Research and development expenses” in the period in which it is acquired.
Goodwill GoodwillThe difference between the purchase price and the fair value of assets acquired and liabilities assumed in a business combination is allocated to goodwill. Goodwill is evaluated for impairment on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstances suggest that impairment may exist.
Hedging Activities
Hedging Activities
We recognize the fair value of hedging instruments that are designated and qualify as hedging instruments pursuant to U.S. GAAP, foreign currency forward contracts, as either assets or liabilities on our consolidated balance sheets. Changes in the fair value of these instruments are recorded each period in “Accumulated other comprehensive income (loss)” as unrealized gains and losses until the forecasted underlying transaction occurs. Unrealized gains and losses on these foreign currency forward contracts are included in “Prepaid expenses and other current assets” or “Other assets,” and “Other current liabilities” or “Other long-term liabilities,” respectively, on our consolidated balance sheets depending on the remaining period until their contractual maturity. Realized gains and losses for the effective portion of such contracts are recognized in “Product revenues, net” in our consolidated statement of operations in the same period that we recognize the product revenues that were impacted by the hedged foreign exchange rate changes. We classify the cash flows from hedging instruments in the same category as the cash flows from the hedged items.
Certain of our hedging instruments are subject to master netting arrangements to reduce the risk arising from such transactions with our counterparties. We present unrealized gains and losses on our foreign currency forward contracts on a gross basis within our consolidated balance sheets.
We also enter into foreign currency forward contracts with contractual maturities of less than one month designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities including intercompany balances. These contracts are not designated as hedging instruments pursuant to U.S. GAAP. Realized gains and losses for such
contracts are recognized in “Other income, net” in our consolidated statement of operations each period.
Comprehensive Income
Comprehensive Income
Comprehensive income consists of net income and other comprehensive income (loss), which includes foreign currency translation adjustments and unrealized gains and losses on foreign currency forward contracts and certain marketable securities. For purposes of comprehensive income disclosures, we record provisions for or benefits from income taxes related to the unrealized gains and losses on foreign currency forward contracts and certain marketable securities. We do not record provisions for or benefits from income taxes related to our cumulative translation adjustment, as we intend to permanently reinvest undistributed earnings in our foreign subsidiaries.
Foreign Currency Translation and Transactions Foreign Currency Translation and TransactionsThe majority of our operations occur in entities that have the U.S. dollar denominated as their functional currency. The assets and liabilities of our entities with functional currencies other than the U.S. dollar are translated into U.S. dollars at exchange rates in effect at the end of the year. Revenue and expense amounts for these entities are translated using the average exchange rates for the period. Net unrealized gains and losses resulting from foreign currency translation are included in “Accumulated other comprehensive income (loss).”
Share Repurchase Programs
Share Repurchase Programs
Repurchases of our common stock are recorded as reductions to “Common Stock” and “Additional paid-in capital” pursuant to our established accounting policy. Repurchases in excess of the par value will be recorded as reductions to “Retained earnings” in the event that “Additional paid-in capital” is reduced to zero.
Net Income Per Common Share Net Income Per Common ShareBasic net income per common share is based upon the weighted-average number of common shares outstanding during the period. Diluted net income per common share utilizing the treasury-stock method is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive.
Recently Adopted Accounting Standards and Recently Issued Accounting Standards
Recently Adopted Accounting Standards
Income Taxes
In 2019, the Financial Accounting Standards Board (“FASB”) issued ASU 2019-12, Income Taxes (Topic 740) (“ASU 2019-12”), which simplifies the accounting for income taxes. ASU 2019-12 became effective on January 1, 2021. The adoption of ASU 2019-12 did not have a significant impact on our consolidated financial statements.
Internal-Use Software
In 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU 2018-15”), which clarifies the accounting for implementation costs in cloud computing arrangements. ASU 2018-15 became effective on January 1, 2020. The adoption of ASU 2018-15 resulted in an insignificant amount of additional assets recorded on our consolidated balance sheet.
Fair Value Measurement
In 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which modifies the disclosure requirements for fair
value measurements. ASU 2018-13 became effective on January 1, 2020. The adoption of ASU 2018-13 resulted in additional disclosures related to our Level 3 inputs. Please refer to Note D, “Fair Value Measurements,” for further information.
Credit Losses
In 2016, the FASB issued ASU 2016-13, which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 became effective on January 1, 2020. The adoption of ASU 2016-13 did not have a significant impact on our consolidated financial statements.
Leases
On January 1, 2019, we adopted ASC 842 using the modified-retrospective method. Until December 31, 2018, we applied build-to-suit accounting and were the deemed owner of our leased corporate headquarters in Boston and research site in San Diego. Under the amended guidance that became effective January 1, 2019, we account for these buildings as finance leases. As of January 1, 2019, we recorded a cumulative effect adjustment to increase our “Accumulated deficit” by $40.3 million to reflect our build-to-suit leases as finance leases pursuant to ASC 842.
Recently Issued Accounting Standards
We do not expect any recently issued accounting standards to have a significant impact on our consolidated financial statements.
XML 54 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
Nature of Business and Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Schedule of Property and Equipment
Property and equipment are recorded at cost, net of accumulated depreciation. Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset generally as follows:
DescriptionEstimated Useful Life
Buildings and improvements
15 to 40 years
Furniture and equipment
7 to 10 years
Leasehold improvements; assets under finance leasesThe shorter of the useful life of the assets or the estimated remaining term of the associated lease
Computers and software
3 to 5 years
Property and equipment, net consisted of the following:
As of December 31,
20212020
(in millions)
Buildings and improvements$892.5 $876.1 
Furniture and equipment407.3 346.7 
Leasehold improvements363.5 234.6 
Computers and software293.7 258.6 
Land33.1 33.1 
Total property and equipment, gross1,990.1 1,749.1 
Less: accumulated depreciation
(896.0)(790.6)
Total property and equipment, net
$1,094.1 $958.5 
XML 55 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaborative and Other Arrangements (Tables)
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Collaborative Arrangement on Research and Development During the three years ended December 31, 2021, we recognized the following amounts in total related to these agreements:
202120202019
(in millions)
Total research and development expenses incurred under the Original CTX001 JDCA and A&R JDCA$230.4 $101.2 $60.3 
Vertex’s share recognized in “Research and development expenses” in consolidated statements of operations
129.0 50.6 30.1 
XML 56 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
Earnings Per Share (Tables)
 12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
The following table sets forth the computation of basic and diluted net income per common share for the periods ended:
202120202019
(in millions, except per share amounts)
Net income $2,342.1 $2,711.7 $1,176.8 
Basic weighted-average common shares outstanding257.7 259.8 256.7 
Effect of potentially dilutive securities:
Stock options1.1 1.8 2.2 
Restricted stock units (including PSUs)
1.1 1.7 1.7 
Employee stock purchase program
0.0 0.1 0.1 
Diluted weighted-average common shares outstanding259.9 263.4 260.7 
Basic net income per common share$9.09 $10.44 $4.58 
Diluted net income per common share$9.01 $10.29 $4.51 
Schedule of Potential Gross Common Equivalent Shares
We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:
202120202019
(in millions)
Stock options0.7 0.3 2.8 
Unvested restricted stock units (including PSUs)0.4 0.3 — 
XML 57 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets Subject to Fair Value Measurements (Excluding Vie Cash and Cash Equivalents, Which are Recorded as Restricted Cash and Cash Equivalents (Vie))
The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $3.3 billion and $2.8 billion of cash as of December 31, 2021 and 2020, respectively):
As of December 31, 2021As of December 31, 2020
Fair Value Hierarchy
Fair Value Hierarchy
Total
Level 1
Level 2
Level 3
Total
Level 1
Level 2
Level 3
(in millions)
Financial instruments carried at fair value (asset position):
Cash equivalents:
Money market funds$3,478.1 $3,478.1 $— $— $3,141.1 $3,141.1 $— $— 
Marketable securities:
Corporate equity securities230.9 230.9 — — 195.8 15.7 180.1 — 
U.S. Treasury securities86.4 86.4 — — — — — — 
Government-sponsored enterprise securities69.0 69.0 — — 80.0 80.0 — — 
Corporate debt securities90.9 — 90.9 — 231.6 — 231.6 — 
Commercial paper252.7 — 252.7 — 163.3 — 163.3 — 
Prepaid expenses and other current assets:
Foreign currency forward contracts44.5 — 44.5 — — — — — 
Other assets:
Foreign currency forward contracts2.0 — 2.0 — — — — — 
Total financial assets
$4,254.5 $3,864.4 $390.1 $— $3,811.8 $3,236.8 $575.0 $— 
Financial instruments carried at fair value (liability position):
Other current liabilities:
Foreign currency forward contracts$(5.6)$— $(5.6)$— $(59.2)$— $(59.2)$— 
Long-term contingent consideration(186.5)— — (186.5)(189.6)— — (189.6)
Other long-term liabilities:
Foreign currency forward contracts(2.7)— (2.7)— (4.3)— (4.3)— 
Total financial liabilities$(194.8)$— $(8.3)$(186.5)$(253.1)$— $(63.5)$(189.6)
Schedule of Fair Value of Our Contingent Consideration Liabilities
The following table represents a rollforward of the fair value of our contingent consideration liabilities:
Year Ended December 31, 2021
(in millions)
Balance at December 31, 2020
$189.6 
Decrease in fair value of contingent payments
(3.1)
Balance at December 31, 2021
$186.5 
XML 58 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
Marketable Securities and Equity Investments (Tables)
 12 Months Ended
Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]  
Summary of Cash, Cash Equivalents and Marketable Securities
A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $3.3 billion and $2.8 billion of cash as of December 31, 2021 and 2020, respectively), is shown below:
As of December 31, 2021As of December 31, 2020
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair Value
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair Value
(in millions)
Cash equivalents:
Money market funds
$3,478.1 $— $— $3,478.1 $3,141.1 $— $— $3,141.1 
Marketable securities:
U.S. Treasury securities$86.6 $— $(0.2)$86.4 $— $— $— $— 
Government-sponsored enterprise securities
69.0 — — 69.0 80.0 — — 80.0 
Corporate debt securities
91.1 — (0.2)90.9 231.3 0.4 (0.1)231.6 
Commercial paper
252.8 — (0.1)252.7 163.3 — — 163.3 
Total marketable debt securities499.5 — (0.5)499.0 474.6 0.4 (0.1)474.9 
Corporate equity securities
69.4 167.1 (5.6)230.9 51.4 144.4 — 195.8 
Total marketable securities$568.9 $167.1 $(6.1)$729.9 $526.0 $144.8 $(0.1)$670.7 
Available-for-sale debt securities were classified on our consolidated balance sheets at fair value as follows:
December 31,
20212020
(in millions)
Cash and cash equivalents$3,478.1 $3,141.1 
Marketable securities
499.0 474.9 
Total
$3,977.1 $3,616.0 
Available-for-sale debt securities by contractual maturity were as follows:
December 31,
20212020
(in millions)
Matures within one year$3,912.3 $3,526.2 
Matures after one year through five years
64.8 89.8 
Total
$3,977.1 $3,616.0 
Schedule of Company’s Net Unrealized Gains on Corporate Equity Securities During the three years ended December 31, 2021, our net unrealized gains on corporate equity securities held at the conclusion of each period were as follows:
202120202019
(in millions)
Net unrealized gains$17.1 $136.2 $143.2 
Schedule of Sale of Equity Investments
During the years ended December 31, 2020 and 2019, we sold the common stock of publicly traded companies, which were primarily sales of our investment in CRISPR, resulting in the following:
20202019
(in millions)
Proceeds received$437.6 $94.9 
Weighted-average cost basis$103.3 $29.8 
XML 59 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
Accumulated Other Comprehensive Income (Loss) (Tables)
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
Unrealized Holding Gains (Losses), Net of Tax
Foreign Currency Translation AdjustmentOn Available-For-Sale Debt SecuritiesOn Foreign Currency Forward ContractsTotal
(in millions)
Balance as of December 31, 2018
$(11.2)$(0.5)$12.4 $0.7 
Other comprehensive income before reclassifications10.3 1.0 11.5 22.8 
Amounts reclassified from accumulated other comprehensive income (loss)— — (25.5)(25.5)
Net current period other comprehensive income (loss)10.3 1.0 (14.0)(2.7)
Balance as of December 31, 2019
$(0.9)$0.5 $(1.6)$(2.0)
Other comprehensive loss before reclassifications(14.7)(0.2)(54.5)(69.4)
Amounts reclassified from accumulated other comprehensive income (loss)— — 2.9 2.9 
Net current period other comprehensive loss(14.7)(0.2)(51.6)(66.5)
Balance as of December 31, 2020
$(15.6)$0.3 $(53.2)$(68.5)
Other comprehensive income (loss) before reclassifications2.0 (0.8)59.7 60.9 
Amounts reclassified from accumulated other comprehensive income (loss)— — 23.5 23.5 
Net current period other comprehensive income (loss)2.0 (0.8)83.2 84.4 
Balance as of December 31, 2021
$(13.6)$(0.5)$30.0 $15.9 
XML 60 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
Hedging (Tables)
 12 Months Ended
Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Cash Flow Hedging Instruments
The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:
As of December 31,
20212020
Foreign Currency(in millions)
Euro$1,364.5 $745.1 
British pound sterling
287.7 160.4 
Australian dollar
96.3 99.9 
Canadian dollar
89.9 86.5 
Swiss Franc54.1 — 
Total foreign currency forward contracts
$1,892.5 $1,091.9 
Schedule of Foreign Exchange Contracts, Condensed Consolidated Statements of Operations
During the three years ended December 31, 2021, we recognized the following related to foreign currency forward contracts in our consolidated statements of operations:
December 31,
202120202019
(in millions)
Designated as hedging instruments - Reclassified from AOCI
Product revenues, net$(30.0)$(3.7)$32.5 
Not designated as hedging instruments
Other income, net$(18.6)$22.1 $(4.8)
Total reported in the Consolidated Statement of Operations
Product revenues, net$7,573.4 $6,202.8 $4,160.7 
Other income, net$4.9 $296.6 $192.2 
Schedule of Foreign Exchange Contracts
The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our consolidated balance sheets:
As of December 31, 2021
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets
$44.5 
Other current liabilities
$(5.6)
Other assets
2.0 
Other long-term liabilities
(2.7)
Total assets
$46.5 
Total liabilities
$(8.3)
As of December 31, 2020
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets
$— 
Other current liabilities
$(59.2)
Other assets
— 
Other long-term liabilities
(4.3)
Total assets
$— 
Total liabilities
$(63.5)
Schedule of Offsetting Liabilities The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our consolidated balance sheets:
As of December 31, 2021
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$46.5 $— $46.5 $(8.3)$38.2 
Total liabilities(8.3)— (8.3)8.3 — 
As of December 31, 2020
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$— $— $— $— $— 
Total liabilities(63.5)— (63.5)— (63.5)
Schedule of Offsetting Assets The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our consolidated balance sheets:
As of December 31, 2021
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$46.5 $— $46.5 $(8.3)$38.2 
Total liabilities(8.3)— (8.3)8.3 — 
As of December 31, 2020
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$— $— $— $— $— 
Total liabilities(63.5)— (63.5)— (63.5)
XML 61 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
Inventories (Tables)
 12 Months Ended
Dec. 31, 2021
Inventory Disclosure [Abstract]  
Schedule of Inventories by Type
Inventories consisted of the following:
As of December 31,
20212020
(in millions)
Raw materials$42.4 $46.2 
Work-in-process224.0 161.3 
Finished goods
86.7 73.3 
Total
$353.1 $280.8 
XML 62 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment
Property and equipment are recorded at cost, net of accumulated depreciation. Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset generally as follows:
DescriptionEstimated Useful Life
Buildings and improvements
15 to 40 years
Furniture and equipment
7 to 10 years
Leasehold improvements; assets under finance leasesThe shorter of the useful life of the assets or the estimated remaining term of the associated lease
Computers and software
3 to 5 years
Property and equipment, net consisted of the following:
As of December 31,
20212020
(in millions)
Buildings and improvements$892.5 $876.1 
Furniture and equipment407.3 346.7 
Leasehold improvements363.5 234.6 
Computers and software293.7 258.6 
Land33.1 33.1 
Total property and equipment, gross1,990.1 1,749.1 
Less: accumulated depreciation
(896.0)(790.6)
Total property and equipment, net
$1,094.1 $958.5 
XML 63 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
Additional Balance Sheet Detail (Tables)
 12 Months Ended
Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Prepaid, and Other Assets
Prepaid expenses and other current assets consisted of the following:
As of December 31,
20212020
(in millions)
Tax related prepaid and receivables$358.6 $228.6 
Other187.2 79.7 
Total
$545.8 $308.3 
Summary of Accrued Expenses
Accrued expenses consisted of the following:
As of December 31,
20212020
(in millions)
Product revenue accruals$847.4 $781.9 
Payroll and benefits191.3 169.4 
Research, development and commercial contract costs171.6 136.7 
Royalty payable200.4 165.4 
Tax related accruals
211.3 104.2 
Other
56.6 47.4 
Total
$1,678.6 $1,405.0 
Summary of Other Current Liabilities
Other current liabilities consisted of the following:
As of December 31,
20212020
(in millions)
Contract liabilities$171.7 $191.5 
Finance lease liabilities46.9 42.4 
Fair value of cash flow hedges5.6 59.2 
Other44.2 24.3 
Total$268.4 $317.4 
Schedule of Additional Cash Flow Information
The cash, cash equivalents and restricted cash balances at the beginning and ending of each period presented in our consolidated statements of cash flows consisted of the following:
As of December 31,
2021202020192018
(in millions)
Cash and cash equivalents$6,795.0 $5,988.2 $3,109.3 $2,650.1 
Prepaid expenses and other current assets
5.1 0.7 8.0 4.9 
Other assets
— — 3.4 3.3 
Cash, cash equivalents and restricted cash per consolidated statement of cash flows$6,800.1 $5,988.9 $3,120.7 $2,658.3 
XML 64 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases (Tables)
 12 Months Ended
Dec. 31, 2021
Leases [Abstract]  
Schedule of Lease Cost
The components of lease cost recorded in our consolidated statement of operations were as follows:
202120202019
(in millions)
Operating lease cost$33.9 $23.1 $12.0 
Finance lease cost
Amortization of leased assets51.9 51.2 49.8 
Interest on lease liabilities47.4 50.2 52.8 
Variable lease cost33.6 30.8 28.0 
Sublease income(0.4)(4.0)(6.4)
Net lease cost$166.4 $151.3 $136.2 
Schedule of Components of Lease in Balance Sheets
Our leases are included on our consolidated balance sheets as follows:
As of December 31,
20212020
(in millions)
Finance leases
Property and equipment, net$400.1 $431.2 
Total finance lease assets
$400.1 $431.2 
Other current liabilities$46.9 $42.5 
Long-term finance lease liabilities509.8 539.0 
Total finance lease liabilities
$556.7 $581.5 
Operating leases
Operating lease assets$330.3 $325.6 
Total operating lease assets
$330.3 $325.6 
Other current liabilities$33.3 $10.5 
Long-term operating lease liabilities377.4 350.5 
Total operating lease liabilities
$410.7 $361.0 
Schedule of Finance Lease, Liability, Maturity
Maturities of our finance and operating lease liabilities as of December 31, 2021 were as follows:
Year
Finance Leases
Operating Leases
Total
(in millions)
2022$87.9 $41.9 $129.8 
202393.2 42.0 135.2 
202497.6 38.6 136.2 
202595.9 35.7 131.6 
202694.2 33.7 127.9 
Thereafter
327.4 290.3 617.7 
Total lease payments
796.2 482.2 1,278.4 
Less: tenant allowance— (6.5)(6.5)
Less: amount representing interest
(239.5)(65.0)(304.5)
Present value of lease liabilities
$556.7 $410.7 $967.4 
Schedule of Operating Lease, Liability, Maturity
Maturities of our finance and operating lease liabilities as of December 31, 2021 were as follows:
Year
Finance Leases
Operating Leases
Total
(in millions)
2022$87.9 $41.9 $129.8 
202393.2 42.0 135.2 
202497.6 38.6 136.2 
202595.9 35.7 131.6 
202694.2 33.7 127.9 
Thereafter
327.4 290.3 617.7 
Total lease payments
796.2 482.2 1,278.4 
Less: tenant allowance— (6.5)(6.5)
Less: amount representing interest
(239.5)(65.0)(304.5)
Present value of lease liabilities
$556.7 $410.7 $967.4 
Schedule of Weighted-Average Remaining Lease Terms and Discount Rates
The weighted-average remaining lease terms and discount rates related to our leases were as follows:
As of December 31,
20212020
Weighted-average remaining lease term (in years)
Finance leases10.7311.58
Operating leases12.8114.10
Weighted-average discount rate
Finance leases
8.11 %8.36 %
Operating leases
2.19 %2.28 %
Schedule of Supplemental Cash Flow Information
Supplemental cash flow information related to our leases was as follows:
202120202019
(in millions)
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases$21.5 $16.3 $10.7 
Operating cash flows from finance leases$46.2 $48.9 $50.5 
Financing cash flows from finance leases$47.0 $42.3 $39.2 
Right-of-use assets obtained in exchange for lease obligations
Operating leases
$36.3 $293.6 $34.6 
Finance leases
$— $33.1 $— 
XML 65 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
Common Stock, Preferred Stock and Equity Plans (Tables)
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Schedule of Stock and Stock Equity Plans The following table contains information about our equity plans:
As of December 31, 2021
Title of Plan
Group Eligible
Type of Award
Granted
Awards
Outstanding
Additional Awards
Authorized for Grant
(in thousands)
2013 Stock and Option PlanEmployees, Non-employee Directors and ConsultantsNSO, RS, RSU and PSU7,306 9,558 
2006 Stock and Option PlanEmployees, Non-employee Directors and ConsultantsNSO, RS and RSU292 — 
Total
7,598 9,558 
Schedule of Outstanding and Vested Options
The following table summarizes information related to the outstanding and exercisable options during the year ended December 31, 2021:
Stock Options
Weighted-average
Exercise Price
Weighted-average Remaining Contractual Life
Aggregate Intrinsic
Value
(in thousands)(per share)(in years)(in millions)
Outstanding at December 31, 20204,238 $140.47 
Granted27 $217.20 
Exercised(518)$125.78 
Forfeited(136)$177.28 
Expired
— $— 
Outstanding at December 31, 20213,611 $141.76 5.42$288.6 
Exercisable at December 31, 20213,149 $136.13 5.19$269.6 
Schedule of Stock Options Outstanding and Exercisable
The following table summarizes information about stock options outstanding and exercisable at December 31, 2021:
Options Outstanding
Options Exercisable
Range of Exercise Prices
Number
Outstanding
Weighted-average
Remaining Contractual Life
Weighted-average
Exercise Price
Number
Exercisable
Weighted-average
Exercise Price
(in thousands)(in years)(per share)(in thousands)(per share)
$36.28–$100.00
1,085 3.70$82.14 1,085 $82.14 
$100.01–$150.00
362 3.56$123.15 362 $123.15 
$150.01–$200.00
2,114 6.53$173.03 1,652$171.04 
$200.01–$286.27
50 8.92$248.51 50 $248.51 
Total
3,611 5.42$141.76 3,149 $136.13 
Schedule of Restricted Stock and Restricted Stock Units Activity
The following table summarizes our restricted stock unit activity during the year ended December 31, 2021:
Restricted Stock Units (excluding PSUs)
Number of Shares
Weighted-average
Grant-date
Fair Value
(in thousands)(per share)
Unvested at December 31, 20202,722 $206.99 
Granted1,927 $208.48 
Vested(1,331)$193.29 
Cancelled
(409)$214.68 
Unvested at December 31, 20212,909 $213.17 
Schedule of PSU Activity
The following table summarizes our PSU activity during the year ended December 31, 2021:
Performance-Based RSU
Number of Units
Weighted-average
Grant-date
Fair Value
(in thousands)(per share)
Unvested at December 31, 2020 (1)656 $202.06 
Granted (2)954 $212.44 
Vested(431)$183.94 
Cancelled
(101)$214.72 
Unvested at December 31, 20211,078 $215.85 
(1) “Unvested” represents our PSUs at target to the extent performance has not been certified plus the actual number of shares that continue to be subject to service conditions for which the performance has been achieved and certified.
(2) “Granted” represents (i) the target number of shares issuable for grants during 2021 and (ii) any change in the number of shares issuable pursuant to outstanding PSUs based on performance certification during 2021.
Schedule of Shares Issued Under Employee Stock Purchase Plan
In 2021, the following shares were issued to employees under the ESPP:
Year Ended December 31, 2021
Number of shares (in thousands)219 
Average price paid per share$171.57 
XML 66 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-based Compensation Expense (Tables)
 12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Stock-Based Compensation Expense
The effect of stock-based compensation expense during the three years ended December 31, 2021 was as follows:
202120202019
(in millions)
Stock-based compensation expense by line item:
Cost of sales$6.3 $5.6 $5.6 
Research and development expenses268.3 262.7 224.6 
Selling, general and administrative expenses
166.8 161.2 130.3 
Total stock-based compensation expense included in costs and expenses
441.4 429.5 360.5 
Income tax effect(82.9)(147.0)(124.2)
Total stock-based compensation included in costs and expenses, net of tax$358.5 $282.5 $236.3 
Schedule of Stock-Based Compensation Expense by Type of Award
The stock-based compensation expense by type of award during the three years ended December 31, 2021 was as follows:
202120202019
(in millions)
Stock-based compensation expense by type of award:
Restricted stock units (including PSUs)$384.3 $360.4 $254.3 
Stock options36.8 59.7 96.7 
ESPP share issuances24.4 13.0 11.2 
Stock-based compensation expense related to inventories(4.1)(3.6)(1.7)
Total stock-based compensation expense included in costs and expenses
$441.4 $429.5 $360.5 
Schedule of Unrecognized Stock-Based Compensation Expense
The following table sets forth our unrecognized stock-based compensation expense as of December 31, 2021, by type of award and the weighted-average period over which that expense is expected to be recognized:
As of December 31, 2021
Unrecognized Expense
Weighted-average Recognition Period
(in millions)(in years)
Type of award:
Restricted stock units (including PSUs)$423.3 1.91
Stock options19.1 1.09
ESPP share issuances12.6 0.54
Total unrecognized stock-based compensation expense$455.0 
Schedule of Assumptions Used to Estimate the Grant Date Fair Value of Options
The fair value of each option granted during 2021, 2020 and 2019 was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:
202120202019
Stock options granted27,30222,6361,520,743
Expected stock price volatility35.03%35.87%36.99%
Risk-free interest rate0.86%0.43%2.32%
Expected term of options (in years)4.504.674.27
Expected annual dividends———
Schedule of Assumptions Used to Estimate the Grant Date Fair Value Employee Stock Purchase Plan The following table reflects the weighted-average assumptions used in the Black-Scholes option pricing model for 2021, 2020 and 2019:
202120202019
Expected stock price volatility34.06%37.70%33.43%
Risk-free interest rate0.05%0.11%2.08%
Expected term (in years)0.690.710.74
Expected annual dividends———
XML 67 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Schedule of Components of Income Before Provision for (Benefit From) Income Taxes The components of income before provision for income taxes during the three years ended December 31, 2021, consisted of the following:
202120202019
(in millions)
United States$2,030.7 $2,885.4 $1,263.4 
Foreign
699.7 231.5 131.5 
Income before provision for income taxes$2,730.4 $3,116.9 $1,394.9 
Schedule of Components of Provision for (Benefit From) Income Taxes
The components of the provision for income taxes during the three years ended December 31, 2021, consisted of the following:
202120202019
(in millions)
Current taxes:
Federal$374.9 $71.4 $— 
Foreign141.5 37.6 37.2 
State
26.5 18.9 13.5 
Total current taxes
542.9 127.9 50.7 
Deferred taxes:
Federal(36.9)510.2 184.3 
Foreign(98.4)(239.6)(24.8)
State
(19.3)6.7 7.9 
Total deferred taxes(154.6)277.3 167.4 
Provision for income taxes$388.3 $405.2 $218.1 
Schedule of Reconciliation of the Provision for (Benefit From) Income Taxes
A reconciliation between the U.S. federal statutory rate of 21% and our effective tax rate is as follows:
202120202019
Federal statutory tax rate21.0 %21.0 %21.0 %
State taxes, net of federal benefit0.8 %0.6 %0.6 %
Foreign income tax rate differential(0.3)%0.2 %0.4 %
Tax credits(6.4)%(1.8)%(4.3)%
Tax rate change
(3.5)%(1.2)%— %
Stock compensation (benefit), shortfalls and cancellations
0.0 %(2.3)%(4.0)%
Long-term intercompany receivable write-off— %(1.7)%— %
Uncertain tax positions
2.0 %1.3 %1.0 %
Inter-entity transfer of intellectual property rights
— %(6.7)%— %
U.S. tax on foreign earnings, net of credits0.7 %2.7 %— %
Other
(0.1)%0.9 %0.9 %
Effective tax rate14.2 %13.0 %15.6 %
Schedule of Deferred Tax Assets and Liabilities The components of the deferred taxes were as follows:
As of December 31,
20212020
(in millions)
Deferred tax assets:
Net operating loss$106.6 $140.6 
Tax credit carryforwards202.4 406.1 
Intangible assets802.8 507.5 
Stock-based compensation94.6 89.2 
Accrued expenses48.6 47.3 
Finance lease liabilities103.4 118.7 
Operating lease assets81.1 65.0 
Other41.7 22.1 
Gross deferred tax assets1,481.2 1,396.5 
Valuation allowance(220.4)(213.8)
Total deferred tax assets1,260.8 1,182.7 
Deferred tax liabilities:
Property and equipment(118.2)(117.0)
Acquired intangibles(87.0)(87.0)
Operating lease liabilities(64.8)(63.3)
Other(56.3)(32.6)
Total deferred tax liabilities(326.3)(299.9)
Net deferred tax assets$934.5 $882.8 
Summary of Unrecognized Tax Benefits
Unrecognized tax benefits during the three years ended December 31, 2021 were as follows:
202120202019
(in millions)
Balance at beginning of the period$86.6 $33.9 $19.5 
Increases related to current period tax positions42.0 26.7 14.5 
Increases related to prior period tax positions19.9 26.7 0.6 
Decreases related to prior period tax positions— — (0.2)
Settlement with tax authorities— — (0.5)
Statute of limitations expiration
(1.3)(0.7)— 
Balance at end of period
$147.2 $86.6 $33.9 
XML 68 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Information (Tables)
 12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Revenues by Product
Product revenues, net consisted of the following:
202120202019
(in millions)
TRIKAFTA/KAFTRIO$5,697.2 $3,863.8 $420.1 
SYMDEKO/SYMKEVI420.4 628.6 1,417.7 
ORKAMBI771.6 907.5 1,331.9 
KALYDECO684.2 802.9 991.0 
Total product revenues, net$7,573.4 $6,202.8 $4,160.7 
Revenues and Property and Equipment by Location
Net product revenues are attributed to countries based on the location of the customer and consisted of the following:
202120202019
(in millions)
United States$5,287.3 $4,826.4 $3,060.3 
Outside of the United States
Europe1,972.9 1,126.5 885.9 
Other
313.2 249.9 214.5 
Total product revenues outside of the United States
2,286.1 1,376.4 1,100.4 
Total product revenues, net
$7,573.4 $6,202.8 $4,160.7 
Long-lived assets by location consisted of the following:
As of December 31,
20212020
(in millions)
United States$1,348.1 $1,207.7 
Outside of the United States
United Kingdom60.9 61.5 
Other15.4 14.9 
Total long-lived assets outside of the United States76.3 76.4 
Total long-lived assets$1,424.4 $1,284.1 
Significant Customers
Gross product revenues and accounts receivable from each of our customers who individually accounted for 10% or more of total gross product revenues and/or 10% or more of total accounts receivable consisted of the following:
Percent of
Total Gross Product Revenues
Percent of
Accounts Receivable
Year Ended December 31,
As of December 31,
20212020201920212020
McKesson Corporation22 %20 %17 %21 %14 %
Accredo/Curascript12 %15 %14 %10 %10 %
Walgreen Co.10 %14 %15 %<10 %10 %
Lloyds Pharmacy*<10%<10%<10%15 %19 %
*A wholly-owned subsidiary of McKesson Corporation in the U.K.
XML 69 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
Nature of Business and Accounting Policies - Business Narrative (Details)
 12 Months Ended
Dec. 31, 2021
segment
Accounting Policies [Abstract]  
Number of operating segments 1
XML 70 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
Nature of Business and Accounting Policies - Revenue Recognition (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Contract liabilities   $ 171.7 $ 191.5  
Revenues related to performance obligations   191.5 62.3 $ 24.9
Revenue   $ 7,574.4 $ 6,205.7 $ 4,162.8
ORKAMBI        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]        
Revenue $ 155.8      
XML 71 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
Nature of Business and Accounting Policies - Stock-Based Compensation Expense (Details)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Percentage of employees eligible for acceleration of equity awards (less than) (percent) 5.00%
XML 72 R46.htm IDEA: XBRL DOCUMENT v3.22.0.1
Nature of Business and Accounting Policies - Property and Equipment (Details)
 12 Months Ended
Dec. 31, 2021
Buildings and improvements | Minimum  
Property, Plant and Equipment [Line Items]  
Property and equipment useful life 15 years
Buildings and improvements | Maximum  
Property, Plant and Equipment [Line Items]  
Property and equipment useful life 40 years
Furniture and equipment | Minimum  
Property, Plant and Equipment [Line Items]  
Property and equipment useful life 7 years
Furniture and equipment | Maximum  
Property, Plant and Equipment [Line Items]  
Property and equipment useful life 10 years
Computers and software | Minimum  
Property, Plant and Equipment [Line Items]  
Property and equipment useful life 3 years
Computers and software | Maximum  
Property, Plant and Equipment [Line Items]  
Property and equipment useful life 5 years
XML 73 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1
Nature of Business and Accounting Policies - Goodwill Hedging Activities Foreign Currency Gain (Loss) (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2021
USD ($)
segment
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Derivative [Line Items]      
Number of operating segments | segment 1    
Net foreign currency transaction loss | $ $ 13.9 $ 16.1 $ 5.2
Foreign currency forward contracts | Not designated as hedging instrument      
Derivative [Line Items]      
Derivative term 1 month    
XML 74 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
Nature of Business and Accounting Policies - Leases (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Jan. 01, 2019
Lessee, Lease, Description [Line Items]      
Accumulated deficit $ (3,200.8) $ (858.7)  
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Property and equipment, net Property and equipment, net  
Accounting Standards Update 2016-02 | Cumulative Effect, Period of Adoption, Adjustment      
Lessee, Lease, Description [Line Items]      
Accumulated deficit     $ 40.3
XML 75 R49.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaborative and Other Arrangements - Additional Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Collaborative arrangement research and development expenses $ 1,100.0 $ 184.6 $ 318.3
XML 76 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaborative and Other Arrangements - CRISPR Therapeutics AG (Details)
 3 Months Ended 12 Months Ended
Jun. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
target
Jul. 01, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Up-front payment   $ 125,800,000 $ 84,600,000 $ 63,300,000  
Collaborative arrangement research and development expenses   1,100,000,000 184,600,000 318,300,000  
CRISPR Therapeutics          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement, option payment       $ 30,000,000  
Right to license, number of targets (up to) | target       3  
Collaborative arrangement development and regulatory potential milestone payments maximum       $ 410,000,000  
CRSIPR A&R JDCA          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement development and regulatory potential milestone payments maximum $ 200,000,000        
Up-front payment $ 900,000,000        
Allocation of net profits and net losses, percent         60.00%
CRSIPR A&R JDCA | CRISPR          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Allocation of net profits and net losses, percent         40.00%
CRISPR DMD/DM1          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement development and regulatory potential milestone payments maximum   787,500,000      
Up-front payment       175,000,000  
Collaborative arrangement, milestone payment   12,500,000 25,000,000    
CRISPR Therapeutics | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement research and development expenses   230,400,000 101,200,000 60,300,000  
CRISPR Therapeutics | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Research and development expenses          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement research and development expenses   $ 129,000,000.0 $ 50,600,000 $ 30,100,000  
XML 77 R51.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaborative and Other Arrangements - Kymera, Moderna and Other In-License Agreements (Details)
 12 Months Ended
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
target
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Up-front payment $ 125,800,000 $ 84,600,000 $ 63,300,000
Kymera Therapeutics      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Up-front payment     $ 50,000,000
Right to license, number of targets (up to) | target     6
Collaborative arrangement development and regulatory potential milestone payments maximum     $ 170,000,000
Investment in collaborative partner, pursuant to convertible loan agreement   20,000,000  
Moderna Agreement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Up-front payment   75,000,000  
Collaborative arrangement development and regulatory potential milestone payments maximum   380,000,000  
ApolLo1 Bio, LLC      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Collaborative arrangement, milestone payment 15,000,000    
Collaborative arrangement, option payment 60,000,000    
Mammoth Biosciences, Inc      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Up-front payment 31,000,000    
Arbor Biotechnologies, Inc      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Up-front payment $ 25,000,000    
Skyhawk Therapeutics Inc      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Up-front payment   $ 40,000,000  
Molecular Templates, Inc      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Up-front payment     $ 25,900,000
XML 78 R52.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaborative and Other Arrangements - Merck KGaA (Details) - Merck KGaA
 1 Months Ended
Jan. 31, 2017
pre-clinical_program
clinical-stage_program
oncology_research_and_development_program
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Right to license, number of development programs | oncology_research_and_development_program 4
Right to license, number of clinical stage programs | clinical-stage_program 2
Number of pre-clinical stage programs | pre-clinical_program 2
XML 79 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
Earnings Per Share - Schedule of Computation (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share      
Net income $ 2,342.1 $ 2,711.7 $ 1,176.8
Basic weighted-average common shares outstanding (in shares) 257.7 259.8 256.7
Effect of potentially dilutive securities:      
Employee stock purchase program (in shares) 0.0 0.1 0.1
Diluted weighted-average common shares outstanding (in shares) 259.9 263.4 260.7
Basic net income per common share (in dollars per share) $ 9.09 $ 10.44 $ 4.58
Diluted net income per common share (in dollars per share) $ 9.01 $ 10.29 $ 4.51
Stock options      
Effect of potentially dilutive securities:      
Share-based payment arrangements (in shares) 1.1 1.8 2.2
Restricted stock units (including PSUs)      
Effect of potentially dilutive securities:      
Share-based payment arrangements (in shares) 1.1 1.7 1.7
XML 80 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
Earnings Per Share - Anti-dilutive Securities (Details) - shares
shares in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Stock options      
Antidilutive Securities Excluded from Computation of Earnings Per Share      
Antidilutive securities excluded from computation of earnings per share (in shares) 0.7 0.3 2.8
Restricted Stock Units (excluding PSUs)      
Antidilutive Securities Excluded from Computation of Earnings Per Share      
Antidilutive securities excluded from computation of earnings per share (in shares) 0.4 0.3 0.0
XML 81 R55.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements - Additional Information (Details)
$ in Millions
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash $ 3,300.0 $ 2,800.0
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Remaining milestone payment $ 678.3  
Level 3 | Minimum | Discount Rate    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, measurement input (percent) 0.009  
Level 3 | Maximum | Discount Rate    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, measurement input (percent) 0.023  
XML 82 R56.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Financial instruments carried at fair value (liability position):    
Long-term contingent consideration $ (186.5) $ (189.6)
Recurring basis    
Financial instruments carried at fair value (asset position):    
Derivative asset current, foreign currency forward contracts 44.5 0.0
Derivative asset noncurrent, foreign currency forward contracts 2.0 0.0
Total financial assets 4,254.5 3,811.8
Financial instruments carried at fair value (liability position):    
Derivative liability current, foreign currency forward contracts (5.6) (59.2)
Long-term contingent consideration (186.5) (189.6)
Derivative liability noncurrent, foreign currency forward contracts (2.7) (4.3)
Total financial liabilities (194.8) (253.1)
Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Derivative asset current, foreign currency forward contracts 0.0 0.0
Derivative asset noncurrent, foreign currency forward contracts 0.0 0.0
Total financial assets 3,864.4 3,236.8
Financial instruments carried at fair value (liability position):    
Derivative liability current, foreign currency forward contracts 0.0 0.0
Long-term contingent consideration 0.0 0.0
Derivative liability noncurrent, foreign currency forward contracts 0.0 0.0
Total financial liabilities 0.0 0.0
Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Derivative asset current, foreign currency forward contracts 44.5 0.0
Derivative asset noncurrent, foreign currency forward contracts 2.0 0.0
Total financial assets 390.1 575.0
Financial instruments carried at fair value (liability position):    
Derivative liability current, foreign currency forward contracts (5.6) (59.2)
Long-term contingent consideration 0.0 0.0
Derivative liability noncurrent, foreign currency forward contracts (2.7) (4.3)
Total financial liabilities (8.3) (63.5)
Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Derivative asset current, foreign currency forward contracts 0.0 0.0
Derivative asset noncurrent, foreign currency forward contracts 0.0 0.0
Total financial assets 0.0 0.0
Financial instruments carried at fair value (liability position):    
Derivative liability current, foreign currency forward contracts 0.0 0.0
Long-term contingent consideration (186.5) (189.6)
Derivative liability noncurrent, foreign currency forward contracts 0.0 0.0
Total financial liabilities (186.5) (189.6)
Money market funds | Recurring basis    
Financial instruments carried at fair value (asset position):    
Cash equivalents: 3,478.1 3,141.1
Money market funds | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Cash equivalents: 3,478.1 3,141.1
Money market funds | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Cash equivalents: 0.0 0.0
Money market funds | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Cash equivalents: 0.0 0.0
Corporate equity securities | Recurring basis    
Financial instruments carried at fair value (asset position):    
Marketable securities: 230.9 195.8
Corporate equity securities | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Marketable securities: 230.9 15.7
Corporate equity securities | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Marketable securities: 0.0 180.1
Corporate equity securities | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Marketable securities: 0.0 0.0
U.S. Treasury securities | Recurring basis    
Financial instruments carried at fair value (asset position):    
Marketable securities: 86.4 0.0
U.S. Treasury securities | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Marketable securities: 86.4 0.0
U.S. Treasury securities | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Marketable securities: 0.0 0.0
U.S. Treasury securities | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Marketable securities: 0.0 0.0
Government-sponsored enterprise securities | Recurring basis    
Financial instruments carried at fair value (asset position):    
Marketable securities: 69.0 80.0
Government-sponsored enterprise securities | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Marketable securities: 69.0 80.0
Government-sponsored enterprise securities | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Marketable securities: 0.0 0.0
Government-sponsored enterprise securities | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Marketable securities: 0.0 0.0
Corporate debt securities | Recurring basis    
Financial instruments carried at fair value (asset position):    
Marketable securities: 90.9 231.6
Corporate debt securities | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Marketable securities: 0.0 0.0
Corporate debt securities | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Marketable securities: 90.9 231.6
Corporate debt securities | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Marketable securities: 0.0 0.0
Commercial paper | Recurring basis    
Financial instruments carried at fair value (asset position):    
Marketable securities: 252.7 163.3
Commercial paper | Recurring basis | Level 1    
Financial instruments carried at fair value (asset position):    
Marketable securities: 0.0 0.0
Commercial paper | Recurring basis | Level 2    
Financial instruments carried at fair value (asset position):    
Marketable securities: 252.7 163.3
Commercial paper | Recurring basis | Level 3    
Financial instruments carried at fair value (asset position):    
Marketable securities: $ 0.0 $ 0.0
XML 83 R57.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]      
Balance at December 31, 2020 $ 189.6    
Decrease in fair value of contingent payments (3.1) $ 13.1 $ 4.5
Balance at December 31, 2021 $ 186.5 $ 189.6  
XML 84 R58.htm IDEA: XBRL DOCUMENT v3.22.0.1
Marketable Securities and Equity Investments - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Summary of cash, cash equivalents and marketable securities      
Cash $ 3,300,000,000 $ 2,800,000,000  
Other-than-temporary declines in fair value of available-for-sale debt securities 0 0 $ 0
Net unrealized gains 17,100,000 136,200,000 143,200,000
Weighted-average cost basis 69,400,000 51,400,000  
Publicly Traded Companies Sale      
Summary of cash, cash equivalents and marketable securities      
Proceeds received 0 437,600,000 94,900,000
Weighted-average cost basis   $ 103,300,000 $ 29,800,000
Other assets      
Summary of cash, cash equivalents and marketable securities      
Equity securities without readily determinable fair value, amount $ 85,800,000    
XML 85 R59.htm IDEA: XBRL DOCUMENT v3.22.0.1
Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Total marketable debt securities    
Fair Value $ 3,977.1 $ 3,616.0
Corporate equity securities    
Amortized Cost 69.4 51.4
Gross Unrealized Gains 167.1 144.4
Gross Unrealized Losses (5.6) 0.0
Fair Value 230.9 195.8
Amortized Cost 568.9 526.0
Gross Unrealized Gains 167.1 144.8
Gross Unrealized Losses (6.1) (0.1)
Fair Value 729.9 670.7
Cash equivalents:    
Total marketable debt securities    
Fair Value 3,478.1 3,141.1
Marketable securities:    
Total marketable debt securities    
Amortized Cost 499.5 474.6
Gross Unrealized Gains 0.0 0.4
Gross Unrealized Losses (0.5) (0.1)
Fair Value 499.0 474.9
Money market funds | Cash equivalents:    
Total marketable debt securities    
Amortized Cost 3,478.1 3,141.1
Gross Unrealized Gains 0.0 0.0
Gross Unrealized Losses 0.0 0.0
Fair Value 3,478.1 3,141.1
U.S. Treasury securities | Marketable securities:    
Total marketable debt securities    
Amortized Cost 86.6 0.0
Gross Unrealized Gains 0.0 0.0
Gross Unrealized Losses (0.2) 0.0
Fair Value 86.4 0.0
Government-sponsored enterprise securities | Marketable securities:    
Total marketable debt securities    
Amortized Cost 69.0 80.0
Gross Unrealized Gains 0.0 0.0
Gross Unrealized Losses 0.0 0.0
Fair Value 69.0 80.0
Corporate debt securities | Marketable securities:    
Total marketable debt securities    
Amortized Cost 91.1 231.3
Gross Unrealized Gains 0.0 0.4
Gross Unrealized Losses (0.2) (0.1)
Fair Value 90.9 231.6
Commercial paper | Marketable securities:    
Total marketable debt securities    
Amortized Cost 252.8 163.3
Gross Unrealized Gains 0.0 0.0
Gross Unrealized Losses (0.1) 0.0
Fair Value $ 252.7 $ 163.3
XML 86 R60.htm IDEA: XBRL DOCUMENT v3.22.0.1
Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]    
Debt Securities $ 3,977.1 $ 3,616.0
Cash and cash equivalents    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities 3,478.1 3,141.1
Marketable securities    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities $ 499.0 $ 474.9
XML 87 R61.htm IDEA: XBRL DOCUMENT v3.22.0.1
Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]    
Matures within one year $ 3,912.3 $ 3,526.2
Matures after one year through five years 64.8 89.8
Total $ 3,977.1 $ 3,616.0
XML 88 R62.htm IDEA: XBRL DOCUMENT v3.22.0.1
Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
AOCI, Net of Tax [Roll Forward]      
Beginning balance $ 8,686.8 $ 6,085.2 $ 4,435.2
Other comprehensive income (loss) before reclassifications 60.9 (69.4) 22.8
Amounts reclassified from accumulated other comprehensive income (loss) 23.5 2.9 (25.5)
Total other comprehensive income (loss) 84.4 (66.5) (2.7)
Ending balance 10,100.0 8,686.8 6,085.2
Foreign Currency Translation Adjustment      
AOCI, Net of Tax [Roll Forward]      
Beginning balance (15.6) (0.9) (11.2)
Other comprehensive income (loss) before reclassifications 2.0 (14.7) 10.3
Amounts reclassified from accumulated other comprehensive income (loss) 0.0 0.0 0.0
Total other comprehensive income (loss) 2.0 (14.7) 10.3
Ending balance (13.6) (15.6) (0.9)
On Available-For-Sale Debt Securities      
AOCI, Net of Tax [Roll Forward]      
Beginning balance 0.3 0.5 (0.5)
Other comprehensive income (loss) before reclassifications (0.8) (0.2) 1.0
Amounts reclassified from accumulated other comprehensive income (loss) 0.0 0.0 0.0
Total other comprehensive income (loss) (0.8) (0.2) 1.0
Ending balance (0.5) 0.3 0.5
On Foreign Currency Forward Contracts      
AOCI, Net of Tax [Roll Forward]      
Beginning balance (53.2) (1.6) 12.4
Other comprehensive income (loss) before reclassifications 59.7 (54.5) 11.5
Amounts reclassified from accumulated other comprehensive income (loss) 23.5 2.9 (25.5)
Total other comprehensive income (loss) 83.2 (51.6) (14.0)
Ending balance 30.0 (53.2) (1.6)
Total      
AOCI, Net of Tax [Roll Forward]      
Beginning balance (68.5) (2.0) 0.7
Total other comprehensive income (loss) 84.4 (66.5) (2.7)
Ending balance $ 15.9 $ (68.5) $ (2.0)
XML 89 R63.htm IDEA: XBRL DOCUMENT v3.22.0.1
Hedging - Narrative (Details) - Foreign currency forward contracts
 12 Months Ended
Dec. 31, 2021
USD ($)
Not designated as hedging instrument  
Derivative Instruments and Hedging Activities Disclosures [Line Items]  
Derivative term 1 month
Not designated as hedging instrument | Cash Flow Hedging  
Derivative Instruments and Hedging Activities Disclosures [Line Items]  
Notional amount of foreign currency forward contract $ 580,700,000
Minimum | Cash Flow Hedging  
Derivative Instruments and Hedging Activities Disclosures [Line Items]  
Derivative term 1 month
Maximum | Cash Flow Hedging  
Derivative Instruments and Hedging Activities Disclosures [Line Items]  
Derivative term 18 months
XML 90 R64.htm IDEA: XBRL DOCUMENT v3.22.0.1
Hedging - Notional Amount (Details) - Designated as hedging instruments - Cash Flow Hedging - Foreign currency forward contracts - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Derivative [Line Items]    
Notional amount of foreign currency forward contract $ 1,892.5 $ 1,091.9
Euro    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 1,364.5 745.1
British pound sterling    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 287.7 160.4
Australian dollar    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 96.3 99.9
Canadian dollar    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 89.9 86.5
Swiss Franc    
Derivative [Line Items]    
Notional amount of foreign currency forward contract $ 54.1 $ 0.0
XML 91 R65.htm IDEA: XBRL DOCUMENT v3.22.0.1
Hedging - Cash Flow Hedging Instruments (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]      
Product revenues, net $ 7,574.4 $ 6,205.7 $ 4,162.8
Other income, net 4.9 296.6 192.2
Foreign Currency Forward Contract | Reclassification out of Accumulated Other Comprehensive Income | Foreign currency forward contracts | Not designated as hedging instrument      
Derivative Instruments, Gain (Loss) [Line Items]      
Other income, net (18.6) 22.1 (4.8)
Product revenues, net      
Derivative Instruments, Gain (Loss) [Line Items]      
Product revenues, net 7,573.4 6,202.8 4,160.7
Product revenues, net | Foreign Currency Forward Contract | Reclassification out of Accumulated Other Comprehensive Income | Foreign currency forward contracts | Designated as hedging instruments      
Derivative Instruments, Gain (Loss) [Line Items]      
Product revenues, net $ (30.0) $ (3.7) $ 32.5
XML 92 R66.htm IDEA: XBRL DOCUMENT v3.22.0.1
Hedging - Derivative Fair Value (Details) - Designated as hedging instruments - Foreign currency forward contracts - Cash Flow Hedging - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Derivative [Line Items]    
Gross Amounts Recognized $ 46.5 $ 0.0
Gross Amounts Recognized (8.3) (63.5)
Prepaid expenses and other current assets    
Derivative [Line Items]    
Gross Amounts Recognized 44.5 0.0
Other assets    
Derivative [Line Items]    
Gross Amounts Recognized 2.0 0.0
Other current liabilities    
Derivative [Line Items]    
Gross Amounts Recognized (5.6) (59.2)
Other long-term liabilities    
Derivative [Line Items]    
Gross Amounts Recognized $ (2.7) $ (4.3)
XML 93 R67.htm IDEA: XBRL DOCUMENT v3.22.0.1
Hedging - Offsetting Derivatives (Details) - Cash Flow Hedging - Designated as hedging instruments - Foreign currency forward contracts - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Total assets    
Gross Amounts Recognized $ 46.5 $ 0.0
Gross Amounts Offset 0.0 0.0
Gross Amounts Presented 46.5 0.0
Gross Amounts Not Offset (8.3) 0.0
Legal Offset 38.2 0.0
Total liabilities    
Gross Amounts Recognized (8.3) (63.5)
Gross Amounts Offset 0.0 0.0
Gross Amounts Presented (8.3) (63.5)
Gross Amounts Not Offset 8.3 0.0
Legal Offset $ 0.0 $ (63.5)
XML 94 R68.htm IDEA: XBRL DOCUMENT v3.22.0.1
Inventories (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Inventory Disclosure [Abstract]    
Raw materials $ 42.4 $ 46.2
Work-in-process 224.0 161.3
Finished goods 86.7 73.3
Total $ 353.1 $ 280.8
XML 95 R69.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property and Equipment - Property and Equipment, Net (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Total property and equipment, gross $ 1,990.1 $ 1,749.1
Less: accumulated depreciation (896.0) (790.6)
Total property and equipment, net 1,094.1 958.5
Buildings and improvements    
Property, Plant and Equipment [Line Items]    
Total property and equipment, gross 892.5 876.1
Furniture and equipment    
Property, Plant and Equipment [Line Items]    
Total property and equipment, gross 407.3 346.7
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Total property and equipment, gross 363.5 234.6
Computers and software    
Property, Plant and Equipment [Line Items]    
Total property and equipment, gross 293.7 258.6
Land    
Property, Plant and Equipment [Line Items]    
Total property and equipment, gross $ 33.1 $ 33.1
XML 96 R70.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property and Equipment - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Property, Plant and Equipment [Abstract]      
Depreciation expense $ 125.6 $ 109.5 $ 106.9
XML 97 R71.htm IDEA: XBRL DOCUMENT v3.22.0.1
Intangible Assets and Goodwill (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Indefinite-Lived Intangible Assets [Line Items]      
Other indefinite-lived intangible assets $ 400.0 $ 400.0  
Goodwill $ 1,002.2 $ 1,002.2  
Semma Therapeutics, Inc.      
Indefinite-Lived Intangible Assets [Line Items]      
Other indefinite-lived intangible assets     $ 387.0
Goodwill     554.6
Exonics Therapeutics      
Indefinite-Lived Intangible Assets [Line Items]      
Other indefinite-lived intangible assets     13.0
Goodwill     $ 397.1
XML 98 R72.htm IDEA: XBRL DOCUMENT v3.22.0.1
Additional Balance Sheet Detail - Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Tax related prepaid and receivables $ 358.6 $ 228.6
Other 187.2 79.7
Prepaid expenses and other current assets $ 545.8 $ 308.3
XML 99 R73.htm IDEA: XBRL DOCUMENT v3.22.0.1
Additional Balance Sheet Detail - Accrued Expenses and Other Current Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Accrued expenses    
Product revenue accruals $ 847.4 $ 781.9
Payroll and benefits 191.3 169.4
Research, development and commercial contract costs 171.6 136.7
Royalty payable 200.4 165.4
Tax related accruals 211.3 104.2
Other 56.6 47.4
Total 1,678.6 1,405.0
Other current liabilities    
Contract liabilities 171.7 191.5
Finance lease liabilities 46.9 42.4
Fair value of cash flow hedges 5.6 59.2
Other 44.2 24.3
Total $ 268.4 $ 317.4
XML 100 R74.htm IDEA: XBRL DOCUMENT v3.22.0.1
Additional Balance Sheet Detail - Additional Cash Flow (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Restricted Cash and Cash Equivalents Items [Line Items]        
Cash and cash equivalents $ 6,795.0 $ 5,988.2 $ 3,109.3 $ 2,650.1
Cash, cash equivalents and restricted cash per consolidated statement of cash flows 6,800.1 5,988.9 3,120.7 2,658.3
Prepaid expenses and other current assets        
Restricted Cash and Cash Equivalents Items [Line Items]        
Restricted cash and cash equivalents 5.1 0.7 8.0 4.9
Other assets        
Restricted Cash and Cash Equivalents Items [Line Items]        
Restricted cash and cash equivalents $ 0.0 $ 0.0 $ 3.4 $ 3.3
XML 101 R75.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases - Additional Information (Details)
ft² in Thousands
 12 Months Ended
Dec. 31, 2019
ft²
renewal_option
Dec. 31, 2015
ft²
term
Dec. 31, 2011
ft²
lease
building
Corporate Headquarters      
Lessee, Lease, Description [Line Items]      
Number of leases | lease     2
Area of real estate property (in square feet)     1,100
Lease agreements number of buildings | building     2
Option to extend lease term     15 years
Optional term of lease agreement (in years)     10 years
San Diego Lease      
Lessee, Lease, Description [Line Items]      
Area of real estate property (in square feet)   170  
Length of lease   16 years  
Amount of optional renewal terms | term   2  
Optional renewal term length   5 years  
Innovation Square Lease      
Lessee, Lease, Description [Line Items]      
Area of real estate property (in square feet) 269    
Optional term of lease agreement (in years) 10 years    
Lease agreement initial term 15 years    
Number of optional renewal terms | renewal_option 2    
XML 102 R76.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases - Components of Lease Expense (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Leases [Abstract]      
Operating lease cost $ 33.9 $ 23.1 $ 12.0
Finance lease cost      
Amortization of leased assets 51.9 51.2 49.8
Interest on lease liabilities 47.4 50.2 52.8
Variable lease cost 33.6 30.8 28.0
Sublease income (0.4) (4.0) (6.4)
Net lease cost $ 166.4 $ 151.3 $ 136.2
XML 103 R77.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases - Balance Sheet Classification of Lease Assets and Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Finance leases    
Property and equipment, net $ 400.1 $ 431.2
Total finance lease assets 400.1 431.2
Other current liabilities 46.9 42.5
Long-term finance lease liabilities 509.8 539.0
Present value of lease liabilities 556.7 581.5
Operating leases    
Total operating lease assets 330.3 325.6
Other current liabilities 33.3 10.5
Long-term operating lease liabilities 377.4 350.5
Present value of lease liabilities $ 410.7 $ 361.0
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Property and equipment, net Property and equipment, net
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Other current liabilities Other current liabilities
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Other current liabilities Other current liabilities
XML 104 R78.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases - Maturities of Operating and Financing Lease Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Finance Leases    
2022 $ 87.9  
2023 93.2  
2024 97.6  
2025 95.9  
2026 94.2  
Thereafter 327.4  
Total lease payments 796.2  
Less: tenant allowance 0.0  
Less: amount representing interest (239.5)  
Present value of lease liabilities 556.7 $ 581.5
Operating Leases    
2022 41.9  
2023 42.0  
2024 38.6  
2025 35.7  
2026 33.7  
Thereafter 290.3  
Total lease payments 482.2  
Less: tenant allowance (6.5)  
Less: amount representing interest (65.0)  
Present value of lease liabilities 410.7 $ 361.0
Total    
2022 129.8  
2023 135.2  
2024 136.2  
2025 131.6  
2026 127.9  
Thereafter 617.7  
Total lease payments 1,278.4  
Less: tenant allowance (6.5)  
Less: amount representing interest (304.5)  
Present value of lease liabilities $ 967.4  
XML 105 R79.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases - Weighted-Average Remaining Lease Terms and Discount Rates (Details)
Dec. 31, 2021
Dec. 31, 2020
Weighted-average remaining lease term (in years)    
Finance leases 10 years 8 months 23 days 11 years 6 months 29 days
Operating leases 12 years 9 months 21 days 14 years 1 month 6 days
Weighted-average discount rate    
Finance leases 8.11% 8.36%
Operating leases 2.19% 2.28%
XML 106 R80.htm IDEA: XBRL DOCUMENT v3.22.0.1
Leases - Supplemental Cash Flow Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash paid for amounts included in the measurement of lease liabilities      
Operating cash flows from operating leases $ 21.5 $ 16.3 $ 10.7
Operating cash flows from finance leases 46.2 48.9 50.5
Financing cash flows from finance leases 47.0 42.3 39.2
Right-of-use assets obtained in exchange for lease obligations      
Operating leases 36.3 293.6 34.6
Finance leases $ 0.0 $ 33.1 $ 0.0
XML 107 R81.htm IDEA: XBRL DOCUMENT v3.22.0.1
Common Stock, Preferred Stock and Equity Plans - Common Stock and Preferred Stock (Details)
 12 Months Ended
Dec. 31, 2021
vote
shares
Dec. 31, 2020
shares
Equity [Abstract]    
Common stock, shares authorized (in shares) 500,000,000 500,000,000
Common stock, number of votes per share | vote 1  
Preferred stock, shares authorized (in shares) 1,000,000 1,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
XML 108 R82.htm IDEA: XBRL DOCUMENT v3.22.0.1
Common Stock, Preferred Stock and Equity Plans - Share Repurchase Program (Details) - USD ($)
shares in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Jun. 30, 2021
Nov. 30, 2020
Jul. 31, 2019
Dec. 31, 2018
Equity, Class of Treasury Stock [Line Items]              
Repurchases of common stock $ 1,425,400,000 $ 539,100,000 $ 186,000,000.0        
Share Repurchase Program 2018              
Equity, Class of Treasury Stock [Line Items]              
Number of shares authorized to be repurchased             $ 500,000,000
Repurchases of common stock (in shares)     0.8        
Repurchases of common stock     $ 150,000,000        
Share Repurchase Program 2019              
Equity, Class of Treasury Stock [Line Items]              
Number of shares authorized to be repurchased           $ 500,000,000  
Repurchases of common stock (in shares)   2.1 0.2        
Repurchases of common stock   $ 464,000,000 $ 36,000,000        
Share Repurchase Program 2020              
Equity, Class of Treasury Stock [Line Items]              
Number of shares authorized to be repurchased         $ 500,000,000    
Repurchases of common stock (in shares) 2.0 0.3          
Repurchases of common stock $ 424,900,000 $ 75,100,000          
Share Repurchase Program 2021              
Equity, Class of Treasury Stock [Line Items]              
Number of shares authorized to be repurchased       $ 1,500,000,000      
Repurchases of common stock (in shares) 5.3            
Repurchases of common stock $ 1,000,000,000            
Number of shares remaining for repurchases $ 499,700,000            
XML 109 R83.htm IDEA: XBRL DOCUMENT v3.22.0.1
Common Stock, Preferred Stock and Equity Plans - Stock and Option Plans (Details) - shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Awards outstanding (in shares) 7,598,000  
Additional awards authorized for grant (in shares) 9,558,000  
2013 Stock and Option Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Awards outstanding (in shares) 7,306,000  
Additional awards authorized for grant (in shares) 9,558,000  
Additional shares authorized (in shares)   5,000,000
2006 Stock and Option Plan    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Awards outstanding (in shares) 292,000  
Additional awards authorized for grant (in shares) 0  
Maximum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expiration period 10 years  
XML 110 R84.htm IDEA: XBRL DOCUMENT v3.22.0.1
Common Stock, Preferred Stock and Equity Plans - Outstanding and Vested Stock Options (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Stock Options      
Outstanding at beginning of period (in shares) 4,238,000    
Granted (in shares) 27,302 22,636 1,520,743
Exercised (in shares) (518,000)    
Forfeited (in shares) (136,000)    
Expired (in shares) 0    
Outstanding at end of period (in shares) 3,611,000 4,238,000  
Stock options exercisable at end of period (in shares) 3,149,000    
Weighted-average Exercise Price      
Outstanding at beginning of period ( in usd per share) $ 140.47    
Granted ( in usd per share) 217.20    
Exercised ( in usd per share) 125.78    
Forfeited ( in usd per share) 177.28    
Expired ( in usd per share) 0    
Outstanding at end of period ( in usd per share) 141.76 $ 140.47  
Weighted average exercise price exercisable at the end of the period ( in usd per share) $ 136.13    
Weighted-average Remaining Contractual Life      
Outstanding (in years) 5 years 5 months 1 day    
Exercisable (in years) 5 years 2 months 8 days    
Aggregate Intrinsic Value      
Outstanding $ 288.6    
Exercisable 269.6    
Total intrinsic value of stock options exercised 43.0 $ 255.0 $ 325.9
Total cash received from employees as a result of employee stock option exercises $ 64.2 $ 228.2 $ 317.8
Weighted Average      
Aggregate Intrinsic Value      
Market share price ( in usd per share) $ 221.27    
XML 111 R85.htm IDEA: XBRL DOCUMENT v3.22.0.1
Common Stock, Preferred Stock and Equity Plans - Stock Options Outstanding and Exercisable (Details)
shares in Thousands
 12 Months Ended
Dec. 31, 2021
$ / shares
shares
Stock options outstanding and exercisable  
Options outstanding (in shares) | shares 3,611
Options outstanding, weighted-average remaining contractual life 5 years 5 months 1 day
Options outstanding, weighted-average exercise price ( in usd per share) $ 141.76
Options exercisable (in shares) | shares 3,149
Options exercisable, weighted-average exercise price ( in usd per share) $ 136.13
$36.28–$100.00  
Stock options outstanding and exercisable  
Exercise price, low end of range ( in usd per share) 36.28
Exercise price, high end of range ( in usd per share) $ 100.00
Options outstanding (in shares) | shares 1,085
Options outstanding, weighted-average remaining contractual life 3 years 8 months 12 days
Options outstanding, weighted-average exercise price ( in usd per share) $ 82.14
Options exercisable (in shares) | shares 1,085
Options exercisable, weighted-average exercise price ( in usd per share) $ 82.14
$100.01–$150.00  
Stock options outstanding and exercisable  
Exercise price, low end of range ( in usd per share) 100.01
Exercise price, high end of range ( in usd per share) $ 150.00
Options outstanding (in shares) | shares 362
Options outstanding, weighted-average remaining contractual life 3 years 6 months 21 days
Options outstanding, weighted-average exercise price ( in usd per share) $ 123.15
Options exercisable (in shares) | shares 362
Options exercisable, weighted-average exercise price ( in usd per share) $ 123.15
$150.01–$200.00  
Stock options outstanding and exercisable  
Exercise price, low end of range ( in usd per share) 150.01
Exercise price, high end of range ( in usd per share) $ 200.00
Options outstanding (in shares) | shares 2,114
Options outstanding, weighted-average remaining contractual life 6 years 6 months 10 days
Options outstanding, weighted-average exercise price ( in usd per share) $ 173.03
Options exercisable (in shares) | shares 1,652
Options exercisable, weighted-average exercise price ( in usd per share) $ 171.04
$200.01–$286.27  
Stock options outstanding and exercisable  
Exercise price, low end of range ( in usd per share) 200.01
Exercise price, high end of range ( in usd per share) $ 286.27
Options outstanding (in shares) | shares 50
Options outstanding, weighted-average remaining contractual life 8 years 11 months 1 day
Options outstanding, weighted-average exercise price ( in usd per share) $ 248.51
Options exercisable (in shares) | shares 50
Options exercisable, weighted-average exercise price ( in usd per share) $ 248.51
XML 112 R86.htm IDEA: XBRL DOCUMENT v3.22.0.1
Common Stock, Preferred Stock and Equity Plans - Restricted Stock and Restricted Stock Units (Details) - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Restricted Stock Units (excluding PSUs)      
Number of Shares      
Beginning of the period (in shares) 2,722,000    
Granted (in shares) 1,927,000    
Vested (in shares) (1,331,000)    
Cancelled (in shares) (409,000)    
End of the period (in shares) 2,909,000 2,722,000  
Weighted-average 
Grant-date Fair Value      
Beginning of the period ( in usd per share) $ 206.99    
Granted ( in usd per share) 208.48    
Vested ( in usd per share) 193.29    
Cancelled ( in usd per share) 214.68    
End of the period ( in usd per share) $ 213.17 $ 206.99  
Restricted stock vested in period, total fair value $ 281.1 $ 370.3 $ 178.2
Restricted Stock      
Number of Shares      
Vested (in shares) 0    
Weighted-average 
Grant-date Fair Value      
Restricted stock vested in period, total fair value   $ 21.4 $ 70.7
XML 113 R87.htm IDEA: XBRL DOCUMENT v3.22.0.1
Common Stock, Preferred Stock and Equity Plans - Performance-based RSUs (PSUs) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Performance-based RSUs      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Potential awards, percent of target shares, minimum 0.00%    
Potential awards, percent of target shares, maximum 200.00%    
Number of Units      
Beginning of the period (in shares) 656    
Granted (in shares) 954    
Vested (in shares) (431)    
Cancelled (in shares) (101)    
End of the period (in shares) 1,078 656  
Weighted-average 
Grant-date Fair Value      
Beginning of the period ( in usd per share) $ 202.06    
Granted (in usd per share) 212.44    
Vested ( in usd per share) 183.94    
Cancelled ( in usd per share) 214.72    
End of the period ( in usd per share) $ 215.85 $ 202.06  
Restricted stock vested in period, total fair value $ 92.2 $ 138.5 $ 73.3
Financial performance shares      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 3 years    
Tranche one | Performance-based RSUs      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Percent of awards in tranche 50.00%    
Performance period 1 year    
Vesting period 3 years    
Tranche one | Financial performance shares      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting percentage 33.30%    
Tranche two | Performance-based RSUs      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Percent of awards in tranche 50.00%    
Performance period 3 years    
Vesting period 3 years    
Tranche two | Financial performance shares      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting percentage 33.30%    
Tranche three | Financial performance shares      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting percentage 33.30%    
XML 114 R88.htm IDEA: XBRL DOCUMENT v3.22.0.1
Common Stock, Preferred Stock and Equity Plans - Employee Stock Purchase Plan (Details) - ESPP share issuances
 12 Months Ended
Dec. 31, 2021
period
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Offering period (in months) 12 months
Number of purchase periods | period 2
Duration of purchase period 6 months
Eligible employee purchase price percentage of fair value 85.00%
Number of shares authorized (in shares) 1,800,000
Number of shares (in shares) 219,000,000
Average price paid per share ( in usd per share) | $ / shares $ 171.57
XML 115 R89.htm IDEA: XBRL DOCUMENT v3.22.0.1
Common Stock, Preferred Stock and Equity Plans - Employee Benefits (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Equity [Abstract]      
Maximum percentage of annual compensation contributed by the participant (percent) 60.00%    
Defined contribution plan, cost $ 21.8 $ 19.2 $ 15.8
XML 116 R90.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-based Compensation Expense (Details)
 12 Months Ended
Dec. 31, 2021
USD ($)
installment
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Dec. 31, 2019
USD ($)
$ / shares
shares
Stock-based compensation expense:      
Stock-based compensation expense related to inventories $ 441,400,000 $ 429,500,000 $ 360,500,000
Income tax effect (82,900,000) (147,000,000.0) (124,200,000)
Total stock-based compensation included in costs and expenses, net of tax 358,500,000 282,500,000 236,300,000
Stock-based compensation expense related to inventories (4,100,000) $ (3,600,000) $ (1,700,000)
Share-based Payment Arrangement, Additional Disclosure [Abstract]      
Unrecognized Expense $ 455,000,000.0    
Weighted-average assumptions for options and ESPP subscriptions granted      
Stock options granted (in shares) | shares 27,302 22,636 1,520,743
Stock Options      
Weighted-average assumptions for options and ESPP subscriptions granted      
Expected annual dividends $ 0.00    
Employee stock purchase plan      
Weighted-average assumptions for options and ESPP subscriptions granted      
Expected stock price volatility (percent) 34.06% 37.70% 33.43%
Risk-free interest rate (percent) 0.05% 0.11% 2.08%
Expected term of options (in years) 8 months 8 days 8 months 15 days 8 months 26 days
Expected annual dividends $ 0 $ 0 $ 0
Granted (in usd per share) | $ / shares $ 51.71 $ 65.88 $ 47.79
Restricted stock units (including PSUs)      
Stock-based compensation expense:      
Stock-based compensation expense $ 384,300,000 $ 360,400,000 $ 254,300,000
Share-based Payment Arrangement, Additional Disclosure [Abstract]      
Unrecognized Expense $ 423,300,000    
Weighted-average Recognition Period 1 year 10 months 28 days    
Stock options      
Stock-based compensation expense:      
Stock-based compensation expense $ 36,800,000 $ 59,700,000 $ 96,700,000
Share-based Payment Arrangement, Additional Disclosure [Abstract]      
Unrecognized Expense $ 19,100,000    
Weighted-average Recognition Period 1 year 1 month 2 days    
Weighted-average grant-date fair value, granted ( in usd per share) | $ / shares $ 65.94 $ 88.37 $ 61.32
Weighted-average assumptions for options and ESPP subscriptions granted      
Expected stock price volatility (percent) 35.03% 35.87% 36.99%
Risk-free interest rate (percent) 0.86% 0.43% 2.32%
Expected term of options (in years) 4 years 6 months 4 years 8 months 1 day 4 years 3 months 7 days
Expected annual dividends $ 0 $ 0 $ 0
ESPP share issuances      
Stock-based compensation expense:      
Stock-based compensation expense 24,400,000 13,000,000.0 11,200,000
Share-based Payment Arrangement, Additional Disclosure [Abstract]      
Unrecognized Expense $ 12,600,000    
Weighted-average Recognition Period 6 months 14 days    
Performance-based RSUs      
Weighted-average assumptions for options and ESPP subscriptions granted      
Potential awards, percent of target shares, minimum 0.00%    
Potential awards, percent of target shares, maximum 200.00%    
Granted (in usd per share) | $ / shares $ 212.44    
Performance-based RSUs | Tranche one      
Weighted-average assumptions for options and ESPP subscriptions granted      
Vesting period 3 years    
Performance-based RSUs | Tranche two      
Weighted-average assumptions for options and ESPP subscriptions granted      
Vesting period 3 years    
Financial performance shares      
Weighted-average assumptions for options and ESPP subscriptions granted      
Number of installments | installment 3    
Vesting period 3 years    
Financial performance shares | Tranche one      
Weighted-average assumptions for options and ESPP subscriptions granted      
Vesting percentage 33.30%    
Financial performance shares | Tranche two      
Weighted-average assumptions for options and ESPP subscriptions granted      
Vesting percentage 33.30%    
Financial performance shares | Tranche three      
Weighted-average assumptions for options and ESPP subscriptions granted      
Vesting percentage 33.30%    
Non-financial performance shares      
Weighted-average assumptions for options and ESPP subscriptions granted      
Vesting period 3 years    
Cost of sales      
Stock-based compensation expense:      
Stock-based compensation expense related to inventories $ 6,300,000 5,600,000 5,600,000
Research and development expenses      
Stock-based compensation expense:      
Stock-based compensation expense related to inventories 268,300,000 262,700,000 224,600,000
Selling, general and administrative expenses      
Stock-based compensation expense:      
Stock-based compensation expense related to inventories $ 166,800,000 $ 161,200,000 $ 130,300,000
XML 117 R91.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Components of Income and Provision for (Benefit from) Income Taxes (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Components of income (loss) before provision for (benefit from) income taxes      
United States $ 2,030.7 $ 2,885.4 $ 1,263.4
Foreign 699.7 231.5 131.5
Income before provision for income taxes 2,730.4 3,116.9 1,394.9
Current taxes:      
Federal 374.9 71.4 0.0
Foreign 141.5 37.6 37.2
State 26.5 18.9 13.5
Total current taxes 542.9 127.9 50.7
Deferred taxes:      
Federal (36.9) 510.2 184.3
Foreign (98.4) (239.6) (24.8)
State (19.3) 6.7 7.9
Total deferred taxes (154.6) 277.3 167.4
Provision for income taxes $ 388.3 $ 405.2 $ 218.1
XML 118 R92.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Effective Income Tax Reconciliation (Details)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Tax Disclosure [Abstract]      
Federal statutory tax rate 21.00% 21.00% 21.00%
State taxes, net of federal benefit 0.80% 0.60% 0.60%
Foreign income tax rate differential (0.30%) 0.20% 0.40%
Tax credits (6.40%) (1.80%) (4.30%)
Tax rate change (3.50%) (1.20%) 0.00%
Stock compensation (benefit), shortfalls and cancellations 0.00% (2.30%) (4.00%)
Long-term intercompany receivable write-off 0.00% (1.70%) 0.00%
Uncertain tax positions 2.00% 1.30% 1.00%
Inter-entity transfer of intellectual property rights 0.00% (6.70%) 0.00%
U.S. tax on foreign earnings, net of credits 0.70% 2.70% 0.00%
Other (0.10%) 0.90% 0.90%
Effective tax rate 14.20% 13.00% 15.60%
XML 119 R93.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Narrative (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Tax Carryforwards [Line Items]      
Effective tax rate 14.20% 13.00% 15.60%
Deferred tax benefit $ 44.1    
Deferred tax benefit   $ 209.0  
Valuation allowance 220.4 $ 213.8  
Domestic Tax Authority      
Tax Carryforwards [Line Items]      
Operating loss carryforwards 29.8    
Tax credit carryforwards 4.1    
Operating loss carryforwards, subject to expiration 26.0    
State and Local Jurisdiction      
Tax Carryforwards [Line Items]      
Operating loss carryforwards 616.3    
Tax credit carryforwards 237.2    
Foreign Tax Authority      
Tax Carryforwards [Line Items]      
Deferred tax benefit 94.8    
Operating loss carryforwards 292.5    
Tax credit carryforwards 22.2    
Operating loss carryforwards, subject to expiration $ 44.3    
XML 120 R94.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Deferred tax assets:    
Net operating loss $ 106.6 $ 140.6
Tax credit carryforwards 202.4 406.1
Intangible assets 802.8 507.5
Stock-based compensation 94.6 89.2
Accrued expenses 48.6 47.3
Finance lease liabilities 103.4 118.7
Operating lease assets 81.1 65.0
Other 41.7 22.1
Gross deferred tax assets 1,481.2 1,396.5
Valuation allowance (220.4) (213.8)
Total deferred tax assets 1,260.8 1,182.7
Deferred tax liabilities:    
Property and equipment (118.2) (117.0)
Acquired intangibles (87.0) (87.0)
Operating lease liabilities (64.8) (63.3)
Other (56.3) (32.6)
Total deferred tax liabilities (326.3) (299.9)
Net deferred tax assets $ 934.5 $ 882.8
XML 121 R95.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Balance at beginning of the period $ 86.6 $ 33.9 $ 19.5
Increases related to current period tax positions 42.0 26.7 14.5
Increases related to prior period tax positions 19.9 26.7 0.6
Decreases related to prior period tax positions 0.0 0.0 (0.2)
Settlement with tax authorities 0.0 0.0 (0.5)
Statute of limitations expiration (1.3) (0.7) 0.0
Balance at end of period 147.2 86.6 33.9
Unrecognized tax benefits 147.2 86.6 33.9
Net unrecognized tax benefits which would affect the tax rate if recognized 129.5 $ 75.8 $ 33.9
Deferred Tax Assets      
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Balance at end of period 14.4    
Unrecognized tax benefits 14.4    
Accounts Payable and Accrued Liabilities      
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Balance at end of period 132.8    
Unrecognized tax benefits $ 132.8    
XML 122 R96.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies - Revolving Credit Facility (Details)
 1 Months Ended 12 Months Ended
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Dec. 31, 2021
USD ($)
credit_agreement
Line of Credit Facility [Line Items]      
Number of credit agreements | credit_agreement     2
Indemnification claims     $ 0
Revolving Credit Facility      
Line of Credit Facility [Line Items]      
Line of credit facility, maximum borrowing capacity $ 2,000,000,000 $ 500,000,000  
Line of credit facility, additional borrowing capacity $ 500,000,000    
Debt covenant, consolidated leverage ratio 3.50    
Debt covenant, increase in consolidated leverage ratio 4.00    
Debt covenant, minimum consolidated EBITDA 2.50    
Letter of Credit      
Line of Credit Facility [Line Items]      
Line of credit facility, maximum borrowing capacity   $ 50,000,000  
Minimum | Base Rate | Revolving Credit Facility      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (percent) 0.50% 0.125%  
Minimum | Eurodollar | Revolving Credit Facility      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (percent) 1.50% 1.125%  
Maximum | Base Rate | Revolving Credit Facility      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (percent) 0.875% 0.50%  
Maximum | Eurodollar | Revolving Credit Facility      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (percent) 1.875% 1.50%  
XML 123 R97.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies - Contingencies (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]    
Contingent liabilities $ 0 $ 0
XML 124 R98.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Information - Revenues by Product (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2021
USD ($)
segment
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Revenue from External Customer [Line Items]      
Number of operating segments | segment 1    
Total product revenues, net $ 7,574.4 $ 6,205.7 $ 4,162.8
TRIKAFTA/KAFTRIO      
Revenue from External Customer [Line Items]      
Total product revenues, net 5,697.2 3,863.8 420.1
SYMDEKO/SYMKEVI      
Revenue from External Customer [Line Items]      
Total product revenues, net 420.4 628.6 1,417.7
ORKAMBI      
Revenue from External Customer [Line Items]      
Total product revenues, net 771.6 907.5 1,331.9
KALYDECO      
Revenue from External Customer [Line Items]      
Total product revenues, net 684.2 802.9 991.0
Product revenues, net      
Revenue from External Customer [Line Items]      
Total product revenues, net $ 7,573.4 $ 6,202.8 $ 4,160.7
XML 125 R99.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Information - Revenue by Geographic Location (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]      
Total product revenues, net $ 7,574.4 $ 6,205.7 $ 4,162.8
Product revenues, net      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Total product revenues, net 7,573.4 6,202.8 4,160.7
United States | Product revenues, net      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Total product revenues, net 5,287.3 4,826.4 3,060.3
Europe | Product revenues, net      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Total product revenues, net 1,972.9 1,126.5 885.9
Other | Product revenues, net      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Total product revenues, net 313.2 249.9 214.5
Total product revenues outside of the United States | Product revenues, net      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Total product revenues, net $ 2,286.1 $ 1,376.4 $ 1,100.4
XML 126 R100.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Information - Significant Customers (Details)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Product Concentration Risk | Percent of Total Gross Product Revenues | McKesson Corporation      
Concentration Risk [Line Items]      
Concentration risk percentage 22.00% 20.00% 17.00%
Product Concentration Risk | Percent of Total Gross Product Revenues | Accredo/Curascript      
Concentration Risk [Line Items]      
Concentration risk percentage 12.00% 15.00% 14.00%
Product Concentration Risk | Percent of Total Gross Product Revenues | Walgreen Co.      
Concentration Risk [Line Items]      
Concentration risk percentage 10.00% 14.00% 15.00%
Product Concentration Risk | Percent of Total Gross Product Revenues | Lloyds Pharmacy      
Concentration Risk [Line Items]      
Concentration risk percentage 10.00% 10.00% 10.00%
Credit Concentration Risk | Percent of Accounts Receivable | McKesson Corporation      
Concentration Risk [Line Items]      
Concentration risk percentage 21.00% 14.00%  
Credit Concentration Risk | Percent of Accounts Receivable | Accredo/Curascript      
Concentration Risk [Line Items]      
Concentration risk percentage 10.00% 10.00%  
Credit Concentration Risk | Percent of Accounts Receivable | Walgreen Co.      
Concentration Risk [Line Items]      
Concentration risk percentage 10.00% 10.00%  
Credit Concentration Risk | Percent of Accounts Receivable | Lloyds Pharmacy      
Concentration Risk [Line Items]      
Concentration risk percentage 15.00% 19.00%  
XML 127 R101.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Information - Property and Equipment, Net by Location (Details) - USD ($)
$ in Millions
Dec. 31, 2021
Dec. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total long-lived assets $ 1,424.4 $ 1,284.1
United States    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total long-lived assets 1,348.1 1,207.7
United Kingdom    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total long-lived assets 60.9 61.5
Other    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total long-lived assets 15.4 14.9
Total long-lived assets outside of the United States    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total long-lived assets $ 76.3 $ 76.4
XML 128 R9999.htm IDEA: XBRL DOCUMENT v3.22.0.1
Label Element Value
Accounting Standards Update [Extensible Enumeration] us-gaap_AccountingStandardsUpdateExtensibleList Accounting Standards Update 2016-02 [Member]
XML 129 vrtx-20211231_htm.xml IDEA: XBRL DOCUMENT 0000875320 2021-01-01 2021-12-31 0000875320 2021-06-30 0000875320 2022-01-31 0000875320 us-gaap:ProductMember 2021-01-01 2021-12-31 0000875320 us-gaap:ProductMember 2020-01-01 2020-12-31 0000875320 us-gaap:ProductMember 2019-01-01 2019-12-31 0000875320 vrtx:CollaborativeandRoyaltyMember 2021-01-01 2021-12-31 0000875320 vrtx:CollaborativeandRoyaltyMember 2020-01-01 2020-12-31 0000875320 vrtx:CollaborativeandRoyaltyMember 2019-01-01 2019-12-31 0000875320 2020-01-01 2020-12-31 0000875320 2019-01-01 2019-12-31 0000875320 2021-12-31 0000875320 2020-12-31 0000875320 us-gaap:CommonStockMember 2018-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000875320 us-gaap:RetainedEarningsMember 2018-12-31 0000875320 2018-12-31 0000875320 2018-01-01 2018-12-31 0000875320 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2018-12-31 0000875320 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0000875320 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0000875320 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0000875320 us-gaap:CommonStockMember 2019-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000875320 us-gaap:RetainedEarningsMember 2019-12-31 0000875320 2019-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0000875320 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000875320 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000875320 us-gaap:CommonStockMember 2020-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000875320 us-gaap:RetainedEarningsMember 2020-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000875320 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000875320 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000875320 us-gaap:CommonStockMember 2021-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000875320 us-gaap:RetainedEarningsMember 2021-12-31 0000875320 vrtx:ORKAMBIMember 2019-10-01 2019-12-31 0000875320 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2021-01-01 2021-12-31 0000875320 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2021-01-01 2021-12-31 0000875320 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-12-31 0000875320 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-12-31 0000875320 srt:MinimumMember us-gaap:TechnologyEquipmentMember 2021-01-01 2021-12-31 0000875320 srt:MaximumMember us-gaap:TechnologyEquipmentMember 2021-01-01 2021-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2021-01-01 2021-12-31 0000875320 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000875320 vrtx:CRISPRTherapeuticsAGMember 2019-01-01 2019-12-31 0000875320 vrtx:CRSIPRARJDCAMember 2021-04-01 2021-06-30 0000875320 vrtx:CRSIPRARJDCAMember 2021-07-01 0000875320 vrtx:CRSIPRARJDCAMember vrtx:CRISPRMember 2021-07-01 0000875320 vrtx:CRISPRTherapeuticsAGMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-01-01 2021-12-31 0000875320 vrtx:CRISPRTherapeuticsAGMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2020-01-01 2020-12-31 0000875320 vrtx:CRISPRTherapeuticsAGMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2019-01-01 2019-12-31 0000875320 vrtx:CRISPRTherapeuticsAGMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-01-01 2021-12-31 0000875320 vrtx:CRISPRTherapeuticsAGMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2020-01-01 2020-12-31 0000875320 vrtx:CRISPRTherapeuticsAGMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2019-01-01 2019-12-31 0000875320 vrtx:CRISPRDMDDM1Member 2019-01-01 2019-12-31 0000875320 vrtx:CRISPRDMDDM1Member 2021-01-01 2021-12-31 0000875320 vrtx:CRISPRDMDDM1Member 2020-01-01 2020-12-31 0000875320 vrtx:KymeraTherapeuticsMember 2019-01-01 2019-12-31 0000875320 vrtx:KymeraTherapeuticsMember 2020-01-01 2020-12-31 0000875320 vrtx:ModernaAgreementMember 2020-01-01 2020-12-31 0000875320 vrtx:ApolLo1BioLLCMember 2021-01-01 2021-12-31 0000875320 vrtx:MammothBiosciencesIncMember 2021-01-01 2021-12-31 0000875320 vrtx:ArborBiotechnologiesIncMember 2021-01-01 2021-12-31 0000875320 vrtx:SkyhawkTherapeuticsIncMember 2020-01-01 2020-12-31 0000875320 vrtx:MolecularTemplatesIncMember 2019-01-01 2019-12-31 0000875320 vrtx:MerckKGaAMember 2017-01-01 2017-01-31 0000875320 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000875320 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000875320 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0000875320 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0000875320 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000875320 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2020-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2020-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2020-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2020-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0000875320 us-gaap:FairValueInputsLevel3Member 2021-12-31 0000875320 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2021-12-31 0000875320 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2021-12-31 0000875320 us-gaap:CashAndCashEquivalentsMember vrtx:CashAndMoneyMarketFundsMember 2021-12-31 0000875320 us-gaap:CashAndCashEquivalentsMember vrtx:CashAndMoneyMarketFundsMember 2020-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:USTreasurySecuritiesMember 2020-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2021-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2020-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2021-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2020-12-31 0000875320 vrtx:MarketableSecuritiesMember 2021-12-31 0000875320 vrtx:MarketableSecuritiesMember 2020-12-31 0000875320 us-gaap:CashAndCashEquivalentsMember 2021-12-31 0000875320 us-gaap:CashAndCashEquivalentsMember 2020-12-31 0000875320 vrtx:PubliclyTradedCompaniesSaleMember 2020-01-01 2020-12-31 0000875320 vrtx:PubliclyTradedCompaniesSaleMember 2019-01-01 2019-12-31 0000875320 vrtx:PubliclyTradedCompaniesSaleMember 2020-12-31 0000875320 vrtx:PubliclyTradedCompaniesSaleMember 2019-12-31 0000875320 vrtx:PubliclyTradedCompaniesSaleMember 2021-01-01 2021-12-31 0000875320 us-gaap:OtherAssetsMember 2021-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-01-01 2021-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0000875320 srt:MinimumMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2021-01-01 2021-12-31 0000875320 srt:MaximumMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2021-01-01 2021-12-31 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000875320 currency:CAD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 currency:CAD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000875320 currency:CHF us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 currency:CHF us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:NondesignatedMember 2021-12-31 0000875320 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-12-31 0000875320 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-12-31 0000875320 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000875320 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0000875320 us-gaap:BuildingMember 2021-12-31 0000875320 us-gaap:BuildingMember 2020-12-31 0000875320 us-gaap:FurnitureAndFixturesMember 2021-12-31 0000875320 us-gaap:FurnitureAndFixturesMember 2020-12-31 0000875320 us-gaap:LeaseholdImprovementsMember 2021-12-31 0000875320 us-gaap:LeaseholdImprovementsMember 2020-12-31 0000875320 us-gaap:ComputerSoftwareIntangibleAssetMember 2021-12-31 0000875320 us-gaap:ComputerSoftwareIntangibleAssetMember 2020-12-31 0000875320 us-gaap:LandMember 2021-12-31 0000875320 us-gaap:LandMember 2020-12-31 0000875320 vrtx:SemmaTherapeuticsInc.Member 2019-12-31 0000875320 vrtx:ExonicsTherapeuticsMember 2019-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2021-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2020-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2019-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2018-12-31 0000875320 us-gaap:OtherAssetsMember 2020-12-31 0000875320 us-gaap:OtherAssetsMember 2019-12-31 0000875320 us-gaap:OtherAssetsMember 2018-12-31 0000875320 vrtx:FanPierLeasesMember 2011-01-01 2011-12-31 0000875320 vrtx:FanPierLeasesMember 2011-12-31 0000875320 vrtx:SanDiegoLeaseMember 2015-12-31 0000875320 vrtx:SanDiegoLeaseMember 2015-01-01 2015-12-31 0000875320 vrtx:InnovationSquareLeaseMember 2019-12-31 0000875320 vrtx:InnovationSquareLeaseMember 2019-01-01 2019-12-31 0000875320 vrtx:ShareRepurchaseProgram2018Member 2018-12-31 0000875320 vrtx:ShareRepurchaseProgram2018Member 2019-01-01 2019-12-31 0000875320 vrtx:ShareRepurchaseProgram2019Member 2019-07-31 0000875320 vrtx:ShareRepurchaseProgram2019Member 2020-01-01 2020-12-31 0000875320 vrtx:ShareRepurchaseProgram2019Member 2019-01-01 2019-12-31 0000875320 vrtx:ShareRepurchaseProgram2020Member 2020-11-30 0000875320 vrtx:ShareRepurchaseProgram2020Member 2021-01-01 2021-12-31 0000875320 vrtx:ShareRepurchaseProgram2020Member 2020-01-01 2020-12-31 0000875320 vrtx:ShareRepurchaseProgram2021Member 2021-06-30 0000875320 vrtx:ShareRepurchaseProgram2021Member 2021-01-01 2021-12-31 0000875320 vrtx:ShareRepurchaseProgram2021Member 2021-12-31 0000875320 vrtx:StockandOptionPlan2013Member 2021-12-31 0000875320 vrtx:StockAndOptionPlan2006Member 2021-12-31 0000875320 vrtx:StockandOptionPlan2013Member 2019-01-01 2019-12-31 0000875320 srt:MaximumMember 2021-01-01 2021-12-31 0000875320 srt:WeightedAverageMember 2021-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars3628ToDollars10000Member 2021-01-01 2021-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars3628ToDollars10000Member 2021-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars10001ToDollars15000Member 2021-01-01 2021-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars10001ToDollars15000Member 2021-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars15001ToDollars20000Member 2021-01-01 2021-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars15001ToDollars20000Member 2021-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars20001ToDollars28627Member 2021-01-01 2021-12-31 0000875320 vrtx:ExercisePriceRangeFromDollars20001ToDollars28627Member 2021-12-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0000875320 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0000875320 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0000875320 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0000875320 us-gaap:PerformanceSharesMember 2021-01-01 2021-12-31 0000875320 us-gaap:PerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-01-01 2021-12-31 0000875320 us-gaap:PerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-01-01 2021-12-31 0000875320 us-gaap:PerformanceSharesMember 2020-12-31 0000875320 us-gaap:PerformanceSharesMember 2021-12-31 0000875320 us-gaap:PerformanceSharesMember 2020-01-01 2020-12-31 0000875320 us-gaap:PerformanceSharesMember 2019-01-01 2019-12-31 0000875320 vrtx:EmployeeStockPurchasePlanMember 2021-01-01 2021-12-31 0000875320 vrtx:EmployeeStockPurchasePlanMember 2021-12-31 0000875320 vrtx:FinancialPerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-01-01 2021-12-31 0000875320 vrtx:FinancialPerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-01-01 2021-12-31 0000875320 vrtx:FinancialPerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2021-01-01 2021-12-31 0000875320 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0000875320 us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0000875320 us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0000875320 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0000875320 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0000875320 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-12-31 0000875320 vrtx:EmployeeStockPurchasePlanMember 2021-01-01 2021-12-31 0000875320 vrtx:EmployeeStockPurchasePlanMember 2020-01-01 2020-12-31 0000875320 vrtx:EmployeeStockPurchasePlanMember 2019-01-01 2019-12-31 0000875320 us-gaap:RestrictedStockMember 2021-12-31 0000875320 us-gaap:EmployeeStockOptionMember 2021-12-31 0000875320 vrtx:EmployeeStockPurchasePlanMember 2021-12-31 0000875320 us-gaap:StockOptionMember 2021-01-01 2021-12-31 0000875320 vrtx:FinancialPerformanceSharesMember 2021-01-01 2021-12-31 0000875320 vrtx:NonFinancialPerformanceSharesMember 2021-01-01 2021-12-31 0000875320 us-gaap:EmployeeStockMember 2021-01-01 2021-12-31 0000875320 us-gaap:EmployeeStockMember 2020-01-01 2020-12-31 0000875320 us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0000875320 us-gaap:ForeignCountryMember 2021-01-01 2021-12-31 0000875320 us-gaap:DomesticCountryMember 2021-12-31 0000875320 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0000875320 us-gaap:ForeignCountryMember 2021-12-31 0000875320 vrtx:DeferredTaxAssetsMember 2021-12-31 0000875320 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2021-12-31 0000875320 us-gaap:RevolvingCreditFacilityMember 2019-09-30 0000875320 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2019-09-01 2019-09-30 0000875320 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2019-09-01 2019-09-30 0000875320 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:EurodollarMember 2019-09-01 2019-09-30 0000875320 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:EurodollarMember 2019-09-01 2019-09-30 0000875320 us-gaap:LetterOfCreditMember 2019-09-30 0000875320 us-gaap:RevolvingCreditFacilityMember 2020-09-30 0000875320 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2020-09-01 2020-09-30 0000875320 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2020-09-01 2020-09-30 0000875320 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:EurodollarMember 2020-09-01 2020-09-30 0000875320 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:EurodollarMember 2020-09-01 2020-09-30 0000875320 us-gaap:RevolvingCreditFacilityMember 2020-09-01 2020-09-30 0000875320 vrtx:TRIKAFTAKAFTRIOMember 2021-01-01 2021-12-31 0000875320 vrtx:TRIKAFTAKAFTRIOMember 2020-01-01 2020-12-31 0000875320 vrtx:TRIKAFTAKAFTRIOMember 2019-01-01 2019-12-31 0000875320 vrtx:SYMDEKOSYMKEVIMember 2021-01-01 2021-12-31 0000875320 vrtx:SYMDEKOSYMKEVIMember 2020-01-01 2020-12-31 0000875320 vrtx:SYMDEKOSYMKEVIMember 2019-01-01 2019-12-31 0000875320 vrtx:ORKAMBIMember 2021-01-01 2021-12-31 0000875320 vrtx:ORKAMBIMember 2020-01-01 2020-12-31 0000875320 vrtx:ORKAMBIMember 2019-01-01 2019-12-31 0000875320 vrtx:KalydecoMember 2021-01-01 2021-12-31 0000875320 vrtx:KalydecoMember 2020-01-01 2020-12-31 0000875320 vrtx:KalydecoMember 2019-01-01 2019-12-31 0000875320 us-gaap:ProductMember country:US 2021-01-01 2021-12-31 0000875320 us-gaap:ProductMember country:US 2020-01-01 2020-12-31 0000875320 us-gaap:ProductMember country:US 2019-01-01 2019-12-31 0000875320 us-gaap:ProductMember srt:EuropeMember 2021-01-01 2021-12-31 0000875320 us-gaap:ProductMember srt:EuropeMember 2020-01-01 2020-12-31 0000875320 us-gaap:ProductMember srt:EuropeMember 2019-01-01 2019-12-31 0000875320 us-gaap:ProductMember vrtx:OtherCountriesOutsideoftheUnitedStatesandEuropeMember 2021-01-01 2021-12-31 0000875320 us-gaap:ProductMember vrtx:OtherCountriesOutsideoftheUnitedStatesandEuropeMember 2020-01-01 2020-12-31 0000875320 us-gaap:ProductMember vrtx:OtherCountriesOutsideoftheUnitedStatesandEuropeMember 2019-01-01 2019-12-31 0000875320 us-gaap:ProductMember vrtx:OutsidetheUnitedStatesMember 2021-01-01 2021-12-31 0000875320 us-gaap:ProductMember vrtx:OutsidetheUnitedStatesMember 2020-01-01 2020-12-31 0000875320 us-gaap:ProductMember vrtx:OutsidetheUnitedStatesMember 2019-01-01 2019-12-31 0000875320 vrtx:McKessonCorporationMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-12-31 0000875320 vrtx:McKessonCorporationMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-12-31 0000875320 vrtx:McKessonCorporationMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-12-31 0000875320 vrtx:McKessonCorporationMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2021-01-01 2021-12-31 0000875320 vrtx:McKessonCorporationMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2020-01-01 2020-12-31 0000875320 vrtx:AccredoCurascriptMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-12-31 0000875320 vrtx:AccredoCurascriptMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-12-31 0000875320 vrtx:AccredoCurascriptMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-12-31 0000875320 vrtx:AccredoCurascriptMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2021-01-01 2021-12-31 0000875320 vrtx:AccredoCurascriptMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2020-01-01 2020-12-31 0000875320 vrtx:WalgreenCo.Member us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-12-31 0000875320 vrtx:WalgreenCo.Member us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-12-31 0000875320 vrtx:WalgreenCo.Member us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-12-31 0000875320 vrtx:WalgreenCo.Member us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2021-01-01 2021-12-31 0000875320 vrtx:WalgreenCo.Member us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2020-01-01 2020-12-31 0000875320 vrtx:LloydsPharmacyMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-12-31 0000875320 vrtx:LloydsPharmacyMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-12-31 0000875320 vrtx:LloydsPharmacyMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-12-31 0000875320 vrtx:LloydsPharmacyMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2021-01-01 2021-12-31 0000875320 vrtx:LloydsPharmacyMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2020-01-01 2020-12-31 0000875320 country:US 2021-12-31 0000875320 country:US 2020-12-31 0000875320 country:GB 2021-12-31 0000875320 country:GB 2020-12-31 0000875320 vrtx:OtherCountriesOutsideoftheUnitedStatesandtheUnitedKingdomMember 2021-12-31 0000875320 vrtx:OtherCountriesOutsideoftheUnitedStatesandtheUnitedKingdomMember 2020-12-31 0000875320 vrtx:OutsidetheUnitedStatesMember 2021-12-31 0000875320 vrtx:OutsidetheUnitedStatesMember 2020-12-31 iso4217:USD shares iso4217:USD shares vrtx:segment pure vrtx:target vrtx:oncology_research_and_development_program vrtx:clinical-stage_program vrtx:pre-clinical_program vrtx:lease utr:sqft vrtx:building vrtx:term vrtx:renewal_option vrtx:vote vrtx:period vrtx:installment vrtx:credit_agreement VERTEX PHARMACEUTICALS INC / MA 0000875320 2021 FY false http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization P1M http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent 0.333 0.333 0.333 0.333 0.333 0.333 10-K true 2021-12-31 --12-31 false 000-19319 MA 50 Northern Avenue Boston MA 04-3039129 02210 617 341-6100 Common Stock, $0.01 Par Value Per Share VRTX NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false 51600000000 254576691 Portions of the definitive proxy statement for the 2022 Annual Meeting of Shareholders, which we expect to hold on May 18, 2022, are incorporated by reference into Part III of this Annual Report on Form 10-K. 42 Ernst & Young LLP Boston, Massachusetts 7573400000 6202800000 4160700000 1000000.0 2900000 2100000 7574400000 6205700000 4162800000 904200000 736300000 547800000 3051100000 1829500000 1754500000 840100000 770500000 658500000 -3100000 13100000 4500000 4792300000 3349400000 2965300000 2782100000 2856300000 1197500000 4900000 22200000 63700000 -61500000 -58200000 -58500000 4900000 296600000 192200000 2730400000 3116900000 1394900000 388300000 405200000 218100000 2342100000 2711700000 1176800000 9.09 10.44 4.58 9.01 10.29 4.51 257700000 259800000 256700000 259900000 263400000 260700000 2342100000 2711700000 1176800000 -800000 -200000 1000000.0 -21800000 14300000 7000000.0 83200000 -51600000 -14000000.0 2000000.0 -14700000 10300000 84400000 -66500000 -2700000 2426500000 2645200000 1174100000 6795000000 5988200000 729900000 670700000 1136800000 885400000 353100000 280800000 545800000 308300000 9560600000 8133400000 1094100000 958500000 1002200000 1002200000 400000000.0 400000000.0 934500000 882800000 330300000 325600000 110800000 49300000 13432500000 11751800000 195000000.0 155100000 1678600000 1405000000 268400000 317400000 2142000000 1877500000 509800000 539000000.0 377400000 350500000 186500000 189600000 116800000 108400000 3332500000 3065000000 0 0 0.01 0.01 1000000 1000000 0 0 0 0 0 0 0.01 0.01 500000000 500000000 254479046 254479046 259889549 259889549 2500000 2600000 6880800000 7894000000 15900000 -68500000 3200800000 858700000 10100000000 8686800000 13432500000 11751800000 255200000 2500000 7421500000 700000 -2989500000 4435200000 -40300000 -40300000 -2700000 -2700000 1176800000 1176800000 1000000.0 186000000.0 186000000.0 6000000.0 6000000.0 4800000 100000 345900000 346000000.0 362200000 362200000 259000000.0 2600000 7937600000 -2000000.0 -1853000000 6085200000 -66500000 -66500000 2711700000 2711700000 2400000 539100000 539100000 800000 200300000 200300000 4100000 262700000 262700000 433100000 433100000 259900000 2600000 7894000000 -68500000 858700000 8686800000 84400000 84400000 2342100000 2342100000 7300000 100000 1425300000 1425400000 600000 135900000 135900000 2500000 102500000 102500000 445500000 445500000 254500000 2500000 6880800000 15900000 3200800000 10100000000 2342100000 2711700000 1176800000 441400000 429500000 360500000 125600000 109500000 106900000 -154600000 277300000 167400000 17100000 311900000 197600000 -3100000 13100000 4500000 -14400000 -78700000 -16900000 274700000 223400000 225600000 92800000 132000000.0 64000000.0 91800000 297600000 -35400000 31900000 51300000 -22800000 305400000 122200000 172900000 16800000 425100000 38000000.0 2643500000 3253500000 1569300000 0 0 1154200000 528200000 431400000 537200000 499300000 372300000 475900000 0 437600000 94900000 235000000.0 259800000 75400000 77000000.0 19300000 39300000 -340900000 99400000 -1235300000 102000000.0 264900000 343200000 1425400000 539100000 186000000.0 135900000 200300000 6000000.0 47000000.0 42300000 39200000 22600000 13300000 10000000.0 5700000 -1800000 4800000 -1478000000 -505300000 126800000 -13400000 20600000 1600000 811200000 2868200000 462400000 5988900000 3120700000 2658300000 6800100000 5988900000 3120700000 56300000 54500000 55600000 476300000 191800000 24700000 Nature of Business and Accounting Policies<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) is global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases with a focus on specialty markets. We have multiple approved medicines that treat the underlying cause of cystic fibrosis (“CF”), a life-threatening genetic disease, and we have several ongoing clinical and research programs to advance and extend treatment of CF. Beyond CF, we have a pipeline of investigational therapies in other serious diseases where we are leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals. Please refer to Note Q, “Segment Information,” for enterprise-wide disclosures regarding our revenues, major customers and long-lived assets by geographic area.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when a customer obtains control of promised goods or services. We record the amount of revenue that reflects the consideration that we expect to receive in exchange for those goods or services. We apply the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) we satisfy each performance obligation. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We only apply the five-step model to contracts when it is probable that we will collect the consideration to which we are entitled in exchange for the goods or services that we transfer to the customer. Once a contract is determined to be within the scope of Accounting Standards Codification (“ASC”) 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASC 606”) at contract inception, we review the contract to determine which performance obligations we must deliver and which of these performance obligations are distinct. We recognize as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. Generally, our performance obligations are transferred to customers at a point in time, typically upon delivery. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Revenues, Net</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products principally to a limited number of specialty pharmacy and specialty distributors in the United States (“U.S.”), which account for the largest portion of our total revenues. We make international sales primarily to specialty </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">distributors and retail chains, as well as hospitals and clinics, many of which are government-owned or supported. Our customers in the U.S. subsequently resell the products to patients and health care providers. We recognize net product revenues from sales when our customers obtain control of our products, which typically occurs upon delivery to our customers. Our payment terms are approximately 30 days in the U.S. and consistent with prevailing practice in international markets. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from (a) invoice discounts for prompt payment and distribution fees, (b) government and private payor rebates, chargebacks, discounts and fees and (c) costs of co-pay assistance programs for patients, as well as other incentives for certain indirect customers. Reserves are established for the estimates of variable consideration based on the amounts earned or to be claimed on the related sales. The reserves are classified as reductions to “Accounts receivable, net” if payable to a customer or “Accrued expenses” if payable to a third-party. Where appropriate, we utilize the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in net product revenues only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary from our estimates, we adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invoice Discounts and Distribution Fees: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide invoice discounts on product sales to our customers for prompt payment and pays fees for distribution services, such as fees for certain data that customers provide to us. We estimate that, based on our experience, our customers will earn these discounts and fees, and deduct the full amount of these discounts and fees from our gross product revenues and accounts receivable at the time such revenues are recognized.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates, Chargebacks, Discounts and Fees: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contract with government agencies (our “Third-party Payors”) so that products will be eligible for purchase by, or partial or full reimbursement from, such Third-party Payors. We estimate the rebates, chargebacks, discounts and fees we will provide to Third-party Payors and deduct these estimated amounts from our gross product revenues at the time the revenues are recognized. For each product, we estimate the aggregate rebates, chargebacks and discounts that we will provide to Third-party Payors based upon (i) our contracts with these Third-party Payors, (ii) the government-mandated discounts and fees applicable to government-funded programs, (iii) information obtained from our customers and other third-party data regarding the payor mix for such product and (iv) historical experience.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Incentives: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other incentives that we offer include co-pay mitigation rebates that we provide to commercially insured patients who have coverage and who reside in states that permit co-pay mitigation programs. Based upon the terms of our co-pay mitigation programs, we estimate average co-pay mitigation amounts for each of our products in order to establish appropriate accruals.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make significant estimates and judgments that materially affect our recognition of net product revenues. We adjust our estimated rebates, chargebacks and discounts based on new information, including information regarding actual rebates, chargebacks and discounts for our products, as it becomes available. Claims by third-party payors for rebates, chargebacks and discounts frequently are submitted to us significantly after the related sales, potentially resulting in adjustments in the period in which the new information becomes known. Our credits to product revenue related to prior period sales have not been significant and primarily related to rebates and discounts. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclude taxes collected from customers relating to product sales and remitted to governmental authorities from revenues. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract Liabilities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded contract liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $171.7 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $191.5 million as of December 31, 2021 and 2020, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive. Upon exceeding the annual reimbursement amount, products are provided free of </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">charge, which is a material right. These contracts include upfront payments and fees. We defer a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. Our product revenue contracts include performance obligations that are one year or less.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as our fiscal year. In these markets we recognize revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year. During the years ended December 31, 2021, 2020 and 2019, we recorded $191.5 million, $62.3 million and $24.9 million, respectively, of revenues that were recorded as contract liabilities at the beginning of the year. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">French Early Access Programs</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we began distributing ORKAMBI through early access programs in France and remained engaged in reimbursement discussions with the French government until November 2019, when we reached an agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs. From the time we began distributing ORKAMBI through early access programs in France, we expected the difference between the amounts collected based on the invoiced amount and the final amount for ORKAMBI distributed through early access programs would be returned to the French government.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the third quarter of 2019, we recognized net product revenues for ORKAMBI sales in France under the early access programs based on a transaction price that reflected our estimate of consideration we expected to retain that would not be subject to a significant reversal in amounts recognized. When determining if variable consideration should be constrained, we consider whether there are factors outside our control that could result in a significant reversal of revenue. In making these assessments, we consider the likelihood and magnitude of a potential reversal of revenue. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon reaching an agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs in November 2019, we updated the transaction price to reflect the final amount for ORKAMBI distributed through early access programs. As a result, we recognized net product revenues of $155.8 million related to prior period ORKAMBI early access program sales in the fourth quarter of 2019 because the updated transaction price for ORKAMBI distributed through these programs exceeded our previous estimate of the consideration we expected to retain that would not be subject to a significant reversal in amounts recognized. We paid the final amount due to the French government in 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Revenues</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not recorded significant revenues other than our product revenues during the three years ended December 31, 2021; however, in future periods, we may recognize collaborative revenues generated through collaborative research, development and/or commercialization agreements related to one or more of the following: nonrefundable, upfront license fees; development and commercial milestones; funding of research and/or development activities; and royalties on net sales of licensed products. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to our collaborator. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each collaborative research, development, and/or commercialization agreement that results in revenue, we identify all material performance obligations and determine the transaction price by estimating the amount of variable consideration at the outset of the contract. We constrain (reduce) the estimate of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the estimated transaction price is established, amounts are allocated to each separate performance obligation that has been identified on a relative standalone selling price basis.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Upfront License Fees: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we determine that a license to our intellectual property is distinct from the other performance obligations identified in an arrangement, we recognize revenue from the related nonrefundable, upfront license fees based on the relative standalone selling price prescribed to the license compared to the total selling price of </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the arrangement. We recognize revenue when the license is transferred to our collaborator and our collaborator is able to use and benefit from the license. For licenses that are not distinct from other obligations identified in the arrangement, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, we apply an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development and Regulatory Milestone Payments: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on facts and circumstances, we may include certain milestones in the estimated transaction price or fully constrain the milestones. We include a milestone payment in the transaction price in the reporting period that it is probable that recording revenue in the period will not result in a significant reversal in amounts recognized in future periods. This may result in us recognizing revenues from certain milestones and a corresponding contract asset in a reporting period before the milestone is achieved. We fully constrain milestone payments that have not been included in the transaction price to date until we conclude that their achievement is probable and that recognition of the related revenue will not result in a significant reversal in amounts recognized in future periods. We re-evaluate the probability of achievement of such development milestones and any related constraint each reporting period and adjust our estimate of the overall transaction price, including the amount of collaborative revenue that we have recorded, if necessary. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Activities/Transition Services: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are entitled to reimbursement from our collaborators for specified research and development expenses, we account for the related services as separate performance obligations if these services represent a material right. We also determine whether to account for the reimbursement of research and development expenses as collaborative revenues or an offset to research and development expenses in accordance with the provisions of gross or net revenue presentation. We recognize the corresponding revenues or record the corresponding offset to research and development expenses as we satisfy the related performance obligations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentration of credit risk consist principally of money market funds and marketable securities. We place these investments with highly rated financial institutions, and, by policy, limit the amount of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. We also maintain a foreign currency hedging program that includes foreign currency forward contracts with several counterparties. We have not experienced any credit losses related to these financial instruments and do not believe we are exposed to any significant credit risk related to these instruments. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to credit risk from our accounts receivable related to our product sales and collaborators. We evaluate the creditworthiness of each of our customers and have determined that all our material customers are creditworthy. To date, we have not experienced significant losses with respect to the collection of our accounts receivable. We believe that our allowances, which are not significant to our consolidated financial statements, are adequate at December 31, 2021. Please refer to Note Q, “Segment Information,” for further information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, our marketable securities consisted of investments in available-for-sale debt securities and corporate equity securities with readily determinable fair values. We classify marketable securities available to fund current operations as current assets on our consolidated balance sheets. Marketable securities are classified as long-term assets on our consolidated balance sheets if (i) they have been in an unrealized loss position for longer than one year and (ii) we have the ability and intent to hold them (a) until the carrying value is recovered and (b) such holding period may be longer than one year. Our marketable securities are stated at fair value. The fair value of these securities is based on quoted prices for </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">identical or similar assets. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We record unrealized gains (losses) on available-for-sale debt securities as a component of “Accumulated other comprehensive income (loss),” which is a separate component of shareholders’ equity on our consolidated balance sheet, until such gains and losses are realized. Realized gains and losses, if any, are determined using the specific identification method.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record changes in the fair value of our investments in corporate equity securities to “Other income, net” in our consolidated statements of operations. Realized gains and losses, which are also included in “Other income, net,” are determined on an original weighted-average cost basis. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted Accounting Standards Update (“ASU”) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2016-13”) as of January 1, 2020, which did not have a significant impact on our consolidated financial statements. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires us to record an allowance for credit losses using an expected loss model, which replaces the incurred loss model required under the previous guidance. A credit loss is limited to the amount by which the amortized cost of an investment exceeds its fair value. A previously recognized credit loss may be decreased in subsequent periods if our estimate of fair value for the investment increases. To determine whether to record a credit loss, we consider issuer specific credit ratings and historical losses as well as current economic conditions and our expectations for future economic conditions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We deduct invoice discounts for prompt payment and fees for distribution services from our accounts receivable based on our experience that our customers will earn these discounts and fees. Our estimates for our allowance for credit losses, which has not been significant to date, is determined based on existing contractual payment terms, historical payment patterns, current economic conditions and our expectation for future economic conditions. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation Expense</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We expense the fair value of employee restricted stock units and other forms of stock-based employee compensation over the associated employee service period on a straight-line basis. Stock-based compensation expense is determined based on the fair value of the award at the grant date and is adjusted each period to reflect actual forfeitures and the outcomes of certain performance conditions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For awards with performance conditions in which the award does not vest unless the performance condition is met, we recognize expense if, and to the extent that, we estimate that achievement of the performance condition is probable. If we conclude that vesting is probable, we recognize expense from the date we reach this conclusion through the estimated vesting date. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide to employees who have rendered a certain number of years of service to Vertex and meet certain age requirements, partial or full acceleration of vesting of these equity awards, subject to certain conditions including a notification period, upon a termination of employment other than for cause. Approximately 5% of our employees were eligible for partial or full acceleration of any of their equity awards as of December 31, 2021. We recognize stock-based compensation expense related to these awards over a service period reflecting qualified employees’ eligibility for partial or full acceleration of vesting. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note N, “Stock-based Compensation Expense,” for tables displaying our stock-based compensation expense by type of award and by line item within our consolidated statements of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are comprised of costs we incur in performing research and development activities, including salary and benefits; stock-based compensation expense; outsourced services and other direct expenses, including clinical trial and pharmaceutical development costs; collaborative payments; and infrastructure costs, including facilities costs and depreciation expense. We recognize research and development expenses as incurred. We capitalize nonrefundable advance payments we make for research and development activities and expense the payments as the related goods are </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delivered or the related services are performed.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value our inventories at the lower-of-cost or net realizable value. We determine the cost of our inventories, which include amounts related to materials and manufacturing overhead, on a first-in, first-out basis. We perform an assessment of the recoverability of our capitalized inventory during each reporting period and write down any excess and obsolete inventories to their net realizable value in the period in which the impairment is first identified. Shipping and handling costs incurred for inventory purchases are capitalized and recorded upon sale in “Cost of sales” in our consolidated statements of operations. Shipping and handling costs incurred for product shipments are recorded as incurred in “Cost of sales” in our consolidated statements of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize inventories produced in preparation for initiating sales of a product candidate when the related product candidate is considered to have a high likelihood of regulatory approval and the related costs are expected to be recoverable through sales of the inventories. In determining whether to capitalize such inventories, we evaluate, among other factors, information regarding the product candidate’s safety and efficacy, the status of regulatory submissions and communications with regulatory authorities and the outlook for commercial sales, including the existence of current or anticipated competitive drugs and the availability of reimbursement. In addition, we evaluate risks associated with manufacturing the product candidate and the remaining shelf-life of the inventories. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost, net of accumulated depreciation. Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset generally as follows: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.410%"><tr><td style="width:1.0%"/><td style="width:43.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:52.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 to 40 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 to 10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements; assets under finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The shorter of the useful life of the assets or the estimated remaining term of the associated lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintenance and repairs to an asset that do not improve or extend its life are charged to operations. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in our consolidated statements of operations. We perform an assessment of the fair value of the assets if indicators of impairment are identified during a reporting period and record the assets at the lower of the net book value or the fair value of the assets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize internal costs incurred to develop software for internal use during the application development stage. Amortization of capitalized internally developed software costs is recorded in depreciation expense over the useful life of the related asset.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine whether an arrangement contains a lease at inception. If a lease is identified in an arrangement, we recognize a right-of-use asset and liability on our consolidated balance sheet and determine whether the lease should be classified as a finance or operating lease. We do not recognize assets or liabilities for leases with lease terms of less than 12 months.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to Vertex by the end of the lease term, (ii) we hold an option to purchase the leased asset that we are reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alternative use at the end of the lease term. All other leases are recorded as operating leases.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate implicit is not readily determinable, we utilize our incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not separate lease and non-lease components when determining which lease payments to include in the calculation of our lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, we reflect the option in the lease term if it is reasonably certain we will exercise the option.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases are recorded in “<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFlZjExYzk5NDc0ZTRhOTY5NGQ3ZjYzZDA5N2JiNDBmL3NlYzphZWYxMWM5OTQ3NGU0YTk2OTRkN2Y2M2QwOTdiYjQwZl8xNjAvZnJhZzo3ZTZiMWUyMzg4OGY0YTcwYmU5MDI3NzQ1YzZlZDRiZS90ZXh0cmVnaW9uOjdlNmIxZTIzODg4ZjRhNzBiZTkwMjc3NDVjNmVkNGJlXzMyOTE4_0cb06ed0-64fd-4913-85d5-b798413ecfcf"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFlZjExYzk5NDc0ZTRhOTY5NGQ3ZjYzZDA5N2JiNDBmL3NlYzphZWYxMWM5OTQ3NGU0YTk2OTRkN2Y2M2QwOTdiYjQwZl8xNjAvZnJhZzo3ZTZiMWUyMzg4OGY0YTcwYmU5MDI3NzQ1YzZlZDRiZS90ZXh0cmVnaW9uOjdlNmIxZTIzODg4ZjRhNzBiZTkwMjc3NDVjNmVkNGJlXzMyOTE4_2abd7673-e32b-4dc6-abe5-ae91a0cabab9">Property and equipment, net</span></span>,” “Other current liabilities” and “Long-term finance lease liabilities,” and operating leases are recorded in “Operating lease assets,” “Other current liabilities” and “Long-term operating lease liabilities” on our consolidated balance sheet.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the income tax bases of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. On a periodic basis, we reassess the valuation allowance on our deferred income tax assets weighing positive and negative evidence to assess the recoverability of our deferred tax assets. We include, among other things, our recent financial performance and our future projections in this periodic assessment. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record liabilities related to uncertain tax positions by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. We evaluate our uncertain tax positions on a quarterly basis and consider various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in our tax returns, and changes in facts or circumstances related to a tax position. We adjust our liabilities to reflect any subsequent changes in the relevant facts and circumstances surrounding the uncertain positions. We accrue interest and penalties related to unrecognized tax benefits as a component of our “Provision for income taxes.” </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the U.S. Tax Cut and Jobs Act of 2017, we are subject to a territorial tax system, under which we must establish an accounting policy to provide for tax on Global Intangible Low Taxed Income (“GILTI”) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a current tax expense in our “Provision for income taxes.”</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review each collaboration agreement pursuant to which we license assets owned by a collaborator in order to determine whether or not we have a variable interest via the license agreement with our collaborator and if the variable interest is a variable interest in our collaborator as a whole and whether or not we are the primary beneficiary of that variable interest entity (“VIE”). If we determine we are the primary beneficiary of a VIE at the onset of our collaboration agreement, the collaboration is treated as a business combination and we consolidate the financial statements of the VIE into our consolidated financial statements until we are no longer the primary beneficiary of the consolidated VIE, or no longer have a variable interest in the VIE. As of December 31, 2021 and 2020, we did not have any consolidated VIEs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of In-process Research and Development Assets and Contingent Payments </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The present-value models we use to estimate the fair values of in-process research and development assets and contingent payments pursuant to collaborations and acquisitions incorporate significant assumptions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discounted cash flow models pertaining to in-process research and development assets include: (i) assumptions regarding the probability of obtaining marketing approval for a product candidate; (ii) the timing of and the expected costs to develop and commercialize a product candidate; (iii) estimates of future cash flows from potential product sales with respect to a product candidate; and (iv) appropriate discount and tax rates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base our estimates of the probability of achieving the milestones relevant to the fair value of contingent payments, which could include milestone, royalty and option payments, on industry data. Estimates included in the discounted cash flow models pertaining to contingent payments also include: (i) estimate regarding the timing of the relevant development and commercial milestones and royalties, (ii) and appropriate discount rates. We record any increases or decreases in the fair value of our contingent payments as charges or credits to “Change in fair value of contingent consideration” in our consolidated statement of operations. Please refer to Note D, “Fair Value Measurements,” for further information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-process Research and Development Assets</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record the fair value of in-process research and development assets as of the transaction date of a business combination. Each of these assets is accounted for as an indefinite-lived intangible asset and is maintained on our consolidated balance sheet until either the underlying project is completed or the asset becomes impaired. If the asset becomes impaired or is abandoned, the carrying value of the related intangible asset is written down to its fair value, and an impairment charge is recorded in the period in which the impairment occurs. If a project is completed, the carrying value of the related intangible asset is amortized as a part of “Cost of sales” over the remaining estimated life of the asset beginning in the period in which the project is completed. In-process research and development assets are tested for impairment on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstances suggest that impairment may exist. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development that is acquired in a transaction that does not qualify as a business combination under U.S. GAAP and that does not have an alternative future use is recorded to “Research and development expenses” in the period in which it is acquired.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between the purchase price and the fair value of assets acquired and liabilities assumed in a business combination is allocated to goodwill. Goodwill is evaluated for impairment on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstances suggest that impairment may exist. As noted in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above, we have one operating segment, pharmaceuticals, which is our only reporting unit.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hedging Activities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the fair value of hedging instruments that are designated and qualify as hedging instruments pursuant to U.S. GAAP, foreign currency forward contracts, as either assets or liabilities on our consolidated balance sheets. Changes in the fair value of these instruments are recorded each period in “Accumulated other comprehensive income (loss)” as unrealized gains and losses until the forecasted underlying transaction occurs. Unrealized gains and losses on these foreign currency forward contracts are included in “Prepaid expenses and other current assets” or “Other assets,” and “Other current liabilities” or “Other long-term liabilities,” respectively, on our consolidated balance sheets depending on the remaining period until their contractual maturity. Realized gains and losses for the effective portion of such contracts are recognized in “Product revenues, net” in our consolidated statement of operations in the same period that we recognize the product revenues that were impacted by the hedged foreign exchange rate changes. We classify the cash flows from hedging instruments in the same category as the cash flows from the hedged items. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our hedging instruments are subject to master netting arrangements to reduce the risk arising from such transactions with our counterparties. We present unrealized gains and losses on our foreign currency forward contracts on a gross basis within our consolidated balance sheets. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into foreign currency forward contracts with contractual maturities of less than one month designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities including intercompany balances. These contracts are not designated as hedging instruments pursuant to U.S. GAAP. Realized gains and losses for such </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contracts are recognized in “Other income, net” in our consolidated statement of operations each period.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive Income</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income consists of net income and other comprehensive income (loss), which includes foreign currency translation adjustments and unrealized gains and losses on foreign currency forward contracts and certain marketable securities. For purposes of comprehensive income disclosures, we record provisions for or benefits from income taxes related to the unrealized gains and losses on foreign currency forward contracts and certain marketable securities. We do not record provisions for or benefits from income taxes related to our cumulative translation adjustment, as we intend to permanently reinvest undistributed earnings in our foreign subsidiaries.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation and Transactions</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our operations occur in entities that have the U.S. dollar denominated as their functional currency. The assets and liabilities of our entities with functional currencies other than the U.S. dollar are translated into U.S. dollars at exchange rates in effect at the end of the year. Revenue and expense amounts for these entities are translated using the average exchange rates for the period. Net unrealized gains and losses resulting from foreign currency translation are included in “Accumulated other comprehensive income (loss).” Net foreign currency exchange transaction losses, which are included in “Other income, net” on our consolidated statement of operations, were $13.9 million, $16.1 million and $5.2 million for 2021, 2020 and 2019, respectively. These net foreign currency exchange losses are presented net of the impact of the foreign currency forward contracts designed to mitigate their effect on our consolidated statement of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchase Programs</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repurchases of our common stock are recorded as reductions to “Common Stock” and “Additional paid-in capital” pursuant to our established accounting policy. Repurchases in excess of the par value will be recorded as reductions to “Retained earnings” in the event that “Additional paid-in capital” is reduced to zero.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Income Per Common Share</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per common share is based upon the weighted-average number of common shares outstanding during the period. Diluted net income per common share utilizing the treasury-stock method is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive. Potentially dilutive shares result from the assumed exercise of outstanding stock options and assumed vesting of restricted stock units (including performance-based restricted stock units) (the proceeds of which are then assumed to have been used to repurchase outstanding stock using the treasury-stock method).</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Financial Accounting Standards Board (“FASB”) issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2019-12”), which simplifies the accounting for income taxes. ASU 2019-12 became effective on January 1, 2021. The adoption of ASU 2019-12 did not have a significant impact on our consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internal-Use Software</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the FASB issued ASU 2018-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2018-15”), which clarifies the accounting for implementation costs in cloud computing arrangements. ASU 2018-15 became effective on January 1, 2020. The adoption of ASU 2018-15 resulted in an insignificant amount of additional assets recorded on our consolidated balance sheet.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the FASB issued ASU 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2018-13”), which modifies the disclosure requirements for fair </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value measurements. ASU 2018-13 became effective on January 1, 2020. The adoption of ASU 2018-13 resulted in additional disclosures related to our Level 3 inputs. Please refer to Note D, “Fair Value Measurements,” for further information.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Losses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the FASB issued ASU 2016-13, which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 became effective on January 1, 2020. The adoption of ASU 2016-13 did not have a significant impact on our consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2019, we adopted ASC 842 using the modified-retrospective method. Until December 31, 2018, we applied build-to-suit accounting and were the deemed owner of our leased corporate headquarters in Boston and research site in San Diego. Under the amended guidance that became effective January 1, 2019, we account for these buildings as finance leases. As of January 1, 2019, we recorded a cumulative effect adjustment to increase our “Accumulated deficit” by $40.3 million to reflect our build-to-suit leases as finance leases pursuant to ASC 842.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect any recently issued accounting standards to have a significant impact on our consolidated financial statements.</span></div> <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals. Please refer to Note Q, “Segment Information,” for enterprise-wide disclosures regarding our revenues, major customers and long-lived assets by geographic area.</span></div> 1 <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div> <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when a customer obtains control of promised goods or services. We record the amount of revenue that reflects the consideration that we expect to receive in exchange for those goods or services. We apply the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) we satisfy each performance obligation. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We only apply the five-step model to contracts when it is probable that we will collect the consideration to which we are entitled in exchange for the goods or services that we transfer to the customer. Once a contract is determined to be within the scope of Accounting Standards Codification (“ASC”) 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASC 606”) at contract inception, we review the contract to determine which performance obligations we must deliver and which of these performance obligations are distinct. We recognize as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. Generally, our performance obligations are transferred to customers at a point in time, typically upon delivery. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Revenues, Net</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products principally to a limited number of specialty pharmacy and specialty distributors in the United States (“U.S.”), which account for the largest portion of our total revenues. We make international sales primarily to specialty </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">distributors and retail chains, as well as hospitals and clinics, many of which are government-owned or supported. Our customers in the U.S. subsequently resell the products to patients and health care providers. We recognize net product revenues from sales when our customers obtain control of our products, which typically occurs upon delivery to our customers. Our payment terms are approximately 30 days in the U.S. and consistent with prevailing practice in international markets. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from (a) invoice discounts for prompt payment and distribution fees, (b) government and private payor rebates, chargebacks, discounts and fees and (c) costs of co-pay assistance programs for patients, as well as other incentives for certain indirect customers. Reserves are established for the estimates of variable consideration based on the amounts earned or to be claimed on the related sales. The reserves are classified as reductions to “Accounts receivable, net” if payable to a customer or “Accrued expenses” if payable to a third-party. Where appropriate, we utilize the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in net product revenues only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary from our estimates, we adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invoice Discounts and Distribution Fees: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide invoice discounts on product sales to our customers for prompt payment and pays fees for distribution services, such as fees for certain data that customers provide to us. We estimate that, based on our experience, our customers will earn these discounts and fees, and deduct the full amount of these discounts and fees from our gross product revenues and accounts receivable at the time such revenues are recognized.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates, Chargebacks, Discounts and Fees: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contract with government agencies (our “Third-party Payors”) so that products will be eligible for purchase by, or partial or full reimbursement from, such Third-party Payors. We estimate the rebates, chargebacks, discounts and fees we will provide to Third-party Payors and deduct these estimated amounts from our gross product revenues at the time the revenues are recognized. For each product, we estimate the aggregate rebates, chargebacks and discounts that we will provide to Third-party Payors based upon (i) our contracts with these Third-party Payors, (ii) the government-mandated discounts and fees applicable to government-funded programs, (iii) information obtained from our customers and other third-party data regarding the payor mix for such product and (iv) historical experience.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Incentives: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other incentives that we offer include co-pay mitigation rebates that we provide to commercially insured patients who have coverage and who reside in states that permit co-pay mitigation programs. Based upon the terms of our co-pay mitigation programs, we estimate average co-pay mitigation amounts for each of our products in order to establish appropriate accruals.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make significant estimates and judgments that materially affect our recognition of net product revenues. We adjust our estimated rebates, chargebacks and discounts based on new information, including information regarding actual rebates, chargebacks and discounts for our products, as it becomes available. Claims by third-party payors for rebates, chargebacks and discounts frequently are submitted to us significantly after the related sales, potentially resulting in adjustments in the period in which the new information becomes known. Our credits to product revenue related to prior period sales have not been significant and primarily related to rebates and discounts. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclude taxes collected from customers relating to product sales and remitted to governmental authorities from revenues. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contract Liabilities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded contract liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $171.7 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $191.5 million as of December 31, 2021 and 2020, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive. Upon exceeding the annual reimbursement amount, products are provided free of </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">charge, which is a material right. These contracts include upfront payments and fees. We defer a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. Our product revenue contracts include performance obligations that are one year or less.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as our fiscal year. In these markets we recognize revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year. During the years ended December 31, 2021, 2020 and 2019, we recorded $191.5 million, $62.3 million and $24.9 million, respectively, of revenues that were recorded as contract liabilities at the beginning of the year. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">French Early Access Programs</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we began distributing ORKAMBI through early access programs in France and remained engaged in reimbursement discussions with the French government until November 2019, when we reached an agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs. From the time we began distributing ORKAMBI through early access programs in France, we expected the difference between the amounts collected based on the invoiced amount and the final amount for ORKAMBI distributed through early access programs would be returned to the French government.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the third quarter of 2019, we recognized net product revenues for ORKAMBI sales in France under the early access programs based on a transaction price that reflected our estimate of consideration we expected to retain that would not be subject to a significant reversal in amounts recognized. When determining if variable consideration should be constrained, we consider whether there are factors outside our control that could result in a significant reversal of revenue. In making these assessments, we consider the likelihood and magnitude of a potential reversal of revenue. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon reaching an agreement with the French government for ORKAMBI, including ORKAMBI distributed through early access programs in November 2019, we updated the transaction price to reflect the final amount for ORKAMBI distributed through early access programs. As a result, we recognized net product revenues of $155.8 million related to prior period ORKAMBI early access program sales in the fourth quarter of 2019 because the updated transaction price for ORKAMBI distributed through these programs exceeded our previous estimate of the consideration we expected to retain that would not be subject to a significant reversal in amounts recognized. We paid the final amount due to the French government in 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Revenues</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not recorded significant revenues other than our product revenues during the three years ended December 31, 2021; however, in future periods, we may recognize collaborative revenues generated through collaborative research, development and/or commercialization agreements related to one or more of the following: nonrefundable, upfront license fees; development and commercial milestones; funding of research and/or development activities; and royalties on net sales of licensed products. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to our collaborator. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each collaborative research, development, and/or commercialization agreement that results in revenue, we identify all material performance obligations and determine the transaction price by estimating the amount of variable consideration at the outset of the contract. We constrain (reduce) the estimate of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the estimated transaction price is established, amounts are allocated to each separate performance obligation that has been identified on a relative standalone selling price basis.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Upfront License Fees: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we determine that a license to our intellectual property is distinct from the other performance obligations identified in an arrangement, we recognize revenue from the related nonrefundable, upfront license fees based on the relative standalone selling price prescribed to the license compared to the total selling price of </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the arrangement. We recognize revenue when the license is transferred to our collaborator and our collaborator is able to use and benefit from the license. For licenses that are not distinct from other obligations identified in the arrangement, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, we apply an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development and Regulatory Milestone Payments: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on facts and circumstances, we may include certain milestones in the estimated transaction price or fully constrain the milestones. We include a milestone payment in the transaction price in the reporting period that it is probable that recording revenue in the period will not result in a significant reversal in amounts recognized in future periods. This may result in us recognizing revenues from certain milestones and a corresponding contract asset in a reporting period before the milestone is achieved. We fully constrain milestone payments that have not been included in the transaction price to date until we conclude that their achievement is probable and that recognition of the related revenue will not result in a significant reversal in amounts recognized in future periods. We re-evaluate the probability of achievement of such development milestones and any related constraint each reporting period and adjust our estimate of the overall transaction price, including the amount of collaborative revenue that we have recorded, if necessary. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Activities/Transition Services: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are entitled to reimbursement from our collaborators for specified research and development expenses, we account for the related services as separate performance obligations if these services represent a material right. We also determine whether to account for the reimbursement of research and development expenses as collaborative revenues or an offset to research and development expenses in accordance with the provisions of gross or net revenue presentation. We recognize the corresponding revenues or record the corresponding offset to research and development expenses as we satisfy the related performance obligations.</span></div> 171700000 191500000 191500000 62300000 24900000 155800000 <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentration of credit risk consist principally of money market funds and marketable securities. We place these investments with highly rated financial institutions, and, by policy, limit the amount of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. We also maintain a foreign currency hedging program that includes foreign currency forward contracts with several counterparties. We have not experienced any credit losses related to these financial instruments and do not believe we are exposed to any significant credit risk related to these instruments. </span></div>We are also subject to credit risk from our accounts receivable related to our product sales and collaborators. We evaluate the creditworthiness of each of our customers and have determined that all our material customers are creditworthy. To date, we have not experienced significant losses with respect to the collection of our accounts receivable. We believe that our allowances, which are not significant to our consolidated financial statements, are adequate at December 31, 2021. Cash and Cash EquivalentsWe consider all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, our marketable securities consisted of investments in available-for-sale debt securities and corporate equity securities with readily determinable fair values. We classify marketable securities available to fund current operations as current assets on our consolidated balance sheets. Marketable securities are classified as long-term assets on our consolidated balance sheets if (i) they have been in an unrealized loss position for longer than one year and (ii) we have the ability and intent to hold them (a) until the carrying value is recovered and (b) such holding period may be longer than one year. Our marketable securities are stated at fair value. The fair value of these securities is based on quoted prices for </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">identical or similar assets. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We record unrealized gains (losses) on available-for-sale debt securities as a component of “Accumulated other comprehensive income (loss),” which is a separate component of shareholders’ equity on our consolidated balance sheet, until such gains and losses are realized. Realized gains and losses, if any, are determined using the specific identification method.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record changes in the fair value of our investments in corporate equity securities to “Other income, net” in our consolidated statements of operations. Realized gains and losses, which are also included in “Other income, net,” are determined on an original weighted-average cost basis. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted Accounting Standards Update (“ASU”) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2016-13”) as of January 1, 2020, which did not have a significant impact on our consolidated financial statements. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires us to record an allowance for credit losses using an expected loss model, which replaces the incurred loss model required under the previous guidance. A credit loss is limited to the amount by which the amortized cost of an investment exceeds its fair value. A previously recognized credit loss may be decreased in subsequent periods if our estimate of fair value for the investment increases. To determine whether to record a credit loss, we consider issuer specific credit ratings and historical losses as well as current economic conditions and our expectations for future economic conditions.</span></div> Accounts Receivable We deduct invoice discounts for prompt payment and fees for distribution services from our accounts receivable based on our experience that our customers will earn these discounts and fees. Our estimates for our allowance for credit losses, which has not been significant to date, is determined based on existing contractual payment terms, historical payment patterns, current economic conditions and our expectation for future economic conditions. <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation Expense</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We expense the fair value of employee restricted stock units and other forms of stock-based employee compensation over the associated employee service period on a straight-line basis. Stock-based compensation expense is determined based on the fair value of the award at the grant date and is adjusted each period to reflect actual forfeitures and the outcomes of certain performance conditions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For awards with performance conditions in which the award does not vest unless the performance condition is met, we recognize expense if, and to the extent that, we estimate that achievement of the performance condition is probable. If we conclude that vesting is probable, we recognize expense from the date we reach this conclusion through the estimated vesting date. </span></div>We provide to employees who have rendered a certain number of years of service to Vertex and meet certain age requirements, partial or full acceleration of vesting of these equity awards, subject to certain conditions including a notification period, upon a termination of employment other than for cause. Approximately 5% of our employees were eligible for partial or full acceleration of any of their equity awards as of December 31, 2021. We recognize stock-based compensation expense related to these awards over a service period reflecting qualified employees’ eligibility for partial or full acceleration of vesting. 0.05 <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are comprised of costs we incur in performing research and development activities, including salary and benefits; stock-based compensation expense; outsourced services and other direct expenses, including clinical trial and pharmaceutical development costs; collaborative payments; and infrastructure costs, including facilities costs and depreciation expense. We recognize research and development expenses as incurred. We capitalize nonrefundable advance payments we make for research and development activities and expense the payments as the related goods are </span></div>delivered or the related services are performed. <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value our inventories at the lower-of-cost or net realizable value. We determine the cost of our inventories, which include amounts related to materials and manufacturing overhead, on a first-in, first-out basis. We perform an assessment of the recoverability of our capitalized inventory during each reporting period and write down any excess and obsolete inventories to their net realizable value in the period in which the impairment is first identified. Shipping and handling costs incurred for inventory purchases are capitalized and recorded upon sale in “Cost of sales” in our consolidated statements of operations. Shipping and handling costs incurred for product shipments are recorded as incurred in “Cost of sales” in our consolidated statements of operations.</span></div>We capitalize inventories produced in preparation for initiating sales of a product candidate when the related product candidate is considered to have a high likelihood of regulatory approval and the related costs are expected to be recoverable through sales of the inventories. In determining whether to capitalize such inventories, we evaluate, among other factors, information regarding the product candidate’s safety and efficacy, the status of regulatory submissions and communications with regulatory authorities and the outlook for commercial sales, including the existence of current or anticipated competitive drugs and the availability of reimbursement. In addition, we evaluate risks associated with manufacturing the product candidate and the remaining shelf-life of the inventories. <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost, net of accumulated depreciation. Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset generally as follows: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.410%"><tr><td style="width:1.0%"/><td style="width:43.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:52.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 to 40 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 to 10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements; assets under finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The shorter of the useful life of the assets or the estimated remaining term of the associated lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintenance and repairs to an asset that do not improve or extend its life are charged to operations. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in our consolidated statements of operations. We perform an assessment of the fair value of the assets if indicators of impairment are identified during a reporting period and record the assets at the lower of the net book value or the fair value of the assets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize internal costs incurred to develop software for internal use during the application development stage. Amortization of capitalized internally developed software costs is recorded in depreciation expense over the useful life of the related asset.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost, net of accumulated depreciation. Depreciation expense is recorded using the straight-line method over the estimated useful life of the related asset generally as follows: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.410%"><tr><td style="width:1.0%"/><td style="width:43.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.088%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:52.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 to 40 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 to 10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements; assets under finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The shorter of the useful life of the assets or the estimated remaining term of the associated lease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.505%"><tr><td style="width:1.0%"/><td style="width:48.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,990.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(896.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(790.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P15Y P40Y P7Y P10Y P3Y P5Y <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine whether an arrangement contains a lease at inception. If a lease is identified in an arrangement, we recognize a right-of-use asset and liability on our consolidated balance sheet and determine whether the lease should be classified as a finance or operating lease. We do not recognize assets or liabilities for leases with lease terms of less than 12 months.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A lease qualifies as a finance lease if any of the following criteria are met at the inception of the lease: (i) there is a transfer of ownership of the leased asset to Vertex by the end of the lease term, (ii) we hold an option to purchase the leased asset that we are reasonably certain to exercise, (iii) the lease term is for a major part of the remaining economic life of the leased asset, (iv) the present value of the sum of lease payments equals or exceeds substantially all of the fair value of the leased asset, or (v) the nature of the leased asset is specialized to the point that it is expected to provide the lessor no </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alternative use at the end of the lease term. All other leases are recorded as operating leases.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance and operating lease assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term using the discount rate implicit in the lease. If the rate implicit is not readily determinable, we utilize our incremental borrowing rate at the lease commencement date. Operating lease assets are further adjusted for prepaid or accrued lease payments. Operating lease payments are expensed using the straight-line method as an operating expense over the lease term. Finance lease assets are amortized to depreciation expense using the straight-line method over the shorter of the useful life of the related asset or the lease term. Finance lease payments are bifurcated into (i) a portion that is recorded as imputed interest expense and (ii) a portion that reduces the finance liability associated with the lease.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not separate lease and non-lease components when determining which lease payments to include in the calculation of our lease assets and liabilities. Variable lease payments are expensed as incurred. If a lease includes an option to extend or terminate the lease, we reflect the option in the lease term if it is reasonably certain we will exercise the option.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases are recorded in “<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFlZjExYzk5NDc0ZTRhOTY5NGQ3ZjYzZDA5N2JiNDBmL3NlYzphZWYxMWM5OTQ3NGU0YTk2OTRkN2Y2M2QwOTdiYjQwZl8xNjAvZnJhZzo3ZTZiMWUyMzg4OGY0YTcwYmU5MDI3NzQ1YzZlZDRiZS90ZXh0cmVnaW9uOjdlNmIxZTIzODg4ZjRhNzBiZTkwMjc3NDVjNmVkNGJlXzMyOTE4_0cb06ed0-64fd-4913-85d5-b798413ecfcf"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFlZjExYzk5NDc0ZTRhOTY5NGQ3ZjYzZDA5N2JiNDBmL3NlYzphZWYxMWM5OTQ3NGU0YTk2OTRkN2Y2M2QwOTdiYjQwZl8xNjAvZnJhZzo3ZTZiMWUyMzg4OGY0YTcwYmU5MDI3NzQ1YzZlZDRiZS90ZXh0cmVnaW9uOjdlNmIxZTIzODg4ZjRhNzBiZTkwMjc3NDVjNmVkNGJlXzMyOTE4_2abd7673-e32b-4dc6-abe5-ae91a0cabab9">Property and equipment, net</span></span>,” “Other current liabilities” and “Long-term finance lease liabilities,” and operating leases are recorded in “Operating lease assets,” “Other current liabilities” and “Long-term operating lease liabilities” on our consolidated balance sheet.</span></div> <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the income tax bases of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. On a periodic basis, we reassess the valuation allowance on our deferred income tax assets weighing positive and negative evidence to assess the recoverability of our deferred tax assets. We include, among other things, our recent financial performance and our future projections in this periodic assessment. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record liabilities related to uncertain tax positions by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. We evaluate our uncertain tax positions on a quarterly basis and consider various factors, including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in our tax returns, and changes in facts or circumstances related to a tax position. We adjust our liabilities to reflect any subsequent changes in the relevant facts and circumstances surrounding the uncertain positions. We accrue interest and penalties related to unrecognized tax benefits as a component of our “Provision for income taxes.” </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the U.S. Tax Cut and Jobs Act of 2017, we are subject to a territorial tax system, under which we must establish an accounting policy to provide for tax on Global Intangible Low Taxed Income (“GILTI”) earned by certain foreign subsidiaries. We have elected to treat the impact of GILTI as a current tax expense in our “Provision for income taxes.”</span></div> <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review each collaboration agreement pursuant to which we license assets owned by a collaborator in order to determine whether or not we have a variable interest via the license agreement with our collaborator and if the variable interest is a variable interest in our collaborator as a whole and whether or not we are the primary beneficiary of that variable interest entity (“VIE”). If we determine we are the primary beneficiary of a VIE at the onset of our collaboration agreement, the collaboration is treated as a business combination and we consolidate the financial statements of the VIE into our consolidated financial statements until we are no longer the primary beneficiary of the consolidated VIE, or no longer have a variable interest in the VIE. As of December 31, 2021 and 2020, we did not have any consolidated VIEs.</span></div> <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of In-process Research and Development Assets and Contingent Payments </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The present-value models we use to estimate the fair values of in-process research and development assets and contingent payments pursuant to collaborations and acquisitions incorporate significant assumptions. </span></div>Our discounted cash flow models pertaining to in-process research and development assets include: (i) assumptions regarding the probability of obtaining marketing approval for a product candidate; (ii) the timing of and the expected costs to develop and commercialize a product candidate; (iii) estimates of future cash flows from potential product sales with respect to a product candidate; and (iv) appropriate discount and tax rates. We base our estimates of the probability of achieving the milestones relevant to the fair value of contingent payments, which could include milestone, royalty and option payments, on industry data. Estimates included in the discounted cash flow models pertaining to contingent payments also include: (i) estimate regarding the timing of the relevant development and commercial milestones and royalties, (ii) and appropriate discount rates. We record any increases or decreases in the fair value of our contingent payments as charges or credits to “Change in fair value of contingent consideration” in our consolidated statement of operations. <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-process Research and Development Assets</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record the fair value of in-process research and development assets as of the transaction date of a business combination. Each of these assets is accounted for as an indefinite-lived intangible asset and is maintained on our consolidated balance sheet until either the underlying project is completed or the asset becomes impaired. If the asset becomes impaired or is abandoned, the carrying value of the related intangible asset is written down to its fair value, and an impairment charge is recorded in the period in which the impairment occurs. If a project is completed, the carrying value of the related intangible asset is amortized as a part of “Cost of sales” over the remaining estimated life of the asset beginning in the period in which the project is completed. In-process research and development assets are tested for impairment on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstances suggest that impairment may exist. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development that is acquired in a transaction that does not qualify as a business combination under U.S. GAAP and that does not have an alternative future use is recorded to “Research and development expenses” in the period in which it is acquired.</span></div> GoodwillThe difference between the purchase price and the fair value of assets acquired and liabilities assumed in a business combination is allocated to goodwill. Goodwill is evaluated for impairment on an annual basis as of October 1, and more frequently if indicators are present or changes in circumstances suggest that impairment may exist. 1 <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hedging Activities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the fair value of hedging instruments that are designated and qualify as hedging instruments pursuant to U.S. GAAP, foreign currency forward contracts, as either assets or liabilities on our consolidated balance sheets. Changes in the fair value of these instruments are recorded each period in “Accumulated other comprehensive income (loss)” as unrealized gains and losses until the forecasted underlying transaction occurs. Unrealized gains and losses on these foreign currency forward contracts are included in “Prepaid expenses and other current assets” or “Other assets,” and “Other current liabilities” or “Other long-term liabilities,” respectively, on our consolidated balance sheets depending on the remaining period until their contractual maturity. Realized gains and losses for the effective portion of such contracts are recognized in “Product revenues, net” in our consolidated statement of operations in the same period that we recognize the product revenues that were impacted by the hedged foreign exchange rate changes. We classify the cash flows from hedging instruments in the same category as the cash flows from the hedged items. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our hedging instruments are subject to master netting arrangements to reduce the risk arising from such transactions with our counterparties. We present unrealized gains and losses on our foreign currency forward contracts on a gross basis within our consolidated balance sheets. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into foreign currency forward contracts with contractual maturities of less than one month designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities including intercompany balances. These contracts are not designated as hedging instruments pursuant to U.S. GAAP. Realized gains and losses for such </span></div>contracts are recognized in “Other income, net” in our consolidated statement of operations each period. P1M <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive Income</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income consists of net income and other comprehensive income (loss), which includes foreign currency translation adjustments and unrealized gains and losses on foreign currency forward contracts and certain marketable securities. For purposes of comprehensive income disclosures, we record provisions for or benefits from income taxes related to the unrealized gains and losses on foreign currency forward contracts and certain marketable securities. We do not record provisions for or benefits from income taxes related to our cumulative translation adjustment, as we intend to permanently reinvest undistributed earnings in our foreign subsidiaries.</span></div> Foreign Currency Translation and TransactionsThe majority of our operations occur in entities that have the U.S. dollar denominated as their functional currency. The assets and liabilities of our entities with functional currencies other than the U.S. dollar are translated into U.S. dollars at exchange rates in effect at the end of the year. Revenue and expense amounts for these entities are translated using the average exchange rates for the period. Net unrealized gains and losses resulting from foreign currency translation are included in “Accumulated other comprehensive income (loss).” -13900000 -16100000 -5200000 <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchase Programs</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repurchases of our common stock are recorded as reductions to “Common Stock” and “Additional paid-in capital” pursuant to our established accounting policy. Repurchases in excess of the par value will be recorded as reductions to “Retained earnings” in the event that “Additional paid-in capital” is reduced to zero.</span></div> Net Income Per Common ShareBasic net income per common share is based upon the weighted-average number of common shares outstanding during the period. Diluted net income per common share utilizing the treasury-stock method is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive. <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Financial Accounting Standards Board (“FASB”) issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2019-12”), which simplifies the accounting for income taxes. ASU 2019-12 became effective on January 1, 2021. The adoption of ASU 2019-12 did not have a significant impact on our consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internal-Use Software</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the FASB issued ASU 2018-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2018-15”), which clarifies the accounting for implementation costs in cloud computing arrangements. ASU 2018-15 became effective on January 1, 2020. The adoption of ASU 2018-15 resulted in an insignificant amount of additional assets recorded on our consolidated balance sheet.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the FASB issued ASU 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2018-13”), which modifies the disclosure requirements for fair </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value measurements. ASU 2018-13 became effective on January 1, 2020. The adoption of ASU 2018-13 resulted in additional disclosures related to our Level 3 inputs. Please refer to Note D, “Fair Value Measurements,” for further information.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Losses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the FASB issued ASU 2016-13, which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 became effective on January 1, 2020. The adoption of ASU 2016-13 did not have a significant impact on our consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2019, we adopted ASC 842 using the modified-retrospective method. Until December 31, 2018, we applied build-to-suit accounting and were the deemed owner of our leased corporate headquarters in Boston and research site in San Diego. Under the amended guidance that became effective January 1, 2019, we account for these buildings as finance leases. As of January 1, 2019, we recorded a cumulative effect adjustment to increase our “Accumulated deficit” by $40.3 million to reflect our build-to-suit leases as finance leases pursuant to ASC 842.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect any recently issued accounting standards to have a significant impact on our consolidated financial statements.</span></div> -40300000 Collaborative and Other Arrangements<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into numerous agreements pursuant to which we collaborate with third parties on research, development and commercialization programs, including in-license and out-license agreements or acquire assets. Our “Research and development expenses” included $1.1 billion, $184.6 million and $318.3 million related to upfront and milestone payments pursuant to our in-license agreements and asset acquisitions in 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-license Agreements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into a number of in-license agreements in order to advance and obtain access to technologies and services related to our research and early-development activities. We are generally required to make an upfront payment upon execution of our license agreements; development, regulatory and commercialization milestones payments upon the achievement of certain product research, development and commercialization objectives; and royalty payments on future sales, if any, of commercial products resulting from our collaborations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of our in-license agreements, our collaborators typically lead the discovery efforts and we lead all preclinical, development and commercialization activities associated with the advancement of any product candidates and fund all expenses. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically can terminate our in-license agreements by providing advance notice to our collaborators; the required length of notice is dependent on whether any product developed under the license agreement has received marketing approval. Our license agreements may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, these license agreements generally remain in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRISPR Therapeutics AG</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CRISPR-Cas9 Gene-editing Therapies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we entered into a strategic collaboration, option and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. We had the exclusive right to license certain targets. In 2019, we paid an aggregate of $30.0 million to exclusively license three targets, including CF, pursuant to the CRISPR Agreement. We recorded the $30.0 million total option payment to “Research and development expenses.” For each of the three targets that we elected to license, CRISPR has the potential to receive up to an additional $410.0 million in development, regulatory and commercial milestones as well as royalties on net product sales. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into a joint development and commercialization agreement with CRISPR pursuant to the terms of the CRISPR Agreement (the “Original CTX001 JDCA”), under which we and CRISPR were co-developing and preparing to co-commercialize CTX001 for the treatment of hemoglobinopathies, including treatments for sickle cell disease and transfusion-dependent beta thalassemia.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2021, we and CRISPR amended and restated the Original CTX001 JDCA (the “A&amp;R JDCA”), pursuant to which the parties agreed to, among other things, (a) adjust the governance structure for the collaboration and adjust the responsibilities of each party thereunder; (b) adjust the allocation of net profits and net losses between the parties; and (c) exclusively license (subject to CRISPR’s reserved rights to conduct certain activities) certain intellectual property rights to us relating to the products that may be researched, developed, manufactured and commercialized under such agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the A&amp;R JDCA, we are now leading global development, manufacturing and commercialization of CTX001, with support from CRISPR. Subject to the terms and conditions of the A&amp;R JDCA, we also have the right to conduct all research, development, manufacturing and commercialization activities relating to the product candidates and products under the A&amp;R JDCA (including CTX001) throughout the world subject to CRISPR’s reserved right to conduct certain activities. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the A&amp;R JDCA, we made a $900.0 million upfront payment to CRISPR in the second quarter of 2021. We concluded that we did not have any alternative future use for the acquired in-process research and development and recorded this upfront payment to “Research and development expenses.” CRISPR has the potential to receive an additional one-time $200.0 million milestone payment upon receipt of the first marketing approval of CTX001 from the U.S. Food and Drug Administration or the European Commission. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and CRISPR shared equally all expenses incurred under the Original CTX001 JDCA. On July 1, 2021, with respect to CTX001, the net profits and net losses incurred pursuant to the A&amp;R JDCA began to be allocated 60% to us and 40% to CRISPR, while all other product candidates and products continue to have net profits and net losses shared equally between the parties. We concluded that the Original CTX001 JDCA and the A&amp;R JDCA are cost-sharing arrangements, which result in the net impact of the arrangements being recorded in “Research and development expenses” in our consolidated statements of operations. During the three years ended December 31, 2021, we recognized the following amounts in total related to these agreements: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses incurred under the Original CTX001 JDCA and A&amp;R JDCA</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex’s share recognized in “Research and development expenses” in consolidated statements of operations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a separate strategic collaboration and license agreement (the “CRISPR DMD/DM1 Agreement”) with CRISPR. Pursuant to this agreement, we received an exclusive worldwide license to CRISPR’s existing and future intellectual property for Duchenne muscular dystrophy (“DMD”) and myotonic dystrophy type 1 (“DM1”) and we made an upfront payment of $175.0 million to CRISPR. We concluded that we did not have any alternative future use for the acquired in-process research and development and recorded the upfront payment to “Research and development expenses.” We recorded $12.5 million and $25.0 million to “Research and development expenses” in 2021 and 2020, respectively, related to pre-clinical milestones earned by CRISPR under the CRISPR DMD/DM1 Agreement. CRISPR has the potential to receive up to an additional $787.5 million in research, development, regulatory and commercial milestones for the DMD and </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DM1 programs as well as royalties on net product sales. CRISPR has the option to co-develop and co-commercialize all DM1 products globally and forego the milestones and royalties associated with the DM1 program. We fund all expenses associated with the collaboration.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Kymera Therapeutics Inc.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a strategic research and development collaboration agreement with Kymera Therapeutics Inc. (“Kymera”) to advance small molecule protein degraders against multiple targets. Kymera’s proprietary platform technology is being applied in the collaboration activities in exchange for an upfront payment of $50.0 million. We have the exclusive right to license up to six protein targets, for each of which Kymera may receive up to $170.0 million in payments, including development, regulatory and commercial milestones as well as royalties on net product sales. We determined that substantially all of the fair value of the Kymera collaboration agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. We concluded that we did not have any alternative future use for the acquired in-process research and development and recorded the $50.0 million upfront payment to “Research and development expenses.”</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the upfront payment, we purchased $20.0 million of Kymera’s preferred stock that converted to common stock when Kymera became a publicly traded company in 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Moderna, Inc.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we entered into a strategic collaboration and licensing agreement with Moderna, Inc. (“Moderna”), pursuant to which the parties are seeking to identify and develop messenger ribonucleic acid (“mRNA”) therapeutics for the treatment of CF. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we entered into a new strategic collaboration and licensing agreement with Moderna (the “2020 Moderna Agreement”) aimed at the discovery and development of lipid nanoparticles and mRNAs that can deliver gene-editing therapies to lung cells for the treatment of CF. Pursuant to the 2020 Moderna Agreement, we paid Moderna an upfront payment of $75.0 million and Moderna is eligible to receive up to $380.0 million in development, regulatory and commercial milestones as well as royalties on net product sales. We determined that substantially all the fair value of the 2020 Moderna Agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. We concluded that we did not have any alternative future use for the acquired in-process research and development and recorded the upfront payment to “Research and development expenses.”</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Additional In-License Agreements and Other Arrangements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we entered into a strategic collaboration and license agreement with ApoLo1 Bio, LLC (“ApoLo1”) related to our drug discovery efforts in APOL1-mediated kidney disease. In 2021, based on positive results from a Phase 2 proof-of-concept study of VX-147 in patients with APOL1-mediated focal segmental glomerulosclerosis, we paid ApoLo1 a $15.0 million milestone and exercised our $60.0 million option to buy-out all future development milestones, regulatory milestones and future royalties on net product sales. We recorded these payments to “Research and development expenses” because we concluded that we did not have any alternative future use for the acquired in-process research and development.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the collaborative arrangements described above, we recorded upfront, option and milestone payments totaling $125.8 million in 2021, $84.6 million in 2020 and $63.3 million in 2019 to “Research and development expenses” related to additional in-license agreements and other business development transactions that we do not consider to be individually significant to our consolidated financial statements. These payments included upfront payments of $31.0 million to Mammoth Biosciences, Inc. (“Mammoth”) and $25.0 million to Arbor Biotechnologies, Inc. (“Arbor”) in 2021, $40.0 million to Skyhawk Therapeutics, Inc. (“Skyhawk”) in 2020, and $25.9 million to Molecular Templates, Inc. (“Molecular”) in 2019.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Mammoth, Arbor, Skyhawk, Molecular and several other in-license agreements that are not individually significant to our consolidated financial statements, we determined that substantially all the fair value of each individual agreement was attributable to in-process research and development and no substantive processes were acquired that would constitute a business. We concluded that we did not have any alternative future use for the acquired in-process research and development </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">associated with the agreements and recorded the upfront payments for these agreements to “Research and development expenses.” Please refer to Note D, “Fair Value Measurements,” and Note E, “Marketable Securities and Equity Investments,” for further information regarding our investments in our collaborators.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Out-license Agreements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into licensing agreements pursuant to which we have out-licensed rights to certain product candidates to third-party collaborators. Pursuant to these out-license agreements, our collaborators become responsible for all costs related to the continued development of such product candidates and obtain development and commercialization rights to these product candidates. Depending on the terms of the agreements, our collaborators may be required to make upfront payments, milestone payments upon the achievement of certain product research and development objectives and may also be required to pay royalties on future sales, if any, of commercial products resulting from the collaboration. The termination provisions associated with these collaborations are generally the same as those described above related to our in-license agreements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Merck KGaA, Darmstadt, Germany</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into a strategic collaboration and license agreement (the “Oncology Agreement”) with Merck KGaA, Darmstadt, Germany (the “Licensee”). Pursuant to the Oncology Agreement, we granted the Licensee an exclusive worldwide license to research, develop and commercialize four oncology research and development programs including two clinical-stage programs targeting DNA damage repair: our ataxia telangiectasia and Rad3-related protein kinase inhibitor program, or ATR program, including VX-970 and VX-803, and our DNA-dependent protein kinase inhibitor program, or DNA-PK program, including VX-984. In addition, we granted the Licensee exclusive, worldwide rights to two pre-clinical programs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we entered into an agreement with Merck KGaA, Darmstadt, Germany (the “DNA-PK Agreement”) whereby we licensed the two lead Vertex DNA-PK compounds from our DNA-PK program for use in the field of gene integration for six specific indications. Merck KGaA, Darmstadt, Germany has the potential to receive additional milestones, primarily related to approval and reimbursement in various markets, as well as royalties on net product sales.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cystic Fibrosis Foundation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a research, development and commercialization agreement that was originally entered into in 2004 with the Cystic Fibrosis Foundation, as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc. This agreement was most recently amended in 2016. Pursuant to the agreement, as amended, we agreed to pay royalties ranging from low-single digits to mid-single digits on potential sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor, and tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor). For combination products, such as ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), sales are allocated equally to each of the active pharmaceutical ingredients in the combination product. We record our royalties payable to the Cystic Fibrosis Foundation to “Cost of sales.”</span></div> 1100000000 184600000 318300000 30000000 3 30000000 3 410000000 900000000 200000000 0.60 0.40 During the three years ended December 31, 2021, we recognized the following amounts in total related to these agreements: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses incurred under the Original CTX001 JDCA and A&amp;R JDCA</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex’s share recognized in “Research and development expenses” in consolidated statements of operations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 230400000 101200000 60300000 129000000.0 50600000 30100000 175000000 12500000 25000000 787500000 50000000 6 170000000 50000000 20000000 75000000 380000000 15000000 60000000 125800000 84600000 63300000 31000000 25000000 40000000 25900000 4 2 2 Earnings Per Share<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net income per common share for the periods ended:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,342.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,711.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of potentially dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including PSUs)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase program</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.09 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units (including PSUs)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net income per common share for the periods ended:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,342.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,711.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of potentially dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including PSUs)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase program</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.09 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2342100000 2711700000 1176800000 257700000 259800000 256700000 1100000 1800000 2200000 1100000 1700000 1700000 0.0 100000 100000 259900000 263400000 260700000 9.09 10.44 4.58 9.01 10.29 4.51 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units (including PSUs)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 700000 300000 2800000 400000 300000 0 Fair Value Measurements<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy is used to classify assets and liabilities based on observable inputs and unobservable inputs used in order to determine the fair value of our financial assets and liabilities:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.037%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment strategy is focused on capital preservation. We invest in instruments that meet the credit quality standards outlined in our investment policy, which also limits the amount of credit exposure to any one issue or type of instrument. We maintain strategic investments separately from the investment policy that governs our other cash, cash equivalents and marketable securities as described in Note E, “Marketable Securities and Equity Investments.” Additionally, we utilize foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on our consolidated statement of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three years ended December 31, 2021, we did not record any other-than-temporary impairment charges related to our financial assets.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $3.3 billion and $2.8 billion of cash as of December 31, 2021 and 2020, respectively):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial instruments carried at fair value (asset position):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,141.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,141.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government-sponsored enterprise securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total financial assets</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,254.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,864.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,811.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,236.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial instruments carried at fair value (liability position):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(189.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(189.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total financial liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(194.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(253.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(189.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note E, “Marketable Securities and Equity Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Corporate Equity Securities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our investments in publicly traded corporate equity securities as “Marketable securities” on our consolidated balance sheets. Generally, our investments in the common stock of publicly traded companies are valued based on Level 1 inputs because they have readily determinable fair values. However, certain of our investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments. Please refer to Note E, “Marketable Securities and Equity Investments,” for further information on these investments.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Contingent Consideration</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we acquired Exonics Therapeutics, Inc. (“Exonics”), a privately-held company focused on creating transformative gene-editing therapies to repair mutations that cause DMD and other severe neuromuscular diseases, including DM1. Our Level 3 contingent consideration liabilities are related to $678.3 million of development and regulatory milestones potentially payable to Exonics’ former equity holders. We base our estimates of the probability of achieving the milestones relevant to the fair value of contingent payments on industry data attributable to rare diseases. The discount rates used in the valuation model for contingent payments, which were between 0.9% and 2.3% as of December 31, 2021, represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Due to the uncertainties associated with development and commercialization of product candidates in the pharmaceutical industry and the effects of changes in other assumptions </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including discount rates, we expect our estimates regarding the fair value of contingent consideration to change in the future, resulting in adjustments to the fair value of our contingent consideration liabilities, and the effect of any such adjustments could be material.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a rollforward of the fair value of our contingent consideration liabilities:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.345%"><tr><td style="width:1.0%"/><td style="width:70.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.441%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in fair value of contingent payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $3.3 billion and $2.8 billion of cash as of December 31, 2021 and 2020, respectively):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Hierarchy</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial instruments carried at fair value (asset position):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,141.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,141.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government-sponsored enterprise securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total financial assets</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,254.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,864.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,811.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,236.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial instruments carried at fair value (liability position):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(189.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(189.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total financial liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(194.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(253.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(189.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3300000000 2800000000 3478100000 3478100000 0 0 3141100000 3141100000 0 0 230900000 230900000 0 0 195800000 15700000 180100000 0 86400000 86400000 0 0 0 0 0 0 69000000.0 69000000.0 0 0 80000000.0 80000000.0 0 0 90900000 0 90900000 0 231600000 0 231600000 0 252700000 0 252700000 0 163300000 0 163300000 0 44500000 0 44500000 0 0 0 0 0 2000000.0 0 2000000.0 0 0 0 0 0 4254500000 3864400000 390100000 0 3811800000 3811800000 3811800000 3236800000 575000000.0 0 5600000 0 5600000 0 59200000 0 59200000 0 186500000 0 0 186500000 189600000 0 0 189600000 2700000 0 2700000 0 4300000 0 4300000 0 194800000 0 8300000 186500000 253100000 0 63500000 189600000 678300000 0.009 0.023 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a rollforward of the fair value of our contingent consideration liabilities:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.345%"><tr><td style="width:1.0%"/><td style="width:70.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.441%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in fair value of contingent payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 189600000 -3100000 186500000 Marketable Securities and Equity Investments<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $3.3 billion and $2.8 billion of cash as of December 31, 2021 and 2020, respectively), is shown below:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.790%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,141.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,141.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">568.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">729.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">526.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">670.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities were classified on our consolidated balance sheets at fair value as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.505%"><tr><td style="width:1.0%"/><td style="width:48.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,141.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,616.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities by contractual maturity were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.505%"><tr><td style="width:1.0%"/><td style="width:48.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,912.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,526.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-indent:-0.01pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures after one year through five years</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,616.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a limited number of available-for-sale debt securities in insignificant loss positions as of December 31, 2021, which we do not intend to sell and have concluded we will not be required to sell before recovery of the amortized costs for the investments at maturity. We did not record any charges for other-than-temporary declines in the fair value of available-for-sale debt securities or gross realized gains or losses in 2021, 2020 or 2019. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record changes in the fair value of our investments in corporate equity securities to “Other income, net” in our consolidated statements of operations. During the three years ended December 31, 2021, our net unrealized gains on corporate equity securities held at the conclusion of each period were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.505%"><tr><td style="width:1.0%"/><td style="width:51.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.690%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2020 and 2019, we sold the common stock of publicly traded companies, which were primarily sales of our investment in CRISPR, resulting in the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.505%"><tr><td style="width:1.0%"/><td style="width:48.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.485%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds received</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average cost basis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, we did not sell any common stock of publicly traded companies.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the carrying value of our equity investments without readily determinable fair values, which are recorded in “Other assets” on our consolidated balance sheets, was $85.8 million.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $3.3 billion and $2.8 billion of cash as of December 31, 2021 and 2020, respectively), is shown below:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.790%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,141.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,141.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">568.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">729.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">526.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">670.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities were classified on our consolidated balance sheets at fair value as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.505%"><tr><td style="width:1.0%"/><td style="width:48.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,141.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,616.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities by contractual maturity were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.505%"><tr><td style="width:1.0%"/><td style="width:48.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,912.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,526.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-indent:-0.01pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures after one year through five years</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,616.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3300000000 2800000000 3478100000 0 0 3478100000 3141100000 0 0 3141100000 86600000 0 200000 86400000 0 0 0 0 69000000.0 0 0 69000000.0 80000000.0 0 0 80000000.0 91100000 0 200000 90900000 231300000 400000 100000 231600000 252800000 0 100000 252700000 163300000 0 0 163300000 499500000 0 500000 499000000.0 474600000 400000 100000 474900000 69400000 167100000 5600000 230900000 51400000 144400000 0 195800000 568900000 167100000 6100000 729900000 526000000.0 144800000 100000 670700000 3478100000 3141100000 499000000.0 474900000 3977100000 3616000000 3912300000 3526200000 64800000 89800000 3977100000 3616000000 0 0 0 During the three years ended December 31, 2021, our net unrealized gains on corporate equity securities held at the conclusion of each period were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.505%"><tr><td style="width:1.0%"/><td style="width:51.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.690%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 17100000 136200000 143200000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2020 and 2019, we sold the common stock of publicly traded companies, which were primarily sales of our investment in CRISPR, resulting in the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.505%"><tr><td style="width:1.0%"/><td style="width:48.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.485%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds received</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average cost basis</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 437600000 94900000 103300000 29800000 0 85800000 Accumulated Other Comprehensive Income (Loss)<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in accumulated other comprehensive income (loss) by component:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Holding Gains (Losses), Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">On Available-For-Sale Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">On Foreign Currency Forward Contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2018</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2019</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.5)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69.4)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.7 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.9 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in accumulated other comprehensive income (loss) by component:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Holding Gains (Losses), Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">On Available-For-Sale Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">On Foreign Currency Forward Contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2018</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2019</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.5)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69.4)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.7 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.9 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -11200000 -500000 12400000 700000 10300000 1000000.0 11500000 22800000 0 0 25500000 25500000 10300000 1000000.0 -14000000.0 -2700000 -900000 500000 -1600000 -2000000.0 -14700000 -200000 -54500000 -69400000 0 0 -2900000 -2900000 -14700000 -200000 -51600000 -66500000 -15600000 300000 -53200000 -68500000 2000000.0 -800000 59700000 60900000 0 0 -23500000 -23500000 2000000.0 -800000 83200000 84400000 -13600000 -500000 30000000.0 15900000 Hedging<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency forward contracts - Designated as hedging instruments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of our forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under U.S. GAAP having contractual durations from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFlZjExYzk5NDc0ZTRhOTY5NGQ3ZjYzZDA5N2JiNDBmL3NlYzphZWYxMWM5OTQ3NGU0YTk2OTRkN2Y2M2QwOTdiYjQwZl8xNzgvZnJhZzozMzgxNmJiODUzZTM0YTVkYWE0YWNiNjM4ODA0OTY0YS90ZXh0cmVnaW9uOjMzODE2YmI4NTNlMzRhNWRhYTRhY2I2Mzg4MDQ5NjRhXzQzNw_ecd4c0e1-ff79-4edd-839b-5bb94e710a52">one</span> to eighteen months. We recognize realized gains and losses for the effective portion of such contracts in “Product revenues, net” in our consolidated statements of operations in the same period that we recognize the product revenues that were impacted by the hedged foreign exchange rate changes. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We formally document the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as our risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. We also formally assess, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of December 31, 2021, all hedges were determined to be highly effective.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider the impact of our counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of December 31, 2021 and December 31, 2020, credit risk did not change the fair value of our foreign currency forward contracts.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.505%"><tr><td style="width:1.0%"/><td style="width:48.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">British pound sterling</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian dollar</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollar</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swiss Franc</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency forward contracts - Not designated as hedging instruments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into foreign currency forward contracts with contractual maturities of less than one month, which are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under U.S. GAAP. We recognize realized gains and losses for such contracts in “Other income, net” in our consolidated statements of operations each period. As of December 31, 2021, the notional amount of our outstanding foreign currency forward contracts where hedge accounting under U.S. GAAP is not applied was $580.7 million. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three years ended December 31, 2021, we recognized the following related to foreign currency forward contracts in our consolidated statements of operations:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.619%"><tr><td style="width:1.0%"/><td style="width:59.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.097%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Designated as hedging instruments - Reclassified from AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total reported in the Consolidated Statement of Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,573.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,202.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,160.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our consolidated balance sheets:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we expect the amounts that are related to foreign exchange forward contracts designated as cash flow hedges under U.S. GAAP recorded in “Prepaid expenses and other current assets” and “Other current liabilities” to be reclassified to earnings within twelve months.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note A, “Note A, “Nature of Business and Accounting Policies,” we present the fair value of our foreign currency forward contracts on a gross basis within our consolidated balance sheets. The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our consolidated balance sheets: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:34.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.862%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P18M <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.505%"><tr><td style="width:1.0%"/><td style="width:48.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">British pound sterling</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian dollar</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollar</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swiss Franc</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1364500000 745100000 287700000 160400000 96300000 99900000 89900000 86500000 54100000 0 1892500000 1091900000 P1M 580700000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three years ended December 31, 2021, we recognized the following related to foreign currency forward contracts in our consolidated statements of operations:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.619%"><tr><td style="width:1.0%"/><td style="width:59.875%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.019%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.097%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Designated as hedging instruments - Reclassified from AOCI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Not designated as hedging instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total reported in the Consolidated Statement of Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,573.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,202.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,160.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -30000000.0 -3700000 32500000 -18600000 22100000 -4800000 7573400000 6202800000 4160700000 4900000 296600000 192200000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our consolidated balance sheets:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div> 44500000 5600000 2000000.0 2700000 46500000 8300000 0 59200000 0 4300000 0 63500000 The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our consolidated balance sheets: <div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:34.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.862%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our consolidated balance sheets: <div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:34.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.858%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.862%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 46500000 0 46500000 8300000 38200000 8300000 0 8300000 8300000 0 0 0 0 0 0 63500000 0 63500000 0 63500000 Inventories<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.505%"><tr><td style="width:1.0%"/><td style="width:48.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.505%"><tr><td style="width:1.0%"/><td style="width:48.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 42400000 46200000 224000000.0 161300000 86700000 73300000 353100000 280800000 Property and Equipment<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.505%"><tr><td style="width:1.0%"/><td style="width:48.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,990.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(896.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(790.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded depreciation expense of $125.6 million, $109.5 million and $106.9 million in 2021, 2020 and 2019, respectively, which includes our finance lease amortization.</span></div> 892500000 876100000 407300000 346700000 363500000 234600000 293700000 258600000 33100000 33100000 1990100000 1749100000 896000000.0 790600000 1094100000 958500000 125600000 109500000 106900000 Intangible Assets and Goodwill<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, we had $400.0 million of in-process research and development intangible assets classified as “Intangible assets” on our consolidated balance sheets. In 2019, we recorded $387.0 million and $13.0 million of in-process research and development intangible assets related to our acquisitions of Semma Therapeutics, Inc. (“Semma”) and Exonics, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, goodwill of $1.0 billion was recorded on our consolidated balance sheets. During 2019, we recorded goodwill of $554.6 million and $397.1 million related to our acquisitions of Semma and Exonics, respectively.</span></div> 400000000 400000000 387000000 13000000 1000000000 1000000000 554600000 397100000 Additional Balance Sheet Detail<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.327%"><tr><td style="width:1.0%"/><td style="width:53.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax related prepaid and receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.327%"><tr><td style="width:1.0%"/><td style="width:53.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue accruals</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research, development and commercial contract costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax related accruals</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,678.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.327%"><tr><td style="width:1.0%"/><td style="width:53.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash, cash equivalents and restricted cash balances at the beginning and ending of each period presented in our consolidated statements of cash flows consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.327%"><tr><td style="width:1.0%"/><td style="width:46.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.926%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.926%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.926%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,795.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,988.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,109.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash per consolidated statement of cash flows</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,800.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,988.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,120.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restricted cash, if any, is included in “Prepaid expenses and other current assets” and “Other assets” on our consolidated balance sheets.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.327%"><tr><td style="width:1.0%"/><td style="width:53.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax related prepaid and receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 358600000 228600000 187200000 79700000 545800000 308300000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.327%"><tr><td style="width:1.0%"/><td style="width:53.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue accruals</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research, development and commercial contract costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax related accruals</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,678.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,405.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 847400000 781900000 191300000 169400000 171600000 136700000 200400000 165400000 211300000 104200000 56600000 47400000 1678600000 1405000000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.327%"><tr><td style="width:1.0%"/><td style="width:53.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of cash flow hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 171700000 191500000 46900000 42400000 5600000 59200000 44200000 24300000 268400000 317400000 <div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash, cash equivalents and restricted cash balances at the beginning and ending of each period presented in our consolidated statements of cash flows consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.327%"><tr><td style="width:1.0%"/><td style="width:46.840%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.926%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.926%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.926%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,795.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,988.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,109.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash per consolidated statement of cash flows</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,800.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,988.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,120.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,658.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6795000000 5988200000 3109300000 2650100000 5100000 700000 8000000.0 4900000 0 0 3400000 3300000 6800100000 5988900000 3120700000 2658300000 Leases<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finance Leases</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our finance lease assets and liabilities primarily relate to our corporate headquarters in Boston and research site in San Diego (the “Buildings”). These Buildings are classified as finance leases because the present value of the sum of the lease payments associated with the Buildings exceeds substantially all of the fair value of the Buildings. We also have outstanding finance leases for equipment and land.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Headquarters</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2011, we entered into two lease agreements, pursuant to which we lease approximately 1.1 million square feet of office and laboratory space in two buildings in Boston, Massachusetts for a term of 15 years. Base rent payments commenced in December 2013 and will continue through December 2028. We utilize this initial period as our lease term. We have an option to extend the lease term for an additional ten years.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">San Diego Lease</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we entered into a lease agreement pursuant to which we lease approximately 170,000 square feet of office and laboratory space in San Diego, California for a term of 16 years. Base rent payments commenced in the second quarter of 2019 and will continue through May 2034. We utilize this initial period as our lease term. We have an option to extend the lease term for up to two additional five-year terms.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Leases</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases relate to our real estate leases that are not classified as finance leases.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Innovation Square Lease</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into an agreement to lease approximately 269,000 square feet of office and laboratory space near our corporate headquarters in Boston, Massachusetts. The lease agreement includes an initial term of 15 years plus a period to install leasehold improvements, with an option to extend the lease term for up to two additional ten-year periods. Base rent payments commenced in 2021. We have utilized the initial period, which commenced in the third quarter of 2020 upon occupation of the building, as our lease term. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to our accounting policy, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Note A, “Nature of Business and Accounting Policies,” for further information on the accounting treatment for our finance and operating leases.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aggregate Lease Information </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost recorded in our consolidated statement of operations were as follows: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.529%"><tr><td style="width:1.0%"/><td style="width:50.147%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.255%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.143%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.255%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.143%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.257%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our variable lease cost during 2021, 2020 and 2019 primarily related to operating expenses, taxes and insurance associated with our finance leases.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leases are included on our consolidated balance sheets as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.505%"><tr><td style="width:1.0%"/><td style="width:48.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFlZjExYzk5NDc0ZTRhOTY5NGQ3ZjYzZDA5N2JiNDBmL3NlYzphZWYxMWM5OTQ3NGU0YTk2OTRkN2Y2M2QwOTdiYjQwZl8xOTMvZnJhZzo4MDkwODUwNjNhNDQ0MWE4OGIwNjM4NWI0OWZlNGE2MS90YWJsZTo0N2E0ZGZjZjFjMTY0ZGE1YjcyYThlZjFmNjNhNWRlMS90YWJsZXJhbmdlOjQ3YTRkZmNmMWMxNjRkYTViNzJhOGVmMWY2M2E1ZGUxXzQtMC0xLTEtMA_8ebd3895-53c6-48ac-96ce-8dd3f6399c18"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFlZjExYzk5NDc0ZTRhOTY5NGQ3ZjYzZDA5N2JiNDBmL3NlYzphZWYxMWM5OTQ3NGU0YTk2OTRkN2Y2M2QwOTdiYjQwZl8xOTMvZnJhZzo4MDkwODUwNjNhNDQ0MWE4OGIwNjM4NWI0OWZlNGE2MS90YWJsZTo0N2E0ZGZjZjFjMTY0ZGE1YjcyYThlZjFmNjNhNWRlMS90YWJsZXJhbmdlOjQ3YTRkZmNmMWMxNjRkYTViNzJhOGVmMWY2M2E1ZGUxXzQtMC0xLTEtMA_af1c3bcb-a925-4493-8497-80a7b5aeba41">Property and equipment, net</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFlZjExYzk5NDc0ZTRhOTY5NGQ3ZjYzZDA5N2JiNDBmL3NlYzphZWYxMWM5OTQ3NGU0YTk2OTRkN2Y2M2QwOTdiYjQwZl8xOTMvZnJhZzo4MDkwODUwNjNhNDQ0MWE4OGIwNjM4NWI0OWZlNGE2MS90YWJsZTo0N2E0ZGZjZjFjMTY0ZGE1YjcyYThlZjFmNjNhNWRlMS90YWJsZXJhbmdlOjQ3YTRkZmNmMWMxNjRkYTViNzJhOGVmMWY2M2E1ZGUxXzctMC0xLTEtMA_cbdfc205-9d8a-4208-9fec-008105c012b9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFlZjExYzk5NDc0ZTRhOTY5NGQ3ZjYzZDA5N2JiNDBmL3NlYzphZWYxMWM5OTQ3NGU0YTk2OTRkN2Y2M2QwOTdiYjQwZl8xOTMvZnJhZzo4MDkwODUwNjNhNDQ0MWE4OGIwNjM4NWI0OWZlNGE2MS90YWJsZTo0N2E0ZGZjZjFjMTY0ZGE1YjcyYThlZjFmNjNhNWRlMS90YWJsZXJhbmdlOjQ3YTRkZmNmMWMxNjRkYTViNzJhOGVmMWY2M2E1ZGUxXzctMC0xLTEtMA_d9b8470b-b640-4673-a9ba-6e1d0fb9fb07">Other current liabilities</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFlZjExYzk5NDc0ZTRhOTY5NGQ3ZjYzZDA5N2JiNDBmL3NlYzphZWYxMWM5OTQ3NGU0YTk2OTRkN2Y2M2QwOTdiYjQwZl8xOTMvZnJhZzo4MDkwODUwNjNhNDQ0MWE4OGIwNjM4NWI0OWZlNGE2MS90YWJsZTo0N2E0ZGZjZjFjMTY0ZGE1YjcyYThlZjFmNjNhNWRlMS90YWJsZXJhbmdlOjQ3YTRkZmNmMWMxNjRkYTViNzJhOGVmMWY2M2E1ZGUxXzE1LTAtMS0xLTA_7f8665b8-56a9-4069-b9e7-ec65a5d9dc2b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFlZjExYzk5NDc0ZTRhOTY5NGQ3ZjYzZDA5N2JiNDBmL3NlYzphZWYxMWM5OTQ3NGU0YTk2OTRkN2Y2M2QwOTdiYjQwZl8xOTMvZnJhZzo4MDkwODUwNjNhNDQ0MWE4OGIwNjM4NWI0OWZlNGE2MS90YWJsZTo0N2E0ZGZjZjFjMTY0ZGE1YjcyYThlZjFmNjNhNWRlMS90YWJsZXJhbmdlOjQ3YTRkZmNmMWMxNjRkYTViNzJhOGVmMWY2M2E1ZGUxXzE1LTAtMS0xLTA_8fdc4ac5-1d24-404f-925f-1610bdd02555">Other current liabilities</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of our finance and operating lease liabilities as of December 31, 2021 were as follows: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"/><td style="width:42.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.383%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.383%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: tenant allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount representing interest</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease terms and discount rates related to our leases were as follows: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.029%"><tr><td style="width:1.0%"/><td style="width:53.941%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.552%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.73</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.58</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.81</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.10</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to our leases was as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.470%"><tr><td style="width:1.0%"/><td style="width:59.968%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.868%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.117%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> Leases<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finance Leases</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our finance lease assets and liabilities primarily relate to our corporate headquarters in Boston and research site in San Diego (the “Buildings”). These Buildings are classified as finance leases because the present value of the sum of the lease payments associated with the Buildings exceeds substantially all of the fair value of the Buildings. We also have outstanding finance leases for equipment and land.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Headquarters</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2011, we entered into two lease agreements, pursuant to which we lease approximately 1.1 million square feet of office and laboratory space in two buildings in Boston, Massachusetts for a term of 15 years. Base rent payments commenced in December 2013 and will continue through December 2028. We utilize this initial period as our lease term. We have an option to extend the lease term for an additional ten years.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">San Diego Lease</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we entered into a lease agreement pursuant to which we lease approximately 170,000 square feet of office and laboratory space in San Diego, California for a term of 16 years. Base rent payments commenced in the second quarter of 2019 and will continue through May 2034. We utilize this initial period as our lease term. We have an option to extend the lease term for up to two additional five-year terms.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Leases</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases relate to our real estate leases that are not classified as finance leases.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Innovation Square Lease</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into an agreement to lease approximately 269,000 square feet of office and laboratory space near our corporate headquarters in Boston, Massachusetts. The lease agreement includes an initial term of 15 years plus a period to install leasehold improvements, with an option to extend the lease term for up to two additional ten-year periods. Base rent payments commenced in 2021. We have utilized the initial period, which commenced in the third quarter of 2020 upon occupation of the building, as our lease term. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to our accounting policy, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Note A, “Nature of Business and Accounting Policies,” for further information on the accounting treatment for our finance and operating leases.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aggregate Lease Information </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost recorded in our consolidated statement of operations were as follows: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.529%"><tr><td style="width:1.0%"/><td style="width:50.147%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.255%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.143%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.255%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.143%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.257%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our variable lease cost during 2021, 2020 and 2019 primarily related to operating expenses, taxes and insurance associated with our finance leases.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leases are included on our consolidated balance sheets as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.505%"><tr><td style="width:1.0%"/><td style="width:48.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFlZjExYzk5NDc0ZTRhOTY5NGQ3ZjYzZDA5N2JiNDBmL3NlYzphZWYxMWM5OTQ3NGU0YTk2OTRkN2Y2M2QwOTdiYjQwZl8xOTMvZnJhZzo4MDkwODUwNjNhNDQ0MWE4OGIwNjM4NWI0OWZlNGE2MS90YWJsZTo0N2E0ZGZjZjFjMTY0ZGE1YjcyYThlZjFmNjNhNWRlMS90YWJsZXJhbmdlOjQ3YTRkZmNmMWMxNjRkYTViNzJhOGVmMWY2M2E1ZGUxXzQtMC0xLTEtMA_8ebd3895-53c6-48ac-96ce-8dd3f6399c18"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFlZjExYzk5NDc0ZTRhOTY5NGQ3ZjYzZDA5N2JiNDBmL3NlYzphZWYxMWM5OTQ3NGU0YTk2OTRkN2Y2M2QwOTdiYjQwZl8xOTMvZnJhZzo4MDkwODUwNjNhNDQ0MWE4OGIwNjM4NWI0OWZlNGE2MS90YWJsZTo0N2E0ZGZjZjFjMTY0ZGE1YjcyYThlZjFmNjNhNWRlMS90YWJsZXJhbmdlOjQ3YTRkZmNmMWMxNjRkYTViNzJhOGVmMWY2M2E1ZGUxXzQtMC0xLTEtMA_af1c3bcb-a925-4493-8497-80a7b5aeba41">Property and equipment, net</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFlZjExYzk5NDc0ZTRhOTY5NGQ3ZjYzZDA5N2JiNDBmL3NlYzphZWYxMWM5OTQ3NGU0YTk2OTRkN2Y2M2QwOTdiYjQwZl8xOTMvZnJhZzo4MDkwODUwNjNhNDQ0MWE4OGIwNjM4NWI0OWZlNGE2MS90YWJsZTo0N2E0ZGZjZjFjMTY0ZGE1YjcyYThlZjFmNjNhNWRlMS90YWJsZXJhbmdlOjQ3YTRkZmNmMWMxNjRkYTViNzJhOGVmMWY2M2E1ZGUxXzctMC0xLTEtMA_cbdfc205-9d8a-4208-9fec-008105c012b9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFlZjExYzk5NDc0ZTRhOTY5NGQ3ZjYzZDA5N2JiNDBmL3NlYzphZWYxMWM5OTQ3NGU0YTk2OTRkN2Y2M2QwOTdiYjQwZl8xOTMvZnJhZzo4MDkwODUwNjNhNDQ0MWE4OGIwNjM4NWI0OWZlNGE2MS90YWJsZTo0N2E0ZGZjZjFjMTY0ZGE1YjcyYThlZjFmNjNhNWRlMS90YWJsZXJhbmdlOjQ3YTRkZmNmMWMxNjRkYTViNzJhOGVmMWY2M2E1ZGUxXzctMC0xLTEtMA_d9b8470b-b640-4673-a9ba-6e1d0fb9fb07">Other current liabilities</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFlZjExYzk5NDc0ZTRhOTY5NGQ3ZjYzZDA5N2JiNDBmL3NlYzphZWYxMWM5OTQ3NGU0YTk2OTRkN2Y2M2QwOTdiYjQwZl8xOTMvZnJhZzo4MDkwODUwNjNhNDQ0MWE4OGIwNjM4NWI0OWZlNGE2MS90YWJsZTo0N2E0ZGZjZjFjMTY0ZGE1YjcyYThlZjFmNjNhNWRlMS90YWJsZXJhbmdlOjQ3YTRkZmNmMWMxNjRkYTViNzJhOGVmMWY2M2E1ZGUxXzE1LTAtMS0xLTA_7f8665b8-56a9-4069-b9e7-ec65a5d9dc2b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFlZjExYzk5NDc0ZTRhOTY5NGQ3ZjYzZDA5N2JiNDBmL3NlYzphZWYxMWM5OTQ3NGU0YTk2OTRkN2Y2M2QwOTdiYjQwZl8xOTMvZnJhZzo4MDkwODUwNjNhNDQ0MWE4OGIwNjM4NWI0OWZlNGE2MS90YWJsZTo0N2E0ZGZjZjFjMTY0ZGE1YjcyYThlZjFmNjNhNWRlMS90YWJsZXJhbmdlOjQ3YTRkZmNmMWMxNjRkYTViNzJhOGVmMWY2M2E1ZGUxXzE1LTAtMS0xLTA_8fdc4ac5-1d24-404f-925f-1610bdd02555">Other current liabilities</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of our finance and operating lease liabilities as of December 31, 2021 were as follows: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"/><td style="width:42.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.383%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.383%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: tenant allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount representing interest</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease terms and discount rates related to our leases were as follows: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.029%"><tr><td style="width:1.0%"/><td style="width:53.941%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.552%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.73</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.58</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.81</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.10</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to our leases was as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.470%"><tr><td style="width:1.0%"/><td style="width:59.968%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.868%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.117%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2 1100000 2 P15Y P10Y 170000 P16Y 2 P5Y 269000 P15Y 2 P10Y <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost recorded in our consolidated statement of operations were as follows: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.529%"><tr><td style="width:1.0%"/><td style="width:50.147%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.255%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.143%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.255%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.143%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.257%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of leased assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 33900000 23100000 12000000.0 51900000 51200000 49800000 47400000 50200000 52800000 33600000 30800000 28000000.0 400000 4000000.0 6400000 166400000 151300000 136200000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leases are included on our consolidated balance sheets as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.505%"><tr><td style="width:1.0%"/><td style="width:48.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFlZjExYzk5NDc0ZTRhOTY5NGQ3ZjYzZDA5N2JiNDBmL3NlYzphZWYxMWM5OTQ3NGU0YTk2OTRkN2Y2M2QwOTdiYjQwZl8xOTMvZnJhZzo4MDkwODUwNjNhNDQ0MWE4OGIwNjM4NWI0OWZlNGE2MS90YWJsZTo0N2E0ZGZjZjFjMTY0ZGE1YjcyYThlZjFmNjNhNWRlMS90YWJsZXJhbmdlOjQ3YTRkZmNmMWMxNjRkYTViNzJhOGVmMWY2M2E1ZGUxXzQtMC0xLTEtMA_8ebd3895-53c6-48ac-96ce-8dd3f6399c18"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFlZjExYzk5NDc0ZTRhOTY5NGQ3ZjYzZDA5N2JiNDBmL3NlYzphZWYxMWM5OTQ3NGU0YTk2OTRkN2Y2M2QwOTdiYjQwZl8xOTMvZnJhZzo4MDkwODUwNjNhNDQ0MWE4OGIwNjM4NWI0OWZlNGE2MS90YWJsZTo0N2E0ZGZjZjFjMTY0ZGE1YjcyYThlZjFmNjNhNWRlMS90YWJsZXJhbmdlOjQ3YTRkZmNmMWMxNjRkYTViNzJhOGVmMWY2M2E1ZGUxXzQtMC0xLTEtMA_af1c3bcb-a925-4493-8497-80a7b5aeba41">Property and equipment, net</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFlZjExYzk5NDc0ZTRhOTY5NGQ3ZjYzZDA5N2JiNDBmL3NlYzphZWYxMWM5OTQ3NGU0YTk2OTRkN2Y2M2QwOTdiYjQwZl8xOTMvZnJhZzo4MDkwODUwNjNhNDQ0MWE4OGIwNjM4NWI0OWZlNGE2MS90YWJsZTo0N2E0ZGZjZjFjMTY0ZGE1YjcyYThlZjFmNjNhNWRlMS90YWJsZXJhbmdlOjQ3YTRkZmNmMWMxNjRkYTViNzJhOGVmMWY2M2E1ZGUxXzctMC0xLTEtMA_cbdfc205-9d8a-4208-9fec-008105c012b9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFlZjExYzk5NDc0ZTRhOTY5NGQ3ZjYzZDA5N2JiNDBmL3NlYzphZWYxMWM5OTQ3NGU0YTk2OTRkN2Y2M2QwOTdiYjQwZl8xOTMvZnJhZzo4MDkwODUwNjNhNDQ0MWE4OGIwNjM4NWI0OWZlNGE2MS90YWJsZTo0N2E0ZGZjZjFjMTY0ZGE1YjcyYThlZjFmNjNhNWRlMS90YWJsZXJhbmdlOjQ3YTRkZmNmMWMxNjRkYTViNzJhOGVmMWY2M2E1ZGUxXzctMC0xLTEtMA_d9b8470b-b640-4673-a9ba-6e1d0fb9fb07">Other current liabilities</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFlZjExYzk5NDc0ZTRhOTY5NGQ3ZjYzZDA5N2JiNDBmL3NlYzphZWYxMWM5OTQ3NGU0YTk2OTRkN2Y2M2QwOTdiYjQwZl8xOTMvZnJhZzo4MDkwODUwNjNhNDQ0MWE4OGIwNjM4NWI0OWZlNGE2MS90YWJsZTo0N2E0ZGZjZjFjMTY0ZGE1YjcyYThlZjFmNjNhNWRlMS90YWJsZXJhbmdlOjQ3YTRkZmNmMWMxNjRkYTViNzJhOGVmMWY2M2E1ZGUxXzE1LTAtMS0xLTA_7f8665b8-56a9-4069-b9e7-ec65a5d9dc2b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFlZjExYzk5NDc0ZTRhOTY5NGQ3ZjYzZDA5N2JiNDBmL3NlYzphZWYxMWM5OTQ3NGU0YTk2OTRkN2Y2M2QwOTdiYjQwZl8xOTMvZnJhZzo4MDkwODUwNjNhNDQ0MWE4OGIwNjM4NWI0OWZlNGE2MS90YWJsZTo0N2E0ZGZjZjFjMTY0ZGE1YjcyYThlZjFmNjNhNWRlMS90YWJsZXJhbmdlOjQ3YTRkZmNmMWMxNjRkYTViNzJhOGVmMWY2M2E1ZGUxXzE1LTAtMS0xLTA_8fdc4ac5-1d24-404f-925f-1610bdd02555">Other current liabilities</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 400100000 431200000 400100000 431200000 46900000 42500000 509800000 539000000.0 556700000 581500000 330300000 325600000 330300000 325600000 33300000 10500000 377400000 350500000 410700000 361000000.0 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of our finance and operating lease liabilities as of December 31, 2021 were as follows: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"/><td style="width:42.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.383%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.383%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: tenant allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount representing interest</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of our finance and operating lease liabilities as of December 31, 2021 were as follows: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.071%"><tr><td style="width:1.0%"/><td style="width:42.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.383%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.383%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: tenant allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount representing interest</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 87900000 41900000 129800000 93200000 42000000.0 135200000 97600000 38600000 136200000 95900000 35700000 131600000 94200000 33700000 127900000 327400000 290300000 617700000 796200000 482200000 1278400000 0 6500000 6500000 239500000 65000000.0 304500000 556700000 410700000 967400000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease terms and discount rates related to our leases were as follows: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.029%"><tr><td style="width:1.0%"/><td style="width:53.941%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.552%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.73</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.58</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.81</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.10</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> P10Y8M23D P11Y6M29D P12Y9M21D P14Y1M6D 0.0811 0.0836 0.0219 0.0228 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to our leases was as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.470%"><tr><td style="width:1.0%"/><td style="width:59.968%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.868%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.117%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 21500000 16300000 10700000 46200000 48900000 50500000 47000000.0 42300000 39200000 36300000 293600000 34600000 0 33100000 0 Common Stock, Preferred Stock and Equity Plans<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock and Preferred Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are authorized to issue 500.0 million shares of common stock. Holders of common stock are entitled to one vote per share. Holders of common stock are entitled to receive dividends, if and when declared by our Board of Directors, and to share ratably in our assets legally available for distribution to our shareholders in the event of liquidation. Holders of common stock have no preemptive, subscription, redemption or conversion rights. The holders of common stock do not have cumulative voting rights.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are authorized to issue 1.0 million shares of preferred stock in one or more series and to fix the powers, designations, preferences and relative participating, option or other rights thereof, including dividend rights, conversion rights, voting rights, redemption terms, liquidation preferences and the number of shares constituting any series, without any further vote or action by our shareholders. As of December 31, 2021 and 2020, we had no shares of preferred stock issued or outstanding. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchase Programs</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, our Board of Directors approved a share repurchase program (the “2018 Share Repurchase Program”), pursuant to which we repurchased $500.0 million of our common stock in 2018 and 2019. During the year ended December 31, 2019, we repurchased 0.8 million shares of our common stock under the 2018 Share Repurchase Program for an aggregate of $150.0 million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, our Board of Directors approved a second share repurchase program (the “2019 Share Repurchase Program”), pursuant to which we repurchased $500.0 million of our common stock in 2019 and 2020. During the years ended December 31, 2020 and 2019, we repurchased 2.1 million and 0.2 million shares, respectively, of our common stock under the 2019 Share Repurchase Program for an aggregate of $464.0 million and $36.0 million, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, our Board of Directors approved a third share repurchase program (the “2020 Share Repurchase Program”), pursuant to which we repurchased $500.0 million of our common stock in 2020 and 2021. During the years ended December 31, 2021 and 2020, we repurchased 2.0 million and 0.3 million shares, respectively, of our common stock under the 2020 Share Repurchase Program for an aggregate of $424.9 million and $75.1 million, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, our Board of Directors approved a fourth share repurchase program (the “2021 Share Repurchase Program”), pursuant to which we are authorized to repurchase up to $1.5 billion of our common stock by December 31, 2022. During the year ended December 31, 2021, we repurchased 5.3 million shares of our common stock under the 2021 Share Repurchase Program for an aggregate of $1.0 billion. We expect to fund further repurchases of our common stock through a combination of cash on hand and cash generated by operations. As of December 31, 2021, $499.7 million remained authorized for repurchases of common stock under the 2021 Share Repurchase Program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repurchases of our common stock are recorded as reductions to “Common stock” and “Additional paid-in capital.”</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock and Option Plans</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of each of our stock and option plans is to attract, retain and motivate our employees, consultants and directors. Awards granted under these plans can be nonstatutory stock options (“NSOs”), incentive stock options (“ISOs”), restricted stock units (“RSUs”) including performance-based RSUs (“PSUs”), restricted stock (“RSs”), or other equity-based awards, as specified in the individual plans.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issued under all of our plans are funded through the issuance of new shares. The following table contains information about our equity plans:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.003%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.003%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.003%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.003%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of Plan</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Group Eligible</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Type of Award </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Awards </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Authorized for Grant</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013 Stock and Option Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees, Non-employee Directors and Consultants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NSO, RS, RSU and PSU</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,558 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2006 Stock and Option Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees, Non-employee Directors and Consultants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NSO, RS and RSU</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:56.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,598 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,558 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All options granted under our 2013 Stock and Option Plan (“2013 Plan”) and 2006 Stock and Option Plan (“2006 Plan”) were granted with an exercise price equal to the fair value of the underlying common stock on the date of grant. As of December 31, 2021, we are only authorized to make new equity awards under our 2013 Plan. Under the 2013 Plan, no stock options can be awarded with an exercise price less than the fair market value on the date of grant. In 2019, our shareholders approved an increase in the number of shares authorized for issuance pursuant to the 2013 Stock and Option Plan of 5.0 million shares.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three years ended December 31, 2021, grants to current employees and directors primarily had a grant date that was the same as the date the award was approved by our Board of Directors. During the three years ended December 31, 2021, for grants to new employees and directors, the date of grant for awards was the employee’s first day of employment or the date the director was elected to our Board of Directors. All options awarded under our stock and option plans expire not more than 10 years from the grant date.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to the outstanding and exercisable options during the year ended December 31, 2021: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"/><td style="width:30.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.003%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.003%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.003%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average Remaining Contractual Life</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(per share)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(518)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,611 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.42</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,149 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value in the table above represents the total pre-tax amount, net of exercise price, that would have been received by option holders if all option holders had exercised all options with an exercise price lower than the market price on the last business day of 2021, which was $221.27 based on the average of the high and low price of our common stock on that date.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value (the amount by which the fair market value exceeded the exercise price) of stock options exercised during 2021, 2020 and 2019 was $43.0 million, $255.0 million and $325.9 million, respectively. The total cash we received as a result of employee stock option exercises during 2021, 2020 and 2019 was $64.2 million, $228.2 million and $317.8 million, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about stock options outstanding and exercisable at December 31, 2021: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:14.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.994%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.994%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.994%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.994%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.994%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.575%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Exercisable</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining Contractual Life</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(per share)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$36.28–$100.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.01–$150.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.56</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$150.01–$200.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.03 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.04 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$200.01–$286.27</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.92</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:32.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,611 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.42</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units (excluding PSUs) and Restricted Stock </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our restricted stock unit activity during the year ended December 31, 2021: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.160%"><tr><td style="width:1.0%"/><td style="width:56.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.380%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.008%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Stock Units (excluding PSUs)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average <br/>Grant-date </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,927 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(409)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,909 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of restricted stock units that vested during 2021, 2020 and 2019 (measured on the date of vesting) was $281.1 million, $370.3 million and $178.2 million, respectively. The total fair value of restricted stock that vested during 2020 and 2019 (measured on the date of vesting) was $21.4 million and $70.7 million, respectively. We have not granted any restricted stock since 2016, therefore, we did not have any restricted stock vest in 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance-based RSUs (PSUs)</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potential range of shares issuable pursuant to our PSU awards range from 0% to 200% of the target shares based on financial and non-financial measures. Fifty percent of PSUs that could be earned have a one-year performance period with the amount actually earned dependent upon our financial performance and with vesting of the earned shares in three equal installments over a three-year period. The remaining 50% of PSUs that could be earned have a three-year performance period with the amount actually earned dependent upon the achievement of multiple clinical development milestones and with the earned shares cliff vesting at the end of the three-year performance period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our PSU activity during the year ended December 31, 2021:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:56.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance-Based RSU</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Units</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average <br/>Grant-date <br/>Fair Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2020 (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.06 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1) “Unvested” represents our PSUs at target to the extent performance has not been certified plus the actual number of shares that continue to be subject to service conditions for which the performance has been achieved and certified.</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2) “Granted” represents (i) the target number of shares issuable for grants during 2021 and (ii) any change in the number of shares issuable pursuant to outstanding PSUs based on performance certification during 2021.</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of PSUs that vested during 2021, 2020 and 2019 (measured on the date of vesting) was $92.2 million, $138.5 million and $73.3 million, respectively. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an employee stock purchase plan (the “ESPP”). The ESPP permits eligible employees to enroll in a twelve-month offering period comprising two six-month purchase periods. Participants may purchase shares of our common stock, through payroll deductions, at a price equal to 85% of the fair market value of the common stock on the first day of the applicable twelve-month offering period, or the last day of the applicable six-month purchase period, whichever is lower. Purchase dates under the ESPP occur on or about May 14 and November 14 of each year. As of December 31, 2021, there were 1.8 million shares of common stock authorized for issuance pursuant to the ESPP.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the following shares were issued to employees under the ESPP:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.315%"><tr><td style="width:1.0%"/><td style="width:61.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares (in thousands)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price paid per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Benefits</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a 401(k) retirement plan (the “Vertex 401(k) Plan”) in which substantially all of our permanent U.S. employees are eligible to participate. Participants may contribute up to 60% of their annual compensation to the Vertex 401(k) Plan, subject to statutory limitations. We may declare discretionary matching contributions to the Vertex 401(k) Plan. We pay matching contributions in the form of cash. For the years ended December 31, 2021, 2020 and 2019, we contributed approximately $21.8 million, $19.2 million and $15.8 million to the plan, respectively.</span></div> 500000000 1 1000000 0 0 0 0 500000000 800000 150000000 500000000 2100000 200000 464000000 36000000 500000000 2000000 300000 424900000 75100000 1500000000 5300000 1000000000 499700000 The following table contains information about our equity plans:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.003%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.003%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.003%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.003%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of Plan</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Group Eligible</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Type of Award </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awards </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Awards </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Authorized for Grant</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013 Stock and Option Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees, Non-employee Directors and Consultants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NSO, RS, RSU and PSU</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,558 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2006 Stock and Option Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees, Non-employee Directors and Consultants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NSO, RS and RSU</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:56.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,598 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,558 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table> 7306000 9558000 292000 0 7598000 9558000 5000000 P10Y <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to the outstanding and exercisable options during the year ended December 31, 2021: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"/><td style="width:30.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.003%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.003%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.003%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average Remaining Contractual Life</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(per share)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(518)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,611 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.42</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,149 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4238000 140.47 27000 217.20 518000 125.78 136000 177.28 0 0 3611000 141.76 P5Y5M1D 288600000 3149000 136.13 P5Y2M8D 269600000 221.27 43000000 255000000 325900000 64200000 228200000 317800000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about stock options outstanding and exercisable at December 31, 2021: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:14.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.994%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.994%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.994%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.994%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.571%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.994%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.575%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Exercisable</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining Contractual Life</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(per share)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$36.28–$100.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100.01–$150.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.56</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$150.01–$200.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.03 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,652</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.04 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$200.01–$286.27</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.92</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:32.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,611 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.42</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 36.28 100.00 1085000 P3Y8M12D 82.14 1085000 82.14 100.01 150.00 362000 P3Y6M21D 123.15 362000 123.15 150.01 200.00 2114000 P6Y6M10D 173.03 1652000 171.04 200.01 286.27 50000 P8Y11M1D 248.51 50000 248.51 3611000 P5Y5M1D 141.76 3149000 136.13 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our restricted stock unit activity during the year ended December 31, 2021: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.160%"><tr><td style="width:1.0%"/><td style="width:56.240%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.380%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.008%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Stock Units (excluding PSUs)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average <br/>Grant-date </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,722 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,927 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(409)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,909 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2722000 206.99 1927000 208.48 1331000 193.29 409000 214.68 2909000 213.17 281100000 370300000 178200000 21400000 70700000 0 0 2 0.50 P1Y P3Y 0.50 P3Y P3Y <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our PSU activity during the year ended December 31, 2021:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:56.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance-Based RSU</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Units</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average <br/>Grant-date <br/>Fair Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2020 (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.06 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1) “Unvested” represents our PSUs at target to the extent performance has not been certified plus the actual number of shares that continue to be subject to service conditions for which the performance has been achieved and certified.</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2) “Granted” represents (i) the target number of shares issuable for grants during 2021 and (ii) any change in the number of shares issuable pursuant to outstanding PSUs based on performance certification during 2021.</span></td></tr></table></div> 656000 202.06 954000 212.44 431000 183.94 101000 214.72 1078000 215.85 92200000 138500000 73300000 P12M 2 P6M 0.85 P12M P6M 1800000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the following shares were issued to employees under the ESPP:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.315%"><tr><td style="width:1.0%"/><td style="width:61.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares (in thousands)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average price paid per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 219000000 171.57 0.60 21800000 19200000 15800000 Stock-based Compensation ExpenseWe recognize share-based payments to employees as compensation expense using the fair value method. The fair value of stock options and shares purchased pursuant to the ESPP is calculated using the Black-Scholes option pricing model. The fair value of restricted stock units, including PSUs, is based on the intrinsic value on the date of grant. Stock-based compensation, measured at the grant date based on the fair value of the award, is typically recognized as expense ratably over the requisite service period. <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effect of stock-based compensation expense during the three years ended December 31, 2021 was as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by line item:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense included in costs and expenses</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation included in costs and expenses, net of tax</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock-based compensation expense by type of award during the three years ended December 31, 2021 was as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by type of award:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including PSUs)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP share issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense included in costs and expenses</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize a portion of our stock-based compensation expense to inventories, all of which is attributable to employees who support the manufacturing of our products.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our unrecognized stock-based compensation expense as of December 31, 2021, by type of award and the weighted-average period over which that expense is expected to be recognized: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.327%"><tr><td style="width:1.0%"/><td style="width:53.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized Expense</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average Recognition Period</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type of award:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including PSUs)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.91</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.09</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP share issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.54</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unrecognized stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of the three years ended December 31, 2021, we issued stock options to our non-employee directors. In 2019, we issued stock options with service conditions, which were generally the vesting periods of the awards, to our employees. We use the Black-Scholes option pricing model to estimate the fair value of stock options at the grant date. The Black-Scholes option pricing model uses the option exercise price as well as estimates and assumptions related to the expected price volatility of our stock, the rate of return on risk-free investments, the expected period during which the options will be outstanding, and the expected dividend yield for our stock to estimate the fair value of a stock option on the grant date. The </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">options granted during 2021, 2020 and 2019 had a weighted-average grant-date fair value per share of $65.94, $88.37 and $61.32, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option granted during 2021, 2020 and 2019 was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.827%"><tr><td style="width:1.0%"/><td style="width:49.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.196%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.196%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.199%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options granted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,302</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,636</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520,743</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.03%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.87%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.99%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.86%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.32%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.27</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average valuation assumptions were determined as follows:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected stock price volatility: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility is calculated using the trailing one-month average of daily implied volatilities prior to the grant date. Implied volatility is based on options to purchase our stock with remaining terms of greater than one year that are regularly traded in the market. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-free interest rate: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base the risk-free interest rate on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected option term.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected term of options: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term of options represents the period of time options are expected to be outstanding. We use historical data to estimate employee exercise and post-vest termination behavior. We believe that all groups of employees exhibit similar exercise and post-vest termination behavior and therefore do not stratify employees into multiple groups in determining the expected term of options.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected annual dividends: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimate for annual dividends is $0.00 because we have not historically paid, and do not intend for the foreseeable future to pay, a dividend. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units and Performance-based Restricted Stock Units</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We award restricted stock units with service conditions, which are generally the vesting periods of the awards.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant PSUs to certain members of senior management. Half of the PSUs contain financial goals as the performance metric and the other half contain non-financial goals. A target number of shares is established for each award; however, the actual number of shares that are issued when an award vests may range from zero to 200% of the target amount depending upon the level of achievement of the applicable performance metric. The financial-based PSUs vest in three equal installments over a three-year period and are expensed ratably over that same period based upon an assessment of the likely level of achievement. The non-financial based PSUs cliff vest at the end of the three-year performance period and are expensed on a straight-line basis over that same period based upon an assessment of the likely level of achievement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair value of each purchase right granted during 2021, 2020 and 2019 was $51.71, $65.88 and $47.79, respectively. The following table reflects the weighted-average assumptions used in the Black-Scholes option pricing model for 2021, 2020 and 2019:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.827%"><tr><td style="width:1.0%"/><td style="width:49.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.196%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.196%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.199%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.06%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.70%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.43%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.05%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.69</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in our Black-Scholes option pricing model were determined utilizing calculations similar to those described under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> above.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effect of stock-based compensation expense during the three years ended December 31, 2021 was as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by line item:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense included in costs and expenses</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation included in costs and expenses, net of tax</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6300000 5600000 5600000 268300000 262700000 224600000 166800000 161200000 130300000 441400000 429500000 360500000 82900000 147000000.0 124200000 358500000 282500000 236300000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock-based compensation expense by type of award during the three years ended December 31, 2021 was as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.804%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by type of award:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including PSUs)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP share issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense included in costs and expenses</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 384300000 360400000 254300000 36800000 59700000 96700000 24400000 13000000.0 11200000 4100000 3600000 1700000 441400000 429500000 360500000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our unrecognized stock-based compensation expense as of December 31, 2021, by type of award and the weighted-average period over which that expense is expected to be recognized: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.327%"><tr><td style="width:1.0%"/><td style="width:53.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized Expense</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average Recognition Period</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Type of award:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including PSUs)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.91</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.09</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP share issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.54</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total unrecognized stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div> 423300000 P1Y10M28D 19100000 P1Y1M2D 12600000 P0Y6M14D 455000000.0 65.94 88.37 61.32 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option granted during 2021, 2020 and 2019 was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.827%"><tr><td style="width:1.0%"/><td style="width:49.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.196%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.196%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.199%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options granted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,302</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,636</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520,743</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.03%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.87%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.99%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.86%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.32%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.27</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr></table></div> 27302 22636 1520743 0.3503 0.3587 0.3699 0.0086 0.0043 0.0232 P4Y6M P4Y8M1D P4Y3M7D 0 0 0 0.00 0 2 3 P3Y P3Y 51.71 65.88 47.79 The following table reflects the weighted-average assumptions used in the Black-Scholes option pricing model for 2021, 2020 and 2019:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.827%"><tr><td style="width:1.0%"/><td style="width:49.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.196%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.196%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.199%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.06%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.70%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.43%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.05%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.69</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr></table> 0.3406 0.3770 0.3343 0.0005 0.0011 0.0208 P0Y8M8D P0Y8M15D P0Y8M26D 0 0 0 Income Taxes <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S. federal, state, and foreign income taxes. The components of income before provision for income taxes during the three years ended December 31, 2021, consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.648%"><tr><td style="width:1.0%"/><td style="width:55.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,030.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,885.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,730.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,116.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the provision for income taxes during the three years ended December 31, 2021, consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.648%"><tr><td style="width:1.0%"/><td style="width:55.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current taxes</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S. federal statutory rate of 21% and our effective tax rate is as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.648%"><tr><td style="width:1.0%"/><td style="width:55.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign income tax rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax rate change</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation (benefit), shortfalls and cancellations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term intercompany receivable write-off</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inter-entity transfer of intellectual property rights</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. tax on foreign earnings, net of credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 14% effective tax rate for 2021 was lower than the U.S. statutory rate primarily due to discrete tax benefits of (i) $94.8 million associated with an increase in the United Kingdom’s (“U.K.”) corporate tax rate from 19% to 25%, which was enacted in June 2021 and will become effective in April 2023, and (ii) $44.1 million resulting from an R&amp;D tax credit study that we completed in 2021. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 13% effective tax rate for 2020 was lower than the U.S. statutory rate primarily due to (i) a discrete tax benefit of $209.0 million associated with an intra-entity transfer of intellectual property rights to our U.K. entity, (ii) a discrete tax benefit associated with the write-off of a long-term intercompany receivable, (iii) a discrete tax benefit associated with an increase in the U.K.’s corporate tax rate from 17% to 19%, which was enacted and became effective in July 2020, and (iv) excess tax benefits related to stock-based compensation. The impact of these items was partially offset by U.S. income tax on foreign earnings.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 16% effective tax rate for 2019 was lower than the U.S. statutory rate primarily due to excess tax benefits related to stock-based compensation and research and development tax credits.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are determined based on the difference between financial statement and tax bases using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred taxes were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.505%"><tr><td style="width:1.0%"/><td style="width:48.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,182.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a periodic basis, we reassess the valuation allowance on our deferred income tax assets, weighing positive and negative evidence to assess the recoverability of our deferred tax assets. As of December 31, 2021, we maintained a valuation allowance of $220.4 million related primarily to U.S. state tax attributes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had net operating loss (“NOL”) carryforwards of $29.8 million and tax credit carryforwards of $4.1 million, which are subject to annual utilization limitations for U.S. federal income tax purposes. As of December 31, 2021, we had NOL carryforwards of $616.3 million and tax credit carryforwards of $237.2 million for U.S. state income tax purposes. In 2030, $26.0 million of our U.S. federal NOLs will begin to expire, while the remaining portion may be carried forward indefinitely. The state NOL and tax credit carryforwards expire at various dates through 2041 and may be used to offset future state income tax liabilities. As of December 31, 2021, we had foreign NOL carryforwards of $292.5 million and foreign tax credit carryforwards of $22.2 million. The foreign NOL carryforwards may be carried forward indefinitely, with the exception of $44.3 million that will expire at various dates through 2040. The foreign tax credit carryforwards will begin to expire in 2024.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized tax benefits during the three years ended December 31, 2021 were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.648%"><tr><td style="width:1.0%"/><td style="width:55.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current period tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to prior period tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to prior period tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement with tax authorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Statute of limitations expiration</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we have classified $14.4 million and $132.8 million of our unrecognized tax benefits as credits to “Deferred tax assets” and “Accrued expenses,” respectively, on our consolidated balance sheet.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. Unrecognized tax benefits represent the aggregate tax effect of differences between tax return positions and the benefits recognized in our consolidated financial statements. As of December 31, 2021, 2020 and 2019, we had $129.5 million, $75.8 million and $33.9 million, respectively, of net unrecognized tax benefits, which would affect our tax rate if recognized. We do not expect that our unrecognized tax benefits will materially change within the next twelve months. We did not recognize any material interest or penalties related to uncertain tax positions during the three years ended December 31, 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, foreign earnings have been retained by our foreign subsidiaries for indefinite reinvestment. Upon repatriation of those earnings, in the form of dividends or otherwise, we could be subject to U.S. federal withholding taxes payable to various foreign countries and income taxes in certain states. We are permanently reinvested for book/tax basis differences. These permanently reinvested basis differences could reverse if we sell our foreign subsidiaries or various other events, none of which were considered probable as of December 31, 2021. The tax liabilities described above would not be material to our consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We have various income tax audits ongoing at any time throughout the world. Except for jurisdictions where we have NOLs or tax credit carryforwards, we are no longer subject to any tax assessment from tax authorities for years prior to 2018.</span></div> The components of income before provision for income taxes during the three years ended December 31, 2021, consisted of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.648%"><tr><td style="width:1.0%"/><td style="width:55.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,030.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,885.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,730.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,116.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 2030700000 2885400000 1263400000 699700000 231500000 131500000 2730400000 3116900000 1394900000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the provision for income taxes during the three years ended December 31, 2021, consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.648%"><tr><td style="width:1.0%"/><td style="width:55.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current taxes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current taxes</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(239.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 374900000 71400000 0 141500000 37600000 37200000 26500000 18900000 13500000 542900000 127900000 50700000 -36900000 510200000 184300000 -98400000 -239600000 -24800000 -19300000 6700000 7900000 -154600000 277300000 167400000 388300000 405200000 218100000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S. federal statutory rate of 21% and our effective tax rate is as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.648%"><tr><td style="width:1.0%"/><td style="width:55.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign income tax rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax rate change</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation (benefit), shortfalls and cancellations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term intercompany receivable write-off</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inter-entity transfer of intellectual property rights</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. tax on foreign earnings, net of credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.210 0.210 0.210 0.008 0.006 0.006 -0.003 0.002 0.004 0.064 0.018 0.043 -0.035 -0.012 0 0.000 -0.023 -0.040 0 -0.017 0 0.020 0.013 0.010 0 -0.067 0 0.007 0.027 0 -0.001 0.009 0.009 0.142 0.130 0.156 0.14 -94800000 44100000 0.13 -209000000 0.16 The components of the deferred taxes were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.505%"><tr><td style="width:1.0%"/><td style="width:48.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,182.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 106600000 140600000 202400000 406100000 802800000 507500000 94600000 89200000 48600000 47300000 103400000 118700000 81100000 65000000.0 41700000 22100000 1481200000 1396500000 220400000 213800000 1260800000 1182700000 118200000 117000000.0 87000000.0 87000000.0 64800000 63300000 56300000 32600000 326300000 299900000 934500000 882800000 220400000 29800000 4100000 616300000 237200000 26000000 292500000 22200000 44300000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized tax benefits during the three years ended December 31, 2021 were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.648%"><tr><td style="width:1.0%"/><td style="width:55.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current period tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to prior period tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to prior period tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement with tax authorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Statute of limitations expiration</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of period</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 86600000 33900000 19500000 42000000.0 26700000 14500000 19900000 26700000 600000 0 0 200000 0 0 500000 1300000 700000 0 147200000 86600000 33900000 14400000 132800000 129500000 75800000 33900000 Commitments and Contingencies<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revolving Credit Facilities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vertex and certain of its subsidiaries have entered into two credit agreements (the “Credit Agreements”) with Bank of America, N.A., as administrative agent and the lenders referred to therein (the “Lenders”). The Credit Agreements were not drawn upon at closing and we have not drawn upon them to date. Amounts drawn pursuant to the Credit Agreements, if any, will be used for general corporate purposes. Any amounts borrowed under the Credit Agreements will bear interest, at our option, at either a base rate or a Eurocurrency rate, in each case plus an applicable margin based on our consolidated leverage ratio (the ratio of our total consolidated funded indebtedness to our consolidated EBITDA for the most recently completed four fiscal quarter period). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, Vertex and certain of its subsidiaries entered into a $500.0 million unsecured revolving facility (the “2019 Credit Agreement”) with the Lenders, which matures on September 17, 2024. Under the 2019 Credit Agreement, the applicable margins on base rate loans range from 0.125% to 0.500% and the applicable margins on Eurocurrency loans range from 1.125% to 1.500%. The 2019 Credit Agreement provides a sublimit of $50.0 million for letters of credit.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Vertex and certain of its subsidiaries entered into a $2.0 billion unsecured revolving facility (the </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“2020 Credit Agreement”) with the Lenders, which matures on September 18, 2022. Under the 2020 Credit Agreement, the applicable margins on base rate loans range from 0.500% to 0.875% and the applicable margins on Eurocurrency loans range from 1.500% to 1.875%. The 2020 Credit Agreement does not support letters of credit.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to satisfaction of certain conditions, we may request that the borrowing capacity for each of the Credit Agreements be increased by an additional $500.0 million. Any amounts borrowed pursuant to the Credit Agreements are guaranteed by certain of our existing and future domestic subsidiaries, subject to certain exceptions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreements contain customary representations and warranties and affirmative and negative covenants, including financial covenants to maintain (x) subject to certain limited exceptions, a consolidated leverage ratio of 3.50 to 1.00, subject to an increase to 4.00 to 1.00 following a material acquisition and (y) a consolidated interest coverage ratio of 2.50 to 1.00, in each case measured on a quarterly basis. As of December 31, 2021, we were in compliance with the covenants described above. The Credit Agreements also contain customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct costs related to the Credit Agreements are recorded over the term of the Credit Agreements and were not material to our financial statements. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guaranties and Indemnifications</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Massachusetts law, our Articles of Organization and By-laws provide that we will indemnify certain of our officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that we could be required to make under these indemnification provisions is unlimited. However, we have purchased directors’ and officers’ liability insurance policies that could reduce our monetary exposure and enable us to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and we believe the estimated fair value of these indemnification arrangements is minimal.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We customarily agree in the ordinary course of our business to indemnification provisions in agreements with clinical trial investigators and sites in our drug development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for us, and our real estate leases. We also customarily agree to certain indemnification provisions in our drug discovery, development and commercialization collaboration agreements. With respect to our clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of our contractual obligations arising out of the research or clinical testing of our compounds or product candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by us, to violations of law by us or to certain breaches of our contractual obligations. The indemnification provisions appearing in our collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for our collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although we believe the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that we could be required to make under these provisions is generally unlimited. We have purchased insurance policies covering personal injury, property damage and general liability that reduce our exposure for indemnification and would enable us in many cases to recover all or a portion of any future amounts paid. We have never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, we believe the estimated fair value of these indemnification arrangements is minimal.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Contingencies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain contingent liabilities that arise in the ordinary course of our business activities. We accrue a reserve for contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. Other than our contingent consideration liabilities discussed in Note D, “Fair Value Measurements,” there were no material contingent liabilities accrued as of December 31, 2021 or 2020.</span></div> 2 500000000 0.00125 0.00500 0.01125 0.01500 50000000 2000000000 0.00500 0.00875 0.01500 0.01875 500000000 3.50 4.00 2.50 0 0 0 Segment Information<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment reporting is prepared on the same basis that our chief executive officer, who is our chief operating decision maker, manages the business, makes operating decisions and assesses performance. We operate in one segment, pharmaceuticals. Enterprise-wide disclosures about revenues, significant customers, and property and equipment, net by location are presented below.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues by Product</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.648%"><tr><td style="width:1.0%"/><td style="width:55.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRIKAFTA/KAFTRIO</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,697.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,863.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SYMDEKO/SYMKEVI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,417.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ORKAMBI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KALYDECO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,573.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,202.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,160.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenues by Geographic Location</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues are attributed to countries based on the location of the customer and consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.648%"><tr><td style="width:1.0%"/><td style="width:55.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,287.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,826.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,060.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside of the United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,972.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues outside of the United States</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,286.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,573.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,202.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,160.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Significant Customers</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross product revenues and accounts receivable from each of our customers who individually accounted for 10% or more of total gross product revenues and/or 10% or more of total accounts receivable consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.476%"><tr><td style="width:1.0%"/><td style="width:27.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.065%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percent of </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Gross Product Revenues</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percent of </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accounts Receivable</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accredo/Curascript</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Walgreen Co.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt;10 %</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lloyds Pharmacy*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt;10%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt;10%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt;10%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="30" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*A wholly-owned subsidiary of McKesson Corporation in the U.K.</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-lived Assets by Location</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets by location consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.327%"><tr><td style="width:1.0%"/><td style="width:53.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside of the United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-lived assets outside of the United States</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-lived assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.648%"><tr><td style="width:1.0%"/><td style="width:55.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRIKAFTA/KAFTRIO</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,697.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,863.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SYMDEKO/SYMKEVI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">628.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,417.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ORKAMBI</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,331.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KALYDECO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,573.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,202.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,160.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5697200000 3863800000 420100000 420400000 628600000 1417700000 771600000 907500000 1331900000 684200000 802900000 991000000.0 7573400000 6202800000 4160700000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues are attributed to countries based on the location of the customer and consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.648%"><tr><td style="width:1.0%"/><td style="width:55.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,287.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,826.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,060.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside of the United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,972.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues outside of the United States</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,286.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,573.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,202.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,160.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets by location consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.327%"><tr><td style="width:1.0%"/><td style="width:53.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,348.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,207.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside of the United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-lived assets outside of the United States</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-lived assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5287300000 4826400000 3060300000 1972900000 1126500000 885900000 313200000 249900000 214500000 2286100000 1376400000 1100400000 7573400000 6202800000 4160700000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross product revenues and accounts receivable from each of our customers who individually accounted for 10% or more of total gross product revenues and/or 10% or more of total accounts receivable consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.476%"><tr><td style="width:1.0%"/><td style="width:27.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.065%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percent of </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Gross Product Revenues</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percent of </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accounts Receivable</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accredo/Curascript</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Walgreen Co.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt;10 %</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lloyds Pharmacy*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt;10%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt;10%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&lt;10%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="30" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*A wholly-owned subsidiary of McKesson Corporation in the U.K.</span></td></tr></table></div> 0.22 0.20 0.17 0.21 0.14 0.12 0.15 0.14 0.10 0.10 0.10 0.14 0.15 0.10 0.10 0.10 0.10 0.10 0.15 0.19 1348100000 1207700000 60900000 61500000 15400000 14900000 76300000 76400000 1424400000 1284100000 EXCEL 130 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( +&$250'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "QA$E4_AM56.\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2@,Q$(=?17+?G?T#%L,VETI/%00+BK>03-O@9A.2D=V^O=G8;A%] "&7S/SR MS3>03GFN7,#GX#P&,ACO)ML/D2N_9B$IJKNP2))+4G"#"S\0F2BTXJK@))_@!IAAA,'&[P+JA9BK?V)S!]@E.46SI,9Q+,SQS6[3GYM-X_[+1--U31%E<[#OJEYN^+UZGUV_>%W$[9.FX/Y MQ\970='!KW\AO@!02P,$% @ L81)5)E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" "QA$E4MGV &UP& "B&0 & 'AL+W=ODU2ST[3=L,^T!)M"9%(CZ3B MY-_O*-F2$\@G ?MBZ^T>/;PCGSN>3M=2/>J(TT3HLTYDS.ICKZ>#B*=, M'\H5%W!G(57*#)RJ94^O%&=A;I0F/==QAKV4Q:)S?II?FZCS4YF9)!9\HHC. MTI2IEPN>R/59AW:V%Z;Q,C+V0N_\=,66?,;-U]5$P5FO1 GCE L=2T$47YQU M?/KQTCNR!OD3#S%?ZYUC8H)!8)>/R[ M >V4[[2&N\=;].M\\#"8.=-\))-O<6BBL\YQAX1\P;+$3.7Z$]\,:&#Q IGH M_)>LBV?[_0X),FUDNC$&!FDLBG_VO''$CL&QL\? W1BX;PSHOC=X&P.OK4%_ M8]#//5,,)??#)3/L_%3)-5'V:4"S![DS7Y/V[#^0=B06YB),$(J-/>P;>8Y_N!1O,BP+3W8-)77(KA8DTN1(A M#U\#](!@R=+=LKQP4<1+'AP2CQX0UW%I#:$1;OX'$Z6Y6V-^V6">67.G[NVO M1N.5/O=R/ _U^=_^7!L%\_X?!+)?0O9SR/X^!\D@@]5HR/W+BM=%##>G3ON+1$X0/ M=2K1=-HPFO)E;-7WTGDT_^]-8?77V]'X_\FQD9WXU( MC]SZ&-D=A:=MR(Y%(!4$DMF8'I"9@9E&I"(CF0FC7N _K!\!CHZ3="N2;AN2 M]^R9C$.8?_$B#G*F2,0;()U^UW.\$^JB,:]$FWIM&/IAJ+C6!]L#<@//D2^B MWGB3@F/@&K7$%QB7]+;0*C!F'^*U[M7QDX(M0:U,&X M5;F"-B2+G!F4]?NIX !#>H01J9(#Q17]1MID-8FDP)2X <3KT^Z0.JAKJM1 M<5V_CPUD!;D@U'T__T!F/,@4>*N6%HXTDFD*C.GUWZ?V*,KE*NEG:"_0X()H*4E*Z8J'??_]L?N%46<''M'H^NI\3/PMA +>$;PR%W MY\7C=<*6M:[49F&3S) [ /9+5 M+<3+#ZMY>*;O72ME?I]H\K6KR)3,0-6'S8EV'9X,\ MW&'D#OJ#H^'PA.ZAM=./P:5XN^G5.YLD6,QSN\-;2V[61M6FZ;6?EXXW/4/ MC%65ICP\O?A *2QH[9':!H"]TM;;:6K;E)-_'- DL.V*HK]=7BT_0/AYV[U7 M/5Y\O;AE-F-IDO %F#J'1Q R57P0*$Z,7.4M\KDT1J;Y8<09+#?[ -Q?2&FV M)_8%Y6>9\_\ 4$L#!!0 ( +&$253R&L3'( ( ' % 8 >&PO=V]R M:W-H965T&ULC91=;YLP%(;_BL7%KJJ0.!_;.H*4-*T6*9FB M5NLT3;MPX 2L8IO9A]'^^]F&T$Q*4&[ QS[OX_<8CJ-:Z1>3 R!Y%84T\R!' M+&_#T"0Y"&8&J@1I5PY*"X8VU%EH2@TL]2)1A'0XG(6"<1G$D9_;Z3A2%19< MPDX34PG!]-L2"E7/@U%PG'CD68YN(HRCDF7P!/B]W&D;A1TEY0*DX4H2#8=Y ML!C=+FF$I^,C_<'7;FO9,P-WJOC!4\SGP:> I'!@58&/JOX*;3U3QTM48?R3U$TN M_1R0I#*H1"NV#@27S9N]MN=P*J 7!+054.^[VX@F1 QJ,;0H=TU,,;=T6./6]\;9'DUV)O4-M?XG"_8 )[7$Q[5Q,KW+QC0DX9Z%??:^E0?*!B?(+ M^:DJF9'-9M?C:M:YFEWE:J.2B[]7/V&I;!/(&[)EQK DKPP@FG/.PI,N$* S MW^N&)+8:;!JBF^VNDT731>_IS5VT93KCTI "#E8Z''RTAZ>;_FX"5*7OJ;U" MVZ%^F-LK$;1+L.L'I? 8N VZ2S;^!U!+ P04 " "QA$E4.7KXMWP% "? M%@ & 'AL+W=O*RF/<,D)'%"$BH!20GF6ZZ0.!4%K7X^LIQ?'F9X]O[B)=L?I'JQ M6"V/=,^V3'X_/E?PM.B\I%G!2I'Q$E5L]S#[@N\W)%8&->+OC%W$X#-25%XY M_Z$>OJ8/,T=%Q'*62.6"PK\S6[,\5YX@CG];I[/N-Y7A\/.[]]]K\D#FE0JV MYOD_62H/#[-HAE*VHZ=:^#5F6FHU'G84$E7RXI?4*70X$U] MJ)-96P/]K%1UW\H*OLW 3J[6O!0\SU(J68JV$OY!4:5 ?(>^'5E%57$$^HR^ M;S?HXX=/2!QHQ03*2O24Y;GZ\@Y]&#XN%Q+"4LX721O"8Q,"F0@!$_3$2WD0 MZ+FU@P7PZ4B1=U*/Q.IQPY(Y8XMK!QNQ*Y MM3]WPM\+.[/RQ,2]Q9?7^?)J7Y[=EZE(C:%?&ZII<5Z%?NC-O>7B/$R=#@N( MX\_#:]A&AWDX(/.H@UV%[W?A^]94K+F WJ1EBM@;3#YA3TK0>0VL25%>5<,+ MFC-C_S;FX8!,['AS,LJ,C@K=8.Z.$J.C?"^.]!R MS]0 W=&L0F>:GYCJQ00F(A!7-82/(DO;66PB&6N!?78UCCH(:Z"-#IJL('9Z MA7&L%/_B$@J7:$O7J!2.'D$8D_$J6AMPKNO%XVFU,>!('/@#?]>D!K*)K:2^ ME@DO&-I5O$"\$THC):R'$$9$*Y )%_GZ #'@,([#R3J1GA+Y!27)0-LE-*/B M9N1"# T2CXGH($+&TW)C0 7N0$:N2?1:B=W;2+1=9F3AZ@LFP./UOC;!8,%K M1,RPJ7+T2HWM4OU-'EC5UN(.E4P:J7BW%$0'P2*8!V,B.@S'P\)=$^DU&_NW M+)57!J<4AHX5/V?UJ0$>6WI(TK>)>> ;%H_K:+L2 \[%.!BG8F/ 83<>INR: M9+^%P/8]Q//_HZ7O MPHTJ><#O-@KZ5UH XC.!H,F&M._:8"VW<5?S+K+ BU M+1YQ/<-<,^!"C+4=HP&'<1A,;8UPOX7 D773V-- ,*A!B(H"RE0?9&R[1]Q+ M.+9K^",568(^*A$_B;3^D=K[)V/:&E_1<#,Y=[0EJZ,P=+TF;SH,!'LB8Z17 M;&)7[$V6G]1Y\.--C%IG(T;C-C"@@!$9+U ##!A-M#+IY9I@:P]LFV/K20 K M(-410@G-DU/>J+>M&T@OH\0NHVTW9&V+"7/.#!KIA^,UL3;"XL&2:)-F@@53 M8DIZ,25V,1WV@8V,KH JRG%/FV @^>.>-L*<23*]GA*[GL*$3D^)1%5[G#9H MZK7G7N"(_51ZRP&=]$I"[$IB.:*WEJ,SNI;"M0$'AW2B]XV.@U/Z=*Y[Y2!V MY6CV+N^9MJ6EG^+$/L5O2G(_LHE]9-N2W%C&PT$USF^L2YJVU3""QH-L,;BY M*UBUKV] !6C4J93-?5?WMKME_5+?+8[>/^+[37-7VKMIKFZ?:+7/2H%RM@.7 M4%R(J&IN0YL'R8_U_> KEY(7]<<#HW#@5 #X?L>Y?']0/]#=2:_^ U!+ P04 M " "QA$E4G?,:TI0# "\"@ & 'AL+W=O,"P^6%+ ECQA/LX]_:J=/$-,#V M_;OWSY8\D%EC19:"_:"Y+N;.U$$YV> ]T]_$X2]2$YH8?YE@ROZC0VWK.RC; M*RW*&@P[*"FOKOBU%J(%")(3@+ &A%U ? (0U8#HHX"X!L16F8J*U6&%-5[, MI#@@::S!F[FQ8EHTT*?"!R$ MZ%YP72CTB>D[/Z/''HJHS^!U52")93OD473"A%U"7:0GN%BN%0E_*9:+QF M!"F2[275E*@KQ(D>$K4*F+9D&/LM$2I)!XW"CJ"54=(6=%C+M&&;?I1M1:[A M"BSAL(%NRJ$[24EX]F86#ECFH#VWWV-%V7RW&K^:R^@B#-SIY14:!;$;(!FW0T2GL:C8-X6*5IH]+TK$J? MNT( >ZX8K@ZT_#=T;U/ 0\2FO=UT64W[K$"\;BGUK0+?C89I73>TKL_2^D=H MS) X64[5QW Y1.NZGZ_8C?W6K]LR^HAQDKB3#LT!J["EQ1'-P/]S]/EGB2X' MR T>9'Z_K\5A;Y?+(;LDGO3*=< .&F#L=HO6:QWK)9%;.QXIR,F>Z^I8;%:; M$>S6#AZ=]3LSFMEQX8^;:JZ[QW)KZIN1#;CTW10V):M1J7K08F>'A[70,(K8 MVP+&2R*- ;S?"*'?'TR 9F!=_ ]02P,$% @ L81)5('?5T>! @ _ 4 M !@ !X;"]W;W)KQCVH-A,+%26,DF)VWW]*-GQTJXI^F)=S'-(BN3)&J6? M3(5HX;D6THR"RMKU31B:HL*:F8%:HZ0_2Z5K9NFH5Z%9:V2E!]4BC(?#B[!F M7 9YYN]F.L_4Q@HN<:;!;.J:Z9Q92EZC-%Q)T+@X<]0'1Q !!W@/@M(#T 2#I M\EE V@'\4X=M*OX=ILRR/-.J >VLB M,HLES"TM5%-K0"UAHFKJI,J5>(MP)PM5(QS/F":#"BTOF#B!,WB<3^'XZ 2. M@$NXYT)0.4T66@K.N0B++I!Q&TA\() HAGM%Q :^R!++UP0A9=6G%N]2&\OUW'MUDK3-S^)H<)6%V_W*_&\5I8/DM=&T-;K> M,[KL+=J>RJ.35;*O4[L-R*;,M*ZE< MB!VK]#=K49=4Z==ZLY2[FM&\;5062PQAM"PIKV;7J_:SN_IZ)1I5\(K=U4 V M94GKE\^L$/NK&9J]?O"=;[;*?+"\7NWHAMTS]6-W5^NW9>\EYR6K)!<5J-GZ M:O8)?;@A@6G06OS-V5Z.GH$)Y4&(1_/R);^:0:.(%2Q3Q@75OY[8#2L*XTGK M^-DYG?5]FH;CYU?OO[7!ZV >J&0WHOB'YVI[-4MF(&=KVA3JN]C_P;J 0N,O M$X5L_P?[SA;.0-9()KVJQ1[4QEI[,P]M;MK6.AI>F6&\5[7^ENMVZOI&5%(4/*>*Y> S+6B5 M,7!OW$EP"7[ 5^,J+0F=>KI9*=VR:+[.ND\^'3O!$)['!XW7^IP^YAQ'S-N_9&IF)NZ9I4"5$H=Y@>/1])[)*W'8,HC ME5M JQQDYH'];/@3+707SEP=7*6M*[/*GJZC. U7RZ=Q1@Y&X<@H3)-D@7NS M(YU!KS/PZOQ*ZT>FZ$/!@&194W/%F5/CP4T\ZC[&Z2(]$6E;13%=;&73+8S4Z@M MJW5%&4]]E^[84A0&H951VXK 9$'=^+5_9=0M'B#Q,3J/ TCN(A.--IF M"2)D:MC37F1Z)KD:H;5Z:9-J5OI.0TU-SM#4GJ$P#:QY8)NE8;((W5(1'(H[ M](K]78A\K\NVLV1#AS2(1R6FJ\UG[8[%CJP[']&H]P#" M4XE^HV-] R40]NJ[96NFIV(.%'WV*<3VV)%@<5K0'69)@J>6.AK(@_SH^:9G M(U6\VH""Z>V,3RBQ%RV!HT7;"768X7"TNHZ%#NA!?O9\:PN01YY-$X2@57D< M9D$Z57G0 !WDI\ZA]GC4.5!# H+M<78Q*0[1Y$@/O$'1F[8M!:Q3%B46%SNXHD !.5=J!"LB/A6]'>!T-D5.K7>YQE(S(U$FUS0B*IP"&!RI@ M/Q6..7M&:^=KG"^,@E-(8 (A@>((']D/A35)M+Q>H2K'G5'DX.9>Z< M:F1O8V!J%1-L@R,DZ83FT?'"#XY!LS@ISN=4VXP@<6S-"Y=9""=S/: $^U$R MZ,Y$952;Z:$?)<_;,$3E%&WS B6151>=9ND45O" %?P6K!2]]',I=E'&/C&X MS& RN?0&S."W8.:<1ALAA#A0T]F-9R^!T=0T&#B#_0>;&U&67)E=[>'DT$^& M;$IO9.DXW:%Y38YU#MC"L9>']UM:LZTH].24O_Z28!1_;#?DZL6'13Q0!_NI MHX]1W090*I$]SL$%7$"D(5D#?;IOV$> YA!"\P.DT:+3U:BM/A'^R_*/H!(5 M UQ* Z[V -8HJ3>\N4ZE,XDVEZPD^DR.@QRXA?W<,H,MJLD(PT-\[ACG (?! M/(C3.0RB-D8=AD+Z:NS,PUZ=[N6/M'5[QXLR'@Y'V"G 93904,O"1 M^/GX*<^YJ79ZI9IS]"6O0$9W7*]R-*[%!&B?I1$4A R")'Y!Z M;]243='>WW5G?%'N],(P5ZU/>@96^IV!=X60\KU3OXU*%%I7/0ZKRVCRA$H& M5A(_*[\S1?5'>F]'ZTI/#/>-F0-X&#I2[#ACZ6/TQ(44&=WN^<%XJ-IRLMXX M-1-[GPF1=70E-A:32.,S3H=_$_('1!(_(BWHM*OQ?X836!>2[O./R]!Y_EF. M+JW-7PR^TGK#*ZEW2FO=$BYB[:(^7,(?7I38M??8#T(I4;:/6T:U?&.@OU\+ MH5Y?S-5X_Z>0Z_\ 4$L#!!0 ( +&$253/[%GOT@( +4) 8 >&PO M=V]R:W-H965T&ULG59=;]HP%/TK5K2'5NJ($Q(@%2"U5-7V M, D5;7N8]F 20ZPZ=F8[L.W7[]I),VC#5WD ?]QS[CDW-]CCK53/.J?4H-\% M%WKBY<:4M[ZOTYP61/=D207LK*0JB(&I6ONZ5)1D#E1P/\1XX!>$"6\Z=FMS M-1W+RG FZ%PA714%47_N*9?;B1=X+PM/;)T;N^!/QR59TP4U7\NY@IG?LF2L MH$(S*9"BJXEW%]S. FP!+N(;HUN],T;6RE+*9SOYG$T\;!513E-C*0C\;.B, MOAM1K.CX^@?X%@8L0S\:)%?HD0DPS@A'H) IM"*\HND),H$IGJ*2JKNUU M5VUK_I'CMZ_F9HI[&,JXV:W@B: ]Z5$K/;I,>OW\$:E,+A7["QM7X*!>[91> M\P]V5 78?5ZI/QVW9R!N#<3O,L"TKDZ+C]^(>BW[6,2>X$$K>/ NP? GK T1 M&1/K4ZH')U4?B]A3/6Q5#X^JGLFB@-?FO?T]/*>_3P3MZ1ZUND<7Z+ZXN4=O MZAACW-G>YT3N.4A:!\GE#L[K[N2-IC".HF&"H\$K]5V1R6B4Q%'2K3[ _T\@ M?+G^"YJ]H3_'16=HMPU_YTRU%YHO1*V9T(C3%6!Q;PCOO:KO"/7$R-(=LTMI MX-!VPQSN5539 -A?26E>)O;D;F]JTW]02P,$% @ L81)5+RM6#*1!@ M R$ !@ !X;"]W;W)KG),L$Y&XCF\RZ.C0IG!L7_^( M?E%WGG?F+JK(.ZGHY[+1<2BTWE)'T IK'DT<5$O MB-J;3V%:B+5[RTK^;TEH1Y)?U,690:W<[O;^2[?99'(!+! M#,2*XWUW^:S]Q3:D!%P;W[PV8E?A(_"IB&E.P/L_:%4=&<)?VL/?$,:W/1Y[ M&95%6JPK\+[=XH*LTCAEIL!7;Q+XE7,YY4EPR 1TR 142W-[I)V1=5H(37PO MS*(BYJ/'9VB_OH] Q+BX> (P/ ;(@:%I\>SC!W5\P8S[4^1Y$S2?WAMDX8,L M_$Q93Y!RMH_IM:2X+FYKV6>4;C9VG0E6K1:Z%9IXJLU2MPE%V#\/MUFZX9[AYXO 2H.*3S\>XOCH2NUF=\G(O_$WN M@I8UYQU:\ZR3NT_=6$G=5*9N)E+W&!2\?N&+GD6/IGGVM"4W1MT!O1@P4I3[ M!^6^5?F?7-9>J4F6K[4(8>!/PLY,#YHITH*#M, J[89L=V6\X5-78RS>;]J5 MF,%V2ILR>!_8;X\4-(L)#V+"EXHQ#5QH$!#ZG5P;,%)TS@XZ9U:=Y^U1>DC9 M9D.R!/#:&)!\F]'OA(@E".A=EJXCU@?VF:ZL*]YJHDB'3E/#.%;QGZIJ5V^- MW>G>%3QAP1TI.%<8V/+]LQI: K*I]J)T^U8D;%59\,T4&BLFJ T;=CM#NY!& MZNX*.^,OC0(EDC>9]?2PH2>TX[/>(IU LBCN#9N$U G)O91 MEU++03-5B/N9<:5@;4Z0US>.#7^@^QQ13Q!R)B.VQ\=W0HWV M"VFG@KR;GX9@P0P'7;L+::1,.&FM#["9"&#>N@'7:OQC34 M23?V?:TZ&C13]3= A'8BVF$MG96Z-8!0J\N&[51Y#2+ABQDYN%N'IMK&[5'4 MP!#::?A,:LMHB@H/S_2]=]!./;DT $1V #Z?WD,#BW0,CIT^#J*&@\C.P;5ER:1 M7MB[\AI6HN GU!:H@1^RP^_5M072$1BZ$]=IO6!WB)_CHO:K02BR(]1>L3;#.2M1W',$-*;&=E*^M3;".2N@8'DD/F:GR&Z)B.U%? M4IM@G5:NZ^F2A\Q4R0W4L/T ^/3:!!J7@>'DY[F]LAKV83O[[+6)2ATWU,?6&P@UI"7QJLL#AL=,],T]:/M>+? SY'Y3KE MJ9B1%7=T)@&/4.Y_<=_?,+JM?[^]HXS1O+[CAILG7?PL]U)6Y/F0Y>7M M;%]5Q\_+99GLY4&4"WV4.?RRT\5!5'!;/"[+8R%%6C>'R(%0^N[NI MG]T7=S?Z5&4JE_<%*4^'@RA>OLI,/]W.Z.SUP0_UN*_,@^7=S5$\R@=9_7F\ M+^!NV?62JH/,2Z5S4LC=[>P+_1S[S#2H$?]6\JD<7!-#9:OU3W/S+;V=>69& M,I-)9;H0\.K M&4GE3IRRZH=^^J=L"06FOT1G9?T_>6JQWHPDI[+2A[8QS."@\N:O>&X-,6A MPXD&K&W Q@W\B0:\;<#?VL!O&_BU91HJM1UB48F[FT(_D<*@H3=S41NS;@WT M56[6_:$JX%<%[:J[C$H(]]U7NU+\FN>RO2R@R7, MO2/ 7@E\98YDL"*>?"/,812:T>7MS#VD>O[DY73O8\&XY>-T?GUH.8_-= M;?-=H0\$]GZS!9CW/+0L HLH7427L-B&41J%BU4'NV 0= P"IZ6^I/^%W=$X:Z4A M!"4Z3U0F2=Y1,\_-76*,>BST68'+D>W+NZT:=G,*G59]J'3R!"-+VR@>>@/4!:FH(Q4Y2<42$DJB MKA*)K,$I"Q;AB B"\FPB&"I*#=;:.!L:Y($2]/@]Y3DH?()2"<"GE1[,^]95)-3NA"G(6 MV4F:E 1[W&Q;V/3FLH3]7-1^B28B#R%DL490U$+%",J?VE=TD'JID_*_JKTL M2*[S>1VA%.3>\I.)6"@=:D_4M^($@HI65D3&^IK<7I3U?)@[>>T%K$UIEFT0 M84HR);8JNQIM:9\L*7<:\$N2Z)-) !"@I#J+;2:G[<=M=V"1/[;- M!L4Q/K9TC.."R8W09V;J3LW?\C/XMRXF-G/;^F+<-1MDTY9& PLO]BEG8Q(( M*IR(3;3/S#1P,K@OY%&H]#59-(NO:V=OO 'E%2"\J,T+@;&+^-,RLW$\F J[ MM$_PU)WA.X\[BA?C;B@3) U;<72#H )J90\$!5XVI9UHG].I.ZD#C^(D^R5" M>=A9F'N!'7*PQ,\6EJLAL(A-!IT^J5-W5F^"Z""TH%2P+&S[EHWR84=;R6!E M;1H^M2!]0J?NC/['6W4J2L].RBST^5A6;1 <9X&%BQ$<#<+UP#LOCVI]DF?> MNXXW"F)=^0XASOK2J2O3!!%MB(LU"9"4OSG2[FI8#3 M4"JWU15YV(YP,;F K<8[>(/A?&Z=56*T/QY-V8G<8&X]T:6O#Z>R/F%_O$AD6)Q'J=HB8D=1ZD<#<(N%;69Z@ZV;O)/IPT#DI328";PXV_8_="7J67$>51-6(0"!<= <$U&>]QJ!NPL!/^1Q&"*&-#%* M'#GF4R/;QCH5 P;@^V-':7&7)Z?5Q+&.]X*$OU&00"Q(=)ZW[SV>5+6_7$KS M9"^SE$!:(_)PS/2+K(M51&\S]5C7.]#%Y9C(X(&U>3 <\SPK5G!;U\RGS-#K M%7Y%K[R: ?@V&T62S!1[<$K,GH(_#GT2\XN%MP7$E-;^:)"!#J1^,S)$>41> %]LK9.,HF7XKP7G1PM^CX M=;>#R%('SKX:)Y^;&P*G25EO/6,0E"4F(ZSBUP:!,<^2DPB*3M7'>"\U^'6I M,:P0&RJ?FA4V&NL,TCEO"XX%B(Y")>;5YB1A6Q:L*+7./@B,K4+KC!0C.#]D M4W4GWFL,[JYR;-Y,\N]_6S'*_K&5CRK/C5L;F2T+I='C+;=+'L%ZM;)SAHWC M%)9\7%E&<"P,5E,BB_?2A[NES[L-($W-T4G=UB_A"M+@^ T!@L-,%".XD8DN MW]3V@LAW%TT>3L=C5K^6%QE)59EDNCP5LBM?&.D)&Z'Y!@3$@?/]<*]7?+=> MJ55M7<8U.D3EE31V1M\6VWHB"*T3-8;RKL8@3'?\HKEX!..@RP>ZT]A2E)7FYN/(;JGW>&F=Q!E^"8,*6B^2RFN:GTL?Y09*NK2A_JR[T4 M<+ P /A]I^&TVMZ8 ;J/D^[^!U!+ P04 " "QA$E4$HL+F;0H #SA0 M&0 'AL+W=O-_N+?N^^V3TU-?K-TF]_-VZQKX9=EVF[R'C]WJ MU&\[EY\^?T7=ON^?/VJ&OJ\:][3(_;#9YM__1U>WN MAWMG]_2+=]5JW>,7I\^?;?.5>^_ZC]NW'7PZ#;.4U<8UOFJ;K'/+'^Y=G#WY M\1M\GA[XM7([;_[.\"2+MOV,'Z[*'^X]Q VYVA4]SI##/]?NTM4U3@3;^%WF MO!>6Q('V;YW]%9T=SK+(O;MLZT]5V:]_N/?]O:QTRWRH^W?M[C^=G.T MM:?_9CM^]IM'][)B\'V[D<&P@TW5\+_Y%X&#&?#]PR,#SF7 .>V;%Z)=OLC[ M_/FSKMUE'3X-L^$?=%0:#9NK&D3*^[Z#7RL8US__.>^'SF7M,OMQ\/";]UG> ME-E%4;1#TU?-*GO;UE51.?_LM(?U<-1I(7/_R'.?'YG[[#Q[TS;]VF'YVPWR/PND?T7R/CLPW<YK)MSLW_F;P^D7;Z7?MT,F7#[+*9ZNZ M7>1UMJC:WA7KIJW;U3XKVLTV;_99O\[[K&JNG>\]_)MYV#+L?UD5\*EIKW-B MW[[-"I ZO$TV7P7;9U[;9VP$3].O.NJ]K!9V7E'3"N MYV]S> X8*X,Y_=8555[W>^"H[K,#Z99]L BFVS:FDQ( A$'SW4.1C1%>L,=KOJ\HU'@.7E M==X4CAYP7V"-DK<-0K7'75Z^FF<_NGT+WU^^FH6%\FQ;;1V2&S[$F*E6A 98 M#8[_GJFS< M/@[H]UN7G<'G'(8Z/\NVH*D L/5VG9^< 6CZJN_V6^ /%.;(+DVQ9\!O!E\, M==YE)6"S:[=K./0\^V7HA%P<@LW0!1[VP[NKGRY>?;@XQ?^^N_HENP\*Z$M> MY,N^[4Y[]X?^65W+7[14^ 1T\?Z_W[QX^=,OI_#O3R]_O-!T)0$_B4LTR!391Z>=TAI //=N@+2).):.-< D;HM0*O$ MO>%<74ETROP9Y=>V VI +O3$&4#\]1Y_=]N>QR+[?6PJ_/0>EZ/=7FR '(L\ M\-S'^?MY]K>+B[>1]4#SHUE X\&^Z>AD-%@$) (%9!ALO(4U3]I= TOX8>$K M(*2.Z. "R!)$$*P%AP6"=IT*-!!U>!P6QR2M\H(7B! ]MH@1EQ),HK6@Q[Q,.+Y=* ["EML,-Y!ND/:($ M.1>=%H1'55=])5-%J,D)D%H1[,?&\"IX1AR X+T#TQ#U(+/%/2E21**#98[2 MMAPZQ%IRD"V*Y)(5&EJMM&@$",!^70%".U(@.%.'@H]5Q77.XIR%NX&;E-LJA%A=(!DKF MR8I^@ T"@D$?>X#:4"/XETC]RZ[=P)@6#A<.-L\NUSG@@JC&X+]SRO,L. *< M=&81)@PV_,0B"[X#?G; V2[[W( 8F&?O& ?P;]&N0/8@'7_"Z>GC'TZ1A$H0 M*#Z*4#0Q_P"4#: "^6V:H%9*']!*KTNJ*CRYR=)0)# PQ4.91G MV &L@:F%MQ3HB%PD\Q:GH7\(D M)[YWVVS3EJXFH=65+(]*4(O=!DV''@A,MOT$] K8@:68=8'W">)'0: X(7B! M!'T*L\ TND*8!>!,A'K+;$@#@%Z2BTCI[:(6HR:A:S/;GL8 LP-[%[W=#AA3 MNO]D=["]#5 UT+^:6/B(40&HT@IGUU/$P4,5#FF(_8@K$GSB_->@K0$)*0 / M9D2DK,,:U,Z1 M7D94@A:?P,KS&E6/O@&@;$''58+=5:!9P:\-&GI$UZWPIIB72%1]S6P](NL) MH@ZKL!?!1$N+")N"@4=R,&P6]QBHNA39A5I(Z,$7H+S)[HB&"Q@C30G*U&>7 M;1E)7BV2B_>7P3OZ]N&WLR!32*1=1BBAKKL,BM<,QV%A"CA0W&R#UA&J?3PD MH!0#(Y9.4R9E2!ZA%)P!;. >GD=5SY8JCV#:\T>)+.&<>2H?MX%N^MGUR/@//H_M =^PJM9 M3+.@EY>A+8F :8;- A7-TGBV8D'N"7GQ:\1-5RT&, '\M"5MS>=H.3/ZQ48/ M; 9.$NA< #@H59$FN..^[4EY\XF(#,A (VNY48<2G$!'AP*OJN(C'=DG.[J@ M14$^K%&7SA!W.P00_ M:;%OU&,[ Y]@[)O,53')2$[3S#H4"@+Q!"2V&/Q,&PC;1)ZIKU3J,&=CZ%HY%9BMN8NW@$&OP=-D@ MND8IYD?L !Z_3A#M.Q($#!@BYS;9$UL2UI"P]*%(BJ36%L4 PQ**P[TFL_+! MM_F>5!<*""9O"H!\(4,*IGKT$,S8?0H6 C?*:)#V,)2D%ECYUX G]N*0GPNR M.U+,AZC+N^3<"@T^/]MN: BA??X4-<"D?@5*S$BP>P8<^^0=&>P!1HKE=L M/L=0$.U/Z#)A&;;P46!*OHC9=8VB7?C\DY8D35L4><@,,-CG:M)]A/6Y^1(=G8O!0:$*I+HI%^0 M@-CW:)4R1#][L8-Q8S.D)*6/:HDX8%.D30SWSDS1#2ZZ7L>&@G'0E8".K@?) M_HF"8<1&@&LX!:EFH(H:V9^ 1B:Z0\^K'C"B"19Y.;:FDRE4:Y)/_S4@7P)K MH"CU PI#3R)@TA,$"AQ I371MA@DU(@^*LKCO3K?XJ^2T,:H+3E*PMP9;\X4W0).:$[M<*0BC,JE8R,VSSS%0A]M <;GJ+S M%#R:,(3 "QYJCG"KM11T1LDV(0^J?7XEX?I'(S!=6%K\" ?H$M7",*HIVGA#N1"16(8T5YS'Q MOT4]2;(:'TB4@7HCL\"'X3F5OL0;1#5Q(=TD[&!@,T+!2D_.(IL3-@POIQLF MZD'8"G(.U0M'GTH2H^S-#76=4NCDN$@+JZ[U_I!=*!)W*(A5L:.1S#")(SI+ M^:B"1$->6@V98CL@.'@]9)18S0NHI]38?=RLB/ !A)11PN/(8 MO>[NIH'ZT(9<#NX1&0Y8LQ* F]6O^:#W\X=,;A)HXB!(=A@XX]PFC*)-MN M:Q#M8@6804N,;Y;!'IM)J*B*07HQZ=&04IBG ?=6@E)QER0@8LR>Q".9D)OJ M"Q$C$9;BC,Q%#"!-*GNP_6G^JV )/I%OC&VH4&])/XAB5+,3'%!UKP6!X7F# M()#3<")T[4#D@O\VH,\^2))9'18"VG=AQ:E)394>?8F@AI M!N.WH5QQ2H2.K\DGC+JQ&N6\31+4F[)9.+#+VMFJ[?(NO!=43.-VEH+3W$ D M[$BAP72X=0V$9^K1VS/S+(P[5>+DN./4H MN,#+!QQ+H&GP%B$$ZEYBS8E+,LNV+1I_C \VCR1-PI .N:PC:88Q/,-AQ:RA MJ 2P2R5AAI&UI)NAGRHJA&!3B4P6XBHT%RGW:"E,/% )O9A9E(L34+%2^L*< MW^=?G-= K4JN*+5H+I),[=BCIS!.A'&4E&BO#N#\=)PWHQDCU6I@-'MM$=-=PS&QM1WAQ4=Y)%Y M9Z"@^F'8 A:;8!E'=4FT5%(>.[>!P\.(?W!/2*NMJRU/M,EI>G6^)H_'\,M] MNH28>ZSAU,TU-*/Q3G(S:8M=L(KP],81,\%LB3L[AEH"4-ST5F.+8]8]A-FQ M:#,[D9AU;ERV!P,>#4O@*(G=39*_V&A8^P,G)RVU!'8&2-$$3,BCY R581P% MYPTTFP@TF4$$4>Y]6W")CII=28H%I1.E4_*-T\"$V2CZ=6*JZ6*[B:2K3P3A M$3#&X']%I2C7E.W&5?S3;-WNT"^?R6)AWK*E+49X85CY1D3M,.P3U]JT';EI M379V#A^H+I)%M1#PPJVJALK 0@B *9//_R)F^6FKB%*8]D!FT7\?BN0Z^^M, MX402,A5[L^POWY[/'Z6"\?R;^5_C ZG8LR4(\8PQ.NMOI,&# _+!7L$A@61> MYAUHH(NBP#K%MQJZ!*S#*1[/N'Q@!="+CC1,I/5._;IKA]4:G5HI$6)_A20^^#8@$#8A-#X]&T^(/ @F;?6C5_B9U(,?#D(H^Z[M_0H+60#29M$<#KGZM2#"1 M5(*E/F?+*SK.WVM$NAUZU'V42Z GPI$9?>45V6 M]UJ,:+9#R@ MWB-&1B^*:K*I4%OA<@"3V\XMM0X*=;:KA36# 6%Y]-"(_=?S*<9_J@EY6@[N MJ"S$R=!/EOI0O-SF8P_E" ! I$!PNF]+4HIMC-K/'105SB6'P;HT MNT]Y;?<@R;3?,#=%@+\V&TEEJ2S2ZKVEA>#GIKE'X3 X@&C3I3L\!M74V5U/ M2>'*VY*"69!R5(5R4/WEN8S\F+?,9USGGF->6GRJ5A='I["KADKU:JZZKZ5@ MA7")W0^HX)EQ7POC0'=UCDW^^IGE!K2I=J MJ[,4/49[9O%_78=UCLP&4XYPG%DEUAT$4FJLWPXBH!-?@*Z,QK;.1JT0 M7?R>*\'2T4(DYBCS&PJI[>P P5'1W5B2A :.Y$L,7$EV!FT"?&8!FF)9&43( M&BR*Y(.)O"#=I]ACS!W'UNB,2?&'1O1)VY.-RJ'@T-G'7(3-.US3/TGH:4%G M+(:^;6!:!XD%GN0Q(O0.*AD40+=P?03B1XU8 XJC"; M@@9HWF*AN2.8Q0.%80RV)E:2$@VNF7XRT_SNWPI(/K*QYH]H?DY%D>3R! MQ[=.[ "NXY%"1]LQ$4RDD)Z3#$V=P&'AEAPH-. FP04>)BS*AOX8.0?P]ZK^;-[G M]CHH%"7('1S98D=9DCUK-E2J3G?":#;8XF".8,RD(*T2.K A_CRDD>HX21B< MMX912*H MAO'&FFTCJS]/$9?$Q-BID/CJ(282JGJ^2FAC=7"M[6"1'MQTK4) M277"K#IFJ6SB*DUU$A(I )YGZ!ZVUP3C8]"U=>5UX95+LV!R='!4RK9 MFH;=D5'%.MR*);M#TW&6/O0U^Z8"X] V9!%[!(>4VL4ZD]@6>DFI[NQ=Y3]G MKT)[9(5<.!@!9Y/N&CGA3M!B/",GSX$.8$:I5D\Z*= ":;%U7 I7T9KP$A'$ M+TC&>0!2Y^S7>"=]\KPWPM4:* X]J%&+)YZAZ@=I/"/+ MS&+5[5 M &;%5,)7=@[PY9Y323ZAN)^<5I.QP7_JR09CE<:Q*["(2JE\U#(K8*AEF]$>6ME_<'C\,4N[V)^WNO]#'RA 3&=ZZA8 MSID[&% _Q!HE%L@"B[I%:]E&8Q@)RTE2(4IM11%R"ZJ*.82IYO'WB0:R]'*P MCIF=(=8)U$SXSDX0A.94[:.-*9D(6BR62"3MH1W+"^U (:WYE@]-]&JA4U)) M1J"U#6WDVDB/41"79DR7K #JY0-;"?'"B#&B+!@%4X1P22:&ECM.$IF&H0GH M< >S-@[C7NE!C+.IQ1L:>W ?=NW@&-[>:XWX*]WO!%-8XR N^4]WWB\Q/$UU M<^%W$'NY9SE*?[S\?8 SUT2RGTR2 I$CPJ2NX)GR4-:TH-XJSL3W(J#8]," MJR2;I59@W(T>:E:E[P)WXN).YMF;*/[>!_&',?^IBIF9D-&$Q P]0F6\5B1V M^&M)UPF YP1)'VATT=OAS ER30UM$ MX.Z3HR%TGPM6]^:B"8X7#> >8W@4Y3R5\K9B^R%IXF(AA*^5)5PP6CT(3$XZ M28QI:HYH>HE"V%HDL@\R7^S]'M ,<<[4+@GGW$#1I<8G+'OB-M!G%8"XU.=6^/M M:-313QT0M-R#<<,;3AJLZ&1VOP:8(? =5[J???=4^>I6>IL)H@F!?%J^&(3$ M/1> ,RS0'TF@$I\CQP44+PM@HY3POBIVB$)7T>CZ (X;6>@7\>:'_@#A'(Y- M1,Y-LB1VC84RZ'8S:A>;@)"YM037#-+B1A!$_446A/72C^TAH'@$-JKABS8QE?F7, MK1.UWE\S,=S_T&X!@8_.OWWP)'N3WH^0/HF].9-3FEWHZK']G8#]][P9L!E) MZI\4K&7%F56YV,I:!]5FB\&8*4J?,A(X(GP'+JZ.BUO MCE!-KJ\1N@8 Z1J MWG!+4&+S,FOD34PGTQ)TR8*>&CQ@]$R\%-V0HK+/Z>P56!@Y-05< MV*51D&BCN993^X+LHK M-?\I%RBF=^R]4#D9>W'5FH"%FG:#$Z#K'7./VM)5]&*!L%5)0;"),?,L]+N^ MBZX&E=R2=W'G+N:;.]AN]FR.]*-%._YK>M)8]\>6".T2N(%9XLUC?KK\O5=7 M)KWD(^S;?:%<3XS=4B;/]LC/+%;'C:JSK\7JK4A]W[?%YQ/>WR7@"@P 'OB2 MHR]N[+P,",Q/UM6,LBBQ3&CK0I M7XHP^=RH:IIV7K:.*19E%""GUM3@Y!1XI(T;9X(#X)9RE]A!D_*X#0\# 6F, M_,8E-?(_E[AQFBR@6R.Q7# ^>&2#(?=**-+:V8PND.(Y/2?T8]5F3%[I,CB6 M8W*QW4RIT+2680LZ.R !>_'6%*Y,0J*/-2KF0L -7I*LH]"<2OO?Q\V>6*U6 MNQB U)T&]T/,3J:061(ZTIO5+)%HFB!'PHB&,%/OC$MU\FQT.1:#@-$9"[5( M4&)='&B)Y'J/Q_^NQK*!'59JIFVNMYQ4;ESA=%%RRF.--J,@M;]-&!P$Y&1Z MDD7Y6.H(6R/P?@>^9B\['#!X/G1$=G#OKZ$2T8>U#1@OPNPA6+!Z8]57N2Q'LD@O-=#_[O940,?* MHJ-+V2BKY;EU@ZS2+ I/SD0BNHGE*I%8"A2!)- M0?')G2C;)"F9Y]*"&79Y>CD%*3P:81= M<)D7VD+!<&.X@*&,:M8<4;^>1&M7[JS(RFG:6W"IE4=9!/&E+7 M7%(S8.T&%[J@N%J['*0WR>YEU?G^!*\GYK^PIBYZZW)B\@]#/7M,L'/3=,QV M$Z<'M)9AUWNMR#V>R-Z!)PL P%M<4)2CRR:7B[<+D!RN=PEH60A7T["\J>45 M/?"JTT(".K,IG@*;$-OF]!(8T%MES:8X7Q0N7BW%Y\+9-)HMHL>.V\XY'A"-V-ZS95Y_$_=8,KJ%HF\(Z<]<>&*7@8O M\#+7M(82XCR< 1RILF+330OU0K[WX)'*!X^9V4,",YC?L)T8E&P/Y5!\";O( M7+N B,4N+:Y?&'Z@,B(V',/>U?V7LU._B.UP,7Z_@19%.E/>CXDXJE9%CF;O MB7M:9DF4"A>O.1'H*%N=>E5TQ+RH1'C M,"1%(B1->[5Q:>JV__$ M6=9J276YHQ\$QCQ8J4GYM3()EYN9&]2]-"I042%6\&[9'@V3?>3)7N-D/PX5 M96<8BR"R\74(+%S.'B.+?/-0'*=70]>0MSP"TG?XU)D^]1J-94H9V;F>:J*+ M Y(<@,5W!Y LQP2.7[?:V4/-/(?GU539]Y11BT\K-;']CK;YT&N:W+?+ M?H?H?82[?RR;?Y-3VLO4=Z(&XY)$X7UE=A#)%]V%0?(N':A7<[L\6W9Z3$*9(D9KJ"/'G@(XL4" M.+W) A,7E$.66'!RG_;7J: ;+9F)8 X?K,*D<8F2K64OW9@/>!Y3=BT6SD1Y M9;0"$I@9XU!712;&MPGI7KH;=W>H6JD_OAXK?RK6)D,Y4ABK6'D>"]--RY3< M*41(LQ8VP'>%WCM'VV.14V+P\924#:>1SI"U[,O(''H#QH1<"L+F-A$S9][V MJ?6LRC3M6J" *J?"A/URMZ2:71-TO9Y$%S(JDST@$@:Q$Y%&SKJ]#)DE5FV89ZR\N:=-;QJN+U( MHH'V*@%,H/!3&N'PZ88$EC8X8ZYT+]#B!R^%&&F#$.@U=\08T2$TS1,M-.BX M-#E>IHV\O@,]@W9M,D2U4(RH+;@T4"ZFB+#%4\YBZ0$J"LQI;K77(=:K',PM MM;&2?.:7"^Q#, T#@E_0ML'7PO -7.FJY(2@+2.OO, 4"1TU2$A+&_YP.YC MQA=M24Z-ZE 3@>&'#2,1UPWN,-8>U9X5!6?(,+/5YUK=2!5:QR1DNCS,<5\V MD':2)-#"1@V^9IFDA5X:3TT?IAC?VM4AM$IS@?X$EP\47RU7@5P[;JOICR.6 M7YO"1K(0^-CQ&;$-AM&KJ'!'OQY]XT9R 5V0[S2$3%R8CZ]Z0",Q229,XFR$ MK" 2#?%$DTU35QF_TF6#$KP*+1$B#*2=9O2(%_%P6,24] UQ%*+@T#.^6*OM M.F;D3@K8;CCN//OE"!!1%TF96LB0L+?JJ+6X[?B^LF R*4 .IXQAGBX$^F\U M:U%@-0;%!QK($M*K1+"9(\0,-"G;"8UV5^OZ=I,S-;';VW:90&51 ;"YIY'> MAX4R-5Y3I)?7)C$!,E!%LV-B2 \4BK5&X[E?E -M01$$/3AU)<^!J@J50P+G MACH)3P)M<3617%.>.M$8YAF=NP_U+Q+^P+HS@!UHPE !JH@K,#Y:.W5:H&,C.-B&0D M$6/XYX@/RN[F%5> ?: [V5[HE55]_N6.$C+\8\B\R#@F0#Q/R_I7Z[8412;S]%I?9L;_$M5OA?FFXAQX<$K C*,(K5&::0*<.*I9K6,F 3A?$DB_R=ZCDZ%HX M%J]6Q0]ZP%'#Z73T>.) MN\O#7EA=FGE9WH')74*!2H8MT72Y5Z'[XDBEL)\ ML8(F>H>VT,^2L0FT#TVP]&"_H>2*NBND49F=0A10FV&3]*EAI;078[-,7N*3 M]W(=2."1*>JVFKO4R 4J)[P!-#3Z0:B[QF24TE+%7G.XXUC-]RE&SCUM/1 MNT'"^>2R:;,4-[=B-#)YLYB]=#%9%&8'("/93K?6 MPE PLN0F#C(' A;"T7DC9")%)4UY0M?(51P)P1H!3.)/LI@3A<#FENJWVO\E M@0,5 >;>P@N?."_TE@Y0#=GEP-OY>[OPV PHU^1\-U.W*;E]IL=K/# NBBE/ M&.WW8!%N9A*B"R]AHE<$F=MMF^05CM379)T'SG)_06+]&[\6]@ILV(:K"UZW M.])AI2HT+?S\V]7K#U>AY%->%K&(^E5[CM)W-&HGD:L#'<;WMFK]YS*CR07H M$M+&'8; ;/.5X \FRI72P$MLIPS7E=)+F<;7G"37EH"3ZPQ:1"#?+;80IK'NT,"P5Y7.9LVNEYZI=7D70O:=]O7AA[5[X!21Q)R$-+#LZ6(I:6??QM<97+Y6.Y@?W M>-R^2)[!!.'6ED8N;4G/DN!R)OEC^R-=8.'$Z&A:7L8W=^HU"_J*4@P!G,CK6+!B MF@H?!NZ22BZN-[U%W-84=G"\.B+NP+P[-#@REO<3LM&W)X#E[V-56.AB2*YU MCB_MY+)9C4E@>@X[O)9@4NK)MBQ#Y:[FKSB!&((<#K3O5SU(==HV?+[J'G_D M/AXRRC3!R_&W@SS>TW@9?U]MI(I.'8A@9G!,VX38TSNU.#P\/3=,GKQ'1ZS3 M "M]-56X#3#MTARW-TXND^L=_/;^DQ LHM.@493W[OA[6Y=3$.6B306WN<8@ MV#02W4LCAQ/$I_4L?.>BNNIAQIG<*;:76!P7((:QY!6;=_O,S:M_QY=/W)T@ MIWC$=LHP^06F3&DO4DMBX]WIXK4LN41-8M+$@E/XBW@+?1S[V%F0T5UM^N%H MB]+D6;WD"=DDCG? :UD(O_*2[.8CZ$VN!;M3Y<@X:S=9X_@BU#@:,6P:?/SM M';!?(;$C9 ]A]S5B-W"1O8Q#NV&G=3$0HE3/3OMGS\[K3S\IX#_=^T. M_DOIHQ= ^L^? 3VMW*6K:\\-[C_<.[MGOD50_G#OXNS)Q?F]4Q@9'W_^;)NO MW!O .*;':K>$H0_GWSV^QYDM_="W6YPR6[1]WV[H3RPE&PO=V]R M:W-H965TS M;:9!VNGNXN)^H"7:YD2O$:4XWK]^?^>0E"C93MUV[M[[88%!8\ODX7F_>#0O M5WEY:Y9*5>(^33+SZF!95<5/Q\J R_S/,RE16^EHMC4Y1*QKPI M38XGH]'3XU3J[.#U2WYV7;Y^F==5HC-U70I3IZDLUV]4DJ]>'8P/_(,;O5A6 M].#X]8K4=)J0*,/3"KO!G(Z(Z%\JDK\ MJK&O>@UJ$CG+2TG,$3*+Q<=JJ4HQ+4N9+1387YF7QQ5.HO7'D8/ZQD*=[( Z MGHBK/*N61KS-8A5W 1P#Q0;/B1!B!9R1,=2ZLIX,)UJ0QHMP_RN7BG,YE%6B;B$QY:OHC_ MGLY,54*Q_N6MEJ):ZC(6A2PKK8Q@XS5*EM%R 'NY M@Q\H"!HC$^4I3B&^.EF(HLP7I4S- %A$21WK;(%/1XF.X DL!? M[?<6N;R$ MC?]>ZQ)/C5'P5>)C78H__]?99#)Z<>-P8 @A&NJ^($B&UXU?N&/!A M 9X)F4,4EZ$T\"E9'W54@^C0I#Y#PEE"I N5J5(FR1I[6<@,*Y6WA$K#<,=B M?(= U+V*:F_ =.HF:2]"52 >+FK@F9?K'=K9"-.TTN2S8%3 >JD!C1' B9$J MF3W0Z+B.JF^R@GSVFY4E,*059;Z62;5N#\6:>5W58(R10 G6,L?"]8 /;L#Y MLXG_!G&*C F,2ID;K=V27@W%=:"51 Y4)#6>=5L58]"#DY?0@G6A(Y93@AR! M <7:1/F= E/5'&F$4VUX#EZ!M4!31?!=[E%=1+P>P MI9%!!(#DYIUZSNO,(N"= *M;2P*6,QO@_.'<=IOJC$^XT^RMO(5D>8657N,[ M7'K!>#:*G*AL =R!J]NC#;@ C&(F(8.O5>RU0U(.,A8HJ2WSRUC-^S5+R(&0']!$27/H@("9+729CC^@ MY).<%-2+3JNS2B=6\UALF8M5S'-G2'2&];"D?LYKY+-$+ZPY6&UR/I7]7A)8 M$SD]?(]R'%62&EJO>E^0.(?B_.;RT_6-^ P>R$+!!45&3']VCX_.I7DN?@;Z M1RK6+ V[D.!Q\KA/-EO.H Z^! BS#5, YQ=;X^X$7ZE[D%3Z1^F3(WRNH M4.5B'Q)_R*9B$*S?R9HX15*OB 6R-HJ=T[).8:0X14EZ4AM:%G)Z$7*Z"5#K MH0V&UD.I>\1\0QE225D\D>)9Z;UX)8*91[]M>;NTE"H3N,].6IZ83[;9F^_ MY?BP3S!J;"TTH[X(FV"Z39X=*_T(%=3$BO//?Q^-QN*O%^=3;V,#Y^N;W)M0 M&ZI&P<[SM^.Y;?AI M=U*P0>31*#EL;@/JV?ALO*5#%8O_A7@TZYR)6)1'3:GJU'RN7:)%WY/ZJ8>!1&\=??C9R\XHT1R#\:PRS16O3*;93F?V>9ICYMG M,"KH"$#6-CTM%!'7PJA=K> TEC'U89<=CLM,?#9-24*3"@WP:U;/)7,]WC#8 M)E/W>J.;#>PM1% M@8S8)N66P4/QJ>5YZSHLO"QV5:#S))N()B:WV0BKE(]F7C*4M6RM0_9#/TB\ M=PBIGV$WLFN3U!!G\2B(?,R8QQ1D\GJQ1)7/RU=YF<1B7SU\6 W9S^#GS/4$ MFY)A@X^IC,%,3KZD_.J!/34 M?K-$#BC6);S8A;2OV3!4&%*HN:9EI7T Z1X'MT2>;5:Q,XAS+M$G67+&8ZHC M.HS5(^AJ#EPHMYT/;Z"$H4X+N 2O8N$>H$E@&KO!IF]O'[IRWW>4 <:T+6-J MIR#D^9[+A?6V;6Z]QBFHA#F]N8 M<&/NI-4@F_$K&J4[<4EX[;QLAEVU3W\JL\47+#:GMM1 M^&J8F7IFQ@W7?#L!%#4T<./<,[A=6ED&MSO&G1U-W-Z,U%27CY\]Z1;FGDG_ MY]%9_2'!.6P*'(XGPR?=VXI)C_KOL"1V&O;*83+J7CD,0G>#HO/(-W3#RAP' M9;:5Z+2X]1N[U'KX_:V$9V?/ A[H'?=0>S85O)B!H,TO@*2_J_J6CD./&M>D ML;6YP\IAT2O5*4R[0VTTMC5(8I$&>FIALX*P$])<'>SJE0=DL!UL=,2W[NKX MK*%X#YTM9;=U>)E%PP<]8>, =QI)SS-V^RP[S_3.P2X(NY.^,6]2(C#-X:GJ MA"N72G&C"5R .I*/1-E >2==F12):IM_+5!V@N3C2JWP\UH44"$:D@AZC-3' MMQD%\M9$VP"VI0_05E6:W?"2$A+;8-_NR9X$F?2PN=7[2B?3VHC1]PW%3?MQ M'O3Y;-;DV$O%=M?&X$5[#3I_)Q5VA_Y7FW:@-U;VDL#[:Y2'".SL%ERZ[@L( MJ4N!@J%6_HFC;*=R 0%95:6>U96<)1SZ]O7H6=XB*17N4L;VY)D#8")/7 M"5?TB*)575&Q.:/F-3;\OPA('1W[0\+39>N=?0'3 VM[ZC6@24,Q;!*B /%M M6)^:*TX_H4/1K644^'9'661L?6J:8JO]>84,Q$M_IB*9$L^+>@;[@,Y49/NL MG 7QU@:[T5!1 ZM*??<#\39'3L"+I>K O=NR[W=.\&)=T"*W7KNC&: M6JQZWKEP$2DI(KQ*";\PR[,Z2A0PE1%TRI^:WOPR;=UEZ%>WMH?/WSEV4":P MR0ZZT/D1EG1R7JY3_ ^;&6_GMNC!"Z=$%V1%DEK:8!ZX8(,DT>[ZBW3G&ZL$ M1E7V[HZ:6SIRJC6>4+?[ >[TNXK;J6@ODOQ/.YQ^)WOE"L2M1Y0!O@OMO%7/ M7Y^<_3LO5/;RS=L=\W;V_,'HS)KTM6 'QQI+416&>4^%CU(*(QB>DZC"K.LD-/$Z)TTUK]8X;$IG5DZW] M41Z1NB>K9/3!BL.GG<#8E!"S>GU$;7.R,:=_H3JT%MVQ^UZ]X#;N8>BA>II@ MO.T[:DN*QV0JJW^WG0VWI251=V@RM(18F0BNB,+-#(K8=.28#\Y$.R,96\;_ MN#M'$05%^I/A6>B;K:(>=D8-72IBB_BG)\'$H;;EU?

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

7#3=TJ^2?HK35]2@? ML9*VO)/V7NU_I8%/YO *)8U_LGUO.YN-6-$9J^K!&1G4HNE'_C3H<.:01R\X M)(-#XO/N _DL[[CERX56>Z:=-=#;O(BW):VI9+?*6!.P6]X*RZ7XA\J MK36U7&#"FY)]L!5IMC*&K&%WPA12F4X3^VNU,5:CH?Y^)9WTE$[JTTG?K@+? M!7BDR.@).]N0\525IUIT$*:QC/>4"X7-9RRD4EL& [95$KM8-+M+J.(^HC94 M;^!YK(][1.PGT:!9I406YF?VD3]A_TKN@-HAN(NIX2P>^48BAPLVR?)PBC%) MW-A+'^>S,&&S>3AC'Q5JA.4LS<+Q\@MGLYA>$^&N"ZJ &?% M(\[ MO8"P[Q0=4VZ$*"%K'T_86*<_RR&!/%D"M[WZL"E/;"6'YQ22#8":CS- M\#P7]I1A$OO@40KE>A6S*=!\UD<1XV ZZ]6.@S3*PFBP/-9?"KX1$EWT=HK> M'BF>8U]XJC,W0K*,O1.-[U=).&B_L$RG$#M-P.$=%YH][K-XF](B#D,((>B3YWZ$@)#U$TT +;TU-Z:9(BWA1L9:T4+[E#0 ! 4%4I[VB2HK2U\U8 M#+4/>$[G.W1/HGCN'OGS"CALWWC/F5ZP:3";NS; _@KF>0[-(% 01W,(!\F" M:1:%\?\X.3)81RAL#LP4E>N+,2S^^$.>Q,G5:9R@#A,$NOWV.K3TDHS/5'34 M\L@E?Z0V[ZDED>\[1\T=)!]0EV=! B:V"'[ :%"Z0G9E7T.7=Q)=?;,:WCZ^ M\NN#[[D>QV7UE>X8^HWY'[P)O_:[&9_]_'&>[/P5Q[5/U]C^'G#Z>KI%K?K+ MPW_F_17L/==H9X/MMX4K!,I&3/?7FO[%JM9?)3;*XF+BIQ5N@J2= =:W2MGC MBPMPNELN_P502P,$% @ L81)5"'/G"6E" 3BD !D !X;"]W;W)K M&UL[5I9C]LX$OXKA'=FD0".K<-GTMU =[+!#)"C M,3TSP6*Q#[1$V\3(HD)1[>[Y]?M549)MN6-T9A?[Y!<=9%6QCJ^*)4(76V/_ M*-=*.?&PR?+RLK=VKG@]');)6FUD.3"%RC&S-'8C'5[M:E@65LF4F3;9, J" MR7 C==Z[NN"Q6WMU82J7Z5S=6E%6FXVTCS'512%7 MZDZYWXI;B[=A*R75&Y67VN3"JN5E[SI\?3,F>B;X7:MMN?75BS%9:H(8T>V%3FAG(ZIZ#<.8M9#3YW]4'!I/)B MZ""+1H9)S7?C^:)O\(61^&ARMR[%/_)4I8<"AE"BU21J-+F)3DI\IY*!B,.^ MB((H/"$O;BV+65Y\TC+QK^M%Z2R"_^\3,D>MS!'+''VWMT[R46:]+@N9J,L> M4J=4]E[U&@7?ZUSFB1+UZ^?*BF4]E-&0D&6I7"EDGHI,RX7.M-,@+*Q&&NGL M$;F12:>$,\* .3&V,)8&UDC2KY6T3ME2Z%S<&, I9T&DA+3)6I0:A)B[D[EX MI]7*B!=NK<3?_S:+HN#-3:6S5.>KDM_#-R\'XM2"^P+%9:<1:WF.Z*@$&9:&[SA$:MS5-/%=6*3:P+XK* MEA5TI^!MUQH!V;9A+PIK'A!CIV!6. B1_EE&E:RDU6 >U6P89I9+#7V]:@O2 MR=A'P7"CR-+"B]9I+0SZXB/<*Y,U8N.,C-O63][WSX]G$R?P(G^1Y$G'D2$-%D M_KV R,D+SRGHG4SF$GT$79TG694JVD;:4':37119!8(FQ#!%Y_ B<,+2UB:# MQ1N8==^4+Z[*_TV\0>S#[==\!JRI.]AAK8:H7_ 0HOTZ18^2 G"VG9R( J@' M TR25(6/?;UC-)6S_Q3B;_T+^D@(JL$GD\14.8.S,)E.'OL-#.%[W MFPWVDW25Y>WIIBK1-)1^G[_>";DE(=CO^_46S+Y<5A;*60CT;3DK[*W;6]\A M$1Q'GWC,7F-!:W23:""N5X#+BH#6('XGG3 %3\))'!(H[&U/ $$X !A-O8<] M8O,2:J>\LA8$>+\HYI%&5G'^F0Q?!N5KCJR/!1>I%Q!6[WCER[TZL+?N M#R*.!W/@T$7& 66QT@;BK%GX2*6@V2KP( M!J.7XL5H$. ZH>=/* 8'5H43C-,=6L5TCR=8D"K?_1/KI94EOY#[^MY_%%[V M8;='Y*3>!5X]X-L.H>\+)Q^4AQY2OK(>))WNRW0[4RK/34;X1K"N,BGY[@@( M"YDQ+W^LE >AOV9$M2U"\Q7@K3D$POO#]NS6DCGND75O^[0^JB8IYHKKNDGSF]DLIR)=H' "@FC+E1-!B+#R9?O?(E[D#L/L(Q<3RM1L>=D$T&QY,0#OI(!=%/4;DX7;,.),EO8.BHSOR3 M]ION5U>WS?":'T(/XB(H.IOZ^(=\"R.*+J9B,8^IAE -"N,Q'C$X$O,I58,9 M+CZ+,3@6\S%X03/%8(@I#$[$?(1I^!N#$2V!DHL"OJ1-*H[(I]&TSY+?:LD%[#=M)N$T1NJ0..7]=63R@WM M'R@8]<<:.44W-?%%!!@SPYCK5QR,Z/6V^UUW"ME-P.<3,HHVEBV?G:CT%;9T M*U>TH])YTB[.W PR E)=)EX_U)3RH*SM2M%1R$_6ER_/69VAP%W240DB]_5I$E7+LCAWL")0ZUQ>Z@U_HN'6B?YSH=:YT.M\Z'6^5#K?*AU/M0Z M'VJ=#[7.AUKG0ZWSH=;Y4.M\J'4^U#H?:IT/M^W_D=N3^3\./TJ[0$4"1)5CA_'%/6/_WGG]QIN _ MYA;&.;/A1_I*498(,+\T:'CK%UJ@_87RZC]02P,$% @ L81)5*Y?F7R1 M#P 73$ !D !X;"]W;W)K&ULO5M9<]RX$?XK M*$6;DJHH:LBY?57)MISU5M9663XJEGNP&"Y,QPI/5N M\F![2 *-1A]?'X!?W"G]W6R$J-A]GA7FY=&FJLIGY^G>E7[U0=97)0EQI9NH\Y_KAM;"I\L) MCJR4NH[/KQ/7QZ-D"&1B:1""AS^N15O1)8A(6#C-T?SR"^) M$[N_&^KO:.^PEQ4WXHW*OLFTVKP\6ARQ5*QYG56?U-W/PNUGBO02E1GZF]W9 ML9/Y$4MJ4ZG<308.]>J-RG,0SG6EDN\!NP*1"*U%:E\P7J3L\K=: M5@_L*N.%>7%>P9HX\SQQ]%];^O$ _2AFOZJBVAAV6:0B[1,X!V8]QW'#\>OX M(,6W(@G9. I8/(JC _3&7@)CHC<>H.?V]\^+E:DT&,F_#M"<>)H3HCGYGTGU MSZ3/NL/IZ_:,;X)Q#7_J:J.T_ ^\KQ23QM2"34>C< 26EV7H1&8#XPQ3:Y98 MF@;GA^QGE:5"[WP@JJ*H9)59FJH0[%95@I5"6V)/GZM%(L"#62IO92J*U 1, MKFD[=QM1@"LF&<A;"3,KI6$\#@9*M##3X"^K[(')@L9S M8T1E6"9N> 9O^2V7&7P7#) /U@3CD*N:D 3W43OV-XYY(%)M@-];X!@7S20H M(.4X?GB'&P[;*10#.!5YB? 4 #JN3*)EB3,#V'-*7V *<)&HXA;H$!XBVIB0 M?89%-P/D4P7$*[M*4N=UQG$)E+\L;CR% [J/]FJ^],9CET'Y@5J!OUP!(2.T MA(%.U&MY3X(IU9U #:3"R)N"Y )/EI0H$C=!"\=CR74E$UER9#5@RHM 3'M M>$?"6J@UV$&19'6*NVJ,PPT)=F46] 70DW$E= YO.LK;81$W4]3Y"K@ 63BI MP"(&#+4FNKQX<$(( ,Q!JG5%[]:U)N;)_F$KW,8E9ZY=:PK9!4D:H$[02@W< M$0?P8P240>\\1>LYH!G48DIBJRM3P63@+V379/Z?1%GK9 ,1#>! W6B>&_:^ M .K1(AAP(,;+4JM;(,D;'VJ)E)8(.T$)_?4OBS@>/4=B@\O1F.CY*9A!K4W- MP7' 8.XV,MG@[EK2*3ONHQ#PA SVC%U:UIV$HF7(WM8:U8'L/ BN 4L@ &W+ M-%H&VXN-PL4>J]]9L 9RFJ@?W"7!!X?TX^9& [2@ZM?L.)IV]A.BW'^I 70L M/T\0O@"+2Y^L@^7_50=+;Z4[.C#[E1"/O-IVM!&'D5\3!XW">$L[Z,&F%)3> M90_!X\H:%L=^94UFD\[&D8GC\:Q]TU^?E/D!]$3[L[[ZN$*KC=1/UB>(Z_^H M3Z^<.'JR/K> JJ_/T98^QW]0GP?$,:#/>!(N^_J<3ULSVZ//7^J"5HJ>HLNU M0J!_LC*C'U7F;M3N+%:7^.(X"J=L=4##$'RV=1<_$3E1&%NZG>[H\G'E#6]_ M #G!?E8-;D+N(NY1591J %T?9%NV]O-0;;2J;S:@+GB]DC8CH0R*FPWD,Q!< M@1K^H1'%I@A8SVT6H,][?%YX_(*>R\ MV[]9:XB)TJA&;C#CJ2GY,"@W9XIO.C.>+-)4XA6>0G,GT#+ AX:6L M>!8VH]OZXJ--IVSU@2DJ\%A+!9GH$Z'%S$9FEIXYB@H3MP5L- 4@7JSPL5/9)62\#& M5IB'0P['(8=3^L$Q9IDR[,3)X,/U1],Z)22=6)Y MKI_]/O>:' &J""2RB=G M=2&K=O"GZR]^<">=!4NCQ@LL=;8B'\.!?M959]:>)5KBG5$^B194(CJRG*04 MH'4@]LFUA)>NJ)$%9=4UJAXEYC)(T^275J10-35JM7)%JT.?1&QRWD;4#$)9 M0K90B#L'%+:26:LL4W>$/51Z@5I1]5A>V?X3 ?8*,VHR %ODTG+/!G/FSUA! MXB2OI&5P$=K),YF/K99,^O8O_MZT?=DFLM.2&:J M-C#-G&*V,=[O%^RRM=X/JCAKC+D;4V#&FXYA@_D%H'_\\\66\?#O/!B/9FP9 M3*<+AIVX/WLU>H\+QLN8L""*G[//"OP>EIXN%V[I"]2^X%-(09WU$Z$(;V)4&D*SP168!A%Q+W0B:0P+,'XP'1@!X R:))K+J$L MXUE-IH!OB/7L 17?0U)E/2)UT8@6.1 $7)16!384>J$ZY]\%F;^S8>M_VR+# M;87L2S=YM2\#*OQZL.-@C @-[SL3!NMF7K0;S[G^+JIF_WLW:.M"5YKT^AYM MWE,@;&F!@!W1=%F:2& M@AF6]L&D'S]0;" @"0K$#D-=J=^ M_R90ANU&R)CV;R+8U:E-KJS1-5MH9I.7SY\;MI;:X%X?*&[3UYSZ6[J_S68A MHD0-=]?M&]AH%RP:>VTM?R I@$0/*%!'B_I,9,31R EIK55.O+3Z"9T)?70K M[0LP]BP"++(?8J@/9?> -#O=$^++^111:/:1/BUG?K;%U#^?Z)$$I<"L*8$"8'L[W(MV(5/E-_#%PB;,F%?R:NWHM*)[[Z> MTB<2H?WI' N>NL$/['RW9)\$\7C!CEDT&863N8^=\1S>@?V$,*393,I.IM'B M% ?'TW"^8.^47@N)PT^B\8P^S&'& F:@EE,?:8[]KT?XB=@XF$41\1.%\QG MQ"1&3A:+<-8P0AH;F!Q-EC@9*GL 'R@'\2F>+6$R&DY;A$@O6XN8#NRL/4%N M.YJ@O(:@M!C>(^/@<.5%2=I;9QNQ*B:%K? MKOH@$_6-Y[7-O/IO$:N$%S[O^-M07,#^;!L87$RPWUQ,R#B P:HV4,9 #'&H MX.*OLIN>C+OMH.-X.MUI M&('=+XJ-BDJMHI'$,'CH:LK 5AT2\Y/*/F449GD[9]AHS&BTX[S3(* MGKLXQ.@3(=1FZ7V!'L+1?5[YS,-DU_F;=UV?_L0+:U]]^(0LUN8@W?F_!U(? M@V='OLO*8U.VL;B#OUNP/(#8V'R,%P2+T?/C"+MX(Q8%H\64CS<+GTT3H*EC9@CQ;A9,&^6@HG43 >1Q26 ME^,P7K(WF*=G>!![,ADM3RG"3\+9XN"B$2RZ'%$10=-2Z#3=-HHM38=*I"TR+J-OC/1[/NZUGPKYHONC"XQ!(/\+\?K9_ M@.$HG&QUJ4=M1W&;O6^B.4ZN?.V+IXX[[!GL6R$CL\ >H )F"RI54YFV!\9[ MYR*#[E0@"MG50'/*FC6U_52%+3*0F6X VK2M(W*^;NV'WH<]#5>7V#F4V8]^ MPN\ *C\U243%]0W$=4?.IQMK60 _N")*K%#%6?O&B1T*D'=RC7TCP&5W7(\L M6\4EE'I!(0V^C?U:*PP\X3XC=^]TY/"W5*[4[B0A-H! Q>A(I*)$D( O=:GL M98.6J2X]NLN Q)PA-'MU=!K1%:X\M#T,B6W++,LIW83L4]-Q$GSW_ */UGRU M#W13*\A'M]TG] '1G,;;Y._&_ZY[O&[$@S MY@L:/ TAWT N7&>NF=><#W3*(B=50^JRGNQJ;7&/D-'3U ;0$'&)2J%$Z,IV MI\NL-LZF*&';:3[9](D^[X+7#L4?%3FNG$_EHS1,I3PF=DPWAXU"S M;0!AVSR8Y.^!L[M9MZW$9O(=!H:C8(LD?UK 7L:]6B4:0YJX%0_';03?CH=- MP]OE7E?^T R[B$VPQ#JX7U&UI[748^X7UTU+68K!WR#HM +:@CP-([D=V*LQRO0\)NUT*[$QZ$4JA\H0PUA"QW8)ORW@UL&:*! M$+RNFKM1:!TYE.%^R/"9:^"/8$K^0"RE_@PP0"?DVWWQQ=2'VCU=8OMA7VN\ MUS,D[RS+#$P)17-( D'35:0VP_[Y@U)Q'0B!T4\:V\P(6YVC?9G.<2HI3B4) M",G>*K/%ZJ^P*!0V:%K^ @<\-V>6B/8'>OV42]FSAVCO#:+^D>P36^'(JNN_ MNT4ZP>MZ[T6A5C;(-(QE;1W-3M'CP(Q#.E^":_#;D,<;Y,V/@I2:F\8BCTNA5&#[GLV-REF/O.4 M>"FA0"]!GQ6%X<\%1%.\V(\7,2$/M;??_5O_ M?P_0C#&,^9,K&$JE%C3(WLWM'FH5$D7Z%>JJE1./S>"@VOA M /B^5E#FN =

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end XML 131 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 132 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 133 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 375 588 1 false 126 0 false 18 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.vrtx.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0002002 - Document - Audit Information Sheet http://www.vrtx.com/role/AuditInformation Audit Information Notes 2 false false R3.htm 1001003 - Statement - Consolidated Statements of Operations Sheet http://www.vrtx.com/role/ConsolidatedStatementsofOperations Consolidated Statements of Operations Uncategorized 3 false false R4.htm 1002004 - Statement - Consolidated Statements of Comprehensive Income Sheet http://www.vrtx.com/role/ConsolidatedStatementsofComprehensiveIncome Consolidated Statements of Comprehensive Income Statements 4 false false R5.htm 1003005 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical) Sheet http://www.vrtx.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical Consolidated Statements of Comprehensive Income (Parenthetical) Statements 5 false false R6.htm 1004006 - Statement - Consolidated Balance Sheets Sheet http://www.vrtx.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 6 false false R7.htm 1005007 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.vrtx.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 7 false false R8.htm 1006008 - Statement - Consolidated Statements of Shareholders??? Equity Sheet http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity Consolidated Statements of Shareholders??? Equity Statements 8 false false R9.htm 1007009 - Statement - Consolidated Statements of Cash Flows Sheet http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 9 false false R10.htm 2101101 - Disclosure - Nature of Business and Accounting Policies Sheet http://www.vrtx.com/role/NatureofBusinessandAccountingPolicies Nature of Business and Accounting Policies Notes 10 false false R11.htm 2110102 - Disclosure - Collaborative and Other Arrangements Sheet http://www.vrtx.com/role/CollaborativeandOtherArrangements Collaborative and Other Arrangements Notes 11 false false R12.htm 2116103 - Disclosure - Earnings Per Share Sheet http://www.vrtx.com/role/EarningsPerShare Earnings Per Share Notes 12 false false R13.htm 2120104 - Disclosure - Fair Value Measurements Sheet http://www.vrtx.com/role/FairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 2125105 - Disclosure - Marketable Securities and Equity Investments Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestments Marketable Securities and Equity Investments Notes 14 false false R15.htm 2131106 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) Notes 15 false false R16.htm 2134107 - Disclosure - Hedging Sheet http://www.vrtx.com/role/Hedging Hedging Notes 16 false false R17.htm 2141108 - Disclosure - Inventories Sheet http://www.vrtx.com/role/Inventories Inventories Notes 17 false false R18.htm 2144109 - Disclosure - Property and Equipment Sheet http://www.vrtx.com/role/PropertyandEquipment Property and Equipment Notes 18 false false R19.htm 2148110 - Disclosure - Intangible Assets and Goodwill Sheet http://www.vrtx.com/role/IntangibleAssetsandGoodwill Intangible Assets and Goodwill Notes 19 false false R20.htm 2150111 - Disclosure - Additional Balance Sheet Detail Sheet http://www.vrtx.com/role/AdditionalBalanceSheetDetail Additional Balance Sheet Detail Notes 20 false false R21.htm 2155112 - Disclosure - Leases Sheet http://www.vrtx.com/role/Leases Leases Notes 21 false false R22.htm 2163113 - Disclosure - Common Stock, Preferred Stock and Equity Plans Sheet http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlans Common Stock, Preferred Stock and Equity Plans Notes 22 false false R23.htm 2174114 - Disclosure - Stock-based Compensation Expense Sheet http://www.vrtx.com/role/StockbasedCompensationExpense Stock-based Compensation Expense Notes 23 false false R24.htm 2177115 - Disclosure - Income Taxes Sheet http://www.vrtx.com/role/IncomeTaxes Income Taxes Notes 24 false false R25.htm 2184116 - Disclosure - Commitments and Contingencies Sheet http://www.vrtx.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 25 false false R26.htm 2187117 - Disclosure - Segment Information Sheet http://www.vrtx.com/role/SegmentInformation Segment Information Notes 26 false false R27.htm 2202201 - Disclosure - Nature of Business and Accounting Policies (Policies) Sheet http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies Nature of Business and Accounting Policies (Policies) Policies http://www.vrtx.com/role/NatureofBusinessandAccountingPolicies 27 false false R28.htm 2303301 - Disclosure - Nature of Business and Accounting Policies (Tables) Sheet http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesTables Nature of Business and Accounting Policies (Tables) Tables http://www.vrtx.com/role/NatureofBusinessandAccountingPolicies 28 false false R29.htm 2311302 - Disclosure - Collaborative and Other Arrangements (Tables) Sheet http://www.vrtx.com/role/CollaborativeandOtherArrangementsTables Collaborative and Other Arrangements (Tables) Tables http://www.vrtx.com/role/CollaborativeandOtherArrangements 29 false false R30.htm 2317303 - Disclosure - Earnings Per Share (Tables) Sheet http://www.vrtx.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.vrtx.com/role/EarningsPerShare 30 false false R31.htm 2321304 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.vrtx.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.vrtx.com/role/FairValueMeasurements 31 false false R32.htm 2326305 - Disclosure - Marketable Securities and Equity Investments (Tables) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables Marketable Securities and Equity Investments (Tables) Tables http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestments 32 false false R33.htm 2332306 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss 33 false false R34.htm 2335307 - Disclosure - Hedging (Tables) Sheet http://www.vrtx.com/role/HedgingTables Hedging (Tables) Tables http://www.vrtx.com/role/Hedging 34 false false R35.htm 2342308 - Disclosure - Inventories (Tables) Sheet http://www.vrtx.com/role/InventoriesTables Inventories (Tables) Tables http://www.vrtx.com/role/Inventories 35 false false R36.htm 2345309 - Disclosure - Property and Equipment (Tables) Sheet http://www.vrtx.com/role/PropertyandEquipmentTables Property and Equipment (Tables) Tables http://www.vrtx.com/role/PropertyandEquipment 36 false false R37.htm 2351310 - Disclosure - Additional Balance Sheet Detail (Tables) Sheet http://www.vrtx.com/role/AdditionalBalanceSheetDetailTables Additional Balance Sheet Detail (Tables) Tables http://www.vrtx.com/role/AdditionalBalanceSheetDetail 37 false false R38.htm 2356311 - Disclosure - Leases (Tables) Sheet http://www.vrtx.com/role/LeasesTables Leases (Tables) Tables http://www.vrtx.com/role/Leases 38 false false R39.htm 2364312 - Disclosure - Common Stock, Preferred Stock and Equity Plans (Tables) Sheet http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansTables Common Stock, Preferred Stock and Equity Plans (Tables) Tables http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlans 39 false false R40.htm 2375313 - Disclosure - Stock-based Compensation Expense (Tables) Sheet http://www.vrtx.com/role/StockbasedCompensationExpenseTables Stock-based Compensation Expense (Tables) Tables http://www.vrtx.com/role/StockbasedCompensationExpense 40 false false R41.htm 2378314 - Disclosure - Income Taxes (Tables) Sheet http://www.vrtx.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.vrtx.com/role/IncomeTaxes 41 false false R42.htm 2388315 - Disclosure - Segment Information (Tables) Sheet http://www.vrtx.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.vrtx.com/role/SegmentInformation 42 false false R43.htm 2404401 - Disclosure - Nature of Business and Accounting Policies - Business Narrative (Details) Sheet http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesBusinessNarrativeDetails Nature of Business and Accounting Policies - Business Narrative (Details) Details 43 false false R44.htm 2405402 - Disclosure - Nature of Business and Accounting Policies - Revenue Recognition (Details) Sheet http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesRevenueRecognitionDetails Nature of Business and Accounting Policies - Revenue Recognition (Details) Details 44 false false R45.htm 2406403 - Disclosure - Nature of Business and Accounting Policies - Stock-Based Compensation Expense (Details) Sheet http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesStockBasedCompensationExpenseDetails Nature of Business and Accounting Policies - Stock-Based Compensation Expense (Details) Details 45 false false R46.htm 2407404 - Disclosure - Nature of Business and Accounting Policies - Property and Equipment (Details) Sheet http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPropertyandEquipmentDetails Nature of Business and Accounting Policies - Property and Equipment (Details) Details 46 false false R47.htm 2408405 - Disclosure - Nature of Business and Accounting Policies - Goodwill Hedging Activities Foreign Currency Gain (Loss) (Details) Sheet http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesGoodwillHedgingActivitiesForeignCurrencyGainLossDetails Nature of Business and Accounting Policies - Goodwill Hedging Activities Foreign Currency Gain (Loss) (Details) Details 47 false false R48.htm 2409406 - Disclosure - Nature of Business and Accounting Policies - Leases (Details) Sheet http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesLeasesDetails Nature of Business and Accounting Policies - Leases (Details) Details http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesTables 48 false false R49.htm 2412407 - Disclosure - Collaborative and Other Arrangements - Additional Information (Details) Sheet http://www.vrtx.com/role/CollaborativeandOtherArrangementsAdditionalInformationDetails Collaborative and Other Arrangements - Additional Information (Details) Details 49 false false R50.htm 2413408 - Disclosure - Collaborative and Other Arrangements - CRISPR Therapeutics AG (Details) Sheet http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails Collaborative and Other Arrangements - CRISPR Therapeutics AG (Details) Details 50 false false R51.htm 2414409 - Disclosure - Collaborative and Other Arrangements - Kymera, Moderna and Other In-License Agreements (Details) Sheet http://www.vrtx.com/role/CollaborativeandOtherArrangementsKymeraModernaandOtherInLicenseAgreementsDetails Collaborative and Other Arrangements - Kymera, Moderna and Other In-License Agreements (Details) Details 51 false false R52.htm 2415410 - Disclosure - Collaborative and Other Arrangements - Merck KGaA (Details) Sheet http://www.vrtx.com/role/CollaborativeandOtherArrangementsMerckKGaADetails Collaborative and Other Arrangements - Merck KGaA (Details) Details 52 false false R53.htm 2418411 - Disclosure - Earnings Per Share - Schedule of Computation (Details) Sheet http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails Earnings Per Share - Schedule of Computation (Details) Details 53 false false R54.htm 2419412 - Disclosure - Earnings Per Share - Anti-dilutive Securities (Details) Sheet http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails Earnings Per Share - Anti-dilutive Securities (Details) Details 54 false false R55.htm 2422413 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 55 false false R56.htm 2423414 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) Details 56 false false R57.htm 2424415 - Disclosure - Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) Details 57 false false R58.htm 2427416 - Disclosure - Marketable Securities and Equity Investments - Additional Information (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails Marketable Securities and Equity Investments - Additional Information (Details) Details 58 false false R59.htm 2428417 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) Details 59 false false R60.htm 2429418 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) Details 60 false false R61.htm 2430419 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) Details 61 false false R62.htm 2433420 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails Accumulated Other Comprehensive Income (Loss) (Details) Details http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables 62 false false R63.htm 2436421 - Disclosure - Hedging - Narrative (Details) Sheet http://www.vrtx.com/role/HedgingNarrativeDetails Hedging - Narrative (Details) Details 63 false false R64.htm 2437422 - Disclosure - Hedging - Notional Amount (Details) Sheet http://www.vrtx.com/role/HedgingNotionalAmountDetails Hedging - Notional Amount (Details) Details 64 false false R65.htm 2438423 - Disclosure - Hedging - Cash Flow Hedging Instruments (Details) Sheet http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails Hedging - Cash Flow Hedging Instruments (Details) Details 65 false false R66.htm 2439424 - Disclosure - Hedging - Derivative Fair Value (Details) Sheet http://www.vrtx.com/role/HedgingDerivativeFairValueDetails Hedging - Derivative Fair Value (Details) Details 66 false false R67.htm 2440425 - Disclosure - Hedging - Offsetting Derivatives (Details) Sheet http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails Hedging - Offsetting Derivatives (Details) Details 67 false false R68.htm 2443426 - Disclosure - Inventories (Details) Sheet http://www.vrtx.com/role/InventoriesDetails Inventories (Details) Details http://www.vrtx.com/role/InventoriesTables 68 false false R69.htm 2446427 - Disclosure - Property and Equipment - Property and Equipment, Net (Details) Sheet http://www.vrtx.com/role/PropertyandEquipmentPropertyandEquipmentNetDetails Property and Equipment - Property and Equipment, Net (Details) Details 69 false false R70.htm 2447428 - Disclosure - Property and Equipment - Narrative (Details) Sheet http://www.vrtx.com/role/PropertyandEquipmentNarrativeDetails Property and Equipment - Narrative (Details) Details 70 false false R71.htm 2449429 - Disclosure - Intangible Assets and Goodwill (Details) Sheet http://www.vrtx.com/role/IntangibleAssetsandGoodwillDetails Intangible Assets and Goodwill (Details) Details http://www.vrtx.com/role/IntangibleAssetsandGoodwill 71 false false R72.htm 2452430 - Disclosure - Additional Balance Sheet Detail - Prepaid Expenses and Other Current Assets (Details) Sheet http://www.vrtx.com/role/AdditionalBalanceSheetDetailPrepaidExpensesandOtherCurrentAssetsDetails Additional Balance Sheet Detail - Prepaid Expenses and Other Current Assets (Details) Details 72 false false R73.htm 2453431 - Disclosure - Additional Balance Sheet Detail - Accrued Expenses and Other Current Liabilities (Details) Sheet http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails Additional Balance Sheet Detail - Accrued Expenses and Other Current Liabilities (Details) Details 73 false false R74.htm 2454432 - Disclosure - Additional Balance Sheet Detail - Additional Cash Flow (Details) Sheet http://www.vrtx.com/role/AdditionalBalanceSheetDetailAdditionalCashFlowDetails Additional Balance Sheet Detail - Additional Cash Flow (Details) Details 74 false false R75.htm 2457433 - Disclosure - Leases - Additional Information (Details) Sheet http://www.vrtx.com/role/LeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 75 false false R76.htm 2458434 - Disclosure - Leases - Components of Lease Expense (Details) Sheet http://www.vrtx.com/role/LeasesComponentsofLeaseExpenseDetails Leases - Components of Lease Expense (Details) Details 76 false false R77.htm 2459435 - Disclosure - Leases - Balance Sheet Classification of Lease Assets and Liabilities (Details) Sheet http://www.vrtx.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails Leases - Balance Sheet Classification of Lease Assets and Liabilities (Details) Details 77 false false R78.htm 2460436 - Disclosure - Leases - Maturities of Operating and Financing Lease Liabilities (Details) Sheet http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails Leases - Maturities of Operating and Financing Lease Liabilities (Details) Details 78 false false R79.htm 2461437 - Disclosure - Leases - Weighted-Average Remaining Lease Terms and Discount Rates (Details) Sheet http://www.vrtx.com/role/LeasesWeightedAverageRemainingLeaseTermsandDiscountRatesDetails Leases - Weighted-Average Remaining Lease Terms and Discount Rates (Details) Details 79 false false R80.htm 2462438 - Disclosure - Leases - Supplemental Cash Flow Information (Details) Sheet http://www.vrtx.com/role/LeasesSupplementalCashFlowInformationDetails Leases - Supplemental Cash Flow Information (Details) Details 80 false false R81.htm 2465439 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Common Stock and Preferred Stock (Details) Sheet http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansCommonStockandPreferredStockDetails Common Stock, Preferred Stock and Equity Plans - Common Stock and Preferred Stock (Details) Details 81 false false R82.htm 2466440 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Share Repurchase Program (Details) Sheet http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansShareRepurchaseProgramDetails Common Stock, Preferred Stock and Equity Plans - Share Repurchase Program (Details) Details 82 false false R83.htm 2467441 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Stock and Option Plans (Details) Sheet http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockandOptionPlansDetails Common Stock, Preferred Stock and Equity Plans - Stock and Option Plans (Details) Details 83 false false R84.htm 2468442 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Outstanding and Vested Stock Options (Details) Sheet http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails Common Stock, Preferred Stock and Equity Plans - Outstanding and Vested Stock Options (Details) Details 84 false false R85.htm 2469443 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Stock Options Outstanding and Exercisable (Details) Sheet http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockOptionsOutstandingandExercisableDetails Common Stock, Preferred Stock and Equity Plans - Stock Options Outstanding and Exercisable (Details) Details 85 false false R86.htm 2470444 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Restricted Stock and Restricted Stock Units (Details) Sheet http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansRestrictedStockandRestrictedStockUnitsDetails Common Stock, Preferred Stock and Equity Plans - Restricted Stock and Restricted Stock Units (Details) Details 86 false false R87.htm 2471445 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Performance-based RSUs (PSUs) (Details) Sheet http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails Common Stock, Preferred Stock and Equity Plans - Performance-based RSUs (PSUs) (Details) Details 87 false false R88.htm 2472446 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Employee Stock Purchase Plan (Details) Sheet http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansEmployeeStockPurchasePlanDetails Common Stock, Preferred Stock and Equity Plans - Employee Stock Purchase Plan (Details) Details 88 false false R89.htm 2473447 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Employee Benefits (Details) Sheet http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansEmployeeBenefitsDetails Common Stock, Preferred Stock and Equity Plans - Employee Benefits (Details) Details 89 false false R90.htm 2476448 - Disclosure - Stock-based Compensation Expense (Details) Sheet http://www.vrtx.com/role/StockbasedCompensationExpenseDetails Stock-based Compensation Expense (Details) Details http://www.vrtx.com/role/StockbasedCompensationExpenseTables 90 false false R91.htm 2479449 - Disclosure - Income Taxes - Components of Income and Provision for (Benefit from) Income Taxes (Details) Sheet http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails Income Taxes - Components of Income and Provision for (Benefit from) Income Taxes (Details) Details 91 false false R92.htm 2480450 - Disclosure - Income Taxes - Effective Income Tax Reconciliation (Details) Sheet http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails Income Taxes - Effective Income Tax Reconciliation (Details) Details 92 false false R93.htm 2481451 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.vrtx.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 93 false false R94.htm 2482452 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details) Sheet http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails Income Taxes - Deferred Tax Assets and Liabilities (Details) Details 94 false false R95.htm 2483453 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details) Sheet http://www.vrtx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails Income Taxes - Unrecognized Tax Benefits (Details) Details 95 false false R96.htm 2485454 - Disclosure - Commitments and Contingencies - Revolving Credit Facility (Details) Sheet http://www.vrtx.com/role/CommitmentsandContingenciesRevolvingCreditFacilityDetails Commitments and Contingencies - Revolving Credit Facility (Details) Details 96 false false R97.htm 2486455 - Disclosure - Commitments and Contingencies - Contingencies (Details) Sheet http://www.vrtx.com/role/CommitmentsandContingenciesContingenciesDetails Commitments and Contingencies - Contingencies (Details) Details 97 false false R98.htm 2489456 - Disclosure - Segment Information - Revenues by Product (Details) Sheet http://www.vrtx.com/role/SegmentInformationRevenuesbyProductDetails Segment Information - Revenues by Product (Details) Details 98 false false R99.htm 2490457 - Disclosure - Segment Information - Revenue by Geographic Location (Details) Sheet http://www.vrtx.com/role/SegmentInformationRevenuebyGeographicLocationDetails Segment Information - Revenue by Geographic Location (Details) Details 99 false false R100.htm 2491458 - Disclosure - Segment Information - Significant Customers (Details) Sheet http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails Segment Information - Significant Customers (Details) Details 100 false false R101.htm 2492459 - Disclosure - Segment Information - Property and Equipment, Net by Location (Details) Sheet http://www.vrtx.com/role/SegmentInformationPropertyandEquipmentNetbyLocationDetails Segment Information - Property and Equipment, Net by Location (Details) Details 101 false false R9999.htm Uncategorized Items - vrtx-20211231.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - vrtx-20211231.htm Cover 102 false false All Reports Book All Reports vrtx-20211231.htm a10k_2021-exhibit1024.htm a10k_2021-exhibit1036.htm a10k_2021-exhibit1037.htm a10k_2021-exhibit1039.htm a10k_2021-exhibit211.htm a10k_2021-exhibit231.htm a10k_2021-exhibit311.htm a10k_2021-exhibit312.htm a10k_2021-exhibit321.htm vrtx-20211231.xsd vrtx-20211231_cal.xml vrtx-20211231_def.xml vrtx-20211231_lab.xml vrtx-20211231_pre.xml vrtx-20211231_g1.jpg vrtx-20211231_g10.jpg vrtx-20211231_g2.jpg vrtx-20211231_g3.jpg vrtx-20211231_g4.jpg vrtx-20211231_g5.jpg vrtx-20211231_g6.jpg vrtx-20211231_g7.gif vrtx-20211231_g8.gif vrtx-20211231_g9.jpg http://fasb.org/srt/2021-01-31 http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 136 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "vrtx-20211231.htm": { "axisCustom": 2, "axisStandard": 34, "contextCount": 375, "dts": { "calculationLink": { "local": [ "vrtx-20211231_cal.xml" ] }, "definitionLink": { "local": [ "vrtx-20211231_def.xml" ] }, "inline": { "local": [ "vrtx-20211231.htm" ] }, "labelLink": { "local": [ "vrtx-20211231_lab.xml" ] }, "presentationLink": { "local": [ "vrtx-20211231_pre.xml" ] }, "schema": { "local": [ "vrtx-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 819, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 18, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 23 }, "keyCustom": 78, "keyStandard": 510, "memberCustom": 46, "memberStandard": 75, "nsprefix": "vrtx", "nsuri": "http://www.vrtx.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.vrtx.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Nature of Business and Accounting Policies", "role": "http://www.vrtx.com/role/NatureofBusinessandAccountingPolicies", "shortName": "Nature of Business and Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "if286ac31e63841bd8f3cd9aa72fd509b_D20210101-20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2491458 - Disclosure - Segment Information - Significant Customers (Details)", "role": "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails", "shortName": "Segment Information - Significant Customers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "if286ac31e63841bd8f3cd9aa72fd509b_D20210101-20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2492459 - Disclosure - Segment Information - Property and Equipment, Net by Location (Details)", "role": "http://www.vrtx.com/role/SegmentInformationPropertyandEquipmentNetbyLocationDetails", "shortName": "Segment Information - Property and Equipment, Net by Location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110102 - Disclosure - Collaborative and Other Arrangements", "role": "http://www.vrtx.com/role/CollaborativeandOtherArrangements", "shortName": "Collaborative and Other Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116103 - Disclosure - Earnings Per Share", "role": "http://www.vrtx.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120104 - Disclosure - Fair Value Measurements", "role": "http://www.vrtx.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125105 - Disclosure - Marketable Securities and Equity Investments", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestments", "shortName": "Marketable Securities and Equity Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2131106 - Disclosure - Accumulated Other Comprehensive Income (Loss)", "role": "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss", "shortName": "Accumulated Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2134107 - Disclosure - Hedging", "role": "http://www.vrtx.com/role/Hedging", "shortName": "Hedging", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2141108 - Disclosure - Inventories", "role": "http://www.vrtx.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2144109 - Disclosure - Property and Equipment", "role": "http://www.vrtx.com/role/PropertyandEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2148110 - Disclosure - Intangible Assets and Goodwill", "role": "http://www.vrtx.com/role/IntangibleAssetsandGoodwill", "shortName": "Intangible Assets and Goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorFirmId", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "false", "longName": "0002002 - Document - Audit Information", "role": "http://www.vrtx.com/role/AuditInformation", "shortName": "Audit Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorFirmId", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2150111 - Disclosure - Additional Balance Sheet Detail", "role": "http://www.vrtx.com/role/AdditionalBalanceSheetDetail", "shortName": "Additional Balance Sheet Detail", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2155112 - Disclosure - Leases", "role": "http://www.vrtx.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "vrtx:CommonStockPreferredStockAndEquityPlansDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2163113 - Disclosure - Common Stock, Preferred Stock and Equity Plans", "role": "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlans", "shortName": "Common Stock, Preferred Stock and Equity Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "vrtx:CommonStockPreferredStockAndEquityPlansDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2174114 - Disclosure - Stock-based Compensation Expense", "role": "http://www.vrtx.com/role/StockbasedCompensationExpense", "shortName": "Stock-based Compensation Expense", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2177115 - Disclosure - Income Taxes", "role": "http://www.vrtx.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2184116 - Disclosure - Commitments and Contingencies", "role": "http://www.vrtx.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2187117 - Disclosure - Segment Information", "role": "http://www.vrtx.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Nature of Business and Accounting Policies (Policies)", "role": "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies", "shortName": "Nature of Business and Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Nature of Business and Accounting Policies (Tables)", "role": "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesTables", "shortName": "Nature of Business and Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311302 - Disclosure - Collaborative and Other Arrangements (Tables)", "role": "http://www.vrtx.com/role/CollaborativeandOtherArrangementsTables", "shortName": "Collaborative and Other Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001003 - Statement - Consolidated Statements of Operations", "role": "http://www.vrtx.com/role/ConsolidatedStatementsofOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317303 - Disclosure - Earnings Per Share (Tables)", "role": "http://www.vrtx.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321304 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.vrtx.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2326305 - Disclosure - Marketable Securities and Equity Investments (Tables)", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables", "shortName": "Marketable Securities and Equity Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2332306 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)", "role": "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2335307 - Disclosure - Hedging (Tables)", "role": "http://www.vrtx.com/role/HedgingTables", "shortName": "Hedging (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2342308 - Disclosure - Inventories (Tables)", "role": "http://www.vrtx.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2345309 - Disclosure - Property and Equipment (Tables)", "role": "http://www.vrtx.com/role/PropertyandEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2351310 - Disclosure - Additional Balance Sheet Detail (Tables)", "role": "http://www.vrtx.com/role/AdditionalBalanceSheetDetailTables", "shortName": "Additional Balance Sheet Detail (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2356311 - Disclosure - Leases (Tables)", "role": "http://www.vrtx.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "vrtx:ScheduleOfStockAndStockOptionEquityPlansTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2364312 - Disclosure - Common Stock, Preferred Stock and Equity Plans (Tables)", "role": "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansTables", "shortName": "Common Stock, Preferred Stock and Equity Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "vrtx:ScheduleOfStockAndStockOptionEquityPlansTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002004 - Statement - Consolidated Statements of Comprehensive Income", "role": "http://www.vrtx.com/role/ConsolidatedStatementsofComprehensiveIncome", "shortName": "Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2375313 - Disclosure - Stock-based Compensation Expense (Tables)", "role": "http://www.vrtx.com/role/StockbasedCompensationExpenseTables", "shortName": "Stock-based Compensation Expense (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2378314 - Disclosure - Income Taxes (Tables)", "role": "http://www.vrtx.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2388315 - Disclosure - Segment Information (Tables)", "role": "http://www.vrtx.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404401 - Disclosure - Nature of Business and Accounting Policies - Business Narrative (Details)", "role": "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesBusinessNarrativeDetails", "shortName": "Nature of Business and Accounting Policies - Business Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Nature of Business and Accounting Policies - Revenue Recognition (Details)", "role": "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesRevenueRecognitionDetails", "shortName": "Nature of Business and Accounting Policies - Revenue Recognition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "vrtx:Percentageofemployeeseligibleforaccelerationofequityawards", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Nature of Business and Accounting Policies - Stock-Based Compensation Expense (Details)", "role": "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesStockBasedCompensationExpenseDetails", "shortName": "Nature of Business and Accounting Policies - Stock-Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "vrtx:Percentageofemployeeseligibleforaccelerationofequityawards", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i264170f9b7e345fd9eea4c2e7a5afeb4_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - Nature of Business and Accounting Policies - Property and Equipment (Details)", "role": "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPropertyandEquipmentDetails", "shortName": "Nature of Business and Accounting Policies - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i264170f9b7e345fd9eea4c2e7a5afeb4_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408405 - Disclosure - Nature of Business and Accounting Policies - Goodwill Hedging Activities Foreign Currency Gain (Loss) (Details)", "role": "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesGoodwillHedgingActivitiesForeignCurrencyGainLossDetails", "shortName": "Nature of Business and Accounting Policies - Goodwill Hedging Activities Foreign Currency Gain (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409406 - Disclosure - Nature of Business and Accounting Policies - Leases (Details)", "role": "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesLeasesDetails", "shortName": "Nature of Business and Accounting Policies - Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "if88080ea7543473db9359a4626a78a2c_I20190101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-8", "first": true, "lang": "en-US", "name": "vrtx:CollaborativeArrangementResearchAndDevelopmentExpenses", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412407 - Disclosure - Collaborative and Other Arrangements - Additional Information (Details)", "role": "http://www.vrtx.com/role/CollaborativeandOtherArrangementsAdditionalInformationDetails", "shortName": "Collaborative and Other Arrangements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R5": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003005 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)", "role": "http://www.vrtx.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical", "shortName": "Consolidated Statements of Comprehensive Income (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "vrtx:CollaborativeArrangementUpFrontLicenseFee", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413408 - Disclosure - Collaborative and Other Arrangements - CRISPR Therapeutics AG (Details)", "role": "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails", "shortName": "Collaborative and Other Arrangements - CRISPR Therapeutics AG (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i07194a4348874e5cbc2b09c300ea28be_D20190101-20191231", "decimals": "-5", "lang": "en-US", "name": "vrtx:CollaborativeArrangementOptionPayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "vrtx:CollaborativeArrangementUpFrontLicenseFee", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414409 - Disclosure - Collaborative and Other Arrangements - Kymera, Moderna and Other In-License Agreements (Details)", "role": "http://www.vrtx.com/role/CollaborativeandOtherArrangementsKymeraModernaandOtherInLicenseAgreementsDetails", "shortName": "Collaborative and Other Arrangements - Kymera, Moderna and Other In-License Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i389a88031832412c92ec7738a071ae44_D20190101-20191231", "decimals": "-5", "lang": "en-US", "name": "vrtx:CollaborativeArrangementUpFrontLicenseFee", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i7f6428b0c0c545d8bb4e54193ba53070_D20170101-20170131", "decimals": "INF", "first": true, "lang": "en-US", "name": "vrtx:CollaborativeArrangementRightToLicenseNumberOfDevelopmentPrograms", "reportCount": 1, "unique": true, "unitRef": "oncology_research_and_development_program", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415410 - Disclosure - Collaborative and Other Arrangements - Merck KGaA (Details)", "role": "http://www.vrtx.com/role/CollaborativeandOtherArrangementsMerckKGaADetails", "shortName": "Collaborative and Other Arrangements - Merck KGaA (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i7f6428b0c0c545d8bb4e54193ba53070_D20170101-20170131", "decimals": "INF", "first": true, "lang": "en-US", "name": "vrtx:CollaborativeArrangementRightToLicenseNumberOfDevelopmentPrograms", "reportCount": 1, "unique": true, "unitRef": "oncology_research_and_development_program", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418411 - Disclosure - Earnings Per Share - Schedule of Computation (Details)", "role": "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "shortName": "Earnings Per Share - Schedule of Computation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i0e7943a5b00c47879fae55970034bca2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419412 - Disclosure - Earnings Per Share - Anti-dilutive Securities (Details)", "role": "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "shortName": "Earnings Per Share - Anti-dilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i0e7943a5b00c47879fae55970034bca2_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422413 - Disclosure - Fair Value Measurements - Additional Information (Details)", "role": "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i4b0b5a15e1d244ca91430d20a94ba839_I20211231", "decimals": "-5", "lang": "en-US", "name": "vrtx:BusinessCombinationRemainingMilestonePayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423414 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details)", "role": "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "shortName": "Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i804c89731d5f445e9744d8fbee6ee99d_I20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DerivativeAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i40c6bd02ca564bb49ae6636c87338999_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424415 - Disclosure - Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details)", "role": "http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails", "shortName": "Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427416 - Disclosure - Marketable Securities and Equity Investments - Additional Information (Details)", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "shortName": "Marketable Securities and Equity Investments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ImpairmentOfInvestments", "us-gaap:ImpairmentOfInvestments", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ImpairmentOfInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428417 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details)", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails", "shortName": "Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGain", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004006 - Statement - Consolidated Balance Sheets", "role": "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429418 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details)", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "shortName": "Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430419 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details)", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails", "shortName": "Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i40c6bd02ca564bb49ae6636c87338999_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433420 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)", "role": "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i8837041e88444c09bd6931283deae42b_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeTermOfContract", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436421 - Disclosure - Hedging - Narrative (Details)", "role": "http://www.vrtx.com/role/HedgingNarrativeDetails", "shortName": "Hedging - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "id42b21c39ed846d9bc16c69edec0710a_I20211231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i8ede869f3d8543afaa3eb09664c60658_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437422 - Disclosure - Hedging - Notional Amount (Details)", "role": "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "shortName": "Hedging - Notional Amount (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i8ede869f3d8543afaa3eb09664c60658_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438423 - Disclosure - Hedging - Cash Flow Hedging Instruments (Details)", "role": "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "shortName": "Hedging - Cash Flow Hedging Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i27e90e03d8b2459bb9a6a12f2863462c_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherNonoperatingIncomeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i8ede869f3d8543afaa3eb09664c60658_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439424 - Disclosure - Hedging - Derivative Fair Value (Details)", "role": "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "shortName": "Hedging - Derivative Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i38933de0d6fc4d7894e19824d8331ad1_I20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i8ede869f3d8543afaa3eb09664c60658_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440425 - Disclosure - Hedging - Offsetting Derivatives (Details)", "role": "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails", "shortName": "Hedging - Offsetting Derivatives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i8ede869f3d8543afaa3eb09664c60658_I20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DerivativeAssetFairValueGrossLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443426 - Disclosure - Inventories (Details)", "role": "http://www.vrtx.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446427 - Disclosure - Property and Equipment - Property and Equipment, Net (Details)", "role": "http://www.vrtx.com/role/PropertyandEquipmentPropertyandEquipmentNetDetails", "shortName": "Property and Equipment - Property and Equipment, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005007 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.vrtx.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447428 - Disclosure - Property and Equipment - Narrative (Details)", "role": "http://www.vrtx.com/role/PropertyandEquipmentNarrativeDetails", "shortName": "Property and Equipment - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherIndefiniteLivedIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449429 - Disclosure - Intangible Assets and Goodwill (Details)", "role": "http://www.vrtx.com/role/IntangibleAssetsandGoodwillDetails", "shortName": "Intangible Assets and Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherIndefiniteLivedIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "vrtx:TaxRelatedPrepaidAndReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452430 - Disclosure - Additional Balance Sheet Detail - Prepaid Expenses and Other Current Assets (Details)", "role": "http://www.vrtx.com/role/AdditionalBalanceSheetDetailPrepaidExpensesandOtherCurrentAssetsDetails", "shortName": "Additional Balance Sheet Detail - Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "vrtx:TaxRelatedPrepaidAndReceivables", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "vrtx:ProductSalesAccruedLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2453431 - Disclosure - Additional Balance Sheet Detail - Accrued Expenses and Other Current Liabilities (Details)", "role": "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails", "shortName": "Additional Balance Sheet Detail - Accrued Expenses and Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "vrtx:ProductSalesAccruedLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454432 - Disclosure - Additional Balance Sheet Detail - Additional Cash Flow (Details)", "role": "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAdditionalCashFlowDetails", "shortName": "Additional Balance Sheet Detail - Additional Cash Flow (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i2ebee08d9bd34881bf84993e97801871_I20191231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i33a8301d73d54e5894b975489df62883_D20110101-20111231", "decimals": "INF", "first": true, "lang": "en-US", "name": "vrtx:LeaseAgreementNumberOfLeases", "reportCount": 1, "unique": true, "unitRef": "lease", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2457433 - Disclosure - Leases - Additional Information (Details)", "role": "http://www.vrtx.com/role/LeasesAdditionalInformationDetails", "shortName": "Leases - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i33a8301d73d54e5894b975489df62883_D20110101-20111231", "decimals": "INF", "first": true, "lang": "en-US", "name": "vrtx:LeaseAgreementNumberOfLeases", "reportCount": 1, "unique": true, "unitRef": "lease", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2458434 - Disclosure - Leases - Components of Lease Expense (Details)", "role": "http://www.vrtx.com/role/LeasesComponentsofLeaseExpenseDetails", "shortName": "Leases - Components of Lease Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "vrtx:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "vrtx:FinanceLeaseRightOfUseAssetGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2459435 - Disclosure - Leases - Balance Sheet Classification of Lease Assets and Liabilities (Details)", "role": "http://www.vrtx.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails", "shortName": "Leases - Balance Sheet Classification of Lease Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "vrtx:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "vrtx:FinanceLeaseRightOfUseAssetGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2460436 - Disclosure - Leases - Maturities of Operating and Financing Lease Liabilities (Details)", "role": "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails", "shortName": "Leases - Maturities of Operating and Financing Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "vrtx:ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesRelatedtoLeasesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2461437 - Disclosure - Leases - Weighted-Average Remaining Lease Terms and Discount Rates (Details)", "role": "http://www.vrtx.com/role/LeasesWeightedAverageRemainingLeaseTermsandDiscountRatesDetails", "shortName": "Leases - Weighted-Average Remaining Lease Terms and Discount Rates (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "vrtx:ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesRelatedtoLeasesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i0a6bf2f027a8456abd8cf118c288edaa_I20181231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006008 - Statement - Consolidated Statements of Shareholders\u2019 Equity", "role": "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity", "shortName": "Consolidated Statements of Shareholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i0a6bf2f027a8456abd8cf118c288edaa_I20181231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "vrtx:LeaseSupplementalCashFlowInformationTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2462438 - Disclosure - Leases - Supplemental Cash Flow Information (Details)", "role": "http://www.vrtx.com/role/LeasesSupplementalCashFlowInformationDetails", "shortName": "Leases - Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "vrtx:LeaseSupplementalCashFlowInformationTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2465439 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Common Stock and Preferred Stock (Details)", "role": "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansCommonStockandPreferredStockDetails", "shortName": "Common Stock, Preferred Stock and Equity Plans - Common Stock and Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "INF", "lang": "en-US", "name": "vrtx:CommonStockVotesPerEachShare", "reportCount": 1, "unique": true, "unitRef": "vote", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchasedDuringPeriodValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2466440 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Share Repurchase Program (Details)", "role": "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansShareRepurchaseProgramDetails", "shortName": "Common Stock, Preferred Stock and Equity Plans - Share Repurchase Program (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "iac27ddc1848e4c20b3fb1dcda50ac36a_I20181231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "vrtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2467441 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Stock and Option Plans (Details)", "role": "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockandOptionPlansDetails", "shortName": "Common Stock, Preferred Stock and Equity Plans - Stock and Option Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "vrtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i40c6bd02ca564bb49ae6636c87338999_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2468442 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Outstanding and Vested Stock Options (Details)", "role": "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails", "shortName": "Common Stock, Preferred Stock and Equity Plans - Outstanding and Vested Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2469443 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Stock Options Outstanding and Exercisable (Details)", "role": "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockOptionsOutstandingandExercisableDetails", "shortName": "Common Stock, Preferred Stock and Equity Plans - Stock Options Outstanding and Exercisable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i24449c998efa4ae8963b29c0ba173b4c_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2470444 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Restricted Stock and Restricted Stock Units (Details)", "role": "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansRestrictedStockandRestrictedStockUnitsDetails", "shortName": "Common Stock, Preferred Stock and Equity Plans - Restricted Stock and Restricted Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i143f776e90d541608f9a4dad77535b4f_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i18cce837150a4666afaab841fa166211_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "vrtx:ShareBasedCompensationByShareBasedPaymentAwardAwardPercentageOfTargetMinimum", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2471445 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Performance-based RSUs (PSUs) (Details)", "role": "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "shortName": "Common Stock, Preferred Stock and Equity Plans - Performance-based RSUs (PSUs) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i18cce837150a4666afaab841fa166211_D20210101-20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibb7507a8d2a148cdbd5d09f5346d91cd_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "vrtx:SharebasedCompensationArrangementbySharebasedPaymentAwardOfferingPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2472446 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Employee Stock Purchase Plan (Details)", "role": "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansEmployeeStockPurchasePlanDetails", "shortName": "Common Stock, Preferred Stock and Equity Plans - Employee Stock Purchase Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibb7507a8d2a148cdbd5d09f5346d91cd_D20210101-20211231", "decimals": null, "first": true, "lang": "en-US", "name": "vrtx:SharebasedCompensationArrangementbySharebasedPaymentAwardOfferingPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2473447 - Disclosure - Common Stock, Preferred Stock and Equity Plans - Employee Benefits (Details)", "role": "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansEmployeeBenefitsDetails", "shortName": "Common Stock, Preferred Stock and Equity Plans - Employee Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007009 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2476448 - Disclosure - Stock-based Compensation Expense (Details)", "role": "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails", "shortName": "Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2479449 - Disclosure - Income Taxes - Components of Income and Provision for (Benefit from) Income Taxes (Details)", "role": "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails", "shortName": "Income Taxes - Components of Income and Provision for (Benefit from) Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "vrtx:IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2480450 - Disclosure - Income Taxes - Effective Income Tax Reconciliation (Details)", "role": "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails", "shortName": "Income Taxes - Effective Income Tax Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "vrtx:IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "vrtx:IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2481451 - Disclosure - Income Taxes - Narrative (Details)", "role": "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:IncomeTaxReconciliationTaxCreditsResearch", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2482452 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)", "role": "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails", "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "i40c6bd02ca564bb49ae6636c87338999_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2483453 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)", "role": "http://www.vrtx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails", "shortName": "Income Taxes - Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "icf04896225b249dbb3e3e27b3c79d946_I20181231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "vrtx:NumberOfCreditAgreements", "reportCount": 1, "unique": true, "unitRef": "credit_agreement", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2485454 - Disclosure - Commitments and Contingencies - Revolving Credit Facility (Details)", "role": "http://www.vrtx.com/role/CommitmentsandContingenciesRevolvingCreditFacilityDetails", "shortName": "Commitments and Contingencies - Revolving Credit Facility (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "vrtx:NumberOfCreditAgreements", "reportCount": 1, "unique": true, "unitRef": "credit_agreement", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "vrtx:ContingentLiabilities", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "vrtx:ContingentLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2486455 - Disclosure - Commitments and Contingencies - Contingencies (Details)", "role": "http://www.vrtx.com/role/CommitmentsandContingenciesContingenciesDetails", "shortName": "Commitments and Contingencies - Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "vrtx:ContingentLiabilities", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ide629bfee6064696a1b0d9c550c603af_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "vrtx:ContingentLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2489456 - Disclosure - Segment Information - Revenues by Product (Details)", "role": "http://www.vrtx.com/role/SegmentInformationRevenuesbyProductDetails", "shortName": "Segment Information - Revenues by Product (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ic5ada478704749b39823f9551ca1c440_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibaa50f2109884dc29991bb84b2bacad9_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2490457 - Disclosure - Segment Information - Revenue by Geographic Location (Details)", "role": "http://www.vrtx.com/role/SegmentInformationRevenuebyGeographicLocationDetails", "shortName": "Segment Information - Revenue by Geographic Location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20211231.htm", "contextRef": "ibd79e2d8528643639785da754940b9df_D20210101-20211231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9999": { "firstAnchor": null, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - vrtx-20211231.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - vrtx-20211231.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 126, "tag": { "country_GB": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED KINGDOM", "terseLabel": "United Kingdom" } } }, "localname": "GB", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.vrtx.com/role/SegmentInformationPropertyandEquipmentNetbyLocationDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.vrtx.com/role/SegmentInformationPropertyandEquipmentNetbyLocationDetails", "http://www.vrtx.com/role/SegmentInformationRevenuebyGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "currency_AUD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Australia, Dollars", "terseLabel": "Australian dollar" } } }, "localname": "AUD", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_CAD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Canada, Dollars", "terseLabel": "Canadian dollar" } } }, "localname": "CAD", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_CHF": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Switzerland, Francs", "terseLabel": "Swiss Franc" } } }, "localname": "CHF", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_EUR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Euro Member Countries, Euro", "terseLabel": "Euro" } } }, "localname": "EUR", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_GBP": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United Kingdom, Pounds", "terseLabel": "British pound sterling" } } }, "localname": "GBP", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r697", "r698", "r699" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/AuditInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r697", "r698", "r699" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r697", "r698", "r699" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r697", "r698", "r699" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r700" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r695" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r694" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r694" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r694" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r708" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r694" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r694" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r694" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r694" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r723" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r697", "r698", "r699" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r693" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r696" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r69", "r72", "r137", "r138", "r305", "r313", "r721" ], "lang": { "en-us": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r2", "r144", "r152", "r158", "r252", "r396", "r397", "r398", "r440", "r441", "r504", "r507", "r509", "r510", "r726" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesLeasesDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r2", "r144", "r152", "r158", "r252", "r396", "r397", "r398", "r440", "r441", "r504", "r507", "r509", "r510", "r726" ], "lang": { "en-us": { "role": { "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesLeasesDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r2", "r144", "r152", "r158", "r252", "r396", "r397", "r398", "r440", "r441", "r504", "r507", "r509", "r510", "r726" ], "lang": { "en-us": { "role": { "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesLeasesDetails" ], "xbrltype": "domainItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by currency.", "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "stringItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Continent of Europe.", "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationRevenuebyGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r218", "r332", "r337", "r654" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r304", "r312", "r349", "r350", "r582", "r583", "r584", "r585", "r586", "r587", "r607", "r651", "r655", "r690", "r691" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesRevolvingCreditFacilityDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockandOptionPlansDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r304", "r312", "r349", "r350", "r582", "r583", "r584", "r585", "r586", "r587", "r607", "r651", "r655", "r690", "r691" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesRevolvingCreditFacilityDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r218", "r332", "r337", "r654" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r214", "r332", "r335", "r610", "r650", "r652" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/SegmentInformationRevenuebyGeographicLocationDetails", "http://www.vrtx.com/role/SegmentInformationRevenuesbyProductDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r214", "r332", "r335", "r610", "r650", "r652" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/SegmentInformationRevenuebyGeographicLocationDetails", "http://www.vrtx.com/role/SegmentInformationRevenuesbyProductDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r304", "r312", "r339", "r349", "r350", "r582", "r583", "r584", "r585", "r586", "r587", "r607", "r651", "r655", "r690", "r691" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesRevolvingCreditFacilityDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockandOptionPlansDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r304", "r312", "r339", "r349", "r350", "r582", "r583", "r584", "r585", "r586", "r587", "r607", "r651", "r655", "r690", "r691" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesRevolvingCreditFacilityDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockandOptionPlansDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "auth_ref": [ "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r689", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r722" ], "lang": { "en-us": { "role": { "documentation": "Information by name of property.", "label": "Name of Property [Axis]", "terseLabel": "Name of Property [Axis]" } } }, "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "auth_ref": [ "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r689", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719" ], "lang": { "en-us": { "role": { "documentation": "Name of the property, for example, but not limited to, ABC Shopping Center.", "label": "Name of Property [Domain]", "terseLabel": "Name of Property [Domain]" } } }, "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r71", "r72", "r137", "r138", "r305", "r313" ], "lang": { "en-us": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedCashFlowStatementTableTextBlock": { "auth_ref": [ "r720" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations.", "label": "Condensed Cash Flow Statement [Table Text Block]", "terseLabel": "Schedule of Additional Cash Flow Information" } } }, "localname": "ScheduleOfCondensedCashFlowStatementTableTextBlock", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailTables" ], "xbrltype": "textBlockItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r215", "r216", "r332", "r336", "r653", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r709", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719" ], "lang": { "en-us": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationPropertyandEquipmentNetbyLocationDetails", "http://www.vrtx.com/role/SegmentInformationRevenuebyGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r215", "r216", "r332", "r336", "r653", "r675", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r709", "r710" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationPropertyandEquipmentNetbyLocationDetails", "http://www.vrtx.com/role/SegmentInformationRevenuebyGeographicLocationDetails" ], "xbrltype": "stringItemType" }, "srt_WeightedAverageMember": { "auth_ref": [ "r582", "r584", "r587", "r690", "r691" ], "lang": { "en-us": { "role": { "documentation": "Average of a range of values, calculated with consideration of proportional relevance.", "label": "Weighted Average [Member]", "terseLabel": "Weighted Average" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r549" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesLeasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r145", "r146", "r147", "r148", "r229", "r230", "r249", "r250", "r251", "r252", "r253", "r254", "r292", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r440", "r441", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r572", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r724", "r725", "r726", "r727", "r728" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible Enumeration]", "terseLabel": "Accounting Standards Update [Extensible List]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable and Accrued Liabilities [Member]", "terseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails", "http://www.vrtx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r45", "r575" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r676" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Percent of Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r8", "r25", "r220", "r221" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails", "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r13", "r14", "r50" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Royalty payable" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r83", "r91", "r92", "r93", "r94", "r470" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "On Foreign Currency Forward Contracts" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r76", "r77", "r78", "r83", "r91", "r92", "r93" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]", "terseLabel": "On Available-For-Sale Debt Securities" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r28", "r80", "r82", "r83", "r639", "r663", "r667" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r91", "r92", "r541", "r542", "r543", "r544", "r545", "r547" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r79", "r83", "r91", "r92", "r93", "r141", "r142", "r143", "r471", "r658", "r659", "r728" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Total", "verboseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r75", "r83", "r91", "r92", "r93", "r471", "r542", "r543", "r544", "r545", "r547" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation Adjustment", "verboseLabel": "Foreign Currency Forward Contract" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "Additional Balance Sheet Detail" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetail" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r26" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r141", "r142", "r143", "r396", "r397", "r398", "r509" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r145", "r146", "r147", "r148", "r158", "r229", "r230", "r249", "r250", "r251", "r252", "r253", "r254", "r292", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r438", "r439", "r440", "r441", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r572", "r611", "r612", "r613", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r724", "r725", "r726", "r727", "r728" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Common stock withheld for employee tax obligations" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r351", "r353", "r402", "r403" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r353", "r387", "r401" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense related to inventories" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, after Tax", "totalLabel": "Total stock-based compensation included in costs and expenses, net of tax" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Area of real estate property (in square feet)" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r131", "r200", "r204", "r210", "r248", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r468", "r473", "r527", "r573", "r575", "r617", "r637" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r10", "r11", "r58", "r131", "r248", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r468", "r473", "r527", "r573", "r575" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r513" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total financial assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Financial instruments carried at fair value (asset position):" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r236" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r237" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r234", "r260" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "order": 1.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale [Abstract]", "terseLabel": "Total marketable debt securities" } } }, "localname": "AvailableForSaleSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r238", "r240", "r632" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "terseLabel": "Matures after one year through five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r238", "r239", "r631" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Matures within one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r231", "r235", "r260", "r620" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "netLabel": "Debt Securities", "terseLabel": "Fair Value", "totalLabel": "Total" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r354", "r390" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansRestrictedStockandRestrictedStockUnitsDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAdditionalCashFlowDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails", "http://www.vrtx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r486", "r490" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAdditionalCashFlowDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails", "http://www.vrtx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Buildings and improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Buildings and improvements" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/PropertyandEquipmentPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r121", "r459" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.vrtx.com/role/ConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "netLabel": "Decrease in fair value of contingent payments", "terseLabel": "(Decrease) increase in fair value of contingent consideration", "verboseLabel": "Change in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows", "http://www.vrtx.com/role/ConsolidatedStatementsofOperations", "http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r455", "r456", "r458" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Balance at December 31, 2021", "periodStartLabel": "Balance at December 31, 2020" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Contingent consideration, measurement input (percent)" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r455", "r457" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 2.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "negatedLabel": "Long-term contingent consideration", "terseLabel": "Long-term contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r40", "r575", "r670", "r671" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r6", "r40", "r124" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAdditionalCashFlowDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAdditionalCashFlowDetails", "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents:" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash equivalents:", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r17", "r125" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "terseLabel": "Marketable Securities and Equity Investments" } } }, "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r118", "r124", "r127" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAdditionalCashFlowDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash\u2014end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash\u2014beginning of period", "totalLabel": "Cash, cash equivalents and restricted cash per consolidated statement of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAdditionalCashFlowDetails", "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r118", "r540" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgeDerivativeInstrumentLiabilitiesAtFairValue": { "auth_ref": [ "r489" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of all liability derivatives designated as cash flow hedging instruments.", "label": "Cash Flow Hedge Derivative Instrument Liabilities at Fair Value", "terseLabel": "Fair value of cash flow hedges" } } }, "localname": "CashFlowHedgeDerivativeInstrumentLiabilitiesAtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r317", "r318", "r319", "r320" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansShareRepurchaseProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r460", "r461", "r463" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaborative and Other Arrangements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.", "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails", "http://www.vrtx.com/role/CollaborativeandOtherArrangementsKymeraModernaandOtherInLicenseAgreementsDetails", "http://www.vrtx.com/role/CollaborativeandOtherArrangementsMerckKGaADetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "auth_ref": [ "r340", "r519" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r53", "r289", "r621", "r642" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r141", "r142", "r509" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value ( in usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansCommonStockandPreferredStockDetails", "http://www.vrtx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r24", "r315" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r24", "r575" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.01 par value; 500,000,000 shares authorized, 254,479,046 and 259,889,549 shares issued and outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Compensation Related Costs, Policy [Policy Text Block]", "terseLabel": "Stock-based Compensation Expense" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets [Abstract]", "verboseLabel": "Deferred tax assets:" } } }, "localname": "ComponentsOfDeferredTaxAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Liabilities [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r86", "r88", "r89", "r99", "r626", "r645" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r98", "r107", "r625", "r644" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r273", "r275", "r454" ], "lang": { "en-us": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Computers and software" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/PropertyandEquipmentPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r185", "r186", "r218", "r524", "r525", "r676" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r185", "r186", "r218", "r524", "r525", "r669", "r676" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r185", "r186", "r218", "r524", "r525", "r669", "r676" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r180", "r634" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r185", "r186", "r218", "r524", "r525" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r183", "r185", "r186", "r187", "r524", "r526", "r676" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r185", "r186", "r218", "r524", "r525", "r676" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "auth_ref": [ "r472", "r475", "r476" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "terseLabel": "Variable Interest Entities" } } }, "localname": "ConsolidationVariableInterestEntityPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r321", "r322", "r333" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r334" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenues related to performance obligations" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r340", "r347", "r668" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r103", "r610" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r101" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CreditConcentrationRiskMember": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.", "label": "Credit Concentration Risk [Member]", "terseLabel": "Credit Concentration Risk" } } }, "localname": "CreditConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r132", "r435", "r444" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r132", "r435" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r132", "r435", "r444", "r446" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current taxes" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current taxes:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r132", "r435", "r444" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate (percent)" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Schedule of Prepaid, and Other Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r132", "r436", "r444" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r132", "r436", "r444" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r410", "r411" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "verboseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r122", "r132", "r436", "r444", "r445", "r446" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Total deferred taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred taxes:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r21", "r22", "r426", "r618", "r635" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r132", "r436", "r444" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r427" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r429" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r429" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r433", "r434" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration", "terseLabel": "Operating loss carryforwards, subject to expiration" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r433", "r434" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r432", "r433", "r434" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r433", "r434" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r428" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance", "terseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails", "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r433", "r434" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred Tax Liabilities, Intangible Assets", "negatedLabel": "Acquired intangibles" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "auth_ref": [ "r433", "r434" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.", "label": "Deferred Tax Liabilities, Leasing Arrangements", "negatedTerseLabel": "Operating lease liabilities" } } }, "localname": "DeferredTaxLiabilitiesLeasingArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r433", "r434" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "negatedTerseLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r433", "r434" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedTerseLabel": "Property and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r348" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Defined contribution plan, cost" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansEmployeeBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "terseLabel": "Maximum percentage of annual compensation contributed by the participant (percent)" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansEmployeeBenefitsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r122", "r281" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/PropertyandEquipmentNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r122", "r198" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueGrossLiability": { "auth_ref": [ "r61", "r74", "r488" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeAssets", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Asset, Fair Value, Gross Liability", "negatedTerseLabel": "Gross Amounts Offset" } } }, "localname": "DerivativeAssetFairValueGrossLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "auth_ref": [ "r64", "r68" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.", "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "totalLabel": "Legal Offset" } } }, "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": { "auth_ref": [ "r63", "r68" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative assets.", "label": "Derivative Asset, Not Offset, Policy Election Deduction", "negatedTerseLabel": "Gross Amounts Not Offset" } } }, "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r62", "r67", "r72", "r523" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "totalLabel": "Gross Amounts Presented" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsCurrent": { "auth_ref": [ "r62" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Current", "terseLabel": "Derivative asset current, foreign currency forward contracts" } } }, "localname": "DerivativeAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsNoncurrent": { "auth_ref": [ "r62" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Noncurrent", "terseLabel": "Derivative asset noncurrent, foreign currency forward contracts" } } }, "localname": "DerivativeAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails", "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesGoodwillHedgingActivitiesForeignCurrencyGainLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r60", "r72", "r73", "r488", "r589" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Gross Amounts Recognized" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r60", "r72", "r73", "r488", "r589" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "negatedTerseLabel": "Gross Amounts Recognized" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r72", "r487", "r489", "r492", "r493" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails", "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesGoodwillHedgingActivitiesForeignCurrencyGainLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r500", "r512" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Hedging" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/Hedging" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivatives and hedging activities.", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r484", "r487", "r492" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r484", "r487", "r492", "r493", "r494", "r498", "r499" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r62", "r67", "r72", "r523" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "negatedTotalLabel": "Gross Amounts Presented" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r62" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 1.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Current", "negatedLabel": "Derivative liability current, foreign currency forward contracts" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r62" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 3.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Noncurrent", "negatedTerseLabel": "Derivative liability noncurrent, foreign currency forward contracts" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityFairValueGrossAsset": { "auth_ref": [ "r61", "r70", "r74", "r488" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Liability, Fair Value, Gross Asset", "terseLabel": "Gross Amounts Offset" } } }, "localname": "DerivativeLiabilityFairValueGrossAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "auth_ref": [ "r64", "r68" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.", "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "negatedTotalLabel": "Legal Offset" } } }, "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": { "auth_ref": [ "r63", "r68" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative liabilities.", "label": "Derivative Liability, Not Offset, Policy Election Deduction", "terseLabel": "Gross Amounts Not Offset" } } }, "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails", "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesGoodwillHedgingActivitiesForeignCurrencyGainLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r480", "r482" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount of foreign currency forward contract" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r479", "r481", "r482", "r484", "r485", "r491", "r492", "r495", "r497", "r499", "r500" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails", "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesGoodwillHedgingActivitiesForeignCurrencyGainLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTermOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative, Term of Contract", "terseLabel": "Derivative term" } } }, "localname": "DerivativeTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesGoodwillHedgingActivitiesForeignCurrencyGainLossDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r139", "r479", "r481", "r484", "r485", "r496" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Hedging Activities" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as hedging instruments" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-based Compensation Expense" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpense" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r354", "r390" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Expense by Type of Award" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Domestic Tax Authority" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r100", "r150", "r151", "r152", "r153", "r154", "r160", "r162", "r167", "r168", "r169", "r173", "r174", "r510", "r511", "r627", "r646" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net income per common share (in dollars per share)", "verboseLabel": "Basic ( in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r100", "r150", "r151", "r152", "r153", "r154", "r162", "r167", "r168", "r169", "r173", "r174", "r510", "r511", "r627", "r646" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net income per common share (in dollars per share)", "verboseLabel": "Diluted (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r170", "r171" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income Per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r170", "r171", "r172", "r175" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r540" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of changes in exchange rates on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r413" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate", "totalLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails", "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r134", "r413", "r448" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal statutory tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r413", "r448" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "terseLabel": "Tax rate change" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r413", "r448" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Foreign income tax rate differential" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r413", "r448" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 9.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent", "terseLabel": "Stock compensation (benefit), shortfalls and cancellations" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r413", "r448" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": { "auth_ref": [ "r413", "r448" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.", "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent", "terseLabel": "U.S. tax on foreign earnings, net of credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r413", "r448" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State taxes, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": { "auth_ref": [ "r413", "r448" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent", "negatedLabel": "Tax credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Additional Disclosure [Abstract]", "terseLabel": "Share-based Payment Arrangement, Additional Disclosure [Abstract]" } } }, "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r388" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Amount Capitalized", "negatedTerseLabel": "Stock-based compensation expense related to inventories" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r389" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized Expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average Recognition Period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r387" ], "calculation": { "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, Tax Benefit", "negatedTerseLabel": "Income tax effect" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee stock purchase plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options", "verboseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationRevenuesbyProductDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansShareRepurchaseProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r91", "r92", "r93", "r141", "r142", "r143", "r146", "r155", "r157", "r177", "r252", "r315", "r316", "r396", "r397", "r398", "r440", "r441", "r509", "r541", "r542", "r543", "r544", "r545", "r547", "r658", "r659", "r660", "r728" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r522" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Fair Value" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract]", "terseLabel": "Corporate equity securities" } } }, "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesFvNiCost": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "order": 2.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.", "label": "Equity Securities, FV-NI, Cost", "terseLabel": "Amortized Cost", "verboseLabel": "Weighted-average cost basis" } } }, "localname": "EquitySecuritiesFvNiCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGain": { "auth_ref": [ "r247" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r247", "r647" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "negatedLabel": "Gains on equity securities" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": { "auth_ref": [ "r247" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Loss", "negatedTerseLabel": "Gross Unrealized Losses" } } }, "localname": "EquitySecuritiesFvNiUnrealizedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r18", "r20", "r243", "r636", "r672", "r673", "r674" ], "lang": { "en-us": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "verboseLabel": "Corporate equity securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r244" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Equity securities without readily determinable fair value, amount" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EurodollarMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.", "label": "Eurodollar [Member]", "terseLabel": "Eurodollar" } } }, "localname": "EurodollarMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r513", "r514", "r515", "r520" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r306", "r308", "r309", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r514", "r579", "r580", "r581" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r513", "r514", "r517", "r518", "r521" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Fair Value by Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r306", "r340", "r341", "r346", "r347", "r514", "r579" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level\u00a01" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r306", "r308", "r309", "r340", "r341", "r346", "r347", "r514", "r580" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level\u00a02" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r306", "r308", "r309", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r514", "r581" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level\u00a03" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r306", "r308", "r309", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r579", "r580", "r581" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r519", "r521" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r553", "r560", "r570" ], "calculation": { "http://www.vrtx.com/role/LeasesComponentsofLeaseExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesComponentsofLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r555", "r564" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Operating cash flows from finance leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Finance Leases" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r551", "r569" ], "calculation": { "http://www.vrtx.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiability", "weight": 1.0 }, "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "totalLabel": "Present value of lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails", "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r551" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r569" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of Finance Lease, Liability, Maturity" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r551" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.vrtx.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "verboseLabel": "Long-term finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "http://www.vrtx.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r569" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r569" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r569" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentDueNextTwelveMonths", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r569" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Five", "terseLabel": "2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r569" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r569" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r569" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r569" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityUndiscountedExcessAmount", "weight": 1.0 }, "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: amount representing interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r554", "r564" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedTerseLabel": "Payments on finance leases", "verboseLabel": "Financing cash flows from finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows", "http://www.vrtx.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r550" ], "calculation": { "http://www.vrtx.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "totalLabel": "Total finance lease assets" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization [Abstract]", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r553", "r560", "r570" ], "calculation": { "http://www.vrtx.com/role/LeasesComponentsofLeaseExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization of leased assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesComponentsofLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails", "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesLeasesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r567", "r570" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesWeightedAverageRemainingLeaseTermsandDiscountRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r566", "r570" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesWeightedAverageRemainingLeaseTermsandDiscountRatesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r241", "r242", "r244", "r245", "r246", "r255", "r256", "r257", "r258", "r259", "r261", "r262", "r263", "r264", "r307", "r314", "r500", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r701", "r702", "r703", "r704", "r705", "r706", "r707" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "negatedTotalLabel": "Total financial liabilities" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Liabilities Fair Value Disclosure [Abstract]", "terseLabel": "Financial instruments carried at fair value (liability position):" } } }, "localname": "FinancialLiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign Tax Authority" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r536", "r537", "r538", "r539" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedLabel": "Net foreign currency transaction loss" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesGoodwillHedgingActivitiesForeignCurrencyGainLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation and Transactions" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign currency forward contracts" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails", "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesGoodwillHedgingActivitiesForeignCurrencyGainLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and equipment", "verboseLabel": "Furniture and equipment" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPropertyandEquipmentDetails", "http://www.vrtx.com/role/PropertyandEquipmentPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r269", "r270", "r575", "r616" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "http://www.vrtx.com/role/IntangibleAssetsandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets and Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IntangibleAssetsandGoodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r484", "r494" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails", "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesGoodwillHedgingActivitiesForeignCurrencyGainLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails", "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesGoodwillHedgingActivitiesForeignCurrencyGainLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfInvestments": { "auth_ref": [ "r233" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.", "label": "Other than Temporary Impairment Losses, Investments", "terseLabel": "Other-than-temporary declines in fair value of available-for-sale debt securities" } } }, "localname": "ImpairmentOfInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r133", "r447" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "United States" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r96", "r200", "r203", "r206", "r209", "r212", "r614", "r623", "r629", "r648" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations", "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r133", "r447" ], "calculation": { "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]", "terseLabel": "Components of income (loss) before provision for (benefit from) income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r285", "r287" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r134", "r414", "r424", "r431", "r442", "r449", "r451", "r452", "r453" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r135", "r156", "r157", "r199", "r412", "r443", "r450", "r649" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes", "totalLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations", "http://www.vrtx.com/role/IncomeTaxesComponentsofIncomeandProvisionforBenefitfromIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r90", "r408", "r409", "r424", "r425", "r430", "r437" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r407", "r413" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount", "negatedLabel": "Deferred tax benefit" } } }, "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "auth_ref": [ "r413" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount", "terseLabel": "Deferred tax benefit" } } }, "localname": "IncomeTaxReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r126" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r121" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r121" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r121" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r121" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "auth_ref": [ "r121" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred obligations classified as other.", "label": "Increase (Decrease) in Other Deferred Liability", "terseLabel": "Deferred income taxes" } } }, "localname": "IncreaseDecreaseInOtherDeferredLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r121" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r121" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements": { "auth_ref": [ "r163", "r164", "r169" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of equity unit purchase agreements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements", "terseLabel": "Employee stock purchase program (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r163", "r164", "r165", "r169" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Share-based payment arrangements (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-lived Intangible Assets [Line Items]", "terseLabel": "Indefinite-Lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IntangibleAssetsandGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r272", "r274" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r628" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Interest expense" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r117", "r119", "r126" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r32", "r267" ], "calculation": { "http://www.vrtx.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r7", "r55", "r575" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.vrtx.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "http://www.vrtx.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r16", "r56", "r128", "r176", "r265", "r266", "r268", "r608" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r34", "r267" ], "calculation": { "http://www.vrtx.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r33", "r267" ], "calculation": { "http://www.vrtx.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterestAndDividend": { "auth_ref": [ "r105" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Interest and Dividend", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterestAndDividend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/PropertyandEquipmentPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r568", "r570" ], "calculation": { "http://www.vrtx.com/role/LeasesComponentsofLeaseExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Net lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesComponentsofLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Finance lease cost" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesComponentsofLeaseExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r568" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/PropertyandEquipmentPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOperatingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases, Operating [Abstract]", "terseLabel": "Operating leases" } } }, "localname": "LeasesOperatingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeaseTermOfContract1": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Finance Lease, Term of Contract", "terseLabel": "Option to extend lease term" } } }, "localname": "LesseeFinanceLeaseTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails", "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails", "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r569" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Operating Lease, Liability, Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r569" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r569" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDueAfterYearFive", "weight": 1.0 }, "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r569" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentDueNextTwelveMonths", "weight": 1.0 }, "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r569" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDueYearFive", "weight": 1.0 }, "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r569" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDueYearFour", "weight": 1.0 }, "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r569" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentDueYearThree", "weight": 1.0 }, "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r569" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentDueYearTwo", "weight": 1.0 }, "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r569" ], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityUndiscountedExcessAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: amount representing interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Optional term of lease agreement (in years)" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease agreement initial term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r48", "r131", "r205", "r248", "r293", "r294", "r295", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r469", "r473", "r474", "r527", "r573", "r574" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r31", "r131", "r248", "r527", "r575", "r619", "r641" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r51", "r131", "r248", "r293", "r294", "r295", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r469", "r473", "r474", "r527", "r573", "r574", "r575" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r46" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r46", "r130" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r622" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security.", "label": "Marketable Securities", "verboseLabel": "Marketable securities:" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r9", "r49" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r633" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Discount Rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "verboseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r118" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r118" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r118", "r120", "r123" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r84", "r87", "r93", "r97", "r123", "r131", "r145", "r150", "r151", "r152", "r153", "r156", "r157", "r166", "r200", "r203", "r206", "r209", "r212", "r248", "r293", "r294", "r295", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r511", "r527", "r624", "r643" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.vrtx.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.vrtx.com/role/ConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows", "http://www.vrtx.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://www.vrtx.com/role/ConsolidatedStatementsofOperations", "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r144", "r145", "r146", "r147", "r148", "r149", "r152", "r158", "r173", "r229", "r230", "r249", "r250", "r251", "r252", "r253", "r254", "r292", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r438", "r439", "r440", "r441", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r572", "r611", "r612", "r613", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r724", "r725", "r726", "r727", "r728" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Standards and Recently Issued Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r216" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Total long-lived assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationPropertyandEquipmentNetbyLocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not designated as hedging instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesGoodwillHedgingActivitiesForeignCurrencyGainLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesBusinessNarrativeDetails", "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesGoodwillHedgingActivitiesForeignCurrencyGainLossDetails", "http://www.vrtx.com/role/SegmentInformationRevenuesbyProductDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r83", "r94" ], "calculation": { "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "terseLabel": "Other comprehensive income (loss) before reclassifications" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OffsettingAssetsTableTextBlock": { "auth_ref": [ "r65", "r66" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative and other financial assets that are subject to offsetting, including master netting arrangements.", "label": "Offsetting Assets [Table Text Block]", "terseLabel": "Schedule of Offsetting Assets" } } }, "localname": "OffsettingAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OffsettingDerivativeAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Offsetting Derivative Assets [Abstract]", "terseLabel": "Total assets" } } }, "localname": "OffsettingDerivativeAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingDerivativeLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Offsetting Derivative Liabilities [Abstract]", "terseLabel": "Total liabilities" } } }, "localname": "OffsettingDerivativeLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingLiabilitiesTableTextBlock": { "auth_ref": [ "r65", "r66" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative and other financial liabilities that are subject to offsetting, including master netting arrangements.", "label": "Offsetting Liabilities [Table Text Block]", "terseLabel": "Schedule of Offsetting Liabilities" } } }, "localname": "OffsettingLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r200", "r203", "r206", "r209", "r212" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r561", "r570" ], "calculation": { "http://www.vrtx.com/role/LeasesComponentsofLeaseExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesComponentsofLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r551" ], "calculation": { "http://www.vrtx.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails", "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r551" ], "calculation": { "http://www.vrtx.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r551" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.vrtx.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "http://www.vrtx.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r556", "r564" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r550" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease assets", "verboseLabel": "Total operating lease assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "http://www.vrtx.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r567", "r570" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesWeightedAverageRemainingLeaseTermsandDiscountRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r566", "r570" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesWeightedAverageRemainingLeaseTermsandDiscountRatesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r432" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r140", "r159", "r191", "r478" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "Nature of Business and Accounting Policies" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r13", "r14", "r15", "r50" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r57", "r575" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r486", "r498" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAdditionalCashFlowDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r466", "r467", "r470" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized holding (losses) gains on marketable securities, net" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r466", "r467", "r470" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r80" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "terseLabel": "Unrealized gains (losses) on foreign currency forward contracts, net of tax of $(21.8), $14.3 and $7.0, respectively" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent": { "auth_ref": [ "r81" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent", "terseLabel": "Unrealized (losses) gains on foreign currency forward contracts, tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r85", "r88", "r466", "r467", "r470" ], "calculation": { "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/ConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive income (loss)", "verboseLabel": "Other comprehensive income (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/ConsolidatedStatementsofComprehensiveIncome", "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other current liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other current liabilities.", "label": "Other Current Liabilities [Table Text Block]", "terseLabel": "Summary of Other Current Liabilities" } } }, "localname": "OtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r276" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after impairment of indefinite-lived intangible assets classified as other. Excludes financial assets and goodwill.", "label": "Other Indefinite-lived Intangible Assets", "terseLabel": "Other indefinite-lived intangible assets" } } }, "localname": "OtherIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IntangibleAssetsandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r12", "r13", "r50", "r575" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities", "totalLabel": "Total" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails", "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current [Abstract]", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r52" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "verboseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r123" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other non-cash items, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r106" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherSundryLiabilitiesCurrent": { "auth_ref": [ "r50", "r290" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.", "label": "Other Sundry Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherSundryLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r115" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Repurchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r115" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Payments in connection with common stock withheld for employee tax obligations" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r108", "r110", "r232" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedLabel": "Purchases of available-for-sale debt securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r111" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Payments to acquire businesses, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r112" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance-based RSUs" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r354", "r390" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansEmployeeStockPurchasePlanDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockandOptionPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansEmployeeStockPurchasePlanDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockandOptionPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r23", "r311" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value ( in usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansCommonStockandPreferredStockDetails", "http://www.vrtx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r23", "r311" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansCommonStockandPreferredStockDetails", "http://www.vrtx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansCommonStockandPreferredStockDetails", "http://www.vrtx.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r23", "r575" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r10", "r38", "r39" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailPrepaidExpensesandOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailPrepaidExpensesandOtherCurrentAssetsDetails", "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAdditionalCashFlowDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r113", "r391" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised", "terseLabel": "Issuances of common stock under benefit plans" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r108", "r109", "r232" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale", "terseLabel": "Maturities of available-for-sale debt securities" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r114", "r116" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other financing activities" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds received" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfTradingSecuritiesHeldforinvestment": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale of securities classified as trading securities and held for investment purposes. Excludes proceeds from trading securities purchased and held principally for the purpose of selling them in the near term (thus held for only a short period of time).", "label": "Proceeds from Sale of Debt and Equity Securities, FV-NI, Held-for-investment", "terseLabel": "Sale of equity securities" } } }, "localname": "ProceedsFromSaleOfTradingSecuritiesHeldforinvestment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r113", "r391" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Total cash received from employees as a result of employee stock option exercises" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductConcentrationRiskMember": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.", "label": "Product Concentration Risk [Member]", "terseLabel": "Product Concentration Risk" } } }, "localname": "ProductConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product revenues, net", "verboseLabel": "Product revenues, net" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/SegmentInformationRevenuebyGeographicLocationDetails", "http://www.vrtx.com/role/SegmentInformationRevenuesbyProductDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r283", "r553", "r560" ], "calculation": { "http://www.vrtx.com/role/PropertyandEquipmentPropertyandEquipmentNetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "negatedTerseLabel": "Less: accumulated depreciation" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/PropertyandEquipmentPropertyandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r59", "r284", "r560" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.vrtx.com/role/PropertyandEquipmentPropertyandEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "http://www.vrtx.com/role/PropertyandEquipmentPropertyandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r19", "r282", "r550" ], "calculation": { "http://www.vrtx.com/role/PropertyandEquipmentPropertyandEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "terseLabel": "Total property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/PropertyandEquipmentPropertyandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r42", "r284" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]", "verboseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPropertyandEquipmentDetails", "http://www.vrtx.com/role/PropertyandEquipmentPropertyandEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r286", "r677", "r678", "r679" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/PropertyandEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPropertyandEquipmentDetails", "http://www.vrtx.com/role/PropertyandEquipmentPropertyandEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r41", "r284", "r677", "r678" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r19", "r284" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesTables", "http://www.vrtx.com/role/PropertyandEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r19", "r282" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]", "verboseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPropertyandEquipmentDetails", "http://www.vrtx.com/role/PropertyandEquipmentPropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property and equipment useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "terseLabel": "AOCI, Net of Tax [Roll Forward]" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r83", "r94" ], "calculation": { "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "negatedTerseLabel": "Amounts reclassified from accumulated other comprehensive income (loss)" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Schedule of Foreign Exchange Contracts, Condensed Consolidated Statements of Operations" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r405", "r609", "r692" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "verboseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "auth_ref": [ "r43", "r278", "r279", "r692" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.", "label": "Research, Development, and Computer Software, Policy [Policy Text Block]", "terseLabel": "Research and Development Expenses" } } }, "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r17", "r124", "r127", "r615", "r638" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAdditionalCashFlowDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash and cash equivalents" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAdditionalCashFlowDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restricted Cash and Cash Equivalents Items [Line Items]", "terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]" } } }, "localname": "RestrictedCashAndCashEquivalentsItemsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAdditionalCashFlowDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "netLabel": "Restricted stock units (including PSUs)", "verboseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansRestrictedStockandRestrictedStockUnitsDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (excluding PSUs)", "verboseLabel": "Restricted stock units (including PSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansRestrictedStockandRestrictedStockUnitsDetails", "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r27", "r316", "r399", "r575", "r640", "r662", "r667" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedTerseLabel": "Accumulated deficit", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets", "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r141", "r142", "r143", "r146", "r155", "r157", "r252", "r396", "r397", "r398", "r440", "r441", "r509", "r658", "r660" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r196", "r197", "r202", "r207", "r208", "r214", "r215", "r218", "r331", "r332", "r610" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "netLabel": "Total product revenues, net", "terseLabel": "Product revenues, net", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesRevenueRecognitionDetails", "http://www.vrtx.com/role/SegmentInformationRevenuebyGeographicLocationDetails", "http://www.vrtx.com/role/SegmentInformationRevenuesbyProductDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r129", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r338" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationPropertyandEquipmentNetbyLocationDetails", "http://www.vrtx.com/role/SegmentInformationRevenuebyGeographicLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r565", "r570" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Finance leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r565", "r570" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r185", "r218" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Percent of Total Gross Product Revenues" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Summary of Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r83", "r546", "r547" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Potential Gross Common Equivalent Shares" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "terseLabel": "Schedule of Fair Value of Our Contingent Consideration Liabilities" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "terseLabel": "Summary of Cash, Cash Equivalents and Marketable Securities" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails", "http://www.vrtx.com/role/CollaborativeandOtherArrangementsKymeraModernaandOtherInLicenseAgreementsDetails", "http://www.vrtx.com/role/CollaborativeandOtherArrangementsMerckKGaADetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]", "terseLabel": "Schedule of Collaborative Arrangement on Research and Development" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Provision for (Benefit From) Income Taxes" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r169" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r353", "r386", "r401" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table]", "terseLabel": "Revenue from External Customers by Products and Services [Table]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationRevenuesbyProductDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Revenues by Product" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r513", "r514" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Financial Assets Subject to Fair Value Measurements (Excluding Vie Cash and Cash Equivalents, Which are Recorded as Restricted Cash and Cash Equivalents (Vie))" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.", "label": "Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]", "terseLabel": "Schedule of Foreign Exchange Contracts" } } }, "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of Components of Income Before Provision for (Benefit From) Income Taxes" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r276", "r277" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets by Major Class [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IntangibleAssetsandGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r16", "r35", "r36", "r37" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories by Type" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "terseLabel": "Schedule of Cash Flow Hedging Instruments" } } }, "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r42", "r284" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPropertyandEquipmentDetails", "http://www.vrtx.com/role/PropertyandEquipmentPropertyandEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": { "auth_ref": [ "r17", "r127", "r615", "r638" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table]", "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAdditionalCashFlowDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r102", "r217" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "verboseLabel": "Revenues and Property and Equipment by Location" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r95", "r217" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationPropertyandEquipmentNetbyLocationDetails", "http://www.vrtx.com/role/SegmentInformationRevenuebyGeographicLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r354", "r390" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansEmployeeStockPurchasePlanDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansRestrictedStockandRestrictedStockUnitsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockandOptionPlansDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of employee stock purchase plan activity.", "label": "Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]", "terseLabel": "Schedule of Shares Issued Under Employee Stock Purchase Plan" } } }, "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockOptionsOutstandingandExercisableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "terseLabel": "Schedule of Stock Options Outstanding and Exercisable" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r361", "r374", "r377" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Outstanding and Vested Options" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Assumptions Used to Estimate the Grant Date Fair Value Employee Stock Purchase Plan" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Assumptions Used to Estimate the Grant Date Fair Value of Options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of Restricted Stock and Restricted Stock Units Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r183", "r185", "r186", "r187", "r524", "r526" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "verboseLabel": "Significant Customers" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r192", "r194", "r195", "r200", "r201", "r206", "r210", "r211", "r212", "r213", "r214", "r217", "r218", "r219" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r104" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r121" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted-average \u2028Grant-date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Cancelled ( in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in usd per share)", "verboseLabel": "Granted ( in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansRestrictedStockandRestrictedStockUnitsDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "End of the period (in shares)", "periodStartLabel": "Beginning of the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of Shares", "verboseLabel": "Number of Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "End of the period ( in usd per share)", "periodStartLabel": "Beginning of the period ( in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r376" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Restricted stock vested in period, total fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested ( in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansRestrictedStockandRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Weighted-average assumptions for options and ESPP subscriptions granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": { "auth_ref": [ "r383" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments", "terseLabel": "Expected annual dividends" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected stock price volatility (percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate (percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansEmployeeStockPurchasePlanDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansRestrictedStockandRestrictedStockUnitsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockandOptionPlansDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Additional shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockandOptionPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Additional awards authorized for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockandOptionPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted-average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Stock options exercisable at end of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price exercisable at the end of the period ( in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r376" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Total intrinsic value of stock options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Granted (in shares)", "verboseLabel": "Stock options granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant-date fair value, granted ( in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r390" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r363", "r390" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period (in shares)", "periodStartLabel": "Outstanding at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Stock Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of period ( in usd per share)", "periodStartLabel": "Outstanding at beginning of period ( in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": { "auth_ref": [ "r352", "r390" ], "lang": { "en-us": { "role": { "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased", "terseLabel": "Average price paid per share ( in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansEmployeeStockPurchasePlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r352", "r358" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansRestrictedStockandRestrictedStockUnitsDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised ( in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Expired ( in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited ( in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted ( in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche One [Member]", "terseLabel": "Tranche one" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche Three [Member]", "terseLabel": "Tranche three" } } }, "localname": "ShareBasedCompensationAwardTrancheThreeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Tranche two" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.", "label": "Share-based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]", "terseLabel": "Schedule of PSU Activity" } } }, "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]", "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockOptionsOutstandingandExercisableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]", "terseLabel": "Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockOptionsOutstandingandExercisableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]", "terseLabel": "Stock options outstanding and exercisable" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockOptionsOutstandingandExercisableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "terseLabel": "Exercise price, low end of range ( in usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockOptionsOutstandingandExercisableDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "terseLabel": "Options exercisable (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockOptionsOutstandingandExercisableDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding", "terseLabel": "Options outstanding (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockOptionsOutstandingandExercisableDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "terseLabel": "Exercise price, high end of range ( in usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockOptionsOutstandingandExercisableDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Market share price ( in usd per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansShareRepurchaseProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansShareRepurchaseProgramDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Vesting percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": { "auth_ref": [ "r386" ], "calculation": { "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount", "terseLabel": "Stock-based compensation expense" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockandOptionPlansDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r381", "r400" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term of options (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r390" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Options exercisable, weighted-average exercise price ( in usd per share)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockOptionsOutstandingandExercisableDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price", "terseLabel": "Options outstanding, weighted-average exercise price ( in usd per share)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockOptionsOutstandingandExercisableDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options outstanding, weighted-average remaining contractual life" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockOptionsOutstandingandExercisableDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedTerseLabel": "Common stock withheld for employee tax obligations (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and Local Jurisdiction" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r54", "r91", "r92", "r93", "r141", "r142", "r143", "r146", "r155", "r157", "r177", "r252", "r315", "r316", "r396", "r397", "r398", "r440", "r441", "r509", "r541", "r542", "r543", "r544", "r545", "r547", "r658", "r659", "r660", "r728" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "verboseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations", "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r141", "r142", "r143", "r177", "r610" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations", "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Stock Issued During Period, Shares, Employee Benefit Plan", "terseLabel": "Issuance of common stock under benefit plans (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r23", "r24", "r315", "r316" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Number of shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r23", "r24", "r315", "r316", "r366" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Stock Issued During Period, Value, Employee Benefit Plan", "terseLabel": "Issuance of common stock under benefit plans" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]", "terseLabel": "Stock Options" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Number of shares authorized to be repurchased" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansShareRepurchaseProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Number of shares remaining for repurchases" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansShareRepurchaseProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r23", "r24", "r315", "r316" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedTerseLabel": "Repurchases of common stock (in shares)", "terseLabel": "Repurchases of common stock (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansShareRepurchaseProgramDetails", "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r23", "r24", "r315", "r316" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Repurchases of common stock", "terseLabel": "Repurchases of common stock" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansShareRepurchaseProgramDetails", "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r24", "r29", "r30", "r131", "r227", "r248", "r527", "r575" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/ConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r2", "r3", "r92", "r131", "r141", "r142", "r143", "r146", "r155", "r248", "r252", "r316", "r396", "r397", "r398", "r440", "r441", "r464", "r465", "r477", "r509", "r527", "r541", "r542", "r547", "r659", "r660", "r728" ], "calculation": { "http://www.vrtx.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityPolicyTextBlock": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.", "label": "Stockholders' Equity, Policy [Policy Text Block]", "terseLabel": "Share Repurchase Programs" } } }, "localname": "StockholdersEquityPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r563", "r570" ], "calculation": { "http://www.vrtx.com/role/LeasesComponentsofLeaseExpenseDetails": { "order": 5.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedTerseLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesComponentsofLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "auth_ref": [ "r415", "r423", "r425" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Summary of Income Tax Contingencies [Table Text Block]", "terseLabel": "Summary of Unrecognized Tax Benefits" } } }, "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r432" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforwards" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Tax related accruals" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TechnologyEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment used in the creation, maintenance and utilization of information systems which include computers and peripherals.", "label": "Technology Equipment [Member]", "terseLabel": "Computers and software" } } }, "localname": "TechnologyEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r222", "r223", "r224", "r225", "r226", "r228" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table Text Block]", "terseLabel": "Schedule of Sale of Equity Investments" } } }, "localname": "TradingSecuritiesAndCertainTradingAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r241", "r242", "r244", "r245", "r246", "r307", "r314", "r500", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r701", "r702", "r703", "r704", "r705", "r706", "r707" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r145", "r146", "r147", "r148", "r158", "r229", "r230", "r249", "r250", "r251", "r252", "r253", "r254", "r292", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r438", "r439", "r440", "r441", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r572", "r611", "r612", "r613", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r724", "r725", "r726", "r727", "r728" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesLeasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": { "auth_ref": [ "r340", "r630" ], "lang": { "en-us": { "role": { "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).", "label": "US Government-sponsored Enterprises Debt Securities [Member]", "terseLabel": "Government-sponsored enterprise securities" } } }, "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r136", "r340", "r347", "r630" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasury securities" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r122" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "terseLabel": "Net unrealized gains" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of unrealized gains and losses on investments.", "label": "Unrealized Gain (Loss) on Investments [Table Text Block]", "terseLabel": "Schedule of Company\u2019s Net Unrealized Gains on Corporate Equity Securities" } } }, "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r406", "r417" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of the period", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r418" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedTerseLabel": "Decreases related to prior period tax positions" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r420" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "negatedTerseLabel": "Settlement with tax authorities" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r419" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Increases related to current period tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r418" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Increases related to prior period tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r421" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedLabel": "Statute of limitations expiration" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Net unrecognized tax benefits which would affect the tax rate if recognized" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r178", "r179", "r181", "r182", "r188", "r189", "r190" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r562", "r570" ], "calculation": { "http://www.vrtx.com/role/LeasesComponentsofLeaseExpenseDetails": { "order": 4.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/LeasesComponentsofLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r390" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]", "terseLabel": "Effect of potentially dilutive securities:" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r161", "r169" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Diluted weighted-average common shares outstanding (in shares)", "verboseLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Shares used in per share calculations:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r160", "r169" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic weighted-average common shares outstanding (in shares)", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "sharesItemType" }, "vrtx_AccredoCurascriptMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accredo/Curascript [Member]", "label": "Accredo/Curascript [Member]", "terseLabel": "Accredo/Curascript" } } }, "localname": "AccredoCurascriptMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "vrtx_AccruedResearchDevelopmentAndCommercialContractCosts": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for R&D and commercial of the entity. It is used to reflect the current portion of liabilities (due within one year or within the normal operating cycle, if longer).", "label": "Accrued Research Development and Commercial Contract Costs", "terseLabel": "Research, development and commercial contract costs" } } }, "localname": "AccruedResearchDevelopmentAndCommercialContractCosts", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_AggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Aggregate intrinsic value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "AggregateIntrinsicValueAbstract", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails" ], "xbrltype": "stringItemType" }, "vrtx_AmountofOptionalRenewalTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of Optional Renewal Terms", "label": "Amount of Optional Renewal Terms", "terseLabel": "Amount of optional renewal terms" } } }, "localname": "AmountofOptionalRenewalTerms", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vrtx_ApolLo1BioLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ApolLo1 Bio, LLC", "label": "ApolLo1 Bio, LLC [Member]", "terseLabel": "ApolLo1 Bio, LLC" } } }, "localname": "ApolLo1BioLLCMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsKymeraModernaandOtherInLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "vrtx_ArborBiotechnologiesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arbor Biotechnologies, Inc", "label": "Arbor Biotechnologies, Inc [Member]", "terseLabel": "Arbor Biotechnologies, Inc" } } }, "localname": "ArborBiotechnologiesIncMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsKymeraModernaandOtherInLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "vrtx_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets And Liabilities, Lessee [Table Text Block]", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Schedule of Components of Lease in Balance Sheets" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "vrtx_AuditInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Audit Information [Abstract]", "label": "Audit Information [Abstract]" } } }, "localname": "AuditInformationAbstract", "nsuri": "http://www.vrtx.com/20211231", "xbrltype": "stringItemType" }, "vrtx_BusinessCombinationRemainingMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Remaining Milestone Payment", "label": "Business Combination, Remaining Milestone Payment", "terseLabel": "Remaining milestone payment" } } }, "localname": "BusinessCombinationRemainingMilestonePayment", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CRISPRDMDDM1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CRISPR Therapeutics DMD/DM1 [Member]", "label": "CRISPR DMD/DM1 [Member]", "terseLabel": "CRISPR DMD/DM1" } } }, "localname": "CRISPRDMDDM1Member", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails" ], "xbrltype": "domainItemType" }, "vrtx_CRISPRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CRISPR", "label": "CRISPR [Member]", "terseLabel": "CRISPR" } } }, "localname": "CRISPRMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails" ], "xbrltype": "domainItemType" }, "vrtx_CRISPRTherapeuticsAGMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CRISPR Therapeutics AG", "label": "CRISPR Therapeutics AG [Member]", "terseLabel": "CRISPR Therapeutics" } } }, "localname": "CRISPRTherapeuticsAGMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails" ], "xbrltype": "domainItemType" }, "vrtx_CRSIPRARJDCAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CRISPR Amended and restated the Original CTX001 JDCA", "label": "CRSIPR A&R JDCA [Member]", "terseLabel": "CRSIPR A&R JDCA" } } }, "localname": "CRSIPRARJDCAMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails" ], "xbrltype": "domainItemType" }, "vrtx_CashAndMoneyMarketFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time.", "label": "Cash and Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "CashAndMoneyMarketFundsMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "vrtx_CashFlowLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Flow, Lessee [Abstract]", "label": "Cash Flow, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities" } } }, "localname": "CashFlowLesseeAbstract", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "vrtx_CollaborativeArrangementAgreementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Listing of significant collaboration agreements.", "label": "Collaborative Arrangement Agreement [Domain]", "terseLabel": "Collaborative Arrangement Agreement [Domain]" } } }, "localname": "CollaborativeArrangementAgreementDomain", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails", "http://www.vrtx.com/role/CollaborativeandOtherArrangementsKymeraModernaandOtherInLicenseAgreementsDetails", "http://www.vrtx.com/role/CollaborativeandOtherArrangementsMerckKGaADetails", "http://www.vrtx.com/role/IntangibleAssetsandGoodwillDetails", "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "vrtx_CollaborativeArrangementAllocationOfNetProfitsAndLossesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent", "label": "Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent", "terseLabel": "Allocation of net profits and net losses, percent" } } }, "localname": "CollaborativeArrangementAllocationOfNetProfitsAndLossesPercent", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails" ], "xbrltype": "percentItemType" }, "vrtx_CollaborativeArrangementDevelopmentAndRegulatoryPotentialMilestonePaymentsMaximum": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are approved and commercialized.", "label": "Collaborative Arrangement Development And Regulatory Potential Milestone Payments Maximum", "terseLabel": "Collaborative arrangement development and regulatory potential milestone payments maximum" } } }, "localname": "CollaborativeArrangementDevelopmentAndRegulatoryPotentialMilestonePaymentsMaximum", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails", "http://www.vrtx.com/role/CollaborativeandOtherArrangementsKymeraModernaandOtherInLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CollaborativeArrangementInvestmentinCollaborativePartnerAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Investment in Collaborative Partner, Amount", "label": "Collaborative Arrangement, Investment in Collaborative Partner, Amount", "terseLabel": "Investment in collaborative partner, pursuant to convertible loan agreement" } } }, "localname": "CollaborativeArrangementInvestmentinCollaborativePartnerAmount", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsKymeraModernaandOtherInLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CollaborativeArrangementMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Milestone Payment", "label": "Collaborative Arrangement, Milestone Payment", "terseLabel": "Collaborative arrangement, milestone payment" } } }, "localname": "CollaborativeArrangementMilestonePayment", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails", "http://www.vrtx.com/role/CollaborativeandOtherArrangementsKymeraModernaandOtherInLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CollaborativeArrangementOptionPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Option Payment", "label": "Collaborative Arrangement, Option Payment", "terseLabel": "Collaborative arrangement, option payment" } } }, "localname": "CollaborativeArrangementOptionPayment", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails", "http://www.vrtx.com/role/CollaborativeandOtherArrangementsKymeraModernaandOtherInLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CollaborativeArrangementResearchAndDevelopmentExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Research and Development Expenses", "label": "Collaborative Arrangement, Research and Development Expenses", "terseLabel": "Collaborative arrangement research and development expenses" } } }, "localname": "CollaborativeArrangementResearchAndDevelopmentExpenses", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsAdditionalInformationDetails", "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CollaborativeArrangementRightToLicenseNumberOfDevelopmentPrograms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Right To License, Number Of Development Programs", "label": "Collaborative Arrangement, Right To License, Number Of Development Programs", "terseLabel": "Right to license, number of development programs" } } }, "localname": "CollaborativeArrangementRightToLicenseNumberOfDevelopmentPrograms", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsMerckKGaADetails" ], "xbrltype": "integerItemType" }, "vrtx_CollaborativeArrangementRightToLicenseNumberOfTargets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Right To License, Number Of Targets", "label": "Collaborative Arrangement, Right To License, Number Of Targets", "terseLabel": "Right to license, number of targets (up to)" } } }, "localname": "CollaborativeArrangementRightToLicenseNumberOfTargets", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails", "http://www.vrtx.com/role/CollaborativeandOtherArrangementsKymeraModernaandOtherInLicenseAgreementsDetails" ], "xbrltype": "integerItemType" }, "vrtx_CollaborativeArrangementRighttoLicenseNumberOfClinicalStagePrograms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Right To License, Number Of Clinical Stage Programs", "label": "Collaborative Arrangement, Right to License, Number Of Clinical Stage Programs", "terseLabel": "Right to license, number of clinical stage programs" } } }, "localname": "CollaborativeArrangementRighttoLicenseNumberOfClinicalStagePrograms", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsMerckKGaADetails" ], "xbrltype": "integerItemType" }, "vrtx_CollaborativeArrangementRighttoLicenseNumberOfPreClinicalStagePrograms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Right to License, Number Of Pre-Clinical Stage Programs", "label": "Collaborative Arrangement, Right to License, Number Of Pre-Clinical Stage Programs", "terseLabel": "Number of pre-clinical stage programs" } } }, "localname": "CollaborativeArrangementRighttoLicenseNumberOfPreClinicalStagePrograms", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsMerckKGaADetails" ], "xbrltype": "integerItemType" }, "vrtx_CollaborativeArrangementUpFrontLicenseFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the up-front license fee paid by the entity pursuant to a collaborative arrangement.", "label": "Collaborative Arrangement Up-front License Fee", "terseLabel": "Up-front payment" } } }, "localname": "CollaborativeArrangementUpFrontLicenseFee", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails", "http://www.vrtx.com/role/CollaborativeandOtherArrangementsKymeraModernaandOtherInLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CollaborativeArrangementsByAgreementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant terms of collaboration arrangements, by individual agreement.", "label": "Collaborative Arrangements by Agreement [Axis]", "terseLabel": "Collaborative Arrangements by Agreement [Axis]" } } }, "localname": "CollaborativeArrangementsByAgreementAxis", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCRISPRTherapeuticsAGDetails", "http://www.vrtx.com/role/CollaborativeandOtherArrangementsKymeraModernaandOtherInLicenseAgreementsDetails", "http://www.vrtx.com/role/CollaborativeandOtherArrangementsMerckKGaADetails", "http://www.vrtx.com/role/IntangibleAssetsandGoodwillDetails", "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "vrtx_CollaborativeandRoyaltyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative and Royalty [Member]", "label": "Collaborative and Royalty [Member]", "terseLabel": "Other revenues" } } }, "localname": "CollaborativeandRoyaltyMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "vrtx_CommonStockPreferredStockAndEquityPlansDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosures related to shares available for future issuance, descriptions of the stock and option plans, and the rights associated with each share.", "label": "Common Stock, Preferred Stock and Equity Plans Disclosure [Text Block]", "terseLabel": "Common Stock, Preferred Stock and Equity Plans" } } }, "localname": "CommonStockPreferredStockAndEquityPlansDisclosureTextBlock", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlans" ], "xbrltype": "textBlockItemType" }, "vrtx_CommonStockVotesPerEachShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Votes Per Each Share", "label": "Common Stock, Votes Per Each Share", "terseLabel": "Common stock, number of votes per share" } } }, "localname": "CommonStockVotesPerEachShare", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansCommonStockandPreferredStockDetails" ], "xbrltype": "integerItemType" }, "vrtx_ContingentLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of material contingent liabilities outstanding", "label": "Contingent Liabilities", "terseLabel": "Contingent liabilities" } } }, "localname": "ContingentLiabilities", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DebtCovenantConsolidatedLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consolidated leverage ratio that must be maintained in order to be in compliance with debt covenants.", "label": "Debt Covenant, Consolidated Leverage Ratio", "terseLabel": "Debt covenant, consolidated leverage ratio" } } }, "localname": "DebtCovenantConsolidatedLeverageRatio", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "pureItemType" }, "vrtx_DebtCovenantIncreaseInConsolidatedLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Covenant, Increase In Consolidated Leverage Ratio", "label": "Debt Covenant, Increase In Consolidated Leverage Ratio", "terseLabel": "Debt covenant, increase in consolidated leverage ratio" } } }, "localname": "DebtCovenantIncreaseInConsolidatedLeverageRatio", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "pureItemType" }, "vrtx_DebtCovenantInterestCoverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum consolidated EBITDA that must be maintained in order to be in compliance with debt covenants.", "label": "Debt Covenant, interest Coverage Ratio", "terseLabel": "Debt covenant, minimum consolidated EBITDA" } } }, "localname": "DebtCovenantInterestCoverageRatio", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "pureItemType" }, "vrtx_DebtandEquitySecuritiesCost": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt and Equity Securities, Cost", "label": "Debt and Equity Securities, Cost", "totalLabel": "Amortized Cost" } } }, "localname": "DebtandEquitySecuritiesCost", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DebtandEquitySecuritiesFairValue": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt and Equity Securities, Fair Value", "label": "Debt and Equity Securities, Fair Value", "terseLabel": "Fair Value" } } }, "localname": "DebtandEquitySecuritiesFairValue", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DebtandEquitySecuritiesUnrealizedGain": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt and Equity Securities, Unrealized Gain", "label": "Debt and Equity Securities, Unrealized Gain", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "DebtandEquitySecuritiesUnrealizedGain", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DebtandEquitySecuritiesUnrealizedLoss": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt and Equity Securities, Unrealized Loss", "label": "Debt and Equity Securities, Unrealized Loss", "negatedTerseLabel": "Gross Unrealized Losses" } } }, "localname": "DebtandEquitySecuritiesUnrealizedLoss", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DeferredTaxAssetsAccruedExpensesAndOther": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The tax effect as of the balance sheet date of the amount of the estimated future tax deductions arising from currently nondeductible expenses in accrued and other expenses, which can only be deducted for tax purposes when such items are actually incurred, and which can only be realized if sufficient tax-basis income is generated in future periods to enable the deduction to be taken.", "label": "Deferred Tax Assets, Accrued Expenses and Other", "terseLabel": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsAccruedExpensesAndOther", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DeferredTaxAssetsIntangibles": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets related to intangible assets.", "label": "Deferred Tax Assets Intangibles", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxAssetsIntangibles", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DeferredTaxAssetsLeaseObligation": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Lease Obligation", "label": "Deferred Tax Assets, Lease Obligation", "terseLabel": "Finance lease liabilities" } } }, "localname": "DeferredTaxAssetsLeaseObligation", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DeferredTaxAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets [Member]", "label": "Deferred Tax Assets [Member]", "terseLabel": "Deferred Tax Assets" } } }, "localname": "DeferredTaxAssetsMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails", "http://www.vrtx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "domainItemType" }, "vrtx_DeferredTaxAssetsOperatingLeaseAssets": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets, Operating Lease Assets", "label": "Deferred Tax Assets, Operating Lease Assets", "terseLabel": "Operating lease assets" } } }, "localname": "DeferredTaxAssetsOperatingLeaseAssets", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_EffectiveIncomeTaxRateReconciliationInterEntityTransferOfIntellectualPropertyRightsAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Inter-Entity Transfer Of Intellectual Property Rights, Amount", "label": "Effective Income Tax Rate Reconciliation, Inter-Entity Transfer Of Intellectual Property Rights, Amount", "negatedTerseLabel": "Deferred tax benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationInterEntityTransferOfIntellectualPropertyRightsAmount", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_EffectiveIncomeTaxRateReconciliationInterEntityTransferOfIntellectualPropertyRightsPercent": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 11.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Inter-Entity Transfer Of Intellectual Property Rights, Percent", "label": "Effective Income Tax Rate Reconciliation, Inter-Entity Transfer Of Intellectual Property Rights, Percent", "terseLabel": "Inter-entity transfer of intellectual property rights" } } }, "localname": "EffectiveIncomeTaxRateReconciliationInterEntityTransferOfIntellectualPropertyRightsPercent", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "vrtx_EffectiveIncomeTaxRateReconciliationIntercompanyReceivableWriteOffPercent": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 8.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Intercompany Receivable Write-Off, Percent", "label": "Effective Income Tax Rate Reconciliation, Intercompany Receivable Write-Off, Percent", "terseLabel": "Long-term intercompany receivable write-off" } } }, "localname": "EffectiveIncomeTaxRateReconciliationIntercompanyReceivableWriteOffPercent", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "vrtx_EffectiveIncomeTaxRateReconciliationUncertianTaxPositionsPercent": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails": { "order": 10.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Uncertian Tax Positions, Percent", "label": "Effective Income Tax Rate Reconciliation, Uncertian Tax Positions, Percent", "terseLabel": "Uncertain tax positions" } } }, "localname": "EffectiveIncomeTaxRateReconciliationUncertianTaxPositionsPercent", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesEffectiveIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "vrtx_EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Stock Purchase Plan [Member]", "label": "Employee Stock Purchase Plan [Member]", "terseLabel": "ESPP share issuances" } } }, "localname": "EmployeeStockPurchasePlanMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansEmployeeStockPurchasePlanDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "vrtx_ExercisePriceRangeFromDollars10001ToDollars15000Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the range of exercise prices from $100.01 to $150.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information.", "label": "Exercise Price Range from Dollars 100.01 to Dollars 150.00 [Member]", "terseLabel": "$100.01\u2013$150.00" } } }, "localname": "ExercisePriceRangeFromDollars10001ToDollars15000Member", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockOptionsOutstandingandExercisableDetails" ], "xbrltype": "domainItemType" }, "vrtx_ExercisePriceRangeFromDollars15001ToDollars20000Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the range of exercise prices from $150.01 to $200.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information.", "label": "Exercise Price Range from Dollars 150.01 to Dollars 200.00 [Member]", "terseLabel": "$150.01\u2013$200.00" } } }, "localname": "ExercisePriceRangeFromDollars15001ToDollars20000Member", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockOptionsOutstandingandExercisableDetails" ], "xbrltype": "domainItemType" }, "vrtx_ExercisePriceRangeFromDollars20001ToDollars28627Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range From Dollars 200.01 to Dollars $286.27", "label": "Exercise Price Range From Dollars 200.01 to Dollars $286.27 [Member]", "terseLabel": "$200.01\u2013$286.27" } } }, "localname": "ExercisePriceRangeFromDollars20001ToDollars28627Member", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockOptionsOutstandingandExercisableDetails" ], "xbrltype": "domainItemType" }, "vrtx_ExercisePriceRangeFromDollars3628ToDollars10000Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the range of exercise prices from $36.28 to $100.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information.", "label": "Exercise Price Range from Dollars 36.28 to Dollars 100.00 [Member]", "terseLabel": "$36.28\u2013$100.00" } } }, "localname": "ExercisePriceRangeFromDollars3628ToDollars10000Member", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockOptionsOutstandingandExercisableDetails" ], "xbrltype": "domainItemType" }, "vrtx_ExonicsTherapeuticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exonics Therapeutics [Member]", "label": "Exonics Therapeutics [Member]", "terseLabel": "Exonics Therapeutics" } } }, "localname": "ExonicsTherapeuticsMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/IntangibleAssetsandGoodwillDetails" ], "xbrltype": "domainItemType" }, "vrtx_FanPierLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the fan pier leases.", "label": "Fan Pier Leases [Member]", "verboseLabel": "Corporate Headquarters" } } }, "localname": "FanPierLeasesMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_FinanceLeasandOperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Finance Leas and Operating Lease, Liabilities, Payments, Due [Abstract]", "label": "Finance Leas and Operating Lease, Liabilities, Payments, Due [Abstract]", "terseLabel": "Total" } } }, "localname": "FinanceLeasandOperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "vrtx_FinanceLeaseAndOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease And Operating Lease, Liability", "label": "Finance Lease And Operating Lease, Liability", "totalLabel": "Present value of lease liabilities" } } }, "localname": "FinanceLeaseAndOperatingLeaseLiability", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentDueNextTwelveMonths": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_2": { "order": 1.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease And Operating Lease, Liability, Payment, Due Next Twelve Months", "label": "Finance Lease And Operating Lease, Liability, Payment, Due Next Twelve Months", "totalLabel": "2022" } } }, "localname": "FinanceLeaseAndOperatingLeaseLiabilityPaymentDueNextTwelveMonths", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentDueYearThree": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_2": { "order": 3.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease And Operating Lease, Liability, Payment, Due Year Three", "label": "Finance Lease And Operating Lease, Liability, Payment, Due Year Three", "totalLabel": "2024" } } }, "localname": "FinanceLeaseAndOperatingLeaseLiabilityPaymentDueYearThree", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentDueYearTwo": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_2": { "order": 2.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease And Operating Lease, Liability, Payment, Due Year Two", "label": "Finance Lease And Operating Lease, Liability, Payment, Due Year Two", "totalLabel": "2023" } } }, "localname": "FinanceLeaseAndOperatingLeaseLiabilityPaymentDueYearTwo", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease And Operating Lease, Liability, Payments, Due", "label": "Finance Lease And Operating Lease, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_2": { "order": 6.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease And Operating Lease, Liability, Payments, Due After Year Five", "label": "Finance Lease And Operating Lease, Liability, Payments, Due After Year Five", "totalLabel": "Thereafter" } } }, "localname": "FinanceLeaseAndOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_2": { "order": 5.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease And Operating Lease, Liability, Payments, Due Year Five", "label": "Finance Lease And Operating Lease, Liability, Payments, Due Year Five", "totalLabel": "2026" } } }, "localname": "FinanceLeaseAndOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_2": { "order": 4.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease And Operating Lease, Liability, Payments, Due Year Four", "label": "Finance Lease And Operating Lease, Liability, Payments, Due Year Four", "totalLabel": "2025" } } }, "localname": "FinanceLeaseAndOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_FinanceLeaseAndOperatingLeaseLiabilityTenantAllowance": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease and Operating Lease, Liability, Tenant Allowance", "label": "Finance Lease and Operating Lease, Liability, Tenant Allowance", "negatedTotalLabel": "Less: tenant allowance" } } }, "localname": "FinanceLeaseAndOperatingLeaseLiabilityTenantAllowance", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_FinanceLeaseAndOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease And Operating Lease, Liability, Undiscounted Excess Amount", "label": "Finance Lease And Operating Lease, Liability, Undiscounted Excess Amount", "negatedTotalLabel": "Less: amount representing interest" } } }, "localname": "FinanceLeaseAndOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_FinanceLeaseLiabilityTenantAllowance": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "vrtx_FinanceLeaseAndOperatingLeaseLiabilityTenantAllowance", "weight": 1.0 }, "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Liability ,Tenant Allowance", "label": "Finance Lease, Liability ,Tenant Allowance", "negatedTerseLabel": "Less: tenant allowance" } } }, "localname": "FinanceLeaseLiabilityTenantAllowance", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_FinanceLeaseRightOfUseAssetGross": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Right-Of-Use Asset, Gross", "label": "Finance Lease, Right-Of-Use Asset, Gross", "terseLabel": "Property and equipment, net" } } }, "localname": "FinanceLeaseRightOfUseAssetGross", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_FinanceLeasesOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Leases, Other Current Liabilities", "label": "Finance Leases, Other Current Liabilities", "terseLabel": "Other current liabilities" } } }, "localname": "FinanceLeasesOtherCurrentLiabilities", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesBalanceSheetClassificationofLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_FinancialPerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial Performance Shares", "label": "Financial Performance Shares [Member]", "terseLabel": "Financial performance shares" } } }, "localname": "FinancialPerformanceSharesMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "vrtx_GoodwillAndIntangibleAssetsIndefiniteLivedAssetsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Describes an entity's accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.", "label": "Goodwill and Intangible Assets Indefinite-Lived Assets [Policy Text Block]", "terseLabel": "In-process Research and Development Assets" } } }, "localname": "GoodwillAndIntangibleAssetsIndefiniteLivedAssetsPolicyTextBlock", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "vrtx_InProcessResearchAndDevelopmentAssetsAndContingentPaymentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets and contingent payments of an acquired entity to be used in the research and development activities of the combined enterprise.", "label": "In-process Research and Development Assets and Contingent Payments [Policy Text Block]", "terseLabel": "Fair Value of In-process Research and Development Assets and Contingent Payments" } } }, "localname": "InProcessResearchAndDevelopmentAssetsAndContingentPaymentsPolicyTextBlock", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "vrtx_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This block of text may be used to disclose all or parts of the required information for reconciliation of income tax provisions.", "label": "Income Tax Expense (Benefit) Continuing Operations, Income Tax Reconciliation [Table Text Block]", "terseLabel": "Schedule of Reconciliation of the Provision for (Benefit From) Income Taxes" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationTableTextBlock", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "vrtx_IndemnificationClaims": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of indemnification claims currently outstanding", "label": "Indemnification Claims", "terseLabel": "Indemnification claims" } } }, "localname": "IndemnificationClaims", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_InnovationSquareLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Innovation Square Lease", "label": "Innovation Square Lease [Member]", "terseLabel": "Innovation Square Lease" } } }, "localname": "InnovationSquareLeaseMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_KalydecoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "KALYDECO inventories, net", "label": "KALYDECO [Member]", "terseLabel": "KALYDECO" } } }, "localname": "KalydecoMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/SegmentInformationRevenuesbyProductDetails" ], "xbrltype": "domainItemType" }, "vrtx_KymeraTherapeuticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Kymera Therapeutics [Member]", "label": "Kymera Therapeutics [Member]", "terseLabel": "Kymera Therapeutics" } } }, "localname": "KymeraTherapeuticsMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsKymeraModernaandOtherInLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "vrtx_LeaseAgreementNumberOfLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of leases entered by the reporting entity.", "label": "Lease Agreement, Number of Leases", "terseLabel": "Number of leases" } } }, "localname": "LeaseAgreementNumberOfLeases", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vrtx_LeaseAgreementsNumberOfBuildings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents number of buildings under lease agreements.", "label": "Lease Agreements Number of Buildings", "terseLabel": "Lease agreements number of buildings" } } }, "localname": "LeaseAgreementsNumberOfBuildings", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vrtx_LeaseSupplementalCashFlowInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease, Supplemental Cash Flow Information [Table Text Block]", "label": "Lease, Supplemental Cash Flow Information [Table Text Block]", "terseLabel": "Schedule of Supplemental Cash Flow Information" } } }, "localname": "LeaseSupplementalCashFlowInformationTableTextBlock", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "vrtx_LesseeLeasingArrangementsCapitalLeasesRenewalTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee Leasing Arrangements, Capital Leases, Renewal Term", "label": "Lessee Leasing Arrangements, Capital Leases, Renewal Term", "terseLabel": "Optional renewal term length" } } }, "localname": "LesseeLeasingArrangementsCapitalLeasesRenewalTerm", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vrtx_LesseeLeasingArrangementsCapitalLeasesTermofContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee Leasing Arrangements, Capital Leases, Term of Contract", "label": "Lessee Leasing Arrangements, Capital Leases, Term of Contract", "terseLabel": "Length of lease" } } }, "localname": "LesseeLeasingArrangementsCapitalLeasesTermofContract", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vrtx_LesseeOperatingLeaseLiabilityTenantAllowance": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, Tenant Allowance", "label": "Lessee, Operating Lease, Liability, Tenant Allowance", "negatedTerseLabel": "Less: tenant allowance" } } }, "localname": "LesseeOperatingLeaseLiabilityTenantAllowance", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_LesseeOperatingLeaseNumberOfRenewalOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Number Of Renewal Options", "label": "Lessee, Operating Lease, Number Of Renewal Options", "terseLabel": "Number of optional renewal terms" } } }, "localname": "LesseeOperatingLeaseNumberOfRenewalOptions", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vrtx_LineOfCreditFacilityAdditionalBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increased borrowing capacity available in the future.", "label": "Line Of Credit Facility Additional Borrowing Capacity", "terseLabel": "Line of credit facility, additional borrowing capacity" } } }, "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_LloydsPharmacyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lloyds Pharmacy", "label": "Lloyds Pharmacy [Member]", "terseLabel": "Lloyds Pharmacy" } } }, "localname": "LloydsPharmacyMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "vrtx_MammothBiosciencesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mammoth Biosciences, Inc", "label": "Mammoth Biosciences, Inc [Member]", "terseLabel": "Mammoth Biosciences, Inc" } } }, "localname": "MammothBiosciencesIncMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsKymeraModernaandOtherInLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "vrtx_MarketableSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Marketable Securities [Member]", "label": "Marketable Securities [Member]", "terseLabel": "Marketable securities:", "verboseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "vrtx_McKessonCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "McKesson Corporation [Member]", "label": "McKesson Corporation [Member]", "terseLabel": "McKesson Corporation" } } }, "localname": "McKessonCorporationMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "vrtx_MerckKGaAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Merck KGaA", "label": "Merck KGaA [Member]", "terseLabel": "Merck KGaA" } } }, "localname": "MerckKGaAMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsMerckKGaADetails" ], "xbrltype": "domainItemType" }, "vrtx_ModernaAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Moderna Agreement [Member]", "label": "Moderna Agreement [Member]", "terseLabel": "Moderna Agreement" } } }, "localname": "ModernaAgreementMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsKymeraModernaandOtherInLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "vrtx_MolecularTemplatesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Molecular Templates, Inc", "label": "Molecular Templates, Inc [Member]", "terseLabel": "Molecular Templates, Inc" } } }, "localname": "MolecularTemplatesIncMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsKymeraModernaandOtherInLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "vrtx_NonFinancialPerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-Financial Performance Shares", "label": "Non-Financial Performance Shares [Member]", "terseLabel": "Non-financial performance shares" } } }, "localname": "NonFinancialPerformanceSharesMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "vrtx_NumberOfCreditAgreements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Credit Agreements", "label": "Number Of Credit Agreements", "terseLabel": "Number of credit agreements" } } }, "localname": "NumberOfCreditAgreements", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesRevolvingCreditFacilityDetails" ], "xbrltype": "integerItemType" }, "vrtx_ORKAMBIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ORKAMBI [Member]", "label": "ORKAMBI [Member]", "terseLabel": "ORKAMBI" } } }, "localname": "ORKAMBIMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesRevenueRecognitionDetails", "http://www.vrtx.com/role/SegmentInformationRevenuesbyProductDetails" ], "xbrltype": "domainItemType" }, "vrtx_OperatingLossAndTaxCreditCarryforwardsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization and tax credit carryforwards.", "label": "Operating Loss and Tax Credit, Carryforwards [Table]", "terseLabel": "Operating Loss and Tax Credit, Carryforwards [Table]" } } }, "localname": "OperatingLossAndTaxCreditCarryforwardsTable", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "vrtx_OtherContractLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Contract liabilities, Current", "label": "Other Contract Liabilities Current", "terseLabel": "Contract liabilities" } } }, "localname": "OtherContractLiabilitiesCurrent", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_OtherCountriesOutsideoftheUnitedStatesandEuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Countries Outside of the United States and Europe [Member]", "label": "Other Countries Outside of the United States and Europe [Member]", "terseLabel": "Other" } } }, "localname": "OtherCountriesOutsideoftheUnitedStatesandEuropeMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/SegmentInformationRevenuebyGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "vrtx_OtherCountriesOutsideoftheUnitedStatesandtheUnitedKingdomMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Countries Outside of the United States and the United Kingdom [Member]", "label": "Other Countries Outside of the United States and the United Kingdom [Member]", "terseLabel": "Other" } } }, "localname": "OtherCountriesOutsideoftheUnitedStatesandtheUnitedKingdomMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/SegmentInformationPropertyandEquipmentNetbyLocationDetails" ], "xbrltype": "domainItemType" }, "vrtx_OutsidetheUnitedStatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outside the United States [Member]", "label": "Outside the United States [Member]", "terseLabel": "Total product revenues outside of the United States", "verboseLabel": "Total long-lived assets outside of the United States" } } }, "localname": "OutsidetheUnitedStatesMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/SegmentInformationPropertyandEquipmentNetbyLocationDetails", "http://www.vrtx.com/role/SegmentInformationRevenuebyGeographicLocationDetails" ], "xbrltype": "domainItemType" }, "vrtx_PaymentToAcquirePreferredStockAndNotesReceivable": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment to Acquire Preferred Stock and Notes Receivable", "label": "Payment to Acquire Preferred Stock and Notes Receivable", "negatedTerseLabel": "Investment in equity securities and notes receivable" } } }, "localname": "PaymentToAcquirePreferredStockAndNotesReceivable", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "vrtx_Percentageofemployeeseligibleforaccelerationofequityawards": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees eligible for acceleration of equity awards", "label": "Percentage of employees eligible for acceleration of equity awards", "terseLabel": "Percentage of employees eligible for acceleration of equity awards (less than) (percent)" } } }, "localname": "Percentageofemployeeseligibleforaccelerationofequityawards", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/NatureofBusinessandAccountingPoliciesStockBasedCompensationExpenseDetails" ], "xbrltype": "percentItemType" }, "vrtx_ProceedsFromFinanceLeases": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Finance Leases", "label": "Proceeds From Finance Leases", "terseLabel": "Proceeds from finance leases" } } }, "localname": "ProceedsFromFinanceLeases", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "vrtx_ProductSalesAccruedLiabilities": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of product sales allowances and reserves that reflect a liability established to represent expected future costs.", "label": "Product Sales Accrued Liabilities", "terseLabel": "Product revenue accruals" } } }, "localname": "ProductSalesAccruedLiabilities", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailAccruedExpensesandOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_PubliclyTradedCompaniesSaleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Publicly Traded Companies Sale [Member]", "label": "Publicly Traded Companies Sale [Member]", "terseLabel": "Publicly Traded Companies Sale" } } }, "localname": "PubliclyTradedCompaniesSaleMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract]", "label": "Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract]", "terseLabel": "Right-of-use assets obtained in exchange for lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "vrtx_SYMDEKOSYMKEVIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SYMDEKO/SYMKEVI [Member]", "label": "SYMDEKO/SYMKEVI [Member]", "terseLabel": "SYMDEKO/SYMKEVI" } } }, "localname": "SYMDEKOSYMKEVIMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/SegmentInformationRevenuesbyProductDetails" ], "xbrltype": "domainItemType" }, "vrtx_SanDiegoLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "San Diego Lease [Member]", "label": "San Diego Lease [Member]", "verboseLabel": "San Diego Lease" } } }, "localname": "SanDiegoLeaseMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Line Items]", "terseLabel": "Summary of cash, cash equivalents and marketable securities" } } }, "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "vrtx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of the cash and cash equivalents and available-for-sale investments held by the entity.", "label": "Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table]", "terseLabel": "Schedule of Cash Equivalents and Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "vrtx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents the grouping of share-based compensation award types.", "label": "Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type [Axis]", "terseLabel": "Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type [Axis]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeAxis", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "vrtx_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents an individual share-based compensation award type.", "label": "Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type [Domain]", "terseLabel": "Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type [Domain]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardAwardTypeDomain", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "vrtx_ScheduleOfStockAndStockOptionEquityPlansTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This schedule discloses the information pertaining to stock and stock option plans relating to the entity's equity.", "label": "Schedule of Stock and Stock Option, Equity Plans [Table Text Block]", "terseLabel": "Schedule of Stock and Stock Equity Plans" } } }, "localname": "ScheduleOfStockAndStockOptionEquityPlansTableTextBlock", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansTables" ], "xbrltype": "textBlockItemType" }, "vrtx_ScheduleofUnrecognizedSharebasedCompensationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure as of the latest balance-sheet date presented of the total compensation cost related to outstanding, nonvested share-based compensation awards not yet recognized, net of estimated forfeitures, and the weighted average period over which those unrecognized costs are expected to be reported.", "label": "Schedule of Unrecognized Share-based Compensation Expense [Table Text Block]", "terseLabel": "Schedule of Unrecognized Stock-Based Compensation Expense" } } }, "localname": "ScheduleofUnrecognizedSharebasedCompensationExpenseTableTextBlock", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseTables" ], "xbrltype": "textBlockItemType" }, "vrtx_ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesRelatedtoLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Weighted-Average Remaining Lease Terms and Discount Rates Related to Leases [Table Text Block]", "label": "Schedule of Weighted-Average Remaining Lease Terms and Discount Rates Related to Leases [Table Text Block]", "terseLabel": "Schedule of Weighted-Average Remaining Lease Terms and Discount Rates" } } }, "localname": "ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRatesRelatedtoLeasesTableTextBlock", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "vrtx_SemmaTherapeuticsInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Semma Therapeutics, Inc. [Member]", "label": "Semma Therapeutics, Inc. [Member]", "terseLabel": "Semma Therapeutics, Inc." } } }, "localname": "SemmaTherapeuticsInc.Member", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/IntangibleAssetsandGoodwillDetails" ], "xbrltype": "domainItemType" }, "vrtx_ShareBasedCompensationAllocationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Share-based Compensation Allocation [Abstract]", "terseLabel": "Stock-based compensation expense:" } } }, "localname": "ShareBasedCompensationAllocationAbstract", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "vrtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployeePurchasePricePercentageOfFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents the percentage of the fair market value of the entity's common stock on the first day of the applicable offering period or last day of the applicable purchase period that eligible employees may purchase shares of the entity's common stock under the employee stock purchase plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Eligible Employee Purchase Price Percentage of Fair Value", "terseLabel": "Eligible employee purchase price percentage of fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEligibleEmployeePurchasePricePercentageOfFairValue", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansEmployeeStockPurchasePlanDetails" ], "xbrltype": "percentItemType" }, "vrtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOutstandingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Outstanding, Number", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Outstanding, Number", "terseLabel": "Awards outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOutstandingNumber", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockandOptionPlansDetails" ], "xbrltype": "sharesItemType" }, "vrtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments", "terseLabel": "Number of installments" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "integerItemType" }, "vrtx_ShareBasedCompensationByShareBasedPaymentAwardAwardPercentageOfTargetMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation By Share-Based Payment Award, Award Percentage Of Target, Maximum", "label": "Share-Based Compensation By Share-Based Payment Award, Award Percentage Of Target, Maximum", "terseLabel": "Potential awards, percent of target shares, maximum" } } }, "localname": "ShareBasedCompensationByShareBasedPaymentAwardAwardPercentageOfTargetMaximum", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "percentItemType" }, "vrtx_ShareBasedCompensationByShareBasedPaymentAwardAwardPercentageOfTargetMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation By Share-Based Payment Award, Award Percentage Of Target, Minimum", "label": "Share-Based Compensation By Share-Based Payment Award, Award Percentage Of Target, Minimum", "terseLabel": "Potential awards, percent of target shares, minimum" } } }, "localname": "ShareBasedCompensationByShareBasedPaymentAwardAwardPercentageOfTargetMinimum", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseDetails" ], "xbrltype": "percentItemType" }, "vrtx_ShareBasedCompensationByShareBasedPaymentAwardPercentofAwardsinTranche": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation By Share-Based Payment Award, Percent of Awards in Tranche", "label": "Share-Based Compensation By Share-Based Payment Award, Percent of Awards in Tranche", "terseLabel": "Percent of awards in tranche" } } }, "localname": "ShareBasedCompensationByShareBasedPaymentAwardPercentofAwardsinTranche", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails" ], "xbrltype": "percentItemType" }, "vrtx_ShareBasedCompensationbyShareBasedPaymentAwardPerformancePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation by Share-Based Payment Award, Performance Period", "label": "Share-Based Compensation by Share-Based Payment Award, Performance Period", "terseLabel": "Performance period" } } }, "localname": "ShareBasedCompensationbyShareBasedPaymentAwardPerformancePeriod", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansPerformancebasedRSUsPSUsDetails" ], "xbrltype": "durationItemType" }, "vrtx_ShareRepurchaseProgram2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Repurchase Program 2018 [Member]", "label": "Share Repurchase Program 2018 [Member]", "terseLabel": "Share Repurchase Program 2018" } } }, "localname": "ShareRepurchaseProgram2018Member", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansShareRepurchaseProgramDetails" ], "xbrltype": "domainItemType" }, "vrtx_ShareRepurchaseProgram2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Repurchase Program [Member]", "label": "Share Repurchase Program 2019 [Member]", "terseLabel": "Share Repurchase Program 2019" } } }, "localname": "ShareRepurchaseProgram2019Member", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansShareRepurchaseProgramDetails" ], "xbrltype": "domainItemType" }, "vrtx_ShareRepurchaseProgram2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Repurchase Program 2020 [Member]", "label": "Share Repurchase Program 2020 [Member]", "terseLabel": "Share Repurchase Program 2020" } } }, "localname": "ShareRepurchaseProgram2020Member", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansShareRepurchaseProgramDetails" ], "xbrltype": "domainItemType" }, "vrtx_ShareRepurchaseProgram2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Repurchase Program 2021", "label": "Share Repurchase Program 2021 [Member]", "terseLabel": "Share Repurchase Program 2021" } } }, "localname": "ShareRepurchaseProgram2021Member", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansShareRepurchaseProgramDetails" ], "xbrltype": "domainItemType" }, "vrtx_SharebasedCompensationArrangementbySharebasedPaymentAwardDurationofPurchasePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Duration of Purchase Period", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Duration of Purchase Period", "terseLabel": "Duration of purchase period" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardDurationofPurchasePeriod", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansEmployeeStockPurchasePlanDetails" ], "xbrltype": "durationItemType" }, "vrtx_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofPurchasePeriods": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Purchase Periods", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Purchase Periods", "terseLabel": "Number of purchase periods" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofPurchasePeriods", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansEmployeeStockPurchasePlanDetails" ], "xbrltype": "integerItemType" }, "vrtx_SharebasedCompensationArrangementbySharebasedPaymentAwardOfferingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Offering Period", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Offering Period", "terseLabel": "Offering period (in months)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOfferingPeriod", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansEmployeeStockPurchasePlanDetails" ], "xbrltype": "durationItemType" }, "vrtx_SkyhawkTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skyhawk Therapeutics Inc", "label": "Skyhawk Therapeutics Inc [Member]", "terseLabel": "Skyhawk Therapeutics Inc" } } }, "localname": "SkyhawkTherapeuticsIncMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsKymeraModernaandOtherInLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "vrtx_StockAndOptionPlan2006Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The element describes the details pertaining to the 2006 Stock and Option Plan.", "label": "Stock and Option Plan 2006 [Member]", "terseLabel": "2006 Stock and Option Plan" } } }, "localname": "StockAndOptionPlan2006Member", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockandOptionPlansDetails" ], "xbrltype": "domainItemType" }, "vrtx_StockandOptionPlan2013Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock and Option Plan 2013 [Member]", "label": "Stock and Option Plan 2013 [Member]", "terseLabel": "2013 Stock and Option Plan" } } }, "localname": "StockandOptionPlan2013Member", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansStockandOptionPlansDetails" ], "xbrltype": "domainItemType" }, "vrtx_TRIKAFTAKAFTRIOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TRIKAFTA/KAFTRIO", "label": "TRIKAFTA/KAFTRIO [Member]", "terseLabel": "TRIKAFTA/KAFTRIO" } } }, "localname": "TRIKAFTAKAFTRIOMember", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/SegmentInformationRevenuesbyProductDetails" ], "xbrltype": "domainItemType" }, "vrtx_TaxCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Tax Carryforwards [Line Items]", "terseLabel": "Tax Carryforwards [Line Items]" } } }, "localname": "TaxCarryforwardsLineItems", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "stringItemType" }, "vrtx_TaxRelatedPrepaidAndReceivables": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/AdditionalBalanceSheetDetailPrepaidExpensesandOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax Related Prepaid and Receivables", "label": "Tax Related Prepaid and Receivables", "terseLabel": "Tax related prepaid and receivables" } } }, "localname": "TaxRelatedPrepaidAndReceivables", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/AdditionalBalanceSheetDetailPrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_UnrecognizedTaxBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unrecognized Tax Benefits", "label": "Unrecognized Tax Benefits [Line Items]", "terseLabel": "Unrecognized Tax Benefits [Line Items]" } } }, "localname": "UnrecognizedTaxBenefitsLineItems", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "stringItemType" }, "vrtx_UnrecognizedTaxBenefitsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unrecognized Tax Benefits", "label": "Unrecognized Tax Benefits [Table]", "terseLabel": "Unrecognized Tax Benefits [Table]" } } }, "localname": "UnrecognizedTaxBenefitsTable", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "stringItemType" }, "vrtx_WalgreenCo.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Walgreen Co. [Member]", "label": "Walgreen Co. [Member]", "terseLabel": "Walgreen Co." } } }, "localname": "WalgreenCo.Member", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/SegmentInformationSignificantCustomersDetails" ], "xbrltype": "domainItemType" }, "vrtx_WeightedAverageDiscountRateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Discount Rate [Abstract]", "label": "Weighted Average Discount Rate [Abstract]", "terseLabel": "Weighted-average discount rate" } } }, "localname": "WeightedAverageDiscountRateAbstract", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesWeightedAverageRemainingLeaseTermsandDiscountRatesDetails" ], "xbrltype": "stringItemType" }, "vrtx_WeightedAverageRemainingContractualLifeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Weighted Average, Remaining Contractual Life [Abstract]", "terseLabel": "Weighted-average Remaining Contractual Life" } } }, "localname": "WeightedAverageRemainingContractualLifeAbstract", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/CommonStockPreferredStockandEquityPlansOutstandingandVestedStockOptionsDetails" ], "xbrltype": "stringItemType" }, "vrtx_WeightedAverageRemainingLeaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted-Average Remaining Lease [Abstract]", "label": "Weighted-Average Remaining Lease [Abstract]", "terseLabel": "Weighted-average remaining lease term (in years)" } } }, "localname": "WeightedAverageRemainingLeaseAbstract", "nsuri": "http://www.vrtx.com/20211231", "presentation": [ "http://www.vrtx.com/role/LeasesWeightedAverageRemainingLeaseTermsandDiscountRatesDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 18 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r107": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r140": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r159": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r175": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r191": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r219": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r243": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r268": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19347-109286" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r286": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r288": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21459-112644" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r338": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r404": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.15)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r453": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r463": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2AA", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r478": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r512": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r548": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r571": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(1)(i)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 5))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r693": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r694": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r695": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r696": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r697": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r698": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r699": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313" }, "r700": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r701": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r702": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r703": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r704": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r705": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r706": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r707": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r708": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r709": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r710": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r711": { "Footnote": "5", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r712": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r713": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column C", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r714": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column D", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r715": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column E", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r716": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column F", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r717": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column G", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r718": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column H", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r719": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column I", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r720": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "i", "Publisher": "SEC", "Section": "3", "Subsection": "10" }, "r721": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08" }, "r722": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "c", "Publisher": "SEC", "Section": "5", "Subparagraph": "Schedule III", "Subsection": "04" }, "r723": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" } }, "version": "2.1" } ZIP 137 0000875320-22-000007-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000875320-22-000007-xbrl.zip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�UU7.,D+N(#IW<$ SF_OS'V)/OO&X M&-+8F-D#@=LPV?7&=OQ$635]0\)MHM2''F-%'$U2SI8Y4D^4Y<,_M62 M@W:8O,-R[QYW?Q;*Z%>P)GXHJ% MQ.(S:;.V:X8VF O\:D@5^A/! AH1M; !<;^^84VG\M#* M@2T4,C*\F79-8\V[3V1$B E&R!X9PX(?#*/ M;]6(WJ>*:/0TB%8^ZP3\[(N:.HYZD#B<5Q';G03=A/N #:C[J2A_R6C=9?]G ME80^-EF8#5HP@F]-"P8*:WK-4SN0@A#S2!87OH,.K)R39V@?E7'ZBIGQ],2P M<+(NVRJUD5CV93:(Z4C48>A6!G ;?QYCY&! !E5Z=#-Q12)DAWJP=Z&S8LU MJ9]"AH5IC(0YA$%7V,0VRAE8CJ9OBJAY/1C(PV1L?:.%%3>]T=':^-2BRNDD M!$46[T<\D[.N)NA[@TP>J+4EUSH+PW!RPW7*& B"F<<6$B'C%$)GZ.(.XJ F$!F+I$[/23X@5+!#TC M0CE4;YU4Z?"USM 0(&3LF$>[*"WJ)M5S!LOY]NSX*MU^X*:$3?4IUH='L$DG MS/25G( 6:Y)CKNX]!^5$R_WPP=%WA\EQJ/PU")1=4(PSEQO&]YM+R81*B.'Q M5_KX>@0T)AN<6K0M,Y"C-.%XBJ%UE"/OF]?(N@J=U_S33[>^'"9#MEKDH3D6 M_"\:SK'GX>R:/8/#Q9(6JNBP&FU1)1-[[MM ]&/X=?W#\L9PCIKGC>5(O+*) M>MY&@N\QCUT/OL;41A7MWG':ZMWU5FCHX@6#CL(R.N_*LY59CF]C ?)H,%M5 M][(PHJI]D@21Z=FBQ)E$*0]S=\+89L$VMHART=OFWIF" *F32AMAG-"USZX- MMY9X:EY(HL*#]^<6E;2M8?Y/S(%4A3-#=J$8G?P]G.*R70KMLP>YV\\B6@\4 M/?'@(U6*Z !7^J\2',N3"TJI;P>3QV=1&?!_I5AWPH9J]\[3,<4#%"F'T 8W MR_C:-B/ D88O-T6*E[N>;RPHP=4^1-"ZIMIT&8O61R_,R'9)_Z/V0F*I(30Y M'R9GT7AVRC&"TU'UG#<\(VB!2N=SIE7M3S&3Q(765C([O8=D.^0KLEB!H\H; M)<]E'AX^D:G*X<-Q_<<3"]'0//NBN'Z" Z%!(-I.[^$;O3&\MOACR)\&W<^^ M"&0)%"R"UD]/UAP+8S;!";[!Z4E**4HU2?.0H42:*OA6>*OFT?@DQ4Y%J!Y= M7V;6V]8*+V7CO(QVL%_L-&JGQV8BL87APV),Z2SH*Q_/98W1_&9Y8 =^[="U MH806R,K4^2G651EZ>*1CPI.'\/07'IX$5Z]E)B#6V5(!JVJ<&[U]8 IK7/X; M$95I"OS7KA0W':%EV >]S$?XE15;YI=1A()78P7\6C4_.(U[P6FL,A=_A M$F+-6GUZWW)*S<=L2O#O9!V0O9WPN<;@A+/3&TT:9CJ2.*(9=JEVBH,"*@U+ M@@S0T9C#;#J5,8D9P;QESDA0'FR#0ZFQS! I!$\?!KY\_- M\3S)422*=AR(SD#;1?L5PR??FA.S>\:+B1+*R$"14XB'T^(L-#>K"D0^/1\H MF&WD>J*>5.DSEQW%)Q4H(N2512"UZ=/7DUT[*;GI M[$K.1_M+TX,%[S6V#7V$@;VW!='K"@2*#/V45R+Z>!'97P#JOWQ^VK(,9DLN4# M(5N.7*NO@C\NPI1Z+*EO$FJL@T+"^56L2IA'$H#:L S=>D8Y[3$61]-4\54L M$3FX#0YSTO:;*';]Z@X2Q!/Y?&-%A@9#0$A&31EM$^6>0N]S[ <;Y+?ZQ%_% MZE$TN/'3LQ3<[@HP936XV%-AQ1>R#:IM=;6+Q>QK89CL+1;*6@CI^C,"=KP# MXV66%X1\J3ACL!E-MPKOO9TY,,X1<%?KH^E1[(U!H.1G+QRF&0#B:W7T"4[[ M%9ZIDFM[\0@"F\B%9=$Y^ZR6I@*<(0:.4*6>0^1.?V1RUS[P9:#,E M=;\2^G2J+8;&Q)BB)D6\5-Y<)[!^^2+P-P1&Y821AC+6]^V+L\NT?ZH]T;W9 MAJ]B:>/Z*6D[0?ATV"J->'KYDT!\OHI5Z16*J;442[QL.K ?OA0GA\J77AVN ML4^^U1..Z =$+;WGGT)U^*M8P[9J6=\IR51E[+A$_'7X,-A0A_[YS$UK MQQB1>ET1(AHQ: O"I64+^-N*>Z!G;I+5VMSIWH,S3$M)]<2YF]&XSF5P@C1C MC.#6KV$] X@#UFJ.P\J(J791U0O'L!HYIY1D-U/V%-3 AWF:W^3,AU83$+9 M)P86%1GS=Q!^$(\3NT!ZW3:Y BV5O'4TF\^;R[>A%/^"A>L&)'#W8NN?UU5I M(EI?JQ0XD5.KAK&W)&2NX:E)*EQX<:G$FW <3V6!J9N.8VC0]9(NC5 ,B)P7 M?@Z:>'918_W[Q,R9)X[!+3MQS*76HR<_/$Z^\>Q3OF,.#LR7V\'TF!U8P9%/H^ 3BRG7:!W_B$@,HMCB[E@D^1$PS""(BAOF$6/KQX!8 MY6 V! 0 IWK[P^67WNB+P^2'$+0MWO8F="F)9%%!=(EVG7>JC*\:W# ME\;5\BF$KM:@_L#/UWA'9-?3D]5SQR?'(O2RVY- M:QGU;=UFW%[2H[(Q8!HB/,TAV(45RPA6H.TD7#@A2\0(M9)ZS0H>%39CGBIJ MT]$T,)LIQ@+_'): WR6[\PMX+/9(G7LAYP\?[)$Z?\Q*"E0U.7H8=# 1=AI= MD8ZY&N($23\U0JE)2U2AV2+T8N+UQ!!/A+ 4-*Y/-L-K$ZP_T)3B#;#)-*_! MW>+33.B8**TO4[++J F(_1RC+2QD51Y@E!X2,SL%?+VK92'BM@*A&]A_9[YQ>0GA;;I_PLOX]Y8E;1I O9 M=FA_IR_2&OO!XL H_/#XH:L![4!?1P=<_C&N(^A3"D^IZX"[/.&?!18NE [0 M&X(9AOPS344\(V&]3IO?(9CB@@0#U1.9,6R13X?)X^!6' MPOP)ZAO0SVW0A!TF8X;6]K%6]1K91\@]BTY2UBB' 5XN@1QHSJH+!X33OQ/7MPZ-$K)IHXEP^9;3&.,G&-WU;U=:I,>/C5O)&W0J?<-'^ Y-); MY@)6#R\Z&QX>[2TM-\1KC]TIC-+FW.)MJ#LC3'#P=-AMO'O.[VE_[&;PY0-+ MCVTZX&(1'O$I", ,U&.,'.?>WC6U+(-G'!]DUA5T0F=$<'+TPP/0NQOA O9T M959G?B-G+\Z/_*,O+NJ@[F!J[9SU'B5YGIO.='SCW) ^H%Q. MM6861=\OLWL;<^HYL*PQE":,9NM6H&;UXRF$.Z>1U%G-E"7!U+'5UY_^ MU";\MVP0WY_I',*-!XD6&Y]O]1JDR=-EI:&94)E#+U$A!P0OXNXA R_HT9DW MF8R?\X]/O^G5T1N:^MKWA8T[R>=BO/WZ_M0F+S M"FI$,PO2+#&OV]*@#TMDTY''Z?T062L?S)]O6SN?6V27EOFDBVIZ/7!GT/>_ M8RJ?+D8^ETPJ)DF(51P%III(VJWG']'2ZNL1.^H\+Z/H0-KX].Y]RF=/-#[3 M1:FT_T_8$;AS7I_'QU_6SHUM,E<846P/DY^.7__[^8N3\S0Y?_O3\=FSTS2Y M_/?9\Q<_G;-'>/7V]*?CEU?'QKG3R'&+T-KPYUX;LN_'T8C2(?S6>T2[IQK? M^G\R3;T-AM_XK)H)#(5'CIXFMHWB&NC.:B=$I:!"?P< M[$JUPI -Z1^"1L2KOCC\^=#SM]\Z&N7,C//3X62F2ONHH@WDY8CN2#?B0'. M>!V0%G#LJXD/E2#L!.W/!=%%XP2"L E@/^M"KIJO)EW=,(/!#?(G+="_04Y] MS%00WQ8A1/"'T!I)Z1\I%>#D$=Y"L MUJRX,R80G[%0BOAWFO0O^)4J E:AF MT[1NE8K-00,O@&0$U1ASS(+WF_C;UOJ[G(Z!%&\33.76W([*P!W["\]_PM(R M^B?C@^(C=06-4#!I#^UJQN9?_5&$A2T?V+?63994;Y7D"EPS M#<4*M:+BX:,/@!)?N*U[H(QD%*>SFBD*WMX5LZ%19JF)LH/JWFQ9>"\@Y,PL M:4!!*5/*QC=)#DE#;&UQ>4F9A'VR M"5%WHU+*M!I39F6)O%*:=DPD*ZJM9$((<5F"PN\*\!L=#823)WS*SPNZF4 ' MV"VR*',E+8P>9N11>NEB=+I+59:;_J02S5#KL^'!D]$Y],%?=9:'DL[@#(/F MT[(G]\;CX5)M\'=VD(OC@G.TQ"0OS#U46@A)6M,SBV,94:Z(2&'-@8ND%0UB M3'E[ZZSC@2O9!*=[:,8Y< E0Z"AYSF.0]H.?\NGU!/DQ$6?4M4RL<_S3I20, MX'%<;SU'OZMDD8,R& DYP'#K6PLP 6KNVJTLQ M"$SGY#GC>#(>AT>PDJA_(_I!BHX[S.US-D.8-M8!YTS(R6F'CB#%'*IFO;=! M%B:3U>.:,960C^EXP<(2\'TRQ9UXBX[(O"]^+T/SS: M%X7_F)6<.)5V<:[AI#/3'CHG>3T[P$.XP5]C\]LWX?@2JVPF\\?X'_GL']SV MQLPN8F/]6?4)%QQ5ED^M.S8G'8DG&+5O5U"EREPE;XGUR'Q5J'[08Z,")'V8 MW5SS/2%=)9ZCTF$0A*')X&J'R2]YIZ1G94%2U-9>M)3;_(0=?FWE8?O'[C#A=@ MPF["LH>QH<2!NN94H1]S1!B\DHR?%"$)Z7XOO$C/^X<5Z/@9U M7%*C#'-0]2@"L6D8(M,PLSHPP2E+;<0%B,B!HFJD2YJBT7C99!RUSE^P#VW> M6HDB*56F&T#=]N0RB&[/G# M;VP"ZQU=%?..7HV9I)6&\_VEE<5R@R'E(R+W#1NE@^$"\XK^PS^,*A#CID,L M7#9SQ]@I[*\3Q Z]OK#&"8 98VF457CB-09F].N4YY"6OLT_/ 7E\QX^>/@P MM=!\PMUZ/CJ6>]QCDFWJ:@BVB4[?B/P,SXAF[J)6WNB$(5D,UA;QP8C_=A/R MOZ/'22H5<7HQI'.#&B5!!9>#FPP/D_->LCD=A.*D4'S#J.NE,.=5S_%JA.:EJXE>] M\/<)X?2%!RB'^(Z^;%(#G'3.\?R+TTOAF:#IX!G9H&/T*_$>_(X2@ZN\46.O MF3\?PHK#3 T8&V+9"MJ!4FX;OY@CKY[:7X)6GL\E90CWK1#)10<6?7#F;/:_ M\^6+P([;U8X2-OI/_Q.<;!.)^T6/3PI?,RSFZH>CE($/0$O0^RG MF#YI"%=47[,*$3),P6YEZVQ*[0"G9#,WX31QOJ)G->>.G#!4C[=:7*EEWCPQ M[9(@T?QW)R5MW&HS"&B>EZ8S^HZ%)O[AL>S0SX<_X924?(*5;&Q >OC@Z$' MOH<_& %C2E#P(O*;4 +!; FM,O]-JE1BJ)G(.K\AN!K=Q8Q[?%KQKL#D_*%?%1?[1XP?J MS1A.T,M+;X;7X=.AU'6W/\6 2&RK]@YE5DP[#KNT5H?7#R&//1*UGSVA7R=Z MX*Y40NJ)^N+6Z[3USMH+,Z%:Z'Q7,SUQV)77=0:LZ%*,B% M>4<=ZV+6F J.I^X9;H>/0D*);W%Q\V;,.--Z3V7F(%X)M C-:Q]UR*R85C1; M%!X5(S&]7$Q$STHB; I:]6HF\V*,;\8U:]0":7*2E=DL2Y/CKJ$:$?SXK,Y^ MRPNC=B*L 'BLZC8-_$?2:YSOL!-TA!?)+I22)R%1O*6.=S=5(6!C>'6L@DMJ M%UN*'#FUC'7>Q7#[O*LU3\<6@9!B;DUD1TLS&?7V>(?&ZPR_F(I) M&LN5V#H"*LQLPD/<@3/E($\^AM0F.(FM(IJ84N9-3 \9HY9F:;:D MV?WA.@N:M7$CH'9FFTB5:T)/GS 8@E?$98AE]AL$VA53>WE) R$)?Q <]E1* M282[H+R?:85&UPGIU_V1[75]4!8/GX4. FY=OD;Z/R=CT,"Y 1.-RG.6SZE9 M(YZ5K?,$0(X]*0(ETIK ),Z#SW*#LPL7(*@@93MYF.,=M/.\_=&K#2YO#1[Z MES%JQ)-M&PN5&LB@I;9(>V'F\&4\5SE.MU/I:,6_-D8CB*2'3)*&$ZIZ3H[R M(?&M" R$ZW4B9#**19J6,B36AS4K.-?+4YUW4F6\N:%2')G@$PW=<.4RXX$/,WN4[UQ%./BARJ ##CL\ MD"4HK'CQ\&)DLUA/^FO1RKGR)J\K\;N:V NZDI4-C]6(QM<0-3U K&K2J9( MR)>L80(?CXUEI!G*^J++"-@Y5!"XLFHF>*;#^W&S#>\H7<&QTUQ6MQPX3QP_F_]_C!_]U+RJWXR">%V<7K\___>+%97+\YGGRX\]GQV^2 MD^.+TZOCUPG\?/SJQ=F+-U>[9[>.*;GNQX@^.DHQ+7Y$BFN9"7SM?;YB(_TH M??+@0-T3V,>2YNUK\>9\U)U/EGX,#BD55\4BO>3:5 FT SJM*YE*'D%; MPT-RO8)#4.25CQH[95/ R:RY-5>^]&LU48#W;%/"N9KN8A)$)KS10-AK1)S- M4C-W0$;B!,QM+%2:M0Z93RQC3.S)!B9=7C#Y:TDG%XN\%";Y3\EP MPXPSX!CB.70AV^075\-^\I]OI2.9.5'5O:4(D2H,4BUA;J69' KM[88CCJGX M=Y@ *7)W(U_DKE5Y:4P#(\TOG*C_=$3]H',UQ?%N:V*ODD@<4<*K"83O$OXA M477XA'0QS#@^GD!D2)D Y=;*O;;Q[Q1V)@W;PK<2LJWX^-'IS^1-0=JP0YL MAMGT&ASC#MUA(TNLS%@UI):^*S73FBP0'Q(0KTU;A MOW?33N>K9@N9OPHB^C_,#:6T8 B.(%/-]NZV6G$:ZI^$YH+=TKUR[;*40@C* M#^:T\U(2RJ"IN;+XK,)YO>@ Y+5628BI0PZ=O=TWCQ_\]S_BF_)GAQ^X^][; M70ZZKJ\6PLG^]O%_ZZ-(6(T"SK/:\.J/C_S?"Y=A>7F9KY-O?KF0V!C,]3_N MN.&C[_X[\B7\Q7FKCI[$?]YZBY1=EKM?>S?%^H."K&S'2>:'\+)H%NJ&_8+< M5Q>PIY3@0,/_8X=L@F\U_D=80JVC5TD5:DT:61=*T5;R83]GM%LIY %U!S.9 M?N!9^B?F% 7J*Z/O?"(13U^&,$D^8XZJIIB)(7^'\R-!.I[R MN1")]:I?7R$I78N/((^_E@F*4_3:!'8GF4L=A$ E#O:$"GS(1K+29O@!Y*J2R%#"3^M:J](<5/;-"^TN!+OBT; M2;S#+:Q'3YD_%1<$]K3UB(0YIP[AA#0K-GJ5X$=^!<P\?Q?] ML=HMA> &)>V@R.?ARW:#.:>(MAJK >HQ3BMNK6Z=I&NUD9*NDY[HON$GZHCP%%8>2>N38R?DOI\\/CIXD^#4D823( M"EP&)REQ>VF(!\21/;C%6,Z?!N'!FOLVM%D_&TGI^=BK:J"G]4Z>UG3(_R3U<0*H]+9_+>VM5F8NUW?@TIMK'#.KL% MGV/N./:3-56-^JOJ/O(C.AKYK/5'&9X0"GKD@Y.,T=/PL<&64D+4T?-PRIM( MFO2*I/D<=T3.YSEVO"W\ ["F-Q[.,FOBA42J0]\[B_ON<ULZ-_-A0? ' M3!3+0"$5CMU3)E%YZ]:#YWJ9 1[SQ$:H3Y6;S6Y0PN[6[A@%PR'WXV2#LN>Z M$>X2#D>B\ T^)%3ZU1V0F>NH2%3;2E%*R9&$N&]J(0R><93\$" M;+BAQ/B2L>"P4%,>TUH 6G55L,DC][5>9*6TBWYN8(]TY'],8O/1?4YLGE_] M^.)M4.=E>^]/C3TQZ^]C)?E/F<::I.P+, K5WO8._E.\W/$!,# MIC\;MV!W(08M8377@''[7+T[ 2B&^6D<\$3Y;("7DT;L)J&*'84I3 M581PQ6BDPI#,8]GH]CR<0+N4&*?8V(XX/_J4 J9Y7@BU%\'-YUV-K:7DOG)U MZI(AGEKD>O&>*4F1MUW:%W>1?N+$0VB,8MD]]<%E&B)7-D ]&)E!DH(B9**TS%^20[(?ZE9HPE6[Q2UN()0]9*K]*P" MP84P++[) Y#?(XO3-R_.W$%B;(#YP]>OR7%YYU79&4ZH#SQNG'_HS\\11!ND6W^)R_I9>A+ M3^,;? LWH G'H!OE)G0__G/PP0X?L!_6UO!_,[VS_/F0_O3/=C;RM^\/'WW[ M<.N?'QP>;?_J'9?][O#Q#T^^P%6__^&[/_ZJCP^??/_HHR[[3UI>7F+81121 M_^>_OONOWD;+UAVM6R*/F24J^C)&[7\>KM\G1['DX&2U_D;S=>YRKH_^"J5! M@O8&SEG/'3E-!_'XRL:C2K\,E0H:[RV:QP?[[1HE5[ZYKE*DM^'&$@= MFG-V:,CY\<7\: T_^3#.Z7_^)N?M7R 7M=O &4M>.UPG;"J3E99CF$W.7O.RBB=?X>!^5Y=@/*\KAHFV578(N,.2;) M[U'*NW5.OOW^#WS7G3\G,48L35XQ=NJMXLS1ZK!%NISF5&G.IVJ2]D;(+^AE MB^G@Y/@P.:XGW?2Z<%^/X?EV;WBV'BAS?LX9ZU\N_ICC\[/N_,?"7FB0W-!??\[0W-8.6>94V;9V4%IZ*XKK*V MR9O?<[AVTS(]W%NFC\@[O#6C_."7_]ME- EA;ZN&A;>LQE:6EX?)NVQ18H;\ M7_579*R^?;0W5A]QGD*KQSZ/UU^^G^J\0>J"D\/D>#6IJ^;STN [:8X>?[LW M1Z/)!7-VCJ?$OGQG$OR?A)K<)83T\_K0PGT"2RTB4S\*SH&#-V')CM=U7F#C M]@-N"M"IF@+0'Y*&R/=>NDG=(1U:'^OH!]]B M$)[T,+E<.G^++=FEUXB"MYE;NJYY[*/O$Y2+PMSK,'E)-^\6.++XX8,'C['M MX5]9Z;^2)@U.SG'U#$?3]+1W>6)G9[SS$Y]T"[NE\_#.($7Y:R:UDK4 M&YZ:N-V/9S(V)2)ZD49T7*!F$C5]U""@B .QV2GY7LC1UUT&-8"-OVD#%\LU@] M*G@(1U1KOT&"4STRZ3I@>08QLGKPQZ &/T[IS^6$/_0G_(PP%_YR@>[\8RW! MO[H"=>.#)]Q8I2_RP>^=9:12'W+Y3$ZUO Q2!J!V<3@K"9][)E_F%SB''_E, M'SWP+^(YG^"W1RR8LMBW-#B!Q _ULSX(2M])D=4@6K_ /9C,-V/>DV9*O'K( M>D=_P?$K=-B0Y2+597SPG;^[,1(/!S?_J-H\KM'Q!*46;)?PN1.)0SR0%Z\F MP[Y>P:W7Z'4PO#[_V^R3OR MGV^RAN?8>OS0J?!4>FUM5!A>=0G+N) VP!?%-;)3'2;/"NR;CQ[Q&=V;S.2E MBH-<4956T(@7/%WF1^'8X5,W^KY!Y:D1OA2-!L>/-1XU,[J9V5/8-VZR/%Z! M[D$FP&-:>7JCXUI8@L)C"K-_6 K["+)^;W3*E+F47B$2X;P9G.RWR-!"5*#R MRL1H+[L)6Q$,\3TAZB*&KSE#*S(>TM\\3V&?AI,M3QC;RC.>5O\8S M>NJYB4Z8^ NI#\T>O!QNJ&+8R][ M?"//^7))0Y&*J3FMR%J95^NQ4?";R/Q%X='#D3/\OQURE3[/LT59(>,;V5@_ MFB+\NG=U:\TI"A-WX4ETG&6..GC;H*,LMIA<9_1V9PYIF\7,;34&.T@(C*O@ M@=5Q_/_'0&W5O0O;^RWSYI(*_:!S2 NN/MZHD_:8MS*\!+FR;)^(5'&.22NF M)F36475NZ@K<0V_;4* \275,I A?4&/;"W6&IB6RE5>> SDE6N1WR[QU2V=O MZR^C=]" K"%+'AQ:_$S?=_%7\>&NW4':_#<:@S-E(DO%V5BT+/_N.W[M:(HE,929$@5N=GN[&S9@T$(3)-; M'SR0B+K@[WBG$^S\-3E?UM/RR^2A>NCSZ+O\L.U=HBT[GOV*A)MC_B"]U-GI MU4@H=>?J(+LI7AS4TJ5$V' 5E%W66/2;+<(:Q>7;O,?X=B;)D>,(=TDF*;O; M:'9#*2%]LD8. "COB6N=KBBG;AH?X145<;'O*BY M571MFVK#0U%%.6)ZS9R'HZ*BP(7JFM[[TO*L0'/D(+N&1MRR,7/&59.J*655 M^0$T$1&RESZ1BS%Y?"<<)%;5UV%&Q<#=:4)ZDW<,(N+O(L+)0,*_S8881<-=<05A+QZS0.G -%^RQOD NT;\ ^+KEPXFK0/+ : MG*^(=P86@AP(GR[AO3KZ7E@AFT^^W2E2%%>OO @,O)4?^,4@5EUNVN5JD$:Q MWY*G>=*7$LV;7DY13.0*(2-Q@?/#^9];_,O7R%^Z@QH0C0FU1GQ8_7T&7#[H MQ6:H&$UR3XA]]$.] E>_<-0O:'U$F8@N_R.Z=>@X;"^\1-[L$]1A]BE'5)L. MF@CK"($57"?HC(# Z)BRQ%:NFZVN>F]-".E);&WSF\:G^G M+JJZG8/2J)(K<*V:0$VGOLZW-A)3H['U+GXE*3>5S1W5$"1%I9=\Q$G&HV\/ MS6+%"N$32TUO<CYX( @7R0$OW 5#GY/#L\.TUZ! MRU>TPBLK2BNP](]6NLZFKW"T7]!H8_6SN,9UT16KJLP$^'6BA+TGF!VTE_YP M6)T!J;\==ZI$O^X1HP/*>C@1/9<5[G9AS6NQ*"]^PXJ]* B M^UYD8'K[Q,M:?=V_*E@*??8Y&*A6(UFAH9/7&7C#LN+E!Q "._-C"V:O44S8TB1X?AK M>/?P.I&*F. (6Y [?]0X-W9GY(G?^Y3JUV6;S>=^#L*+\Q'_)O+2 M/Q)N8^0T"M\LRD6 ,5%$]^0C@\0+##I &QSS1"_\SB\X3FMP#!^/YDV^DT$2 M1P]27%W7(#2+J3LI)4CGDS$;6KXR<:(9;@;+RF/4Y8(/OJ<+RM'N&CXQ6S2B M!B6%#CD(XY$S]F*9&)"+?C1.=V-&H;9Z?D_O(VE'"6KS\" BJ(!SW8AK]>JIV7B M68)[!$'6LC"'DPTOKJ=/-"_KKS3^IF?9KSA+:>-UN!X#[VQ5F*5RM9:,601< M-'#RQTJF>K^-7$;9.IF3/J/YC?)NOKAZLG2KG-8,'V":BS>" P?=?SKQKUM1 MP;<$"J ;C:AMCZKXU #W10Z^(VYE/W!E/;"O8=X+8_+PVWT-\P^:3JLP3,G" M>%/IP6N7XH5@)GV18T !H<<0Q&8V MNGT@1=WSD5]^T(\F"QL#GM"1<:M59N&I3>I3';#G-,YM/.5!,]/4"Y_26%TR M,UN2+UP;\N@2SK[P:JF-^SB4G']HF_;Y0;RB^.;Q+;9!NS"8!A4 %BA:A^CZ M 4MF R&2I7MK)0$3%O/KW\I5, MGI>%^10)YGTU6Y_L@7VRQ_;)/L<.'\-='"5PT@]DZ/C4&&]6D?%\:YRFI MB)(TZ\4T2;+;-/J=6352F=>)VI".AEX ?+I*O-/.#H&K[;;-R M 3-.ZLTDR$_+>9&M.'G]3ZX4<2G[+28BGW/&'((/+35>3@M75]31?+Y>@MDI M5O*%-Y)JE^SI>DJ9TRAASTOR#JZ2U3U82DC1TGEI#V85ZC,:+Q+=2_.V]GXM6 TX M^DV"-*=-S5A6.:XO/[BZ/@1BO*CE\QL]3U1B^>H6C\.RW M=U 9HE/+7;X?4H9WM7Y^P&>S7O16K6&>)'@M@SO)8)1M^IH_[RCI<%ZWR\I4 MSF*TWPDZ$+![A%=/UM[:QX@_4R2N?(Y9DFCD"&*&C#S,0E%&^@29[_%+DS:# M%\2:>--A'5P&\YJ!9)L&M!@\5\&#*SDR]I-UC?_(B0*<#TQ'"Q0'ME&N]8/< MCX35R0S=4N.7H7^BZI6"5=B3QLE8TKKZ%7R+1MQIK3P_9#R&K$"T0Q\/ AGN M(**6ZNX:?CJ)D-:J@!#NEX/FJ#L> @0RWLVS*;YL'3G66;OEF;;=F1)'Z#)2 M2T\U;W%BM1:,%G7'FEN!WUZD_O MX\C!$)C$UD>+W=B1!QL*@=S/W^&!%<"'T8KT%;/IJ+6-8B!R7%GH=7KNHP1O?9/Z!DMJVWN,/U]84+67OM?:>;"_?O^7NQT8?7J$^O/+Z M,(1@ES@"64.P,#CJ4D_-L-CWLE>?>_!(0N(F)-9M<4L?G][OXSIE198,&KEW MZ#URW.%3AN/S@;9:O+$8+'G?LJU18/VI$><3H8_-M%HC0O8F;_Q)\1 A:YT> M'HTWV1IGUA?6^52.-"&;'CP76D!>K8/\!^@.?]4%L/O]N>H_Z$ 61/ M_FN?V/ZLV6A7+\Z2H^/#Y.WIY4_)R^.3J_-/F;[\)TH17?'CYV?RI$=!D_,, MX-4*[5I;3:_A=SC$'8>S&W&2 M,#ET5!:'S[([UX'NKMLL+VEHX\PUTSJ?@-J9.(F9M=*NJ6 N0MKAR'X"<57' M@P4GB"N#6->56D/\B/'$R>D\P;2?&!">^D9FC9X9[A$_,OK5-)RRFDX[3&K@ MDDW$*4I-B (+(&]2$7RK*UJRG*:Z?4MK5N37#GV"#N/T%!T+L*7P"QV066Q" M]#2EC <^*'@ E-4!7W/JM(,GVKHI77U&@#?WR7X:J\!?P;',YYM[,QKS\N>S ML^.W_T[.7][_<_C!6;$J-32WNYM@1(E27T(8!R%JL^W4I @6G79-PV44 J/. M'/RUT!@I"+%,:CW$$D*CYU .$!Q>$)8%GS"!(H5O7KL-?_P3!B#>&S%Y2^_Y M%ET1FA:;X')KY/*1[T->#9,K'2"!$DE+S*+T%\H/43A^]_2O&W?<6YO'A]_B M6KQ#Q8OV))I0#]H/PY00Q->V=7%FTJ&LA;FN*1F8&F,FCX\6>T#@ZY.7TNLT M3VX=C>WL2IURW'2$7%);I-@B>#UN3JSYW/#]&A?N&BMT4:(39[1Q@KEV-_M8 MC;J7H\^0H^.B4)LFV2"0&1KO&V@1;A VN5*,D7RZK5K*C^MG23?6%"%1,,1= M._#AT(.#8L86U66M2N')2_(,!G(%5AU\I8Y^EAC8A=O%MZ FAY?A3CW1NMTJ M6OX5.;-UAXV//(A/-/5[P?P,P3SUF[!V;4[5Y4G-?I@D+7%<.:B?M:,<@$HO M_!>GF=.$=M[5U$HW)C$W25FU* ]Z<4($2T72B]AG>77[K?Z\K8;CC[X6XD;A M6%/K2]XTN VTRQ(W1/N(00E]<8X.62LT6AO^@F@/E!<"-U+>:;T&IX;T"_8Q M@-F$S5YTOIYAC1<'0&X.'VR#XE(9\[:J= O*P6 .#8(*9*%A]P[N559@_O- M.ZK)D;;\^![+O;A\AKB\,O!WWRS<+O-Z=H M)QL0B0T1NSEWK:X.BL2T:CAS ML21\.N5X/#:K@+UO..-KKKIR&0+%3\F[WGA5*$6^A!1JIE6FF?M/AS4+T'VK M25"XDZ,LQ.V=-/64Z/^:JQ*7/5:!:7OFCOP@ .$BEV44@:9,_%;;(Q M._R1W>;@O#1>4(J]E'SAH[_,8(?#V2<<15&XAU=2ON$9MIGH42,)D[XPI)SR^A/@#32P9W)2[HITEK"C[#9PNRQC_N^?!XK3F.+)47D(67(05ER M/,Y_D*A^*#.W' 6 ZX]2$7:=8L0TM@*D@"E^[&E52D%,XJQZW]D;BM%>1KZL MC!AVP1P;E#..Q(H*3"]A+41*. 2W1;L6GJZ(2BF:=8P^)B8[9 MA2R2CR"EU M3#. ,*A2B5*;*@;R;5]ZT4J)S9E[:*8XGMLN H^0S1 69Q.E>S'[@F+V/$< M+9&*@F)P)8(W*6309*16-T#2K._6E\U>:3 H";9JV!"$V4:R4+U+C:BU/<+Q M?F!B'GX?O\6^"_\+^OPF&_S6)WKVNN^+FEBK>[IVB<"%G$ QU#3C6EM01/@@ MZ#;;P!F28)QF8>X3YJF9.$%PWN15X6-74UOLI_CLA>=UUC'H()L@VPK_G1*! MH"&7^227*'!^4&031T[^JF)7#NNC144Y7_H")F&8-R:'AG#P_W%1/IJG;2^+GQT2C%6H.2>/6%F-'=?9AHN!$S 9D@[N M2D7VP MG/"..(OAXY.1>W'^?% .+#:F)B21*"VB%,=@@9ND/$U/R^K M3<6IL.TW&>-/B4(%6R%PGT9+9*SCE(&4*'&F&^GXG':*45Q3*SZVOF5M9G)P MH(K1A 9MS%+4CT][2BGDNUF_P>7^.6I.^4ZS;(55=]'Q7>RF^O?+]L9MKDAWE>D0< 8/KH $SL"AZ5>E8WDETFLX^XDY$#091BI"[&-@@R6YTV3DX4DISXDZ-%]3>HJS (Q Z>2K):Q+Q#R) MGD]7YGL7]$_"DS#TC/.^E#F$79SF:^[G18P..$I/#KPCD^O9E[RJ M8[9QD#=ME/>-+<3QU&'O@1EAAX\"D4S=K6,5*_,=E,]J+Q)?6"3FV31T*:&G M77(#$Y]6]SX/-2TI6XTI!.Q(%_M]1]77W5WSC5@H]G[87Z4<,$DO5:*L;3'G M8;:_Y<1HUI'6+6*VR/;K:TUFU/*O\M/*3+;KTF?OW65PV3\X"'&@(](%R.&/>W2,E]O@>\T)'=J7-E\!UR8 M9#J1Q6.O4+^LN-481:JPD>G;S5Z/?_G4(VR ::8!+=QJ MML:F!J-_Y^4<;;#K]6"T=Z8A4?-S%GX+\#$O:>@E*5JI>?,\ FE.=5QQ[S\9 MDN(CVP_-Z'[VM Z@F6\4/UA76= ML[6@;KY1B2. 'MV/5,5M*928($.W> _R)!6339%V+_-%R!YFNX4D8! M9'.=%TC\ZS74Q].M["W.GUKXK$>/(DW?./_E]/G!T1.P0"5-X.NT+SHT+%H]XPG7WKE&?]$ M0WFS]]2%'Q9?!B7P&<8X&>A$)00HH'F^)6NG&Q/MDQ;\FNL$='%S]!VQ/3-,WV!XSW>CD>0H+UV:X M604F159YEB;'%^>OCP[P*B3RU_D,AS//=';0U1%\:PV1"7SR^ I^?G[VG*=0 MGQT=)I=H>;PR69NUC,4@?&?4=TNU!^I++X2^F$&H38L4!XAZLH46\[Z' MOJ?:+@(.A8(U!4'P++",1GR_=F4#)BG=@E#@?! Q;*S7L,"$VL\;B:-QX64F MW)(E?;Y](\@%DZ@.E#"EG3UH2AN'<8-6B*[!SCRB+@N[0]RR >,(84-5,B!, M.*KH(,5K&-#5M?:K!M!M:$EEI(]!CT4ET;IW&L?[ 9%4#1P16)XI';DYCC:@ MH^WJ%5-F"7T:K _7RN3<-$?.:JP.,!,2 M#U7YY?\>_/#=8YR),$, ?7BD459*EE&2-U3AH"X1)V=W:I+)\"S$E\JR*?P1D>+VY<*8IX,2X87.,VNM?# TGD<,%EV(W^YR2WB0VDDCH M5$YI\^MM'"0%;D6CD3N_?MX5-=$BH5;N@.#G9S^FQS+-XE)V.H-&.S$.F2K^B4=$X5!GI M!:MDT>$YP+DTT8KYX '.$,W0R.>;T-SI"PSP7(M<" ^E"Y1573F&2J#3YT^! M[U(9P>DD1BQF/:/L'\??7)^+5'(QT).@=?@8XX+%11 MW:KS<,OT.5,BU4/4J;\+9_HIN E#50@Q(;VR1#4K3Y\FI'TI$8_5/]+N8^G. MB%>KYTS$^5!27&SA0E7(JW#IVRIQ$!:?$EU3ZN!]CSD@7T]4B3/P/'D.NHCE MS@W@EZUTN;N85MKS%O\.WN(=]' Q?BKI3?_(S::R;5:XT5.1'.,P#O:-TBT$ M+@6J_&)CB%RZ]1!F_ZER@%,$SR[$3)RE5TCZ7;LYTG($5^8F#6),94<56]8;_WXMP'WX7[OO_3> MWP[X<&,^00KI!M!GW2=K5I^BF.SWZT_?+^WX-^F38?]0E(ZLMW<+V0U5%#+\ M;BQ(W3T?(QZ1EDVJ&VW2NG6U= AP* 734V"G'3?+4X##I'(9T0?=8CI,5E# M$''*7U)$G?FF0$XV2Z)ES8,LT4^EM@I.XI19L6G:3PQI>GXS=ADQ["UP/MS% M*-9+#8Y$9Y\7D8T]TM84KL]>^]XH&6RQ&:;=ZZ@W$NY/"0L_X$1?E5=(&5@U MI%OE R[G&0\?G6]L:H)2E7YY;<$_"@Y_%TG;?4H-[.;DF'NDA8Y-\,(3@W,) MGI4_PR3*K%!OXR0=29Y$'AOZX82VQIMDC1Y;SJ?B_0QCSI93%]ID#JG6ZF-T M\/' R9^%0'8;7?+ N C_)NL+*9])/8/G_SM !%_T4I:;>C/.8\E^5#HG=5N--TD [KOC+O)?@9WR;=9<.%% ME,B4)R_ E8,ZZ15N>FI>]?EHNI%U.W7/1TRH,H[CXUZ:9D-)Z<*;(4D0P:?* MT']O'^J?U3@1YP=Q#;_+K-^7TWH:)A;W7ADWHPF[H2/H*1?<[^4)Y@RG_\*W M<9%-2Q:LT0(E#@0I\)!%>I\J3/)E:N/-BJ;J"80^@A\PVZR06M^[R@PCR&^8 M(5>>* 4;EA',%^03=K_M9"[9PHP3$OA>.G8E;QNK>@%7_$WGF@F2L,ZY]H^- M:C3\99D7\-++NEIOXJ\H>ULIHL^737E>$??-:>,=[8;(IN\EM501Z!_5-<(8 M0P4V7''[F(!TG$9@%X.Z,P=Z1W)4$;O*)[:;:3XKM""B4F(M$T24^2FC1#5/ M'\Z\% ;OKN?"'":7\I'@G1%T1? /QAE$H<>'B529P1Z9JZ:8[IWF MY,S*@0HT-,(B5KHB#4]!ZQL#:&!'7308CD:U$>Z&.7$&M7;B$KVE:1?TE"08 M%*58BAWIP"8^QQHCO)2KVF@N\1=P86^\*.C^:-/]+S2GI"&&3M[F M4MP(AX**@(5(D#CXL48( &H4'L#_\ BNJ PPV<2GXVK)Z1@-C%39YTTLXOD* MV:WP&(A19ZDE^$&&O*^QQ'(2QT=L-Y-;&/ M7UF-S)ILY3$:8-G6'EUN82_KKFYPG";X-SC-@%A)PUK' )!240X8.C&R ?17 MA$6#%>+YF(SM2G&WX'0PCQ\1"U2@AB2S@5B,A@IM(R9BH3 ]SYTQ B.Z<;5Q MQ +X9S>S&_MAJ7_2L-1[JR3C#C*S?X9RHZ)4(%RA#P\%'9/#0R'76^CZ4#DJ MD4!$7*T+>S]R,R"LQ>WK&E:.'EI549I?M\EWQ7M4I( T:%8=^@DS5<^V<@?? M!G%;^7)L-8&U0K&@N#M<7M22L,TV=*/:\MFEW(TM'\B8G@'DAC.N#2*L(.:; M=9(4= ?^TB. N!+>37\KY"=L"%"'N_]T>-60X47-C.L+3C_AB*]+[-B&RQ"1 M,PX*6F4R68_?E4]L3_(')R5" 6NNVAPR2U#:Y\^U9Q$>I'"9MRAX\UF=W69% M?X*'1\>P,CU,7@@:3K)D7A0;.%%HKA"1B0@<#'TS;FOJ^;6PV$AKX*&%6R)=8^4#LN^>DYL."%>NY,)$\H'N MFO+3]G6L1&58U!)5B465 C&B&30%$35;TV MJU7QO**^VQOX<$E3U"LZK2;&Y=J29T"OF-B^0T,PH<@!P^ ,0V300SNHR0>) MC&UJ'8*VJJ?3+8U2CP=9II -PFC:'/IIG4VOLP7]B+4["'%2%O"6>A52.VP M!81&#L"V33K^'7NU-'N*_@N!%3B"U\ZMO3-&[-M-HX11?&J,AJ^:]D#1$1G[+J[,+RY057);M=-'#683V)8?*Z.WX) D^CM+$ +*X5C@P M-1?$-X&?I(G2,G@I0G';ZZ:DV^"D=9HE$O+ L5?__4Q;]^9TD)>JK'F6?U*: M0W2Y* LQ944M(P3<,BOFZ:B+:V1CW%L:4-.//<((6\:&PES!S?[5 *9&^1"=_L-NR@(D#/)J[%XFHN9)CB'<$^ M9SNW;:"?E+)RF 3UCO2^)GLO=OW1@WU-]H]923H[7/%:(<\^! LO3$9TRU05 M3;]NI6@F+6<]= K(?8]U/O?9'!\@-!'GH:2)4AY4N];29Y%UI< ZXG#_,+D( M1YF A4A]%MH[16D.0C'T3B%F%J^2YDICG-$?*YW&ZF%P@Q;!P_#IE5R30,#Z M;_CO1AGM?6=&%YR[L*ST2CF.._!@1F\.4G(&,IJ XKAW1;K"]CT"?PIL5=-# M4R?^%GA#TD3D$P F9;6'?'_!O2@@2.438('YV0WX](ISW-+S:].R MW[9G8RX[*6M@@2S6[ M$")EHY.E_3S+^WI1$7AD,>MQJ'_-N$41<($D9#19LN"2T=* QELF4 M^KH$ 5P@1K;(0A.=).:SDMLH*+VF.Z0#10EHDPDR> LY6.T[SWH5&HNP)'85 MWURY@\)\.0;B4+XGG?E*=#044-@4RB#!LB6GWOO+8 MST:&ULL 2#_!WHRA]_0]I8>$&$'1R>)#FII40-HS_J (!V'-I1M"KI.7C1GP MQH CV^O H!^P8*5_+OL$?M)+WI LJV!SWI:\>H$]4AUIL%;F* 1R"7L#/B!; MV<7LK%[?7F&5E)DTPA"BH=QKFY1!.HL>VTKMLXLP\E-LA8 =&DB*3 F?A@Z MB/-#F6FE 36 56+X6I@FU=CZ?Y1IE %[ DPV*M,@1QBB35VTVFFD(D13IZBK MVR,ZG']Z"AT)71+ *:?A(*6,K^0\ ((O^2$"&Q[M.W^&-)]EDIH@$LBTAA-&W-_2##;Q-D=4,-^2Q==A8Y#ORJ,T-C]V+ M#L?8]/KW\=6.3XX#SBR& \%S>O6"( M7F\BG2@]%-V(07OZJ:?,B;R"?2!$+?QOB1. YLXI,X ^4"-_0T9+3_P'EZ+U M0?1I_&C1NN[BT1\Q4N)C$$4D(EVKNI@Q0-*?$!R;XE;K5AK:17SYC!&J7%I% M"[R3X@06137!FH*0V(;&3^M;SSK?!"Z?'X[RP,,;:Z+2+2JI#S;"1*KL1C5/ M%'7:%(KJ( @TJ>]LS9)-C'=$63S+<4?YSZ17\+M4=:4X?+.6OYFZHS$1Y'R) MIJ"):>*/90JK5D)N-V4^5[ \XPYKF5O"#XUR_A@P58C7= ?-"DS(1 M>&*N$R3)#5_1+@\=<(( J%S##GI^:>W, E6&W+76D_7@:C2;JI%6#B/WIM\] M)K-A/:>V84&F8(O>1O2-0NNS6;5NU9G'AF<&'G.WU77HZ EV<>:0R%N8(,GS M[!"J_IN3U=G#K.Z%P7QTM(=9_3$K&1]WT;"A&0?,,,1Z;+](Q7&=G!,4J-(B M+9 B32%#=$>CP3X&M-?_,88(';:Y&%XL:\>%$-'&EE&J91 U199B*P\[>%G8 MMI%AJQ^L>\$C+\V Z@UJNMS#9TG9^!O'L1;^%HFJ\')1DA(T$*L9!E>9_FV- M278PO7.UM#SE8_HD(Q'R2ENG>1%B6+#9$8'8D(337$S366;G3^PP2;ADC"R MA!KCF%F,WU[%:7@!8K9VUS9RU%W-MA=GY/&B*#J)',FH8W\R\#S METCE0"U9R$Y"7BJYL78@ CVM= 3:/8H[ II^2\!.POK?#8@I:0Z$9(@WH M])7-$(MH##AE\@8# #33CU1RK9S6W=0]M=-P69IYLS*PH>& 44IA^!2^C+JV M1\XXH)*W"CFXZ!=PJLL&%4PYW?226NJXT]VB0.6-N\EF69J<9?6F@$NFR>L* MJ55 ]Z>T#/^NZNLT.4&.CZHN<431NXS(.UKL6#F#@Y5-EW#P6MS;$R3YF"*# M QCA7\"%K= :XV5^S%9K^!IV#/_<9DOX)FAD*-W<>$GLNS /=]11$'87Z''U+LJS^F<@#Y7>,>@23 M2\G2*CS]QIE43#7%="V'L71%SR^$D&A.4<:!^2#_'L[L*2A:=EZ>U=EO^2[. M0SJAOBW/2Q<;E/,Z72&?Y!3JV@08E7<%MY MZ$#/IQ"L1*1-="!=$\@2Z.'!E-#$L1T4[G-2)3T=A6]H>%\U-RG1Y8R&JPU4 M5QPM2L7X?_;@NB^(":J[PDEAT1@5H:+27+CT2Q%)OF3[&=,#;A-Z4T:^%UT^ MHVSAIU^-39+R!OGT[QY<^47!Y%S-ZE5*:C=W-3.(R/&D[+9DYGV7[(&"DLFD MTU;N=^M+[I9[3QWZ!#E#X,JXF\YU9ZFF8Y:$RK=8L<<<&#/-96KE^W0[C%S9 M;^,7Q?@+Z8T460)PHLT/KO/I]00;:]A18A8AA)M-N$ -V^H*HFS L&/T&^K> MV:\:ZM7H+-LJOH 1(E;-O2!\24$0A"WM2)04*8KJEJ.VFMJ*0T$<@[,>\H0Q M'OM]^H(=(5$^95SEVI!UDA>*:.((BP$X>L JL++*5(5;[_?S&PI.%#Q?*".G M*5/\PT<>)O_B,6'$-$VP(KH-YOGGA21!="1@9"8LTL)*%GZDGJOMX9-D- M"T^O>AQ;F)+T5I^^.,0M,ZIW%,L[G*/IR8E],4EK",6.%A"2'LH+M2H\>C[K MLD+3OI1LQMRAQHH1S&B UUM08H4)3)20.-JF/;SD7NS^HX=[>,D?LY*#S*HH M'A[00!G?40738!+')'6CN6AWH,9]!-/OS;%-RS?.0M9KMP;5E_8XS5?5C*:H M,UT0".F,&J2H3E KX[DPSM[DC0Z6$\QW7&SU'+@&CK+.-AXW%\U-=B/98Y,Z M)Y*T1O#LPDSLRHPJ3=8WQ**XN(:D=A9<-Y$^U1A]+L]BX>:UKQ=CYQR:V6(3 MOXT%K-AIXSNH[,^%@Y)E4]N#<"N?Y435"!=/GG6SA6N3XRF!AQX^./HA;+(V M8VNUU\@$9S]&!&" 1Z*D5=3A&!>L_2B^3CD3/KV?@"A(M:/@M\>WFCD( 74658J\R-IP,V!(K=^" MPPW)C;6G;TA&3< 66 DXS'ZL"5+!PE<)W]79X3F6"_(,K#PN1.J/+S<,Z[2+ M(;VFYE?@V2,W;AQV@"K25#%[>N_D[#+J>J)9B_(B3Y\V_EF7@S0\P_34,]=BC'J,Q.-# M4Q2%I2*FXXV 86K)%37D]"I.;%T8:#,"R0IG?N5)VJB0GZ%QFNGL D_NEHJ* M&IS:7N94\?VIC(VD:T9!;A])X0/RK,T4N1!$T_")6UR&2I?T#:78R"-%327U M776E')ZHUZ#',4S&1NP8@3F7420)#ZNY 5VZ'13=8X2BFR&I5AO(MD9*H8WR ML0@Y%;S2#5*51^+J5M*F0=Z*+98/Z-V'=(B&\) Y?;/"$M%+H![M:B!+DD@#\K8O.<*B_&S+I MB%"5YER6;M"-SNW;Y-*4?:?>(YQ&F][[:-0=/.3WIX7W,'F% M"%QB_,0^UT_L^ANT^TE+L(.H ZG@\6E"NFZ3;FL6'N]BK"UV&$]DU,?X:2W$ M//+"KB;\32?G#C#2F)-&6YO%@&Z0@=!I-AOSSY7G3/N?9XY; Q@;L#F8; [D M1WER^"S^DG_B%H%=3"#'+-;' 6QDU\A1\#)(9@VS$B%3 M\ &MGNOT(KH4=:Y\0-_B5_Y_]MZUR8WCRA;]*X@[YTY8$=5MDJ(T]C#B1K1( MR:9MF0R*MN;<;]5 H;M$H JN1[>@7W]RK_W(G5F%;E)64X0.)F)FJ 90CWSL MW(^UU]( -CZ?'@*6)TY"$M(94(VDZ=5?O?GKQ;=?O<0;?_>_O_WKU_]\B6;Y M\)YEI*M8M]2S0&J&W<"^? BN_UC@[XM]6!-*/RR7H\+A MF)QF%*F/?:^!:VZ))H>=". !9TQ-$V,'_T:BDX-Y SUVI;MF4\V=VG8W#*FY M>W&O2,"NL;C\'4NU8)'.X"8R"MIN1$%VI<2.QHK&_\5>ZJ1'5!^V'XE9M1;G M'A5FTKHTV?J4XXB@I%S\V7?)WC9G*VW-JQ7DSLXK)= $ZAW\3 M#20P&1@_PK'&3I)[M.5!/\X>0,8_[FIR[G+.$#F8L5KRO!5%TSZ81@E4H#7% M.:^#&KN31[5LI%&FSS[S$7J6WU=R4MP(AT)*U:7BN6)2_PV!8K1Q'1ZY__R/ MQU\^>O:]0JNYTR,*QLTKH?L[J])A4D$4SG*JJ\%1V+8;$B"K-#]R>WCA6L/% M@3>M_IWW?/'+CEXND#6H>"EILO).RFK@?38@^F"N5>,PL_ZI9OA1:X:?_^9J MAB=TUL\AB$V/*(E&I4_C'MNPJM= .W-\@;PMNY<_1CS5H#-FU/?S MN#L)1UWP\\(G8NIRQ3?8VZ'N1=\QDJYIJ_V)R/8!%Y60W87CCJ(R@FS5Y#^/ MS,M0)PJI[^7_2+*]U_)>.?A+!,^;(A1;3]8P X?[A,)]8/N1H!E*N@ M'-]TGFFWEH-0T=TOPSF]@.\SK4@TMM(./+N6N@F]PBNK+CB$&IY1QHUKH%Z[ M-SKZWHT=&\8J5I+%9]\N^+([Y<\8\Y?<6TQQLD /?*QY!6?V\LW9G=>EBGF6 MYV__Y]&CQU@?__R?LS_\X5&FLS7WNM1&< 62B#-Y\S7^Y]G'F@KNZ$[):(6* M=B)-5K@:[:3#T].%)$K!E-$7XCA0-%N@/1G/?9*D8UJ2C5Z]\N*@FC6AT$$> MD_7.0TA69/PI>J1!]W[?+&IV. M%A3#/5RAQKEW)&Z'5AGE]UP?G=O#Q<08'^6FOF<\*0F:C&G&'(_-OP_>;]AK MI2@Y5%;]J$WR%*5LL@TMM=4 \\M]#Q@]E$2., ?U#2,(I!C#11Z\,X4NNI2T MRL+KY8ZZSSP5?4TO">!E&-ANK ?Q5;N6G%F?.8X.4;2]2#\3$$<6JWBP8&;L M\4^B/B*P9!>6>+WDHHUE\.$U*R5A/X2%S_YUZ6K6L+E<3@D#&@QQSG202#&& M-QL;VN%2T &:<%GOZ$IUD]Z0!>;#3Y:ET2E1-BC27MX9.XX->NR(L; QNVX$ MA[OQ,AP1ICYG[1(W2LP$8M"$84#L0S0.W)")L[WMN*8@.!^(/?H3WXN=3$84 M :H4Y6:6AH?9Z7.ZY!ZS>F:#1GMPA.=X*;C#_HY4G#M.6U?_XCX4(B;C!*MP M/]N(X+7UB7A 6:7*@#U,8%5M5G?G 0OF<,$TTT^^>7&1P*;,M[YL5^+&4XI5 MOITX[Z#==%);9,'N\2$\^B?C44]0:K((;7@8\(N%K$,"H)O P,):IB1"C7?( M]+HSA>>?74GY5"SA!48.@C)"HG7?2G.##M.GI[[9*(8?H!("XZ656!_M16"% MD:,#T'M *)X0M\&.CAO]ONL9*APT2N(S/N$$"D'_/\6&."@P*M($Q7!5^KN3 M#G/C -96D*NP0,:J7?2MG0O9V'"%CV5A8E!Z[:Q+]C#:5?QSGHOAS"D1DV39 M,IRR<"XS[$&WH0)08+6#2[5IP_!*1R05S.G6M[2;;V,KFT:^YXNOI=QZ6_V\ M><5Y&:\1R3!!L;5L@7/F8H6YB>[B\^N-OTHVN6:G=X M.T)4A?1XRE8%;)??;N:D%.$7P'R_:]I;9HGEGPOC'-4NX9ZL9E?N'011+G]V MO[N!O<[V=A4,+E'B0TA"B3=]ODW,O[5UV\* M/;=::9#B;0>;J"Y0FG96,IY(2ZE9C.?ARX3)*N2A\<&?R .-SQM>H>YI!IZW MV^"G#)70?,,YH@>BH+D>E O?3/F<,<*L[T=-U=(O#(_:7,5/FARFR0/(+LBHO 9"B-\Y^DQ5$VNE3&5THAW+(SSVSH' MHF,BM"LF_1 /S;3ZN"QWC(2KIXQ_::VRN@<9,,;^6WA"5XJ+;!1["@O#A/UK+$4WW$DMN88& M7$':/I0T4-H[T&#N?#W7IL$=1"!95.A@E$'I3WWEG\C.__SI;PXC\BN-9-AC M(5K92M\)[0 0O4H*D!7B#!LKN46"R6V8"T,AZG89_ :7X+@N2?%QXH?8?S?' M>-Z\9:09?%T,C!XZWGSS01]M=U=)IT.P*0Q/HH+H5!7)/C704CV.[5_=)F(2XUH@E0#R%#JDSJ:S%9%UR__+7I*V$V M]1@)O^)\;"708W=6:60[?^A*.91P.63*ZQR8,]'XT8@N3[]Q-H&]/O82_2MP MS^8:FF8)-S, U\GSMRK1KTE[LQ3>;-E(! MX3@OJ5';]IZ6J;4ZC6W@+]#"U^5Q\?5ZB,;&-U.>U\M,("Q[M$U=C?2*4'5D M7G\;T4&EX\I-^..*TE5A==:E6!/QT&03*@=:S$U27[5D-:V!(J$3B,_*Y""N MAL0!5SIK\RM@YK6")UMO$G27^S#BC!38P*DMUO+2#&I4_*)#,3-%MK+A9RG= MA=608P$:( =P5N^3H9WI'0BGTE) M1JTWQ6/%/V%60;]SE(-1_GM:75M0_X3T-".[Y/5]9JG1_ 2C9+PK:[88$4@_ M&U(+,YOK_)Y[UN-L=7@;21[J/@.(17N=J<-!)ID/JCM)5N[#UR3M?LE(+HS' M-F:+V_#L7#$Q2Q'V!Y+^%A;R&N/6^5N.R/3DGNLQ1+]6V\VH3$JQDGL._?L* M$7RA)G!)"(8U3ODNO)P_Y" ^5U5:VU$ MNR1: #@I*F/$I5@NO$NENKFIN[:QIY_,+#FJ\=JW54I#\RA)@)"A::>%S%@S-Z1+ZG,Z:_S;=P_9?:,M@Q9]A .J['9_2X6S_& M76U#8[E84X):M\F]&2S([^E\)@9(92TKHO- A82^"GN!FDFK* ZB:Z1R K-[ M\%+OAS1Q>&=SU1W9RLQUT)A$%$?CWE4"+KQXN;S&GPA\C'1;=<.<-;QB,B<@ M(8Z:+=>HY\V0&1,!GNE;RUZT[;+WQ"Z(3]VZM &C2IC]LG+Z@)Q#2+!/8=AQ M-1/EE9$#;>ZR[*\7ZV!&G)QJBQ0%M0$:&F9(NBMMD_SLVB/(S;2&Y(A1(KPE+7K-P[RE2W,1A#([AC,S*J1#)L M2)Y%=\B_B'\+(:^X]QW\PXHG.Q! 8GE-^D")SLEUV^]HS?NZ.M<&A/J9Y27= MXM/UQ0##1GV@L!+#F#N&9W-WR$OIJXH9R:00_2H]ALUFX8#JPBG#JUHV1KAP MI!OPH;I[+C*W_SLYY/^MNX MO^'/;$A5TP:WR"S%S([',?!.27>VK)*U)*]^$ZFS15X#"0@$[""?@7L_RJG2 M[#U&9D=@&IDX>R/MH.ZOZ]W.PJ;M76*]]QP?O"A_"1OTZU9JYL^&-TAYOXE! MIFL%QZL_U]S.6VG(#V- 6^*U3_G*?Y ZD>1WFT M)V:BF#9JKE++I*/\WF?0'[.'IP ?R%<(T1(HT1I/1$5;F\GKZ0 M)GFAI=/7YF-JEK="#:!FM_#@J+ ?#.NVL&J7%;M &3UN2\:\X:M$YDA?F3E3 M"2Y-80"7>F5,BT,WEN3#8>J84Z?GO]WIV1+!AJQ%YO6TAJFP;&C2.7--2'JK M./J^*5O&I];VA]0]HX3HX#GK9OR2',H2OTNPU)XM50SVEI6!>5>9MS)!(?LF MBTDS%Y.=D@\K%O"T%!ZR-[NJA@.M,.8HGB;@ 2?@DHO_8+%<*QNKTXMP:)A_ MC01O9I(T:Z>G'Z)<\2SLF=-$/=Q$Y:3Q'J944F/*995&ZZ8.1M(UJ8/GK)OS M[XXP+%=V3:;O%(UH[Z:[2_1/N_LR2OI%Y+P(OQU MASV9.^< 3>[;$7[V\KK>K#K%]S__AMW6)LRJ9I7IASZ#S-]X?4T]+I]/'B(\ M.)-3Q$33S%31D\=(AE%;R-^Z3O @JYTA(>KGZ@C/,0=+30&L MP*6@1ZH?>[!>2.+C)JP"5FC)>@4YS]+L(TB-5Y, 3S>\EAAO/F-/I062. B1 MMBUI'5#Y=(8!!)<,NYCPVQNR@U01X]*-0(K8!T%=PL58!VX>M@>QT@<3VK($ M,5LBLS+Y[17.@1CBO4+$M./.--G\3ROZDWQU+EO^R\28<^]>2QE[8G(G+=<* MDO.E3JL%LFZ.9!VI.Y&,3:P1"#7!$>Z1;]-%K1RRL274\>(0#\6].;M)M)",+ M >1U\@J"P!+3<,^(MIW^'"=(?=VV8/BY9Q_-A4;'Z(8EJ+T9EACT'%' P0= MO256@-U&%21H%@CJTI"O@(/DD!55+[=V<+*N M=)X]Y8#Y>UP+I?T7)7TFFHT"ZJFWTNL^\PIE[L$<7'J$H-BD^V>XSA<:=]%- M*>*I_4X:%)O*F@L4(JR7L+B-'L)%"$(C08&W]#XPFUKLGW.M&(S[D=)/"VE8 M_@U>^I+@NXG62.>N>\?I:( B45*)?34"5*DMV*(J+=:.^!R$9IU"#*B!QL0 MW#^## M@M'\J;K/]CKAX;B6T?(76Y>(?6O3]HS\IJVYA>Z.T(V8L0)WH9U[8:37S.O( MU >7O%+4..OVK)IKIJ?IEUW8&[%R.J$*8B7&3!S7\%CXTAOKL5K\[NM_?+;X M>WN^^.+S+W__Y-'CIX6V91[\33Q'OO[V8D&2=\';/@%"/HFU__F7)T#(+S.2 M=&"B<3%*UR3QOI.F]^*3]&< $\ 0"73=CII+!MLPA(7@DS%>,54.O@31$IS_ M;R\ND,N.37&.4\],0Z?:LML!1?,%.>A?BK"GC;: OO.T990@.^34^CV(A51$!5JE.)L%7"F51*K- M$A9:HQ3/*R=TX=6KJ:%.Q'9GV\)Y% 0^9XM2U]5[X*C^TW9#\$#+)?OBL5KI@[8 M!U^0WJU8?$4NA-;UWG+MLE#'^LVW%V_!+'XEQ4T4;BE$OJ-J^WJN;E@.!NZ; MQO@X.^PF%A&%N.^J%MCSO%)IJ50(^YEI6WQ-T,;Y.]3&#*FG7]A)CN,ZV(H0 M\2Z7X)*]HD2Q8YR5O#Z_R$'L(XL,(88,#T@A.$;O@R?CT%Q$]KL:R"V:"GF>Q M+GMN_4X0N,H(R4R:+F7/<'#+)3#256+;:D]',*4$>:F"!8(#O'6!0X!XQ[N67+HX?E M[N^BL17A[+B%")YQI_PR8O0=.1!.A> ['.?9#Z\MR[,W8YABZH28Z2$ZP/:L MVQOV8#W-ITVEBET%FCU0C5%4V#JGW4JH-\X7?V\;)H7Y(5RS7PD%+I<,G71D M0K=MV7!:-,0 /U,T]NQ*Z:41@%&30T*'K_T>$]+NNY!J<\U9.3&X,#\0*E]!33(_) R5X56C7MG>N^[C?E7=ULNWOO.7\R4S=RS@P_7G(H%F7%3XL MJI(_<3%AO*/63;K0)"S3TX]7T2IYQDF!.2^G4?/19<7SQP4YR3- (*\=-TFB:BT:'VK53Z*[X72GQ(R9Y!UV:IYC_3I873*AB&%U^5F MF" $97S=D$P=C^-,$>!B\R3YARE]R2$XZ[9$3D'$,I% MVN68$'-,S2#*C&4]!1 5[X.)YPU,EV;,YRA2 +,GK!<,ZL<>9FGBG^DZXV64 M9R1CG=1P3N3@S,.1@FN ] O*^$ ISE!/'E2_" MNIL^N'-7-CGE/<>>P2U)T#'/.N$-4"Q$(KI8MKM*52BOFGE<0Q28<B MX!N\F%,SX@.N LURV3&!/!9:B:03&:79NIIQX ?WRY9NO MN/P7F8T0=O91;LHI* U,.#%SW=,">$@2 /B(O512?=PZ8X1G.9,0CT3-SHD@ M+A%/Y2H_!U*,IYE^P)F>W;'$*5M&E>_L.V&RAS8\,^Q"U^YVC"]BTNGLRZ>Y M>\"YBS ?1K#3/-R$H(8*J4S<8TAT=.2]/\)UT]Z*5>^]H+B R+6EBPON7"-* MBM:6USI-_P-.?TG3I,*>'F3350-7M$$[3Q-X<%7D:^(T80\X898W!2)]1WWU MDY GW8=CLRYOVDY[2\)^E?Z"&^OH*>A+3$>K^D0*WZ14K3*1=1YY&LL BZKK MVNXTZP_)#1*5 _IQMV,V]%6ESK/J'\YY45:A[V,;:_Q3U/^**@Q6?9V)IT^S M_("S['>JI$3NK%G6#0?#4N&*$L%E5B-5V?::TO%59%PZQU4'Q5Z9B@)SIOX9+,$/=W< M-_-O<0MG! -<[J?=&*WRBLQ2]B 0[^LPT-'7AX#$LC[#6_XU6X\$?,G:$WV*B]$0?:JBWLO<&%A=%3-9?*X;%N.+M MY(Y=)H6;J<)U'^F&\N7RJ]:#;2KT60QXWZX"TVX+/=%Z$YZ.!.NTPR_^1=O) M("XUJ+IJ.)7X4:W4+WE?YVKT(8)Z6I8%LFW _E0I/EKQX.+;WK1+S466LW:@J MEP"=->66O4X_':Q5KI/KE TF@GZ7L?W0P#P$8XF=],DKF&+K!+E#/R]\\J*8 M:&:QL"&;?HC=9;LTS)*7HLY81H^RFQP'X\@4V6O>H@Z$O3E,$8V*:UU.OBZ M09:FON[A"3RA%C\J:O$/)]3B__4;/NM@[*IE-]:Y0Y;UQ!BJ$0Y6<%P9L4X) MCA 7:<03TWG!9HJ]&D[[B9<9T5N[FC;6HOHJ6#Q4;>> M$MXYBEL[?JD9Z 3R>N#Y8.I#EY7R)(E.L[0\Q#%WFIZ'-G3";FF)EZA_-B4' MC<5=X0CE4^DN--8)E?=19S,RU-HQQ+&ZZ/;D;0SH%@T.A\(HIU/6JQ3H)+NN M*=IGM I.$_N0I39N9!,Z">$UCC1J2-P63"=1]@L1R$ &SZ15PJNLJBVAW8V/ ME\FU=)T44=H]\TU1=RW7ZP3+!8 M+_R^TA[537C'MBLYA65,#0:,FAA"60]\?@EE:U7Y@40A>(G--OUR_#_$%J %("*=QS31\&V%MX#*M:1N@ MD.#X3!R"_WZR%\YK))W6]^BFJ([0S^!F_!32!N^I.%U5XY< M?2HOJ8V9/P?-05AUU\&A$;]U?1:V?X7N@VW+Z3K'0HH?V'90_ I?3.QURBJT MK&]JKF)W<(3#A:OP?UD7^QBM9,Y9X0=]?I#UH((I?7YA&7C1'".!Z,OX5G+<5"LHT%V$H_SLK_7R':F/++X;RF%D M+!56:[]XU[2W8 '$8)!OQ[19$, -'X0COMSC__=$18D%7@C=H3;]0_V& 9O; M427?:,63]A-#B"F7P?]5L!*U"!O@5$#YG]15EM6BJH4$L6)D@*CHE0TN$>XS M$O! H6V6\E#KL>NJ?MK_+L,/VJN-+4B&%'""JPDJ*2+#16D(<)PW]2HVI?0 MA%;.)C(%>-+;ZU:!C#AD"J'XD>'U"U):_18D,-R%RO^N5^>+KT3W2CSG MRZXM5]ID;'E\MB4TBMNV'QSQ/6Q@*01/E]5P2Y6Z3+HFHFBU[DA<-R!6(F]D M-W9+TO!BSR0R-X>);O7[Z@T8+TJF:M'S0B+T0B0GZGA?^R(F?X\,>9AR)7IV M^Q+RK*27'=[@DNY.-0R*)0D9*)RT-'EHU#7Z6(!&J46W6HZQ&)+=(;DL/5<3 M%D9[R_I(,X.)WFR\!4*7RRHB!U>88-X880"8I(B1[/J\C#6,?-&4G(7NK+%@ M'Z.E5BNR#CX?17-EO>TGIZ*8Y,+6+8[G75A?2H8;C8R0+F&?TGE6CCWK^HGJ M"GU(L)#2WU)2I'NN*/,"U T8Z6UQP7BG;?EN_B[; M8FVV\K7!!B"E-$WN>_QOJ907D?2&$TT#2,W>+:(&3G0 MEC+;G5A.\LK6[(.6I'D:;#I,)LDE,9C&D+8=X@\0SP/L.[DQ43=60\J;Q^"# M9XNJN2JOQ'6S8<.C@C\QH=4*QHU9I43EML"R:&@,$:T_>F8>&O[[\3-/CR[T3+_/SRO#([>^#%$R#XS>.V.DI[>P M6[RI+BF">6VV<2V*)-FCN6?7AW5G )/=NE-S30GD7.,KX 5 M&9[-G=*[ZWT?]F\INEDL_0"+:U## 8).2F#WP[BZ8NN*O2]N1*HGX9]4.:R- ML=*>QC-69AY*%WT>99&7H>3CI>[2&\(BIGL.C.Y">(BY.Q<&UQ:=6>#A*%\T0"VQ8 8Q=EQ' MT5:R;5Z1V17XL/B N5=3]_VH;(EE,(^=/B+I?@V4']]48?=T]+L?QF;)[]M7 M]4_06.*P?8TAAN&>B=Y?#LRF&&RS20?S=.!EY8PLV$\I?+_#";[S21PEG__Q M-P??^95&,MF0/A-.WX$6B79UU>L\K2W>GSK6]980,96S)0N1$\[ _ASL[C61 M+$X?'/8F/6%2K9$(A/686][JH >5#2[!@"2G+!A.-$S4OY_D$9.HBR'X":/T MUT+97R-UH0SY8M578',DIYM.A3SA&:,3GW(,1[+RN3;5%6N4,&B_'I"X(3$? M_\+L!(*$9:WYE;&+YI2&%S$2<3K69)B3GXHTC!S-VK[>'B;H\_' M::"#; #9<9YJP.)Z$T!T7.20?Y"0:%N\1S*EGC]YBF4T69BS(WM"K] M\Y@@^$I=X7+5[HQG*08+2'N4TKBM+M ,7W3?GE$;"GE\,D 2(O5C0ZD\#),& M2?(V_=VCP5P5I)Q9-LU82K[F^;??Z29W?@14Y-="&D--IIP:8#^5N+SHC-]G MKAO&27GD@G^[H[)&O_@=TM5.Y2H,T57;@2]\G24):3CI:W3GRRHL7S@5PBE% MS]Z[<%-D@Z '_9?PJH2!>5PLGCQZ\N2S*&+$LM.2^G;XF3"75^*7R_71QT_O M=&#-B38'5?9IBKX^_P?N@GV^RB2MJ_4:3TL>=D]%O[J_+DP&5U1C)6NPJF[: M(6U02+3%#6J%T)*U)(-EW/<#D<^*VZV"50TG?DTC:V_14%\M$J[I-Y[CGJP_ MZ9(PDS/OBH.;#U?,LKN\LSAH] R D678[RYZ9MY-7A*3'W+^IF&/1"Z[[,W< MM";$_7<=1^Q_;L-2&VC=''7-"*F,L),Y*.+&'KI*:BVDLGR^^+?U"P4&! M-V$$1W@;3D-;+31&U@>>W^A6QDZ?QD)JS1SD%/(^69F*L5&@#2[ZVXJ?JZ3@ M:]=V"CZ60T!)O#$TE#RX8J9IK&>,#\I)E=O<$+LHR)4QM0!Z%H1U],807ESO M"^LQPTJH@3DQ%%-G2@DUG330/9LYHY*[>S,C*968Q@GO%[:6=%G$*Q2"L$#% M$HW%(D-U":Y_FJ1%3AGHIC0K318)/B'2CCL#+K^7E-3D)S555X/QJV.$F0Y'P**W3$ M?/4+TB1,D];1XTJ5#:6.8(NJ]B[SK>/>]X8INEA9E<"=B85?YF'$EC&'NH[I M+M5MA0G3?:9H(T&TPOU*%,IG%,@+#TJ.2YW%%[OVUK$)'V,D\WWE(&&5SM)= M$\[>_>=/'WW%G[Z6F;:/X2).NB6F49(S G>MEL0A%/C^LI5B5"9LU--AJ044 M=_TY,V M5,L*RSA$9(^(CX KH20Z%!ZJX12*#;$,%)7[PN6P-B7DI7W'.B=PR#3JIX*P-Z3NV,N2WJH'$1RX*@4YQ>*"#XW/Z.#L6X(R:$F!5\XPV5+DBH8GX1[@ M?7S$+LW!AAID0/E* +ALEU$@-P@O9(G9">+?MXCD7<*.7GK96 MN=UR>\U*<%Y+-3GQXUXDNIFN1 @+87'=VS@46*I7)7C3)$F^5 I)FN78,G(_ M#ATFP1,MXV$"YW445*KSC([R:# -9;Q[>B9[5Z'M#GFLX@RJ%Z)F5$@2<%2$ MA=?QV3,IE'OXQT[48*08I':+BU;K==4EG^K: P#!Z7 !L9@H:Y?$JG M.S@)P2=&5] 53IS2#\7TZ."'L\4ZDRH+MU(6*W&Z@=:/"66J$="G%W+L?>OV M/@Y@U'K/QH:*<>6.UF)NE4*D(JA\WD;-U89R=)2BD?IS$YZ!:%BW1/RQBY]B M1Q6N"ZC$H*3YJJ>%\QA/^?<'A>?CN8Y:XBWCO<@M[ M 6H>'C8"YO YA)(TYR'Q('(;>[T8U44P"ED-+[5^B>W?7:GP^@T$>)$!C$G\ MNXT8)9M\=*)S-&]A!K,^[/S)@@(O\ MB>JW@@I'$YVY$+?]6DFQT*ICL+,IA=FBKZIW<-D3D><#JJ]'Z8V( 8O.HI;8 M5@=F;7H8H$=@1[KER#>0\6XW&X!*)V22?-Q(_G).-I=]@@.K)55:I>POLAJ@ M5A9=U+H-IX)G7W:4B;/0M(QN,6,>BH>C__;%($K\$Z9%[2D*9"*JELT3C5Z;4"N>186,112YXTTG5?JJ9?'CG16G#/A=)GUZ&"X-\+V2D M2\"^N+5. 'DIX2Q%]+V,*CMV ?/>FP8%&L*C^3TE6M*^LL8L>2C0M]XL;== MQM%MZYNQ2?/UJX-6,.44RXT?5LG]]Z5;K+KREC\#:TW4=VF\Z%HKL1E1XV#=^L8T;TZ:L.GM3<&;'HN6$7WH MKE5H#YQ'I7Q8-C.7&.9B!O>"T&U5)4W1U5(OERQ\7[MH@2?;ZMBT1WEC'9QY MS4/)/C&ZC:I1P-T!O?78W &)=1>;Y>66G$S>WUX(+Y,^7?&AHX![@BV (9G^ MINT._T0AF>MQLR;G.RE0TY"XL)#G4Q8O<*E24M067N4EBG?'GH M=PFC1P*TA1U[4XO(8SYI:T[K#-$H&GST][.FBN_$Q3PMVXQ<\CQ.'RZ=IO_\ MC\=?/GH&35\9>/Y+,OJSLU8W-L4_A*_UJWKI,M,EM$VTB$A<%PK>#1NSI%HC M('_]==E9D'S';,>BJQ027*J*?XRS)P7 .'OE#$%FE8,O6W7T$H>*)'DW%O_5 MGO42JI=DAG!;AD)R1RV^.'U>6^$VK-.; MA'/[F^JJ[CE;D#<.;L)_]\MR5TDG7MR8LF#LV11>(8H"8;=7AH3H*@?T-V)3 M=MZ68[]P(S)W:>\L<7^(TF?0&3K=VT>X*R?I2,#"_E0U6!4O:$!>QP&)Y -P M"?_TXO4;,_"$*TE_VQ@B.4)(ZI7VR"7G-QN. ,D@WI M"*+;O@\CRM5!=6 T )GLW?#.#--5_.+:^=]"_E5P,U3PFM$O2M)"Y[9=^+4GNL2_%F%#/- :9NRS4K[&6!%WD\$8T<31LZOO SR<2#F)>_+M.5%.23_ ;\"Q)D M-2/K$Y-N\M*9D^ +C_E6GX,[)'#+?L'NS:(;"0S&_4K)U*;7P[FK4*UV'/I: MZ./I#GF_AV&\^#_^>EYH]+FE7OE\ZV>B]6+B-Y1'=K$$M$6M*4]3^/1>[@WY M;;K(YH&5NY"5RV]B>%6U9M&8Q;HL!@Y8+R(P5WB7MYN+J[%>24H8DR3]0KU5 MJP531R 'A=?TYL#@P#I?/)]BF_A-:O"JUU=MI]X5$LYP[4%8+5._,$ZA238; M81R8$@T1A3#:5]^E8IO ICS3!UGJBN"YE?2A"5JU$),OCZG,5[.T&[%SQ[E; MFUIEI+0(J/X6H:7*;CM7Q*=]X_O72^9CI\^4\=$3 &!Q'-\YD8#>GU./?!O\ MYA+V?5?V6LMUGSQ7/^*UG+!4 _H=?4F*SL^?O[Z0:O-G43XB.TO"**>UID=P MHOX>7!&KS2[1-0JXT'#VH-L@7E";3.)22()P=Q1V%NL!*88+>_YXFMR(8)[ M#:-%*V(FC,U0NH Y ?&;.\T*JRD8K0(*+\)DPJLA40ZLQ6$_Q?E>;=I+!NYA MI'8&W@ \!S- Q_/(#WL X^J:!G*$NXUW?L[RX2CV>6PB;O0(;23!=VDUW]<0 M@9(S/%'/&.QR;()^9:*;N$)QG-1(<)<'^PGR ?9< *TA:'$Z4F?RM%$6W7A( MP=_A$Q6&<#L5AS^)M??T\:DX_,N,9#S%M2-54)9)JDFB!TL(^,V>XY]B'P'# M45!?TUKRG8U!'"$U*\]@8"?1[$X/C_WU2/VQ8>"^#@=/.)&6BXLPXUE@R)G* M356NHC=,.L\[^L_@!7W^Y=-GP;,*0TW_B[YX?/3T_]6#=V@)ZGW;=IO5+05> MW)5G$+A(\+RLF-C&X-7[JNS$*2#GA8X^#L_/%]\E4EJSR3^0JUL]^;2J;U1F&0W6GSE[]I+H/1 +O0Z'F\*HZ*$NEH@^]4\" M<7K\QS]^R0I46VZKDQ*372XFX]Y6R^LFK.HK+K38=-'%31A(?G>Q9!*D/[]\ M?7%Q$&(PWRLRK8'QNHR$2E* :+O8.Q?3#;$_I_8LBCZMB))%KUC; [>;-CO M1'1N3JPJNCXZP@!\SC6AIX6K$&XG*0 MNQQU%>3M'!TR%GY8I]0N+9)9+J5F MB-6#.=',Q$D!=1NF#M*XV>PI>V]24!G86#%*=]#$=A4NV.XKH6-!ZM(2DQQP M4I>AROE"::^.>F*\%K*]@^TFN:CT'8S(R([,Y2B9+W L<41,5.9I5A'$"COT M&\BS$^>1#TAFP@OMW.3%-C88 0UP,ZLZ-EJEKH!8EJ25*WD8["5YHR.LI29B MC]X;\:P&\ZD)A'G-3=VUL4E:EAK^.6[I!;$T#[5$3O4YR@@V MTA49+"ARNPP 5R";T$5=ES^5W8HB?\?3%'RE+5E9V7V:&Q"V]XT06-'YTG)Z MQV1Q^W1K);W*V+)L+F*?+H[5<%RM#+Y!;4FMFA[VS2)[4^ZTQAJ+<8K!"Q*: M(U]QS&2!V;'&F$A\NJ%,>;N&ZQ-V'HXN;M ;2G)J>/%UX&CJN->[F#X@:9*" M(U_$1FAA$>2C;.RBBY8Z$3+PYG5%/C)[/8SVHLH]IS&DP]8?66PUZ/7I+(\4 M#ADZP5T3S0LU=1@QMJ2$U?2BREWK1B M\2DAP:4Q@KI+KIX;?%?JA5#D5=D18X>2FP_#A$7V7;\$"DZN%2ZG7YO/ &7\9'FW3+E'9G O;N(-$T,ZNE]:T?-O=P%!G9*[15F$M\=+Q M'7>7K);.#=-0[RJT@KJ&8H4_4"$A1J9A=Q#TD1JZ_AU&ER=/ M6"[FUZH76M\V42J1(4HG(M9_<3(&CX5/7VIE .2Q7E(G-)_\'$I$WI4IMMK# MW#6O8M/ /&4Y@H=C+.YG))LD$G[W.6^%Q@#AIQU2],D-80=GGEVGGVIF@_40 M)"M+R]12B6-&YK9+OE38MR*#N<=R(,\P]S/@D_?F>0+*D'Z'O@*@:=A[. +E M2;7[@BGDRIS7!@E$N"H9 *YB,JQ(?TM#$4':DFBUCKEAO^,DY,^99LE .6Z; MUN)H\'D7C' Q5+7P:MD3$ZTXEG?9IR+S2V!H?-YN)90DN,@^W88YR8;M ".#Q.G>.8)L.G?JP='N] M83AN:9O<5+U!P.6&5)"]85]'>V#>^TZ44X31E3;\B^ <:U:.D2&\6;CAH3GC M7230YDB_[]HF; 5Q]'W/L\PL&TJ\$)$']9>6E#1<2A*.A"5H3BE7K;Q4[*<, M7 *.?I:$%R59AQ5CNE,'3#/-/XR]]*1<[I5.R@Q2& [ 5N#26O])INTEQL2- M3C4W-FY@/F!1S P/I!E,]@E4#+!ITHERJOU]$AF'IT].M;\';"[0?1B&CKA! M^"ASX9J0;?1FP'J-]]9V3LR970VT*?5X)?B>5VF_;%:&%C!IP;O78BO'+ M"!?"C'N?+!P+\)[M#0XM/!('C+^30-B1L-DJ@P*)=L0>7)[J)_9ISRW%D6Y0 M__M#8I.3SN<'ZWP:,"#CTX//J<@AJV=6<8UWU>K#7+,VC=0$3(A0F3B#+40[ M*?8^X(1+:S#RV2X/ 30>@Z K:\%VU$X4RNJ?$_5,2BRNRYNV@_N&:AFL3-[' M71%%)"M7VR#;^<:FT^KXB%7A6KS("[Q=ER*< =W>9%Y'#'EDE(9 MK$)!;B0=?.YN(6@%:,')>'JE#:(/DREI1="E"Q M,M9.O+6];(5@6;4^[.R,,IEW#&VW MRV1A>-N^4X 4B;YJ,Y'#Z1&+.YH2\"Z*-*/G"-$:K;N(LBRT -SG!K9K!"I) MU6' TGQQ.Y,&+U?1E2,L/5RX MHD"QB$7GLNM*.8R\>Q*SHBDJB(@'R%PQ#(.LTI[GE=8DH>FH<;J>X*LK0.>H M>ZJE#MV5-UQ%BC,"P]?JT0RITAX%Z(GF6:8N>TYF%2AZ@YC MW) 4ZH%ZQJ&B!*.!9Q[X2!G1Z=V9B8WQB$3^7G>J9--=I30?#)^)#(AZ'!R1&@X MG.,PV]3A55;:_^:NUU34%!36;&(Y'B5 M#J:Z$H0X9J"KQ#-859="!,F=[RH*!8--\Y,XAF[>;(3?G[ 5#XBM M &X05>4Y:IWJQ^!+:0^*$NW/(&]=]B)C]TWDZ"<%TT3MRPBXRWG2Y^,[L=Y> MZ]@J= '#?4"(2$4-T@'V/B6C'$3CB905YV9$?\!GF.%9_OL4^SQ<[/-J0ET+ MQ3RFT>)I -LA/+*ZF]!?3_>$]JD):%AHY/J18BPH#$5PK.:]!\(?9J =N5&Z M"[F9A1TPG;HRS'4F-&1.;8:&.+S.G0?'G73WW/E\D>XY M0*XBJ79P]EK2B3YT%#G>G^R!$@)NNKTJA8^Q 7[*;*VX[>FG3%''D&4XRG4? MQD9Y3511WI ?W @FS'[2_*=CQ-&_\1BQU&VUYV8 3[K;YV?"AYR=IYW\BQA_ M6&S=G6GO@JQ)9++N7I*R+)2FHJH1W' S('C@D'?@,)]IX9?R?4BX"U'5:?(? M;O*?'[) M@8 9I40?LTKPG8[&4F64CG0\>3Y,W=CUX^5K8)RTW(O&]Q)_Q32 M".Z2WZ?]_U&6@.[]@_C0Z>3%QD4B2X1"@>GFN#8T08"AH>O&L<)ZT:*9X]DN M!0L15=K9G9B+Y,;36GG(M?*B[IV-P(@G1X>/]E;)=[FK'4WDU4!=Z]QB%'EA M,I9*E:8/?UA7'1=<2#V2DW7>*8)N$*M[1_RKUMYNO,Z3(^ JJ#SW"4'Y#VX1O$Y&9:\"R[RWKHE$]5,\'I,+.ZY(JERSVL MS^3*4R^,N2+$&4_5_ZQK$=3,IVWU44VP<$LP*Y$112!<65?BQL]C()1^D /O ML;?PV':>)UY31%FYN"55388I-3;X M >?X9,(C7B4Q!&1^KN#KMA7#$QZ;.V8Z^;373W-'X'1@.JQ:#JK@030 M4M$QUL)2_0)2TTQ>>G%;"2E:I9VO@H!Q+(7;2]U.DE6-QR==3!X@5[I!/EM0!XRU@/!M491+FRJ^8FT._<+H$?45&BL;8"> M=4V GX$94 Q)ARAIX.B.&8KRO#,69GC\:J?>*-J;?;N2QS9LM]IK%"GVRF[[ M032/GU+U>HZA0\9KHB09M@$#\M8C\_XK*\[]Q3A'F9K6JH^[/'W1"_%6VNRF M!%VV.$$(Y:)U=_Z!7,6A] Z-17Y M\H5#J>I_P2>\@AS 7UX\OYCSER_+Y;NKCIB#S^0=U_B?9Q_KC0OK@03@'<;V MUW/L_Y__#QEC44CZX()^L(?/W_[/HT>/"XV7T73M>6..\.S^_KI"(>FV$H1( M29G-NN'Z4'0TT4L! MX"0A)D1]!$9B/#"3EHD,ES'QJCB)2)UE(;4%4)./W5V5-$-<=G>$KYDFGR@> M*;TB_ZEP:\/&K2KJ(UT8KW3/+4X)-0>_PZ9^5VWJZ[9=X58J$Q[%ZXO%U]]> MQ,XC+PGF-9O2MG/I-U8_5#,'D[,[4O3I.(HT@70&3G?!*CSMC:C*.6(^YPY0 MKCB,'7?;I(\%W#9JC>@AU4Y8)F4*IE AWT[/;%9#MKW5/)6V_D0-G0,]K@+. M)GTXNA.%B4-4E+2>62,@!VA'JOU5*.;U=A3NSES M=V$NW!(UE,7YXG7$R*OZ)6T>P'-$BM G=)SKUK, 0YDG :T.3!L5_)TC$KN= M;0]QPV;X5&KGG9)8Q*FX'N3.(<)"WS!XK@I5P@"\XXEZ_^@!A@DD[JEWBB8=4&9;0\QEB.X3*D06 M3J@V*B\Z-BOI-UW1*GWW'H&_[[=M= G'GAOQAH7AT;U11%]RXT9\5:8-]1E? MC59ORGJC(>MX+\_C2Y.QC!W,;EF3#//J?(32\,LJQI<:92W#A:IT:%DR1I1KU'KCN5L=^-.CY^A.7$4 MC-_?C830*Q;?3JQU^)+4$9IP8E$X^)H+0L>9E&'CR)8Q$@TXL*G+7<4NR7(7 M^1' _N&PJ7ES $R[I\=7J1LZ2I&%2P]Q8['/8$6@?2.VD1:IP_'U MF,Y%Y R*"MB6"D2:^4A;[3JRLK"X46&NJ0;2EK#"Y8=/K<>WB('-W)?P+[8H M85J^"BX/=,/2]3 #=$*.*2-5L))0S)I,_= MAE.6/'B&'/(C!L@4\#T,E4Z'$P M1T9%Z_M\@%,\0].Q"U%^>040\&WX('BOO5/[L9GR?.P@,D^T\@8#_$I\D=R. MM&_4IQJE< &)Y;PG2^*%M/M W183X?.;(?5Y:/4NA2QQ6U6#^ )1*! CT#\+C$-:R2EAA'8ML>)&7XNL&H6DMZMT2M3M2@7^>*&)YQ?88PF=I2(T(E$@4?COUC3X?_EJ03^&!",L?T<.+;ZI91EYP3.TYN@;#D6;_@^TQO M)HYP6YF'E2XSO-OM=;M%F,7O2X-L[!7>GW+8&/SN7R',KX=$&E[R>9 A:%*Z MU8.70JIQ:4R-1Y@83/<.Y9TO-W5_KK#\0=+]SVX)5!V5/8CN8]IKPXR_P/+% MSO7.MMLP5-O=(.Y@*1 [F[K4:1=LM9X XN3[]SLHXON;=NV_F[X>E[+2$A\.W_JS3R%A[+;#9<"9&>M@K[<1+"1CZ5_+\EG M/9DZE9?1I/]<.'U\J_Y[%1U'N=]7Y0_D'V0*#X2:(_2YY\8FCSI/U?!/8OZ? M?G&JAO\R(WDPC4(FIJ!<0?E#VTE*>&K(*(?0(Y=N8M=A@U5IAF:>2AT.ODMM ML/44@=/H3Q@P3G#@0P6+#<9[&5LL9Q(JFD&+/6#?5CEWY[M!;T8.Y&I MSR25G8E!37ZFA4 *04+$RJJW(L-Y?":7:Q9M-TFNIMF:$%I2+D@.082O3H#- MYF.2 L+R$(D7U??2SY,+=TIJI6*Z3Q'IH;FC$N' M80&Z]2LGM+!, 6&69$^D'[AQ15@?AA01W&EIO)LJC$/PB+_C' 9*D7//FBVM MV58\]0[(D=(WI"*;@AUG\B["0H;RFVU_Y]*L:YJS!%.GV9WH32XI&,;#P0S( M$3J;WO-ML,U5F%>&&*R\)\J/L&3"OTTY-LMK1]Y\OGC;LG"]]+\.95JL\@ZC M)BWB]KK9M M^45FQH2;I$J2I[E'?4<;=O93Y- BIT.BS$B7^:&M\4_MRN8$*EL4HU?AW%ZL M'N)&Z4TL^2CH*;:54Q0.BYD7$DVHRE6TXM,# -%D/X0+53%*Y,<5EA^Y,M]^[P^" M).U_?,;DX*QRFV^_>/[F%:;XNMKL- ^E\/;)=$?*H+E9;]AE"'^E/L%Z&"5? M85^NK?,0.9@$B&XX]53$5A^3)O6MHX+Q.N-_9R]8W92:A*WJ,",D4T/ F5B1 M>?[--X50J0*/U7C@'"-;;^HP\.U:EFQ<^C-O[9=GU70MNWE(#D.559VA:4Y: M$LZ^GJJF''TVK<$Z+<&H2#PE+7!.',-T$J9HWQ7P:F)5J\D^3 K.!S2(@Q4< M8V>98X'F"[IO$A/ZJ@W_8&)?5JT=^XBJ2>D1,NPQ$D%;SMC*%S>,A8#WP_8V MV'^')?S>IFS4OQC:L%&=64EN<[[X M-H0VK?I'*,%8DGGL31)<3KV$87N[;1NB=58V"RQ*,,4N#%6WCY(77"&E3YU@ MF\EA<.B*UT5BG&G -3,>J;FE0U"QH1!\BU>L5G8Q\FO# M&;YBAEI:CLOE*.31J^@O*,<'D>E>1(M5ZQJCD9'2:6/BM;)#D=J96,)%!8: M30O%QW=DO%S/F@@A&4_!C&475BD!596")U8^5J-2G_!YC?2$/ZP-BGB9EMW" MZMJ4+ B^32LF*H"M"ZKC6+F<5-KGJC%@K[,(60RP"\F9S3^Z+-2^&"L)\#$Y MP%3X+R+(*M\UQ6&@*P4E$3,L]]H##CDY3R4%<*<1,T,L(\Y#7+K2PZP74TA' M/QV*\]5=:3Q-U>QG6;S9UVJ[8 M/##%?EH_M!RN5>/9B0LG$C9#\&0A;]V#I2)PSQMH2+[['/]X0J% MPMX=K$4S+\#;@81J CK2=T!G<>BPX\5U1MHMM<3 \JXID M&[I*<=.M8%LJZY>1-:O.[I1@;L)2Q%A9DDL!EEI#7VL!T7? $&%N>*$R5<'A M>2%FG$J$./0:_/,PZ7D\ MHV*RJ6GF;PG;>.ES_^$L0,=9\$5.XA"?AF5X^N5OKJS[J0SM"Q?6T9;=5%>H MVT@ *6@KS@+"OTFC3GY,LCX!@ W>2Q]^4M_0 3QX]?HR[ VK# M3;LP[CWC-G'<1->0TF^[GKN*R0TF2BRZ2I;_LI0PIFE927X8BJ+<],S50L7,)_T@(3:JT4UBBY#C[F* MF4(7MQA3? 0: MFY]IL FWL")CT7,M6SEDA),,-MBMG&]BJD70V8"_QT+ 9&O7ZPQH0P-$C=ME M1\4^&:M?8:02JC?SN5,3%SU2]U!'6*QZ>QVUVJ19F]]/3$G8S\%R]D@_,,;HML>-)3E)6 M'[=QL&L6 3VF8D3PDZXM!0F(W(:0X?,.C4H9,Y04;+4HDJ/E7V036/C'$WB# M-"CIZF)L7;'X7?W9Q"#U6X+3;-M-#"H M\J=F*WX'CX9MH9^Y@A6R:(8'^%V=/2@*-&TWK<\]:F2\P$':>$(5DJFZ M\OQ"61AH'"W8(<$QY21=V(%I0UUT2OB7S(9C8, M 3\^4U1R"7 2/++,U=K:=YI6'\TE==OFP !P], L$K:>!L? 0Z&FC [COOC$ MH60-ZQ_']R\,7N56E/M;7*I=[1=L(D- M%\G]5!QA;>T?CC$,CLF\^5/G_^Z,X-X?#CT'%3B%@!-GK:U$-H&G-9B+W9AH M(SG1>$JU2>5^;':$SUF"5NE(SWDF3B-!FK F.RSVG+2M5G8FY4*[%'"*BP@E MEII/Y.)4OR-_B%]M^NJ6'X<_ :4,KHAM&4GN*/G'2#+&:HEQ[%EG)58TUYOQ M1V[_ERO:?L*T7G6EY5U[2=P:1GQ(2EBBNKM)B7;#0(63GAI:)<-,U] 1\?GK MR.Q%9&AT6P6*^X@X"3@@^X6?64R-D.F2MS1=.^48M!3(CA'?CL,HR%=PC=SI\W)K;>F2\P1O<>CWV7 MY@T&TI50"3$C-SEOW)!'6(^;;->I<7%Y2:X>_I.6YPLZ/R]< MZ@9>Q<7?B;MS_@I?//KB=Y>?_>[)9TG&A\&8'6B*EN^9:#U5BS\)\_+TOWYS MU>)?:21C(9:"+E@MP22@,:F;@E,3<^@]2G99K' _4=;($$C^J)V]KQYY]]ZXT+MRR*N^E>:? MK(LG20XB>SU7YF"Q&F1H&\!M)^V![*#1M,SY9XM_B(M):53Z9?"\EZ(C@3#3 M#?<=H-3Y475X ,NASJF'7M? 2F3@B)P?3MB14S2:\6:;#YZPA7M_;-LV?-M5 MN05SC"[BT>7F0W!+%+LL@=YSA;$A ,ERV8U9Q^W/8=I>!.^#^ BM=I;^IJ!B077E0Q.=<-SA-:^YO[?G MB\>/BB^??ED\_<-CNY9PMX<_R>)D?(F^(2>X^L4_*0CZT='++ZMZ)\HF?V\1 M%_ZM&@:FY/G+&';YX\ >4W 15+Q>T$^LHCOOXBT>+;;@I!=EXTK]>_.U_O_CZ^:L)F"9] 1+]6XHT MA#RO>U8,V)-'SUZ771F"R]WUXN4_\:?'SV"ML+]@(-SKU(HDIHM91&F@RC8G.@QB#OC5)I?6#D-.=O:,ZWGR1V*\--QN>/AO MP^Y__,1F, SWAI*1%K6_ D?XXJNV?3=I5;)Q3F:@CRN#+WN.T; >NS#5%2MK M1U)Y\-$.1@8X0:CIG8[8OCS^O(@")8?LR]_&71AWL2.8#?Y+:G."@7[9+,\+ MX';)#]$21\%?-\.3V9R#YN,#[(,QC=]M%'A%/TAYL1,#BU7)H\71L'3Z'WP_F1N1! M;NJKEAHMP'/*^%B&$=V18O(H!9T\G[.9W^S'-[L".:"4I:E#:A@1B^.>0UTK M5VTW!'-6MPO1!B?3896@$L>;"9=X)(*"$'9A@($G3@HB,K[[E.."?+_Y^P7FZ%]WYXGDX'7:4 M%*#F;A'$I&=O2@%M,>9,VDGZR3BP'9R,CF$O\^L0L)98":X:WBWA65,TPO-_ M/E_\*:S;W52I*VR(1LJ&"EFM,UG?(ICD&PKT.*O*W6UUZ2D5Y 3DFJ1V>%,% M\5( M9%CA0L"TY?&P\AR6=?59M6K!RU]3(?ZE^:N%;%U*(-)BUD8;^N4HI0Y M\C9CDJI)6Z*^'CLK][!-SNJ2<8D*3A5I_*)H4!37T5@FE$ MP)_AXZ\ !GLI9!CA(;ZKK[;EV<5FU4%7,?SF;=MN_E0U(98A55R,2$=0(^F% M7@DP5L#_[IDD<^!:[W 2;4 3Q14H%)2FCSGS9$*)HS.MA9\$;[8;.S!21*7* MN*O?MWIL^#$OO9BP.(#/X>(=I(<29BW;^E:[5]'%& I,.P"CB/F%J8U*KCE?J85EJR9A[LR0FP0V0KV M\AT$B8ER$1>6[/=)BBZQ_&^O1Z%>9UL4[E*D*Y@2V.'W\.A3@Z;K00UT7!.' M&FW\4\Y\AW?S9& ]8^QTC+4A765QV6]G#RQK?(TYM8?C1MW:(=I$A:#'W8[B$5?2L--Q:TUODL]ME&L0WP"\(QR(D[('UAB,\DU M.XBOZ>'QS\=>8P!_#CI'UL')CUNF\VV".<-8<$"-3FU.SLM).D,:< _\V2H4 MK6JWQ$5RH,O) < +1\\JDM_$+Y)4E$S]V]:P/9%)C+I:_76[657LXV=(6Z,2 M+&]:3B?TU3"$Q<4H"#8K0E)D]YK5RYM1RO-;XE1J_R36_=,_G$KMO\Q(SA;H MN+E%&F:4"80!8V*RB_>IX5&PN><]S"W3)4 VLOW4 M!ID.+X"\/N!3TKK]$6P)WL7C3*NU4!W\:;H2Q\;%6-3?@@O;58C6P(3JD8@% M0RF[P"!.:,"JH0]^J.8P'#*"W+DL&9RZD[>0V,[>S;F9?;59G\6GE(Q7^("< M%*JN)!V^EV!)6(JN(LMX\H:+*S,)]I1X8Q4W9B5:B"P&[ +."8CI/>S^;\;F M40-*3K%W4Q+;^X8JX5P5$^%@\WY MXFOAJ1+O*%WEAQ]7IC=YY G(*R9"?!3/)##H@1&-"@9H\XMZ@/9QA0_OPRX8 M@FC:QZ],EN\(?4A^HV" VB7[>\Q6R:^$4LH4]BD+0F75"/:7 P"3'-?Q[7/5 M"F$MPBH1CA:NA"C&:-S985_3+B*=C?"%?55V:8[!13K/OW&ZSZ6I'BJK-A.H M WMOV,WC+E:.>X%)_L9S9ZYW1LD,-O>*,/C$]5YCK?)4$:=T!>Z_L M;C6GB3R0Z$MZO6O1[B:AUKOENR&YO6F74B1AB6PK0V&I34B44)^#9Y+3I?=-T>]+[NL_REZE>F M 2J'HXKIJ/[[0\[U'>^GL.G7PW]__F5F[\]^18,/E-J7SWZ]!HQT;!X_/?^" MQH)7 '/1SU* 8X+1@AU9L!VQ@!@#_JQBF;KY5HYGIVE\N&F\"4X^3V*]O20Q M*%C],$>X,3^ZOH*I?CNEYQENKG:A6>+T0K9TF^Z/L6?%Q M@E-3E:Q&3:=^\!&[$>GO7.TB&'5)6\>SB7;X#&J9E6,RPMA5U5: M;EQ\<"TBT96)-:KJA/"RET;QVMPZ.K;EGBO^2@.^+W?6^#SYK M&+#3"GK %22H=4=F0&H"([OE1-Q&:8'3##SD# @%+"-,PX:FQ![ M"H%)&WQY.- L<^K""R3X-58,!GRCE8/.316:/&6_HE/3&/CT/):;&/L>I0). M9O3C',1(,C!GDJ.;%BPI:6Q=-;5IS+91AX=G_'#V]31]#WH*DN(:31\"TRP$ MC@&.P6P(>\N&.R/WXOQ<>-[#\W5"X7Q4%,X??W,HG-/^_M#]K0?C4/Z8)O1H MNQ-B3]*2NW)/BIS\O9/%_0@SPI[H^;4PG M"K(ZH9IJ+S=28R17>PGM2!286_J%!<&4Y?#IX++Q&DC[TYIXP#5!6![NK?0, M?;7/+W%A">C<\*6P,H 1 <25 M4$7Z_#03#S@3U /1#5K>I7\RAK7.M&6+F&2(MI'3#5)SI1HI;:Q.JH"G:7O M:9.R%^NNBC#"&$ZJI=2Y%V'6NH364UB0(O3!@P-B-OC*WEHG!\#.U;X3Z,6BA#;$,]J/6E(.(&Z?F*L6+@;; M8(O+-XO(@+.BIK.N,)!+?-;(6A.&:=7&6 5 E^E)@!,?.B4$.1\JN,,)E3>1 MU!X_2OQ.G%RVQ13*%S J*6RC"&E!#G2(72NM]6U2#@^74=L]>E M/77D9[87P//+LQL! XTLJ M8>C"=(O9@?R_>JRH<4Q(VS%%$K'&JEA]NU6Y) MX&()4)L\"[*V>>+ .&48.PHV((#'EFDZ" .NO<2@<$8.0.FO,.SKL6]$J; ]VE5@E2GJK21Y_"&00]%1Q"REF&3E^5*G%%EUFRJ M*Z'SKCIJ/TWQ?P+5FJ)"CK'?S:'O::H'G#Y2#0 ZIG\7K&^81>M".:1(XZ#+ M1RM'\R(>ZM?AS^%5@-*#&Y0>[\"'F1S-!%;L61=N3X9M/66,+DB M:3:=:M=QAP:='TD>!O08=2.;-K((SXC2&/H:MD]4G%C!*6S'5JZ?M^3@7J 3 M=KN9=2%8WKL?VN4[HQ)!(U[3\TTOJZ9"+RJ]T&:CD_.NVKN7X4Y\2J%9T4I/ MMXZE?0CIO<3@;H6C'HVO]&!C>)D_M[>$/V<+-/\2(@3$/3QX3N$GL7=:F!(F MHX<@]M. "I"Y0@SY[=KVUMG+Q_>=>2=YADR$!VX3/P\Q[_/CJAX779SH>995 MAH&M.O3S06M/&%N*A8J^MW7#4.IPUX*;SZ+,GX%R^7!E5HQQ*?H(HMG>-A&6IXTYD??#]VS&7$_T9(;KCIQOTCKQ\B?%HA(8 MEAZS#E8\MQ6&FOG1#BKQQ2/?;9W\)=BV=%*(D3T>QHZWENE>8-SJ@4ZILV9L^ZWE.U M4& $,2\LIV 70795@GG5(338CV^[JS!W/VGI:=*!YIH>=!+[V*;1:_RX[$ @ M.W-L@!B063[5+YAM8LJ\L&<=-M)X[2 ^,V^]$.X%#K^V$BY@W ]-K,= M'>^Y\H3J@%H]A0-'"W'A@>KMMKX2!3/VO3EN9GTU0( 7HM&M8^>SRV3^W26D M6S5BD7T?1\JVDX"1 2P5L**'=3<8(3T4+>UCV%!>&M M5B:12%%,7'G7M3!-R!J('HQ9KH(/V.@@EC$EJ/&)B.#)D_V,YK9/QH_^OIJ$ MXK.](/,-+\?G*;^=>P^6+D7&@+U](3M=Y)N=X9&Z##IOB/$@V4+A MNR>PT2S#T%1X,IQFAIQ=&)% M4B?WI!6.S*\9)L2$,<46_ISJH5UI2INY4?>X"XRJ98TUI\??F3SSKFIWE!6F MWSS_!E'U0/XB/;T+7O.0F3T0HH=$F(I\&:Q1U1"*2KI0C#LR;;RE))EK%)5? M3Z#N @(!MF[A+9)#"P5%Q#Z_M M8?A*0W"S?N*F3_K*&8(:!'J4&*4+",-G+^D.RAW$& 7,=[TYX'2)&'1HTS7^ MRH+4P<<3U)"CFG(7EAQ !OFEMZHVO.S?LKO&603/M1M9C?A^L!^2)*'[$HRM MBGN&SGD7/H?O$A?&W/L4+(]9P1J0-"]]^=+I/H/70W25.$WMMAQD6\(!+\V8\SC:PL7N'?S9#LS(LE9_:D$CH1'DJ0 M?27F(LXF%IJ];A$7*&ITE)$*SP!:5K%RV5NXH6H[:9^H=])IX3CCU>CT8P]A M2([_PP9F5YYYE%>4Y4\%N?VSN8W27X_#V8IHR4#2H%0XFA70!CZ:ZS!UC:R) M^'B<,BEU^KOJ;.IGTL6,'T&DU\EA#$,+WP8LY\ M>S:"6"@G79%@6H@H->RV,\HN=4J]N:U[>E52(DE)7+6PD*IZ]61QK@:S*#/, M#4<8(?R9RW#NC#/=7HX&-GL51]=0!$4"1/3:SS%+5J MN6;N@8SNM]^TMXC[*3#N688>4[HIE^\M),IT]U3T-$UQRMD H52U% M[QD:HF"]>TJ(P?2]C@I7'J+E@7V)#WS >; DWSSL:B_,V(F.+FL$0+.)4@R/ M'ZEJTV CW+0$85V92$ACM.(5E3G+KJ;>U^"I[(@E&2Y+W2#+JIZC3DN*#0K_ M,F10$QDEV6VJ!Y Z*"N&73\X5"U1,5$8WMU4P<"47+Q(;FC%U/ONR.+N=NY' M]A9.%'+!A8J6Z81C/ECAS=1?(#(T1)6?>H HT668Y(;Y7W Z<#5R">YOXJQ8 M$23$K7\0$^CCN]=2)CE9DD+9(;3[E$.2]7.V[ 338W2".OSN:G$'>5)>2?S0 MH0\O5W0II'(02:/AQC+G+[T*GV=6:T[HV#-8B8IEQD=)L)O4; \;GG7H>]IC M86ISI4@\D!Q8)8$BB&2Q(9^H;E*5/Q?_D S9^&$?!']VFJ@6M)DRFR&LS"-0&S:N4>Q^6/N6F/ M582Q<14W+Z65]$000@4$G&F$S&GK7**^!&,2_@:M'E[PEIQODLQJX6UMD=/W MS-="YSGWQ6S@T%B% R583L[;ILZ*(W\7=Y@3N/#C:$LPSDK5 R"_RW5E$M 2 M!$-PUZPL>_@\H-Q#&(&^:J0<-4G5A2^ZCNEDEI#=;=>)IH$@.LJEG<]V/QE6 MGQ5PK,6=ALG^=1<3!> M4GRW'HP"XV'8#]U%HEG*%H6,Z?LQM?GD2:QPN,(J-PW$"JQ$U1=SS^#>A$0Y M17$ '2/;RYIA+L(U!-Y8K>X$#S^\W"7D4;B@4??OP+-) TGPA1&>*DUEW? ^ M6(\H*@U2RV7G=7X-88%.?=KW>OTB?W^^&J]UFBZARG>[3ZDXNFHR=[PHR!\9 M6.X>&$#B\$SW'VOFSNV0=&.(NT#[LJ&P.UVR%!G#N^N02&RO2&V M,+;9/#6+#XLDSR>%.35IN4Z*GY-R4QPN$::UUY1&![E&7Q9T,ZZSZN%$)\JR M!VYZVL097FXJ %C)[Q@;B(=*_ITTR,)_G=TR;(IU/DX-O@]+=-)?1>^["'FGVEID1?M^1D*@"\'NF4)1 M*'\GXH5GBH?77YJ]OAQ75QP\<<#.CDF_[X=J>]J]#SGO7%:-4^N/;ZO$D)#: MW9UI)_3!1T4?//[-H0].._??L=B.1)JV,NN,173$$89;KWST1*#HWFG13-F9 M.;WUUW-367'=.-9V0W32QQ=]T4BP5FS9) A<3+5]8E&.Y/'WB- )5 ML_A+V8R$%_W\L:]HX%.X6XH(7W7A'9+Q*[C*R$GD$+M]U54_U@,G3O#[A+N[ MJ:[:@<%_)2E\E*R>VO;#&?]P\=88"9ZWL:WQ(BJE"+(%N<^A=1@/?0=^A JE[HDTN)E+R1A@JR#"'&[S;E+0$#-FUS M124LH%IJ;6N(]+OP'>2J]3#^- M@NU6N+250.AYAJGJ(I16:/HI&[1M5PQ,15/;3?N.<1".ZTPZ)?'3\$CG,JF2 M0@O!%DIS;%0\84O.5+\BC/X5/87UGE%]%95]ZF6H=9P%;(_SG1V=M MV1"9_ZF^$0@/BI+@U[,JYXZX%5=(5;.N4'ABBA=91<:\6:'>+))JJ)E.BC=- M[!9I\J2Y+VX6OS4$/8U4"8!L[2USLKL?W_K"PRCX#!.<=?!XGH(DV6U)S3N% M,;S'3C4Z;C^ HYUW#1_]N7"-=+Q7CD%ZE_B]I#06#D5!>ZM8D:4KG1:-?>L8 M6Z4%>!WEF[P2EO;#\K)V@N")7D.U'#F;^_O^.ER+E4TY&Q]";SMK9 A=N7XR MS,4A,357PPJ;FW-]K#/E^3%%%#57LE=]97F <$05RF?.A57E-"Y4]0B-PJ:# MLJL:T1SF*[$H5UPU89.!")FZ?MJFVD>)-^(]JM9^L"Y'=*V%5][6,@K3IMV9 M6Z.-H/2[?3(GK//';0DJ#]U8JX#(N\.L+9VE>8"F@D]F:6=-:=-=G?2,,5H( MSJ'IGK>$6"BA83-VW%T?:14F+0NSYH(.HQ$XIIDB,'V1\(N*0X"J>^T%,:T$ MW,Y6[#&)W"W%TI>8VB6#])2*W6:6>6:<4O(/8[>/W:;3 :+.Q,X"@VRHXH>T MU&03J,#<)2W]&U%$757!ZQRD.8>5B<+12D/MND.YN5 OJ=@)[6*U:^ "E&I0 MB3#JU8H#JL]N>T8$RVMT5HQA=4RTRFG)3&&3>]EA#F\M=(%.5A$U:;I^4L:E M'P>_0>1N:8 M/U]\PS 4:CHM#%@:E@M-A/8P29%XL\^DW.Z0FCLTR(R/2%Y@+E_8U3X<9:AE MN#INV//*U'>,/ 0D#%2_DXXL'O1C=%@N<,R]$SRH._-$\M[T3UUGJB0^986H M?6(!J+BU184')$9I1X)>WDS_<;HU!K7B ):6-08S04YP/3N'#YFLA@ ]8(WB$3*I HJZ0D'U?)6G JQMB].Z68.&5 HA]LR_

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w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